<SEC-DOCUMENT>0001144204-12-034010.txt : 20120608
<SEC-HEADER>0001144204-12-034010.hdr.sgml : 20120608
<ACCEPTANCE-DATETIME>20120608165132
ACCESSION NUMBER:		0001144204-12-034010
CONFORMED SUBMISSION TYPE:	424B1
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20120608
DATE AS OF CHANGE:		20120608

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVELOS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001279704
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043321804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-180631
		FILM NUMBER:		12898406

	BUSINESS ADDRESS:	
		STREET 1:		ONE GATEWAY CENTER, SUITE 504
		CITY:			NEWTON
		STATE:			MA
		ZIP:			02458
		BUSINESS PHONE:		617-244-1616

	MAIL ADDRESS:	
		STREET 1:		ONE GATEWAY CENTER, SUITE 504
		CITY:			NEWTON
		STATE:			MA
		ZIP:			02458

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COMMON HORIZONS INC
		DATE OF NAME CHANGE:	20040211
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B1
<SEQUENCE>1
<FILENAME>v315674_424b1.htm
<DESCRIPTION>RULE 424(B)(1)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Filed pursuant to Rule 424(b)(1)</B></P>

<P STYLE="margin: 0; text-align: right"><B>File No. 333-180631</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img src="logo.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Novelos Therapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5,420,800 Units Consisting of </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5,420,800 Shares of Common Stock
and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Class A Warrants to Purchase 2,710,400
Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Class B Warrants to Purchase 5,420,800
Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering up to&nbsp;5,420,800 units
consisting of 5,420,800 shares of our common stock, Class A Warrants to purchase up to&nbsp;2,710,400&nbsp;shares of our common
stock and Class B Warrants to purchase up to 5,420,800 shares of common stock. The Class A Warrants and Class B Warrants will
be exercisable immediately after the closing of this offering. The Class A Warrants will be exercisable until the close of business
on the fifth anniversary of the date of issuance at an exercise price equal to $1.25 and the Class B Warrants will be exercisable
until the close of business on the 90<SUP>th</SUP> day following the date of issuance at an exercise price equal to $1.00.
Each investor will receive, for each unit purchased, a share of common stock, a Class A Warrant to purchase one-half of a share
of our common stock and a Class B Warrant to purchase one share of our common stock. The units will not be certificated and the
common stock and warrants will be immediately separable and will be separately transferable immediately upon issuance. The securities
are being offered on a &ldquo;best efforts&rdquo; basis, and we are not required to sell any specific dollar amount or number
of securities. The offering price for the units and the exercise price of the warrants will remain fixed for the duration of the
offering. All costs associated with the registration will be borne by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is quoted on the OTCQX platform of OTC
Markets under the symbol NVLT. We do not intend to apply for a listing of the warrants on any securities exchange and we do not
expect that the warrants will be quoted on OTC Markets. On June 7, 2012, the last reported sale price of our common stock on the
OTCQX was $1.69 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in the offered securities involves a high degree
of risk. See &ldquo;Risk Factors&rdquo; beginning on page 6</B> <B>of this prospectus for a discussion of information
that you should consider before investing in our securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE
SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE.
ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Per&nbsp;Unit</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 76%; text-indent: -0.25in; padding-left: 0.25in">Public offering price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;1.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,420,800</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Placement agent&rsquo;s fees (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;&nbsp;0.07</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">379,456</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Proceeds, before expenses, to us</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;&nbsp;0.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,041,344</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD>In addition we have agreed to issue the placement agent warrants
                                                             to purchase up to an aggregate of 5% of the number of shares of common
                                                             stock sold in this offering and to pay the placement agent a non-accountable
                                                             expense allowance equal to 1% of the gross offering proceeds.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Rodman &amp; Renshaw, LLC has agreed to act as our exclusive
lead placement agent in connection with this offering. In addition, Rodman &amp; Renshaw, LLC may engage one or more sub-placement
agents or selected dealers. The placement agent is not purchasing the securities offered by us, is not required to sell any specific
number or dollar amount of securities, but will assist us in this offering on a &ldquo;reasonable best efforts&rdquo; basis. We
have agreed to pay the placement agent a cash fee equal to 7% of the gross proceeds of the offering of securities by us. We estimate
the total expenses of this offering, excluding the placement agent fees, will be approximately $200,000.
Because there is no minimum offering amount required as a condition to closing in this offering, the actual public offering amount,
placement agent fees, and proceeds to us, if any, are not presently determinable and may be substantially less than the total
maximum offering amounts set forth above. See &ldquo;Plan of Distribution&rdquo; beginning on page 53 of this prospectus for more
information on this offering and the placement agent arrangement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The offering of units will terminate on June 14, 2012,
unless the offering is fully subscribed before that date or we decide to terminate the offering prior to that date. In either
event, the offering may be closed without further notice to you. The offering of the shares underlying the warrants is being
made on a continuous basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 7%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The date of this
prospectus is June 7, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Cancer-Targeting, Broad Spectrum, Multi-Product
Technology Platform </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img src="pg5a.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> FDG Compared with <B>LIGHT</B> as a
Cancer PET Imaging Agent in a Lung Cancer Patient with a Brain Metastasis </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img src="pg5b.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Time-Lapse Photography Illustrating
Tumor Regression in Mouse After a Single Dose of <B>HOT</B> </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="pg5c.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I> The images provided above are
for illustrative purposes only and may not be indicative of all results. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I> The above illustrations do not
refer to products approved by the FDA. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I> Novelos has not received any revenue
from the sale of its products </I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOVELOS THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 88%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 2%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 10%; vertical-align: bottom; text-align: center; border-bottom: Black 1pt solid">Page</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">PROSPECTUS SUMMARY</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">1&nbsp;</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">RISK FACTORS</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">6</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">FORWARD-LOOKING STATEMENTS</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">20</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">USE OF PROCEEDS</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">21</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">CAPITALIZATION</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">22</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">22</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">DILUTION</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">24</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">24</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">BUSINESS</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">30</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">LITIGATION</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">42</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">PROPERTIES</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">42</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">MANAGEMENT</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">43</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">50</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">51</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">PLAN OF DISTRIBUTION</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">53</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">DESCRIPTION OF SECURITIES</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">55</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">56</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">WHERE YOU CAN FIND MORE INFORMATION</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">57</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">LEGAL MATTERS</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">57</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">EXPERTS</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">57</TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top"> GLOSSARY OF SCIENTIFIC TERMS </TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 58 </TD></TR>
<TR STYLE="background-color: transparent">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">FINANCIAL STATEMENTS</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">F-1</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No dealer, salesperson or other person has been authorized to
give any information or to make any representations other than those contained in this prospectus in connection with the offer
contained in this prospectus and, if given or made, such information or representations must not be relied upon as having been
authorized by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neither the delivery of this prospectus nor any sale made hereunder
shall under any circumstances create an implication that there has been no change in our affairs since the date hereof. This prospectus
does not constitute an offer to sell or a solicitation of an offer to buy securities other than those specifically offered hereby
or of any securities offered hereby in any jurisdiction where, or to any person to whom, it is unlawful to make such offer or solicitation.
The information contained in this prospectus speaks only as of the date of this prospectus unless the information specifically
indicates that another date applies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus has been prepared based on information provided
by us and by other sources that we believe are reliable. This prospectus summarizes certain documents and other information in
a manner we believe to be accurate, but we refer you to the actual documents, if any, for a more complete understanding of what
we discuss in this prospectus. All of such documents are filed as exhibits to the registration statement of which this prospectus
is a part. In making a decision to invest in the securities offered in this prospectus, you must rely on your own examination of
us and the terms of the offering and securities offered in this prospectus, including the merits and risks involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are not making any representation to you regarding the legality
of an investment in the securities offered in this prospectus under any legal investment or similar laws or regulations. You should
not consider any information in this prospectus to be legal, business, tax or other advice. You should consult your own attorney,
business advisor and tax advisor for legal, business and tax advice regarding an investment in our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> You may only rely on the information contained in this prospectus
or that we have referred you to. We have not authorized anyone to provide you with different information. This prospectus does
not constitute an offer to sell or a solicitation of an offer to buy any securities other than the securities offered by this
prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities in any circumstances
in which such offer or solicitation is unlawful or in any state or to any person within any state to whom such offer would be
unlawful under the laws or securities regulations of such state. No offers will be made to, nor accepted from, any person that
does not meet the definition of an &ldquo;institutional investor&rdquo; under the blue sky laws of its state of domicile unless
otherwise specified in the &ldquo;Plan of Distribution&rdquo; section below. Neither the delivery of this prospectus nor any sale
made in connection with this prospectus shall, under any circumstances, create any implication that there has been no change in
our affairs since the date of this prospectus or that the information contained by reference to this prospectus is correct as
of any time after its date. In this prospectus, references to &ldquo;Novelos Therapeutics, Inc.,&rdquo; &ldquo;the Company,&rdquo;
&ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our,&rdquo; refer to Novelos Therapeutics, Inc. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<DIV STYLE="padding: 3pt; border: Black 1pt solid; width: 100%; overflow: auto">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This summary highlights information contained elsewhere
in this prospectus and does not contain all of the information that you should consider in making your investment decision. Before
investing in our securities, you should carefully read this entire prospectus, including our financial statements and the related
notes and the information set forth under the headings &ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s Discussion and
Analysis of Financial Condition and Results of Operations,&rdquo; in each case included elsewhere in this prospectus.&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>On April 8, 2011, Novelos entered into a business combination
with Cellectar, Inc., a privately held Wisconsin corporation that designed and developed products to detect, treat and monitor
a wide variety of human cancers (the Acquisition). References in this prospectus to &ldquo;Cellectar&rdquo; relate to the activities
and financial information of Cellectar, Inc. prior to the Acquisition, references to &ldquo;Novelos&rdquo; relate to the activities
and financial information of Novelos Therapeutics, Inc. prior to the Acquisition and references to &ldquo;we&rdquo; &ldquo;us&rdquo;
or &ldquo;the Company&rdquo; relate to the activities and obligations of the combined company following the Acquisition.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Please refer to the Glossary of Scientific Terms on page
58 of this prospectus for definitions of certain technical and scientific terms used throughout this prospectus. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our Business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Novelos Therapeutics, Inc. is a pharmaceutical company developing
compounds for the treatment of cancer.&nbsp; Since the Acquisition, we have been <FONT STYLE="color: black">developing novel drugs
for the treatment and diagnosis of cancer based on the Cellectar compounds. </FONT> We believe our three <FONT STYLE="color: black">cancer-targeted
compounds (referred to as LIGHT, HOT and COLD) are selectively taken up and retained in cancer cells, including cancer stem cells,
versus normal cells.</FONT> Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal
cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of
mortality in cancer: primary tumors, metastases and stem cell-based relapse. I-124-CLR1404 (<FONT STYLE="color: black">LIGHT) is
a small-molecule cancer-targeted positron emissions tomography (PET) imaging agent. We believe LIGHT has first-in-class potential
and Phase 1-2 clinical trials are ongoing. I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic
that delivers cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells. We believe HOT
also has first-in-class potential. HOT Phase 1b dose-escalation trial is ongoing and we expect HOT to enter Phase 2 trials in the
first quarter of 2013 as a monotherapy for solid tumors with significant unmet medical need, subject to additional funding. CLR1404
(COLD), a pre-clinical cancer-targeted non-radioactive chemotherapy, works primarily through Akt (</FONT>a serine/threonine protein
kinase)<FONT STYLE="color: black"> inhibition</FONT>. <FONT STYLE="color: black">Together, we believe our compounds are able to
&ldquo;find, treat and follow&rdquo; cancer anywhere in the body in a novel, effective and highly selective way.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> LIGHT is a small-molecule imaging agent that we believe
has first-in-class potential for selective detection of tumors and metastases in a broad range of cancers.&nbsp; LIGHT is comprised
of a small, non-pharmacological quantity of CLR1404 (COLD, acting as a cancer-targeted delivery and retention vehicle) labeled
with the short-lived radioisotope, iodine-124, a new PET imaging isotope.&nbsp; PET imaging used in conjunction with CT scanning
has now become the imaging method of choice in oncology.&nbsp; In studies to date, LIGHT selectively illuminated malignant tumors
in 52 of 54 animal models of cancer, demonstrating evidence of broad-spectrum, cancer-selective uptake and retention. Investigator-sponsored
Phase 1-2 trials of LIGHT as a PET imaging agent are ongoing at the University of Wisconsin. The investigator-sponsored IND for
LIGHT was submitted on March 28, 2003 and was approved by the FDA on April 25, 2003. The IND is held by Dr. Lance Hall at the
University of Wisconsin, who both initiates and conducts the investigation and under whose immediate direction the investigational
drug is administered. Novelos, the National Cancer Institute or the University of Wisconsin Institute for Clinical and Translational
Research provide funding for the trials and the data is shared with Novelos while the trials progress and at the conclusion of
the trials. The trials include, lung cancer, brain cancer and, starting in the second quarter of 2012, other solid tumors. These
human trials, if successful, will serve three important purposes.&nbsp; First, they would provide proof-of-concept for LIGHT itself
as a PET imaging agent with the potential to supplant the current &ldquo;gold standard&rdquo; agent, 18-fluoro-deoxyglucose (FDG),
due to what we believe to be LIGHT&rsquo;s superior cancer-specificity and more favorable logistics of clinical use.&nbsp; Second,
favorable results would advance potential partnering discussions for LIGHT. Third, tumor uptake data will accelerate clinical
development of HOT by predicting efficacy and enabling calculation of efficacious doses of HOT for Phase 2 trials. </P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<DIV STYLE="border: Black 1pt solid; padding: 3pt; width: 100%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">HOT is a small-molecule, broad-spectrum, cancer-targeted molecular
radiotherapeutic that we believe has first-in-class potential.&nbsp; HOT is comprised of a small, non-pharmacological quantity
of CLR1404 (COLD), acting as a cancer-targeted delivery and retention vehicle and incorporating a cytotoxic dose of radiotherapy
(in the form of iodine-131, a radioisotope that is already in common use to treat thyroid and other cancer types).&nbsp; It is
this &ldquo;intracellular radiation&rdquo; mechanism of cancer cell killing, coupled with delivery to a wide range of malignant
tumor types that we believe imbues HOT with broad-spectrum anti-cancer activity.&nbsp; Selective uptake and retention has also
been demonstrated in cancer stem cells compared with normal cells, offering the prospect of longer lasting cancer remission. In
2009, we filed an IND with the FDA to study HOT in humans.&nbsp; In early 2010, we successfully completed a Phase 1a dosimetry
trial demonstrating initial safety, tumor imaging and pharmokinetic consistency and establishing a starting dose for a Phase 1b
dose-escalation trial.&nbsp; Radiation dosimetry measures how much radiation is absorbed by tumors and body organs in order to
optimize delivery of radiation therapy. The ongoing Phase 1b dose-escalation trial is aimed at determining the Maximum Tolerated
Dose of HOT.&nbsp; We plan to initiate HOT Phase 2 efficacy trials as a monotherapy for solid tumors with significant unmet medical
need as soon as a minimal efficacious dose is established, provided that we obtain the additional funding necessary for that purpose.&nbsp;
We may determine such an effective dose upon seeing a tumor response in the Phase 1b trial or calculating it from ongoing PET imaging
trials in cancer patients with LIGHT (since PET imaging is quantitative, enabling determination of tumor radiation exposure at
a given dose level).&nbsp; Preclinical <I>in vitro</I> (in cell culture) and <I>in vivo</I> (in animals) experiments have demonstrated
selective killing of cancer cells along with a benign safety profile. HOT&rsquo;s anti-tumor/survival-prolonging activities have
been demonstrated in more than a dozen xenograft models (human tumor cells implanted into animals) including breast, prostate,
lung, glioma (brain), pancreatic, ovarian, uterine, renal and colorectal cancers and melanoma.&nbsp; &nbsp;In all but two models,
a single administration of a well-tolerated dose of HOT was sufficient to demonstrate efficacy.&nbsp; In view of HOT&rsquo;s selective
uptake and retention in a wide range of solid tumors and in cancer stem cells, its single-agent efficacy in xenograft models and
its non-specific mechanism of cancer-killing (radiation), we expect first to develop HOT as a monotherapy, initially for solid
tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COLD is a cancer-targeted chemotherapy that, in pre-clinical
experiments, has been observed to inhibit the phosphatidylinosotol 3-kinase (PI3K)/Akt survival pathway and induce apoptosis through
caspase activation and inhibit cell proliferation in cancer cells versus normal cells.&nbsp; Caspases are molecules that can stimulate
apoptosis. COLD also exhibits significant <I>in vivo</I> efficacy in mouse xenograft tumor models, including non-small cell lung
cancer and triple-negative breast cancers, producing long-lasting tumor growth suppression and significantly increased survival.&nbsp;
We believe COLD has the potential to be best-in-class versus other Akt inhibitors in development and believe that&nbsp;COLD has
important advantages over competitor agents including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Selective uptake and retention
by cancer cells/cancer stem cells compared to normal cells/stem cells.&nbsp; This results in significantly greater potency of
COLD as an inhibitor of cell proliferation in cancer cells versus normal cells (greater than a 10-fold difference), and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Suitability for intravenous
administration, avoiding dose-limiting gastrointestinal toxicity seen with orally administered Akt-inhibiting alkyl phosphocholines
(APCs) and potentially enabling greater systemic drug exposure and, hence, Akt-inhibition in cancer cells, resulting in superior
efficacy.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our core technology platform is based upon the research conducted
by Cellectar&rsquo;s founder and our Chief Scientific Officer, Dr. Jamey Weichert, which commenced in 1994 at the University of
Michigan (U. Mich.) where phospholipid ether analogs were initially designed, synthesized, radiolabeled, and evaluated. Since 1998,
Dr. Weichert has continued his research at the University of Wisconsin (U. Wisc.) and founded Cellectar in 2002 to further develop
and commercialize the technology. Cellectar obtained exclusive rights to the related technology patents in North America owned
by U. Mich. in 2003, and continued development of the platform while obtaining ownership of numerous additional patents and patent
applications in North America, Europe and Japan (lasting until 2025, 2028 and 2030, without extensions) prior to the Acquisition.
The license granted by U. Mich. to Cellectar (the U. Mich. license) gives us the exclusive right to develop, manufacture, market
and sublicense our HOT and LIGHT compounds, and provides, among other things, that we pay a royalty equal to 3% of net sales of
any licensed products sold by us or our sublicensees, with a reduction in such royalties in the case of certain incoming or outgoing
sublicense arrangements. The license also requires us to make payments to U. Mich., ranging from $50,000 to $200,000, upon the
achievement of certain key regulatory and commercial milestones, for an aggregate of up to $400,000 in milestone payments. The
license expires upon the expiration of the last covered Michigan patent (currently 2016 without extensions).&nbsp; U. Mich. may
terminate the agreement if we cease operations, if we fail to make any required payments under the agreement, or if we otherwise
materially breach the agreement, subject to the applicable notice and cure periods. If the U. Mich. license expires or terminates
for any reason, it will not impact the ownership of the additional patents that we have independently obtained. However the early
termination of the U. Mich. license would result in the loss of our rights to use the covered patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Key Risks and Uncertainties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are subject to numerous risks and uncertainties, including
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">We will require additional capital in order to continue our operations, and may have difficulty
raising additional capital;</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<DIV STYLE="padding: 3pt; border: Black 1pt solid; width: 100%">



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We are a development stage company with a history of losses and can provide no assurance of our future operating results;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">We and our Chief Executive Officer are defendants in a securities fraud class action lawsuit.
We are also defending counterclaims in another lawsuit that we initiated, and if we are not successful in defending claims against
us, the resulting liability could be substantial;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">At present, our success depends solely on the successful commercialization of Cellectar compounds;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">We have a history of recurring losses and an accumulated deficit which, among other factors,
raise substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">The failure to complete development of our therapeutic technology, to obtain government approvals,
including required FDA approvals, or to comply with ongoing governmental regulations could prevent, delay or limit introduction
or sale of proposed products and result in failure to achieve revenues or maintain our ongoing business;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results
of earlier studies and trials may not be predictive of future trial results;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">We may be required to suspend or discontinue clinical trials due to unexpected side effects or
other safety risks that could preclude approval of our product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">We have limited in-house research and manufacturing capacity and will rely, to some extent, on
research and manufacturing facilities at various universities, hospitals, contract research organizations and contract manufacturers
for a portion of our research, development, and manufacturing. In the event we exceed our in-house capacity or lose access to those
facilities, our ability to gain FDA approval and commercialization of our drug delivery technology and products could be delayed
or impaired; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">We are exposed to product, clinical and preclinical liability risks that could create a substantial
financial burden should we be sued.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For a more detailed description of the material risks and uncertainties
we face, please see &ldquo;Risk Factors&rdquo; beginning on page 6 of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our headquarters and manufacturing operation, which is compliant
with current Good Manufacturing Practices (cGMP), is located at 3301 Agriculture Drive, Madison, Wisconsin 53716. Our principal
executive offices are located at One Gateway Center, Suite 504, Newton, Massachusetts 02458. Our telephone number is (617) 244-1616
and our web address is www.novelos.com. The information included or referred to on, or accessible through, our website does not
constitute part of, and is not incorporated by reference into, this prospectus.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<DIV STYLE="padding: 3pt; border: Black 1pt solid; width: 100%">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; font-style: italic">Securities offered by us:</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 46%">Up to 5,420,800 units. Each unit will consist of one share of our common stock, a Class A Warrant
    to purchase up to one-half of a share of our common stock at an exercise price of $1.25 per     share and a Class B Warrant
    to purchase up to one share of our common stock at an exercise price of $1.00 per share. Investors     will be permitted to
    purchase only even numbers of units, hence Warrants will be exercisable only for whole numbers of shares.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-style: italic">Description of Class A Warrants:</TD>
    <TD>&nbsp;</TD>
    <TD>The Class A warrants will be exercisable on or after the closing date of this offering until the close of business
    on the fifth anniversary of the date of issuance.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-style: italic">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-style: italic">Description of Class B Warrants:</TD>
    <TD>&nbsp;</TD>
    <TD>The Class B Warrants will be exercisable on or after the closing date of this offering until the close of business on
    the 90<SUP>th</SUP> day following the date of issuance.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-style: italic">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-style: italic">Securities Purchase Agreement:</TD>
    <TD>&nbsp;</TD>
    <TD>The securities to be offered by us in this offering will be issued and sold pursuant to a securities purchase agreement between us and each investor.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-style: italic">Common Stock to be outstanding after this offering:</TD>
    <TD>&nbsp;</TD>
    <TD>43,186,000 shares. (1)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-style: italic">Use of Proceeds:</TD>
    <TD>&nbsp;</TD>
    <TD>We expect to use the net proceeds received from this offering to fund our research and development activities, including furthering the development of LIGHT and HOT and for general corporate purposes, including capital expenditures, working capital, and, potentially, acquisition activities. For a more complete description of our anticipated use of proceeds from this offering, see &ldquo;Use of Proceeds.&rdquo;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-style: italic">Risk Factors:</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See &ldquo;Risk Factors&rdquo; beginning on page 6
        and the other information included in this prospectus for a discussion of factors you should carefully consider before deciding
        whether to purchase our securities.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-style: italic">OTCQX symbol for our Common Stock:</TD>
    <TD>&nbsp;</TD>
    <TD>NVLT</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 37pt"><FONT STYLE="font-size: 10pt">(1) </FONT></TD><TD><FONT STYLE="font-size: 10pt">The
                                                                                                 number of shares of our common
                                                                                                 stock to be outstanding after
                                                                                                 this offering is based on&nbsp;37,765,200
                                                                                                 shares of common stock outstanding
                                                                                                 as of June 5, 2012 and excludes,
                                                                                                 as of that date: </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">shares issuable upon the exercise of warrants sold in this offering;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">an aggregate of 4,827,638 shares of common stock issuable upon the exercise of outstanding stock
options issued to employees, directors and consultants, including under our 2006 Stock Incentive Plan;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">an aggregate of 2,281,112 additional shares of common stock reserved for future issuance under
our 2006 Stock Incentive Plan;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol"> &middot; </FONT></TD><TD><FONT STYLE="font-size: 10pt"> an
                                                                                                           aggregate of 15,713,686
                                                                                                           additional shares of
                                                                                                           common stock reserved
                                                                                                           for issuance under
                                                                                                           outstanding warrant
                                                                                                           agreements entered
                                                                                                           into in connection
                                                                                                           with financing transactions
                                                                                                           completed during 2011
                                                                                                           with expiration dates
                                                                                                           between March 31, 2016
                                                                                                           and December 6, 2016,
                                                                                                           at exercise prices
                                                                                                           ranging from $0.60
                                                                                                           per share to $0.75
                                                                                                           per share; and </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot; </FONT></TD><TD><FONT STYLE="font-size: 10pt">an
                                                                                                             aggregate of 223,874
                                                                                                             additional shares
                                                                                                             of common stock reserved
                                                                                                             for issuance under
                                                                                                             various outstanding
                                                                                                             warrant agreements,
                                                                                                             with expiration dates
                                                                                                             between May 7, 2012
                                                                                                             and December 31,
                                                                                                             2015, at exercise
                                                                                                             prices ranging from
                                                                                                             $0.60 per share to
                                                                                                             $100.98 per share.
                                                                                                             </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless we specifically state otherwise, the share information
in this prospectus is as of June 5, 2012 and reflects or assumes no exercise of outstanding options or warrants to purchase shares
of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The shares issued to Cellectar shareholders in the Acquisition
constituted immediately following the Acquisition (and immediately prior to the private placement that followed the Acquisition),
approximately 85% of our outstanding common stock after giving effect to the Acquisition. Since the former stockholders of Cellectar
retained the majority voting interest in the combined business following the Acquisition, the Acquisition has been accounted for
as a reverse acquisition whereby Cellectar, Inc. is treated as the acquirer for accounting and financial reporting purposes. As
such, the historical financial information presented in this prospectus represents the historical financial information of Cellectar,
except for the capital structure which represents the historical amounts of Cellectar retroactively adjusted to reflect the legal
capital structure of Novelos by applying the exchange ratio established in the Acquisition.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<DIV STYLE="padding: 2; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Summary Historical Financial Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The following table summarizes our financial data. We have
derived the following summary of our statements of operations data for the three months ended March 31, 2012 and 2011 and the
summary of our balance sheet data as of March 31, 2012 from our unaudited consolidated financial statements appearing elsewhere
in this prospectus. We have derived the following summary of our statements of operations data for the fiscal years ended December
31, 2011 and 2010 and the summary of our balance sheet data as of&nbsp;December 31, 2011 and 2010&nbsp;from our audited financial
statements appearing elsewhere in this prospectus. The following summary of our financial data set forth below should be read
together with our financial statements and the related notes to those statements, as well as the section titled &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations,&rdquo; appearing elsewhere in this prospectus. </P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Three&nbsp;Months&nbsp;Ended<BR>
    March&nbsp;31, </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Year&nbsp;Ended<BR> December&nbsp;31, </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> 2012 </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> 2011 </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> 2011 </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> 2010 </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"> Statement of Operations Data: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 48%; text-align: left; padding-left: 9pt"> Research and development costs </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 1,328,314 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 471,404 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 3,599,080 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 2,984,207 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt"> General and administrative costs </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 997,671 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 131,726 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,692,433 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,156,549 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt"> Merger costs </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 250,434 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 746,207 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 52,925 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt"> Total costs and expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,325,985 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 853,564 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,037,720 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,193,681 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt"> Other expense </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (30,918 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (111,688 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (397,702 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (366,582 </TD><TD STYLE="text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt"> Net loss </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (2,356,903 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (965,252 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (7,435,422 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (4,560,263 </TD><TD STYLE="text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt"> Basic and diluted net loss per common share </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (0.06 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (0.08 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (0.31 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (0.36 </TD><TD STYLE="text-align: left"> ) </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> March&nbsp;31, </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> December&nbsp;31, </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> 2012 </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> 2011 </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> 2010 </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"> Balance Sheet Data: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 61%; text-align: left; padding-left: 9pt"> Current assets </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 4,025,876 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 5,815,927 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 1,279,781 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt"> Working capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,519,575 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 5,312,346 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 374,964 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt"> Total assets </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 8,648,503 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10,563,176 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,802,142 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt"> Long term debt, including current portion </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 450,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 450,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,846,728 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt"> Total stockholders&rsquo; equity </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,561,327 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 9,481,123 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 133,762 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Investing in our securities involves a high degree of risk.
Before you invest in our securities, you should be aware that our business faces numerous financial and market risks, including
those described below, as well as general economic and business risks. The following discussion provides information concerning
the material risks and uncertainties that we have identified and believe may adversely affect our business, financial condition
and results of operations. Before you decide whether to invest in our securities, you should carefully consider these risks and
uncertainties, together with all of the other information included in this prospectus.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to Our Business and Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We will require additional capital in order to continue our
operations, and may have difficulty raising additional capital.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We expect that we will continue to generate
significant operating losses for the foreseeable future. At March 31, 2012, our consolidated cash balance was approximately
$3,788,000. We believe our cash on hand, together with the net proceeds from this offering (assuming $5,420,800 of units are
sold in this offering), would be adequate to fund operations into the second quarter of 2013<I>.</I> During that time, we
anticipate that we will incur approximately $8,600,000 in costs, subject to the availability of funds. Of this amount,
approximately $6,000,000 is estimated for research and development activities and $2,600,000 is estimated for general and
administrative costs. The research and development costs consist of approximately $2,000,000 for the development of HOT
(including approximately $1,000,000 in Phase 1b trial costs and $800,000 in Phase 2 trial costs), $600,000 for the
development of LIGHT and $3,400,000 for our general, unallocated research and development costs including salaries, overhead,
patent and other costs that are not specific to a certain development project. In addition to these estimated costs, we may
incur up to an estimated total of $4,300,000 in clinical development costs during 2013 and 2014, if necessary, to complete
the Phase 1b dose-escalation trial and Phase 2 trials in HOT.&nbsp;We have expended and expect to continue to expend
substantial funds on the research, development and clinical and pre-clinical testing of our drug compounds. We will require
additional funds to conduct research and development, establish and conduct clinical and pre-clinical trials, establish
commercial-scale manufacturing arrangements and provide for the marketing and distribution of our products. Our ability to
execute our operating plan depends on our ability to obtain additional funding via the sale of equity and/or debt securities,
a strategic transaction or otherwise. Although we have not entered into negotiations for a financing or
strategic transaction, we plan to actively pursue financing alternatives. However, there can be no assurance that we will
obtain the necessary funding or that it will be available on a timely basis or upon terms acceptable to us. If we obtain
capital by issuing debt or preferred stock, the holders of such securities would likely obtain rights that are superior to
those of holders of our common stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our capital requirements and our ability to meet them depend
on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">the number of potential products and technologies in development;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">continued progress and cost of our research and development programs;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">progress with pre-clinical studies and clinical trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">the time and costs involved in obtaining regulatory clearance;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">costs of developing sales, marketing and distribution channels and our ability to sell our drugs;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">costs involved in establishing manufacturing capabilities for clinical trial and commercial quantities
of our drugs;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">competing technological and market developments;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">market acceptance of our products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">costs for recruiting and retaining management, employees and consultants;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">costs for educating physicians regarding the application and use of our products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">whether or not we obtain listing on a national exchange and, if not, our prospects for obtaining
such listing;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">uncertainty and economic instability resulting from terrorist acts and other acts of violence
or war; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">the condition of capital markets and the economy generally, both in the U.S. and globally.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may consume available resources more rapidly than currently
anticipated, resulting in the need for additional funding sooner than expected. We may seek to raise any necessary additional funds
through the issuance of warrants, equity or debt financings or executing collaborative arrangements with corporate partners or
other sources, which may be dilutive to existing stockholders or have a material effect on our current or future business prospects.
In addition, in the event that additional funds are obtained through arrangements with collaborative partners or other sources,
we may have to relinquish economic and/or proprietary rights to some of our technologies or products under development that we
would otherwise seek to develop or commercialize by ourselves. If we cannot secure adequate financing when needed, we may be required
to delay, scale back or eliminate one or more of our research and development programs or to enter into license or other arrangements
with third parties to commercialize products or technologies that we would otherwise seek to develop ourselves and commercialize
ourselves. In such event, our business, prospects, financial condition, and results of operations may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We are a development stage company with a history of losses
and can provide no assurance of our future operating results.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We are a development stage company and have incurred net
losses and negative cash flows since inception. We currently have no product revenues, and may not succeed in developing or commercializing
any products which will generate product or licensing revenues. We do not expect to have any marketable products on the market
for several years. Our primary activity to date has been research and development. In addition, development of our product candidates
requires a process of pre-clinical and clinical testing, during which our product candidates could fail. We may not be able to
enter into agreements with one or more companies experienced in the manufacturing and marketing of therapeutic drugs and, to the
extent that we are unable to do so, we will not be able to market our product candidates. Eventual profitability will depend on
our success in developing, manufacturing, and marketing our product candidates. We have experienced net losses and negative cash
flows from operating activities since inception and we expect such losses and negative cash flows to continue in the foreseeable
future. As of December 31, 2011, we had working capital of $5,312,346 and stockholders&rsquo; equity of $9,481,123, respectively.
As of March 31, 2012, we had working capital of $3,519,575 and stockholders&rsquo; equity of $7,561,327. For the period from Cellectar&rsquo;s
inception in November 2002 until the business combination with Novelos on April 8, 2011, and thereafter through December 31, 2011,
Cellectar (and, from and after the business combination, Novelos) incurred aggregated net losses of $31,480,426. Net loss for
the year ended December 31, 2011 was $7,435,422 and the net loss for the three months ended March 31, 2012 was $2,356,903. We
may never achieve profitability. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
<B>We and our Chief Executive Officer are defendants in a securities fraud class action lawsuit. We are also defending counterclaims
in another lawsuit that we initiated. If we are not successful in defending claims against us, the resulting liability could be
substantial.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A putative class action complaint was filed on March 5, 2010
in the U.S. District Court for the District of Massachusetts by an alleged shareholder on behalf of himself and all others who
purchased or otherwise acquired our common stock in the period between December 14, 2009 and February 24, 2010, against us and
our President and Chief Executive Officer, Harry S. Palmin. The complaint claimed, among other things, that the defendants violated
Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder in connection with alleged
misleading disclosures related to the progress of the Phase 3 trial of NOV-002 in advanced non-small cell lung cancer. On June
23, 2011, the case was dismissed without prejudice. On August 5, 2011, the plaintiffs filed a second amended complaint realleging
that the defendants violated Section 10(b) of the Exchange Act and Rule 10b-5 in connection with alleged misleading disclosures
related to the Phase 3 clinical trial for NOV-002 in non-small cell lung cancer. On September 9, 2011, the defendants filed a motion
to dismiss the second amended complaint. The plaintiffs&rsquo; opposition to the motion&nbsp;was filed on&nbsp;October 14, 2011
and the defendants filed a reply brief on November 4, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, on June 28, 2010, we received a letter from counsel
to ZAO BAM and ZAO BAM Research Laboratories (Russian companies, collectively referred to as BAM) alleging that we modified the
chemical composition of NOV-002 without prior notice to or approval from BAM, constituting a material breach of a technology and
assignment agreement we had entered into with BAM on June 20, 2000 (the June 2000 Agreement). On September 24, 2010, we filed a
complaint in Suffolk Superior Court seeking a declaratory judgment by the court that the June 2000 Agreement has been replaced
by a subsequent agreement between the parties dated April 1, 2005 (the April 2005 Agreement), that Novelos&rsquo; obligations to
BAM are governed solely by the April 2005 Agreement and that the obligations of the June 2000 Agreement have been performed and
fully satisfied. BAM answered the complaint, denying the material allegations, and stating its affirmative defenses and certain
counterclaims. In June 2011, BAM filed an amended counterclaim alleging additional claims related to Novelos&rsquo; acquisition
of Cellectar. On June 15, 2011 we filed our response to their amended counterclaim. On August 5, 2011, we filed a motion for judgment
on the pleadings as to our declaratory judgment count and all counts of BAM&rsquo;s amended counterclaim. The motion&nbsp;was opposed
by BAM and a hearing on the motion&nbsp;was held&nbsp;on September 27, 2011. On October 17, 2011, the court ruled on our behalf
for each of our declaratory judgment claims and dismissed all counts of BAM&rsquo;s counterclaim. Judgment in favor of the Company
was entered on October 20, 2011. On November 14, 2011, BAM filed a notice of appeal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While we intend to continue to vigorously defend ourselves in
these actions, the uncertainties of litigation and the uncertainties related to insurance coverage and collection as well as the
actual value of claims make it difficult to accurately predict the financial effect these claims may ultimately have on us. We
may not be successful in defending such claims, and the resulting liability could be substantial and may not be covered by insurance.
At the time the class action complaint was filed, we carried a total of $10 million in directors and officers liability insurance
coverage, consisting of $5 million in primary coverage (including costs to defend) and $5 million in excess liability coverage.
The BAM dispute is not covered by insurance. In addition, the lawsuits divert management&rsquo;s attention and resources, whether
or not the claims are ultimately successful, and this could adversely affect our business. As a result, there can be no assurance
as to the long-term effect litigation will have on our business, prospects, financial condition or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>At present, our success depends solely on the successful
commercialization of Cellectar compounds.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prior to the Acquisition, Novelos had for over ten years been
developing oxidized glutathione-based compounds for the treatment of cancer, including NOV-002, an injectable small-molecule compound
based on a proprietary formulation of oxidized glutathione that Novelos had been developing for use in combination with standard-of-care
chemotherapies for the treatment of solid tumors, and NOV-205, a hepatoprotective agent with immunomodulating and anti-inflammatory
properties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the Acquisition, development of NOV-002 and NOV-205
was suspended and we are now focused on the development of novel drugs for the treatment and diagnosis of cancer based on the cancer-targeting
technologies of Cellectar: I-124-CLR1404 (LIGHT, labeled with a short-lived radioisotope, iodine-124),<SUP> </SUP>I-131-CLR1404
(HOT, a radiolabeled compound) and CLR1401 (COLD). As a result, the successful commercialization of LIGHT, HOT and COLD is crucial
for our success. Our proposed products and their potential applications are in an early stage of clinical and manufacturing/process
development and face a variety of risks and uncertainties. Principally, these risks include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">future clinical trial results may show that the cancer-targeting technologies of Cellectar are
not well tolerated by recipients at its effective doses or are not efficacious;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">future clinical trial results may be inconsistent with Cellectar&rsquo;s previous preliminary
testing results and data from Cellectar&rsquo;s earlier studies may be inconsistent with clinical data;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">even if the cancer-targeting technologies of Cellectar are shown to be safe and effective for
their intended purposes, we may face significant or unforeseen difficulties in obtaining or manufacturing sufficient quantities
at reasonable prices or at all;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">our ability to complete the development and commercialization of the cancer-targeting technologies
of Cellectar for our intended use is substantially dependent upon our ability to obtain and maintain experienced and committed
partners to assist us with obtaining clinical and regulatory approvals for, and the manufacturing, marketing and distribution of,
our products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">even if the cancer-targeting technologies of Cellectar are successfully developed, commercially
produced and receive all necessary regulatory approvals, there is no guarantee that there will be market acceptance of our products;
and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">our competitors may develop therapeutics or other treatments which are superior or less costly
than our own with the result that our product candidates, even if they are successfully developed, manufactured and approved, may
not generate sufficient revenues to offset the development and manufacturing costs of our product candidates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we are unsuccessful in dealing with any of these risks, or
if we are unable to successfully commercialize the cancer-targeting technologies of Cellectar for some other reason, our business,
prospects, financial condition, and results of operations may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We have a history of recurring losses and an accumulated
deficit which, among other factors, raise substantial doubt about our ability to continue as a going concern, which may hinder
our ability to obtain future financing.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our financial statements as of December 31, 2011 were prepared
under the assumption that we will continue as a going concern. The independent registered public accounting firm that audited our
2011 financial statements, in their report, included an explanatory paragraph referring to our recurring losses&nbsp;since inception&nbsp;and
expressing substantial doubt in our ability to continue as a going concern. Our financial statements do not include any adjustments
that might result from the outcome of this uncertainty. Our ability to continue as a going concern depends on our ability to obtain
additional equity or debt financing, attain further operating efficiencies, reduce expenditures, and, ultimately, to generate revenue.</P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The failure to complete development
of our therapeutic technology, to obtain government approvals, including required FDA approvals, or to comply with ongoing governmental
regulations could prevent, delay or limit introduction or sale of proposed products and result in failure to achieve revenues or
maintain our ongoing business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our research and development activities and the manufacture
and marketing of our intended products are subject to extensive regulation for safety, efficacy and quality by numerous government
authorities in the U.S. and abroad. Before receiving clearance to market our proposed products by the FDA, we will have to demonstrate
that our products are safe and effective for the patient population for the diseases that are to be treated. Clinical trials, manufacturing
and marketing of drugs are subject to the rigorous testing and approval process of the FDA and equivalent foreign regulatory authorities.
The Federal Food, Drug and Cosmetic Act and other federal, state and foreign statutes and regulations govern and influence the
testing, manufacturing, labeling, advertising, distribution and promotion of drugs and medical devices. As a result, clinical trials
and regulatory approval can take many years to accomplish and require the expenditure of substantial financial, managerial and
other resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to be commercially viable, we must successfully research,
develop, obtain regulatory approval for, manufacture, introduce, market and distribute our technologies. This includes meeting
a number of critical developmental milestones including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">demonstrating benefit from delivery of each specific drug for specific medical indications;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">demonstrating through pre-clinical and clinical trials that each drug is safe and effective;
and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">demonstrating that we have established viable Good Manufacturing Practices capable of potential
scale-up.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The timeframe necessary to achieve these developmental milestones
may be long and uncertain, and we may not successfully complete these milestones for any of our intended products in development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the risks previously discussed, our technology
is subject to developmental risks that include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">uncertainties arising from the rapidly growing scientific aspects of drug therapies and potential
treatments;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">uncertainties arising as a result of the broad array of alternative potential treatments related
to cancer and other diseases; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">anticipated expense and time believed to be associated with the development and regulatory approval
of treatments for cancer and other diseases.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to conduct the clinical trials that are necessary to
obtain approval by the FDA to market a product, it is necessary to receive clearance from the FDA to conduct such clinical trials.
The FDA can halt clinical trials at any time for safety reasons or because we or our clinical investigators do not follow the FDA&rsquo;s
requirements for conducting clinical trials. If we are unable to receive clearance to conduct clinical trials for a product, or
the trials are halted by the FDA, we will not be able to achieve any revenue from such product in the U.S. as it is illegal to
sell any drug for use in humans in the U.S. without FDA approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Even if we do ultimately receive FDA approval for any of our
products, these products will be subject to extensive ongoing regulation, including regulations governing manufacturing, labeling,
packaging, testing, dispensing, prescription and procurement quotas, record keeping, reporting, handling, shipment and disposal
of any such drug. Failure to obtain and maintain required registrations or to comply with any applicable regulations could further
delay or preclude development and commercialization of our drugs and subject us to enforcement action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Clinical trials involve a lengthy and expensive process with
an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to receive regulatory approval for the commercialization
of our product candidates, we must conduct, at our own expense, extensive clinical trials to demonstrate safety and efficacy of
these product candidates. Clinical testing is expensive, it can take many years to complete and its outcome is uncertain. Failure
can occur at any time during the clinical trial process. For example, we incurred costs of over $35 million in clinical trial expenses
over a period of 4 years in connection with the Phase 3 trial of NOV-002 for non-small cell lung cancer, and NOV-002 did not ultimately
demonstrate efficacy for that indication.</P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may experience delays in clinical testing of our product
candidates. We do not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed
on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory approval
to commence a trial, in reaching agreement on acceptable clinical trial terms with prospective sites, in obtaining institutional
review board approval to conduct a trial at a prospective site, in recruiting patients to participate in a trial or in obtaining
sufficient supplies of clinical trial materials. Many factors affect patient enrollment, including the size of the patient population,
the proximity of patients to clinical sites, the eligibility criteria for the trial, competing clinical trials and new drugs approved
for the conditions we are investigating. Prescribing physicians will also have to decide to use our product candidates over existing
drugs that have established safety and efficacy profiles. Any delays in completing our clinical trials will increase our costs,
slow down our product development and approval process and delay our ability to generate revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, the results of preclinical studies and early clinical
trials of our product candidates do not necessarily predict the results of later-stage clinical trials. Product candidates in later
stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through initial clinical
testing. The data collected from clinical trials of our product candidates may not be sufficient to support the submission of a
new drug application or to obtain regulatory approval in the United States or elsewhere. Because of the uncertainties associated
with drug development and regulatory approval, we cannot determine if or when we will have an approved product for commercialization
or achieve sales or profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our clinical trials may not demonstrate sufficient levels of
efficacy necessary to obtain the requisite regulatory approvals for our drugs, and our proposed drugs may not be approved for marketing.
We suffered significant setbacks in the development of NOV-002 and NOV-205, as some of the promising results of earlier trials
were not demonstrated in later stage trials. As a result, following the Acquisition, development of these compounds has been suspended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We may be required to suspend or discontinue clinical trials
due to unexpected side effects or other safety risks that could preclude approval of our product candidates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our clinical trials may be suspended at any time for a number
of reasons. For example, we may voluntarily suspend or terminate our clinical trials if at any time we believe that they present
an unacceptable risk to the clinical trial patients. In addition, regulatory agencies may order the temporary or permanent discontinuation
of our clinical trials at any time if they believe that the clinical trials are not being conducted in accordance with applicable
regulatory requirements or that they present an unacceptable safety risk to the clinical trial patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Administering any product candidates to humans may produce undesirable
side effects. These side effects could interrupt, delay or halt clinical trials of our product candidates and could result in the
FDA or other regulatory authorities denying further development or approval of our product candidates for any or all targeted indications.
Ultimately, some or all of our product candidates may prove to be unsafe for human use. Moreover, we could be subject to significant
liability if any volunteer or patient suffers, or appears to suffer, adverse health effects as a result of participating in our
clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We have limited in-house research and manufacturing capacity
and will continue to rely, to some extent, on research and manufacturing facilities at various universities, hospitals, contract
research organizations and contract manufacturers for a portion of our research, development, and manufacturing. In the event we
exceed our in-house capacity or lose access to those facilities, our ability to gain FDA approval and commercialization of our
drug delivery technology and products could be delayed or impaired.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We remain in the research and development and clinical and pre-clinical
trial phase of product commercialization and have limited experience in establishing, supervising and conducting commercial manufacturing.
Accordingly, if our products are approved for commercial sale, we will need to establish the capability, or engage a contract manufacturer
that has the capability, to commercially manufacture our products in accordance with FDA and other regulatory requirements. There
can be no assurance that we would be able to successfully establish any such capability, or identify a suitable manufacturing partner
on acceptable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the present time, we have limited research, development or
manufacturing capabilities within our facilities. Our manufacturing facility in Madison, Wisconsin has adequate capacity to supply
drug product for Phase 2 studies of HOT, but we will need to expand for larger Phase 3 studies. LIGHT is currently
manufactured by our collaborator, the University of Wisconsin at Madison, in small quantities, for use in
investigator-sponsored clinical trials pursuant to a materials transfer agreement expiring in June 2013. However, this agreement
may be terminated at any time by either party. We rely and expect to continue to rely, to some extent, on contracting with third
parties to use their facilities to conduct research, development and manufacturing. The limited facilities we have to conduct research,
development and manufacturing may delay or impair our ability to gain FDA approval and commercialization of our drug delivery technology
and products.</P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may rely on third-party contract research organizations,
service providers and suppliers to support development and clinical testing of our products. This may expose us to the risks of
not being able to directly oversee the production and quality of the manufacturing process. Furthermore, these contractors, whether
foreign or domestic, may experience regulatory compliance difficulties, mechanical shutdowns, employee strikes or other unforeseeable
acts that may delay production. Failure of any of these contractors to provide the required services in a timely manner or on commercially
reasonable terms could materially delay the development and approval of our products, increase our expenses and materially harm
our business, prospects, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that we have a good working relationship with our
contractors. However, should the situation change, we may be required to relocate these activities on short notice, and we do not
currently have access to alternate facilities to which we could relocate our research, development and/or manufacturing activities.
The cost and time to establish or locate an alternate research, development and/or manufacturing facility to develop our technology
would be substantial and would delay obtaining FDA approval and commercializing our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We are exposed to product, clinical and preclinical liability
risks that could create a substantial financial burden should we be sued.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our business exposes us to potential product liability and other
liability risks that are inherent in the testing, manufacturing and marketing of pharmaceutical products. In addition, the use,
in our clinical trials, of pharmaceutical products that we or our current or potential collaborators may develop and then subsequently
sell may cause us to bear a portion of or all product liability risks. While we carry an insurance policy covering up to $5,000,000
per occurrence and $5,000,000 in the aggregate of liability incurred in connection with such claims should they arise, there can
be no assurance that our insurance will be adequate to cover all situations. Moreover, there can be no assurance that such insurance,
or additional insurance, if required, will be available in the future or, if available, will be available on commercially reasonable
terms. Furthermore, our current and potential partners with whom we have collaborative agreements or our future licensees may not
be willing to indemnify us against these types of liabilities and may not themselves be sufficiently insured or have a net worth
sufficient to satisfy any product liability claims. A successful product liability claim or series of claims brought against us
could have a material adverse effect on our business, prospects, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Acceptance of our products in the marketplace is uncertain
and failure to achieve market acceptance will prevent or delay our ability to generate revenues.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our future financial performance will depend, at least in part,
on the introduction and customer acceptance of our proposed products. Even if approved for marketing by the necessary regulatory
authorities, our products may not achieve market acceptance. The degree of market acceptance will depend on a number of factors
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">receiving regulatory clearance of marketing claims for the uses that we are developing;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">establishing and demonstrating the advantages, safety and efficacy of our technologies;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">pricing and reimbursement policies of government and third-party payers such as insurance companies,
health maintenance organizations and other health plan administrators;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">our ability to attract corporate partners, including pharmaceutical companies, to assist in commercializing
our intended products; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">our ability to market our products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Physicians, patients, payers or the medical community in general
may be unwilling to accept, use or recommend any of our products. If we are unable to obtain regulatory approval or commercialize
and market our proposed products as planned, we may not achieve any market acceptance or generate revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We may face litigation from third parties who claim that
our products infringe on their intellectual property rights, particularly because there is often substantial uncertainty about
the validity and breadth of medical patents.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may be exposed to future litigation by third parties based
on claims that our technologies, products or activities infringe on the intellectual property rights of others or that we have
misappropriated the trade secrets of others. This risk is exacerbated by the fact that the validity and breadth of claims covered
in medical technology patents and the breadth and scope of trade-secret protection involve complex legal and factual questions
for which important legal principles are unresolved. Any litigation or claims against us, whether or not valid, could result in
substantial costs, could place a significant strain on our financial and managerial resources and could harm our reputation. The
U. Mich. license does require, and license agreements that we may enter into in the future would likely require, that we pay the
costs associated with defending this type of litigation. In addition, intellectual property litigation or claims could force us
to do one or more of the following:</P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">cease selling, incorporating or using any of our technologies and/or products that incorporate
the challenged intellectual property, which would adversely affect our ability to generate revenue;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">obtain a license from the holder of the infringed intellectual property right, which license
may be costly or may not be available on reasonable terms, if at all; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">redesign our products, which would be costly and time-consuming.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we are unable to protect or enforce our rights to intellectual
property adequately or to secure rights to third-party patents, we may lose valuable rights, experience reduced market share, assuming
any, or incur costly litigation to protect our intellectual property rights.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our ability to obtain licenses to patents, maintain trade-secret
protection and operate without infringing the proprietary rights of others will be important to commercializing any products under
development. Therefore, any disruption in access to the technology could substantially delay the development of our technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The patent positions of biotechnology and pharmaceutical companies,
such as ours, that involve licensing agreements are frequently uncertain and involve complex legal and factual questions. In addition,
the coverage claimed in a patent application can be significantly reduced before the patent is issued or in subsequent legal proceedings.
Consequently, our patent applications and any issued and licensed patents may not provide protection against competitive technologies
or may be held invalid if challenged or circumvented. To the extent we license patents from third parties, as in the case of the
U. Mich. license, the early termination of any such license agreement would result in the loss of our rights to use the covered
patents, which could severely delay, inhibit or eliminate our ability to develop and commercialize compounds based on the licensed
patents. Our competitors may also independently develop products similar to ours or design around or otherwise circumvent patents
issued or licensed to us. In addition, the laws of some foreign countries may not protect our proprietary rights to the same extent
as U.S. law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also rely on trade secrets, technical know-how and continuing
technological innovation to develop and maintain our competitive position. Although we generally require our employees, consultants,
advisors and collaborators to execute appropriate confidentiality and assignment-of-inventions agreements, our competitors may
independently develop substantially equivalent proprietary information and techniques, reverse engineer our information and techniques,
or otherwise gain access to our proprietary technology. We may be unable to meaningfully protect our rights in trade secrets, technical
know-how and other non-patented technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may have to resort to litigation to protect our rights for
certain intellectual property or to determine their scope, validity or enforceability of our intellectual property rights. Enforcing
or defending our rights is expensive, could cause diversion of our resources and may not prove successful. Any failure to enforce
or protect our rights could cause us to lose the ability to exclude others from using our technology to develop or sell competing
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Confidentiality agreements with employees and others may
not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our intellectual
property, which could limit our ability to compete.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We operate in the highly technical field of research and development
of small molecule drugs, and rely in part on trade-secret protection in order to protect our proprietary trade secrets and unpatented
know-how. However, trade secrets are difficult to protect, and we cannot be certain that our competitors will not develop the same
or similar technologies on their own. We have taken steps, including entering into confidentiality agreements with our employees,
consultants, outside scientific collaborators, sponsored researchers and other advisors, to protect our trade secrets and unpatented
know-how. These agreements generally require that the other party keep confidential and not disclose to third parties all confidential
information developed by the party or made known to the party by us during the course of the party&rsquo;s relationship with us.
We also typically obtain agreements from these parties which provide that inventions conceived by the party in the course of rendering
services to us will be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual
property rights to us. Enforcing a claim that a party has illegally obtained and is using our trade secrets or know-how is difficult,
expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing
to protect trade secrets or know-how. The failure to obtain or maintain trade-secret protection could adversely affect our competitive
position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We may be subject to claims that our employees have wrongfully
used or disclosed alleged trade secrets of their former employers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As is common in the biotechnology and pharmaceutical industry,
we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors
or potential competitors. Although no claims against us are currently pending, we may be subject to claims that we or these employees
have used or disclosed trade secrets or other proprietary information of their former employers, either inadvertently or otherwise.
Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation
could result in substantial costs and be a distraction to management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The use of hazardous materials, including radioactive materials,
in our research and development imposes certain compliance costs on us and may subject us to liability for claims arising from
the use or misuse of these materials.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our research and development, manufacturing and administration
of our drugs involves the controlled use of hazardous materials, including chemicals and radioactive materials, such as radioactive
isotopes. We are subject to federal, state and local laws and regulations governing the storage, use and disposal of these materials
and some waste products and are required to maintain both a manufacturer&rsquo;s license and a radioactive materials license with
State of Wisconsin agencies. We believe that our safety procedures for the storage, use and disposal of these materials comply
with the standards prescribed by federal, state and local regulations. However, we cannot completely eliminate the risk of accidental
contamination or injury from these materials. If there were to be an accident, we could be held liable for any damages that result,
which could exceed our financial resources. We currently maintain insurance coverage, with limits of up to $2,500,000 depending
on the nature&nbsp;of the claim,&nbsp;for damages resulting from the hazardous materials we use; however, future claims may exceed
the amount of our coverage. Also, we do not have insurance coverage for pollution cleanup and removal. Currently the costs of complying
with federal, state and local regulations are not significant, and consist primarily of waste disposal expenses and permitting
fees. However, they could become expensive, and current or future environmental regulations may impair our research, development,
production and commercialization efforts. If we are unable to maintain the required licenses and permits for any reason, it will
negatively impact our research and development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Due to our limited marketing, sales and distribution experience,
we may be unsuccessful in our efforts to sell our proposed products, enter into relationships with third parties or develop a direct
sales organization.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not established marketing, sales or distribution capabilities
for our proposed products. Until such time as our proposed products are further along in the development process, we will not devote
any meaningful time and resources to this effort. At the appropriate time, we intend to develop our own sales and marketing capabilities
or enter into agreements with third parties to sell our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have limited experience in developing, training or managing
a sales force. If we choose to establish a direct sales force, we may incur substantial additional expenses in developing, training
and managing such an organization. We may be unable to build a sales force on a cost-effective basis or at all. Any such direct
marketing and sales efforts may prove to be unsuccessful. In addition, we will compete with many other companies that currently
have extensive marketing and sales operations. Our marketing and sales efforts may be unable to compete against these other companies.
We may be unable to establish a sufficient sales and marketing organization on a timely basis, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we choose to enter into agreements with third parties to
sell our proposed products, we may be unable to establish or maintain third-party relationships on a commercially reasonable basis,
if at all. In addition, these third parties may have similar or more established relationships with our competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may be unable to engage qualified distributors. Even if engaged,
these distributors may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">fail to adequately market our products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">fail to satisfy financial or contractual obligations to us;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">offer, design, manufacture or promote competing products; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">cease operations with little or no notice.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we fail to develop sales, marketing and distribution channels,
we would experience delays in product sales and incur increased costs, which would have a material adverse effect on our business,
prospects, financial condition, and results of operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we are unable to convince physicians of the benefits of
our intended products, we may incur delays or additional expense in our attempt to establish market acceptance.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Achieving use of our products in the target market of cancer
diagnosis and treatment may require physicians to be informed regarding these products and their intended benefits. The time and
cost of such an educational process may be substantial. Inability to successfully carry out this physician education process may
adversely affect market acceptance of our proposed products. We may be unable to timely educate physicians regarding our intended
proposed products in sufficient numbers to achieve our marketing plans or to achieve product acceptance. Any delay in physician
education may materially delay or reduce demand for our proposed products. In addition, we may expend significant funds towards
physician education before any acceptance or demand for our proposed products is created, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The market for our proposed products is rapidly changing
and competitive, and new therapeutics, new drugs and new treatments that may be developed by others could impair our ability to
maintain and grow our business and remain competitive.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The pharmaceutical and biotechnology industries are subject
to rapid and substantial technological change. Developments by others may render our technologies and intended products noncompetitive
or obsolete, or we may be unable to keep pace with technological developments or other market factors. Technological competition
from pharmaceutical and biotechnology companies, universities, governmental entities and others diversifying into the field is
intense and is expected to increase. Most of these entities have significantly greater research and development capabilities and
budgets than we do, as well as substantially more marketing, manufacturing, financial and managerial resources. These entities
represent significant competition for us. Acquisitions of, or investments in, competing pharmaceutical or biotechnology companies
by large corporations could increase our competitors&rsquo; financial, marketing, manufacturing and other resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our resources are limited and we may experience management,
operational or technical challenges inherent in such activities and novel technologies. Competitors have developed or are in the
process of developing technologies that are, or in the future may be, the basis for competition. Some of these technologies may
accomplish therapeutic effects similar to those of our technology, but through different means. Our competitors may develop drugs
and drug delivery technologies that are more effective than our intended products and, therefore, present a serious competitive
threat to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not know of any current or potential direct competitors
for HOT and LIGHT. Marketed drugs Zevalin&reg; (Spectrum Pharmaceuticals) and Bexxar&reg; (Glaxo Smith Kline) provide examples
of targeted radiotherapeutics specifically for lymphoma indication. FDG is the current standard for PET imaging for cancer and
may be an alternative diagnostic imaging agent to LIGHT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The potential widespread acceptance of therapies that are alternatives
to ours may limit market acceptance of our products even if they are commercialized. Many of our targeted diseases and conditions
can also be treated by other medication or drug delivery technologies. These treatments may be widely accepted in medical communities
and have a longer history of use. The established use of these competitive drugs may limit the potential for our technologies and
products to receive widespread acceptance if commercialized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If users of our products are unable to obtain adequate reimbursement
from third-party payers, or if additional healthcare reform measures are adopted, it could hinder or prevent our product candidates&rsquo;
commercial success.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The continuing efforts of government and insurance companies,
health maintenance organizations and other payers of healthcare costs to contain or reduce costs of healthcare may adversely affect
our ability to generate future revenues and achieve profitability, including by limiting the future revenues and profitability
of our potential customers, suppliers and collaborative partners. For example, in certain foreign markets, pricing or profitability
of prescription pharmaceuticals is subject to government control. The U.S. government and other governments have shown significant
interest in pursuing healthcare reform. Any government-adopted reform measures could adversely affect the pricing of healthcare
products and services in the U.S. or internationally and the amount of reimbursement available from governmental agencies or other
third-party payers. The continuing efforts of the U.S. and foreign governments, insurance companies, managed care organizations
and other payers of healthcare services to contain or reduce healthcare costs may adversely affect our ability to set prices for
our products, should we be successful in commercializing them, and this would negatively affect our ability to generate revenues
and achieve and maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New laws, regulations and judicial decisions, or new interpretations
of existing laws, regulations and decisions, that relate to healthcare availability, methods of delivery or payment for healthcare
products and services, or sales, marketing or pricing of healthcare products and services, also may limit our potential revenue
and may require us to revise our research and development programs. The pricing and reimbursement environment may change in the
future and become more challenging for several reasons, including policies advanced by the current or future executive administrations
in the U.S., new healthcare legislation or fiscal challenges faced by government health administration authorities. Specifically,
in both the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the
healthcare system in ways that could affect our ability to sell our products profitably. In the U.S., changes in federal healthcare
policy were enacted in 2010 and remain the subject of continued reconsideration by Congress. Some proposed reforms could result
in reduced reimbursement rates for our product candidates, which would adversely affect our business strategy, operations and financial
results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our ability to commercialize our products will depend in part
on the extent to which appropriate reimbursement levels for the cost of our products and related treatment are obtained by governmental
authorities, private health insurers and other organizations, such as health maintenance organizations (HMOs). Third-party payers
are increasingly challenging the prices charged for medical drugs and services. Also, the trend toward managed healthcare in the
U.S. and the concurrent growth of organizations such as HMOs that could control or significantly influence the purchase of healthcare
services and drugs, as well as legislative proposals to reform healthcare or change government insurance programs, may all result
in lower prices for or rejection of our drugs. The cost containment measures that healthcare payers and providers are instituting
and the effect of any healthcare reform could materially harm our ability to operate profitably.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We depend on key personnel who may terminate their employment
with us at any time, and our success will depend on our ability to hire additional qualified personnel.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our success will depend to a significant degree on the continued
services of our chief executive officer, Harry Palmin, Cellectar founder and our chief scientific officer, Dr. Jamey Weichert,
and our senior vice president of research and development, Dr. Christopher Pazoles. There can be no assurance that these individuals
will continue to provide services to us. In addition, our success may depend on our ability to attract and retain other highly
skilled personnel. We may be unable to recruit such personnel on a timely basis, if at all. Our management and other employees
may voluntarily terminate their employment with us at any time. The loss of services of key personnel, or the inability to attract
and retain additional qualified personnel, could result in delays in development or approval of our products, loss of sales and
diversion of management resources. To date, we have not experienced difficulties attracting and retaining highly qualified personnel,
but there can be no assurance we will be successful in doing so in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>Our stock price has experienced price fluctuations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There can be no assurance that the market price for our common
stock will remain at its current level and a decrease in the market price could result in substantial losses for investors. The
market price of our common stock may be significantly affected by one or more of the following factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">announcements or press releases relating to the biopharmaceutical sector or to our own business
or prospects;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">regulatory, legislative, or other developments affecting us or the healthcare industry generally;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">sales by holders of restricted securities pursuant to effective registration statements or exemptions
from registration; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">market conditions specific to biopharmaceutical companies, the healthcare industry and the stock
market generally.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Five of our stockholders beneficially&nbsp;own approximately
60% of our outstanding common stock, which limits the influence of other stockholders. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 5, 2012, 60% of our outstanding common stock
is&nbsp;beneficially owned&nbsp;by five stockholders. The interests of these stockholders may differ from those of other stockholders.
These stockholders will likely continue to have the ability to significantly affect the outcome of all corporate actions requiring
stockholder approval, including the following actions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">the election of directors;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">the amendment of charter documents; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.95pt"></TD><TD STYLE="width: 28pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">the approval of certain mergers and other significant corporate transactions, including a sale
of substantially all of our assets.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>There may be a limited public market for our securities;
we presently fail to qualify for listing on any national securities exchanges.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock currently does not meet all of the requirements
for initial listing on a registered stock exchange. Specifically, our cash on hand is not sufficient to fund operations for twelve
months and the bid price of our common stock is less than the minimum bid price required to obtain a listing. Trading in our common
stock continues to be conducted in the over-the-counter market (currently the OTCQX). As a result, an investor may find it difficult
to dispose of or to obtain accurate quotations as to the market value of our common stock, and our common stock may be less attractive
for margin loans, or for investment by financial institutions, as consideration in future capital raising transactions or other
contexts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our common stock has historically been a &ldquo;penny stock&rdquo;
under SEC rules. It may be more difficult to resell shares of common stock classified as &ldquo;penny stock&rdquo;.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock has historically been a &ldquo;penny stock&rdquo;
under applicable SEC rules (generally defined as non-exchange traded stock with a per-share price below $5.00). These rules impose
additional sales practice requirements on broker-dealers that recommend the purchase or sale of penny stocks to persons other
than those who qualify as &ldquo;established customers&rdquo; or &ldquo;accredited investors.&rdquo; For example, broker-dealers
must determine the appropriateness for non-qualifying persons of investments in penny stocks. Broker-dealers must also provide,
prior to a transaction in a penny stock not otherwise exempt from the rules, a standardized risk disclosure document that provides
information about penny stocks and the risks in the penny stock market. The broker-dealer also must provide the customer with
current bid and offer quotations for the penny stock, disclose the compensation of the broker-dealer and its salesperson in the
transaction, furnish monthly account statements showing the market value of each penny stock held in the customer&rsquo;s account,
provide a special written determination that the penny stock is a suitable investment for the purchaser, and receive the purchaser&rsquo;s
written agreement to the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Legal remedies available to an investor in &quot;penny stocks&quot;
may include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">if
                                                                                                             a &quot;penny stock&quot;
                                                                                                             is sold to the investor
                                                                                                             in violation of the
                                                                                                             requirements listed
                                                                                                             above, or other federal
                                                                                                             or states securities
                                                                                                             laws, the investor
                                                                                                             may be able to cancel
                                                                                                             the purchase and
                                                                                                             receive a refund
                                                                                                             of the investment.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">if
                                                                                                             a &ldquo;penny stock&rdquo;
                                                                                                             is sold to the investor
                                                                                                             in a fraudulent manner,
                                                                                                             the investor may
                                                                                                             be able to sue the
                                                                                                             persons and firms
                                                                                                             that committed the
                                                                                                             fraud for damages.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">However, investors who have signed arbitration agreements may
have to pursue their claims through arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These requirements may have the effect of reducing the level
of trading activity, if any, in the secondary market for a security that becomes subject to the penny stock rules. The additional
burdens imposed upon broker-dealers by such requirements may discourage broker-dealers from effecting transactions in our securities,
which could severely limit the market price and liquidity of our securities. These requirements may restrict the ability of broker-dealers
to sell our common stock and may affect your ability to resell our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Many brokerage firms will discourage or refrain from recommending
investments in penny stocks. Most institutional investors will not invest in penny stocks. In addition, many individual investors
will not invest in penny stocks due, among other reasons, to the increased financial risk generally associated with these investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For these reasons, penny stocks may have a limited market and,
consequently, limited liquidity. We can give no assurance at what time, if ever, our common stock will not be classified as a
&ldquo;penny stock&rdquo; in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we fail to maintain effective internal controls over
financial reporting, the price of our common stock may be adversely affected.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our internal control over financial reporting may have weaknesses
and conditions that could require correction or remediation, the disclosure of which may have an adverse impact on the price of
our common stock. We are required to establish and maintain appropriate internal controls over financial reporting. Failure to
establish those controls, or any failure of those controls once established, could adversely affect our public disclosures regarding
our business, prospects, financial condition or results of operations. In addition, management&rsquo;s assessment of internal
controls over financial reporting may identify weaknesses and conditions that need to be addressed in our internal controls over
financial reporting or other matters that may raise concerns for investors. Any actual or perceived weaknesses and conditions
that need to be addressed in our internal control over financial reporting or disclosure of management&rsquo;s assessment of our
internal controls over financial reporting may have an adverse impact on the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We are required to comply with certain provisions of Section
404 of the Sarbanes-Oxley Act of 2002 and if we fail to continue to comply, our business could be harmed and our stock price could
decline. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rules adopted by the SEC pursuant to Section 404 of the Sarbanes-Oxley
Act of 2002 require an annual assessment of internal controls over financial reporting, and for certain issuers an attestation
of this assessment by the issuer&rsquo;s independent registered public accounting firm. The standards that must be met for management
to assess the internal controls over financial reporting as effective are evolving and complex, and require significant documentation,
testing, and possible remediation to meet the detailed standards. We expect to incur significant expenses and to devote resources
to Section 404 compliance on an ongoing basis. It is difficult for us to predict how long it will take or costly it will be to
complete the assessment of the effectiveness of our internal control over financial reporting for each year and to remediate any
deficiencies in our internal control over financial reporting. As a result, we may not be able to complete the assessment and
remediation process on a timely basis. In addition, although attestation requirements by our independent registered public accounting
firm are not presently applicable to us we could become subject to these requirements in the future and we may encounter problems
or delays in completing the implementation of any resulting changes to internal controls over financial reporting. In the event
that our Chief Executive Officer or Chief Financial Officer determine that our internal control over financial reporting is not
effective as defined under Section 404, we cannot predict how regulators will react or how the market prices of our shares will
be affected; however, we believe that there is a risk that investor confidence and share value may be negatively affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our common stock could be further diluted as the result
of the issuance of additional shares of common stock, convertible securities, warrants or options.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the past, we have issued common stock, convertible securities
(such as convertible preferred stock and notes) and warrants in order to raise money. We have also issued options and warrants
as compensation for services and incentive compensation for our employees and directors. We have shares of common stock reserved
for issuance upon the exercise of certain of these securities and may increase the shares reserved for these purposes in the future.
Our issuance of additional common stock, convertible securities, options and warrants could affect the rights of our stockholders,
could reduce the market price of our common stock or could result in adjustments to exercise prices of outstanding warrants (resulting
in these securities becoming exercisable for, as the case may be, a greater number of shares of our common stock), or could obligate
us to issue additional shares of common stock to certain of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shares eligible for future sale may adversely affect the
market.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, certain of our stockholders may be eligible
to sell all or some of their shares of common stock by means of ordinary brokerage transactions in the open market pursuant to
Rule 144 promulgated under the Securities Act, subject to certain limitations. In general, pursuant to amended Rule 144, non-affiliate
stockholders may sell freely after six months subject only to the current public information requirement. Affiliates may sell
after six months subject to the Rule 144 volume, manner of sale (for equity securities), current public information and notice
requirements. Of the approximately&nbsp;38 million shares of our common stock outstanding as of June 5, 2012, approximately 13.2
million shares are tradable without restriction, and approximately an additional 15.2 million shares that had been issued in unregistered
transactions and are held by non-affiliates are tradable without time or volume limitations pursuant to Rule 144. We are obligated
to register the resale of an additional 4,000,000 shares of our common stock. Any substantial resales of our common stock pursuant
to Rule 144 or an effective registration statement may have a material adverse effect on the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Provisions of our charter, bylaws, and Delaware law may
make an acquisition of us or a change in our management more difficult.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain provisions of our amended restated certificate of incorporation
and bylaws could discourage, delay or prevent a merger, acquisition or other change in control that stockholders may consider
favorable, including transactions in which an investor might otherwise receive a premium for their shares. These provisions also
could limit the price that investors might be willing to pay in the future for shares of our common stock or warrants, thereby
depressing the market price of our common stock. Stockholders who wish to participate in these transactions may not have the opportunity
to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Furthermore, these provisions could prevent or frustrate attempts
by our stockholders to replace or remove our management. These provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&bull;</B></FONT></TD><TD><FONT STYLE="font-size: 10pt">provide
                                                                                                                                           for
                                                                                                                                           the
                                                                                                                                           division
                                                                                                                                           of
                                                                                                                                           our
                                                                                                                                           board
                                                                                                                                           into
                                                                                                                                           three
                                                                                                                                           classes
                                                                                                                                           as
                                                                                                                                           nearly
                                                                                                                                           equal
                                                                                                                                           in
                                                                                                                                           size
                                                                                                                                           as
                                                                                                                                           possible
                                                                                                                                           with
                                                                                                                                           staggered
                                                                                                                                           three-year
                                                                                                                                           terms
                                                                                                                                           and
                                                                                                                                           further
                                                                                                                                           limit
                                                                                                                                           the
                                                                                                                                           removal
                                                                                                                                           of
                                                                                                                                           directors
                                                                                                                                           and
                                                                                                                                           the
                                                                                                                                           filling
                                                                                                                                           of
                                                                                                                                           vacancies;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&bull;</B></FONT></TD><TD><FONT STYLE="font-size: 10pt">authorize
                                                                                                                                           our
                                                                                                                                           board
                                                                                                                                           of
                                                                                                                                           directors
                                                                                                                                           to
                                                                                                                                           issue
                                                                                                                                           without
                                                                                                                                           stockholder
                                                                                                                                           approval
                                                                                                                                           blank-check
                                                                                                                                           preferred
                                                                                                                                           stock
                                                                                                                                           that,
                                                                                                                                           if
                                                                                                                                           issued,
                                                                                                                                           could
                                                                                                                                           operate
                                                                                                                                           as
                                                                                                                                           a
                                                                                                                                           &ldquo;poison
                                                                                                                                           pill&rdquo;
                                                                                                                                           to
                                                                                                                                           dilute
                                                                                                                                           the
                                                                                                                                           stock
                                                                                                                                           ownership
                                                                                                                                           of
                                                                                                                                           a
                                                                                                                                           potential
                                                                                                                                           hostile
                                                                                                                                           acquirer
                                                                                                                                           to
                                                                                                                                           prevent
                                                                                                                                           an
                                                                                                                                           acquisition
                                                                                                                                           that
                                                                                                                                           is
                                                                                                                                           not
                                                                                                                                           approved
                                                                                                                                           by
                                                                                                                                           our
                                                                                                                                           board
                                                                                                                                           of
                                                                                                                                           directors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&bull;</B></FONT></TD><TD><FONT STYLE="font-size: 10pt">require
                                                                                                                                           that
                                                                                                                                           stockholder
                                                                                                                                           actions
                                                                                                                                           must
                                                                                                                                           be
                                                                                                                                           effected
                                                                                                                                           at
                                                                                                                                           a
                                                                                                                                           duly
                                                                                                                                           called
                                                                                                                                           stockholder
                                                                                                                                           meeting
                                                                                                                                           and
                                                                                                                                           prohibit
                                                                                                                                           stockholder
                                                                                                                                           action
                                                                                                                                           by
                                                                                                                                           written
                                                                                                                                           consent;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&bull;</B></FONT></TD><TD><FONT STYLE="font-size: 10pt">establish
                                                                                                                                           advance
                                                                                                                                           notice
                                                                                                                                           requirements
                                                                                                                                           for
                                                                                                                                           stockholder
                                                                                                                                           nominations
                                                                                                                                           to
                                                                                                                                           our
                                                                                                                                           board
                                                                                                                                           of
                                                                                                                                           directors
                                                                                                                                           or
                                                                                                                                           for
                                                                                                                                           stockholder
                                                                                                                                           proposals
                                                                                                                                           that
                                                                                                                                           can
                                                                                                                                           be
                                                                                                                                           acted
                                                                                                                                           on
                                                                                                                                           at
                                                                                                                                           stockholder
                                                                                                                                           meetings;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&bull;</B></FONT></TD><TD><FONT STYLE="font-size: 10pt">limit
                                                                                                                                           who
                                                                                                                                           may
                                                                                                                                           call
                                                                                                                                           stockholder
                                                                                                                                           meetings;
                                                                                                                                           and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&bull;</B></FONT></TD><TD><FONT STYLE="font-size: 10pt">require
                                                                                                                                           the
                                                                                                                                           approval
                                                                                                                                           of
                                                                                                                                           the
                                                                                                                                           holders
                                                                                                                                           of
                                                                                                                                           75%
                                                                                                                                           of
                                                                                                                                           the
                                                                                                                                           outstanding
                                                                                                                                           shares
                                                                                                                                           of
                                                                                                                                           our
                                                                                                                                           capital
                                                                                                                                           stock
                                                                                                                                           entitled
                                                                                                                                           to
                                                                                                                                           vote
                                                                                                                                           in
                                                                                                                                           order
                                                                                                                                           to
                                                                                                                                           amend
                                                                                                                                           certain
                                                                                                                                           provisions
                                                                                                                                           of
                                                                                                                                           our
                                                                                                                                           restated
                                                                                                                                           certificate
                                                                                                                                           of
                                                                                                                                           incorporation
                                                                                                                                           and
                                                                                                                                           restated
                                                                                                                                           bylaws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, because we are incorporated in Delaware, we are
governed by the provisions of Section 203 of the Delaware General Corporation Law, which may, unless certain criteria are met,
prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining
with us for a prescribed period of time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We have not paid dividends in the past and do not expect
to pay dividends for the foreseeable future. Any return on investment may be limited to the value of our common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No cash dividends have been paid on Novelos common stock. We
do not expect to pay cash dividends in the near future. Payment of dividends would depend upon our profitability at the time,
cash available for those dividends, and other factors as our board of directors may consider relevant. If we do not pay dividends,
our common stock may be less valuable because a return on an investor&rsquo;s investment will only occur if our stock price appreciates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>Risks Related
to this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our management team will have immediate and broad discretion
over the use of the net proceeds from this offering and we may use the net proceeds in ways with which you disagree.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There is no minimum offering amount required as a condition
to closing this offering and therefore net proceeds from this offering will be immediately available to our management to use
at their discretion. We currently intend to use the net proceeds from this offering to fund our research and development activities,
for general corporate purposes, and possibly for acquisitions of other companies, products or technologies, though no such acquisitions
are currently contemplated. See &ldquo;Use of Proceeds.&rdquo; We have not allocated specific amounts of the net proceeds from
this offering for any of the foregoing purposes. Accordingly, our management will have significant discretion and flexibility
in applying the net proceeds of this offering. You will be relying on the judgment of our management with regard to the use of
these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds
are being used appropriately. It is possible that the net proceeds will be invested in a way that does not yield a favorable,
or any, return for us or our stockholders. The failure of our management to use such funds effectively could have a material adverse
effect on our business, prospects, financial condition, and results of operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>You will experience immediate and substantial dilution as
a result of this offering and may experience additional dilution</B> <B>in the future.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You will incur immediate and substantial dilution as a
result of this offering. After giving effect to the sale by us of up to&nbsp;$5,420,800 in units offered in this offering, at
an assumed public offering price of $1.00 per unit, and after deducting the placement agent fees
estimated offering expenses payable by us, investors in this offering can expect an immediate dilution of
$0.75 per share, or 75%, at the assumed public offering
price, assuming no exercise of the warrants. In addition, in the past, we issued options and warrants to acquire shares of
common stock. To the extent these options are ultimately exercised, you will sustain future dilution. We may also acquire or
license other technologies or finance strategic alliances by issuing equity, which may result in additional dilution to our
stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>There is no public market for the warrants to purchase common
stock in this offering.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There is no established public trading market for the warrants
being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply for listing the
warrants on any securities exchange. Without an active market, the liquidity of the warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If you are not an institutional investor, you may purchase
shares in this offering only if you reside within the states in which we will apply to have the securities registered or are exempt
from registration, and, if required, meet any requisite suitability standards.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Because our common stock is quoted on the on the over-the-counter
market (currently the OTCQX) and not listed on a national securities exchange, this offering must be registered, or be exempt
from registration, in any state in which the units are to be offered or sold. We will apply to register the units, or will seek
to obtain an exemption from registration, only in certain states. In addition, if we register the units in the State of California,
sales will only be made to residents of California who have not less than (i) a $60,000 liquid net worth (exclusive of home, home
furnishings and automobile) plus $60,000 gross annual income, or (ii) a $225,000 liquid net worth. Investors in Wisconsin must
qualify as &ldquo;Accredited Investors&rdquo; as that term is defined in Rule 501(a) of Regulation D under the Securities Act
of 1933, as amended, and modified by Section 413 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010. If
you are not an &ldquo;institutional investor,&rdquo; you must be a resident of these jurisdictions to purchase our shares in the
offering. The definition of an &ldquo;institutional investor&rdquo; varies from state to state, but generally includes financial
institutions, broker-dealers, banks, insurance companies and other qualified entities. If you are not an institutional investor,
you may purchase shares in this offering only if you reside in the jurisdictions where there is an effective registration or exemption,
and, if required, meet any requisite suitability standards. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The offering may not be fully subscribed, and, even if the
offering is fully subscribed, we will need additional capital in the future. If additional capital is not available, we may not
be able to continue to operate our business pursuant to our business plan or we may have to discontinue our operations entirely.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The placement agent in this offering will offer the securities
on a &ldquo;reasonable best efforts&rdquo; basis, meaning that we may raise substantially less than the total maximum offering
amounts. We will not provide any refund to investors if less than all of the units are sold. Therefore, in evaluating the offering,
you should not assume that we will receive all of the proceeds from this offering that we would receive if all the units are sold.
If the offering is not fully subscribed, the length of time we will be able to fund our operations with the proceeds will be shortened,
as we do not generate positive cash flow. In order to continue to fund our operations, we would likely have to raise additional
proceeds through debt or equity financing activities. Any equity financings will likely be dilutive to existing stockholders,
and any debt financings will likely involve covenants restricting our business activities. Additional financing may not be available
on acceptable terms, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus, including the documents that we incorporate
by reference, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended
(the Securities Act), and Section 21E of the Exchange Act. Such forward-looking statements include those that express plans, anticipation,
intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. These forward-looking
statements are based on our current expectations and projections about future events and they are subject to risks and uncertainties
known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In some cases, you can identify forward-looking statements
by terminology, such as &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;plans,&rdquo;
&ldquo;believes,&rdquo; &ldquo;seeks,&rdquo; &ldquo;may,&rdquo; &ldquo;should&rdquo;, &ldquo;could&rdquo; or the negative of such
terms or other similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties that could
cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their
entirety by reference to the factors discussed throughout this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should read this prospectus and the documents that we reference
herein and therein and have filed as exhibits to the registration statement, of which this prospectus is part, completely and
with the understanding that our actual future results may be materially different from what we expect. You should assume that
the information appearing in this prospectus is accurate as of the date on the front cover of this prospectus or such prospectus
supplement only. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those
expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking
statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation
to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to
reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict
which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor,
or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
We qualify all of the information presented in this prospectus and any accompanying prospectus supplement, and particularly our
forward-looking statements, by these cautionary statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on an assumed public offering price of $ 1.00 per
unit, we estimate that the net proceeds to us from the sale of the&nbsp;securities that we are offering, assuming gross
proceeds of $5.4 million, assuming the offering is fully
subscribed, will be approximately $4.8 million, after
deducting the placement agent fee and estimated offering expenses. In addition, if all of the warrants included in the units
offered pursuant to this prospectus are exercised in full for cash, we will receive approximately an
additional $8.8 million in cash.&nbsp;&nbsp;However, the
warrants contain a cashless exercise provision that permit exercise of warrants on a cashless basis at any time where there
is no effective registration statement under the Securities Act of 1933, as amended, covering the issuance of the underlying
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may not be successful in selling any or all of the securities
offered hereby. Because there is no minimum offering amount required as a condition to closing in this offering, we may sell less
than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect to use any proceeds received from this offering as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">to
                                                                                                             fund our research
                                                                                                             and development activities,
                                                                                                             including the further
                                                                                                             development of our
                                                                                                             LIGHT and HOT compounds
                                                                                                             in a wide range of
                                                                                                             cancers; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">for
                                                                                                             general corporate
                                                                                                             purposes, such as
                                                                                                             general and administrative
                                                                                                             expenses, capital
                                                                                                             expenditures, working
                                                                                                             capital, prosecution
                                                                                                             and maintenance of
                                                                                                             our intellectual
                                                                                                             property, and the
                                                                                                             potential investment
                                                                                                             in technologies or
                                                                                                             products that complement
                                                                                                             our business.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We believe that our cash on hand, together with the
net proceeds from this offering (assuming $5.4 million of units are sold in this offering and no exercise of the warrants
being issued pursuant to the offering) would be adequate to fund operations into the second quarter of 2013. We estimate that
our&nbsp;costs during that time will be&nbsp;approximately $8.6 million. This amount consists of
approximately $2.0 million for HOT development, approximately $0.6 million for LIGHT development, approximately $3.4 million
for general, fixed and overhead research and development expenses that are not allocated to specific projects and
approximately $2.6 million in general and administrative costs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The above cost estimates contemplate the following clinical
development activity:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol"> &middot; </FONT></TD><TD><FONT STYLE="font-size: 10pt"> completion
                                                                                                             of the investigator-sponsored
                                                                                                             LIGHT Phase 1-2 imaging
                                                                                                             trials in&nbsp;lung
                                                                                                             cancer and brain
                                                                                                             cancer in the fourth
                                                                                                             quarter of 2012 which
                                                                                                             we anticipate will
                                                                                                             generate additional
                                                                                                             proof-of-concept
                                                                                                             data in the second
                                                                                                             quarter of 2012 and,
                                                                                                             when completed, will
                                                                                                             enable calculation
                                                                                                             of efficacious doses
                                                                                                             of HOT for Phase
                                                                                                             2 trials in these
                                                                                                             indications; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>initiation
                                                                                                               and completion
                                                                                                               of an investigator-sponsored
                                                                                                               LIGHT Phase1-2
                                                                                                               imaging trial in
                                                                                                               solid tumors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>continuation
                                                                                                               of the HOT Phase
                                                                                                               1b dose-escalation
                                                                                                               trial; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">initiation
of a HOT Phase 2 trial in lung cancer or brain cancer in the first quarter of 2013 which we anticipate will generate initial efficacy
data in mid-2013.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We estimate that an additional $11.2 million in funding will
be required in order to operate through the completion of the HOT Phase 1b dose-escalation trial and HOT Phase 2 trials in two
cancer indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have no current understandings, commitments or agreements
with respect to any acquisition of or investment in any technologies or products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Even if we sell all of the securities subject to this offering
on favorable terms, of which there can be no assurance, we will still need to obtain additional financing in the future in order
to fully fund these product candidates through the regulatory approval process. We may seek such additional financing through
public or private equity or debt offerings or other sources, including collaborative or other arrangements with corporate partners,
and through government grants and contracts. There can be no assurance we will be able to obtain such additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although we currently anticipate that we will use the net proceeds
of this offering as described above, there may be circumstances where a reallocation of funds may be necessary. The amounts and
timing of our actual expenditures will depend upon numerous factors, including the progress of our development and commercialization
efforts, the progress of our clinical studies, whether or not we enter into strategic collaborations or partnerships and our operating
costs and expenditures. Accordingly, our management will have significant flexibility in applying the net proceeds of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The costs and timing of drug development and regulatory approval,
particularly conducting clinical studies, are highly uncertain, are subject to substantial risks and can often change. Accordingly,
we may change the allocation of use of these proceeds as a result of contingencies such as the progress and results of our clinical
studies and other development activities, the establishment of collaborations, our manufacturing requirements and regulatory or
competitive developments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending the application of the net proceeds as described above
or otherwise, we may invest the proceeds in short-term, investment-grade, interest-bearing securities or guaranteed obligations
of the U.S. government or other securities.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>CAPITALIZATION
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The following table sets forth our cash and cash equivalents
and capitalization, each as of March 31, 2012: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">on
                                                                                                             an actual basis; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">on
                                                                                                             a pro forma as adjusted
                                                                                                             basis to give effect
                                                                                                             to the issuance of
                                                                                                             the&nbsp;securities
                                                                                                             offered hereby.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should consider this table in conjunction with our financial
statements and the notes to those financial statements included elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> As&nbsp;of&nbsp;March&nbsp;31,&nbsp;2012 </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Actual </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B> Pro&nbsp;Forma&nbsp;As </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B> Adjusted&nbsp;(1) </B></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 69%; text-align: left; text-indent: -0.25in; padding-left: 0.25in"> Cash and cash equivalents </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 3,787,576 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 13%; text-align: right">8,587,576</TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 0.25in"> Wisconsin Department of Commerce Loan </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 450,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp;450,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 0.25in; padding-bottom: 1pt"> Capital lease obligations </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"> &nbsp; </TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"> 5,782 </TD><TD STYLE="text-align: left; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"> &nbsp; </TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"> 5,782 </TD><TD STYLE="text-align: left; padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 0.25in"> Total debt obligations </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 455,782 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp;455,782  </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 0.25in"> Stockholders&rsquo; equity (deficit): </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 0.25in"> Common stock, par value $0.00001 per share: 150,000,000 shares authorized;
    36,962,264 issued as of March 31, 2012 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 369 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 423 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 27pt"> Additional paid in capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 41,398,287 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 46,198,233 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 27pt; padding-bottom: 1pt"> Deficit accumulated during
    the development stage </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"> &nbsp; </TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"> (33,837,329 </TD><TD STYLE="text-align: left; padding-bottom: 1pt"> ) </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"> &nbsp; </TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"> (33,837,329 </TD><TD STYLE="text-align: left; padding-bottom: 1pt"> )</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 0.25in"> Total stockholders&rsquo; equity </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,561,327 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 12,361,327 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 0.25in; padding-bottom: 2.5pt"> Total capitalization </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"> $ </TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"> 8,017,109 </TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"> $ </TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"> 12,817,109 </TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<HR NOSHADE SIZE="1" STYLE="color: Black; width: 10%; margin-top: 0; margin-bottom: 0">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD><FONT STYLE="font-size: 10pt">Assumes
                                                                                                 that $5.4 million of&nbsp;units&nbsp;are&nbsp;sold
                                                                                                 in this offering at an assumed
                                                                                                 offering price of $1.00 per&nbsp;unit
                                                                                                 and that the net proceeds thereof
                                                                                                 are approximately $4.8 million after
                                                                                                 placement agent fees and estimated
                                                                                                 offering expenses.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>MARKET FOR COMMON
EQUITY AND RELATED STOCKHOLDER MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Market Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock was quoted on the OTC Bulletin Board under
the symbol NVLT beginning on June 14, 2005 and until February 16, 2012, since which time it has been quoted on the OTCQX platform.
The following table provides, for the periods indicated, the high and low bid prices for our common stock. These over-the-counter
market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission, and may not represent actual transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Fiscal&nbsp;Year&nbsp;2010</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 72%; text-align: left">First Quarter</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">466.36</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">26.16</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42.66</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14.67</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23.08</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.17</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.82</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: none; text-align: left; padding-bottom: 1pt"><P STYLE="font-weight: bold; border-bottom: Black 1pt solid"><B>Fiscal
                                                                                                Year 2011</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">High</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">Low</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">First Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.52</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.82</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.95</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.55</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.13</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.39</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.33</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid"> Fiscal&nbsp;Year&nbsp;2012 </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"> &nbsp; High</TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"> &nbsp; Low</TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 72%; text-align: left"> First Quarter </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 0.99 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 0.40 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second Quarter (through June 5, 2012)</TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2.20 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.75 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The above share prices have been adjusted to&nbsp;give effect
to&nbsp;a 1-for-153 reverse split of our common stock completed April 8, 2011 in connection with the Acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 5, 2012 there were 360 holders of record of our
common stock. This number does not include stockholders for whom shares were held in a &ldquo;nominee&rdquo; or &ldquo;street&rdquo;
name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not declared or paid any cash dividends on our common
stock and do not anticipate declaring or paying any cash dividends in the foreseeable future. We currently expect to retain future
earnings, if any, for the development of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our transfer agent and registrar is American Stock Transfer
and Trust Company, 59 Maiden Lane, New York, NY 10038.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Equity compensation plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table provides information as of December 31,
2011 regarding shares authorized for issuance under our equity compensation plans, including individual compensation arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have two equity compensation plans approved by our stockholders:&nbsp;&nbsp;the
2000 Stock Option and Incentive Plan and the 2006 Stock Incentive Plan.&nbsp;&nbsp;During 2004 and 2005, we also issued options
to our directors and consultants that were not approved by our stockholders and during 2011 we issued options to certain consultants
that were not approved by our stockholders.&nbsp;&nbsp;These options are exercisable within a ten-year period from the date of
the grant and vest at various intervals with all options being fully vested within three years of the date of grant.&nbsp;&nbsp;The
option price per share is not less than the fair market value of our common stock on the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>Equity compensation
plan information</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Plan&nbsp;category</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;shares&nbsp;to
    be&nbsp;issued&nbsp;upon exercise&nbsp;of&nbsp;outstanding options,&nbsp;warrants&nbsp;and rights&nbsp;(#)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-average exercise&nbsp;price&nbsp;of
    outstanding&nbsp;options, warrants&nbsp;and&nbsp;rights ($)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;shares remaining&nbsp;available&nbsp;for
    future&nbsp;issuance&nbsp;under equity&nbsp;compensation&nbsp;plans (excluding&nbsp;shares&nbsp;reflected in&nbsp;column&nbsp;(a))&nbsp;(#)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(a)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(b)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(c)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 58%; text-align: left; text-indent: -9pt; padding-left: 9pt">Equity compensation plans approved by stockholders</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">4,717,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1.63</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,281,112</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Equity compensation plans not approved
    by stockholders</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">110,138</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">10.16</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,827,638</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">1.82</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,281,112</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Our pro forma net tangible book value as of March 31, 2012
was $5,885,865, or $0.16 per share of common stock, based upon 36,962,264 shares outstanding as of that date. Net&nbsp;tangible
book value per share is determined by dividing such number of outstanding shares of common stock into our net tangible book value,
which is our total tangible assets less total liabilities. After giving effect to the sale of the&nbsp;securities in this offering
at the assumed public offering price of $1.00 per unit, after deducting the placement agent fee and
other estimated offering expenses payable by us, our pro forma as adjusted net tangible book value at March 31, 2012 would have
been approximately $10.7 million, or $0.25 per share. This represents
an immediate increase in net tangible book value of approximately $0.09 per share to our existing stockholders,
and an immediate dilution of $0.75 per share to investors purchasing securities in the offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table illustrates the per share dilution to investors
purchasing securities in the offering:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 71%; text-align: center"></TD>
    <TD STYLE="width: 2%"></TD>
    <TD STYLE="width: 12%; text-align: right"></TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 12%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"> Assumed public offering price per unit </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right">1.00</TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Net tangible book value per share as of March 31, 2012 </TD>
    <TD> $ </TD>
    <TD STYLE="text-align: right"> 0.16 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"> Increase per share attributable to sale of securities to investors </TD>
    <TD STYLE="border-bottom: Black 1pt solid"> $ </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> &nbsp; 0.09</TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right"></TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"> Pro forma as adjusted net tangible book value per share after the offering </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 0.25 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD> Dilution per share to investors </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.75 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing illustration does not reflect potential dilution
from the exercise of outstanding options or warrants to purchase shares of our common stock. The foregoing illustration also does
not reflect the dilution that would result from the exercise of the warrants sold in the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>MANAGEMENT'S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>The following discussion and analysis should be read together
with our financial statements and the related notes appearing elsewhere in this prospectus. This discussion contains forward-looking
statements reflecting our current expectations that involve risks and uncertainties. See &ldquo;Special Note Regarding Forward-Looking
Statements&rdquo; for a discussion of the uncertainties, risks and assumptions associated with these statements. Actual results
and the timing of events could differ materially from those discussed in our forward-looking statements as a result of many factors,
including those set forth under &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Acquisition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 8, 2011, we completed the Acquisition.&nbsp;&nbsp;Immediately
prior to the Acquisition, we completed a 1-for-153 reverse split of our common stock. We then issued 17,001,596 shares of our
common stock to the former shareholders of Cellectar as consideration for the Acquisition, constituting approximately 85% of our
outstanding common stock after giving effect to the Acquisition.&nbsp;&nbsp;Upon the closing of the Acquisition, we completed
the private placement of 6,846,537 shares of our common stock and warrants to purchase an additional 6,846,537 shares of our common
stock.&nbsp;&nbsp;The Acquisition was accounted for as a reverse acquisition whereby Cellectar, Inc. was treated as the acquirer
for accounting and financial reporting purposes. As such, references to the results of operations for the twelve months ended
December 31, 2010 represent the historical results of Cellectar. References to the results of operations for the twelve months
ended December 31, 2011 include the historical results of Cellectar from January 1, 2011 through April 8, 2011 and include the
consolidated results of the combined company from April 9, 2011 through December 31, 2011.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the Acquisition, we have been implementing a
revised business plan focused on the development of the Cellectar compounds.&nbsp;&nbsp;We conduct our operations from Cellectar&rsquo;s
headquarters in Madison, Wisconsin and our executive offices are in Newton, Massachusetts. Further development of our other compounds
(NOV-002 and NOV-205) has been suspended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 8, 2011, immediately prior to the Acquisition, Cellectar
paid approximately $627,000 in full settlement of a note payable to a bank.&nbsp;&nbsp;The payment was made in order to avoid
an event of default that would have occurred as a result of the change of control that occurred as a result of the Acquisition.&nbsp;&nbsp;On
April 8, 2011, the holders of Cellectar convertible notes converted outstanding principal of $2,720,985 and accrued unpaid interest
into a total of 4,181,535 shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a pharmaceutical company developing novel drugs for
the treatment and diagnosis of cancer. We believe our three <FONT STYLE="color: black">cancer-targeted compounds are selectively
taken up and retained in cancer cells, including cancer stem cells, versus normal cells.</FONT> Thus, our therapeutic compounds
appear to directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in
cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem
cell-based relapse. <FONT STYLE="color: black">LIGHT is a small-molecule cancer-targeted PET imaging agent. We believe LIGHT has
first-in-class potential and Phase 1-2 clinical trials are ongoing. HOT is a small-molecule, broad-spectrum, cancer-targeted molecular
radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. We believe
HOT also has first-in-class potential. HOT Phase 1b dose-escalation trial is ongoing and we expect HOT to enter Phase 2 trials
in the first quarter of 2013, as a monotherapy for solid tumors with significant unmet medical need, subject to additional funding.
COLD, a pre-clinical cancer-targeted non-radioactive chemotherapy, works primarily through Akt inhibition</FONT>. <FONT STYLE="color: black">Together,
we believe our compounds are able to &ldquo;find, treat and follow&rdquo; cancer anywhere in the body in a novel, effective and
highly selective way. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> LIGHT is a small-molecule imaging agent that we believe
has first-in-class potential for selective detection of tumors and metastases in a broad range of cancers.&nbsp; LIGHT is comprised
of a small, non-pharmacological quantity of CLR1404 (COLD, acting as a cancer-targeted delivery and retention vehicle) labeled
with the short-lived radioisotope, iodine-124, a new positron emission tomography (PET) imaging isotope.&nbsp; PET imaging used
in conjunction with CT scanning has now become the imaging method of choice in oncology.&nbsp; In studies to date, LIGHT selectively
illuminated malignant tumors in 52 of 54 animal models of cancer, demonstrating evidence of broad-spectrum, cancer-selective uptake
and retention.&nbsp; Investigator-sponsored Phase 1-2 trials of LIGHT as a PET imaging agent are ongoing at the University of
Wisconsin. The trials include lung cancer, brain cancer and, starting in the second quarter of 2012, other solid tumors.&nbsp;
These human trials, if successful, will serve three important purposes.&nbsp; First, they would provide proof-of-concept for LIGHT
itself as a PET imaging agent with the potential to supplant the current &ldquo;gold standard&rdquo; agent, 18-fluoro-deoxyglucose
(FDG), due to what we believe to be LIGHT&rsquo;s superior cancer-specificity and more favorable logistics of clinical use.&nbsp;
Second, favorable results would advance potential partnering discussions for LIGHT. Third, tumor uptake data will accelerate clinical
development of HOT by predicting efficacy and enabling calculation of efficacious doses of HOT for Phase 2 trials. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">HOT (iodine-131 radiolabeled CLR1404) is a small-molecule,
broad-spectrum, cancer-targeted molecular radiotherapeutic that we believe has first-in-class potential. HOT is comprised of a
small, non-pharmacological quantity of CLR1404 (COLD) acting as a cancer-targeted delivery and retention vehicle and incorporating
a cytotoxic (cell-killing) dose of radiotherapy (in the form of iodine-131, a radioisotope that is already in common use to treat
thyroid and other cancer types). It is this &ldquo;intracellular radiation&rdquo; mechanism of cancer cell killing, coupled with
selective delivery to a wide range of malignant tumor types that we believe imbues HOT with broad-spectrum anti-cancer activity.
Selective uptake and retention has also been demonstrated in cancer stem cells compared with normal stem cells, offering the prospect
of longer lasting cancer remission. In 2009 we filed an IND with the FDA to study HOT in humans. In early 2010 we successfully
completed a Phase 1a dosimetry trial demonstrating initial safety, tumor imaging and pharmacokinetic consistency and establishing
a starting dose for a Phase 1b dose-escalation trial. Radiation dosimetry measures how much radiation is absorbed by tumors and
body organs in order to optimize delivery of radiation therapy. The ongoing Phase 1b dose-escalation trial is aimed at determining
the Maximum Tolerated Dose of HOT. We expect to initiate HOT Phase 2 efficacy trials as a monotherapy for solid tumors with significant
unmet medical need as soon as a minimal efficacious dose is established, in the event that we obtain the additional funding necessary
for that purpose. We may determine such an effective dose upon seeing a tumor response in the Phase 1b trial or calculating it
from ongoing PET imaging trials in cancer patients with LIGHT (since PET imaging is quantitative, enabling determination of tumor
radiation exposure at a given dose level). Preclinical <I>in vitro</I> (in cell culture) and <I>in vivo</I> (in animals) experiments
have demonstrated selective killing of cancer cells along with a benign safety profile. HOT&rsquo;s anti-tumor/survival-prolonging
activities have been demonstrated in more than a dozen xenograft models (human tumor cells implanted into animals) including breast,
prostate, lung, glioma (brain), pancreatic, ovarian, uterine, renal and colorectal cancers and melanoma. In all but two models,
a single administration of a well-tolerated dose of HOT was sufficient to demonstrate efficacy. In view of HOT&rsquo;s selective
uptake and retention in a wide range of solid tumors and in cancer stem cells, its single-agent efficacy in xenograft models and
its non-specific mechanism of cancer-killing (radiation), we expect first to develop HOT as a monotherapy, initially for solid
tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COLD is a cancer-targeted chemotherapy that, in pre-clinical
experiments, has been observed to inhibit the phosphatidylinosotol 3-kinase (PI3K)/Akt survival pathway, which is overexpressed
in many types of cancer.&nbsp; As a result, in such pre-clinical experiments COLD has been observed to selectively inhibit Akt
activity, induce apoptosis through caspase activation and inhibit cell proliferation in cancer cells versus normal cells.&nbsp;
COLD also exhibits significant <I>in vivo</I> efficacy in mouse xenograft tumor models, including non-small cell lung cancer and
triple-negative breast cancers, producing long-lasting tumor growth suppression and significantly increased survival.&nbsp; We
believe COLD has the potential to be best-in-class versus other Akt inhibitors in development due to (a) cancer cell/cancer stem
cell targeting, resulting in cancer-selective inhibition of Akt and cell proliferation or (b) suitability for intravenous administration
that we believe offers the prospect of greater systemic exposure and hence Akt inhibition in cancer cells, which we believe would
result in superior efficacy.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prior to the Acquisition, for more than 10 years, Novelos had
been developing oxidized glutathione-based compounds for the treatment of cancer, including NOV-002, an injectable small-molecule
compound based on a proprietary formulation of oxidized glutathione that Novelos had been developing for use in combination with
standard of care chemotherapies for the treatment of solid tumors. From 2005 through 2010 Novelos raised approximately $67 million
in capital for the development of our compounds. From November 2006 through January 2010, Novelos conducted a Phase 3 trial of
NOV-002 plus first-line chemotherapy in advanced non-small cell lung cancer which, when completed in February 2010, did not meet
its primary and secondary efficacy endpoints.&nbsp;&nbsp;Following the completion of the Phase 3 trial during 2010, Novelos continued
clinical development of NOV-002 in breast cancer and NOV-205 in hepatitis C, although further development of those compounds has
been suspended. Novelos also explored strategic alternatives which resulted in the completion of the Acquisition in April 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I> Executive summary </I></B> .&nbsp;&nbsp;In March
2010, Cellectar completed a Phase 1a dosimetry trial of HOT in humans (the Phase 1a Trial), demonstrating initial safety and establishing
dosing parameters for a Phase 1b dose-escalation trial.&nbsp;&nbsp;Following the completion of the Phase 1a Trial and as a result
of limited funding, Cellectar suspended research and manufacturing activities, terminated certain non-key personnel and implemented
salary reductions in an effort to contain costs while Cellectar concentrated on its fundraising efforts.&nbsp;&nbsp;The increases
in research and development costs for the three months ended March 31, 2012 compared to the three months ended March 31, 2011
and for the year ended December 31, 2011 compared to the year ended December 31, 2010 are primarily attributable to the cost reduction
efforts implemented in mid-2010 as well as the increases associated with the recommencement of research activities following the
Acquisition.&nbsp;&nbsp;Following the Acquisition, we have resumed development activities including the commencement of clinical
trials in HOT and LIGHT. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and</I></B> <B><I>development expense.</I></B>
&nbsp;&nbsp;Research and development expense consists of costs incurred in identifying, developing and testing, and manufacturing
product candidates, which primarily include salaries and related expenses for personnel, costs of our research and manufacturing
facility, cost of manufacturing materials, fees paid to professional service providers for independent monitoring and analysis
of our clinical trials, and costs to secure intellectual property. The Company analyzes its research and development expenses
based on four categories as follows: clinical projects, preclinical projects, chemistry and manufacturing costs, and general fixed
and overhead costs that are not allocated to the functional project costs, including personnel costs, manufacturing facility costs,
related overhead costs and patent costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>General and administrative expense.</I></B> &nbsp;&nbsp;General
and administrative expense consists primarily of salaries and other related costs for personnel in executive, finance and administrative
functions.&nbsp;&nbsp;Other costs include insurance, costs for public and investor relations, directors&rsquo; fees and professional
fees for legal and accounting services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I> Three Months Ended March 31, 2012 and 2011 </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I> Research and Development. </I> &nbsp;&nbsp;Research
and development expense for the three months ended March 31, 2012 was approximately $1,328,000 (comprised of approximately $254,000
in clinical project costs, $70,000 of preclinical project costs, $62,000 of manufacturing and related costs and $942,000 in general
unallocated research and development costs) compared to approximately $471,000 (comprised of $3,000 of preclinical project costs,
$3,000 of manufacturing and related costs and $465,000 in general unallocated research and development costs) for 2011.&nbsp;&nbsp;The
approximately $857,000, or 181.9%, increase in research and development resulted from increases in all categories. The $254,000
increase in clinical projects and the $59,000 increase in manufacturing and related costs in the three months ended March 31,
2012 versus 2011 were related to costs associated with the Company&rsquo;s Phase 1-2 trial for LIGHT and its Phase 1b trial for
HOT. The $67,000 increase in preclinical costs for the three months ended March 31, 2012 versus 2011 was related to contributions
made to the UW for use towards unrestricted research activities. The $477,000 increase in general unallocated research and development
costs for the three months ended March 31, 2012 versus 2011 was primarily due to an approximately $217,000 increase in salary
costs as a result of increases in personnel following the Acquisition and the removal of salary reductions that were in place
in the first quarter of 2011 in order to conserve cash, an approximately $102,000 increase in stock-based compensation resulting
from stock options granted during 2011, an approximately $57,000 increase in patent costs as well as increases in subcontracted
services, facilities and equipment maintenance costs incurred as we continue manufacturing and research activities in support
of the ongoing clinical trials. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I> General and Administrative. </I> &nbsp;&nbsp;General
and administrative expense for the three months ended March 31, 2012 was approximately $998,000 compared to approximately $132,000
in 2011.&nbsp;&nbsp;The $866,000, or 656.1%, increase in general and administrative costs were primarily related to the following
items: salary increased approximately $242,000 resulting from the addition of employees following the Acquisition and the removal
of salary reductions that were in place in the first quarter of 2011 in order to conserve cash; stock-based compensation increased
by $257,000 associated with stock options granted in 2011; the cost of subcontracted services increased by approximately $235,000
as a result of increased legal and accounting fees, investor relations activities, directors&rsquo; fees and costs associated
with public company reporting. Insurance costs increased approximately $34,000, rent increased approximately $18,000 associated
with the addition of the Massachusetts location and travel costs increased approximately $14,000 due principally to an increase
in travel between our Massachusetts and Wisconsin offices. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I> Merger Costs. </I> Merger costs during the three
months ended March 31, 2012 were $0 compared to approximately $250,000 in legal related fees in connection with the Acquisition
for the same period in 2011. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I> Grant income.&nbsp;&nbsp; </I> Qualifying therapeutic
discovery projects, among others, include those designed to treat or prevent diseases or conditions by conducting clinical or
pre-clinical activities for the purpose of securing FDA approval of a product.&nbsp;&nbsp;The Company received payments of approximately
$44,000 in the three months ended March 31, 2011, under a cash grant from the U.S. Internal Revenue Service as a qualifying therapeutic
discovery project credit pursuant to Patient Protection and Affordable Care Act. The payment has been recorded as a component
of other income in the three months ended March 31, 2011. No grant income was received in the three months ended March 31, 2012. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I> &nbsp; </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I> Loss on </I> <I>Derivative Warrants.</I> We recorded
a loss on derivative warrants of approximately $29,000 in the three months ended March 31, 2012. This amount represents the change
in fair value, during the respective period, of outstanding warrants that contain &ldquo;down-round&rdquo; anti-dilution provisions
whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants is subject to change
in the event of certain issuances of stock at prices below the then-effective exercise prices of the warrants. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I> Interest expense, net </I> .&nbsp;&nbsp;Interest
expense, net, for the three months ended March 31, 2012 and 2011 consists approximately of the following: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Three Months Ended March
    31, </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> 2012 </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> 2011 </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left"> Interest expense, convertible notes </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> &mdash; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> (146,000 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Interest expense, bank note </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &mdash; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (12,000 </TD><TD STYLE="text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"> Interest expense, other </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (2,000 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &mdash; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"> Interest income </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> &mdash; </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 2,000 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (2,000 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (156,000 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black"> The decrease in interest expense
on the convertible notes and bank note was a result of the settlement of those obligations in April 2011. Interest expense in
2012 relates to </FONT> notes payable to the Wisconsin Department of Commerce issued in September 2010. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Twelve Months Ended December 31, 2011 and 2010</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development.</I> &nbsp;&nbsp;Research and development
expense for the year ended December 31, 2011 was approximately $3,599,000 (comprised of approximately $166,000 in clinical project
costs, $207,000 of preclinical project costs, $205,000 of manufacturing and related costs and $3,021,000 in general unallocated
research and development costs) compared to approximately $2,984,000 (comprised of $200,000 in clinical project costs, $459,000
of preclinical project costs, $58,000 of manufacturing and related costs and $2,267,000 in general unallocated research and development
costs) for 2010.&nbsp;&nbsp;The approximately $615,000, or 20.6%, increase in research and development resulted from increases
in manufacturing and general unallocated research costs partially offset by decreases in clinical and preclinincal costs. The
$34,000 decrease in clinical projects in the year ended December 31, 2011 versus 2010 was related to a $200,000 decrease in costs
related to the completion of the Phase 1a trial in March 2010 partially offset by clinical costs incurred in 2011 related to the
Company&rsquo;s Phase 1b trial for HOT. The $252,000 decrease in preclinical projects, for the year ended December 31, 2011 versus
2010 was primarily related to a $210,000 decrease in subcontracted preclinical research as those activities had increased in the
first half of 2010 in preparation for future clinical trials. These decreases were offset by an increase of approximately $754,000
in general unallocated research and development costs primarily due to an approximately $215,000 increase in salary and related
costs as a result of increases in personnel following the Acquisition, an approximately $165,000 increase in stock-based compensation
resulting from stock options granted in May 2011 and December 2011 following the Acquisition, an approximately $87,000 increase
in patent costs as well as increases in subcontracted services, facilities and equipment maintenance costs incurred as we resumed
manufacturing and research activities following the Acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>General and Administrative.</I> &nbsp;&nbsp;General and
administrative expense for the year ended December 31, 2011 was approximately $2,692,000 compared to approximately $1,157,000
in 2010.&nbsp;&nbsp;The $1,535,000, or 132.7%, increase in general and administrative costs were primarily related to the following
items: Salary increased approximately $582,000 resulting from the addition of employees in connection with the Acquisition and
the removal of salary reductions that had been in place in order to conserve cash; stock-based compensation increased by $390,000
associated with stock option grants made in May and December 2011; the cost of subcontracted services increased by approximately
$331,000 as a result of increased investor relations activities, directors&rsquo; fees and costs associated with public company
reporting. Insurance costs increased approximately $67,000, rent increased approximately $49,000 associated with the addition
of the Massachusetts location following the Acquisition and travel costs increased approximately $53,000 due principally to an
increase in travel between our Massachusetts and Wisconsin offices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Merger Costs. </I> Merger costs during the year ended December
31, 2011 consisted of $450,000 in investment banking fees, approximately $286,000 in legal fees and approximately $10,000 in insurance
costs compared to approximately $53,000 of merger costs in 2010, primarily related to legal fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Grant income.&nbsp;&nbsp;</I> Qualifying therapeutic discovery
projects, among others, include those designed to treat or prevent diseases or conditions by conducting pre-clinical or clinical
activities for the purpose of securing FDA approval of a product.&nbsp;&nbsp;The Company received payments of approximately $44,000
in the year ended December 31, 2011 compared to $200,000 for 2010 under a cash grant from the U.S. Internal Revenue Service as
a qualifying therapeutic discovery project credit pursuant to Patient Protection and Affordable Care Act. The payments have been
recorded as a component of other income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Loss on</I> <I>Derivative Warrants.</I> We recorded a loss
on derivative warrants of approximately $12,000 in the year ended December 31, 2011. This amount represents the change in fair
value, during the respective period, of outstanding warrants that contain &ldquo;down-round&rdquo; anti-dilution provisions whereby
the number of shares for which the warrants are exercisable and/or the exercise price of the warrants is subject to change in
the event of certain issuances of stock at prices below the then-effective exercise prices of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Interest expense, net</I>.&nbsp;&nbsp;Interest expense,
net, for the years ended December 31, 2011 and 2010 consists approximately of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;Ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 72%; text-align: left">Interest expense, convertible notes</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(159,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(305,000</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Beneficial conversion feature, convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(258,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(214,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Interest expense, bank note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,500</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(55,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest expense, other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Interest income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(430,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(566,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since the convertible notes were converted based on <FONT STYLE="color: black">revised
conversion terms that resulted in the issuance of an additional 343,963 shares of common stock than would have been issued if
the convertible notes had been converted in accordance with their original terms, the value of these additional shares of approximately
$258,000 was recorded as a component of interest expense at the date of conversion in 2011. </FONT>Since the convertible notes
were convertible into common stock at the date of issuance at a price per share which is less than the estimated fair value of
our common stock at that date, the estimated intrinsic value of the beneficial conversion feature of approximately $214,000 was
recorded as a component of interest expense on the date of issuance in 2010. <FONT STYLE="color: black">The decrease in interest
expense on the convertible notes and bank note was a result of the settlement of those obligations in connection with the Acquisition.
</FONT>The increase in other interest expense is principally a result of the issuance of notes payable to the Wisconsin Department
of Commerce in September 2010. <FONT STYLE="color: black">The reduction of interest income was a result of a decrease in average
cash balances and interest rates. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We have financed our operations since inception primarily
through the sale of equity securities and securities convertible into equity securities. To date, Cellectar and Novelos have raised
capital aggregating approximately $110 million.&nbsp;&nbsp;Novelos has raised capital aggregating approximately $83 million, including
proceeds from the April 2011 private placement and the December 2011 underwritten offering.&nbsp;&nbsp;Since its inception and
prior to the Acquisition, Cellectar had raised capital aggregating approximately $27 million.&nbsp;&nbsp;As of March 31, 2012,
we had approximately $3,788,000 in cash and cash equivalents. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> During the three months ended March 31, 2012, approximately
$1,703,000 in cash was used in operations. During this period we reported a net loss of approximately $2,357,000. However, this
loss included the following non-cash items: approximately $140,000 in depreciation and amortization expense, approximately $417,000
in stock-based compensation, and approximately $29,000 in loss on derivative warrants. After adjustment for these non-cash items,
we used approximately $6,000 in cash for the payment of accounts payable and accrued liabilities. Other changes in working capital
provided cash of $75,000.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> During the three months ended March 31, 2012, we purchased
approximately $15,000 of equipment. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The consolidated financial statements included
elsewhere in this prospectus have been prepared on a basis that assumes that we will continue as a going concern and that
contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the
normal course of business. We have incurred losses since inception in devoting substantially all of our efforts toward
research and development and have an accumulated deficit of $33,837,329 at March 31, 2012. During the three months ended
March 31, 2012, we generated a net loss of $2,356,903 and we expect that we will continue to generate operating losses for
the foreseeable future. At March 31, 2012, our cash balance was approximately $3,788,000. We believe our cash on hand is
adequate to fund operations into the middle of the third quarter of 2012. Our ability to execute our operating plan beyond
that time depends on our ability to obtain additional funding via the sale of equity and/or debt securities, a strategic
transaction or otherwise. On April 9, 2012, we filed with the SEC a Registration Statement on Form S-1 for the sale of up to
5,000,000 units consisting of common stock and warrants to purchase shares of common stock. The registration statement was
declared effective on June 7, 2012. We plan to actively pursue this and other financing alternatives; however we have not
entered into negotiations for any such alternative transaction. There can be no assurance that we will obtain the necessary
funding. Other than the uncertainties regarding our ability to obtain additional funding, there are currently no known
trends, demands, commitments, events or uncertainties that are likely to materially affect our liquidity. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of financial statements and related disclosures
in conformity with accounting principles generally accepted in the United States, or GAAP, requires management to make certain
estimates, judgments and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial
statements, as well as the reported amounts of revenues and expenses during the periods presented. Management bases its estimates
and judgments on historical experience, knowledge of current conditions and various other factors that are believed to be reasonable
under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities
that are not readily apparent from other sources. Actual results could differ from those estimates. We review these estimates
and assumptions periodically and reflect the effects of revisions in the period that they are determined to be necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that the following accounting policies reflect our
more significant judgments and estimates used in the preparation of our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Accrued Liabilities.</I> As part of the process of preparing
financial statements, we are required to estimate accrued liabilities. This process involves identifying services that have been
performed on our behalf, and estimating the level of service performed and the associated cost incurred for such service as of
each balance sheet date in our financial statements. Examples of estimated expenses for which we accrue include: contract service
fees such as amounts paid to clinical research organizations and investigators in conjunction with clinical trials; fees paid
to vendors in conjunction with the manufacturing of clinical materials; and professional service fees, such as for lawyers and
accountants. In connection with such service fees, our estimates are most affected by our understanding of the status and timing
of services provided relative to the actual levels of services incurred by such service providers. The majority of our service
providers invoice us monthly in arrears for services performed. In the event that we do not identify certain costs that have begun
to be incurred, or we over- or underestimate the level of services performed or the costs of such services, our reported expenses
for such period would be too high or too low. The date on which certain services commence, the level of services performed on
or before a given date and the cost of such services are often determined based on subjective judgments. We make these judgments
based on the facts and circumstances known to us, in accordance with GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Goodwill and Other Intangible Assets.</I> As of December
31, 2011 there was approximately $1,675,000 of goodwill recorded in connection with the Acquisition. We are required to evaluate
goodwill for impairment annually or <FONT STYLE="color: black">whenever events or changes in circumstances suggest that the carrying
value of an asset may not be recoverable. </FONT>The Company evaluates goodwill for impairment annually in the fourth fiscal quarter
and additionally on an interim basis if an event occurs or circumstances change such as a decline in the Company&rsquo;s stock
price, or a material adverse change in the business climate, which would more likely than not reduce the fair value of the reporting
unit below its carrying amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Stock-based Compensation</I>. We account for stock-based
compensation by measuring the cost of employee services received in exchange for an award of equity instruments based on the grant-date
fair value of the award, using the Black-Scholes option-pricing model. The cost of non-performance based awards is recognized
over the period during which an employee is required to provide service in exchange for the award, the requisite service period
(usually the vesting period). For stock options with performance-based vesting provisions, recognition of compensation expense
commences if and when the achievement of the performance criteria is deemed probable and is recognized over the relevant performance
period. We account for transactions in which services are received from non-employees in exchange for equity instruments based
on the fair value of such services received or of the equity instruments issued (using the Black-Scholes option-pricing model)
whichever is more reliably measured. The measurement of stock-based compensation for non-employees is subject to periodic adjustments
as the options vest, and the expense is recognized over the period during which a non-employee is required to provide services
for the award (usually the vesting period).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounting for equity instruments granted or sold by us under
accounting guidance requires fair-value estimates of the equity instrument granted or sold. If our estimates of the fair value
of these equity instruments are too high or too low, our expenses may be over- or understated. For equity instruments granted
or sold in exchange for the receipt of goods or services, we estimate the fair value of the equity instruments based on consideration
of factors that we deem to be relevant at that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Derivative Warrants.</I> Certain warrants to purchase common
stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of
the FASB ASC, are classified as liabilities on our balance sheet. In such instances, net-cash settlement is assumed for financial
reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants are
considered derivative instruments as the agreements contain &ldquo;down-round&rdquo; provisions whereby the number of shares for
which the warrants are exercisable and/or the exercise price of the warrants is subject to change in the event of certain issuances
of stock at prices below the then-effective exercise price of the warrants. The primary underlying risk exposure pertaining to
the warrants is the change in fair value of the underlying common stock. Such financial instruments are initially recorded at
fair value, or relative fair value when issued with other instruments, with subsequent changes in fair value recorded as a component
of gain or loss on derivatives in each reporting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The fair value of the outstanding
derivative warrants is estimated as of a reporting date.</FONT> <FONT STYLE="font-size: 10pt">The Company uses valuation methods
and assumptions that consider among others the fair value of the underlying stock, risk-free interest rate, volatility, expected
life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. We estimate volatility
based on an average of our historical volatility and volatility estimates of publicly held drug development companies with similar
market capitalizations. If our estimates of the fair value of these derivative warrants are too high or too low, our expenses
may be over- or understated. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Fair value measurements.</I> We account for certain financial
assets at fair value, defined as the price that would be received to sell an asset or pay to transfer a liability (i.e., exit
price) in the principal, most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market
participant would use in pricing a asset or liability. If management made different assumptions or judgments, material differences
in measurements of fair value could occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Contingencies.</I> From time to time, we may become
involved in legal disputes regarding our products in development, intellectual property rights, stockholder claims or other matters.
We are currently involved in two such matters that are ongoing. We assess each matter to determine if a contingent liability should
be recorded. In making this assessment, we may consult, depending on the nature of the matter, with external legal counsel and
technical experts. Based on the information we obtain, combined with our judgment regarding all the facts and circumstances of
each matter, we determine whether it is probable that a contingent loss may be incurred and whether the amount of such loss can
be reasonably estimated. Should a loss be probable and reasonably estimable we record a loss. In determining the amount of the
loss, we consider advice received from experts in the specific matter, current status of legal proceedings, if any, prior case
history and other factors. Should the judgments and estimates made by us be incorrect, we may need to record additional contingent
losses that could materially adversely impact the results of operations and financial conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Business of Novelos</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Novelos Therapeutics, Inc. (Novelos or the Company) is a pharmaceutical
company developing compounds for the treatment of cancer.&nbsp; On April 8, 2011, Novelos entered into a business combination
with Cellectar, Inc. (Cellectar), a privately held Wisconsin corporation that designed and developed products to detect, treat
and monitor a wide variety of human cancers (the Acquisition). Following the Acquisition, we have been <FONT STYLE="color: black">developing
novel drugs for the treatment and diagnosis of cancer. </FONT> We believe our three <FONT STYLE="color: black">cancer-targeted
compounds (referred to as LIGHT, HOT and COLD) are selectively taken up and retained in cancer cells, including cancer stem cells,
versus normal cells.</FONT> Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal
cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of
mortality in cancer: primary tumors, metastases and stem cell-based relapse. I-124-CLR1404 (<FONT STYLE="color: black">LIGHT)
is a small-molecule cancer-targeted positron emissions tomography (PET) imaging agent. We believe LIGHT has first-in-class potential
and Phase 1-2 clinical trials are ongoing. I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular
radiotherapeutic that delivers cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells.
We believe HOT also has first-in-class potential. HOT Phase 1b dose-escalation trial is ongoing and we expect HOT to enter Phase
2 trials in the first quarter of 2013 as a monotherapy for solid tumors with significant unmet medical need, subject to additional
funding. CLR1404 (COLD), a pre-clinical cancer-targeted non-radioactive chemotherapy, works primarily through Akt (</FONT>a serine/threonine
protein kinase)<FONT STYLE="color: black"> inhibition</FONT>. <FONT STYLE="color: black">Together, we believe our compounds are
able to &ldquo;find, treat and follow&rdquo; cancer anywhere in the body in a novel, effective and highly selective way. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Market Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our target market is broad and represents the market for the
treatment and diagnosis of cancer. According to Drug Discovery News (April 2009) and PharmaLive (October 8, 2009), the global
market for cancer pharmaceuticals reached an estimated $66 billion in 2007, nearly doubling from $35 billion in 2005 and is expected
to grow to $80 billion by 2012.&nbsp; Furthermore, the US National Cancer Institute (January 12, 2011) estimates that the overall
cost of treating cancer in the US will increase to $158 billion by 2020 from $125 billion in 2010 and Global Industry Analysts
(GIA) forecasts the global market for cancer therapies to reach $225 billion by 2017 (November 2011). According to BCC Research
(April 2011), the total market for next-generation cancer diagnostics was $776 million in 2010 and is growing at a compounded
annual growth rate of 47%, to reach a forecast market size of $5.3 billion in 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Technology Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our compounds are optimized phospholipid ether (PLE) analogs
that interact with lipid rafts, which are specialized microdomains within cell membranes. Importantly, the core chemical structure
shared across all three products provides selective targeting of cancer cells, including cancer stem cells, in preference to normal
cells (due to enrichment of lipid rafts in the former).&nbsp; COLD was deliberately designed to contain iodine (in the form of
the stable, non-radioactive isotope, I-127), thus enabling additional, distinct products differing only with respect to the form
of iodine they contain &ndash; HOT contains short-lived radioactive I-131 and LIGHT contains the even more short-lived radioactive
I-124. As a result, three cancer-targeted product profiles have been generated from a single chemical structure that is the foundation
of our technology platform &ndash; a diagnostic imaging agent, LIGHT, a molecular radiotherapeutic agent, HOT and a non-radioactive
chemotherapeutic agent, COLD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our core technology platform is based on research conducted
by Cellectar&rsquo;s founder and our Chief Scientific Officer, Dr. Jamey Weichert, beginning in 1994 at the University of Michigan
(U. Mich.), where phospholipid ether analogs were initially designed, synthesized, radiolabeled, and evaluated. Since 1998, Dr.
Weichert has continued his research at the University of Wisconsin (U. Wisc.) and subsequently founded Cellectar in 2002 to further
develop and commercialize the technology. Cellectar obtained exclusive rights to the related technology patents owned by U. Mich.
in 2003 and continued development of the platform while obtaining ownership of numerous additional patents and patent applications
(lasting until 2025, 2028 and 2030 without extensions) prior to the Acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><B>Products in Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>LIGHT (</I></B><I>labeled with a short-lived radioisotope,
iodine-124)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> LIGHT is a small-molecule imaging agent that we believe
has first-in-class potential for selective detection of tumors and metastases in a broad range of cancers.&nbsp; LIGHT is comprised
of a small, non-pharmacological quantity of CLR1404 (COLD, acting as a cancer-targeted delivery and retention vehicle) labeled
with the short-lived radioisotope, iodine-124, a new PET imaging isotope.&nbsp; PET imaging used in conjunction with CT scanning
has now become the imaging method of choice in oncology.&nbsp; In studies to date, LIGHT selectively illuminated malignant tumors
in 52 of 54 animal models of cancer, demonstrating evidence of broad-spectrum, cancer-selective uptake and retention. Investigator-sponsored
Phase 1-2 trials of LIGHT as a PET imaging agent are ongoing at the University of Wisconsin. The investigator-sponsored IND for
LIGHT was submitted on March 28, 2003 and was approved by the FDA on April 25, 2003. The IND is held by Dr. Lance Hall at the
University of Wisconsin, who both initiates and conducts the investigation and under whose immediate direction the investigational
drug is administered. Novelos, the National Cancer Institute or the University of Wisconsin Institute for Clinical and Translational
Research provide funding for the trials and the data is shared with Novelos while the trials progress and at the conclusion of
the trials. The trials include lung cancer, brain cancer and, starting in the second quarter of 2012, other solid tumors. These
human trials, if successful, will serve three important purposes.&nbsp; First, they would provide proof-of-concept for LIGHT itself
as a PET imaging agent with the potential to supplant the current &ldquo;gold standard&rdquo; agent, 18-fluoro-deoxyglucose (FDG),
due to what we believe to be LIGHT&rsquo;s superior cancer-specificity and more favorable logistics of clinical use.&nbsp;Second,
favorable results would advance potential partnering discussions for LIGHT. Third, tumor uptake data will accelerate clinical
development of HOT by predicting efficacy and enabling calculation of efficacious doses of HOT for Phase 2 trials. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chemically, LIGHT is 18-(p-[I-124]iodophenyl) octadecyl phosphocholine,
identical to COLD except that the iodine is the radioactive&nbsp;&nbsp;isotope, I-124, which has a radiation half-life of 4 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We compared LIGHT and FDG side by side (24 hours apart) in
the same tumor-bearing mouse that was also treated with carageenan to induce inflammation.&nbsp; As expected, FDG demonstrated
significant uptake into the inflammatory lesion and organs such as heart and bladder compared to the malignant tumors, which were
poorly imaged.&nbsp; LIGHT, on the other hand, showed no uptake into the inflammatory lesion and organs, yet clear and demonstrable
uptake into the tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, the radioisotopic half-life of only 110 minutes
for fluorine-18 labeled agents, such as FDG, severely limits their delivery range relative to the point of manufacture.&nbsp;
I-124 has a four-day half-life that permits worldwide distribution of LIGHT from one manufacturing location.&nbsp; Additionally,
the longer half-life affords a longer imaging window of up to seven days following injection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> An investigator-sponsored Phase 1-2 trial of LIGHT as a
PET imaging agent for patients with advanced non-small cell lung cancer (NSCLC) was initiated in December 2011 at the University
of Wisconsin Carbone Cancer Center (UWCCC) and first patient was enrolled in February 2012. Dr. Anne M. Traynor at UWCCC is the
principal investigator for this trial. Novelos provides funding for the trial and the data is shared with Novelos while the study
progresses and at the conclusion of the study. Up to 9 patients will be enrolled across two dose levels (5 mCi and 3 mCi) in this
Phase 1-2 trial. The first cohort comprising three patients dosed with LIGHT at 5mCi has been successfully completed. We saw strong
uptake of LIGHT in cancerous tumors against very low background and have not observed any adverse safety signals. Although still
early and in a small number of subjects, there is some suggestion that LIGHT imaging was more tumor-selective than the comparator
modality 18F-fluorodeoxyglucose (18F-FDG) PET. Having observed initial cancer-specific uptake with LIGHT at 5 mCi dose in NSCLC
patients, and as we seek a minimally efficacious dose, we will enroll three patients at 3 mCi dose in the next cohort. We expect
data from this second cohort to be available mid-2012. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Another investigator-sponsored Phase 1-2 trial of LIGHT
as a PET imaging agent for brain cancer was initiated in December 2011 at UWCCC and first patient was enrolled in March 2012.
Dr. Lance Hall at the UWCCC is the principal investigator for this trial. This trial is being funded by an Institute for Clinical
and Translational Research (ICTR) grant, whereas the data is shared with Novelos while the study progresses and at the conclusion
of the study. Up to 20 patients will be enrolled at a 5 mCi dose. We expect initial data from this trial in the second quarter
of this year. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> An investigator-sponsored Phase 1-2 trial of LIGHT as a
PET imaging agent for metastatic brain cancer was initiated in January 2012 at UWCCC and first patient is expected to be enrolled
in the second quarter of this year. Dr. Lance Hall at the UWCCC is the principal investigator for this trial. This trial is being
funded by a $1.2 million grant from the National Cancer Institute. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> According to Bio-Tech Systems (November 2010), sales of
FDG in the US in 2009 were approximately $300 million and projected to grow to approximately $900 million in 2017. FDG accumulates
in any tissue having increased glucose metabolism compared to surrounding tissue. As a result and in contrast to LIGHT, FDG is
not selective for malignant tumors. FDG localizes in certain normal tissue such as heart, kidney and brain tissues that also have
high glucose metabolism. FDG is also known to localize in inflammatory sites. Other major limitations to the use of FDG are found
in pelvic imaging due to the high renal (kidney) clearance of the compound. These characteristics of FDG, therefore, decrease
its diagnostic specificity for certain malignancies. FDG is no longer covered by patent and is typically manufactured onsite at
PET imaging medical facilities because of its limited (110 minute) half-life. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>HOT (</I></B><I>iodine-131 radiolabeled compound<B>)</B></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">HOT is a small-molecule, broad-spectrum, cancer-targeted molecular
radiotherapeutic that we believe has first-in-class potential.&nbsp; HOT is comprised of a small, non-pharmacological quantity
of CLR1404 (COLD), acting as a cancer-targeted delivery and retention vehicle and incorporating a cytotoxic dose of radiotherapy
(in the form of iodine-131, a radioisotope that is already in common use to treat thyroid and other cancer types).&nbsp; It is
this &ldquo;intracellular radiation&rdquo; mechanism of cancer cell killing, coupled with delivery to a wide range of malignant
tumor types that we believe imbues HOT with broad-spectrum anti-cancer activity.&nbsp; Selective uptake and retention has also
been demonstrated in cancer stem cells compared with normal cells, offering the prospect of longer lasting cancer remission. In
2009, we filed an IND with the FDA to study HOT in humans.&nbsp; In early 2010, we successfully completed a Phase 1a dosimetry
trial demonstrating initial safety, tumor imaging and pharmokinetic consistency and establishing a starting dose for a Phase 1b
dose-escalation trial.&nbsp; Radiation dosimetry measures how much radiation is absorbed by tumors and body organs in order to
optimize delivery of radiation therapy. The ongoing Phase 1b dose-escalation trial is aimed at determining the Maximum Tolerated
Dose of HOT.&nbsp; We plan to initiate HOT Phase 2 efficacy trials as a monotherapy for solid tumors with significant unmet medical
need as soon as a minimal efficacious dose is established, provided that we obtain the additional funding necessary for that purpose.&nbsp;
We may determine such an effective dose upon seeing a tumor response in the Phase 1b trial or calculating it from ongoing PET
imaging trials in cancer patients with LIGHT (since PET imaging is quantitative, enabling determination of tumor radiation exposure
at a given dose level).&nbsp; Preclinical <I>in vitro</I> (in cell culture) and <I>in vivo</I> (in animals) experiments have demonstrated
selective killing of cancer cells along with a benign safety profile. HOT&rsquo;s anti-tumor/survival-prolonging activities have
been demonstrated in more than a dozen xenograft models (human tumor cells implanted into animals) including breast, prostate,
lung, glioma (brain), pancreatic, ovarian, uterine, renal and colorectal cancers and melanoma.&nbsp; &nbsp;In all but two models,
a single administration of a well-tolerated dose of HOT was sufficient to demonstrate efficacy.&nbsp; In view of HOT&rsquo;s selective
uptake and retention in a wide range of solid tumors and in cancer stem cells, its single-agent efficacy in xenograft models and
its non-specific mechanism of cancer-killing (radiation), we expect first to develop HOT as a monotherapy, initially for solid
tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chemically, HOT is 18-(p-[I-131]iodophenyl) octadecyl phosphocholine,
identical to COLD except that the iodine in its structure is the radioactive (&ldquo;hot&rdquo;) isotope, I-131, which has a radiation
half-life of eight days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Single intravenous, well-tolerated doses of HOT administered
therapeutically in animals (i.e., after primary tumors were established) have been observed to result in significant anti-tumor
and/or survival benefit compared to control animals in mouse xenograft tumor models including ovarian, pancreatic, non-small cell
lung, triple-negative breast, prostate, glioma, colorectal and kidney cancers.&nbsp;Survival benefit generally reflected the degree
of tumor growth suppression.&nbsp; Efficacy was also seen in a xenograft model employing human uterine sarcoma cells which over-express
efflux pumps known to underlie resistance to many standard chemotherapeutic drugs. The broad <I>in vivo</I> efficacy profile of
HOT across many tumor types is reflected in the fact that selective tumor localization of LIGHT (which uses the same cancer-targeting
drug delivery and retention vehicle as HOT) has been demonstrated in over 50 xenograft, spontaneous and transgenic cancer models.&nbsp;
HOT was also tested in combination with a standard efficacious dose of gemcitabine in a pancreatic cancer xenograft model.&nbsp;
Single doses of HOT or gemcitabine given alone were equally efficacious while the combination therapy was significantly more efficacious
than either treatment alone (additive).&nbsp; In each xenograft study, the dose of HOT was ~100 &micro;Ci, which is at least 50%
less than the maximum tolerated dose in mice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Extensive, IND-enabling, Good Laboratory Practices (GLP) <I>in
vivo</I> and <I>in vitro</I> pre-clinical pharmacokinetic/distribution, toxicology and drug safety studies were successfully completed
using non-pharmacological concentrations/doses of COLD consistent with its role as a delivery/retention vehicle in HOT.&nbsp;
Tissue distribution studies supported prediction of acceptable human organ exposures and body clearance for HOT.&nbsp; Importantly,
and in sharp distinction from biological products labeled with I-131, the small molecule HOT showed very minimal variation in
excretion kinetics and tissue distribution among individuals within species or across a 500-fold variation in dose.&nbsp; Single-
and repeated-dose animal toxicology studies indicated very high margins of safety (80-200x) over the anticipated maximum human
therapy dose of HOT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2010 we completed a Phase 1a dosimetry trial with
a single intravenous dose of 10 mCi HOT in eight patients with relapsed or refractory advanced solid tumors.&nbsp; Single doses
of HOT were well tolerated.&nbsp; The reported adverse events were all considered minimal, manageable and either not dose limiting
or not related to HOT. There were no serious adverse events reported.&nbsp; Analysis of total body imaging and blood and urine
samples collected over 42 days following injection indicated that doses of HOT expected to be therapeutically effective can be
administered without harming vital organs.&nbsp; Two subjects (one with colorectal cancer metastasized to lung and another with
prostate cancer) had tumors that were imaged with 3D nuclear scanning (SPECT/CT) on day 6 after administration of HOT.&nbsp; Uptake
of HOT into tumor tissue (but not adjacent normal tissue or bone marrow) was clearly demonstrated in both subjects.&nbsp; Echoing
animal studies, pharmacokinetic analyses demonstrated a prolonged half-life of radioactivity in the plasma after HOT administration
(approximately 200 hours) and that there was no significant variation in excretion or radiation dosimetry among subjects.&nbsp;
The trial established an initial dose of 12.5 mCi / m<SUP>2</SUP> (for example, 20 mCi dose for a patient with 1.6m<SUP>2</SUP>
body surface area) for the Phase 1b escalating dose trial that is ongoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The primary objective of this Phase 1b dose-escalation trial
in patients with a range of advanced solid tumors is to define the Maximum Tolerated Dose (MTD) of HOT.&nbsp; In addition to determining
the MTD, the Phase 1b trial is intended to evaluate overall tumor response (using standard RESIST I criteria) and safety.&nbsp;
Concurrently, separate studies are expected to generate quantitative imaging data in cancer patients using LIGHT.&nbsp; These
imaging trials with LIGHT are expected to predict efficacy and enable calculation of a minimal efficacious dose of HOT for Phase
2 trials, planned to begin in early 2013, in the event we obtain the additional funding necessary for that purpose, with an initial
focus on solid tumors with significant unmet medical need.&nbsp; &nbsp;Based on its broad-spectrum mechanism of action and wide-ranging
single agent activity in animal cancer models, HOT&nbsp;is anticipated to&nbsp;be used as monotherapy through proof-of-concept
clinical trials, with subsequent exploration of combination with chemotherapeutic agents (a number of which are known to be radiosensitizers
and thus with potential to enhance the efficacy of HOT).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tumor treatment with radioactive isotopes has been used as
a fundamental cancer therapeutic for decades.&nbsp; The goals of targeted cancer therapy &mdash; selective delivery of effective
doses of isotopes that destroy tumor tissue, sparing of surrounding normal tissue, and non-accumulation in vital organs such as
the liver and kidneys &mdash; remain goals of novel therapies as well.&nbsp; We believe our isotope delivery technology is poised
to achieve these goals.&nbsp; Because, to date, HOT has been shown to reliably and near-universally accumulate in cancer cells
and because the therapeutic properties of the iodine-131 are well known, we believe the risk of non-efficacy in human clinical
trials is less than that of other cancer therapies at this stage of development, although no assurance can be given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other targeted radiotherapies include the marketed drugs Zevalin&reg;
(90Y, Spectrum Pharmaceuticals) and Bexxar&reg; (I-131, GSK).&nbsp; In both cases, tumor-targeting is monoclonal antibody-based
and limited to non-Hodgkins lymphoma, which is a type of cancer involving cells of the immune system.&nbsp; Thus, these agents
are not appropriate comparators for HOT because of their limited therapeutic utility (only one type of tumor) and because their
target indication is often well-managed by other drugs (unlike HOT, which has potential to treat tumor types for which the current
standard of care is associated with very poor outcomes). Notably, both Zevalin&reg; and Bexxar&reg; were approved on the basis
of objective response rates (shrinking of tumors) without data to support improvement in survival, suggesting that regulatory
approval of radiopharmaceuticals may be based on relatively shorter and smaller pivotal clinical trials than is often the case
in oncology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In conclusion, we believe that HOT is not subject to the full
extent of development risk typically associated with early-stage cancer therapeutics for the following reasons:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">HOT
                                                                                                             is selectively taken
                                                                                                             up by and retained
                                                                                                             in cancer versus
                                                                                                             normal cells and
                                                                                                             its delivery vehicle
                                                                                                             (COLD) is intended
                                                                                                             to be given to patients
                                                                                                             in sub-pharmacological
                                                                                                             doses, resulting
                                                                                                             in an improved safety
                                                                                                             profile compared
                                                                                                             to standard chemotherapy.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">HOT
                                                                                                             does not rely on
                                                                                                             inhibition or enhancement
                                                                                                             of a specific pathway;
                                                                                                             it works by exposing
                                                                                                             cancer cells to sustained
                                                                                                             lethal radiation
                                                                                                             from within.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">To
                                                                                                             date, HOT (as demonstrated
                                                                                                             with LIGHT studies)
                                                                                                             has shown near-universal
                                                                                                             cancer-specific retention
                                                                                                             in more than 50 <I>in
                                                                                                             vivo</I> tumor models,
                                                                                                             making the molecule
                                                                                                             potentially effective
                                                                                                             in numerous cancer
                                                                                                             types (broad-spectrum)
                                                                                                             as compared to type-specific
                                                                                                             therapies.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">We
                                                                                                             believe we have completed
                                                                                                             all applicable preclinical
                                                                                                             safety, pharmacology
                                                                                                             and toxicology studies
                                                                                                             that we believe will
                                                                                                             be required for an
                                                                                                             NDA including both
                                                                                                             single-dose and multi-dose
                                                                                                             studies.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">HOT
                                                                                                             is a small molecule
                                                                                                             that is easily characterized
                                                                                                             and synthesized and
                                                                                                             is therefore not
                                                                                                             subject to scale-up
                                                                                                             and manufacturing
                                                                                                             risks typically associated
                                                                                                             with large molecules
                                                                                                             such as monoclonal
                                                                                                             antibodies.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">HOT
                                                                                                             exploits a new cancer-selective
                                                                                                             delivery and retention
                                                                                                             mechanism, but is
                                                                                                             paired with a proven
                                                                                                             and effective radioisotope
                                                                                                             (I-131) for therapy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>COLD</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COLD is a cancer-targeted chemotherapy that, in pre-clinical
experiments, has been observed to inhibit the phosphatidylinosotol 3-kinase (PI3K)/Akt survival pathway and induce apoptosis through
caspase activation and inhibit cell proliferation in cancer cells versus normal cells.&nbsp; Caspases are molecules that can stimulate
apoptosis. COLD also exhibits significant <I>in vivo</I> efficacy in mouse xenograft tumor models, including non-small cell lung
cancer and triple-negative breast cancers, producing long-lasting tumor growth suppression and significantly increased survival.&nbsp;
We believe COLD has the potential to be best-in-class versus other Akt inhibitors in development and believe that&nbsp;COLD has
important advantages over competitor agents including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Selective
                                                                                                             uptake and retention
                                                                                                             by cancer cells/cancer
                                                                                                             stem cells compared
                                                                                                             to normal cells/stem
                                                                                                             cells.&nbsp; This
                                                                                                             results in significantly
                                                                                                             greater potency of
                                                                                                             COLD as an inhibitor
                                                                                                             of cell proliferation
                                                                                                             in cancer cells versus
                                                                                                             normal cells (greater
                                                                                                             than a 10-fold difference),
                                                                                                             and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Suitability
                                                                                                             for intravenous administration,
                                                                                                             avoiding dose-limiting
                                                                                                             gastrointestinal
                                                                                                             toxicity seen with
                                                                                                             orally administered
                                                                                                             Akt-inhibiting alkyl
                                                                                                             phosphocholines (APCs)
                                                                                                             and potentially enabling
                                                                                                             greater systemic
                                                                                                             drug exposure and,
                                                                                                             hence, Akt-inhibition
                                                                                                             in cancer cells,
                                                                                                             resulting in superior
                                                                                                             efficacy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-indent: -0.35in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chemically, COLD is 18-(p-[I-127] iodophenyl) octadecyl phosphocholine,
an APC subtype within the phospholipid ether (PLE) class.&nbsp; The iodine atom in its structure is the stable, non-radioactive
(&ldquo;cold&rdquo;) isotope, I-127.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COLD exhibits significant <I>in vivo</I> efficacy in mouse
xenograft tumor models, including non-small cell lung cancer and triple-negative breast cancers. In these models, human cancer
cells are transplanted into and then grow and sometimes metastasize in immunosuppressed animals.&nbsp; Tumor-bearing mice treated
therapeutically (i.e., after primary tumors were established) with intravenous COLD (100-times the mass dose&nbsp;used as a carrier
in the radiotherapy agent, HOT) once a week for 5 weeks, showed almost complete suppression of tumor growth compared to saline-treated
control animals. Tumor growth suppression by COLD was maintained long after the end of the treatment period.&nbsp; Importantly,
survival in COLD-treated groups at experiment termination (100-200 days post tumor-cell injection) was 90% or more compared to
20% or less in control groups.&nbsp; Additionally, in a side-by-side comparison, COLD was much more effective in suppressing tumor
growth and increasing survival in the lung cancer model than a standard dosing regimen of erlotinib (Tarceva<SUP>&reg;</SUP>,
a marketed epidermal growth factor receptor kinase inhibitor).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The <I>in vivo</I> efficacy of COLD is believed to be at least
in part the result of selective inhibition of the apoptosis-suppressing PI3K/Akt signaling pathway in cancer cells.&nbsp; This
pathway, which is activated by growth factors such as PDGF (platelet-derived growth factor), EGF (epidermal growth factor), and
insulin, is overactive in many human cancers and contributes to cell growth, proliferation, survival and resistance to radiation
and chemotherapeutics.&nbsp; COLD selectively inhibits Akt activation in human cancer cells compared to normal proliferating cells
(e.g., human fibroblasts).&nbsp; At the same concentrations, COLD induces apoptosis through caspase activation&nbsp;and suppresses
proliferation in a wide range of human cancer cell lines including prostate carcinoma, ovarian carcinoma, triple-negative breast
carcinomas, pancreatic adenocarcinoma and non-small cell lung cancer. At these concentrations, COLD does not inhibit proliferation
of normal cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other cancer targeting APCs have also been reported to be active
in xenograft models and to selectively inhibit tumor cell proliferation via a mechanism that involves induction of apoptosis&nbsp;through
caspase activation subsequent to inhibition of Akt activation and signaling.&nbsp;However, APCs are generally dose-limited <I>in
vivo</I> (including in man) by side effects stemming from the necessity for their oral administration (due to their hemolytic
properties), thus limiting Akt inhibition and anti-tumor efficacy.&nbsp; In contrast, data to date support the contention that
COLD can be safely administered intravenously at doses that we believe will result in greater drug exposure compared to other
APCs and, thus, in greater Akt inhibition and improved efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Non-APC Akt inhibitors in development are not cancer-targeting
and thus have the potential for an unfavorable therapeutic index (due to non-selective inhibition of Akt, and hence proliferation)
in normal versus cancer cells.&nbsp; In contrast, selective uptake and retention of COLD results in greater than a 10-fold more
potent inhibition of Akt activity and cell proliferation in cancer cells versus normal cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Technology</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LIGHT, HOT and COLD are optimized phospholipid ether (PLE)
analogs that interact with lipid rafts, which are specialized microdomains within cell membranes.&nbsp; Importantly, the core
chemical structure shared across all three products provides selective targeting of cancer cells in preference to normal cells
(due to enrichment of lipid rafts in the former).&nbsp; COLD was deliberately designed to contain iodine (in the form of the stable,
non-radioactive isotope,<SUP> </SUP>I-127), thus enabling additional, distinct products differing only with respect to the form
of iodine they contain &ndash; HOT contains short-lived radioactive I-131 and LIGHT contains even more short-lived I-124. As a
result, three cancer-targeted product profiles have been generated from a single chemical structure &mdash; a diagnostic/imaging
agent (LIGHT), a molecular radiotherapeutic agent (HOT) and a non-radioactive chemo-therapeutic agent (COLD).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Using a fluorescent-labeled analog of COLD (CLR1501 or GLOW1),
selective uptake and retention has been demonstrated in cancer cells <I>in vitro</I>.&nbsp; Twenty-four hours after treatment,
a variety of human tumor cell types (melanoma, colorectal, uterine, pancreatic, ovarian, glioblastoma) show six- to ten-fold more
staining with GLOW1 relative to&nbsp;&nbsp;normal cells (e.g., skin fibroblasts).&nbsp; Significantly, uptake/retention was also
seen in cancer stem cells, which are known to be relatively resistant to both chemotherapy and radiation and may therefore contribute
to eventual relapse of disease following conventional chemotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Malignant tumor targeting, including targeting of cancer stem
cells, has also been demonstrated <I>in vivo</I>. For example, mice without intact immune systems, and inoculated with Panc-1
(pancreatic carcinoma), were injected with CLR1502 (GLOW2, a fluorescent-labeled analog of COLD that is active in the near-infrared
range) 24 or 96 hours prior to imaging.&nbsp; <I>In vivo</I> optical imaging showed pronounced accumulation of GLOW2 in tumors
versus non-target organs and tissues.&nbsp; Similarly, PET imaging of tumor-bearing animals (colon, glioma, triple negative breast
and pancreatic tumor xenograft models) administered the imaging agent LIGHT clearly shows selective uptake and retention by both
primary tumors and metastases, including cancer stem cells.&nbsp; Furthermore, PET/CT analysis following co-injection of HOT (for
therapy) and LIGHT (for imaging) revealed time-dependent tumor shrinkage and disappearance (over 9 days) in a cancer xenograft
model.&nbsp; Finally, we believe that the capability of our technology to target cancer stem cells <I>in vivo</I> was demonstrated
by treating tumor-bearing mice with GLOW1 and then removing the tumor and isolating cancer stem cells, which continued to display
GLOW1 labeling even after three weeks in cell culture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The basis for selective tumor targeting of our compounds lies
in differences between the plasma membranes of cancer cells as compared to those of most normal cells.&nbsp; Specifically, cancer
cell membranes are highly enriched in &ldquo;lipid rafts&rdquo;.&nbsp; Lipid rafts are specialized regions of the membrane phospholipid
bilayer that contain high concentrations of cholesterol and sphingolipids and serve to organize cell surface and intracellular
signaling molecules (e.g., growth factor and cytokine receptors, the phophatidylinosotol 3-kinase (P13K)/Akt survival pathway).
Lipid rafts are central to the activity of our compounds in two ways:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Lipid
                                                                                                     rafts are portals of entry
                                                                                                     for PLEs such as LIGHT, HOT
                                                                                                     and COLD.&nbsp; The marked
                                                                                                     selectivity of our compounds
                                                                                                     for cancer cells versus non-cancer
                                                                                                     cells is due to the fact
                                                                                                     that cancer cells have far
                                                                                                     more lipid rafts. In addition
                                                                                                     to accumulating in lipid
                                                                                                     rafts, LIGHT, HOT and COLD
                                                                                                     are transported into the
                                                                                                     cytoplasm, where they distribute
                                                                                                     to organelle membranes (mitochondria,
                                                                                                     ER, lysosomes) but not the
                                                                                                     nucleus.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Lipid
                                                                                                     rafts also regulate signaling-based
                                                                                                     cell functions including
                                                                                                     apoptosis and cell proliferation,
                                                                                                     and COLD disrupts this regulation.
                                                                                                     For example, one key signaling
                                                                                                     pathway that is regulated
                                                                                                     by interactions with lipid
                                                                                                     rafts and phospholipids is
                                                                                                     the phosphatidylinosotol
                                                                                                     3-kinase (PI3K)/Akt pathway.&nbsp;
                                                                                                     Akt (a serine/threonine protein
                                                                                                     kinase) is activated in lipid
                                                                                                     raft regions via phosphorylation
                                                                                                     by PI-dependent kinases and
                                                                                                     goes on to phosphorylate
                                                                                                     anti-apoptotic proteins (e.g.,
                                                                                                     Bcl-xL and FLIP) resulting
                                                                                                     in their inactivation and
                                                                                                     thus promotion of tumor cell
                                                                                                     survival.&nbsp; COLD pharmacologically
                                                                                                     inhibits the activation of
                                                                                                     Akt.&nbsp; In cancer cells,
                                                                                                     Akt inhibition is associated
                                                                                                     with induction of apoptosis
                                                                                                     and decreased cell proliferation/survival.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pivotal role played by lipid rafts
is underscored by the facts that (a) GLOW1 co-localizes with lipid raft components (cholesterol, ganglioside M1) in plasma membranes
of cancer cells and (b) disruption of lipid raft architecture suppresses uptake of GLOW1 and radiolabeled COLD into cancer cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legacy Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the Acquisition, Novelos had
been developing NOV-002, a small-molecule immunomodulating and anti-cancer compound based on a proprietary formulation of oxidized
glutathione.&nbsp; NOV-002 has been administered to approximately 1,000 cancer patients in clinical trials and was in Phase 2
development for solid tumors in combination with chemotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From November 2006 through January 2010,
we conducted a Phase 3 trial of NOV-002 plus first-line chemotherapy in advanced non-small cell lung cancer (NSCLC) following
three Phase 2 trials (two conducted in Russia and one conducted by us in the U.S.) that had demonstrated clinical activity and
safety.&nbsp; The Phase 3 trial enrolled 903 patients, 452 of whom received NOV-002.&nbsp; In February 2010, we announced that
the primary endpoint of improvement in overall survival compared to first-line chemotherapy alone was not met in this pivotal
Phase 3 trial.&nbsp; Following evaluation of the detailed trial data, we announced in March 2010 that the secondary endpoints
also were not met in the trial and that adding NOV-002 to paclitaxel and carboplatin chemotherapy was not statistically or meaningfully
different in terms of efficacy-related endpoints or recovery from chemotherapy toxicity versus chemotherapy alone. However, NOV-002
was safe and did not add to the overall toxicity of chemotherapy.&nbsp; Based on the results from the Phase 3 trial, we have discontinued
development of NOV-002 for NSCLC in combination with first-line paclitaxel and carboplatin chemotherapy.&nbsp; The aggregate costs
incurred in connection with our development of NOV-002, including administrative overhead, were approximately $70 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the Acquisition, Novelos had
also been developing NOV-205, a second oxidized glutathione-based compound. NOV-205 had been administered to approximately 200
hepatitis patients in clinical trials and was in Phase 2 development for chronic hepatitis C non-responders.&nbsp; An IND for
NOV-205 as a monotherapy for chronic hepatitis C was accepted by the FDA in 2006.&nbsp; A U.S. Phase 1b clinical trial with NOV-205
in patients who previously failed treatment with pegylated interferon plus ribavirin was completed in December 2007.&nbsp; Based
on favorable safety results of that trial, in March 2010 Novelos initiated a multi-center U.S. Phase 2 trial evaluating NOV-205
as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus
ribavirin.&nbsp; Safety was established in twenty patients receiving either 30mg or 60mg of NOV-205 daily for 49 days; however,
no viral load reduction was observed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further development of NOV-002 and NOV-205
has been suspended.&nbsp; At this time, we expect to devote our resources to the development and commercialization of the Cellectar
compounds, and we do not expect to conduct any further development of the oxidized glutathione compounds. The IND for NOV-205
was withdrawn on July 5, 2011.&nbsp;&nbsp;We anticipate that the IND for NOV-002 will be placed on inactive status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Manufacturing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We manufacture HOT and COLD at our current Good Manufacturing
Practices compliant (cGMP) radiopharmaceutical manufacturing facility in Madison, Wisconsin.&nbsp; This facility, consisting of
approximately 19,500 square feet, contains offices, laboratories, a radiopharmaceutical research lab, a cGMP radiopharmaceutical
manufacturing suite and a cGMP analytical laboratory for product release.&nbsp; Our manufacturing facility holds a State of Wisconsin
Department of Health Services Radioactive Materials License which authorizes the use and possession of radioactive material for
both manufacturing and distribution activities. This license establishes a possession limit of 9 Curies of iodine-131. The facility
also holds a State of Wisconsin DHS Radioactive Materials License which authorizes the use and possession of radioactive materials
by Cellectar for research and development. The research and development license permits the use and possession of iodine-125, iodine-131
and iodine-124 in quantities sufficient to support in-house HOT manufacturing and other research needs. To date, small quantities
of LIGHT have been manufactured by our collaborator, the University of Wisconsin in Madison, in connection
with investigator-sponsored clinical trials, pursuant to a materials transfer agreement expiring in June 2013. The materials transfer
agreement contains standard provisions for the protection of data and intellectual property and may be terminated by either party
at any time before expiration. We are in the process of negotiating a fee-based arrangement with the University of Wisconsin covering
the manufacture of LIGHT. If the University was unable to manufacture LIGHT for any reason, we believe we could manufacture
it at our Madison facility without material additional investment.&nbsp; The drug substance is identical for all three products
with the exception of the different iodine isotope used in each.&nbsp; The base molecule is a dry powder produced via a six-step
synthetic scheme.&nbsp; The release specifications for drug substance have been established and validated.&nbsp; The impurity levels
at small scale are very low suggesting that larger scale production should be feasible.&nbsp; We have also demonstrated 24-month
stability for the drug substance in desiccated and refrigerated form.&nbsp; We believe our laboratories are well equipped with
the appropriate equipment for manufacturing pilot and small-scale batches in accordance with cGMP.&nbsp; We believe we have adequate
capacity for any Phase 2 trials of HOT and the potential for larger scale build-out for larger Phase 3 trials.&nbsp; All investigational
drug substance and product intended for human use during clinical studies will be manufactured according to ICH guidelines, FDA
requirements (CFR part 211) and cGMP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Sales and Marketing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not entered into any joint development or similar partnering
agreements with respect to LIGHT, HOT or COLD.&nbsp; We plan to pursue and evaluate all available options to develop, launch and
commercialize our compounds.&nbsp; These options presently include, but are not limited to, entering into a partnering arrangement
with a pharmaceutical company or various pharmaceutical companies with strong development and commercial expertise and infrastructure
in the U.S, Europe and/or Japan.&nbsp; While we currently do not plan to build our own sales force or utilize a contract sales
organization for launch and commercialization of our compounds, we may reconsider in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>LIGHT</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FDG is the current gold standard for cancer PET imaging.&nbsp;
According to Bio-Tech Systems (November 2010), sales of FDG in the US in 2009 were approximately $300 million and projected to
grow to approximately $880 million in 2017.&nbsp; FDG accumulates in any tissue having increased glucose metabolism compared to
surrounding tissue.&nbsp; As a result, and in contrast to LIGHT, FDG is not selective for malignant tumors.&nbsp; FDG localizes
in certain normal tissue such as heart, kidney and brain tissues that also have high glucose metabolism.&nbsp; FDG is also known
to localize in inflammatory sites.&nbsp; Other major limitations to the use of FDG are found in pelvic imaging due to the high
renal (kidney) clearance of the compound.&nbsp; We believe these characteristics of FDG, therefore, decrease its diagnostic specificity
for certain malignancies. FDG is no longer covered by patent and is typically manufactured onsite at PET imaging medical facilities
because of its limited (110 minute) half-life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We compared LIGHT and FDG side by side (24 hours apart) in the
same tumor-bearing mouse that was also treated with carageenan to induce inflammation.&nbsp; As expected, FDG demonstrated significant
uptake into the inflammatory lesion and organs such as heart and bladder compared to the malignant tumors, which were poorly imaged.&nbsp;
LIGHT, on the other hand, showed no uptake into the inflammatory lesion and organs, yet clear and demonstrable uptake into the
tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, the radioisotopic half-life of only 110 minutes
for fluorine-18 labeled agents, such as FDG, severely limits their delivery range relative to the point of manufacture. I-124 has
a four-day half-life that permits worldwide distribution of LIGHT from one manufacturing location.&nbsp; Additionally, the longer
half-life affords a longer imaging window of up to seven days following injection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>HOT</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">HOT&rsquo;s &ldquo;intracellular radiation&rdquo; mechanism
of cancer cell killing, coupled with delivery to a wide range of malignant tumor types, imbues HOT with broad-spectrum anti-cancer
activity.&nbsp;Selective uptake and retention has also been demonstrated in cancer stem cells compared with normal stem cells,
offering a prospect of longer lasting cancer remission. Other targeted radiotherapies include the marketed drugs Zevalin&reg; (manufactured
by Spectrum Pharmaceuticals) and Bexxar&reg; (manufactured by GlaxoSmithKline).&nbsp; In both cases, tumor-targeting is monoclonal
antibody-based and limited to non-Hodgkins lymphoma, which is a type of cancer involving cells of the immune system.&nbsp; Thus,
these agents are not appropriate comparators for HOT because of their limited therapeutic utility (only one type of tumor) and
because their target indication is often well-managed by other drugs (unlike HOT which has potential to treat tumor types for which
the current standard of care is associated with very poor outcomes). Notably, both Zevalin&reg; and Bexxar&reg; were approved on
the basis of objective response rates (shrinking of tumors) without data to support improvement in survival, suggesting that regulatory
approval of radiopharmaceuticals may be based on relatively shorter and smaller pivotal clinical trials than is often the case
in oncology.&nbsp; We do not believe Zevalin&reg; or Bexxar&reg; would be competing products of HOT in any material respect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>COLD</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe COLD has the potential to be best-in-class versus
other Akt inhibitors in development.&nbsp; We believe COLD has important advantages over competitor agents including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font-size: 10pt">&bull;&nbsp;</TD>
    <TD STYLE="width: 94%; font-size: 10pt">Selective uptake and retention by cancer cells/cancer stem cells compared to normal cells/stem cells.&nbsp; This results in significantly greater potency of COLD as an inhibitor of cell proliferation in cancer cells versus normal cells (greater than a10-fold difference), or</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font-size: 10pt">&bull;&nbsp;</TD>
    <TD STYLE="width: 94%; font-size: 10pt">Suitability for intravenous administration, avoiding dose-limiting gastrointestinal toxicity seen with orally administered Akt-inhibiting APCs and potentially enabling greater systemic drug exposure and, hence, Akt-inhibition in cancer cells, resulting in superior efficacy.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have established a broad U.S. and international intellectual
property rights portfolio around our cancer-targeting phospholipid ether technology platform including LIGHT, HOT and COLD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our proprietary rights include patents and patent applications
that are either owned by us or exclusively licensed to us by the University of Michigan (the Michigan patents). LIGHT and HOT are
covered by the Michigan patents that provide compound (composition of matter) coverage in the US and Canada and expire in 2016.&nbsp;
Our patents and applications cover methods of use, composition and method of manufacture related to LIGHT, HOT and COLD.&nbsp;
Many of these patents and applications are filed in key commercial markets worldwide.&nbsp; These patents will generally expire
between 2025 and 2030 unless extended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In particular, LIGHT is covered by the Michigan compound patents
as well as two of our U.S. patents, one of which is directed to its use for virtual colonoscopy (expiring 2025) and another of
which is directed to its use for <I>in vitro</I> diagnostics (expiring 2025).&nbsp; LIGHT is also covered by pending U.S. and European
patent applications directed to its use for <I>in vivo</I> diagnostics and once issued should expire in 2025.&nbsp; Lastly, the
use of LIGHT for diagnostics purposes with cancer stem cells is pending in the U.S., Europe, and Japan. Patents resulting from
these applications are expected to expire in 2030.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">HOT is covered by two additional series of our patents and applications
aside from the Michigan patents.&nbsp; The first is directed to a method of use for cancer therapy and has also been filed in Europe
and Japan, in addition to the U.S.&nbsp; These are expected to expire in 2025.&nbsp; Secondly, an application directed to cancer
stem-cell therapy is pending in the U.S., Europe, and Japan. Patents resulting from these applications are expected to expire in
2030. Some of these resulting patents may be extendable on a country-by-country basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COLD is covered by a series of pending applications directed
to methods of using COLD for cancer therapy and&nbsp;is expected to&nbsp;be filed/nationalized in foreign countries by 2012.&nbsp;
These patents, once issued, would expire in 2030.&nbsp; Some of these resultant patents may be extendable on a country-by-country
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Separate from any patent protection and following product approval
by regulatory authorities, data exclusivity may be available for HOT and COLD for up to 10 years on a country-by-country basis
(e.g., up to 5 years in the U.S.).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The early termination of the University of Michigan license
agreement would result in the loss of our rights to use the covered patents, which could severely delay, inhibit or eliminate our
ability to develop and commercialize compounds based on the licensed patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the above noted patents/applications directed
to LIGHT, HOT and COLD, we own other patents/applications directed to different forms of phospholipid ethers and methods of manufacturing
of phospholipid ethers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also own all intellectual property rights worldwide (excluding
Russia and the other states of the former Soviet Union, the Russian Territory) related to our clinical-stage pipeline compound,
NOV-002, and other pre-clinical compounds based on oxidized glutathione.&nbsp; Issued composition-of-matter patents cover proprietary
formulations of oxidized glutathione that do not expire until 2019, and these patents include methods of manufacture for oxidized
glutathione formulated with various metals.&nbsp; In our dispute with ZAO BAM and ZAO BAM Research Laboratories (Russian companies,
collectively referred to as BAM), one of the remedies BAM is seeking is the revocation of our rights in these compounds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Licenses / Collaborations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2003, Cellectar entered into a license agreement
with the University of Michigan (the U. Mich. license), which granted Cellectar exclusive rights to the development, manufacture
and marketing of products under several composition of matter patents in North America that expire at varying dates in 2016.&nbsp;
The U. Mich. license expires upon the expiration of the last covered patent.&nbsp; We are responsible for an annual license fee
of $10,000 and are required to pay costs associated with the maintenance of the patents covered by the U. Mich. license.&nbsp;
Additionally, we are required to make milestone payments of $50,000 upon the filing of a New Drug Application (NDA) for a licensed
product intended for use in a therapeutic or diagnostic application (such milestone fees may be deferred and paid within twelve
months of the first commercial sale of such product) and make certain milestone payments within a year following the first commercial
sale of any licensed products.&nbsp; The sales milestones range from $100,000 to $200,000, dependent upon whether the drug is for
use in a diagnostic or therapeutic application, provided that if sales in the first 12 months are less than the amount of the milestone,
then we are required to pay 50% of all sales until the milestone is satisfied. The milestone payments may total up to $400,000.
The U. Mich. license provides that we pay a royalty equal to 3% of net sales of any licensed products sold by us or our sublicensees
for such licensed products, provided however if the sublicense fee payable to us is between 4% and 5% of net sales, then the royalties
payable to U. Mich. shall be equal to 50% of the sublicense fee.&nbsp; Furthermore, the U. Mich. license provides for a reduction
in the royalties owed by up to 50% if we are required to pay royalties to any third parties related to the sale of the licensed
products.&nbsp; If we receive any revenue in consideration of rights to the licensed technology that is not based on net sales,
excluding any funded research and development, we are required to pay U. Mich. 10% of amounts received. During 2003, pursuant to
the U. Mich. license, Cellectar paid approximately $54,000 of back patent costs and issued 203,483 shares of common stock to U.
Mich. as partial consideration for the rights described above. U. Mich. may terminate the agreement if we cease operations, if
we fail to make any required payment under the agreement, or if we otherwise materially breach the agreement, subject to applicable
notice and cure periods.&nbsp; To date, we have made all payments as they have become due, there have been no defaults under the
U. Mich. license, nor have we ever been notified of a default by U. Mich. We may terminate the agreement with six months&rsquo;
notice to U. Mich. and the return of licensed product and related data.&nbsp; The U. Mich. license contained milestones that required
certain development activities to be completed by specified dates. All such development milestones have been either completed or
removed by subsequent amendment to the agreement.&nbsp; U. Mich. has provided no warranties as to validity or otherwise with respect
to the licensed technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 5, 2012 we had 19 full time employees. We believe
our relationships with our employees are good.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The production, distribution, and marketing of products employing
our technology, and our development activities, are subject to extensive governmental regulation in the United States and in other
countries.&nbsp; In the United States, we are subject to the Federal Food, Drug, and Cosmetic Act, as amended, and the regulations
of the FDA, as well as to other federal, state, and local statutes and regulations, including the federal, state and local laws
and regulations governing the storage, use and disposal of hazardous materials, including radioactive isotopes.&nbsp; These laws,
and similar laws outside the United States, govern the clinical and preclinical testing, manufacture, safety, effectiveness, approval,
labeling, distribution, sale, import, export, storage, record-keeping, reporting, advertising, and promotion of drugs.&nbsp; Product
development and approval within this regulatory framework, if successful, will take many years and involve the expenditure of substantial
resources.&nbsp; Violations of regulatory requirements at any stage may result in various adverse consequences, including the FDA&rsquo;s
and other health authorities&rsquo; delay in approving or refusal to approve a product.&nbsp; Violations of regulatory requirements
also may result in enforcement actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following paragraphs provide further information on certain
legal and regulatory issues with a particular potential to affect our operations or future marketing of products employing our
technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Research, Development, and Product Approval Process</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The research, development, and approval process in the United
States and elsewhere is intensive and rigorous and generally takes many years to complete.&nbsp; The typical process required by
the FDA before a therapeutic drug may be marketed in the United States includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 5%; font-family: Symbol">&middot;</TD>
    <TD STYLE="width: 89%">preclinical laboratory and animal tests performed under the FDA&rsquo;s Good Laboratory Practices regulations, referred to herein as GLP;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>submission to the FDA of an IND, which must become effective before human clinical trials may commence;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>human clinical studies performed under the FDA&rsquo;s Good Clinical Practices regulations, to evaluate the drug&rsquo;s safety and effectiveness for its intended uses;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>FDA review of whether the facility in which the drug is manufactured, processed, packed, or held meets standards designed to assure the product&rsquo;s continued quality; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>submission of a marketing application to the FDA, and approval of the application by the FDA.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Preclinical Testing</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During preclinical testing, studies are performed with respect
to the chemical and physical properties of candidate formulations. These studies are subject to GLP requirements. Biological testing
is typically done in animal models to demonstrate the activity of the compound against the targeted disease or condition and to
assess the apparent effects of the new product candidate on various organ systems, as well as its relative therapeutic effectiveness
and safety. An IND must be submitted to the FDA and become effective before studies in humans may commence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Clinical Trials</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Clinical trial programs in humans generally follow a three-phase
process.&nbsp; Typically, Phase 1 studies are conducted in small numbers of healthy volunteers or, on occasion, in patients afflicted
with the target disease.&nbsp; Phase 1 studies are conducted to determine the metabolic and pharmacological action of the product
candidate in humans and the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness.&nbsp;
In Phase 2, studies are generally conducted in larger groups of patients having the target disease or condition in order to validate
clinical endpoints, and to obtain preliminary data on the effectiveness of the product candidate and optimal dosing. This phase
also helps determine further the safety profile of the product candidate.&nbsp; In Phase 3, large-scale clinical trials are generally
conducted in patients having the target disease or condition to provide sufficient data for the statistical proof of effectiveness
and safety of the product candidate as required by United States regulatory agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the case of products for certain serious or life-threatening
diseases, the initial human testing may be done in patients with the disease rather than in healthy volunteers. Because these patients
are already afflicted with the target disease or condition, it is possible that such studies will also provide results traditionally
obtained in Phase 2 studies. These studies are often referred to as &ldquo;Phase 1-2&rdquo; studies. However, even if patients
participate in initial human testing and a Phase 1/2 study carried out, the sponsor is still responsible for obtaining all the
data usually obtained in both Phase 1 and Phase 2 studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Before proceeding with a study, sponsors may seek a written
agreement from the FDA regarding the design, size, and conduct of a clinical trial. This is known as a Special Protocol Assessment
(SPA). Among other things, SPAs can cover clinical studies for pivotal trials whose data will form the primary basis to establish
a product&rsquo;s efficacy. SPAs help establish upfront agreement with the FDA about the adequacy of a clinical trial design to
support a regulatory approval, but the agreement is not binding if new circumstances arise. There is no guarantee that a study
will ultimately be adequate to support an approval even if the study is subject to an SPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">United States law requires that studies conducted to support
approval for product marketing be &ldquo;adequate and well controlled.&rdquo; In general, this means that either a placebo or a
product already approved for the treatment of the disease or condition under study must be used as a reference control. Studies
must also be conducted in compliance with good clinical practice requirements, and informed consent must be obtained from all study
subjects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The clinical trial process for a new compound can take ten years
or more to complete. The FDA may prevent clinical trials from beginning or may place clinical trials on hold at any point in this
process if, among other reasons, it concludes that study subjects are being exposed to an unacceptable health risk. Trials may
also be prevented from beginning or may be terminated by institutional review boards, who must review and approve all research
involving human subjects. Side effects or adverse events that are reported during clinical trials can delay, impede, or prevent
marketing authorization. Similarly, adverse events that are reported after marketing authorization can result in additional limitations
being placed on a product&rsquo;s use and, potentially, withdrawal of the product from the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Submission of NDA</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the completion of clinical trials, the data is analyzed
to determine whether the trials successfully demonstrated safety and effectiveness and whether a product approval application may
be submitted. In the United States, if the product is regulated as a drug, an NDA must be submitted and approved before commercial
marketing may begin. The NDA must include a substantial amount of data and other information concerning the safety and effectiveness
of the compound from laboratory, animal, and human clinical testing, as well as data and information on manufacturing, product
quality and stability, and proposed product labeling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each domestic and foreign manufacturing establishment, including
any contract manufacturers we may decide to use, must be listed in the NDA and must be registered with the FDA.&nbsp; The application
generally will not be approved until the FDA conducts a manufacturing inspection, approves the applicable manufacturing process
and determines that the facility is in compliance with cGMP requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Prescription Drug User Fee Act, as amended, the FDA
receives fees for reviewing an NDA and supplements thereto, as well as annual fees for commercial manufacturing establishments
and for approved products. These fees can be significant. For fiscal year 2012, the NDA review fee alone is $1,841,500, although
certain limited deferral, waivers, and reductions may be available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each NDA submitted for FDA approval is usually reviewed for
administrative completeness and reviewability within 45 to 60 days following submission of the application. If deemed complete,
the FDA will &ldquo;file&rdquo; the NDA, thereby triggering substantive review of the application. The FDA can refuse to file any
NDA that it deems incomplete or not properly reviewable. The FDA has established performance goals for the review of NDAs&mdash;
six months for priority applications and 10 months for standard applications. However, the FDA is not legally required to complete
its review within these periods and these performance goals may change over time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Moreover, the outcome of the review, even if generally favorable,
typically is not an actual approval but an &ldquo;action letter&rdquo; that describes additional work that must be done before
the application can be approved. The FDA&rsquo;s review of an application may involve review and recommendations by an independent
FDA advisory committee. Even if the FDA approves a product, it may limit the approved therapeutic uses for the product as described
in the product labeling, require that warning statements be included in the product labeling, require that additional studies be
conducted following approval as a condition of the approval, impose restrictions and conditions on product distribution, prescribing,
or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Post NDA Regulation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Significant legal and regulatory requirements also apply after
FDA approval to market under an NDA. These include, among other things, requirements related to adverse event and other reporting,
product advertising and promotion and ongoing adherence to cGMPs, as well as the need to submit appropriate new or supplemental
applications and obtain FDA approval for certain changes to the approved product labeling, or manufacturing process. The FDA also
enforces the requirements of the Prescription Drug Marketing Act which, among other things, imposes various requirements in connection
with the distribution of product samples to physicians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The regulatory framework applicable to the production, distribution,
marketing and/or sale of our product pipeline may change significantly from the current descriptions provided herein in the time
that it may take for any of our products to reach a point at which an NDA is approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Overall research, development, and approval times depend on
a number of factors, including the period of review at FDA, the number of questions posed by the FDA during review, how long it
takes to respond to the FDA&rsquo;s questions, the severity or life-threatening nature of the disease in question, the availability
of alternative treatments, the availability of clinical investigators and eligible patients, the rate of enrollment of patients
in clinical trials, and the risks and benefits demonstrated in the clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Other United States Regulatory Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the United States, the research, manufacturing, distribution,
sale, and promotion of drug and biological products are potentially subject to regulation by various federal, state, and local
authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services (formerly the Heath Care Financing
Administration), other divisions of the United States Department of Health and Human Services (e.g., the Office of Inspector General),
the United States Department of Justice and individual United States Attorney offices within the Department of Justice, and state
and local governments. For example, sales, marketing, and scientific/educational grant programs must comply with the anti-fraud
and abuse provisions of the Social Security Act, the False Claims Act, the privacy provision of the Health Insurance Portability
and Accountability Act, and similar state laws, each as amended. Pricing and rebate programs must comply with the Medicaid rebate
requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Health Care Act of 1992, each as amended. If products
are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and
requirements apply. All of these activities are also potentially subject to federal and state consumer protection, unfair competition,
and other laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our research and development, manufacturing and administration
of our drugs involves the controlled use of hazardous materials, including chemicals and radioactive materials, such as radioactive
isotopes. Therefore, we are subject to federal, state and local laws and regulations governing the storage, use and disposal of
these materials and some waste products and are required to maintain both a manufacturer&rsquo;s license and a radioactive materials
license with State of Wisconsin agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Moreover, we are now, and may become subject to, additional
federal, state, and local laws, regulations, and policies relating to safe working conditions, laboratory practices, the experimental
use of animals, and/or the use, storage, handling, transportation, and disposal of human tissue, waste, and hazardous substances,
including radioactive and toxic materials and infectious disease agents used in conjunction with our research work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Foreign Regulatory Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We and any future collaborative partners may be subject to widely
varying foreign regulations, which may be quite different from those of the FDA, governing clinical trials, manufacture, product
registration and approval, and pharmaceutical sales. Whether or not FDA approval has been obtained, we or any future collaboration
partners must obtain a separate approval for a product by the comparable regulatory authorities of foreign countries prior to the
commencement of product marketing in these countries. In certain countries, regulatory authorities also establish pricing and reimbursement
criteria. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA
approval. In addition, under current United States law, there are restrictions on the export of products not approved by the FDA,
depending on the country involved and the status of the product in that country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Reimbursement and Pricing Controls</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In many of the markets where we or any future collaborative
partners would commercialize a product following regulatory approval, the prices of pharmaceutical products are subject to direct
price controls by law and to drug reimbursement programs with varying price control mechanisms. Public and private health care
payers control costs and influence drug pricing through a variety of mechanisms, including through negotiating discounts with the
manufacturers and through the use of tiered formularies and other mechanisms that provide preferential access to certain drugs
over others within a therapeutic class. Payers also set other criteria to govern the uses of a drug that will be deemed medically
appropriate and therefore reimbursed or otherwise covered. In particular, many public and private health care payers limit reimbursement
and coverage to the uses of a drug that are either approved by the FDA or that are supported by other appropriate evidence (for
example, published medical literature) and appear in a recognized drug compendium. Drug compendia are publications that summarize
the available medical evidence for particular drug products and identify which uses of a drug are supported or not supported by
the available evidence, whether or not such uses have been approved by the FDA. For example, in the case of Medicare coverage for
physician-administered oncology drugs, the Omnibus Budget Reconciliation Act of 1993, with certain exceptions, prohibits Medicare
carriers from refusing to cover unapproved uses of an FDA-approved drug if the unapproved use is supported by one or more citations
in the American Hospital Formulary Service Drug Information, the American Medical Association Drug Evaluations, or the United States
Pharmacopoeia Drug Information. Another commonly cited compendium, for example under Medicaid, is the DRUGDEX Information System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In recent years, there have been positive developments regarding
medical reimbursement for therapeutic radiopharmaceuticals in the United States.&nbsp; The Centers for Medicare and Medicaid Services
have proposed that the reimbursement for radiopharmaceuticals shift from a cost-to-charge ratio (CCR) to an average selling price
(ASP) plus 4% model.&nbsp; There has been support expressed for this proposal by government agencies, key industry members and
the industry consortium, The Council on Radionuclides and Radiopharmaceuticals.&nbsp; The historical CCR model resulted in a reimbursement
rate that was lower than the cost to purchase the drugs, thus creating a disincentive for hospitals to prescribe radiopharmaceuticals.&nbsp;
The current ASP proposal is a solution to this reimbursement problem.&nbsp; Furthermore, there are proposals pending, which, if
adopted, would decrease the physician reimbursement for chemotherapy and conventional radiation therapy.&nbsp; The proposed reduction
in physician reimbursement for chemotherapy could likely result in the movement of a large volume of cancer care from the physician&rsquo;s
office to the hospital environment.&nbsp; The proposed reduction in physician reimbursement for radiation therapy would result
in a gap in revenue for radiation oncologists.&nbsp; Both proposed reductions favor an increase in opportunities to prescribe therapeutic
radiopharmaceuticals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LITIGATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A putative federal securities class action complaint was filed
on March 5, 2010 in the United States District Court for the District of Massachusetts by an alleged shareholder of Novelos, on
behalf of himself and all others who purchased or otherwise acquired our common stock in the period between December 14, 2009 and
February 24, 2010, against Novelos and our President and Chief Executive Officer, Harry S. Palmin.&nbsp; On October 1, 2010, the
court appointed lead plaintiffs (Boris Urman and Ramona McDonald) and appointed lead plaintiffs&rsquo; counsel.&nbsp; On October
22, 2010, an amended complaint was filed.&nbsp; The amended complaint claims, among other things, that the defendants violated
Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder in connection with alleged
misleading disclosures related to the progress of the Phase 3 clinical trial of NOV-002 for non-small cell lung cancer.&nbsp; On
December 6, 2010, we filed a motion to dismiss the complaint with prejudice.&nbsp; On January 20, 2011, the plaintiffs filed their
opposition to our motion and on March 3, 2011, we filed our response to their opposition. On June 23, 2011, the motion to dismiss
was granted and the case was dismissed without prejudice.&nbsp; &nbsp;On August 5, 2011, the plaintiffs filed a second amended
complaint realleging that the defendants violated Section 10(b) of the Exchange Act and Rule 10b-5 in connection with alleged misleading
disclosures related to the Phase 3 clinical trial for NOV-002 in non-small cell lung cancer. On September 9, 2011, the defendants
filed a motion to dismiss the second amended complaint. The plaintiffs&rsquo; opposition to the motion&nbsp;was filed on&nbsp;October
14, 2011 and the defendants filed a reply brief on November 4, 2011. The Company and Mr. Palmin believe the allegations are without
merit and intend to continue to vigorously defend against them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 28, 2010, we received a letter from counsel to ZAO BAM
and ZAO BAM Research Laboratories (Russian companies, collectively referred to as BAM) alleging that we modified the chemical composition
of NOV-002 without prior notice to or approval from BAM, constituting a material breach of a technology and assignment agreement
we had entered into with BAM on June 20, 2000 (the June 2000 Agreement).&nbsp; The letter references our amendment, submitted to
the FDA on August 30, 2005, to our investigational new drug application dated August 1999 as the basis for BAM&rsquo;s claims and
demands the transfer of all intellectual property rights concerning NOV-002 to BAM.&nbsp; Mark Balazovsky, a director of Novelos
from June 1996 until November 2006 and a shareholder of Novelos through at least June 25, 2010, is, to our knowledge, still the
general director and principal shareholder of ZAO BAM.&nbsp; On September 24, 2010, we filed a complaint in Suffolk Superior Court
seeking a declaratory judgment by the court that the June 2000 Agreement has been replaced by a subsequent agreement between the
parties dated April 1, 2005 (the April 2005 Agreement), that Novelos&rsquo; obligations to BAM are governed solely by the April
2005 Agreement and that the obligations of the June 2000 agreement have been performed and fully satisfied.&nbsp; On November 29,
2010, BAM answered the complaint, denying the material allegations, and stating its affirmative defenses and certain counterclaims.
On January 14, 2011, we responded to the counterclaims, denying BAM&rsquo;s material allegations and stating our affirmative defenses.&nbsp;
On June 9, 2011, BAM filed an amended counterclaim alleging additional claims related to Novelos&rsquo; acquisition of Cellectar.&nbsp;
In that amended counterclaim, BAM alleges that the acquisition evidences Novelos&rsquo; abandonment of the technology assigned
to it by BAM constituting a breach of the June 2000 Agreement or, if that agreement is determined to no longer be in effect, a
breach of the April 2005 Agreement and/or a breach of the implied duty of good faith and fair dealing with respect to the April
2005 Agreement.&nbsp; &nbsp;On June 15, 2011 we filed our response to their amended counterclaim.&nbsp; On August 5, 2011, we filed
a motion for judgment on the pleadings as to our declaratory judgment count and all counts of BAM&rsquo;s amended counterclaim.&nbsp;
The motion&nbsp;was opposed by BAM and a hearing on the motion&nbsp;was&nbsp;held&nbsp;on September 27, 2011. On October 17, 2011,
the court ruled on our behalf for each of our declaratory judgment claims and dismissed all counts of BAM&rsquo;s counterclaim.
Judgment in favor of the Company was entered on October 20, 2011. On November 14, 2011, BAM filed a notice of appeal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not anticipate that these litigation contingencies will
have a material adverse effect on the Company&rsquo;s future financial position, results of operations or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROPERTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We lease our executive office in Newton, Massachusetts.&nbsp;
Our office consists of approximately 2,000 square feet and is rented for approximately $5,300 per month.&nbsp; This lease may be
terminated by either party with one month&rsquo;s notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We lease office, laboratory and manufacturing space in Madison,
Wisconsin.&nbsp; The space consists of approximately 19,500 square feet and is rented for approximately $12,600 per month and expires
on September 14, 2014.&nbsp; The lease may be renewed for two-year periods through 2024 with an increase of 3% in annual rent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that our present facilities are adequate to meet
our current needs.&nbsp; If new or additional space is required, we believe that adequate facilities are available at competitive
prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 47; Options: NewSection; Value: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 5, 2012 our directors and executive officers
are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 94%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; font-weight: bold">Name</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 10%; font-weight: bold; text-align: center">Age</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 51%; font-weight: bold">Position</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Stephen A. Hill, B.M. B.Ch., M.A., F.R.C.S. (1)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">54</TD>
    <TD>&nbsp;</TD>
    <TD>Chairman of the Board (term expiring at 2012 annual meeting or upon his successor being duly elected and qualified)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Harry S. Palmin</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">42</TD>
    <TD>&nbsp;</TD>
    <TD>President, Chief Executive Officer and Director (term as Director expiring at 2013 annual meeting or upon his successor being duly elected and qualified)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>J. Patrick Genn</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">55</TD>
    <TD>&nbsp;</TD>
    <TD>Vice President of Investor Relations</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Kimberly A. Hawkins</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">40</TD>
    <TD>&nbsp;</TD>
    <TD>Vice President of Clinical Development</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Christopher J. Pazoles, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">62</TD>
    <TD>&nbsp;</TD>
    <TD>Senior Vice President of Research and Development</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Joanne M. Protano</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">43</TD>
    <TD>&nbsp;</TD>
    <TD>Vice President, Chief Financial Officer and Treasurer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Jamey P. Weichert, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">55</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Scientific Officer and Director (term as Director expiring at 2013 annual meeting or upon his successor being duly elected and qualified)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Thomas Rockwell Mackie, Ph.D. (2)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">57</TD>
    <TD>&nbsp;</TD>
    <TD>Director (term expiring at 2011 annual meeting or upon his successor being duly elected and qualified) (3)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>James S. Manuso, Ph.D. (2)(1)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">63</TD>
    <TD>&nbsp;</TD>
    <TD>Director (term expiring at 2011 annual meeting or upon his successor being duly elected and qualified) (3)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>John Neis (4)(2)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">56</TD>
    <TD>&nbsp;</TD>
    <TD>Director (term expiring at 2012 annual meeting or upon his successor being duly elected and qualified)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>John E. Niederhuber, M.D. (4)(1)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">73</TD>
    <TD>&nbsp;</TD>
    <TD>Director (term expiring at 2011 annual meeting or upon his successor being duly elected and qualified) (3)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Howard M. Schneider (4)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">68</TD>
    <TD>&nbsp;</TD>
    <TD>Director (term expiring at 2013 annual meeting or upon his successor being duly elected and qualified)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Michael F. Tweedle, Ph.D. (2)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">60</TD>
    <TD>&nbsp;</TD>
    <TD>Director (term expiring at 2012 annual meeting or upon his successor being duly elected and qualified)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 6%">(1)</TD>
    <TD STYLE="width: 90%">Member of the nominating and corporate governance committee.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(2)</TD>
    <TD>Member of the compensation committee.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(3)</TD>
    <TD STYLE="padding-left: 1.5pt; text-indent: -1.5pt">Our certificate of incorporation provides for the&nbsp;division of the Board into three classes, Class I, Class II and Class III, as nearly equal in size as possible with staggered three-year terms.&nbsp; At each annual meeting of our stockholders, the terms of one such class expires.&nbsp; The terms of the Class I directors were to expire at the 2011 annual meeting of stockholders.&nbsp; However, we did not hold an annual meeting of stockholders in 2011.&nbsp; Accordingly, each such director is currently serving in accordance with our by-laws until his successor is duly elected and qualified.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(4)</TD>
    <TD>Member of the audit committee.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our executive officers are appointed by, and serve at the discretion
of, our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stephen A. Hill</B>.&nbsp; Dr. Hill was elected the chairman
of the board of directors of Novelos in September 2007. Dr. Hill was the President and CEO of 21CB, a nonprofit initiative of UPMC
designed to provide the United States government with a domestic solution for its biodefense and infectious disease biologics portfolio,
from March 2011 until December 2011.&nbsp; Dr. Hill served as the President and Chief Executive Officer of Solvay Pharmaceuticals,
Inc. from April 2008 until its acquisition by Abbott Laboratories in 2010.&nbsp; Prior to joining Solvay, Dr. Hill had served
as ArQule's President and Chief Executive Officer since April 1999.&nbsp; Prior to his tenure at ArQule, Dr. Hill was the Head
of Global Drug Development at F. Hoffmann-La Roche Ltd. from 1997 to 1999.&nbsp; Dr. Hill joined Roche in 1989 as Medical Adviser
to Roche Products in the United Kingdom.&nbsp; He held several senior positions at Roche, including Medical Director where he was
responsible for clinical trials of compounds across a broad range of therapeutic areas, including CNS, HIV, cardiovascular, metabolic
and oncology products.&nbsp; Subsequently, he served as Head of International Drug Regulatory Affairs at Roche headquarters in
Basel, Switzerland, where he led the regulatory submissions for seven major new chemical entities.&nbsp; Dr. Hill also was a member
of Roche's Portfolio Management, Research, Development and Pharmaceutical Division Executive Boards.&nbsp; Prior to Roche, Dr.
Hill served seven years with the National Health Service in the United Kingdom in General and Orthopedic Surgery.&nbsp; Dr. Hill
is a Fellow of the Royal College of Surgeons of England and holds his scientific and medical degrees from St. Catherine's College
at Oxford University. Dr. Hill&rsquo;s extensive experience in a broad range of senior management positions with companies in the
life sciences sector make him a highly qualified member of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 48; Value: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Harry S. Palmin</B>.&nbsp; &nbsp;Mr. Palmin has served as
our president and a director since 1998 and our chief executive officer since January 2005.&nbsp; From 1998 to September 2005,
he served as our acting chief financial officer.&nbsp; From 1996 to 1998, he was a vice president at Lehman Brothers and from 1993
to 1996, he was an associate at Morgan Stanley &amp; Co.&nbsp; Mr. Palmin earned a B.A. in economics and business and a M.A. in
international economics and finance from the International Business School at Brandeis University.&nbsp; He has also studied at
the London School of Economics and the Copenhagen Business School.&nbsp; Mr. Palmin&rsquo;s experience managing the funding and
development of our product candidates for 13 years and his knowledge of capital markets are strong qualifications to serve on our
board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>J. Patrick Genn</B>. Mr. Genn was appointed vice president
of investor relations in December 2011. He has 28 years of senior management experience in finance, banking and investment management.
Mr. Genn was previously President of Continuum Investment Holdings, Inc. from 2006 through mid-2010 while serving on the board
of directors of several biotech and technology companies including Cellectar, Inc. From 2001 through 2005, he was an advisor and
consultant to several companies including Carmel Valley Ventures and Continuum Investment Partners. Mr. Genn held several senior
management positions at Wells Fargo between 1987 and 2001. He was a member of the senior management team that launched the mortgage
lending division in 1987 and the premier banking division in 1993. He was also a member of the core mergers and acquisitions integration
team and managed private client services in San Diego, CA. Mr. Genn received a B.B.A. in Marketing and a M.S. in Product Management
from the University of Wisconsin-Madison.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Kimberly A. Hawkins.&nbsp;</B> Ms. Hawkins has served as
our vice president of clinical development since November 2010 and served as our director of clinical development since May 2006.
She has worked for 17 years in the biopharmaceutical industry managing and overseeing clinical operations for multiple global Phase
1, 2 and 3 clinical studies. From 2001 to 2006, Ms. Hawkins was a senior manager in clinical development at Antigenics, Inc., a
cancer biotechnology company where she managed multiple Phase 1 and 2 studies.&nbsp; From 1994 to 2001 she was employed by Genzyme
Corporation, Center for Clinical Research Practice where she held the positions of clinical research associate, trainer of good
clinical practice and study coordinator.&nbsp; From 1993 to 1994 she held the position of clinical research coordinator at Boston
Medical Center. Ms. Hawkins has a B.S. degree in Human Physiology from Boston University and a Master&rsquo;s Degree in Public
Health from Boston University School of Public Health.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Christopher J. Pazoles</B>.&nbsp; Dr. Pazoles has served
as our vice president of research and development since July 2005.&nbsp; He has 30 years of biopharmaceutical research and development
and senior management experience.&nbsp; From May 2004 to June 2005, he held a senior research and development position at the Abbott
Bioresearch Center, a division of Abbott Laboratories.&nbsp; From October 2002 to January 2004, he served as chief operating officer
and head of research and development at ALS Therapy Development Foundation.&nbsp; From 1994 to October 2002, Dr. Pazoles served
as vice president of research for Phytera, Inc.&nbsp; From 1981 to 1994, he served as a researcher and senior manager with Pfizer.&nbsp;
Dr. Pazoles holds a Ph.D. in microbiology from the University of Notre Dame.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Joanne M. Protano</B>.&nbsp; Ms. Protano was appointed our
vice president, chief financial and accounting officer, and treasurer in December 2007.&nbsp; She has 20 years of finance and senior
management experience. She previously held the position of Senior Director of Finance and Controller of the Company from June 2006
to December 2007.&nbsp; From 1996 to 2006, she held various management and senior management positions with Ascential Software,
Inc. and predecessor companies including Assistant Controller, Reporting for Ascential Software, Vice President and Chief Financial
Officer for the Ascential Software Division of Informix Software, Inc. and Corporate Controller of Ardent Software, Inc.&nbsp;
Prior to her tenure in the technology industry, from 1990 to 1996 she was employed by Deloitte and Touche LLP as an audit manager,
serving technology and healthcare clients.&nbsp; Ms. Protano received a B.S. in business administration from Bryant College.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Jamey P. Weichert.&nbsp;</B> Dr. Weichert was the primary
founder of Cellectar serving as Cellectar&rsquo;s Chairman and Chief Scientific Officer since 2002.&nbsp; He was appointed as the
Chief Scientific Officer and a director of Novelos at the time of the Acquisition.&nbsp; Dr. Weichert is an Associate Professor
of the Departments of Radiology, Medical Physics, Pharmaceutics and member of the Comprehensive Cancer Center at the University
of Wisconsin, Madison.&nbsp; He has a bachelor&rsquo;s degree in chemistry from the University of Minnesota and a doctorate in
medicinal chemistry from U. Mich.&nbsp; His research interests include the design, synthesis and evaluation of biomimetic CT and
MRI imaging agents and diapeutic radiopharmaceuticals.&nbsp; He has been involved in molecularly targeted imaging agent development
his entire professional career and has developed or co-developed several imaging agents nearing clinical trial status. Dr. Weichert
serves or has served on the editorial boards of numerous scientific journals and has authored more than 40 peer reviewed publications
and 150 abstracts.&nbsp; He also has 20 issued or pending patents related to drug delivery, imaging and contrast agent development.&nbsp;
Dr. Weichert&rsquo;s experience founding and managing the development of Cellectar&rsquo;s product candidates and his knowledge
of radiation technology are strong qualifications to serve on our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 49; Value: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Thomas Rockwell Mackie.&nbsp;</B> &nbsp;Dr. Mackie became
a director of the Company at the time of the Acquisition. He served as a director of Cellectar since December 2006.&nbsp; In 1997,
he co-founded TomoTherapy Incorporated, a maker of advanced radiation therapy solutions for the treatment of cancer and other diseases
and served as Chairman of its board of directors from 1999 until its Acquisition by Accuray Incorporated in June 2011. Dr. Mackie
also served as President of TomoTherapy Inc. from 1997 until 1999 and as Treasurer from 1997 until 2000. Since 1987, Dr. Mackie
has been a professor in the departments of Medical Physics and Human Oncology at the University of Wisconsin, where he established
the TomoTherapy research program. Dr. Mackie also co-founded Geometrics Corporation (now merged with ADAC Corp.), which developed
a radiotherapy treatment planning system. Dr. Mackie currently serves as a director of Shine Medical Technologies and Bioionix
Inc. and served on the management committee of Wisconsin Investment Partners from 2006 to 2009.&nbsp; &nbsp;Dr. Mackie has a B.Sc.
in Physics from the University of Saskatchewan and a Ph.D. in Physics from the University of Alberta in Edmonton. Dr. Mackie&rsquo;s
qualifications to serve on our board of directors include his extensive senior management experience with radiation technology
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>James S. Manuso</B>.&nbsp; Dr. Manuso has served as one of
our directors since August 2007.&nbsp; Since January 2005, Dr. Manuso has served as Chairman and Chief Executive Officer of SuperGen,
Inc. (now renamed Astex Pharmaceuticals, Inc.), served as President&nbsp;of SuperGen from January 2005&nbsp;through July 2011 and
has served as a director of SuperGen since February 2001.&nbsp; Dr. Manuso is co-founder and former president and chief executive
officer of Galenica Pharmaceuticals, Inc.&nbsp; Dr. Manuso co-founded and was general partner of PrimeTech Partners, a biotechnology
venture management partnership, from 1998 to 2002, and Managing General Partner of The Channel Group LLC, an international life
sciences corporate advisory firm.&nbsp; He was also president of Manuso, Alexander &amp; Associates, Inc., management consultants
and financial advisors to pharmaceutical and biotechnology companies.&nbsp; Dr. Manuso was a vice president and Director of Health
Care Planning and Development for The Equitable Companies (now Group Axa), where he also served as Acting Medical Director. He
currently serves on the board of directors of the Biotechnology Industry Organization (BIO) and its Health Section Governing Board
and serves on the board of privately-held KineMed, Inc.&nbsp; He previously served on the boards of Merrion Pharmaceuticals Ltd.
(Dublin, Ireland),&nbsp;&nbsp;&nbsp;Inflazyme Pharmaceuticals, Inc. (Vancouver, Canada), Symbiontics, Inc., (ZyStor, Inc., sold
to BioMarin), Quark Biotech, Inc., Galenica Pharmaceuticals, Inc., Supratek Pharma, Inc., and EuroGen, Ltd. (London, UK).&nbsp;
Dr. Manuso earned a B.A. in economics and chemistry from New York University, a Ph.D. in experimental psychophysiology from the
Graduate Faculty of The New School University, a certificate in health systems management from Harvard Business School, and an
executive M.B.A. from Columbia Business School.&nbsp; Dr. Manuso&rsquo;s experience founding, leading and serving as a director
for pharmaceutical companies makes him a highly qualified member of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>John Neis.&nbsp;</B> Mr. Neis became a director of our Company
at the time of the Acquisition. He served as director of Cellectar since February 2008.&nbsp; Mr. Neis has been Managing Director
of Venture Investors LLC since 1986 and heads the firm&rsquo;s Healthcare practice. He has over 23 years&rsquo; experience in the
venture capital industry and serves on the Board of Directors of companies from formation through initial public offering or sale.&nbsp;
Mr. Neis also currently serves on the boards of directors of Virent Energy Systems, Deltanoid Pharmaceuticals, Inviragen, Inc.
and Mithridion, Inc. He is a former member of the Boards of Directors of several firms including TomoTherapy, Third Wave Technologies
(acquired by Hologic) and NimbleGen Systems (acquired by Roche).&nbsp; Mr. Neis was appointed to the Board of the Wisconsin Technology
Council and he also serves on the advisory boards for the Weinert Applied Ventures Program and Tandem Press at the University of
Wisconsin - Madison.&nbsp; Mr. Neis has a B.S. in Finance from the University of Utah, and a M.S. in Marketing and Finance from
the University of Wisconsin, Madison. He is a Chartered Financial Analyst. Mr. Neis&rsquo; extensive experience leading emerging
companies makes him a highly qualified member of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>John E. Niederhuber.&nbsp;</B> &nbsp;&nbsp;Dr. Niederhuber
became a director of our Company at the time of the Acquisition.&nbsp; From August 2010 to the present, Dr. Niederhuber has served
as executive vice president of Inova Health System and chief executive officer of the Inova Translational Medicine Institute. Since
July 2011, he has been an adjunct Professor of Oncology at the Johns Hopkins University School of Medicine and Deputy Director
of The Johns Hopkins Clinical Research Network. Since August 2010, Dr. Niederhuber has served as a Director on the Emergent Biosolutions
Board. Dr. Niederhuber&nbsp;&nbsp;served as Director of the National Cancer Institute (NCI) from 2005 to 2010. He has also served
as NCI's Chief Operating Officer and Deputy Director for Translational and Clinical Sciences. Dr. Niederhuber served as Chair of
the National Cancer Advisory Board (NCAB) from 2002 to 2004. In addition to his management and advisory roles, Dr. Niederhuber
has remained involved in research, through his laboratory on the National Institutes of Health (NIH) campus. Under his leadership,
the Tumor and Stem Cell Biology Section, which is a part of the Cell and Cancer Biology Branch of NCI's Center for Cancer Research,
is studying tissue stem cells as the cell-of-origin for cancer.&nbsp; Dr. Niederhuber also holds a clinical appointment on the
NIH Clinical Center Medical Staff.&nbsp; As a surgeon, Dr. Niederhuber's clinical emphasis is on gastrointestinal cancer, hepatobiliary
(liver, bile duct, and gall bladder) cancer, and breast cancer. He is recognized for his pioneering work in hepatic artery infusion
chemotherapy and was the first to demonstrate the feasibility of totally implantable vascular access devices. Dr. Niederhuber is
a graduate of Bethany College in West Virginia and the Ohio State University School of Medicine. He was an NIH Academic Trainee
in Surgery at the University of Michigan from 1969 to 1970 and was a Visiting Fellow in the Division of Immunology at The Karolinska
Institute in Stockholm, Sweden from 1970 to 1971. He completed his training in surgery at the University of Michigan in 1973 and
was a member of the faculty of the University of Michigan from 1973 to 1987, being promoted to Professor of Microbiology/Immunology
and Professor of Surgery in 1980. During 1986 and 1987, he was Visiting Professor in the Department of Molecular Biology and Genetics
at The Johns Hopkins University School of Medicine in Baltimore, MD.&nbsp; Dr. Niederhuber&rsquo;s qualifications to serve on our
board of directors include his extensive experience with cancer research.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 50; Value: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Howard M. Schneider</B>.&nbsp; Mr. Schneider has served as
one of our directors since February 2005.&nbsp; Mr. Schneider is currently retired.&nbsp; From January to December 2003, he served
as chief executive officer of Metrosoft, Inc., and had been an advisor to such company from July to December 2002.&nbsp; From May
2000 to May 2001, he served as president of Wofex Brokerage, Inc. and from 1965 to 1999, he served as an executive at Bankers Trust
Company holding a variety of positions in the commercial banking and investment banking businesses.&nbsp; Mr. Schneider received
a B.A. in economics from Harvard College and a M.B.A. from New York University.&nbsp; Mr. Schneider&rsquo;s extensive senior management
experience in the financial sector makes him a highly qualified member of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Michael F. Tweedle.&nbsp; &nbsp;</B> Dr. Tweedle became a
director of Novelos at the time of the Acquisition.&nbsp;Since May 2009 he has served as&nbsp;Professor and Stefanie Spielman Chair
in Cancer Imaging in Radiology and the James Comprehensive Cancer Center of Ohio State University, Director of the Wright Center
Molecular Imaging (MI) Agents Laboratory of Ohio State University, and since May 2010, has had an adjunct appointment in the Chemistry
Department of Ohio State University. Prior to joining Ohio State University, his academic appointments included Adjunct Associate
Professor at University of Pennsylvania and the Science Advisory Board of New York University. Dr. Tweedle was the President of
Bracco Research USA Inc. from 1995 to 2009 where he was the lead scientist and chief executive for creation of new molecular imaging
pharmaceuticals. His industrial experience in drug discovery research also includes appointments at the Diagnostics Drug Discovery
Division at Bristol-Myers Squibb, New England Nuclear, NEN/DuPont Pharmaceuticals, and The Squibb Institute for Medical Research.&nbsp;
He has invented and led translational development of diagnostic imaging pharmaceuticals for nuclear medicine, one of the first
gadolinium-based MRI agents (ProHance TM), X ray, Optical and US agents, and a radiotheranostic. In 2005 he won the Harry Fisher
Medal.&nbsp; Dr. Tweedle holds a B.A from Knox College, B.A. (1973), a Ph.D. from Rice University (1978) and was a Stanford University
NRS Fellow.&nbsp; Dr. Tweedle&rsquo;s qualifications to serve on our board of directors include his extensive experience with radiation
and cancer research and drug discovery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The board of directors has adopted a Code of Ethics applicable
to all of our directors, officers and employees, including our principal executive officer, principal financial officer and principal
accounting officer. A copy of the Code of Ethics is available at our website www.novelos.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Compensation of Directors and Executive
Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Summary Compensation:</I> The following table sets forth
certain information about the compensation we paid or accrued with respect to our principal executive officer and our two most
highly compensated executive officers (other than our chief executive officer) who served as executive officers during the year
ended December 31, 2011 and whose annual compensation exceeded $100,000 for that year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other annual compensation in the form of perquisites and other
personal benefits has been omitted as the aggregate amount of those perquisites and other personal benefits was less than $10,000
for each person listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Name&nbsp;and&nbsp;Principal&nbsp;Position</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Salary <BR>($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Bonus <BR>($) <BR>(1)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option <BR>Awards&nbsp;($) <BR>(2)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">All&nbsp;other <BR>compensation <BR>($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total&nbsp;($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 34%; text-align: left">Harry S. Palmin (3)(4)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 8%; text-align: center">2011</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">270,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">917,570</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">1,187,570</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">President, Chief Executive Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2010</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">270,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">270,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Christopher J. Pazoles (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">246,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">271,470</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">517,720</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Senior Vice President of Research and Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">2010</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">$</TD><TD STYLE="text-align: right; vertical-align: top">235,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">$</TD><TD STYLE="text-align: right; vertical-align: top">39,167</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">$</TD><TD STYLE="text-align: right; vertical-align: top">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">$</TD><TD STYLE="text-align: right; vertical-align: top">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">$</TD><TD STYLE="text-align: right; vertical-align: top">274,167</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Joanne M. Protano (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">190,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">203,603</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">393,603</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Vice President, Chief Financial&nbsp;Officer and Treasurer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">2010</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">$</TD><TD STYLE="text-align: right; vertical-align: top">175,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">$</TD><TD STYLE="text-align: right; vertical-align: top">29,167</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">$</TD><TD STYLE="text-align: right; vertical-align: top">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">$</TD><TD STYLE="text-align: right; vertical-align: top">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">$</TD><TD STYLE="text-align: right; vertical-align: top">204,167</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 51; Value: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">(1)&nbsp;</TD>
    <TD STYLE="width: 93%">Bonus amounts for Dr. Pazoles and Ms. Protano in 2010 represent retention bonuses paid as of October 1, 2010 pursuant to their respective retention agreements dated May 14, 2010.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(2)&nbsp;</TD>
    <TD>The amounts shown in this column represent the aggregate grant-date fair value of each stock award, without regard to the portion of the award that vested during the respective year and was estimated on the grant date using the Black-Scholes option-pricing model. There were no option grants during 2010.&nbsp; The compensation expense associated with the vested portion of the option grants as recorded in our statement of operations for the year ended December 31, 2011 was $123,718 for Mr. Palmin, $48,547 for Dr. Pazoles and $36,411 for Ms. Protano.&nbsp;&nbsp; The unrecorded compensation expense associated with the unvested portion of the option grants is $793,852 for Mr. Palmin, $222,923 for Dr. Pazoles and $167,192 for Ms. Protano. See Note 10 to the financial statements for a description of the assumptions used in estimating the fair value of stock options and recognition of compensation expense.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(3)</TD>
    <TD>Effective January 1, 2012, all salaries were increased by 2%, including the salaries of the named executive officers.&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(4)</TD>
    <TD>The aggregate grant-date fair value for option awards granted to Mr. Palmin during 2011 excludes $772,305 related to performance-based awards because such awards with an aggregate value of $381,277 were forfeited during 2011 and it is not yet probable that performance awards with a grant-date fair value totaling $391,028 will vest.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employment Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 31, 2006, we entered into an employment agreement
with Harry Palmin effective January 1, 2006, whereby he agreed to serve as our president and chief executive officer for an initial
term of two years at an annual salary of $225,000.&nbsp; The agreement is automatically renewed for successive one-year terms unless
notice of termination is provided by either party at least 90 days prior to the end of such term.&nbsp; The agreement was renewed
for an additional one-year term on January 1, 2011 in accordance with its terms.&nbsp; On December 17, 2007, the Board of Directors
approved an increase in Mr. Palmin&rsquo;s annual salary to $270,000 effective January 1, 2008.&nbsp; He is eligible to receive
an annual cash bonus at the discretion of the compensation committee and he is entitled to participate in our employee fringe benefit
plans or programs generally available to our senior executives.&nbsp; The agreement provides that in the event that we terminate
Mr. Palmin without cause (as defined below)&nbsp;or he resigns for good reason (as defined below), we will (i) pay Mr. Palmin his
pro rata share of the average of his annual bonus paid during the two fiscal years preceding his termination; (ii) pay Mr. Palmin
his base salary for 11 months after the date of termination; (iii) continue to provide him benefits for 11 months after the date
of termination; and (iv) fifty percent of his unvested stock options will vest.&nbsp; The agreement provides for the vesting of
unvested options upon a Change of Control, defined as the sale of all or substantially all of the assets or issued and outstanding
capital stock of the Company, (ii) merger or consolidation involving the Company in which stockholders of the Company immediately
before such merger or consolidation do not own immediately after such merger or consolidation capital stock or other equity interests
of the surviving corporation or entity representing more than fifty percent (50%) in voting power of capital stock or other equity
interests of such surviving corporation or entity outstanding immediately after such merger or consolidation, or (iii) a change,
without the approval of the board of directors, in the composition of the board of directors such that directors who were serving
as of the date of the agreement cease to constitute a majority of the board of directors. The agreement also contains a non-compete
provision, which prohibits Mr. Palmin from competing with us for one year after termination of his employment with us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Cause&rdquo; means (i) gross neglect of duties for which
employed; (ii) committing fraud, misappropriation or embezzlement in the performance of duties as our employee; (iii) conviction
or guilty or nolo plea of a felony or misdemeanor involving moral turpitude; or (iv) willfully engaging in conduct materially injurious
to us or violating a covenant contained in the employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Good Reason&rdquo; means (i) the failure of our board
of directors to elect Mr. Palmin to the offices of president and chief executive officer; (ii) the failure by our stockholders
to continue to elect Mr. Palmin to our board of directors; (iii) our failure to pay Mr. Palmin the compensation provided for in
the employment agreement, except for across-the-board cuts applicable to all of our officers on an equal percentage basis, provided
that such reduction is approved by our board of directors; (iv) relocation of Mr. Palmin&rsquo;s principal place of employment
to a location beyond 50 miles of Newton, Massachusetts; (v) a reduction of base salary or material reduction in other benefits
or any material change by us to Mr. Palmin&rsquo;s function, duties, authority, or responsibilities, which change would cause Mr.
Palmin&rsquo;s position with us to become one of lesser responsibility, importance, or scope; and (vi) our material breach of any
of the other provisions of the employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 52; Value: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2011, the employment agreement
between the Company and Harry Palmin dated January 31, 2006 was amended to remove the obligation of the Company to continue to
pay Mr. Palmin&rsquo;s salary and benefits for a period of 11 months following termination by the Company without Cause or termination
by Mr. Palmin with Good Reason.&nbsp; The Company may elect that the obligation of Mr. Palmin not to compete with the Company survive
for a period of one year from his termination, provided however that Mr. Palmin would continue to receive his base salary during
that one-year noncompetition period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We had entered into retention agreements with each of our four
vice presidents.&nbsp; The agreements provided for the lump-sum payment of six months&rsquo; base salary and benefits to each such
officer following a termination without cause or a resignation with good reason occurring on or before November 14, 2011.&nbsp;
Certain of the agreements provided that if the executives were employed by us as of October 1, 2010, they would receive a payment
of two months&rsquo; base salary as a retention bonus on that date. The retention bonus was paid in October 2010 and would have
been deducted from the severance amounts that became payable upon a subsequent involuntary termination.&nbsp; The retention agreements
expired in November 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Outstanding Equity Awards at Fiscal Year-End</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth certain
information regarding stock options held as of December 31, 2011 by the executive officers named in the summary compensation table.
There were no option grants during 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 88%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="17" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Individual&nbsp;Grants</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Name</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year <BR>of&nbsp;Grant</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of <BR>securities <BR>underlying <BR>unexercised <BR>options <BR>(# exercisable)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of <BR>securities <BR>underlying <BR>unexercised <BR>options <BR>(# unexercisable)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise<BR>
or <BR>base&nbsp;price <BR>($/share)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Expiration <BR>date</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 26%; text-align: left">Harry S. Palmin</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">2011</TD><TD STYLE="width: 1%; text-align: left">(1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">335,100</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">0.45</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right">12/16/2021</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2011</TD><TD STYLE="text-align: left">(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">335,100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5/18/2021</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2011</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,775</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">586,425</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5/18/2021</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2009</TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,090</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">543</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">114.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">12/8/2019</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2008</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,614</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65.79</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">12/15/2018</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2007</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,307</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">12/17/2017</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2006</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">980</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">139.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">12/11/2016</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2005</TD><TD STYLE="text-align: left">(5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,633</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1/31/2015</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2005</TD><TD STYLE="text-align: left">(5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">980</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3/31/2015</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2004</TD><TD STYLE="text-align: left">(6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,156</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4/1/2014</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2003</TD><TD STYLE="text-align: left">(7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">107.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">8/1/2013</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Christopher J. Pazoles</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2011</TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.45</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">12/16/2021</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2011</TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">166,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5/18/2021</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2009</TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">871</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">436</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">114.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">12/8/2019</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2008</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,307</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65.79</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">12/15/2018</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2007</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">816</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">12/17/2017</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2006</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">653</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">139.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">12/11/2016</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2005</TD><TD STYLE="text-align: left">(8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">654</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4/8/2015</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Joanne M. Protano</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2011</TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.45</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">12/16/2021</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2011</TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,999</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">125,001</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5/18/2021</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2009</TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">871</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">436</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">114.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">12/8/2019</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2008</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,307</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65.79</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">12/15/2018</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2007</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">653</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">12/17/2017</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2006</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">261</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">139.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">12/11/2016</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2006</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">392</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">139.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6/16/2016</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 53; Value: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">(1)</TD>
    <TD STYLE="width: 94%">These shares vest quarterly in increments of one-sixteenth over four years from the date of grant.&nbsp; The exercise price equals the closing price on the date of grant.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(2)</TD>
    <TD>These shares vest based on the achievement of specified milestones.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(3)</TD>
    <TD>These shares vest quarterly in increments of one-twelfth over three years from the date of grant.&nbsp; The exercise price equals the closing price on the date of grant.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(4)</TD>
    <TD>These shares vest annually in increments of one-third over three years from the date of grant.&nbsp; The exercise price equals the closing price on the date of grant.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(5)</TD>
    <TD>These shares initially vested over a two-year period.&nbsp; Pursuant to their terms, the shares fully vested upon the completion of a non-bridge loan financing, which occurred in the second quarter of 2005.&nbsp; The exercise price equals the fair market value of our common stock on the date of grant as determined by our board of directors.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(6)</TD>
    <TD>These shares initially vested one-third upon grant and one-third annually over the following two years. Pursuant to their terms, one additional year of vesting occurred upon the completion of a non-bridge loan financing, which occurred in the second quarter of 2005.&nbsp; The exercise price equals the fair market value of our common stock on the date of grant as determined by our board of directors.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(7)</TD>
    <TD>These shares vest annually in increments of one-third over three years from the date of grant. The exercise price equals the fair market value of our common stock on the date of grant as determined by our board of directors.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(8)</TD>
    <TD>These shares vested in increments of one-fourth every six months over two years from the date of grant. The exercise price equals the fair market value of our common stock on the date of grant as determined by our board of directors.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Options granted pursuant to the 2006 Stock Incentive Plan will
become fully vested upon a termination event within one year following a change in control, as defined.&nbsp; A termination event
is defined as either termination of employment other than for cause or constructive termination resulting from a significant reduction
in either the nature or scope of duties and responsibilities, a reduction in compensation or a required relocation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Director Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Summary Compensation:&nbsp;&nbsp;</I> The following table
sets forth certain information about the compensation we paid or accrued with respect to our directors who served during the year
ended December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 96%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Name&nbsp;and&nbsp;Principal&nbsp;Position</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Director <BR>Fees <BR>($)&nbsp;(2)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option <BR>Awards <BR>($)&nbsp;(3)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">All&nbsp;other <BR>compensation <BR>($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total&nbsp;($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Stephen A. Hill, Chairman (1)</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">2011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">46,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">201,368</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">247,618</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">T. Rockwell Mackie (1)</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">2011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">134,245</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">159,745</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">James S. Manuso, Director (1)</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">2011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">134,245</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">161,745</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">John Neis, Director (1)</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">2011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">134,245</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">158,995</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">John E. Niederhuber, Director (1)</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">2011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">134,245</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">158,245</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Howard M. Schneider, Director (1)</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">2011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">134,245</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">174,745</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Michael F. Tweedle, Director (1)</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">2011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">134,245</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">155,995</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; width: 35%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD><TD STYLE="text-align: center; width: 9%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 9%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 9%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 9%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 9%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: 9pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">(1)</TD>
    <TD STYLE="width: 95%">As of December 31, 2011, outstanding options to purchase common stock held by directors were as follows:&nbsp;&nbsp;Dr. Hill 227,285; Dr. Mackie 150,000; Dr. Manuso 151,958; Mr. Neis 150,000; Dr. Niederhuber 150,000; Mr. Schneider 151,629; Dr. Tweedle 150,000.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(2)</TD>
    <TD>Director fees include all fees earned for director services including quarterly fees, meeting fees and committee chairman fees.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(3)</TD>
    <TD>The amounts shown in this column represent the aggregate grant-date fair value of the stock awards during the year, without regard to the portion of the awards that vested during the respective year and was estimated on the grant date using the Black-Scholes option-pricing model. The compensation expense associated with&nbsp; the vested portion of the option awards as recorded in our statement of operations for the year ended December 31, 2011 was $54,005 for&nbsp; Dr. Hill and $36,001 each for Dr. Mackie, Dr. Manuso,&nbsp; Mr. Neis,&nbsp; Dr. Niederhuber, Mr. Schneider&nbsp; and&nbsp; Dr. Tweedle.&nbsp; The unrecorded compensation expense associated with the unvested portion of the option awards was $147,363 for Dr. Hill and $98,244 each for Dr. Mackie, Dr. Manuso, Mr. Neis, Dr. Niederhuber, Mr. Schneider and Dr. Tweedle. The fair value of each stock award was estimated on the grant date using the Black-Scholes option-pricing model. See Note 10 to the financial statements for a description of the assumptions used in estimating the fair value of stock options and recognition of compensation expense.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 54; Value: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">During 2011, we paid our non-employee
directors a cash fee of $5,000 per quarter.&nbsp;&nbsp;The non-employee directors also received a fee of $1,500 for any board or
committee meeting attended and $750 for each telephonic board or committee meeting in which the director participated.&nbsp;&nbsp;We
also paid our chairman an additional annual fee in the amount of $15,000, our non-employee director who serves as the chair of
the audit committee an additional annual fee of $10,000 and our non-employee directors who served as the chairman of the compensation
and the nominating and corporate governance committees an additional annual fee of $5,000.&nbsp;&nbsp;We reimbursed directors for
reasonable out-of-pocket expenses incurred in attending board and committee meetings and undertaking certain matters on our behalf.&nbsp;&nbsp;Directors
who are our employees do not receive separate fees for their services as directors.&nbsp;&nbsp;There has been no change to cash
fees payable to non-employee directors for 2012.</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITY OWNERSHIP OF CERTAIN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BENEFICIAL OWNERS AND MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the close of business on June 5, 2012, there were 37,765,200
shares of our common stock outstanding. The following table provides information regarding beneficial ownership of our common
stock as of June 5, 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 4%; font-family: Symbol">&middot;</TD>
    <TD STYLE="width: 85%">Each person known by us to be the beneficial owner of more than five percent of our common stock;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>Each of our directors;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>Each executive officer named in the summary compensation table; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>All of our current directors and executive officers as a group.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The address of each executive officer and director is c/o
Novelos Therapeutics, Inc., One Gateway Center, Suite 504, Newton, Massachusetts 02458. The persons named in this table have sole
voting and investment power with respect to the shares listed, except as otherwise indicated. In these cases, the information
with respect to voting and investment power has been provided to us by the security holder. The identification of natural persons
having voting or investment power over securities held by a beneficial owner listed in the table below does not constitute an
admission of beneficial ownership of any such natural person. Shares included in the &ldquo;Right to Acquire&rdquo; column consist
of shares that may be purchased through the exercise of options or warrants that are exercisable within 60 days of June 5, 2012<I>.
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"> Name&nbsp;and&nbsp;Address&nbsp;of&nbsp;Beneficial&nbsp;Owner </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Outstanding </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Right&nbsp;to <BR>Acquire </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Total </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Percentage </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 44%; text-align: left"> Venture Investors LLC (1) (2) <BR>University Technology Park <BR>505 S. Rosa Road;
    Suite 201 <BR>Madison, Wisconsin&nbsp;&nbsp;53719 </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; text-align: right"> 5,634,308 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; text-align: right"> 3,162,500 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; text-align: right"> 8,796,808 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; text-align: right"> 21.5 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"> CLS Capital Holdings Limited (3)(4) <BR>Bordeaux Court, Les Echelons <BR>St. Peter Port, Guernsey,
    GY13DR <BR>Channel Islands </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,333,334 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,333,334 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6,666,668 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 16.2 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"> Jamey P. Weichert (5) <BR>c/o Novelos Therapeutics, Inc. <BR>3301 Agriculture Drive <BR>Madison,
    Wisconsin&nbsp;&nbsp;53716 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,706,730 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 56,666 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,763,396 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 12.6 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"> Fidelity Management and Research Co. (3)(6) <BR>82 Devonshire Street <BR>Boston, Massachusetts
    02109 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,500,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,500,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 5,000,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 12.4 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"> Greenway Properties Inc. (7) <BR>725 Heartland Trail, Suite 102 <BR>Madison, Wisconsin&nbsp;&nbsp;53707 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,267,400 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,600,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,867,400 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 9.8 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"> Harry S. Palmin (8) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,190 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 220,513 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 224,703 </TD><TD STYLE="text-align: left"></TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> * </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Christopher J. Pazoles </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 87,851 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 87,851 </TD><TD STYLE="text-align: left"></TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> * </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"> Joanne M. Protano </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 66,200 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 66,200 </TD><TD STYLE="text-align: left"></TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> * </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Stephen A. Hill </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 96,035 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 96,035 </TD><TD STYLE="text-align: left"></TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> * </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"> Thomas Rockwell Mackie </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 116,121 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 62,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 178,621 </TD><TD STYLE="text-align: left"></TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> * </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> James S. Manuso </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 64,458 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 64,458 </TD><TD STYLE="text-align: left"></TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> * </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"> John Neis (1) (2) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 5,634,308 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,162,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 8,796,808 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 21.5 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> John E. Niederhuber </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 62,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 62,500 </TD><TD STYLE="text-align: left"></TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> * </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"> Howard M. Schneider </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 653 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 64,129 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 64,782 </TD><TD STYLE="text-align: left"></TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> * </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Michael F. Tweedle </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 62,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 62,500 </TD><TD STYLE="text-align: left"></TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> * </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"> All directors and officers as a group (13 persons) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10,532,655 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,174,347 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 14,707,002 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 35.1 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 55; Value: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">(1)</TD>
    <TD STYLE="width: 97%">Ownership consists of shares of common stock held by Venture Investors Early Stage Fund IV Limited Partnership and Advantage Capital Wisconsin Partners I, Limited Partnership.&nbsp; VIESF IV GP LLC is the general partner of Venture Investors Early Stage Fund IV Limited Partnership and Venture Investors LLC is the submanager and special limited partner of Advantage Capital Wisconsin Partners I, Limited Partnership. The investment decisions of VIESF IV GP LLC and Venture Investors LLC are made collectively by six managers, including Mr. Neis.&nbsp; Each such manager and Mr. Neis disclaim such beneficial ownership except to the extent of his pecuniary interest therein.&nbsp; The address of Mr. Neis is c/o Venture Investors LLC, 505 South Rosa Road, #201, Madison, Wisconsin 53719.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD> (2) </TD>
    <TD> Shares in the &ldquo;Right to Acquire&rdquo; column consist of warrants to purchase 2,000,000 shares common stock at
    $0.75 per share, expiring on March 31, 2016, warrants to purchase 1,100,000 shares of common stock at $0.60 per share expiring
    on December 6, 2016, both held by Venture Investors Early Stage Fund IV Limited and options to purchase&nbsp;62,500 shares
    of common stock at exercise prices ranging from $0.45 to $1.40 per share, issued to Mr. Neis. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(3)</TD>
    <TD>Shares in the &ldquo;Right to Acquire&rdquo; column consist of warrants to purchase shares of common stock at $0.60 per share expiring on December 6, 2016.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(4)</TD>
    <TD>Interlock Director Ltd. has sole dispositive and voting power over shares held by CLS Capital Holdings Limited. Interlock Director Ltd. exercises such power through Michael Kupenga and a combination of two directors of Virtus Directors Limited.&nbsp; The Virtus directors consist of the following individuals: David Allison, Roderick Arthur, Nicholas Moss, Trevor Pinchemain, Stephen Kirk, Grada Hek, Martin LePage, Lesley Pinchemain, Cerisse Fisher, Pierre Renier and Jonathan Seymour.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(5)</TD>
    <TD>Dr. Weichert serves as a director and our Chief Scientific Officer. The shares beneficially owned by him have been included in the total of directors and officers as a group.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(6)</TD>
    <TD>Consists of shares held by Fidelity Select Portfolios: Biotechnology Portfolio and Fidelity Advisor Series VII: Fidelity Advisor.&nbsp; Dispositive and voting power for the shares is held by the Fidelity Funds Board of Trustees.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(7)</TD>
    <TD>Shares in the &ldquo;Outstanding&rdquo; column include shares held by Jeffery Straubel.&nbsp; Jeffrey Straubel is the President and principal owner of Greenway Properties, Inc. and has sole dispositive and voting power over shares held by Greenway Properties, Inc.&nbsp; Shares in the &ldquo;Right to Acquire&rdquo; column consist of warrants to purchase 1,000,000 shares common stock at $0.75 per share, expiring on March 31, 2016, warrants to purchase 600,000 shares of common stock at $0.60 per share expiring on December 6, 2016.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(8)</TD>
    <TD>Ownership of Harry Palmin includes shares owned by his wife, Deanna Palmin.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not have a written policy for the review, approval or
ratification of transactions with related parties or conflicted transactions.&nbsp; When such transactions arise, they are referred
to the Audit Committee for consideration or for referral to the Board of Directors for its consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">One of our directors, John Neis, is a managing director of Venture
Investors LLC, which beneficially owns approximately 22% of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 56; Value: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Jamey Weichert, our Chief Scientific Officer and principal
founder of Cellectar, and a director and shareholder of the Company, is a faculty member at the University of Wisconsin-Madison
(U. Wisc.).&nbsp;During the year ended December 31, 2011, we made contributions totaling $206,500 to U. Wisc. for use towards
unrestricted research activities. During the three months ended March 31, 2012, we made contributions to UW totaling $81,500 for
use towards unrestricted research activities and paid UW $92,754 for costs associated with clinical trial agreements. No payments
were made during the three months ended March 31, 2011. &nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are obligated to ZAO BAM, a Russian company engaged in the
pharmaceutical business, under a royalty and technology transfer agreement. Mark Balazovsky, a director until November 2006, is
the majority shareholder of ZAO BAM. Pursuant to the royalty and technology transfer agreement between Novelos and ZAO BAM, we
are required to make royalty payments of 1.2% of net sales of oxidized glutathione-based products. We are also required to pay
ZAO BAM $2 million for each new oxidized glutathione-based drug within eighteen months following FDA approval of such drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If a royalty is not being paid to ZAO BAM on net sales of oxidized
glutathione products, then we are required to pay ZAO BAM 3% of all license revenues. If license revenues exceed our cumulative
expenditures including, but not limited to, preclinical and clinical studies, testing, FDA and other regulatory agency submission
and approval costs, general and administrative costs, and patent expenses, then we would be required to pay ZAO BAM an additional
9% of the amount by which license revenues exceed our cumulative expenditures. During 2008, we paid ZAO BAM $15,000, which was
3% of the upfront license payment received under the collaboration agreement with Lee&rsquo;s Pharm, described in Note 5 to the
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 28, 2010, we received a letter from counsel to ZAO BAM
and ZAO BAM Research Laboratories (collectively, BAM) alleging that we modified the chemical composition of NOV-002 without prior
notice to or approval from BAM, constituting a material breach of a technology and assignment agreement we had entered into with
BAM on June 20, 2000 (the June 2000 Agreement).&nbsp; The letter references our amendment, submitted to the FDA on August 30, 2005,
to our investigational new drug application dated August 1999 as the basis for BAM&rsquo;s claims and demands the transfer of all
intellectual property rights concerning NOV-002 to BAM.&nbsp; Mark Balazovsky, a director of Novelos from June 1996 until November
2006 and a shareholder of Novelos through at least June 25, 2010, is, to our knowledge, still the general director and principal
shareholder of ZAO BAM.&nbsp; On September 24, 2010, we filed a complaint in Suffolk Superior Court seeking a declaratory judgment
by the court that the June 2000 Agreement has been replaced by a subsequent agreement between the parties dated April 1, 2005 (the
April 2005 Agreement), that the Company&rsquo;s obligations to BAM are governed solely by the April 2005 Agreement and that the
obligations of the June 2000 agreement have been performed and fully satisfied.&nbsp; &nbsp;On November 29, 2010, BAM answered
our complaint, denying the material allegations and stating its affirmative defenses and certain counterclaims. On January 14,
2011, we responded to the counterclaims, denying BAM&rsquo;s material allegations and stating our affirmative defenses. On June
9, 2011, BAM filed an amended counterclaim alleging additional claims related to Novelos&rsquo; acquisition of Cellectar.&nbsp;
In that amended counterclaim, BAM alleges that the acquisition evidences Novelos&rsquo; abandonment of the technology assigned
to it by BAM constituting a breach of the June 2000 Agreement or, if that agreement is determined to no longer be in effect, a
breach of the April 2005 Agreement and/or a breach of the implied duty of good faith and fair dealing with respect to the April
2005 Agreement.&nbsp; On June 15, 2011 we filed our response to their amended counterclaim.&nbsp; On August 5, 2011, we filed a
motion for judgment on the pleadings as to our declaratory judgment count and all counts of BAM&rsquo;s amended counterclaim.&nbsp;
The motion was opposed by BAM and a hearing on the motion&nbsp;was held&nbsp;on September 27, 2011. On October 17, 2011, the court
ruled on our behalf for each of our declaratory judgment claims and dismissed all counts of BAM&rsquo;s counterclaim. Judgment
in favor of the Company was entered on October 20, 2011. On November 14, 2011 BAM filed a notice of appeal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the assignment to Novelos of the exclusive worldwide
intellectual property and marketing rights of oxidized glutathione (excluding the Russian Territory), Novelos is obligated to the
Oxford Group, Ltd., or its assignees, for future royalties. Simyon Palmin, a founder of Novelos, a director until August 15, 2008
and the father of our president and chief executive officer, is president of Oxford Group, Ltd. Mr. Palmin was also an employee
of Novelos until September 2008 and performed consulting services to the Company through December 2009. Pursuant to the agreement,
as revised May 26, 2005, Novelos is required to pay Oxford Group, Ltd., or its assignees, a royalty in the amount of 0.8% of our
net sales of oxidized glutathione-based products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Director Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each member of the Audit Committee, the Compensation Committee
and the Nominating and Corporate Governance Committee and seven of our nine directors meet the independence requirements of the
Nasdaq Stock Market for membership on the committees on which he serves.&nbsp; The board of directors considered the information
included in transactions with related parties as outlined above along with other information the board considered relevant, when
considering the independence of each director. Harry S. Palmin and Jamey P. Weichert are not independent directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 57; Value: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are offering units consisting of up to 5,420,800 shares
of common stock, Class A Warrants to purchase an additional 2,710,400 shares of common stock and Class B Warrants to purchase
an additional 5,420,800 shares of common stock, each
unit consisting of one share of common stock, Class A Warrant to purchase an additional one-half of a share of common stock and
a Class B Warrant to purchase an additional share of common stock for $1.00 per unit,
with aggregate gross proceeds of up to $5,420,800.&nbsp;&nbsp;
However, there is no minimum offering amount required as a condition to closing and we may sell significantly fewer shares of
common stock and warrants in the offering.&nbsp; The offering of the units will terminate on June 14, 2012,
unless the offering is fully subscribed before that date or we decide to terminate the offering prior to that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In determining the offering price for the units and the exercise
price of the warrants, we will consider a number of factors including, but not limited to, the current market price of our common
stock, trading prices of our common stock over time, the illiquidity and volatility of our common stock, our current financial
condition and the prospects for our future cash flows and earnings, and market and economic conditions at the time of the offering.&nbsp;
Once the offering price is determined, the offering price for the units and the exercise price of the warrants will remain fixed
for the duration of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rodman &amp; Renshaw, LLC, which we refer to as the placement
agent, has entered into a placement agency agreement with us in in which it has agreed to act as lead placement agent in connection
with the offering. The placement agent may engage one or more sub-placement agents or selected dealers to assist with the offering.
Among other things, the placement agent will assist us in identifying and evaluating prospective investors and approach prospective
investors regarding the offering. The placement agent will assist us on a &ldquo;reasonable best efforts&rdquo; basis. The placement
agent will have no obligation to buy any of the securities from us, nor is it required to arrange the purchase or sale of any specific
number or dollar amount of securities. We will enter into a securities purchase agreement directly with each investor in connection
with this offering, which will set forth the terms of the offering, as described in this prospectus, will include customary representations
and warranties regarding the offering, the units to be issued and sold, and our business, and will contain customary conditions
to closing and other customary terms. The placement agent agreement terminates within twelve months of the date of our agreement
and further provides that the agreement may be terminated by Rodman at any time upon ten days&rsquo; prior written notice, or by
us at any time after the end of the term upon ten days&rsquo; written notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> This offering will be made only to persons who qualify as
&ldquo;institutional investors&rdquo; under the securities laws of the state of their residence, or for entities, of their domicile,
or to legal entities to whom offers and sales may be made without qualification or registration of this offering under the securities
laws of their state of domicile. If we sell to investors in Wisconsin, they must qualify as &ldquo;Accredited Investors&rdquo;
as that term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended, and modified by Section 413
of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010.&nbsp; </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have agreed to pay Rodman a placement fee equal to 7%
of the aggregate gross proceeds to us from the sale of the securities in the offering and, subject to compliance with FINRA Rule
5110(f)(2)(D), a non-accountable expense allowance equal to 1% of the gross proceeds of this offering.&nbsp; We have advanced
the sum of $50,000 against the 1% non-accountable expense allowance, which pursuant to FINRA Rule 5110(f)(2)(D) shall be reimbursed
to us in the event that the offering is terminated and to the extent the expenses have not been actually incurred.&nbsp; We estimate
total expenses of this offering, excluding the placement agent fee, will be approximately $200,000.&nbsp;
The following table shows the per share and total fees we will pay to the placement agent assuming the sale of all of the units
offered pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 42%; text-align: left">Per unit</TD><TD STYLE="width: 4%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: left">$</TD><TD STYLE="width: 42%; text-align: right">0.07</TD><TD STYLE="width: 4%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">379,456</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the cash fees set forth above, we have agreed
to issue to the placement agent warrants to purchase up to an aggregate of 5% of the aggregate number of shares of common stock
sold in this offering (excluding any shares of common stock issuable upon exercise of the warrants).&nbsp; The placement agent
warrants shall have substantially the same terms as the warrants offered by this prospectus, except that the exercise price shall
be 125% of the public offering price per share, or $1.25 per share, and the expiration date shall
be five years from the effective date of the registration statement of which this prospectus forms a part. Pursuant to FINRA Rule
5110(f)(2)(H)(vi) and (vii), the placement agent warrants do not have anti-dilution protections.&nbsp; Pursuant to FINRA Rule 5110(g)(1),
neither the placement agent warrants nor any shares of common stock issued upon exercise of the placement agent warrants may be
sold, transferred, assigned, pledged, or hypothecated, or be subject to any hedging, short sale, derivative, put, or call transaction
that would result in the effective economic disposition of such securities by any person for a period of 180 days immediately following
the date of effectiveness or commencement of sales of this offering, except the transfer of any security: (i) by operation of law
or by reason of reorganization, (ii) to any FINRA member firm participating in the offering and the officers and partners thereof,
if all securities so transferred remain subject to the lock-up restriction described above for the remainder of the time period,
(iii) if the aggregate amount of our securities held by the placement agent or related person does not exceed 1% of the securities
being offered, (iv) that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no
participating member manages or otherwise directs investments by the fund, and participating members in the aggregate do not own
more than 10% of the equity in the fund, or (v) the exercise or conversion of any security, if all securities received remain subject
to the lock-up restriction set forth above for the remainder of the time period.&nbsp; Because there is no minimum offering amount
required as a condition to closing, the actual total proceeds received by us and total offering commissions and warrants issuable
to the placement agent, if any, are not presently determinable and may be substantially less than the maximum amount set forth
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 58; Value: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have agreed to indemnify the placement agent against certain
liabilities under the Securities Act of 1933, as amended. The placement agent may be deemed to be an underwriter within the meaning
of Section&nbsp;2(a)(11) of the Securities Act and any commissions received by it and any profit realized on the sale of the securities
by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act.&nbsp; The
placement agent would be required to comply with the requirements of the Securities Exchange Act of 1934, as amended, or the Exchange
Act, including without limitation, Regulation M under the Exchange Act.&nbsp; These rules&nbsp;and regulations may limit the timing
of purchases and sales of shares of common stock and warrants to purchase shares of common stock by the placement agent.&nbsp;
Under these rules&nbsp;and regulations, the placement agent many not (i)&nbsp;engage in any stabilization activity in connection
with our securities; and (ii)&nbsp;bid for or purchase any of our securities or attempt to induce any person to purchase an of
our securities, other than as permitted under Regulation M, until they have completed their participation in the distribution.&nbsp;
The placement agent has informed us that it will not engage in overallotment, stabilizing transactions or syndicate covering transactions
in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 59; Value: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under our amended and restated certificate of incorporation,
our authorized capital stock consists of 150,000,000 shares of common stock, $0.00001 par value per share, and 7,000 shares of
preferred stock, $0.00001 par value per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our amended and restated certificate of incorporation authorizes
us to issue shares of our preferred stock from time to time in one or more series without stockholder approval.&nbsp; No shares
of preferred stock are outstanding,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All outstanding shares of our common stock are duly authorized,
validly issued, fully-paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Voting.</I> Holders of our common stock are entitled to one
vote per share held of record on all matters to be voted upon by our stockholders. Our common stock does not have cumulative voting
rights. Persons who hold a majority of the outstanding common stock entitled to vote on the election of directors can elect all
of the directors who are eligible for election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Dividends.</I> Subject to preferences that may be applicable
to the holders of any outstanding shares of our preferred stock, the holders of our common stock are entitled to receive such lawful
dividends as may be declared by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Liquidation and Dissolution.</I> In the event of our liquidation,
dissolution or winding up, and subject to the rights of the holders of any outstanding shares of our preferred stock, the holders
of shares of our common stock will be entitled to receive pro rata all of our remaining assets available for distribution to our
stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Other Rights and Restrictions.</I> Our amended and restated
certificate of incorporation prohibits us from granting preemptive rights to any of our stockholders. All outstanding shares are
fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Class A and Class B Warrants to be Issued as Part of
this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Warrants offered in this offering will be issued in&nbsp;a
form filed as an exhibit to the registration statement of which this prospectus is a part. You should review a copy of the form
of Class A and Class B Warrant for a complete description of the terms and conditions applicable to the Class A and Class B Warrants.
The following is a brief summary of the Class A and Class B Warrants and is subject in all respects to the provisions contained
in the form of warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each Class A Warrant represents the right to purchase one-half
of a share of common stock at an exercise price equal to $1.25, subject to adjustment as described below. Each Class A Warrant
may be exercised on or after the applicable closing date of this offering through and including the close of business on the fifth
anniversary of the date of issuance. Each Class B Warrant represents the right to purchase one share of common stock at an exercise
price equal to $1.00, subject to adjustment as described below. Each Class B Warrant may be exercised on or after the applicable
closing date of this offering through and including the close of business on the 90<SUP>th</SUP> day following of the date of
issuance. Each Class A and Class B Warrant will have a cashless exercise right in&nbsp;the event that the shares of common stock
underlying such Class A and Class B Warrants are not covered by an effective registration statement at the time of such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The exercise price and the number of shares underlying the
Class A and Class B Warrants are subject to appropriate adjustment in the event of stock splits, stock dividends on our common
stock, stock combinations or similar events affecting our common stock. In addition, in the event we consummate any merger, consolidation,
sale or other reorganization event in which our common stock is converted into or exchanged for securities, cash or other property
or we consummate a sale of substantially all of our assets, then following such event, the holders of the Class A and Class B
Warrants will be entitled to receive upon exercise of the Class A and Class B Warrants the kind and amount of securities, cash
or other property which the holders would have received had they exercised the Class A and Class B Warrants immediately prior
to such reorganization event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No fractional shares of common stock will be issued in connection
with the exercise of a Class A and Class B Warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal
to the fractional amount multiplied by the market value of a share of common stock. A Class A and Class B Warrant may be transferred
by a holder, upon surrender of the Class A and Class B Warrant, properly endorsed (by the holder executing an assignment in the
form attached to the Class A and Class B Warrant). The Class A and Class B Warrants will not be listed on any securities exchange
or automated quotation system and we do not intend to arrange for any exchange or quotation system to list or quote the Class
A and Class B Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Takeover Effect of Certain Charter and By-Law Provisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Provisions of our charter and our by-laws could make it more
difficult to acquire us by means of a merger, tender offer, proxy contest, open market purchases, removal of incumbent directors
and otherwise. These provisions, which are summarized below, are expected to discourage types of coercive takeover practices and
inadequate takeover bids and to encourage persons seeking to acquire control of us to first negotiate with us. We believe that
the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal
to acquire or restructure us outweigh the disadvantages of discouraging takeover or acquisition proposals because negotiation of
these proposals could result in an improvement of their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 60; Value: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Authorized but Unissued Stock</I>. We have shares of common
stock and preferred stock available for future issuance, in some cases, without stockholder approval. We may issue these additional
shares for a variety of corporate purposes, including public offerings to raise additional capital, corporate acquisitions, stock
dividends on our capital stock or equity compensation plans.&nbsp; The existence of unissued and unreserved common stock and preferred
stock may enable our board of directors to issue shares to persons friendly to current management or to issue preferred stock with
terms that could render more difficult or discourage a third-party attempt to obtain control of us, thereby protecting the continuity
of our management. In addition, if we issue preferred stock, the issuance could adversely affect the voting power of holders of
common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Amendments to by-laws</I>. Our certificate of incorporation
and by-laws authorize the Board to amend, repeal, alter or rescind the by-laws at any time without stockholder approval.&nbsp;
Allowing the Board to amend our by-laws without stockholder approval enhances Board control over our by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Classification of Board; removal of directors; vacancies.&nbsp;</I>
Our certificate of incorporation provide for the&nbsp; division of the Board into three classes as nearly equal in size as possible
with staggered three-year terms;&nbsp; that directors may be removed only for cause by the affirmative vote of the holders of two-thirds
of our shares of capital stock entitled to vote; and&nbsp; that any vacancy on the Board, however occurring, including a vacancy
resulting from an enlargement of the board, may be filled only by the vote of a majority of the directors then in office.&nbsp;
The limitations on the removal of directors and the filling of vacancies could have the effect of making it more difficult for
a third party to acquire, or of discouraging a third party from acquiring, control of us. Our certificate of incorporation requires
the affirmative vote of the holders of at least 75% of our shares of capital stock issued and outstanding and entitled to vote
to amend or repeal any of these provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Notice Periods for Stockholder Meetings</I>. Our by-laws
provide that for business to be brought by a stockholder before an annual meeting of stockholders, the stockholder must give&nbsp;written
notice to the corporation not less than 90 nor more than 120 days prior to the one year anniversary of the date of the annual meeting
of stockholders of the previous year; provided, however, that in the event that the annual meeting of stockholders is called for
a date that is not within 30 days before or after such anniversary date, notice by the stockholder must be received not later than
the close of business on the tenth day following the day on which the corporation's notice of the date of the&nbsp;meeting is first
given or made to the stockholders or disclosed to the general public, whichever occurs first.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Stockholder action; special meetings</I>.&nbsp; Our certificate
of incorporation provides that stockholder action may not be taken by written action in lieu of a meeting and provides special
meetings of the stockholders may only be called by our president or by our Board. These provisions could have the effect of delaying
until the next stockholders' meeting stockholder actions that are favored by the holders of a majority of our outstanding voting
securities. These provisions may also discourage another person or entity from making a tender offer for our common stock, because
that person or entity, even if it acquired a majority of our outstanding voting securities, would be able to take action as a stockholder
only at a duly called stockholders' meeting, and not by written consent. Our certificate of incorporation requires the affirmative
vote of the holders of at least 75% of our shares of capital stock issued and outstanding and entitled to vote to amend or repeal
the provisions relating to prohibition on action by written consent and the calling of a special meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Nominations</I>.&nbsp; Our by-laws provide that nominations
for election of directors may be made only by (i) the Board or a committee appointed by the Board; or (ii) a stockholder entitled
to vote on director election, if the stockholder provides notice to the Secretary of the Corporation presented not less than 90
days nor more than 120 days prior to the anniversary of the last annual meeting (subject to the limited exceptions set forth in
the bylaws). These provisions may deter takeovers by requiring that any stockholder wishing to conduct a proxy contest have its
position solidified well in advance of the meeting at which directors are to be elected and by providing the incumbent Board with
sufficient notice to allow them to put an election strategy in place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DISCLOSURE OF COMMISSION POSITION ON</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our charter contains provisions to indemnify our directors and
officers to the maximum extent permitted by Delaware law. We believe that indemnification under our charter covers at least negligence
on the part of an indemnified person. Our charter permits us to advance expenses incurred by an indemnified person in connection
with the defense of any action or proceeding arising out of the person&rsquo;s status or service as our director, officer, employee
or other agent upon an undertaking by the person to repay those advances if it is ultimately determined that the person is not
entitled to indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 61; Value: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the&nbsp;registrant has been advised that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a reporting company and file annual, quarterly and special
reports, and other information with the Securities and Exchange Commission. Copies of the reports and other information may be
read and copied at the SEC&rsquo;s Public Reference Room at 100 F Street NE, Washington, D.C. 20549. You can request copies of
such documents by writing to the SEC and paying a fee for the copying cost. You may obtain information on the operation of the
Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a web site at http://www.sec.gov that contains reports,
proxy and information statements and other information regarding registrants that file electronically with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus is part of a registration statement on Form
S-1 that we filed with the SEC. Certain information in the registration statement has been omitted from this prospectus in accordance
with the rules and regulations of the SEC. We have also filed exhibits and schedules with the registration statement that are excluded
from this prospectus. For further information you may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">read a copy of the registration statement, including the exhibits and schedules, without charge
at the SEC&rsquo;s Public Reference Room; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">obtain a copy from the SEC upon payment of the fees prescribed by the SEC.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The validity of the securities being offered by this prospectus
will be passed upon for us by Foley Hoag LLP, Boston, Massachusetts. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The audited financial statements of Novelos Therapeutics, Inc.
included in this prospectus and elsewhere in the registration statement have been so included in reliance upon the report of Grant
Thornton LLP, independent registered public accounting firm, upon the authority of said firm as experts in accounting and auditing
in giving said report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 62; Value: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GLOSSARY OF SCIENTIFIC TERMS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Akt -</I></B> Akt (also known as Akt/PKB)&nbsp;is an important
cell signaling enzyme (a serine/threonine protein kinase) that plays a key role in multiple cellular processes such as glucose
metabolism, cell proliferation,&nbsp;apoptosis, transcription and cell migration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Apoptosis -</I></B> A highly regulated, normal cell process
leading to programmed cell death by which organisms can eliminate damaged or aberrant cells.&nbsp; Apoptosis is often abnormally
suppressed in cancer cells, contributing to their uncontrolled proliferation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Caspases -</I></B> Caspases are a family of enzymes (cysteine-aspartic
proteases&nbsp;or&nbsp;cysteine-dependent&nbsp;aspartate-directed proteases)&nbsp; that play essential roles in&nbsp;apoptosis&nbsp;(programmed
cell death),&nbsp;necrosis, and&nbsp;inflammation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cytotoxic -</I></B> Cytotoxicity is the quality of being
toxic to cells (i.e. cell-killing).&nbsp; Many cancer chemotherapeutic drugs are cytotoxic to cancer cells (and, to some extent,
normal cells) thus resulting in unwanted side-effects e.g. nausea/vomiting, hair loss, suppression of the immune system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Dosimetry -</I></B> Radiation&nbsp;dosimetry&nbsp;is the
calculation of absorbed dose and optimization of dose delivery in&nbsp;radiation therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Lipid Rafts -</I></B> Specialized regions of the membrane
phospholipid bilayer that contain high concentrations of cholesterol and sphingolipids and serve to organize cell surface and intracellular
signaling molecules (e.g. growth factor and cytokine receptors, the phophatidylinosotol 3-kinase (P13K)/Akt survival pathway).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Radiolabeled -</I></B> Refers to a molecule containing
a radioisotope as a part of its structure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Radioisotope -</I></B> Also referred to as radioactive
isotopes or radionuclides.&nbsp; These are variants of atoms of particular chemical elements (e.g. iodine) with an unstable nucleus
that can undergo radioactive decay during which ionizing radiation (e.g. gamma rays, subatomic particles) is emitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Uptake &ndash;</I></B> An act of taking in or absorbing,
especially into a living organism, tissue or cell.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Xenograft -</I></B> Tissue, organs or cells from an individual
of one species transplanted into or grafted onto an individual of another species.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 63; Value: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO FINANCIAL STATEMENTS FOR NOVELOS
THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(a Development Stage Company)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 90%; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 10%; vertical-align: top; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Page</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt">Report of Independent Registered Public Accounting Firm</TD>
    <TD STYLE="text-align: center">F-2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt">Consolidated Balance Sheets at March 31, 2012, December 31, 2011 and 2010</TD>
    <TD STYLE="text-align: center">F-3</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt">Consolidated Statements of Operations for the Three Months Ended March 31, 2012 and 2011, Years Ended December 31, 2011 and 2010, and the Cumulative Development-Stage Period from November 7, 2002 (date of inception) to December 31, 2011</TD>
    <TD STYLE="text-align: center">F-4</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt">Consolidated Statements of Stockholders&rsquo; Equity&nbsp;for the Three Months Ended March 31, 2012, Years Ended December 31, 2011 and 2010, and&nbsp;the Cumulative Development-Stage Period from November 7, 2002 (date of inception) to December 31, 2011</TD>
    <TD STYLE="text-align: center">F-5</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt">Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2012 and 2011, Years Ended December 31, 2011 and 2010, and the Cumulative Development-Stage Period from November 7, 2002 (date of inception) to December 31, 2011</TD>
    <TD STYLE="text-align: center">F-6</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt">Notes to Consolidated Financial Statements</TD>
    <TD STYLE="text-align: center">F-7</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 64; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Directors and Shareholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Novelos Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying consolidated balance sheets
of Novelos Therapeutics, Inc. and Subsidiary (a Development Stage Company) (a Delaware corporation) (the Company) as of December
31, 2011 and 2010, and the related consolidated statements of operations, stockholders&rsquo; equity, and cash flows for each of
the two years in the period ended December 31, 2011 and the period from November 7, 2002 (date of inception) through December 31,
2011. These financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an
opinion on these financial statements based on our audits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audits in accordance with the standards of
the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have,
nor were we engaged to perform an audit of its internal control over financial reporting. Our audit included consideration of internal
control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for
the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly,
we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures
in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In our opinion, the consolidated financial statements referred
to above present fairly, in all material respects, the financial position of Novelos Therapeutics, Inc. and Subsidiary, as of December
31, 2011 and 2010, and the results of their operations and their cash flows for each of the two years in the period ended December
31, 2011 and the period from November 7, 2002 (date of inception) through December 31, 2011, in conformity with accounting principles
generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying financial statements have been prepared assuming
that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred
losses since its inception and, as of December 31, 2011, had an accumulated deficit of $31,480,426. These conditions, along with
other matters as set forth in Note 1, raise substantial doubt about the Company&rsquo;s ability to continue as a going concern.
Management&rsquo;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Grant Thornton LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boston, Massachusetts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 9, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOVELOS THERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(a Development Stage Company)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March&nbsp;31,<BR> 2012<BR> (unaudited)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,<BR> 2011<BR> (audited)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,<BR> 2010<BR> (audited)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 61%; text-align: left; text-indent: -9pt; padding-left: 27pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,787,576</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5,505,960</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">673,739</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">555,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 27pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">183,300</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">254,967</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">51,042</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 45pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,025,876</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,815,927</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,279,781</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">FIXED ASSETS, NET</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,919,943</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,044,565</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,510,489</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">GOODWILL</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,675,462</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,675,462</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">OTHER ASSETS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,222</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,222</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,872</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,648,503</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,563,176</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,802,142</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">471,629</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">478,041</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">392,881</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Accrued interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">305,049</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,397</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,305</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Notes payable, current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">204,802</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 27pt">Capital lease obligations, current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,275</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,235</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,085</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 45pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">506,301</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">503,581</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">904,817</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">LONG-TERM LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 8.7pt; padding-left: 9pt">Convertible debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,720,985</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 8.7pt; padding-left: 9pt">Notes payable, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">450,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">450,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">920,941</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 8.7pt; padding-left: 9pt">Deferred rent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127,368</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">124,381</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,311</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 8.7pt; padding-left: 9pt">Capital lease obligations, net of current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,507</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,091</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,326</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 26.7pt; padding-left: 9pt">Total long-term liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">580,875</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">578,472</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,763,563</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">TOTAL LIABILITIES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,087,176</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,082,053</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,668,380</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">COMMITMENTS AND CONTINGENCIES (Notes 13 and 14)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">STOCKHOLDERS&rsquo; EQUITY:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -9pt; padding-left: 27pt">Preferred stock, $0.00001 par value; 7,000 shares authorized; none issued and outstanding as of March 31, 2012, December 31, 2011 and 2010</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Common stock, $0.00001 par value; 150,000,000 shares authorized; 36,962,264,&nbsp; 36,907,824 and 12,820,102 shares issued and outstanding at March 31, 2012, December 31, 2011 and 2010, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">369</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">369</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">128</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 27pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,398,287</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,961,180</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,178,638</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 27pt">Deficit accumulated during the development stage</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(33,837,329</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(31,480,426</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(24,045,004</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 45pt">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,561,327</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,481,123</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">133,762</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,648,503</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,563,176</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,802,142</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><I>See report of independent
registered public accounting firm and accompanying notes to the consolidated financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOVELOS THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(a Development Stage Company)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;Ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">Cumulative<BR> Development-<BR> Stage&nbsp;Period<BR> from&nbsp;November<BR> 7,&nbsp;2002&nbsp;(date&nbsp;of<BR> inception)<BR> through<BR> December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012<BR> (unaudited)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011<BR> (unaudited)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011<BR>
(audited)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010<BR>
(audited)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">&nbsp;2011<BR> (audited)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">COSTS AND EXPENSES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 35%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,328,314</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">471,404</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,599,080</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,984,207</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">20,805,039</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">997,671</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131,726</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,692,433</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,156,549</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,662,611</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Merger costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">250,434</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">746,207</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">52,925</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">799,133</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 27pt">Total costs and expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,325,985</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">853,564</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,037,720</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,193,681</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">31,266,783</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">LOSS FROM OPERATIONS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,325,985</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(853,564</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,037,720</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,193,681</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(31,266,783</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">OTHER INCOME (EXPENSE):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Grant income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,479</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,479</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">244,479</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Loss on derivative warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28,846</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,158</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,158</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Interest expense, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,072</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(156,167</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(430,023</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(566,156</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(447,125</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in">Other income (expense)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(426</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,161</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.5in">Total other expense, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(30,918</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(111,688</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(397,702</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(366,582</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(213,643</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">NET LOSS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,356,903</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(965,252</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,435,422</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,560,263</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(31,480,426</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">BASIC AND DILUTED NET LOSS PER COMMON SHARE</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.06</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.08</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.31</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.36</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2.84</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON SHARE</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">36,910,217</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,820,102</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">23,959,008</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,820,102</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,090,838</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><I>See report of independent
registered public accounting firm and accompanying notes to the consolidated financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOVELOS THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(a Development Stage Company)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&rsquo;
EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common&nbsp;Stock</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Additional<BR> Paid-in<BR> Capital</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deficit<BR> Accumulated<BR> During&nbsp;the<BR> Development<BR> Stage</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<BR> Stockholders&rsquo;<BR> Equity</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Par<BR> Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">BALANCE AT NOVEMBER 7, 2002</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 35%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of common stock for cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6,440,123</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">64</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">590,205</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">590,269</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of common stock in exchange for professional services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">101,220</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,107</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,108</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">BALANCE AT DECEMBER 31, 2002</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,541,343</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">599,312</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">599,377</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of common stock for cash, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,958</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,937</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,937</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of common stock in exchange for licensed technology</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">203,483</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,410</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,412</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(295,790</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(295,790</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">BALANCE AT DECEMBER 31, 2003</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,782,784</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">684,659</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(295,790</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">388,936</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(342,761</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(342,761</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">BALANCE AT DECEMBER 31, 2004</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,782,784</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">684,659</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(638,551</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,175</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of common stock for cash, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">610,664</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">835,862</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">835,868</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(481,837</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(481,837</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">BALANCE AT DECEMBER 31, 2005</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,393,448</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,520,521</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,120,388</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,206</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of common stock for cash, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,202,179</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,097,050</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,097,072</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Common stock repurchased</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(43,819</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(31,667</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(31,667</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,994</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,994</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(963,440</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(963,440</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">BALANCE AT DECEMBER 31, 2006</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,551,808</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,629,898</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,083,828</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,546,165</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of common stock for cash, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">249,999</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Exercise of warrant to purchase common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,045</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">249,999</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">570,392</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">570,392</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,090,325</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,090,325</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">BALANCE AT DECEMBER 31, 2007</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,687,103</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">97</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,700,288</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,174,153</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,526,232</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of common stock for cash, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,132,999</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,931,531</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,931,562</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">477,488</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">477,488</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,090,715</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,090,715</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">BALANCE AT DECEMBER 31, 2008</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,820,102</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">128</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,109,307</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,264,868</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,844,567</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">502,199</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">502,199</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,219,873</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,219,873</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">BALANCE AT DECEMBER 31, 2009</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,820,102</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">128</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,611,506</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,484,741</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,126,893</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">353,340</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">353,340</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Intrinsic value of beneficial conversion feature associated with convertible debt issued in exchange for cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">213,792</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">213,792</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,560,263</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,560,263</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">BALANCE AT DECEMBER 31, 2010</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,820,102</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">128</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,178,638</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24,045,004</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">133,762</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of common stock upon conversion of convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,181,535</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,184,665</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,184,707</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of common stock in a business combination</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,959,871</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,219,873</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,219,903</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Cash paid in lieu of fractional shares in a business combination</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(41</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(145</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(145</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of common stock and warrants, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,928,204</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">169</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,164,377</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,164,546</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Intrinsic value of beneficial conversion feature associated with the conversion of convertible debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">257,973</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">257,973</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of common stock upon the cashless exercise of warrants and reclassification of derivative liability to additional paid-in-capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,153</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,339</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,339</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">907,460</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">907,460</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,435,422</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,435,422</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">BALANCE AT DECEMBER 31, 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,907,824</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">369</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">40,961,180</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(31,480,426</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9,481,123</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of common stock upon cashless exercise of warrants and reclassification of derivative liability to additional paid-in-capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,440</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,754</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,754</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">417,353</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">417,353</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,356,903</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,356,903</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">BALANCE AT MARCH 31, 2012 (UNAUDITED)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">36,962,264</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">369</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">41,398,287</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(33,837,329</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,561,327</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>See report of independent registered
public accounting firm and accompanying notes to the consolidated financial statements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOVELOS THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(a Development Stage Company)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three&nbsp;Months&nbsp;Ended<BR> March&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;Ended<BR> December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Cumulative<BR> Development-Stage<BR> Period&nbsp;from&nbsp;November<BR> 7,&nbsp;2002&nbsp;through<BR> December&nbsp;31,&nbsp;2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>2012<BR> </B>(unaudited)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>2011<BR> </B>(unaudited)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>2011<BR> </B>(audited)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>2010<BR> </B>(audited)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">(audited)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 35%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(2,356,903</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(965,252</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(7,435,422</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(4,560,263</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(31,480,426</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Adjustments to reconcile net loss to cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.5in">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">139,771</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144,174</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">584,841</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">580,114</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,416,038</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 0.5in">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">417,353</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,462</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">907,460</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">353,340</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,854,873</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.5in">Intrinsic value of beneficial conversion feature associated with convertible debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">257,973</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">213,792</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">471,765</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.5in">Issuance of stock for technology and services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89,520</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 9pt; padding-left: 0.25in">Impairment of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,671</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,671</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 9pt; padding-left: 0.25in">Loss on disposal of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,009</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,477</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 9pt; padding-left: 0.25in">Loss on derivative warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,846</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,158</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,158</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Changes in:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.5in">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,458</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(175,883</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,584</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(238,797</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.5in">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,412</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">293,383</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(294,969</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(322,707</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">97,912</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 27pt">Accrued interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">145,802</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">158,673</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">305,049</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">463,722</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 27pt">Deferred rent</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,987</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,323</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,070</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,973</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">124,381</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 35.6pt">Cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,702,691</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(324,566</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,970,090</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,382,447</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(25,132,706</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash acquired in a business combination</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">905,649</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">905,649</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Purchases of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,149</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(118,411</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,652</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,486,592</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from sale of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 0.25in">Purchases of short-term certificates of deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,500,730</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from short-term certificates of deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,500,730</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Change in restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(55,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Payment for intangible assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(19,671</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 45pt">Cash provided by (used in) investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(15,149</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,287,238</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,652</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,648,614</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from issuance of convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,720,985</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,720,985</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from long-term obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">450,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,677,945</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Payments on long-term obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(49,998</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(675,743</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(190,789</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,227,944</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Payments on capital lease obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(544</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(508</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,085</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,944</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,648</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from issuance of common stock, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,164,546</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,874,254</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -9pt; padding-left: 0.25in">Proceeds from exercise of warrant</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Repurchase of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(31,667</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash paid in lieu of fractional shares in a business combination</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(145</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(145</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in">Change in deferred issuance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">28,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">99,461</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">28,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 45pt">Cash provided by (used in) financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(544</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(50,506</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,515,073</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,077,713</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">35,287,280</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">INCREASE (DECREASE) IN CASH AND EQUIVALENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,718,384</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(375,072</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,832,221</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(306,386</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,505,960</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">CASH AND EQUIVALENTS AT BEGINNING OF PERIOD</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,505,960</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">673,739</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">673,739</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">980,125</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">CASH AND EQUIVALENTS AT END OF PERIOD</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,787,576</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">298,667</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,505,960</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">673,739</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,505,960</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Interest paid</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,563</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,716</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">54,454</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">208,689</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Fair value of derivative warrants reclassified to additional paid-in capital upon cashless exercise</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">19,754</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">48,339</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">48,339</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Issuance of common stock upon conversion of notes payable and accrued interest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,184,707</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,184,707</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Fair value of assets acquired in exchange for securities in a business combination</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">78,407</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">78,407</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Fair value of liabilities assumed in exchange for securities in a business combination</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(439,615</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(439,615</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Excess of purchase price over net assets acquired in a business combination</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,675,462</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,675,462</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>See report of independent registered
public accounting firm and accompanying notes to the consolidated financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOVELOS THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(a Development Stage Company)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B> &nbsp;(ALL INFORMATION AS OF AND
FOR THE THREE MONTHS ENDED <BR>
MARCH 31, 2012 AND 2011 IS UNAUDITED) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>1. NATURE OF BUSINESS, ORGANIZATION
AND GOING CONCERN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Novelos Therapeutics, Inc. (&ldquo;Novelos&rdquo; or the &ldquo;Company&rdquo;)
is a pharmaceutical company developing compounds for the treatment of cancer. On April 8, 2011, Novelos completed a business combination
with Cellectar, Inc. (&ldquo;Cellectar&rdquo;), a privately held Wisconsin corporation that designed and developed products to
detect, treat and monitor a wide variety of human cancers, and Cell Acquisition Corp. (the &ldquo;Merger Subsidiary&rdquo;), a
Wisconsin corporation and a wholly owned subsidiary of Novelos. Pursuant to the transaction Cellectar was merged into the Merger
Subsidiary (the &ldquo;Acquisition&rdquo;, see Note 4). References in these financial statements and notes to &ldquo;Cellectar&rdquo;
relate to the activities and financial information of Cellectar prior to the Acquisition, references to &ldquo;Novelos&rdquo; relate
to the activities and financial information of Novelos prior to the Acquisition and references to &ldquo;the Company&rdquo; or
&ldquo;we&rdquo; or &ldquo;us&rdquo; or &ldquo;our&rdquo; relate to the activities and obligations of the combined Company following
the Acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immediately prior to the Acquisition, Novelos completed a 1-for-153
reverse split of its common stock.&nbsp; Novelos then issued to the shareholders of Cellectar at that date 17,001,596 shares of
its common stock as consideration for the Acquisition, representing a ratio of 0.8435 shares of Novelos common stock in exchange
for one share of Cellectar common stock (the &ldquo;Exchange Ratio&rdquo;) as set forth in the Agreement and Plan of Merger (the
&ldquo;Merger Agreement&rdquo;) dated April 8, 2011.&nbsp; The shares issued to Cellectar shareholders in the Acquisition constituted
approximately 85% of Novelos&rsquo; outstanding common stock after giving effect to the Acquisition.&nbsp; Upon the closing of
the Acquisition, the Company completed the private placement of 6,846,537 shares of its common stock and warrants to purchase an
additional 6,846,537 shares of its common stock for gross proceeds of approximately $5,135,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Accounting principles generally accepted in the United States
require that a company whose security holders retain the majority voting interest in the combined business be treated as the acquirer
for financial reporting purposes.&nbsp; Accordingly, the Acquisition was accounted for as a reverse acquisition whereby Cellectar,
Inc. was treated as the acquirer for accounting and financial reporting purposes. The financial statements presented herein as
of and for the three months ended March 31, 2011 and as of and for the twelve months ended December 31, 2010 represent the historical
financial information of Cellectar, except for the capital structure which represents the historical amounts of Cellectar, retroactively
adjusted to reflect the legal capital structure of Novelos by applying the Exchange Ratio. On April, 8, 2011, Cellectar was merged
into the Merger Subsidiary a wholly owned subsidiary of Novelos; as such, the financial statements presented herein as of and
for the twelve months ended December 31, 2011 include the historical results of Cellectar from January 1, 2011 through April 8,
2011, except for the capital structure which represents the historical amounts of Cellectar, retroactively adjusted to reflect
the legal capital structure of Novelos by applying the Exchange Ratio, and include the consolidated results of the combined company
from April 9, 2011 through December 31, 2011. The financial statements as of and for the three months ended March 31, 2012 include
the consolidated results of the combined company for that period. All per-share amounts and outstanding shares, including all
common stock equivalents, and stock options, have been retroactively restated in these financial statements and notes for all
periods presented to reflect the capital structure of Novelos by applying the Exchange Ratio.&nbsp;&nbsp;The cumulative capital
activity from the date of inception (November 7, 2002) up to the closing of the Acquisition, as presented in the accompanying
statement of stockholders&rsquo; equity, equals 17,001,596 shares of common stock, which represents the equity interests the legal
parent (Novelos) issued to effect the Acquisition. The number of authorized shares of common stock disclosed on the balance sheet
(150,000,000) represents the number of authorized shares of Novelos common stock following the Acquisition.&nbsp; Additionally,
on the accompanying balance sheet as of December 31, 2010 and statements of stockholders&rsquo; equity for the period from inception
(November 7, 2002) to December 31, 2010 the aggregate par value of the issued common stock was reduced to reflect the $0.00001
par value of Novelos common stock associated with the shares of Cellectar common stock adjusted for the Exchange Ratio and the
difference was reclassified to additional paid-in capital. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the Acquisition, the Company has implemented
a revised business plan focused on the development of the Cellectar compounds.&nbsp; Development of Novelos&rsquo; other compounds
(NOV-002 and NOV-205) has been suspended.&nbsp; The Company is conducting its operations from Cellectar&rsquo;s headquarters in
Madison, Wisconsin and the Company&rsquo;s executive offices are in Newton, Massachusetts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company is subject to a number of risks similar to those
of other small pharmaceutical companies. Principal among these risks are dependence on key individuals, competition from substitute
products and larger companies, the successful development and marketing of its products in a highly regulated environment and the
need to obtain additional financing necessary to fund future operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying financial statements have been prepared on
a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, realization
of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has incurred losses
since inception in devoting substantially all of its efforts toward research and development and has an accumulated deficit of
$31,480,426 at December 31, 2011. During the year ended December 31, 2011, the Company generated a net loss of $7,435,422 and the
Company expects that it will continue to generate operating losses for the foreseeable future.&nbsp; The Company believes that
its cash on hand is adequate to fund operations into the middle of the third quarter of 2012.&nbsp; The Company&rsquo;s ability
to execute its operating plan beyond that time depends on its ability to obtain additional funding via the sale of equity and/or
debt securities, a strategic transaction or otherwise.&nbsp; The Company plans to continue to actively pursue financing alternatives,
but there can be no assurance that it will obtain the necessary funding.&nbsp; The accompanying financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying consolidated financial statements reflect the
application of certain accounting policies, as described in this note and elsewhere in the accompanying notes to the consolidated
financial statements.&nbsp; The consolidated financial statements as of and for the twelve months ended December 31, 2011 are presented
on a consolidated basis to reflect the Acquisition described in Note 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Principles of Consolidation</I></B> &mdash;<FONT STYLE="color: black">The
consolidated financial statements include the accounts of the Company and the accounts of its wholly-owned subsidiary. All intercompany
accounts and transactions have been eliminated in consolidation. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Development Stage Company</I></B> &mdash; The Company
has been in the development stage since its inception.&nbsp; The primary activities since inception have been organizational activities,
research and development and raising capital.&nbsp; No significant revenues have been generated from planned operations.&nbsp;
As of March 31, 2012, December 31, 2011 and 2010, the Company remained in the development stage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The summary unaudited condensed statement of operations for
the cumulative development-stage period from November 7, 2002 (date of inception) through March 31, 2012 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">COSTS AND EXPENSES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 87%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">22,133,353</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,660,282</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in">Merger costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">799,133</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.5in">Total costs and expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">33,592,768</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">LOSS FROM OPERATIONS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(33,592,768</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">OTHER EXPENSE, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(244,561</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">NET LOSS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(33,837,329</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2.87</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,775,244</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE><BR STYLE="clear: both">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The summary unaudited condensed statement of cash flow for the
cumulative development-stage period from November 7, 2002 (date of inception) through March 31, 2012 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 87%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(33,837,329</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Adjustments to reconcile net loss to cash used in operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,486,472</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in">Changes in working capital</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">515,460</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 45pt">Cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(26,835,397</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash acquired in a business combination</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">905,649</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Purchases of fixed assets, net of $7,000 proceeds from sale of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,494,741</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Change in restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(55,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in">Payment for intangible assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(19,671</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 45pt">Cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,663,763</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from issuance of common stock and warrants, net of issuance costs, repurchase of common stock, and cash paid in lieu of fractional shares in a business combination</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,092,442</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Change in deferred issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from issuance of long-term obligations and convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,398,930</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in">Payments on long-term obligations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,233,136</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 45pt">Cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">35,286,736</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">INCREASE IN CASH AND EQUIVALENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,787,576</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">CASH AND EQUIVALENTS AT BEGINNING OF PERIOD</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">CASH AND EQUIVALENTS AT END OF PERIOD</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,787,576</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Interest paid</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">208,689</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Fair value of derivative warrants reclassified to additional paid-in capital upon cashless exercise</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">68,093</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Issuance of common stock upon the conversion of notes payable and accrued interest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,184,707</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Fair value of assets acquired in exchange for securities in a business combination</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">78,407</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Fair value of liabilities assumed in exchange for securities in a business combination</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(439,615</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Excess of purchase price over net assets acquired in a business combination</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,675,462</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE><BR STYLE="clear: both">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Use of Estimates</I></B> &mdash; The preparation of financial
statements in conformity with accounting principles generally accepted in the United States requires management to make estimates
and judgments that may affect the reported amounts of assets, liabilities, revenue and expenses and disclosure of contingent assets
and liabilities. On an on-going basis, management evaluates its estimates including those related to unbilled vendor amounts and
share-based compensation. Management bases its estimates on historical experience and on various other assumptions that are believed
to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.
Actual results may differ from those estimates under different assumptions or conditions. Changes in estimates are reflected in
reported results in the period in which they become known.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cash and Cash Equivalents</I></B> &mdash; All short-term
investments purchased with maturities of three months or less are considered to be cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Restricted Cash</I></B> &mdash; Restricted cash at March
31, 2012 and December 31, 2011 consists of a certificate of deposit required under the Company&rsquo;s lease agreement for its
Madison, Wisconsin facility (see Note 13).&nbsp; Restricted cash at December 31, 2010 consists of a certificate of deposit required
for collateral for a promissory note with a bank (see Note 8) and a certificate of deposit required under the Company&rsquo;s lease
agreement for its Madison, Wisconsin facility (see Note 13).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Fixed Assets</I></B> &mdash; Property and equipment are
stated at cost. Depreciation on property and equipment is provided using the straight-line method over the estimated useful lives
of the assets (5 years).&nbsp; Due to the significant value of leasehold improvements purchased during the initial 3-year lease
term and the economic penalty for not extending the building lease, leasehold improvements are depreciated over 17 years (their
estimated useful life), which represents the full term of the lease, including all extensions (Note 13).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Goodwill</I></B> &mdash; Intangible assets at March 31,
2012 and December 31, 2011 consist of goodwill recorded in connection with the Acquisition. Goodwill is not amortized, but is required
to be evaluated for impairment annually or <FONT STYLE="color: black">whenever events or changes in circumstances suggest that
the carrying value of an asset may not be recoverable. </FONT>The Company evaluates goodwill for impairment annually in the fourth
fiscal quarter and additionally on an interim basis if an event occurs or there is a change in circumstances, such as a decline
in the Company&rsquo;s stock price or a material adverse change in the business climate, which would more likely than not reduce
the fair value of the reporting unit below its carrying amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Impairment of Long</I></B>-<B><I>Lived Assets</I></B>
&mdash; Long-lived assets other than intangible assets consist of fixed assets, which w<FONT STYLE="color: black">e periodically
evaluate for potential impairment. </FONT>Whenever events or circumstances change, an assessment is made as to whether there has
been an impairment in the value of long-lived assets by determining whether projected undiscounted cash flows generated by the
applicable asset exceed its net book value as of the assessment date. During 2010, following a reduction in staff and suspension
of research and manufacturing activities in order to reduce operating costs, it was determined that the trademarks previously capitalized
as intangible assets had been impaired and the carrying value was reduced to zero.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock-Based Compensation</I></B> &mdash; The Company uses
the Black-Scholes option-pricing model to calculate the grant-date fair value of stock option awards. The resulting compensation
expense, net of expected forfeitures, for awards that are not performance-based is recognized on a straight-line basis over the
service period of the award, which is generally three years for stock options. For stock options with performance-based vesting
provisions, recognition of compensation expense, net of expected forfeitures, commences if and when the achievement of the performance
criteria is deemed probable. The compensation expense, net of expected forfeitures, for performance-based stock options is recognized
over the relevant performance period. Non-employee stock-based compensation is accounted for in accordance with the guidance of
FASB ASC Topic 505, <I>Equity.&nbsp;</I> As such, the Company recognizes expense based on the estimated fair value of options granted
to non-employees over their vesting period, which is generally the period during which services are rendered and deemed completed
by such non-employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development</I></B>
&mdash; Research and development costs are expensed as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Income Taxes</I></B> &mdash; Income taxes are accounted
for using the liability method of accounting.&nbsp; Under this method, deferred tax assets and liabilities are determined based
on temporary differences between the financial statement basis and tax basis of assets and liabilities and net operating loss and
credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse.&nbsp; The
effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the
enactment date.&nbsp; Valuation allowances are established when it is more likely than not that some portion of the deferred tax
assets will not be realized.&nbsp; Management has provided a full valuation allowance against the Company&rsquo;s gross deferred
tax asset.&nbsp; Tax positions taken or expected to be taken in the course of preparing tax returns are required to be evaluated
to determine whether the tax positions are &ldquo;more likely than not&rdquo; to be sustained by the applicable tax authority.&nbsp;
Tax positions deemed not to meet a more-likely-than-not threshold would be recorded as tax expense in the current year.&nbsp; There
were no uncertain tax positions that require accrual to or disclosure in the financial statements as of December 31, 2011 and 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Comprehensive Loss</I></B> &mdash; There were no components
of comprehensive loss other than net loss in all of the periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Grant Income</I></B> &mdash; Cellectar received a cash
grant of approximately $44,000 and $200,000 for the years ended December 31, 2011 and 2010, respectively, from the U.S. Internal
Revenue Service as a qualifying therapeutic discovery project credit pursuant to the Patient Protection and Affordable Care Act.&nbsp;
This grant has been recorded as a component of other income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Fair Value of Financial Instruments</I></B> &mdash; The
guidance under FASB ASC Topic 825, <I>Financial Instruments</I>, requires disclosure of the fair value of certain financial instruments.
Financial instruments in the accompanying financial statements consist of cash equivalents, accounts payable, convertible debt
and long-term obligations.&nbsp; The carrying amount of cash equivalents, investments and accounts payable&nbsp;approximate&nbsp;their&nbsp;fair
value due to their short-term nature.&nbsp; The estimated fair value of the convertible debt, determined on an as-converted basis
including conversion of accumulated unpaid interest, was approximately $3,264,000 at December 31, 2010, respectively.&nbsp; There
was no convertible debt outstanding at March 31, 2012 or December 31, 2011. The carrying value of long-term obligations, including
the current portion, approximates fair value because the fixed interest rate approximates current market rates of interest available
in the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Derivative Instruments</I></B> <I>&nbsp;</I> &ndash; The
Company generally does not use derivative instruments to hedge exposures to cash flow or market risks.&nbsp; However, certain warrants
to purchase common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and
Hedging Topic of the Financial Accounting Standards Board Accounting Standards Codification (&ldquo;FASB ASC&rdquo;), are classified
as liabilities.&nbsp; In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of
the underlying contracts do not provide for a net-cash settlement. These warrants are considered derivative instruments because
the agreements contain &ldquo;down-round&rdquo; provisions whereby the number of shares for which the warrants are exercisable
and/or the exercise price of the warrants are subject to change in the event of certain issuances of stock at prices below the
then-effective exercise price of the warrants. The number of shares issuable under such warrants was 50,419 and 77,729 at March
31, 2012 and December 31, 2011, respectively. The primary underlying risk exposure pertaining to the warrants is the change in
fair value of the underlying common stock.&nbsp; Such financial instruments are initially recorded at fair value with subsequent
changes in fair value recorded as a component of gain or loss on derivatives on the consolidated statements of operations in each
reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the
fair value to equity. At March 31, 2012 and December 31, 2011, these warrants represented the only outstanding derivative instruments
issued or held by the Company.&nbsp; There were no outstanding derivative instruments at December 31, 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I> Concentration of Credit Risk </I></B> &mdash;
Financial instruments that subject the Company to credit risk consist of cash and equivalents on deposit with financial institutions.
The Company&rsquo;s excess cash as of March 31, 2012 and December 31, 2011 is on deposit in a non-interest-bearing transaction
account that is fully covered by FDIC deposit insurance. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>New Accounting Pronouncements</I></B> &mdash;&nbsp;In
January 2010, the FASB issued ASU No.&nbsp;2010-06, <I>Improving Disclosures about Fair Value Measurements</I>, which requires
additional disclosures about the amounts of and reasons for significant transfers in and out of Level&nbsp;1 and Level&nbsp;2 fair
value measurements. This standard also clarifies existing disclosure requirements related to the level of disaggregation of fair
value measurements for each class of assets and liabilities and disclosures about inputs and valuation techniques used to measure
fair value for both recurring and non-recurring Level&nbsp;2 and Level&nbsp;3 measurements. Since this new accounting standard
only required additional disclosure, the adoption of the standard in the first quarter of 2010 did not impact the accompanying
financial statements. Additionally, effective for interim and annual periods beginning after December&nbsp;15, 2010, this standard
will require additional disclosure and require an entity to present disaggregated information about activity in Level&nbsp;3 fair
value measurements on a gross basis, rather than one net amount.&nbsp; The adoption of this accounting standard did not impact
the accompanying financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2010, the FASB issued ASU No. 2010-29, <I>Disclosures
of Supplementary Pro Forma Information for Business Combinations</I>, which, if comparative financial statements are presented,
requires the supplemental pro forma disclosure of revenue and earnings to be presented as if the business combination had occurred
at the beginning of the comparable prior annual reporting period only.&nbsp; This standard also expands the supplemental pro forma
disclosures required under FASB ASC Topic 850, <I>Business Combinations</I>, to include a description of the nature and amount
of material nonrecurring pro forma adjustments directly attributable to the business combination in the reported pro forma revenue
and earnings.&nbsp; This standard is effective for the Company for any business combinations completed after January 1, 2011.&nbsp;
The Company adopted the provisions of this standard during the first quarter of 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2011, the FASB issued ASU No. 2011-04, <I>Amendments
to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. Generally Accepted Accounting Principles (&ldquo;GAAP&rdquo;)
and International Financial Reporting Standards (&ldquo;IFRSs&rdquo;).</I> &nbsp;This standard updates accounting guidance to clarify
the measurement of fair value to align the guidance and improve the comparability surrounding fair value measurement within GAAP
and IFRSs.&nbsp; The standard also updates requirements for measuring fair value and expands the required disclosures.&nbsp; The
standard does not require additional fair value measurements and was not intended to establish valuation standards or affect valuation
practices outside of financial reporting.&nbsp; This standard will become effective for the Company on January 1, 2012. The adoption
of this standard on January 1, 2012 did not have a material impact on the Company&rsquo;s financial statements or required disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2011, the FASB issued ASU No. 2011-05, <I>Presentation
of Comprehensive Income.</I> &nbsp;This standard eliminates the current option to report other comprehensive income and its components
in the statement of changes in equity. The standard is intended to enhance comparability between entities that report under US&nbsp;GAAP
and those that report under IFRS, and to provide a more consistent method of presenting non-owner transactions that affect an entity&rsquo;s
equity. Under the ASU, an entity can elect to present items of net income and other comprehensive income in one continuous statement,
referred to as the statement of comprehensive income, or in two separate, but consecutive, statements. Each component of net income
and each component of other comprehensive income, together with totals for comprehensive income and its two parts, net income and
other comprehensive income, would need to be displayed under either alternative. The statement(s) would need to be presented with
equal prominence as the other primary financial statements. The ASU does not change items that constitute net income and other
comprehensive income, when an item of other comprehensive income must be reclassified to net income or the earnings-per-share computation
(which will continue to be based on net income). The new US&nbsp;GAAP requirements are effective for public entities as of the
beginning of a fiscal year that begins after December&nbsp;15, 2011 and interim and annual periods thereafter. Early adoption is
permitted, but full retrospective application is required under the accounting standard. The adoption of this standard on January
1, 2012 did not have a material impact on the Company&rsquo;s financial statements or required disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2011, the FASB issued ASU No. 2011-08, <I>Intangibles
&ndash; Goodwill and Other (Topic 350) Testing Goodwill for Impairment.</I> &nbsp;&nbsp;This standard simplifies how an entity
tests goodwill for impairment and allows an entity to first assess qualitative factors in determining whether it is more likely
than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary
to perform the two-step goodwill impairment test.&nbsp;&nbsp;This standard is effective for entities as of the beginning of a fiscal
year that begins after December 15, 2011 and interim and annual periods thereafter.&nbsp;&nbsp;Early adoption is permitted. The
adoption of this standard on January 1, 2012 did not have a material impact on the Company&rsquo;s financial statements or required
disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2011, the FASB issued ASU No. 2011-12, <I>Deferral
of Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income
in ASU 2011-05, </I>which defers the requirement in ASU No. 2011-05 that companies present reclassification adjustments for each
component of accumulated other comprehensive income. All other requirements of ASU No. 2011-05 remain unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Reclassifications</I></B> &mdash; Certain prior-period
amounts have been reclassified to conform to the current-period presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>3. FAIR VALUE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accordance with Fair Value Measurements and Disclosures Topic
of the FASB ASC 820, the Company groups its financial assets and financial liabilities generally measured at fair value in three
levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine
fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18.35pt"></TD><TD STYLE="width: 18.35pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Level 1: Input prices quoted in an active market for identical financial assets or liabilities.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18.35pt"></TD><TD STYLE="width: 18.35pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial
assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs
that are observable or can be corroborated by observable market data.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18.35pt"></TD><TD STYLE="width: 18.35pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Level 3: Input prices quoted that are significant to the fair value of the financial assets or
liabilities which are not observable or supported by an active market.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Assets and liabilities measured at fair value on a recurring
basis are summarized below:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March&nbsp;31,&nbsp;2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level&nbsp;1</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level&nbsp;2</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level&nbsp;3</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair&nbsp;Value</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 48%; font-weight: bold">Liabilities:</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9pt">Warrants</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">32,397</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">32,397</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,&nbsp;2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level&nbsp;1</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level&nbsp;2</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level&nbsp;3</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair&nbsp;Value</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 48%; font-weight: bold">Liabilities:</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9pt">Warrants</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">23,305</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">23,305</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,&nbsp;2010</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level&nbsp;1</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level&nbsp;2</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level&nbsp;3</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair&nbsp;Value</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">Liabilities:</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; width: 48%; padding-bottom: 2.5pt">Warrants</TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 1%">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right; width: 10%">-</TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 1%">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right; width: 10%">-</TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 1%">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right; width: 10%">-</TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 1%">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right; width: 10%">-</TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company uses the Black-Scholes option pricing model and
assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility,
expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Assumptions
used are generally consistent with those disclosed for stock-based compensation (see Note 10).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>4. ACQUISITION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Merger Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 8, 2011, Novelos acquired Cellectar through a merger
with and into the Merger Subsidiary, pursuant to the Merger Agreement entered into on that date.&nbsp; As a result of the Acquisition,
the Merger Subsidiary, which was renamed Cellectar, Inc., owns all assets of and operates the business previously owned and operated
by Cellectar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the Acquisition, the former stockholders of Cellectar received
an aggregate number of shares of Novelos common stock constituting approximately 85% of the outstanding shares of Novelos common
stock, after giving effect to the Acquisition but before giving effect to the concurrent private placement of Novelos securities
described below.&nbsp; Prior to the Acquisition, Novelos amended and restated its certificate of incorporation and in connection
therewith, among other things, effected a 1-for-153 reverse split of its common stock resulting in&nbsp;2,959,871 shares of Novelos
common stock outstanding. Novelos then issued 17,001,596 shares of Novelos common stock to the stockholders of Cellectar upon the
effective date of the Acquisition.&nbsp; Warrants and options to purchase Novelos common stock that were outstanding prior to the
Acquisition remained outstanding following the Acquisition. These consist of warrants to purchase a total of 315,164 shares of
Novelos common stock with prices ranging from $16.07 to $191.25 and options to purchase a total of 49,159 shares of Novelos common
stock with prices ranging from $1.53 to $1,072.53.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">XMS Capital Partners, the financial advisor to Cellectar in
connection with the Acquisition, received a cash fee of $200,000 upon the completion of the Acquisition in consideration of their
services.&nbsp; Rodman &amp; Renshaw, LLC (&ldquo;Rodman&rdquo;), financial advisor to Novelos in connection with the Acquisition,
received a cash fee of $250,000 upon the completion of the Acquisition in consideration of their services.&nbsp; These amounts
were recorded as merger costs and expensed as incurred on the date of the Acquisition.&nbsp; In addition to the investment banking
fees, the Company also incurred an additional $296,207 of merger-related legal and other costs during the year ended December 31,
2011 and $52,925 during the year ended December 31, 2010 which were included as a component of expense in the respective period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Acquisition was completed principally to leverage synergies
between Novelos&rsquo; strategic focus and experience in developing and funding the development of cancer drugs and Cellectar&rsquo;s
portfolio of cancer-targeted compounds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Purchase Accounting</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Acquisition was accounted for using the purchase method
of accounting as a reverse acquisition.&nbsp; In a reverse acquisition, the post-acquisition net assets of the surviving combined
company includes the historical cost basis of the net assets of the accounting acquirer (Cellectar) plus the fair value of the
net assets of the accounting acquiree (Novelos).&nbsp; Further, under the purchase method, the purchase price is allocated to the
assets acquired, liabilities assumed, and identifiable intangible assets based on their estimated fair values with the remaining
excess purchase price over net assets acquired allocated to goodwill.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value of the consideration transferred in the Acquisition
was $2,219,903 and was calculated as the number of shares of common stock that Cellectar would have had to issue (adjusted for
the Exchange Ratio) in order for Novelos shareholders to hold a 15% equity interest in the combined Company post-acquisition (but
prior to the concurrent private placement), multiplied by the estimated fair value of the Company&rsquo;s common stock on the acquisition
date.&nbsp; The estimated fair value of the Company&rsquo;s common stock was based on the offering price of the common stock sold
in the private placement which was both completed concurrently with and conditioned upon the closing of the Acquisition.&nbsp;
This price was determined to be the best indication of fair value on that date since the price was based on an arm&rsquo;s length
negotiation with a group consisting of both new and existing investors that had been advised of the pending Acquisition and assumed
similar liquidity risk as those investors holding the majority of shares being valued as purchase consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the Company&rsquo;s determination
of fair values of the assets acquired and the liabilities as of the date of acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 87%; text-align: left; padding-bottom: 2.5pt">Consideration &ndash; issuance of securities</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">2,219,903</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Prepaid expenses and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">71,892</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,515</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(380,130</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(59,485</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt">Goodwill</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,675,462</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total purchase price &ndash; net of cash acquired of $905,649</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,314,254</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company determined that the acquired Novelos legacy technology
had no value as of the date of the acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Goodwill</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Of the total purchase price of $2,219,903, $1,675,462 was allocated
to goodwill.&nbsp;Goodwill represents the excess of the purchase price of an acquired business over the fair value of the underlying
net tangible and intangible assets. The goodwill includes the value of the Novelos work force (management team). None of the goodwill
associated with the Acquisition is deductible for income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no changes in goodwill during the year ended December
31, 2011, after the initial purchase accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company is required to perform an annual impairment test
related to goodwill which is performed in the fourth quarter of each year, or sooner if changes in circumstances suggest that the
carrying value of an asset may not be recoverable. During the fourth quarter of 2011, the annual test was performed and it was
determined that there had been no impairment to goodwill.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no changes in circumstances during the three months
ended March 31, 2012 that would suggest that the goodwill is not recoverable. There were no changes in goodwill during the three
months ended March 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>5. FIXED ASSETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fixed assets consisted of the following at December 31:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 96%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left">Office and laboratory equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,069,889</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,984,375</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Computer software</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Leasehold improvements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,324,672</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,317,597</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,398,561</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,301,972</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less accumulated depreciation and amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,353,996</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,791,483</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Fixed assets, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,044,565</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,510,489</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the years ended December 31, 2011 and 2010, the Company
incurred approximately $585,000 and $580,000 of depreciation expense, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended March 31, 2012, the change to
net fixed assets consisted of an increase of approximately $140,000 to accumulated depreciation and amortization and purchases
of equipment totaling approximately $15,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>6. LICENSE AGREEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>2003 License Agreement with the University of Michigan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2003, Cellectar entered into an exclusive license
agreement (the &ldquo;U. Mich. Agreement&rdquo;) with the Regents of the University of Michigan, (&ldquo;U. Mich.&rdquo;) for the
development, manufacture and marketing of products under several composition-of-matter patents in North America that expire at
varying dates in 2016.&nbsp; The U. Mich. Agreement expires upon the expiration of the last covered patent.&nbsp; The Company is
responsible for an annual license fee of $10,000 and is required to pay costs associated with the maintenance of the patents covered
by the U. Mich. Agreement.&nbsp; Additionally, the Company is required to make milestone payments of $50,000 upon the filing of
a New Drug Application (&ldquo;NDA&rdquo;) for a licensed product intended for use in a therapeutic or diagnostic application (such
milestone fees may be deferred and paid within 12 months of the first commercial sale of such products) and make certain milestone
payments within a year following the first commercial sale of any licensed products.&nbsp; The sales milestones range from $100,000
to $200,000, dependent upon whether the drug is for use in a diagnostic or therapeutic application, provided that if sales in the
first 12 months are less than the amount of the milestone, then we are required to pay 50% of all sales until the milestone is
satisfied.&nbsp;The milestone payments may&nbsp;total up to $400,000. The U. Mich. Agreement provides that the Company pay a royalty
equal to 3% of net sales of any licensed products sold by the Company or its sublicensees for such licensed products, provided
however if the sublicense fee payable to the Company is between 4% and 5% of net sales, then the royalties payable to U. Mich.
Shall be equal to 50% of the sublicense fee.&nbsp; Furthermore, the U. Mich. Agreement provides for a reduction in the royalties
owed by up to 50% if the Company is required to pay royalties to any third parties related to the sale of the licensed products.&nbsp;
If the Company receives any revenue in consideration of rights to the licensed technology that is not based on net sales, excluding
any funded research and development, the Company is required to pay U. Mich. 10% of amounts received.&nbsp; U. Mich. May terminate
the agreement if the Company ceases operations, if the Company fails to make any required payment under the agreement, or if the
Company otherwise materially breaches the agreement, subject to the applicable notice and cure periods.&nbsp; To date, the Company
has made all payments as they have become due, there have been no defaults under the U. Mich. Agreement, nor has the Company been
notified of a default by U. Mich. The Company may terminate the agreement with six months&rsquo; notice to U. Mich. And the return
of licensed product and related data.&nbsp; The U. Mich. Agreement contained milestones that required certain development activities
to be completed by specified dates. All such development milestones have either been completed or have been removed by subsequent
amendment to the agreement.&nbsp; U. Mich. Has provided no warranties as to validity or otherwise with respect to the licensed
technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company paid approximately $600 and $300 to U. Mich. For
the reimbursement of patent maintenance fees during the years ended December 31, 2011 and 2010, respectively.&nbsp; As of December
31, 2011 and 2010, all annual license fees have been paid in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the U. Mich. Agreement, during 2003 Cellectar
paid approximately $54,000 of back patent costs and issued 203,483 shares of common stock to U. Michigan as partial consideration
for the rights described above.&nbsp; The estimated fair-market value of the issuance was $80,412 and was recorded as a license
cost and is included as a component of stockholders equity in the accompanying balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>License Agreement with Wisconsin
Alumni Research Foundation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2006, Cellectar entered into a license agreement
(the &ldquo;WARF Agreement&rdquo;) with the Wisconsin Alumni Research Foundation (&ldquo;WARF&rdquo;) under which Cellectar received
a license, with a right to grant sublicenses, to develop, manufacture, and market products with respect to certain patents.&nbsp;
The WARF Agreement required an initial license fee of $8,800 and provided that Cellectar pay royalties equal to 0.3% of sales of
any licensed products.&nbsp; Cellectar was also required to reimburse WARF for patent filing fees and related costs.&nbsp; During
the year ended December 31, 2010 there were no costs related to the patents under the WARF Agreement.&nbsp;&nbsp;During 2010, the
WARF Agreement was terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Novelos License Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During 2007, Novelos entered into a Collaboration Agreement
with Lee&rsquo;s Pharmaceutical (HK) Ltd. (&ldquo;Lee&rsquo;s Pharm&rdquo;) whereby Lee&rsquo;s Pharm obtained an exclusive license
to develop, manufacture and commercialize NOV-002 and NOV-205 in China, Hong Kong, Taiwan and Macau (the &ldquo;Chinese Territory&rdquo;).
Under the terms of the agreement the Company is entitled to receive up to $1,700,000 in future milestone payments upon the completion
of development and marketing milestones by Lee&rsquo;s Pharm and to receive royalty payments of between 12-25% of net sales of
NOV-205 and NOV-002, as applicable, in the Chinese Territory and receive royalty payments of 12-15% of net sales of NOV-205 in
the Chinese Territory. The agreement expires upon the expiration of the last patent covering any of the licensed products, or twelve
years from the date of the first commercial sale in China, whichever occurs later.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During 2009, Novelos entered into a collaboration agreement
(the &ldquo;Collaboration Agreement&rdquo;) with Mundipharma International Corporation Limited (&ldquo;Mundipharma&rdquo;) to develop,
manufacture and commercialize, on an exclusive basis, Licensed Products (as defined in the Collaboration Agreement), including
NOV-002, in Europe (other than the Russian Territory), Asia (other than the Chinese Territory) and Australia (collectively referred
to as the &ldquo;Mundipharma Territory&rdquo;).&nbsp; Mundipharma is an independent associated company of Purdue Pharma, L.P. (&ldquo;Purdue&rdquo;).&nbsp;
The Collaboration Agreement provides for Mundipharma to pay the Company royalties and fixed milestone payments based on sales and
commercial launches in the licensed territories.&nbsp; For countries in which patents are held, the Collaboration Agreement expires
on a country-by-country basis within the Mundipharma Territory on the earlier of (1) expiration of the last applicable Novelos
patent within the country or (2) the determination that any patents within the country are invalid, obvious or otherwise unenforceable.&nbsp;
For countries in which no patents are held, the Collaboration Agreement expires the earlier of 15 years from its effective date
or upon generic product competition in the country resulting in a 20% drop in Mundipharma&rsquo;s market share.&nbsp; The Company
may terminate the Collaboration Agreement upon breach or default by Mundipharma.&nbsp; Mundipharma may terminate the Collaboration
Agreement upon breach or default, filing of voluntary or involuntary bankruptcy by Novelos, the termination of certain agreements
with companies associated with the originators of the licensed technology, or 30-day notice for no reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has suspended development of the products covered
by the collaboration agreements described above. The Company does not anticipate that the collaboration agreements will have a
material effect on its future results of operations, cash flows, and financial position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>7. CONVERTIBLE DEBT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 25, 2010, Cellectar issued nine convertible promissory
notes (&ldquo;Convertible Notes&rdquo;) in an aggregate principal amount of $2,720,985.&nbsp; The Convertible Notes provided for
interest of 12% compounded annually with a maturity date of the earlier of (i) the date on which Cellectar&rsquo;s cash reserves
fall below $250,000 or (ii) January 20, 2011.&nbsp; Upon an event of default, as defined, the interest rate increased by 10% to
22%.&nbsp; The outstanding principal balance, together with any unpaid interest, was convertible immediately, by the lenders, into
common stock of the Company at $0.82987 per share (giving effect to the Exchange Ratio).&nbsp; Furthermore, the Convertible Notes
were subject to an automatic conversion feature equal to 70% of the per share price of a qualified financing, should the Company
complete a qualified financing transaction which raises at least $20,000,000 in proceeds to the Company.&nbsp; Since the Convertible
Notes were convertible into common stock at date of issuance at a per share price which was less than the estimated fair value
of the Company&rsquo;s common stock at that date, the Convertible Notes contained a beneficial conversion feature (&ldquo;BCF&rdquo;).&nbsp;
The estimated intrinsic value of the BCF of $213,792 was determined as the difference between the conversion price and the estimated
fair value of Cellectar common stock on the date of issuance, multiplied by the 3,278,786 shares of common stock into which the
Convertible Notes were convertible at issuance. This amount was recorded as a component of interest expense on the date of issuance.&nbsp;
The estimated per-share fair value of Cellectar common stock was determined by management based on a number of factors including
an independent valuation, which was determined to be the best indication of the fair value as of the issuance date of the Convertible
Notes.&nbsp; Since the conversion price was subject to adjustment in the event of a qualified transaction, as defined, the Convertible
Notes also contain a contingent beneficial conversion feature (&ldquo;CBCF&rdquo;).&nbsp; This contingency did not materialize;
therefore no intrinsic value was allocated to the CBCF.&nbsp; As of December 31, 2011 and 2010, principal of $0 and $2,720,985
was outstanding, respectively, on the Convertible Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2010, the Convertible Notes were classified
as a long-term obligation on the accompanying December 31, 2010 balance sheet as a result of the conversion of the short-term obligation
through the issuance of equity securities in connection with the Acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 20, 2011, the Convertible Notes matured but remained
unpaid.&nbsp; Following the maturity and default of the Convertible Notes, the holders of the Convertible Notes agreed that all
of the outstanding Convertible Notes would be automatically converted simultaneous with the completion of an acquisition and financing
(the &ldquo;Conversion Time&rdquo;), if completed.&nbsp; The amount of shares issued upon such conversion would be dependent on
the amount of investment made by the note holders at the Conversion Time and were negotiated based on outstanding principal and
projected accrued interest based on an assumed closing date for the acquisition and financing.&nbsp; Since the number of shares
to be issued upon conversion could not be determined until the Conversion Time, the Convertible Notes contained a CBCF.&nbsp; On
April 1, 2011, Cellectar&rsquo;s Board of Directors voted to accept the note holders consent to convert the Convertible Notes into
4,181,535 shares of common stock immediately prior to the Acquisition.&nbsp; On April 8, 2011, immediately prior to the Acquisition,
the principal and unpaid interest on the Convertible Notes was converted into the agreed total of 4,181,535 shares of common stock.&nbsp;
Upon conversion of the Convertible Notes, the Company reclassified the aggregate outstanding principal and interest totaling $3,184,707
to a component of additional paid-in capital.&nbsp; The revised conversion terms resulted in the issuance of an additional 343,963
shares of common stock over the 3,837,572 shares of common stock that would have been issued if the unpaid principal and accrued
interest on the Convertible Notes had been converted on that date in accordance with their original terms at the stated conversion
price.&nbsp; On the date of conversion, the Company determined that the value of these additional shares was $257,973, based on
the $0.75 per share offering price of the common stock sold in the private placement completed concurrently with the Acquisition,
which is the best indication of fair value on the date of conversion.&nbsp; Since the conversion was not completed until April
8, 2011, the value of the additional shares of $257,973 was recorded as a component of interest expense during the second quarter
of 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>8.&nbsp; LONG-TERM NOTES PAYABLE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 11, 2008, Cellectar entered into a loan agreement
with a bank to borrow up to $1,200,000.&nbsp; The borrowing, evidenced by a note (the &ldquo;Bank Note&rdquo;), bore interest at
a rate of 7.01% per annum, could be prepaid without penalty and was payable in 48 monthly principal and interest payments of $20,520
with a balloon payment of any remaining unpaid principal and interest on March 28, 2012.&nbsp; In the event of default of payment,
Cellectar would be required to pay a late charge equal to 5% of the delinquent payment and the interest rate on the unpaid principal
would be increased by 3%.&nbsp; The Bank Note was collateralized by substantially all assets of Cellectar and a deposit account
in the amount of $500,000.&nbsp; As of December 31, 2010, the cash collateral is classified as restricted cash in the accompanying
balance sheet.&nbsp;&nbsp; On April 8, 2011, immediately prior to the Acquisition, Cellectar paid approximately $627,000 in full
settlement of the Bank Note. The payment was made in order to avoid an event of default that would have occurred as a result of
the change of control that occurred at the time of the Acquisition. As of December 31, 2011 and 2010, $0 and $470,941 are classified
as a long-term note payable in the accompanying balance sheets, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 15, 2010, Cellectar entered into certain loan agreements
with the Wisconsin Department of Commerce (&ldquo;WDOC Notes&rdquo;) to borrow a total of $450,000.&nbsp; The WDOC Notes bear interest
at 2% per annum beginning on the date of disbursement and allow for the deferral of interest and principal payments until April
30, 2015.&nbsp; In the event of default of payment, interest on the delinquent payment is payable at a rate equal to 12% per annum.&nbsp;
Monthly payments of $20,665 for principal and interest shall commence on May 1, 2015 and continue for 23 equal installments with
the final installment of any remaining unpaid principal and interest due on April 1, 2017.&nbsp; As of December 31, 2011 and 2010,
$450,000 is classified as a long-term note payable in the accompanying balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Long-term notes payable consists of the following as of December
31:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left">Bank Note, 7.01% interest</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">675,743</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Wisconsin Department of Commerce,&nbsp; 2% interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">450,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">450,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">450,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,125,743</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(204,802</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Long-term note payable, net of current portion</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">450,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">920,941</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2011, long-term notes payable matures as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 82%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Years ended December 31,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 87%; text-align: left; text-indent: -9pt; padding-left: 9pt">2015</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">119,957</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">243,591</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt; text-align: left">Thereafter</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">86,452</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">450,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the years ended December 31, 2011 and 2010, the Company
incurred approximately $17,500 and $62,000 of interest expense related to these long-term notes payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No payments were made on long-term obligations in the three
months ended March 31, 2012. The Company incurred approximately $2,200 of interest expense related to the long-term notes payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 31, 2012, the outstanding principal on the WDOC
Notes of $450,000 is classified as long-term debt outstanding in the accompanying balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>9. STOCKHOLDERS&rsquo; EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 1, 2008, Cellectar converted from a Wisconsin limited
liability company to a Wisconsin corporation (the &ldquo;Conversion&rdquo;). Each issued and outstanding unit of equity in the
limited liability company immediately prior to the Conversion was converted into one issued and outstanding share of Cellectar
common stock and each unexercised unit option outstanding immediately prior to the Conversion was converted into an option to acquire
the same number of shares of the corporation&rsquo;s common stock.&nbsp; For the purpose of presentation in these financial statements,
all amounts and disclosures related to equity issuances prior to the Acquisition have been retroactively restated by applying the
Exchange Ratio in order to reflect the capital structure of Novelos and therefore the issuance of Novelos common stock, rather
than member units in the limited liability company or common stock of Cellectar, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> From inception until the Acquisition on April 8, 2011, Cellectar
issued 12,559,218 shares of common stock for net proceeds of approximately $21,710,000. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>April 2011 Private Placement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concurrently with and conditioned upon the execution of the
Merger Agreement, the Company entered into a Securities Purchase Agreement with certain accredited investors under which the Company
sold an aggregate of 6,846,537 units, each unit consisting of one share of its common stock and a warrant to purchase one share
of its common stock, at a price of $0.75 per unit, for gross proceeds of approximately $5,135,000 (the &ldquo;April Private Placement&rdquo;).&nbsp;
The warrants have an exercise price of $0.75 and expire on March 31, 2016.&nbsp; The warrant exercise price and/or the common stock
issuable pursuant to such warrant will be subject to adjustment only for stock dividends, stock splits or similar capital reorganizations
so that the rights of the warrant holders after such event will be equivalent to the rights of warrant holders prior to such event.&nbsp;
The relative fair value of the warrants issued to the investors was $2,124,286 at issuance and has been included as a component
of stockholders&rsquo; equity.&nbsp; The Company uses the Black-Scholes option pricing model to value warrants and applies assumptions
that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life
and dividend rates in estimating fair value for the warrants. Assumptions used are generally consistent with those disclosed for
stock-based compensation (see Note 10).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Securities Purchase Agreement includes certain registration
requirements which were subsequently extended by the consent of purchasers holding a majority of shares of the Company&rsquo;s
common stock issued in the April Private Placement, which holders constituted the requisite holders, as defined. The Company is
required to file with the SEC no later than May 29, 2012 (the &ldquo;Filing Deadline&rdquo;), a registration statement covering
the resale of the shares of common stock, and the shares of common stock underlying the warrants, issued pursuant to the Securities
Purchase Agreement that are not otherwise saleable under an available exemption from registration requirements.&nbsp; The Company
is also required to use commercially reasonable efforts to have the registration statement declared effective by July 28, 2012
(the &quot;Effectiveness Deadline&quot;), and to keep the registration statement continuously effective under the Securities Act
of 1933, as amended (the &ldquo;Securities Act&rdquo;), until the earlier of the date when all the registrable securities covered
by the registration statement have been sold or the second anniversary of the closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event the Company fails to file the registration statement
within the timeframe specified by the Securities Purchase Agreement, or if it fails to obtain effectiveness of this registration
on or prior to July 28, 2012 (if there is no review by the SEC) or by August 28, 2012 (if there is review by the SEC) with respect
to the maximum number of shares permitted to be registered by the SEC, the Company will be required to pay to the purchasers liquidated
damages equal to 1.5% per month (pro-rated on a daily basis for any period of less than a full month) of the aggregate purchase
price of the units purchased until the registration statement is filed or declared effective, as applicable, not to exceed 5% of
the aggregate purchase price.&nbsp; The Company will be allowed to suspend the use of the registration statement for not more than
30 consecutive days, on not more than two occasions, in any 12-month period.&nbsp; The Company has also granted piggy-back registration
rights with respect to any shares of common stock that it is required to exclude from the registration statement as a condition
of its effectiveness, and has also agreed to file further registration statements with respect to any such shares six months after
the effective date of the initial registration statement. As of December 31, 2011, and through the date of this filing, the Company
has not concluded that it is probable that damages will become due; therefore, no accrual for damages has been recorded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company paid to Rodman, the placement agent for the financing,
a cash fee equal to $200,000 and issued warrants to purchase 192,931 shares of its common stock (having an exercise price of $0.75
and which expire March 31, 2016) in consideration for their advisory services with respect to the financing pursuant to the placement
agency agreement between Rodman and the Company.&nbsp; Rodman is entitled to registration rights with respect to the shares of
common stock issuable upon exercise of these warrants.&nbsp; The cash fee was recorded as a reduction of gross proceeds received.&nbsp;
The estimated fair value of the warrants issued to the placement agent was $112,096 and was recorded as a component of stockholders&rsquo;
equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>December 2011 Underwritten Offering</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 6, 2011, the Company completed an underwritten public
offering of 10,081,667 shares of its common stock and warrants to purchase up to an aggregate of 10,081,667 shares of its common
stock at an exercise price of $0.60 per share, expiring on December 6, 2016, for gross proceeds of $6,049,000 and net proceeds
of $5,298,140 after deducting transaction costs (the &ldquo;Underwritten Offering&rdquo;). The warrant exercise price and the common
stock issuable pursuant to such warrant are subject to adjustment only for stock dividends, stock splits and similar capital reorganizations
so that the rights of the warrant holders after such event will be equivalent to the rights of the warrant holders prior to such
event. The relative fair value of the warrants issued to the investors was $2,350,320 at issuance and has been included as a component
of stockholders&rsquo; equity.&nbsp; The Company uses the Black-Scholes option pricing model to value warrants and applies assumptions
that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life
and dividend rates in estimating fair value for the warrants. Assumptions used are generally consistent with those disclosed for
stock-based compensation (see Note 10). In connection with the Underwritten Offering, the Company paid to Rodman, the underwriting
agent, a cash fee of $302,000, which was recorded as a reduction of the gross proceeds received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Legacy Warrants</I> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Outstanding warrants to purchase 315,164 shares of common stock,
originally issued in connection with Novelos equity and debt financings from 2007 through 2010, remained outstanding subsequent
to the Acquisition (Note 4).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Common Stock Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes information with regard to outstanding
warrants to purchase common stock as of December 31, 2011.&nbsp; There were no outstanding common stock purchase warrants as of
December 31, 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Offering</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;Shares<BR> Issuable&nbsp;Upon<BR> Exercise&nbsp;of<BR> Outstanding<BR> Warrants</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise<BR> Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Expiration&nbsp;Date</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 43%">December 6, 2011 Underwritten Offering</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">10,081,667</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">0.60</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 16%; text-align: right">December 6, 2016</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>April 8, 2011 Private Placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,039,468</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">March 31, 2016</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Legacy warrants (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77,729</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">July 27, 2015</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legacy warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">105,040</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">16.065</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">July 27, 2015</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Legacy warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,524</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">99.45-100.98</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">December 31, 2015</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Legacy warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">8,561</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">$</TD><TD STYLE="text-align: right; padding-bottom: 1pt">191.25</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="text-align: right; padding-bottom: 1pt">May 2, 2012</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,403,989</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1)&nbsp; The exercise prices of these warrants are subject
to adjustment for &ldquo;down-rounds&rdquo; and have been accounted for as derivative instruments as described in Note 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 4, 2011, 18,153 shares of common stock were issued in
connection with the cashless exercise of warrants to purchase 27,310 shares of common stock at $0.75 per share.&nbsp; The Company
reclassified $48,339 from the derivative liability to additional paid-in capital upon the exercise of the warrants. In connection
with the December 2011 Underwritten Offering, 5,000 warrants previously issued to Rodman were cancelled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended March 31, 2012, the Company issued
a total of 54,440 shares of common stock in connection with the cashless exercise of warrants to purchase 27,310 shares of common
stock at $0.60 per share expiring on July 27, 2015 and 200,000 shares of common stock at $0.75 per share expiring on March 31,
2016. The Company reclassified $19,754 from the derivative liability to additional paid-in capital upon the exercise of certain
of the warrants. As of March 31, 2012, 17,176,679 warrants remained outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Reserved Shares</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following shares were reserved for future issuance upon
exercise of stock options and warrants or conversion of debt:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 96%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,<BR> (unaudited)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 48%">Warrants</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">17,176,679</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">17,403,989</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,827,638</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,827,638</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">769,189</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Convertible notes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,822,062</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,646,370</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total number of shares reserved for future issuance</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22,004,317</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,822,062</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22,231,627</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,415,559</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>10.&nbsp; STOCK-BASED COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prior to the Acquisition, Cellectar&rsquo;s Board of Directors
determined exercise prices and vesting periods on the date of grant, subject to the provisions of the 2006 Unit Option Plan and
the 2008 Stock Incentive Plan (collectively, the &ldquo;Cellectar Plans&rdquo;). Options have been granted at or above the estimated
fair-market value of the common stock at the grant date. Options granted pursuant to the 2006 Cellectar Plan and 2008 Plan generally
would have become fully vested in the event of a business combination whereby the options are not assumed or replaced by the surviving
company, as defined. On March 17, 2011, in contemplation of the Acquisition, Cellectar terminated the remaining options outstanding
granted under the Cellectar Plans and the Cellectar Plans were terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Acquisition, the Company assumed options
to purchase 49,159 shares of common stock at exercise prices ranging from $1.53 to $1,072.53.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>2006 Novelos Stock Option Plan.</I> &nbsp; Following the
Acquisition, option grants to directors and employees will be made under the Novelos Therapeutics 2006 Stock Incentive Plan (the
&ldquo;Plan&rdquo;).&nbsp; On May 18, 2011, the Board of Directors of the Company approved certain amendments to the Plan to, among
other things, increase the aggregate number of shares of the Company&rsquo;s common stock reserved for issuance under the Plan
(including any shares that have already been issued thereunder), to 7,000,000 and remove the 750,000 share annual individual limitation
on grants under the Plan.&nbsp; On June 30, 2011, the Company&rsquo;s stockholders approved those amendments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A total of 7,000,000 shares of common stock are reserved for
issuance under the Plan for grants of incentive or nonqualified stock options, rights to purchase restricted and unrestricted shares
of common stock, stock appreciation rights and performance share grants.&nbsp; A committee of the board of directors determines
exercise prices, vesting periods and any performance requirements on the date of grant, subject to the provisions of the Plan.&nbsp;
Options are granted at or above the fair market value of the common stock at the grant date and expire on the tenth anniversary
of the grant date.&nbsp; Vesting periods are generally between one and four years.&nbsp; Options granted pursuant to the Plan generally
will become fully vested upon a termination event occurring within one year following a change in control, as defined.&nbsp; A
termination event is defined as either termination of employment or services other than for cause or constructive termination of
employees or consultants resulting from a significant reduction in either the nature or scope of duties and responsibilities, a
reduction in compensation or a required relocation.&nbsp; As of December 31, 2011, there are an aggregate of 2,281,112 shares available
for future grants under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Accounting for Stock-Based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company uses the Black-Scholes option-pricing model to calculate
the grant-date fair value of stock option awards. The resulting compensation expense, net of expected forfeitures, for non-performance
based awards is recognized on a straight-line basis over the service period of the award, which is generally three years for stock
options. For stock options with performance-based vesting provisions, recognition of compensation expense, net of expected forfeitures,
commences if and when the achievement of the performance criteria is deemed probable. The compensation expense, net of expected
forfeitures, for performance-based stock options is recognized over the relevant performance period. Evaluation of the probability
of meeting performance targets is evaluated at the end of each reporting period. Non-employee stock-based compensation is accounted
for in accordance with the guidance of FASB ASC Topic 505, <I>Equity.&nbsp;</I> As such, the Company recognizes expense based on
the estimated fair value of options granted to non-employees over their vesting period, which is generally the period during which
services are rendered and deemed completed by such non-employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes amounts charged to expense for
stock-based compensation related to employee and director stock option grants and stock-based compensation recorded in connection
with stock options granted to non-employee consultants:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three&nbsp;Months&nbsp;Ended<BR> March&nbsp;31,<BR> (unaudited)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;Ended<BR> December&nbsp;31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">Cumulative<BR> Development-<BR> Stage&nbsp;Period<BR> from<BR> November&nbsp;7,<BR> 2002&nbsp;through<BR> December&nbsp;31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Employee and director stock option grants:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 35%; text-align: left; padding-left: 9pt">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">78,044</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">23,526</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">190,172</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">61,791</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">488,558</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">248,968</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">34,936</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">570,884</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">291,549</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,148,187</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">327,012</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,462</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">761,056</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">353,340</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,636,745</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Non-employee consultant stock option grants:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,014</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,157</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,157</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">43,327</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">110,247</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">181,971</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">90,341</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">146,404</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">218,128</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">417,353</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">58,462</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">907,460</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">353,340</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,854,873</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 14, 2010, the expiration date of vested options held
by a former employee was extended until July 8, 2015.&nbsp; The extension constituted a modification to the terms of the award
and additional stock-based compensation was measured as the excess of the fair value of the modified award over the fair value
of the original award immediately before the modification.&nbsp; Accordingly, incremental stock-based compensation expense of approximately&nbsp;$20,000
was recorded in connection with the modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company granted 5,026,500 stock options to employees and
non-employees during the twelve months ended December 31, 2011 under the Plan, of which 670,200 were performance-based awards.
As of December 31, 2011, 335,100 of these performance-based awards were outstanding and 335,100 had been forfeited. No compensation
expense has been recognized related to the performance-based awards as the Company does not believe that it is probable that the
performance targets will be met. The Company issued options to purchase a total of 200,000 shares of common stock to non-employees
outside of any formalized plan, but 100,000 were forfeited as a result of the cancellation and replacement as described below.&nbsp;
Exercise prices for all grants made in the during the twelve months ended December 31, 2011 were equal to the market value of the
Company&rsquo;s common stock on the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 18, 2011, the Company cancelled 100,000 options originally
granted on April 25, 2011 with an exercise price of $3.00 per share and issued 100,000 replacement stock option awards with an
exercise price of $1.40.&nbsp; The cancellation and replacement constituted a modification to the terms of the award and additional
stock-based compensation was measured as the excess of the fair value of the modified award over the fair value of the original
award immediately before the modification.&nbsp; Accordingly, incremental stock-based compensation expense of $4,494 was recorded
in connection with the modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No stock option awards were issued in the three months ended
March 31, 2012 and 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Assumptions Used In Determining Fair Value</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Valuation and amortization method</I>. The fair value of
each stock award is estimated on the grant date using the Black-Scholes option-pricing model.&nbsp; The estimated fair value of
employee stock options is amortized to expense using the straight-line method over the vesting period. The estimated fair value
of the non-employee options is amortized to expense over the period during which a non-employee is required to provide services
for the award (usually the vesting period).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Volatility.</I> Cellectar estimated volatility based on a
review of volatility estimates of publicly held drug development companies in a similar stage of development. Subsequent to the
Acquisition, the Company estimates volatility based on an average of (1) the Company&rsquo;s historical volatility since its common
stock has been publicly traded and (2) review of volatility estimates of publicly held drug development companies with similar
market capitalizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Risk-free interest rate</I>. The risk-free interest rate
is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Expected term</I>. The expected term of stock options granted
is based on an estimate of when options will be exercised in the future. The Company applied the simplified method of estimating
the expected term of the options, as described in the SEC&rsquo;s Staff Accounting Bulletins 107 and 110, as the Company has had
a significant change in its business operations as result of the Acquisition and the historical experience is not indicative of
the expected behavior in the future. The expected term, calculated under the simplified method, is applied to groups of stock options
that have similar contractual terms. Using this method, the expected term is determined using the average of the vesting period
and the contractual life of the stock options granted. The Company applied the simplified method to non-employees who have a truncation
of term based on termination of service and utilizes the contractual life of the stock options granted for those non-employee grants
which do not have a truncation of service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Forfeitures.</I> &nbsp; Stock-based compensation expense
is recorded only for those awards that are expected to vest.&nbsp; FASB ASC Topic 718 requires forfeitures to be estimated at the
time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&nbsp; The term
&ldquo;forfeitures&rdquo; is distinct from &ldquo;cancellations&rdquo; or &ldquo;expirations&rdquo; and represents only the unvested
portion of the surrendered option.&nbsp; An annual forfeiture rate of 0% was applied to all unvested options as of December 31,
2010 as Cellectar had experienced very few forfeitures through 2009 and there was insufficient history to develop an accurate estimate
of future forfeitures.&nbsp; An annual forfeiture rate of 0% was applied to all unvested options as of December 31, 2011 as the
historical experience of forfeitures is not representative of expected future forfeiture rates as a result of the significant changes
in the business operations as a result of the Acquisition. Additionally, the majority of the 2011 forfeitures were related to unmet
milestones on performance-based options that are not representative of the expected future forfeiture rates for the Company&rsquo;s
service-based awards. This analysis will be re-evaluated semi-annually and the forfeiture rate will be adjusted as necessary.&nbsp;
Ultimately, the actual expense recognized over the vesting period will be for only those shares that vest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes weighted-average values and assumptions
used for options granted to employees, directors and consultants in the periods indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Twelve&nbsp;Months<BR> Ended<BR> December&nbsp;31,&nbsp;2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.4pt">Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110 - 115</TD><TD STYLE="text-align: left">%&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.4pt">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.89% &ndash; 3.17</TD><TD STYLE="text-align: left">%&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.4pt">Expected life (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.5 &ndash; 6.25</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 85%; padding-left: 0.4pt">Dividend</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.4pt">Weighted-average exercise price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.16</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.4pt">Weighted-average grant-date fair value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.98</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stock Option Activity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of stock option activity under stock option plans
is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of<BR> Shares<BR> Issuable&nbsp;Upon<BR> Exercise&nbsp;of<BR> Outstanding<BR> Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average<BR> Exercise&nbsp;Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average<BR> Remaining<BR> Contracted<BR> Term&nbsp;in<BR> Years</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Aggregate<BR> Intrinsic<BR> Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 48%; text-indent: -9pt; padding-left: 9pt">Outstanding at November 7, 2002</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 10%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 10%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">922,654</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.52</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(12,653</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.04</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Outstanding at January 1, 2009</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">910,001</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.86</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 9pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,929</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.76</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">&nbsp;&nbsp;Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(9,194</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.72</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Outstanding at December 31, 2009</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">991,736</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.68</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in">Canceled</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(222,547</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.63</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Outstanding at December 31, 2010</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">769,189</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;&nbsp;Canceled</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(769,189</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Options acquired in connection with a business combination</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,159</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">100.52</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,226,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 9pt">Canceled</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,992</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">115.16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(438,029</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.44</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Outstanding at December 31, 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,827,638</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.82</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Canceled</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Outstanding at March 31, 2012 (unaudited)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,827,638</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.82</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Vested, December 31, 2010</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">743,450</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.69</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.07</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Unvested, December 31, 2010</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">25,739</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.62</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.08</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Exercisable at December 31, 2010</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">743,450</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.69</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.07</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Vested, December 31, 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">636,634</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.48</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.17</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Unvested, December 31, 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,191,004</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.12</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.59</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Exercisable at December 31, 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">636,634</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.48</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.17</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Vested, March 31, 2012 (unaudited)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,096,038</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.27</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.09</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">56,121</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Unvested, March 31, 2012 (unaudited)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,731,600</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.10</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.34</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">527,919</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Exercisable at March 31, 2012 (unaudited)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,096,038</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.27</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.09</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">56,121</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no stock options granted during the twelve months
ended December 31, 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The aggregate intrinsic value of options outstanding is calculated
based on the positive difference between the estimated per-share fair value of common stock at the end of the respective period
and the exercise price of the underlying options.&nbsp;At December 31, 2011 and 2010, the estimated fair-market value of common
stock was less than the exercise price of the underlying options, as such, the aggregate intrinsic value is $0.&nbsp; There have
been no option exercises to date. Shares of common stock issued upon the exercise of options are from authorized but unissued shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The weighted-average grant-date fair value of options granted
during the year ended December 31, 2011 and for the period from November 7, 2002 to December 31, 2011 was $0.98 and $1.28, respectively.&nbsp;
There were no options granted during the year ended December 31, 2010.&nbsp; The total fair value of shares vested during December
31, 2011 and 2010 and for the period November 7, 2002 (date of inception) to December 31, 2011 was $756,400, $199,600 and $2,806,400,
respectively.&nbsp; &nbsp;The weighted-average grant-date fair value of vested and unvested options outstanding at December 31,
2011 and 2010 was $1.31 and $0.89 and $2.01 and $1.91, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2010, there was approximately $58,000 of
total unrecognized compensation cost, all of which was attributable to unvested stock-based compensation arrangements related to
employees, which was recognized in the twelve months ended December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 4, 2011, in contemplation of the Acquisition and in
accordance with terms of the applicable option agreements, Cellectar accelerated the vesting on all outstanding and unvested options
at that date and notified all option holders that any unexercised options as of March 17, 2011 would then be terminated.&nbsp;
On March 17, 2011, Cellectar terminated all outstanding options.&nbsp; The remaining unamortized compensation expense of $58,000
was recorded related to the acceleration of outstanding options in the quarter ended March 31, 2011.&nbsp; No additional compensation
expense was recorded related to the acceleration of unvested shares as the acceleration did not represent a modification to the
original terms of the options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2011, there was $2,956,117 of total unrecognized
compensation cost related to unvested stock-based compensation arrangements.&nbsp; Of this total amount, the Company expects to
recognize $1,321,168, $1,051,631, $507,630 and $75,688 during 2012, 2013, 2014 and 2015, respectively.&nbsp; The Company expects
3,855,904 in unvested options to vest in the future.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 31, 2012, there was $1,935,626 of total unrecognized
compensation cost related to unvested stock-based compensation arrangements.&nbsp; Of this total amount, the Company expects to
recognize $748,791, $728,122, $352,444 and $106,269 during 2012, 2013, 2014 and 2015, respectively.&nbsp; The Company expects 3,396,500
in unvested options, excluding performance-based awards, to vest in the future.&nbsp; The weighted-average grant-date fair value
of vested and unvested options outstanding at March 31, 2012 was $1.15 and $0.89, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>11. &nbsp;INCOME TAXES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Tax provision (benefit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.25in">Federal</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.25in">State</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Total current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 9pt">Deferred</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; padding-left: 0.25in">Federal</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(944,333</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(1,592,000</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.25in">State</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(161,963</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(290,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Total deferred</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,106,296</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,882,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Change in valuation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,106,296</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,882,000</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax assets consisted of the following at December 31:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt">Federal net operating loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">19,447,371</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">6,116,804</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Federal research and development tax credit carryforwards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,956,146</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">390,600</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">State net operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,444,816</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">814,492</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">State research and development tax credit carryforwards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">597,608</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">220,738</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Capitalized research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,007,013</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Capital loss carryforward (expires beginning in 2012)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">340,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">333,206</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">552,859</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">555,198</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Charitable contribution carryforwards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,370</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,725</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accrued liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">35,314</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">25,327</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,761,042</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,170,545</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deferred tax liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Depreciable assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(346,870</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(434,056</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total deferred tax liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(346,870</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(434,056</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,414,172</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,736,489</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Less valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(38,414,172</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,736,489</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total deferred tax assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2011, the Company had federal and state net
operating loss carryforwards (&ldquo;NOLs&rdquo;) of approximately $57,198,000 and $46,533,000 respectively, which expire beginning
in 2031 and 2025, respectively.&nbsp; In addition, the Company has federal and state research and development and investment tax
credits of approximately $1,956,000 and $905,000, respectively.&nbsp; The amount of NOLs which may be utilized annually in future
periods will be limited pursuant to Section 382 of the Internal Revenue Code as a result of substantial changes in the Company&rsquo;s
ownership that have occurred or that may occur in the future.&nbsp; The Company has not quantified the amount of such limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Because of the Company&rsquo;s limited operating history, continuing
losses and uncertainty associated with the utilization of the NOLs in the future, management has provided a full allowance against
the gross deferred tax asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company did not have unrecognized tax benefits or accrued
interest and penalties at any time during the years ended December 31, 2011 or 2010, and does not anticipate having unrecognized
tax benefits over the next twelve months.&nbsp; The Company is subject to audit by the IRS and state taxing authorities for tax
periods commencing January 1, 2008. Additionally, the Company may be subject to examination by the IRS for years beginning prior
to January 1, 2008 as a result of its NOLs. However, any adjustment related to these periods would be limited to the amount of
the NOL generated in the year(s) under examination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the three months ended March 31, 2012, the federal and state
NOLs increased by approximately $2,357,000 as a result of the loss recorded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>12. &nbsp; NET LOSS PER SHARE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic net loss per share is computed by dividing net loss by
the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by
dividing net loss, as adjusted, by the sum of the weighted average number of shares of common stock and the dilutive potential
common stock equivalents then outstanding.&nbsp; Potential common stock equivalents consist of stock options and convertible debt.&nbsp;
Since there is a net loss attributable to common stockholders for the years ended December 31, 2011 and 2010, the inclusion of
common stock equivalents in the computation for those periods would be antidilutive. Accordingly, basic and diluted net loss per
share is the same for all periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following potentially dilutive securities have been excluded
from the computation of diluted net loss per share since their inclusion would be antidilutive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,<BR> (unaudited)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Twelve&nbsp;Months&nbsp;Ended<BR> December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Cumulative<BR> Development-<BR> Stage&nbsp;Period<BR> from&nbsp;</B>&nbsp;<B>November<BR> 7,&nbsp;2002<BR> (inception)<BR> through<BR> December&nbsp;31,</B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 35%; text-align: left; padding-bottom: 2.5pt">Convertible debt</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">3,822,062</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">3,646,370</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Warrants</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,176,679</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,403,989</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,403,989</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Stock options</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,827,638</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,827,638</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">769,189</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,827,638</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>13.&nbsp; COMMITMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Real Property Leases</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 5, 2007, Cellectar entered into a 36-month lease
for office and manufacturing space, commencing September 15, 2007.&nbsp; The lease provides for the option to extend the lease
under its current terms for seven additional two-year terms.&nbsp; Rent is $8,050 per month for the first year and then escalates
by 3% per year for the duration of the term including any lease extension terms.&nbsp; The lease also requires the payment of monthly
rent of $1,140 for approximately 3,400 square feet of expansion space.&nbsp; The monthly rent for the expansion space is fixed
until such time as the expansion space is occupied at which time the rent would increase to the current per square foot rate in
effect under the original lease terms.&nbsp; The Company is responsible for certain building-related costs such as property taxes,
insurance, and repairs and maintenance.&nbsp; Rent expense is recognized on a straight-line basis and accordingly the difference
between the recorded rent expense and the actual cash payments has been recorded as deferred rent as of each balance sheet dates.&nbsp;
Due to the significant value of leasehold improvements purchased during the initial 3-year lease term and the economic penalty
for not extending the building lease, straight-line rent expense and the associated deferred rent has been calculated over 17 years,
which represents the full term of the lease, including all extensions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company is required to remove certain alterations, additions
and improvements upon termination of the lease that altered a portion of the rentable space.&nbsp; In no event shall the cost of
such removal, at commercially reasonable rates, paid by the Company exceed $55,000 (&ldquo;Capped Amount&rdquo;). Any amount in
excess of the Capped Amount shall be the obligation of the landlord.&nbsp; The Company is required to maintain a certificate of
deposit equal to the Capped Amount during the term of the lease, which amount is shown as restricted cash on the accompanying balance
sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The lease has been extended, in accordance with its terms, through
September 14, 2014. Future minimum lease payments under this non-cancelable lease are approximately as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Years ended December 31,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 87%; text-align: left; text-indent: -9pt; padding-left: 9pt">2012</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">126,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">123,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt; text-align: left">Thereafter</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">343,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company also leases office space in Newton, MA, which has
a term that is month-to-month and requires monthly rental payments of $5,300.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rent expense was approximately $56,000 and $44,000 for the three
months ended March 31, 2012 and 2011, respectively and $197,000 and $159,000 for the years ended December 31, 2011 and 2010, respectively
and approximately $1,141,000 from inception to December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Equipment Lease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain equipment is leased under a capital lease.&nbsp; The
lease agreement requires monthly principal and interest payments of $217 and expires on September 3, 2014.&nbsp; The outstanding
obligation is being amortized using a 7% interest rate based on comparable borrowing rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table provides the estimated future minimum rental
payments under all capital leases together with the present value of the net minimum lease payments as of December 31, 2011:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Minimum<BR> lease<BR> payments</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Less&nbsp;interest</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Present&nbsp;value<BR> of&nbsp;net<BR> minimum<BR> lease<BR> payments</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 43%; text-align: center">2012</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">2,608</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">373</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">2,235</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,608</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">211</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,397</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: center; padding-bottom: 1pt">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,739</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">45</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,694</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,955</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">629</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,326</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The equipment recorded under capitalized leases is included
in fixed assets as of December 31:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left">Office equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">10,973</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">10,973</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less accumulated amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,123</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,928</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,850</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,045</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>14.&nbsp; CONTINGENCIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Litigation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the Acquisition, the Company is party to certain legal
matters that existed with Novelos prior to the Acquisition. The following summarizes the status of those matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Class Action</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A putative federal securities class action complaint was filed
on March 5, 2010 in the United States District Court for the District of Massachusetts by an alleged shareholder of Novelos, on
behalf of himself and all others who purchased or otherwise acquired Novelos common stock in the period between December 14, 2009
and February 24, 2010, against Novelos and its President and Chief Executive Officer, Harry S. Palmin.&nbsp; On October 1, 2010,
the court appointed lead plaintiffs (Boris Urman and Ramona McDonald) and appointed lead plaintiffs&rsquo; counsel.&nbsp; On October
22, 2010, an amended complaint was filed.&nbsp; The amended complaint claims, among other things, that Novelos violated Section
10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder in connection with alleged misleading
disclosures related to the progress of the Phase 3 clinical trial of NOV-002 for non-small cell lung cancer.&nbsp; On December
6, 2010, the defendants filed a motion to dismiss the complaint with prejudice.&nbsp; On January 20, 2011, the plaintiffs filed
their opposition to our motion and on March 3, 2011, the defendants filed their response to the opposition. On June 23, 2011, the
motion to dismiss was granted and the case was dismissed without prejudice.&nbsp; Because the dismissal was without prejudice,
the plaintiffs could&nbsp;reinstitute the&nbsp;proceeding by filing&nbsp;an amended complaint.&nbsp; On August 5, 2011, the plaintiffs
filed a second amended complaint realleging that the defendants violated Section 10(b) of the Exchange Act and Rule 10b-5 in connection
with alleged misleading disclosures related to the Phase 3 clinical trial for NOV-002 in non-small cell lung cancer. On September
9, 2011, the defendants filed a motion to dismiss the second amended complaint. The plaintiffs&rsquo; opposition to the motion&nbsp;was
filed on&nbsp;October 14, 2011 and the defendants filed a reply brief on November 4, 2011. The Company and Mr. Palmin believe the
allegations are without merit and intend to continue to vigorously defend against them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>BAM Dispute</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 28, 2010, Novelos received a letter from counsel to
ZAO BAM and ZAO BAM Research Laboratories (Russian companies, collectively referred to as &ldquo;BAM&rdquo;) alleging that it modified
the chemical composition of NOV-002 without prior notice to or approval from BAM, constituting a material breach of a technology
and assignment agreement Novelos had entered into with BAM on June 20, 2000 (the &ldquo;June 2000 Agreement&rdquo;).&nbsp; The
letter references the amendment, submitted to the FDA on August 30, 2005, to Novelos&rsquo; investigational new drug application
dated August 1999 as the basis for BAM&rsquo;s claims and demands the transfer of all intellectual property rights concerning NOV-002
to BAM.&nbsp; Mark Balazovsky, a director of Novelos from June 1996 until November 2006 and a shareholder of Novelos through at
least June 25, 2010, is, to our knowledge, still the general director and principal shareholder of ZAO BAM.&nbsp; On September
24, 2010, Novelos filed a complaint in Suffolk Superior Court seeking a declaratory judgment by the court that the June 2000 Agreement
has been replaced by a subsequent agreement between the parties dated April 1, 2005 (the &ldquo;April 2005 Agreement&rdquo;), that
Novelos&rsquo; obligations to BAM are governed solely by the April 2005 Agreement and that the obligations of the June 2000 agreement
have been performed and fully satisfied.&nbsp; On November 29, 2010, BAM answered the complaint, denying the material allegations,
and stating its affirmative defenses and certain counterclaims. On January 14, 2011, Novelos responded to the counterclaims, denying
BAM&rsquo;s material allegations and stating its affirmative defenses.&nbsp; On June 9, 2011, BAM filed an amended counterclaim
alleging additional claims related to Novelos&rsquo; acquisition of Cellectar.&nbsp; In that amended counterclaim, BAM alleges
that the acquisition evidences Novelos&rsquo; abandonment of the technology assigned to it by BAM constituting a breach of the
June 2000 Agreement or, if that agreement is determined to no longer be in effect, a breach of the April 2005 Agreement and/or
a breach of the implied duty of good faith and fair dealing with respect to the April 2005 Agreement.&nbsp; On June 15, 2011 the
Company filed its response to their amended counterclaim.&nbsp; On August 5, 2011, the Company filed a motion for judgment on the
pleadings as to its declaratory judgment count and all counts of BAM&rsquo;s amended counterclaim.&nbsp; The motion&nbsp;was opposed
by BAM and a hearing on the motion&nbsp;was held&nbsp;on September 27, 2011. On October 17, 2011, the court ruled on the Company&rsquo;s
behalf for each of its declaratory judgment claims and dismissed all counts of BAM&rsquo;s counterclaim. Judgment in favor of the
Company was entered on October 20, 2011. On November 14, 2011, BAM filed a notice of appeal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not anticipate that these litigation contingencies will
have a material impact on the Company&rsquo;s future financial position, results of operations or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>15.&nbsp; EMPLOYEE RETIREMENT PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 1, 2009, Cellectar adopted a Safe Harbor defined
contribution plan under Section 401(k) of the Internal Revenue Code which covered eligible employees who meet minimum age requirements
and allowed participants to contribute a portion of their annual compensation on a pre-tax basis.&nbsp; Cellectar contributed 3%
of each participant&rsquo;s compensation.&nbsp; Contributions made for the year ended December 31, 2010 was $23,000. The plan was
canceled effective August 30, 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the Acquisition, the Company has a defined contribution
plan under Section 401(k) of the Internal Revenue Code which allows eligible employees who meet minimum age requirements to contribute
a portion of their annual compensation on a pre-tax basis.&nbsp; The Company has not made any matching contributions under this
plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>16.&nbsp; RELATED PARTY TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jamey Weichert, the Company&rsquo;s Chief Scientific Officer
and principal founder of Cellectar, and a director and shareholder of the Company, is a faculty member at the University of Wisconsin-Madison
(&ldquo;UW&rdquo;).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2011, the Company made contributions
totaling $206,500 to UW, for use towards unrestricted research activities.&nbsp; No payments were made to UW during the year ended
December 31, 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended March 31, 2012, the Company made
contributions to UW totaling $81,500 for use towards unrestricted research activities and paid UW $92,754 for costs associated
with clinical trial agreements. No payments were made during the three months ended March 31, 2011.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>17.&nbsp; SUPPLEMENTAL PRO FORMA INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The table below summarizes&nbsp;net loss for the periods shown
as though the Acquisition occurred as of January 1, 2010:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For&nbsp;the&nbsp;Twelve&nbsp;Months&nbsp;Ended&nbsp;December&nbsp;31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,256,438</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,704,966</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The pro forma&nbsp;net loss&nbsp;has been adjusted for the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%">1) &nbsp;&nbsp;</TD>
    <TD STYLE="width: 98%">Elimination of $165,000, and $361,000 of interest expense for the twelve months ended December 31, 2011 and 2010, respectively; such amounts relate to interest accrued on the Convertible Notes which were converted immediately prior to the Acquisition (see Note 7) and the Bank Note which was paid in full settlement of the note immediately prior to the Acquisition (see Note 8).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;2) &nbsp;&nbsp;</TD>
    <TD>Recognition of an additional beneficial conversion feature (&ldquo;BCF&rdquo;) of $463,000 in the year ended December 31, 2010 and the elimination of BCF of $258,000 in the year ended December 31, 2011 in connection with the conversion of the Convertible Notes, which is assumed to have occurred on January 1, 2010 for the purpose of pro forma presentation (see Note 7).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3) &nbsp;&nbsp;</TD>
    <TD>Elimination of Acquisition costs incurred during the year ended December 31, 2011 and 2010, which are assumed to have been incurred prior to January 1, 2010 for the purpose of presentation in the pro forma statements of operations.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;4) &nbsp;&nbsp;</TD>
    <TD>Elimination of $450,000 of investment banking fees incurred upon the consummation of the Acquisition on April 8, 2011 from the twelve months ended December 31, 2011.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;5) &nbsp;&nbsp;</TD>
    <TD>Elimination of dividends and deemed dividends on Novelos&rsquo; preferred convertible stock, which is assumed to have been exchanged for common stock at January 1, 2010 in order to reflect the post-acquisition capital structure for the purpose of pro forma presentation.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;6) &nbsp;&nbsp;</TD>
    <TD>Elimination of Novelos historical revenue related to the amortization of deferred revenue that was determined to have no fair value in purchase accounting.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;7) &nbsp;&nbsp;</TD>
    <TD>Elimination of liquidated damages accrued in 2010 related to Novelos&rsquo; convertible preferred stock. The liquidated damages are assumed not to have accrued as the preferred stock&nbsp;is assumed to&nbsp;have been exchanged for common stock at January 1, 2010 in order to reflect the post-acquisition capital structure for the purpose of pro forma presentation.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>18. PROPOSED REVERSE STOCK SPLIT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 30, 2011, the Company held a special meeting of stockholders.&nbsp;
At the meeting, the stockholders approved, among other things, separate amendments to the certificate of incorporation that would
effect a reverse split of the Company&rsquo;s common stock within a range of 1:2 to 1:10, and authorized the Company&rsquo;s board
of directors to determine the ratio at which the reverse split will be effected by filing the appropriate amendment to the certificate
of incorporation, or to determine not to proceed with the reverse split at all.&nbsp; The purpose of the proposed reverse split
was to increase the price per share of the Company&rsquo;s common stock in order to exceed the minimum price per share required
to secure a listing on a national securities exchange and was contemplated in connection with the Company&rsquo;s underwritten
public offering that closed on December 6, 2011 (see Note 9). The Company did not obtain the NASDAQ listing and did not effect
the reverse split in connection with the offering. While the Company may effect a reverse split at a later date, the Company has
no immediate plans to proceed with the reverse split or a listing on a national securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">In Humans, <B>HOT</B> Targets Cancerous
Tumors - Not Normal Tissue or Bone Marrow</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(SPECT/CT imaging of HOT in Phase 1a trial
patients; Bright areas = HOT uptake)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img src="pg97a.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Our Therapeutic Compounds ( <B>HOT</B> and
<B>COLD</B> ) Selectively Target Cancer Stem Cells</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Fluorescence photomicrographs; Green =
uptake of fluorescent-labeled COLD)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img src="pg97b.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">cGMP Radiopharmaceutical Manufacturing Facility
at Our Headquarters in Madison, WI</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img src="pg97c.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>The images provided above are for
illustrative purposes only and may not be indicative of all results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>The above illustrations do not refer
to products approved by the FDA.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Novelos has not received any revenue
from the sale of its products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 95; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`-`$@`P$1``(1`0,1`?_$`.(```(!`P4!````````
M``````D*"``'"P$#!`4&`@$``@$%`0$`````````````!P@&``(#!0D$`1``
M``4#`@,%!0,&!PD0`P```0(#!`41!@<`$B$3"#$4%18)05$B%QAA,B-Q@4(D
M&0J1H<%2,R6UT6)R0W,TEG<XL8*R4[-$U(75)E8G-T<H&EAX.1$``0($!`,$
M!P0$!PL+!0```1$"``,$!2$Q$@9!$P=182(4<8&1,A46"*&Q0A?!T2,S4F*2
MLG0U-O#A<L)C)%0E=288\8*BTD-3<X.3-$1D53<H./_:``P#`0`"$0,1`#\`
M9LO#I\]7!Y<MP/K5ZU<01%MNIN2=6_&/,5]X<1<(HNH=C'.5@,`.'2+<P$%3
ML&FB?)OW3N4]DN;;)K@Y`<2?2GKA>KOMGK?.JWU-NO,AE,U2&Z1W]\+EY"]8
M_P!2S'=ZW;9<EE.WW)[5NF>M4TRA8L<G%2[FW'JC!V[CU5DC`)!.E4Q`$3%$
M>S3'VGI%T[O5/+JY=(]DB8P/*N*J?2,H5*^=>.K=CN4^VU%?+FF2\@N:T(HX
M*#!%_3%];RZK^R47#?69<,.12[GC9+'>3",&D$S:RBXBB6VY]),0;D!X<`Y3
MC@`&-M-30VZE=&9%#2/NFU&NT2$5F9(.:=\%?H[]25?>+LRR;X?+$F:'`3,A
MK":%])7UPTX@HF=,AR*%4(N4%4SD-O24(J`'*=,^X2B0P&J`APH.ED#B9C@6
MZ:IN"'NAU),UNAKM6MDS%I&2'^Y8WU0J4M*5W`(#01I0!X\!"FLC@XCNXCNC
M,>7J;S`3XL.X]L#UZK\3=?5\WS#2G2SU&8]Q'9#6`[O+6_==EJ7`]?3_`#Q,
M#U-XG_1M3HFVB7M`0KJ;;4N.Q:.6[X_1S)\_'%I3M3V0+M]6;J5=*T.V?<)=
M)3`#!P!RSXP##(?4)ZT]A]75L=&GS.L2;OZ\F*,Q;%QL;68H6W)6V/,.^N$Y
MU$N<@WBP1-SBC0Q1H`AQT=;58NC]RV7.W5,D/:^4#@O$>J%ANV[^O%EWC+Z?
MS:MDVYU,S6R8UOX7%1QP$,$=(>.NK^P8:Z2=6F:[.S'-R;MDO;2UHVJ%NI6^
MT3;%*]9.3@!!?BJN`B4VT-+SN.X;7JW"79);I<A<02JA/UXB&LZ>6G?-JIYC
M][5;*JI>N+0,,?","<AA$IKNO.T\?6_)W;><[&6U;D0U4<2$G+.DVK9%(H"8
M0$5#`*BI]M"D"IC#P`-1UH`E!H5((4O"60&Z6ERP('*'K4X6MJ1=1.-+$N7(
M0MA.FE,J*H0\.H<AN!TDUBF<G2,'8;:%=?(NBUL%ZY$>=V7S/@F2;L-]#'B9
MU)9V4M:`<A%B&(?:`\0X#JHJ";]./71T_=3>V-L:ZB1]V`B19>SI\Q8Z<`*&
M%4&A5#`1^5(Y1`13$PT]@:J*B9(#7LK[.W[0`?Y=5%1KJHJ*U45%:J*BM5%1
M6JBHK5145JHJ*U45&@\0$/LU45%EL^V[F.YL6W)#X%O2W\?93<I(>6;LN>(/
M.PD:LFNF=?OT82AG*:Z!1)0.RM=;&UU%OIJMLRYL,RC7%HXQH=RR+W56B93V
M"<V1<'#!YX=G$0O3ZA.5?5=Z)L.1.5[OZIL77%'RUUQ]JI1]G8U1BG[=T^;J
MK`Z,N[YB*A`%$P`%!H%-'78EFZ9[ONLVWT5),D3I<O60YRZL<0./?"A]4;WU
MJV!8I-QN5SE39$V;H#F-"M*9X$K'2^B'UP]4'51U&90MW.V4G]\PD/C-"7C(
MIRQ9LVK.1\9*D99(K-%$/NF`.-=9^LO3VP[=L5+5VF7R@9PU9J2=7V)%WTX=
M2-U;JWC4T]ZJ75+6T+])(`1'-*8=\-)E$PF((B%!+6GMXEKPXZ71P[.!AUF%
MAEM+\)I$;^K8NC3<%:5XZJ*BA,`=HZJ*C75145JHJ*U45&@F`.T=5%1KJHJ*
MU45%:J*CA+!1-8.W\-0!$>T?@$>-*![?9[-8VN<YX"GPS&CVD1YYS&.:_``.
M:X'^3"Q_3CT)8XZ[>COJ:L:Y&K.&OR&ZM\WR>.+_`"-43R-O3A9I<4&RZHT5
M7A7(CRUDAK0#;B\0TQ%_WM>-J[AMQD3GFA%NE![#DFMZN0)XD^P#"$VVMTOL
MW4?9%[IS*;*O?Q>>Z7-;@=6A@#7%R^`IE@5)QA7K.V!LE]-^5[DQ'EB`=6]=
MMJ/EP,``H1"6:D4VL[@@72I2%<1[H"@=-1(PB`A[PTU>W+O9=S6=E;;'F;(<
MP<Q2#XB.&`3T'&$NW1MF[;)NKK+<&3)-QDS$U'!I`.!;^M4AFCT:?5G5GB6]
MTH]3%SE\=(W3CL2Y%FG8?UV@@4J;6U)YXL8"E?I(@!6RIJ&4`0(-1`-++UBZ
M5FC+MRV.7^S+B7M'?Q'Z1#@_3SUU-2?D[=4UIEL:!*FE0[L1Q)1.S`0TJ0PG
M`*B`@)1&I0$`'@%*"(C4*&TM0U(KL'=D.^U[)@UR_=")WJ(HR11`>)@&G:`A
MV![.(#JUK=!)'&/I347IXD(@,^7$DS>M%TNF,0@F^F7)12GV$`Y`"34+4IP+
MNK0U.WLX:+-L7\IJU"0#6!J<$PA<KNV6[ZB+=+<UI#;67`\5`P@RH)@0.!A[
M1[:>VHB-```]NA"X$:1)#-:#/L`3MABR!KUN5.`X0.CU/\)3&9^EFZO+;A\:
M=L5=&\V\8U54*E-,XW<:28.D$MO>"@U,8Y`'@`EXUU?--2"`S26]B']<7OYI
M:6RU#D4`Y+]_VPH6004+7;LWF^("@!1#ECM`/AH(`7;2GV:LYKN"+&,<QD@/
MGH)JC+*-X3G$*;QI[>!1J'NJ("(?FH.L7F']@C)$J^B'&5T9:ZI<5VY:LC(P
MCF/ETKFEYR+440<1D-"J`X=G%=+XBINBE!(2C4AMPU`:ZSL;4/:)OAY*X]OW
MQ\;Q7U0ZISN[I%YBI`(FF4IUEMI"[B%VB=103%*&\0U>I+M3<97=B5C'SI8:
M7/\`"UN+B2@`])PCBA-QM`K)Q=1K_P`_;E]ONYAO9]NLW*>[W6O![VF/*;K;
M`\?YQ(Y9_P`HU?OBAG(HH;CRD64OO\0:B'_*AQU:9%2J`%5/X3EPBG7:TM:7
MFID:1_E&_KCED>)K)E7;K(+HG$`(HD<%2&'M'\0AA)3[:\-8WB9*4S4``4DA
M$`SC*VI;,:R;)+7R7D`:2J^L81LJ2C)N<4W#Y@@H%!%-=VBBH%?:)#J"--7M
ME5#VATL*T\0TF/DRX4,IYES9LMCQF'/:#]J1MA-1YS%*G)Q)C"--H/T#&,(T
MH!0*I41'\FKV29Z),8]>T`H8^2[E;7X<^47DX`/:5^V.:"YA,)1``X`(`!3'
M$1'MXAPH'OUYG/()*@,9[W;W)'J!<Y6!J/`XG"+.9,ZB\(8;3,IE'*UB612@
M@C/3[%F[$![![F9<78_F)K>T%AO%SE"=04TZ;*/$-*>U$B+7G>VU["K+I6R)
M,YN8)!/J`*Q8Z)]1[HBG),D3&]2V+U7QS[")+S!F13&$P%`I7#Q-%N(F$>'Q
M<=;2;L7=[)7,9;YSNX8G[!$=H^LG3BNJ/*R;@P3NT@AOM(_3$NX"ZH&ZXU"8
MMF;AK@B792':R<+(MI-DJ10`,`@NS563K0?>%/;J+55/74-3Y6ND3),\>\UX
M(+?:!!!HKA0W*F%1;9\J>TA06.#A]A,=\%3``'I7V@'9_+P'6)X#G8'P@@B/
M0PN<Q)H&O(POS^\8``=%MEIAP*;,,$/Y-D>_I3^'1YZ`2V_-U1-(5[J=%[%.
M8[\.*PI_U:`,V#0!F#17HG<6../L$#`_=O0_^5&8?]4:/\4\CHE?407_`"Y2
MMU%!/;]SH$'TC#_?6KF\11/'=FR'0R!0-U>(A[>P/9PH`>S2<M,SEN;+34''
M/TQT2:[6&D@*G"/K>/NKP$0H`\:5_P!VFLS6E/$1JBBY'AB''CP$6HR3G'$F
M'&`2F4<BV?8K82F4+YDG&,:J<@#Q%)LNL5RIP']$@U'7NMEFO5Z>76FFFSZ=
MI1SFL<@(*8E"(CNX=W;;VK*YM_JY-.>#2X:B.YN96(G#ZJ'03WD$C]1MEE1%
M7D]^$DH6.`^[;4SX60MP)N_2K34E?T\W<)!GMIE0^[J&K^3GZXA3NM?3V6YO
M-K0R6YNH$M*(J9Y")4XSS[AW,L>62Q5DNR[[9[`.8]N3C*37*0?NF,T16!VF
M`^\24U'*VT7.W/#*Z1,ENQP<".':0D2ZP;SVSNQNK;E?35!!Q`<%]BK%W2JB
M(`(AMJ`\!*-0$/?Q^SLUJ&3=;7//NM.(XQ*9A#'B5G,/'A_=ZXKFB)0$-H5K
M4#`/LJ`#VAPJ&KI<SFR^:SW._NCX-90I@J&/'W;?UG6''J3-\W7;EI129#"9
M]<$LRB$*D`1,!%'SA$%1``$=I:FIKV4M-4ULX2*23-F/(7PM)&>6`SC77*\V
MBSRG3KE52),L9:G`8)BH)QQ[(CV7KTZ.S/>X!U'XH,ZW`3EA=#$I=PC0H<TR
M@)\1^W6\?L_=.@/905&D\2QWW)$('5WIVV;RGW>D+E3W@`O^$I$2-M>^+6OB
M)0GK,N."NF$<A5&3@))I+,S@';5PR743*(>X>/V:T-;25MM>67&4^00%\8+<
M^*%,(G-!=*"[TPK+542)]/Q+'A_J\)P/='HDW13G!+>D*H$`YR%,&XH"`4'8
M)N84./M`-80"6!^!:<B,H];)['OT`C40J<0.\9Q\*B'+6'V<I0?S<L?[FL<M
MKN:O^6;^B*F@M85_C?S8$!Z-11'#74<4>`GZN,V[!X"(?U[0!J-:4T4NJLO_
M`%G1M.#OATL'^4^`)T!<V9M^ZM:X@F\3P#V>%D7%]2_TY;,Z[,5'2:@QMW-E
MGMG#G'5Z@W(0ZB@([O+DTLF!55X=\J'`3<4C&J&O/TTZAU^R:X4CWN=:IA1X
MQ.G^,/T^CMSVG67I-1]2+(&RI;67VF:3+?@.8.+7$_8L(2Y%QUD3"619_'F0
M8>4LN_+#F^2[:B15J^9OF:PJ,92,=&HL#1;:4Z*Q*@)>->&GKH:ZV[EM4N90
MN;4T+VJY<$7TQS!N]JNVR[R:*>QTFZ2G)W8=XP/J/ZH;9]&WU9D<R,H?I=ZC
M9Y-#*\*T1C\?7U)N2)$OV,;D(5"&DG2VTI[G:D3':;L<D`1^\%-*9U:Z6S+-
M4NO]E874!)UM'X5Q+@,T"(?;#T?3SUP%XI6;0W5-2N:/V$T@I,"@:7')J*$)
M189%*J4Y:A[0$0"@A^:@\:A[=+^UP>TN:J`IE#@O<&G0<T]1]$!KRU__`&@Z
M7/\`]9\E_P!J'T6;9_\`B6L_IX_1"Z77_P#HR@_V28,B<0^(.(>_\E.(@(\.
M`:#YF,9-;+)(F/1$"PQI):!,*:&J3]L!1B_5;LJ^?4=D>B%DSC%L:C#R]ENK
MO<*`(S.3B(&4=PB"AAY)6`-^8W_OE@_-HSS>E]91[$&['J:DN#G-4>%B+EF3
MDH[X6V3USEW#JPW9U.0+8Y93'(5=/!&!/X6Z0XAQ0+AF1`2.LO!SOIZZB,@X
M]4:K)P9Y1:X[464*()JV[.*J.6Q$##]\C83"4U/NB%-!74V3/+YN#'+I3''O
M[/7#'5#W/TNF8,5/7$7R_I?X!A_@XCK!%\'4].N#M_I9Z6<[];^0T"LS$MJ2
M):1G@<HZT1$H&,1)J9:A*SLT*:90`:B!1'4AVU9ZF^WNEM,A29[]*<,\23EE
M$7WCN&5MC:MPO4P@&GE$A?X2>$>TQ)[H0ZNK5]5_I6R%9&0AD++OYJ#BV<CQ
M5GRZL)*MXV27,XAYZWGK8XO6"+EKM()PXE5*;WZGV\=J7#IQ>Y<Z3+;,D$(-
M2%NI%([%3*`UTVWS2]:=IUEDKIKY-QEO5QEX'02@(/'O$`@]7;HJOOH2FL?7
MCAG*N;W>';W;K03@\[D:ZIEW;]Y-"@KRW3\T@1(C65:EW)@8`J8!`..COTBW
M-:]ZS3:+G2TTNNERRX`,P(:%&/V>F%RZ]]/;KTXFTURM%953;/,:0YQF%6NR
M1`F:YI'G?2$Q/C#K0R'E#%/4-EK.(7C'P</<F-/`LO7-"DDH]!1^A=#3NA7I
MQ=/F:7(4*(=B9Q]VO7U9NU5LJEDU=CHJ1U)-:YLXNEXM+4TH%!Q+B%RP$>'H
M/:K%U%N4^Q;DJ:T5VACI#1,(!TZC,4G#(-12IQAR[!6&+9P#BNV,46;(W++6
M_:S=1".D;PFWEQ3[@JJJJYCOY9\)G+H044^$!$>'MTGMWN3]PO=6/#&&8$&D
M(!ZOOCH9M^U46WK;+ME/S#3R<M95Q1.,#MZ]O3CQGG!IE'/3S,.9<8WW'V,]
MD6TG;V1)B(LR+"V8IRY05=6\B[1CRH+BD`+&X&&OOT1]E;ZKK?.H[$:2FFT1
MF!A>6@NQ.>?#[H"_53I91W2BN.YFUU53U$F4Z86AR-P"H/U#'A`OO24]-R]\
MRV?:W5-U`YFS22,)<H2N*+.C+]N!FUG(^!D#)I7+/=[<*G=1LRNUJD@("0Z7
M'L'1"ZN;[H[?4G:]MHZ;SDMJ/<`T<`<"..,"#H5TMKMPV]NZ;Y65<ND?/U4P
MU'QM!17-*EN((Q3AA%YO5_\`5TN'`\\_Z7^F>0:DR<#-)'(F0$N4]-9Y7R)>
MZ6W`DJ('N9P10!$YJBC4.%1UKNE?2RFO<OYGW"T,MPQ8PD#F:5U+QPP3+.)'
MU]ZWS+)JV=LYS_B7[N;,:"2TX`!IR7OQBZ7IL>EA:?DB`ZE^L=DZS=G?([)M
M<J#'(SUW<<79T3(D*\CFXQ\J91%>87;+`=<3$`B8_"4NM7U#ZD,\\ZQ[4$NC
MMD@Z58FIYX^CNC;]'.CC*FV2=U;YF3*N[S2)C63%TM&8U=N>67J@JV0^B;I2
MR?:\C9]W8%Q@[A)%J+8Q65H0L8^;`)=H'9OV#1!R@JG0-I@,`@(:%MOWENJW
MUWFI5:]S%R+E'L,&V_=,]D7VWNH9U%)E$A-<M&.'H(A2#/<QU%^BCUFEM[#5
M^S\WA*XT4;OMBR[F?OY.`N"TW*YPD+=<-EEC(LY6+4(*2:R0!0=HTIIH]OR[
M%U6VB7W:2UEPE-TF8T*XS`#CACZSA"0[HJMV=`=[\BVSGS+#,?JE!S@09)(S
M':BCAE#>?23U/6+U=8+LO-]A+&+'7.SY4G$JG*=[;UPM*)2T(^(3^C59N:@4
M1`-Y*&#AI7=S[;K-L7F=::L>)A!&(Q:50_KA[-A[MH=\[9D7ZWN#M8&L9%KA
MF$./H@2W[Q@(?199G^N&!#^%@^T6>@#@[=<].$G])A>_JU!^0:'^GKZN6[]8
M@7_[M]_M49A_U1)?V\CHD?43_9ZE_I#?N=`@^D7^V%9_0W_>R'0/\4'"OW>'
M^^#^+2=,*!V*>(QT.E%P:TL"N2`$>KOZLKGI+$,#8)4CWN=9R+,\G[@<E3?1
M^.(9T@<R2IVF[XYYRD.Y%,U.4`@8='7I3TH=NQPN-Q<6VL'#$*>\C-.Q,\(5
M[K[UR=LT/VGMU'7E[!K?CX%X-.1/;$=/2Z].,W4U;4?UJ==4I<>9YZ^7*TGC
M:S+VEI)[$M8L%A$MQS46NOW8ZKY0HBW;%*"1$PJ(<0UO^HW469MV<=G[29*I
M94IO+>]K`I+/"N*XN124X]\0[HUTE.[:>5OKJ',FU;YCUDRW/+FN7$%R9`+@
M,(863Z=L"&AP@BX6Q8$)RA0&,\C6Z#3EB0";01\/$M`*%*UJ.@%+OU];4NJ/
M-3Q5-.>HIVY?W"&PG;)VJV7Y5UOIG4Y"%I:%3+.%U/5@]/8O2O"#UP]$3R<P
MM-VC*-U<EVS8K]U'0YF#ER**%QQL8W'NJ!6K@=KI$Q#)&(>H4T>>F>^3N2K9
MM+=C94Y]5X&3"S'(E"1@,L_TPJO6SI:-C43]]=/B^CE4[F&:QCT`+WM8H:2I
M"N`XH%.42U](?U6UNL%JOA'-!X]AGBUH@9&/E6)0;L,C0338BL\1;*#N2FF@
M4,N0O`U=X=NM)U7Z5#:$U]WLWCM.H!X4>!SL4`S+4XXH>,2WH+UR^=4VON0A
MM[8$8]"CT[3B`?O@FO6CU-1'2/TU9)SK,-222]I1(%@XDY@)XM<LDJ#.'8"8
M0``(9XJ!CU_0*.AAM.PS=S;DDV=G@IIAQ/<,2GW0:>I&\V;%VA5;C8T.FRP6
ML;VN*@'VXP'_`-.KI=8^H!8B76SULW-)YLN"^+@N!&Q<8O99ZAC7'\-&OSMD
MVJ-M-7";-:0.!*'Y@&,`!]NB=OK<+]DU3=J[:T2)<N6#,<Y@U&825TDXD:0.
MY<H7OI)L>1U/ML[?>]YDZIF3JIPER6S$EZ`&G$#)23@H*(L%Z^A;H\/%^$GZ
M;\0=Q$NP$2VA';MAN`_C;1<#4/[ZNAM*WIN=K@]E;-,SM0)[$@]-Z7=.9<OE
MLM-,T9(2YR^QRQ"#.GIKW#C/Q7+OIYY(N7`65(5JI)HXS1E'4CAZ^3-$Q54A
MWEKOCKMXI=\!-@*H\-PA4-26R;_E7*H?:]Y4K:JC(:.8FDXG)0F`[H'FXNC]
M98)PW#TRJGT5PE!SS3EZRGX8H''`GL)B$?H>YBSYF#JKZRICJ'N6X)+(+9E!
ML;B@9-=PE%6Y,QTJX9.F$/#F5[I&MT^7\)4TRB)>(CQT1.M-DVY:;!:W[=E,
ME4\UC20"I]U<\X'_`-.^X]Q;AWI=YNYY[YUR8QX*E&M_:`$!OI"*,D[X9E5_
MHE_\@I_P#Z7%GO\`_G-_Q8<2H]T_\[^;`B/1M*!</=1`!_\`EMFL>/VSE=%/
MJM_6])_L^7_.?"^?3Y_4-S_VS/\`YK(+\H4!``_G!0:TH%0H(T'@/#0C>XRY
MJM"E4]ISAA7Z=:N*`0'+U6?3%MKK5L%:^K$9Q\)U$V3&KJV[.$;I(%O=@@0R
MXVC<"B0)\P%^7M;*F$13.(!Q+4-&'IAU$K=H5HM]8\NLLT^(G'2O9W0OO6SH
MU;^H5N^)VEC6;A8,$3Q>GOA%V>MV]<67O(P4]'SMAY"L.<52>-%#+1DS;T]%
MKIJ)K$5JDLF""I-R1R5!4O9PT[U'.H[];WS9<MLVVS):$HH\0!7V1S3J:>\;
M:N1HZESI%;*F:>PA"<DXJ/5#FWI!^JRQZF;<C<`9VFVD5GRU8ULV@YIZJ5%'
M*44W)R@<HG5,!"W&U(4H+(UW+!\0!72;]7>F%;MR;\:L+%MDUZN`R9CB>U"%
M/<8Z"]`NM=+N>D;M?<KTOTANF2YV<QH">LB+V9;"GK/]+@^WZ:<F!3_K0^M/
M:\>DM9V>?'Z(WMVP^HRW]OP@P37/%Y+X]P[E:]V^[O%JX^NF=:<L*J`Y8Q#I
M1OMH(<0<`4?9P#0ZL5-)KKY24CT5\QH/H7]4&K=E;,M>U;E<531(?I[O"GWF
M,9Q;^3[KMS*<9F6-DET+QC+Z&_F\F50Y7"LV,R:6<&,?<!CG<";8:H]@TUT5
MJ;/35-B;MH@)-DX#U?JCCRR_W&1?W7B2]PKVU/,:>((*^S]$-Y=>:%N]7_1G
M@OK?Q\W3=/X^"CT;R[J'.71C7Z22,HR>&3`XIC#3J9P.!ONE-3MXZYX;JLCM
MN[AJ;?4XB4]P'H7PGV?='7O8>YZ;>&SJ2^2C^]E-!_PVIK^T'VP%O&-AS&6,
MB65C6`2,I*WK.Q\.V$A#J&01<K%!TZ,4@".QNVWF'V!J*1+8(WZ[6;(+"."<
M&]!6/7!6X+Q,9.WPU8J!M);L"F5..:/$RB&TTM+[EZ&$-P!P"FF>Z`[2J*N:
M_<CF:I<HEK"G$'Q)Z\/5"7_5?O4TE'*V?2/+9TQHF3`,,/P@^J(&>@=D24M#
MKTC[7:.%48C)%A7##RS1,3\A=6-2\2CEE2@(%,=NL4VT3`-*\-$SKA;?,[--
M3/8E3+G"8#W`$'[X#'TOWB=:.H5/1M>>15RG->.!Q">PPWSUI=-$!U<=.62,
M)S[=$R]Q0J[BUY!8GQPMVQR9G,%)IG+4R8INB@4PAQ$AQ#2F;/W%6;8OU/=Y
M#RU@>W4.UBX@^J'VZE;0I][[/K[1,:UU6&ETDG^&!X4])C'U8NOG)_0_U30M
MS"D^A+\P9?RT?<L6!3(G?M(YZ9E-1ZB2@@5PUE(\IA(4>T#@.GWOM#;=][9Q
M:"V?3ZF^OB/9'+2U7"^].=W-F#5)N%'5-UCN:?$T^D*(R.F&\KVIF_%5C98L
ME\B]MN^(".GHY0ARJ`EWM`JB[-3:/PK,U]R9R]H"77.^[V:ILUUJ;5,]^6YP
M'I&1'I"1ULV[N"CW7M^EW'1?^VGRVS/4,Q[<('7ZEEWW'E-_B/H)QJ]51O3J
M3G4W.2'K-0X&M7!=NK@[O"1>BD8JC=":(F#(HU#<)Q`-3WI_;Y%'35.[+B/\
MSI99#%XS#DGW>DP(NL5ZJKM<+9TTM3M-RN,P/F<%E-.(]&9/H$$$DFUNX'P9
M)M[:9-HFV\3XTD"0+)(I4T&S"U[>6&.1`!X!Q:%J/M,(UU"6SIFYMPR:N:XO
MJJN>"?0XC#T)AZ!!6J&4>SMIS9-&T,I+?0'2G:UIQ]9"^N,;[;MZ-<@]2T#D
M3*;U=U'W5F6.NV]9!8AWS@(YQ=!'SLQ4@$QW1D&A03!,`,;:4`#@&NB,VV3:
M/:8I:%DMC6TITK@%+<4Q$<D**\2KAOAE[O#GOI7UFN8<3@7*.!3N]$/;LO53
MZ'6#9FR;Y)F$6S)JV:()IV+=VQ-)LB1)-,I0AZ4*0@![M(A4=/=U39CJN9*E
M%TR=AXAF2J>]'3&BZN;`E2I4N54S&R9<AN`:3@`!DA4]PCG#ZK_1"/\`[FS7
M^@=W?]DZO_+S=H_^/+_E#]<>S\Z>GW^FSO\`TG_]2%^?7(SUA?JV:X(E\!N[
MBONXK,>W*SGQ9V1<S<[.%DTD56B:JCR,2`X`\3K0!'B/#1]Z&T%XVK,J679T
MADA\W4&ES3P3MPA3_J8W#9-[3:"JVTV?43)4HM>X,<.*XC3G$B?W;NZKZC"]
M1V*[EA[EB(!JK;5ZP#>:BI!@S(_>E.QDC-#O4DB&4="0IC%`:!0??J,?4'4T
M=PNU/<*4R7.=K#M"<-.:$^KT1./I*F5U`+C:ZOFMES&2G-:]0`6ZP=((["%]
M42;_`'C'_8LLOM_]8K?K4*#_`)@^#LXTUIOI\_M94?\`A?KB1_5NT#8U$WLJ
MS_-@8/[M]_M49A_U1)?V\CHF?43_`&>I?Z0W[G0'/I%_MA6?T-_WLAR^8D$X
MF#E)94:)1<<\DE/\FQ;J.CA^<J5-)[(D.JIK:=GO/G-'M<(Z"5-4**WS*LY2
MI#W>QI,8S'/-\2V>.IG)U\S[MR]?9"S!(I*JN3F.HE&KW(6)8MBJF,8P-D6E
M`*6NT*4UTAL]JD[4V:9$@`3FTX=_T0?UQQ\W%=:_=V^S4UCBY]34EK5[W$#V
M1DE</6G&65BO&MIQ+=-E&V_8=L135JB!2I$!K#LR&,4I0H`F4`P\`#MUSQO-
M1/K[S/KIQ68Z<\GVD#[(ZX[7M]+9ML4%IE`!LFGE#UA@7[8N81,I2@`"/"ON
M]HU]WVZUY<'N)$2)SM;BZ+(]2UDQF2>GW-%B3+9)Y'7+C:[XU9NL`<LYSP[M
M1`QJA0#$<ID,`^PP:V^WZJ=17NEJJ<I.9/8A]:?=$2WS04MRVA<:.L`=3NI7
MDKVM&II]3@#&.:Z5,FS_`$^]4F(KZMUTK'R%D92B(ATJDI05XUQ-!#2[-<@B
M'.;N&0GW%'AP#W:Z"[BM4G<VU*RWS0#.\D9I](:H,<FMFUM?8-ZTEPHWN:]E
M6"4[`Y2#ZH=X]8+#MV9]]/[)L;8;%>5G89.WLD,HEHF9=U)LH%0L@];-T"`<
MRZPLE#'V@`B(EX:2WI?<Z6U;[HW5":3,T8^E(Z,=>+%7;JZ6$4"A[`R<\#^"
MFH_?"A/1?ZG?4ST2,']L8XF8Z<L%Y*JOG>/+M:+.F#-^<]7CB.4Y9746Y74+
M18H`'Q@/#3:[SZ:[4WI<)E?4-<RK+0T.:43!5]I.<(GL/K/O+IS)%JM;I9M0
M?J+7A5*`88A,!!;K:_>5+X;]U3N_IH@WFP2E<.(.Z7#50ZFWXN6D[14(7>'9
M40I7CH25/TYR3.U4=84Q0$A<O[N$&VE^KZYF:SS=!(,D>\6ZERP3$\8F=AG]
MX@Z6+W=MH[*]FWOAQTY5!$S]PFG<<.V-N`2+.'#$I#))"':($-0.W4.NO0#=
M<JGFFVS&3G,"^'`]^)*03=O_`%4[3KY[&WB2Z0\J'9D)P/$P0#I2P5A(V>\S
M]:V"<D1-XVKU)P-M)O(F`(T6B&,O"%`SN4([0.*B3R2W@99%0A#@>HCJ#[FO
M%U=:I&W+Q*<VKI"!J=Q#06X>I((>P-H;8=N*HZA[6J&OHJUCVEC<E>YKE/8A
M:?;!#5_Z-7_(G_C(8`_C'4#9[W_G#_%@R5&+#Z'?S8$!Z-0&+A_J,W#7_P"7
M>;@"@[NR=IPI7A[M%7JMC>*1/_M\O^<^%\^GW^HKG_MF?_-9!B0[2_X/\FA+
M_P!L885V+HT.3<(?"`AP'B`=H"-!X^T-98^@)E`&_5X]*ECU7VV[SEA:)8QG
M4%;#(5'\:W32:M\FP[(HJGC7ZA!)2:12(((*\1-]T?9HU]+>J55M>>+%<'EU
MNFD:23@TJ`GH3V>B%<Z^=$9&\*=VX]NM`NTH$S&M`\3=))(`S<J0E6VD+UQM
M>S=XQ7F;$R!8D^)DE4U7,=/VO<40Z.'X@&(5=-VU.40$HA15/M[=.@V707NE
M;SRV913&89$8CU]L<[I,RX[7NA)YDJXR7JN+2"T@YJ"A([4]4,M>G5UKW3UL
M>H5TR3^0(P&^0L88`R#9%US2!B`RNI4`2=-9Y)$OQ(.7"8_CE'M.-0X:6?>F
MSY&S]@W*3()TS:Y6@Y`:LA[(;SI-U`O'4+JU;JVX-:)DBATN(S*-&?'C#267
M+,0R+B_(-@*@:EXV;<=O[P&@D5DHITW0.(\!$"KG+I:K/4FDO-+634`E3&D^
MC4%^Q8>#<M$;K8+A1`*YU,]H':2TIW*L8Q&^K/E<?7I>%ASK0[69LZYYJ`?M
MU2&14[W#R"[4=R:GQ)\PI"C7V@8!UTPLLVENUNE762X.U2@Q1PR.'W1QEO-/
M56FZ3;;5-+)LF:X.48XJ/9V=T,K^@MG&&R9CK.703D1TFM%7'#2USV"D[4W$
M%I+-N[7#&-T50VF49.Q([(`#V@/#2N_4!M:9)J96XZ5@=("->0._!?UF'0^D
MW><AK*G9=8\ZWN,V6"[CQ#5R7-!Q2)7^G)TLFPKFO/N8,LH!&V_TZ#<-M1+Z
M12*DW56;HK/7LVBLJ8"""$0`%*<*@!C`%:Z6>GH)\VXRZ.F&J94O"8*BF'6N
M=SIK=:7W2M.B11M>XG)0AS^X=\*[]:G41)]4W4OEW,TDZ569W#=#YI:[<P4)
M'VA$.#L85LF2H@4YVB0*'[/C-771;8VVW[3L-';&YB6IX*7'453CC''SJ5N6
MHWCOBKN[G$T\R:[2I)1HR`4X##(=L$C]`#&$M>77&K>Z;=12$Q?8$T_E')2#
MR$9*<*E'1R*BO`"JFJ<0+[0"O9H>]?*ZGHMJOIP]:J;-#=*\-).7""Q]+MEG
M7+?#:QK3RJ0<Q>":D1>]8>1$HB%0&O`>(C3LX\1#@'9I(P=(ERS[V?V1TT<"
M9<P,]XN!'M$)R?O#G2G%X^RSCWJ<M:).TB\N)R%KW\+5``8MKP@TFJL7*+F2
MX)NIN/74W'/3>=&E:CION@6[V3[-46"K<LZ1.:9:E26O4$!>#=.0PCGG]6&R
M9EJW!(W/;I?^;5LMW.(&`F,(4'TAPB^'[O\`];T;%VID+I9R?/A'LK,9S&2<
M?/Y9R0J*%MM"&6NJ%*HH(<LL?RQ<I$#@!1&FM1UZV-/%RD[BH)9=S48X-'$X
M`H!CCG$H^F+J/26R15[0N\T-HY5.Z<QSW8*,7-:I0*#@!!2O3YMN2SGDO-_J
M`WHV5%;+DPXQ]@=F]*.Z`P5:#SND>[:)J5%LI=DFV4<G$M-Q`*/M'0?WW5LL
M5LI]JT1#V2&"8\C\4QV)!3/M[L(-_2RV3]RW^X=3[PU)U8XR:9I_!*9@K5Q:
M2J%$7&")9KM=2\,-Y4M5L03.+@Q]=T4@0E!$73J">I-R%`?A^-4X!J&6*<R3
M?:.L.$N5/9EAAJ"^R"KNBDFW+;%PI&XU$RD>P#M(:Y(QK&)')<>=0.-5[D;$
M;I6CEZW$9MK((@=%/PVZ4&L@DY2/\`E)L'=7A3[-=&+Q);<+&:JB<7<RDP`.
M1#3E[8Y#61KK=O>0VXM`;*K&AX(P1K^(R(SSC)@1=K6')QT>_;VC:BR+YBR>
MHJIP$2=-1%RV163.0X-#@('(J`AQ&H:YP5%?<VUDVFG3IPY<XHKW<"1VYQU^
MI+38ZFCDU<FEI2R?+:X)*EHA"X>'OCLO(MD_^#+7_P!'XG_H6LGGJ[_OIO\`
M+=^N/5\O67_1:;_TI?\`U8^1L>SZ_#:%L%+3M\#BP"@<0J7NE!I^36`5U7S.
M?/GS@6^%OC?E[8^&Q6@MPIJ836E!^REY?R8MCC[*N(+DRIE'$EAMV1+PQ2W@
M"W\6+@TV,>P7N-`[N+C?$VZ*;9T^%L3>=(!W)`8*AQU[:NBKY%')K*HO,J>Y
MQ9J))0(IQ/>(TMFN6W:G<-9:[.R4VMHY;.<6-:T*_5I&`&6DK`=?WC'CT562
M!?;F"WJ>SAW!Z/M^S1GZ`?VLG_\`@_I,+_\`5>?]P:,G_2O\40,7]W"`0ZJ\
MQ5X?^4*']N(Z(WU$_P!G:7^D-^YT!SZ1?[85G]#?][(<DGF'BMOS<7Q_K.'D
MHX*<1J]9K-@H`]O%72A4+@RH:]Q1K9P)]16.@59)-1;)DAH4OD3&^UKA&,0R
MG;DOBC.=_P!NS**S21L'+$LS?-5BB04O"+K,](2@U$.8@3<`\:^P==(+5/D7
MS9<JI8]5EAN>:`1QPN<JHLFZG2:EI;/IJISAVX.)!C);87NF/O?$F+[MC5TW
M3&?Q_:DH@NB;>F;O,&R44`#<*T,(A[ZAKGE?9+Z2\U5%,".%1,'JUE/LCKUM
M.MI;[MF@N\ERB;32CGQ+&J/4<XNJD("`T]_\@:T[9392M'$Q)BY7%O\`!P^Q
M8M;F^XXZT<.Y4N>672;QT'8%VR+E9<P$1*1O"/#@!SCP`#FH'Y1UMK)*F3[Q
M2RI(+IAGL0#_``@OV1'=V54FBVS75500)+*682O^"4]I01C;^GZQ)?-W4QBR
MR;=9J/Y&]LM02R#9!,RAR,U[D))R*Y]H5!)LP3.)C#P``^W3_;@JY5AVG4U,
MYZ!E,H*H7(WW3V^B.1NT:2LW!U`I94ACB9]P#B!D!KQRP1(R*'49GNQ>DW!L
MIE;)#5\\LRT@MR&EDXQ`BZQ$)-XP@TU116H0[5,S@#*5[$P'2!V.T7*^W5TB
MEF`5)+IC40$8ZD7@0L=8MTW^W;3VVZYW667T+#+EN;F""`W$9)AQ"0,SJ-]$
M[H\ZKEB97Q^YE\.S]Y((7(,K8PMUK;FPED`>IOU8!019$.Y*X`QQ3,4!'V4T
M3;'U?W7M9S[35_MA)F(2[WE`0@GCE`3W'].NQ-^O&ZK(33^>E-F:1[BN"J`G
MA[P(&K=G[MAD!!98UE=0]N/F_$R"<];[AFX$0'X=QFAE"`)RAQ_+HF47U'TS
MF<FMH7AQ&+@,D@1W'Z1;^TN%#62G4W81C[</[\0<SMZ&W7)AJ!D+EBX&U\K0
MT2DJ[<^1I$5)HC1.HG.6'>E*Y=*%*%1*F!A$.P-2^R=<-L7,NIIY,E[\`"H^
MW*!KN/Z;]^;;E>9T>9H6J3H0GO5,?T1ZWT0.IZ_L&=8$%@UV^EF^/\KJ2\+<
MEE/Q<D:0=U1S=19&5;1RQ0&,D4U&HI+$"@4[=:_K'MBCONV!>+>UB2I?,#@`
M">W$8E0>*XQL?IXWM>ML;^;8[@Z8VW3M4ITDEV#SBTZ2?PZ<P,H:\S;ZB72'
MA:S+PN&XLZX\=2=NQTJ"=LQ<^TD)U_*M"+HI1"#!FHNN+M1X3EFJ``4>(Z6"
MS;&W1=KA+DTU+,%,YX<YSFD(,,02@3VF'@W-U:V78[=4S75]--KY3'%LMA)5
MR(`<^/>("=Z*WJ)X&MRWLYXVS#?\!C6X[KS)=64[65NI^A'QLM&7<\,\68-G
MJIR)=\8JT*)34$P&`:\=%WJ]L*_.FT=PMLHS4HF,?D4<'.X#$C$=\+O]/G5K
M;%$:ZSWR8*5L^M?.EN<J$O#06DY#+#CVPRICW+F-LLLW<KC.^;8OJ,CG`,G[
MVV91M*MVCPR?-*@X5:J'(DH9+C0>.E]J[;6VYX;7RWRYY&1""'#L]\M&X)3Z
MBT5$N?*EN0EA5%RBY)1J%1]^O+&WC95*!0J(^WV[0`.`_D[!U=[V`]Y,.U8Q
MO+)?C4,;Q7(CL,+C>L=Z3B6;XV6ZG>G2$0:Y;A6"CN_K/C&Y2)Y!BF)>\#(Q
M[=`"I%N9J4#&,%*N2`/:;M/G1GJP=NSO@>YFOF4A<`QY5050*<D7/NA2.OW1
M2EW#2G=.UI1-Q"F9+9I#2$4D!%7UY\($!Z#C=PS]12`9O$%&;YC860&KUHX3
M50=-'+=HDDNW=(+%34262.F("`E`0'1<Z\O?5;#?52F%LMT]K@6D$$J<#GA`
M'^FBFJY?5=DJ<U\N<R2\%KT!0`+AAC@(>R+\1A,'$2@-!H/&OY0XT[-)"T/,
MI9I'-(!P]&4=,]3@KL#++B#VX80J!ZV'I8W;*7C/=8'3S;3FX$IA$B^8;#@V
MBBTFE(MR`7SG#LD""#A)=N0.^$+4Q=N[33=%>IU)34CMMW^8V2-'[-Y7$J`G
M'%,<N$(U]0W1&Y5%=-WEMIO.EU4P-F2FM4R_"7%XTA45J%511"^G25G>8Z9>
MH[$^8HQ5TQ4LR[X\]Q-3$5;++P#IRFPGXUXW4Y1S%[HH<3`<H"`D#3!;JL=/
MN':<ZU2)TB?336.(<CM8*%,<L^Z%8V;?+AL?>--<YS3(J:>8P.:]KP"T.&I4
M0^[WYPW'ZUW6!;^.>B:.M[',FP)/=596#:/<19FY73BRWK1O)3DLJ=*AC@LS
M.5N*HU&HTTI/1S:,VNWG-G7<$4MN)"@$^(%`JKAZ(>KZB.HE-2],Y;;3-E.-
MW8!GX@P@%6@$8\"HSA-_#F%LG=0%]Q>-,/69,WO=<PY(W;MXIJ==HQ2.)2]\
ME7@!R8^/;)_&HHH(!M[-./=MRVFQ4GQ"Y5,EHE@Z6XC`9*#CE_>CGW8-JWS=
M-RDT5LE3'SGZ6G2US@W@22T$=^></R>F'T"0'0C@X+8=N&\QE:^#MY_)UP("
M*B2\CRMK>%CSJ@*@1<050Q"\?B/4?=I"NI6^7[WO\R9+PHF$Z0%3--6).?#N
MX1U"Z,=+)73?;Z3R'W6H:.8Y$`&8:,`5!S6"7<L!"@B(@-:APH-?9V>[0\+`
M7M?Q:,(,C5;B(B5UN],5L]7'3ED'"T^@CWR<AW3JTY$Y`,O#7:Q2%6%D&Y_O
M)B#C\,XA^@<=2;:6XG[:W#37)I\(F>((=)''4G9F,8'_`%,V93[VV?5VAX/F
M"S5+<`I#L\,#FB>R$)NF#I9R_D3K)M[IA:DE;7N]M=LE:V17;%9RS<PUK1+C
MNMW.72J!2'3CWL:F8I0'X5N:7MKIYMV[MH&;(;N"I8R93<G7*P.ETU/"UW'2
M3V$'L,<P]H['OURZ@RMITLNI%4*MLN<Y@(T2=0YCG+@`&J<<%3",BM8%CP6.
M+*M:P+48HQ=N6?!1ENPC!N0A"-HZ+;E:I%VE*!:F!/<(^T1$?;KGW7UHK:]]
M5,.J:][G'CGD/0,A'6>RVN78[336VE"RY$L,0Y89NP3$G$QZ\Q#"FJ4#5$0.
M`5`/B$P``U`>`A37G30WPGQZM03[HV<F5HF`O.J7^OMA,OUE?2SOC'62KJZI
M<$6N^N#%UYNEI^_X"WVBSJ1L*YP$JDA.D9()***0[\X<T3)E'E'TWW2'JC1U
M="VQ7J9*DU[6"6S7JTO!!!.:`A!V9QSWZ^]%KY9[W-W58)3JJUU4V9,>)::I
M)&ER$!"CE*$+D8(AZ3GJ[8QR+CJT.GSJ'NZ/LC+MDQS2WX.XKB=%CX2^XEB0
MK=@`OUQ(1I-M&I2IJ)+"&\0X4T/.J72NXVJX3+U;0*BAG$S#R\=).)*=F.6<
M%?HKUZL5;:J?;&YW"BN-,P299>2`\Y#42J.P[A#"+*X8:1:@_82\.^8'3*JF
M\:R+59LHF8NX%`72742V"4:@->S01FTT^2[1-ES&S.P@K[$6&ED7:VU$KS$N
MHDFG/X@]I'WQ!_JCZ[+%PRV&P,:E1S-U%W20\78&'[%<(SDPK*NPY#.5N11F
MHHC!6]'JJ`HX67$@;"B`<=2"P[5FW2>RIN.J1:&.#G/>-*@9Z5`SR&8@:[VZ
MFVBRRW6FRS&UNY*D%DILI7M83@#,+5`()5-0]"1M]*&*T>D3!]R7OGR\()#)
M=^S3W*.?;]E'Y&T(UN.=6**<>D]7'8E$6\W539H!N`M""(<!UFW)<VW^[LMU
MJEO-ND`-DH/>[3ZT'J2,O3[;;-B[>F7G=$YDNYU/CJ)CB,44M:O\53VXF!'>
MO=U'8'RQTB6=`XURY8%[S:&6(-\I$6W<3"3D"LDX]^4[L4&ZQS@@F>FXPA2@
MZ,'0FRW.W;JGON=-/E-,CPG2@!7BHR3LXI``^IG=^U]P[,IK?9:Z1.JV5&HL
M:27(@&`$#K]`3+F,\5=2N5YO)5]6M8T9(8M;Q\>]N67;1;9Z\+,D54;(*N#%
M(=4B1=U*UIH@]?K96W+;TF5:Y,V?4LFM?X0H`&H%4"\8$?TR[AM&U]VSJJ^5
M4FFI)TETM7J"20TA/8F4..XXS]A;,#U_&8MRA9=^OXE!N[DVEL3;25<,6K@X
ME27<IMCG%)-0Q!`!&FDZKK-<[9*9Y^3,DF<2A<$4@*0(Z&6+=FVK^YTNR5<J
MH=)'B#2I0]T+8^M7Z5-Z7C=L[U:].EMN+A<R[1-UE^P8A(R\PH\:-CD"[H2/
M(``[,*!?UI(E3B)1.`"(CIB^D?4VW4]N;M2_S!):S%KT*GN.8P]'KA/^O_1&
MKFW.;O3;<N=/=,*OEC3I:>)``#D*]IRB^7H?^HA9ER8FCND+,-R-[2RQBU16
M+LPEUN/"5+KM:HG;1R!9`43DE841%,R1J&,3B`4#6@ZO]/;K)N7S-89?F;;-
M.IQ:-1QQ!1N.(1</3$E^G7J=;9=D9L[<TUM+<)$TB7J**A]PEV"CAE#&";U)
M)-145VH(5$X+'7(1,J92@.\5!,"9B"7CN`::`3>89C@V5-,PN0@IGD@&:0V;
MY[6,=4NFR.2YP(=J1H:@S).?K2%X?6J]0NV&&+I;HYP-,EO_`#/EH2P%W-+)
MWSJMLVR=4G>HQ4(TKD5I67,()`F2HID$1,(:8#I'L:JEW27NO<+336FG:\C6
M$+B6.:"AQ`!.'>ARA7^OW5&F=:)FQ=J,-=<ZX!CG2U=H`<'$-TX*0W',(L=3
MZ+/I6W'T^.D>I_J%A$XO)<O%+,,<V*N!7+FQX>2(4SJ6ES4$J4W((%`"D^\B
M0:=NL_5[J;1[@E-VQ9'!U))*/F!07?Q3BGV1KOI]Z+5=BF#>>XI9EU>@\J44
MX_B(Q=J'#'U1-_UL3(E].#/1EQ+R^[VZ"@G-M*`#-,P#A4-QMPT`H<1'@''4
M!Z/,8.H4L%&@L()F+RT08X)P[X)?U$/FGI76-IPA=,E]QS5`O$Y1!WTI_4=?
M8YQ%C#I[ZTHN?Q0JI!-!PEEJ^6#Z,M&^[05*5.&AUIMR@5LTDXY(2I$%4Q04
M)MXUU-.I^RZ:?>Y]SVS-94'5^V9+3"9F=(.)&E.U3`KZ)]6GV"STVV=]-FTU
M.6M-//FM<&NE$`>\FE`\8>DK#%4-/P5Q,F\I!2L5,1[I,JR+R+DV<@V53.4#
M)G36:K*I&*8!#VZ!DR774TPR:Z3,DO'\()]B+#;TMTMM;+;46V?*J)#A@YDQ
MI&/K,='>^1;&QK!R5T9!NNW;1MV+:'>/YB>E&;!JW;I`(J?YPH510?<4@&$W
ML#6>EMMPN4T2;;+=,J'$`:6DE>\Y`>SOCQ7?<%FL=.^=>:B1(HVL+BZ9,8%[
MFM)4^PK"P7I[],B74WZFN:>N.U+9>0737;MZ7-*XWFG<<O&LK^N"0*I&K2,"
MBHFD"L4=455Q4``*.X*!IC-\[I99-@TVTS.#KV^4P/85+F@8NQR1<.)RA->E
M^QG[LZKU&_:>6YFV94Z:YA<PMYCC@S2H&"*<.T1,JY?V#GFNX?,_T]^:?')+
MQ[Q#Q/O_`(UWI?Q.N[X>=WK=OV^W4+I_S?Y(\GS.0GX.6J04)_\`P\^<J/B/
MEO,?BU\U%Q5-,=&[_P#K^[$N]_3AR^9^'S^_UWT)79^EV;>S^YK+)_.+RYYG
MF.7K/[W0O#+NCSS_`/AQ62GD^1I\/+YOO*?>_$OV)!)>AOZ(_)UY?1#Y(\F^
M8DO-OD7O/AWF#NOX7>.\_'SN[=E.&A_NOYB\XSX\G-0Y:>[^#A!0Z;_(G(JO
MD9?+:VZ_?1<435$YR=GY_P"0-1:"9'RM]TM:4W<:^Z@_FKKY^(=J_HC',73^
M'2N*Y)'#-7:/+V[:#6NS;V#3\]/?PUBF\_G>+F(GATIFG?\`\BQ\F<KDCE<K
ME+CJ5$XY0O%CKZ2OVW!?D37S_P#*^\/FGY=Y/DKS;W<O?>5R_P!7\:Y5.]=V
M_#YM=W'3!UGS7^2?^N.;Y?6-'-]]%P^U842T_)__`!$GY<_?:7:N6O+72-6>
M/9W=D,3$KQ_F\*?=I7]*E./;I?6\O2S4G/TC[L.Z&_*:#H_A%?;[(XKCE[%>
M\;.[\I3F\[E\GE[1YO,W?#RN77=NX4[=7.Y^EO+U^8U8:=*YX(N&:98Q:_1R
M7?NO*Z2NI?6O!(79]0+]B;XM,_.SRC\S^4X\0^3G>?'^]T'9XCY=_JWG[NVO
MQ>_3#["_.'D-\ES?AJ8\_EKIX]^7K[(4CJI^0_/?\9T?%D*<G6NI,.[/U>J(
MLY9_9C;>EOZI/GWY`^337Y+^:/&O!/)'B9MO>>[?C<W[N_?^/RZ?HTUNML_/
M'EKQ\J^5U:SS/X:X^[KXYI`]N_Y6I:/FSSOE^4-',7E:,%]S%,LH/#T/?0AY
M&)]%/RK\&[JEXAY-[MYEY5>'C7>?Z[W;_O;_`(:Z"F[/G?S'^]GF>;AGHTHG
MA71X5TIWPT'3'\L?)-_+KRG,5VOW]?O%?WGBSR3AE$\4*<SV5Y?LVUINX5IJ
M&8\$T^I5]4%^9KU<="=VE?O7[(YFJBR.,OMW([OYQMO9]Z@4^VON^W7Q_,Y3
MN5[Z=R^I</;'UO-UC1JT(51$]:X^A/7`S\2?1)^T'SY\N/#_`*L_(\'\R>53
MD>%<W\;N&[]6\2V\GOW)_&I3?HAW;Y[^0J'S_F?E?GC3^[3NU<=*_P!Z`CMG
M\O\`\SKG\"7YRY3N8FOE\-2+@O;P2"8DK[*5X?P<:TT,/V'/_9JL&WQZ1J3F
M8+_>C7^=7WCM_BIV:]?@U>#]XD7-3#3EQCII;N?<'GBW=O"^[*]][]W?N7==
MAN\=[Y_ZOW?EUW;_`(:=NO53<_4/+:_.X)I]Y>&F-=<O)>7?\0Y/D$*ZM:)Q
MU)A"V_6_^PL\T2OS`\N?,JI^]_)#OG??$]YJ]Y\!_4.^\[[W+^*NF`V=^;/(
M;S4^'_\`U>G+[T_1"<]1?^'7SIY^OXJO_P`/F>]WK@J_;E$2\6_L]MR7A_U_
M^0.8//[K\S/+G=Z_%L[KQY7*IV<-M=;V[?-/,/F/@O.3#W57[XAME^5N>/*_
M,?P/O]Q/O@\W0E^S\[F]^DKRCYLY!O,?C7>/FSR^&_QGS+_WCY.[MV_A5T%-
MW_-_+?\`&?ZI4IR$Y?JT<.Q8:#IS^7&@?+/*^((%\PO.7_G8KVI$M>H_Y&_)
M:^OJ.\`^3/AB7GKS)S/!/#.\);?$.3\?)[QLIJ$[?^,^?E?"=>O4.7JTKGCG
MZL\8GV\OESX#,^:OZL_$FM%[D@."/_U_]B?=_IS^Z2FSQ.O+VC]VOX>W;V4X
M4T:)?YR>=G<CG<WDXZ.5EW=\+]_^MOE6:O+<U?Q\_6G%."QHZ_8`["<_Z=MF
M\*5\1W;OLY?';M[=7C\Z^2_7YG2F.OE>[QCQ3O\`AGYC.=R$7#]\J\$3A$W^
MAK]FYYFOGZ'?EGYF\(C/.OD3O7>_!^>;PSOO>>'(YU=OMU!=\_./D*;YG7R^
MK]GIT:EXKIX=L%+IC^5_G:GY$3S2#6NM$[M4$@7W[!W4V?XS=R]O+X[MV_AM
M[:ZA;E4<M>=PTIJ^V"_,Y?(=S.7Y?'5KU)WY0"7KQ_8Y>9T_GQY1^<G//W/Y
M/]Y^8_BG-_`W^3OB\1YG9O\`Q.VNC+L_\TOA[O*\[X1^+S"(G=Q1,DA4>H_Y
M!>=_SC^T*E/)<S5KXK^!5S[X@W&?2_0?&_VDORVY1:]X^8?A7A&WXN;R_P!9
M[IW?W\::DTKSW*/+^%<_5_%75P[_`&??`RH_ANMWF?F?X!J\2II1/Y2)!->@
M3]E-W]?Z5_(/S0YQ_$_.O.^;7?-WQ]Z\X?UIWG=7=R_BK7[-0K>OYF\G_6/-
M^&I_V&G1I[TX>F#UTW_)CS;/EW3\:1VGS7,UKI.I-6"HN7J@QJ=?BW4W4]FV
MG9PVTXTK^:NA1*TI_E.*IJ]:80PDO5RCHT:TPTJGVX18;J3^0?RBGOJ5\N_*
M+O<3Y@\V[O+_`#O$$/#/$=G^+[_LI7A6E>&MMM[XWYP_"M7G$<B:=6E<47#L
M[XC6\OEWX,_YOY7P?6Q>9JT:N"Z/%FO='CLZ_2'\CV_U`?*7Y&^!-?!?-O@W
M@/@_=4O#_+O,_%KW79RNZ_'3;[=;.U_-?QI_POS'Q+6=>2:E_$N"]B^J(SNC
M\MOEF7\Q^0^7.4WDHNK0GAY?XT]''/&%_+@^@/Q)S]+OUK>7N<ZW?)?YD^3>
M9S24\*[Q^I=PI]S9\/NT7V?,&EOS%\-\ZF',1?7IP6%2O7ROYL?(WS!\*4_^
MW_=_]/Q)V1[_`!Q^S0\;M_ZG_J/\6[ZV\.^J'S[Y)[QS0[MW[O/]3\KG?\?\
M%*UX:PW7YQ^''X!\-\OJ*<C1S=7'/%,DC;6?\L?.T_YA_&/,ZQI\WS-"+X-7
M+\"?;VPQQCKR!Y3MSY7>6/(/AA/+7DWN/EGPO8GRO#?#?U'E_P"#Q]^@1<?B
J?GS\8YWQ#'5S$5?7XD[$P2'*L_P?R<KX+R/AFD<OE>YH3BF&K+/&/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>pg5a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg5a.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`&.`IX#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#[S_8L_8Y\
M*?M*?!_PAXJU'PSXY^(7Q'\1V?B[Q1XIU6X^,7Q/LK[463QWK&GSZE<;OB#I
MM@&$EQ8P&.WC0_.I6+:KL/LC_ATUI7_1%/&__A\OB)_\]:O1/^"('_)+O`__
M`&3#QY_ZMN&OWYKZ;,\<\%C*F'HX;!^SA9Q4J+ND^BY)PBDK))**LDNQ^69=
MPGA\^J9OC\5FV?4*G]OYS05+!X^%*A&G0QU6,%&%3#5I1M'1I3Y=$E%+0_G"
M_P"'36E?]$4\;_\`A\OB)_\`/6H_X=-:5_T13QO_`.'R^(G_`,]:OZ/:^!/^
M'@G@_P#Y'_\`X43\?O\`AD/_`(_?^&^-GP+_`.&6_P#A#_\`CS_X6W]@_P"%
MZ?\`#3'_``H'^VOW?_#1'_#.?_"B_P#A7?\`QDU_PL/_`(9#_P",@JX/[8K?
M]`N!_P#!$O\`Y;Y+[CTO^(=9=_T/.)__``YT/_F$_+W_`(=-:5_T13QO_P"'
MR^(G_P`]:C_ATUI7_1%/&_\`X?+XB?\`SUJ_<#Q]^U=^RW\*OBEX+^!OQ0_:
M4^`/PW^-?Q(_X1S_`(5W\'_'WQC^'?@_XI>/?^$P\17GA#PC_P`(7\/_`!#X
MCT[Q9XI_X2GQ9IVH>%_#G]AZ1??VWXBL;S1-,^U:E:SVR'B[]J[]EOP!XZ\/
M?"_QY^TI\`?!/Q,\7>/X/A1X3^'?B[XQ_#OPWXZ\3_%*YT?X=^(;;X:^'O".
ML^([+7]:\?W&@?%_X3:Y!X.TW3[GQ%+H_P`4/AWJ<>G-9>-O#4^IG]L5O^@7
M`_\`@B7_`,M\E]P?\0ZR[_H><3_^'.A_\PGX?_\`#IK2O^B*>-__``^7Q$_^
M>M1_PZ:TK_HBGC?_`,/E\1/_`)ZU?N_K/[0?P$\._&/PG^SMX@^-_P`(="_:
M!\>:!<^+/`WP+UGXE>#-,^,?C/PM9P>);J[\2^$_AC>ZU!XV\1:!:VW@SQA<
M7.LZ/HEYIT$'A3Q+-+<K'H6J-:X'_#5W[+?_``O3_AE[_AI3X`_\-,?]&[_\
M+C^'?_"]/^1/_P"%A_\`))/^$C_X3_\`Y$#_`(KG_D7_`/D3_P#BIO\`D"_Z
M;1_;%;_H%P/_`((E_P#+?)?<'_$.LN_Z'G$__ASH?_,)^'__``Z:TK_HBGC?
M_P`/E\1/_GK4?\.FM*_Z(IXW_P##Y?$3_P">M7[O^&OV@_@)XS^(-S\)?!_Q
MO^$/BOXJV>@>+/%EW\,_#7Q*\&:[\0;7PMX#^)>L_!?QSXEN?!FEZU=>(X-`
M\&?&+P[X@^$_BS69=-73O#OQ+T+6?`FL7-GXITR]TJ#Y#\>_M^^/?`_Q[L_V
M=K?_`()U_MN>-?&WB+0/C'XX^'NJ>$_%7_!/B#PM\2?AI\#?&?PQ\#>-_B1X
M:O?&7[>7A#5M&T`ZM\:?A5<:-H?Q#T3P/\0;_3O&=M-)X*M;G0O%MIX?/[8K
M?]`N!_\`!$O_`);Y+[@_XAUEW_0\XG_\.=#_`.83\W/^'36E?]$4\;_^'R^(
MG_SUJ/\`ATUI7_1%/&__`(?+XB?_`#UJ_<#P#^U=^RW\5?BEXT^!OPO_`&E/
M@#\2/C7\-_\`A(_^%B?!_P``_&/X=^,/BEX"_P"$/\16?A#Q=_PFGP_\/>(]
M1\6>%O\`A%O%FHZ?X7\1_P!N:18_V)XBOK/1-3^RZE=06S\!KG_!07]@GPQH
M^H>(?$O[;O[(?A[0-)_X5?\`VKKFN?M*?!G2='TS_A>'@74_BA\%O[0U._\`
M&EO967_"W_AGHNL_$3X7_:9X_P#A/_`NDZGXN\)_VMH%A=:A$?VQ6_Z!<#_X
M(E_\M\E]P?\`$.LN_P"AYQ/_`.'.A_\`,)^/W_#IK2O^B*>-_P#P^7Q$_P#G
MK4?\.FM*_P"B*>-__#Y?$3_YZU?N!\1/VKOV6_A!X%@^*'Q9_:4^`/PO^&=S
MX_\`$/PHMOB)\1/C'\._!/@6X^*7A'6/%WA[Q9\-8/%WB7Q'IF@2^/\`PQK_
M`(`\>:'XA\'1Z@WB+1=8\$^+M,U+3K:]\-ZS!9<!?_MV?LMI\=/V:OV<?#WQ
M?\`>._BS^U?X`U[XQ_"#P]X+^('P[U3^V_@7H?@_5O%T/QMLY[OQ?IW_``E/
M@#Q3_9T&C^`4^'<?C;QAX]\[Q'XV\(^$]7^$WPB^/'Q$^%1_;%;_`*!<#_X(
ME_\`+?)?<'_$.LN_Z'G$_P#X<Z'_`,PGX_?\.FM*_P"B*>-__#Y?$3_YZU'_
M``Z:TK_HBGC?_P`/E\1/_GK5^P.H?MY?LA^$_`NF?$;XL_M&_`'X'>$]?_L/
M4_"VL_%K]H3X`Z!H_BSP+\0=8^*%M\"OBAX;\2Z7\4-=\)ZGX`_:1\)_![QY
M\3?@9J$>OIK'BSP+H&OMJ6AZ!XL\&>/O"?A/U[XC?M!_`3X/>*?AEX&^+GQO
M^$/PL\;?&O7V\)_!OP?\1OB5X,\$>*?BUXI34=`T=_#7PR\/^)M:TS5O'FOK
MJWBOPMI;:-X5M-5U%=1\2Z!9&V%SK.G17)_;%;_H%P/_`((E_P#+?)?<'_$.
MLN_Z'G$__ASH?_,)^$'_``Z:TK_HBGC?_P`/E\1/_GK4?\.FM*_Z(IXW_P##
MY?$3_P">M7[@?%']I7X6_#/]G/7/VH;;5O\`A:'PSMO`&F>/O`?_``J&_P##
MOC;6/CG_`,)=:Z?_`,*F\%_`CR]>L-`^)OC_`./.OZ[X3\#?`GPYHWB!?^%H
M^.O&W@SPSX:O+F]\2:;YWS%\2?\`@IW\!/AI^R5^R)^UO>^$?B]XCTG]NO7_
M`-ESP/\`LO\`P;\-:!X,/QC^(GQ+_:[T33?$WPI^&]R_B+Q_X=^#O@S7X/#E
MUJFL^+-<\<_&#PY\/M'@\-:S9VGC75=6N?#FG:^?VQ6_Z!<#_P"")?\`RWR7
MW!_Q#K+O^AYQ/_X<Z'_S"?FY_P`.FM*_Z(IXW_\`#Y?$3_YZU'_#IK2O^B*>
M-_\`P^7Q$_\`GK5^X'_#5W[+?_"]/^&7O^&E/@#_`,-,?]&[_P#"X_AW_P`+
MT_Y$_P#X6'_R23_A(_\`A/\`_D0/^*Y_Y%__`)$__BIO^0+_`*;6_HW[0?P$
M\1?&/Q9^SMX?^-_PAUW]H'P'H%MXL\<_`O1OB5X,U/XQ^#/"UY!X:NK3Q+XL
M^&-EK4_C;P[H%U;>,_!]Q;:SK&B6>G3P>*_#4T5RT>NZ6UT?VQ6_Z!<#_P""
M)?\`RWR7W!_Q#K+O^AYQ/_X<Z'_S"?A!_P`.FM*_Z(IXW_\`#Y?$3_YZU'_#
MIK2O^B*>-_\`P^7Q$_\`GK5^T'P*_;`^`G[0L^EZ/X&\=Z!:^-O$6@>/OB+X
M/^&>O>)_!D'Q+\=?`3P9\8_%/P7\/_M1^"?!FC^)M:U;Q/\`LQ?&75O#=IXP
M^!_QMTN*?P9\1/A]XS\"^(+*^M;GQ%%I4'0>`?VKOV6_BK\4O&GP-^%_[2GP
M!^)'QK^&_P#PD?\`PL3X/^`?C'\._&'Q2\!?\(?XBL_"'B[_`(33X?\`A[Q'
MJ/BSPM_PBWBS4=/\+^(_[<TBQ_L3Q%?6>B:G]EU*Z@MG/[8K?]`N!_\`!$O_
M`);Y+[@_XAUEW_0\XG_\.=#_`.83\/\`_ATUI7_1%/&__A\OB)_\]:C_`(=-
M:5_T13QO_P"'R^(G_P`]:OV@T;]MK]C+Q%J/BS1_#_[7/[,6NZMX#^$-M^T'
MXYTO1OCW\*M3U'P9\!+SPMX:\<VGQO\`%EE9>*Y[GP[\(;KP3XS\'^,+;XE:
MQ%9^#)_"WBOPUX@BUIM)UW2[NZZ#6_VF_@KX`_X4;HWQS^(?@#]G#XF?M$?V
M1IGPO^"WQR^*?PC\*?%+Q/XZU'_A%[74/A?X7TK3/'_B#0/B/X_\-:_XR\-^
M$];T_P"$OB7X@Z/+XBUG2+;0-<URRUO0[_4S^V*W_0+@?_!$O_EODON#_B'6
M7?\`0\XG_P##G0_^83\/_P#ATUI7_1%/&_\`X?+XB?\`SUJ/^'36E?\`1%/&
M_P#X?+XB?_/6K]W[G]H/X"6?Q+T;X+W?QO\`A#:_&+Q%K_B7PGX?^$]S\2O!
MD'Q+UWQ3X,^'WA/XM>,/#6C>!)=:7Q3J>O\`A3X5>//`WQ,\2Z-9:5/J.A?#
M[QGX3\9ZI;6OASQ%H^I7F_\`"_XK_"WXX>!=#^*'P6^)7@#XO_#/Q/\`VG_P
MC7Q$^%_C'P[X_P#`OB'^Q=8U#P]K/]A^+O">HZMH&K?V3K^DZKH>I_8-0N/L
M&L:9J&F77E7ME<P1G]L5O^@7`_\`@B7_`,M\E]P?\0ZR[_H><3_^'.A_\PGX
M`_\`#IK2O^B*>-__``^7Q$_^>M7B7[1?_!.CPA\(?@O\1?&NL_#;QMX6?3_!
MOBY]$U@_&GXFW3V^OVGA37-6TUHHK7XEWK>=$=,ENHVE@,&;?;(265'_`*JJ
M_.C_`(*F_P#)G_C_`/Z\/%7_`*J_XA5W97F,L5F6!P]7"8)TJV*HTZB]@W>$
MIQ35I3E%IK1J46FM&CAS+@K"95@ZN88?.>(JE;"2H5:<*^8TIT926(I1M4C#
M"4Y2BTW=1G%^9\`?M_?";]J']I7_`((B_LY^$?V;-'^(_P`1?C+KW@#]B[Q1
MK%AX)\<0>%_&_B'0;/PWX/U;QC>S^)=8\6>%#?&0.-0U:*XU\76I%9)7CNI`
MPK^6+_AUK_P61_Z-@_;!_P##_P#AC_Z(2O\`03_8A_Y,N_9#_P"S7_@#_P"J
MH\)U]05\O4A*?*HU\11Y;O\`V>O4H\U[?'[-KFMRKEO?EN[;L][B3@G+N)\5
M0Q>-S/B/!3P^'^KPI9/GN.RK#RC[2=5U*M#"U(0J5FYN+JR7.Z<80O:$;?YI
MG_#K7_@LC_T;!^V#_P"'_P##'_T0E3V__!+?_@L2KDW'[+O[8<B;2`$_:`\,
M`ALK@\?M#IQC<.IZCCN/]*RBJPSJX7$4L1'$XJLZ4U-4L3B*N(H3M]FK1J2<
M*D-KQDFM%V1\V_"+(9)K^W^.U?JN,<X3Z;-5KK;IW?E;_->_X==?\%?O^C6/
MVQ__`!('PS_]$71_PZZ_X*_?]&L?MC_^)`^&?_HBZ_TH:*]__6'%_P#0)E7_
M`(;<-Y?W?+^K*V7_`!!W(/\`HHO$#_Q-LZ_^7_U=^5O\X+PQ_P`$P/\`@JS;
MWLTOBC]D[]LZ]L#:R1PV]K^T'H"3+=F:W:.8M#^TI:?NQ"MPA!G;YG4F(X#K
MW/\`P[,_X*/_`/1G'[;W_B0^C_\`T4U?Z(E%>;B<?7Q55U9<E%N,8\F&@L/2
M7*K75.G:*D[)R:5VTNQY6,\!N',96=>7&'BKAVXQC[/!^)'$F%HKE5KJE2Q,
M8*3WE)*\GN?YW?\`P[,_X*/_`/1G'[;W_B0^C_\`T4U'_#LS_@H__P!&<?MO
M?^)#Z/\`_135_HB45A[:M_S]J_\`@R7^?DON.7_B7SAK_HM_%_\`\6AQ1_\`
M-9_GJQ?\$Z_^"EL,4<*?L8?MB%(HTC4R_&/P+/*5C4*IDGG_`&DI)II"`"\L
MTDDLC9>1V<ECIP_\$\?^"D"QJ)OV+/VPWD&=S+\7O`@!^8D8_P",DEZ+@'Y1
MR._4_P"@O171EN,AEM>IB%EV5XZ52G*FZ>9X&ECJ,>:<)NI"E5]U5;P455LY
M*$IQ32G*_F8KZ,W".)Y;<;>+^&:DY2EA_$G/.:HW;XY5W7>EFUR\MVVY<S4>
M7^$?_A@K]KS_`*,`_;B_\//X+_\`HMZX;XF_LK_'[X,_#_Q=\5OBI^Q3^VKX
M)^''@'1+SQ-XU\7ZE\7-!OM.\->'--3SM3UJ^M-"_:FU;6)[/3[<-<7*:;IE
M]=^2CF&UE8!#_?C7YR_\%>O^47_[>'_9L?Q5_P#4;NZTI8JC.I3@\KRFTIPB
M[8*-[2DD[>]V9\7C/H?\'T,'BJU/Q6^D0IT<-7JPOXR<1-<].E*<;KEU5XJZ
MZI'\C/\`PI_P;_S\^/O_``[?Q8_^;6OTO_X(F64OA/\`X*(_%'PCH^N^,&\+
MZC^Q=?>([SP_K7CGQEXGTF37[+XX^"],M-86Q\3:[J]O!J-OIUY=V45W`D4R
MVUS<0A]DT@;X@K[M_P"".'_*3/XB?]F*:O\`^K_\!5[^88'!4<OQE2C@\+2J
M1IT>6I3P]*$XWQ>'B^648*2O%M.SU3:>C9_F!]`OQ*\1N)/I,<&Y3Q%Q_P`;
M9]E5?*>+YU\LSKBK/<TR^M.APOF=6A.K@L=CZ^&J2HU80JTI3IMTZD(S@U**
M:_K#HHHKX\_W_"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#\!O\`
M@B!_R2[P/_V3#QY_ZMN&OWYK^=7_`(([^/\`PC\./@S\/]<\9ZM_8VEW7@#Q
MOI5O=?8-3U'S+^?XI2WD4'D:597UPNZWL;J3S7A6%?*V-('>-7_:;_AJGX"_
M]#W_`.6OXS_^9VO?SO#8BKF-:=.A6J1M%<T*4YQNKW5XQ:NNNI\)P[G.48*E
MG%#&YKEN$KKB//I.CBL=A</5499A5<9.G5JPFHR6L7:SZ,QOVVO@MXI_:2_8
MR_:Y_9V\#7^@:5XV^/G[,7Q[^"W@_5/%EUJ-CX6TWQ3\4_A5XK\#>'[_`,2W
MNCZ5KNK6>@6>K:[:7&LW6EZ)K.HV^G1W,UEI6H7*16DW@7B7]M[X@^/-.MOA
MQ^S7^RU^TZ_[1VJZ_P"$_"OBBP^/G[-?Q+^%GP<_9NT[6?%.C>%/B9\7?B#\
M8?'MY\,/V?OVE]`^`$>JWFOS?"S]C?\`:2^*?BG]I&?1H-/^!WC)_A?JNN_'
M_P`!^K_%?XL_LE_'#X6_$KX+?%#7_P#A)_AG\7_`'C'X7_$3PU_97Q+T7_A(
M?`OC_P`.ZCX3\7:'_;/A[3=)U_2?[6T#5M0L/[3T/5=,UBP^T?:M,U"RO8H+
MF/\`$C_AQ+_P;:_]&L?^9O\`V\__`)[U>3]2QG_0)B?_``15_P#D#Z'_`%DX
M=_Z'^2_^'3`__+R?]K3P;^TM\:[7]HGX$+K_`.WW\/\`QS^U5^UYI/P0_:8^
M#O[./[&/[/ME^RC#^PO\6_VC/`?[(%Y^T7K'[5GQ+_8U\7:Q\4/'_B3_`()N
MM\,O$GC;4OAS^UE\:?C!\&?B1JLD^O\`PI^$_P`!_P!GGXH^"O@%].?$/]GS
MQ3XX_9B_X*M>+K3X(:_X=^,7_!4;]IW6_P!D?Q!%;?#74;GXE_#;X"3Z_P##
MG_@D;X/^.NLWT6BZ?XI^+'PA^'_PJ\*^.?\`@I/X:T*]B\&>#+#X??%?Q9X6
MTOQMI/ARZUC]H#Q!\N?\.)?^#;7_`*-8_P#,W_MY_P#SWJ/^'$O_``;:_P#1
MK'_F;_V\_P#Y[U'U+&?]`F)_\$5?_D`_UDX=_P"A_DO_`(=,#_\`+S[B^#FG
M3^(OB#X]_9Y^,G[-'Q>\=?%7XJ?\%&OB=^U)^T1\0-9\(?&/X9?!SP9\-/V>
MOB7>>-/^"=/QT\)_'&P\':7^SC\9]?T#X7_LR_\`!-KX27/P`^"_Q1G^(,\]
M_P")?&7Q]\&ZMXI^'?[4-C=?(?[$O[.WC/Q;\-/V1OV7OC?\?_\`@JSJ?Q#^
M%VO_``$^.'[4GPC\6?LE_`3X6?LQ>'OVD_V?_B#X4_:A^(FO>)?VN?&_[`GP
MWU']I30/%'[9O@FRBUGQU\!?VL?V@/C;^T;K_CFY^,>H^-OB/\/-3^+_`,=]
M$YG_`(<2_P#!MK_T:Q_YF_\`;S_^>]1_PXE_X-M?^C6/_,W_`+>?_P`]ZCZE
MC/\`H$Q/_@BK_P#(!_K)P[_T/\E_\.F!_P#EY^O_`/P3)^%'_"M_V.?ACXO\
M0_#7_A5GQK_:B_M?]M+]J7PO>>#O^$'\16/[4G[6U\_QR^-V@>(]$OM.L?%E
MK_PK?Q9XPG^#_@O2_B)<^(/B)X/^%OPY\`_#_P`7>*O$FI>$'U>ZX#Q-IG[1
MEA\=/^"H/[1'P!^%_P#;'Q,\/_LA_L__`+./[-7@[XJ:?=>&O#OQP_:,^`/@
M_P#:J_:7T'6-%U&_USPAH&O?`'Q-K_[:?PK^#<OC:+XB^$[J/XI?#CX_>$=:
MD\&V7@72?%_B'\O_`/AQ+_P;:_\`1K'_`)F_]O/_`.>]1_PXE_X-M?\`HUC_
M`,S?^WG_`//>H^I8S_H$Q/\`X(J__(!_K)P[_P!#_)?_``Z8'_Y>8VJ67[0O
MA_QGX`\8?LQZM_P4:_:`^#O[!/[$?[<_[2G[-/P[_:7_`&!OA-^S%\'+_P#;
M7^#7P$\-_LY?LN_LU^#OA!\,?V'/V*_VE-1T"?X,?M-?&F+3O`6C>'_"G@CX
MDSIX0T?X!^/?$WB/X+_&[PEX'^W/A/\`"'P+_P`$Q_C5X4^&_@OX$?'[XC?!
M3P/^P)^S1^S+^Q?;?"7X$ZQ\6=8U;XN>&_BY^TMXE_:QM/$GBSX9^#-%^"G[
M,_C_`/:8U+6OV//&OQS^-7Q^US]F?X*_';QUHF@>./&GQ!GTWX$^+]9^%_QY
M_P`.)?\`@VU_Z-8_\S?^WG_\]ZC_`(<2_P#!MK_T:Q_YF_\`;S_^>]1]2QG_
M`$"8G_P15_\`D`_UDX=_Z'^2_P#ATP/_`,O/)_V4_AIJ/PPT3]GS]H?3?B5^
MVY^RE^S]\?/V(_"GQH_9A\*_L`_L4>%OVL_"WPBU']M+]K7]KC]N;]H3]FZ'
MPWI7["'[;%S\$=`^$?@GXV?L8_#"/QAH?@W]FOPM^U'IWPD\&:TOAGQ))\$-
M-\$?`K[<^%7A7QU^QQ\2/CAXLM?@I^UY^T)XL^!7_!,7XH_M4_L\^'OBAX'T
M>3QU\0/VC/VN?VKOVJOVL_\`@H!^SKKGQA_9.^%-]^RK=?'[XD?%'P?^Q9X:
MTSX9^"+;QO=>&='T'3]9_9T\)^(_">I?%;7/%_SW_P`.)?\`@VU_Z-8_\S?^
MWG_\]ZC_`(<2_P#!MK_T:Q_YF_\`;S_^>]1]2QG_`$"8G_P15_\`D`_UDX=_
MZ'^2_P#ATP/_`,O/J/\`9O\`V?/%/[$F@?M4?&^R^"&O_'OXJ_\`!/S_`()R
M_LO?\$\/V=K2U^&NH^&/B#^UQX6_8O\`V8KO]IG6_%?P6\10Z+X[\1^'-`_:
MA^,7[0.E_`75?ACX&LOBEIVC_$O]EJPU&[\2_$?Q2EOX*^'W@6B7>G?\$G?V
M7OVX_A9\=?V>/B]^VS<_#;]F+X2^&?AF%_9_\4WGP<_:"_8H_9)_X)F?`?X;
M^*/!_P`1OCMKN@_$3]FO]GKX0P?&?P+^VU\0M?\`V;OBS\5+SQOI\_Q&^)OB
M3X9?!?XP^-OVB/`6D_'+F?\`AQ+_`,&VO_1K'_F;_P!O/_Y[U'_#B7_@VU_Z
M-8_\S?\`MY__`#WJ/J6,_P"@3$_^"*O_`,@'^LG#O_0_R7_PZ8'_`.7GZ0^,
M/V8O%/PP_9*_X)C?L#^'WU_XBZ3\._B]^P1\.?'/QST;P9J,&G>#O"W_``3U
MT32/VL[3XF^+/!ME?:[;>&]`^-GC;]C3P?\`L^6RZQX[M-.\">*?VA?#6KQ:
M_P".M6T#2_`OCW\Y?@K^RO\`M&>++7]F7X;?%7X,^/\`P3X`_9A_:\^'W_!/
M']D7Q1J>@76JZQX3_8A_X)S?M&7?[:$7[:GQ1M-"&C^;_P`/`/\`AW9^Q-^R
M)J"?$'3?!WA/PGXZ\(:'^U'^S_+#X`_:6LO@1XL@_P"'$O\`P;:_]&L?^9O_
M`&\__GO4?\.)?^#;7_HUC_S-_P"WG_\`/>H^I8S_`*!,3_X(J_\`R`?ZR<._
M]#_)?_#I@?\`Y>=-^Q+^SMXS\6_#3]D;]E[XW_'_`/X*LZG\0_A=K_P$^.'[
M4GPC\6?LE_`3X6?LQ>'OVD_V?_B#X4_:A^(FO>)?VN?&_P"P)\-]1_:4T#Q1
M^V;X)LHM9\=?`7]K']H#XV_M&Z_XYN?C'J/C;XC_``\U/XO_`!WT3U[X#>-?
M&'@C]EOX8?VW^PY\?OB_^TQ^PG\`?VF/VY/C?_;?A+XZ?!;^V_\`@JYXJ^'?
MCO\`X6M\+_@;_:7POC\`?M0_\-=^/_VE/VZ/[(\:_LK?\+N_9O\`A-]F\+_\
M('X2DT7XB_LZ>1\]_P##B7_@VU_Z-8_\S?\`MY__`#WJ/^'$O_!MK_T:Q_YF
M_P#;S_\`GO4?4L9_T"8G_P`$5?\`Y`/]9.'?^A_DO_ATP/\`\O/H35/V(_'7
M[&'P?_86_9L_8:^!O@#Q#\3/V/O@#^TY^UMI_P`2M$^$>C_#+X6_M-_MO?`_
M]A>/]A3X7^$/CE9Z'XB\(Z!X;\?_`+76O_M87WQ<U?QYXR^-4GBR7P[^S=XH
M\(R:OKME?ZG\3_AEX%I$7Q<\)_%SX-^//@VG_!3K]J/]F?\`X)_?LA_MG?M.
M?!GX-_&O]BKX*_L7^!?%G[5WP3^"OA/]G?\`9]_92^%/A'P3_P`$\?V9_C]H
MO]M?`']ICXZ:;X5T>+X37'PW\6:Q)X'C^".I?$G6O@9\<_AUX3@_X<2_\&VO
M_1K'_F;_`-O/_P">]1_PXE_X-M?^C6/_`#-_[>?_`,]ZCZEC/^@3$_\`@BK_
M`/(!_K)P[_T/\E_\.F!_^7G3?MC?L%^*?A_^QE_P3V_X)C?!/X<:_P")?!/P
MX^$/CKX<^-_CU\+/@UJ-IX6T_P`4_&OX5>'_`/@E-\0OB;XJ^'/A)-2TG0]?
MUC2?^"H'QY_X*/>,EU?XA'4?%6G?LC?%WPYK>OBV\;^,OCW\)_KS]I*+Q3XA
M_:U\2:)X<^!?Q>;XA_$G7_V</V;O&W@S5_@WJ/QL_8H_;G_X)W7.MZ3JOQA\
M3?M&?$W7_@CK7P=^`.O_`+-_AS]H;_@H+#\-O@O_`,-$_![XG_%OQOX1\(W'
MQ)\'_M#_``\^+7P(^"^K_#O_``XE_P"#;7_HUC_S-_[>?_SWJ/\`AQ+_`,&V
MO_1K'_F;_P!O/_Y[U'U+&?\`0)B?_!%7_P"0#_63AW_H?Y+_`.'3`_\`R\^A
M/%_[*/\`POC_`(7!_P`)]^S7Y7_#R+_@KS\/_P#A?W_"7_!S_A)_^$&_9;_X
M)>?9O^%5_P#"X/[:\.6G_"T/@#^UI_P[?L_^%?\`_":?\(I\._`W_#R*V_X1
MS_A:WV"+_A?'Z-?L7>$_%,&H_MD?&3QAX:U_P)JW[17[;GQ@\66G@#Q+HVHZ
M9J/AWPM^S]X6^&O[!_@;Q+;:AJEMIESXET#X[>"?V0O#_P"TSX3UF+0M(TZU
M\+?&O1O#.CW/C+2?#UE\1O&?XP_\.)?^#;7_`*-8_P#,W_MY_P#SWJ^^_P!A
MS]F;_@D[_P`$V_\`A:'_``Q;X)_X4S_PN;_A"O\`A97_`!4G[2?Q$_X23_A7
M?_"6_P#"'?\`)5]>\=?V/_8__"=>*O\`D`?V7_:']J?\33[=]AT[[&?4L9_T
M"8G_`,$5?_D`_P!9.'?^A_DO_ATP/_R\_7^OSH_X*F_\F?\`C_\`Z\/%7_JK
M_B%7TG_PU3\!?^A[_P#+7\9__,[7PU_P46^-7PS^(_[*OQ'T/P9XE_MG5+7P
M_P",-5N+7^QO$&G>780?#CQO9RS^?JNE6-NVVXOK6/RDF:9O-WK&421D]/)<
M+BH9OELIX:O",<9AW*4J-2,4O:1U;<4DO-L\C/L]R/$Y3BZ&'SG*L17J^PC3
MHT<QPE6K4E]8HOEA3IUI3G*R>D4WIL?9/[$/_)EW[(?_`&:_\`?_`%5'A.OJ
M"OE_]B'_`),N_9#_`.S7_@#_`.JH\)U]05X9]B%%%%`!1110`4444`%%%>,_
M'_0OCOXC^%?B32_V:_B)\/OA=\8Y$M9_"7BWXI?#O5?BCX%@FMKF.:ZT[7O"
M>B>-?`.JRV^K6R2:>NJV7B#S]%>==372M9^S?V9<@'LU%?R"_M-_M\?\%]_V
M*VO;K]IOPW^S;X>\#6,BQ_\`"^/AQ^SWXQ^)?[/EQ"?)07VI^/;/XPZ/K7PT
MM9+B7[+$?C1X/^&JW5T%@TN;5/,AEE\%L?\`@MM_P4[O[2WO;?XE?LORV]U&
MLT$L/[-_B*:&6%^8I8ID^/>R6.5-LB2(2K*P*D@@GU\HR/,<\Q4\'EM*G7Q-
M/#O%2INO1IVH1J4Z4I\]2I&'NU*M.+AS<_O746E)K\4X[^D)X6^&N/AEG&>;
MYUDN+JN?L?K'!W&'U;$Q@H\U3!8_^PU@<QI)MQE6R_$XJE"<94ZDX32B_P"W
M2OSE_P""O7_*+_\`;P_[-C^*O_J-W=?A/_P\^_X*@?\`1;?V8_\`Q%#Q)_\`
M1(UY%\?/VT/^"A'[2?P7^)GP#^)GQO\`@$OP]^+GA#5_`OC/_A%?V9-:T7Q&
MWAS7K<V>JQZ+J]]\?=:M-,U&6T>2*VOI])U&.VD<2FTF*A3=+)L;&K3E*--*
M-2$F_:)V2E%O1+HK[=M.E_P_'?M`?HJ5L%C*-/Q%QLJE7"XBG3C_`*D\<KFG
M.E.,8WEPZHJ\FE>326[:6IX]7W;_`,$</^4F?Q$_[,4U?_U?_@*OA*K/PQ^(
M'Q\_9Z^.,_Q\_9U^('@7P?XPU3X4W_P@U^R^(GPNN_B9HM]X:O/%^C>-(KK3
M[;3_`(@?#^YTO5(-4T:&)YY+K48)[21HUMX)%,C_`$N-HSQ&"Q5"G;VE6%)0
M4FTFXXFA4:O9I6A"3ULG:RU:3_QK^ASXE<'>$OCYPMQQQYF=3)^&LMR[B?#X
MW'TL!F&9SHU<QX>S'`X./U/*\-C,;457%5Z5)RI8>:I\_/4<*<93C_=/17\A
MO_#S[_@J!_T6W]F/_P`10\2?_1(T?\//O^"H'_1;?V8__$4/$G_T2-?+_P!B
M8[^6E_X,7^7]6?E?_9[_`(J"_11_Z.-C?_$(XZ_^AP_KRHK^.E?^"LW_``4U
MU#QCI_PS\)?%OX"_$CXKZQ$L^C_";X8?L7^._B#\2[^UD63R]5E\(>%OVAM2
MU31/#`F1+:^\<>)H]$\#:'-<6I\0>)=)@N(YC^UW["%G_P`%B/$WBN'Q[^WA
MXP_9=\!?"AK&_P#[+^!_@/X4ZE/\<M4N+FTNX-.O?'/C?1/C/XP^&'P[FTV]
M:SU*30/"%_\`&2/5;6)K.X\2Z%<SRI9\6(PE3"NU6=+GT]R-12FKWU<4M%HT
MV]G;NK_O?ACXS\#^,.#J9IP%/B3,LGA#GAG>8\&\5\.Y-BO>47#+LTXAR?+,
M'FE6+:]I2RVKBYT4U*M&G%IO]:****Y3]6"BBB@`HHHH`***_'__`(+D_&?]
MI3X!_L#>)?B-^RKXE\>^$/B?9?%3X1:5<>(_AOX/L_&WB?3/!^M>+[:P\2/%
MH]_X6\86\5E<02V]I>:@VBR-:QW`"7%NTNXB5W9;O1'/BL1'"87$XN=.M5AA
M</6Q$Z6'I3KXBI&C3E4E3H4*:<ZU::BXTJ4$YU)N,(IMH_8"BO\`-,_X>E?\
M%D?^CG_VP?\`PP'AC_Z'NC_AZ5_P61_Z.?\`VP?_``P'AC_Z'NN?VU3_`*`L
MQ_\`"'$?_(>:^\_,_P#B+F0_]"'CK_Q#LX_^4_U9^5_]+.BO\U"'_@J3_P`%
MC&D43?M0_MAI&<[F7]G_`,,$CY21C_C'ENK8!^4\'MU%[_AZ+_P5^_Z.G_;'
M_P#$?O#/_P!#I7L9?EN(S&C*M"5#"J-5TO9YA6A@JTFHTY\\:5?EG*DU42C4
M2<7*,XIWBT1/Q@R&#2?#W'LKJ]X\%YS)>C:HM7\O\U?_`$H:*_S7O^'HO_!7
M[_HZ?]L?_P`1^\,__0Z5>TW_`(*B_P#!7%KZSCU']JC]LA+"2[MDO9U_9^\/
M&6"T:9%N98A%^SFY:1(2[J/)F)95"QN<JW9+(,5&,I?6LLERQ<N6.8X>4G97
MM&*E>4G>R2U;T6ZOE/QDR"$)3_U;\0I<L7+EAP1G<IRY5>T8JA>4GLHK5O1;
MJ_\`I)T5_G=_\/,_^"C_`/T>/^V]_P"(\:/_`/0LT?\`#S/_`(*/_P#1X_[;
MW_B/&C__`$+->1[&M_SZJ_\`@N7^7FOO/"_XF#X:_P"B(\7_`/Q5_%'_`,R'
M^B)17^=W_P`/,_\`@H__`-'C_MO?^(\:/_\`0LUIV7_!1W_@I3?Q--!^V9^V
M7&BR&,B]^"7@_3I2P5&)6#4/V9[69X\.`)5C,3,'17+QNJQ.,J<>:I&5.-TN
M::<(W>RO))7?34BI](CA:E'GJ\&>+E*%TN:IX9<30C=[+FEA4KOHKZG^AC17
M^?#;_P#!0_\`X*3ER+C]M']L%4VDAE^$/@(G=E<#Y?V;VXQN/W>HZ]J]$\,_
MM_?MP75A-)XH_;O_`&U].U`7<B0P67P;\$21/9B&W:.5BG[*M^!(TS7"$><I
MVQH?+`(9_1HY=3K8%8[^ULDI1=1T_JM;,J-/')IVYGA6G4]F]U-)Q:UN?/9E
M]*KA#+8SF_#WQNQT8RC%/+?"[.\7*?-:TH4HSC6<5?WFZ<>7JDFK_P![5%?P
MC_\`#>O[7G_1_P#^W%_X9CP7_P#0D5O^$_VT_P!L/QO)K4'AS_@HW^U1<WOA
MN]MM/U_2K_0/@5H.MZ-=7UA;ZI8KJ6AZ_P#LWZ9J]I%?Z?=0W=A<S626M]"9
M&M9IC#.(U2RUUY<E#'Y;6G9RY*6*]I+E5KOEA3;LKJ[M971\?G7TX_##AK+Z
MF;<1<!^.>0972G2IU<RSKPLS?*LOI5*\U3HTZF,QV(H8>$ZU2484H2J*52<E
M&"<FD?W,T5_$!XA_:C_;UTO0-<U.V_X*#_M0FXT[1]3OK<2V7[.C1&:TLI[B
M(2*O[/Z,T9DC4.H925R`P)R/ZZ/V+O'GBOXJ?L=?LG?$_P`>:LVO>.?B/^S1
M\"/'GC/7'M;*Q?6O%?B_X6^%?$/B+5GLM-MK/3K1M1U?4;R\:UL+2ULK<S&*
MUMH($CB7'&8*K@I0C5E3DZD7)>S<FDD[._-"&OI<_4?`OZ2/AO\`2&H\2U_#
MV6>N'"E7*:.;+/,KCEDE+.H9C/!/#*&*Q2K1:RO%>U=X.FU#1J::^EZ***XS
M]\"BBB@`HHHH`****`"BBB@`HHHH`_E`_8=_Y-8^$_\`UY>)_P#U-_$U?5]?
M*'[#O_)K'PG_`.O+Q/\`^IOXFKZOK]+J?Q*G^.7_`*4S^1^(?^1_GG_8XS/_
M`-3:X4445!XX4444`%%%%`!1110`5\P_M5?M7?#7]DSP`GB_QO)-J_B#6Y+G
M3_`/P^TB>V3Q)XWUBU2![I;07#>5IGA[1$NK6Z\5>*;U#I^AVMS96L4>I^(]
M9\->'==]C^*7C=/AG\,OB+\2)=-?6(OA]X$\7>-Y-(CNA8R:JGA3P_J&O/IJ
M7K6]TMF]\M@;5;IK6Y%N91*;>8)Y;?R]:)\'?C[^WMIWQ._;)^+_`,6_A/\`
M"GX=^'_%/@WX<:G\3_C#JOC;0OAUHGB'Q9<>=X1^$'PWT#P)X-^)WBF+3M`M
M-4_MC4(XM$GLM'T^_O\`QUX^\2S:CJOB#Q'>?JGA-X?Y;QYG\X<19_A^&N%<
MJJY7_;F8M^TS+$3S?'QR_*LER+!1I8BMC,YSG&-X?"*&&Q$,-"%?%5*.(E1I
MX/%?4<-</3SJK5K5%-X3#/WX4WRSK5.251PYW:-*C3A%SKU6^91<*=-*53VM
M+[D_X?=:9_T;+KW_`(=31O\`YCZ/^'W6F?\`1LNO?^'4T;_YCZ^!=$_X)^?$
M>]T3XY^/O$?Q=_9W\%_!#X`^-=$^'OB?]H2X^(.M?$?X/^+/%WB<V,WAS1_A
MAJGP'\'?%SQ3X_N]3TK5--UV\@T3PC)/X4TR[(\<1>&-1L=4T^QW]3_X)C?M
M(:'\4?CW\*-=O?AMI.L?`+]E/QC^V;J/B"3Q/JNH^#OB3\#/!]MH]U_;?PIU
MS0O#6K'Q!?\`B2/68T\.6^N6GABQ>YL-4L];U/1+NS,+_P!AQ^CS]&">*JX.
M/B%Q,Z]&-64E_;F5>RG+#T,EQ.*P]#$/A?ZOB<9@L/Q'D5?'X'#U:N,P-'-,
M)4Q="C"I=?9_ZEX%14O[/K6=O^7]:^KJ1BVO:749.C549-*,G"2BW8^ZM*_X
M+;^%Y=4TV'7?V<O%VF:)-?V<.K:GI7C_`$'7-0TW3IKB..]U"TT:;0M&359;
M&W:2Z&GC5+*6[$1@@F\YXU;]H_`_CCPE\2?"6@>._`FOZ=XH\(^*-.BU30M=
MTN4RV=_9RED)`=8YK>YMYDEM+^PNXH+_`$V_@N=/U"VMKVVN+>/^1S]GG]C[
MQ)^T%\*?V@_C?_PMCX0_"#X7_LR_\*G_`.%G>)_BJWQ6N?*_X7/XDUOPCX+_
M`+!T7X1_"GXK^(=6W^(=%_L_5/\`B4VWV#^T].N_WUBNI7.G?>?[-T7[1_\`
MP3O_`&U?A[^Q]\0+SPUXJ\`_M`2Z1KNGR^&?$%UKWP_UC1_%?@/Q#XN\*?&3
MX6:U<:=I]YY&KKX7DT+6+>ZTC2TUR.WN(]2L8M1T?2M1@_+/''P`X`X+P6.J
M<!<6XO$YWPY'$U>(N&N(\31GBZ^%H87(<=B:F2XVAEF6X/$8[*<#Q)D689GE
M,98C%1RS.,'C;T%[.EB_&SCA"-/+YYAE]*=..'IU*]6,ZCG"I0@JKE-.<G*G
M*"P]?EYO<K>SG"'[R*C/^AJBBBOX[/ST****`"BBB@`HHHH`****`"O+OCA_
MR17XO_\`9+OB!_ZB>K5ZC7EWQP_Y(K\7_P#LEWQ`_P#43U:NC"?[WA?^PBC_
M`.G(G7@/]^P7_87AO_3T#]P?V(?^3+OV0_\`LU_X`_\`JJ/"=?4%?+_[$/\`
MR9=^R'_V:_\``'_U5'A.OJ"OR\_L4****`"BBB@`HHHH`****`&2Q13Q20S1
MQS0S1O%+%*BR12Q2*4DCDC<%'C="5=&!5E)5@02*_&']J#_@AG^Q_P#&^ZU'
MQ?\`!J#5/V1OB?=&>Y;5/@S8Z<OPEU_4)I6NI)/''P"OO(\`WL=[>.]WK>L_
M#S_A5WQ$UJ9V%U\05C>5)/VAHK6A7KX6M3Q&&K5</7I2YZ5:C4E2JTY6:YH5
M(.,X.S:O%IV;6S9X^?</9%Q1EF(R;B3)\MSW*<4K5\OS7!8?'82HTI1C/V.(
MIU(1JP4I.E6@HU:4GS4YPDDS^+?X_?L=_MK_`+)<MU??%[X,GXM?"VR\R1_C
M]^S':ZYXZ\/6%DUXT<-Y\0?@U<03_%[X<"VL`VH:[?Z5:?$_P%H-G"UU?_$5
M/,>VM?G+PEXR\)^/M!LO%'@CQ+H?BSPYJ*EK+6_#VIV>K:;<;<"2-+NREFB$
M\+'R[BW=EGMY0T4\<<JL@_O5K\V_VH?^"4W[(?[3^M:Q\0+GPGJ_P1^.&LR?
M:[WX[?`#4+3X>>/=;U)9%ECOOB%I:Z;JGP[^,3JR+"%^,/@CQVUO:&2#39=/
M+^:OLX;/:T9)8J$:L/=3E3BHU%K[TK74).STBE!75N9)W7^:WC1^S+X!XG>+
MSCP=SNIX?YQ4<ZRX=S>6,SCA#$59<TO9T,3*5?/,CA.<N:4X2SK#48)4<-EM
M&FHJ'\N=%?;?Q._X)3?\%#/A=XDTSPW\/M!^$G[5?A76=2AT[3/B=IGC6R_9
M_P!7\,6KH=VJ?&#X>^+V\606FFV:(@N?$/P?\1_$?6-<OII9+7X2>%;&**)_
MM#X`?\$,](NI+7Q1^V[\9=6^+5W)''(WP#^"EWK_`,*O@/IP8;IM.\5>++.Z
ML_C/\8MDB1Q3SWOB'X:>!?$&GO>:9K_PDNK&\G@?TZF=8*%+GA*=6;<HQIJ+
MA+FBDTY.22C!WC[ZYNJ492A**_B;A/\`9R?2,SWBG%Y%GV6Y#P=DV7UXPQ'%
MF8YU@\RRW&T6U)5,CP645<5F>85*E)^TITL9ALJI0E^XQN)P6(4J4?P_\'R>
M+OBYXOO_`(;?L\_#?QM^T5\3=,N38:QX/^$]EI^I6GA&^(^2+XF_$#6=1T7X
M9?"6-LJR-\2O&7ABYO8]RZ1::I<A;5_U\^`?_!$[XI^/8M-\0_MG_%Z+X>Z+
M(;2\N/@'^R]XCU,ZE=QJT$\FE?$#]I'6_#_A[Q0]O<*GE:AI/P9\&?#75M'N
MOM5MIOQ<\4:<T5Y/_0A\-_AC\-_@YX,T3X<_"3P#X-^&/@#PU;FT\/\`@GP#
MX:T?PCX5T6W9VD>+3-!T&SL-,LQ+*[S3F"V1IYWDFF+RR.[=S7AXG.,77;4)
M?5Z=VXQIM\Z3324JFCDTGJXJ";]Y132M_IWX,_0$\"_"EX+-,XRVIXF<689P
MJ_VSQA1HU<HPV)C9^TRKA.#J93AX1E&%6A/-GGN/PM>/M,-F-*ZC'P_X"_LU
M?`3]E_PA)X%_9_\`A/X+^%7ANZNEU#5X/"ND16VJ>)]86+R6\0>-/$EP;GQ)
MXW\33Q`)=^)_%VKZWX@O0!]KU*8\U[A117E;[G]N4Z=.C3IT:-.%*E2A"G2I
M4X1A3ITX1484Z<(I1A"$4HPA%*,8I))))!11106%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%?QC?MZ?\I2_VYO\`KR_9=_\`5":!7]G-
M?QC?MZ?\I2_VYO\`KR_9=_\`5":!7MY#_OE7_L&G_P"G:)_$7[0__E%?C;_L
M<\%_^M5E1\R>,O\`D4/%7_8MZY_Z:[JO[#O^"=G_`"C\_86_[,Y_9C_]4IX(
MK^/'QE_R*'BK_L6]<_\`37=5_8=_P3L_Y1^?L+?]F<_LQ_\`JE/!%:\0?Q</
M_P!>Y_\`I2/YA_9/_P#(N\<_^PWP[_\`3'&I]C4445\^?Z]A1110`4444`%%
M%%`!1110`4444`?R@?L._P#)K'PG_P"O+Q/_`.IOXFKZOKY0_8=_Y-8^$_\`
MUY>)_P#U-_$U?5]?I=3^)4_QR_\`2F?R/Q#_`,C_`#S_`+'&9_\`J;7"BBBH
M/'"BBB@`HHHH`****`/%OVDM'U;Q%^SM\?/#^@Z=>ZQKFN_!;XIZ/HVD:;;2
MWFHZIJVI^!M=LM.TZPM(%>:ZO;Z\GAMK6VA1Y9YY8XHU9V`/\[_[._Q=_9_^
M(O\`P3K\6_L._&'XO67[/OB?3?VL_!_[4G@/XD>)?!WQ"\:^"-=BF^&MO\'?
M''@[6[/X7>$?'/BW3-8T/PZEYXC\/@>'X]-UO6?LVC:EK>@VXN+Y/ZB:_%/_
M`(*(?\$X+KXAW6L?'S]G#P]%+\1KN:34/B-\+=/FT[2[?XC32MNN/%_A234;
MK3M(TWX@;B9O$6GWEY8:9XXB$NK+<6OC.*Z/C/\`;?`WC'AOA;B66%XKQN=9
M)E6;8[A[%4N*,@J8-YAPWFO#V8U,=EN.J8/,,LS?"8_*Z[Q&(P6;X>I@,3-8
M.O*K1I3G3<7]SP=GM#+GB<!B?80IXN3E2K8ARC0]I*FZ4Z6(J*I3]E&<>25&
MOSPA2JP:K/V=1U*/S;X5^(O[&_B']CGXV_\`!/W4/VE=6\':-X:_;"TC]ISX
M%_M'>/?@KX[TSPC\34B^%UK\(/%.B^*OA[\-A\9/'G@BW;3H]2U_P:[VU_=:
MK%-I,GB9?"5XVH:#:?6]C^W;^R!X@^.'Q?\`!=C\6;CP3\&_#_\`P12U_P#X
M)E?!OXQ?$;P/\1I;;X@^/[630(-`\6^(/#'PY\%>.?&?A;0=3DU#7+JXN9_"
M?GVVE:`\\FF0ZKJ%CHDWXJ_\,2?MM?\`1IGQ;_\``WX8_P#SQ:/^&)/VVO\`
MHTSXM_\`@;\,?_GBU_:&,S+Z/&8XW'8S,/'3/,7''5<PQJP53$Y)3P6#SG-J
M624LUSS"4\/P11K+'8]Y%AZT\+B:^)R7"UL7F$LNRG!1Q*A2_08Y_A(1C&&+
MR*/*HQYEF6&<I4Z;J.%*3>/:Y8^U:4DE4DHPYYRM=_>W[/FN?LT_#']D;_@H
MA^RMXD_;,^!3^*/VG-(_8ZU+X9^/]-\!_M>W7PU-[\(_C-XY\9>._#_B":7]
MEZV\?Z3J^DZ#;:/<PSQ_#Z\T#4Y?%>AVVFZY=3VGBA/#G5_$#XX_#/\`:)_X
M*5_\$Y/#?[/-QXG\>?#7]E3X*_"?]F_3?'=[X9U/1[WQMH?P6^%OQ9BUCXFW
M/AZYMTU7P[X=N=3\8VU@LVNV.D20-]B^VVEC-J%M`_YU:=^PM^V[J>HZ?ID?
M[+'Q(TY]1OK2P34-;U?X;6.C:>UY<1VPOM8O;?QU?W%GI5F9/M&HW5O87UQ;
MV<<TL%G=2HD$G])W[%G[%G@G]D7P3)%%):^*OBUXJM;5OB+\16M3#)?R0GSH
M?#/AF&;?/HW@G1IW?^SM.WBYU.Z#ZWK;SZE.!;?EGCSQ[X42RO.L1PKQGGO'
M7$O%]7'U,3AU6RS#\/Y1B,;P_P`'<,XS.L53PO#N68G$8ZKD_!N783+\#2Q4
ML)1JXK.,=5A1Y\'AZGC9UQ'@J&3XK"QK8"O/$X2O@:%/!8B&)JVK+%-SJSIX
MBO"C1HRQDZC<XJI7E&E1IW2JU:7VO1117\*GX\%%%%`!1110`4444`%%%%`!
M7EWQP_Y(K\7_`/LEWQ`_]1/5J]1KR[XX?\D5^+__`&2[X@?^HGJU=&$_WO"_
M]A%'_P!.1.O`?[]@O^PO#?\`IZ!^X/[$/_)EW[(?_9K_`,`?_54>$Z^H*^7_
M`-B'_DR[]D/_`+-?^`/_`*JCPG7U!7Y>?V*%%%%`!1110`45\;_$3]O/]FWP
M+XOU?X7^'_%.M_'/XTZ'*+35_@E^S;X2U_X[_$WP]?NH>WM?'^E_#RRUG1_A
M!!=*08-<^,VN_#SPR<H)-;C,D8?AQ\3_`/@H?\52?^%<_LS_``?_`&8/#\Y!
MA\3?M7_%-/B?\2;5)&81-+\!?V9[S6/`MT%BQ<7'F?M<Z5<12^78K:2>=-?6
M(!^@%%?`7_#)?[1_CPF?XZ?\%`_C?>0R+MN?!?[,?@/X6?LQ?#Z8LHW31ZE/
MH?QA_:&LIHY`?LPL/VBK:V6%BEW;7TP2X4'_``2]_8<U4!OB5\%7_:'N&):Z
MNOVL/B/\5_VM)-0D8JQ>^A_:1\<?%"RFBC?S#962VD>FZ5'/<VVD6=A:7$MN
MP!ZG\0_VZ_V)/A)+);_%+]L+]EWX<W<;B$V/C?X^_"OPQJ#W#-LCM8=/UGQ5
M9WMQ>328B@LX()+JXF988(9)75#Y9_P\_P#V)KL,WAGXI^*_B/$#\MQ\'?@+
M^T1\:K64-D0O;W7PE^%'C2VNH[QU>'3Y;>66/4;F*:VL6N+B&6)/JKX>?`OX
M)?".)(/A1\'?A7\,8(T,4</P\^'OA+P7%'&RE&C2/PWI&FHJ,C%"B@*5)4C!
M(KU.@#X#_P"'C'PDN<R:+\"_V_-;LA\IO?\`AW/^VYX7_?#F2$:9X_\`@7X/
MUX^6"A^TC2#8R[MMO=S/',L3?^'@&FW!,ND?L??M_:Q8-Q#J'_#*WBSPX)RH
M`E`TCQOJ/A;Q+;>5*'AW7^AV:3F,W%FUS92V]U-]_44`?`1_;MUY,7<G[!W[
M?J:$^!#KP^$/PVF\V0C:8SX2MOC1/\1K;$ZRVYFOO!5K;9B^U"<Z=/:7MP#_
M`(*`:1;YEUO]D7]OW0K,#`O3^R?XX\4;IB1L@&F?#Z?QCKP+KO?[2^DK81",
MK<7D,DD"3??M%`'P'_P\:^$%J=^N_`_]OS0;9@5ANO\`AW!^W-XL$T_!$'V+
MX<_`/QIJML3&'D%U>Z?:Z>/+,37@N9+>"8'_``5"_8<MB?\`A)/C+J/P[10'
M>?XO?"'XX?!BT2%CLBNI+SXK_#;P;:QV5S<?Z#9WSS+9WNI@Z7:3S:B#:U]^
M44`?,WPU_;4_8W^,\MO!\'OVM/V9OBO-=OY=K#\-?CQ\+/'4MS)OO(]EO'X7
M\5:H\S^9I]^FV,,V^QO%QNMI@GTS7COQ*_9W_9_^,\-S;_&'X&?!WXL6]ZGE
M7D'Q*^&7@KQW#=Q[+./R[F+Q1HFJI.GEZ?8)LE5UV6-FN,6T(3YC_P"'8/[%
MFD8?X7_##Q%^SG<PDM93_LI?&'XS_LL6^GG>9$BM]$^`/Q`^'GAN?3HR5C_L
M+4-%O?#\UI%!I]SI4^G016B@'W]17P"_[*_[5'@,&;X'?\%!OBE=)&XEM/!_
M[5_PF^%'[1O@2!D))@?4_`VF?LY_':[M[DE5N3JGQVU.:-54V#V9,HF#\8OV
M^_A:=GQ2_9)\!?M"Z%``TGC#]D#XQZ/HGC*YA4#[3<7?P+_:9D^&.C:0+?F6
M*TT+]H[X@ZEJ$(ECMK-;Y+:ROP#[^HKY(^%'[<7[-_Q:\86?PPM?&6I_#?XT
M7L$]Q;_`GX[^#_%GP)^-%[%9J&U"X\/?#SXJZ/X6USQQI-@KQ27'B;X?P^*_
M"CV]Q9WEKKMS97UE<W'UO0`4444`%%%%`!1110`4444`%%%%`!1110`URP5B
M@5G"DHKL45FP=H9PKE5)P"P1RHR0K$8/\Y/[5W_!8S_@HG^Q;K6L?\+Z_P""
M1?A/P_\`#33IF%C\?M%_;G\5^+O@;J-EYP@BU'5O''A3]A;65^&D,\Q,4%M\
M8K#X=:A<NI-I:7$,EO-/_1Q3)8HIXI(9HXYH9HWBEBE19(I8I%*21R1N"CQN
MA*NC`JRDJP()%-.U]$VTTKWLF]G9-7MT5[=[G%F.'Q6*P6(H8+,*N5XNI3:P
M^.HT,+B9X>JM83>'QE&M0K4^:RJTY1C*=-RC3JT9N-6'\G=C_P`')'Q\U%(Y
M;3_@GK\%YH9H$N89X_V^?&<D$T$@1HY898OV"722.1'5XW0E'0AE8@C/I'AG
M_@OM^T_XJL)M0T__`()]_`6&&&[DLF6]_;]^(4<IECAMYV95@_X)\W"&,I<(
M`2X;<'!0``M]Q_M/_P#!#']B_P".ESJWB_X2:5JG[(OQ6U*XO-3G\3_`:#3M
M+^'GB#6;L2/->>._@1?PR_"W7'U&[D^V>(==\,:/X%^(NO2I%]I^(,306[P_
MB?\`$W_@G;^V[^QK#JB>*OA0_P"T7\)X[V?4$^,_[,6F:YXKUJPA,%M;^;XX
M_9PF74OBWX>:5+1[D+\,[CX[:7I\&]];\0:;&JRR?38"/#%3*O9XOZY3SI5[
M^U<N3!2H-K2/+.3C-*Z;G&.NJ;Z?PIXWYG].+@'+L9FOA[5X3\2<OP\HS4<C
MX3H+B*GAHNU257AFOBZF(Q=65XJG0R/%9QB)>])T8139]W_\/T/VKO\`HP#]
MGK_Q8#\2/_I>-?EC\0?B+\1_C]^TM\?OVFOB5X!\$_"O5?C+-\+K:P^'W@;X
MFZ[\7=/T33_AM\.]*\$_;+SQMK_PI^#5S=WFM7-E-??V?#X+B@TZ`Q1?VE?R
M,[1\9X-\?>#/B%ILFK^"O$ND^)+&"XFL[M]-NTEGTZ^MIYK:YT_5;)ME]I6H
MVUQ;SP7&GZE;VMY!-#+'+`CHP'75Z6%R_#86HZM#G4K2IRO/F32DE*+36CC.
M"O9IJ2:>ET?Y0^,?TP?'WQ1X7SGPQ\2)Y/A,MKX[!2S?+(<+0R3-L/C,GQU+
M&T:%?VLEB<)4I8O#TW6HSI0J/E=.:2<D\G7[";5="UK2[=HDN-2TC4K"!YF9
M84FO+.:WB:5D21UB5Y%,C)'(P4$JC'"G]!OV=O\`@KO^U=\`OV?O@7\"O^&(
M/V>O%G_"E?@Y\,?A+_PE/_#=GQ(T+_A)?^%<>"=$\'?\)!_8?_#`>L_V-_;/
M]C?VC_97]KZK_9WVG[)_:5]Y/VJ7X/HJ\5@,/C)0E64VX)QCRR<=&TW>V^Q\
M)X(_26\4/H^TN)*/AUBLFPT.*JF55<W_`+6RBCFCG/)HYA#`^P=6I#V"BLSQ
M7M%&_M'*%[<B/U3_`.'Z'[5W_1@'[/7_`(L!^)'_`-+QH_X?H?M7?]&`?L]?
M^+`?B1_]+QK\H_A5IOQ)_:-\02^%/V6/A'XZ_:.U6VN9[#6/$7P_@TNS^$'@
MZ_A4A[;QW\<?%&HZ)\+M!O+:4@WWA?3O$>O_`!%6U2>XTSP-JSP_9W_8OX$_
M\$.O%/B@Z9XC_;6^.EZEJDZWS_`/]EC6O$G@7PN-D[M#I?C?]H2\@T3XP>-8
M4A\IY)?AKH_[/H%TKV]V=;L`?M'B8FADV%;A*56I5BTG3IS<FM[\TK*$6G&S
MBY<Z<E[J6L?]+_!SQ(_:*>,7U;'X7+N#^#.%Z_)/_6?C;A"&3X:M0E+^)EF5
MR=3.LUYX1G*A6PV`CEU22C"KF-!3C)^76?\`P7T_:HU[QM!\+O`O_!.?X2?%
M+XKW<44]M\+/A1^VQ\9?B-X^2WN45[74=9\/^%/^"<FIS^$/#LY>)9/&7C5_
M#?@K34D%UK'B+3K%)KJ+]ZOV4_B)^TS\4OA5:^,?VJ_V;/"7[*?Q(U+4)&M?
MA#X8^/UI^T7>:3X?-C826UQXM\:Z1\,OAMX9T_Q-)J4FIVMQX?\`"[>--&MK
M"TT^_3QA<7>HW6D:1V7P._9Y^!O[-'@J+X=_`'X4>!/A'X-2X:^N-$\#>'=/
MT*+5=5DCCBN==\0W=K"NH>)?$=\L2-J?B3Q!=ZGKNJ2KY^HZC=3%I#['7A59
M4Y2O2INE"R7(ZCJN]M6YN,+W?:,4E96O=O\`TRX+R?BW)\HA1XTXQCQGGDU3
M>)S##</Y=PUEM.<8M3CE^5X.>+Q%&E4E)N3QV:9A4:A3]G*C^\4RBBBLS[`*
M***`"BBB@`HHHH`_E`_8=_Y-8^$__7EXG_\`4W\35]7U\H?L._\`)K'PG_Z\
MO$__`*F_B:OJ^OTNI_$J?XY?^E,_D?B'_D?YY_V.,S_]3:X45\Z?M6^._%?P
M^^".NWO@35?^$<\<>-/%WPC^"?@WQE]ATW5_^%>>*_VB/C!X#^`GAWXH?\(]
MK-G>Z1XM_P"%7ZO\2;/XA?\`"%:JEKIOC;_A&O\`A$[[5M$M=9EUBQU_VC?B
M%>_#;X7MJVG/J]KJ'BWXB_!'X,V&M>'[W0;'7O"-[^T'\;/A[\"+7Q]HC>*O
M"?CGPO>ZO\/9_B/'XXTW1?$GA+6]!\07OA^'0M8M%T_4;B>'%SC'GO?W(*;_
M`,+Y]O/W'^'RX*>%JU5AG!P;Q6)GA:2;:?M8?5[N6EE!_6::33;TG=)).7NE
M%?`/A_\`;'^).L:7HGQ2O_@!I&B?LXZ[\=--^"6A_$J3XR1:IXW^(%E\0/VA
M8?@#\#OC;\)/AUI/PYNO"_C#X%_%&?Q7\,O'47BWQ-\6_A_KT?@_6_&'B#P/
MX2^)?A/1/AMXJ^,QX4_:B^)/CO5]<\,_!OP!I'Q&^)&H?$7]HZ75?"OQ-^*\
M7@+X;?![X;?L\?'37?V4])DN_'?PZ^`7Q"\8Z;J_QY\8_#;Q+\3?A9X/\=>!
M]=EU^73?VB[#3/BVVB_!G1/"\T+$4G:SDW)*27).[BVDI).*<DW)).*=]7M&
M372\IQT5-RITHQIS=*<OK.&=.%6*E*=*I4C6E3I3A"$I35:=-1M&+:G4I0J?
M?U%?`/@[]J'QO9_LG_M5_M@>,_"VKF#X>ZO^U5XK\)?`3Q!>>#])U[X?:#^R
M@OB;X4ZM\+=;\?\`@<>+=!UK5_&OC_X'>-OB/J7BBT;QC9>$+WXHS>!]"U;Q
MWX7\":%XBU_YT\*_'9M(E^$,'PG_`."EVK_M\_%^[^(OP(\(>/?A/\._#_[)
M_C[P1J7@_P`9_$GP/X$^./Q:\2^$_P!F3X)_\+6^#OPZ^'W@KQ#XL\?:!XQ\
M5?&.R\$>#?&&G^`O#/COQAXY368O"OC>7B::Y':34XJ:UA%\K=HOEG.,FY+5
M1C&4U:THQDXQ>M/)<54=9<U).A7>&FU'$58>WA%.O3=6AAZU&G'#RE&%2M7J
M4L/-R<Z%:M1A4JP_8FBOS2UO_@HUX/\`#_QLA^&U_JG[+MQHMQ\=/#_[/\?A
M71/VQ_!'B;]KA?&'B;XH:;\$].U";]F'PWX)U70;;2+;Q_JMKXC\0:=<?'J+
MQOX2^#46I>+_`!5X.T;XD:-K'P8L?#/AE^T)^WSXW^)WPWMM9T[X16?A[XS?
MM<_%OX>Z]X8\(?&9/$6I?"3X,?L>_$3XS^"OBOK?@;PM?_L6:7XAB\(^*?$/
MP]\`^!?B)\5?BA\2?'\'BWQ7\1O!?A+X?:1^R)XA^._A'5/@T/%45)13E*7-
MRM1A)\KYHQ7-HK)RG&*>S;[)M5#(<P=.5:I&AAZ:IJK&5?$T8>UC[.I6:I<L
MI.4H4:-6K..DHPAMS2A&7[04445T'C'#?$_7=1\+_#7XA^)M(DCBU;P[X&\6
MZ[I<LL23Q1:CI&@:AJ%E))!(#'-&ES;Q,\3@I(H*,"I-?R*?\$I_^"NW[>7[
M3G[?GP-^!/QI^+.B^*OAIXZ_X6FGB+1+;X9?#?P[/<'PQ\'?B%XRT=[?5_#O
MA?2]7M&MM=\.:9,PBOMD\"2VUPLL<SBOZT_CA_R17XO_`/9+OB!_ZB>K5_G_
M`'_!"K_E*W^R[_UT^.7_`*SG\8*\[,YSIRR=TYSA[7'8BG5Y)RBJD(O+N6,T
MFE**]I4LFFO?DNK/TW@[+\!B>%N,<3B<%A,1B,-@<3+#5Z^'I5JN'E#+L54C
M*A4J0E*C.-1*:E3<9<T8RO>,;?Z*5%%?@SX+\2Z))\-O^"6-A\9_'O[:'B;P
MO\1OV`?BA\6_&<GP9^(G[=OCKXD^-/C%K,O[$?B1/&'C[4?V9M?UWXOZWI&E
MO\2_B;;Z+)XNNKCX>^"XO%%IX5T2+0X)?"FCQ]=6M[)QT3YE>\I<J7[RE35W
M9V5ZM[_W;6UT^#P&7O'<]IU$X3Y>2E0]O5FEA,=BW[."J4^:=L$X1A=7=3F<
MHJ%I?O-17YI>#?B=\0OA+\"_BQXE\,6GQ%N?!6O_`+47P3^$O[)UQ^TO;_&*
M_P#&^@^"/CSJ_P"S/\#K_P`8?$71OC=?Z-^TGXETCP1^TG\1/C3XPM?"'Q9\
M0^%?&'C'P?H>G>%_`_C'P?\`"G5_AGXGTG(\7_M'?M:^!?C?X'_9:^W?LZ>.
MOB?XV\7?"S_BZ7_"NOB7\-?`>A^`_B[\'_V[?%/_`"3'_A;_`,5/$.M^+OAE
MXA_8R_X2W_DJ&AZ-\7=&\7_\*J_XLO?6_P#PNJW7UB*4>:,KRY4N6THMRE*,
M.5Z.2FXR<)*-G%)OEYDGJLHKS=9TZM'EHJI*7M7*E4C3HTJ%6NZL>6<*53#+
M$T:>)I2J.5.LYTX>U5*<U^HE%?EW\(/$_P"UKX=\0?M^:S\0OC_^SIK6D?##
MXNZ)HL.J^,OAO\2_AI\._A?G]EO]D?QWX@^),5]K?[1OQ(M?#_PB^'_@?Q/X
ML\9:S\$DE\._\+"^)T?B+Q%>_M`?"/2/'>I7GA+SJZ_:R^*?C?1/&?P^UCQ#
MJX\4?#SXZ?\`!,'7_P#A8NB?LY_M&_L4WNL^#_VB/V[=!^&?B3X=S?"+]H#7
M_$?C_4](&@_#+Q)9>(/'NG>*[CP1\1-!^(VI?#R3PU83^"O$UQXE7UF*7O1E
M&3]K:,G"[=+GNO=G*]U"3NDTK>\U=7T625ISM2KT:U)/`\]:G#$J,%C_`*HH
M2?M*%-)1EC*,>6<H3G=NG"2A4Y/V)HKY=^,_Q!^+:_%OX5_`GX-:S\.O!7BC
MQ_\`#KXR_%J_\??$[P#XF^*V@V.@_!KQ-\#O!UUX/M/`7A7XH?!C4&U?Q3J'
MQYTO6K?Q?-\0'LO#]EX*O]&D\':]/XMM]:\)?%^F^/\`]HO]HK]H/]E;P_)\
M3?"/@7P/X<_X;#U[XE^%/#'ACXNZ'_PLCXB?L)_MB?#/]G'7?$UMKO@7]HCP
M#J^F>$?B?I'B74];\)?!WQ]-\6_ACX$_M;6M-^+OA_\`:<NH?!&N>!'.O&,G
M%1E*2E&-E9*\I4H[M_9]M3;TV>EVFEAA\LG6IPK3KT:-*5.M5;DJLYJ%*GC*
MB?)"FTW5^HXJ,%SZ.G>IR*=-S_7*BOS2_;(EU[5?VE_V:?!-OX-_:B^)_A?5
M?@7^U?XIUCX=?LO?M#7O[/.O7.O>%O'_`.Q[I/AOQKXIUN/]H_\`9ET_Q#I'
MA?3_`!GXJT*STNZ\9ZW>VU[XW-W8>&)X/[1U72B+QE\6_A+X6^!7@3X-?"?X
MB_"[Q/\`'G]J+Q#\+K^Q_;H^-GB;]HS7M!T&+]F'XN_%6Z^)/AWQ%X5_:8_:
M%U"ZTC0]0^$NERZ1\*IOB9X0LO&-[I'B[PQ(_P`)I_']O\:-)'7M.<7!\L)1
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M)X`^'^D?#_7M$\&>)/CSH.N^$O$?AGP_\$_!OQ8^.UI\3M(O+W2O@MX22Q,6
MY+DFN5M-VBTN50=1NTG94W42D]G9N#FK%3R:O&%&:KX:3KTX5(04JL9R]O/$
M+!P@I4DISQD</*=&-U*"DHXB-"2:/TMKR[XX?\D5^+__`&2[X@?^HGJU?$?C
MGXI>,/''[7_[.]WX8U;5]*^$'@[]J+Q+^SM!>Z'XK\;Z3I?Q9\86W[&?[77Q
M*^.]KKNAZ+XHE^%/Q1^'7@#QKX0^!W@GPIJNLZ%<^-_AI^T+\)?VCO!EQ'H+
MZ4S:O]N?'#_DBOQ?_P"R7?$#_P!1/5J[,!453%T;*RABZ,+_`,UI4Y7]/>LM
M[I7OK9*EA)X3'93SR3EB)83$N*7\-3Q<H*FW=WDHTTYIJ+A.4J;5X-O]P?V(
M?^3+OV0_^S7_`(`_^JH\)U]05\O_`+$/_)EW[(?_`&:_\`?_`%5'A.OJ"OS,
M_KH***\U^,_Q5\+?`GX/?%CXW^.99X/!7P;^&GCOXJ^,)[9!+<P^%OAYX7U7
MQ=X@EMXR5$D\>DZ/=O$A90\@520#F@#A_CE^T3X8^"K>'/#=OH'B;XH?&'Q^
MNII\+O@=\.H=-OOB%X[DTA+?^U=5']KZCI'A[P;X#\/S7VF0^+OB?X]UOPU\
M/O"D^KZ+8:OX@BUG7_#^E:MX&/V8?C)^T2&U7]L_XI7MGX/O566S_90_9P\7
M^,/`'PFTV"0(WV'XK_&#1I/"7QC_`&@[^(B2VOK$W/PH^#&N6%S<:;X@^"7B
M)H;?6']%_9&^$?B3PMX-D^,GQE@M;[]I_P"/>E^'O&7QMU@.+R/PK+)927WA
MKX%^"[N2"WDLOA9\$[35KOPKX4T^"WLH]<U<^*/B3KMI+XY\?^+=4U'ZYH`X
MCX=?#/X<_!_P?H_P]^$_@+P;\,_`?AZ`VVA>"_`/AG1O"'A;1X&8N\>FZ#H%
MG8:79K(Y,DOD6J&65FDD+2,S'MZ**`/S%TWX>6O[:7Q^_;*T;XQ>/_C]H'A/
M]E+X_>"?V??A'X._9]_:;_:,_97T=='U_P#9#_9;_:7\7>._'>H_LV?%/X6>
M+/B9X_\`%'BS]H.\\)LWCWQ+K_@7P;X%^&_@6V^&/@7P)XLU_P"-7B_XO=!^
MT5\0_P!I/]FSX.?"NP'[1/PAG\1OK_B/PKJ?QC^(/[)/QM_:6^,?Q@U&UGOM
M1^&7P\^'O[$7[(/C7X9>*?BI\7M6^%5AXJ^)/QZ^)OPC\3^'?"WA.#X*_$#X
MB^%OV3_"WP=\9ZZ?V8O7OBA^R9=>+?'6N?$CX._M)?'[]D?Q9XZ_LR?XN7/[
M/NG_`+.>L:/\9-8\.Z/I_AKPCXN\=^$_VD_V>_VAO"=IX_\`#7A/3;/P4WQ$
M\!:'X)\=>-/`NC^!?`_Q.\0^.O"?P?\`@KHWPXY_Q5^PI\/FT[X1'X'?$KXO
M?LK>-O@IH'Q3\'>$?BK\';SX:>-_B#J?@SX[>*?!OQ#^.NB^/;C]JCX8?M'^
M%OB+K_QI^*OPX^'_`,7/B=\8/&GA76OCWXK^)?AJ\\4WWQ6-SX_^*L?CP`^)
M/A3^W=^UY^T_??LF^`_@98?`'X?Z_P#&CP!_P4KN_BA\3OCE\&OC]9_\(QK'
M_!/3]L;X&?LIZ?\`$'PO^RUJ?CWX5_$S1?\`A=E[XR\2:EK?[,OQ:^+/@CQU
M\!O^$XTB37_C5X\U_P"`^N>`?C[O_`_]LK]LW]J'QOXX^&?PCA_9B\)>-OV7
M=`UVY^,B_$;P-\5=3\+?M0^*?#7[:_[>/[&2:-\,M<\,_%6UU;]C+0/%VK?\
M$^O%/CQO$OBKPO\`MTZCX"T[X^Z!H0\)_$:Y^!FHZE\=?KS]G_\`8(^#G[-N
MO_"KQ!X"\3_%[6KGX/:!^VSX:\+?\+(^($_Q&U'4M._;P_:=^'W[5WQ<N?&O
MC'Q5IU_\0_'&O^'_`(A_#;0M'\#^+/%'C#4O%-QX6O-<E^)FL_$GQMJ1\:0\
M#8_\$U_A]X8U_P`1^(/AA\?OVG?@Y<_$O7_BI>?';_A67B_X::/J/QR\&?%+
M]IW]HK]JX_#'7_&.K?"37/B'\)=`^'_Q#_:T_:&T?X<^/?V7/&'P!^/>B^%O
MB(LNK?&/7_&W@CX;^-/!P!\A?M-_\%*?VB?`'QM_:U\)_!?P5K_BRV_8^U_0
M?"=O\!O"?_!-K]OG]K#Q3^U9XIN/V;/@]^TY#X:\-?MC?L[:M:?L_?LI:_\`
M$./XSZ5\$-&T;XF?#'XR:C\*]1\/VWQ[\9VWB?P3X^T3X>:-].Z;^UQ\4M.^
M/W[96N?&GXI_LA_LY_L.?L6?'[P3\'_$OC_XH-XBTGQUX]_X6=^R'^RW\7=&
MMM<^(_BSXI?#_P"$/P*_X1#XO?M":5I^F>+[_3/BY_PNW1_%&G_"^U^'_P`&
M/$_@6V^)WQC]>\<?L3P>)/B7\2/'G@C]IO\`:=^`_ASXY:_H?BS]H'X4?!;7
M/@YH7A;XR^*=*^'W@KX.ZAXEO_B+XJ^"GC/]I3X1Z_XB^#'PT^'/PPNM9_9I
M^/'P.U'PQIW@K2O'7PXN?`_QBOO$/Q*UKW[X:_!;PM\+/&?[0?CGP_?Z_>:M
M^TE\7M%^-/CFWUFZTZXT[2O%.A?`3X(?L[6EAX3ALM*T^YL=`D\$_`/P?JES
M:ZQ=Z[J+^*=2\2WL6JPZ3>:7HFC`'YB_$WXX_'OXS?MR_L@>+OV#?VH/V8OB
M;^S]XX_8C_;F\>Z=X2G_`.$S^(?P<^./BGX+_M'_`+#_`(/\36<WQN^#?QQG
M\$^'=?NKGQG#\-/A]\8X/@E\:-1_9BGB^/EQJ'PQ^.TGQ-3P+X%\"UG_`(*I
M?''X>^%OVID3QM\(?VF=6\`_\$Y?VVOVX?@I\7/"?["7[7_[(/P$U34?V1-.
M^%(T"U\->*?C5\:_BYX)_;8^$/QLN?C=X<\3:-\5?V7?C)HGA;PSX,\&VVHV
MOB#QII/QU\`>*O"OZ<_M7_L*?#[]KWQ3X+\0>._B5\7O!NDZ%\(?C[^SO\0/
M`WPYO/AI9^%OCM^SU^T_J/P:O?CC\&_B;=^-/AAXX\;:%H'C6V^!O@_1U\7?
M!'QA\'OBSX:TZ\U^7PE\1="U:\L=4TSR'Q7_`,$OO!_Q2_X6;J'QX_:J_:\^
M/?BSXI?LA_M/?L0ZKXN\?>)O@7X=_P"$=^!?[5?_``JV?QO'X+^'?P=_9_\`
MA;\%/#OC_P`.ZE\+;34_#GQ)A^%\_C#Q%_PD5YH?Q?U3XI>$_!'P8\/?"T`/
M$?Q/_;V@^*7P<_9J_P"$[_9#\#?&OXW>`/VE/VE/^$T_X4-\9OB_\+?A-\+?
M@/XB_91\`_\`#.G_``CG_#3'P,\6?&SQ_<>+/VH_[6_X:N_M[X#^'=;\._#K
M[#_PQUX5U+QS]L\$?(>H_P#!3C]IJZ\)_`3PGK/A_P``?"#XU_%3Q_\`\%0+
M3QCXA^%_[(?[:'_!2WP+X/T?_@GO^V]IO[)FG?#[0_@]^S1=_"+XUZY_PFVF
M^._#7B74_P!IKQ9<_#WP+8ZQX"U#1KGX*Z!J7QM\(:'\-_MS]NSX;_%75/%/
MP6^+WP2\%?M.W_Q#\#Z!\6OAN_Q%_8U\<?L96'Q[\*^#/BIJ/PF\3Z_X*F^&
MW_!0?0[C]E[Q9\(?'VN?!OPCKOCGQQ;^)-)^/?P]\9_#;X5:#\--#\0?#SXF
M_'"_\,^0_LU?\$[_`!%X;^`/P@\_XI_'[]E?X\>`O'_[='B7P=XX\$>-_A;\
M;/C5X1^!?[;_`.UYXH_:AU'X"_&+Q-^TOX)_:T^&?Q%\?BRT_P"`?_"Y_B-#
M_P`+)\8-\7/A+JO_``K[]H?Q?X&\3>+_`!!\4`#XC^&?[<W[<ND_$']OC]KO
MXI76@6WP=_9>_P""<OA7X^:C^R7XV_9U_:/_`&?O&?Q-T[X,?$O_`(*P>!_#
M/Q!\"V7QD^-%WJW[*&O_`+4NK?LT:+\=]>F^('[.WQ5\4V'P$\=_`_X"ZM!X
MC\1_`I_CY\5/?=$_X*4_M$_#3PM^TUXY^)G@K7_VA_!/P,_8C_:<_:X;QA;?
M\$VOV^?^"6WA;P[XI_9KT[P9K&A_`K6?$'[9VK?&S2?B3K_[0^D^+O%&J>&M
M=\!W>DZC\(].^"GBR]UWP3\1[;QMILO@SZ]OO^":_P`/M?\`%/C/6O&_Q^_:
M=^(GA;XT_LQ/^RE^U%\,_''B_P"&FL^%OVI?A]/J/[3NNW6K?$CQ0GPDM/C%
M\.-?'B/]KGXOZMH>D?LM_%+]GKX:>!M./@KX?_#OX>>$/A5X%\.>`K+OM-_8
MG@\0>%OBSX&_:3_:;_:=_;#\$_&'X0^//@5XA\'_`!IUSX.?#GPM8?#3XK:=
M'H_Q0TNP\/\`['WP4_9<TG5]?\8Z3::7I=KX^\<6GC#X@_#;3K/5;+X,^*?A
MM;>/?BA%XX`/`O!6M?MF^&/^"C_[/7PO_:)^*WPA^(7@GQ!^Q'^W1X]TO4/@
M+X.^*OP'\+>)/%/AGX[_`/!.7P]96?Q!_9^\<_&#]H/2;C7_`(7Z3XKUN?X?
M_&.W^,VJ:CK6G?&;XA>"H?AC\,[;PK=^*OC+^K-?$?PG_8G@^'_Q[\._M,_$
M#]IO]IW]I#XQ>%?A#\5/@5HFM?&G7/@YI?A;3_AI\6/&?P3^(&KZ78?"WX#?
M!3X(?"K2=?TGQ3\$-)N[7Q]HO@K3?B#XJT[Q-JOAWXI>*?B%X<\%_!/2?A/]
MN4`>:_%?X-?"3X[^#[SX?_&KX9^!?BOX(OY8;FY\+?$'PMHWBW1#>VK%[/4H
M+#6[.]@M-5T^7%QINJVBP:CIMTD=W875O<QQRK\E#]G[]H#]FHC5?V3?B5JW
MQ.^&UDRS:A^RA^TGXV\1^,K1-/C(-S:_`;]HSQ+<^(OBC\--76U18=#\&_%*
M_P#BQ\(%2ST[PMX;TWX,Z5=7WBJR^_Z*`/#O@=\?O!OQVTG7'T;3_$G@SQQX
M)U&#0?B?\(OB%IUMH/Q.^%OB.X@:YM](\7Z':W^J6$MIJ=LCWWACQ?X9U?Q#
MX#\<:0HUWP/XJ\1Z(Z:@WN-?#7[;?AK6?`W@C4?VQ/A1I@/QP_9C\*:WXSDM
M+)8H9_C%\#]`QXI^+G[/_B#=);Q:G;>+O#6F:EJOPTEO[F*+P7\9-.\&^*H9
MUTE?%.D>(?LOPUXBT?Q?X<T#Q9X>O8]2T#Q1HFE>(M#U&(,(K_1];L8-2TR]
MC#A7$=U97,$Z!U5@L@#`'(H`VJ***`"BBB@`HHHH`****`"BBB@`HHKC/&_Q
M'^'GPSTO^W/B/X\\&?#_`$7Y_P#B<>-_%&A^%-+_`'9B63_B8:]?6%I^[:>%
M7_??(9H@V#(F0#LZ*^#=0_X*A_\`!/&UO+C3-)_;%^`WC_5[.5H+S0_@_P".
M],^-OB"SN5SNM;S0/A`_C?6;2[7Y2UI<6,=RHE@)B`N(#)5_X>3?L]WWR>%?
M`7[:GCN4G$3^$/\`@G7^WK?:-,5&Z=$\8W_[.6F>!DN+5/FGLY_$\5\&VP1V
MTES)'"X!+^U'_P`$S_V/OVMM5E\:?$/X9IX4^,8MEM[#X_?"+4)?AG\:K-8H
MA#:Q:GXP\/1QQ>/=(LT&+?PC\4=+\=>""V'G\,SNJ,OX=?'O_@DO^VQ\"9)]
M9^#.I^'?VTOAI;S7#OI!?PW\'/VGM'TTR>9;%]+U*[TKX%?%RZL[=9VU34M&
MUWX$7UQ_H=MX?^'FL7K2B7]OS^W_`*=.?-TG]C[]O[5]/?\`X]]1'[+'BGP\
M+C;\LO\`Q)_&NI^%_$UGY4ZR0?\`$ST*Q^T>5]JL_M.GSVEY<`_;E\;7`\[3
M?^">O[?NI6+DFVOCX&_9\T,W*`E3)_9/BS]I3P_XBLAN#*(M5T;3[@@"183"
M\<C]6&QN)PCO1J.*NVX2M*F[IQ=X2NKV;U5FFE)-2C%K\:\5OH_>$/C5A)4/
M$/@K*LWQRH^QPO$%"F\MXFP,8QDJ2PN?X!T,Q]C1E+VD<#B*V(RZI4C%U\'6
MBN5_S3?"']E#]N#]HS6[O0_A/^R[X[^'VE:=//IVO?%/]K#1_$W[.O@+P_JD
M$OD7-EIWA7Q+X=NOC1\1[NS9+MX;GP/\-KKX?ZG<60T^3XG:,M];ZBG[,_`G
M_@AS\!/#\]GXF_:S\;^(OVN?%"P()O`6KV<_PY_9@LYA(DKQK\!]$UO5V^(5
MG)MV3V'Q[\<?&'1GE2*^TW1=%N8H!!]@_P##;_Q$_P"D<_[?G_A.?LM?_16T
MW_AOB1?EF_8G_;^AF7Y98?\`AGFTN?*D'$D7VFP\=7=C<>6V4\^RNKFTEQYE
MO<30LDC:XG,L7BERU*G+3LTZ=-<D9*22ES:N4TTK6E)Q2;224I7^%\(OH>>`
MO@Q4HX_ASA"&=\18>:J4N*^,JE'B'/:%2,N:G4P/M,-A\IRFM2U4<1DV59=B
M9Q;56M45K?<OAWPYX>\(:%I/A?PGH6C>%_#.@6%MI6A>'?#NEV.BZ%HNEV<:
MPV>FZ3I&FP6VGZ=86L*K%;6=G;PV\$:JD4:J`!LU\!G_`(*-?!VQ)/B3X*?M
M[^&8>56YF_X)S?MQ>*[<R)_KDE?X;?`7QN;**%<R/?ZBMGI;(K&&^EQBAO\`
M@J+^P=8`/XQ_:!TGX1V^5W7OQ^\%_$W]G?38HW8JMQ<:G\<_!7P]T^VM"B7%
MQ]LN+F.T%G8ZG?&86>EZC/:\!_3Y]^45X9\+OVH/V:/CB+8_!7]HCX%_&`7D
M2S6A^%WQ;\`?$`74+V\=VDML?"?B#5Q/$UK-%<K)%N5K>6.8$QNK'W.@`HHH
MH`****`"BBB@`HHHH`_E`_8=_P"36/A/_P!>7B?_`-3?Q-7U?7RA^P[_`,FL
M?"?_`*\O$_\`ZF_B:OJ^OTNI_$J?XY?^E,_D?B'_`)'^>?\`8XS/_P!3:Y\Z
M?M&_![QY\7]-^%H^'OQ"\(^!-7^&GQ=T3XJ36?Q$^&NL_%SX=^-_^$=\*>--
M*\/Z%XO\":)\4?A%=:C_`,(KXX\0>$_C!X+U1_%9_P"$6^)WPP\#>*[+3I-7
MT73;[3_#/B]X%_:7T[X>W'Q.^)_B[X=?M"3_`+/6KZM^T1X7^!'P4^`'C_X8
MR_'/7OAG\'?C&W@_X4ZY!XA^/7[13ZUJ\_Q?UKX3?$_X9ZKIWA'4;WP=\2?A
M5X<U?2_"^O>*)_#6M>#OOZBN>5*,G*5Y*4K:J<[75N5N'-R.UD[.+3UNG=WY
M:&85Z,:5.U&=*DY6A*A0]IR5)-U8QQ*I?6:;J)N/M*=6-2":Y)1Y8V^`?@C^
MQQ\2?AUX/_9R^$?Q*^/^D?%_X+?LQ:1\/9?!/AK_`(4W%X(\8>+O&'PU\$-X
M7\&2?%3Q#:?$;7_`'B_X=?#[7KQOB!\+/!]G\(O#_C?PCXW\`_`GQCKGQ;\:
M^._AEKOC#XBG@3]CCXD_"2R\&GX4?'_2/#?BB_\`@7\*_@E\?_'^O_!N+QAX
MP^)%[\-M>^)_C'4OC;\.YKWXC6.@^`?CI\1?'_QU^,OQ$\>^+?B]H'[3&@^*
M/&^O^&M>\1^$M<GTGQHGQ(^_J*2P])<MHR7*K1?M*G-%6BK*7/S)6BE:^UU]
MJ5])YMCYNJYU:35>2E6I_5,(J-22G4J<TZ"H*BY.I5E-R<+RER2DVZ=-P^1K
M7]E?R_V5/AY^S)>^._[2_L+_`(4U_P`+8\;77ACS/^%]?\(I\1_!WQ`_:#_X
M6'X;E\0S?VQ_PUM_97Q`TCXR_P#"2:_XK_X23_A;/C&_\;?\+`_M+6[+7_7?
M$GPK_M+XK?#_`.+?AG7?^$.\0Z#]M\.?$G[%I?VW_A<'PI/ASQM_PCWPX\2;
MM1M+&#_A"OB?XDT7XF^"?&%SINM>(_!OV+X@>#/"4^@^'OC;\4/[<]<HJU3@
MDDE914(K5Z*FVX*][Z7=_P"9-J5T['/+&XF;FY5+^TGBJD_<IVE/&1A'$2:Y
M+>^J<&E:U.4(SI*$TI'P#\.OV./B3X,U3]E/1]6^/^D:Q\(/V,=72+X-_#S1
M?@W%X>U[Q'X/T[]GKXH_LZ^&H_C-\0-3^(WBV?Q7\1?#?A?QUI6HVGC#X=>&
M_A!X(U&]B\?1ZW\)-1?Q9X%N_A#U'PX_9,\1?#75OV4M5TGXK:=>7?P&^`OQ
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MV_9^_:`^'O[$'@+2OV(/"\?[37[<?B?]F[[;X3\1^*_@-^SQK?BB'X<Z5J=]
M<>)/!WP\^(WB6#Q&?!`\7>'?#^KV^B6ECHFLI>1Z-I%K:ZGH&E:GI^H"695'
M1G:IRQH*FE&K.;E4G6<[>R44G*7N-R4M^6G+G;DN:?10P$,QPTZF&G*IFSQ4
MI5,!1P[I86G@%2IQ6)5=_N:,WB;JK3G4IT>:O3CAE34H8:G]Y_M=_`'7OVF/
M@-XT^$WA3XN^/_@?XIUNT:;P]\0?AYKFH:-?V.IPVUU!'IOB*VL+BV_X23P5
MK4%U/IOBCPU<RI%J&GW!FM9;35+/3KZU_D(_89_X(B_MR:+^VIJ=GXY\1^-O
MV9_!WP+UJ9]6_:)^&>M76DZWXYTCQ#I-Y8K8?L\^*(X8A?WGC3PMJE_IVLZ]
M=6K6?P^T_4-3T[QKH<OBB!/`6K?T]_\`#P__`*L9_P""BG_B,W_X;5YOHW[?
M_P"T9;_$/Q5J_C/_`()X_M96G[.6LV6FV/P<UWPU\.='UOXW2>)]!@0^/I?B
MM\+;;XA75[X1\*ZQ=ZG:1?#G4GCLI[NWT#5+J^2^.M0P>'>'$PP6+J4)SG5;
MI2<OW<:O+RVYFYVC:";4$ZD>63]V#E\+C]3DN+XJR+`9C@<-3P<*&-I.-.&+
MK8%S6)JSI49/"1G5?MZSH.I+ZM4YZ7)"I7]F_9U(U/U/TVQBTO3K#3()KVXA
MTZRM;&&?4K^\U349XK2".WCFO]3U":YO]1O9$C#W5_?7$]Y=SM)<7,TLTCR-
M\2_L;?`C6?"_P8_8L\1?%+PKXN^'/QF_9W_9&E_9DU?P)JNN>`]9TV#^TX/@
M78^--7O+SP-K'C72-5^WZO\`LZ^%]9\"7^D^,H?(\*>([Z+Q7H%KXEN6TKPO
MR7_#P_\`ZL9_X**?^(S?_AM7KGP"_;.^&/Q^\::_\+K?PE\9?@]\7O#OAP^-
MKOX2_'_X5^)/A7XYU#P!_;2>&U\?^'+;5HKC1?%/@\^(F_L.;5_#NMZFMCJ9
MBMM1BLS=V1N>Q5L-5J0M4CS)-1@UR1DY3I37*I1C><90@X1B[VYGRM*\?FIY
M?G.!PM;GPE7V=2<*E:O"7UFK3C3P^+I3=65&K5Y*%2EB:L:]:O&SG[*/MHRG
MRU?<_BO\,=!^+_@B_P#`_B&[U?2X)=7\(^*=$U_P_<65OKWA/QO\._&&@_$3
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MQ%<_%?XNVFD?'#Q=\/OBE?\`@2Q;X4KX4\"?&_X3:;\#['X8_&KP)>7?PJO/
M'!\7>#+K]GKX;:S9^%O'7C+QS\']:U*SU6+Q;\,?$6D:M<:4,BP_8E\'MJ_B
M_P`4>,OB[\=/B;XU\>ZO^RKK?BSQ?XY\1>"&O;Z]_8\^.FM?'KX3PZ1X<\*?
M#SPKX`\$Z1=Z]K">&O&GA_P!X/\`"N@^(-!T]O$,.FZ;\5O$GCOXD^+?M"BD
MZ--N[C=^]NY->_S<SLW:[4YI.VBG)*RD[ZK,L;&"A&NXQ2HI<L*496P_U=TD
MYQ@IM1>%PTI)R:J2P]&53FE2@UX7\6O@;%\3=>\'^-M!^)?Q%^#/Q(\$:1XO
M\+:'\1?AE%\-M2UX>"/B!>^#M6\;>"KO1/C!\.?BQX`N-(\1Z]\.?AWKMQJ@
M\&1^,--O?!MA::!XGTC1=8\6Z5XCR/AY^S)X#^&OB/X=>+=&U?Q=J/B'X>^$
M?V@/#;ZAK5_HTO\`PFFL_M/_`!6^'OQN^-/Q`\6VFFZ!I=C#XN\4_$_X>Q>)
M[:R\&VWA#P'X>_X2GQ/HOAWP3I?AY?"^D^&?HNBFZ<')R<4Y.S;UW3BT[7LG
M>$-4KOEC>]E;)8O$QI1H1JM4H*:C%1BGRU(UH2BYJ//*'+B*ZC"4G&'MJK@H
MNI-OYT^,/[/<_P`4O'OP]^)WAWXV?%WX(>./ASX1^)7@33=;^%=G\&-3_MGP
MI\5=9^%WB#Q1I6O:;\:?@]\7](?9J_P@\&W>EWVC6&C:E:>3J-O+>7-K?O"A
MI'[/<_G_``JU+XA?&SXN_&/Q#\'/B[K?Q@\'^)/'=G\&-$U+^TM;^#'Q"^"$
MGA35;/X2?![X8>'K[PC8^'OB?XL\06(31+?Q7_PE=Q9S7OBN]\/647AROHNB
MCV<.9RL[MJ37-+E<H\O++DORW7)&SM?0:QF(5*%%2@H4X5*4'["A[6-.JZKJ
M4U7]G[?DG[:KS0]IRVG)6LSY&\=_L@>'/%_B#5?&7A_XK_%WX6^.-0_:+L?V
MF[3Q?X$;X4ZAJ6A>/+3]ENS_`&0KC2-*TOXG?"KXC>%9O".I_":VFEOK#6_#
MNLZS'XKU"\UG3=?T^U2PTRQU_%7P;\'^!_V<OB]\*;?X:_$7X^>#OB7J_P`=
M]2\7_"_P_P"(O!&B>-_&5E^U+\4_''C?XI^']$\1>)O&?P7\+Z/I&F3_`!7\
M5+ILUUXY\.Z]IO@_3(8+#6]=\8P6DVK_`%%12]E"\FHI.:DI/?X[<SM*\;NR
MO>+YN5*5TDBOK^*:H1G4<X8:5&5.+]QI8=-48.K2=.ORTU*:IJ-6+INI4E3<
M)SE)_G5X<^!'Q6\%6O\`P3G\'WWA7_A+?$/PV^+OQ+^._P"U/\5/#&N>'(O`
M=I\5O'_[-O[2FE_%KQ5;:=XDUCPMXTO?^%Q?M(?M$ZKXC\):'X$^'#^'/#>C
M2ZU!>:/\-O#VE^&]"G^Q/CA_R17XO_\`9+OB!_ZB>K5ZC7EWQP_Y(K\7_P#L
MEWQ`_P#43U:NC`4XT\5AU&]GB<.[-IVY72II+1.W+!-WN[MZVLETTL74Q>8Y
M?.JH*<,333E!27.ZV85<7.4DY22E[3$3BE!0BJ<8+E<E*<OW!_8A_P"3+OV0
M_P#LU_X`_P#JJ/"=?4%?+_[$/_)EW[(?_9K_`,`?_54>$Z^H*_,S^NPKP']J
MWX)_\-*?LP?M%?L\+J\?A^;XY?`_XJ?"6T\0S0R7$?AZ^^(7@?7/"MAK[V\)
M66<:)>ZI;ZIY*'=*;01@'=@^_44`>`_LQ?&L?'SX,>$O'>HZ1-X3\=PP2>%O
MB[\/+^2)M;^%_P`8?"^S2?B/\/==BC"[;OP[XDANX]/O1%'9^(O#L^B>+-%:
MZ\/Z_I-]=<#_`,%!?BAXZ^!_[!/[;WQI^%^N?\(Q\3/A!^R'^TI\4/AWXE_L
MS1]:_P"$>\=>`/@SXT\6>$=<_L;Q#I^K:!JW]DZ_I.GW_P#9FN:5J>CW_P!G
M^RZGI][92SVTC_BU\"/'6F^-]1_:`_9?UGPSX0^-VI6NF6?Q"\'>-Y-<3X-_
MM$Z'H=G%8:3I'Q(AT$7>H>#O'^BZ9;P:/X(^.WAK1-<\3^%]-BM-"\5^%OB;
MX'TW3O!=I\__`!?^*_P]_;*^!O[0G[`_Q4O?$7[''[0W[2?[/_QJ^!5GX.^,
M>@V5[=3O\2_AYK_P^O\`QU\$M:L]?TGX>_M+>'/#K>(TU]=/^''CZ'Q''IR6
M-EX^TGX::SJ$NGV`!\A67[5_@'1_&'PD7]F'_@M=_P`/"_BSXB^/W[._@$_L
MG?\`">_\$Q?BE_PG7PM^)7QT^'GP]_:`\:?\(?\`LA?LQ?"CX_2_\*&^`/B?
MXF_M!?\`"1^%/'>D^'?`O_"K?^$Z^*5GXB^$WAOQQX9UCZ=^,?\`P4GU']G[
M]I/P%\'/C)X0_9B\`^'/BG\7OAC\*?AMX&UG]MSPL_[?/CO3OC)\;;/]FSX=
M?&#PG^Q18?"6\\+:[\(==^*MX_B^YUK3OVI;CQ3X>_9VTKQ+\0/$W@[1OC%X
M3\3_`+.>D?;GC[X&_P!N?%+P7\<OAWXH_P"%9_%G0/\`A'/"'C;6XM$_M_P[
M\9_@79>(KS5]8^#_`,5/"\>KZ!_;_P#8']O^+O%'P!^($&KV7C#]G[XI:_K6
MM^'KG7_A-\3/VCO@;\?/B/QC_P`$\OC'XHU_6M`LOVK=`T+X%ZQ^VY\'_P!N
MO6/#_P#PSO!K_P"T+\2OB#\+_P!IWX4_M%1?#7XX_M%^(/B_?Z3XX^$/A_2?
MAMI?P5^!UGX&^"GPE^)?P;^$WPT_9?\``%W\3_B)\-_@AXP\`?'``X#XW_MV
M?M.ZAX:T7QY\'?@MH'AO]GZ__P""C7[/G[&L/QLL_BUH'B#XQV,_AC_@J#\-
M?V+_`-I";XG?L[>-OA-I?@GPK\(?B%<^&?C5\,/`7CGX6_'CXR_&..#QQ\'?
M'4WPJ^&TFM>/_$'P#[_P3^VY\8_%Z>$?AC\%?A3H'Q;^.GC[XO?\%/I].M?V
MA?CO!\&_A]HWP<_8+_;OOOV5O$TQ^(_P;_96^(VK2Z_+JWQ&^#MK\)/A]-\"
M[R<?#2W\4-\4OCYXL^)'@I/%?QI/$O\`P3R^,>KI;?#'0OVK=`\)_LO:-^VY
MX3_;KTGX;V?[.\&J_&/Q#\0;?]N_1OV_/B!\-?B=\<-:^+]YX6UWX0Z[\5;S
MQY:^`K/X9_`OX-_$OP)`GP=;Q1\3_BGH?@'XI>%OV@=_3OV"OBE\,[[P1\0/
M@#^T#X`\+_&OP1X__P""B>HV?B+XP_`#Q%\6?A;>_"W_`(*+_MC6G[9/C[P=
M<_#/P7^T)\#O%B>/_A]XL\&?"OPAX0^)47Q@7P[>^'=$^(-SK7PHGU+QYX<E
M^&8!@6'_``4-^,?C_7_@%\,?@C^REH'CCXQ?&'0/V\X/%UKXQ_:(@^'/P<^$
M/Q!_X)V_M._"?]E;XVPZU\1[?X0>-?B'XN^$/B[XA^-?%EK\'_B#X/\`@7J'
MQ+\03V?PI;QU\`_AMX<^('Q+\5_`+@'_`&[/VG?B1\<?V4?#OP!^"V@>)=6^
M(_PA_P""GOA;XN?!SQC\6M`\#?!SPM\>_P!A3]K_`/90_9H\4^/M:_:#'PF\
M9_&*Z^$/AWQ'/\??"'P?U3X>_`+5?&?Q5G^*?PIUOXK_``*^%VDGQ5XG^!>!
M>?L<?M&?"W]IK]CBQ^`WQ@_X1SQ9X5^`/_!6+XG?$[XW^*?V>;KXB_LY^(OC
M5^V!^VA^Q)^T'X]^''C/X:V?Q`\)^+/"?@#Q9XL\6?&7QG^SUX`\._M.^%_B
MYX=M?A!X43Q-\7?C=X3\!?&/1?BE]>?`?]AO_A2_Q(^"/Q0N?BA_PE.O_#CP
M!^W]IWCRS@\%?\(_H_CCXI?\%$?VKO@E^V%\6?&/A&WD\6Z]>_#SP!X.^)GP
MQ\6:'\._AKK.H?$OQ%9^!?&7A[3/$OQ7\2Z_X(U+Q/X\`/`O''_!3#QUX<^$
M?A7XNM\./V0_@[X3A\?_`!6^!GQ.^(/[;O\`P4!T?]E#X*Q_M&?!CXU?&OX"
M^/?A+\`OB!9_L\_&?Q9\8O[/\6?L[?$WQE8:_P#$;X6_L[76O?"/5_AAXJT#
MPWJGBS4/C%\/?@5WWP@_X*"^.OVF?BE\)O"?[./[-?\`;GPS^(G[(?[$?[<7
MB'XL_&'XQZ/\+?\`A`?@K^V+XB^.NFP>#KGP'X1\%_&+7_$?Q^\.:!\'8_$O
MA#P=H]R/A'XV_P"+@:-XV^/7P9O?"OP[D^-.!X4_X)Y?&/X5>-]3\;_!?]JW
M0/">K>-=?_:D@\8:UXU_9W@^*'BGX;_#[]IW]M?X\?MB^((?V0[G6/B_I7@G
MX#_%Z^N?CCI7@WXL?$'XF?#W]I/X:?'34?V<?V5/%OC/X!VND_!^7P#XI]>_
M8N_8;_X9"_X0[_BZ'_"PO^$3_8$_8)_8;_Y$K_A$_P"T/^&(/^&C/^+H?\C;
MXF^R_P#"SO\`A?W_`")7^D_\(7_PB?\`R-OBS^WO^),`?(?PF_X*;_MC?'?1
M_P!C.?X9_P#!/7P!9Z_^W+\`;G]J'X6Z9\2_VVK'PMH_P]^!?@/P+\,]0^+O
MCGXX:YX-_9M^)M[H7V_XF?'GX`^$?V;O#/PG\/?&CQA\5/`OQ+NOB)\=O#_[
M)6O^!_%7POL_7OBA_P`%)]1T;X"?LY?M1?#_`,(?LQ?#S]G[]HCX0_"'XK:%
M\5?^"A_[;GA;]AOPL^H_';P9J'Q#\!_!_P`*7'A?X2_M47/BCXO:#X)T/5O$
M?Q.T76K7P/X6TK3K[PT_PM\8_&22+XF1_"SU[]G/]AO_`(4#_P`,$_\`%T/^
M$L_X8@_8$\8_L-_\B5_8/_"SO^$L_P"&+O\`BZ'_`"-NL_\`"%_V?_PR%_R)
M7_%6?:O^%A?\C;;?\(G_`,5-Y#\.O^">7QC^"7A;]ESP_P#!?]JW0/#>K?`_
M]B/X)?L*>,/'/C7]G>#XE>*;'X??"33K&R\0?$K]D.TUCXOZ?X)_9A^+WQDN
M;?2M8^+%Y\3?!_[6?PT\=:C\&_V5(O&?PP\4:3\`Y=+^((!O^%/^"@OCKX\_
M\*RU7]D?]FO_`(6UH'B']D/]F']N+X@:-\3_`(QZ/\#_`(I6'P5_:Z_X6E<_
M!_P=\&?#5MX+^*/PS^)GQ^FLO@9\4K7Q/X.^*?QI_9Q^$>A>(I/AI8+\>K_0
M/%WB_P`6?#+P+]K3_@M'\+?V6?BY^T3X'UG4OV0[#0/V2/[)_P"%T^$_C1^W
M%X=^!G[7GCSS/@KX#_:*U7_AD;]E:Z^#OCBR_:!_M7X9_$KPUX5^%/\`PEGQ
MK^!__"ROC]IGC7X4W/\`PAV@>'K#XF>(/7OA3_P3R^,?[/7A;X&^'_@!^U;H
M'@?5O"G[$?[)'["GQQ\<^(_V=X/'GBGQ9\/OV/M.^)-E\/\`XE?LZVE]\7]*
M\$_`?XO7US\<?B[K%]>?&?P?^V#\-/[1;X5Q7?PPU/2?`_C32_BSZ]K_`.RW
M^T9H'Q<^.?B_]G?]IWP!\'O`'[4'C_PW\4/C3I_BO]FVZ^+GQJT#QUIGP5^$
MO[.6JZY^SU\4+KXZ>#/A-\/MGPF^!WPZU'P9IGQD_9H_:1T?0/BY'XI\8^+M
M/^)'@#7;#X0Z``'Q,_;D_P"%=_!__@J%\5_^%7_VQ_P[;_X6!_Q(/^$U_L__
M`(7-_P`(+^PO\#OVTO\`D*?\(E??\*[_`+4_X7-_PK7_`)!WCK[#_P`(W_PF
M/^F?VQ_PBNE_(?[*'[8G[8WB[_AGFV_:;\*^`-!_X6[_`,%.OVZOV7O#VM_!
MGXW6/C;^UO#OP*_X>E:O/X&^)?A?Q=^QC\,/(\`?"#_AECP!\/\`X8>)OAYX
MO\.?%+XT?V'X8^,'Q3\0>!/+^(GP-^*'KW[47_!/+XQ_&_0/VXOAC\*_VK=`
M^!OP=_X*"Z!XFG^.UK>_L[P?%3XQZ3\0==_9B^'_`.RL9OAC\1]6^+_ACX>>
M&_A#K7P\^#7PLM?'OP^\2?`OQK\2]6@O/C&WP]^/GPH\1^./AOXK^"&_\+?V
M"OBEX)\=?#C4/%G[0/@#Q5\,_@G^WW^U'^W)\)O"/A[X`>(O!OCJV_X:QT?]
MOV#QY\+_`(B?$34OVA/&^@>,_P"P-?\`VX;;4_"/C7PU\+_AS]FT?X5SZ'K/
MA+6KWQY'XA\$@'?_`+-7[6GQT^/GPMTGX_3_`+)_E_!3XN_`&Q_:2_9DO/AA
M\=O!_C;XI>._!_B/P[H/C3P!\,?C-X!^*?AO]GWPG\%?C]\2/"?C#P]+X8T'
MPC\5/CK\"](\1:'\2]%^(G[17@33=!^'GB/XM?`GQG_X*O\`CJS^%O\`P4(^
M$UGK/[(?A7]K?]GW]@3]N;]H[P7<_L??M@Z/^VU_PI?QU^R=X=T;PUXCT?\`
M:-\)^/OV</@+>_"+Q_I'Q,^)7@&3X>^"?$?@/XBZ/X\_X0_XQ:;XTC\'2^`[
M/1O''VY\%OV)OC'\-O@)?_LHZ]^USK]O^S]X._9BNOV2/V>!\!?AK!\#?CW\
M.?A]#X,TKX;^#?BM\0?CMK7CWXP7/C?]IWX8>"?#.A?\*_\`B3\(?!?[-OPT
ML_&>M?$+QCXD^!OB>34OAAI/P>\!\:?\$O?C'\7?"WC3PW\5?VH/A#I&DZC_
M`,$Y?VP_^"<'PM^&W[.?['4'P+^`GP6^'W[4>G?`&PT7Q]X1^'6K?M!?%;QM
M-K_P_MO@C;Z#J_@V3XO6GPT\1^#+7X;:%\//"?P2U;P=\0/$_P`9P#W[Q+^W
MGJ.D_MKVW[(VE^!/A";F'7_"?AV7P[X^_:?\+?"G]K7XFZ=XE\$:-X\UCXV?
MLL_LJ>,/`\.D_M$?LQ?#'2=>O;;XG?%BT^/?@CQ38:W\$?VK/"G@;X5_$#QM
M\%/#_A?XJ?HU7Q'\;_V8_C'\;_B#HNGZ[^T+H"?LO0?%[]GSX\ZM\(KSX)07
M7QCTGX@_LT_$OX:_&?X?^'?AC\?]%^)/ACPMX;^$.M?%7X->`O%7CWPS\3/V
M?OC5\2]6@\1?&/P]X7^,O@S0_%/PMM/@A;^('[:?@ZW\7:U\'_V>?"^K_M3?
M'O1KEM+UGP-\,[R*+P#\--79(V5?C_\`'*6TU#X>?!F"T2>"_O\`PYJ%SK_Q
M?O\`1VFO_`_PE\;W$(L)`"[^W9X]OO"W[./CKP/X0@BUCXQ?M`:9J7[/GP)\
M)^;*MQXB^*?Q6TC4?#6D7L\=HDU]'X3\`:;<ZM\4/B9K%K!*/"_PQ\%>,/$]
MQLM](D:OHGX6^`M/^%?PR^'/PPTFYEO=*^''@3PCX"TR\GBC@GN]/\'^']/\
M/6=S-#$6BAEGMM.CEDBC8QQNY1"5`->(?!KX`>)-)\93?'?]H#Q5I/Q._:&U
M'1[_`,/:;?Z!I^H:1\,O@SX+U6ZL[R^^'?P4\,:M?:C>Z99:G-INEW'CWX@Z
MW<3^._BCJ^F65UK,^A^$='\%_#WP7]54`%%%%`!1110`4444`%<KXV\=>"?A
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M('AV6-H?L^M?`+2OC6+B6Z@$-H]O!JMSI:GPU_P4K^)X\S7OB;^RO^R7HEPQ
M,OA_X7^!_'7[5GQ)M[=MIB-C\6_B5J'P%^'>DZ@JE_M<%[^SAXWL5FVQVM[-
M%$;FZ^_J\A_:#^-/A;]FWX"?&_\`:)\<V&OZKX)^`?PA^)7QI\8:7X3M=.OO
M%.I>%OA9X,UKQSX@L/#5EK&JZ%I-YK]YI.A7=OHUKJFMZ-IUQJ,EM#>ZKI]L
M\MW"`?+_`/P[\\.^+`'^/7[3_P"VI^T)-(3+>67B']HKQ)\#_"-]*XQ+!J'P
M\_9`L_V;_`>M:.R@1IH/B3P]KNE%$26YM[J^\V]F[3P5_P`$[?V#/A[JI\0^
M%/V.OV;;+Q6Y5KCQOJ'P=\"^(?']ZZ+(!)J7C_Q'HNK>,]3E)GN97FU#7+F5
MY[N\N'=I[RZDES?"<_\`P4'\+>*?#7BOXJS?LQ?%7X>>*]?T;1O%7P4^!7P^
M\>^`_B7\"].\8:C;0#Q9I?[0/Q<^/FH>"?VGM`^#=S<6]AX^MI/@!^RCXI^)
M'P^7Q3\8?AYX:TSXA^%O"W[)_P`53Q+^VQ!X,^(-MH?C#]F3]IWPI\&+SXO>
M$_@5:?M5^)=#^#FA?!RZ^)?CSXEZ-\"_`VEVWP]U3XUVO[7<^@>,_CYXB\/_
M``C\)^/HOV86^'WB*?7=&^+^C^*;S]FO4[+XW3@'VC8:?8:59V^G:796FFZ?
M9QB&TL;"VAL[.UA7.V*WM;=(X((UR<1Q(JC)P.:MU^<OAK_@I1\/O$^OW+P?
M`']IW1_@[H_[3OBS]CGQ5^TKXE\(?#30/@YX;_:%T#]IW6?V0O#W@^VTO4/B
MW%\;_B-H'Q&^-\7@KPSX3^*/P8^#?Q+^$VBS_$O1M.^*'CGX=^(_AW^T#H/P
M:]>^&O[7^C_%7XI:CX)\*_!#X_3?#.+Q_P#%?X1:!^T[_P`(WX%U/X%^*?BY
M\#/$7C'P9\6O`'V'PW\1M>^/'P\_X0[QS\,?BMX%_P"%C_&OX'_"[X*^*?&'
M@#^P?`_Q.\3WOQ,^!B?%4`^O**^!/@Y_P4$\'_&'Q%\$D7X$_'[X=_";]J7?
M_P`,G?M#^/D^!<WPM_:1^W?"WQ9\>O!__"%^&OA[\=/'_P`?O`'_``G_`,`?
M`'COXQ^'/^&@O@E\&?[,\.^%;SPGXZ_X0[XLZIX9^'.N]_\`L;?M?Z/^VO\`
M"WP[\</`GP0^/WPQ^$/CSP!\,_B)\+_''QR\-^!?`_\`PL_1_B'X=EUS4(/"
M_@K3/B-XG^)FF?\`"`7L2Z#K?B'QUX)\'>!?B#]LTCQU^S[XN^-'PAU[0_B1
MJ(!]>45^4W[,?_!0GXV_%SX)>._B+X\_8-_:=A\;:-^T[^T3\"OAYX"^'UK^
MS9JL_P`2X/A3^TG^T=\,X]+@UVW_`&M?%'P\^&NO_!OX>?`]+#X^>/OV@OB3
M\$?@YXS^,:3>&/V:/%/Q3N?B!\*O"_B+?/\`P5!\'R^.M!^".E?LJ_M>>(?V
MG=6_X7-9ZS^S1X>\,_`O5O'7@#Q%\#]'_97\=^)?#GQ$^)]M^T`?V6O"O]N?
M!G]L7X+?&7PCXTNOV@Y/A;J>CZM/\)K_`,?:3^T[?^$_@-XG`/TZHK\Y?$O_
M``4H^'WAC7[9Y_@#^T[K'P=UC]IWPG^QSX5_:5\->$/AIK_P<\2?M"Z_^T[H
MW[(7B'P?<Z7I_P`6Y?C?\.=`^'/QOE\:^&?%GQ1^,_P;^&GPFUJ?X::SIWPO
M\<_$3Q'\1/V?M!^,N_\`\/!/!_\`PF'E_P#"B?C]_P`*!_X7]_PR]_PU_L^!
M?_"B_P#A>G_"]/\`AE/_`(0;_A"_^%Z?\-9?\G9?\8Y_\)-_PS+_`,(?_P`)
MA_Q7_P#PD'_"@?\`B\5`'N/Q2_9`_9,^.37+_&G]F#]GKXN2WDK3W4_Q+^#'
MPY\<W$UPUP]Y]I>Y\3>'-3G-T+R1[Q+D2"=+MVNDD6<^97A!_P"":?[-WA\F
M?X,:O^T%^S/>!@8(_P!G;]I?XX_#KP?`%W%%?X.#QQJWP)U#R7;?;/J_POU&
M2T!F@M'@M;R_@N_FC]G3_@J;\5?B?HEUH7C']@?]IV]^-^K?%[]M/1OA[\,/
MA]J_[&5A/XQ^#G[)W[6OC?\`9X\;^+(-:\9?MQ1^"=/U_P"`=S??`3X9_'RV
M\1^/?#4_COXQ_$V;Q1^S%X:^*GP0TCQ;XR\!?3LO_!03P?K'AWX5O\*?@3\?
MOC?\6?BE_P`+^Q^SQX!3X%^'?BEX%_X9,^*6B_`7]J?_`(33Q+\9OCI\*/@#
M+_PH;X_>)_"OP<\1_P#"#_&WQK_PG7B+Q%9^+/@I_P`+2^$UAK_Q&T<`9'\"
M_P!O#X:@'X5_MM^&_C)I%M@)X6_;&_9\\)Z_K]Y:)S%IEA\6OV8]6_9N70+B
M,;84\1^)OA-\4[Z6TBVZEI^J:M<2ZX$_X:I_:8^%W_)RO[$'CR+0[;"W_P`3
M?V/?&4'[6O@RT12/],N_AROA7X3_`+44[7,9\X:9X&_9_P#B-)93)<64NH7*
M)97^I^A_L-_M':Q^U?\``&;XTZSH_P#8/V[X_?M@_#O0-+G\$^.OAOK$/@7X
M%?M>?'/X%?#F?Q=X!^)L=KX_\'^/[[P!\-_#5_\`$3P]XLTKPYK&E^.KKQ#:
MW/A'P?Y:^%M(^O*`/#?@E^TO\!/VCM/U;4/@E\5?"'Q!?PY=)8>*]$TG43;^
M+_!>I21I-'I7CKP/JL>G^,O`^KR02Q7":3XMT+1M1>VF@N%M3!-%(_N5?.7Q
ML_9,^`'[06H:3XC^(_@"V;XA>&[>2V\'_&#P9JVN_#7XW>"(9',QA\&?&7X>
MZGX9^)7AJR:Z$5Y<Z3I?B:#1M1NK:UDU33KX6\2KX6WB7]I_]DHF;XEWOB#]
ML#]G*S5C=_$[P]X0T^V_:K^$>EQ8QJ'Q$^'7@33M/\-?M%>$[&!9)=4\5?![
MPGX,^*NCV\5I$/@[\4)IM:\6Z<`?H#17/>$O%OA;Q]X7\/\`C;P1XBT7Q=X/
M\5Z18>(/#'BCPYJ=GK.@>(-#U6VCO--U;1]5L)I[+4-/OK66.XM;NUFDAFB=
M71R#70T`%%%%`'\H'[#O_)K'PG_Z\O$__J;^)J^KZ^4/V'?^36/A/_UY>)__
M`%-_$U?5]?I=3^)4_P`<O_2F?R/Q#_R/\\_['&9_^IM<****@\<****`"OF/
MX^_M4>#/@'J7ASPQ/X2\>_%+X@^*-/U#7=-^'/POA\%R^)X/"VDW=EI^I>+-
M8OOB%XV^'G@S0=#BU+4;/3K'^V?%ECJGB&]-]#X8TS6SHFOG2_IROR[_`&UO
MA-XG\8_M+_LK77PN\7^&?AYX_P#B/HWQ<^%OB#Q/XP\"ZK\2_#]WX.\*^&_^
M%JZ-;7/A+2OB#\-+XZAI>MZ3J\.EW^G>+M*"1^*-3?5[;6XK72[6SB:J./[I
M7E=-VY;J":=1Q4Y0CS*"DUS2LFK\M2WLY>3GU/BFIDF;O@G"Y+C>*J.78K%Y
M-A.(JN+H9'7Q&"I2Q=:&95<#4HXV.'C@Z.)GR8:K2K5JL*="-:A[5UZ72I_P
M5$_9YO3+J.A>%_C1XA\%^&Y;BQ^+WQ!T_P`"V%CX<^!6N:9$DWB/P[\1-*\1
M^)M#\>ZSK'A&)Q)XM3X1^#/BA9:!&KRWU]'$K.'#_@J%^SW`(]3UGPK\:M`\
M%^(WM+3X1>/]0\!V-[X?^.FLZJHD\.^'_AWHOA[Q+K?Q!T;5_%41^T>&D^+O
M@GX7V6K6:R7T-\+**6X3Y$^(G_!/C4OA1J7PW^$?AOX\:G>_#3]L3XV>+?"/
MQT3Q!\/],O\`X@0^(O&OP?\`BQ\4_B=XE^%'BJT\1Z;X5\#:3XNA^&-SH.F>
M%/$7PY^(1\*7/BFZUZSU^_;3H=*NH_`'[!&N_$SQE\3/@QXM_:"U/3="_8Y^
M)/@H_`.'1?`>DCQK?$_#'PMXM^$/CWXR>*;WQ!<Z=\0]"TRS\3^)_A_XD\)^
M$?!?PAN?%5_X4UO49/%D)O;=K7&,ZRA>5.4IJ4X24)4XPE5A2A/EAS/F5.:F
MJB<WSPDU%N232^+E7\97F%2%/*?#..6+-9SIRK9IQ0LP?"LLHQ$<-CYRI8.I
MAEFE;BW#5,OERT94J64)1>5.M)9V?7H_X*:?"@D^&_\`A3O[0@^,ZPIJQ^`!
M\._#3_A8)\&O++;+X_'C`?%<_`!O"?VR%M.>4?&HZW%JS1:-+HB:M/#9/EZ7
M_P`%(_V:[*36M3\"_##XM:MH,&M7M[\?/&'A'X?>$M+T_P"$7CJQM;6S\6Z=
M\5M-U3Q?X?\`&7C+QKX6TK3;%O$TOPC\,_%Z3^Q;72)]/U#5-/N]">\^!=9_
M9]^(VE?"/]H']M)OBWX8F_:!^!.L?&KX(QVT7PIO8/@OXK^%7P=^(>M:8=,N
M/`,OQ.N_'>D>+/$GB?3F\5?\)3;_`!@O+/1XFM=`_P"$:U2TM[JZU#["^`G_
M``2NO_&^K_M1_!_PI^T;JWA2UU'5O#_BCXJ^)-<^&>C^*=2UKQO\:-"?4/&^
MN_#32[;Q3X;L_`^B:KI5C=:+HVD>(Y/'\7AB[TG3[XW7BB]N-=>?\I\9/&G@
M/P&X!S+Q.\3LYQ'#W!638C*<-F>;PR?'9U/!SSK'T,IRRI/+\EIXW,\1'$9C
MB:%*JL%@JTX4:MW2H\DZR^CX1X.^E!QH\=E^0\*>$V+SC`</\/YGF5!9[Q%A
M,+A\;'B7+,GXYHJIBL1%2P.687.,LKY#3C5Q5:.,J.KB<;GM*E+`+U$_\%/?
M@!;O'J>I>%/C#I?@#Q`5MOA7\4Y?"OAO4_!?QKUF_263PKH'P\LO#OC36O'M
MGJ'C](A_P@-W\1_!/P_T'Q2]SIT.G:RTVKZ3'>P?\/-/A:EQ+X7N?@M^T/:?
M%UH%U72O@A+H7PIF\<Z]X262ZAO?'6F>*+'XP7?P5@\*:3=6T.GZM=:U\6=(
MU*PU?5O#NB3:6-9\2:%8:A\\>`_^"9^M_%?XFZ3^S%:_M`6'A_X7?`[2/#_Q
M'^"&K:-X.AOO$5C'X'^('B/P;\(D\0^+M0\07^F?%O3='\+>"YO%VDVVF^%/
MA@_Q!TBYTZ[U37[_`$[0O$5QXM\Q_:'_`&;?''@;QM^TQ\4OAK\4[;QE\:_V
M:O%FK_L_>"M-U'X?3VGPW\6>'(/V6_!'[47CCP[>^!1XJB\4/XD\5^.-1T31
M++Q#IOQ,MH]$3P3HE_$=2T6X\2^']<^4X<^E!X1<4^(LO"K)>(LPQO&\.",)
MXBULHEPIQ1EL<'PAF&9Y5DF&S7&X[-LHP>#H5ZV:YQA,-ALK=9YG1E[6&88*
ME4P^*5'VZ_A5]+:A"O./!?A`XU,#Q=7R^6(XGS6:JXFAP]#BOP_HU:>"S2;Y
MLUX?<L5Q)!UJ-"565.66X_*(RIX6M]LR_P#!3CX,36@OM!^%_P"T'XJ@T*9K
M/XL+H?@3PW'>?!#4H0L]WHWCO3-=\=:+J?B;6K+2WC\07.D_!6S^+-__`,(Y
M>:+KD,$VG>*/"L^MYC_\%*?V6T\1+XVO_!/Q+M/!D^FW_ASP-^TB_P`/-#U+
MP;\0([J6'4+3PCX(N-%\0:K\719^-=9T^TM?!TGB#X?>&_"/CSQ#'HL'AO5M
M7N]4\//J'RK\.OV+OB1J_B[P_P"'_A!^TCX=T^']I7QQX3U/XA>+_''PQ$UU
MJNJ^//@;K7CB3XB_"D>&O&=C8_#"5_!_@#2/AWX,T7Q2OQJT6\\0Z'X=O+NY
MGU:#Q9=>._5-+_X)IW>J>%_!/P@;XWZQHOPD^''@_P`&:]X,L]*\$:<GQ#T/
MQUX"^('C6W^%?A_Q+XDU+6+_`,-:QX;^$1^'WP[\3MX?O?`EOXD\:W%OX?'B
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M>O#FB?&GX&_%;XF_L]^!]5T7X.ZK_P`*=N_!%C/X:O?%]SXK^%E[\8[KQCJV
MM>,M3MO#>IFZTOXT:!;:'=>!O"*P6=[;1>(X/$WC6D_`;XGZ!X>\*^/_``Q\
M9]%T'X@_M!?M;>(OV;OVBI=9^%5OXCL-"\<>!O&'Q&^#6C_$3X-:?:^.]!_X
M1.T'A/X9^$;'0?#GQ!7XKVVH:2WA'Q)KD\FI)XRD\8?K:EB/:0@E=2J1LI.G
MS*CS*+=2:<:<:BJ3IPJRO"E&BY5(N,DU'\NI8WZ1-;+W6CPSX-PS)9#@7[*O
MG7%E'+I<7U^(W#%X)U)XF-:.14^#,/B\PH-5Y8ZEG\(47B\QP<HX27Z'6_\`
MP5&_9RN+>\\4C0?B\/@X3/:^&_CS#X*T[4_AOXYU@7,FGZ7HOA32-%\2ZG\7
M))?$^L1_V!X1UO7?A?H7A'Q/K]SI.C:/XCN[_P`0^'H-5]P^`_[7G@KXZ>*M
M0\!_\()\4/A/X[M_#MYXSTKPG\5-+\(6]_XI\$Z;JFDZ)JGBGP]JGP^\;?$+
MPS+;:/J^OZ!8:WH6IZ]I?C+0Y->T.?6/#-C9:QIMS=?F-9?\$_"/B[-^P^OQ
MIU>V_9S\&?!WPO\`&GP&EKX+TV7XOZ+?:;\2]6L_AYX4UGXA:OKFL>%_$/AS
MX>^,/"VC>+[*1/AEH^M:];Z-HOA?7]4N]+3Q!+XE^I/V(/@QK\OQ2^+/Q<^)
M/CSP_P#$G7/@_P"+OB'^S7\+M:\)_#R\^&^@3Z)%'\,]3^+7B?4-!U?QO\2+
MR;Q=+\2?#%S\.UO-/\3QZ19Z1X$OKBQTW3KKQ?K>E:==L1%T92:<*L>:*C;X
ME5K4ZW/[O,J=)T>2DU[TZDESOD:9]7@GXMT^(,+#/,F\/J'"5?..+9U\7EN8
M9_5XAI<)PPN'_P"(>8S#T<75I9=4SW-,?];AQ70E&KAZ6`4,3EF%P%2E6HR_
M42BBBMS[@****`"BBB@`KR[XX?\`)%?B_P#]DN^('_J)ZM7J->7?'#_DBOQ?
M_P"R7?$#_P!1/5JZ,)_O>%_["*/_`*<B=>`_W[!?]A>&_P#3T#]P?V(?^3+O
MV0_^S7_@#_ZJCPG7U!7R_P#L0_\`)EW[(?\`V:_\`?\`U5'A.OJ"OR\_L4**
M**`"O/OB?\)OA=\;?!VI?#SXQ?#KP1\4_`FKM$^I>#_B%X7T7Q?X;O)K<LUK
M<S:/KUE?V!O+.1C+97@@%U93XGM9H9E5QZ#10!\`)^Q_\7_@^&F_9$_:P^(7
M@+1;<F2R^"'[1]G>_M5_`J(!@SV>CZCXM\2^&_VEO!=LT*C3])TSPY^T4?A_
MX4MO);2?AI/;VHTZ<'[1G[8WPO*VWQW_`&(=4^(&EPD12_$;]B[XJ^$OBYI7
ME#(75]>^%7QF'[/_`,5="$X1C/X>\`6'QNO=.GFM((=4UFT-[JEE]_T4`?"&
ME_\`!3']B9K^RT3Q_P#&NT_9X\4W\L=K:>#OVMO"'CW]D;Q7>WT@(%EH^B_M
M)^%_A?<>)G9P1;7GA4ZYI>IQ^7>:1?ZA87%M=S?:OA[Q+X<\7:/9>(?">OZ+
MXGT#4HEN-.USP]JMCK6CW\#J&2:RU/39[FRNHG5E99()Y$96!#$$&KFI:9IN
MM6%UI6L:?8ZMIE]$UO>Z;J5I;WUA>0-@M#=6=U'+;W$3$#='-&Z'`RIQ7Q5X
MA_X)I_L%^(-7OO$D'[*_PD\#^*]3E-QJ?C/X.Z`_P*\;ZC=;_-6[O_&OP8NO
M`7BJ\O(YQ'<PWESK$MU!=V]G=PRQW-E:2P@'W'17P%_P[Z\.:&0/AC^U9^WM
M\+(8P!;6MK^UO\2/C1:V8/#I;P?M5S?M!(82DMY'%;3^?:V27:KIT%F-*\/_
M`-D)_P`,N?M@:.67PW_P4U^-^N)D(C?%[]GG]C?Q5<>0ZB29Y9/A3\"_@/`]
M_'<KY=C<1VL-E!ICR6M[IFI:B8]9B`/OZBO@0_";_@I78$OI'[;G[*&HLV4:
M/QY_P3Z^(.MP)"#E)+=?!'[??PRG2^)`66:>YNK)T+B+38'*21H?!7_!4FP(
M(_:7_8#\6"7(,9_8=_:(^'IL2F"'$O\`P\*^)O\`:GG[B#'Y.C_9/*#>;>_:
M-EL`??E%?`?_``CG_!4G_HL?[`?_`(C7^T1_]%?0/!'_``5)O_WA_:=_8#\*
MA/D%H/V%?VB/'_VGJQN?[1_X>*?#7[#C(B^Q?V7J&=AG^WCS/L\0!]^45\!C
MX0_\%)-2.=<_;C_9DTOS"()5^''[`7B_P\L5F0`\]C_PL']N'XMO#K@#2M#>
MWKZEHR.MH9?#=PD-U'?I_P`,K?M:ZT-OBO\`X*:_M`:3%)D3P_"'X#_L9^"O
M,B4;5BAN?B1^S]\;;^T$ZLXOI[>\2\+>7)I5UH[QEG`/OVN;\6>,O"'@+1;C
MQ)XY\5^&_!GAVT9$NM>\6:YI?AW1;9Y`Q1+C5-8NK.QA9PCE%DG4L$8@$*<?
M$A_X)Y>"M=W#XH?M,?MW_%F*4$7=GJO[8OQC^%&EWX<,)XM1T3]F;6_@3HM]
M870;9>:-<Z?)HEU;[[*?37L9I[:7IO"O_!-[]@_PEK4/BBV_92^#'B;QC;!Q
M:^._B=X0L_C#\0;7SBINC:^/_BP?&GC*V:^9(I-2>#7(VU*6"VEOS<R6UNT8
M!A7G_!33]C&]N[K2?A9\5+W]IKQ!;7$UB^@?LA^`/B%^U=<Q:E;R-!/8:KJ_
MP"\+^/\`PKX5DM;E&M-1O?&7B#P[I.C7*M#K6HZ<R/MK#X]_MN?%4>5\%OV,
M;3X.:-<#$7Q`_;1^+'A;PM=I;LDA35=#^"O[/ES\</%6O#S1$!H'C_QQ\#]6
M\EII+J6QFBBMKG[WM+2UL+6VL;&VM[*RLK>&TL[.TACMK6TM;:-8;>VMK>%4
MA@MX(42*&&)$CBC141550!8H`^`&_8M\>?%QA=_MB_M/_$KXU:=<!6O/@K\(
M([[]EW]FTEU)N;&_\)?#_P`2ZK\9_B'H=T7-OJ'A?XR_'[XD^"M5L88;>\\)
M!9M1%]]G>`/AWX`^%'A'1?`'PN\#^$?AQX%\-VB6'A[P9X%\.:/X3\*Z'9)]
MVUTG0-!L[#2M/@!R?*M;6)"Q+$%B2>QHH`****`"BBB@`HHHH`*^*?VQO&_C
M"6;X&_LV?#;7M4\)>-OVJ?B5=^!]7\;Z'/\`8==^'_P5\%^%M7^(7QS\6^&]
M5Q))HOC&]\&Z(GPX\`:];6U[=^&O'WQ%\+^*([0P:'<W%O\`:U?`W[:=O-\.
M/&?[,'[7KQ3S>$?V:/B%XPL?C6\$32MH7P`^-G@B^\">.?'\WE!YX](^%7B^
MV^&GQ-\9W"P7,=C\./"7C;4GA5[*&YMP#[,\!>`_!OPN\%^&/AW\//#>E>$/
M`_@S1;#P]X7\,Z':I9Z5HNC:;`MO9V5I`N3MCC7=)-*TEQ<S-)<W,TUQ++*_
M6U#;7-O>6]O>6=Q#=6EU#%<VMU;2QSV]S;SHLL%Q;SQ,\4T,T3+)%+&S1R(R
MNC%2"9J`"O(?V@_@MX6_:2^`GQO_`&=O'-_K^E>"?CY\(?B5\%O&&J>$[K3K
M'Q3IOA;XI^#-:\#>(+_PU>ZQI6NZ39Z_9Z3KMW<:-=:IHFLZ=;ZC';37NE:A
M;)+:3>O44`?$?A.#_@H/XI\4^&O"GQ5A_9B^%7P\\*:_HVL^*OC7\"OB#X]\
M>?$OXZ:=X/U&VG'A/2_V?OBY\`]/\$_LPZ!\9+FWM[_Q]<R?'_\`:N\4_#?X
M?-XI^#WP\\2ZG\0_%/A;]K#X5?`GQO\`^";WQ[^,_P`<=%\>>)_AW^Q'X[\4
M^"OVW/V?/VE?#/[;OQ6N/&?B[]K6V^`GPB_:_P#AK\<M._9-^#_@)/@Q:^'/
MV2=`^&OP=T._^&&B^*?AU\>/B'X,^.NM^$?&/CKXD_!7P5\5?VT_C)\8/A5^
MC?[0?Q@^*5C\4OA-^S#\`;GP!X7^-?QF\`?&7XP6?Q/^,'A#Q%\1/A;\._A;
M^SYXB^"/ACQ]<W/PT\%_$#X6>+/B9X_\4>+/V@_A7X4\(>$(OB;\+/#NE^'=
M4^(/Q2UKX@7VI?#/PY\&?C-X#\<OVGOVI/V2/@#XB\:?'7PIX`\?:_X)^/W[
M$?@M?C!\&/A;\1+GP+\8?A;^TS^UY\(_@=\3;/P1^R[H'Q-^,/[1?A3X_?"C
MP;XU\4V>E>`=+\1_&GP[X_UBY^#OC[P#XC\;:_XV^(W[-'P:`#_ABWXI?\,J
M_P#"C?[?\`?\)9_P\Z_X;2_M'^U/$7_"._\`"K?^'S7_``\3_L#[7_PBO]I?
M\)__`,*4_P"*7_LO^R/^$=_X6E_Q)/\`A*O^$3_XK>N__9K^#_[4GP'\8>(_
MA7]F^`-Q^S//\?OVKOV@_P#A:W_"7_$36_CIXY_X:C^.GQC_`&B_^%3?\*0_
MX5_X5\`?"#_A77C_`.-W]B_\+E_X7]\<_P#A.?!_PF\K_A2/@C6OC9_:7P'(
MO^"@G@_1_#OQ4?XK?`GX_?!#XL_"W_A0.?V>/'R?`OQ%\4O'7_#6?Q2UKX"_
MLL?\(7XE^#/QT^*_P!B_X7S\?O#'BKX.>'/^$X^-O@K_`(07Q%X=O/%GQK_X
M5;\)K_0/B-K&!X@_X*4?#[X<^#/B9X@^./P!_:=^"?C;X2Z_^RK9^+O@=K/A
M#X:?&#XQR^#/VR_CV?V:_@5\3O">B_LK_%O]H'PMX[T#Q#\5=(^(&CW/@+P7
MXPUWX]Q0?#'Q++8_!S4KGQ)\*K/XC`'S%^P/_P`$SO\`AD;Q%^S[H7_#$G_!
M,7P/_P`,U^`+/P#_`,-N?#7PQ_PD?[8W[0G_``C?PMO_`(1_\)IJ/AW_`(9H
M^#O_``SMX_\`C/\`VA_PLCXK^(_^&D_VHO[-L3XQ^"?V/XA?\+&_X7EX(^G?
MV8_V`M$^&WP$_82\+?%KQE\7I/C%^R-^S%^S#\%M43X+?M<?M:_#CX">(/%/
MP#\&:!IU[?W_`,&_`WQ.^&7PJ^*F@:MXIL-2%U=?%CX1ZAJ/CCP8=*\*^.]*
MN_#EC:>&;#G_``O_`,%0?!^K_%+5_A?XP_95_:\^$G_"`^/_`(&_!SXZ_$3X
M@>&?@7=_"WX!_'3]ISQ%HGA[]GSX)>+_`!=\./V@/B#_`,++\?\`Q+_X6#\"
M-<N7_9FT_P"/7@_X2^'?VC?@_J?Q\\6?"?[3X[@\"=__`,/!/!__``F'E_\`
M"B?C]_PH'_A?W_#+W_#7^SX%_P#"B_\`A>G_``O3_AE/_A!O^$+_`.%Z?\-9
M?\G9?\8Y_P#"3?\`#,O_``A__"8?\5__`,)!_P`*!_XO%0!\Q6_[(_[9L'P2
M^*/P+U+PI^S%XJ^&Z?MN?M,?M"67PWU']H/XJZ-X6_;4^`G[3G[2?[5GQWU3
M]G[]I?5K3]E/4]6_9UT#P;JWQK^$OB;Q?X>\"67[4W@S]IK3OA9XQ_9P^+&F
M:5\"_C%XY&HX'[!W_!-;XI?LN?M7>)OCQJOA3]D/X1_#/Q+_`,-9ZCHWP,_9
M.T+Q%X-\"_#'_AHSX;_\$C=`\->#O#/ANY\">%=`UG_A$M?_`&$?C3#\0OB5
M:VG@7_A:VL>(/!_Q?L/A1\.+WXG>+/A+\(.?\"_\%6OVA=8\+?`SQ/XV_8J^
M+WA63XD_\%&OVK/V.9/#.GZ%\)O''BGXEZ!\)]._X*1)\//!_P`(=.^%7[4O
MQ,MO"OQ>\&^-OV2?@]\.OVC?BC\=[_X?_LQ:!J/B#XH?$G0/'-A^S]I]Q\9/
MAW]N?\/!/!__``A_F?\`"B?C]_PO[_A?W_#+W_#(&SX%_P#"]/\`A>G_``HO
M_AJS_A!O^$T_X7I_PR;_`,FF_P#&1G_"3?\`#37_``A__"'_`/%`?\)!_P`+
M^_XL[0!^0_Q*^(^L:+KFG?L#?#OXN_LA^*KVP_X*\_"C]HK4/AI_PL[QU)_P
M4*\9:/XS_P""QG@[]M?XH>$_^&$-<\`>`M?^$O@#X)Z!XO\`%WQ;_P"&J8/B
M9\=_`OQ4_9-^!_\`POKP]\,_#WPS^/>F?$KX)_7GPU_X)G?\*W_:"U'Q/_PQ
M)_P3%\>_VC^UY\5_VIO^&\OB5X8_X2G]L:Q_X6K^TMXQ_:C_`+#T[X1?\,T6
M/V7Q_P##?_A,/^&??A1\6/\`AN!_^$/L?"W@[]H;_A!=1_L3_AF2Z]]/_!4'
MP?+XZT'X(Z5^RK^UYXA_:=U;_A<UGK/[-'A[PS\"]6\=>`/$7P/T?]E?QWXE
M\.?$3XGVW[0!_9:\*_VY\&?VQ?@M\9?"/C2Z_:#D^%NIZ/JT_P`)K_Q]I/[3
MM_X3^`WB?U[Q+^VQ!X,^(-MH?C#]F3]IWPI\&+SXO>$_@5:?M5^)=#^#FA?!
MRZ^)?CSXEZ-\"_`VEVWP]U3XUVO[7<^@>,_CYXB\/_"/PGX^B_9A;X?>(I]=
MT;XOZ/XIO/V:]3LOC=.`?F-K?_!,WX]^(O&^FZ]\7/V3/^"<O[7?@GX/_%[_
M`(*5ZU\&_AA^T9\7O&>I>%O&?A;_`(*,_MKK^UV_Q6\76?B;]@WXQ:3\'?B]
M\`])\$^%OA#I/@[PKH7Q=T[XEZ=\6OB3XD/Q@^&-MX"T[PA\7/KS2OV4/CW\
M%)_V5?BM^SM\$_V(]#\;?`_X0_M7_!;5/V5/`_B/QG^RG^S%X-\+?M;?&/X#
M?'2]O_AO\0O`WP"^-FK:YK_PIU;]GO1/!>N75Q^SO\-=._:*U_X@^-?CU-I7
M[/MS:VGP1U,\9?\`!6;X?>$/!GQ3^*<'[)O[;GC'X._!_P"+WQ=_9W\5?%'P
M;\+?AIJ6G:S^T+\,/CWXJ_9D\/?!OX6_#[4/C/I/QO\`C?K_`,;_`(WZ3X*^
M'OPB\7?!GX5^/?A,?%/Q:\*^&_BA\1?ACXC\"?M`Z/\`!;[<O_VE?A;_`,)%
M^S5X>\(ZM_PM+_AJO^WM:^%^N?"N_P##OC?P[_PJWP[\+=6^*&H?'[6M3TS7
MO^2`_P#)._AW%\5/#T'B+P[_`,+2^/?P!\(SRP?\+2T/4*`.`_8;^!OQ2_9W
M^`,WP[^-/BCP!XT^)FI_'[]L'XP>)?%/POT3Q%X8\"ZS_P`-%_M>?'/]H71K
MG0_"GBS5_$FO^$=N@?%#2H-3\(7_`(N\<_\`"*:Q%J'AZU^('C^RTVV\9ZY]
M>444`%%%%`'Y]V$2?LN?MC^"_`'AB&.Q^!G[:Z_%+6;7PC`!'IOP]_:K\!Z)
M_P`+(\0ZIX0L@$M]*T+X_?#2R^('B_QWHMFR:?;_`!*^&$_CC3]*_P"$A^*?
MQ&UN^_02OS^\>N/CQ^W7\"/"WAI4U#PI^Q#_`,)U\:_BKXDB)FT[2/C9\6?A
M#XH^"_PC^%=O-%_HTGBX_"'XL_%CXC^,+%K@:AX2\,ZI\+KJ_P!->S^*.AW\
M'Z`T`%%%%`'\H'[#O_)K'PG_`.O+Q/\`^IOXFKZOKY0_8=_Y-8^$_P#UY>)_
M_4W\35]7U^EU/XE3_'+_`-*9_(_$/_(_SS_L<9G_`.IM<****@\<****`"OD
M']HJ.'2_CG^PSXMF7,<?Q]\>^`;E_)N9/LEOXZ_9D^.=[9W>8'95\[Q)X0\.
MZ+B6UD1?[9^TO=6<-M.9OKZOSDU3XFO^TW^T'\-_@S;>#M:\&Z_^S#\>_%GQ
M<^+\'B-WABC\&^"],^*?P]^"5_X:N!;6\^L77QFOO$W@[XH:4L-I_8VD>"=+
M\5Z3J6M3:Q'H\>LYSDDZ<7.4.>K2CS13;Y/:0]JEK%2?LN=NGS)S@I_94FO1
MRU3C4Q%=>T5*C@L?&O*C:52%/$X'$X9/DYZ;<*DZL:#E.4*'M*U*C5JP]M#F
M]@_:S>?2+W]E;QO''+)#X*_:[^%27C1M$B0P?%;0?'?[/<,D[30SIY1O_C%9
M1*H199)Y(8H)H)WBFCS_`-CH?\+!T3QY^U+J$B+K?[2?B)-5L=)M[9[6T\,?
M#;X<W&L>!OAAX>_>WVH2WVKOHEI>>*?$^J-):0W7B7Q3JMO8:5IFFV5E:K\G
M?MT?M3:K#:^)O@]I'@.XL?B=\&_B1X'_`&B%TKQ!JGD:%XL^#OP(\9_!?X@>
M#O'$.H6^DRW)T[XH?&[Q%X2^#.@:3I*W%ZVM:#\2;J758T\!>(=.3Z>_9#\3
M^'?AG^R1)J'C77K+0/"WP:\>?M.^"M>\0ZS>&.QTS1O@U^T9\7?A_+>W5W+%
M`'ABM?":^4;>VACG_=QZ=9I%);6PE5(>UE&-U%0<YRYVH.K&2C43BVTW&DL/
MS.\%"T7RR<N==<L+6AE%.K4P\EBL5BZ."PLJ2O*ME?LWCZ5.M'V7-*I5S'$U
MIX94ZK7)2FIP<I14?GF;0[OQC_P31_;*UK1FEN-1^(M]_P`%!?B9X8C5K6>&
M[CE^,?QLUKX=01_9!/$]MJNA:-X6:_,%Q>^=->W\ME>/%+;&/ZW\6_M-3?`K
MPS^T=^TCX6CEU/PCH_[#+_%6\T^POY1?ZKJ=A?>)=5^'=_;QZ=+>01W&F>'[
MSQWK]UJ^C/=7!\/^']8,POK6PTS4-%_,KX=_M(^)_#'[./B+]BOQ!\&?%/P[
M^.GCCP!J7A#X0Z1XGN7_`+'U/Q7^TWKOB_7O"OAG6]3?3570+KX2?#[Q_P"$
M=>^)4/B'[!XEN+[0_B)IFC>%KMO#-G=Z_P"G?MJWMU\)_#R?LTPV$%SX.^+7
M['L/P[T/Q1=ZY<V=_J'C#P=\4?@_^S)9Z,NERWTFGP&3P1^UMK^K6XDANF$\
MNKW]BT-SI][>M_/_`-(_PAP_CEX9X/PVS'!8?%9!GO&7AUB^):.8T(Z\+\/<
M4Y?Q%G=.BZL7&AC\7@,LGE^$JSE"-&OF&&K*3I2;E^L>&?$LN!.*L\S+'4JM
M3'8G(>,<LRC"X;$5(Y9F&8<08+`X2CC,95M%XC)<OP]>KG>78S+UB<5#/LJR
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MXV&<X"OE68U:7$.3<M"A3HX">.RW.\?X:\/Y#A\ORW#8C$R6`X<H9WE.(R2A
MA'2JUL+P/1K<-4,)0]I4P,?T4^,$>@?!GXT_\$]?AEX)>[M;71_B!X5L[T?:
M[>)QX"_9L^&_CGXD^&K?7IHC96^GPWN@^#O'WAZUU.UL8;!KW7;JVO[<VTMI
M;)]"7_Q$E\.?M]?&'X'Z+I]H/AYXZTOXC?%?0KN.%X9=-^('PYMOV:-/^,%K
M:2>8?M>F>(/$GQ^TW5[EIH8S:>*[/Q0MI=7<-U+:Z5\R_M>>,_!_A[XY_LZ?
M$/3?"]SXZC^$J:U\7_CKJ7A^Z.J0Z'^SIK_PU^,?P9\.3WVF7$@\/:E#X@\9
M?%K6/%>@:=!<GQ%XQT;X8>.;+P[I7B.72V72>/\`@7\:;3QS^T=XL^)WQ'@L
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M_$&A>']5@\2^#M=DU#P_I\-]I]L_HWC#X\)-I_\`P3U^+>D^%KWQ7;?#/X4>
M'OVAOC6WAM@\O@+X6?&;X/?\*?\`#LMQ;20W*K+KWC#Q[-XOTG3YM;COM3\'
M_!?XEW6E:?K]WH32:?\`TC&IS4X-N:E*-&%TI<UXU:3Q-*?+&+3O+#^T7-%P
MB^:4>5IK\-GAIX>IBH+V<,+*KFE622P\Z551R[%SR2OAY5:TJ=3#IK'SA%+$
M4JU2-!Q=3$8>E3G]?7T#:/\`M]^%KF2+<OQ%_8_\>P6DYQ^X;X,?&CX;R:A$
MNVY8_P"E#X\Z8[^?9Q`?8T^RW-QF\BMJOP8:Y^%'[17QG_9[6]34O"/BO2[K
M]JSX?336\T>KZ'J/Q8^)GC9?C1X.U"X2YFLK[2;'X@/8^-?"U^EGI-V+;XAZ
MIX=N;;4#X6&N:EY_\!/B5=?M5?'GPK\<-,\/7W@WP_\``SX%^+_A'X\\,:ZE
MQ_;>A?M!_&^^^`WQ%^('PRFN7M+1+K4O@-IOPST[PAXV=[733%XP\57FE&RE
MN]$O$TS!_9*^)UW^T)^T5\0?C#J^@1>&-5T;]E[X'^"+_08+FZN$TGQ5=_'3
M]JV#QSILDEW;6<\L5L/`?@^>S\^WBN;.6]U*PNE6YMYE&M*<9N,N=NFY5(TN
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MQ<;SP-8?$23XD^';+0!K_BGP7H?ACQ+X)USQ/Z-\<OA7_P`+D^'=QX-AUW_A
M&=7L?%WPQ^(_A/7I=+_MW3=-\>?!GXG>#_C%\/9_$7A]-1T6Z\1>$3XX\">'
MXO&7AS3?$7A76?$'A236=&T3QAX0U>]LO$VE?%WQ:_83^*?Q@U[P?\6_$/[4
M&KV?[0'AO2/%_@J76?"T'[1OPK^!=G\-O%][X.U2\\,>"OA'\!/VO_@[\2/#
MVK_VU\/?#7B#5/%/BC]HCX@R^+=7U/Q/#XPTO7?#>@?L^^'?V?\`"K*NG^ZA
MS6BK)N"BVY-2YFVI7C&THJ-D_>4G=QMZN`IY74II8_$2H.56HIRA"O.K3IPA
M3E1=)0IRH\M:;K4J\JOM)T[49TJ=E44_J+Q'^TWX#\+_`+0'A7]G"_TCQ=-X
MX\7_`/"`_P!FZK9V&C2>%(/^%C>"OVLO'>B?;KZ;7[?5XOLND?L<?$ZVU7[/
MH5SY&I:[X$AM/MUKJ?B"\\+_`$77PQ\)_P!ASPI\(_C?HGQ-T+Q-]N\#^!?"
M,O@3X4?"W6-%U+7/^%:>%-"^#_[/GP?^$^E:'XW\2^+=?U>;_A4>D?#S]H^[
M\*WTUA'J4?\`PVC\=[>VO-.NO%_Q%U/XG_<]72=5J?M4HOG?*DTUR65M59O6
MZNU%M*[BCGQT<%&5!8&I.I!X6DZ\JD90DL3>?M4X2NHZ*#<83J4TVU&I-*X5
MY=\</^2*_%__`+)=\0/_`%$]6KU&O+OCA_R17XO_`/9+OB!_ZB>K5V83_>\+
M_P!A%'_TY$G`?[]@O^PO#?\`IZ!^X/[$/_)EW[(?_9K_`,`?_54>$Z_/O6O$
M?[87QR_:U_;9\%>`_P!L[QE^S]\._P!GCXK_``F^&G@KP7X*^"W[/'C2"ZL?
M%/[*WP'^,^M:UK&O?%+X:^,/$ESJUUXK^)VO0JD>J1:;;Z7;Z;;6UC%)#//<
M_H)^Q#_R9=^R'_V:_P#`'_U5'A.OB;X#?\GH_P#!53_LZ'X"?^N^OV0*_&L]
MQ5?!9-F.+PLU3Q%"GAG2J.$*G(ZF/PE&;Y*L9P=Z=2<?>B[<UU:237]-\8YC
MC,KRA8O`5G0Q$<70@JBA3J>Y.-12BX585*<D]-XNS2:LTF'_``I7]N?_`*2A
M_&?_`,1J_8P_^<71_P`*5_;G_P"DH?QG_P#$:OV,/_G%U]HT5^7_`.MO$'_0
M>O\`PCP/_P`RGY7_`*[<3_\`0S_\LLO_`/F0^+O^%*_MS_\`24/XS_\`B-7[
M&'_SBZ/^%*_MS_\`24/XS_\`B-7[&'_SBZROVO?^*Q^*G["/P1;_`(G>A>.O
MVK8?BA\4O!-A^]U:X^&G[,/P>^*GQW\$?$343IVWQ)X>\"_#7]M#PK^QM+K7
MBVPNM*T"X\:^)/AK\*/&>H:CH7Q<?P5XQ^&?`?Q6_;5^)6K?!#4=!_:QW6?[
M6_[5O[;/@'P1H&B?`GX3ZYI/PY_X)Y?#7QK^TQXJ^%O[8WP]F33I==\=>.M1
MT+PW^S-\-?@Y^U#XIUKQ#^QO+X*_:8_9XO\`Q]^S+\=OB+XJT[Q_\:>RGQ#Q
M#4I1J?VK2IWC*;53!86R@O;[.G@JC<K86O*47%)1C#EE.<W"'?2XGXHJT8U?
M[:I4^:,JC53`X2R@OK+33I8"JW.V#Q,YQ<(I0C3Y9U)U'3A]]_\`"E?VY_\`
MI*'\9_\`Q&K]C#_YQ='_``I7]N?_`*2A_&?_`,1J_8P_^<77P)I/[47[2?QK
M\`_#_P``_#/Q'^U;XZ\:^%?^%P>,?&GCO]C[P%^P18?$OXA?L_R_M+?''X'_
M`+"?[06N>.OVX_%GA#]FC4_`O[5_PB^`WC[XQ:G)^SC\%O$EM\0M?7PS\2?`
MNK?LY_!'4?!O@+XU[O[(7Q]_:9_;K\(>!?"%]\7/BM^R];Z9^S?\+?VJK'XI
M^%?"G[,6N?M#_&OX2?M+_'']J_P3^R3>?$/3O%'@#XZ?LX_#?7=3_9Q_9U\-
M_%_]H#1/AY\.99_%/QD^+VE:9X`E_9R\'?"CQ+\+OB9I+.^)80J5)YIAHQHU
M.2LGAL&ZE)2E*-.I.DL$ZOLZKBG3E&$G*,X3:46Y+6?$'%M.G5JU,ZPL(T*O
MLZZ>&P3J45*4X4JM2C'+W6]E6<8NE*$)N4:E.;C&#<H_;W_"E?VY_P#I*'\9
M_P#Q&K]C#_YQ='_"E?VY_P#I*'\9_P#Q&K]C#_YQ=?DCXG_:M_:?U?X&/XSU
M/XA>!?B=\8O`7[*7_!7/XU?"+Q]X2^"?P].DW'[0&L_M66?[,W_!'GXI?`_P
MMKMG\3-1T'_AJ?X.^*_C!\/?V,-"MO&/CBY_:]\%>(/%NC6/B']HC44UK7KK
MZM^+_P`=?VG_`-DWXL:%X"D^.7_#3>N_&'P+X#'C*7QQ\,_A[X?^&G[*?QA^
M/G[:O[)7[(W[/>N>#_!7P>TCP7\1=.^!GC"\^/\`^T;XZ\/_``A_:!^.'Q0^
M*GQBT#]DF[\">!OVFO#FN^#OC-\3M6IYUQ*I1@LTH.<ZE:G"'U3"IRE1J<DF
MF\"HQC).$X.JZ;E&<4H\S2=2S[BU2A!9SAY5*E2O2A#ZGA8N<\/5]G-J4LN4
M(PDI4ZE-UI4I3C4BE#G:B_L'_A2O[<__`$E#^,__`(C5^QA_\XNC_A2O[<__
M`$E#^,__`(C5^QA_\XNO,?ALO[1/PS_;A\$_`S6_VJ/'7[2_P=O?V4OC?\6/
MB!:?$GX:?`C3/B7\.?B7+\7?V=/!_P`#[GQMXX^`?PS^$/A;3/`OC_PM9?M$
M1?!#PI>_#+PQK_B37_`'[1>KZIX[^+VG>$O#OA_X#_H_7%5XHX@I."_M.G44
MX*I&4,'A$K.4HV:J8*G-.\6]8V<7&2;33//K\8<3T7!?VO3JJI352,J>"P:7
M*Y3C9JK@*4T[P;UA9Q<91;C),^+O^%*_MS_])0_C/_XC5^QA_P#.+K@O'GPP
M_P""B.B?\(9_PBW_``4Y^(-U_:_CWP[HGB/_`(2;X!?L8:1]G\*W_P!L_M>Z
M\/\`_%CD_M/Q/#Y5O_96D?/]MW7'R-Y7'Z'5\^_'^+PS+_PI/_A)O"OB7Q3Y
M?[07PWE\/_\`"-SR0?\`".>)D_MG^RO%6O\`EQR>=X:TC-Q_:L#[(Y/M$&Z1
M<#/7E7$N>XK'X>A4Q:JPG[3FI_5,$N;EHU)K6-/#O1Q4M*L=M>9>Y+FJ<;\3
MQ@VLTM9K7ZEE_627_0'+O;;[MUYA_P`*5_;G_P"DH?QG_P#$:OV,/_G%T?\`
M"E?VY_\`I*'\9_\`Q&K]C#_YQ=?:-%>?_K;Q!_T'K_PCP/\`\RE_Z[<3_P#0
MS_\`+++_`/YD/B[_`(4K^W/_`-)0_C/_`.(U?L8?_.+H_P"%*_MS_P#24/XS
M_P#B-7[&'_SBZ^T:*/\`6WB#_H/7_A'@?_F4/]=N)_\`H9_^667_`/S(?%W_
M``I7]N?_`*2A_&?_`,1J_8P_^<71_P`*5_;G_P"DH?QG_P#$:OV,/_G%U\M?
MLV_LN>!];_:O_:KUR#XH_MDCP=^R_P#%;X"_!KP'\-_%'_!0;]O'Q_X9N_B+
MX=^"_@#]JOQE\6_$5IXN_:0U'2_%VA?$;2_VG/AC\*=7^"OC[1?&?@.TT_\`
M9_N/$,DFIV_QB\4^%-$^</@=^WA^TM^SU^Q[^RY^US^UEIW@7Q3\'?VD_`OQ
MB^..M>#?AUXF\??%7XU:+_PE/[*W[3/_``5#U'QGX;^(GQ*F^&GA;0/`N@>%
MOAIXC_9I^$7[%MWX.\4_\*F\)I\-]1G_`&YOB%IWA:_\.:EZ#S[B&?,L/F:J
MRC'#RY)X'+Z4Y/$8>>)A&G%4JCG*-.#4MDI:7LTWZCXCXHJ<RPV<.K*,<-+D
MJ9?EE&<WBL-4Q<(THJE5<Y1I4VI[)2T3:<7+]-/^%*_MS_\`24/XS_\`B-7[
M&'_SBZ/^%*_MS_\`24/XS_\`B-7[&'_SBZ^/OA5^WU\;G^*G@63XP6WE?!WQ
MA_PL'4?BM)J/_!.O_@H5^R+X*_8Y\%>$O@]\1_C)>?$KXE?MJ_M=V/A;X._%
MOP+X0U'X?:9\%;^_OO@U^S1JWCO5OB/HOQ;MM%^'FG>&-5^%.JFD?M;?ML:!
M^S3\#/B%\?9_@9\(_C_^TGX%^&7B_2/@5X'_`&.OVWOVD_B7^S_I.E>`8M;^
M./B?QA\!/@_K]]\;OC-YGC77OA7X.\0>&KS1OV8?!7[(.O\`Q:M/!GCWX]?M
M&>+M$^']I\=T\\XH4E%YA!-\G*G@L-SR<_:74:?U'VLO9QI5)S:@X\L8\CFZ
MM%5)?$/&$9*,LS@G+V?+%X'"\\W-U>90I++_`&T_91H59U'&FX\D8NG*HZU"
M-7[!_P"%*_MS_P#24/XS_P#B-7[&'_SBZ/\`A2O[<_\`TE#^,_\`XC5^QA_\
MXNO@3]F[]O3]L+]L#XE^)_@C\`S\#/\`BSG_``LO3_C;^TY\7?V6?VJ?@GH"
M_P#$_P#ASH_P3\6_#K]CWXK?$GP5\4=6_M;XH^"OV[?V1/B1\.]0^/7_`!2/
MQ+_95\2?&CQ#\4/!G_%(_LR_%;W/X)?\%"M6D\1^+K']IY?`O@3PMHG@7XK:
M3X"\2>"?#?C74M6^-?QA_9)_;K^-G[#O[3\G@KP)I>L?$+Q39?\`"6>*;G]B
MG4_@1^S[;VWBOXJ>(/&O[3;?!_X;^,?VDO%/AS5=0T,J9WQ32YHRQT'4CR-T
M(X3!.NE4YG3O1>#4U*<(RJJE)*O"E%U*M*$7%LJ\0<94>:,LRA*K#D;P\<'@
M7B4JO,Z5Z#P*J1G4IPG65"48XB%&+JUJ-.#BY?1'_"E?VY_^DH?QG_\`$:OV
M,/\`YQ='_"E?VY_^DH?QG_\`$:OV,/\`YQ=>]_`W5_BWXA^$G@/Q)\=O"^A>
M`_BUXFT*+Q/XT^'7AVX@U+3_`(7ZAXCGGUNU^%5QXDL_$7B?2_'6N_"_2[^P
M\`>*/B9H-]IOAGXH>)O#FK_$/PQX1\!^'_$VF^"/#WJU<,N*^((RE'^T(/ED
MXWCA<!*+L[7C)8:THO=-:-:H\^?&G$\)R@\TC)QE*/-#"9=*,N5M7C)82THN
MUXR6C5FM#XN_X4K^W/\`])0_C/\`^(U?L8?_`#BZ^=OVN;G]OS]F3]E_X^?M
M#Z'_`,%'_B9XPUGX*_"CQK\2],\*>)?V<?V1+?P]XCOO"&AW>M6VBZY/H?P8
MTW6HM)U&6T6UOWTG4=/U);664V5]:7'EW$?ZM5\"?\%4_P#E&S^W-_V:]\9/
M_4*U:O0RCB;.\5FV5X:OC54H8C,<%0K0^JX.//2JXFE3J0YH8>,X\T)-<T91
MDKWBT[,NAQEQ+5KT:4\R;A4JTZ<TL)@8MQG.,9)2CA8RBVF[2BU);III,_:.
MBBBOU0_>0J.:&&XAEM[B*.>">-X9X)D66&:&52DD4L;ADDCD1F1T=2KJ2K`@
MD5)10!\`M\/_`(U?L=NTG[._@^Y^.G[,:3/<W'[,]MKFGZ3\6O@I:NH\Z#]F
M/Q#XRUK2_!GBCX;VK@3:=^SUX[U_P9!X&LGOK+X2?$*U\,:=X/\`@M:_0OP1
M_::^"?[0]OK2_"_QM;:CXE\)S167CWX;^(-/U;P5\7/AGJLJ1R+HOQ.^$WC&
MQT/XA?#_`%9DECEM[3Q5X<TLW]K+!J&FO>Z==6MW/[S7SQ\;_P!E+X`_M$7.
MB:Q\4_AW8:EXU\*0RP^"/BKX:U+7/A]\:?AZ)GEED?X=?&CX?ZGX9^*7@-GF
ME>>9?"GBW28KJ4[KN.<94@'T/17P`/@G^W#\'"&^!_[4OASX_>%(`?)^&?[:
M?@ZW;Q1!`BM]FTOP[^TI\"=)\(Z[I=A!MCADU'XH?!7X\^+;P2/=7WB:YN(M
MMR?\-A_'#X>X@_:(_8._:#\+PPG_`$WQW^S?>^%?VO?AIMC&+A],TOP!<>&?
MVFM1$1!EB27]E^PEN[>2`6D<M^;K3K0`]#_:#^#_`,4K[XI?";]I[X`VW@#Q
M1\:_@SX`^,OP?L_AA\8/%_B+X=_"WXB?"W]H/Q%\$?$_CZVN?B7X+^'_`,4_
M%GPS\?\`A?Q9^SY\*_%?A#Q?%\,OBGX=U3P[I?Q!^%NM?#^QU+XF>'/C-\&?
M(?B/\!OVM?VA/A4D?Q>\1?"'P;XVNOVG?V"_BSI/P4\!^)M;\9_!SX4_#[]D
MG]LWX-?M"_$"33?C3K7P:\`?%7XO?%[XO>%O`'B2XDU+7?AY\,_AIH<\'PF^
M%6@^`_#MSX5^*7[1/QL]!\(?\%'_`-A?QEKD'A*']IWX6^#/'=R`8/AI\8]7
MN/@+\5I"'6.6-?A5\;K/X??$436DLD4&H0GPP)M.N)[>WOTMY[B".3[1M+NU
MO[6VOK&YM[VRO;>&[L[RTFCN;6[M;F-9K>YMKB%GAGMYX726&:)WCEC=71F5
M@2`?E=^U_P#L`^*?VF?&_P"U'KUW#\(?%?@GXN?"'_@F5HOA_P"&'Q.CU'4?
M"WQ'\4_L`_MK_M$?M=^,/A3\8[.7P9XHTG0?A#\>M)^(7@;X0WGC&RT+XJ:C
MX<T[6_'OB35/@_XPMO#&C^$/'O`>%/\`@GSXIM_A5XE\.^#_`-DG_@G+^PWJ
MVN_M._\`!/#XL7?@?]D"PU&\T[Q9X6_8[_;-^&/[2?CGQ%\1_C-I?[.'[.5S
MXMU_6_!/A[Q!X0^#WPKE^`5OIW@'Q39ZKK>L?&S7=)^,U[I?P;_9BB@#\Q?'
MO[%OQ2\4_P##5W]GZ_X`A_X7K_P4Z_X)]?MI>$?MFJ>(H_[.^%O[*'_#LO\`
MX6)H'B/R/"MQ]D\?ZS_PQC\4/^$+TO3/[7\.ZC_;W@'^W/%7AS^U/$/_``BW
M`_\`#'W[4G]E_P##,G]F?`'_`(9G_P"&^_\`AN3_`(:&_P"%O?$3_A>G_*1C
M_AYO_P`*O_X9:_X9^_X0#_D?_P#C''_A-?\`AKG_`)$__B_W_")?VU_Q8&OU
MXHH`_(?X0?L??M2>'_'7P5T_QYIGP!TOX9_L[_\`!3K]M?\`;2\)^+O"/Q>^
M(GBOQU\1_A;^UWH__!3J>VT#Q#\.]9_9^\$Z!\.O'_@+7_VS/A-ID^EZ;\4/
MB/X=\2Z/HWQ$UR/Q5H=[H?AKP]XRY_\`:(_X)O>*?C!XE^,GC;Q!\._V8OVB
MM)U/_@HUX1_;;\#?LW_M$7&HK\'/BUX6TS_@E]\.O^"?EWX(^,GB"]^#'QDM
MO`.O^$_&UOXP^._A'4='^#WQKT[4I_`?PZT"5?"FK>,M4\5?#']F**`/RF_9
M8_8<\4_!KX]_"+XRVGP'_8C_`&4_!/A7X0_MF^"O$'P`_8UT34=+\+:+XI_:
M"\9_\$_+_P`'ZY-XKB^$OP:TGXT:_J&D_LA>.=7\<_$B]^$_P/U'PWIWB;X5
M?"#2_`_Q"MOA_K'QA\3^`_&__@F]\>_C/\<=%\>>)_AW^Q'X[\4^"OVW/V?/
MVE?#/[;OQ6N/&?B[]K6V^`GPB_:_^&OQRT[]DWX/^`D^#%KX<_9)T#X:_!W0
M[_X8:+XI^'7QX^(?@SXZZWX1\8^.OB3\%?!7Q5_;3^,GQ@^%7[KT4`?@3^S7
M\'_VI/CQ\)_$?PK^S?`&W_9G@_X*\_M7?M!_\+6_X2_XB:)\=/`W_#+G_!;S
MXQ_M%_\`"IO^%(?\*_\`%7@#XO\`_"Q?'_P1_L7_`(7+_P`+^^!G_"#>#_BS
MY7_"D?&^M?!/^TOCQZ]_P2Y^'/A;4/B#^T;\8/`GQ-T#XT_L_?#K7]9_9B_8
ME\9^$ET[Q%\'+'X":S\2_'7[7GBM_P!ECQ=H^O\`B'P3HGPA\)7/[1OPG_X)
MX>(?!GPEN3X,CG_X)7?#RRU*^TZ3PAX:^"WP#_9BOFGXN?MF_LC_``$O5TGX
MT?M,?`KX9Z_+<-9V?A7QA\4O!NC^,=4OT02'3-$\&W.L+XIUW53&PD32M'TB
M^U&1#O2V9030!]+45\`C]O\`T7QKN@_9P_9C_:]_:3FD9XK36_#WP5O?@;\-
M;@YV+J5I\5_VM]5_9\\"^*/#D+9DN]9^&VJ^/Y9((;F+1--US5HHM)G06_\`
MP4B^+Y1+Z\_9Q_8O\)73!ICX=G\1?M:?')K#!Q';:AK^A_!GX+?#SQ$[,&D>
M?P[^T)H%G'`T,:ZG)?BZTH`^S_'OQ"\!?"KPEK7C[XG>-O"7PZ\#>'+1[_Q!
MXQ\<>(M(\*>%]$LHQE[K5=>UV[L=+T^!>GFW5U$A.%!)(%?%P^.'QM_:NW:'
M^RSH7B+X.?!V\#0ZW^UU\6/`]YHNLZUIDKB&>+]F'X+>-K&QUOQ3JMU:-/<:
M1\9OBWH.D?"32)&T;7O"W@WX_P"CWE_ING=AX!_8/^"/AOQ;I/Q.^)UWX\_:
MD^,F@W*WV@?%K]J#Q':_$_7O"6HJ"JZG\-/!4.C^'O@S\&-2*/<1RW_P6^%_
MP[NKJ&[O+>[EG@N98V^T:`/,OA%\(/`?P/\`!5GX#^'NE3Z?I$-[J6LZG?ZG
MJ5_KWB;Q7XHUR[?4/$?C/QIXIUBXO-=\6^,O$VIRS:EX@\2Z[?7NJ:G>2EY[
MCRTABB]-HHH`****`/Y0/V'?^36/A/\`]>7B?_U-_$U?5]?*'[#O_)K'PG_Z
M\O$__J;^)J^KZ_2ZG\2I_CE_Z4S^1^(?^1_GG_8XS/\`]3:X4445!XX4444`
M%?(O@-()?VX_VF;NQMS!##^S?^R!I6K3K"8XK_7X/'W[8.I$L2%66ZL/#^K:
M#'+=H'>>VN[*SFDV:5;Q1_75?(7P(Q)^TE^W).Z1M/%\2O@OIR3^7&)Q86_[
M.7PTU"WLS,%$KVUO?:MJEU!"[,D,^H7DD:JUQ*6B3M*EM\<DKI/>E53WT3M>
MSLVGJK.S750BYT,P5Y)+"TI2Y9R@VH9C@)13<5S2BYJ/-#FC&<;QFY4W*G/X
MX_;GCFOOCOK5G`_EZ0/@?^S#8^/))K>2\L(O#WB3_@H+\*+**YU"R5TCO;>U
M\+Z9\39IK5RHGLA?02)<Q2O&OUU^W!INF:/^ROX^:STVPL=#T_QE\,/%_B>U
MM--A6QDT*#X]^!?&7Q(U&^L;>W:&X&I:6OB75O$$]Q$1?RW6HWNI3%KBZN:S
M6TOP1K/[6'[6\'Q)TWPSJ_@=_P!D?]DZS\6V7C2RTW4O"<OA*W^(/[;6I:O#
MX@L-9BGT>?1A%+=W.J#4('MY;=!]L+P6T*Q>$^,Y?$=[_P`$6/'FH^,Y]3O_
M`!+-_P`$X/&_B&>X\2N][XCM[P?L[ZOKF@R:_<W<*SS^+=&0:8=5U&?S;P^(
MK&>^:]N[L?;I<ZUU[5\O+[2A.[IIQ2E17(FKWBI2IRI3E[MY5E5J2<E**CZU
M"O2Q57*HQ4>;!8W+:$J=54FJT,1"B^>5.C"E6<(U\+B:<W.O/GHRP_(Z-1UK
M_2O[3,CR_%;]A33+$Q#6Y_VK=9U*SDD8`V.E:1^R;^U#)XHO2OES-Y=SH5S=
M^&E=8B!>^([&-Y;99C=0^7?M@Z?J6J?M!?L86'AR`3^([_Q)\3+52(X[@V7A
M^U_X5OX@OM:DM!Y5[<6GA[Q-H/@S7;UM/NH;BSMM.DOR/*M7N;7TKXO0B[_;
M%_8VAGEC2WT_PM^U#K]M'(\?[[6;;PU\-=`M5@C9TD:Y31_$_B"021B41VJ7
M:/%B430>8F6^T7]M_P"+GB/7]3>6Y\/:%^SA?Z);O+NBTWX(>.='^,W@;551
M9HUCT_3].^,.D:MXJ\47R7=O9):0:++JWFW%OH<3>+Q-3<\CS*A%<\,9[#"X
MI\E=RPV#Q=7#83,,51C1C*52M@LOE6QU%6=*5:C&%5N"G$^S\,I87!\9\+YI
MBZF"YLLRC.LXR[#8VA.IA,RSK+*7$&(X=R+'QDE3GA<ZS^E@<MQ,I-X:.%QU
M2-5JU5+UO]A#P5KG@']BG]C33O$D']DZGX@_9B\`>(+K2I%<?;]<GO=:U'7O
M$EC-</+<7-OJNE>(/!EW/$DSI9QWFFWEU!;WNN227GY^_P#!/:R\-_$QOA%I
M6H6.E:GX8\1_L3_LI^$O"-M?:9972VVG>+OVJ/C/HE]KFERE((;63PC!9?#7
MQ#IUI$L%X]_!X=NX=0:_L+>^3]G?VB=/@\#_`+'?PH6!=+TG6M"_9ZUSP1IF
MCB?3()K"&#X&C7;F;2;<F9=0@T>Z\!:7I\VFV$4EJ;>_COY9A;Z<D5S^8'[)
MO@7PYK?Q!_X)K:5HVE0:"-`O/@7Y.J:/;6/]L+;>'/V(/B3\7/'^@274:IJ%
MM\.=>UO0_P!GRZ\0^&Y9CH4WC_\`X1_QI)8R>*9;'4A_F9X+?2*QO%'T%./O
M%ZIF;EB>&,-]+O+L9*G4A5Y<;D^*XTX\X:QE*;J.=667<,SRK!X3#X?$8KZS
M/%*K*I.--./[MB^`,NQW$O&N45\+##XF>-\).)\'F-&O2IXG#99A<RP'"_$&
M34*;BK/.,SXIRW&RQ$:<,5AZ&2590I057ZRO4_A[J&L>#O\`@I#^TO\`#;4[
M>+2]-E^$GPK@T:"+3O+@U#0_"/B#XC^%OAY<1WSV:2PS:J?#'QHUF#3$O;RS
M@LH9+);V]O-%NFB^<?B3I.F6O[,7_!3'6;9-.BLK+]H_Q4^IZVZVXO+OP'HC
M?"/QO\0/#EQJ449N)=+@UG6OBE;P:3>">PM[W6-562QN8[^]%[[S^V1H?B&\
M_P""B'Q5L?A)=Z;-XY\6_`'X2P^&;^VUFTA_X13QCX?USXTZY,BWFGR3/H+?
M9]&\86'B73[F33;]F^)DU_<6[OXBLK^3.@TWP9=?\$A]:M/#&E06WA77OV`O
M%]_<Z?+;1VUW=WWBCX$ZQJOBVX\211XEE\5ZQX@U/6K_`,;75\\FKW_BN]UJ
M]UF>?5[B]F?^O/HH^(&,\2_`3POXVQ6)J8G%<0^&_`>=9A.KR6P6>U."LFP6
M?9/&C)N4%1S3#8C-:DG&-+$T\XPU9QE6G74/@/%OAS+^'\RX7A0P>"PE3%_7
M,OKX6C&G.IC\-@N.\^Q&6<28B<5)Q6(PK7#&$HXBI4QD/]5<<ZDEA5@'+W+]
MI8VW_"W/V#%U%X(]-_X:Q\2,WVI(VMYM57]C7]K9=`MI3+F*.0ZJ\%SILCJ'
M_MNTTJ*UD6^EM(YLGX#Z;::!^U7^V)X>MK6QTVVLM'_9@N/#&CZ<EI;6.D>`
M4^&_B#P]H.GV&FV>R#2=.MO$?AGQK#96"6UO'%'&S0*;=X53`_:_DM[W]@7X
MA:U?V]QJ_C>U^#6GZG\+=57R[GQ1I7Q]U+0[/2O@QXH\+ZE=B6ZT_P`<6'Q4
MU?PS<Z!K5H9-4@U:2-[9+N:4VMQW_A(-'^W)\=\E3)/^R;^R2+ED4JDK6?Q>
M_;5\@JC/(8U1KZ[*J'8D2@2/(8XRO]*I?O.5*+<VYN4H/3EHU9/DE>7OJ-!)
MRM%\M3DY;7F_PGVCH976Q$E4E2J8=9=K&E-0J+/,FFO9.2C*G!RS&E*?*Y5%
MRU[SY*L*,L[]D58WO_VL=0LXI8='U+]L/XK-I22*50R:1X<^'WAGQ-+`^^6*
M6*?QSH7BJ=F@FD"3R30SI:WD5U8VL7[#>FZ/:?"#QG>Z/::<MM?_`+3W[:4=
MGJ=C:6\+ZGH=A^V/\>H-!0W4*![[3M,L7.G:#,SO;G1X;62Q9[2:.:7P7P[:
M>*IO^">7[:W_``KXZC;_`!!U'QU_P5@_X1>[T$O!XAF\71?M0_M5Z9X8FTR[
M@5K@:W;RV6D6&BW>VXELVM-.CBAEAM(;:OT`^$L7@&/X7?#L_"O2=+T/X:W'
M@KPS>^`](T2TM;#2K#PEJ&CVE]H,%C:63/:0P#3;BW91!)*C%B_FREC(T4I.
M;C4=WS47*7,Y2][$3C5NI/2Z=.2UN^63T6X\PI2C#$)N<O9YG'#^UC&$5*.7
MX6OA8QK_`!2YL1&O&OHX.I5PTI\T^6<5YM^UOX[\5_#G]FWXP>(/AWJO]C?%
MG4/"-SX$^!]W]ATW4/._:`^*5W:?#'X`Z5]GURSOO#4?]N_&;Q?X&T3[=XOA
M3P5IG]H?VEXTO-/\*VFL7]M^#7Q-_;`_:%GU?X>Z'\*_$WQ%\:>%_P!C+]J+
M]J[PO\6_#]OXUU32KWQAX/\`A'\=/B'\)/#?BOXQ^.=:\??![7O&WPZ_8,\`
M?$7]B'XD_%[2?B-\<+'P1^UAH/[0&K:M\=?BEX=@^`_QT^*7A'^G"BHKT)U7
M>-:5-<JC:*OJIJ=_B2U<4FFFI).,KQ;B]LLS7#Y?3Y:N6T<9/VU2JJE2HH-1
MJ8=X=TVO8SDU&$ZLJ<E-2I5*BK4?9UZ<*L?Q?TW_`(*%_M`:E\._@9>V'A'X
M17_B[XG?%V]L]'\7O>^"M9^&/Q@^#&G?$[X`?L]"^\+R?`+]IW]I71/@_P"+
MK_\`:>_:H^&/PFU+5;CXL?M`P>#?AW\./C3\;KOP)X@\71^!_P!F_7#XF?MA
M_$[4_P!FW]A?5?$?Q2^$7PJ\<?M0^+M*^.WB+XL75G\1/A!\*?AU^RWX'NH_
MBSX-^('Q#O9?&/C+2/`W]K:OXD_9-^$'QE^#'BKXT2>'_C-XC^,OC']G#P#\
M9-!M?'FC?&[P7^T%%+V%6S7UF33A&'O1OLZ?,W:<;N2A**;]Z*FWS-IN5+-<
M"ITYK)Z$)0Q-7$-TJR3E>&(5&"]IAZJA&E4JTJLHI.E4E048T:4'"-+\2/#_
M`/P4!_:%B_9/T3]J?XP^(O@7\"D^)>KZ;\%_AI\)/&7P4U31/&^C?M"^`5AT
M7X^V?Q/\2?&?]M#]G_X4^$M(L_&OP?\`VJ+;P)X$\9?$#X=:I;^#]+^%=SJO
MQ&UWXOWUU\"_$Q^S?^W/^V%\?XO@7KXM/@7X/T'X@_'3P%\&;_0?$_P=\6V?
MBGQS9>*/AMXT_;4NO'VEZCX5_:J^('A_X,Z1K'_!/B3X4:]X*T74#\=M>?\`
M:>U_Q3\._&MIX0\`:7;^-U_;>BA8>K>#>)FU&*4E:2YW=.4G:I:+;3Y5%<L8
MM1:DD^:I9O@73Q$(Y+A8SJU:DZ$W*E+ZM!Q<*5%)X52JPA3Y?:RJ3=6K54ZT
M*E&<H\GY=_L(?MH?&_\`:C\>^--)\=?#SPCX<\/:)X1B\0>)]%TO6_@_9>/?
MV=/'E_K-C;:+\!_BIX8\)?M4_'3XG^(_%VH6,OC>TU'Q-\2_@C^Q_K/AC6?@
MYKVGZ[\(;?Q#XRN?"7PP^\_CA_R17XO_`/9+OB!_ZB>K5ZC7EWQP_P"2*_%_
M_LEWQ`_]1/5J[LOA*&(PL9U)59?6*+<Y))N]6/1;+KJW:[2M&T5S1Q%'%9MA
M*U#"4L%2>)PD8T*4ISBN6I37,Y2M>3MJU&-TDY\]5U*M3]P?V(?^3+OV0_\`
MLU_X`_\`JJ/"=?$WP&_Y/1_X*J?]G0_`3_UWU^R!7VS^Q#_R9=^R'_V:_P#`
M'_U5'A.OB;X#?\GH_P#!53_LZ'X"?^N^OV0*_%N*/^2=S;_KU@__`%:8`_H/
MQ`_Y)]_]AN&_*J?:-%>U:5X+\-W6EZ;=3V$CSW-A9W$SC4=40/+-;QR2,$CO
M4C0,[$A$547.%55``O\`_"!^%?\`H&R_^#35_P#Y/KY.CP,ZU&E5_M11]K3A
M4Y?J3?+SQ4K7^M*]KVO97[(^*H^'N<5J5*M'%Y:HUJ<*L5*KBE)1J1C-*26$
M:ND]4FU=:-[GY>_'#P[^T/#\<?`GQ6^"'[.G[-_Q3U3P3\*?'7P]T?Q_\8/V
MNOC)\"?$V@:?\6?%_@+Q)\2_!UC\//`O[(W[07@[7M"U>X^"?P<UJV\9ZSXA
MM_$UMJ&E:GH>E:-H.EMJE]XO^;_A_P#"O]L+X6_\*._X03]A;]AG0O\`AF[X
M&:O^S9\%_P#C9C^U3J?_``AGP5UW_A3_`/:O@O\`XG/_``3=U#_A(OM7_"A/
MA/\`\5'XK_MWQ9!_PBG^C:[#_;OB7^V/W2_X0/PK_P!`V7_P::O_`/)]'_"!
M^%?^@;+_`.#35_\`Y/KNAP7*$%#Z_2DDG&\L-BU=/G33C#-(02:JU4U&*5JE
M33WY7]&GP)G4*<:;J9/-1CRWEBLX5T_:)IQIJG32:K5DU&$4U5J*W[R1_.OJ
M/[('Q^U+PS\+?!;_`+`O[&VG^#OA)\*?!'P'T3PGX?\`^"M7[<GA?PSXW^!W
MPXT]])\$?!KX_P"@^&_V`M*TO]J+X4^'=+O/$&FV7P[_`&E+7XL>$&T_QS\3
M;.YT>>W^*7Q%C\4<+XB_8P_;)U?P';^!=+_8R_X)^:#I?PX^%/A?X#_`31+#
M_@I/_P`%`]+\!I\#OAY\.M(\-_#3X-?MD^"/"/[*7A*W_;Y^%/A'QC+\0M7;
MX=_&W5+'PAJ?PZ^)OC/X:'1[+5/&GQ3^(OQ,_IB_X0/PK_T#9?\`P::O_P#)
M]'_"!^%?^@;+_P"#35__`)/K>/"E>-FLQAH^97H8YVDW=R2>;-)MWYFM6I23
MNI-'1'@[B"+35?*=)<ROC<\DE)M-R2E)I2D^;F:LY*4HOW9M'\Z_P[_9+_:=
M^'GPZ^&_PZC_`&)/V-O%=O\`#/X4_L4?!_3O$WBC_@IU^TRGB;7O#/\`P3V\
M>7?Q4_99OO$0\+?\$RO"_AIM=\$?$[4M6\;ZO<Z#X;T'3_&FH:I<:)XLTS5_
M!UOIOAFQ[GXH?"/]NCXH>)M?\1ZM^Q;_`,$_)+CXF:%\,O`?QFOM1_X*'_M<
M/XF\0_#KX':A\8_'_P`#H/A;XD\+_L"^#I/@;\5OA+\=_BU)\7/!'QR\)Z??
M^//#VH:8ZZ#+I'C&R^''Q#^%_P"]_P#P@?A7_H&R_P#@TU?_`.3Z/^$#\*_]
M`V7_`,&FK_\`R?4OA&HY.;Q])R;NV\/C=_W>O_(VLFG2I.+5G%TZ;C9TX.,O
M@O/7-U'4R9SD^9R>,SIOF_=>\M;)IT:3BTDXNE2<>5TZ;A^%O["'[*?QW^`?
M[0'[1'Q/^)GPA^!G@/0OC9X%^$GA9/$'@/\`;*_:)_:N^*FK_P#"DKGQA=^$
M'^,/C#]I#]G+P/\`$7XM>.M0O/C)\5=/NOC)XG^,UW_PB_P>\%_LY?L_^$?A
M)8Z%\,KWQQK7ZLU[S_P@?A7_`*!LO_@TU?\`^3Z/^$#\*_\`0-E_\&FK_P#R
M?7-B.":F)JNK/-(J3C3@[8.I*ZIPC3BVZF.J3;Y(13;D[VOO<Y,5P#GN+K.M
M4Q65*;A2@^6OCY75*G"E!N57#U)MJ$(IMS=^5-ZML\&KQ7XT7>H6G_"I_L'Q
M(LOAS]I^-7@2TO?MJ2/_`,)WI\W]J_:?AO:>7')MO?%&U/(=]D:_87W2+D9^
MT-:\&>'++1M6O+:PDCN+33+^YMY#J.IR!)H+666)S'+>O&X5T5BDB.C8VNK*
M2#\7_&BTU"[_`.%3_8/AO9?$;[-\:O`EW>_;7D3_`(033X?[5^T_$BT\N2/=
M>^%]R>0C[XV^W/NC;`QYM;AUY%F&55*N*AB:.,GCX*U*E1G">%P].4N:.(G4
MH.,OK5+DDY\UXS2BI*#E\AQ#P_C,@E1I8NKAJLL1!U(/#2K22C"I&,E+GI4I
M)W>G*FK?$TKH]JHHKI_">BVNNZC-9WDEQ'%'927*M;/&DA=)[:(`F6*9=FV9
MB0%!R%(8`$'Y'!X2ICL50PE*4(U*\U3A*HY*"DTW>3C&<DM.D9/R.+`8*KF.
M,P^!H2IPJXFHJ5.55RC34FFTYN$)R2TWC"3\CF*X;XE>+=?\"^"M:\5>%_A?
MXZ^,VNZ7_9WV'X:_#74/AII?C7Q)]NU:PTZY_L6_^,'Q$^%'PZ@_L>SO+C7]
M1_X2+Q_H/FZ3I=_#I']J:[)IFBZC]1?\*YT3_GZU7_O_`&G_`,@T?\*YT3_G
MZU7_`+_VG_R#7U<>!\V4DW7RV233<95L7RR2=W%\N%C*SV?+*,K;-/4^TCX=
M9W&46\1E,TFFX2KXU1DD[N,G#!QDE+9\LHRL]))V:_`37;/QCXD_9_\`VG?V
M>-7_`.";G_!2"ZT+]KC_`(:,_P"%P>/Y?BE_P2SG^*FH_P##1]MXCT#4_LOB
MJY_;HGL[S_A5'PZUCP[\'/@C_P`)1HGB7_A!?@]\+OA1\/;C^W-"\$V,,NY\
M:+OQ%^T#XF_M[XJ?\$M/^"@?B#2[O]F_]I/]E7Q#X+M_BU_P39T3PSXI^$G[
M5>H?!>\^*UGJ]UHO_!0JP\8V6NR6_P`#O#6D^'=;\,^+/#\^C:?K?BB0Q7>J
M7&AZEH'[O_\`"N=$_P"?K5?^_P#:?_(-'_"N=$_Y^M5_[_VG_P`@UVKA3.%)
M23RA2C*<HR6)S5.,JD8PFXM)<KE",8Z6LDN6UE;T5P5GT91G%Y'&<95)QE'%
MYU&49581IU)1:BG%RA",?=MRI)1M96_G*U?PO^T-X]^&GQS^%OQQ_9U_X+)_
M'O0OCG\#/B;^S[>7'CCXH_\`!%+P5_P@7@KXP:!+X=\>ZMX/\+_`+]HOX,_#
MK7O'5]9QZ2_A_P`8_&#P1\4]6\!?V3=Z=\/W\+Z%X[^*FD>/?5OCAXG^.WQ@
M\3>!/B'X:_8>_P""GGP!^+7PZT+QUX,\._%;X/\`CG_@CQJWB8?#KXGZAX"U
MSXB?#V^\/?'C]KCXV_#&ZT+Q7XE^%'PK\27.LCP!%X\TC4/`&F6/AGQCH?A_
M7?'&B^*_W?\`^%<Z)_S]:K_W_M/_`)!H_P"%<Z)_S]:K_P!_[3_Y!I_ZJYOS
M1ERY(N1R<8JIF"IKGA&%1*DJ:I6J1BE./)RSO)R3;;'_`*F9[S0ER\.KD<W"
M"JYI&E'VD(TZJ5&-)4>6K"*52/)RSO)R3<FW_)U\%?V;/VC/@SX\^,OBSX??
MLQ_\%=O@O<:SKLGA+X4>*?AW^T5_P2M^*OB_5/@+K7Q%^+?[4WBC1_CQIO[5
M/[6'QO\`!/Q`^*T_[6'[5'[0T>C_`!8UW0?&'Q2TOX'>$_@UI-A\3]/\8^,_
MVGM1^,WJ_B?X4_$?4/V@/^">?B?PO_P3"_;F\,_LZ?L!_`SXR?#7PI\'T^,G
M_!.C5[;Q-JVH7/[*MM^SKHOC'3/%O[>_BS_A87@7X/?\*(N/BKI.H^(O%VG^
M-?#/[0'PX_9]^)FD7^M:QX9O[[3_`.F[_A7.B?\`/UJO_?\`M/\`Y!H_X5SH
MG_/UJO\`W_M/_D&MI<.9Y*HZLGDSFX3A*3K9GS2]I0EAY2G)14I3]G.IRRDV
MX2J5)0Y7.5]Y<*<1SJNM)Y!*HZ=2G*;Q&;\TU5PT\+.4Y*"E.?LJE3DE)MTY
MU:DZ?*YRO\\^%]7U#7_#/AW7M6\+Z[X(U36]"TC5]2\%^*+CPS=^)O"&H:EI
M]O>7GA?Q%=>"_$7B_P`'7.NZ!<32:3J]QX3\6>*/#,VH6EQ)H/B+6]+:UU*Y
MW:]I_P"%<Z)_S]:K_P!_[3_Y!H_X5SHG_/UJO_?^T_\`D&O*?`V;-M_6,M5W
MLJV*LO)7PC=EYMONV>,_#G.VVUB<I2;;LJ^,LO)7P3=ELKMONVSQ:O@3_@JG
M_P`HV?VYO^S7OC)_ZA6K5^C_`(KT>UT+58[&TDGDA?3[>[+7+1O)YDMS>PLH
M,44*[`MLA4;"P8N2Q!`7\X/^"J?_`"C9_;F_[->^,G_J%:M7#@\NKY5Q5E6`
MQ+IRK4<TR><I4I2G3<<15PF)IN,I1A)WI5H73BFI75M#Y.K@:V6YNL#7E3E6
MPV,HTZDJ3E*FWSTY7@YPA)JS7Q0B_(_:.BBOQH^/?@'Q#\>_^"B'QD^&NM?'
MK]ISX<>`?A9^Q?\`L:>.?"OA/X$_M!?$OX*:*WB_XN?'']OW0/'7B+7+/X>Z
M[HJ>(-4U71?@W\.]-BN=6^TM86F@)%9>0+JZ\[]9QN,H9?A:N+Q+E&C1Y.=Q
MBYR7M*D*4;16K]^<;VV5WT/Z'S',,/E>#K8[%N:P]#V?M'"+G)>UJPHQM%6;
M]^I&_97?0_9>BOQQ_P"&$M#_`.CL/^"B'_B>7[27_P`W5'_#"6A_]'8?\%$/
M_$\OVDO_`)NJ^?\`]<LD_P"?N(_\)Y_U_P`,_*_R_P#K]P]_S\Q?_A++_P"2
M_JS\K_L=17XX_P##"6A_]'8?\%$/_$\OVDO_`)NJ/^&$M#_Z.P_X*(?^)Y?M
M)?\`S=4?ZY9)_P`_<1_X3S_K_AGY7/\`7[A[_GYB_P#PEE_\E_5GY7_8ZBOQ
MQ_X82T/_`*.P_P""B'_B>7[27_S=4?\`#"6A_P#1V'_!1#_Q/+]I+_YNJ/\`
M7+)/^?N(_P#">?\`7_#/RN?Z_</?\_,7_P"$LO\`Y+^K/RO^LWC#P/X+^(>A
MW'ACQ_X0\+^.?#=VP>Z\/>,/#^D^)M#N7$<D0:XTG6K2]L)F$4TT8:2W8B.6
M1`=KL#\8W7_!+W]@5+FYO_"'[,W@3X,ZE>337-UJ_P"S;=>*/V7=:FO;B3S9
M]2?6?V=/$'POU3^U9G,OF:J+L:BZW-[&UT8[Z\6?YG_X82T/_H[#_@HA_P")
MY?M)?_-U1_PPEH?_`$=A_P`%$/\`Q/+]I+_YNJ/]<LD_Y^XC_P`)Y_U_PS\K
MG^OW#W_/S%_^$LO_`)+^K/RO](']@#3]$)/PT_;#_;^^&.P?Z*!^U-XF^.8M
M"-P4C_AK;2OVB3?E$*IC6#J2OL6299)VDFD=_P`,L?M;Z1N_X1S_`(*<_M`Z
MV5P8?^%M?`+]B?Q2K-)@3B\'PL_9T^!C3QQKN.GK:OI[P2E6OI=4C5H7^;?^
M&$M#_P"CL/\`@HA_XGE^TE_\W5'_``PEH?\`T=A_P40_\3R_:2_^;JC_`%RR
M3_G[B/\`PGG_`%_PS\KG^OW#W_/S%_\`A++_`.2_JS\K_20^"/\`P4-M!]GL
M/V]OA!>VD?\`JKGQ1^P[;:EKLN_YY/MU[X9_:4\%Z)-LE9X[7[%X:TWR[-+>
M*Y^V7<=QJ%TH^&?_``4_MOW%G^V;^P[=VL>1#<>(?^"<?QPOM:E0G.[4+O0/
M^"GGA71YY@25#V'A[2X?+"*;<R!Y9/FS_AA+0_\`H[#_`(*(?^)Y?M)?_-U1
M_P`,):'_`-'8?\%$/_$\OVDO_FZH_P!<LD_Y^XC_`,)Y_P!?\,_*Y_K]P]_S
M\Q?_`(2R_P#DOZL_*_TG_P`*Z_X*D?\`1XO[`G_BMC]HC_Z:Y2#X-_\`!1UQ
MOE_;J_9X25_FE2R_8+UR&S21N76TAO/VR-0NXK96)$$=U?WUPD019[RYE#3/
M\V_\,):'_P!'8?\`!1#_`,3R_:2_^;JC_AA+0_\`H[#_`(*(?^)Y?M)?_-U1
M_KEDG_/W$?\`A//^O^&?E<_U^X>_Y^8O_P`)9?\`R7]6?E?Z0'[-7[:U^/+U
MC_@I+XWTV)1E)?`/[+_[->AWS2-\K">;QSX3^)]D]NJEF@CATVWG28(\UU<0
MJ]O([_AAOQOK!V_$3_@H5^WY\1K<Y22V_P"$X_9[^"XD@8>6T'VO]ES]FOX"
M:G#F![B$7=K?0:C&;C[7%>IJ%GIEY8_-O_#"6A_]'8?\%$/_`!/+]I+_`.;J
MC_AA+0_^CL/^"B'_`(GE^TE_\W5'^N62?\_<1_X3S_K_`(9^5S_7[A[_`)^8
MO_PEE_\`)?U9^5_I`_\`!,7]CS5<O\1?"/Q2^.\LGS7:_M)_M,?M,?M&Z;=R
M,`9O^*:^-?Q=\<>$["REG!NET31]!TWP]97#;M-TFRC2*./Z7^$G[.'[//P`
ML6TSX$?`;X,?!336A%NVG_"3X7>!_AO8M;JQ=8&M/!VAZ-`80Y+"(Q[`Q+!<
MDFOS8_X82T/_`*.P_P""B'_B>7[27_S=4?\`#"6A_P#1V'_!1#_Q/+]I+_YN
MJ/\`7+)/^?N(_P#">?\`7_#/RN?Z_</?\_,7_P"$LO\`Y+^K/RO^QU%?CC_P
MPEH?_1V'_!1#_P`3R_:2_P#FZH_X82T/_H[#_@HA_P")Y?M)?_-U1_KEDG_/
MW$?^$\_Z_P"&?E<_U^X>_P"?F+_\)9?_`"7]6?E?]CJ*_''_`(82T/\`Z.P_
MX*(?^)Y?M)?_`#=4?\,):'_T=A_P40_\3R_:2_\`FZH_URR3_G[B/_">?]?\
M,_*Y_K]P]_S\Q?\`X2R_^2_JS\K_`+'45^./_#"6A_\`1V'_``40_P#$\OVD
MO_FZH_X82T/_`*.P_P""B'_B>7[27_S=4?ZY9)_S]Q'_`(3S_K_AGY7/]?N'
MO^?F+_\`"67_`,E_5GY7_8ZBOQQ_X82T/_H[#_@HA_XGE^TE_P#-U7U?_P`$
MU?&OC#XC?L!?LA>./B!XGUOQKXU\2_`3X>:GXE\6^);Z75/$/B/5I-#MDN=7
MUS5)R;C4]6OFC$]_J-TTEU?73RW5U++<2R2-ZN69S@<V]O\`4YU)?5_9>T]I
M3E3M[7VG):^_\.=[;6\T>WD^?Y=GGUCZA*K+ZK['VOM:3IV]O[7V?+=OF_@S
MOVLNZ/P?_8=_Y-8^$_\`UY>)_P#U-_$U?5]?*'[#O_)K'PG_`.O+Q/\`^IOX
MFKZOK]@J?Q*G^.7_`*4S^8>(?^1_GG_8XS/_`-3:X4445!XX4444`%?SD_'[
MX`_$R^^+_P"T#<VGP&^(NO?M<^,_B'XZ\0_L\?M'>&OAEK5WI^C6NISKIOP%
MU73OVBM'T4>&?A+X?^%7A&Q\'^'_`!UX5\7^,?#ESJD/A3Q:W_",>-+3Q@MA
MXG_HVKRWXV>*/$'@GX4^.?%_A:33H]=\-Z)+K-D=6A>XL'6PG@N+N":&-HWD
M:XL4N;>!5DB)N)(OWL0S(OF9SCL/E.68_.<7[=X7)\%C,TQ,,-&,Z\\/@<-4
MQ-94(2E"+Q/LZ4GAY<\.6KRWDHN2<T?#FKXKY[P7P/A<VS?)LQS7CW@_^R,9
ME&>U.'?:9P\WI8/+,%G.8TL)C93X;Q.*QL%G6$>'E[2C3IXBC.CB\)AJ]+^;
M.Y_9U\;7NA^&K3X>?LJ?'KP]K.G:EH9_;59_AOXJ\'>(?B_\.H[:2+Q?X/\`
M$OC35=/TN/\`:QU'6O'TVA>,+^U\"ZO\2O\`A(O#GAOQ?`VK6R^)K?0/%]U?
MV>XQXJ_MG5OV1OC#=?L:3Z)'!X+^%$W[./Q&U7PGHGQU^V1IXR^('_#(T7@F
M_P#&_A>V\2>%)?"OAW2?&M]\*-&TI=<\*^.=42*T'B9_%7BS]&_V;_\`@LM^
MRU^T%^TQXG_99:ZO/`?C?2[O3?#O@S7_`!1-'8^&OB=XY@@^S>+_``?X>>XC
MAETK5]*\0QW&C^&+;5IB_C80$Z4T6IW&G:3?_KM1@JN$S'#4L=AJE*M2Q5*E
M7A/V<;M5(TZM-58\STY&I2I>[^]<:L'%KWOSSB+Z.]'AW$9GPUGG%'C)EV-H
MX+BCA_%.7'^(CB(_VWQ"LUS#'8?$SRJ=.MC\!BL,\KRW'.->"RF,LOS:EFM2
M*K0_EJ'[//QVCTOQ39>*_@+\<M3_`&F=9NO$LO[&OQ+OO!_BWQAJ/P>\!WMN
MP^`&A6OQUL8=:\-_LX0_"^*6SM_&OA/QEXS\$7T5YI_B&XU+3_&)UQKOQ$3?
ML[_%N]M_#$?PV_9F^/WASXO:+J.B_P##9?B#_A%-?\!Z]\8?AA%`4^+7A+Q)
M\8M;N],\,_M7R>/-9@L=57P_X3\<?%.[\4V-M>0^?ITNH^5<_P!2M%;PP5.#
M=W[1.#IM3A3NXMR;;E"$&ZEY<O/HG3C&+BYWJ2XUX497'&K'QXO\2H5HYYC<
M_5*GQKC*.%6(Q^14^':N7JE1PU.I')J6#IK&X;!QKQQ-#-I5,13QZP$Y96_Y
MA-;^#WB_Q3\1-8^(_BS]F?XZ^*?V/-;\+:;I=Y\/O$/P)^(VMVES\?\`3-7N
M2GQ$U#]D;5?"=W\6KJ$>#KJ'PQI7Q$/PD.D:=J4>M7"216VL3>([KG-/_9Q^
M,_AKP[XYT/6_V:?CA_PNGQ?!XMT;]C[Q/8^#M7\47GPU^&.LZ6FE?"/PJOQ=
M\.2:EX<_9H_X0ES;+XET?XE^.?`6I6>GV=LMY=:M:V%GINF_U/5^1O\`P6J_
M:K^.'['G['5A\6/V?O%=IX-\>7?QC\$^#Y-:N_#GASQ2BZ%K&B^+[_4;:/3/
M%.EZQI(EN)]&L0+EK)YXHUD6&2,R,U<5?*\JHX'V5;`8&KA,-!^SP\L#0G0I
MP=.>'E1HX=J-&%'ZM4EA:=))0A1;A-S3E?OR/P<I8G$8+)<N\0/%J@L9AN"L
MHJ+_`(B)C\-#&4>!\R6;937S)X?`*G7Q./Q<5/B&JL*Z6,C2IU<JP>3X^/UN
M?YKP?LW?&2'1?!>B^#/V=OC9HW[0WA2Z\,S?M;>.],\%^*/!5U\4/`VDZ-=Z
M7\;-$'QRN;30/"G[0T?Q!T^XU+3/`WA7P-XL\8WLB:MI,.D:;X(BTYKKP[K_
M`/"A[C^V6U:S_93^+\/[$@T06.N?!M?V;_B7:>&=0^/HU.2;1?B`G[';^!D\
M=ZE;Z7X374]#U/XB0?"$:)+K.K>&;B2ZUF71$USP?]0_\$)/VV_VDOVV/A?\
M??$G[2'CNT\=:QX&\>^$]#\,W5IX1\'>$5L-,U3P]>W][;O;^#]"T*VO#+=0
MQR":]BGGC`*1R+&2I_>*KPN#P\Z5.O1O3C4<*JBZ5"-W3HQP\%.-./+R2I4X
MNI"+5Y1A*FZ*CR'+Q!X&8##XW'Y3C^//%*K.A3XMR]RPO'F+G2PM+C/&+-,Q
MAE\L7E;='^Q\94JRX:4Z$Z&7.OBJF/H9SBJSQK_EA;]GCX@Q:7XGT[XM?LN?
M'CQGXDO[R]N_V*;I/AMXM\=:S\'_`(736L:_#;P1X9\?:79:Y9_LI:]X2\8V
M&I^*(M.\;Z_\-KKP=HFN>#;>:^C_`.$;/AKP??A_9Y^.7]G^'+#P_P#L^?'F
MW_;+TW^P;C]I#XQZ/HGBWP!>?$S2=-N[*7X^:?<?M/W']@>%OBUI?QA\/V?B
M'0_AAX:\-?$+5KO0KWQ#X&N+/1OATO@X1>%/ZCZ*[HT%""A&<DE*+NDHN5E[
M[ERJ,74G\"J1C#V=*4Z=.,>;F65/PFR>&+HXW_6[Q/=2EGV4<0O"QX[QU/+Z
MN)R;(GP_2P%6A3PL<1+*<PPTI8W.<-'&1Q>9YG*56MCXX%_V<OY?E^`"2Z[+
MJFA?LE?%^Q_8\L-(O[?XB?"F+]G'XC:!X6\2?&J2]T[_`(07QXO[)UUX4T[Q
MGX]L_#7AU/%V@ZKXLT?X.Z[I\>O>)_!>M3-J<?A,>)_`?[,?\$^?"'Q!\&_!
M37['Q?X>U[P1X.U#XE:WJ_P+^'/BFQDT?Q%\.O@W<>&_"%KIGA>_\-SPP77@
MZRD\;6?COQ%X7\#7D-M<^!_!NO\`AWPG+INB?V.-"TSX.U[_`(+\?LB:5^V;
MI7[-ME<+J?P@#W/A?Q+^T['JZKX%T[XCO<)#966DV*6$S:M\/;*='TC5_B,=
M1MM+DU.Y;4]+MKKP;IB>*-:_=2VN;>\M[>\L[B&ZM+J&*YM;JVECGM[FWG19
M8+BWGB9XIH9HF62*6-FCD1E=&*D$QAYTJLI.G757V#E2G&/,E%](14F[48*_
MLH0O34N=J4I)\OO\/>$,?#C%Y=F$\Z\0LSE6X0P_#V`I<8\4+/<'5RNGF]3.
M(YG+#1P.%A#B*5>J\+6QG[AX?*71P5#+L)3KU:F*FHHHKK/L@HHHH`****`"
MO+OCA_R17XO_`/9+OB!_ZB>K5ZC7EWQP_P"2*_%__LEWQ`_]1/5JZ,)_O>%_
M["*/_IR)UX#_`'[!?]A>&_\`3T#]P?V(?^3+OV0_^S7_`(`_^JH\)U\3?`;_
M`)/1_P""JG_9T/P$_P#7?7[(%?;/[$/_`"9=^R'_`-FO_`'_`-51X3KXF^`W
M_)Z/_!53_LZ'X"?^N^OV0*_$N*/^2=S;_KU@_P#U:8`_H[Q`_P"2??\`V&X;
M\JI^LFA?\@/1O^P5IW_I)#6K65H7_(#T;_L%:=_Z20UJUZF"_P!SPG_8-0_]
M-0/K,!_N."_[!,-_Z9@?D#\*?^"3FE?"_P#:Q\'?M20?&C^U+GPC^U_^WK^U
MA'X-B^'-SI2W<W[<OPV\"_#[4_`::\GQ'O8;.T\#S>"8_$U_JZ^';BP\>:S>
MI?7'A;PSK-BNMW.M_P`$,O\`E%E^R[_W6S_UHKXN5^M%?F)X!_X(U_\`!-SX
M7^._!7Q+\"_LX_V'XV^'?BWPYXZ\':W_`,+?^/.I_P!C^*O"6L6>O^'M4_LW
M6/BAJ&D:A_9^KZ?9W?V'5+"^TZ[\GR+ZSN;:26%_CY\-8G*,[RW-.&\#@*E"
M.&SO#YI0S/.LTP]3VF;5>%5#&82I++\[]HZ.&X;5*6#;P-&4YPJJHJDZ\Y?`
M5.$,7D7$>49SPCEV5U<+'!\1X3.L-G'$.<X6K[;/*W!*IX_`U997Q%[5X?!\
M(QH3P#>78>=2I3K1K1JU,34E_-I=ZOH'B[_@G5_P1E_9>^,7[36H_LP?LJ?M
M!>/OVPKW]HCQA:6NDM87-A\+?VC1JO@7^WM4U.UFLM!TZ#Q!XDN=.L?%/C!M
M2^$WPW\2Z[H'QF^)WA/Q/I?POT^&Q]8^$WPN^`G[/O[0'_!;?X(?`7QM^TEX
M:TSPY^P?^V9:Z[^SO\6?AII.@>$/#]IH&C>$KGP=XBTOXF6/QUUS7?B3I&DV
M7C;7-0^`FJ^.?@9HGBF\^!OQ:T_4;_Q[J>KS>(/$7Q3_`*8M4_X)[_L=:W^S
M)X?_`&.M8^"FE:I^SKX3UB3Q#X6\!ZAXG\=W=[X:UZ;Q5K/C*?6M`\>S^*7^
M)&CZK<:WXC\11W-_I_B^WNKGP_X@USPA/+)X1U?4-#N<;X3?\$U?V&O@;X(^
M)GP^^%O[._A+PQH?QA\)>-/`'Q%U-M4\7:[X\U_P'\0]%TG0?&/@>/XI>)/$
M6L?$W1/!VLV6A:5<OX8\/>+M)T.RURU_X2;3K&S\237&JS?"T/#//*4\K]I+
MAVO4P64Y1A/[3JULQEF6#E@.$J7#N(RG`)8-1>45\9"OF<*KK8:]3'8F6*RO
M$5HT*E+\VPW@]Q)0GDJJRX4Q-7+LCR+`_P!LUJ^;2S;+YY9P+0X3Q>198E@(
MP>0XK'T\3G,*SQ&#YJV98N6,R7%XB&&JT?P4O_C!^U-XO^!/_!$OP!\4OV._
M^%/_``2\+_M:?\$V_P#A77[0'_#0?PZ^('_"T?[$\'/HOA'_`(M5X=TRV\6^
M"?\`A-O"5SJ'C7_B>WEQ_P`(W_9G_".:GYNIWL$J^M?\.I?V!O\`A[#_`,,T
M?\*%_P"+)?\`#O'_`(7G_P`(5_PM'XS_`/)4_P#AI+_A`?\`A*?^$C_X6+_P
MEO\`R*7_`!*?[$_M[_A'/^7_`/LC^T_],K][]:_92^`7B'P)^S_\--8\!?;/
M!/[+?BWX5>.O@3HG_"4^-+?_`(07Q5\$M'ET#X8:I_:5KXB@U?Q-_P`(SI$\
MMI]A\8W_`(AT[6MWG^(;/5KE5F'6_P#"C/A9_P`+V_X:7_X1;_B]O_"I?^%&
M?\)K_;?B/_DEG_"8_P#"??\`"+?\(Y_:_P#PB7_(V_\`$V_MO^P?^$C_`.7#
M^U_[,_T.O7I^&LJTL,\ZEEO$+P^-X?K1K9SA,!B*U+!9?@/JN9X"C&ADV$H+
M#UYT\.J-.5)SQ5&A3ECZ\JM.![M'P@G7G@WQ%/)^*WA<QX6KQQ'$&!RO%8BC
MEV5Y9]2SC+,/'#</8'#+"XFI2PL</2G1<\;0P]&69XB5:E"WYM_"G_@E;JOP
MR_:Q\'?M./\`M%_\)#:^$_VO_P!O7]J9OA_+\(K;3&U.P_;<^&W@7P+;_#U_
M%D'Q#N6M+OX17W@MM3L?&D?AZ6'QKHVK/H6I^#]&U:RC\6S?K]117Z5EF49;
MD\,12RW"PPD,7B?KF(C"522JXGZOA\)[5^TG-J7U?"8>E:+4;4D^7F<F_P!?
MR?(<HR"GBZ.3X*G@:>.QGU_%PISJS5;%_5,)@?;R=6I4:E]4P.$HVBXPY:,7
MR\SE*6+XD_Y%W7_^P+JO_I#/7YW_`!_E\,Q?\*3_`.$F\5>)?"WF?M!?#>+P
M_P#\(W!)/_PD?B9_[9_LKPKK_ER1^3X:U?%Q_:L[[XX_L\&Z-LC'Z(>)/^1=
MU_\`[`NJ_P#I#/7PI\6_^$N_XME_PB7_``A__)7?!?\`PDW_``E_]G_\BC_Q
M,O[9_P"$7^W_`/,X?\>W]B?8O^)A_P`?/V;^.O*XE;CB>&6IQIM8C/O?E.--
M*^#RU:RG3JQ5]E>#NVDK-J2_-?$__><MTO\`[/6T2;_Y?T^B:VWW^_8]=KO_
M`(<_\ARZ_P"P5/\`^E=C7`5W_P`.?^0Y=?\`8*G_`/2NQK\WX>_Y'>6_]A,?
MRD?+\+?\E#E/_87#_P!)D>TT445^WG]$GY"?MZ?L=_MT_'[XC_%7Q+^S1^U+
MJOP3\*>+/V/_``;\&_!>A6/QP^,?PX3PU\>-%_:L\&?%G6_BS%I'@/PUK>DZ
M+>W?P7T7Q#\.$\::1)<>*=:@UJ7P/XCT6Z\$W<MW:>'1_MW>._@#_P`%(?\`
M@HYX&U_X/_MP?M1^";/_`(9"_P"%?^#OV=?A_K'QM\+?!;[1\!SK'BO[1X>O
M?%^C:3\.?^%C:MK,.J0_V+:+_P`)?J/A_7+[4MUSI*2R_O97SS\./V:?`GPO
M^/G[27[1>@:MXMO/&W[4?_"G?^%@:7K%_H]QX6T?_A27@R^\#>%/^$.L;+0=
M/U;3_P"T-)U":X\0_P!M:YX@^UZBL4VF_P!DVRO:/\/F_#./J9CEN/R3-,7@
MJ\L[CC,RK5ZOURA1P=+)N*,/"&'P%=QHU/:8[.:%.=-NT:<,/56N!I)?U-X=
M^.7">#X.XTX4\3^!N'N)LIH^&$^&^"LLRK+_`/5O-,TXCQOB9X#YOB*V<\5Y
M73JYCA/J?"WAGFV,P^.A34ZV,Q6;8"HVN*,=*7\R>D_M#?MA_&#]AO\`X)(_
MLX>#OVN[KX+^-/VX/B-^TSHOQ+_:B^)/CKQE-\48$^$/Q^EB\$>&M$^([^*K
M'Q5>ZKXC36X/"GAGP/I^O>']>^*?BJP^&_P=MO'_`(,\&^)?%$&K?6?[/7@/
M]HG2OVTOVP/^"6/Q#_;V^,GQ5^$>N?!O2_VE/`WQD\(?&'67_;&^`]S9_%#X
M10Z#\,];^)FJ2>()?`6OZOX.U.WB\=>%!IVJ>'O&W@;4_"7Q5\%Z+\)V^+GC
M#PC)]T>,?^".7['OC_\`8Y^&7[%OB^#Q_K?@WX-ZGXIU3X9_%2ZU3P</C?X3
MD\<^.M3\<^-K"Q\41^!4\+3Z#XNDU6?P]XB\.7_@B[T'5-%LM`U"YTY_&7A7
MPOXLT?UG]C+_`()N?L\?L0Z_\3_'GP^N?'_Q(^+GQ?UK5-6\<?&SXW:]HWC;
MXKZC::YJ%MKVN:!%XGTOPUX8B@TGQ%XOAG\<>+;C^SI/$/C;Q;=0:IXSUWQ`
MGAWP?;>'/C<JX+XHAB\DAFC]M2HX#A_#X_,?]8<P?LLMP?"M'*,ZX=_LJ$5A
M\5]?SB.)S'Z_[1<WUSZPZD<5A*$9?TGQ[])KP+Q7#WB?B.!*;RO,,QXK\7,X
MX2X/_P"(0<(4UC^,^(O'[&^(OAIXP_Z^8BI4S7(GPGX<U<DX-_U4^IS]C_JW
M_8L,'6R/B#,Z]/\`+']C;]F'X_?&'PI_P4#U?PW^WC^VSJ?Q8^!_[0'[<?['
MG[/^G?%#]ISQIJGPDEN=)^%,W@7X5>/?BKIMAHE]XDN?$WA;Q)\0(/&3^)/!
M5UHDFCZ_X=T'7_#GARWO])2VO/TQ_88_9]_;"^"OC3XPZQ^T]\;+'XL>&_%O
MPE_8N\+?#O2K/XH?%#XA2>%O'GP?^`-MX%_:/UVXL_B%X>T2PTT?$[XL17/C
M2V\2Z&YUGQ_;7$>N>.](T+Q)!)#=?2O[/?[-/@3]FS_A>'_"#:MXMU7_`(7[
M^T-\2_VEO&/_``EE_H]]_9OCOXI_V+_PD.D^&O['T'0OL?A*S_L*T_L:PU3^
MV=8M_,N?MVO:COB\GZ&K[+AG@_#Y5A<JK8F.(AF>!JXNO/DS#%5J%2K7CC,*
MI5H3JSA7M@L1",8R7+3G3ISC%3@Y/^;/''Z1F<<?9[QYEN25,HQ/!'%67\.Y
M5AWB>$<DRW-<'@<IJ\-9[5H9=7PN"H5\KOQ/DM>O4JT'&MB\-C,9AZ]2IA<3
M&E2****^X/Y9/$?B+_R,4/\`V!;+_P!+M5K\RO\`@JG_`,HV?VYO^S7OC)_Z
MA6K5^FOQ%_Y&*'_L"V7_`*7:K7YE?\%4_P#E&S^W-_V:]\9/_4*U:OS?-_\`
MDX."_P"P[AC_`-0\J/P#B#_DK<9_V,:'_N$_:.ORPG_Y2D?M5_\`9@G_``3J
M_P#6B/\`@J;7ZGU^'O[4UW\2]/\`VLO^"F5_\%_$'_")_&*R_P""2/[(EW\)
M_%7_``A^O_$+_A&?B7;?$K_@K;-X$\0?\(!X4\#_`!.\4^./[&\4II6H_P#"
M'^&OAK\0M?\`$WV;^Q=&\#^+-1O;;0-0^HXICSY%C874>>6#CS2ORKFQV&5W
MRJ3LKW=DW;9-Z'ZQQE#VG#F84TU%SG@(*4K\L>;,L)&\N52E97N^6,G;9-Z'
M@_[,W_!2GXE_%#]E/]J;]IGQO\/O`NM7GAOXY^`?"G['OPQ\&S:_X%U;XJ>$
M_P!K7X&?LG?&+]A#X3_%KQ-X@U+XAZ%X+^.?Q&UW]KWX6_"'XO>.].`^"OP\
M\:ZCJ>N)<R_#KPQ>^,]2]6_9V_;F^(OC+]EG]E#QOXF^%6N_M,?M/_'K]F_X
M6_M-^._A'^R+X:\!^`=/^&GPZ^,NC-XC\*:[XA;]I?\`:2T#P=X0T*&XN3\-
MO"P\3?&Z3QY\=/$W@KXE^-?A7\.I_"?P[^+>G_"3\P_%^B^#O!?Q4\3^,?V2
MC^U;\&?AU\*/V&?#7PY_8O\`A#J/_!+K_@J9K&D^"/\`@H#X"^#WQZ_9E^%G
M[7'Q*US6?V.?%LNM_P#"N/V5_'W@O]GV_E\6:3\9M2^,'@J#17^)>@7EY^SC
M\$3=^YP?'S1/V7_B78^*/V+?V</CGXX^'4O[*7[,?[)MA\+?C1^R!_P6!^"W
M_"I_!7[(FO\`Q[U'X:W?AKQOHO\`P3._:KUWXI_\)5H7[05YX=UF#Q=;^#=6
M\)_\*UTK5Y/$?Q&O/'^HIX)_.:N#I34O88.HYU'3JTX3I5J44XTJ<9X:K.7)
M&G']Y*MSPJI59J5%RC*%)S_**V`H3C+ZM@*KJ594J]*G4HUZ,8N%&G">$K5)
M<D*4?WDL1STZZ5:I&=!RC*G1=3]`KW_@HAX#GG^#?A[P+\"_VD/BO\3OC9H7
M[2MWX?\`A-\/_"GPZD\3>%_%_P"Q]\6_`'P2_:0^&_Q&\9>+?BGX2^"G@?7?
MAM\0O&VJ:&OCC6/BLGP.\<ZAX!UW1?AI\6O&?B7QM\#M#^+9X=_X*":%\3=/
MN)/V?/V:_P!I#]I#Q!X0UWQ1X&^.OA'X82_LWZ!J'[-WQ;\%>)M7\&^+/@G\
M6/%/QL_:,^$7PQUCXK>'O$OASQ'!K'AKX*^/OB]!IWAFV\)?$Z\U*'X2_&?X
M!>//BM\,_LU?$;X4?!'XT7OC_P`867[9/Q"TO2/A3X_M_`FIV/\`P2Q_X*>>
M%-0T+XX_M=_M7_&3]J[]OO5],\&1?LF:G;Z1\*?B9XQ?]E^Q^#_AWQ;\0_BU
MXO\`AUX9^#]SX;_X2@ZIJ7CCQS\7?G#]DKXO?&7]C+PGX\\)^`/A=XZ^(?BG
M]J'QUH7[2?[1GQK\<?L+?\%BM"_X0+]K7XC_``5^$'P^_:=\:>#_`(#^'/\`
M@FI=:=\=/`OB/XQ?#?Q5^T9X?\.0_&W]D6RUO_A9MW\#=`T+X%>%O!^@^-KC
M/ZA3:JJGA:LIT^65)U8XB%.NJE6;<9:4I*-'#.E>,7"H\0IKFJQE"#R_LRDU
M65+!UIU*7).BZT<5"EB%5K56XRTHRC'#X1T;QBZ=9XJ-1<U:$J=-_H^?^"F^
MDW?C7X[^-]'^%OCK4_V._P!G_P#X)O\`@K_@H4WQLT[2_!5SJWQU\%?%[2?&
MWCGX<K\-?#6N_%OPCXZ\![?`OP7^+&G6'AOXG_"VRU;QOXUMM:3Q;K'[/_AW
MP!\/]2_:A[KX0_\`!030(_!7@VU_:A\)^.O@Y\1;OX&:9\1)_$.I?!SXE^`_
M!7QW\6>$M6^$OPM^.6G_`+-OP5\>02?M?V/]@?M#?&;X:_"CX6?"_P"//P1^
M&7QJ^.^K?$WX>1?L^^$OC;9ZQ+KL?Y3>!+3P=\,?@1^U)^Q]X2\)_M6WO[.G
MQ?\`'7[$_A3PSKGBO_@G]_P5,O\`XE^./V2OA[^SM^QE^Q]^V#\)_BQIFA_\
M$Z?#VC^#/'7Q`_9T_9K^(FA^!/'?PO\`$US>ZSK_`,6K;4]/N?@#K'A/3/$R
M>K?MG^)OA1^UKXS\=ZYXH^'7[2'C7P=H'PI_9KT?X'?#?XD?\$O/^"GDWAG6
M?$W@3]L7PY^U7^U3\,/BU:6_[#FNZ7_PJG]JS2_V;_V-_A3=^+=6T7XR:A\-
M]/\`"'CCQ#X=^$]S;WOBCPI\8='@<.YPI_5L1&C)TE*K&G5=:-/V6%?.DX.,
MJTZU>K*LI-4X4Z=2$::G&BH:2R["RJ0I_5,5"A*5&,JT*5=UX4O88-^T2<)0
MEB)XC$5I5U.4:<*5&M3A2C.%!0_1_7_^"@FA?#?PS\7=>^/?[-?[2'[/>J?"
MO]F_XW_M5:=X+^($O[-_B_Q-\6/A)^SAI_AR\^--Y\.;KX#?M&?&3P=9:[X*
MN/'?PTTEM$^*?BSX93^(M0^(NA2>$9=?TO1/'VI>#=W_`(;+\?:G_P`B7^P!
M^W-XU\S_`(FUG_Q3_P"S3\+_`+;X!U;_`)$+X@?\7]_:>^$/]F?\)_\`8O$?
M_%G]=_LG]I;X0_\`"-_\9)_`[X(?\)K\*_\`A/\`\;=&MO@%>^`?&MKHO_!/
M?P+^Q_XI\:^.OV9_#'B/P]^R]_P2<_X*6ZM_PG_[-/A']I;X7?%+]K+X<_%3
MXU6G_!,#X!:CXY\"_M%?!WPGJ/PHN/V;K_X(KX!U/^R;J+XE?$OQKX6^*T^A
M?"'A?V]/#O@[]J2Y_;!T_2/V7_\`A;NN_M(^!=9T_P"#_P"TQ^U?_P`$L?\`
M@J9XK^,/['G_`!C_`.&/A=IGP9^#/@JV_P""<GC&\M_`MS\1?!WB+XS>'OB?
MX7_:`^&G_"IOBI^T1\0/B?;_`+/_`,4==\`WVC?'A0RZC*I&,J%6F^9JI*5&
MO*E%+ZLKQA#$\THJ-6K-\N+J2G*C)4D^>G2"GE6'G5C"6&K4WS2524Z&(G1@
ME]52<*=/%\THJ-6M-\N.JSJ3H35%2YZ=$_:\_P#!1#P'XL\3>&_"?[/?P+_:
M0_:HU3QC^S?\!?VM?#-U\'_"GPZ\*^&=0^`O[1>H?%/3?`'BR^\:?M'?%/X"
M^#O"VN_:/A=-)<_#3QCKWAWXI:SI_BK3-6\#>"_&.E^"_C3>?"KNOAW^WI^S
M?\3/@O\`'C]HS0?$VNVGP(_9YT+1_&?C3XEZOX3UV#3]3^'6M_LH?!K]LZU^
M(7A?PO9VM_\`$*]T*/X*?''PG=7&C:MX.T3QXGB;3O$6@1^#I9+33;G5_P`4
M/A7^UMXY\.7/[9,/['?PW\=?#;X(_M!_'/7_``5\)=;A_P""=?\`P4@L/&O[
M&?\`PS[^S_\`!;]@F[^(7A7X;?#?]@_XY_`#XW_\(YXN_9MU;Q5X`_93UO7_
M`-GW_A7FD^!-`\`?&3QOHWC7XD^./A=^S+A?";XU_LN^+_V\=.N?@EX=_:0U
MK_@G]^R/^S?^RE^SY/X3\%_L,_\`!1WXEZ[;?M>?L->./VLM)^&/[/7Q+T&3
M]F3QU<3Z%^S7X._:%T/XU^+-+^++:-\3M`_:0\+?LE?$?P;XAO-;^'OCZ.%2
MRJ/+5?U;$Q5.E3J1<8U)5'+]Q[:C5O3Y(5G*52CAXQ@DY1JU9*5+V+:GDT.6
ML_JF+C&E1I5(N,:LZKE_L_UBA7O2]G"NYRJ4,-&--)SA7K34Z*H2?]`OQ`_:
M.@^'_AGX<F3X0_%;Q9\:_BKH3:[X0_99\'3_``DU#XXRP:-I^A:E\1FUG4=3
M^*^C_`CPYH7PBC\0Z3I?Q"^(VO?&W3_A)%XOUGP9\/?"?Q`\6?$+XJ_"#PM\
M0/#-7_X*(>`]`T/PNFL?`O\`:0A^+7B+]I"X_9*O?V=M(\*?#KQE\6_"'QZN
M?V;_`!%^U;X/\)^*-2\"?%/Q1\&5T+QO\&=-\*>([?XEZ!\7-?\`A;\.H?B1
MX=U#XY^-/A/X?\(?&?7/A7\I_M`?M?6;?''X+_M)_`'X0?M(?$+QC\,?A3\?
MO@?J7PR^,'[!O_!5OX*>&=2\,_'WQ?\`LY^/;SQW8_$SP7_P3G_:`U1-=\&Z
MI^S3HWA^V\"W'PP33_%&G_$+4_$$OCWPU<>!K7P]XW\I^%'Q.\':)^T_X:_:
M:^)GAS]JW5+SQ;_PT3\8/B[\.M"_X)I_\%3-7\%>`?VEOB)\/?V*OV>O@AJ_
MP5MM?_8DL9=>_P"%1_LK_L[_`!5^$/B'XX^)QX,\?>+=6^,?Q2USPC\/_AE\
M.OCMXC^#'PXYZ6!_=*=7"5KNE6FE&-95/K$93Y*#CKRT'34)*;ASRJSBE5E'
MFA'EHY;^Y4ZV"KWE1KU$HPQ"J_68RJ>SP\H>]R89THTY*<J?M)5JD8JO*//3
MC^K/Q(^._C6+_A47PJ^&_@G_`(1O]I?X_P#@7Q)XZ\-^$/BV-)U'0/@9X*\"
M_P#"NK+XN_$?XR/\.O&NH:%XX_X4WKOQ:^'7A%/A5\(OB9J.K?&+XE^,/"WA
MCPW\0?!?PBE^)'[2'PBPM(^*'QQ^`>G^*-0_;&U_X4^-/`5EH5OX@T/X[_`G
MX9>+_AEI\/B:^\3>'?!&B_`#4OV=/$/QC_:'^+7C'XK?$+Q!XET!?@->_!WQ
M'\0]0^-'B;5->^$<WPR^''CW0?A2W[1OQM\>/VMO!U[\2_A;^TC\#/AO^U;X
MD^,7PA\"_%SX3VGPW^+'_!.O_@J9X`^&GC_X:?'C7_@UXD\<6US\1?!_[!_Q
M,\4_#GQUX;\4_`?X9>)_"GBN+X<_$S0-3T#3/'?PTU?P)9:C\1O#_P`7?A#\
MW_$?X[>/_C_HWB?QS\75_:0\->,=(UW]E[QQ\"_V8_A__P`$Z?\`@KUJ?P.\
M"^)OV9?VIO`/[3_B>T^(WQROOV+/"6J?%_7?VF=4^#/PN\&+\6M5_91T74/V
M1?"":[IGPH^&_P`3+C7/BSJ?QU*6!J2C24\/*G2FTJ[="HZZG*ORVH^Y*I&,
M*$H5.>7[AI34I5:W)191RZK.%%5,+.G1G)+$MX>J\1&I+$N*C0O"56$:>&E"
MK[2?^S-*I&<JU=0H2_1_7_\`@H)H7PW\,_%W7OCW^S7^TA^SWJGPK_9O^-_[
M56G>"_B!+^S?XO\`$WQ8^$G[.&G^'+SXTWGPYNO@-^T9\9/!UEKO@JX\=_#3
M26T3XI^+/AE/XBU#XBZ%)X1EU_2]$\?:EX-P_$'_``4Q^&GA/_A./^$J^`?[
M5OAG_A6/@6T^/OQ*_P"$@^%F@:-_PKW]C?4/^$P^P?MA^./[1\>VW_")^!;W
M_A7OC_[)^S;K_P#9_P#P4-N?^$'\8>3^Q:__``C.M?8OS?\`C+\7M:_:TMKW
MQ-\<OA=\<_A7KL_@5_V7+KX2_#']A;_@K7\5_!7B[]DK]H#]H#]FCQE^WI!X
MS^+WB;_@FI\'?%T7CKXN_`#X&3_!WX.^'O`?PQ\$WOPIU:\\3>,Y?C;K&N_$
M?PGJ?[.G=?&+XG>#OBW_`,-H_P!L>'/VK;W_`(:J\=?LL_!F3[7_`,$T_P#@
MJ9I_G_\`!-_X>_\`"M?^&@OV>_$']D_L2)_8WCKQQ_PL[_@H5_PA_C/PW]I\
M<P?\+Y\#[?C#X,_X1/P=_P`*DVA@*34/:X6M&HY6JQIJNZ5/]]AH+V<K5'->
MQJ5:LI>TFO:4Y*+Y.5&\,MHVI^VP6(A5E*U:-*.)E1I?O\)37LI6JN<?85:U
M:4G5J)U:4U!^SY8GZ!?&#]L;XB^!?VO+']G+X8?LX_%;]H2W\,_LWVWQL^*F
MC_"_1O`>F^)K"?XH_$[4_`OP2U+0/B7\9_C%\&?@1I>A:7'\&?CY:_$WP-XP
M\8Z?\6_$^H>(_@YK_P`$/#7CSP=X/_:.U3X7X=C_`,%)/@KJ'PT^*O[2^B7O
MCKQW^SIX)\=?L;_"+P_#X$^"/BS6OB7XF\6?M;:!^SMX_P#!_P`1?"F@6GBF
M_P#'7Q`\"Z]X%_;3_9W2V^&]E\&O"GQJ\,Z_X-^+%EI?AOXJZQXC\#^%=/\`
MAF]_:V^,OA#]I_\`:7^,7PZ^&_CKQEH7Q\_X4U\-/A[XJ^)7_!.O_@L5X7\:
M_L\?!7X/?#U)M&;6O`'@S]@_5O"/[2?V;X__`!A_:;^)VG?#,>,_V<O%CZ3J
M]AX9UW]JC6M"\<^#M`_99\H_9\TWX4?`WX'?L]?`&32OVR?%O@[P-^V3I?Q@
M^.FI:[_P3<_X*>/XF^+7P._9>\(>(?!?_!/*Q:\\/?L(^$=+T[XK?!W2_@!_
MP3:N/B-;>#=&^&?A#QCJ'P"^($OB/4_B%;^-/&EK\6FL!35.#J8:M90PNE*%
M5U:O-&-?&<ZE3<:<X.$\-0TA)U*D.;VE&2J0<<MI*E3=7"5[*G@]*-.LZ];F
MC'$X[VBE3E&E.FZ<\)A[*G)U:M/F]IAY1JP_7;3_`-MVYO/^$M\*77[)7[5N
MF_'_`,*_\*[U$?LR?V;^S_XA^)>L>"OBI_PM`>"?B5_PL7P5^T)XH_97\%>!
M=6E^!GQNT_[?\5_VBOAYJT&O_#7_`(1*715\7?%#X$:%\5_*?%__``4$\7W7
MB_\`9O\`AG\.OV:_BMI/Q"^*O[9-E^RK\<]&^(4OP.U#4/V8-0T/X')^UQK]
MGXQL?"G[1D7A/X@:[\0/V8(H/'O@S6_@W\3?B+X9\`^&=9UGQ#XJB\6?&OP!
MH_[(GQ?_`##_`&A;[P=\5_VG_B+^TOXN_9K\=?MA:%J_V;X5^"/V9OVHO^"=
M/_!4SPQ\'H/@KH?P]^#&N?"WQ[XC"?\`!,3]H+PB?CG\!OC_`''[=">`[R3X
M->(_%FL?"O\`;:\664WQ]\+:%X4T[X0WA^Q<O@[]D#XA?LY:[HWP8\=6>A>&
M/^'H>G_'N7X*_P#!*7_@J9\#=)NO^&Q/VG_@S\;O@5XM^%OPHM/V%/&EGJ/_
M``A_PZ^`'P]^"NN_#OQG\4M._P"%5^"K?P]X>\'?%#XIZ%\,]$M?$=+`48TE
M56&J2J2I<\:+I8BT:SPM2<HN3JW=*E6C!0ISI*52I6IQ5>M"-6D6LLH1HJLL
M)5G5E1<X4'1Q-H8AX*K.4)2=9R=&C7A34*4Z*G5K5Z45B*].%:B?KKH?[<T'
MB&?QE:_#;X5?%;]I+QC;?%;XS>&M.^"OP:\-?"3PA\1?A?\`#KX#?%OQK^RW
MXJ\<_%OQ=\:?VDO!GP@DT+Q]^T/\$OB]>?!74IO&GP[\>?%#P'-)IO@[X)Z_
M<?`/]H'QKX>+W_@HAX#GG^#?A[P+\"_VD/BO\3OC9H7[2MWX?^$WP_\`"GPZ
MD\3>%_%_['WQ;\`?!+]I#X;_`!&\9>+?BGX2^"G@?7?AM\0O&VJ:&OCC6/BL
MGP.\<ZAX!UW1?AI\6O&?B7QM\#M#^+?Y3?`SXS>/_P!D^?P_\0_AM\&/BM\=
M?BU\5OV;_@YX*_:IM?B!^QQ_P5Z^`_AF/]I#PE\6_P!J#]HWXX_&;X<Z_P"%
M_P#@E9\>9/&&A?M!?'?]LKXO>)&\&S>`/@AH7PGT_P`-Z%8^#M#N_#_BNW\'
M?#'W/]FKXC?"CX(_&B]\?^,++]LGXA:7I'PI\?V_@34['_@EC_P4\\*:AH7Q
MQ_:[_:O^,G[5W[?>KZ9X,B_9,U.WTCX4_$SQB_[+]C\'_#OBWXA_%KQ?\.O#
M/P?N?#?_``E!U34O''CGXNYU,!"#J26%JU80;=&T*RG7_=RAR3A!)PC2KRH7
M;5&I7HQK5*=2;E%QRJY;3INK..#K5J=-MX?EAB%4Q*]E.'LZE."3IPHXF6&N
MY*A4Q%".(JTZM24HN/Z>P_M@_#27X&>%?CT^A^.K?0O$/QS\`?LV:OX1FTS0
M&\:^!?C5XQ_:LT#]BWQ%X+\51V_B:?PC>?\`"J/C_K&H^&O'_B/P1XO\8^$]
M1TGPKK_B?X6Z[\2M"N/"]YXDX7PE_P`%"OV?_B#_`,+03P`OCKQC>?"S]N;3
M_P#@GK?Z1I/ANVM]?\7?M`6__"N[CXE-\/\`P[K6L:3KOBCP+\#-"\:^*O&_
MQ@\20Z=;W.A?#3X&_''XI:!H_B?X=>#M.\4>(OS@_P"%G>#O^';_`/PSI_PC
MG[5O_#6G_""_\+F_X69_P[3_`."IG_"M/^'D'_"<_P##5'_#0FW_`(8D\_\`
MX07_`(;M_P"+W_\`"&?\*V_X0;^P/^*)_P"%/?\`"OO^+:5\I>#_``-)\&M?
MM+CX-_$#]JVWL_#WP,\#Z_HGB7Q!_P`$D/\`@ILOBS7O^"JOC'X:>(/V4OVB
M/^"J_CB+5/V/_'4OB3QU%^ROJ+ZO:?LZ>*?%'C'X8?M*_&KQ5XP\1?%O6OAK
M\1;F]_:'\2E/+:,HU^>&)A4C7JQPZ=*OR3I*5+V3FXT9-*7-*+DM5%RGROE5
MBEE.'E'$^TIXN%2.)K1PJE1Q/LYT8SH^Q=1PH3DE/FE%S6JA*4^5\B:_HB^`
MWQ@\3?&WQ-\=O$5K8Z%9_!3P-\5M>^!_PFU*WMM0?Q-X^\3?!C4-2\%_M"^.
M]7O+W4[231-"T3X[VGC3]G_P[X%O/`VF:A'J'P"\4?%_3?'OQ"^'OQN^'UKX
M,[/_`()1?\HVOV)_^S>/AW_Z9HJXS]D_7/@W=_`[P3X+^`/@WXK>`/A+\&-"
M\-_!/P1X3^,'P9_:'^"/B;1/#/PZ\(>'-)\-:;8Z#^TYX*\$?$[Q1H6F^&FT
M;3;;QS<6NN:?K>H6>IV<OB74_$&DZ_':=G_P2B_Y1M?L3_\`9O'P[_\`3-%7
MUG!"2JYRE3E3C%X",83BXS48K%QBZD6W:I))2J6M%SE)Q2C9+[;P[25;/HQI
MRI1B\LA&G4BX5%&"QT8NK%MVJS24ZMK1=24G%1BTE^(O[#O_`":Q\)_^O+Q/
M_P"IOXFKZOKY0_8=_P"36/A/_P!>7B?_`-3?Q-7U?7]%5/XE3_'+_P!*9^*\
M0_\`(_SS_L<9G_ZFUPHHHJ#QPHHHH`\<_:#^*GA#X)?!;XC_`!3^(%WXHTWP
M1X.\-W.H>+-9\%V,NH^)O#V@7$L.G:GXFTNTMP]R[>&+6]DU^ZEM(+N\MK'3
M;FZL[#4+F&*RG_E%_;3_`."P?A72?B+J'[,_PO\`C)\2_CO\%5U3P9)XF^+&
MCZKX8T'[=K.F^+;+Q'=^'M$UJ70]0UGQGX.M$L].TSQ+J#ZOX;TWQ6O]O^'8
M+"Y\*RVVJ:G_`%,_M:_"_5?C7^RY^T3\)-`LK?4/$GQ&^"GQ,\(>%K.[O!I]
MK/XLUOP?J]EX5%S>O-!%;6Z>(9=-DFEN95M!&C"\#VIF1OY%OV//^"$?[77P
MM_:5^$7C[]HWX$?#OXI?!SPUXLLK_P`9^$-.^,_ANTN)[,;X[;5S:R6LD/B"
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MI9$N82-KA&>,\,CNA5CY9\`_`>L?!KX/Z)X*\8:KH4TGA5_$EQ+JNG7-TNF1
MZ3>:[JNNQSW=WJEO8-&]M;WSF[=K>"VMDCV*\J1&YEU/^&@/@/\`]%L^$?\`
MX<CP;_\`+FO"\,,DS'A/A7AC_63BK-WB,1PKDE/&</\`$/\`J[1IY7G-/+\"
MLSAA<7A<IP.;5EAL0JF&5+'9EF,*4)NU22]@Z?VOTF.*\N\9?%'Q+J>&GA3P
M_C<KRKQ0XQ62^(WAO@O$C%/BK@^IGF;KAVMFV2YEQ)G_``QEU;,\#+#9O*MD
M>0\-U:M>52-7#.+J17KE%>1_\-`?`?\`Z+9\(_\`PY'@W_Y<T?\`#0'P'_Z+
M9\(__#D>#?\`Y<U^E_VQE'_0URW_`,+L+_\`+?-?>?S?_P`0X\0_^B#XS_\`
M$7SS_P"83UROP#_X.1_^4>FC?]G%?#;_`-1CXB5^T'_#0'P'_P"BV?"/_P`.
M1X-_^7-?A[_P66_9;\,?MG?";4?%/P._:\TI/'?A5-/UR?X!:M^T3I]U\&_B
M:?#EKJ$=G+H?@O5/%LGA;P7\3K6TOKJ'2/$&EVFG6.O^;-IGB!4NK]=>M.+,
M,URRI@Z\*699=4G*%E%8["W:NF[)U=7;:*UDVDKMI'T?"7`''&$XBRO$XW@S
MC'"X>AB8SE5J<*YZX)M.$5.4<#^[@W*\JLO<II.4VHIM>&?\&N__`"1+]JK_
M`+*GX#_]1+4J_J1K^5G_`((@_L;K^S5H7_"\?VAOVJ++X>7WBU[;7O#?[,?A
MS]HB+PKH%I.D,UG9>*OCKX<\/>+].TGQ/XF.FN1HW@/7%U;3?#MC>E_%-H?$
MV[1?#7])7_#0'P'_`.BV?"/_`,.1X-_^7-&7YMED,%0A5S'+Z<XPMR2QV%OR
MV3C)VJWC*5W>#5XKEN^9N,;XP\/N-L3Q%FF(P/!W&.-HUL3.;JTN%,\5'F2C
M&4:51X-^WA&46O;0BJ52W-1E4IN-27KE%>1_\-`?`?\`Z+9\(_\`PY'@W_Y<
MT?\`#0'P'_Z+9\(__#D>#?\`Y<UV_P!L91_T-<M_\+L+_P#+?-?>?,_\0X\0
M_P#H@^,__$7SS_YA/Y8?^"Y7_!(";3'\6_MM_LM>%9;C2Y)=2\3_`+1/PPT*
MV,DVCF3-[JOQ<\(Z7;Q[Y-%WBZO_`(C:5:K)+HIEE\86T'_"/Q^(Y=!\M_X)
M"_\`!<+2?V?/`5Q^SE^V1K6O:G\,_!7AO4[[X-_$RWM-1\2^)O#=KHM@]S9_
M"#5[&(SWFKZ#>)!_9WPXU'?&WA*[DM/"VIRKX)ETR\\#?UW/\??@)(K(_P`:
MOA"Z.K(Z/\1_!C*Z,"&5E.LD,K`D,I!!!((Q7\:?QR_X(G>-OBO\8OB-\2?"
M7[2'_!-OX0^&/&OB[5_$6C_#/P3\:/&,?AGPC8:C=O/'I.D)>^!;K[-$H8S2
M6UC'9:):7,TUOH&B:'H<6GZ+8^%B\=E^%Q$<7EV9Y>Y5':MAXXO"^R:26LN6
MM%.,FTW%VDIOVD)7OR?J?#_"O%V>935R#C#@;BV-#!04\NS:MP]G?UZE.<G%
M4Z3J9;5J1JT874*\7.E+#VPV(I<BC[;^TWX5^/K+XK?##X<?%'3=-O\`1].^
M)/@+P?X^L-(U7R/[4TJR\8>'M.\0VNFZE]FDFMOM]C!J,=K>?9Y98/M$4GE2
M/'M8][7SWX'^+/[/O@GP7X0\&67QM^$)L_"/A?P_X8M"GQ)\)E3;:!I-II4!
M4W&OSW!4Q6B%3//-,1CS99'W.>H_X:`^`_\`T6SX1_\`AR/!O_RYKW%G&4I)
M/-LM;22;6-PJ3>EVDJSLF]4KO=:L_+I>'7B!.4IT^`.-:=.4G*G"7#&>RE"$
MFW&$G++X-RC%I-N$6VFW&+T7KE%>1_\`#0'P'_Z+9\(__#D>#?\`Y<T?\-`?
M`?\`Z+9\(_\`PY'@W_Y<T_[8RC_H:Y;_`.%V%_\`EOFOO)_XAQXA_P#1!\9_
M^(OGG_S">N45Y'_PT!\!_P#HMGPC_P##D>#?_ES1_P`-`?`?_HMGPC_\.1X-
M_P#ES1_;&4?]#7+?_"["_P#RWS7WA_Q#CQ#_`.B#XS_\1?//_F$]<KR[XX?\
MD5^+_P#V2[X@?^HGJU5/^&@/@/\`]%L^$?\`X<CP;_\`+FO/OBW\:O@WKOPG
M^*>CZ'\6OAGK.KZC\-?'MKI^EZ5X\\+:CJ-_<R>%-7$=O9V-IJLUS=3R'A(8
M(GD8_=4UTX+-LJGC,)"&9Y?*4L3AXQC'&X:4I2E5@HQBE5;;DVDDDVVTENC?
M"^'W'N'Q.'KU^".+Z%"A7HUJU:MPUG-.E1I4ZD9U*M6I/!1A3ITX1<YSG)1A
M%.4FDFS^@W]B'_DR[]D/_LU_X`_^JH\)U\3?`;_D]'_@JI_V=#\!/_7?7[(%
M?;/[$/\`R9=^R'_V:_\``'_U5'A.OB;X#?\`)Z/_``54_P"SH?@)_P"N^OV0
M*_(N*/\`DG<V_P"O6#_]6F`/U_Q`_P"2??\`V&X;\JI]QQZUK$2)%%JVI1Q1
MHL<<<=_=(D:(`J(B+*%5%4!550`H````I_\`;NM_]!G5?_!C=_\`QZLJBOR2
M.;9K&*C',\PC&*48QCC<2HQBE9))5+)):)+1+1'Y%'.\ZA&,(9OFD8Q2C&,<
M?BXQC&*LHQ2JI))))))))61J_P!NZW_T&=5_\&-W_P#'J/[=UO\`Z#.J_P#@
MQN__`(]657RU\9/VQ/@I\&?$@^'=U?\`B3XF?&66QAU2W^!7P3\+ZG\5/B^N
ME7$3W-MK>O>%/#*7">`O#=W:PW4NG^+/B1J'@WPKJLUK+INE:U>ZP]MIT_/C
M>)<3EN"Q>99EQ#5RW+<!0GBL?F68YQ+`Y?@,+3:53%8['8O$T<+@\+2YDZN)
MQ-6E1I)IU)Q6ITX7,N)L=B*6$P689YB\56ER4L/AL7CZ]:I)_9A2IU)3D^NB
M=EJ]#ZZ_MW6_^@SJO_@QN_\`X]1_;NM_]!G5?_!C=_\`QZOG'X'?M-?!']HN
MRUB;X4^.+35];\+7,>G^.O`&M:?JW@[XI_#?6'BBE;0?B5\+?%]CHGC_`,`Z
MW$LT8;3O%7A[2YY`PEMA/`Z2O[S71'.,UE3I589MCYTL11I8C#UJ>/Q%2EB,
M/7@JM#$4*L*TJ=:A7IRC4HUJ4I4JM.49TY2A)-YULWXAPU6I0Q&9YU0KT9NG
M5HU\;CJ5:E./Q0J4JE2,Z<X]8RBI+JC5_MW6_P#H,ZK_`.#&[_\`CU']NZW_
M`-!G5?\`P8W?_P`>K*HI_P!L9M_T-,Q_\+<3_P#+3/\`MW._^ASFO_AQQ?\`
M\N-7^W=;_P"@SJO_`(,;O_X]1_;NM_\`09U7_P`&-W_\>K*HH_MC-O\`H:9C
M_P"%N)_^6A_;N=_]#G-?_#CB_P#Y<:4NLZO-')#-JNI2PRH\4L4M]=21RQR*
M5>.1&E*NCJ2KHP*LI((()%?-?Q_B\,R_\*3_`.$F\*^)?%/E_M!?#>7P_P#\
M(W/)!_PCGB9/[9_LKQ5K_EQR>=X:TC-Q_:L#[(Y/M$&Z1<#/T%7BOQHN]0M/
M^%3_`&#XD67PY^T_&KP):7OVU)'_`.$[T^;^U?M/PWM/+CDVWOBC:GD.^R-?
ML+[I%R,]N68S&8K-,%]:Q.*Q?L_K'LU6Q.*J2ASX>IS\DH^UJPYN6+G[./O*
M*4_=3:\_'8W&8V*EC,7B<5*"482Q5>IB'"+FFXQ=><N5-ZM)K76S=CVJKVGZ
MGJ&E3-<:==-:3O$T+R+%;3%HF='9-MU#/&`7CC;<$#C;@,%+`T:*\?#XBMA:
M]/$8>?LZU&2G3GRQERR6B?+.,HO?:46O(5&M5P]6%:A5J4:U.7-3JTIRA4A)
M;2A.+4HOS33.E_X3+Q5_T&I?_`'2/_E=1_PF7BK_`*#4O_@#I'_RNKFJ*]O_
M`%JS_P#Z&#_\)L'_`/,YZ7]OYY_T.,T_\+L3_P#+?+\^[.E_X3+Q5_T&I?\`
MP!TC_P"5U'_"9>*O^@U+_P"`.D?_`"NKY-^/'[5_P+_9R?1M*^(_B^2;Q[XL
MANI?`/P=\#:)K?Q&^-WQ(DM(KF2:/P#\(_!%AKGCSQ);0M:2Q:CKEIH@\-:!
M@W7B36]&L$FO(^=^"7[:'P/^-_B:7X;6FH>)?A=\<+*PFU34_P!GSXX^&;_X
M5_&FVTJWENXIM>T?PAXA*0_$#PE']BF8^//A?JGCCP'TA'B8W2R01\DN.L?#
M,J.2SX@P$,ZQ&!JYIA\EG5RF.<5\JH3]E7S2AE4HK'U<LHU6J-;,*>'E@Z59
MQI5*T:DHQ?;'&\6SP4\RABN()9=3JJC/'QJY@\'&L_\`EU+$J7L54TU@Y\RN
MKI<RO]J?\)EXJ_Z#4O\`X`Z1_P#*ZC_A,O%7_0:E_P#`'2/_`)75S5%=?^M6
M?_\`0P?_`(38/_YG.+^W\\_Z'&:?^%V)_P#EOE^?=G2_\)EXJ_Z#4O\`X`Z1
M_P#*ZC_A,O%7_0:E_P#`'2/_`)75S5%'^M6?_P#0P?\`X38/_P"9P_M_//\`
MH<9I_P"%V)_^6^7Y]V=+_P`)EXJ_Z#4O_@#I'_RNH_X3+Q5_T&I?_`'2/_E=
M7-44?ZU9_P#]#!_^$V#_`/F</[?SS_H<9I_X78G_`.6^7Y]V7;_4;[5;@76H
MW+7=PL*6ZRM%;PD0QO+(D>RVA@C(5YI6W%"YWX9BJH%_/?\`X*I_\HV?VYO^
MS7OC)_ZA6K5]]U\"?\%4_P#E&S^W-_V:]\9/_4*U:HRO%XG'<293BL75E7Q%
M7-LKYZD[7:IXG#TX1M%*,8PIPA"$8I1C",8Q222.6E6K8C'T*U>K4K5JF)HR
MJ5:LY5*DY>T@KSG-N4G9)7;;T/VCK\L)_P#E*1^U7_V8)_P3J_\`6B/^"IM?
MJ?7Y83_\I2/VJ_\`LP3_`()U?^M$?\%3:_2.+/\`DG\?_P!RO_J;AC]RXV_Y
M)C,_^Y+_`-6&$/J>BBBOQD_`3YO^.'Q@\3>&_$W@3X&?"&QT+4_V@OC+H7CK
MQ'X)E\9VVH3?#KX=_#KX9ZAX"T;XH_&_XA6^GZGH&J>+]"^'6J?%3X;:/HWP
MB\':_I'CSXN>//'?@[PI#K_PP^&S_%/X_?!GRG5_C/\`M`?LM_#3XZ?$S]KB
MV\"_&3X=?!WX&?$W]H>Y^+O[,_PZN?A%]GTGX2Z!+K_BOX.:S\$/BQ^T+\5]
M=G\=:QH5G+XG^%WQ"T#XJZAX*\8^5XU\(_$;1/@9>>!_`GB/X^>4_ML?&_X'
M?`;XX_!_XNW7[4/[&WPR_:3^&OPI^*?@[0?@7^US^TYX0_9U\,_$_P"!W[0O
MB_X77WBS68O$\FF>,O'O@37=&\>_LV>"]5\%?$*S^%WQ0\(:UI_A;XG?"C4O
M!EKK/C?2?BS\'/AGXF_M3?`[]I#PA\4(?CA_P5,_X)A^&]+^,&A?!SX)W_[,
M/PY_;>\(:O\`"3P5^S?K'QQT"X_;LTW7?C->^(?`^L_'?XK?M0?LV6&H>!OA
M_P".;S]GOX+:[^S3.5\'?!KQ+X4U3Q;\4OCOX\];#8252G0DZ+=";BJT_8SG
M5E-U^6U%PBYQC&@XU'.ZH?Q$Y5*RA1?N83`RJTL-)T&\-4<5B)^PJ3K2J/$N
M-J#A!U(PCAG"JZEXX9_O8RE5KJG0?W-\-_\`@HWI]GX9^$O@[X]?"OXK>'_V
MCOB;\*;35_AGX-T3X2>)OAQ#^V!\6_`^G^!]#_:"\+_LJ_";XY:WX2_:"\#Z
M%\-OB3XVTJ&6X_;*\#?LYP6?PDO;S]H2?Q%JG[./P^^*WQM\%]SKO_!1#P'\
M/_"'Q%U[XS_`O]I#X.>,?A;KO[,EIXJ^"^K^%/AU\6/BW+X0_:Z^.)_9X^"G
MQ(\+Z/\`LR_%/X[>&O&VA:]\3M*\=Z3<>!_!_BS6_CC%#\./$4EE\)=0N/$/
MPQM/B!^4W[<WC?\`X)\?M9?M(?"KX]^*/VT/^"1/[0W@[]F/0O#5Q\#OV<?V
MC/VO/@EIWPZ\9>)OB-H?[27@/]JG2/B5JUOH'Q=TO1]"\0Z7XC_8W^*?P[\1
M:M\-/C=J&G^//V7+OPCX=\+_``CM_B-XH^)6I[OP^^(__!-+1=)^%5MIGQ__
M`."&?[+>A:C^U;\./C1^T;\)?V3?VAO@%X;TGQ1\-/V=O!7CKQE^SAX:N_B]
MHVB?"7Q)\9/'7@?]M#3_`(/_`+0L&LW/PZ^`>@:1X*B\1_!B^TKQUH6F^+]3
M^/G4\!0<*=1X7%*4E&=:$*<_<DJG/*C2;:FY3PEDYRPWL?KL^2G5ITXJF=CR
MW#2ITJKP>,4IJ%3$4Z=*I^[DJOM)8>@Y-5'*>!2C*<L)[#Z_4<*5>E2BJ1^G
MFA?\%$/`=_XF7PGXH^!?[2'PWU3PQ\5OAS\#?CO=>,_"GPZN/#/[-WQ;^.FH
M?#_3?V=/`?Q"\:>"/BGXR\'?$O7?CI<?%OX42:-%^RMKW[14'PCT_P")7@[5
MOVGI_@/I>IM>6^[\4/V[O"?PV_X6)XILO@G\<_B9\!?@I_PEO_"^/VH?AVGP
M5D^"OP@_X5A_:%Q\:_[0M?&WQJ\$_&+XI_\`"C=.TK5'^*'_``SO\)/C/_9?
MBS0_%OP;T3_A(/CUX`^(/PK\*_G!:?'_`/8>U3_A'_\`A./^"E?_``3?UK_A
M.?\`@I!XP_;!_:@^R?MC_"*U_P"%D_#3X5?\)Q_PPAH?A_[)K.F?V'XZ^"7_
M``IO_@G+_P`)AIGA_P#X0G0/%7_#/WCC_A+_`!-\4?\`A,O''_"W^%U+]H[]
MFG5/A7\??V)[C]OW_@E,G[*_[1GCK]KO4/&_[0T/_!0OP"O[0&E_#3]M'XP_
M%SXU_%+PEX5_9O?P1)\.K'QUH-G\9O%'P7\`?$35_P!IO7-`TNYL-`_:%\1?
M"_Q5%:ZC^S1JD+`4W*-L-7TE#VL7&LJ:I-J->K2<E&<ZD*BF\/17-.>'GAI2
MA5JQKWS664G.#6#Q&DH*O%QQ"I*@VHXBM1E)1J5*M.HJCPU"//.IA:F$E*G6
MK1Q/-]6VG_!3'XEO\%?#_P`6/%GP#\=?"[6/BC_P4@\8?L??#;X<W?PLU_\`
M:!\6:-\-/V?O%GCB+]H37/$&@?L@^/?CWXZ\>^.K[P+^S+^U%;>#]3\!>!+7
M0/`_QJNO`_A3Q%X9\<_LZ>!M:_:X^)WU98?MW>$]4TG4=$TSX)_'/4?VD-'\
M=:U\.]7_`&-K!/@K>?M`:7K_`(;\%?#7XJ>(M0U'7[?XU2?LT6/@70?A%\9O
M@_\`$+6OBA<_M#Q?#32[GXK_``U^#E]XM@_:0\=>%_@MJGYA_LM_M#?LA^`_
M`?\`P3*\%_''_@HI_P`$PVTO]A3]F_Q9X*U_P_\`#W]NGX8^*=/U+]I#PO\`
M#KX=?LV?`SXS>#O$&L6'PSUG4]"?]FS5_P!JG3?&?@WQ1:Z;H7ASQ-\:]&L[
M?0_B9JG@CPI\3_#/AGQ.U?\`X)\>,_'EA\>OB#^TQ_P10_;-^)UW\5OVW-8\
M8_"G]I_]L?X):)\)-:\,_'OXB_`;0_V<OB?I?B&Z^&/Q^L/#?Q6^`?[(?['_
M`.SS^SOJOA+0O@7ING^,)];\>^-+_P"+%WXEL-?UKXT:/`T9U7!X2M"*E6<'
M3A5E%S52K'#TG[25-/#RI4H>UJ2Q"J2G6I2A4IIU9RU>74*E:4'@J]."GB'!
MTJ=:47.-6O'"T7[2=-/#3HT*?MJLL4JDIXBC.%6DI5JDOV2U?_@HAX#T#0_"
MZ:Q\"_VD(?BUXB_:0N/V2KW]G;2/"GPZ\9?%OPA\>KG]F_Q%^U;X/\)^*-2\
M"?%/Q1\&5T+QO\&=-\*>([?XEZ!\7-?^%OPZA^)'AW4/CGXT^$_A_P`(?&?7
M/A7N_$K]MVY^$VDZUXQ\:_LE?M6Z9\+OAUX%T[Q_^T!\6IM-_9_L_!7[/6DP
M^"K#XD?$.'Q5::K^T)IWCKXQ?\*=\"ZC%K/C_7_V1O!G[2/@K4M6L]?^'OPQ
M\5?$7XH^%/%7@?1?S@^!?QG_`.":7PJ^)?[./C'2OVM_^"-GP6\"_#KP+^U5
MXG\=_!7]FSX]?`+P'\--%_:6^-FO_L^Z%\)_B-X+\/6VJZ+H_C;QU\*OV=/!
MOQH_9]\1_M(ZSI/PU\?>,M`\>:Z_AKX:?#KP+\7/%?PM\$_GY^UWK_\`P3XU
MO1OBMX]\:?%W_@BA^TA;^#?VD+/]L'Q9\>]<^-_P2^.G[?7[1_P.\%?M3:5^
MTKKW[%G@WX;ZMX<M(]$UW1/@1:77[)/P9FU+]H_XO>$/B;\-_AIX*^"%Y\*?
MA)X.^,\FJ?L]JCEU*I6IP>'Q$82Y5-NE5OS2KRIR<$ZE.,8Q@HRIQ]I7J6JT
MY256$*TVJ&54*N(ITWA<3&G+E51RHUV^:>(G2DZ:=:G&,(P4)TH^UQ%6U:E*
M:K0IUYO^@7P[_P`%$/`?B/7;AX?@7^TAI/PETG]I#Q1^R5XG_:)\1>%/AUH?
MPD\/?'K0_P!I#5_V4M!\)V^FW_Q3B^,WQ`T+X@?&:+P=X<\+_$OX0_"/XB_"
MW1Y_B+I&G_$GQIX`\0>`/CMH?PB]7\+?M@_#3QC\'OV0OC%H6A^.I[/]M[_A
M4?\`PHWP3-IF@6WC6X_X6O\`"O5?CO/_`,)49?$R^"O#W_"M?@CX5^('Q.\?
M[O&=Y]HTGX>Z_P"&?AS_`,+"^(NL>`_!7C'\3_V</VAO@=HOP._8F_9,_:3_
M`."BG_!(FZ^"G[(VA?LW:QXI\;?!_P#;I\(7GB;X\^)OV8_"&A:A\&OAW??"
M[Q98>'I/A?H7PO\`COX>^&'Q8N?C+X?^/_B+4/C'J'[/.F:7X@^`_@#X>_M"
M>-OA9\,-W_@F[^UO^P]X+\1_M/?&CXY?M]_L,Z=KNL?M6_MS>!_V;_#5[^U1
M\(K.Y\$?LT^)/VZ_V@OC1>^,)-&\7^)+6\\->.OVC_B+XVG\2^+O$'@/59?`
M/Q@_9_\`A1^Q;K,MI/KO@5]5NXK9;&-.M.&'KMTJB5-4XUIQK4I^U5&[<>95
M9-*K6BE#DH*$+0KN=LZ^4QA3Q$X87$2E1JI4E2A7J0KT:GMHT+MPYE6E*,:U
M>"5/DPRIT[4\2ZEOV3^)7[4ESX6\:ZU\/?A+^SS\<_VJ?%/@K^SH?BI;_`B_
M_9_TG2?A)JWB#2;#Q%X5\*^-O%'[0WQY^`GA:Z\=>(O"VH6GC$^`/`^L^,O&
MOA#P5JW@KQG\2-`\%>%OBQ\'=7^(/"^&/V^?AI\2_B7\.?AK\$?AG\<_CC_P
MLOX&?LW?M/Z9X_\``_@S0-`^&F@?L[?M.Z_\2]`\&_%3QAXJ^+7C+X:?V!_8
M'_"M+K6O$'PMEL)OCOK^@:_::C\*/A3\2_\`A#?B]#\-/S\F_;O^!WPH^,G[
M26L_`']N_P#X)$^*O!W[4_Q6\+?&#4OB+\8/^"@7A#PQXF^!GB:Q_9X^!?[-
M5Y8V/P(\%^&_$^E_M!:%X>TOX!Z-\5;:VN/VD?V<=0\<ZAXNU/X42ZG\.;?P
M]:_%S7=W]B7X_P#_``32_9"LOBCX43_@I7^PSXP\+1_\,]?"_P"!'B7Q!^V/
M\`O$'Q+TC]FG]G7]DKX$?!?P5\._'&LC6?#.G:?_`&?\8O#/[07Q8M/"7@ZV
M'@&UU_XU^,/'>DZ?H?BGXD>-M*M\W@>6C*3PM:514:,J*4*[E4J3]E[=5E%-
M1]E.<E2C%4I2A&3FYWA4>3RU0P\Y/!8B=58>A.@HPQ#E5JU/8_65B(Q34/83
MG.-"$8T92IPDYNI>%1_H'^T?\4/CC#\6_@+^SE^S=K_PI\$_$[XIZ%\9/C!X
MI\>?&_X9>+_BSX#T#X'?`F'X>>$?%UCH'@WP'\8_@GX@U?XK:]\6OV@O@-:^
M'+;4?&.E>$+;X=6_Q=U_4]3;Q+H/@WPMXO\`*?AE^UC\2_#/Q+_:J^`_Q=U'
MP+^T[\4?V:/`O[-'CV[?]C[X4Z_X*U_4-?\`VI=?^+GA;P/\`M<^#?C#X[?'
M+_A"?'6E?\*L\-_$'4_BI\1?C7X#^&FG_#3XW>&?&WQ(L_A%\+O`'B#XM^)O
ME+XL?&?_`()#_M*?M+7/Q*_:F_:W_P""4W[0?P=\!_`SPIX'_9\\`?%CX]?L
MQ_$7_A7?Q+\7^/O'>O\`[3OC"Y\*^+-5O?"US_PL+PMX3_91T7PIX@O[_P`1
M:_X:_P"%=>.].\,6G@/3O&7C*;XD_-^K^-_^"?'A3]GCPO\`LR_#G]M#_@D3
MX]_9Q_9]_:0N/&OP2_92^*'[7GP2\,?"3XZ?LWZW\&_$6FCX,_M5ZYI>@?$?
M1M0UWX6_M)_%CQ?\<?`OC+4_@I\<-=\?S_`/]GSQ-\7]<\0_M'>)?B%^T3I6
ME+!IT849T*_M'"FYOZGRI3G6]JY0Q+M4G)473PLJ-3V%&$YSK.JH4>>II1P"
ME0IT)X;$>U=.DYOZCR152=?VSG#%RY:LYJ@Z>#E0J?5\/"I4J5W64*#G5_5F
M?_@H)H6EZA+\/O$_[-?[2'A+]I.]UWP'I'@G]E'5Y?V;[_XM_$?3_B3X9^.7
MC/PGXH\+^.?"W[1GB+]F#2M"O/"?[+O[3>NW%O\`$']H;P/XFLH?@=XBL+GP
M['K/C;X-:9\3>&\#_MX^)OBA\9+OP%I?@K7?A)HU_P#M(?"7]CO1="^+GPJU
M"3XI>&/VD/"_[/'Q(_;F_:NT3Q_IFF_%G1/"=W\*;O\`9@T3P+\,O@%\9/AI
MXA\<Z%?_`!ZO?%?Q,T?2?CC^S9/\./%WCK\;/V<]7_9#_9&^/7Q"_:W^"G[3
M'_!!;1_B=X_UWXK^%X_@-\+?VQ_AC^S'\)/#/P.^+OPM_8/;2?#J?%7PG\,?
MBEX@U_7?@9\6OV3/B/::=I"_!?PYX0^,\_QZ\;_M$6UO^SSXE\0Z]\!IO5V\
M;?LT^.M)UA_BE_P6'_X)OZ#\5O&__#PKXE^+OCO\%?VI/`/@O5O#?[6OQF\%
M>&_V0?V%_P!I'X6^!(?B]8:MX5_X9S_X)ZMXW^$FN_#E/C)'91>-;OP]XIU'
MQ/\`&#XK6,?[16G;2RZA%RY:-3EG1BH5'2KRG3Q+C[2?[E>U_P!GING&*YG.
MI.5=0C*M%S]ATRRK#P<N6A5<*E"*A5=#$RG1Q;A[2?[A>V_V6DZ48)R=2K4E
MB53C*O%S^K_LE:?MNW+:_P"']&UW]DK]JWP39_$[_A,-._9WUSQQIO[/_AK_
M`(:,\:^&OAIXX^,VB?#7P?X*O?VA/^%K?"+QUX^^%/PT\>>,_#]A^UK\/?V<
M-)\*_P#"-7?@[XOZU\,?B+=:7X-O_#/@I_P49_X3#X*_L;?%CXVZ9_PHW4?V
MFO@9\4OVO-0\*7/@'_A/<_!72O%GPH\"?"_X.^!+GX=_&'Q7XI\1_'/QWXI_
M:V_9<MOA/>>'O`GC;Q9^T5]A\5^%(/V;?@)\8OBGX2^$_P`-_P`4/&O@;_@G
MQ\1]0^+/BKP]\5/^#=W]D+5/$?\`P3\_;Q_96^'GA;]G7]IKX):QJ&G_`!Q_
M::\,_"OPGX`^-?BWXRV/PA^!UQ)H5EX.L/BM\.K_`$70_@W%XO\`A;X9\0^*
MY]%\8_%W2_CWXD\$_"?[F^/_`.T-^R'^T3XSMOBUXH_X**?\$P]&\8_#KX4_
ML?:Q\#O`MO\`MT_#'5O#/A7XX_"K]L7P9^V+^U3\.]7\?V]AX9U2]^%/[0&J
M?LS?L;_"_P`._&75OAWXL\7_``_T_P``>*/B!X=^`^AW&H>*/`?Q4'E]!>RC
M["MRS:]O)4JGM:-N>BHT_?Q-.:G[:G6J33M!X><H?'3IBEE>'C[&/U:ORU)+
MZS*-"K[:@U[2A&-+]YBZ-15/K%+$5*B?+!X6I*GI4I4C]']?_P""@FA?#?PS
M\7=>^/?[-?[2'[/>J?"O]F_XW_M5:=X+^($O[-_B_P`3?%CX2?LX:?X<O/C3
M>?#FZ^`W[1GQD\'66N^"KCQW\--);1/BGXL^&4_B+4/B+H4GA&77]+T3Q]J7
M@WU?X3_M7Z3\3?B7;?"W7/@S\<_@IKOBKP+XK^*OP=N/C1X>\%>'O^%V_"OP
M)K_@3P[XS\=>&O"_AGX@>,/B+\+_`/A&+SXL_"%]9^'W[3/@CX#?&&T_X65I
M6G'X<-KOA3XG:1X#_&SXR_M'?LT_M:6U[XF^.7[?O_!*;X5Z[/X%?]ERZ^$O
MPQ_X*%^`?BOX*\7?LE?M`?M`?LT>,OV](/&?Q>\3>"/@[XNB\=?%WX`?`R?X
M._!WP]X#^&/@F]^%.K7GB;QG+\;=8UWXC^$]3_9T_2#X+_&?]FG]I3]N'Q+\
M2OA3^UO^RE^T'_P@?[*6C>!_A!X`^"_QZ\`_$7XE_#O_`(2_XNZKK_[6OC#Q
M+X5\!ZK>_:?`OQ"_X1/]A[1=&\0:]?\`B+_A&M?^'6JZ=H=IX#_X3+79OB3R
M5L'"G0<YX:I3J*%5UN55W3I2C[)451E)SA)3E-2K2J5)QY%7]FU)4K<-?`PI
M8=U*F$JTJJA7=?D6(=*C*'L5AUAYS<X3C.512KSJU:D5".)]BU)44OT?KR+_
M`()1?\HVOV)_^S>/AW_Z9HJ]=KR+_@E%_P`HVOV)_P#LWCX=_P#IFBKZS@'_
M`)FW_<A_[N'V_AG_`,SO_NF_^[Y^(O[#O_)K'PG_`.O+Q/\`^IOXFKZOK\D/
M$X)_X(S?'H+%YQ_X9(_:E.S$AP%T/XGLTN(V5OW"@S9),8\O,JM$'4_YXU?O
MN:9C]0JQ7L?:^UG6?\10Y>24?[DV[\W9)6TOK;Y'!<'/BK/>*Y_VC]06"SK%
M17^QO%>U>(QF-;U^L8:,.3V*T3J-\]Y*"47/_6HHK_)7HKRO]8?^H/\`\N/_
M`+@>U_Q"'_JH?_,3_P#A,_UJ**_R5Z*/]8?^H/\`\N/_`+@'_$(?^JA_\Q/_
M`.$S_6HHK_)7HH_UA_Z@_P#RX_\`N`?\0A_ZJ'_S$_\`X3/]6_XG_P#)-/B'
M_P!B-XM_],&H5\,?L?\`[,/[//BS]F?X.^)/$_P:^'OB#Q!K7A**_P!6UG6/
M#>GZAJ6H7DU_>F2>ZO+J*6:5\`(@9RL<2I%&J11HB_"W_!"[_E$[XN_[&WX_
M?^F6SK\[_P#@L^JG_@EI_P`$^G-C+(Z^/;I5U(/*(+16\&^*BUC)&$,+2ZB4
M2XA>219432YUA21))VC^<S+"8#-.-LHJYAEV#Q].GP'Q#CH8?&8>ABX0G#-.
M':KY%7I3C&7+S0=6,$U%MV:O$_>O#C,^,.%/HS^(V5<&\;<2\'X[$_2B\,\E
MQ6<\,9MF618O%87!^&7C=55/$?V;F>7U*V&J5L)2K/"U,7.,:D83IQK5J=.,
MOZB_^&0/V7/^B!?"O_PCM(_^1Z/^&0/V7/\`H@7PK_\`".TC_P"1Z_RQ:Z4Z
M+KC6]G<VNEO-:W4,7V=XK*WN&E*Q6:R/Q%)*5:XNDB5WX>=FB0F1&5;G2X5I
M\O/PIP_#FERPY\#ET>:7*Y<L;X%7ERPE*RN^6#=K1;7S<^(O'&ER^T^D=XK4
M^>7)#GXSXOASS493Y8\W%BYI<D)3Y5=\L)2M:+:_U%?^&0/V7/\`H@7PK_\`
M".TC_P"1Z/\`AD#]ES_H@7PK_P#".TC_`.1Z_P`N&?3=;M8(;JZTN2VMKBXO
M+6WGN--@@BGN=/:)+^"*26W19)K-IX%N8T):`S1"0+YBYM#PSXHDC>;^P;X*
MK1JRG31'(3(KE2EN84E=0(V\QHXV6)B@E*-+&'SD^#X1C*7#/#<8RE*,92PN
M5QC*4)JG*,6\$DY0J6A))MQG:+2EH92XJ\:H1C.?TE/%&$)RE"$Y<;\61C*=
M.:I3C&3XN2E*%2U.44VXSM!I2T/]13_AD#]ES_H@7PK_`/".TC_Y'H_X9`_9
M<_Z(%\*__".TC_Y'K_+@N]&UBQ@M;B[LA!'>-=)!YB6JR%[.;R+E)(3^^A>*
M4A2LJ(3GY=V#C,NEVRG``#`$`*$Z?*3M544996(VJ%((*\&M(4N%:D>>GPIP
M_4CS2CS0P.72CS4YNG.-XX%KFA.#A)7O&<7%I.+2UI\1>.-6//2^D=XK58<T
MX<]/C/B^<>>E.5.I'FCQ8US4ZD)4YQO>$X2C)*46E_J9?\,@?LN?]$"^%?\`
MX1VD?_(]'_#('[+G_1`OA7_X1VD?_(]?Y8M?ZROPX_Y)YX#_`.Q,\+_^F.QK
MU<OR;AC'^V_XQ?(:7LO9_P#,LR^?-S\__4)"UO9KO>_2VOQW%_B;XZ\*?V=_
MQOKQ:Q_U_P"M_P#-=\887V7U7ZK_`-5%B>?G^L+^3D]G]KF]WR3_`(9`_9<_
MZ(%\*_\`PCM(_P#D>C_AD#]ES_H@7PK_`/".TC_Y'KZ.K\N_^"S_`,0/'GPM
M_P"":G[27COX8^-O%WPY\<:%_P`*>_L3QEX$\2:SX0\5Z-_:?Q\^%FC:E_97
MB+P_>Z?J^G_VAI&H7^E7WV2\A^UZ;?7EC<>9:W,T3]U7AKABC2JU7PWD35*G
M.HTLHR^[4(N5E_L]KOELOD?+Y?XX^.^88_!8"'C9XL4YXW%X;"0J2\1N,7&G
M+$UJ=&,Y)9S=Q@YJ32U:5EK8^MO^&0/V7/\`H@7PK_\`".TC_P"1Z/\`AD#]
MES_H@7PK_P#".TC_`.1Z_P`W[_AX#^WE_P!'M?M<_P#B2/QD_P#FSJS;_MZ?
MM^7;QQVW[:?[7DTDKB.*-/VD?C(7DD8A55%_X33<Q+'`V@Y/'4&O#>&X22N^
M%<E22NV\KRQ))6N[_5]E;\%\OT]\1?2%2;?T@?$Q)*[;\0.-TDEJVW_;5DDE
MOTMY'^CQ_P`,@?LN?]$"^%?_`(1VD?\`R/1_PR!^RY_T0+X5_P#A':1_\CU_
MG&7_`.W?_P`%`-,E$-_^V?\`M@VLC*'59_VB_C3"71BRAU$OC%"RED=0P&"4
M;!(&:H_\/`?V\O\`H]K]KG_Q)'XR?_-G4QH<(3BI0X6R249).,HY7EDHM::I
MK#M-::-/HOE,.)/I!U(QG3^D'XESA)7C.'B#QM*,ET<91SIIK3=/IY'^D#_P
MR!^RY_T0+X5_^$=I'_R/1_PR!^RY_P!$"^%?_A':1_\`(]?YOW_#P']O+_H]
MK]KG_P`21^,G_P`V='_#P']O+_H]K]KG_P`21^,G_P`V=5]5X3_Z)3)O_#5E
MOE_U#^7X+Y5_K%](;_I(#Q-_\6!QQ_\`/GR7W'^D#_PR!^RY_P!$"^%?_A':
M1_\`(]?G;_P4&^"GPC^%FG?!"_\`AQ\./!W@F^U7X@ZM9ZE>>&]"L-*N;VT@
M\,7LT5M<3VL*220),?-$1;89`KE2R*1_/!_P1:_;-_:V^)O_``4@_9Z^'/Q.
M_::_:`^)?@;Q0OQ;76O"GQ!^,OQ&\8^';\Z+\"OBCK^FO=Z+XA\2:AIMVUGJ
MVFV-_;"ZMID@O+2UNXD6[M+6>#^F[_@J)_R`_@!_V4G6_P#U$[RN+-\IX>J9
M-/&X7A[*,'5P^=9!&A6I9=@85XRAG63S56G4I8>$Z4HRFX1Y9<RY%*ZYDE^P
M_1B\0/&2/TB^'>%>*O%GQ`XFR?,^`/&6OBLMS3C;BC,\JQV'_P"(*^),J=/&
MY=F.95L-6]EB\&JL(5J56,9TJ-:-IQCR_P!8/[$/_)EW[(?_`&:_\`?_`%5'
MA.OB;X#?\GH_\%5/^SH?@)_Z[Z_9`K[9_8A_Y,N_9#_[-?\`@#_ZJCPG7Q-\
M!O\`D]'_`(*J?]G0_`3_`-=]?L@5XG%'_).YM_UZP?\`ZM,`?@?B!_R3[_[#
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M%_PS\;_V;?#OP2\#_`?QW8_`O]DVY\(>.OC9^T7X;_:2U[XF>!OAQ96'[3.C
M>+X=0^&>_P`?_"KQ1X6\>C2_"G[.%A\&K_2-2\<^)_VI-0^`=OJ/Q1MNQ^&7
M[5?['7[,_@O0_`6@?!CQA^S_`./]?_:9^'W[.WBS]G:+PKX0\2_&;1/B[\7_
M`!5\"-/M/'WQ:\2_#/QS\2?`?B+PA!I'[4WP#\>_$/X]7'QA\9:%IK_&+P)\
M.=>\4W'[1/C'0O@]J>_K7A?]L"[^.G[3O[2_[-/AW]DWQ9X>^-7[(7[-'PY_
M9D\1_$CXX_%BSL-2\7_"WQA\;?'^G>-OBGX0\&_L\ZJMI\/-4L?VH_%E_9Z;
MX)^)>MZYK\/PH\*Z7_:GA<?&+5=?^#'QQJ'_``2V_::^)]MJOQ(\;_'#_A2?
MQVN?C?\`LS:X3\,?B+\/_CYI7C'X?_"GX^?LZ_';XH?&;XC?%#X[?L,Z/XG@
M_:G\8^)_AAJ-UHOA_P""_P`/?@O^S+/X,^`?["7[/'B3X87/P)_9S\.>'-'_
M`.=GQ&\9:_TCLWH5_I">*65Y+P737A]B,!PQD'%V(RS+<HXAQ7#'",.),#B.
M!,G?$6)PF!P&;9AQ1/-\YS?A[,N*5C\%2RJ7%7#N`RVK2S+^\\AX6RO@_#.A
MPQDT:5=K%1JXF>&57$XFE&O7=&=3,*[ISK3E"-'V5-8B.'C&;G'#U927)]S_
M`!'\0_\`!.7]J3XRZ=\*;C]H#]G_`%']KOP3J?BKPAX/_P"%/_M$>"O"O[8/
MPY\1>"QK6I^,/"_AN[^'WC&R^+>FGPI<:)K6L>.?AOJ-O?>%)V\/ZA_PL'PA
MJFFZ;?VJ]E;>*_VTOV:\1^)-._X;G^#=EQ_PD?AJU\)_#C]KWPII4.!Y^O\`
M@_S/#/P4^/\`]@L;>:]U35O!%U\$?&E[/-!IGAOX4>--5D\R>/P%_P`I(OVK
M_P#LR'_@GU_ZOC_@II7L/[3GQEN_@5\&?%/C?0=)MO$_Q"O9='\#?![P3<2K
M&/'WQI^(6KV?@WX4^"R!>6,PL=<\;:SH\6OWEO<Q-HOAB/6_$,\D-EI%U/%\
M/X+_`$D_'KP(X]X(\-_`W-\\XFR;B?`^'GU?PKX]QM/C#AG..)/$#)LDSQ8/
M),'AL%D.,X4C6Q6?X3+W7X<QN79CBJF$EC,PS*OA\1]0PU\4\&<*<5Y=B\5Q
M/@<+&>$6-:S;#1^I8W!X?!SK1E4>+4YRJ0@J4ZTJ=?GP^J4J+Y7*7>?LY_M1
M_`_]JWPAKOC/X'^,SXFL_!_C/Q%\-O'V@ZMH'B3P5X[^&WQ(\(W?V'Q3\/OB
M3\/?&ND>'_&O@3QEH-WA+[0O$^A:;>-!);:A:+=:9>6=[<?0-?R:_MNZ!I?_
M``2/\<_LY?$/]E/XF^)%_;=^,_PZ\6>$/VB]`N_!\/BWP%^UY->RZC?ZO^T3
M\9-*34-&-E\:-!^-_CJ;Q-X`U[0K/5?$'BJVO;[X9ZK9P^!;>XN]+_%N[_:?
M_P""B%_+K.K77[3_`.VZ6M_$LNA:Y<6?QH^-VDZ=IWBVZO!')X>ET_1M>T_1
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MCT/QAX1_N%^'/Q`\(_%GX>^!/BIX`U=-?\!_$SP9X7^('@G78[:\LDUKPCXS
MT2Q\1^&]72SU&WM-0M$U+1M2LKQ;:^M;:\@$PBNK>&='C7X;QI\"../`K.\'
MD_%ZRO&X?,J>(>6Y[D&,EF&28[$8"5.EFV7TL5.CAZU+,LGQ%6GA\RP.*P]#
M$X:=2C4E3=#$8>K5\;,,NKY?6Y)QE.A.,94<2J<HPJ)Q3E&:=_95%+F<(RDU
M5I)5:<I6JPI=E7BOQHM-0N_^%3_8/AO9?$;[-\:O`EW>_;7D3_A!-/A_M7[3
M\2+3RY(]U[X7W)Y"/OC;[<^Z-L#'M5?/OQ_E\,Q?\*3_`.$F\5>)?"WF?M!?
M#>+P_P#\(W!)/_PD?B9_[9_LKPKK_ER1^3X:U?%Q_:L[[XX_L\&Z-LC'Y9DB
MOFF%LY1_C:QC5E)?[/5VC0E"J[[/EDK*[E>*DGYE7X'ZQW:7VE_,FOZTUL?0
M5%%%>4:'B'Q\_:&^&?[-O@_3/&/Q,O/$1B\1^)K+P-X)\,>"O!GBOXA^._B!
MX]U72]8UC1_`_@CP5X*TC6_$&O\`B/5=.\/ZS>0P0626-E8:9J&JZQ?Z9I%A
M?:A;?GM\>OCK^TYJ/PG\??&KXOZSKG_!.[]DWP#H=WXB\<:GX*\'2?M+?MM7
MG@B&:ZLM4\1:CIWPW\,_%[X7_`'0]+T^YL_$/B:_\*^&_P!I/7_#/A.UUCQ7
MJ_BWX21^'M7U32?N?]K7X$S_`+17P&\:?#O1-5@\,_$.V_L?QW\&/',L$,S_
M``\^.7PWUBQ\<?!_QT@FM;PM:^'O'VA:'<:Y8I`RZYX9?6_#EVLFGZQ>0R_#
M?QV\<^-_VR_^"5_[1*_"/X4^(_%/QG^-O[-GQL^`\OP3TS7?`.A^)/!WQU\3
M>'O$WP/\=^!_$.L_$/QIX+\':7%\)/B)=ZZ/&=U?^)X;Z3P]X6U6Y\,:=XEU
MRYT/0-8_@#Z=/C9XQ>#TO!O!\#8_*.$_#WQ'XSPO!G'_`(C+^SJ'%'"5;$YA
M@9>PRW/.)J6.X.X4P^:\-U<YQ>#XBS/),SQ.6XK(<QQZQ&74,'3^L_O?@MPI
MPCQ(L[Q&;X:KF6=Y/!8K!Y7B)2J9;7PTJ;]GB)8.@J>(QU2GBH.CB,-.K.@X
M5<.O92G67+V7PTU?]A_]E3XJZM\(?!EMJ^F?%GQGXB\*>'OBE\8]:\&_&KXH
MS:U\2?&0L+[P#X&_:-_;3\0>'O%WA#2_BYXO;Q?X2'PX^%?QH^-.E>.M6'Q/
M^%.D>`O"36WQ5^&.G^)/5$T[]EO_`(*"_!32?$&K>#H/BE\-)_%/C73M"?Q_
M\/?'GPS\>^!?B%\,?&GBGX6>,9])TOQYH'@3XP_!SXE^!O&_A;Q3X:_MFSLO
M!OC;0=3TRYGTN^ME:WNI?GWX]:=\8/VB/'7P#T;1_P!E3]HOX=ZIX!^*?[._
MQ2'Q1^)7Q6_9]D_9KT3PWIGQ"^#7QC^-/A/XG?!;X?\`[4_Q&N/BK\4_#WA#
MP?XI^%OP?\2Z]^SG\2[#X2?M+QZ#\5/@A\2?`.EV6F?M$Z;\>_&KX+7/B?\`
MX(W?\%"])_:D_98_X0[Q/X._X>L_M*?#'PI\<[/X!_$_5?#&J_$_Q=^U'^T+
M\(/BUX+O_AK\0/C/X8\*>./"OACXSQ^&!K=GXAT?QGX8\9Z/XSM]%,_AB?0?
M%7B?_$/"Y!@N*,9P9QQBO%?BO`^,G$7B'P#E.><1OQ/X4X[XNP-7B'_6#"XO
MC3*:.4YOE?$>8RCCJ'#3HT:O%&$SKA67]IX#/:=>CC.'\YQ7]:<RP]*O@89=
MA7E=#!8KV.&6`K87".G1C1Y,)-3I3P].'LW6C:-"5*M%0=*SA5I1_0J'PA^V
M;^S1ON/@YX[_`.&Q?A):>=+_`,*3_:(\41:!^T!X>L5_M"X^P?"[]I_[#<:?
M\0?(,MG9Z3X7_:0\/WWB+57BWZ]^TKI%L/E^BO@%^US\)?V@]9\4^!M$'BSX
M??&7X?PPS_$;X"?%OP[+X'^+W@>VN)8XK75;S09;G4-&\5^$KUY[4:9\1?AM
MXA\;_#76#=VT>C^,+^641BD;3X$_LA?`O7;K0/"O@#X&_`;X,^%?%WC.[\.>
M`?"OA_P+X&\(:!9OJ_C/Q5=:/X6\-6.DZ'82:AJ-UJ^LW<&GV4$NJZYJ-U=2
M+/J%_+)+^4OCG]B"'5?V8[C_`(*%_$KXGR_L8_\`!0/2KSQ=^V)??M(/;)J+
M?!72_$'AG1DTC]EGXMZ%9Z?`WQ2^"7@/X-^$_A_\'O&G@.:RU&?7?%WAK7O&
M?A6WEU[Q7JFGZ_\`Z[?LU/I!>._CQBN/,B\1,VH<7^'G`V%P6`R3Q&SK)5EW
M'V/X@S7&RCD.3YK'*\;B<MSBG4R7!YEF>?8NLLVS_+L9/+(8C/<VAC\/[3^;
MO&3@C@;)5E>(P5&KDV>9YBIT:."RUNMEKY(1=;$U<&Z?M:=&%>KA\.E@8TI-
MU_:0PE65.5-_T#45_!M^T5_P6K_;Q^.6J^$KWP1\4)?V:]+\/^$]%TS6=`^#
M-CH5S8^+/&2Z=:CQ;XOO=6^(?A37_$<6EZGK:WDGA/PWNL$\/>&SI]GJR:IX
M@&IZM<^`Z5_P5#_X*1Z3J>G:I'^VO\8K]]-O[/4$L=6TOX4ZCI5X]G<1W"VF
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MA*TZ%>#A4A:ZW4HM7C.$EI.$XM2A.+<91::85\"?\%4_^4;/[<W_`&:]\9/_
M`%"M6K[[KX$_X*I_\HV?VYO^S7OC)_ZA6K5ED'_(]R7_`+&V7?\`J91'A/\`
M>\+_`-A%'_TY$_:.ORPG_P"4I'[5?_9@G_!.K_UHC_@J;7ZGU^6$_P#RE(_:
MK_[,$_X)U?\`K1'_``5-K]0XL_Y)_'_]RO\`ZFX8_=N-O^28S/\`[DO_`%88
M0^IZ***_&3\!"BBB@`HHHH`**Z3PE;6UYXAT^WN[>"ZMY/M?F07$4<\,FRQN
M73?%*K(VUU5UW*=KJK#!`(]J_P"$;\._]`#1?_!78_\`QBOK^'^%Z.=X.KBJ
MF8U<'*GBIX=4H8"&*4E"E0J>T]I+'85IOVKCR>S:7(GSOF:C]?D'"-?/\'5Q
ME+&4</&EB9X9PJ4ISDY0I4:KFG&25FJR5K7O%OJ?.-%>Z^(E^'O@_P`/Z[XM
M\6KX,\+^%?"^C:IXB\3>)O$0T/1/#_AWP_HEE/J>LZ[KNLZG]ETW2-&TC3;6
MYU#5-4U"YM[*PLK>>[NYXH(I)%Y'P+X_^`'Q1O=9TSX9^-O@[\1=2\.:3X*U
M_P`0Z?X%\2>"O%U[H.A?$GP^GBWX=:UK-IX?O=0GTO2?'WA62/Q-X*U&^C@L
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MY73T6ICT5Z__`&[\(/\`A/?^%5?VQ\-O^%H?\(A_PL'_`(5O_:'AC_A/?^$"
M_MG_`(1S_A-_^$/\[_A(?^$0_P"$A_XD/_"2_P!G?V-_;/\`Q*_MOV[]Q7G/
MQ.^/W[(GP2U^T\*_&;XU_LX?"/Q1J&D6_B"P\-_$[XC_``R\`Z_>Z!=WNH:;
M:ZY::/XJUG2=1N=(N=1TG5+"WU*&W>RFO=-U"UCG:>SN(X\\+X48S&XBEA<'
MB,XQ>*KT%BJ.&PO#=7$8BMAFK_6*5&EF4ZE2A9-JM"+IM+XM[$O#G$13E+-\
M'&*?*W*E424NS;G9/RW,:BNOT[XP?LP:OX2\!^/M)^*7P%U3P)\5/&%I\/?A
MAXUT[QO\/;WPE\1_'U_J>K:)8^!_`?B.VU.71_%_C"\UG0==TBT\->'KS4=:
MN-3T75K"&R>[TZ\BA[#P'KOP@^*?A32O'GPQUCX;?$?P/KOV[^P_&?@/4/#'
MB_PIK/\`9>I7FC:E_97B+P_-J.D:C_9VKZ=J&E7WV2\F^R:E8WEC<>7=6T\2
M95/"^M1P[Q5;'9G2PL:_U66)J</2AAXXF]9?5W6GF:IJO?#8E>Q<E4OAZWN_
MNJG(UX<8EOE6;81RMS65&HWRZ:VY[V]Y:[:KNCR"BOH[_A&_#O\`T`-%_P#!
M78__`!BO-/B%IVGZ=-HHT^PL[$31ZH9A9VL%L)C$VF"(RB!$$AC$DGEE\[/,
M?;C>V?(S#@BC@\#B\72S:K7GAJ%2NJ53+84(U%2CSSBZL<QKN#Y%+E?LIIR4
M4^52<H^?G'`^)RC+L3F-3'T*T,.J3=*%&I&4O:UZ=!6E*32LZBD[K9-;GGE%
M%%?GY\,%%%%`!1110`5Y%_P2B_Y1M?L3_P#9O'P[_P#3-%7KM>1?\$HO^4;7
M[$__`&;Q\.__`$S15^B<`_\`,V_[D/\`W</U3PS_`.9W_P!TW_W?/YA_$;0)
M_P`$:OCHUS')+`O[)W[3YDCBD2&1U&C_`!,X622&=%YP3NB<,`5XSN'\(5GI
MW@OQ##.]E9V%PBSJ\_D0RV4\<C1>6F55;:YBAD16*JH6WEF624!IUD<?W=^)
MVV_\$9OCT?,DCS^R1^U*NZ,98[]#^)Z>6?GC_=R[O*E.XXB=SLDQY;_YY44L
ML$L<T,CQ2Q.LD<D;%'C="&5T92"K*0""#D&OU'CS*:F93P<J&/Q>`Q%"6,5.
MI0J35.2G4PTI*K3C*FY->S7)*%2$HN5YJ:C")X_#^25<VSCC6>&S/&99BL-G
M=14JF&FXPDJF-S"4O;PIU*=:?\)*DU4IQIR<I+VSYH1]9N_AE`QE:QU22,8)
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M1EA)3H)J4Y5IRE)RA*-64)PJQ7S=<:/JUI&\UUIFH6\,9`DFFL[B*%-S!%W2
MO&(P&=E526PS,H&21G.KT^'QEJUK=6D=W"S+8136L\!,T4EVWEI&6O9)C<E;
MF&6%7,AAAD+F>,?+,XKT9;?1?$5I#?2V-M=QW$#1I)<VT?VF)-TB21+*5,L+
M12^8NZ&4`2`R0R$%9#]/C<_QV4JC/,LLA/#UY-1Q."Q//",KRY:4J=2FOWDJ
M<'6BW4C"4)<L6Y4ZO+]CF'$^99(J%3-LHISPV(E*,<9E^+52G&5Y\M&5.K37
M[V=*#Q$6ZL83ISY(.4Z5;E^:JDCBEF8I#')*X1Y"L:,[".)&DD<JH)"1QJSN
MQ&U$5F8@`FO0?&6@:#H<=M]CD=+J>:XD-F\DDTAMG51&R/G;!#:RH4B,RR2W
M'G3;I)C;D)R%\FCJ7GTFYO@J26RQ6NHV\(N"&2=IYC/;2/;LD,D<`562.1_M
M)&PK;M))[6#S*CC\/1Q.'IXA4\0JBA*IAYVC*G4C27.HN2Y92ES1E&3IN$*C
ME.#A)+Z#`9MA\SPM#%X:GBHTL2JJISJX6I:,J=6-%>T4')<LY3YX3C-TW"%5
MRJ0=.:C_`''?\$-;>>U_X)1>,(+F":WG3Q;\?-\,\;PRINT.R==\<BJZ[D97
M7(&58,,@@U^=/_!9^6$?\$M?^"?4#2W@N)/'EW+%`C*-/DAA\&^*4GEN4+!V
MO(7GMTL65&58)]1#LI=`_P"B7_!"\EO^"3WBXL2Q/BWX^Y)))/\`Q);,<D\]
M.*_/'_@L],5_X)7_`/!/VW^W>6)?B#-,=-\@M]K,'@OQ>@OOM6TK#_9_V@P>
M06!N?[3\Q586K%/4FF^+,J4^6;7AMQ"Y-*48N:Q_#CYE'FDXI27,HN4DK)2<
ME>_TG"2E_P`0"X_4K3FOI=>'W,X1G%.2\+_'CFDHQC7E&*:<N65XJ*M4K4X*
M5:'\IM?J"?V5_P!H7X3>'/`WQ%D^%?B&;1'T?0=9T+7\6M\^GR^(;30_$+M?
M:'I=U>WUA_95SJFAG2K;5;'-Y-]CAO;*+37O&D_,>SMGO+RULTR'NKF"V3"[
MSOGE6)<+E=QRXPNY<GC(SFO[0?`7CVP3P9X*"7,ES<:+I&B>'8]$N;6%[J;6
M+:73[,V6G#5;J'2;FWMKR:XNM3L!YZQ1W\4^I"Q=I;>Z_E'Z4'B?Q!X<8?@E
M9-E.79S@L[QF=T\YP>/^N0E*AA<-@*>'6'Q6$K06#E6^OXFA.MB:&+PW)-J=
M&Z3/X9^F1XQ\4^$^%\.XY!DF4\09?Q%C^(Z7$&`S/Z_3E+#X+"992PL<+C,#
MB*:P,\1_:6+PU3$8S#8W">SJ252@VDU_+U<W]_H^LVOB&2Y\,:SXW\6^)/$M
MM%I>MVEM=^']-L=:TE#9^)I[S4GET6WUO4]2\174FK6<4=J+'4=(MYF0ZC/N
MBZ/X=^)KOX/^*_$/B3Q7H]IXM\?3Z%XVT;0-2^WQ^)[6+Q#_`,3."Z@O[:7S
MK/3]3AO[>[FTR\L7\V"*WN+BSMVN)['4'_9O]O#X'?"GQQX*?X\:#X?T'PY:
M>%-)%UXAT;PYI]E9Z!XKLIM3CO+FXU5)9+::PN?[6GNK(/;JTVDPWZ":TFET
MF5KC\+=7\(WVF:AIMQJ[7WAO6]/M2_A^233Y[2]-PWB%]5T&^BC^RPWM_J$,
M=W>WEQ?WZRQ36%E>R3:I$UI:M/Q^'/'O#_BOPF\15P5;*IXB&(R3/\KQ,)O&
MTJN$]O7I953Q>`E0OEN%I8C"+%X>CAJRJ8;%1GB*E3%3]G0X/";Q-X7\;>!W
MB:^75\DGBJ6)X=XGR7%TYRS"C6P7UG$T<CI8[+)X;FRC!4,5@HX["X?"8A5<
M'C:=3%5JN,J.GA_/M4TF:.;7MVCC5K>QTNTNK]]/O]2GN=%M[G47NI+B6\U"
M'48H6-Y,D=V\B027D=Y;7T%M;+=:A&OF&NKI\EU,^E17$=E'':M"+DIY[`00
MP7<MQM=U,KW7EL!$1&!*PC1(U5(O8M4\1_9_$QUN'PY#IL6K106*0Z?KNIC0
M;Z[M;6Q@2_ADUE'N)(!',^Z[N7FTZ5YGN=-$$435RWB_6+;7DG`L=*CEL=>U
M57U2VCCAGO[+6KR]:$V]E9K;Z7#I>G7<23+)!;;Y)[R.3[4OGB-OZ)R;$8]3
MP;K82JZ.(PM)U:WUZE-4*KHT:595\-#$XJE4G3QE#V2JTJM.I_M$[T:CIXFI
M#^KL@Q.9QG@'B,#7E0Q6#HNMB'F5&HL-6E0H4<0L1@Z>+QE&I4I8[#^P5:A6
MIU5]:GS4*LJ6+J4_):_UE?AQ_P`D\\!_]B9X7_\`3'8U_DUD%258%64D,I!!
M!!P00>00>"#R#7^LI\./^2>>`_\`L3/"_P#Z8[&OU+A[_F,_[E__`'.?'^+W
M_-/?]U;_`-YAV=?E!_P7#TU]6_X);_M26,1<2R6_P>EB$<9E>26T^/\`\*KR
M.%(PREFG>!81@DJ9-P5B`I_5^OS-_P""Q5]I^G?\$W/VF;S5(6FLXM*^'2LJ
MHDABN)OC#\/(+&Z*2*X*V=]+;7;F-3.JP,UOBX$1'?GU>KALCSG$T*<JM?#Y
M5F->C2BDY5*M+!UJE.G%.Z<ISBHI---M(_(L!B*^#QV"Q>&I2KXG"XO#XC#T
M8)2G6KT*T*M*E"+T<JE2,813T;:3T/\`-I(()!!!!P0>"".H([$5U%I-9QO"
M;BYOK&!%22VGTZ!9[M+M/)\EHV>ZM)(LA'D#+(S+(D8V]ZP+T(+J?8`$,A9<
M9`PV&X!Z`YSCC'3``Q6E9B66R<K;F6*S=9)W4,S11F5`C,5P1$9Y8TV@C+N`
M"7=4;XF:4H2BY.',N7F7(VN9VLE.,H-N]K2BT[VL?V%4BI0E%S<%)<O,E!M<
MS44DJD9P;DWRI2A).]K.Y]1>#_@EJWBJZT6?2+FTU'1/$EMJ=AIZZZ6BNK*"
M&R@O5U.RDFMW589[ZX:VBO([2.&WU&?^S[A5O;FV\[C_`!M^SKX\\,3RBWTF
M7Q!I\2N]QK6E0,--@9%:24/?L?LY,4:R.XDDC<B-IVA%H]O<S_H!^S-X5\.Z
MA\.9634;;4K1M5TV6&QU4>3]@F@?3UL6AN9WMKB6YOX;FQO(FDFBLK)K6`6U
MM%/I\R/[MJNL^$?#'B+4?#NO:GI&C.UI*I@?7[*SLKM;F%8O/>VDE1;*1&MS
M&IV02SHMQ%*T-P\1'\EYAXR\2Y-Q1F678*C'-J6`E7H5,%B,#*E7Q%+#U>:.
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M`_@!_P!E)UO_`-1.\K^/K_@A+_RE6_98_P"ZW_\`K./Q>K^P7_@J)_R`_@!_
MV4G6_P#U$[ROJ<=_R3.(_P"QWD?_`*NLF/U;Z/?_`"EAP1_V;+QD_P#7-^+)
M_6#^Q#_R9=^R'_V:_P#`'_U5'A.OB;X#?\GH_P#!53_LZ'X"?^N^OV0*^V?V
M(?\`DR[]D/\`[-?^`/\`ZJCPG7Q-\!O^3T?^"JG_`&=#\!/_`%WU^R!7S/%'
M_).YM_UZP?\`ZM,`?C?B!_R3[_[#<-^54^T::Z)(K(ZJZ.K(Z.H971@0RLI!
M#*P)#*0002",4ZBOQ3;8_#6DTTTFFFFFKIIZ--/1IK1I[GY$?";XE67[#=Q\
M0OV7?B/\./VEM4^'O@#QSJVL_LR^*_@Y^R/^U+^T5X*N/V>?'3GQ/X2^'<OB
M;X`?!OXE:9X:U[X(Z[=^*/A1#X4\37EGJJ>`?#/P^U^WFOX->D33_8?^&^O@
MC_T3C]N;_P`5B_\`!2;_`.A.K]%J*_SP\1_V8WT;_$OCSBSQ!S+-O%?A_,^,
ML[QO$6:Y3PKQ)P;@>'L/FN:5?K69U,KP69^'F<8W"4,;CIXC'2PU3,L3"C6Q
M-2GAW2PT:5"G^\Y3]('BK*\LP&6RRW*,=]0PM'"+&8OZ_+%8B-"$:<*N(E#&
M1C.M*$5[2:BN>5Y-7;O^(?A?QA^Q%X.^/FO?M,Z'\/O^"JO_``M_Q/YT/B'4
M]9_9O_X+F^)_!FL:5]I\>7VD^%[[X1>)_AIK'P@G\#^#M0^)_C[4_AQX#;P)
M_P`(9\,-5\3ZCJGP[T'PQJ'V>Y@]_P#AYJ^H_M@_M5>!/B%!X)^,G@W]G?\`
M9/\`#]]XR\)M\9O@?\9/V?\`5OBE^T_\3M*\4^`;;5--\"_'?X<?#WQK?^%_
M@-\'KKQA"-;CTD>'=>\8?'739M,NKC5_AG.UM^GM%?<>%_T#/![PN\2^'/%B
MGQ9XP^('%G"&55<HX97BAQCD/%.5Y/AGEV(RG!O"8;"\&9-C(?V-@<7BX9'A
MUF"P.55ZL,7AL(L3A\-5I>;Q'XV<0<0Y%F.0?V7D^58?,THXFOED,52KSA*K
M3J5X/VF(J4W'%1A*CB&X<\Z4Y1<M7?\`F<_X+6>(?'W[//[8G[&G[8T/PQU3
MQK\+_`7P]^*/PUU75[74TT2TLO&/C47=G9:9;^)X=.\02^"?&<6A:G?^)_A[
MXCU#P_?6L'B70(;W3[75KG1;RP3\S]+_`."M\?A_1O#NEZ7\(?BIKK>%M*T[
MPS:CXF?M2:K\1--\6Z+#X]^&7CF^\4_%*POOA-IMWXY^,MG_`,*]E\/^`_B%
M#JOA[P_\/="NO#&DZ/\`#JYT7P+I>D7O]KGQ)^&W@3XP>!/%/PQ^)WA;2?&O
M@+QKI-QHGB?PQK=N;C3]4T^X*OM;8T=Q:W=K<1P7VF:G8SVVIZ3J=M::II=W
M9ZC9VMU#^!]__P`&U/[(-W?7MW:_M,_MMZ1:W-W<W%MI-AXJ_9CGL=+@FF>2
M'3K*?6?V5=6U>:TLHV6VMI=5U34M2DAB1[[4+RZ:6XD_V]\`O'CZ/W#O!\>&
M?''PWXCXAQV3U(4<BSGA?'X^=/%Y7)YQ-8+-\HGQ9P[@(U<#5SS./8XN$<7/
M%4<TJT:M.DL+1<OC\DXE^H9=1P2Q,L(\/*L[NC&M&JJ]=XASA.-&I4IRC+EA
M*FTHVIPG"<I3G"'X8_$_]OC0_B)\#?&'[.OPV^"WQ;T6+XEOJGAG2-'U/XZQ
M_$[3+C5?B#^TAX&^/TD^F?#'PO\``[P')XI^*=WXY\-)\/\`P'JMG>K=V_@[
MQ9J7A>/P_K^O7\.L/_:C^PYX!\7?"G]BG]C[X7>/]'E\.^//AM^RW^S]X!\;
M>'Y[BSNYM"\7>#OA-X2\.^)-'FNM.N+O3[F73-9TZ]LI+BQN[JSF>`R6UQ/`
MR2M\9_L6_P#!&']E/]B?XH2_&/PWXH^,?QM^(-E8-9>"]9^/>I_"[6HOAI+=
M175KK&L>!M-^&OPF^%NFVOB+6].NCI-UXAUVUU_6-,TC[9IGAJ\T*SU[Q/#K
MGZX5\%])GQF\.?$NMPWD/A/PCFW"W!?#F-XBS_GX@QN+Q>>9MQ)Q>LG_`+>Q
MN+CB<XSZ.%H)9'@*6&H4<RKQE*-?$R]E+$_5Z'F9_G<LTE2IJ:K0I*'[]TU2
MYN2$HTZ=.G&%.T*:J34I3ASSF[)*%-2JE>1?%O\`X2[_`(ME_P`(E_PA_P#R
M5WP7_P`)-_PE_P#9_P#R*/\`Q,O[9_X1?[?_`,SA_P`>W]B?8O\`B8?\?/V;
M^.O7:^??C_%X9E_X4G_PDWA7Q+XI\O\`:"^&\OA__A&YY(/^$<\3)_;/]E>*
MM?\`+CD\[PUI&;C^U8'V1R?:(-TBX&?YKR1.6:85*$:C?MO<E"-1.V'JO6,Z
ME*+M:ZO.-FDU=I1?S%7X'K;6.J;7VEU2>^VWW;GT%1117E&@5^7WB?6Y_P!B
M_P#:4^*.K7_@7XT^*OV<_P!J"V7XP6MW\%O@'\</VA;OX7_M)>'H]`\'?$S2
M-:\*_`?X??$_QAH?ASXW>$/^$+\>:!J%UH>E>$;#QSX&^+-W?:@WB'Q[9177
MZ@T5^7^,OA!P9X\>'.?^%_'U',)\.Y_++Z\\5D^(PF#SS*<PRK'T,PP&:Y'C
ML=@,TPN"S&A4HSPTJU;+\73K9=C,PP%:C/#XVO"7U'!_%N9<%YW1SO+(TJM6
MG2K4*N&Q'/\`5\30K0<94JRIRA-QC-4ZL>646JE.#35C\Z?^&^O@C_T3C]N;
M_P`5B_\`!2;_`.A.KYT_:J^./P+_`&K/@EXT^`VJZI_P4Y^$/A#XDZ'XC\'?
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MO@RL'BG]F7]EGX>^(]4\=?%"]\$1ZE;_``Q\$&W'P:^$GC30OB%9WE_XX&LZ
MW]6?\%/O`_B_XD_\$]/VP_`W@'PWK/C#QEXD^`WCS3_#WA?P[I]SJVO:[J']
ME23QZ=H^E64<U]JFI7"0NMGIMA!<7]_/LM+*WN+J6&%_NZBO[<\!_!K@CZ.O
M"6&X-\/\/CIY='B;->+\QQV<?V,LTSK/LXQ=&OB<7CEP[DG#F28>EA\%@\MR
M7+<%E&1Y9@,!D^58##TL,ZT*^(Q'YEQ3Q[G'%F?8#/L=3P]*IED,)#!8.E+$
M3PE)86JJW_+ZM4KR=>JN?$3E6=2;TYTHQY?X6_AK^V]^RAX;^''P_P!%?PYX
MU\->)/"_P.TGP#X>FT7]E_\`9H^(5A\)OBZN@:C9>-_C]X:\5^,O&ND>.?BG
MK7Q,U&53J7@GQ1?>`O"_AR'7;_5)%\6ZUX.\!2Z3:UK]L/\`89UKXY?##XX:
M3\//B+\.)_AYXE^-C7G@GP_^S_\`!7Q%HOBG2?B%J'C*?PCXPOKJX^+_`(6T
MRWUWP]<^(K?Q6/AU-X1U+PKH6J2WOAGP_P"*6TBSL]6N?W2_;-_X(7_`G]J7
MXNZG\9_`OQ$UK]GOQ+XODGU#XC:/X7\'Z/XG\)>+_$\\S37'C2WT2[U/0V\.
M>)]::223Q;<:=>2Z9XEU%(_$%QI5MXFOO$FM>(?E&P_X-I_!"WUDVK_M@>/;
MK25N[<ZI:Z3\)_"NDZK<Z<)D-[;Z9JMYXGURSTS4)K;S8[+4+O1-8MK*Y:.Y
MGTO4(HWM)O\`:3)_I'_1(S#+X9WQ'E/BKD_%V:91GF#S_!9/#+\9@H?ZT9;F
MN5\399A\;*OA8YA@<SI9SF=:CBLQPL\?@\7C\3FF&KX7-\5CL;B?6PO%M&KA
MJ,JV,PN$G^[G+"5\/C:]2C5P]2+IM5L/A:E*<5*E"5*<)4_:T/91KT*,D\-1
MO?\`!$S6+'XN?MF?MM?M`?#[P=KVF_"76?@W^R[\-9/&>H>`/#'PYL?%_P`8
M/!7A:>'XI:Y<^&/`UYJG@;P[XM\>>(1>_%SQ+X0\-:WK@\-+\0M,.IZE=/JU
MCJ.I_P!-%>8?!GX,_#+]GSX9>$O@]\'O"6F^"/AYX(TT:9H&@:8)76-7EDNK
M[4=1OKJ2?4=:U[6M1GNM7\0^(=7NKW6O$&M7M]K&L7U[J5[<W,OI]?YV^)O&
M.'X]XVSOB?!Y:\GP&.JT*.6Y;*M#$5<)EN`PU'`9?2Q%>E1PU&KB5A,/2^L3
MH8;#4'6<_8T*5/E@OALZS%9ICZF*C!PARQI0YOCE&%_WDU>2C*<I2ER*4E!-
M0YYN+G(KX$_X*I_\HV?VYO\`LU[XR?\`J%:M7WW7P)_P53_Y1L_MS?\`9KWQ
MD_\`4*U:OF,@_P"1[DO_`&-LN_\`4RB<6$_WO"_]A%'_`-.1/VCK\L)_^4I'
M[5?_`&8)_P`$ZO\`UHC_`(*FU^I]?EA/_P`I2/VJ_P#LP3_@G5_ZT1_P5-K]
M0XL_Y)_'_P#<K_ZFX8_=N-O^28S/_N2_]6&$/J>BBBOQD_`0HHHH`****`.J
M\$_\C/IG_;[_`.F^[KWZO`?!/_(SZ9_V^_\`IONZ]^K]5X&_Y%.(_P"QC6_]
M1L(?M/AS_P`B/%?]C6O_`.HF!/.?C#\,=`^-OPC^*?P9\57>KZ?X7^+GPY\;
M_#'Q)?\`A^XLK37[+0/'WAG4_"NL7>AW6I:?JVG6VKVVG:M<3:;<7^EZE90W
MJ0R76GWD"R6\GX3_`+?G["'AS]CS_@G)^WUXJ_9JU_XYZSXQ^)OP)_8N^%OB
M^%=5LM1O;/X0?LF6_@#X,WEQ:1_#_P`'^&-5M]$U;X$)XPO_`(Z3:I<7_A:_
M\/OXINKC3_#?@MM5TL?T/45^V<$\?9UP5F658C"S^NY/@N(,DSW,.'Z[IQP.
M<_V-G>2YZL%BIRH5JE.CB\5D&6JM*$9:8>FY0J1BX2^VQ.%IXB$U+W:DJ52E
M"JK\U/VE.I2YHJZ3<8U9VOW>JW/Y-/V$_P#ASQ_PW9_P3M_X9%_X:7_X7'_P
MSGXK_P"$0V_\*>_X0'^W?^$0_:<_X69_PUU]I_XNE_PT?]C_`.$T^W?\(=_Q
M;W^P_P#A2O\`PK#_`(LC_8%?EWX8'_!-?_AVY^U3_P`-4M\:/^'H)^,&MGQ+
M_P`)W_;/_"]Q\=QJ7C[_`(0-?#W_``D:^5_PI]E'B?\`X:P_X6'GQU_PFK>)
M?^$H9?'7_#)&W^YGX8?LM_LR_!'7[KQ5\&/V=/@3\(O%%]HUQX=O?$GPP^$7
MP_\``.OWGA^[O=.U*ZT*ZUCPIX>TG4;C1KG4=(TF_N-,FN'LIKW2].NI(&GL
MK:2(US]EO]F7Q/\`$J'XS>)/V=/@3XA^,%OK/AWQ%;_%?7/A%\/]6^)4'B#P
MC%I<'A/78?'5_P"'KCQ1%K/AB#1-%A\.ZFFJ+>Z+%I&EQZ;/;)86BQ?M^6^/
M>1Y;FU:LO^(IX[!1GP;F.'S7&<<89\68C&<(9[Q5G:R/&YG#+/9QX6SB7%52
M&-PD(UJM/,,KP><1IUIU%@<-YL\LJ3@E_L496Q$'".&?L%&O2H4_:1@YW]O3
M]@G&3LG"<J=TES/\*_@3\8=`^"7_``41_9-\5?M=?%/2?A'XGU#_`(()_`CP
M_P"./$G[2/C>T\`^(+WXMW?QQTC4O$VA^+=8^*&IZ3J=S\1[G4-)\2W^O:;K
M5P_BB:]TW7;K48&N+/4)(S]H/Q)_P3]^/G_!6"PU;]I'Q]^R[X]_9E\?_P#!
M)_4M"\*^//'WQ'^'0^&^H^,'_:V\9>%KF?X;?$^?Q!:6.C_$C2=.MO'FG:5X
MB\`^)=.\=>&9M/\`$DNBZIIE]IE]-;?NK\3OV7?V9OC;K]IXJ^,W[.WP*^+G
MBC3](M_#]AXD^)WPC\`>/M?LM`M+W4-2M=#M-8\5>']6U&VTBVU'5M4O[?38
M;A+*&]U+4+J.!9[RXDDY#4OV'/V*=:LO#^FZQ^Q_^RWJVG>$M(G\/^%;#4OV
M?OA-?V7AG0+G7]<\57&A^'[6Z\)2P:+I%QXH\3>)/$D^FZ;';64NO^(-<UB2
M!M1U:_N+CQ\/XL\%RQM#/*V`XQRG.ZW!F)X-QSX=Q.4X3!X##XB6+K1QN0U)
MRABZ%:A7J8>G1I5I1IQPT:J3Y^0T>!Q'*Z:EAZE-8B.(C[53E*37*N6JOA::
M3;:UO;I<_`K_`((I?LP?`+]IW]D773HFL_&+1OAI^SW_`,%>;[]J#X%G5-0\
M%:=\0M4E^%'PL^$W_"KM&^,RV7A_7_#%\U_X7\06Z_$/3?!:Z,D^LHS^&-?T
MNUAA=_Z"OV2/V8/`7[&?[/?P_P#V;/ACK/C+Q!X&^&__``E8T+5_B!J.C:MX
MNNE\7^-_$OCW45U;4/#_`(?\+Z3<_9M6\47]I8-;:'9R)ID%E'>/>WJ7%_=>
MO>`?AW\/_A1X2TKP#\+?`W@[X;>!-!.H'0_!7@'PSHO@[PEHQU;4[W6]4.E>
M'/#MCIVCZ<=2UG4M1U?4#9V</VS4[^]O[CS+NZGED[&OS/Q`\1,VXWSG/L1[
M?'83(<VSS^VZ.28C&+%QABZ4,91H8_&5HTJ$,7FU6GC\;4QV/]C3EB<1C,1)
MQ4'3A#LPN$IX:G25HRJTZ7LW44>6\6XMQBKOEIIQBHQN[**ZWN5Y-\3O]?H'
M_7+6/_0])KUFO)OB=_K]`_ZY:Q_Z'I-?E.<_\BC-/^Q?C/\`U'J'@\:_\DSF
M?IA/_4_"GF%%%%?A)^`!1110`4444`%>1?\`!*+_`)1M?L3_`/9O'P[_`/3-
M%7KM>1?\$HO^4;7[$_\`V;Q\._\`TS15^B<`_P#,V_[D/_=P_5/#/_F=_P#=
M-_\`=\_F%\3$#_@C-\>2611_PR3^U*"9$W@@Z'\3P44>7+MD?.R&39^ZE9)-
M\6SS$_SXKNWT>[N+&U\/+JK37,Q@D756L4#2RO$EJL#6Y55W,T@D,I`YCV_Q
M5_H.^)QG_@C-\>OEC;_C$C]J4XD?RU&-#^)YW!O,CS(F-\2;CYDJI'Y<N_RG
M_P`\:OV7BBDYXC"5(U)PE3>-2BG>E-S]E&+K4TXRJ*#7-%<\+._*TV[/@BC.
M>?<;5(U:E-TL[K*$%*HZ%2=3$9G&]>E>,*JIVC*"A.%1-OGDDZ;7=I\/=:DL
MKJ^CN](E%F3'<6L%Z9[Y+H0RS&S6UBA9I9T\EHIO*,D4$KPI+*IN+<2P6_B?
MQ9HBV[W$\LT%QYDL,&JC[0TZ%$43!G==0%L=RM;R),EK,ZR>49=DZCCTFFC2
M2..61$F79*B.RI*FY'V2*I`==\<;[6!&Y$;&54B_%JUW'&T9,,OS0LDD]K:7
M$\?V?R!#$D]Q;S2K:JEO%$;,.+9H5,)C$;R*_P`/+`8BNIPS!X#,J4IWIPJX
M/V#HTY02FH3Y\1[_`#WG&:C&24(QYN9^TA]M++,5B54IYH\LS>C*I>E3K8#Z
MO*A2E3C&:A4]IB_WCJ7G&:C"2C"$.;F?M:?H4?C70-7"Q>(-&$<C+!";R`"?
M:H8O(_F+Y%]:PI(2XAMWNG9'D0E\L)/3M"N=%U'[)9V&KZ;#;K;)L>2:XG%K
M;Q0KY0N(+6&]U%#_`*J`A[5I$ED07`C^=U^89)FE:1BD2F61Y6$<,<2@NVXK
M&B*J11J>$CB5$13M`"X`C4D,"&*'/W@2,9X)RN3C!YP"<=C7CX_@_"8NDJ6'
MQ>+P,5S2A1C4EBL+1J2BHNI2HUY:2TWYU%I).*BE%>%F?`F"QU!4<+CL;EL(
M\TJ="-66-P="K.$82JT</B9>[/3?G46DHN"@E!>L?$_PQ>6-S8Z_'%'+8:II
MUM-)<V[2/B19I[+?/'(J20A)K9],9O+6$W-DS1O)#<V=S=^35Z%IGC'4/*.G
M&2.]6=$BV:\]M)#Y9MYVO?.U"2>Q#)-+A8H+P3[HI!`)PT2K<Y.H6GAZ]>VN
MM+N6TZ.:2TBOM/>.ZO'L-[3+>74<FT+/#"J0R0Q13RRW1EDV"V\M8:[<G>/R
M[#T\NS*'M_JZ]GA\7A(5*REATKT(8FC%2JTIQ@G2C5A"6&G*C4@I4W&"J]^0
MO,\JPM+*<VIO$_58^RPV.P5.K74L,E?#PQ>'@IUJ-6--.C&M3IRPE2="K",J
M+A3C5_MS_P""%W_*)WQ=_P!C;\?O_3+9U^>7_!9[/_#J_P#X)^_\@['_``L&
M;/F[?[6S_P`(7XOQ]BS\_P#9V,_VGM^7[3_9&[G97Z(_\$,A&O\`P2@\6B,R
M%1XJ^/.[S46-Q+_8-B9EVJ\@V)-YB1L6#/&JNZ1,S1I^=W_!9Z$M_P`$K_\`
M@G[<?8?,$7Q!FA.I>>5^R&?P7XO<6/V7<%F_M#[.9_/*DVW]F>6K*+I@_P!-
M4=^+<K=Y*_AMQ$]'R2_W_AUV=U>SVG%I.47*.C>GW7"CB_`/Q`;T3^EYX?6O
MRQ=WX8>._*FJDJ:3;:7+?VE](0J5.6G+^7?P+8'5?&W@_3%D,1U#Q1H%GYPC
M,IA%SJMI"TWE!H_,$2N9"N]`0I!=!\P_I5TG5=.M-;N;?6M;N-4NK*.2"#3#
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MV&S"G3P\\)@JCPTW*G[."C"<X5ZMJM)5)8:KS/@?PSJ'Q`L[NYBU^ZT/4],\
M*WVJQ/JNGV"6`O=/AL7N)(DNUL;=?[4C,D-KJ4UW-:VT-]/&B0"2>.'R>X\/
MZJMK<6MW:M#'JFF6UG)''=HUFFJ"]%Y#_9^FV)FF=;<-<7M[#';+;6LHU>ZL
M4>TC@BF]N\1>(O%VH0K=6UA/KCQZ9I?AL%1JIM]-TG1=(NYK/[:+*659-/L;
M/0X+I;&.WBEGETV6Z1Y[MWSY[-JVJV.N6VDZ7HGA_6?%!_LR_P!.\2Z-=ZK?
M2PRSR:A/86^B7$NNVIM+?6I=2T>%K>\@M-4LY8A9VMFDMR;6;^OLBJ8Y5<;7
MCC<EAAY^QQ6'R^,9\V`CA9*=;GQWU;`U7A:=2JI*6)PU1\T*DZ&'JO$5Y2_N
M_ARKF*KYAB8YAP_#"U%0QF%RN,:CEEL,')5,1[3,?J>6UG@Z=:M&2GB\)5?-
M3J5,-AJLL5B92^<;Y,3+*!@7$:S8/)\PEH[CD$J<7,<P!4[<8X0YC3_6)^''
M_)//`?\`V)GA?_TQV-?Y5/Q':Y'B/4([WP_:>&;L:GJTLND6T%U')8^9>M')
M97$M]<7=Y/+8WD%Y:.;JYFN$FBF$TLSDS2?ZJWPX_P"2>>`_^Q,\+_\`ICL:
M_=^&:GM:5>JN6U6GA*GN3C4C[\:LO=J0]RI'7W9Q]V2M*.C0O%>JJ]#ABLN6
MU:EF55<E2-6%JD,KFN2K"\*L=?=J0?+-6E'1H[.OR0_X+KNT?_!*O]J9UQN`
M^"."1G&?VC/A$N<>HSD9XSU!'%?K?7Y'_P#!=A&D_P""5?[4J(I9F/P/"J!D
MDG]H[X0\?YZ=37OXW_<\7_V#5_\`TU,_-N&_^2BR#_L=95_ZG4#_`#IR2222
M22<DGDDGJ2>Y-7]-O([*[AEGA^TVXFA:XM_->$311RJ[(98PTB;E#`,H)4D-
MABH%=A;?#O6I+.2^NFALEB'-K.)UO)F>*.2!+=!`R22W#316\<)=9?M1:U=$
MG1E#M2\$W%KIUG>V]CJ[#RI#J+W$$*-%*A=B\=O%-+=1VJHKJTMS;1`")9S(
M%N5CC_+_`.U,MJ25*.,H2=2H\.G"LHIU'3=3EC44HKF<+<KIR<N9QY7?;^H5
MG&4U9*C''X>3J57A4X5U%.JZ3J<D*L917.X6<'2FY.4H\CYMO3?"_P`3-6\.
M>#/&>F>$+[76OKN?3;NVOI'`N[70;%61K=EBGD*QV=U+'/)]GEC53;Q.UG):
M3W\-KX#J&K:KJUS)>:IJ5_J5W*S/)=7UY<7=P[-*\S,TT\DDC%II'E)+<R.S
M_>8DSH^I:+-.L4EQ;DK):748:6W8JSJL]M<1!E(!:,))'*K(2`KJ6&T12>1/
MOF6-",%I`A,3QY)9B%Y1R`21G`)0C<_1<,OR;`Y?B<?C,/0H>WS&M3KUL5R0
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M^'Q5#.,3]9]AS4XJ%3`R>&A3G]<KTZWM80G.5)4:5:I>I.\(1_2W_@A+_P`I
M5OV6/^ZW_P#K./Q>K^P7_@J)_P`@/X`?]E)UO_U$[ROY"/\`@AK:267_``5?
M_98BD14,D'QFND56##RKO]FGXM7,)X)`+Q2H^W.4W;2%8%1_7O\`\%1/^0'\
M`/\`LI.M_P#J)WE?08V49<+UI1:E&6=9'*,HM.,HO.<F:::T::U36C6J/TKZ
M/,HS^E=P/.$E*,O#'QCE&46I1E&7@UXLM2BU=------IIW1_6#^Q#_R9=^R'
M_P!FO_`'_P!51X3KXF^`W_)Z/_!53_LZ'X"?^N^OV0*^V?V(?^3+OV0_^S7_
M`(`_^JH\)U^`O_!0V'SO@'_P<I)]D^V[;71YO)^T?9MGV?\`X)E_LHS_`&OS
M,C=_9_E_;_L^?]*^S?9<-YV#XF=8;Z[E6+P:G[-XNKEF&53D<_9^WSG+J7/R
M)ISY>?FY$TY6LFF[GY'QM16(RG#X>4_9QKYI@*,JEH/V:JSG!SM4J4:;Y5+F
MM4K4H:>]4A&\E^^5%?X9^2,X)&1@^XR#@^HR`?J`>U&,YZ<#/4#N!QGJ>>@R
M<9/0$CX[_4'_`*FW_EA_]^'S?_$,_P#J=_\`F-_^_P`_W,**_P`-%I'889W8
M9SAF)&?7!)YY-.X>1V<C!+L2I`Y.2"HD*EAN(.W.\KD#FC_4'_J;?^6'_P!^
M!_Q#/_J=_P#F-_\`O\_W+**_Q0OAY\);CQ5#_;.JW$.A^%K%LZA>SW5O)/>F
MRF%U>0BU,BO9^3:N+6YN+B6UAMY3YJ+<FVOHH?I_PMX.^$_A;68K.:'2[JZM
MHYH]4O/$\MS+;"""X>YNO[233HTMK,6S)(MZMA`FH0V<1\J./R(EC_HK@#Z%
M?'/'&%P&:XGB?ASA+(LUQ%&CEF:\0U(TWFE.K.$7B,OR_!XK$X^I1@IJ2JXJ
MA@Z,I1J476C6@Z9\/G^7Y=D=3&X:EB<\SW'9;A7C,PPF1\-U<8\!A_82Q$:N
M.KO,*>&PU-TU"<G*K*<:=:C6]FZ4^=?[#U%?X]^H>`_A5XBN;BVFT2UUD".?
M1++4/".J&RL]+N[FUOKRPU&6PNXVB>*;^SGAMXAI]GJ<\DUG:&2&-EC7YK^)
MW[/VL>"=&M/%^DO/K'A"]G:P34+;R;Z6PU%-[_9=82V97TU7MOL\L,]Q$C7;
M2221VL$'D>9''/T+..N#\#F&;9=Q+P[QOE.4+FSC$\*5/K6,R>$8RE4K9CE.
M+KX7,*>&IJ,Y3Q>'I8K#4Z4)UJU6E3IU7#FR6EDV9XO`Y;F.89IPSFF9RC3R
MS!<09&\#_:E5PJ3]EE]9YBX5:[]G*$,-66&Q5:HE"A0JN4>;_:DHK_#79T"Q
M"$RQ9^:3?*K@/ED#H8XT=`4)#(0S'KE@5`A#;2"FY6'<-ST`.,`$9.[N>"!V
M);^>/]0?^IM_Y8?_`'X?H/\`Q#/_`*G?_F-_^_S_`'+J\5^-%WJ%I_PJ?[!\
M2++X<_:?C5X$M+W[:DC_`/"=Z?-_:OVGX;VGEQR;;WQ1M3R'?9&OV%]TBY&?
M\3FOZ?O^#5:UU"[_`&YOB"+#X;V/Q&%K\./"-W>?;"\9\":?%\8/`AN?B1:F
M)XS)>^%]R?9TE,D9^W.#&PQC?#\&QP%7ZY/,O:QP].M4=/ZG1I\]J-1)<]?%
M3I1U:UG"7]U<_*SS,YX!>697C,>LV]O]5I*K[+ZBZ7M+3BN7VD<;4<=]^27F
MFC_2RHHHK\T/SX**ZS3-+N[G1H;O3/"UMXENVUQK6\%SKLNBK:::MO:2/(C*
M2DT@:60J!&[YPK*RL#'\!>)_VGOCM\/O&/C+PCIG[`7QI^-6E:/XDNX]+\??
M#_Q5:WOAK4;">WM+J"TMI=1CTVYCNM.\]K:^MC!)';W2R117$R*&KW<3D]#`
MY/A\ZS#,/J^%Q$Z-.$*&6YCF5?VE9591C]6RW#XK%22C2FY5(T'2@DO:5(<T
M>;Z#&Y+ALKR7!9]FF9RPV"QTZ=*G'"Y/G.<8B-:K&I.G"6%R;!8[$\KA1JRE
M6=*-&#C&,IJ52*/M&BOA;_AM#]H+=N_X=5?M/YQMQ_PD&D[<9S]W[;MS_M8W
M8XSCBE_X;1_:#_Z15?M/?^#[1_\`Y,KPWCN'-+9QF3T5[\&<9JSTNE_PB.Z5
M]W9]TM;?.+-.%7>^>9HM=+<`^(+O'2S=^&HV;OJM4M/>>MONBBOA?_AM']H/
M_I%5^T]_X/M'_P#DRN-\/_\`!0[XK>)/$GC/P?I'_!-3XWZQXK\`7>E0>,/#
MGA_XB^%]=UOPI'XALI-1\.CQ9IMK>)=^'+_6;&"ZN;73[Z++Q6TS0W$_E3"*
M'F/#47!2SO&PE4ER4X3X1XPC.K-0E4<:4)9(IU91IPG.2@I.,(2G*T5)KNPT
M\CQF&S#&83,<_P`3A<JP]'%YGB*'ASXB5:.7X7$8S"Y?0Q.-J0X9<<-AZN/Q
MN#P5.M6<*<L7B\+AU+VV(I0E^C5%?"__``VC^T'_`-(JOVGO_!]H_P#\F4?\
M-H_M!_\`2*K]I[_P?:/_`/)E5]>X=_Z&^8_^(;QGY?\`4C\_P];<7]J<*?\`
M0]S;I_S0'B!UM_U3?G_6MONBBOA?_AM']H/_`*15?M/?^#[1_P#Y,K-U7]M3
M]IM+>,Z)_P`$H_VC+B[-S;B5-5\56-E;BS+_`.E/'+:"_E:Y6//V>-H5B=SF
M25%&&<<;P[)I+.,P3?\`-P=QE%;)ZN62)+K:[5WIOM4<RX4DTEGN:)O^;@+C
MZ*V3UE+AR,5OI=J[LEJ[+[ZKX$_X*I_\HV?VYO\`LU[XR?\`J%:M7ZY6W@[P
MW/;6\\FC/;23012R6\M[?F2W>2-7>&0B[P7B8E'(XW*<<5^6/_!7_3[/2_\`
M@GI^W=:6,1@MU_99^+;K&99I<,_@34RQ#322.`3SC=M!)(`R:^^PW"U?*LPR
M?&5,72JQCG.504(4YQDW4QM!*[DU9+5O1O1*VKM]UF'!N*R2GA\?5QF'KPCC
M<)2E3A"I"7[RK%*2<DT[-:IVTUO?1_K_`%^6$_\`RE(_:K_[,$_X)U?^M$?\
M%3:_4^ORPG_Y2D?M5_\`9@G_``3J_P#6B/\`@J;7T_%G_)/X_P#[E?\`U-PQ
M^B<;?\DQF?\`W)?^K#"'T1XJ\5>&?`WAG7_&?C/7]'\*>$?"FCZCXA\3>)O$
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M]B_QGO/$>K^`?#/C_4OCMH7QT\,77A;XDW_BW4-?\07&BW.EZWXM\6_"N[M/
M#ITNZ\#W%K<ZS87/]._0:\)^">,.**.>\5\+/CS&<^<4\JX;QM;*\-D&"P63
M2X?H9WG>94<RK6SW'4(<48%Y7DD:4:$XTL=B\164\/A[?G7#^54%ETLVJ3C[
M6565"ESTY5%1=JG+R12:4ZCI34JTOX<7&,(\TY27YJ_\-G?MI?\`1Y_[7G_B
M3/QJ_P#FUH_X;._;2_Z//_:\_P#$F?C5_P#-K7]%A^`7P#/_``52'_!+3_AF
M;X3_`/#+(_9S_P"$='Q)'PQ\(#XM?\)%_P`*!/QE_P"&H#^T`/"P^*)U7_A,
M"?AY_9A^(1^%OF8M_P"P_P"T0-/'Y%?M7?#[P%X=_P"":/\`P2;\>>'_``1X
M0T+QQ\1_^&[O^%A>,]&\-:-I?BOQY_PB'Q]\.:-X3_X3/Q%964&K^*/^$7TB
M>?2O#O\`;EY??V)ILTMCIOV:UD>(_P"AO!V7?1\XLS+AC+?^)>^!<LGQ;2X8
MQ^4U:F0\&X^$<GXMX4\1.*\HQ6-6!P]5X3'1P_AMF>$Q^53YJN$K8[`S5>O!
MUN3Z7$8&K0A6G[>$U0=:,TJ3C^\H5\)0G&/-%<T;XNG*$UI)0DK)I'E_[/\`
M_P`%-_VVO@!\4_#?Q+'[0?QB^,FF:1.8/$7PN^-GQ<\?^/O`GC;P[=/&-5T2
MYM_%.K>(CX7U>:*-9=!\;:!9?VWX;U2&WN)+?7=`EUWPKX@_N9_9%_:Z^#O[
M:?P=T?XQ_!S6))[&>0:3XM\):L;:W\8_#CQC;VUO<:IX,\9Z7;W%RECJ]BES
M!<VMU;3W6C>(=&NM.\2>&]1U7P_JNFZE=?A?\.?A/\%?&W[27_!-W]CG7_V=
M_@!-\&_VHO\`@D5\,OB'\5?$NG?`CX3:-\2?#GQ5U+X3_%7Q#>?'F/XTZ1X*
ML_BG:>*Y;_X>^']*NI]0\=1>'[V^UJ?4KZRN-=O!=3_*'_!N'=W<7[6'Q_L(
MKFXBL;_]GBPN[ZSCFD2UO;O2?B3H4.E7-W;JPAN;C3(=;UF+3YID>2RCU?4T
MMFB6_NA+_'/TL?#+PIXAX!S[Q!X+X*PWAOGO`.&X4Q%;!Y%'+/[#XGX>XPS[
MB7(L`\5@,!'"K+,YP&9<-9E5JREAHSEA*N';GCJ6(H5,/X6?Y)"6&EC/:1]O
M1IUFY1IN'.L/&A.=*:VE:&(@Z55-M-2IS7*H^S_L?HHHK_+JGB*])<M*M5IQ
M;YG&G4G!.3LF[1DE>R2OOHNR/A:>)Q-&+C1Q%>E%OF<:=6I3BY-).349)7:C
M%7M>R79!1115_7,7_P!!6)_\'U?_`)+R7W%_7\=_T&8O_P`**W_R?DON"BBB
MCZYB_P#H*Q/_`(/J_P#R7DON#Z_CO^@S%_\`A16_^3\E]P4444?7,7_T%8G_
M`,'U?_DO)?<'U_'?]!F+_P#"BM_\GY+[@HHHH^N8O_H*Q/\`X/J__)>2^X/K
M^._Z#,7_`.%%;_Y/R7W!1114SQ.(J1<*F(K3@[7C.K4E%V::O%R:=FDU=:-)
M]$3/%XJK!PJ8G$5(2MS0G6J3@[--7C*33LXIJZT:36J04445B<X4444`%%%%
M`!7D7_!*+_E&U^Q/_P!F\?#O_P!,T5>NUY%_P2B_Y1M?L3_]F\?#O_TS15^B
M<`_\S;_N0_\`=P_5/#/_`)G?_=-_]WS^9N?P[KWB[_@D'\7_``KX6T'6O%/B
M?Q)^R_\`M)Z%X<\->&].O-8\0:]KVK:?\2;'2-(T72-.MKS4-5U/4-0GM[6R
MTRQM9[R_GD2TM4,\R$?PR_\`#`G[=O\`T95^UK_XCC\8O_F-K_1$_8=_Y-8^
M$_\`UY>)_P#U-_$U?5]?O^99?#'5%SU)T_93JVY4G?GE&][Z*W)TWOKLD?%8
M?B_$\+9]Q5'#X.ABEC<YQ;E[:4X.#P^,QJ5G35Y*7MWI)VBXWBDY2O\`YAG_
M``P)^W;_`-&5?M:_^(X_&+_YC:/^&!/V[?\`HRK]K7_Q''XQ?_,;7^AU^V;^
MT#X\_9Z^&.B:U\)OAW_PM?XL^+_%UUHO@+X=R0ZS)!XS_P"$!^'?Q`_:!^(G
MA*WF\-6^J>);/Q=XP^#/P6^)?A+X37.C>&/&.?C/KOPYMM<\,7WA6XU^XL\B
MU_:[T&^\;_%"?P[+I'Q,^%.AZ1\!_!OPAF^%[V6O^-_C-^T;\3O!_C/XRZ_\
M,/`,EWXEL?#?BW2%_9_\0?LZ_%;1O'=L=%^%GAKP?XP^(/CGQU\5+#P5\.OB
M/JGPP\AY+AE-P>)J\RM?W(V3<92M?9OEBVTKM<T+KWE?Z*GXE9Y5H1Q,,DP,
MJ<U-Q_VFKSM4ZU"@Y<N\8.K748SGRQE[*NTVJ,[?Y[G_``P)^W;_`-&5?M:_
M^(X_&+_YC:/^&!/V[?\`HRK]K7_Q''XQ?_,;7^A'H'[;7@_7?B3X-^"S?"+X
MZ:7\8_$VK^.=$\0_#FX\.^"-9O?A7>_#N+]GWQ#XEF^)WC+P?\0_$_PMT?2(
MOA;^TM\-?BW8>(-#\>^(]!U/0;B[^'5EJ4O[0E[X6^"_B3D?`O\`P4(\'_$K
M0?AMK'@G]GO]J+6-0^.'PZMOBE\!?"LW@/P1H6O?%_P?IUEX2NOB3JVFW'B/
MXF:1X7^&FD?":?QQX8T[6_%?Q^\2?"#P1\3;W7?#\G[.'BCXX:?XL\(7_B!?
MV/A+V^MU+WM;D5T_<O%JUU*\X1Y6N93G"%N:45*O^(C<06YO[`P:ARJ:F\5)
M0E3DZW+5C-S49T''#XBJJ\6Z3H8?$8A3]A0JU(?P%?\`#`G[=O\`T95^UK_X
MCC\8O_F-I1^P+^W:,X_8J_:TY!!S^S?\83P?3/@PX/H1@CL17^AS:_MD>`]4
M_P"%>>)M"\!?%W6?@?\`$K_A35MHG[1__"+:-X>^%46L_M!_\(=#\&]%_L+Q
MGXH\,_'#Q#_PFFI_$KX:>'_^$G\"_!WQ=X#\+>(_&G]@^-_%OAG4_`?Q:MOA
M[Z+\"?B=KWQ;LOBGXJO+32++P=I7QT^*GPQ^&<-M;WMMXF?0?@IKW_"FO'=W
MXZCEO]2TMM7U#X[^`OB_?^$KC0+B.RNOA)<_#:ZUBPTKQC-XGTNSJ.28:348
MXJI)N[5H1UBK7DGUA=V4E>+D[)MIF53Q-SJC3E5JY)@Z<(.,6YXBLFJDGI0:
M5W#$*-ZLJ$U&K"DE4E%1E!R_*;_@CI\,?B;\)/\`@F%XP\(?%OX=^.OA?XO3
M7_CEJ,GA?XB>$O$'@KQ&NG7FAVHL=0?1/$VGZ;J:V=Z(9#;7;6P@N?+D,+L$
M;'PG_P`%._V>/C3^T1_P3._80T3X'?"?XA?%GQ-X>\4W.JZIIO@'P_=^(GTK
M0KGPQXDM)K[5+2PAFO(4EU`Z?;V=P`ML";F.8F62V%?U`?$__DFGQ#_[$;Q;
M_P"F#4*\._8?_P"33/@5_P!B/:_^EM]7CUJ'+QUE>%4VE_J%Q!AG-Q3?)+-^
M&Z,G9W2DX-V?V6TUJD?J>09_7POT6./N(H4*;KR^E3X8XYX=SFJ5\9X6^.#J
M4N>+4^11KRBGU27,FFT_\^3PY_P3@_X*'^'M=TO6HOV,?VCV?3;N.Y40?#7Q
M1;7`V9!:WN!I[F"X0,7@FV/Y<JHY5@,'V23]D3_@I0UI%8']BW]IZ>VB&HAC
M<>#?%0EN&U@VK:PTQAT%`T>IRV=O/=VI+V\DZ--LWRR%O]&&BNK'<$Y+F4J4
M\?0I8N="_L:E?#TIU*=TTU";7/%-3FFD[6G)6UE?\+S'C[#YO.C4S/A7)<=4
MP[;H5<1[2I5HW4HM4ZCCSP34YII22:G)6]YW_P`X*Y_8H_X*.7)G\S]B;]I5
MQ=7D=]=)+X'\4LMQ=1/,\<TY308III5:>8>9--(SI/<12^9'<3*[!^QA_P`%
M,8ITN[7]B;XY6ERFC7>@&2#X2>*($GTJ_1$O(+R&UM+9+V6?RH)'N[OSKKSK
M>";SC)#&R_Z0%>&?M/\`Q.UWX)_LT_M#_&;PO9Z3J/B;X2?`SXM?$[P[I^OP
MWESH5]KO@+P#X@\5:19ZU;Z=?:7J%QI-UJ&E6\&HPV.I:=>2V;S1VU]:3LEQ
M'G+@7A^,+RP."Y:<*BM_9^$:Y94U3J)Q]G:?/2BH2YD[Q23NEJ4>,L%7J4,/
M#@SAMRG+ZO3C+#4^1_6(PPTHS3HM2C4IJ%.?.I7A%)W2L?Y[%S^PQ_P4QNA>
M"7]C/]H`'4=4BUJ^9/AGX\#7>JP6<^GPW\Y,IWW,=G<W,"RD;PEU=8.;JX,M
M&Z_8(_X*5W<<$4G[&?Q\"VSQRQ'_`(5+XGD=9HL&&82W%K-()XB"4F5UERS%
MG8M7]0O[)7AWP)<_L_\`[('[7_[8W_!5WXN>#_BQ\5_%>O?M#W]@G[=.C^`/
MV?\`XF;?%^@Z^_P,N/A3XMATGP''X0^%]G:V'A#XJ_#;P!HNA2>%?&7BOXA^
M![[79_#-EX"T[PQ^=?Q6_P"#AO\`;`^'IT$>#O$7_!/'XZMK?]JF\'PM^$_[
M;FC+X56QETQ-/;79/C9?_!X7ZZ\+^X73&\+KKJPR:7?'6&TH2Z2-5P619)A8
MT:DJ-&A:,94%3PV#=2$72I05HP2E3:I3C3Y87M37+=P2O]S@\SS#$XJ>'R?A
MO(JT\OJ5*$ZRP>(P6'HU:7ML'*.&Q$L-[-T_9X6=*,^:B_9J%%P4G[*/XV:S
M_P`$XO\`@H[K]TEYJ?['/[1,\\=O':QE?A5XBA6."-I)%15BTY`?WDLLC,VY
MV>1B6(P!_I.^`;:XL_`O@JSO+>:UN[7PEX<MKJUN8I(+BVN(-'LXI[>X@E5)
M89H95:.6*15DCD5D=0P('\^>D_\`!73]J3P+\(/^"IGB3XO^$OV9/'WQ#_8$
MUCX'>`/#3_!+3OC-X9^'&M_$;XL>/?%'PN\3P^(Y_B?J3^+O$.E_#'QA86,>
MH6NC:3X-B\4/H/B"PT#Q,VCZ[X?\:VR?'C]OK_@L!^S3??LW_#GXG?`[]C/6
MOB_^U=J]W-X"TGX3^%?VHOBK=?#'0?A]X>TS5_C'IOQ0^&WP]U'Q7XJ\6:OX
M<C\<^%];_MOX*^(/'MEH^@>`OB.]IX?\<IJWAS4M-]W+U@\NIS]E*M.$X4KI
M4;1I1A5JX>G"T/=7/54X0BKJT4](ZGRW$T,\XHJ9?AJV%RC`2R^6*I8:G3QR
MC]9C5R[+<TKNE3JQC+V6#R^>&K5&H14(U'32E4BH']'5?"7_``4O^"_Q"_:%
M_8F^,WP@^%?A9O&OCSQ9-\,9-#\,IK?AWPY)J:^&_C!\/_%FK>5K?BN_TW0-
M/FL]$T+4M0AFU"\0&6U2*VBN;R2WM9OR:_97_P""G'_!2S]KC]HGPQ^RUHGP
MA_9X_9Z^*O@?X/-\2?VG[3]HOX-?'SP_J7A9Q\7X='67X8>!;3XOV?B/41=?
M!OQ_\(O$VA>'/B%=>#CX@\4-XSE'B_2?"USX8O9OJ']K3QI\6/C5_P`%4/V8
M/V%[;XZ:Q\#_`(`V7P(OOVJ/B'IWPU^)_B7X+?&#X[:[8>)?B-X.L/A1H?CS
MPG=0>*=5TBVB\-6/B/6?!'A34?!][<>`(_BKXPN?$$OB#PAX#O\`PITXN>'S
M/+L7A7]85''4JF73G3:HUH_7*<J$W2G-25.I251OGE"2A-:1FUROY"7#6-P6
M.6'Q6)PM"I1P>(S2I.C5G7=+"82#K1JQ]@H\TL2DGA?9U(\Z:G*I2A[Z_,_0
MO^"27[3_`(>\'1Z*_P``[36?.O[F?4=,D\=?"&>2XANK@3IB]U'QHD1DL`D=
MM:32RS3"UM[*8G[7#('^0_B[_P`$Q/\`@JMXUUF\7PS^Q)X8TG1XI4M[&]D^
M,'[.[ZO/I]L[21*T\GQF:6T$UQ)+<2K"ZNRLEN3'%]H2X_0?QU^W=\:?V4OB
M1I?[)G_!-OXDZU_P4L34/ASXW_:4\>_&;XW>-_BA^WQXNT2]VMX0T?X+>')?
MV7+?3M4\#Z3::GX#T6&TD\4KK&A1^-/CEX<N?%&J?#WPS+?>);S\J_V@/VR/
MVU?VH?VTK+PE\,?VM/B_\!/&OQ4\7_L=_`Z[^!ND_$?]I[X+>%_A_P#'/QW\
M*?!'@[X[6-GX(2"YC\$>&/A/^T!I/B7PKXZM]5G?QC=7NMV>L^%]*^(EJ_B7
M7=-_$<E\%^!.'LPK9I/$\3\08^M7J.,<ZS/!XBAAZ^(<:M:IAJ>"R[+\/5J-
MPITW.M"O**4(P:LF8<%>$,,GSK%9[6Q+SNIB*.)S*CBN*J^-Q,<)[;$454K?
MV7ED\MCAZN(24XSQT,1.GA\.FO9*"<=;_AS/_P`%(/&'A>YTSQA^R!%HGB.Q
MB9=*U[2_CA^S_-:W[3_98(UU'28?BQ(D7]G6MO+(9;6YMVU.[EADU.*^E,EU
M#X7>_P#!!_\`X*EP/";/]F5+M9(EE<Q_&O\`9ZB-O(2?W#&X^+$):2,`;FB\
MV+D;)Y#G']'G@_\`X*3?MQ^*/^"DT?[$.M>`_@9\*-.N_CG\64\-6WQA^"W[
M0/A'7_BC^RO\-O&#KI7C?X/?$/3?B'XDT+Q=\1O&_P`._"_Q7U_2=0\0_#/P
M1\&Q=>`;)].\<ZYJ/BE?".B?T&5^G9/PCD^!^MQR_$9K'#3Q,I_4Z^)A5PV%
MJN-ZL,)&M1G6P]*<I>U=!5?94Y.U&G2I6IGU%/B7B'@^7LJ5'*XX7-(QS/#Y
M>ZF8XS!X2G6YHR^I*OCI5<-AZU:-2HL/2Q$\-3J1G##0HTHJDO\`.R7_`((5
M_P#!5(X,O[*:NP8DNOQO_9Q0G)!)95^+H5S_`+V`>AZDF>7_`((3?\%2UVRQ
M?LM*T@PP1?C=^SLB[OEQO#?%M5^7[V$8!B""3D$_Z(U%>W_8.#_Y^8G_`,#I
M?_*3?_B*_$7_`$!9+_X38[_YXG\8?_!*'_@E#_P4#_9N_P""@GP#^./QQ^`8
M\%?#+P6/BD/$WB8?%/X*^(UTL>(O@I\1O".B!=$\)?$?7_$%VMYX@U[2=/"Z
M=I-T+;[7]JNA;V,%S<P_O7_P5$_Y`?P`_P"RDZW_`.HG>5^J-?E=_P`%1/\`
MD!_`#_LI.M_^HG>5YG$.$IX+(*M*E*<HRS7(JC=1Q<N9Y[E46DXQ@K6@NE[W
MU[?OWT1>(<;Q+])OA#'8ZEA:5:EP%XTX2,<)"K3ING3\$O$ZLI25:O7DYN5>
M:;4U'E44HIIM_P!8/[$/_)EW[(?_`&:_\`?_`%5'A.OP!_X*(Q13?`'_`(.4
M4FCNY4$.A2A;)%>82P?\$T/V3IX)'5@0+2&:..:_<#='8I<R(0ZJ1^_W[$/_
M`"9=^R'_`-FO_`'_`-51X3K\`?\`@HB5'P!_X.42UY)8CR="`GC65V=F_P""
M:'[)RI9D0LKB/47*Z?*Q)B2*Z=YU>%9%/S>-_P!V5[6^OY)O9+_D?97NVTDO
M5I=W8^<XI;6%RUQ<E)9[E+3BIRDG]8T<8TXRJ2DGLJ<93;TC%RLC_+%HHI0S
M!64$A6(+#UVYQGV&2<=,X/4#'4?3BH5#`N"RC)(!P3P<#/8$X!(Y`SCG%3V:
M++=6\<C;(WFB65]RH4B\Q3(X=N$*H"V_C`![$@Q+M*.7)RH`C4-CEB3C!5OE
M'+'!7GCJ^1:L5\RYBCCA$K2,B%78G.6`<`JT6T2`^6,R(06'[Y023=-0E4IQ
MJ.2IN<%-QY>90<DI.//*$.91NUSRC&_Q22NTGL[;VT_I:_<?<.EZJ?#_`,-M
M`\G4&EU"^TC3G"-:S+);/&;FZUI\3QQ"2\-S+'I][/?27*-]F4Z?9XNKG4(^
M0TJ^N#>G6IK2=[>#48)W-M$VE1QR3O//!':W5B%BL;ATMY9[+R(D2W>%FA@E
MMX#$/3?".F1ZM\/]`BM#"ZRZ*D,M]>XEN[B%[JWEU!H69;4HU]-9175M%,9S
M:W$=A)<+?RZ<LDU/PWIR:-<;-:OO#L4R7LQM;C4)IM.U&TL(_M<5W8^=>)IL
M<^FW]Y(EQ8B]GO\`3%DLI;NPLA=ZE::E;_Z?8W*\?A5PKCL54QN&R+$Y-E]%
MUIT)X?+*$I9'AX\M7&XK%X6AA\+2IT:]6=&A*6'HXKVV)A0@E2Y/FN$>/N'N
M'\!XEY5@LFAF/&.$XKX@ABL+'$4\'G?%6#K9WFD,/#`8[A[)J]>KB\)"I[*$
M.>K*C5K5\9A,52H5*6'CY'J`6RU*1[19!%+<2E+9IA<D('*JC7<"1P7DGS$^
M=##'&SXDCA6-T2O<O"US;ZUX.\1>&W&G6-M>:/-IEV+]IG4"[7S9+VXO6M63
M2XY)ED/VBQNFN(H(KV*016SHUQQ6M:.NJI#>>'M+@MK-9)XQ?WL]M"]_>S:B
MMC;BRM[C40EO"\IMEL;6*V%Z[W#M-"$\FVM>[\)Z9JWA7PYXAN]3A1+D:=->
M?9I'+V)2(2$-(8&C"O=A7-R\%PKM$(RDD4B97O\`#C)\QR_BK/J5'#8R&2U<
M%Q%5Q#I4*>/R?`\_#F8?VGAJN(P^/JP4\SM5JT85,7A\%*C[U.-3#5:E"?K^
M,'%?"?%7`&1*>(P4N+:?$/#<LNX:QN;4Z&;Y?G-+.<-A\93S;)</B<=[.K@\
M,L=@\0LRP^)J9?/$2C-PQK5*I^=VH*!>W82`VZK,_P"XWF7R`&`,9E/,FQCL
M\T_ZTX?)W`FGCC/')(ZC/&.W4#G@D8/.,X.+,SD3#=\ZH(R$8G:,QH3@<@9/
M/0@G[P89!AD*L[,JJBLQ944N50,<A`7)<A`=N6+$XR6;J?\`+C&4_98K$T^:
M+<,37IM)37P5&N;]Y*I+EEKRJ56I-6?/)NTI=L7>,7WBGTZKRM^278:`#G)`
MP"1G/)'88!Y/;.!ZD5_3)_P:VR^&8OVY_%W_``DWBKQ+X6\SPAX#B\/_`/"-
MP23_`/"1^)G^,'@G^RO"NO\`ER1^3X:U?%Q_:L[[XX_L\&Z-LC'\S1!'4$<`
M\\<$9!^A!!'J#FOZBO\`@U)_X2[_`(;G^)G_``B7_"'_`/)*_#'_``DW_"7_
M`-G_`/(H_P#"X/`/]L_\(O\`;_\`F</^/;^Q/L7_`!,/^/G[-_'7#7;C0Q#4
MXTVL/7]^4XP2_<S6LIPJ15]E>$KMV5FTU\]Q=_R3>;Z7_P!E]?\`EY3\U^9_
MH+?&#]L?]D/]GGQ-8^"_C]^U3^S?\#O&.IZ%;>*--\)_&#XX_#'X9^)M1\,W
MNH:GI-GXBL=!\:>*-$U2[T*[U31-9TVVU>WM9-/GU#2-3LXKA[BPNHXMWX+_
M`+4'[-/[2/\`PDO_``SO^T/\#/CW_P`(9_8W_"8?\*7^+7@'XI?\(I_PD7]J
M_P#"/_\`"2_\(/X@UW^PO[=_L+6_[&_M3[+_`&G_`&/JOV+S_P"S[OR>&_:O
MN_C5_9/P9\-_"+Q!XZ\`Z%X]^.?A[P/\;/BW\*O!_A/Q[\5/A%\--;\%?$!_
M#7C#P+X6\<^!_BOX1G_MCX_V?P0^&_Q!\0>(_A%\1]`\`_![Q[\1_B+K]IX"
MT+PEJ7QD^&GRE_P3`U;]M74M)^(D/[8GQ`^.?Q*UVQ\"_L[P:GJ/QB^#_P`)
M_@AI/P\_:)B\%>(+#]J_X)?#'1?A]\#OA+>?&3P+X'^(NGZ3XJ\,_M1Z)K_Q
M&^!'Q4\%?$;P9X`^#?B'6]=^"WQ9^)7Q0_"EAZ4L'4Q"E&-2FH7A*NW*7-55
M-\M)87ENE>3A+$QG&+C4:<914_PR.%HRP%3%*<8U:2IWA+$MSFYUE3?)1C@N
M6Z2<I0EBXU(0<:K3C*"J?N%\.?\`D!W7_85G_P#22QJE\+?^03X@_P"QPUW_
M`-M:YSP_;>.KC3K0^$M5\.Z?9+K-V-:36M-O;VZEA-GIYB;3I;:[BA20$,&2
MXAVC.[>^0L>S\(8[R+0-;2_N8+N[7Q?KWG7-M:M90RDO;E3':O=7C0A4*H0;
MF7<RE\J&V+^P\/?\B3+?^P:/YR/W?A;_`))[*?\`L$A_Z5(]6HHHKV3WPK\9
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M^AM?DA\3]8NK;_@L3^S-I<<<!M[[]G/XF0RNZR&95GM/$]^YC9950,)M`LU4
MM&X$<ER""SQ/#^M]>+X?9EFN-CQ?E^;YQ7SVOPYQAB<AHYEB<%E^7UZU"CD/
M#^8R53#Y9AL+A4Z>*S+$QC.-+FG!1;=K1C]-XV\/\-914\,,YX8X:PO">#XZ
M\*\IXQQF2X+-,ZS;!X?,<3Q3QADE6>&Q6?YAF>91IU</D.%E*C4QE2$*OM)4
MXP4^5%%%%?H1^(!7Y&_\%CO^4?G[=_\`V:O\6?\`U`]3K]<J_(W_`(+'?\H_
M/V[_`/LU?XL_^H'J=>7F?Q93_P!C[)O_`%/I'R?&?_(HI_\`8RR__P!/H_7*
MORPG_P"4I'[5?_9@G_!.K_UHC_@J;7ZGU^6$_P#RE(_:K_[,$_X)U?\`K1'_
M``5-KAXL_P"2?Q__`'*_^IN&*XV_Y)C,_P#N2_\`5AA#RG_@IK^R'XD_;>_9
M$\<_`SP9XCTKPSXSEUSP9X[\(W.NPSOH6J>(?AYXCL?%6F^&]9NK3?=Z1IWB
M.73SI$VO6]IJ<FAM=QZJ='UB.UDTVZ_B^^)_[97[=_@_0O'/[+GQ9\<^(?".
MH:%X2T[X`?$C1-;\"?#C2?C$/A]X5N/[0TOX3^)_C+IOA5?BUXB^'*17WVK3
M="D^(NL>!O$WAG65N=._MGPIX@CEU#_0^K\YOVV_^"77[,/[>.K^%_%?Q3C\
M;^"?'_A:U;28OB+\)-5\.>'?%VN^&<W$UOX4\4S>)?"7C'1M?T33K^YEU+16
MO-%.L:#=SZA'HFK:?8:WK]EJOZK]%OZ1W#_@QF>(ROC_`(*ROC3@O%XJ.;X>
M4\FRC,.(>&\^POLJN&S/(ZV9PC#]]5PF$6(I/$8><*V&P>,H8BG4PBA4_(LG
MSNK@HO!U:]6GA)N;4J4IITI334^:,&G5I5%=3@[N+;E!.\X5/XP_^'C7[:/_
M``K[_A6G_"[M0_L+_A7G_"I/[=_X0[X=?\+1_P"%7;=G_"O/^%U_\(A_PN/_
M`(0SROW'_".?\)W_`&3]G_T?[+Y'[NN?\.?MS?M$^&_A3\-_@A_:'PA\7?"_
MX0?\)A_PK'PQ\5?V8?V8?C/_`,(3_P`+`\23^+O&G]@ZU\7/@]XV\0VG_"2>
M(9_[0U3_`(FS^?\`9M.M/EL=+TVVM/Z;?^(<#]BW_HM7[7G_`(7'P5_^<!1_
MQ#@?L6_]%J_:\_\`"X^"O_S@*_M["?3L^B;@*=2E@?!;-,%2K8ZGFE:GA.!.
M`L/3JYG2PV,P=+,:D*.:0C/'4L'F>986GBY)XB&&QV-H1J*EBZ\:GT,N(<--
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M'VN^`FUZT99=(UG5=!\*_"[P9<:U<:'>+'J.F6.JZE=Z(NHPVUY>:5>36EJT
M/ZC?&'3OC@(=!\4?`[7_``K+K/A=M4EUKX5^/K06?@[XKZ;>I9,FDR>/=+T[
M4?%?PR\5:9)8O_PC'B^PTWQ=X9@35=9M/%?PZ\3M<:'JWA3^8OI+?2SX3\5,
M@_U`\)."L!P-PQGU?"9CQCF6/R;)<IS;/L?EU?$5\KP-7^R/K&'I83#5ZL\1
M]=Q&(J59XC$OFJ8+#QQ4ZWD9GGDL5%83#XN4Z52G.%7$8E57%0G'6A2A.-25
M-3Y8QE5Y(OFY4G3IQE4E[117A/PD_:"\&_%;4];\%R66M_#[XO\`@ZSMKSQY
M\&/'MK#I/C[PM:W5Q)9V^MVT5O<7FB>-?`^H7L$]KHGQ(\`:OXG\!:U<PW%C
M9>(&U:RU'3;+V^UNK6^MX;RRN;>\M+F-9;>ZM9H[BWGB<962&>)GBEC8<JZ,
MRD<@FOX*KX7$8:<J=>C.G*')>ZO!JI%SI3A4C>G4IUH)U*-2$I4ZU/\`>4I3
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M>:\];`X"3;QL\OI^ZLSK4[)8?!XFMS4<!*H_:8SV&*K0A'#TZ57$:M%%%:GC
MA1110`4444`%%%%`!1110`5Y%_P2B_Y1M?L3_P#9O'P[_P#3-%7KM>1?\$HO
M^4;7[$__`&;Q\.__`$S15^B<`_\`,V_[D/\`W</U3PS_`.9W_P!TW_W?/Q%_
M8=_Y-8^$_P#UY>)__4W\35]7U\H?L._\FL?"?_KR\3_^IOXFKZOK^CZG\2I_
MCE_Z4S\;XA_Y'^>?]CC,_P#U-KGD?C'X5_\`":_%;X-_$#5M=W^'O@S_`,+#
M\1Z+X)_LO;]K^*WBWPY:_#_PQ\1_^$DMM1M+Z#_A"OAAXD^-W@G_`(0^[LM4
M\.>)/^%O?\))J$%MXA\`>$KV#Y&^&W[`?_"E?@_\+_!?PP^+&_XG_!?XNM\5
M/`WQ1^)/@3_A+M&US^Q?@AXA_9'^'>A?%#X<^$/&7PRA\1?\()^R!J'A;X4K
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M?A]<?%C1_"U[H=[\)/BWJN@^*?"_BKXN_![2+#QPL_@+2-2\+Z?^S?X2L?`_
MAO7=*\37F@_LG?"#5OB9\5_BG\3+:Z^)">N>(/V<KT:]K?B3X8^-=(^$^H>&
M_P!EW4OV<OV9K?P_\.-!N-!_9LO?$=[-?^*_&NB>%4O]-\+^-](U>?P;^SI'
MIOPX\1:/;Z#X3LO@/#IWAF_T[3_B-XSM9_EWXV:_X?\`V&?%?POA^'/Q/^+N
MK^(?VA?^$U^%GA_X1?$CQ3^U)^VMJ6H^*](TW2?B##\?=/\``^I>/_BU\?9?
M"/P!\!^%_B/IOBGP#\"?#^D:;\5_%?Q>^&>B?%KQY\+/#VD:)\5_`AH?Q^^,
M'Q7M?@1X'\6P^+O!G_"5?MSZ/\*]0^)^F_!SXW_LH:S\5/`?PL_9M\5?MJ6F
MN^#/A'\;KO4/B#X$\(^(OB#\,[;]FOXFZ7XGUGQ_HWQ*\!Z%\6Y-%U'P_P#\
M)[I-MX$Q4J,&Z;A::DDU&HYWG.2E%N5U4O*552<YPC::C)NZI-^E*GF5>%/&
M0Q'/A)4I2C4K8.G1<,-AJ:H5E&BJ<\,Z=*E@_81PU"O4]K0E5IJG[.ICX0R/
M!'_!*_X;>`?C%\#_`!?H\'P+U+X;_L_?$6Y^('@2V\6_L\R^,_VGKNRT_P"'
MOCSP=\,_AQXM_:P\3_%K5-0\4?#KX$ZAXO\`#=W\$M,U'X6-KW@;PM\&/@EX
M93Q)J&M>`HO&VH??_P`"/A7_`,*7^%7A7X?W.N_\);XALO[<\1^/O&W]E_V#
M_P`+!^*WC_Q)K'Q`^+OQ'_X1N/4=5L?"G_"Q/B?XH\6^-O\`A#]%O7\.>$?[
M>_X1OPQ!9>'M+TRRM_.?V*/$&O>-OV3_`("?$WQ5K>KZ]XH^-'PZT3X]^))M
M6U*]U2+1]>^/BR_&76/!OA>349KO4-/^'7@'4/'-QX'^%OAZ_O\`5;WPK\-O
M#WA3PS=:QK,^DR:I=_45;4*5&,8U*5-0YXJ5KO13C3TM=I*T()):*VEKN_GY
MGCLPKU:N%QN*EB?JU5T>9Q@N9X:KB5&=U",I2<L17E*<VYSYU[24N2'+PWQ/
M_P"2:?$/_L1O%O\`Z8-0KP[]A_\`Y-,^!7_8CVO_`*6WU>X_$_\`Y)I\0_\`
ML1O%O_I@U"OYQ?\`@HSX9UKXD_\`!(/]F?X5>#OC1\(OAOXQU[Q+X/\`&$G@
M#XJ?'KP)\"E^-_@3P2/$=IXC\*Z)<_$7Q1X1\)^+U\)^+/%OPZ^(.J:-XBUF
MQT6Q/AO3=6BN6\66WA'3M3^,Q]5T>/LOJJ#J.'!.?R4$[.3_`+<X;2BG9ZMM
M)63;V2;LG_2O"N!CF?T1^,,!*O'"QQ7TH?".E/$R@ZD:$'X6>-3G5E!2A>,(
MIR?-.G!)-SJ0@I37].=%?PX?$;P_\*_C'^RQ_P`$6_@I\,_AY+^S;\$_VZ/V
MN/B#XG^//PW\`>+_`!%XS6?XH>#_`(A_"G]ER_\`B)X)\6_&&;X@^*_"ZR^%
M=1\6:AX7\'3:IJ_A?1O^$ALX/$EGXWU/0X?$%VRQ_P""QW_!2Z/P%JG[26L?
M'OX37OA#Q)%\=+-/@;I>O_L.^&M6^'S^(M&O/`GP5\1^#/`^I>(?&/[6/BB3
MX;_%37G\67W@KQI\-)UU3P/\._#>KZ]XZ\8^$?B!XDU[PM](\VIP=JE&?+R4
MYJ=%^UCRSITZLI-2C2G&$(UJ6O+S-RE[BY=?Q9>'V-KTU/!YAA?:?6,9AI4,
MPC]2JJKAL9BL#1HPE0JX^A4Q&)KX#&I4U65&$:=)K$5'7Y:?]R5>&?M*Z!\7
M/%?P-^(GA?X&:+\#/$GQ*\2:3:Z!I?AW]I73O$VL?`W7]"UC5]-T[QWHOQ$T
MCP?#<Z_JNDZIX!N?$]C:Z=;6\]G?:O/IMMK,,NBRZ@C?R(Z__P`%+/\`@HOH
M_P#PM""]_;?\5Z./@M^PI\#/VI/$NJ6W[-O[+/BT^./B-^T#_P`,^W_@SP'H
MNA2>`O!/_"OO"6DG]I[P-X3\3>)=0U_XCZNP\!^+/B)I.@2#QCHGPP\)?I1_
MP4I^/OQ+US_@DA^PKKWC+XYZM\)HOVN=<_9%\"_M5?&#0O"\=]=Q_#;XN_`W
MQ%XT^,6L2>&/!]II>H2Z/<:EI4>M:]X1\"MX?E\5:#;:C\/H0/#?B/4]&O:_
MM*C5IXCEIUDZ=*4FI.E"]Y.E9252:C:=TY27*DG)<R6O+_J;F.!QV4>TQ>7U
M8XW'T:5.5&&.Q"ART:>.4IT)X3#2K1GAI0J1H49NK-SC2FJ,Y/E\'M/^",W[
M7ML=&%Q^S?\`\$C-<M?#?A+Q3X%\,Z7XM^+_`/P5!\::'X6\*^,CXLGUW2O"
M^@>+OBCK>B^&PVK>.?%GBG2+W0["PU#PUXXUNZ\>^&KO2/&B6^O0MB_X(R?M
M>?\`"5^&?&NI?LW_`/!([Q1XA\(CP9#HD_CKXQ?\%1/B!IZ:;\/;#2-(\%^'
MM4T#QO\`%+Q!X?\`$/A+P]H.@Z-X:L/!WB'2]4\+#PKIEGX5FT>7P]"FF#FO
MVW/C9^PW_P`$_P#Q9J_A+_@E1=_"7X7_`+?^I^+_`(;_`++?Q+U>TNO%=]X5
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MZ&9U:=?!5JTH4Z=58^,ZSJ.LJ#2M+^@:S_X)Z?\`!1RSL/VH-*_X4C_P1VO]
M,_;,UF3Q'^TCI^M^)?\`@H%XALOB'X@.N^)O%-MKD-MKWBC48?!&KZ3XG\7Z
MYXC\/ZE\/$\)WGAO7I--UC0)M-U'0-`N=,^>8?\`@B3^U#!H6I>'8_V5_P#@
MCPUEJNL:)KEU>3?%#_@IQ<>(X[W0+'7]/L(=.\7W'Q,E\6:/I$]MXEU(ZUX?
MTC6K'0?$EU;Z#?\`B+3=4OO"OA>YT?Y,U_\`:X_:3_X)Z_LY?L1_"_X._M4Z
M3H'P=U+]EOX1>*O'MO\`#FW_`&1_&_Q<^%7QF_:3^*/C']I+Q'J'BK]GCXG?
M\);\8?%>B>'O@'XYTWP]H,9U_P"#O@/Q5XEN_!/BJ3X@>%VU2]\&Z]_:9X`T
M?Q5X>\">"M`\=^,1\1/&^A^$O#>C^,OB`/#VG^$1XZ\5:9HUE9>(?&(\)Z1-
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M^TW^V(/@[_P6E_:7_;F\)>!?%FL>'/@/XP\>?`W3[C5_#(O_``W#\=M)_9+^
M(O[/7@K3/%LVD^)=/M(?"OB;XI>`M=\16UO'XJTCQ?K'PMT#Q-K&DZ3'X@T>
M_P!$L*QD,/@Z5&$O:2I5*\82I\\5"$=9SK<BI24N1Q4FK)MR;YDS'AS%9QQ%
MCLPKT%@J&/P>65:]/%O#5JE?$58^RPN&RYXEXZE4I1Q,9NC&?/4C"$.3V,XM
M)?H?K'_!&+]JS7/"G@SP9>?LG_\`!&"WT?P&GB&/0[K1?%__``49\.>*;Y/%
M&I1:KJB>,_'7A[QSI?C?XC)#=0HFA+\0O$/B@>%;!I=)\+C1]*GGLI-7P[_P
M2`_;)\(?%G0_C?X3_9I_X([>&/B/X8^(ME\5_#6I>'_B!_P4DT;0?#_C?3/$
M5OXJTR_T3P'IWC^W\`Z5I&F:W:VTVF^$;'PQ!X/T^RMX='L]!AT:)+!?P+_8
M^^.7QB_9I^.?[1OQ<USXV?M/_!+X[Z-HNL:5\8O%/A7]EOX<?M,^,(['Q'\2
M]"B^*<OQOA_:"^*WPZC^'NJP_&&/X=:->:_JECKFOZSXUUQ]!U'4-`U*[2Q\
M2YGBO_@H7^VO/^T9X9_:C^+'Q!\71_M4>`?A#X<\,_!3QO<>`_A1X,C\*>'/
MB'!<^)]'UC6/AY=_!ZZ\*>.O"7C#X1?%'QU=^'IY-(T74[V7X@^%/'.E^,KW
M0/#NG>'=;\I8K`*,)SPU:,^>*TE0ERQIM14K\BFIQ46H0E"$6TTJBC>2^ZED
MO%4ZU?#T,[RZM1CAYN\Z6:TG5KXF$:LZ3@\5/#SPM2=2$L5B*.)Q%2,9JI/"
M3JRA1G_2;^R7_P`$H?VJ_P!FK]I+X0?&W2/@)_P2\\%CP5XOA/B#Q+X`^*?_
M``48\2>.]*\!^)[>Z\*_$P^!-#^*'Q&U[X>7'B^_\`:[XFL/#G_"4Z1<:-;Z
MQ=V=S<^0L(N(OZ5:_CB^.?\`P6(_:GT'0OV_O%'PA^.>JZ[X9^%7QU_9P_92
M_9L\10VG[.'BS0@U_:?%C4/B!^T9J&K:5\`[6P^)&L?&"P_9@UB^T;P_I]QH
MOPX\)V7QW\077ARRU*#P=X(DL$_:(_:__P""LGP1_::_:2_9KT?_`(*!_#_Q
M+J/P$TGX57&C>+OB%X0_X)W?LX:;X]UWXG>&?`_C?^S;C2_CMXJ\&7&GZ+HG
MAC7?%:7&L^!+[XGW]OK^@>%]+U_1?#]A\0+;7/#OIT<;@\+"4:%'$S@ZFO)"
MC;G?M8*T5.#;G'#3E=1?NJ/,U)J*^*S+AKB+/<11JYIF&3X?$PPO[OZSB,R4
MWAHQRZM/GK2PN*A".'JYSAJ,H3K4[5JM:5.,Z495G_8]17X0?\%@KJT^(?[0
MW_!,3]DCXD_$K5O`_P"S1^TS\<_&MO\`'+PQIUAKUQ9?%N]^'VH?"&Z^%7PO
M\0W7@^[TCQ;:Z/XY\8^*'\%Q7=IKEGH?A?7/$^B_$W6K2ZN_AWHE[I7QG^T;
M^U-^R+^R?\&_C7KW_!%SQ!\)O!GQM^*W[7?P.^"?Q^\9:8FMQ_#+PG=>)+?]
MH3Q-X5U+P%J/QWNH/V8/#GABYUCP9XPT*T\3>$8;GX-:!X"U;4=2#Z1IMMX(
M\1Z)VU<=&E.LI1AR4;*5ZJ5:I+V2JM4:'+^\LIP3<JD%K-[0][YK`\+UL?A<
MOJ4:M=XC,U*=*V!J2RW"45F$\OC4S+,_:I85SJ4,3*,*6%Q,GRX>'Q8E>S_J
MKK\KO^"HG_(#^`'_`&4G6_\`U$[ROY-_$7QQ^,'Q;_:1_:Z^-7[5'QK3XQ:M
M^R[^PU^T!X'\"^*O!NA?LZ:NWC+PW\>H)_V8OA/I.I7G[.GQ!U3X,Z--IOB+
M]L>V\?>/KKPWXX^*6H^&/[#\1^`DN?$6KV5K]A_;;PU\*_\`A3G_``3#_P""
M8/A#^VO[>.J:5<?%!KW^S/[)^S/\<-&\0?&J30S:_P!H:GYI\,O\0&\-G4_M
M,?\`;1TDZS_9^D_;_P"RK+YGB+'K%Y36A&C*G&.89'+FG.+G:/$.50CS0BFH
MN4G46DY6]GK?F5OZU^B'PI_8/T@.#L54S*EBZU;A'QDHNE0PU6-!2K>`OB;B
MJCI8JI*+JQHT?J4KRP])U/KBLHNA-/\`O3_8A_Y,N_9#_P"S7_@#_P"JH\)U
M^`O_``4-:=/@'_P<I&WN8+20VNCJTMRR+&\#_P#!,O\`912YME+I(IGO;9I;
M.U4*'>ZGA6-XI&61/WZ_8A_Y,N_9#_[-?^`/_JJ/"=?@)_P4-2:3X!_\'*2P
M6T%VXMM&=HK@*8TAC_X)F?LH27-RH:2(>?96ZRWEL0Q87,$12.5@(G\'&\WU
M;W5>7U[).57:O+^WLKLKQ4I*[ZQBVMTF]#XGBSE^IY=S<G+_`&YE7-[3D]GR
M^W=_:>T_=\EOC]I[G+?F]VY_EAD`8P0<@$XSP3V.0.1WQD>A-)3AD;OF*90Y
MSN&X$`A?E!R&!!&["D<D]*"=P'W05`7`&"P^8[C@8)'`))!/R]3DUU'U`^.%
MI&V`JK;@K>:Z1*F6"@LTC*``QPY(`3C)YP+,%O(KC<VS='<$!0TFXPQ^8\;>
M6K@?+AB3E4&&=HP-ZS64EQ;1_P"I5H+L@;Y%"I(+=O,>/SE0RJNY5++&Z'@'
MW$^]Y8S`9#A))743/+^ZP-YBB&XIB=G7Y4BV@K&YD"><X^@X<P$,;F>%=;$4
M,)0HXBG7JUZ]>G24:6%4L7B>2G).564,-0J3<DX4J+4%5FI5:,*F5:3C"5DY
M-II))O67NQN^FK7=O6RT;7VKX-O;OQ-X;T1+!K*+Q-X?T]#'=W=C;S61?4([
MV"*PL+J":YNA%);6MNNH7-L(;@021>4;C>)V]&M_`NG3M9W\V@Q6=]%<WEW=
MQ?;)]0ANI;V-C+#.VJ[FGCBN)YIUNHX;:XNG2WDNF+K<QS^)?`>\NH9+C2+5
M9UM)H/M#Q!8(O)DTXR;;ZZFN+AF4E[NX66&PED:VNKV.RGA8:=<7$'WGX3;0
M]1T)DDT/1=0UR%K73[:VO?$>KZ?JNI7U]?26]M>P6,9AL;VQ4W-I!-#!>6<U
MN+"\GN[E1=V[I_L+X#Y!PYX@<*Y-F7$7]J5E@JL<'@*&$Q6&^H8JKDU+!952
MKUXXQO"0J891P^(6$G)P@L70Q#I59JA7C_+7C5Q)G/AUQ1FF'X8QF(P66<0X
M/!9C7CDM3#8/%0H<2+Z]CL'C,;"KELZV`AFL\9*A#$2A+!T,3+#4:&%HU<1A
MW]#_``V^(O[&.D?"V3PCXW_9Y\3W'C-/#^J6J>.M(O6N;FX\3ZDUS=_VN=,;
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MQ6<0KXC#9QB,1.G4Q.`J8G-Z%*%2456K3QF8-8"GC\/BJ].M3G0H4\94PV'P
MZI?##6TE_-)(9+>)VC!6-8DB\V4"-4AAAMH@GF2!@RJJ*0NXE0B%JRG&UF4@
M`J2IQG!*_*2,\\D9[=>`!@#H@^FF7F%[8LJ>3%,7F.V.&(X^T(T$@>_D$H,B
MQ116_F$0QR>8'M,>01(D*F,Q2,6DD<,^_P`IE4>5M)9!R)`AX;#`3'J1_B]Q
M!@Z>%S7'PISPT4J]6I["C-R]BJE2,XT7:>(IQJ4U5]G.E3QF*Y9T*TO:NFZ3
MG_?-*3E"+:>R5VM[+?9.SM=-QCNM+W*JHS?=&<LJ=0/F?.T<GOM//08Y(K^F
M;_@UPM_#A_;H\7#Q1X3\3>)_+\(>!)/#_P#PCDTD`\.^)X_C!X(_LKQ5KICC
MD$_AK1\S_P!JPL4CD^TV^Z5<#/\`,T^TL61=J$X`SD\`9)!)(SG/)(Y*@G:3
M7]/W_!JS?:G;_MS_`!`%G\2K3X>>?\-?!]E=_;A)+_PG6FR_%[P$)OAM:&-)
M=EYXF1(DMVD*1QKIYC:1`JJ/GZ]E0Q6LIVP^(Y?9NK'G?LYJZE3BZT8\MY7C
M3;=E&48Q<I1\#B[_`))K-_\`L%ZVT_>4^^GXG]R'_!1GXQ6W@'X::9IFB_#'
M]N;Q_P#$6S\=>`;CP+J_[&WAG]H"#_A7'C7QEH'QAM_A]\4?BOXB^%7@SQ[H
M7CWX&>`M=\!:C<_&OX<W_P`'_P!KO2=$_MCX6WWQ*_9$^*]GXX^''A?Q:?\`
M!.7XM?'?XF^"O%]G\>/&'CKQ1KOAC_A'_L-K\2OV4/VB?@;XUTC^VM6\<2W/
M]M?&[XP?LP_L-_#K]I3^T+.PT>33O^%-?L6_`/\`X4YI-O8>$?B)_P`+3UW5
M],^*_BWN?V[O$O\`9_A/X)^!/#^E?'/4OC%\9?CFGP]_9WN?@=\:/^%%_P#"
M,_&K2O@K\:OBQHGC?XP>*[W67\+:S\#/`_A;X8^,/%?Q`\%>./A/^U!X3\3?
MV1I-M=_LI_'W48=+\":AW7[)OA+]K7PCX*N[/]K#XH>!?B)KLGD?\([:Z!I]
MEKWC7P[LU;Q'+J__``G_`,;O"_P[_9L^'7QA_M:SN?#DGA7_`(0G]BW]F;_A
M7VDV,WA'Q)_PN;78;CXKZ[^&-TUER3A"-24[PE.I&5:2YTG[*G[*<HTKPGS3
M4L.G*/(YU6G"?XBW265).%.-652\)U*L95YQYTI>PI>QJ2A1<H5.>HIX5.<>
M1SK-2A4_17X<_P#(#NO^PK/_`.DEC5+X6_\`()\0?]CAKO\`[:USGASPO?Z[
M96=W9^+O$7AR+3M:G>ZL]%EM$AU1/LMB5BNA=6URH'S-N8(Q8+&!M57$NS\(
M;>2TT#6[>6\NK^2+Q?KP:\O?LWVJ8L]NP,OV2WM+?*A@B^5;Q#8JY!;<S?KO
M#W_(DRW_`+!H_G(_<^%O^2>RG_L$A_Z5(]6HHHKV3WPHHHH`_'+]K&]\7?"/
M_@H;\"?VBK?]GC]H/XU>#O#/P.\:^&[N\^!7PWU;XA7EAKVM7>IZ;8VMY':W
MNGZ79R6]GJ.H33Q:E>P22VM_#/:17DD)-GZUIW_!3OP</''PQ\#^-?V5/VU_
MA+-\6_B+X3^%OA'Q'\5_@II?@CPK+XL\9:O:Z1I5O=:KJWCB-VBA>Y:^OH],
MM=3U*+3K6[N;;3;HPF,_IG7Y1?\`!56YU+PWI7[&GQ,A\,>*/%.@_"K]M+X2
M>//%EIX/T6Y\0:Y!H/ANWUS7KZ6VTJSS/,\EII%U#!(_DVGVU[6UN+J"2[M_
M,_%^*,KS[@;!<7\79'Q+'#X3'9UA>(\QRBMD6`K4%*K#),GQ\WC>:.(ITHY?
M@(XBK5<7*$X5:TY6<F?UQX:\0<%>,N=>&/AAQGX??6\TRKA#,>!<DXIP?&>;
MY;7]E@(<6<3Y'#^R)0EET\34SG,Y814O;0IXA5H0C&,Y)'ZNT5^5?_#W#X&_
M]$6_:L_\,GJ/_P`M*HZC_P`%B/V;]"MCJ7B;X:?M+>&=&CF@BN];UOX/W5AI
MEE]IF2WA>YN;C6(T56FD1%52\TC,$@BFF9(G^G?BQX:1C*3XYX9481E.3_M;
M"OEA"+G.3M4VC%.3?1*^Q\!3^B]](*M4A2H^$W%]:K4E&%.E1P,*M6K.32A"
MG2IUI3J3FVHPA",I2DTHIMI'ZQ5^1O\`P6._Y1^?MW_]FK_%G_U`]3K]:[6Y
MAO+:WN[=B]O=00W,#E60O#/&LL3%7"LI9&4[6`89P0""*_)3_@L=_P`H_/V[
M_P#LU?XL_P#J!ZG7UF9-2>423NGGN2M-;-/'46G\T?RUQG_R**?_`&,LO_\`
M3Z/URK\L)_\`E*1^U7_V8)_P3J_]:(_X*FU^I]?EA/\`\I2/VJ_^S!/^"=7_
M`*T1_P`%3:XN+/\`DG\?_P!RO_J;ABN-O^28S/\`[DO_`%880^IZ***_&3\!
M"BBB@`HHHH`^*?V]_P!GCXC_`+17[/GBKPU\`]8\&?#_`/:6L+.5O@5\;?%&
MI^,?#NH?!GQ'J4]G;ZQXK\-^)OAX@\96-_<:'#<:?)I5K._AOQ`TEK9^-]&\
M4^%X]0\,ZK\I_P#!&+]E+]MO]AS]FW6_V6?VPO&/PO\`BCI7P^\77VK?`GXE
M_#?QIXP\4W%UX&\7W6H:OK7@KQ7:>.?!WA'6]-OO"_B4W>KZ5<1#6+"?3O%C
M:);W<4'AFWDOOV"HKT89GB(9=4RSEHRPU6HJK<X.56-13A)2IU.:\+<KBH)>
MSM4JODYZDIOO68XA9;4RMJG+#3Q%/$QE.#E5HU:;5G1FY<L(R@ZU.47"2<<3
M7:M4E"I#^2C_`(*#?\%JOBKX-_:W^._[*GAGXS^'_P!D[PK\%_$NF>#K?Q3!
M\*=&^(7CGXE2WO@KPWXFU?64\:?$O0/'OPA\-:?'=Z]-H>G>#;SX;7VOW$>F
MW>JMK6IQ:@EAHGP3I/[0_B+Q4/#NF>'_`-OWX^:_X6^R:C:V]E\+OVP?$?P^
MT&W-JMUK`!M?@CXU\#6>G638NFM(?"EKH%E8?88-*FAN]-U`64/P[_P5OTVR
MO/\`@IQ^VS+<P^8Z_&"QC#>9*F$'PV\`L!B.11U9CDC/.,X`QX=^Q%^QQ<?M
MD_M<?`_]GKP9=Z7X/\5?$KQE'$OCN[TVYU>X\(:/X6TC4?&7B;Q9;:?!>6-S
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MG:)))J%]!>0LMJS6R"XGNH+.Y^6_VB_^"-7P_P#`G[>'[-_[+?@[QY\.OBEX
M/_:E@_9X\2^%OCYX5^'&E6>C7OPZ^/GB6#PK:?%[2O`,/BR]TN?PS;:A!KLV
MGZ3H?Q!N=)U9M+L(['4_"\'BOP]H=C\R?$W_`()W?%#P[\4_CO\`!/X(?L\?
M$GXT^!/V<?VB_&?P+UGXA_##X%^+=5T;Q%\1O#/CC4/AIHNJZ\WA+3O$MEH7
MB;QA<O:6WA'P=>:_J=[I4'B*WT+2+K5;[5K_`%/6^G`\,X#BC"4,+DM;A+`X
MS$X1U<UCF-.GAL1POA9SGAXSS'!XO+Z4EBL;.,HY+#DJX?&TI4\U2K99[/ZS
M]GEO@MPO%8;%XG&\!8K)L;D?]MY#S8/'Y9@<[P%6O+`8*56OC>'\(L#A:6,C
M*CFV73G0SFA+#U\J]C@<9*>*P7Z:Z?\`M,^)OA7>W7BRS_X*,?&3P3J][!HE
MOJ6M^(?VI+?Q5;WDFB6WV'2VU7_A<VI>/(/$KVZ7/D02^,G\1WDD,D%K<7-Q
M$L25^B__``3)_P""S/Q1^,W[8OPF_9`\;?&;P]^U/HWQ=3XDV5M\1/\`A5%I
M\-_'/@'5_`?PU\5?%*SGUWQ1X(TSPC\)O'%CK6D^%+W0)=%\-?#CP]JNGZG/
M'K,^JP6ENVBW7\Y'_!03_@FQXR_X)X?M`:I\)?'GAW5==T2*UT%O!'QK/P\\
M3>"O`GQ0O)OA_P"!O$_C>V^'&LZR9[3Q/:_#S6/&\7@G7[O2-6NY;6]M83J]
MCH5UJ"Z/;>V_\$0-/M[/_@K9^Q:]K`8U?5?C\LK;I77</V4?CJ8U)D9PI(\P
MJ`06`8\[>./C'P6X=POA;G'%.!GD.(P6!X=J9IE-3+<NQ%+$->PHRHUGBJ\Z
M-6-><TOKZQ&"IXBM.-1XF%/$N:A^5>*O@7D68>%G%/BA+$\+YCR<,2SO*\7D
MF35\%7=&EA*5/+:5&M)X-87#8.#CAI9;/*\-#"T:/U=83!U:2I4/]'*BBBOX
M-/\`,$****`"BBB@`HHHH`****`"O(O^"47_`"C:_8G_`.S>/AW_`.F:*O7:
M\B_X)1?\HVOV)_\`LWCX=_\`IFBK]$X!_P"9M_W(?^[A^J>&?_,[_P"Z;_[O
MGXB_L._\FL?"?_KR\3_^IOXFKZOKY0_8=_Y-8^$__7EXG_\`4W\35]7U_1]3
M^)4_QR_]*9^-\0_\C_//^QQF?_J;7"N1\=^!/"GQ+\*:KX*\:Z5_:_A[5_L,
MLT,5]J6D:E8:EI&I6>M^'_$7AWQ!HEYIOB'PIXN\*>(=-TOQ/X-\9>&-4TCQ
M7X-\5Z1HWBGPMK.D>(=(TW4K7KJ*AI---)IJS3U33W375,\F,I0E&<)2A.$E
M*$XMQE&47>,HR33C*+2:::::NG<^78?V-_@)%H.I:)-I'Q%U/4-2U?1-;'Q&
MU[X^?'[Q'\=-&O?#=EX@TW0(?"/[0^O?$[4OCMX(TC2-+\9>/])L?#_@[XBZ
M%H-OI'Q-^*^E)IHT_P"*GQ$MO$VOJ7[)O[/^K^%$\%:EX`^V>'O^%1?&GX&W
M4,OBKQK_`&EJ_P`._P!HO4O"^M_'2W\1>(%\1KXA\2^+OBIXA\'Z)XG\9?$[
MQ!JFI_$[5_%?]L^*9O&'_"0^)_$VI:O]%T5G[*E:WLZ=K6MR1M:ZE;;;F2=M
MKI/='0\?CFU)XS%N2G[12>(K-J?(Z7.GSW4_9MT^9:\C<+\K:"BBBM#E.&^)
M_P#R33XA_P#8C>+?_3!J%?&?[.?P`^`_QT_9+_9M7XV_!/X1_&)?"_@BY/AI
M?BI\-_!OQ"'ATZU>J-8.A#Q;HVKC2#JPTK2QJ9T_[.;\:;8?:O-^QV_E_:_Q
M`L;O4_`7C?3=/@DNK_4?"/B2QLK6(`RW-W=Z->V]M!&"0#)--(D:`D`LPR17
MYU?`#XQ?'CX/?!KX>_#'4_V./C-K%_X,T"/1KG4["_\`#<-G>O%<W$PG@AN+
MGSHT9)E!23)5@PRPPQ_.L^S'"Y/QME&89C2QSP%3A7.\%[?"Y1FF:4UBIYOD
M&(IT:BRW!8R5*<Z6'JU(>UC"+5.5G=6/[,\)N#,^\2/HP>(7"'!F8<*KBO"^
M/GAAQ.\JS[Q"X%X#QD\APGAWXM91C,SP53C;B7ANECJ&'Q^;Y?@\0L#6Q%6G
M/&TE4IJ$G)?=&J?`#X#ZY_PJS^VO@G\(]8_X48=./P3_`+4^&_@W4/\`A3QT
MC^PO[)/PL^UZ--_PKXZ7_P`(OX:_LX^$O[(-E_PCNA?9O*_LC3_L_(7W[('[
M)>J:CX\UC4_V7?V==1U?XI_:_P#A9VJ7WP3^&EWJ/Q&^W^*M*\=7W_">7UQX
M9DN?%_VSQOH>B>,;O_A()=0^T>*M'TKQ#-OU?3[2\A\F_P"&K/C3_P!&3?''
M_P`&?A7_`.2:/^&K/C3_`-&3?''_`,&?A7_Y)KN?'G"KWEF[OO?A'BO73E_Z
M$?\`+[OIIL?*1^B;X]PLH4_#J*6RC](CP"C:]3VKM;Q25KU7[33>H^?XG<]P
M\4_LP?LT^.==\;>*/&O[/'P,\8>)OB7I.DZ!\1O$7BGX2^`?$&N^/]"T&\\,
MZCH>B^-M7U;P_=ZAXJTG1M0\%^#K[2=.UVXO[/3KSPGX9N;.&&?0=+>U[#6_
MA#\)_$WPXB^#GB3X8?#SQ!\(H-(T'P_!\*];\%>&M6^'$.@^%9=.F\,:)%X'
MO],N/#$>D>')M'TF70=-32Q9:/+I>G2:?#;M96QB^7_^&K/C3_T9-\<?_!GX
M5_\`DFC_`(:L^-/_`$9-\<?_``9^%?\`Y)I_Z^\+:^]G'O)J7_&(\5^\FVVG
M_P`(>J;;;ONV^XO^)2_'EJFG1\.6J,HRHK_B8;P!:I2A&$82I_\`&TO<E",8
M1BXV<8Q@DTDK>M:-^R#^R9X<\)^,O`7A[]E[]G;0O`WQ%/A\_$'P7HWP3^&N
ME^$_'1\)ZC)J_A4^,O#MCX9@T?Q.?#6K2RZGX?\`[;L[[^QM1EDO=.^S7+M*
M<C4OV(/V+=9LM`TW6/V0OV7]5T[PIHTOAWPO8:E\`?A1?67AOP_<:_K7BN?0
MM`M;KPG+!H^C3>*/$GB+Q)+IFG1VUE)K^O:UK#P-J.J7US/YY_PU9\:?^C)O
MCC_X,_"O_P`DT?\`#5GQI_Z,F^./_@S\*_\`R34_Z]\*62_X5K)62_U0XJLE
M?FLO^$/1<VMMKZ[FB^BCX_)N27AZI2ESRDOI%>`:<I\D::FW_P`13NY>S4:?
M,]>11C?E21Z)KG[$?[%_B>_M]4\2_LB?LP>(=3M-)\/Z!:ZCKGP"^%.K7]MH
M7A/0].\,>%=%M[R_\)W%Q#I/AKPWH^D^'O#^G1R+9Z-H>EZ=I.G0VUA96UO%
M]/U\.?\`#5GQI_Z,F^./_@S\*_\`R31_PU9\:?\`HR;XX_\`@S\*_P#R351X
M]X6C=QEG$7+5N/"7%:N^[MD>OS,JOT2O'BNH1K4/#BM&FFJ:J_2&\`:BIIJ*
M:@I^*+44THIJ-DTH]D?<=?.VL_L@_LF>(O\`A*_^$@_9>_9VUW_A//&%M\0_
M'/\`;/P3^&NI_P#"9^/[/_A)?LGCGQ7]M\,S_P#"1>,+7_A,_&'V;Q-K'VS6
MH/\`A*_$OE7J_P!NZI]J\E_X:L^-/_1DWQQ_\&?A7_Y)H_X:L^-/_1DWQQ_\
M&?A7_P"2:<N/N%Y?%/.96O;FX2XK=KJSWR/JM'Y"I?1)\=Z+;HX?PWI.7+=T
MOI"^`%-OEDI1NX>**ORRY91OM*S6MF>AZ_\`L0_L7>*]>UOQ3XI_9#_9?\2^
M)_$NKZKX@\1^(]?^`/PHUG7M?U[7;N:_UO6];U?4?"=SJ&JZOK%]<7%[JNI7
M]Q/>ZA=SS7%W---*[MD_\,!?L(]?^&*?V2<[53/_``SA\'/N(5*+_P`B;]U2
MJE5Z*54@`@5R7_#5GQI_Z,F^./\`X,_"O_R31_PU9\:?^C)OCC_X,_"O_P`D
MU#XZX3;N_P"UFWJV^$.*KW[_`/(C\D="^BG]("*48OP_44DHI?2+\!$DDDDD
MEXIV22LDEI:UCW#0/V8/V:?"FA:+X7\+_L\?`SPWX9\-_$;3OC%X=\.Z!\)?
M`.CZ%H'Q<T>SAT[2/BGHND:=X?MM/TKXC:7I]M;V.G>-[&W@\36-G!#;6VIQ
M01(B['BWX`?`?Q]X\\,?%/QW\$_A'XU^)W@G^Q_^$,^(_BWX;^#?$?CSPC_P
MCNL7/B'P_P#\(QXOUC1KSQ#H/]A>(+R[US1_[*U&T_LS6+JYU.R\B]GEG;YW
M_P"&K/C3_P!&3?''_P`&?A7_`.2:/^&K/C3_`-&3?''_`,&?A7_Y)JO]?.%K
M6YLXLK67^J/%=O=VT_L.VG3MT,O^)3?'IS=3V7ATYM33G_Q,/X!<[52W.G+_
M`(BE=J>G.K^]I>^A]/\`Q-^$'PF^-6@6OA3XR?"_X=_%KPO8ZM;Z_9>&_B;X
M)\->/-`L]=M+2^T^UUJUT?Q5IFJZ=;ZM;6&J:G96^HQ6R7D-IJ-];1S+#=W"
M2<CIO[,/[-6C?#;7_@SH_P"SS\#=*^#_`(KU:+7O%'PITWX2^`;'X;>)-<MY
MM%N(-9U_P+:^'XO"^L:M#<>&_#L\6HZCI=S>1S:#HLJ3*^EV+0>'?\-6?&G_
M`*,F^./_`(,_"O\`\DT?\-6?&G_HR;XX_P#@S\*__)-#X]X6;<G+.&VG%M\(
M\5MN+W3?]AWL^JV%'Z)?CS"$:<*/AS"G&<:L:<?I#>`,81J1:E&I&*\4E%34
MK2C-)23LT[V/0]-_8@_8MT:Q\0Z9I'[(7[+^E:;XMTBWT#Q7I^F_`'X46-CX
MGT&SUW1?%%IHGB&TM?"<4&M:1:^)O#?AWQ%;Z;J4=S9P:[H&BZO%"NH:58W$
M'QQ_P4ET#0O"G@;]F;POX7T72?#?AGPWXSNM`\.^'=`TZST?0M`T+1_`\VG:
M1HNBZ1IT-MI^EZ3I>GVUO8Z=IUC;P6=C9P0VUM#%!$B+]"?\-6?&G_HR;XX_
M^#/PK_\`)-?'W[7?B3XW_'[2O`$DG[,/Q0^'FB?#?7-=\8^(M?\`$=QHMY90
M:5'X=N[>XD*:=.TD<=M&);FXE;(2./`1LDIY.<<5Y'FN#I9;EE/.*V-Q>:9#
M2H48\+<2T%-QSS+ZDE*K6R>E1IPC",YRG5J0IPC&4I2239^_?1G\"?$WPW\8
MLIXWX^QWAWEG"^2\'^+BS#'OQU\%L[JTZ^;^$''.19;2P^5Y-XB9GFV.Q6.S
M/,<OR_#4,!@<3B*M7$481IN-W'^Q3]B'_DR[]D/_`+-?^`/_`*JCPG7X`_\`
M!1$*?@#_`,'*(:SDOAY.A$01M*C(R_\`!-#]DYDO"859S'ISA=0E4@1/%:ND
M[)"TC#]_OV(?^3+OV0_^S7_@#_ZJCPG7X!?\%#Y(HO@'_P`'*!FENX4>+080
M]DRI,9+C_@FC^R=!#&Y=E!M)II(XK],[I+%[F-`7908Q,)5*-.G!<TZF8Y%"
M$4DW*4L_RJ,5:5T[MI6:L^NA^%<57^J9;92;_MW*;*,IQDW]8T494Y1J1D^D
MJ<HS3UC)2LS_`"Q2&(W$,1D+N.2,@<+GID*!@9X`]*UK'2-2O+A8;2&=G9H5
M9HXK@[%G^9'E"1EXXRH,@:4(K(ID4E`6'=^!?`%YXDO`TFG:I)IL<<;37D-I
M*0MS(XELK9=A98TU**)X;:[N'L[-9&EFN-0L[*UN;R#[I\/^%M*\-6[C2K/[
M.DL4%I<2;V+RQ1*Y^RF5?*?[-*"3/;1".VEV0%X1Y-N(_P"FO"KZ-_$OB'2J
M9CBZKRK*J-5TI5&I<]10ITZM>I3KT\/C:<8X>,G"O'V%2<*DH-KD524.;B[C
MO(.":6'_`+7ACL5F&.HRQ&!RK`0H0JU*"<5"OC<5B:L%E^&Q//?!UJ>%S"KB
M/957]6IT72KU/AJR^%_C6_-N[^%]96SF1EL+L0R+%(P),`B*&?SUFE"0.;99
M'C>99`6*A'[NV^!NO>9"=3CMH0;T)<M8RR:E!)-*RLB1W5M<S2I8,+JU%Q<I
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M+%4:<E4\0\*>!-`\%:EI$=C9ZA<W=S:WS).]HE[IT%VAMC*UQ<1P2SZ?=W$+
MSVUDTUTL=S:"ZM&ED=K2-_J+P#X=UB[EU/Q',FLPZ5X>M;NZU/4-&EAM=4@A
M$*(ZZ;>3.D)"&\B:]BWK$ELYA5Q>7EE;7?![HK.SEM#-$DTSQS/*D$;W*-"K
M;8HIP@N(8765M\/GQ0W#^7+,CM!#Y7OGA/5;3Q=I-EX3TC5;OPJVGM-=VD%W
M-;:P?$%O-+>3:A:7D'V'28;B.S>9=]DSRVMW:2S_`&JQNTM_/@_L+@_@_`<$
MX*AE>7U\+@G@*6$Q.+P%'$4JU#!4J\JE#,ZN9X3`UECL7FBE4H1CB*E*I0P]
M;,%B:BQ?LZJ7\X>(W%^?Y[3>:9C5EC*LX4\%CLSQ,'.C@\JHN3OA\%@Z%-X>
MA&E/ZK0PV!P]2CA[3QM50I1G3?$^-/#>FV+6VN>&=074?#VIF06GDS2R1Z;>
M^5%="POI5&\,T,R2VT%Y(MZ(%GBN;=I+=[JX\>U>WM]5T^Y@O-.?5<HYFTH"
M7?*8F:7;;227=O';RRLL4*,UQ:^3,%D6>VVB5?M#3_"NB>'_``UXJ776,,%X
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M>:&.W%^OVF"*ZDEMEU*PLO(_<WUU*MA`+>*#C;SX0>-8&N["WTEUCCDC42Q_
M;IHYV$:N9C)#;W%O*98I0,02RQVI$EJ6,XN6;[WBM9920JDC,B[EPR[XTW!2
MP;:`Y*JKD[3NRI;!%=-;>']6T^WCU;4=/OFT#;#+=7%LK26<L-Q)%%Y8U&*W
MO+""X9W6V<L)Y+6[!M+JV$\<ULO\45OH;>'G$%:K4IX+.^%\NQ*G1AC\!/"P
MHY?3C'"U*]6M6S9>SDE'V=1UE4IS6&J8J%.EB82KTW_4E+Z06:8.AAZ.89+D
M>-KVJQE6CB<9@<;C<15J)X>%&G#$3P$%1CS4*=&&!<JKE3G6K.K%U)_DSJF@
MZWH)FAU/3[S3RS&`K+$T>]HF8,TBRA)XHY1')-")(H_.B(D7,0!/]+O_``:K
M6FH7?[<_Q"^P?#>R^(WV;X<>$;N]^VO(G_"":?#\8/`GVGXD6GER1[KWPON3
MR$??&WVY]T;8&/S5\6^'O"WBJ/5=.?2I[C27>Y6TN;E$-_':M([6S,\)"6=R
M@2&=Y(#Y2S1*R1LJE4_4W_@VM\-^'_"?_!03QS:>)O$WB/PI:OX;\'6OA<^&
M=/N4/B/Q(GQE\$_V-X8\01,\9A\+Z[$9)+V[+RVLB6\4L,1A9`/XF\?OHYYA
MX/82CFV79Y'B?AG,)X_!0S*A@L=2KX/$4J6(E"GB81IT/:0J0HUHQQ-!QH59
MT*DZ3J4'S+]#R_Q`P/'?"'$#I8*MEF:9=EN'KX_+J]:G77L:U>E1^N8:M&G3
MO05>=&E6I5J<*N%JXFA1<\1S*L_[C?\`@I#H_P`#M;^!WA6U^/WQ$_X)^?#/
MP='\5M#N--U[_@I#\&O"'QQ^!UWXF3PAXZCL](\*^$_&GQX_9YTO3OBM/I<N
MLWFA^(K?QIJ>H6GA"P\=:;%X7O;?5[K5M$^</^"5$'PTTWQK^U9HOP?L?^";
M_BKX=6/_``HRY\._'?\`X)D?LQZ!\$/@]\0_M^D_$0ZOX$^*7C7PO\>_CEH7
MB?XY_"S7;?4[_5/A/8ZBW_"J_A7\1OA)\2KGQ7K=Y^T9<>"?A?N?MO\`[7?Q
M%_9_^+?Q=M=/^*VA?#[5/`/[&P^)/[&/P)\16?@.#3_^"@_[7GC2']IWPQ<_
ML_6]AXHTJ;XM?&77?AAX@\"?LP7GA?X4?LE>-/AG\3E\3?'K2--^(E_XUTOX
ME?#30=-]S_9'^(GB_4OCC^TQ\&!^T7KO[7?PQ^#>A?"$1_'/Q1:?`ZY\3>&?
MVA]=\7_M`^%/C[^S)XBU_P#9K^&OP@^$MMKOP4\/_#'X)>,-7^'6J>!(?C)X
M#U#XU7%[\0M=O_#7C#X:Z/X<_P`_%&O3RRI!M.E.$:B]_P!U7K8:3<4L->4X
M\].,D\3R+GFE%U*52$/EU'$4LHJPDTZ-2G"JES^ZE+$823<$L)>52//2C-/%
M\BYYQC%U:-6$/UL^'/\`R`[K_L*S_P#I)8U2^%O_`""?$'_8X:[_`.VM<_X:
M\#>&?%5C;ZCKEE=7-YI&JW7V"6WUC6M,$(EM;$R!XM+U&RAN5<@96ZCF7@#&
M`*UOA#9P6&@:W9VWGF&'Q?KPC^TW5U>SX9[=SYEU>S7%U,=S'!EF<JN$4A%5
M1^K\/?\`(DRW_L&C^<C]KX6_Y)[*?^P2'_I4CU:BBBO9/?"BBB@`HHHH`*_,
M;_@L!H.O^)/V$/B?I/AO0-;\1ZE-XA^&TOV'0--GU:]CM[?QYH,TMT]E:![I
M[:,HD4LEO#.T+3)))&(%EEC_`$YHKPN*,CI\3<-\0<.5:[PM//LES/)YXF-/
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M))+HDM#]<J_+"?\`Y2D?M5_]F"?\$ZO_`%HC_@J;7ZGU^6$__*4C]JO_`+,$
M_P""=7_K1'_!4VN/BS_DG\?_`-RO_J;AA<;?\DQF?_<E_P"K#"'U/1117XR?
M@(4444`%%%%`!1110!_FG_\`!6[4[&T_X*<?MM17$X23_A<-B^T1ROA6^&O@
M`#)C1P"<$X)#8P<8()_2'_@BI=?"#]F[]GO]MS_@HA\<YOBA:>"M(T+0/V-/
MAOJ?P2M/#E]\8D\>_'6YTV+Q?J/POTSQ[<Z=X+G\;>#M'O\`P1KVFSZ\=3M;
M;3KC6;F71]3BMWTG5.F_X+#?\$*OV]?BS^UC\:?VJOV57\"?&#P=\8]:TKQ7
M>?#Q_%GA+X>_$+PCJ]CX5T/P_K$%S<_$V]\/^`]5T)CH:7^GZO!XXL;_`,NX
MFLKWP]:FPCU/5OP1U;]@'_@I+X*\$6]UI?[''[3?C/6?%T$\USXF^'WP+\9?
M$;2]#\-Q:C<:7'IOAG7?AQI'B32M=D\7QJ;W6-4T]+ZP?PE+86>F:G<66L>*
M;>/^],#XM\,XSPKX?X)PV;X2&82PV5X'$4JJIPIRIX+$QQN+I8^=3,,+5P>7
MSIX=TL5B)THJM&I#`4H5<3C\-2J_ZP>'OBGP+Q1X+Y'P;F7$^%R7*<AROA^G
MQ57J2PE#$8FEA<?#&_ZKX6>*S3#VS3B+ZE7P6'B\-6@L'2S+'8C#U,IP.8UZ
M/]<'A36/V;?VG/@Y_P`$O/BM^QAXH^.^M>'/^"?'_!2']EK]EWQU?_M!2?#J
M'XN2_"'XL?%OX7W_`(<M-4O_`(/33>$-<\`:'XQU3PA\._"=U#%86FJKH^JO
M.^MC1]/\0ZU0_P""N?QCTK]HO]FCX[^)/V'O$'C;X+:O_P`$T/V__B5>?M/_
M``M\$WP\,>(-<\:ZI\2-4@M_VMU/@@7&OR7^F?&[1_$NO>%?$3ZU;W6CZ=J'
MB+QCJR:-J6A6-KI7\3M[^S)^W9IEW/I^J?LO_M-:5J-I(8;S3=5_9X^(NF:C
M9SK]^"\T^^\$V]Y:3IG#P7,$4J'AD!K>\'?LZ?MO/K]C9O\`LD?M/^,[:_:6
MTNO"^A_`'XF7&LZI%-;S(6TB'2/`UY?'5M.W'4M-D6ROK>*[M(WU"QOM-%Y9
MSD*_"^38C"9_@,XHYGF&49FLY5"O@^'Z$LYBW3ECJ&/JRS:GA,1BZM-XVIEM
M>2P%'!XFO0HTZV!PE.56&F6Y_P"'M7/LCQ^)XW=++,CSK&9GPU#,Z.6YKE&1
M87-\VCF^/HXW#OB1K&8&K7Q.;U98O!4,/B<!4S6MFN"PF*Q>$AA<9_1C_P`'
M*.D_M!:1^W/<^._B5XA\5:G^S)\3=.T75_V15OOB/;>,O`::7H_P=^!VE?&2
M^^'G@S3_`!+K8^'MMJOCH65UKTDN@^&%\;7RVWB&V_MVV6+4A\2_\$0+ZUO?
M^"MW[%GV:7S?*U3]H#?\DB;=_P"RE\=-O^L1,YV-TSC'.,C/P=H/_!-#_@IE
MX[\7W_A7X=?LI_M"ZS);1Z/=_P#%6_"6]^%^H:5:^(89[C2+?QA8_$6Q\-)X
M/U9DM;I+FTUNYMK<K;C4["\O]`OM*U?4/Z-O^"*?_!#K]N3]G;]KGX6?M@?M
M:7'@SX5Z5\(].^(<FB?"2T\3^'O'7CS7]?\`'7PZ\6_#-5UB[^']QJW@#1]'
MTS3/%]]K2ZC:^,O$.IS7EG;:5'H]M;W]YJ-KMQ3XO\&5/!G'\)X+.,#C:F)X
M7GE&7U<-A(8&>*J4H0ITU7P,<SQ]?#9A%QA'-*=9*K#'O$2Q%'!RG*C1\GQ2
M\8.$>'O!GB'PCQ.;Y97SNAPE_J_@_P"S\/A*4<>O81EEN.A3P&>YW3G#,L-"
MCBY9G1K5L#F=2O+,,/4HX?&4HP_LNHKD?$WC_P`$^"]0\(Z7XN\5:%X:O_'O
MB%/"/@NWUS4;;3#XG\536-YJ5MX;T:2[>**]UV\L=/OKBQTJ%VOKY+2X%G!.
M\3J.NK^!Y0G&,)2A*,:B<J<I1:C4C&4H.4&TE)*<90;BVE*,HO5-'^6;C)*,
MG&2C.[A)II22=FXMJTK/1VO9Z/4****DD****`"BBB@`HHHH`*\B_P""47_*
M-K]B?_LWCX=_^F:*O7:\B_X)1?\`*-K]B?\`[-X^'?\`Z9HJ_1.`?^9M_P!R
M'_NX?JGAG_S._P#NF_\`N^?B+^P[_P`FL?"?_KR\3_\`J;^)J^KZ^4/V'?\`
MDUCX3_\`7EXG_P#4W\35]7U_1]3^)4_QR_\`2F?C?$/_`"/\\_['&9_^IM<*
M***@\<****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`KR[XX?\D5^+_P#V2[X@?^HGJU>HUY=\</\`DBOQ?_[)=\0/_43U:NC"
M?[WA?^PBC_Z<B=>`_P!^P7_87AO_`$]`_<']B'_DR[]D/_LU_P"`/_JJ/"=?
M@E^WXN_X'_\`!R;'ONX_,M-,BS8VOVVY;S?^"8O[*L?E);^5+O2;=Y,[8B\J
M!Y9OM-GY?VN'][?V(?\`DR[]D/\`[-?^`/\`ZJCPG7X+?M[@-\$/^#E(%@@.
ME0`NVXJH/_!+K]EP%F"*S$+U.U6;`X4G`/YC3O[?`<LG&7]M<-VDHN;B_P#6
M7*+24%K-IZJ*UE:RU9_2W&K4<JPTFN91S7`-Q]W5*I)M>]&<=5I[T91[QDKI
M_P"=9\&]'LXO#L>JQ07-O_:+*E@]V&*?V<@C">7<22/*T(G:XAF4-/;Q2644
M<+ED=+?ZCL[/0--UW3+'7'L=8T02VOVF2SO+Z""2WO+16^TQO!!;:@\]BUTD
MMS9B"&=KF":TD57)!^??A(+6[\":'#I[3RBWM)$Q<3RF2`^?).(Y4E4VZ,\,
M\#B/3V2TWS>=)FZDO"/6M+^Q1%[NX@R]@J2+:GS9%O)8W43P7I2ZM)K6VFMS
M,1):L;CSHA"AB$AN(/\`>3Z/>74,K\/^'\NA@,/5P^>9+35?'8I5XNM2A4EB
M\U:G_9TJ6,Q5+#2C4526)PT90CA9U,15KTW.'\I>-E?$YEX@\5K$5\52CA,3
M/**-'#MTIPP^$PF&R[`5,'4515,-25&@JF$J4G"FH5_K"A3CR<ONO@7P?::Q
MI.NW-SKM_%X-MYI;4V7VF/1"]Z;""ZFU*_L4U"\MDBT_"3PW$;7,1FM[:34'
MMHTBM;[QG6M8MKO3M-T:RTE[.>Q^T&]G74+Z[CU&:86H6ZCL;B6>.RN&@LX?
MM4L$F+IL%H8(X8(8G:GXPUG4[NX^TO%IMK=?98;FPTVU6QM&L[%F;3K2>U@\
MM+J*PC9(;26Z6>ZA@BA5)6$2+7+SW#322MSL=MRJ2P"[0JJ^T,5\PHH5B=PY
M;`'RD?I6=\1X:K@<:L+F%>$\1C88-X"&&I8:5++H995HX[#.\54?MZ];V*Q%
M;!4H0?+&CA[85+#_`)!E.3XZEC<3C<RQ"K>UGA\1A,-1G.%'"5(8:5"K.M*C
M["CCJ]:56K*I4J4(Q:I8><80E"DJ=_1]%O-<O+?3[!3/>7;%+>VB`DE<J1N9
MP61(8D4M))+-)&D42/-(5A1Y%]2\.P:IINK07WA.+5[CQ5H:MJ%Y;W-O!IPT
MZ.S!MM1MH(%OKB^OKEY;O[/&]O\`V7J41CQ!;-=3QRZ=8^#7AK3O$=SJT,]Y
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MFNKEHM135+>ZF2W$T4;VZO\`;--AM94$ES<K-\*_\%$/A"FG>-]8\:7/Q#'B
M"SNHKO5]/M-2TV^5FCN]4CTJ+3-*G^V:O?2O:0VL(:XD^S:;"DVF110Z>+IK
MBZ_R\\%OI'^).(^F]XA?1:XS\2."JGAM3X-OX39?PYDE+$8V56OB,KQV282M
MQ%PGDRH4<?EV24Z^%S;!YK5PV`C@ZM+&87#4<1A<3%?#>'^;T\O>1XB&98AY
M75SW,\DJY;"K@JN!AB)8'"O*Y8/#Y;0I8G&0Q#JTZ7UJIAXX#*Z]#$X3&N%:
MOE<U^3=IJ<&XZ.LEJ^J2PO=_8/M$0F^PEO):Y,6^*X:'S`T7GE%C$A$8E+*J
M'W'PK87FJ>$XH+_6;D^%#X@M])30+"YM?[0O[^[B!C@L+G40MNT,=]=65RUA
M-.+1HDU+46CMKBSC:X^>&CM;75I5BTMK>YU*"2YNK^.TC5'&GM;6]M;7]X`L
M\ER(;S_0$F5]UO!=F-D$3*>O\/\`B#7?#,UR]O.-/FO(+G3Y6M;A+B2.PEN0
MZO'(T`DM9Y84@N)#!''/;W&8[:\E6+[1-_J'P]Q!7HPA@LP@ZE#`0H98LXQ6
M$@Z.7PI5)QP\*ELNCB,'+%U:>*4\3)W:6'='"X:.%G-_O?$&5U,9A*?]GRHT
MZ_/A\72^M*G-RK1<E6G0:]M+#R@U4IT<33ISKTDN=2A.M#DZ+QC#HUCX@U.R
MTRV73-/MF$;Z2UQ:WDT<T5I;I<PR7-O?ZA$+A+P2DQK>R2QOF!Q#)`\47['?
M\&\2^*1^WYXED\'1^%(S-\']*_X2D^,!I_V=_!\/QG^'/]I)X5>_`:3QO`)D
M&D_9<Z@D<LAM,>9-G\2UA.7A>:"X25I,[GVRQR\F0Q1_O8PT8=G(54;<_P`Q
M"@5^S'_!`F'PTW[>*KXE\/>)_%2Q^"]!D\/V7AVXBMSX6\40_&3X:#2?&?B&
M*&*6[?P[8A[B+58;IQ9R;(5MI(Y8[PO_`#]],[#UZW@=G[QF%PL/88.G3ITG
M0IXJO'&86IE])4?:ULPK4E36'J?7(_4<6J,:M;$5ZE"IBJM2M6^S\/?;83%U
M,-"K7Q'_``B8G#8K$.==>TITZ,)O$5[JM.7M,10I1;Q51MU)4[UYU%",_P"\
MWXD?'+X2?"3PS\6O%GC_`,>:%HFE_`GX4W?QR^+EK;RSZ]XF\#?"2TT_QQJ2
M^/-7\%^'(-7\8OH6IV_PS^(<?AV6QT&[G\4:AX)\4:3X;@U75-$U"S@X7X'_
M`+1T'Q@\3>._AYXE^$/Q6^`/Q:^'6A>!?&?B+X4_&"?X2:MXF'PZ^)^H>/=#
M^'?Q"L?$/P'^*_QM^&-UH7BOQ+\*/BIX;MM&/C^+QYI&H>`-3OO$W@[0_#^N
M^!]:\5_G[_P4I_9L_:)_:!^)?P^N_AMX+\=:A_P@_@6;_AG3XF_!/Q'\"/AC
MK_PN^._B;7]2B^)/_#4OQS\;:[X-_;$^%7[*7C;P[HOP1\/^(?\`AV-XX\,_
MM$^.?AHG[47@_P`??VS_`&A\$-(NOLG]C;]C#P'^PYX9\9_"GX*7.A:;\"-8
MUVP\5^"/`%O\,?AUX2\3>!==;3V\-ZW8:O\`$/X=:%X,N/C%H0\'>'?AIHOA
MWQ;\9O#WC?\`:0N-0\-^*-<^+_[17QID\4>&['X=_P#/#*CA(8)5'64\55LX
MTD^;V:C*":DXOW92BYRY:D$I*RA4BZ+6(_89T,%3P$:KKQGC*UI0HQ?-[)1G
M34E)P=HRE&4Y<E6FE)65.K&5"2Q7Z->"O$.A:/IBVFK:QIVFW.H:K>"RAOKR
M"U:Y,-C8O*(O.=`=JY/4;L$+D@@3?">>"YT77I[>6.>%_&&O[)8G62-]CVZ,
M4=258!E894D$C@D5'X)T'0]7TAI]6T;2=4GL]6N&M)M1TZSO9;5FM+'<;:2Y
MAE>`MW,14GO4OPIBB@T;7HH8HX8E\8:\5CB18T4LUL[%40!1N9F9L#EB6/))
MK]@X>_Y$F6_]@T?SD?NW"W_)/93_`-@D/_2I'J%%%%>R>^%%%%`!1110`444
M4`%?D;_P6._Y1^?MW_\`9J_Q9_\`4#U.OURK\C?^"QW_`"C\_;O_`.S5_BS_
M`.H'J=>7F?Q93_V/LF_]3Z1\GQG_`,BBG_V,LO\`_3Z/URK\L)_^4I'[5?\`
MV8)_P3J_]:(_X*FU^I]?EA/_`,I2/VJ_^S!/^"=7_K1'_!4VN'BS_DG\?_W*
M_P#J;ABN-O\`DF,S_P"Y+_U880^IZ***_&3\!"BBB@`HHHH`****`/$/'FD>
M)?B5XD'PYDL-0T;X76UI;7WQ$UPRO93>/;6_@O4A^'&@R1H;A-&N66"Y\>:M
M!/:RRZ4R^%;)V;6-4N=/]KAAAMH8K>WBB@MX(HX8((8UBAAAB4)%%%$@5(XH
MT54CC155%4*H``%245FJ5.%6K5@I\]54^=SFYM<D%'DAI%4Z7-SU(TXI)2J3
ME)SJ2G.7KYAG-?'8+*\MC1H8/+\IHS5#"X95%3KXW$\CQ^:XMU*E25?,<>Z5
M"G6KMI0PF$P.!HQIX7!8>G`HHHK0\@\<^)'@?69M1M_B9\.A#!\3O#NF#3X[
M*YNC9Z1\0?#5O/=WS>`_$\F1$L)N+V_N_"VM2@R>%?$%[)?H9-,OM<L-1]+\
M/ZL^NZ%I&LR:;J.C2ZIIUG?3:1J]K+9ZII<US`DLVGZA;3)&\5W9RL]O.-OE
ML\9>)GB9';8HJ(TX0<Y133J24I)/W7)*SDXV^)I13::NE[RD[->QB\YKX_*\
MNRW%TJ-:>52JT\#CVIK&T\OK/VG]EU:G,X5\%A\0YXC`QG!5<)/$XNG&I.A5
MI4J')>//`7@OXH>$-=\`_$3POHGC/P7XGL_L&O>&O$6GV^IZ1J=LLT5S"+BU
MN4=!-:7EO;7UA=1[+K3]0M;74+&:WO;6WGC^/'UKXL_L<@0^*I?&OQ]_93LH
MHE@\=>3J7C3]H+]G_3X@J&+X@6&GVMQKOQV^$NE0+\OC_2K2_P#C/X.T^&*7
MQ[IGQ1L?[>^(V@_>%<=\0_`NA_$_P'XR^'/B>778/#GCKPSK7A+79O#'B77_
M``=XBCTG7]/N-,U!M%\5>%M1TGQ'X?U(6MS+]EU71=3LM0LY=LUO<1NH->KE
M^)Y)QPE>G]9P6(JP]MAW&<Y1;]QXC#*G*-2GBJ<&W"4&E4Y53K0JTFZ;\ZE*
MK44,+^]J49UHS="FI3G=RA[2=""E%QQ$H4XI2BU&?)"%>-:AST9^$?LN?MJ?
MLV?MG6OQ8U']F[XFZ'\3M*^#'Q/U+X2^,M8T"ZM[O29/$NF:5I>K'4?#]_;S
MS0>(/".IP:F8M!\6:>TFB:_<:;JXTBZO(+!YV^J*_*C_`()__P#!(?\`9=_X
M)K_$'XG^/?V5O%_QJTKPU\8=`TS1?&?PK\7^/=)\9?#22Z\-ZI<:AX:\4:5'
M/X8M?%EMXF\.17^OZ+97U_XOU6S?1O$.L6UWI\]XUG?V7ZK`@@$$$$`@@Y!!
MY!!'!!'0UKF&`BL3.678?&SP;5/D=7#5XSA/D2G";E"SDY)S33:Y9Q6Z9UXS
M`2ABZU+`T<?7PT/9NC5KX2=*M5C*E3E.;I14G",:TITHMV<N12M:46UHHHK@
M^IXO_H%Q/_@BK_\`(^:^\Y_J&._Z`\7_`.$];_Y#S7WA112$@`DD``$DDX``
MY))/``'4TU@\8VDL+B6W9)*A5;;=K)>YK>ZMZKN#P.-2;>#Q225VWAZJ22U;
M;Y+)6ZBT4@((!!!!`((.00>001P01T-+6=6A6HM*M1JTFVTE5ISIMN-N9)22
MNU=7MM=7W1E4H5J*BZM&K24TW!U*<X*:23;BY)<R2E%NU[*2[H*\B_X)1?\`
M*-K]B?\`[-X^'?\`Z9HJ]=KR+_@E%_RC:_8G_P"S>/AW_P"F:*OO^`?^9M_W
M(?\`NX?I_AG_`,SO_NF_^[Y^(O[#O_)K'PG_`.O+Q/\`^IOXFKZOKY0_8=_Y
M-8^$_P#UY>)__4W\35]7U_1]3^)4_P`<O_2F?C?$/_(_SS_L<9G_`.IM<***
M*@\<*_./]OS]L3XA?LOZO^SSX0^&VE?#`ZU\</&NJ:#?>+OB[?:U!X*\&Z/I
M6H^"M!GU36H-#U'0[JQT:VOO'^GZ_P"(O%LNKS6_ACPYX;U93X<UNXU>WNM%
M_1ROS3_X*2^#]3\>>$_A?X:@^-/[,'P[T.?Q#XAN_$G@+]J";POHN@?$;3(]
M+LK"?4/"/C2_TW4_'7@[Q'X9L=3U#PU/K'PMG\(>-++2/B5>ZQHOQ&\':]HV
M@OJ?R?'%;,,/PMFE;*\36P>.IK!NC7PZPWM8Q>882->$7BJ^&I05?#NK0G5C
M5>)I0J2J8.EB,7"AAZO]`_19RSA#.?'G@++..\CRWB/A;%U.(Z>8Y3F\LZ67
MUJT>$<_J95BJ\,ARG.\=B999G$,!FF'P.(P"R7'XG!T<%Q)C\HX=Q&:9O@8?
M"_[?>H?#7]DFQ_:._:Z\)>'M`O-1^(MYX$\.V_P"\3^$/BGX?\>PL;J\AUC1
M-4T+Q]XG\&>&QX=MM(\::7XJM_$'Q1N(%OOAUK5Q9WT>L>(_#O@JL4_\%+O#
M/Q!G\#Z7\'_"OB'0?%,/[8/P:_9Q^,'@WXT^#[O1_$GAC0/B7+XXLK[5-+C\
M.>*[K2[/Q':ZWX#\2^'5L=6U6[U;P[K/AK68O%'@NWM+SP_>:I^>L?[+7PX@
M_807]FZ#]NC]C[_A:0_:!C^-LFIR_%_PU)X3E@3P4GPM&B2>*WN'UB75AX=C
MC\;'7Y_AW+:2ZY&/`CZ$--;_`(3M/0OAM\'?A%X2T[P'-_POG_@G7\/M7\._
MM8?`#XS:]IOPM_:#\>:KIVK>`/@W:^.'O?.UKXL_$7QO<W7C"]O?'5Y:Z%X=
MTS0/">BVMK8W%]K7C'6)M7LM.\,?D7^MG'4I97@HXC+Z.`>0Y;4QF)Q&:9=B
M,VEC6JCQ/-B<)"EAWC(UHX:%6G4CA&L)4JMT<3B'*O#_`$37T>_HITZ/'7$M
M;)N,,QXLCXL<8X/AO),GX"XUR;P]APO&6`CDSI9'Q!B\RSNGP[5R[$YUBL#C
M<%6X@A5XAPF!A3S/)LGCA\JQ'V]\0_\`@K%^S'\-/B-XV\`>(-#^,=Q9?#CX
MAZ?\,O&_Q$TGP+8W?@/P_P")+I];COA<-/XEM/&5S!I+>$?'[BVT_P`'7FL^
M*;3X>>,-2^'VD^,=+LK&]U'I5_X*>?LS-^TRW[+&/B$/'`^(1^%P\1MX8L1X
M.;QB+[_A'C9JAU[_`(3G^SO^$YSX"&OGP.-";71_;"ZB?`A3QBWY9^,/V8/A
M9KO[1'QE^(-S^TG_`,$Z?B+\/_BQ\4KSQE877Q-^.GCK2_%7@/1?%'B/5/$?
MB0Z5X1^%'Q,\"Z9K>M6#>([K2UM->^(=SIWBJ/PEX?U&RN_AK)X@UZQM/HWX
M?S>,_A?^TQXV\1>!_P#@I#^QYH?[,'Q#_:#\3?&_Q?X*7QM\*-3\9:U;>+[Z
MQU_7]`>SUK1M1O--U"]73K7X;_VSI/Q;LK&WT.(_$:RT"UU^9_!@[<'QMQS/
M&U(X^IDF'P3XBIX:G+`_V;C\3'+U6QB<:E+$YQE-".75J4<$Y9C1QN,K4%.I
M4<G*4</#YKB'Z+_T5Z'#6#J\)X+Q0S;B>/@SB<YQE'BC_73A3):_&$LOX6J1
MJX''9'X<>(6;5>,,!C<1Q/&EP=F?#'#N79K+#X/"4\/2HTIYOB/2OA;_`,%*
MO&/C/Q3!X6\8_"[QUX&.O_MC)\$?"_B2?X$:I+X4LO!VJZI8Z?H/PQ^(FK:I
M\<M$/@_]H:T2[GO/&%YI\'B?2]"L+)[VS^&>KB1X+?Z&OO\`@I%\`=%^%OQ>
M^)?BBQ\6^%=0^"/Q1A^$'C7X4ZUJ7PH;XK-XREOEL)(M!T/2/BCJN@:UIT,M
MAXTG2_MO%`34K#X8?$K4=%CU.Q\*W%Q-^?"^&[D_%==_[6?_``3X3X&_\-_W
M'[:SA?C[))\5R1XI06FA*QM(O"`#^"A(]QHY4F+Q2R1Q>+YM)1I7T?BG^SW^
MRGX__;+L?B]:?M4?LO6O[.'B[Q+X:^)_QJ^$D_QU^&T-MXM^*'A:Q\21JZ?#
M=?#VH?#SQ)X:\67\NGW/CBZ\8:G=>+-7;XC?&ZYLM7TV?Q1"MSE@.*>-,/@Z
MW_"G@,=C)9E#+.;,JV74%3IXVCB:-+.(0IXN5*K@\IQJPM?$1HJD\3@ZU3FC
M.=.FST.+O`?Z,F;\299_Q@_%_"W#=#@JOQP\/P7EO&N;SQV.X:S+A_,L;X;X
MG%8SAVEF&"XD\0.&:V?Y5E-?,9X^.1<2X#`N%;#87&XNF_JWQ1_P5P_9M\$>
M+?$'A/Q=X)^.VA_\(5XPT#P#\0_$4G@KPQJ7ASP!XNU6WU635]$U^YT/QWJF
MI7]YX4N/"OQ!L[Z/PEI?B8^+1\-?&NJ_"K_A8?AVSTK6M7^J?BK\:_%7@;]I
M3]E'X.:3I_A^X\,?'3_A>G_"6WVHVNHS:]IW_"L?`6G>*=!_X1RZMM5M-/M/
MM>H7<D.K_P!IZ7J_VBS5([+^SYPUPWXA>,/V8/A9KO[1'QE^(-S^TG_P3I^(
MOP_^+'Q2O/&5A=?$WXZ>.M+\5>`]%\4>(]4\1^)#I7A'X4?$SP+IFMZU8-XC
MNM+6TU[XAW.G>*H_"7A_4;*[^&LGB#7K&T^]OVNO&GA#XE>/OV</C#^SI^V7
M^QYX7^(7P$\1^.+@Z;\3/BQX0?PUX@\/_$#1M'TS7;::]T:^\07JB>QT%_#5
M[I<&DV%]<Z1XKU'6M%\9>%=>\-Z6=4]#`\7<55<!G]7-\1E=.I@.(,@J97A\
MLQV`6/Q>48;B2E4SVE!5*U'"XB%?(:,505+$UI8AU\13]M&I.G1I?&\4?1V\
M`\!Q;X0Y?X>9-Q[B\'Q;X/\`BUA..\WXWX6XLJ<)<.^(^>^"F-P?A3F&)G@L
MNS//<HQ&6>+.9SGFT\;D^7T<GAE>48MY95P>'Q>98_V?Q-^VM_PJ[QW^VS_P
MLS0/MGPR_9:_X9N_L3_A!=*^T>.]8_X7=HUO_:7]J?V_XKT_P_J']G^(-0L/
ML/V3_A'OLFC+>>?_`&M>K#O\O'_!4KX<^./AK\=M2^%WPX^,.F_%3X7_``2M
M_BYX>\(?$/X<VUS%JVD>(K;0TT'Q==VO@[QU?)-X$\.#QIX&\;>-+F?Q)X:N
M[_X8:W+XM\$7>OZ?8:K>Z5\#?&6:/3?V<?V]?'?Q5_:I_9>^+/QF_:1U_P"`
M$^E^!?@7X\\/ZW;:9H?PP^(&ABQATB!IM+U_4!8^'M5?2%TMM!U*]TSP[X&M
MO$>N^,/$^L:_K<VEVO@#\"_#'P^7]H;7/'7[8G["X\1?$C]C.#]EOP/HG@SX
M[6M_H;W^E_";P%\)_#NO^*_$&OQZ=J&AV>F:)\)_"(U>31_#OB>;Q#J'B#7]
M8M--\,0Z)8:!KODSXWXMJ9E'+L!C<+3HXG"9IF$WC)95.OE^'S7/..'E'M\5
M+,(TJ.+P.68/AZ.&P$?K*<VZ.(7O>_\`HF&^B[]'C!\%3XQXLX8SW%YGD?$/
M`/!^&APW1X_PN5<89MP#X7_15AXB?V7D-+@^MCLRR#BGC;B7QAKYQQ76>23^
MKVS')^9T/]E^Y-'_`."H^E^'OA-X3^(7Q<_9A_:PT6PF\%^!M5\6?$K2/@SI
MVE?!>Z\0>*(-)L/M'A#Q)XE^)2RGPOKWB+4[6+P7<ZK<O)JMEJ^AVT=[>:G=
M^4W1>,O^"C_@CX=?$/PYJ7CUM.\(_`SQ;^Q5X7_:<\.PZO91CXOZOXS\8^,H
M].T'X=:=;6?BV[\*W^IS^&7FN+K2;'[3;:;>:?J_B'4?&=KX,T?5-4M/R%^.
MG[.'Q(^/EI\(M.\6_MK?\$Z[/2_@)\-/"/PR^&^E^'OVH?$.FZ=-I'AJV%M>
M:CKECJGA?Q':6/B+Q1#:Z-;^,-:\-0:9'XHL?#WAK3[W2[>T\/V<<GNGQA_9
MR^%'QW\+^#=.\8_M7?L3Z'K?P\_8O\#?`+PK/9?M#V?B73T^*'PU^(HO[+7+
ME?L?@W_BC_B!\,!JWAK6;N]LM9OO`FL>,KZ[TWPIXVE\*:1J^K<:XUX^J4L1
M2PU;"SJ82AE=7`5LPJ97A)8[%4Z5\PAB/JV*<?8R=6G&-&M4INO5@FZ^'C*M
M'#_13^C']$?!8_*L?G.69[A\'Q!FG'>!XIR[@W"<><1T^%LCQF.HPX/Q&43S
MOA^&(EF-"G@L75K9GE^"Q<<JP6-G3AE>=5Z655,W_2KXI?\`!2WX0_!M/AU9
M>/\`X4?M#:+XQ^(GPYUWXLK\.9?`OAA/''@KP!HH\17J:YX]L+CQY;Z7HDU[
MX;\(>+?&-[H5GK.J^(_`GAGPUK%S\5=(\`7]LNG2>[Z+^U7X-\8?LT:7^U#\
M./`WQ;^*'A;5[2TFL?`'@+P7'JWQ:GOAXR3P'XBT:W\)7>KZ;97U_P""_$$6
MKCQ'<Z;KU[HLVE>'M7USPSJWB+2#I=YJ7XU?M$_"RU_:$\5?L_?%/QI^UC_P
M3[\:^._`WP;M/AE\7_"WC7]H.XTWP5XX\1^&]1\6MI_CRSUWX86G@'Q"T?C0
M^+7\8ZIX3T32_AU:_#_Q/HMEX?L=7^(?A2_O%C^I?&2_!V[_`."?6H?LI>`?
MVHOV-O`_CW6="L-+O8_#'[05[H'POT^V\0?$VT\9?$?PU9ZUX@\:_$KXDZMX
M<U/PY?\`BCPS>C79;FW\>1WUS9ZKH/A+PQX@N/#NA?6X+C+B.69\4_6J^4RR
M?!Y)B*_#W^TX"GF>.S"&#P57`PY'5C@_;8J<\9'%4:F)2I8N-*C['"T8MU/Y
M[XH^C3X+4N"/`7^PLK\0X>(_$GB?D^5>,2_L3BS&<#<*\'XCB'B+!<5UUBH8
M&MQ&LMR/#TN&ZN09G@\EG+,>'ZV/S'^U,_S&K3A@O=O#O_!33X)^(?A]\?\`
MXBGX>_'#0-._9MU#P/HWQ&T'Q)X7\&:9XK77/'/C75_`,>A:;HH^(-P8M8\,
M>(=%NX/%UAXBN?#\VEC$%L-0U&&]L;3EO#/_``5F_9V\0V/Q!O[WP'\>/",7
MPX^%-A\6]8B\4^#/"L-YJ&C>(-3^'>D^"=&T:RT3Q]KEU<:QX_N/BGX,N_"F
MI7L6G^"9=#U1/$VL^+]&\-M!JT_Y=?!?]F>R^&?[.W[3_P`!]4_:[_82U.7X
MWV7PE;PWXIC_`&I(+N32[_X7?$FW\6&TUW3IOA]IP2PUG1M6\01076F7-PVC
M7NB:%IL>EWMCKEWJ/AKZ\_:F^'7P$^-'B?QP_P`-/VJ_V-?AYX)OOV._"G[/
MW@30&^*_@RQM=#\2^`?CMX<^+?AS1E\/Z!<PZ1X>^'=SH?ABT\'Q:IH]U?W_
M`(4^U)>V/@;7;/2XM+O_``J/&G'U7+J6,CBLDACJ&77J99B8Y<OKV8U\QXKI
MT(RQ"Q^'CAXT,OP?#5;$.FU3E/'M/V,I5(4?U7,?HR_1'P/&.,X=K9'XH8KA
M;->,HT\+QSDM3C.;X6X.RO@[Z/F-S6M2R:IPCFU?-J^;<6\2>-N6Y/'%TYXN
MEA^%82@LRA1P.(Q_U'^S7^WZG[4/[3>K_"[P;X&U_P`(?#;1_@%;?$IY/B/X
M<AT/XB7WBC4?$/@RXT>_T\Z/XU\1:'+\/->^'_CSP_KFA3SZ;;:KJLMP-7M+
MR3P_=:9+?_I/7X>_L#_"]O!G[6GBGXG^+OVA_P!BSQMKWCSX+:+\*M%\#_LZ
M?$S2+S4[R?X?^%/A!H&EWFD_#K3O#?AK1M$TZV\$?!V>]U?2O"$$&AZ5-')/
MH7A[0_#N-,T3]PJ_2O#[,<US/)<5BLXQ$L3B99QF$:4YQPU*:P:=*6$4J&$Q
M&)HX:4J,HU'05:;INIK9-(_B7Z7_``=P!P+XFY#D/AQD]#)<CI^&W!N(Q^%P
MU?.\=AY\25:&,AQ%4HYMQ!E.1YCG5*GF=*M@X9K/+,/3Q4<*N52G"<F4445]
MR?RJ%>7?'#_DBOQ?_P"R7?$#_P!1/5J]1KR[XX?\D5^+_P#V2[X@?^HGJU=&
M$_WO"_\`811_].1.O`?[]@O^PO#?^GH'[@_L0_\`)EW[(?\`V:_\`?\`U5'A
M.OP,_P""@0=O@7_P<G!89ILVVD"18+@VTJ0?\.R?V4_M%PK"6'SA:0>9=/9-
M*B:A'"UA(2ERP/[Y_L0_\F7?LA_]FO\`P!_]51X3K\8/VD?@IXV_:.T__@OY
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M48V+R2Q0QV]Q!<)/YKAX?LEM>O#^HGP?_P"#:+_@J5X-G>'7_`_P/%LS/=Q7
M-O\`%OP_/)%>VP\JUE:;^RY+N.>6WU#4K4M;!8WM%\FY((MRWMM]_P`&ZO\`
MP4QFM)(['0?@I;WQ'[J[NOB;:W<8)DWOY\$<%F92RLZJPF1D;RW;S40PR?ZS
M^"OTD/"W(/#7"X+'^*O`^7Y]A,7B,+36.S;+J&/PN58&=)4L-@8XQRG1AFE*
MIS1C&K7PD(85X>=-2E)5/YR\8,MH9OQQB<9E4*>)P.993DL\1B<N;Q&'AF3R
MG#X3'U*[I4Z]%U:6+H5*U6E1H.#C4BHTY-MO\1(8Q=?VE-L3-O:2S.99X6)+
M2Q0J("[1^:Z,Z&*&VCFF$`GN"?L]O(\>%;6\T0N&>ZN+P/</.OVA;13:Q2D!
M+6$6MM;%K6$C$<ER+BYS)B>ZE+1@?OIX>_X-X/\`@HYIFCOH=[X6^";6UU#8
MVMQ<6GC[1#)81VCVK&XT2"6U1[!E6&2*.R6]%N]M(+>:5FCAN(/H?2_^#=#]
MHO3X9EEM?!.H3NVZ"ZO?'"I+"0\2LNRQDM8G@:!9]BA8IQ+<+++.\<(M&_0<
M\^D?]'R-#)JV8>,/`]2KBH8VOCEE.887,LPA6KUH3D\31RR$\OIU,/*K3;C6
MQF">.A#$3PR]I&K)?BN;8G-,BE5@^&N),TA6K<F&_L?(\9F,O848T4ZM:<8?
M[)SSJ5.6#J*<Z=-VC4<>4_(+]D6T^'_A[Q%!XL^(^EZO)9Z?>21K8V:07$=Q
M;QV%GJ.GP/8W=FR2IJ-S>6.J?;II81';V,9@+2W(2Y_72/P[\-OC:^E^.=,T
MV$W&G2ZL4TF[T2ST+6/%B:3!H-UID2:B+V]FT>TM;[5;&%]6CMUN&@U8-:+8
M1Q:=?+J^)/\`@@-^VG;6FK77@2^\)6.M7^F6\5XNI?$.QNX=5N[*&Z"2)J-_
M87^K6,LL<PL;41WD"V*[+DW<IMU27Z(_95_X)<?\%&/A-<7EE\1="\"ZSI=\
M;<M);_%70A'8F">VM(9;&/3M$M=07[+I-QJ0CTU;RWM998]TMVPN(;:T_A[Z
M9V=^&'B5D^:>/?@UXY83&^*W"^0X;A?)^`L5QS#AFGC>&X0Q&%SG+,ER3ZO@
M:,,5F,LPJXW%8K"8Z%+'8;+<-1RZEA<=.C6H_P`]<4^&O&'%F-EQ-1R7/J3J
M8K#8;$8#&Y/F%#,L/@JRP2K1I8>=&C4Q."H5*4ZJIPQU:FI*6(6'5>O6C'X^
ML?A3XI\,>"]<\?\`C:^\0Z5I%Q=2Z[X+\'Z1>MIUII>K7:IH.@:T;9O$5YXA
MAO-#U&X5[XZZJ7H6SL)X+F06U[HLWYA?$'Q=XG;Q=>Z?XGTG4?$EGJ6HZRMS
MJUO<7VOQ6\UW</\`VM'+I$EE)=?97NBKS+)<2RWMB1,&NKJ*6SB_JX\9_P#!
M,SXM:ZUQ;W'PW\&>(7GDMGDUDZYH.GWP73VMS96UIJ;:I!KL-O#+%-,LPGMK
MF>'['#<!8UGM5^'OB;_P1P_;DU[5+RZ\/:/X$GT>ZO;UAI\GQ$TO3[Z:.?4K
MV]M[C4;""&T\-H8XOLA:/38X1#>2R1P0FRAM5M/R?Z!OTB<EP7&'%F+\5LLX
M?X;QG$$75P>?Y\\+P/E&09+@IPIY=EN14?K>,Q^*S*M&ICZ^8X[-\1A,SS/,
M)8/-<QP<YXC%++_,PGAEQCD>?4J4.`<XQF'EEN!PE:;C6JT\+F-+`0CC,PPV
M98#"8;"Q]MB+U*&&ITJV%IJK/"U\5B94I8FK_+-\18O!]Q?P7'@_2M4\.VIM
MK9IK#7MUS(S3`74%ZETEQ*]T;R*5)8U2WM4BMT@G#7(F\Q>#D@GLI8&RK.[G
MRQ'YC9*XRK853AP=N,_-G;G+`']]-?\`^#?+_@H[KNK:CJC^%OA':M?WLMWY
M,/Q4TD"!6<M&L?E:9#"9T4()KS[.LUT_G3SYGN)9#4O_`/@WO_X*77OA^3PV
M=%^$PTR:]:_DB3XJZ;:2_:FM6LS<1WEII\=[%,+8A%,4\<<;C[1"D4ZQNG^L
M&9>.7T;^7&8_">,OAO2S*AA,MG@<12X\P.+KU:^"KSJUXUY5L8YU\?5HSITJ
M>+E2YI5_;8O&8K$RA3A+^G\LR7/L)@<NPE3+\RJ\D:=/%/&2KXFO3A."]J_K
M4Z=2IC)T9-QC[6I!UXQCS5H-RF_PRTKQ-K&BZK<ZOI]S+IFH2+</(+2WMXK)
MOM`1FAETTV[6BV\L@1E18EBBD$#0)"T<3Q_LI_P;T:G>Q?\`!0+Q4ME\2]-\
M!S3_``L\)VMY-/#.A\5Z=<?&;P6U]\)PL(GAN-6\8R>5?V]](MJ(;:SCLBH6
M!II-AO\`@W9_X*7&57_X1OX/,C0RF61OB[8"Y64>4L4*Q_V2T<B21M<"65KJ
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M8?4C=ZQJ]TMA%I^CZGJ?F,EK8+MDDL;::*`NQVH)G0L1CJ4W87PX^)>DV=AX
MCMYO#GQ(,L?C/Q%'((OACX\F57AGBMW!>+0&3EHBZ88[HGCD'#BNJ\)^+-.T
M+3IK.\AO9)9+V2Y5K:.!T"/!;1`$RW,+;]T+$@*1@J0Q)(&AHWC+2-*BO(YI
MM=U)[O4KS4/.N;/2XI(UNG5EML6MU#$ZP!=JR>6K,#]U5"J/UK),\RG#Y3@:
M%;'4*=6G0C"I3DY*49)NZ?N^:_I,_;^'>(LDPN29;A\1F6&I5Z6&C"I3G*2E
M"2D[I^ZU?5=?R8LGQ@\-0W%O:RZ'\18KJ[$QM+:3X9>/$N+H6ZJ]P;>%M`$D
MP@1U>8QJWE*RL^T$$R3?%OP_;PRW%QX?^),$$$;S3SS?"_Q]%###$I>2661_
M#ZI''&BL[N[!44%F(`)K'O\`Q)87GBO1?$::KXBM;+2;"^M)=!BL=+>TOYKQ
MD(NYIYKUY(7B1!'M@1&E7&Z4%(RFAXB\8:5KNB:EI%M>^)M`GU"V>WBUC2;?
M1FU"Q9BI\VW34GO[)RP4Q2)/:RJ\+R*ACD*2IZG^L62?]#+#?^!2_P#D?/\`
M/LSV?]:N'O\`H;83_P`"E_\`(>?Y]F68OBUH$\4<T/A[XE30S1I+%+%\+O'T
MD4L4BAXY(Y$\/E'C="&1U)5E(9200:BC^,'AJ:>YM8=#^(LMS9F(7=O'\,O'
MCSVIGC\V`7,2Z`9(#-%^\B$JKYD?SIN7FO@'X8?\%(/$/B#XNQ?LX7G[`O[<
MV@^-?"7A?X.^*?'_`(A\9Z[_`,$_)-"\#?#SXQ>*OB-X'\&_$CQ1=>"/VY_$
MM]JVBMJGP=^)UQJ^B_#_`$+QEX\L=/\`"$\J^$+R[UKPQ!X@]5\!_MJ_LT1V
MW@;QOXI^//A/PIJ/[1>F?`[7OA[\./'?Q9^`IU@7?[1.G^)+OX*^$/#=WX*^
M)7BOPKX^USXBR^"/'6B?#F\^'?C'QWX;^)-Y\/\`QJWPP\0^,]*T&\U*+HGG
M&5P=GC\+)V@[4ZL:K2FN:#:I.=E*/O1;LG%I[--]53/LFINTLSP<G:$K4JT*
M[4:D>:G)JBZC49Q]Z+=DXM23M)-_5-Q\8/#5KY`NM#^(ML;JXCM+87'PR\>0
M_:+J4,8K:#S-`7S;B0(YCACW2.$8JI"G%C_A:NB?]"U\3?\`PU?Q`_\`F>KY
MI\=_M>_LLWGA7Q/\4;[]J/X<>#/AG^SY\3=0\`_&KQJGQ0^%-GX(\`_$K2]2
MT3PYJ'PQ^*OB[5?$SZ+\/O&VDZYXET'2+OPOKU]H_B:RUGQ%HVFW%G'<:K:6
MMW]`^'_C3\/_`!_X2T3Q;X)UY?$WA#QKX<TWQ'X1\:^#]1T'7M!\0>&_$FF0
MZGH'BCPMK^G:EJ&C:SI&K:7>VFK:)K%A-?:9J-G<6M[:R7-K,C/D\^RB*YI8
M^C&/-RWDII<UHR<;N"7,HRC)K=)IM6,9<2Y%&/-+,J$8\W)S252,>=1C)QNX
M)<RC*,G'=1DFU9EVU^,'AJ^@CNK+0_B+>6LP8Q7-K\,O'EQ!*%9D8QS1:`\;
MA75D8JQPRLIY!%'_``N#PU]J-C_8?Q%^VBW%V;/_`(5EX\^U"U,AA%R;?^P/
M.%N9@8A-L\LR`H&W`BL3P+KMAX/T+^QK[6O$_BF5;Z]NX]2U2QT>VN(X;R7S
MELDAL+F&V6WMF+B+;&K$.2^6R2R37;1_&]OXM77O$Z:?#ILVGOX7%AI1TZ8R
MQHJSM<F]^U*8YE^T^4,HTVUC@*`8_P!8LD_Z&6&_\"E_\CY_GV9G_K5P]_T-
ML)_X%+_Y#S_/LSIU^*_AT/$+G2/'NFPR300->ZK\.O&NEZ=;M<3)!$]W?WVA
MP6EK$99$3S)I47<RJ"690?S9_P""QW_*/S]N_P#[-7^+/_J!ZG7Z#^-O$.G^
M+O#MYH=CKGC#PA=7)B:+7-`M?#\NH6S1-O"K%K*:G8RQ.<;TDM2V51DD0KD_
MFI_P5CG^T_\`!.3]NB87^HZCN_97^*T1N=42VCNF>U^'=Y9RL4M28E6>6W>Z
M(W.YEN)2SL37'BLWRS&5\HH87&4:]5Y[D\E3@Y.7+''47)ZQ2LD^Y\[Q/GN4
M8_+J6'P>/H8BO+,,#-4Z;DY.,*T7)ZQ2LD]=3]EJ_+"?_E*1^U7_`-F"?\$Z
MO_6B/^"IM?J?7Y83_P#*4C]JO_LP3_@G5_ZT1_P5-K3BS_DG\?\`]RO_`*FX
M8]CC;_DF,S_[DO\`U880^IZ***_&3\!"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"NT\#V%KJ6HW]E>Q&:VFTMC)&))82QAU'3IX_WD#QR`"2-&(5P'`*.&1F
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MY2;Y81C&-[1BDDC\7/C]_P`$QM*\'?!+XJ^+?A+\=?VYO%7Q+\,>!/$OB#P1
MX9;]HWQOK?\`;_B'1],N-0T_1TT73+:TU/6)M0EM_LL&E:7<1:GJ,TL=GI[?
M;)H`?@_P7X6^#5E#\'O#GQLTO_@ME\+O$WC[7OAS\--7\<>-/$_B3P1\*H?B
M5XQEL-'N&M]:U[Q*E_%H+:S)J%_:0)I]YKQT.TFFBTFYNH)+8_U)U^3W_!7^
M>;3/@;\`O$KZQ_PC^C>$/VQO@AXE\3:V\FHQ6^DZ#967C6WEU.\?3+>ZN1;:
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MTX4YU,/4K83,:U*->$*E*<Z,I*I&%2$I12FF_P`.XE^CODW!F81RCC'PUSKA
M3-:F%I8V&5\2X3B?(LPG@J\ZM.CBXX+-*V%Q,L+6J4*U.E75)TJDZ-6,)N5.
M:7/>$?#=EX,\*>&/!^G7>JW^G^%/#VB^&["^UW4KG6=<O++0M-MM+M;O6=7O
M&>[U75;B"UCFU'4KIVN;Z\>:ZG9I96)^>*^J*^5ZUX[A&G')X0BHPA'&PC%:
M*,8K!*,4NB222\CX_P`280IPR&G3BH0IQS"$(15HQA!9?&,4NBBDDEV05Y%_
MP2B_Y1M?L3_]F\?#O_TS15Z[7D7_``2B_P"4;7[$_P#V;Q\._P#TS157`/\`
MS-O^Y#_W<*\,_P#F=_\`=-_]WS\1?V'?^36/A/\`]>7B?_U-_$U?5]?*'[#O
M_)K'PG_Z\O$__J;^)J^KZ_H^I_$J?XY?^E,_&^(?^1_GG_8XS/\`]3:X5\O_
M`+57[0NO?L[>%?AUJWA;X9_\+8\3_$SXP>$?@YX<\)?\)G9^!//U[QGIWB*Y
MTB;^WM1T36]/B\W4-$M],\N^CL+-/[2^VW6J6L%FZR_4%?#_`.W3\!->_:)\
M*_`7P3IWA3_A,/#&E_M0?"WQ3\5-,_MVS\/^1\)K+3O%VD^.+[[;/K.B:A+Y
M6GZVEO\`9?#EW)XE?[5YND6[SPF2+YSBJKFU'A_,JF1>U_M94J<<$Z%*%:JJ
ML\11A*4:=7"8^G[M.4Y2G/!8J-.*E4="HH<K_2/`+`>'V9^+_!&#\5?[/?A[
M4S#&5.*(YKC\5EF`J8##93F&)ITJ^+P7$/"6+C[7%T<-3I4,-Q-D-;&5IT\'
M3S7!RQ"K0Y'X%?MY77C[XU?&KX#_`!O^#Z?L[^,?@?X`B^)'C#4-5^*GA7QM
MX1T;PY;Z=X6UW6I_$WBJST_P[H^AI8>&_'?@_P`16]_976OZ0VF7'B$:_J7A
MF]T".SU;S#XO_M]_\$XOB-X*\0Z_J]U\+?CCXK\`^"?%'B;X?>"?BE\+?$VG
M3:_KD\>E6]KX/\,ZO\1/A9?C2=6\6:N=`MM5BT?3-3U33M#L-2\8:IHEQX;\
M%:]>Z5\X_!']@3XX_`/XE?MB?"KPUX&L?&'PC^-OP)\<?"GX5?M!>,;[X?V6
MOZ+J6M>#9]3\.6OB1=%\5S>+_#_@^[U?7M0\%_$^\\,?"W4KSQKXP\%>`/&F
MF^#?#?A.P%K9^)_`?_@GG^T/H6B:S<^./V??'&F?$#P]^S_^T?X5\)^(-1_:
M/^#%]X,FU#XB>"?BSH_A?X?>%/ACH_AKQ'J>EW^J:W\6M4O+Z?5/C#X:\$IX
MBU#QQ\0;[7;&XU>+P=K7Y!6X@\2_J."RK$9!+'UL7BL]PV88G..'L7FJPTL)
MF,*>61=;*,%E63XF%+#2AF&'S.>6X;+<V]E##TGA:\:U6/\`HQEGA!]"%\5\
M4<?Y1XNT^$\LX?R3PGSKA')O#GQAX>X!GG-#B#@VKC..:]/+O$7B?C[Q'R6O
MF&>4L5PAG'`^'XUSKC7P]6-Q.;X^.?Y5B,MR^O\`;_A?XZ?\$K+[X,^!/B]X
MT^&'[-O@=?%U]'X5U#PS_P`*%L?$6JZ+\1--\(>'_%GC?PK96VG_``HM]=\2
M:/X)3Q+H^G:I\0-/\.0^#9+W5M!M6U*UU+Q!I.FW&]J7QG_X)$Z3X+\*_$&[
M\*_LXOX5\9ZUXI\.Z'>Z?^S0=7OAKO@N;08_$FDZYH&D_"R]\0^%+ZP@\4^&
MM6AM_%6E:,^I>'=?TCQ-I0O?#VH6NIR_+'QQ_9A_;/\`C'\&OV+;:+X!7'@[
MQ5^RIKEKX%U'P]X?^//PZMO'NO\`A?P_X7^"M[H7Q;\&>,05\*>!=2N=9\`>
M)-'L%EU+Q'XH\!^*4\)>);3P]XQT6749=*[+X#_\$_/$WA?Q1^QM)K/P-USP
M7X`^''QH^.GQ=\<>'?$/QP\$>/\`7?!6N0^#/A/9_!K5K_6?A[X;^%=I>1WO
MCGX2:)JECX5\*:?XXT^VT>TL5\;ZLMEK6K>$-$RHYAQ?4Q<,!1X)R*I3E@^&
MXT<TQO`N=82$\3F>*R##YECL324Z=&E2RU8[-%B\ME5PF+PZRYYC*;P2J4H=
M^8\(_1UPG#U;BS,?I/\`BO@\72XB\:J^8\"<+_2M\,N(L3A<FX%R+Q8S;@CA
M;)LP>%Q>8XW'\:SX3X"J</\`&E'+N(>'\XJ\90X-I8>'$WU3'XB7Q%^U_P#\
M$K+#XA_#GPWX;^"/[/OB;P%X@;QG'\2_B--^S[>>'Y/AA+HV@V&I^#1:>$-0
M^!,NH_$&'QMJEU<:'-<:!J%I'X6EM#=ZA]K1I8+;Z4FUG_@GCX6\&?%+Q_\`
M%#X/?LG^#?"OPT^.WB/X#S7VE_"2V\27E_XLT.2P6/1CH=[\$O"^O7OC`6]W
M<ZGK>A>!-,^('AS1=#TS4O$%OXZUC0])UW4-'^7-&_9G_:>^`_Q=\+_$GX3?
MLQ:?XTT'X=_M3_MM>//"GP\T3XE?";X9Z&/AA\6_`?PM\"?"U=+N+G6+BU\-
MZ?/9Z5K<FFZ!;>'I+G1K/PT-.U;3-`COM*DGZ#XK_LB_M(ZQ\'OC#;>&/A9X
M+\7^*A_P4R\7?M0^%OAWX]UKPIJ'ASXF?"K4-/.C:7_:-A)KUMH-[I>K7&IB
MY\2^#?%OB3P;J5WX/L/$5LKKKDNBZ-K,X+%\7QAF]7&<(95B,3AYXB>%P-'@
M/'83"PI4\CP%:A4HXFI.M/,:-3,7C$L!0Q#S)8C"UJ,L0J>/R[#8/?B7A[Z.
ME?$^'F`X:^D9Q]DV2YOA,EP^?<49C]++A7/\^KYAB_%3B?+LSP.99-@\+EV&
MX-S+`<%PX;G4XLS3*8\%RRC.LKS&EDSQ?"'&><\1>P1_&;_@D7+X"U;XF0^$
M_P!G*?PCH7BW2O`^KW$'[-#3ZW8>(]=T'6/$NAP7'@^+X5OXP&F:WI/A[Q"V
MC^(ET%O#FJ:AX?UW1;'5I]:T?4M/MO5?@5;?\$W_`-I:7Q9#\$_A#\`_&C^!
MX_#\OB<G]F^P\-Q::OBAM=30PD_B[X<:#!J,EV?#>L&6+2Y+V6P6VB?4$M$O
MM/:Z_.^W_86_:8^+NL_$KQ%\;?@IH&A^'/C?^W#\%/B#XQ^'.C>._A_8:EI7
MP2T.#XV+\0M0OM4^'-YX8TJZBM-"^*FC>'%\1:#JL7Q>\<^)-.\5^,]9T&WU
MF[@\2^(OU!^`?P3\1_#7]J?]M;Q\W@S3/"WP[^,&I_`[6O`U_I,GAR"U\2ZS
MI'@[Q&_Q-U:71=&NWU'3M3NO&^NWNI:U?Z[INGW7B/6=5O\`6XY=3DNKN];W
M.':O$.8YEEBS3@S(,)E&(QU;`XJ3X1Q^`Q[HK`<0XS#9O_MF)JTLLPM:>5Y3
M2G@\71Q%>C7S>G@ZN(IXF%+VWY5XR8#P@X-X*XXEP)]);Q<XA\1,GX6R[BG(
MJ-/Z17"7%G"D,QEQ;X-\.YWX>?\`&.9)@,;QQGV78?CSQ`Q^&XDX>S')LLS/
M*O#?%<2Y?DV+R;$8[^S/#]1\4?\`!.SP5X1^(GCKXJ?!?]F+PGX6\!_'WQ;^
MS\VI>'/@9>^.))?%OA?3'U@Z9J^FQ?`30M5L/$;Z=::C/J%EX>L?&/@VU:V@
M@TGXA^(;F[$,/?\`P*MO^";_`.TM+XLA^"?PA^`?C1_`\?A^7Q.3^S?8>&XM
M-7Q0VNIH82?Q=\.-!@U&2[/AO6#+%I<E[+8+;1/J"6B7VGM=?+OC3]BOXJ?$
M/P=XL\`>+_ALVK>$O'/_``5:U[XZ>*-+3QIX>TQ]2_9G\3:7=:+K?BI=2TCQ
M78:KI[7FF7MS;KHVF7UE\0;0R">RTFWN8XID^T_@'\$_$?PU_:G_`&UO'S>#
M-,\+?#OXP:G\#M:\#7^DR>'(+7Q+K.D>#O$;_$W5I=%T:[?4=.U.Z\;Z[>ZE
MK5_KNFZ?=>(]9U6_UN.74Y+J[O6WR6.>XC-\LHYAPED5+)ZV*6#QE2IPMB*.
M80<\ISW,%C?K+G#`X?"4<5EN6Y>^?!U/:U<QI4W5I5I4?;>9XF5?"K)O#SC;
M,N#_`*0WBMC_`!'RS(/]9.&L)A/'G*,SX0Q*PO'WA+PC4X8614\+B>*<WXAS
M+(^-.-.+Z3PO$N%6!R_@K&XN.7X_+Z.92RS\W/CQ^U1^R;\,_''QK\.?#/\`
MX)W?!CXM^$_V>(-*L?BY\1M1\'^`?AMX>\+^+M5\>)\-H?#SQW_P>\223P7/
MC.[M/#^B7K3P:GXIN]-\:ZOX:\/:GX)\&WOB^[^FM?\`C!_P2H\%Z3\,=2^(
M/PH^"G@6[^+7PB\#_&WPKHNJ_LPV&O7@\#?$"VN9]!FU#5?`7P]\8>$H]566
MQO[2^TRR\27\MO+:&YC:?3+K3[^\\E\<_"?_`(*4?`+QQ^U!HO[+FGZ-X[^'
MWQZ\<WWQM\'>,M.N?A!H7B'X8>/_`!3X\T_7/%6EKHWQ5U62VUV?4O!FDWGP
M^UNUU>RUGP]>6EQX*\?^$-9\#>(;3QIX1O\`SS_@H/\`LU_\%'OCG:?!+P5X
M5FU[XB^%/#/P.^&B?&>T\+>._ACX3\"_$7XX6&MWFH_$&]NO#NO:Y\+!XC,N
MI^&?!/B'PW?>(/"-MX<\)L(;SP%H_A;7;WQ+#'X%6OG^`P7$.+APWB,QS;#U
M(0PV48GPYPU;)\+B)YMCZ%*EE6-RRO@,?FN"EEU/!U<1C(ULTAA8NGBI5^>M
M4P&'_6<#EGA)Q9Q+X/\`#^)\:\IX,X`S7!8C%YSXAY)],[.<M\1L_P`HPGA[
MP?FN/Q_'O#/&^6\7\*<`\3T.,L7Q'E^3\.U<MX"Q&>U:.*R+#Y2\/EF"XLS?
MZR\>?$S_`()1_#*/P#)XX^'OP&T)?B=\/O#/Q3\$A_V5[V_DU;P'XPAOY_#N
MNW,6E_"6^ET,WZ:9>JVE>($TO6K&:);?4=.M+B>WBENZYX^_X)4>&OAEX!^,
M&N^!?V<]-\!?%'5/$ND>`=0N/V<+;^V?$MSX.U/4M&\4W5GX,C^&;^-8=%T/
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M#<5CN'\B_P")I_%F&;X;/<LPG%&98GZ2?`F`X;X@P^<<$^/N>83*^&<RJY36
MP7"OU;BGPT\,^%\XXXXAS//N'<EJ>*F`KYEEF&H/*L3F7UWXL^*G_!)'P5HO
M@#7]?\-?LOKIOQ.\,S^,/!S:/\`=)\47UWX=MM1DT::^UC2/#'PYUC5O"4D>
MN6NJ^'S8>+['0M2/B'P[XMT!;,ZQX/\`%%EI&9XI^-?_``2&\&6'@G5->\+_
M`+.$>F_$3PE;^./"=_I?[-!\16=[X<GU+Q!HDEQJ-QX=^%>JQ>'=1TS7?"GB
M/0->\/\`B1M(\0^'/$&CWFA:_I6FZM&+-OC;]H#]A[]JSXD>)/V=/'DO[/?@
M.ST^R^!OBKP+\4/A/^S)\1?`OP3M_!=QXAU_XO7%]X3TJ^\;0Z]X:TJW\4>%
M?BU8Z=XYD\.VOQ*T+Q7>6_Q<\,W3V6@Z_P"&O%.N?2W[._[!=SX>^,WP4UCX
MF?!6.'X7^`?V0_''A*+0_%WQ'\*_%"'1/B;\3OBQ\4;_`,2^!?&"Z#HO@/2O
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MQ(\%Y`_B31M.T'0=.T;6O$WBWQ-K6BZ)HFBRVLNM:UH'F?P"^,7[$'Q)T3]I
MS4?C)^Q]^SO^S[>_LG^)+30/BI'J'A+X3?$#1K.2]U3Q)X7AL;+5-!\#Z;J6
MI^+#XV\&>)O"MMX8T7P]JP\17[^%[?P3J_BO6/$4NB:1]&?MU_!G]HWQ9K'P
M&^/'[+%[X?N_BY^SSX@\67&G>!_$5IHYL_&>C?$B'PSH/B*W.H^(=9T71HK.
MVT;2+S3]>TJ;4O#VKZCX9UW6M0\(>,_#?C30O#L6L?.?B?X1_P#!0O\`:$_9
MN_;5\+_&S3M'L-4\?^)/!VI_LX_"#5/$OPKDO/#/A[PK\1'^(^N>&(_&/P\\
M.6>E:I]O\/KX:\!^#]:\?^)1?:QXF\*W-[XHC\!:'J$OBO6?4S6CF6$XDSF.
M$X?GB,-@\#BZ^2930X.RW$9#FU.CPU4QE*IC>(52CBL'F-7B.$\NA@Z5?GE1
MIX2,<OG#%SS##_!^'^9\$\0^"GAI5S_Q>PN39WQ'Q5P_E7BCX@YM])/C;*/%
MCP^Q69>-V#X<Q^$X8\')X^MD7$7!F`\&:V&XQQ/$N/RKZO0S/%Y]4J\7X?$\
M.X3A#-^@O/VLO^">'P_\"?$?XV?LR_#;X'>,OB7\%M(\-Z__`,(_X<^&EK\%
M/&C:'XW\8Z-\,=0U?P_XAUKX86.LR:=IP\6K:>)+SPYIVKP:>FK:1HOB%]+3
MQAHTE[]9ZG^V7X"\'>.?VI]"^)UE)X&\#_LNR?`F+6OB!$^O>+6U]OCGID,^
ME$^$?#7A6\UG28])UF\T[1I9;67Q!%/%=OK-\^BZ?9W1C_'+PI_P3O\`VA(?
M@I\;K6;X">,]&^+^O_!7X2_#&RO_`!5^T;\(/&&F^.9O#GQ(^"NH7ECX+\+:
M-X3TM?`_AGPIX1^$-M;Z3:>,OC#>?\(SX9LO"G@?P[:>-"DNI^&_OCXP?LX_
M$?Q'KW_!2"_O_@CK7Q6\+_'ZQ_95LOAEX9\._%3P5\-]=\877@#0[32O$FMZ
M3XGUJ]U"R\)WWPTULV_BVWM_'&AMI'BI_#XT8:-XFTO4[C3[O@R?.^/53IUJ
M>14LJIRH1Q$L%AN%<UP&5U<3')O$FHZF+P<\%5SNBZF.RK@VEC*&'KUL2Y/`
MTL#-QS>G2Q?UGB-X7?1*GC,=EV-\5<;Q]BZ&;5LHH\2YUX]\!\5\=X'(ZWB3
M]"/!T\)P[Q'AN)\!X89G3P7"_'_TE<?PYFF;95EN2PHPXIQ_%6'A5\.\7CL@
M^T_@1^U7\!OVF)O%T'P2\<3>-'\"+X?;Q2S^$/'/AF'3AXI_MK^PQ#<>,/#7
MA^WU1KO_`(1[5_-32);][#[*@U%;0W=E]H^AJ_,[_@G/\-/VE?A';_%GP-\8
M_#'Q&\'?"72;7X4P?`/PS\2OB]\-_C/JGA^TT[P]KF@>-=$TCQ+X"M-(?3/#
MNGQ:)X+_`+(\,/X;\+^%M$M)TMO"VCR7Q\4ZSJWZ8U^K\+9AF6:9#E^/S?#3
MPF8UXXA8K#SRW%Y0X2I8NO0A*.78[$XO&8>E5I4Z=6C]:K*M5HSA7J4<-*J\
M-1_S]\>N$."N`_%GB[A3PZSK#\0\&975RAY%FV&XUX?\0XUZ.8</Y3F>)H5^
M,>%,ER#AK.<=@,?C<5E^9/(LNEE>`S#"XK+,'F>>4<%#.\Q*\N^.'_)%?B__
M`-DN^('_`*B>K5ZC7EWQP_Y(K\7_`/LEWQ`_]1/5J^HPG^]X7_L(H_\`IR)^
M68#_`'[!?]A>&_\`3T#]P?V(?^3+OV0_^S7_`(`_^JH\)U\3?`;_`)/1_P""
MJG_9T/P$_P#7?7[(%?;/[$/_`"9=^R'_`-FO_`'_`-51X3KXF^`W_)Z/_!53
M_LZ'X"?^N^OV0*_$N*/^2=S;_KU@_P#U:8`_H[Q`_P"2??\`V&X;\JI]HT44
M5^*'X<%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!\I^#_AKXUTO
M]N']HCXP7^B^1\.O'7[*7[&GPU\*^(O[1TF7^U/&OPH^+O[=_BCQ_HO]D0W\
MFNV/]@Z%\9OAK??VCJ.F6>DZI_PDGV;1;_4;S1]?M]+_`")\+_\`!/KX]6W[
M(?QQ\)ZS\#]";X[ZW_P;N_LK?\$^OAQ=7&N_"V[\30_'KPO\,?VQ]-^-?P/T
MCQHOB2:WT#0KGQCXO^`,GB+79=>TWX6^+]0M/"^K6_B36X_!%S>:!_1%17=2
MQ]:BY.$:=YK")W4]L&H*FE::^-02JWOS)R4>6^GHT<SQ%!S<(TKS6!3NI[8!
M4U22M46DU32K)WYDY*/)=6_#/]JW]BWXY_\`#3_A'XP?LV>$?'7P^^%WP$\"
M_L1Z=X!TW]EJ3]E/P[\5/[)^$GP]_P""N?P3\4_#7X!>!OVF;.X_9TT3_A`M
M'_;,^!]]JEA\6-,\(>"O^%/77C>V^$^M:A\4?"V@^&J_2#]BCX3Z_P#!?]G;
MPWX/\5VWCJU\4ZQXZ^.7Q8\2Q?%#Q7\-/&?Q+;7_`(]_'?XE_'/6;GXB:O\`
M!?P)\.O@[9^.KS4?B+<W?BWPI\)_#^H?#3P'K\^H>!_`GCOXI>%O#NE?$WQ=
M]645-?&U:]&%&I&G:'LDIJ+562I4Y4X*<W)\R]Z<]5\<Y-63L1B,PK8FA3H5
M(4K4_8I5(PDJTE1I2I0C.;F^9>_.;NM*DYN+BGRA1117&<(5\"?\%4_^4;/[
M<W_9KWQD_P#4*U:OONO@3_@JG_RC9_;F_P"S7OC)_P"H5JU>MD'_`"/<E_[&
MV7?^IE$Z,)_O>%_["*/_`*<B?M'7Y83_`/*4C]JO_LP3_@G5_P"M$?\`!4VO
MU/K\L)_^4I'[5?\`V8)_P3J_]:(_X*FU^H<6?\D_C_\`N5_]3<,?NW&W_),9
MG_W)?^K#"'U/1117XR?@(4444`%%%%`!1110`4444`%%%%`!1110`5UG@_1[
M#6]3GM-1CGD@BL_M:+;WU]I[B>VO;%XB9M/N;6=XP2=\#R-!,IVS1R+Q7)UV
M'@K3;75=4GMKMKQ8H[(72FRU'4=,E\ZVU"PEAW7&F75I</$)%5GMWE:"4J!+
M$X`%>SP]_P`CO+?^PF/Y2/?X6_Y*'*?^PN'_`*3([[X:((_!.B(I8A1J(!=W
MD;_D+7_WGD9G8^[,3[UW5<+\-$$?@G1$4L0HU$`N[R-_R%K_`.\\C,['W9B?
M>NZK]O/Z)"JE[86.I0-:ZC96E_:LRLUM>VT-U`S(=R,T,Z21ED;E25)4\@@U
M;HI-)III--6:>J:>Z:ZIE1E*$HSA*4)PDI0G%N,HRB[QE&2:<91:333335T[
MGYQ?M/\`[)_QG\5?'CX#?M"_LO:]\'?`_C3X0Z!\2/#][8?$?2O%(\.ZG#XX
ML;738;I=-\%+$NHS6]E=:^LJ:B8(X;F33+Q3>36T'V'SKXG:I_P5<^%WPU^(
M7Q,U/Q]^Q=J^F_#KP/XL\=:AI6D>"/BP^K:G8^$=`U#Q!=Z?I:75];VSZC>V
M^GR6UDMQ<00-<RQ"6:*,LZ_K%17P.+\/,NJ8K.,;EF<\3</XC.L1]=QD,DSK
M$8/!/,8Y?@\LACHX*TZ"JK"Y?@H3@E&G45"-X+FE?]OR?QWSW"9=PED_$/"7
MA[QQEO!^#649=/BWA#*\VSF602S[,^(:V2O.\32J8R&'>.SK-7AYM5)X58R7
MLU+EBCP_]FGXF^(?C/\``+X2?%;Q9HEKX;\2^/O`^B>)M:T*RBN(;+3-0U*W
M$L]M:0WEW?WD5J&^>WCO;J2\2)D6[6*X$D,?#U]45\KUYW%N'Q&$R_AO"XO&
M3S#%X;!U</BLPJ4HT9X[$4:&7TZ^,G1A*<:4\34C*M*E&<HTW-Q4I))O^3O&
M?&X+,LZIYCEN64LDR['YIQ#C<!DU&O4Q5'*,%BL7A:^%RREB:L85<12P%"I3
MPE.O5A&I6A252<8RDTBO(O\`@E%_RC:_8G_[-X^'?_IFBKUVO(O^"47_`"C:
M_8G_`.S>/AW_`.F:*NS@'_F;?]R'_NX>7X9_\SO_`+IO_N^?B+^P[_R:Q\)_
M^O+Q/_ZF_B:OJ^OE#]AW_DUCX3_]>7B?_P!3?Q-7U?7]'U/XE3_'+_TIGXWQ
M#_R/\\_['&9_^IM<*X_QM\//`'Q*TJWT+XC>!O!_C_1+34(M6M=&\;>&=%\5
M:5;:K!;7=G!J=OI^NV5_:0ZA#:7]]:Q7L<*W,=M>W<"2"*XF5^PHK"K1I5Z<
MZ->E3K4:BY:E*K"-2G.._+.$U*,E=)VDFCCR_,<PRG&X?,LJQV,RS,<'45;"
M8_+\37P>-PM5)I5</BL-.G7H5$FTITJD9)-J]FS\Q)/$?_!/B36_VDM"TG]F
MCX&ZU/\`LN:E\.]'^(.IQ^`OV8-!\+:CJGQ$O;W28-.\/>,O&?BGPQX3MM0\
M)^(-*UOPMXST[QKK/@V_TSQ7HFH^&["UU;61:6=UZQXJ\+_\$U_`OB&\\(^-
M_#O[#G@[Q9IR0R:AX8\5:1\!/#WB&QCN;2SO[=[S1=7M[/4K5)['4=/O86GM
MD66TOK.X0M#=0._Y?7.GZ)\1_P!G?_@K5\/?AAX2N_%WQS/[9^IZAX@T3P=X
M)U/6/&NK>"9/V@M-3P=";[1M(N;CQ%IVFZWX0^,VIVNAVE[J%QX7/_"2:U?Z
M=I$7B'[5J?M?QI_8_MOB[\>?^"EOQ-\:?#3QSXAN;#X&>"+#X"1+H.K1Z)XL
M\:CX1:%X@_MOP+>6>E1ZOXB\9^%?&?PO\,^&((/"6N&UFT_Q1XL\$^+-'UVP
M\4OIL?X9_;&,E3@\!PIP]CZ^)M4INMEU.G@<-#V_B-B*U"57"X*I5>)P6&X5
MRO+ZSE.:GBL5"]&A5JI5?]5EX;\-TL76I\6>/_C#PCEN2WPN,CEO&>-QG%.<
M8AY5]"W*,MS6C@<_XGP6!ADG$>=>/O'G%^7*EAL-/"Y%D6)4<PS3`Y=-Y?\`
M3O[0-S_P3N_9Q^#_`(?^.'C'X!_`KQ)X&\9:CX?TSP+=?#SX*?"SQ6?&\_B;
M1=0\4:5<^'=4CTVS\+R:1/X1T?6?%46O:EXATW0[S2--9-.U"]U74-%TS4_$
MO%7QK_8+^'GPV\1?$[XI?\$_/$7PHTC1?$W@[PAH^D_$G]C_`.&?A+7/'>O>
M+[;Q1J9M?!@U"5=#N8?#&@>#=?\`$/BJ]UW7-`L[#3X+*SL9]3U_6=&T:_@_
M:K^#GB'QA_P3A_9@\+:A\$_C/\2=?^'^A?`B_P!;\`?##7=.\#?$CPSJMG\&
M-8\#7-]J.F>(?A=\5M5U&+0M9\21:5KGAK3/`=UK>EW%V/$&J-:>'_#/B)6^
M:O@7IWQ"^`G@7]JGQQX,_8>^.GB+PKJ/QX^'^K?LD?!_XM^"-7\=7GP\^(6G
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MX?>+OV;OA1HOQ`LK;PSH?B/6+NUTZP47?AZ36+B[\'>+?#:Z%JGB;2=9TOQ%
MX?N[;Q+8Z%87>DZEJ7$?!;XZ?L)_'_4?#\'PR_X)U^+M>T#7/%VD>#+KQY:?
MLB?"#4?`/A75-6DT@O/XP\2Z'JNKVV@V.C:?KFFZYKSSQO=Z9H=Q'J4EF\4L
M`E^?_`_A3XG>*O@'XO\`"/B7X7?MOW?QW_:]^/O[-O@#]KCXS^)/"OB#X97_
M`(?^'/BGQ-X@N_$NH_"K3K*P\4Z7+\+?ACX5T76/ASXGN=7\.>$="7P_\1K.
M[UVQTCX?V_AKX1>'?!O@9^S;XX\&_'K]FNR^'7[)?[7GPH\<>!/VE5F^(7Q!
M\;^,K;7_``1!\)=&A\&Z?XBTU/'?A[X4_"_P9J.E7&F:+\3E:[TK6ETOQ3H.
MM7WAS3M4^,T7Q0\&^&?AWY=;.,VMPM.ADV2UZ.,O#,YT.&4L3BJE?.EAL+A:
M4(95F&#P^98;*IX:OCL/+%X?!U<0\9]2QTZ6%YU]WEWAOX?*?CUA\V\2O$S*
MLSX;A1Q'`]'-/'.4\DR'!97X:4\YSW/LPQ6)X]X1XCS?@K.^/</G.5\*9O0X
M=S;B/+\HAPT^*.%<-F&>PPU3]:=7N_V!-)_:F\,?LBC]F'X0ZK\3/$WAV3Q`
MVJ:+\&O@C?\`A'PW+'X?\4^*V\.^+)UF3Q/H?B9O#?AF'78M-E\*R1SZ3XI\
M):C#=26>JS367N'COX,?L(_"W2['7/B;\*/V2?AUHNIZM!H.FZOX[\"_!WPC
MI>H:Y<VE]J%MHMCJ'B#2M/M+O5KBPTS4KV#3H)I+R6TT^^N8X6AM+AX_RY^&
M7[(?[67P4_:W_9C\9>(/"'P+\4^(?$/Q0^.GCWXJ_&OP'H'Q*OKC65\=Z8MW
M\1+SXP^($\->'_#7AG4+O1M9UZT^`_ASPYH_A?P1'X]U'6[F^T=KO7O$NH:K
M]M?\%26^+C_LX:+I_P`$_A78?%?QOJOQ3\/6D5A>_!.Q^.\OA?3[;PQXTU>X
M\46'A;6/"WC;P]HT\MSIEGX0O?%6O>%=8M;+1/%FK:3IB67B36]#U2Q^NRO,
M'+(^,<VS7@_!X3$9-F,WEN75>'Z2K++ZF4Y3C</A9PI4Y3QF+I5L37AB:U&:
MH2GRN%2%"-X?SQQWPE3H>*7T;/#WP_\`I'<2<0Y-XE<&8.GQKQC@/%_'U,OG
MQ=A?$/C[AC.,\PN(S#&4L/PYD689=D64XG)<LS&A5S2CAU4AB,'BLSG[+%=7
M+9?\$O8-+M]<FM/V"(=$N]7OO#]IK$L'[/,>EW.O:9:Z%?:EHEOJ#H+2;5]/
MLO%'AF\OM-CF:\M+7Q%H5Q<0QQ:OI[W#YO#?_!/NZTSPOK7@WX/_`+)?Q)T;
MQ1\5-`^#R:MX&T7]F*[TS2O&?B&Q34[?3KV_UO6M!M=2U2VTVXL-0D\&^%9?
M$?Q&U"QU.PN]`\%ZS!*\D7XM_L<_LK>.O'.H?LC_``R^,_P7^-?AW0?!_P`>
M_CA\2?B*?%/P>\?Z#X7_`+'M_AE\#]1\%Z?XDUKXD^";GPYJ7A;X@>-?A%K/
M@_7=&O[JYU?5=`N+BTEFTVX\2^']7N?K7P?^SUXU\`^$?"W@7PI\)OB'IGA;
MP7_P6=T3Q9X:TV3PUXSU.33_`(&>'-,M='T;Q\^I:M!?ZKJ'@*TTZSMH&^(&
MIWUYIEVT9GO=<N+F229_`R_B7'YAAGBJG`F1X3#2E'"Q=/+G]>IXVGE^1X_$
M.5&OE]2BL-&>98C"^]^\C5PTJ;7/2J27Z[Q?X)<(\'YU3R+!?2P\4>(,[HX>
M>?55C>,:<>%<3PSCN,?$[A/*(4\RRKC'"9C/.9X?@K*.(&J#6"K9?G&&Q<9+
M"X[!PG]UZ[9_\$N_"^IZMHOB:U_8'\.ZSH.H3Z3KFDZ[!^SSI&IZ-JMM?2Z9
M<Z9JUAJ"V]UIVH6^I0S:?/97D4-S%?12VDD2SQM&+S:!_P`$SD\,#QL^B_L*
MIX,/BI/`H\6MIOP!7PP?&TFC+XC3P<->,(TK_A*G\/,NNIX>^U_VNVC,NJ"S
M-B1/7Y?^,?V(+7Q]XO\`%'CSQ7\"_B5J?BGQG_P56UWPCXDU&.W^*FF1:A^R
M;XDU.XUG6?$::7I%]8:18>";K4;NXG3XNZ;86=_9K(;>Q\96ULJ0K)X\^$_Q
MG^#'[(7QV^&?P0_9XU77[V7_`(*'^/[/X9>'_&/P)U7XYW6C?"72_`JKX7^(
M'AK2?B#X9\>VM[I5_;^%[+P2OQ2\2:)XLM;W1O$.NV-AJ/\`PEVM:7K5EM3X
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MZUVFB'QYX.^"WA`:R]@]DE\NE'Q#IVG#4&LGU+3DNUM/.-L]_9+,$-U`)/QO
M_9)^$_QCTC]G+]GSP-X@^#GQET3Q=X0_X*;?`WXH>*-.U[X2?%/0UT_X?#P5
M!H%[XV>_\4>&[5;CPYINK>%]6BUO5)+^ZDT&!]'O_$DME;>)-`N]5_2O]M+]
MGG2OVB_VC?V+/"GCKX?>)_&_P>@'[1P^)5UHLGC/2-(T(3^`_"VH>#O[?\9>
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MA3P5''82O!U:CC&+^XH^!'#>/\6\VX%R[Z8/BFN%\NX6QV,GQ!F'&?#F`QF$
MS?)O'CCWP7XCXAQD,;XC8/+L3P+P_@>"(>(52&68K%<39CPMQ!E&(I8#"1J3
MJP_7CX]ZU_P33_9VT7Q7>^-OA7^RSJGBOP?-H5OJ?PG\+>!_@'>_%R>X\02Z
M,]E!8^!-6ET34I9HM%UNT\6745P]JZ>$X[C78EFM$C,OJ'CGP)_P3H^&&JKH
M7Q*\&_L4_#S6WTF'7DT;QSX>^!?A+57T.YN=0L[?6ET_7[/3[MM)GN]*U2UA
MU$0FSEN=-U"!)FEL[A8_P&_:A_9O^,;_`!#_`&G=(TG]EOX]:MXS\8_M?WGQ
M)\._$'PW\.+_`,;>!-3^$=U8?'+5SIF@ZUX6\*W\VCWWB?5/B3X(\4^(9;?Q
M;K>FZ[<Z)IGAWQ-H?@7QO\.[BS\2^T_MW?LT?$SQ;^V_\<O$NH_"KX\S_#'Q
M_P"#/`-[I/COX-?`)/CU=:K<:+X>^%=BMK:VUOXH\*6OA748]:^'>MZ=JVI1
M^*M*^(%MHFG1^'F\.ZE\./BC>76I<&)XNS&A_;F(I>'V58A8/,,IRW"8#^RG
M0>%>(K\6+$XC'8K%X/!PG)QRC*:$W3E#"4)XZC4IU*TZD:%7ZK)/H[<'9J_"
MK)\?],+C[)I\2<)>('&N?\5RX_69QSV&3Y1]'FKD>2\*Y%P]Q)Q'B</2A6\1
M/$#-L-'&8:OQ!FF'X6S#!8[`Y;AL#6S7`?JE,W_!.K2?B-\6_AMXT^"W[-?P
MTOO@[JGPUT/7/$OQ*^'/P,\&^#_$&M?%3P9K/CSPWI'@_6-6\N;5M4A\.^']
M8NM3T^\L-+NXUT^\GL(=1L;2ZO(,+XC>*/\`@F5\.O"7@WQZWPN_97\;^!_%
M_P`:O#OP)N/&7P^\%?L_>(O"?@GQAKVC7WB2ZO\`Q_XEDN=/T3PSX?\`"WAJ
MPD\1^++F:_N-5TG1)K34$T:[ANHBWYL_%7]E/68/!_QR^''BKX;_`+5$&E6T
M?_!/7PQ\-]9^$_P*7XC:Q=:S\,OV5?&7@GQ3=:WX<T#QS#X>OO#?AVR;6/#7
MB?4?`?QAO;'P?\1-3\(P1^+]>L#]EUZ?XM>(;?0O^"6_QDTCX]_"BR^''B>'
M]IU?#GP6?Q'^S#IGP"\2^,[NUM/"WC.+X@7?@?P]HD?A#PQXINOA-:_%#P;=
M^,M#DT[0KCPSX=NOA[+XH\2ZU+>W_BCH?$F,I4<]CB^#\DP<LORSBO-<'B*V
M58=MRR3/,UH83+,5'V4(4ZE?`8/"8>A7C3G2QLZOMZ5>-9PH2\:GX*\.YAF/
MA15X>^D;XH<1T>+N-_H_\`<1Y3EW'^<4U##^*'A9X=YKQ!QUD,Y8_$XK&8/*
MN*N(^(<VS7*ZN,P^-X9PV`IY9C<IJ9=1Q&;4?Z`/!/P0^"WPUU6XUWX<_"'X
M7^`-;N]/ETFZUGP3X`\*>%=5N=*GN;2\GTRXU#0M)L+N;3YKNPL;J6RDF:VD
MN;*TG>-I;>%D]0HHK]^P^&PV$IJCA</0PU%-R5+#TJ=&FI2WDH4XQBF^KM=]
M3_(O.,\SKB'&RS+/\XS3/,QE3IT98_.,PQ>9XV5*DFJ5*6*QM:O7=.FFU3@Z
MCC!-J*285Y=\</\`DBOQ?_[)=\0/_43U:O4:\N^.'_)%?B__`-DN^('_`*B>
MK5WX3_>\+_V$4?\`TY$YL!_OV"_["\-_Z>@?N#^Q#_R9=^R'_P!FO_`'_P!5
M1X3K\T!\0/$WPF^,'_!;KXJ>"_ASKOQB\8_#/XE^"/B!X3^$?A=M03Q-\4_$
MW@S_`()E_LL>(]!^'/AU])T+Q1JBZ[XWU33;7PSI#:;X9\1:@NH:G;FST+5[
M@1Z?<?I?^Q#_`,F7?LA_]FO_``!_]51X3KXF^`W_`">C_P`%5/\`LZ'X"?\`
MKOK]D"OQ3B9I</YHY14XJ&"<H-M*26:8!N+<6I)26C:::O=-,_I#CUQCD492
MBIQCC\(Y0;E%3BO:-Q<HM22DM&XM25[IIG2_L1?M`_$O]J7]F#X8_'?XP?LY
M>.OV2_B+XZ_X33_A(OV??B5)K\OC7P!_PC'Q"\6>#M(_MJ3Q1X&^&NNM_P`)
M5H7A[3/&VG?;O!6BXTGQ)8"V_M&S%OJU_P#-_P#P4RU+Q,C_`+#GA70=!_:0
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MZE.JJ%-5)5(UG&E*<%[7VJK*,>=3]HDSX9\6Q:M\*-2_X)6>"/!]U\<_`.A>
M-/VK?&6G>./`_P`6_C=XU^,'Q+GTG6_^"?W[>?Q:N_AK\9/B1X@^*_QCO/B;
M_P`(E\1=(\/ZBEA=_%+XC^"M'U_P1X6?P/K5WH7A+P?=V?YO_`W]IK]H#P_^
MP7^PY\/_`(T?%[QUXD^*WQH_X=!_'?X)_&9]<N6\??%K]G_QU^U'_P`$U/!7
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M+O[6?[5^D^`_A/XB_9G\4_%35_V?7^%.I_#;X9Z'\(]7T?P]\-O#OB;PYX0N
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M#M`T'0=-RQ>(IUFI4Y57*-6K.,JD8QE"G/D]G0@XU:C4*#@W32<8_O).,(6?
M-AC<52KN,J4JSE&M6J1E5A&$J=*I[-TL/!QK56J>&<).DDXQ_>S<84[/G_GZ
M^(WPF3X5_`O_`(+A?$OP;\:_VR8?&/[)>A?M`>'?V>]0\1?MZ_MM^.=/^'6G
MW/\`P2;_`&>OBY#<6_ASQS^T#XC\->(==T?XG?%WQYXZ\+^*/%VCZ_XF\(>)
MM1TC5/"VKZ/<>$/!S:![G\`HO$VD_MB_"/X=?#[X0_\`!0/]FG5-*T+Q7\5?
MC;8_MS_MK:A^TKX#^-'[-[^#?'_@`^$?@=X;U3]NK]L_1K_XK>#?VD]<_9V\
M;^.?$_@SPWX-UWX4?#JUM]$^('Q,\):7^T!\/?AY\>/T\\1_LV?!7Q9X3_:3
M\#^(/!?]H>%OVO?[=_X:(TO_`(2/Q9:_\+"_X2;X*^"_V=];_P!-LM=MM1\)
M_;?@[\/?!_@__BA[OPS]F_LC_A(+3[/XIU#5-;O>ZU_X:^"O$WC7P!\1M7T7
M?XZ^&/\`PE4/@SQ18:CJVC:MI^D^.-)ATCQCX5U&XT:_T_\`X2;P+XF_L_P[
MKNM>`/%"ZSX*U#QKX'^&OQ`N-`?QU\,?A[XB\,[SS&,Z3IR52;E2E3G.<IMW
M^J4*4?=591J+V\*U3][&7(ZBK07M'.+Z9YK&=%TY*K4E.A*E.=24VT_J.&HP
M?*JZA47UFG7J_OHS]FZJKTU[5S@_Q/\`^"4FG^)O%7PM_8B^+'C3X`_\%/+G
MQCXR_9O^&/C/Q9^TC\;/^"@VH?%C]F_QCXF\7_`6UU/7OB%J7P&U;_@I%\3=
M4O="^(^J:I=7?@;1M2_97AU#P=KOB/PUJ]YX.^&]QH$FH^%</]A7]I.]_;2^
M(7COX<?%/QI^U;=_#K]L_P"!FL_M@_!^UD\.?M:_LDZM\.O"?@/]I_6)=,T/
MP=\;K;0O@1+'YG[*_P`=_P#@GC\/M6TS]C7XJ_$WX*^)O&OPF_:"\=>*_$VI
M7GQMOOBO^U-^@7AW_@F'^R/X7\!W'PITVS_:0N?A+<_"GQ1\#9/A%XB_;J_;
MH\7_``D7X2>+_AUJ_P`*-6\!V_PN\6?M':WX"M-"M/`6MWFB^%XK7P]#/X(G
MATC7/!<^@>(-`T'5=-^RO%OPU\%>.M?^%_BCQ5HO]J:[\&?'6H?$KX:WW]HZ
MM8_\(WXUU3X:?$3X/W^M?9M.O[.SUCS_`(=?%?Q_X=_L[7[?5-)B_M[^UX;"
M/7=+T74].NOC\-4GB)PC7<JO\&H_W<\-[.52I14'.OBIV=65-R5*K0C35).,
M)\SBM,3F6$JU,54A#$.=?^!5?[J>$]E*K6H*#J8G&U+2K3I.:HUL-"G&BG"%
M3G<5^?G_``34^$&C:)X'\??%2Z^(7[2'CGQC'^TA^WS\$X)/C!^UM^U-\<?#
M-I\.OA)^WC\=/AC\.M-L?`/QD^,7CKP%8:[X8\!?"_P7X9MO'-GX9@\>7>GV
M&IG4O$M[<>*/%4^M^4_''0]6^*?_``4M\9_"WQ!X)_;F^(WPZTS]E+]BW4;2
MX_9>_;.\:_LQ_#3X&ZM\2OC[^W-X=\<?$KXJ>%_!_P"V1^S)KOC3_A)-"\#>
M#WN+_P`#^"/C3XUM]`^%UUIUIHMG>2^'](\3_IYX2^"?PZ\!Z?H^D^#=-UWP
MUI>B?%;XL?&R#3=(\<^/+33]2^(OQP\3?$_QI\3M2\46<?B46_C/0O$7C'XQ
M>//%EOX&\71ZWX#\.>)KOP[KWA;PUHFJ>`O`-UX9W=/^&O@K2_B7XM^,%AHO
MD?$7QUX%^'?PU\5>(O[1U:7^U/!7PHU_XH>*/`&B_P!D37\FA6/]@Z[\9OB5
M??VCIVF6>K:I_P`))]FUJ_U&ST?0+?2^=XVU?%5TZDI583C1<I2C*E>O"<4I
MPJQG!1HQE%<DK)OV;C*FY7Y'F%L3C,2G5G.M"I'#N<IQE1YL33G!*=.M&I!0
MH1E%>SG92E[-QE2<G+XU^(.AS_M)?M>?$S]G+QUXR^*WA;X2_!']F_\`9N^-
MFC:/\#_C-\6_V>?$WB[XB_M`_$[]K/P+JNI>._B7\$/&O@+XG:KH7@+PU^SC
MI=KX%\#:/XQT#P'=ZA\1?'NO_$OPU\1O$&C?!S5/A-X9^S-\<OBW\1_VE/V9
M]!\;^/-=UZWTGX4_\%GOAAXFVRP:'I_Q-U#]CG_@HS^RC^R_\*_BQ\0/"7AF
M#1/`5W\5KOP%HFMZMKNL>&_"?ACPSI?B;XB_$:/X=>$O`'@[Q*/!]E^@?QH_
M9R^%?Q\_X1JX\?VOCK3M=\'_`-LP^&O&_P`)_C#\8?@!\2](TGQ)_93^)_"M
MM\4O@+X\^&OQ%;P+XJO/#WA75_%?@";Q1+X*\4:_X+\">(M?T#4==\"^$-1T
M7AOB1^Q1^SM\3O\`A47V_P`-^.OA[_PH;P+XD^%_PA_X9W^.7QW_`&5?^$'^
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M=X\O_P!E#]LG_@HZOQ,^*VF?'?\`9=UW_@HC=_"+P9H?Q5^(NB_LWV7A#]A+
MXT?M!?"[P7\-_&7[.&F^)[;X2_$[0OB_X?\`@I<WOQF\<?$?PWXI^.,>N_%3
MQKJ'P4^+7P7C\%?L\VOP.^R;_P#X)U?LV:AJVG>(FU;]JW3_`!3I_@71?AK<
M>,=`_P""@/[>_AGQKXF\%>&?&OQ*^(7A?1?'_C/P[^TMI?BGXD_\(KXI^+_Q
M&N/"NH_$#5_$VK>&=)\33>%]"O\`3_"VGZ1HVG]U#^Q1^SM%XU\*^/Y?#?CK
M4M=\*_\`"`7C6&N_'+X[^(?!7CKQ9\*])T#1?AS\5/C5\-==^)>H_#KX_P#Q
MS\%V?@_P'-X>^/OQR\*_$/XU:=JWPU^%NOP>/5UWX7_#_4?#=1Q&$A-3C[9Z
M892BZ%**G"A2C3JTI?[1)<F*:YJKL^5+E<:JG*UQQ6!IU%4C]8=EA(SB\-1B
MJE/#48TJU"5L3)>SQK7-6DT^5+D<*RG*WPS\;OBA\2]'_:?^,G[%NB_$3QTN
MN_M7?'/]A?Q[X"\8P^+=?\/6WPH^"OQ*^'OQDC_:?^`7A75M+U"Z\7?##^W?
M@!_P2I_:D\7>`/BI\)KSP]XLL_V@/VL]`DT&S^%.N^%=5_:"GW/V"OCE\6_C
MY\:+70?BYX\UW5O&/[*7[&W@WX8?%C^P98/#W@/XQ_M3:Y^U?^U)^R_^U1\6
M-:\):1!I_AK6M"TGXG?\$V7U;]EO6-/\)_#K6?"OPZ^-GQ9C\1^$M.N/'UIX
M/^'GZ>ZA\-?!6J?$OPE\8+_1?/\`B+X%\"_$3X:^%?$7]HZM%_9?@KXKZ_\`
M"_Q1X_T7^R(;^/0K[^WM=^#/PUOO[1U'3+S5M+_X1O[-HM_IUGK&OV^J85I\
M$_AUINH?$C5M'TW7=!U3XN_%;P/\;/B+J7AWQSX\\/:AXF^(OP\\,_"7P7X;
MU*XO-$\2V%Q9:%)X.^!WPT\)^*/`VER6/@/QYX9T?5]!\=>&O$>E^-/&]KXC
MEXNA*@Z7L.6;HT8JJHPE*%6"A1K2B_=;A6P\$W&ZY:O-H^;VJB6.PTL-*C]7
MY*CH4(JLHTY3A6@H8>O*+?*W3KX6G%N-URUN96ES>VC^-GQF_8>_;2\*_"3]
MNN/]C;XL?M(>&?V@O$7[2'[,ND?L1>+OC-^W/^T'\8O`?@[X"Z;/^P7XR^+/
MBC7/"WQL^,WQ@\-'0M(^)WA3]J&?QK;^,?`/B/XI>,?AT?&7PQT/P[XS^&WC
MS0?`?BK[F_8!\._MBZ3#^U[XD_;(N-=75/BA^V3XY^)_[/7AS7?%'@SQ#/\`
M#K]EGQ1\)/@DOPF^$[:?\/M7UGP=X3UWX57&G^*/`'Q&T?P[?:EHVN?%OP]\
M0/B'I/BWXH:7XWLOBYX__0.BHJ8^K5H2H5*="3DXOV\H-XA*,,/#E55S;Y9?
M5HSE%IKGJ5I*W/IG5S.M7P\L/5I8>;DXMXB5.4L4E&GA:?*J\IN7++ZI"<HM
M->TJUYI)U-"BBBN$\X****`"O@3_`(*I_P#*-G]N;_LU[XR?^H5JU??=?`G_
M``53_P"4;/[<W_9KWQD_]0K5J];(/^1[DO\`V-LN_P#4RB=&$_WO"_\`811_
M].1/VCK\L)_^4I'[5?\`V8)_P3J_]:(_X*FU^I]?EA/_`,I2/VJ_^S!/^"=7
M_K1'_!4VOU#BS_DG\?\`]RO_`*FX8_=N-O\`DF,S_P"Y+_U880^IZ***_&3\
M!"BBB@`HHHH`****`"BBB@`HHHH`****`"NP\%:;:ZKJD]M=M>+%'9"Z4V6H
MZCIDOG6VH6$L.ZXTRZM+AXA(JL]N\K02E0)8G``KCZUM'FTJ&XD.L+JS6ICB
M9!HVI7^EW0NK>]M+RW+W.FZCIEPUN'MLRV[7#03X5)X)8R0/4R2M2P^;8"M7
MG&G2IUXRJ5):1C%)ZOR/9X>Q%'"YWEN(Q%2-*C2Q,9U*DW:,(I23E)J^FIZQ
M\-$$?@G1$4L0HU$`N[R-_P`A:_\`O/(S.Q]V8GWKNJ\'T>\\*Z3IB:>LGBUC
M$URT#V^M^(K2W3[1-+<`&T3QE(,))*Q812PJXX18NM165WX>M]!.E7%_XON+
MXVUY`=0BU;7K6W\RY:=HY1IG_"931[(1*@>$W+"<QL6=?,(7]:_UBR3_`*&6
M&_\``I?_`"/G^?9G[?\`ZU</?]#;"?\`@4O_`)#S_/LSWVBO`OM^C?\`"/?V
M9_:/BC^UO[-^Q?VI_:/B3[!Y_D^3]J_L7_A/-WEX^;[)_:>S=QYOE_)3;ZZT
M&Y\/_P!DVVH>+;?419VD"ZE-JFOW=H)[8P&2=M)_X32W4Q3&)]MLMZGD"1=D
MS&,%C_6+)/\`H98;_P`"E_\`(^?Y]F'^M7#W_0VPG_@4O_D//\^S/?Z*\#UN
M_P!%U+1Y;&PU#Q3I^H2BVS?W6I>)-3M%,4L4DQ&F'QW9DB4(RQA[YC!N#$S,
M@)75[_0[ZWL5L+_Q58W=IJ%G>2S76J>(]2MYXK??Y]NEL/'-E);M/N_=7*7;
MR6V/NRY.3_6+)/\`H98;_P`"E_\`(^?Y]F'^M7#W_0VPG_@4O_D//\^S/>Z^
M5Z[B\U[3TFT^XT+4O$>FR6MXL]VNJW&M>(H+VV56!LQ:W7C6VMX1(Y5I)GBN
M7VKLC6,L7KAZ^(XRS'!8_P#LWZGB:>(]E]<]I[-M\GM/JO)>Z7Q<DK?X7V/S
MOC[-<NS/^R?J&+I8KV'U[VOLFW[/VOU+V?-=+XO9SM_A?8*\B_X)1?\`*-K]
MB?\`[-X^'?\`Z9HJ]=KR+_@E%_RC:_8G_P"S>/AW_P"F:*NW@'_F;?\`<A_[
MN'H>&?\`S._^Z;_[OGXB_L._\FL?"?\`Z\O$_P#ZF_B:OJ^O?M&_X(N?"OPI
M8#0_!'[7O[<7@GPK;7FJ7.C>$M`\=?`:31/#UMJFIWFJOI>DOKG[.6LZPVGV
MMQ?3):G5-6U*_P#)V_:KZZFWS/J_\.?O"O\`T?+^WS_X7'[./_T,%?N4N(,'
M*4I>RQ*YFW;DI.UW>U_;*_K9>A\_FGAEG^.S/,<;3Q>3PIXS'8O%4X3Q&-YX
MPQ&(J5HQGRY>X\T8S2E9M73LVM3YLHKZ3_X<_>%?^CY?V^?_``N/V<?_`*&"
MC_AS]X5_Z/E_;Y_\+C]G'_Z&"E_;V#_Y]XG_`,`I?_+CA_XA1Q%_T&Y+_P"%
M.._^=Q^1GBS_`()P?L8>.?%7B;QMXI^#7]J>)_&'B#6?%/B/4_\`A8?Q6LO[
M1U[Q!J-SJVKWWV+3O'-II]I]KU"[N+C[+8VEK9V_F>5:V\,")&O/_P##K?\`
M82_Z(9_YDWXQ?_/!K]D_^'/WA7_H^7]OG_PN/V<?_H8*/^'/WA7_`*/E_;Y_
M\+C]G'_Z&"OEZF2^'U6I.K5X+R"I5J3E4J5*G#F23J5)S;E.<YRI.4IRDW*4
MI-N3;;;;/WC">)_TO\!A<-@,!])KQ>P6!P6'HX3!X/">,_B?AL+A,)AJ<:.'
MPV&P]',(4:&'H480I4:-*$*=*G",(1C&*2_&S_AUO^PE_P!$,_\`,F_&+_YX
M-'_#K?\`82_Z(9_YDWXQ?_/!K]D_^'/WA7_H^7]OG_PN/V<?_H8*/^'/WA7_
M`*/E_;Y_\+C]G'_Z&"H_L'P[_P"B(X=_\1K(_P#Y2='_`!%OZ9/_`$E'XS?^
M+M\4_P#YY'XV?\.M_P!A+_HAG_F3?C%_\\&C_AUO^PE_T0S_`,R;\8O_`)X-
M?LG_`,.?O"O_`$?+^WS_`.%Q^SC_`/0P4?\`#G[PK_T?+^WS_P"%Q^SC_P#0
MP4?V#X=_]$1P[_XC61__`"D/^(M_3)_Z2C\9O_%V^*?_`,\C\;/^'6_["7_1
M#/\`S)OQB_\`G@T?\.M_V$O^B&?^9-^,7_SP:_9/_AS]X5_Z/E_;Y_\`"X_9
MQ_\`H8*/^'/WA7_H^7]OG_PN/V<?_H8*/[!\._\`HB.'?_$:R/\`^4A_Q%OZ
M9/\`TE'XS?\`B[?%/_YY'XV?\.M_V$O^B&?^9-^,7_SP:/\`AUO^PE_T0S_S
M)OQB_P#G@U^R?_#G[PK_`-'R_M\_^%Q^SC_]#!1_PY^\*_\`1\O[?/\`X7'[
M./\`]#!1_8/AW_T1'#O_`(C61_\`RD/^(M_3)_Z2C\9O_%V^*?\`\\C\;/\`
MAUO^PE_T0S_S)OQB_P#G@T?\.M_V$O\`HAG_`)DWXQ?_`#P:_9/_`(<_>%?^
MCY?V^?\`PN/V<?\`Z&"C_AS]X5_Z/E_;Y_\`"X_9Q_\`H8*/[!\._P#HB.'?
M_$:R/_Y2'_$6_ID_])1^,W_B[?%/_P">1^-G_#K?]A+_`*(9_P"9-^,7_P`\
M&C_AUO\`L)?]$,_\R;\8O_G@U^R?_#G[PK_T?+^WS_X7'[./_P!#!1_PY^\*
M_P#1\O[?/_A<?LX__0P4?V#X=_\`1$<._P#B-9'_`/*0_P"(M_3)_P"DH_&;
M_P`7;XI__/(_&S_AUO\`L)?]$,_\R;\8O_G@T?\`#K?]A+_HAG_F3?C%_P#/
M!K]D_P#AS]X5_P"CY?V^?_"X_9Q_^A@H_P"'/WA7_H^7]OG_`,+C]G'_`.A@
MH_L'P[_Z(CAW_P`1K(__`)2'_$6_ID_])1^,W_B[?%/_`.>1^-G_``ZW_82_
MZ(9_YDWXQ?\`SP:/^'6_["7_`$0S_P`R;\8O_G@U^R?_``Y^\*_]'R_M\_\`
MA<?LX_\`T,%'_#G[PK_T?+^WS_X7'[./_P!#!1_8/AW_`-$1P[_XC61__*0_
MXBW],G_I*/QF_P#%V^*?_P`\C\;/^'6_["7_`$0S_P`R;\8O_G@T?\.M_P!A
M+_HAG_F3?C%_\\&OV3_X<_>%?^CY?V^?_"X_9Q_^A@H_X<_>%?\`H^7]OG_P
MN/V<?_H8*/[!\._^B(X=_P#$:R/_`.4A_P`1;^F3_P!)1^,W_B[?%/\`^>1\
MF>$_"V@^!O"OAGP3X6L?[+\,>#_#^C>%O#FF?:KR]_L[0?#^G6VDZ18_;=1N
M+O4+O[)I]I;V_P!JOKNZO+CR_-NKB:=WD;H*^D_^'/WA7_H^7]OG_P`+C]G'
M_P"A@H_X<_>%?^CY?V^?_"X_9Q_^A@KZBGG6`I4X4J6'K4J5*$:=.G3I484Z
M=.$5&$(0C5480A%*,8Q2C&*2221^#XOPSXLQ^+Q./Q^;9;C<=C<16Q>,QF+Q
M^98G%XO%XFI*MB,3B<16P$ZU?$5ZTYU:U:K.=2K4G*<Y2E)M_-E>7?'#_DBO
MQ?\`^R7?$#_U$]6K[D_X<_>%?^CY?V^?_"X_9Q_^A@K/U?\`X(T^!->TG4]#
MU?\`;;_;UOM)UG3KW2=4LI?'/[.@BO-.U&VEL[VUD,?[,22".XMII87*.CA7
M)5E;!'11XBP=*M2JNEBFJ=6G4:4*5VH24FE^^W=K$X;PMXAH8BA6>,R:2HUJ
M55Q6)QUVJ<XS:5\NM=I65S[M_8A_Y,N_9#_[-?\`@#_ZJCPG7Q-\!O\`D]'_
M`(*J?]G0_`3_`-=]?L@5^HOPW\!:!\*_AWX"^&'A5;Q?"_PX\%^%O`7AM=1N
M?MFH+H'@_0['P]HZWUWY<7VJ\&G:=;"YN?*C\^??+Y:;MH_&0?#_`,3?%GXP
M?\%NOA7X+^(VN_!WQC\3/B7X(^'_`(3^+GA==0?Q-\+/$WC/_@F7^RQX<T'X
MC>'4TG7?"^J-KO@C5-2M?$VD+IOB;P[J#:AIEN+/7=(N#'J%O^9<3)/A_-%*
M2A%PP2E-IM13S3`)R:BG)J*U:2;=K)-GZ/QZHRR*,924(RQ^$4IM2DH1?M$Y
M.,4Y-16K44Y.UDFS])Z\,^._[1OPK_9NTGP3J_Q2NO'7_%R/'0^&O@/0OAK\
M'OC#\=/&OBOQK_PA7C7XC2Z+HOP_^!O@/XB^.KS['X%^'7C?Q1J.HIX=_LG3
M-)\.7]QJ-_:_N%FX;]B+]G[XE_LM?LP?#'X$?&#]HWQU^UI\1?`O_":?\)%^
MT%\2H]?B\:^/_P#A)_B%XL\8Z1_;4?BCQS\2M=7_`(170O$.F>"=.^W>-=:S
MI/ANP-M_9UF;?2;#RC]NCX5?$7XL^./V`M+^'7B[XK?#.X\.?MD^)O%'B;XN
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MTOX@?\%`_%'QL_:T^(7CF/3XM0^(<%I_P39_:I^"6B:E\;-+^!OA'X5?"71O
MA3J'A_PG\"_V=O$O@:Q^'_A'X2?%GPS+IOP^^+/AKX@:I\6?'I^('RG\1O@_
MX\N/V?/@_P#"[Q'^R;H7Q-\->%/VD/\`@I%X7^%_A?XZ?LD_$7]LKX6^"="T
MC]M+XA>'?V,/@UX6_8WM/B[\`OAM\/="\<_L^II^G?LV_ME_%SQMX%_9O_9(
M^`O@";X6+XX^'GPQ_:>L]6'2L'A:CH^RQ$XQFTI\\(SY4_K/OQ?-2E.*^KVY
M94X3E&<)I*<U1CV+`8.JZ'L<5.$:C2J<\(5.1/ZY[\'ST)SBOJMN65*G4E&I
M3J**G46'C_1%17\T?C+X8?%+6_@=^P5XZ^+?P7^*WQY_:3C_`."?G[+>D0^!
MOV@/V6/CU\<?$UW^TAX;\(76L>,=#^"_[6GPV^(?AGQ[_P`$E/VR?&OCWQ%H
MFC_'[]MK]HS2['0K34+#]G/XE^'=>O=9_91^+UOHGJ_[-GP)^,.F_P#!0'_A
M,?&NF?V#\1="_:M_;/\`'WQ&\8>'?V#/BIX=^)?Q#_9@\;ZE^TG8_LW>!?CA
M_P`%0O$_QQL/@C^T'\#-&\%>._V9]9^'_P"SC\+O!GQ#^(7PKU_X??`/X>ZS
M\,_"-G^S/\2_&WPO<LNIQIU)O%QO3A6ERJC*2G*E=)1E&4G[.4DH.NXJE"K*
M%)R<W*,'+*J4:56H\;&]*&(DHJA.2J2H<R2A*$Y/V<Y)4WB)05&%:<*+FZCG
M&'[7W'QR^$EM\<=(_9KD\>:$WQWUOX4^(OCE9_#&WEGN_$T/PD\+^+_"_@'4
MO'FKP6L$UOH&A7/C'Q?I/A_P[+KUSIL_B_4+3Q0GA.#6X_!'C230#XP?&SX=
M?`GPS8^*?B+J6NPV^LZ[;>%_#/A[P9X&\>?%7XB^-O$USI^IZT?#OP]^%/PK
M\->-/B=\0]=L?#6@^)/&6LZ1X(\(Z_J&@^`_"?C'QYK=OI_@[PAXFUS2OF_Q
M#\+_`.R_^"B_P)^)7A?X=_V=H6L?LI?MR_\`"TO'^@>$OL>DZI\2_$GQ'_X)
MC:!X(_X3_P`5:=I\=G?>.M>^'7P9N-%\*_\`"17\NOZIX*^%$VG:1Y^A>!7A
MTL^)7QL^._[)W[/^M>./C9IG_#6GQ6U'QUIWA;X>^'_V1/V3/VB?#>DG_A)[
M:PM-&?XC>#_!GB[]N'XB^%O`O@^\L_$OC#XH_&33;36O[-\%16_A_P`#?"3Q
MU\5CX.\#_$_FC0ISEAE3YJDJL(<U%34:DZDJM6G)4Y^SG3IQ2IQDW5U49*6J
MOR\D<-3G+"*GSU9UX0YJ"FH59U95Z]*4:<_93I4HQ5.,FZSNHS4M5?D^K?AK
M\2O!7Q>\%:+\0OA[K7]N^%M=_M&&WN)M.U;0M6TS5M"U:_\`#OBCPKXJ\+^(
MK#2?%/@KQUX*\4Z3K/@[Q_X`\8Z-H7C7P!XUT+7_``9XST#0O%.A:OI%EW-?
MGY\&O"\_AG_@G?K&D_"[P[\5OCAX]U/X4_'CQ1J>F^(M(^+?[`7Q;_:*_:0\
M>ZG\1/&GQ?\`$5O9_$:W\$?$G]D77?VA?V@O$/C;Q9X7U?3H_#6A?!Z'QSI&
MO?"RXL/`6B>$+I/QM\!_`#XI>)O#O[3GPQT'X&:[X"_9X\9_%;_@BAK_`,/=
M/_9E_8?^/7_!,7P'XCGT3_@I-X@O/VIOB[X&^!\OQC\;?&OX;?%;P/\`#WPE
MX3C^+WQOU:?X'_%O3?AU\,/A7X^C\.:?\(/#7P6^,OCS>E@:566(_P!H=&%+
M$0I1]I!.<H3Q%.BY23G2<:D(5/:^SJ1I^T5.KRM>RJ^SZ*.74:T\3_M+H4Z&
M*IT(>UIIU)4ZF*I8=RDI3HN%6G"K[;V=2%+VL:5;D:]C6]E_4K7S?KG[6OP%
MT#]F_P`&_M:77BS7=1^!'Q#T+X,^(O`GB;PO\-/BEXT\3>+]/_:&UWP5X9^#
M%OX=^%?@_P`%ZY\6M6UWQ_X@^(O@O1](\+V?@:7Q-#J&O6]OJ6D6,D%Z+;\;
M=7^`/A#X7?M,_$C0?BK^SA\5H/\`@GE\-OBM\>-)^!'PV^!?[/OQQ\;>$/A#
M\6_'/[,7_!*+QC\'?BW^S1\(?V7O!/B'Q[\(M=\.>/='_P""@^K>$?VI?@;X
M3\+P?!CXX^+?C5';?%3P/\8?BW-#XO\`<T^#/Q;U?_@C-_P3]^#%CH?Q6\`_
M%K0-"_X(P:1XDM?#O@J";XM_!_4/AU^T7^QCJ7Q%\47'@OQOX-\6Z7H^N_!;
M2_#?B3QAXHM_B'X$USPSX4A\(:O>^/\`P[<^'])UNS-+`T(_57.O.4,17PL9
M248TXPHUW-U%SWK?OJ<5!U%RN-'GC=55.-K678:/U.4\1.5/%8G!1E-1A2C"
MAB'4=1<_-7_?TH1IRJKEE&A[2-U64XV_0/PU^VO^SMXFT#5?$'_"2>.O!_\`
M8?CKX+_#O5O"WQ8^!OQW^"GQ+T_7_P!HKXEZ-\&_@=J%S\)/C!\-/`_Q13P+
M\3OBCK/_``@_A3XH?\(>?AIJ&O\`A_QW:?\`"6Q_\*W^(#^&?5OCE\<OA)^S
M5\)/'GQV^.WCS0OAG\)?AGH4OB+QIXT\12SII^E:>D\%G:V]O:V<%WJFMZ[K
M>J7=AH/A?POH-AJ?B;Q;XFU/2/#'AC2-7\0:OINFW7YO_M2?L4:@OP2\3&_^
M(G[2'[3?Q:^,7[2'_!,3PEX_^)VKW?AGP9\6]-^`OP3_`."@_P`)?'R:/X7G
M_9!^&_[/FE^`-"^#VE_$'X[?%2X^+'ACPSH_Q2\+P^(O$7B;7OB>/#_@7P3'
MX(\I^+O[+_\`9_[&'_!9KX+^`_V>/L7A;PG_`,-$?\,*_"?PC\)?LV@>&?\`
MA87_``2A^#GA36/^&3/`FC>'TT[1O^$X^,7Q._:-\-:G_P`*>TJV_P"$F^)?
MQ"^-FC77VWQ3XL\=VVH%/"X*HZ;C7J*#Q$83BW"[I7P4)N%24:;C+VN(J\LI
MT+.E3YW!2A*$BG@LOJRI2AB*J@\3&G4BW3O*C?+Z<W3JSA2E&?ML56Y)5,-R
MNC3]HX*4)4Y_LGI_Q*\%:I\2_%OP?L-:\_XB^!?`OP[^)7BKP[_9VK1?V7X*
M^*^O_%#POX`UK^UYK"/0K[^WM=^#/Q*L?[.T[4[S5M+_`.$;^TZU8:=9ZQH%
MQJGE'[2'[5_P;_9-\,IXT^-K?%;3?!T>A>+_`!1K'BSX?_L[?M#_`!Q\,^#?
M#/@/3[+5O%?B+XC:]\#/A;\1]+^&6A:7I=Z-275_B%=>&=/U#3[#7;S2[B]M
M_#FOR:9^17_!1'X/:MXS_:6_:ZU>T_9R^.?Q&^(OC3_@F_\``?X;?L/?&#P?
MX#\:^,/AI\,OVZ['Q]_P4&N?A3K5IJ>@W5WH7P?^.?@C7?&G@?Q1X'_:^\0>
M'=$\.?LCZ!J/B"X\8?M"?`"S^-^AV/Q?_3S_`(*+^%_$WC?_`()\?MV^"_!?
MAW7?%_C'Q?\`L;?M/>%_"?A/POI&H:_XF\4>)M?^"7CC2=!\.^'=!TFWN]4U
MO7=;U2[M=-TC2--M;G4-2U"YM[.SMYKB:.-H^JX>-3!<U2<J6)=*-6*E3A*G
MS4\/*<HU+5(\JG6DESTHM>RE!\UO:&?U+"PJY?SU:DZ.+E1C6C&=*G.ESTL-
M*<XU6JL>15*\TO:48N/L9P?-;VA[G\'_`(R^$/CCX9OO%G@O1_BMHFEZ=KMS
MX=N+7XP?`?XX_L\^)I-0M-/TS4I;BQ\%_'[X=_#/QCJ>A/;ZO:QVWBC3=!N_
M#-[J$6IZ39ZO/JFB:S9V'<^%_$6G^+_#/AWQ9I-OKMII?BC0M(\1:;:^*/"_
MB;P1XFMM/UO3[?4K.W\1>"_&FD:!XQ\(:[#;W,<>K^%_%F@Z)XFT#4%N-)U[
M2--U2TNK.'X9^.'P-T_XJ_\`!0?]C'QCXN\!Z[XK\!?";]F_]LWQ$NK/%XF;
MX=:-\6S\;?\`@GGKWPCM_&\>GSP^#M?UVVN/"'BGXD_"WPOX\AU>#3_'GPLT
M[XO>#=(M_'OP?\.>+/"?X9_#/X/_`+0_AGPS_P`$X_[,_9-UWP;\9OAEH7_!
M'+PQXB\?ZE^R3\9/B/\`M(>'/@+HVG_L@>$_VC/$6@_MF:W\7?!O@[]C#X4Z
M'<7_`,7_`-G?X[?L#^$/AAX[^*6I:'9?'G]H?XC?#?2_@S^TG\6_B[X#NC@:
M&(CS1Q#I.48R4*BA)0YJM>DHRFIP<_X4)RG&E'D536FXIU"\/EV'Q4%.&*=!
MRA":A55.:I\];$T5"513IRG_``(3E4C1C[-5=:;@G4/ZEOAW\2O!7Q7T#4/%
M'@#6O[>T+2_'7Q0^&M_??V=JVE^1XU^#/Q+\6_!_XE:+]FUJPTZ\E_X1OXB^
M!?%7AW^T8;>32=8_LO\`M?0+_5-"OM.U.\/B5\2O!7PA\%:U\0OB%K7]A>%M
M"_LZ&XN(=.U;7=6U/5M=U:P\.^%_"OA7POX=L-6\4^-?'7C7Q3JVC>#O`'@#
MP=HVN^-?'_C77=`\&>#-`UWQ3KND:1>_@M\3/@7/<_!+P3)\7/A9KNK:7I/[
M9/\`P5AU2'P3\:O^"=_Q;_X*._L\30?%O_@H/\8/'_PS\>^+OV0?@]XK\(?&
MNV^*VO\`P]A;7OV:/VG]/TG6?A)X0^#?C+XZ>$_$>JV6J?M$_"9]?_0/XA^%
M/B6OPG_X)V?&C6OA/XZT+4?V5/'7A+XT?'?X(6GCO7_VF/C5X1T#7?V*OV@_
MV=/&OAKP_P"-C<Z]XI_:>\=?!_Q3\>=.\2^,-9L-5UWXE_&CPGX"\<:S\-=*
M^*?QBUWP3\-O'D3P=&$HM5I2A*MB*?+91;5&514X1K-\LYUN2,7.%.4:+J0E
M4C:5.,XJ8"A"<&J\IPE7Q5)0Y8P;5"554H0KR?)4GB.2$7.%*4*$JM.56-IT
MHU/LGX/_`!L^'7QV\,WWBGX=:EKLUOHVNW/A?Q-X>\9^!O'GPJ^(O@GQ-;:?
MIFM#P[\0OA3\5/#7@OXG?#S7;[PUKWAOQEHVD>-_".@:AKW@/Q9X.\>:);ZA
MX.\7^&=<U7U:OPS_`&C?A?XL_:LD^-/QN\+_``[^.>F?"GXT>.O^"+_P.\-Z
M9?\`A+XU?`7]H#4]`_9C_P""FVO?%KX]?&#3O!IT_P`"?'_X*>!?"GA'X\W$
M6B_$#Q%:_"[XEZ+<_"3XE?%?2-(T/X4V?PL^+WQ!PO&?P!T_P'>?$+X>:Y^S
MAKM]_P`$_OAE_P`%/-&\1>)/V;_!G[/OB;XC_!O4OV6=>_X)2>#K:QM_A[^R
M9\//!/B@?%OX4P?\%'O'.B_$36?"_P`*?A9XTT;PY^T/9>,?CKXATC2];^'G
MC_QWX9KZC1E?EKRA)7;HN$9U%RTL+*5)-5*;GB?:XAT(TO9T^:=*2<HRO!6L
MNH3YN7$RA-7;P\H0J55RT<'.5&+52DZF+]MBI8>%#V5/GJ49IRA.\(_O36%I
M'B+3];U#Q1IMG;Z[#<>$-=M_#NK2:OX7\3:!I]WJ%SX9\.^+([CPOJVO:1IN
ME^-]"72_%&FVMQXH\%WFO^&;3Q-;>(O!=UJ\/C'PAXLT'1/Y,?`/P>U;Q)\`
MOVB8-2_9R^.?BCXB^)O`O[;WPV_X)EWOC#P'XU_:B^)?[,G[=>D_\%+?^"K:
M>)]:N_VD/"MU\>="_90^.>F:[XO_`&,Y?''[7WQ#^.7@KPYXYU_X?^'_`!Y'
M^T)XWL_@9XA\7^"_T?\`B5^S+JWQ?_:EUK1/B-\(?'7B;X.^)O\`@LGIWQ*\
M4)-H?C73_!7BKX/:?_P0'L/A;<:UXJU'2!I^G>)O@9XF^,6GK\"O'^G:[=ZA
M\*_B3JVH:_\``3X@6'B;3O$WB+P1JFE3+:-*=6,L7=4HXB7-&G#WOJ\J&E->
MW<:CDJLX-*:4:U&I34IJ#D:5<IH4:E>$\;>-&&*GSQI4_?\`JTL/I37UEQJN
M:JU*;4:D5#$4*M-3FH.1^YE?`G_!5/\`Y1L_MS?]FO?&3_U"M6K\#_VI?@]J
MWA+]E;_@H`GQV_9R^.?B70O#7[*7[='@#]@.7P_X#\:VME^S;I/PQ_;"_P""
MIL_C*;P/X\M;KPQX;_9*^!@_8OUK]C&RN]`UKQ?\,?!7[77[)7@GP?\`LW_"
M#PK^T?H7AJP^!LG[X?\`!5/_`)1L_MS?]FO?&3_U"M6KMRS!QPN=Y#*-;VRG
MG6$IW4(Q@_98K!2YH252;FFZSISO&*A5I5()S<6U$\!'!XC`SC7]NJF-=+F4
M(Q@U1EA9<].2JU'--UW3G>,%"M1JTU*HXR<?VCK\L)_^4I'[5?\`V8)_P3J_
M]:(_X*FU^I]?EA/_`,I2/VJ_^S!/^"=7_K1'_!4VOT+BS_DG\?\`]RO_`*FX
M8_9>-O\`DF,S_P"Y+_U880^IZ***_&3\!"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`*\B_X)1?\HVOV)_^S>/AW_Z9HJ]=
MKR+_`()1?\HVOV)_^S>/AW_Z9HJ_1.`?^9M_W(?^[A^J>&?_`#._^Z;_`.[Y
M^@M%%%?HA^J!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`5^0WP&_Y/1_X*J?]G0_`3_UWU^R!7Z\U^0WP&_Y
M/1_X*J?]G0_`3_UWU^R!7A<4?\D[FW_7K!_^K3`'Q'B!_P`D^_\`L-PWY53[
M1HHHK\4/PX****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*\
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MB;;;;;;;;;;NVWJVV]6V]V>&>./V7_V:?B=\2_!_QH^)7[/'P,^(7QB^'O\`
MPC__``@'Q8\<?"7P#XL^)?@?_A$]?N_%?A7_`(0_QWK_`(?U#Q3X9_X1GQ3J
M%_XE\/\`]BZK9?V-K][=ZSIWV;4;F:Y?YW_X*I_\HV?VYO\`LU[XR?\`J%:M
M7WW7P)_P53_Y1L_MS?\`9KWQD_\`4*U:O8R*<Y9YD:E*4E#-<N4%*3:BOKE%
MVBF[15];*R.G#5)SQ.#C.<Y1A7HQ@I2<E"/M8OEBFVHJ^ME97/VCK\L)_P#E
M*1^U7_V8)_P3J_\`6B/^"IM?J?7Y83_\I2/VJ_\`LP3_`()U?^M$?\%3:_3N
M+/\`DG\?_P!RO_J;AC]TXV_Y)C,_^Y+_`-6&$/J>BBBOQD_`0HK"\4>*/#/@
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M*LO&NLV7PHN?^%-?':W^%Q_PV#\-/^&'O^&_/[#\=?\`"G?^&4O^&P?^$:_L
MS0/^%E_\*T_X5%_PNC^P_P"Q_P#A)O\`A%O^$Z_X1;_0/[,_X3+^P/[?_P!%
M_P"$F_L[_B:U3P]924?9MN4J<(\KC)2E5<E"*E%N+;E"<6DWRSA.$K3C)*WA
M<0I1C[-MRG3A'E<9*4ZSFJ<8RBW&4G*G4@TF^6I3G3GRSA**^K**^4_AK^U)
M<^*?&NB_#WXM?L\_'/\`96\4^-?[1A^%=O\`'>__`&?]6TGXMZMX?TF_\1>*
MO"O@GQ1^SS\>?CWX6M?'7AWPMI]WXQ'@#QQK/@WQKXO\%:3XU\9_#?0/&OA;
MX3_&+5_A]ZM\0/CQ\#OA-XF^'/@OXJ?&7X4_#/QC\8M=;PO\(_"?Q`^(GA#P
M9XF^*?B9-0T+27\._#G0?$>L:;JGC?75U3Q1X9TUM(\,VNIZ@NH>(M"LS;BX
MU?3X[A2HU(S4.7FDXN4?9M55**3;E"5-SC-1Y9*3BVHN,HRLXR2F5"M&:I\C
MG*47./LG&M&<$I.4H3I.<)QCRS4W"4E"4)QE:4))>K45Y3J_QX^!V@?%OPO\
M`=>^,OPIT3X[^-]"N/%'@OX*:O\`$3PAIOQ;\7^&;2'Q%<W7B+PO\.+S6(?&
M.OZ%;6_A#Q9<7&KZ3HUWI\,/A?Q%+)<+'HFI-;'Q`^/'P.^$WB;X<^"_BI\9
M?A3\,_&/QBUUO"_PC\)_$#XB>$/!GB;XI^)DU#0M)?P[\.=!\1ZQINJ>-]=7
M5/%'AG36TCPS:ZGJ"ZAXBT*S-N+C5]/CN)5.HW%*G-N<7.*497E!<S<HJUY1
M2C)N2NERRUT9*I56XQ5.HY3@ZD$H2;G!*3<XJUY02A)N2NDHRUT=O5J*\IN/
MCQ\#K3XBZ1\(+KXR_"FV^+6OZ[XB\+Z#\+KCXB>$(?B+K?B;PAX#\+_%/Q9X
M=TCP3)K"^)=2UWPO\,?&_@OXC>(M(L],FU#1/`?B_P`+^+]2M[;P_K^DZA=\
M+\:OVJOA)\`O'GP:^'7Q!O-=A\0?&[78](\.-I&B3ZGI^AZ?<_$7X2?!33_%
M'BBY26*2#0M1^._[0W[//P;M[?0H-?\`$T/B;XS^'?%5_P"';/X2^$/BY\1_
MANXT:LY1A&G.4YQ<X147S3BE)N4%:\E[LK<M[M-*[T'&A6G.$(4JDIU(N=.*
MA+FJ02DW*"M>:M"5G&]W%I7:L?2%%>&:A^T1\--"^)?QF^&OBK5/^$,_X4)\
M#/AA^T1\2O'_`(PO=`\._#30OAI\4M?_`&@-`L-4N_%6HZW#_9G_``BG_#-W
MC_6O'%[K]AH^@:%H%UX?U&'6]0\_6H="\,\)_P#!1#]FGXA?LE?M!_MH?#7Q
M1_PLSX._LU_\-._\)_\`\*ZUOP#XSU^]_P"&6+WQE_PE7_"-_P!@>-KWPM<_
M\+"\+>$[#XD_"+^VO%6@_P#"6?#3X@?#?QCJ/_"/:=XKA^S4L-7DKJE-IRHP
MNHNW-7CST8WVO4CK%7U1<<)B9).-"HTYT*?,HMQY\3#GH1OLG5A[T$WJK=T?
M<U%>4^,?CQ\#OAYXFT;P7X_^,OPI\#>,?$>N_#WPOX>\)^,?B)X0\,^)M>\3
M?%O4/&>D_"GP[HV@ZUK%EJFJ:[\3=4^''Q#TWX>Z18VL^H>--0\!^,[/PW;Z
ME<>%]<CL>%^#7[6'P.^..NZQX+\)^-M"T[XG:)KOQXTZZ^#_`(B\2>$+3XMR
M>&?V>?VD/B)^RMXT^*5O\/\`3?$>K^('^%.I_%KX9Z]IOA?QO):Q:?>PW>D6
M>K)HGB6>\\.V$^QJ\CJ>SGR*UY<KM[R<D[VV:BW?:RU>Q'L*S@ZGLJGLURWG
MR2Y4I*4D[VV<8R=]DEJ]5?Z0HKXV\(?MW_L\>(_$W@_PGXA\8:%\,-4^('PI
M_9,^)_@2Z^('Q"^#<7AGQYJ'[9^H?'/3?@Q\)_ASXT\'_$WQAX.^*/Q6U"X_
M9[\>R-H_PSU[Q?X9\3:?+H6K?#+Q;\0-+O;V\TTT+]N_]GC6_P!H?X=?LLR>
M,-"TKXU_%+0OVF_$7A'P?/\`$+X-ZWJ%WI_[+?QD'P8\4V\MEX-^)OBC5%UW
MQOJFF^/O%/@/PO!IUQXFM/#/P:^.6F_$[2/AM\0OA!X\\":);PN(3DO8SO&+
MG*RO:"INJYW6CBJ<7-R5TENU=7T>#Q2<DZ%2\(.I*T;VIQI2K2G=73A&E%SE
M)-Q45JU=7^R:*\,\`?M0?LT_%?P5-\2OA;^T/\#/B5\.K?QUH'PON/'_`(`^
M+7@'QCX*@^)?BK5O"N@>%_AW-XJ\.^(-1T*+QUXDUWQUX(T70/"3WZZ_K&K>
M,?"NG:=I]Q>>(=(AO/5O"_BCPSXW\,^'?&G@OQ%H7B_P=XOT+2/%'A/Q9X7U
M?3]?\,^*/#.OZ?;ZMH/B+P[KVDW%WI>MZ%K>EW=KJ6D:OIMU<Z?J6GW-O>6=
MQ-;S1R-E*G.%^>$XVEROFBXVE:_*[I6E;6SUMJ8SIU(74Z<X.,N27/"4>6=K
M\KNE:5M>5ZVUM8W:***D@****`"O(O\`@E%_RC:_8G_[-X^'?_IFBKUVO(O^
M"47_`"C:_8G_`.S>/AW_`.F:*OT3@'_F;?\`<A_[N'ZIX9_\SO\`[IO_`+OG
MZ"T445^B'ZH%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!7Y#?`;_`)/1_P""JG_9T/P$_P#7?7[(%?KS7XG7
M%_\`'CX!_M@?MZ>(A^QM^TM\8?!7QU^,OP>^(OPZ\=?!V/X%ZGX;U/0O#O[(
M7[._PGUN"\C\=?'+P!XAT[5-.\;?#SQ/ITMI<Z"J206D%];7$UK=P2-X_$%"
MMBLCS+#8>G*K7K4\+&E3AK*;AF&#JR2O9>[3ISF[M:19\EQI@<7F&2O#X*A/
M$5OK>'G[.FDY<D544I:M*RNKZ]3]":*^.?\`AI_XR_\`2.7]O#_P2_LM?_14
MT?\`#3_QE_Z1R_MX?^"7]EK_`.BIK\H_U=SO_H6XG_P&/_R7G^?9GY'_`*J\
M0_\`0IQ?_@,?_D_/\^S/L:BOCG_AI_XR_P#2.7]O#_P2_LM?_14T?\-/_&7_
M`*1R_MX?^"7]EK_Z*FC_`%=SO_H6XG_P&/\`\EY_GV8?ZJ\0_P#0IQ?_`(#'
M_P"3\_S[,^QJ*^.?^&G_`(R_](Y?V\/_``2_LM?_`$5-'_#3_P`9?^D<O[>'
M_@E_9:_^BIH_U=SO_H6XG_P&/_R7G^?9A_JKQ#_T*<7_`.`Q_P#D_/\`/LS[
M&HKXY_X:?^,O_2.7]O#_`,$O[+7_`-%31_PT_P#&7_I'+^WA_P""7]EK_P"B
MIH_U=SO_`*%N)_\``8__`"7G^?9A_JKQ#_T*<7_X#'_Y/S_/LS[&HKXY_P"&
MG_C+_P!(Y?V\/_!+^RU_]%31_P`-/_&7_I'+^WA_X)?V6O\`Z*FC_5W._P#H
M6XG_`,!C_P#)>?Y]F'^JO$/_`$*<7_X#'_Y/S_/LS[&HKXY_X:?^,O\`TCE_
M;P_\$O[+7_T5-'_#3_QE_P"D<O[>'_@E_9:_^BIH_P!7<[_Z%N)_\!C_`/)>
M?Y]F'^JO$/\`T*<7_P"`Q_\`D_/\^S/L:BOCG_AI_P",O_2.7]O#_P`$O[+7
M_P!%31_PT_\`&7_I'+^WA_X)?V6O_HJ:/]7<[_Z%N)_\!C_\EY_GV8?ZJ\0_
M]"G%_P#@,?\`Y/S_`#[,^QJ*^.?^&G_C+_TCE_;P_P#!+^RU_P#14T?\-/\`
MQE_Z1R_MX?\`@E_9:_\`HJ:/]7<[_P"A;B?_``&/_P`EY_GV8?ZJ\0_]"G%_
M^`Q_^3\_S[,^QJ*^.?\`AI_XR_\`2.7]O#_P2_LM?_14T?\`#3_QE_Z1R_MX
M?^"7]EK_`.BIH_U=SO\`Z%N)_P#`8_\`R7G^?9A_JKQ#_P!"G%_^`Q_^3\_S
M[,^QJ*^.?^&G_C+_`-(Y?V\/_!+^RU_]%31_PT_\9?\`I'+^WA_X)?V6O_HJ
M:/\`5W._^A;B?_`8_P#R7G^?9A_JKQ#_`-"G%_\`@,?_`)/S_/LS[&HKXY_X
M:?\`C+_TCE_;P_\`!+^RU_\`14T?\-/_`!E_Z1R_MX?^"7]EK_Z*FC_5W._^
MA;B?_`8__)>?Y]F'^JO$/_0IQ?\`X#'_`.3\_P`^S/L:BOCG_AI_XR_](Y?V
M\/\`P2_LM?\`T5-'_#3_`,9?^D<O[>'_`()?V6O_`**FC_5W._\`H6XG_P`!
MC_\`)>?Y]F'^JO$/_0IQ?_@,?_D_/\^S/L:O@3_@JG_RC9_;F_[->^,G_J%:
MM7:_\-/_`!E_Z1R_MX?^"7]EK_Z*FOF']M;QM^TC^T=^R-^TA\!/`7_!._\`
M;2L?&OQA^#7C[X=>%;SQ3:?LPZ5X<MM=\5^'[W2-,GUS4[7]IS4KBPTN.ZNH
MVO;N&PO'MX`\HMY-NT^EDV1YMA\WRJO6P%>G1HYE@:U6I**Y84Z>*I3G.5I-
MVC%.3TO9/LS?#<+\00Q.'G+*L5&,:]*4FXQLHJI%MOWMDM7\^S/Z#*_+"?\`
MY2D?M5_]F"?\$ZO_`%HC_@J;7ZGU^6$__*4C]JO_`+,$_P""=7_K1'_!4VON
M^+/^2?Q__<K_`.IN&/UCC;_DF,S_`.Y+_P!6&$/J>OS\_P"";W_!-[X'?\$O
M?@=XJ^`/P!\5?%;Q?X.\7_%;7/C!J6I?&#7/"&O^)H/$VO\`A#P+X+O+&QO/
M!?@7X?Z7%H46E_#_`$:XMK:XT:YU!-0N=3EEU.:WFM;6R_0.BOQZ-:K"E5H1
MG*-*M*G*K33]V<J+FZ;DNK@YSY?\3/P>&(K4Z-;#PJ2C0Q$J4ZU-/W:DJ#FZ
M3DNKINI/E_Q,\,_:@^"__#2/[-/[0_[._P#PDO\`PAG_``OOX&?%KX+_`/"8
M?V-_PD7_``BG_"TO`/B#P/\`\)+_`,(__:NA?V[_`&%_;O\`:G]C?VWH_P#:
M?V7[%_:NG^?]KA^4_BMH7[3_`.VE\'OC;^R]XO\`@K_PR1X6^)'P,^-GP8^+
M'Q8\;^(?A[\=-)\5:M\4_A7XN^&&CW/[+&C_``P^*6A>*==\"Z%XIUU_B/JO
MQ%_:0\,?L^^-=0\%>'/"G@&R_9ZM?%/Q?\6^+?V9OT?HJZ6(G245&,).G-U:
M4I)MT:CY%*<$I*$FU3IZ58U(KD3C&+<F[HXJI0C%1C3DZ=1UJ$YQ;E0JR5-2
MJ02DH2<E2IZ5H58Q<$X1C)R<OS\ATKX]?M&_&3]FW6_B;^S_`*[^SAI?[(_Q
M6\4_&+Q)X@\0?$/X6_$OPS\:/'FM_L\?'3]FNQ\*_`!_AYXJO_&-[\*8[?XX
M^+_B+>_%3X]^"/V>_B+#I_A;X9>&[;]GF\U3XF^/[GX!_#/AWP[^UQK?_!)>
MX_X)[ZE^P)^TAX0^+4/_``3#\4?LJQ^.O$7Q*_87N?A)=_%O0/V/M7^&FDV=
MOJGA/]L;Q1X]70O&_CW3;/PUX7UNZ^'=M!:3Z_I&J^-(O"'A^'7M7T3]Z:*V
MACI4^7EP^'M"5&=*+]O:E*C*M.+BU74I<TZ\Y251S6RBHQ5GT4\QE3Y>7#89
MQISH5*,7]9:HSP\Z]2#BUB5*7-/$U)35651-\JBHQ5G^?D,/QD_:B^,G[-OB
M[Q=^S;\5OV6/!W[+'Q6\4_'"ZNOCAXI_9X\3^)OBIXF\3_L\?'3]G+0/`G@3
M0/V<OCI\==+TW0M-TOXZ^*?'GCKQUX\\4^$=0T74/"/@+P;X-\!?$:W^(WC'
MQC\%_E/_`(*L?L__`+9WQL\,_M!>"_V8/"NNS6_QR_8V\3?!RUU3X5:K^R9X
M"G\?>)K;3_C<=?\`AE^V#\0OVC?AY\0/B=+\*9?#7Q`TS3?V1M`_9CM=`U"/
MXM_$3]H2S^.7Q0^`G@[Q?X.^-O@S]KZ*FEC9T:]*M"C0?L8J-.E.-2=))5'5
M3:E4<Y/VC<[NIHW[MDHI31S"=#$4<1##X9K#Q4*="<*E2@E&JZZ;4ZLJDG[6
M3FFZCLVN6R44ORF^)_P5^.<7[6NH7WPN^%OCIOAU\4/CG^S_`/&KXEW'B+7?
MV4_B'^Q5XZN?AK9?!GP[XG^*7Q@\+_$;P]:?MP_#+]JWP'X!^"6C:9^SAH7[
M,]SXA_9_T[XL?"O]E;XP>-?$.FWGBK]I'2/#?E/_``58_9__`&SOC9X9_:"\
M%_LP>%==FM_CE^QMXF^#EKJGPJU7]DSP%/X^\36VG_&XZ_\`#+]L'XA?M&_#
MSX@?$Z7X4R^&OB!IFF_LC:!^S':Z!J$?Q;^(G[0EG\<OBA\!/!WB_P`'?&WP
M9^U]%53Q]2E5H551P\GAXPC&,X3E&?)R<LJJ=2\I+V<+-.*BHQ45%1BE5+,Z
MM&KAJRH86<L-"$(QJ4YSA4]G[/DG63JWG./LJ:BU**BH1C!1C&*C^1/CO]D3
MXBZEXF_;6\::!\*="/C'XX_\%//^"7WQLT'Q9;WG@.R\3>-_V;_V5=0_X)J:
MMXLU+5]>DU6WU1="^%FJ?";]IS4O#O@;Q+=6NNMJ$?BB\\$>&K^X^(.DR>*#
M]IW]@GXR?MF?%O\`:4\6:I^T%\5OV6-+L?A3X)_9V_9JN/!&@?L\?%;3[J?1
MX;#X_:I^U'ITOQ(^'OC/XD_!W73^T%XB^'OA9_#/P2\;?LZ?%N?Q-^P_\+?C
M*/C#=:I%\!-9^"OZ[441S'$0<)15)3IQC&$Y4U4<>2GA*46E4<X-J&#IK6+2
M4JEDDXJ!#-,53<)05%3I0A"G.5-57#DI8*C&2C5=2FY*G@:4=8-)3JI))P4/
MQ0^(?[.?[5_Q8_:'T?\`;,U+X:Z[X0U3PO\`LW_\$V/&NL_L=W/Q$^"_C?X8
M_%+XR?"'XR?M?^._C]\&?%NKW%IH]QXZ^*W[,G@[XV6?BS]C_P`977C_`.#'
M[/&H?M>-\&/B[XTUS4M+^%T6J_#CN;[X!?'KQ#_P30_X*1?LUGX1Z[HOQ:^)
MFN_\%;](^#FBZOXK^%KZ?\7=/_:F^+_[2OQ6^"'BCPOKFC>/]8TOPWH7BW2_
MC3X9\/W%O\5+GX=^)O#GB;3/$2>)O#ND>'[;2O$.L?KM13>857[->RHI4:E"
MI32C4]WZM%0IP;=1N4;7YG-RF^9KG24%!RS2M+V2]CAXJA5PU6DHQJ^[]4@H
M4H-NJW."7-S.;E4?.U[1*--0_(G]LC]D3XB_%WQ-_P`%//&G@[X4Z%XF\8_'
M'_@D3X=_9$_9Y\67%YX#LO$VL?$74M0_;WU;X@_"G2->UW5;'5/!>A:]JGQ#
M_9RU+Q%>:_=>'/`?B'4(_"]Y=:K?W'@._D\.'PE_9$^(O@/4/V9]6MOA3H7A
MK5-$_P""NW_!1?\`:[^-^I:1>>`[34-2^'7QP\,_\%,?!?P<^*WBB\TK51<>
M,]=\1>#OC%^S7X3M[-)-;\>>'/#-WX=T'Q!I6B:7X"UFU\,_KM12>85W2]C:
M'):VT[V^J+"6^.UN1>TM:WM?>V]T3S/$NA]7M3]G;EVJ7Y?J2P/+_$Y;>S7M
M+<MO;^_\/N'\T=A^PS^U?HWP.N?A7-^RCH6O^,?C#_P06_9!_P""7S?%P?$?
MX+IXF_9V^.,/A#]J/PY\7+'Q*FH:\NJ:E^S?X7U3QO\`#/Q-\>O$_P`)O$WB
M_P`7ZMJ'AGX6#X/?!;]HJXMO$>H?"3U?XA_L1?M/^,O"_BGX6Z=\,?LG_"Z_
M@9_P<9_`B7QYJ/C3X>Q^"OA5JW_!0+]LO0?CE^RKXV^)45GXLO?'5SX%^(7@
M7PF[WY^%O@CXF^-?!.K:YHNG>-_!7A_;K<^B_P!`M%;O-\2Y1G[.@I1J.JFE
M5?OO#RPZE:59I<L&I**2BYQ4I*2<XRZ)9YBI3C/V6&4H595DU&LU[1X:6%4K
M2KR24*<E*,8I0=2*E.,DYQG^*'QK_9Q^,G[7^I_''Q_XT_9:UWP7X.^+>N_\
M$A_A5JW[/W[0&N?L\>*/$WBGX=?L@?\`!1#QK^T7^T=XN\5:3\-?BS\9O@SJ
MGPIU3X,_&:ZL=*\,:E\0[SQYXRU#P-\0_#=Y\,X+>\\!R^/_`-KZ**XJ^)G7
MC"$HPA"G)RA&'/:-Z.'H6]^<W;DPU/5MR;YFVU91X,1BZF(C"$HPA"G)RA"G
M[2T;T,+AK+GJ3;7L\)2U;<G+F<I-<JB4445SG*%%%%`!7D7_``2B_P"4;7[$
M_P#V;Q\._P#TS15Z[7D7_!*+_E&U^Q/_`-F\?#O_`-,T5?HG`/\`S-O^Y#_W
M</U3PS_YG?\`W3?_`'?/T%HHHK]$/U0****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*_+"?
M_E*1^U7_`-F"?\$ZO_6B/^"IM?J?7YY_'3]BKXH_$']HSQ#^T=\&?VK/$'P!
M\0>-/@I\)/@EXU\/0?"'X=_%#1];T?X*^.OCOX[\&:S:3>,?+O=&U,7O[0GC
M6QU.*UDDM;VUMM'?9%-:R-+Y6=X&MF65XK!4)4X5:WL>259RC37L\11K2YG"
M%22O&FTK0?O-)V5VO%XBRVOF^3XS+\-.E"MB/J_)*O*<:2]EBJ%>7-*G3JS5
MX4I*-H2O)I.RNU[)17S+_P`,7?MI?]))=:_\1,^!G_Q^C_AB[]M+_I)+K7_B
M)GP,_P#C]?G_`/J-FW_01EW_`(.Q/_S(?F'_`!#G._\`H*RK_P`'XO\`^83Z
M:HKYE_X8N_;2_P"DDNM?^(F?`S_X_1_PQ=^VE_TDEUK_`,1,^!G_`,?H_P!1
MLV_Z",N_\'8G_P"9`_XASG?_`$%95_X/Q?\`\PGTU17S+_PQ=^VE_P!))=:_
M\1,^!G_Q^C_AB[]M+_I)+K7_`(B9\#/_`(_1_J-FW_01EW_@[$__`#('_$.<
M[_Z"LJ_\'XO_`.83Z:HKYE_X8N_;2_Z22ZU_XB9\#/\`X_1_PQ=^VE_TDEUK
M_P`1,^!G_P`?H_U&S;_H(R[_`,'8G_YD#_B'.=_]!65?^#\7_P#,)]-45\R_
M\,7?MI?]))=:_P#$3/@9_P#'Z/\`AB[]M+_I)+K7_B)GP,_^/T?ZC9M_T$9=
M_P"#L3_\R!_Q#G._^@K*O_!^+_\`F$^FJ*^9?^&+OVTO^DDNM?\`B)GP,_\`
MC]'_``Q=^VE_TDEUK_Q$SX&?_'Z/]1LV_P"@C+O_``=B?_F0/^(<YW_T%95_
MX/Q?_P`PGTU17S+_`,,7?MI?]))=:_\`$3/@9_\`'Z/^&+OVTO\`I)+K7_B)
MGP,_^/T?ZC9M_P!!&7?^#L3_`/,@?\0YSO\`Z"LJ_P#!^+_^83Z:HKYE_P"&
M+OVTO^DDNM?^(F?`S_X_1_PQ=^VE_P!))=:_\1,^!G_Q^C_4;-O^@C+O_!V)
M_P#F0/\`B'.=_P#05E7_`(/Q?_S"?35%?,O_``Q=^VE_TDEUK_Q$SX&?_'Z/
M^&+OVTO^DDNM?^(F?`S_`./T?ZC9M_T$9=_X.Q/_`,R!_P`0YSO_`*"LJ_\`
M!^+_`/F$^FJ*^9?^&+OVTO\`I)+K7_B)GP,_^/T?\,7?MI?]))=:_P#$3/@9
M_P#'Z/\`4;-O^@C+O_!V)_\`F0/^(<YW_P!!65?^#\7_`/,)]-45\R_\,7?M
MI?\`2276O_$3/@9_\?H_X8N_;2_Z22ZU_P"(F?`S_P"/T?ZC9M_T$9=_X.Q/
M_P`R!_Q#G._^@K*O_!^+_P#F$^FJ*^9?^&+OVTO^DDNM?^(F?`S_`./T?\,7
M?MI?]))=:_\`$3/@9_\`'Z/]1LV_Z",N_P#!V)_^9`_XASG?_05E7_@_%_\`
MS"?35>1?\$HO^4;7[$__`&;Q\.__`$S15P7_``Q=^VE_TDEUK_Q$SX&?_'Z^
MS?V8O@7I7[,?[//P8_9[T3Q#JOBW3/@Y\.O"_P`/[7Q1KEO8V>K>(?\`A'=,
M@L9M9O;+3(H;"REU&XCENQ96B-#9I*ELLUQY1GD^JX9R+%Y+]>^M5,-4^L_5
MO9_5YU9V]C]8YN?VE&E:_M8\O+S7M*]K*_VG!_#F.X?_`+1^N5<)5^M_5/9_
:59UI\OL/K7/S^UH4;7]M#EY>:]I7Y;*__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>pg5b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg5b.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`#Q`:0#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#[V_9O_9S^
M$WQ)^"O@?QYXZTCQ/XE\8>*X-:UGQ#KVH?$SXGF]U74[KQ+K+3W=QY/C&&$2
M2$`;8HHXU4!415``]P_X8\_9[_Z$S6O_``Y?Q3_^;6C]C?\`Y-G^$_\`V!=2
M_P#4CUJOIJ@#YE_X8\_9[_Z$S6O_``Y?Q3_^;6C_`(8\_9[_`.A,UK_PY?Q3
M_P#FUKZ:K#US6(M,MV1&S>S1L+=%VDQY!47$@8,HCC;)164^<Z[`-HE>,`^9
M=8_98_9STR)E3P=J\UZ?ECMQ\3?BD?+)4,)+@+XVW1QA65E0E7FR!'A=\L?#
M_P##,'P4_P"A9UK_`,.%\2/_`)KJ^@'9G9G=F=W8L[N2S,S$EF9B269B2222
M2223FLS4M5L=)MWN;Z=(E5'=(RR^=-LV[E@C9E,A!=`QR$C#!YGCC#.&DV[+
M5L#Q+_AF#X*?]"SK7_APOB1_\UU<'XC^#WP#T"X-L/"FLWTL>1<+'\2OB-%Y
M4F2!$G_%52^;(NU_.X1(F41;WF\R*/#^,'[0^C:/#>HFH_9;>W6:*.V,BH)I
M(R'W3KYJ&[G`0S)!;^:8'A\@/;RK+/-^6WQ._;)@@<*^I0K'YZE'GE25Y5'G
M%B]M:8MTN%:53OADEE:!BY=H7*Q/1?WG;Y+;JG=VU36BOU:`_0JYT'X&6TOE
MMX8ED!&Y7A\?_%6X4J20-S6_C29$?Y3NC+[EX/*LK-;T[PK\$=2<)#X7EWLS
MJD1^('Q22=V1!(VV"?QQ`[($W,9%RN58#)5MOX_ZA^U#=S&6XBUIY)F;Y81/
M9111H<[5CW0N2D9(^1W#.NYFE:4DO#X>_:OU7^T(('U&3RI94#"YCB$`+9C4
MLDEO&\AWO&0D,T;-M'F"2-2H5WV7W+_(#]Q].^%?P"N(E-YX1UZ.4K$H^S?$
M;XAR>;*R_O,13^,8&B7<5\M4DN@VYE\TE-S]!;_!3]G>9"TF@>(;1@Q41W'C
MGXFL[`!3O!M?%MS'M))4`R!\JV4"[2WQ)\,_C:-:L[55NHM[0Q2'3IYQ(=B+
M;I*;>127C1``L3+YEDD<A+0B5)8T](\0_%"XT^UDF/DZ?$L6\L62:=60L[,)
M)%A@2)D78PE@<(HEEW`(6B=XVUB[]U*WYI@?3`^"'[.A=E_L;7`H5&$A\<?%
M/8Y8N"B@>)S(&C"*SEHU0B1/+=V$@CW[?]FKX&7:&2UT'4[F-6*&2W^(_P`1
M9D#@*Q0M'XP90P5E)4G(#*<8(K\R=0_:QM=-OOL]S>W,<1=50R1Z9%-*K957
MC23:<NRL\4;JDCH`&6-B=OT3\*/VD-$U]K.:'652YB,;(R;6N$2.()(LEMO<
MR.NY4F^Q)+:R//Y$J+%$ZL>ZW;6/FVI+YZ+3O^"Z`?6G_#,'P4_Z%G6O_#A?
M$C_YKJ/^&8/@I_T+.M?^'"^)'_S75T?AOXI:?J,<2WK1R(Y$<=_:E"LA5HH2
MTD2.\;'?YKRM;2;]R^7%8X&:]2M+RUOH5N+.>*XB;`WQL&VL55]DB_>BE"NI
M>*15D3<`ZJ>*3BUKNNZU73K\UN!XM9?LS?`J&8?;?!VL74#,HD`^(WQ/CFC4
M;@3"8O&D2%LD,5E#!]@16BW%Z]#@_9#_`&=;F&.>#PAK$L,J[D=?B7\4\$<@
M@@^-0592"KJP#(P*L`P('7UKZ+J9TR\65VE^S.K+<11!6,H"/Y1VNRKN24JP
M;<K*I=0=KLK(#S[_`(8\_9[_`.A,UK_PY?Q3_P#FUH_X8\_9[_Z$S6O_``Y?
MQ3_^;6OI6">&YACG@D66&5=R.O0CD$$'!5E(*NK`,C`JP#`@2T`?,O\`PQY^
MSW_T)FM?^'+^*?\`\VM>:_&;]E+X&:#\'OBOKFC^&/$&G:OHWPU\=:KI>H6W
MQ-^*:7%CJ.G>%]4O+&\MW_X30[)K:YABFB;!VR(IP<5]R5Y+\??^2$_&K_LD
MOQ'_`/4.UF@#]]OV?[Z]U3X#_!/4M2O+K4=1U'X1_#>^U#4+ZXFN[V^O;OP;
MHUQ=7EY=7#R3W-U<SR23W%Q/(\TTSO)([.S,?7*\9_9Q_P"3>O@/_P!D9^%_
M_J$:'7LU`!1110`4444`?&/_``4+^(_Q&^$W[''QM\>?"3QA<_#[XC:5I/AG
M3_"OCBRT7PQXCOO"M]XF\=^%O"TNN6&A^--%\2>$]2O]/LM:NKBQMO$6@:QI
M#7:0M>Z==PJT+_+\?[$G_!1_=XG\W_@LS^T05G\/6\/@P1_LO_\`!/4-I7BL
M1PBZU+Q.S?LAD:_X>DE^T/;Z)I2^&]2AC,,<FOSL'E/N'_!4;_DQ3XY?]TS_
M`/5P_#ZOOZ@#\Q[3]B[]MA?!VF6]]_P5]_:^F^($<E@VLZQ:?`C_`()L6W@Z
M[B2\C;4XM,\-S?L)7>M:=)/8>;%83W7BK5%M+PQSW%O>PJUNS_$O[%_[:D^I
M02>#_P#@KY^V#I>D+9;;FT\2_`K_`()K:]J4VHG4=.;S8-0TO]A#PY:VUDND
MIJT/D2:9=SOJ-SIUS]HCMK*YM;_]-:*`/SH\._L:_M60Z6B>+/\`@K7^V_J6
MM?:+UI;KP[\(_P#@F-HNEFT:\F;3HDL=2_X)Y:_=BX@L#;Q7MPVHF*ZO$FN(
M+:SAD2VCVG_8\_:&16=_^"KW[?*(BEG=_AW_`,$ME554$LS,?^";`"JH!))(
M``))Q7W[7F/COQ*UA#=6(*1PI'$TK,$$C2!?M`VM(Y3R4#6[?ZM7:<",N(GR
MP!^>GBSX&_'_`,/V\EQ#_P`%5_V]%6)2Q-]\._\`@EP68!%;!CA_X)NQB(@[
MP?WLN4*2L8_ECD^*_B5XW_:%\$L4M/\`@JI^VC/F4JDEW\,_^"8\@*-&C*RP
MP_\`!/2UGF=&FA,J*B?NWRIPLKQ?5'Q^^)[PVUUI[2B(8+3-*K8_Y:RJLLQ>
M-88"8?-G(E8-;+,LCB9L3?@=^T#XMO=5UBZD:XO)$@2XN+3[1*1M#2S&)'AC
M?:K1I;REY5D>25[F0LVYGD=VTOTO;^OEZ]-`/I+Q-^U?^U[IPF31?^"G7[5T
M\D),<AO/A5_P3<F`D2X$1*6]K^P/#>2!DW9B>""2`A7EW`R1Q>,7O[:/_!14
MR8T[_@H]^T>L(ZM>_!C_`()Y22/E4_Y9P?L11K%M;S!_K)MZE&_=D%3^<>I_
M$J[&I3V\L=X\5M<O;M(EZ8BHCD*3-%;!"K;6#B+S+@/*BQ^;)&3A/9_"3/.)
M'FDDD>.24JSN7./+@3:2V3M`D8@`CYCGU!7]?U_5@/N/0_VD/^"F^KZ;'*W_
M``4U^/$-]<WD5S!)%\!/^"?TMI%HLAAF^SW$#_L:Q2_VB+=WA-\ET+83^7,N
MGR*?LQ]8L?BI_P`%+=0$,L/_``4C_:22VE:(?:)_@W_P3N@`218V:98I/V&U
MEF@57W))"CB50=F7RB\9\)O#T$S0I<M%<0Z=;1*\<BQYN&MXXH8QY7G>9Y3.
MR33+MFA5H4M[C(G05]C>#EC#7SL8O-985C!:,S^6I<SD)GSEB+/;[FVB-W"@
M%F0A:T26EY/7?1+HM.N[^:`\[TO7?^"C,T0DU#_@I?\`M1EL,CQ6WP9_X)S6
M>)0RE7234/V&1))$8SDC[*H#L469O*8O=N?$?_!0"T7?/_P4J_:S";79GC^$
M/_!-Z=46,`NTC0?L&R")0#G,A4$!B"0K8^B;;4[>WLS"VG6<]RK_`+N>:!'#
M1LS._G9'F.Z'"1[752C#.WRL3<]J.IVUFCW-Y)%&2I*11I%$\Q0*NV"WC$:L
MV60,5554MYDK*I9ZD#Y$\6?%C_@HQH,<]Y9?\%*_VFKK3XV4B9_@S_P3K=T6
M1B%2=(OV&HV1HV&UY]@MW#QL'BD;[./E3Q#^UY_P58TW5;>"S_X*1?&>WT[R
M[E+J34O@/^P5/<-.D;F";3Y+?]C.VMKFW:22V-Q#+]GF@19%,GG3*EM]^^+-
M0;4K+5[IX8H2=+O4"Q`Y95MY]C2N3F64(5C:3"!E1`$4*`/SY^*L\=GY-ND(
MVO(UW\I(`-O`%*;0C<2&[SOR%B6/&TI]RFKQYM%9J+MZ:/\`!W_("+3OVS/^
M"JLUQ!:77_!1_P"+)%^\:/J/_"HOV"=/A\/+YC^=,]E/^PY>#Q4JPE'6+^U/
M!SF2%XE>5KJ/[/\`8GPN^-G[;7BKQ1J8\2_\%5?VE3X.,$":$FC?!O\`X)QZ
M7XCNM0N19P[+JXO_`-A[6M-:WL[N#4=S6]FINH]1L87DTV;1YVUW\6/&7Q%O
M8-2GL[)59HEB*R^9-&D;$LX1HU2*617MV210ERB*94WJ\L4A>WX.^--[I$L8
MU!KB%U90+RWFF=!$':1HWB8RS%,)$B1,;F*5R?."0JBQKY=O5?U_6P'](?@[
MP#_P4'\6>`O%UQ:_\%:_VA;KXB'5+^;P$EO\%?\`@GA;>#DT)I5ET6S\7"3]
MA6[UB35)[-E34-4TF:WL[:9A<PZ1-&CVB^C_``Y_97_X*IZY>>%9_''_``5M
M^,>E6UW=ZI_PEGA_PU\$?V`]0OK'3(K.WGTFZT#Q1JG["EA;:E=W-PES:WME
M=>$[7[/%=I?1S2)I,EOJWQ7^S!^TA//<:9937[M>HEN)90CK%.A\PRL3(ZQ,
MN(9[@/YX!B'VAWBN3,E[^\?PR\<_VE%9W=O-&["))H22LR9E0J\3N&VD,&>%
MPKF0R.#&0^9Y$!\67/[''_!3B+X3W4]K_P`%:/V@KWXUPZM/+:6DWP6_X)XZ
M=\.M0T&"9(8+.4+^PAJ6O:9K&HPQ2Z@VHB^U.QTHWD.F'3-4;3Y-2U'QJ7]D
M?_@MG'%8-%_P5(\:7<VH0M-?1GX9?L)V2>%Y5FFA6Q$I_8`O3XP+PI#?_;HX
M_""*;@Z:;,F%M2D_=G2-1&IV4=R55)0S13HN[:DR8)VE@#M=&24`%]@<1EV9
M&-:=']?U:W]>8'XJ:/\`L8?\%:$T#Q,=?_X+`_%RX\3A=-F\'G1_V<_V!K/1
M,S7$3ZI8>((KW]CB]O9FL;19K>WU2PNK-;RZN$NSI4$-D;/4?/O'?[*G_!9#
MP/X%N?$=C_P5D^(7C;5M&LO$NJ>(8/\`A2'["7@BPM=+T;3+>YL;K3$F_8>\
M9W&H7%[+9ZM>7%C/<6/V6"^TW3$NYYM.NM4U+][*X#XL?\DM^)7_`&('C+_U
M'=2H`\U_9!^('BGXL_LF?LO?%3QS?Q:KXV^)?[.WP3^('C'5(;*STV'4O%/C
M+X:^&?$?B"_BT[3H+;3["*\U;4KNXCLK&VM[.U6006L$4$:1J5Q?_!/G_DPC
M]B'_`+-"_9J_]4SX+HH`_"K]C?\`Y-G^$_\`V!=2_P#4CUJOIJOF7]C?_DV?
MX3_]@74O_4CUJOIJ@"M>74-C;2W4Y810J"VU=S,68(BJ.!N=V5`6*J"P+LJ@
ML/)+^]FU"ZEN9BV78B-"VX0PAB8X5(51M0'!(5=[%I&&]V)U=?UD:G,D4&X6
MENS%"2RFXD.`9FC)`55`*P!E\Q5>1F*F4Q1\U--';PRW$S;(H(I)I7PS;8XE
M+NVU0S-M52<*I8XP`3@4`5=2U*TTJTEO;V41PQCVWR/@E8HE)4-(P4D`E555
M:21DB1W7\]/VB/VA;'0+;4)VN8HV2&6*"*!]L@AMU:1H%F4,Y6!W>2]OC&#;
MM((883>M;VT'4?M-_'.S\.:!+=QSBQBMK>[$"R31EYFV2R!R85^TPM<"&%?W
M8N(XTM[F2"3S$2>OYC/VG_VIM1\0W5Y;Z;JJ7"R2F&7%PQ0VZL7**D#LD<<9
M=3!`"8HR_P"[\V:266=[*RWZM/III_F_ELM0G_:(_:^N[W7]5M;34)F5EF1Y
MXV6.163]T(X`A4P6\88@*))(XXS+M24[;F;X$U'XG:KXDN?-:]E\W>Q+)-*T
M<S[C*[`(X"97=N5]N%D)B6.1G9O$/'^J:MJC7&I"4L\I9Y9&)$JQHIWE2,(K
MK&`8LDND?G+&Q=8S6Y\'=#U765(NMTQE1BF\7'EXV@LS3%0R(9%W1R$R;HS&
MK,J`!4!]*:#XKN[WRX'E:5I3(5G(C+AE3>8Y492%*JK`,AVGY,(0S2MV-O+?
MQ2PS_P"E.H*R`@RO\N2-RX;AQ]Z/)'(1Q\I!-?PQ\--<C>.X-BQAC+6[(L$A
M6(YC<NLG^L):-MLC!!)^\DQO(^?L=4@BTQXT>;<#$KL[+MR[22J`B+N;A4&1
MECD,V0O"@'U%\%/C5+!=V>CSW-P'A96BN%#2E'W,KA59`XB:%E5DEW++\ZR-
M,HD1_K'Q_P#%R1;+_3[S;#Y-OMMT=5A,HC`$LCS,'S+,J;8G)C5UC>59Y[:>
M4_F]\,-'NW\3Q7=LFY)2Q52,G<N=[HI=6F7S&PRH58LWEQY*OL]O^-\U_::;
M`SR+'),ENG[I<!8G\MG5"Z!U#3H\L;@F01LA#C[H`/G7XJ^-=4U75+Z]BO[D
MB-+EHB)V"@PJ7(!B$+D.?+W@^7)&4:'``),WP1^/^I_#V]2:]U2[F*RK*3/<
M,HCVS'+0DJZ`-',=Z8+2F-E,93+/P'V*[U&_:$+@C"QX4',9+F,J-PW;L,SN
MS!4`<LR[0E<OX_\``>N6$37%E`8Y"DCL!&\33E2TBX"QI)O8F0R3/Y9F,!C1
M<9+`'[@_#?\`;TTI88;*>^B225DDN))FA@EVJ(A*SK)%<6S7``G)$<5JERD4
M>%$<48/Z*_"/]K;2-9N$2UOX#-<,BO:EHV>:,,9HT>,37*3XA6:>1[:X>]AM
MV\J*&$N[M_$/KOB+QMX8>XFMII(IK;(+2.X*(A_?;E5DW%2N]5;8`#&X)EV1
MOZ=\"OVJ_'OA?5+9KK4Y(C!>+*R"639(B7+$%-[*^UBBDN4(PT6'&\+33:V^
M[=/U3T?S`_T*/"/C32_%=F);>YLQ<A@GDPW`D\_$6]Y8`0-RATN%>*.2X,`A
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M[)+\1_\`U#M9H`_>S]G'_DWKX#_]D9^%_P#ZA&AU[-7C/[./_)O7P'_[(S\+
M_P#U"-#KV:@`HHHH`****`/@'_@J-_R8I\<O^Z9_^KA^'U??U?`/_!4;_DQ3
MXY?]TS_]7#\/J^_J`"BBB@#,UB_73K":<LRRNK0VQ5`Y^TNCF(D,"FU"ID<O
M\NU"`'8JC?*GCC5EVW(:8R^<IWR$LQ9<,SDOL8R%I?.E+[BS&/&XK(M>M>,?
M$:W*KY:+'%!]J2&4-*7>,D>9<_<0I^[CB,<6T2([,Q:3&Q?C#XH>+8["UNV+
MJLS[HH4WJK-*5/[M"JK,'1411*BMY;)%,P,<DA`!\A_%^[M[NZOFD;?)#-;P
M6SC[CR+)(\9C,1*,@L)'4-)A6()^9_+=OQ4^/NH^'M(O;Z1II#:*LR/<2G:]
MQ:/>.MNBHQ@=I1MN-RQ0)(QEB50[D*GZF_%37I%M+\Q%Q+%'))+Y,LD(CNM3
MDCBC=!M)#VB3B>)U=V(E,0>-@[5^)W[2GA/7=?G>33I+@RK-!<+'$T+2/%-;
MQVYND:0[A-%+$T6QVCC:/S7E6;%NI?V?5_\`I*_^V`^7/$\^AW5W]ITF25Y9
M26N3]G,-O*27_>[9&62.Z.%,RI&\,OF"3S1,LIFU_"GC'7]-N-/T^SQ=1B?;
M%'*\ZLJ,FS:[Q^:OV:%07D+VTSQVRNB,D<<7E>;V^EZA:70M[B:\FF"QQ"WF
MBD6XDEDV[`T#`D.X*-&(D1G+@*%3Y9/H_P``^%7M+:`WD:*]Q,'N<A9-\A/E
MQ0JRA-\-LI#2!GEB-PTZ1-)'(Y5`?9GPN\6:Y$(XP)8#';(ZRK+,&M2Y\@6O
MG1E"RLCR-;L'5Q#'+"K26Y"Q?6$'C[6&AA;R;"3,49\R2"82/E`=\@BNDB#M
M]YQ&BH&)"*JX`^7_`(;Z%)/`)(E9GU"9$BCB5G"I:O)#$HB2,,96F:50BNRO
MNMD&UF<5]<Z;\/H(K=4U&]E>141$2R**B!-R_-+/"[3%T$;<06XC;>N)`58:
MP<4FYZQVCUUTO;KLUY?,"6;XO7=OCS5O$)QA?[:N6;!S@[%M6;;\I&[&W(QG
M.!7/'XH7E[=2>1:V\9E;<JW8N+B=V*EY6>XCN(E=BP=R6CC.&"Y=@6.1XE^'
M>JINGLI#?1[0I,*/YN,QJ`]KF2107D?Y;4W`9(S)+Y`9R<?PYX'UU[LB:RGM
M"%=EDO8IK>!,*`7+['W,V[RUC1978L7*)'$T@=H\RM&/)W;;TTO>[T?963]4
M!JZMX@O]2"_VA=H(%E>2*$".""-W!PH`"M(8TW)$TSRRHA?#DO(6\G\8:19:
MY%+`9-WRI*LJ8=8YE1HP<95)8Q$V'C9F#!Y%5DDVO'VFO0R6Z-;S+LE@O##*
MF5;;)$)D==REE;:RD95BIQD$C!KSW4]6ATVWGGNF5(D+1J`"997.X+%$I8!Y
M7`.!PJ@,[E(T=U=627N))+1IK^OQ`^4/$_P^T/4;J[%_;P+-;M-!-)!&$9FM
MYG=BEPJ+<)&90[#RPK,)'#*RL(U\RO/`GA>P995B&Y7B:.WDDN)Y&&\;F9&N
MA%(@VNVV6(0OM\ER=V3Z%\0/B98:3<7/VQUFU&Y4O)#"H!BA4"'[A*I''&@5
M4-Q-&\L44S+(\H61_"(/$VI>,M1^R6R+907*K+<W%G,TEY&D$J#%I,C0*OFL
M(+,*(9Y%\QY'\T;E7`#Z5^&_C*\T'4;:2TD,=U:C*$80R1J\>T),H#0NNR)%
M8!G\Q(6'F*\\9_>_]D;XY2:_#:03WK3.T2Q,1([^9<HH5[CRHX`4\]B`_G")
M5E,\+PSS6TTLO\].C>&+R$03_:&AV(JF*0R.TB;>$>>1I6F!`0R2.K%WR4E9
MP)1]\_LM^*YO#6HA;B[N/+ENEMXXUD>6(W'^@N/]'9U60L[RO$S*R1W++),@
MC>:16NWW>NGY[?<!_55X"\3P>4TT[R&&:...7:JR,KAP8)I3A9`B1-."$W2N
MI61XF=E"^U5\`?!KQM'JVC64N]'#JJ.4*.IP$\T*PB@5@Y"&&1&*.^U8]R%\
M?</A[48;VPBA162:RB@MYD/((5-D4JO@`K*(V)7AHV#*05V22(#>K@/BQ_R2
MWXE?]B!XR_\`4=U*N_K@/BQ_R2WXE?\`8@>,O_4=U*@#P'_@GS_R81^Q#_V:
M%^S5_P"J9\%T4?\`!/G_`),(_8A_[-"_9J_]4SX+HH`_"K]C?_DV?X3_`/8%
MU+_U(]:KWSQ'=K:Z7.@E6.>Y401(0&:16=!<`*0V%$#.&D(`0LH#+(T>?`_V
M-_\`DV?X3_\`8%U+_P!2/6J]#U^[>[U2Z+C"V\C6D2\':EN[*3D*I/F2>9+\
MVXKYFS<RJIH`QJX;XBZQ!HWA74Y99I(7F@9$:%L2K&F);F0A6$I@6%6BF,2R
M',T<90B7%=S7PU^T9\5]-T.WUL7$ENT=M9W$<;O-%Y`M84N(E\J8-"DKW<IG
M>,/(1$TN))/*BB6X:ZOMJO-]%^K\DP/PG_X*&?M":I8Z7K6CZ:[[U>Z5YE:0
M$?,(+K;%<'YE2>-;>`D2^1;(%63,Z[/Y^M&\27'B^XN+B;S1(]W<IF4AB/*E
MV2N<RD'*>6P"A22K*<D*6^[_`-L;XEVGC'Q=K6FVQ1E620%D<")99-T,K1QL
M6<GG>8]Y<*!OE9?*V?%W@7PK*C1PP)*^Y\M_JP6W>8&+2!`K.B,R;RNP!0"W
MEV\CE`>E>&/AQ)XDG2U\EV$@`&=SR-(6!1#&`$9\E,HJYC5@\K1E0K_>GP3_
M`&91H+)=W2A$977>0'<,<C][@E6A8C?L=F)*R12^9+&%<_9Y\(6[ZG8RWB92
M,Q[,0A/,>,-O._)"Y<YN+>1)`78LV=Z/7ZM^"/"^CW=GILLUH)I9I+G.\B2-
M(XY)H2JP2,MNX"1&0O,DTHE=Y5WLL<8`/EN[^'^G6NCF.VBB::"%,A(M@D,:
M,@5?GVJJABL<F(WB3]XTI*N)/B?XA^&;E[\ND#[3,N]X_,(+2$\;I5"#<YN)
MA@@K%-'*1Y*LJ?M'XI^&0O[$3:-!!`8A-NC%LL*3PL(UF622TAWLR`.\3A%V
MXDA5)'D+Q?*?B3X2W2SSR75I=6KI*LD\EQ;R-#$)0&11<P?*WF/,&/\`I`C$
MC%!$&(6,`^8OA3I[V@L3+;>4YEMY-S*&;+R6V#ORQ`9S=&,;@"C.T0\I\G9_
M:%E^TVL$L22,&$+!,#>1&7W<!BHP$9B2P4*-S%0"1[59^`!:+M6[50K!XS`7
MA97!R79W2=V;(7:VY2@4`$C:%9KG@(ZSS=3)<*41-CHLK*57'F+O^SQ*I95D
M:+8R&<^9L(P$`/ST\&F]G\3V(>"4(LP?"QNRQ+$2"V\#:5PY:23HV%(*H`!]
MQ2_#V/Q+I8$T4;!H?W2-&JI&""85\Q9T!1HR-Z*A:.*9X]JER&VO"G[/LAUB
M'4K339KE""8I(K>5I9(XT9)Q+=R[[6+$L:I')'/N7`C#"4B,_4$?PQU6VM-T
MLL4#*CM#%##+/#L5%=3<39CEMRSD^87MW90#)^\?>B@'XG?&CX&K:?:I8[<L
MN66-B-K,A(,:;MVPW$1;$7(#PLGE,R,98_SG\3^"!H,M],K2020L\P\L!55X
MEW`[0@=#M1$R9$:&1D41*BHA_HR^)_AB'4-.N?.M4$HW0R^9&%EC<DQ2P%70
M(KO(48+/NV2K-+C<NUOQP^/GAV/2[F=X1$&2X*2)$KL`B2(!LE<ERBH$)0HB
M*%9N2"6`//\`]F?X[ZSX;^*/ARP!NX[43K!=+F62*2,RQ*_[D-M$<ROA7F#_
M`"&,!S+Y;'^V?]F'XD1ZGI'AN[^T;L6UO,ZQ([/Y+_N;Z%8ID!65G=RDEQ,S
M'[:WE2!8_.'\%?PXO=.TSQO9:FL(A$<Z/!)))&LBK'-#)L=C&6D)6,;5+2>7
M&K9%PRAZ_K'_`."?/Q:AU^VTRT,[S!4M%=8-D=N\OE1Q`R9,;;IH[BSE>-?,
M6);(2['=59FM&K[7U].H']$D,T=Q#%<0MOBGBCFB?#+NCE4.C;6"LNY6!PRA
MAG!`.16MI-Z;#4+:XW[(_,$=P3O*FWD(67<L9#/L4^:BX8>;&C;&*@'SSPM?
M76I^&B('5+FWCFL;.X<+L)2VC>RE=/)(584FAC96CE9Q"9'WL[+4G@XW0T^^
MBO'E>XM]7O(9!+*9F20);O,H?<X.;AYI&*L5>1WDRQ<L:<;<VJ]UVMNW?KZ`
M?3M>2_'W_DA/QJ_[)+\1_P#U#M9KM?"UVUQIOE2.K/:2M"HW%I!`55XBX9F(
M4%I(HB`J".$(HS&QKBOC[_R0GXU?]DE^(_\`ZAVLU`'[V?LX_P#)O7P'_P"R
M,_"__P!0C0Z]FKQG]G'_`)-Z^`__`&1GX7_^H1H=>S4`%%%%`!1110!\`_\`
M!4;_`),4^.7_`'3/_P!7#\/J^_J^`?\`@J-_R8I\<O\`NF?_`*N'X?5]_4`%
M8?B#4?[/T]_+;;<7.8(,-AUW#][,N'21?*CSMD3=LG>'<-K5M.RHK.[*B(I9
MW<A555!+,S$@*J@$DD@``DG%>+^+]8BGENKA'+0&/[/;ET"D0(A,TFP8D*%F
MFD0L&D!DC5T7_5J`>+>-_$7D12;BJ?+@_.8]B@,P4N=JD1JXF=R3AF$BJ!"8
MZ^%_'OB-M;U`0HW[BW9F*!BP$Q+*%8'<%DC0D.(Y&4!D@?<]MN/N'Q5\3K;6
M]RL<L?G2OA8AU8R;R`@5T)B,A);]ZQEMGG"JQB;9\J,S.S.[,[LQ9F8EF9F.
M69F.26)))))))R>:`/,/'6E07+E9E4P:G:O#+@[I!-`%3SE$BO&CQHUNT#*#
MMEB\PH&&Y_@KQSX*>Y-W#<VIBN;99EAWL56":95;;(D:NCP2M'&@?RIHWMG0
MP2!V5C][>*=6M+N5%B=?(L%N&ENF=5A;<(S(RL<*(85AR9BP1\LR_NU623Y_
M\5:SH>M0&."UN7NXW:%+QE2"-[4EQ(IP[S2Q/G=#')'!)$SF0/&?-AFTA%RO
M&S:Z-+X7IOTL^O71-;`?F5JG@>)=>:YFLH8;BWPI,D4)E1P6=@TS+)(895D8
M;85*31R^;YK>;(S;::6L+0-"X"Q-%N0J%4*A!/E[1A1@`)&1@#J_05]A:SX-
MBE2&XFT[<LH:2U%]:JR2(X5G>UEN$"/&5:!FVG++M9I6)4'F=)^'ELU[;/:Z
M6YF$C/"`UU<2CRU9BXMGFD<N@5G7]T2A42JZ;1*J<))VM?S6J^_;3K?;J!<^
M%$=_:#10+.5IHKL,;>8&V9G.I2211EY0HB:=TB4,ZL%1C)MV@L/T(\'0$+?7
M+1KAFA@CE.TME0\D\8_C52'MV;@*Y"XW%#M\9\(^%;?1;.V0VB/JDI!=@%N)
M8WDW1I!;LJ?*YB<1S>3N\V1GC622!8%3ZT^'6@RRRV%I*,M;1F1R1$5BGGDD
MF(9"["3[,AN'1HW&Z2W1U92R(4[626MKZ^;MHO)6WZZL##O?!ZW5O)=W&E&(
M!9G>>/;;W"EVP\TD2,LDC*P\S=<0R*HW2$&-G+>=W_A:ZM(9;B&XBN888C+(
M"K0383)DVH3)&RI&/,),RLV&54+!0_Z`)H%F^F%!#'Y`=IA$6D!_=[]\GFY,
MIF)4(IWC$0,98H=B^.>,O"L$+FYL4\MG26945<^<58O-"53+O,I96BF*;Y?,
M$,AD*^;'('Y2?%;?I5[J5S%!((5CEOPI:1$F=K6.>1UD<./WEP+I%90PC;S5
MC4")D'QMJVM7<[B2]FFN)"KF'=L$",%12%B1HTB!VQF3RXUW\,2SY(_5'XG>
M!1J%G(EO$V%+2:7*9<JDCB,W%G*SKM#2+&WD%V1F58P;M5%V1^=7Q'^$VN64
MMY%';RQ1N9)41(RKQ*_G-+'`JK'#<6?F0&.,V^YY(_W4,<BYF>GK[WDD]==$
ME?O9]^^GJ'Q[XO\`"T/B/5D>VN3'>A%B9E02(4B1R8&5YHDWQD&02K(N/,DA
MD5V5#'T/@SX8IX>G6\FE\V;:T9(1885C,H<^5`5+1N2%?]XKGS84ECEC5WB;
M;T3P=JVE>)+B[U&_GFMH]RV]IY<<*VKQ/(,2_N5)?<[ILS'<+'L2Y-R8HY8_
MKC2=/T6VMK66VM(W_<I)!>-&IN9$F0L96E9(YE:5)/F4D!58QJD<8$8D#P\`
M````````#``'```X``X`'2NZ\":G=6FJI:Q1M-!.PG<9D*V[P*6$I4$1A)CY
M<$A;87<VW[T>6$?.\636,FI&*TMXXY8-ZWEQ$4"W$\A$C`I'E3)"S.LTK8F>
M5GBD&($+=7\.A9$7/F#,WVJ$W&?-_P"/8*#`>/DX/VPC9^\S][_EE36ZZ:@?
MN7^S)XL^T6%G"\B1231V]TJRSJ%A=HHPL21-'$D[PVC6X,ZCY@5\U2P93^J/
M@755$EO$K*(+R)+=MS!`)H8R]LX+H&9I%;RUB4KEKD`EWC53^&7P(\3IIKZ*
MR2%8([>V:25(TR%C2"PO8W-RRJJQSQ1;755&U)G$K(8PWZU^`/$/VV*`)*%<
MQQLDJ2_-N3YHI4D4#[LA\N$H8PQ<",,(@S#5FUV;7X@?7=<!\6/^26_$K_L0
M/&7_`*CNI5U^F:C#J=JMS$K(=QCEC;DQ3*JLR!L`.N&5E=0-RL-RH^Y%Y#XL
M?\DM^)7_`&('C+_U'=2I`>`_\$^?^3"/V(?^S0OV:O\`U3/@NBC_`()\_P#)
MA'[$/_9H7[-7_JF?!=%`'X(?LJ:F=-_99^%#Q,HNIM'U**W!"MM/_"1ZR9)2
MC,"5B3.&VNHF>$2(48@^B5XM^S1-N_9P^#5OMQY7A[5IM^[[WVCQ/K*;=N.-
MGV;.[<=V_&%VY;VF@#B/'NK?V;HIB1]LMZYC*CS5=K>,!I@DD?RIYDCV]O()
M-P>&>5?+9=[)_.5_P4;^-5[X4DU*RBDC9IS<VK+')Y3Q2R!4,S@S%!*;5;/!
M*+Y8DD556.ZB#?OU\<=3CTW1K2831">*.]=878L6,HMXK;S(HV$ABEN55`WR
MIN1B77RV9?Y*/^"E=U+KOB:*&UE98EOO(VJ9(R\ENC6C?*$9C*DB!%^^F^-I
M(CM<9IO2*]6_5_\``2M]_4#\A;CQC=^*/B#J/V@K(DK^<[&1I@^Z<A0#YAC!
M0*T3KL;`7&\DL%^[?AAX-T:XCM78A))8HB\DA+-YTL<DBAL21?,SJ@5%\LL3
M;XSY0$GR]\.?@5J.I>(6NOWHDNRS"4G/EAB)-ZI\JBWRX="S&/Y96!W,Y?\`
M0C0/A1?^';!UDN%DDCA4!PYG7&Q=ZGYD=(]Z*=XCDV1CY8HDC*M('NO@"30]
M!EA"R+&T)16C+`%+A3^ZR$0,SRV[;2JK*$$L(6..,(%^Q_`OC2&RD7-XKZ>`
M[Q-L:X%M.V=Z8C+.+><&:.01+*!<8>(QDW$A_']M;O;/69A%<3J8G=E"2;%\
ME9FA:)<`B)F10OF(N\AG).2V_P"H_AWXTN-,M3'+.TBQ&191(Q9BS$>60JK-
MA7CVYD>,>9)%*7$D@CE0`_8O1O$>E7]K"T-[#)D%(RC*_F!`<A!%N#&':8W9
M"Z;D;$C$.%U)M.T^\3YH8I%8AE*[60,ORY13NB!QN4D)GEOXB37Y5Z%\:X8=
M5,<4[1N0I1H65&PH60Q&:,?9;I'D\N22*1?*6.)Q(&V-7W]\)_'4OBN":.<$
MNL,4\<B(5BDCDW;&(D<S)(JQ,CAO,+L/,:9@RI"`>EMX=TME*F!<,"#MC@5L
M$8.&6$,I]&4A@>00>:R9?`^A33I<26EO)-$5\F:6%I9X@CEXPDS3;U*.2RE=
MN')90I->^>'/"]I+:6]W?0?:+BXV7$4<C$0PP@[HBR1R%)A,A6603!EVLD)A
M5ED\ST$VA`)#Y(!P-N,GL,[N,^M`'SI9>&IK&U:XMM,N5ME"2>>UNW^K:)F$
MRML4O%Y49:6Y`9<%/.E^>('/U.))+5RZAMF."`05<B-T8$'*,K?,O`)"YR!B
MO:_$FN#2+79`\0O9P=@<Y,$.&WW3(04(5EV1"4JC.2^)4AEC/RQXI^)NB:9]
MJ@207%VY8>5:QQGEV7>#"GDQ6R;)!+$&,4<L'%N0W^K`/F3XBVNF#4-1@1P\
M<L2F8!/*!NI%;'E*$5E-S!Y4TK*SONGG+2JV\)^9?QW^'&D>(?M3QA)""880
MG[QE;]X%*@,4(>&(2%8ECRNQ8XI-Z%/J[XO_`!"-I-<323,')E,FR0[&EG!V
M1C.]Q;K"JQVR&2:)HE50CRQ+`_QU+XX.KM.MR[M$D[RJ$6-OG`E*[CM60;@Q
M1"99T=F)>4[#)0!^?_B?X;1>'=1:^CMP%BDDD22-`&.^17+L!&PS\P1SO.Q`
M2K[+@&3]&_\`@G7\4=6T3Q7':S-)#;VL^^,NT[&`8Q-+\FV996MWE2-T1V!F
M5@%6,*_RM\1_$=D%N;(VR*3(X):/=Y!+JR",JF/W6]-A5?E5R``9)/L_I7['
MQW^,[8Q'RP^H(8SM4^7N-UL.S.T[,CY<[>,9Q0!_9K\#?'5O<:5))J%Q&R7"
MJLUQ'&[LDT&YX"8XBP\N2&8M.UO'*AN9XPHA59<?3%G>6]_;QW=I)YMO+O\`
M+DV21[O+D:-_DD5'&'1E^91G&1D$$_GC^SO<;_!NF>:\CS2V%F[22+(WFO+8
MV;DF9@5DD/E2/(-Y=<JT@'FQE_JFS\4:K86MG9VKP1P6C2-M,*N;D2S&=DN&
MD+,%#,Z*;<V[['.7+A77:-/GBFG[U[.[TLEIT;OLO0#Z?\'3;;F\M]N?-@CF
MW[ON_9Y-FW;CG?\`:<[MPV[,8;=E<3X^_P#)"?C5_P!DE^(__J':S5#1-6:!
MK/5+96,<T$<WDR,8S);W,2OY4OELRA@K*PYD1)D1\2!`#<^/$J3?`7XS31-N
MCE^$/Q$EC;!7<DG@S6&1L,`PRI!PP!'0@'BL0/WO_9Q_Y-Z^`_\`V1GX7_\`
MJ$:'7LU>,_LX_P#)O7P'_P"R,_"__P!0C0Z]FH`****`"BBB@#X!_P""HW_)
MBGQR_P"Z9_\`JX?A]7W]7P#_`,%1O^3%/CE_W3/_`-7#\/J^_J`.9\57IMM/
M6WC?;)>2&,@;PQMXQNFVLI"C+&*)U<D/%+(H0C<5^9O%FM,D,I\QHQLD*```
MI$=P0;?F#,Y!>;:S,5B92K1E5KZ`\>-LMK1MVPB+4-K9VD,5M@F#D88L0%P<
M[B`.<5\/_%C7X]*L[V;+9"-#&%+*[7!580GF(LIB.](Y8WVK@#+,NX"@#Y.^
M(_BFVGU:ZFENL6L.X16ZN&\Z9#AS;1%@[']X@9'"_9I))A(4!EE?PB]\3:E=
M@I&ZV<19B!;[EF*[E9`\Y)?<@7!:$0"3<X=2K!1Y;\0/'5\WB*\M;*YA=S&D
MGGO%-)<1*)2R%!<LT06>!H9I-\+[I;BX9=DH818G]K^-K:'RI=/EG>>+S8[C
M^SVEFA65=J#;9[;>.6,J7\FZ@:9';$\90JE:*G)I.\5?9-V=M/+S7]-`0_$#
MQ-#%9RZ39OOE,J+=R+M:-70ETM02C[I8Y%6>8J4$;0"W9F>2:.+DOA]HT6JW
M,OVN*1[.%9995Q,L4I*I##'YL<D?E,7:24,I+2BU>,AE5BE*#0K_`%?58;*.
M,D1%O.MYE=!#)&[)))=`J/+CARH?>&<N/(2)I)@C_1_@#P$EEIX65O+A<EII
MX45'N)@NP0VSO&7:VMFW$S3!S),TQ1$>:5;>I>YL[632MNV^6\]+V35TM;Z*
MW4"%;:-XUM$@1XG06R6JQ*T;1LHB6!80I5D92(Q$%*E2$"XXKH],\(791(S#
M#I=HJAD18XP0)`\F([6$J$;S"#*LK0,ID+8=PRUZ)X?\-0079BLO/D>XV+++
M,(I&MX$;,CJ4CAVI\RLZEP)72)%^?8#](>'?AYI)BC-W`9Y&3S91<KY@56#>
M5$ZE$*3+O^81&W!V;7$OE%I,0/E;3_#%I8S07+S2W$\+,PW+$L!8[@C"$I(Z
MM&"K*?.)$J"0%>%'L/@.Z6SO+FY=2ZQFWW*I`;:\=W&2N>"5#E@I(#$;2RYW
M#T76O`NEI;W26UH%G4Y$<,<&X(2&_P!'D6))0R*1(@=I6D5?)>.1I"*\NBTC
M4M$EN;M'MG6WANEDCD,J2.B*S`/&86*.LD:.T:RJ2R&+SE5BU`'N2^*K7[*R
M"2X102HM_)3S75F!8JZDIM)9LAYU)"LNT@J&RKNY.O1?9K&&0&`_:9'GVQJ2
MJM''"A0RKYDOF,5\QXE`C;DC<5\!CN-1NKL-%/<O=S9C4QRNCE68R&,%658X
M5;+E1MAC`+$*JY'T1X(TR\>V:2\DC;S5AWRQ*5#F!I4<JN"JEG8HI;9N,<LH
MAC39&0#Q;Q#X=E62::*WDD$Q/VNRDC9I`TW+.(G4L\4H?,D14E-VY086(B\)
M\3^"+:_M9TMX$FM7@D#VCJ)IHG,;0F:Q,Z3!IA')(ZA\R(X81&7S%A7]"KKP
M]%=$B5+:8851(X:.8*IWA0Z*9$`8GA9,$$YX9A7BOCKP9>6]X+NPMC)"55)_
MGB4)DL(F#.5:1`!Y9FD;<`UO!@R([$V`_(7QY\*+73[HZC);+?03*JBYC^T6
MYW(N3'.L-Q@2H`^UY"[26Z1D2,(9Q!\P:W:/I=_>0M;2QQI-(UO$H,C-:O*P
M@:,EB9%"8#$N65D=)")$=1^ULOPX74;B>$6%\OGET>U00+:/O(B>*(3PO%(D
MK,<1)(Z,K$1+Y0"KQ?BW]F6PNXI9UTB6-"J&=H872*7S6\B2*6,6Z1".1&1G
M6/3)"\@W-/B6;#T?D^O;IKY=6]_)):(/QWK;T/7+C1+B26*-9HIE430EA&6,
M8?RG278Y1D+L""KHZ.ZLF[8\?VMXY^!.KZ=#>_9K4W]@3,LMNX'G1K&\F%.P
MCE<6Z0,RVUY)<L&C@1XR!\EW_P`.?$-@]PLD</[B6:((XGAF=XBX$91X/+CF
M;804>;8CY#2[07H::UW7=;?\#YV`]^^#_P`5UA\06^GK/<0VS,C[+M(XXD<$
M1+,)4N@L4>6C@O-\J^;:R"-(W\I/+_;;X#^,8]1MH(7F0B-5(\R6/S-DH(9F
MB1Y))95&Y97:1B+HS1JNU-K?SB:+HOB'2]4M;H6AB191'<DW-N1]GD(2;>D=
MR&?8I\U$(<>;'&Q1RH4_JK^RKX_G5K2*>X*O;2"TN%C)1?+4)#;SR16X60$^
M99PQ`I-'(+:Y<212O(4-UYK\M$ONV7EY(#]^/`FJI<12V[.@,X%Q"JM&4,B#
M9.%;/F,\L0AE2/YPL4;OD`%GF^+'_)+?B5_V('C+_P!1W4J\2\"ZSY]I%^^=
M9!Y+1,79)(Y0`R?=)5)'.?+*,A58HE"Y*5[)\3+E;SX1_$*Z3:!/\._%\A57
M$@1F\-ZCOC+@`%HGW1OPI#*054@@(#PK_@GS_P`F$?L0_P#9H7[-7_JF?!=%
M'_!/G_DPC]B'_LT+]FK_`-4SX+HH`_G8_9<F:7]G[X7J7#I!H=Y#'C;A%&O:
MO(Z94<D322[MQ+*Q*$@*%'OE?/'[*'_)OGPV_P"P=JW_`*DFM5['XMU7^Q]!
MOKM9!'.R?9[<DR(3+*#NV21D&*58%FDAD+!5E1.'8K&[2NTN[_I@?*G[17B^
MQDL'FA=8X+>!HWEF*AGM[3SKUKI(W9#"!,(5/G@JD$D;S>4TVV+^6O\`:\:_
M\4>*K&TL[.6^OFO$>&RLH)+FYFN;QBHM;2T@2:>67[2_FP)F29DD7'*J&_J;
M^('@?X=^"?">D?$_]K;5-?\`#_@_Q!-JW_"%?!SPS;"'XK_$BSTZV\UM0G34
M7LCX-\(7\\<%K=:O?)!>M:S01::NF2:EI>LW/Y"?&[_@I_\`&+X<M?:7^R'\
M)/@Q^R7HUO:BRL-;\`_#OPYXE^+=Q:6MP3:1>+?BKXUT[6-5\2:C):F.UU35
M9=/T^XO86=;Q8_M<L;_@-;QHS?BW,,;EO@AP+_Q$G#Y9C,5EN9\=9SQ''@CP
MKPF:8#$8G!8[*L#Q9')>)\\XLS#`8S"5L+F%7@K@[B+(LNQE.MEN99[@<UH5
ML!3]59=3H0C/,L5]3<XQG#"TZ+Q..E"2C*%25#VE"E0A.,E*"Q.(HU9Q:G"E
M*G)3?YS>!/A-\5=#TBV\63?!GXOQ>'PKA?$<?PU\6QZ'!MTUM1`.JG14LU/V
M#-YY?VE&2R2WNF(BA;,_B+XH6($]C$LUG=6\DMO=6MVAANK>ZAE\J2.:"98\
M2V[K(KP3F(PS1_O$E8"->5E_X*]?\%+XO%$]PO[8?QO65OW;6[>(8)=+C7:D
M!V::;.325E1$#EDL4+`/<.5N9))3].^'_P#@K=X[^+"V>A?M^?L\?`']M/PJ
MS:787GBOQ?X!TKX:_'S2]!M;ETO+3PA\6_A;%X2O](N'TZ1H4DO-)NI[FYM=
M.N9KX.M])?9SXH^DGDD?KN<>$WAKQ=E\;U<3@?#[Q4S7#\64H<D7]6RK*^.^
M`N&N&,[K0FJD/K&9<;<)TZJ]G)4*;<H1%0R>I[M/'XS#S>BEBL#3=!Z_%.>&
MQ5:M37E##5VM=6?&"76BW-^UT6?:P4R)Y<+1^8H8JTAADD=D8[F\LQMOE9F=
MBC.M6M3UWR6,=HRX#!/.PK&24L-J0!CY9!P5+N"K`LR[$02M]E?%3]C/P+\2
M/A'XA_:A_P""=OC?QA\;OA;X0$-W\7O@3XQ\/O\`\-)_LZ6US:W5P][XDL?#
M8;3OB-\/[>*RN+G_`(6!X4MG@L+$RKJXN&T3Q%J=A^>?A::X\1FU,V^-4.<N
MI5#)&NX2*I"RR#:DFT2'<LR-%(^-S/\`I'`?B+PQXBY?C<;P]B,;2QF3XW^R
MN).'<[RW&Y%Q3PIG4:%+$SR?B3A_,Z.'S'*\8\/7HXO"5*E*6`S;+L1A,XR7
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M>WWVDP"A2@B;]S']U5;9;-;G<N=W1W,GF8V=:U(6-A=W"E1Y,!9"ZNRO+(`M
MO&RIA]DDKQHYRO#'<R*&:OCCX8?&.WU^V62SO$LKJX0*`I$T-S")&$,RFXC*
M.%;]RTCQQS03,8VRMP&;U[Q%XRAN[2+[=/9:?:6RK/.S3H$><1MF??(0T<*Q
M,[)$"VQ&>2664!6C`/E;XY_%LZ%%J-K!=Q1R%99;Z]\Z*/\`>S!Y'AC\AF:.
M60EC(ZHK0PR1B)(_-:9/SANOCBNH23PP2S$$R0*L)BC24QYQ,D,CB7!4*X:%
MU'R[E99`SU]%?'S3[+Q)J.HR6][&\<DK-!)'=*L3H]M!EH2I^:5]C1E"6#I'
M*C0RNGE'\T/%?AY_"-U<LTP<.)'!D8",(DX5WD"M@,F6!;S`H?S=JB+8S@'H
M'CCQ!+K432SJPW2E(F9M[DO*LQ9\G"*4@^Z#(PD9F>20N7'C.C;-\OF;O+W0
M>9LQOV9DW;-WR[MN=N[C.,\5S\_CG*^06GFB0`1E4<QKA,*8TGN%VE`2HW1`
M#!`!0\XS>*%C;?;PSL[!Q(TDBQ-\V.A7SRY8DDD[2K!64EL%0"'Q_I=BZ/=,
MH\TG,C(`Q`:&5V#JQP[$1`X8H&C<(>$A9/0OV4M7T[P_XN7[0Q1)+JW0,SY"
MAIEGC!41LX`:*4%V)'EAF^]"1+P6LO'JNC27!:;:Q!4N5\PGS&M&WDF0<*[E
M<,>0A/`*GCOAVTEKK2^3+(IFN$+'=\RAQ-*51@`47S$5AM(;.X%B&8$`_L,_
M9EU2TU+PUI\]K(CPKINF6OF!OE,EM!>P$#<%/SL5*Y`W;E*&1&1V^P=0TF?3
MH--N)65X]2M%NHV3&$)(8PG)WEDADMW=RB)OE:.,R"(R-^:/[$NI74W@ZV=I
M;HQK"DRP71E!1TM=)8+)&[`C8[2$`$J#)*\38E9W_7^'3[3Q!X8TVV:1@JVE
ML(IT#`P7=K";5V,;;!*J2+-$Z-\LB%FB=6,<R[4Y\J7;F][T:T^ZU_,"YX6F
MDGT#37E;<RQ2P@X5<1V]Q-;PKA0!\D42)DC<VW<Q9B6.[\797E_9Q^+C2-N8
M?"'XE1`X`PD/A3788EPH`^6.-%SC+8RQ+$DXVAZ5#H=J+!;K[1+-+-=L6"Q,
M^!!$[10AG811+]G5R7DQ)(&+*)$C63XFRH?V?/CI"&S)'\+_`(CRNN#PDO@G
M5%C;.-IW-#*,`DC;E@`RDYRLY2:U3;:Z;^0']#/[./\`R;U\!_\`LC/PO_\`
M4(T.O9J\9_9Q_P"3>O@/_P!D9^%__J$:'7LU2`4444`%%%%`'P#_`,%1O^3%
M/CE_W3/_`-7#\/J^_J^`?^"HW_)BGQR_[IG_`.KA^'U??U`'E'Q!U!6;[(1M
M2U5%+D`?O9Q'<NQ8N1Y2PQ1@$JK"3S,Y3:P_,_\`:#U;S#-!$9X;C[-?7#NA
M\M/W<#<*RR&3*SA)(P1P45]P=17WA\1=8WI<W7F,!-)(R[_W>R'[EJ)1'\AQ
M%"8'P^0I=G<ABS?F%\:-=>\NM143;3`HM%$H!EWW,R"Y@#/D3`P!Y(V4&18W
M=LJ8PL0!\?KX.EU#QA'K*LLXD2W\JU42+-]HMHU6(95EC$2/&EW).\F!Y7DO
M"(?,F;O]3TFZTIHEN3$XF5S&\+LRDH0'4ATC<,H9"24VD.-K$APOIEAINFV>
M9K&&-?/C7]ZLDDV^(_.NR2223$;Y5CY9"R81FW;4(YCQG_S#?^WS_P!M:;;=
MK]$DOE^O=@9'A[23J%T)ID;[);,KN2BM'-,K*R6QWY#*P.^8!'Q&`C;#-&]?
M7/P_\*K%%'<2V,1:6W*1I*H4+C!2&*%U1$B@A4K*K+M%Q\JES`GD\3X`T'3[
MFZB1A"D5HZK!;9<D;%,SLR*-V^4!O*GDE'SK<2DM<)&3]2:?I]M80HEN!@)M
M5ER%\MB&`4;F!W$!F=BSNQ9V<[L4@.;M_#4,$JR1V,:N",/)+YH0AE8.!)+)
MM92`0Z+Y@P0IY(/1V^RPB,=Q+&&:0N`A9CM954':%W8RC<[=O09R<5)+J%M&
M=NYI#W\H!@.`1\Q95.<_PEL$$'!XKG;^[.VZNB&<11S2HC$*=D:LZQY`8+P,
M$@-R2QW$DD`LW=P+B;>H(4*J*",-@9)W89AG<S8P?NXXSFN7UG0XM4C<J$2:
M1#%+N++'/$R[&61HP75U0D)(H+;1Y9X"-%Y3JWB_4;?6)B!PB(CF.66&0J\:
MS+'$Z,5BA0NG[MHY2[(TC.7D++=L_B#?W,R02>;$\LL4411+292TC[,R%H(2
MBJ2O*B0D%N`0`P!TVF>!H+&[^T$Q(A1$=(Y;F;>@E5W0>9Y;)YP`#2!V*>6G
MEHI:0MZWHUY%980>7%L8F(,-L6TQ>64PNU4"*HVC<H.0H'&#D:.\%[';RSLI
M,T*,%0D1M,R@21[@Q92C[E"9SO78S;AM>[J2*EPNU0H:)"0.!P608'0`*B@`
M`#CIG-`'6PZTDTP!6"0Q$YV*PD56^5FB9V((Z9*Y5A@%@&!K6NK&VO4!=$)/
MSK(%1@Q*X4MD$.N,8.0<<*R@G/G>F[_M(V_=V/YG3[F!CKS_`*S9]WG_`(#F
MO3(`1!""""(HP01@@A%!!!Y!!X(/2@#GSH"AV=4MCG@;@^,<8/E[&C1B`,[1
MG.?F.23I'2K7[.8O+5V\LJI?<$W`?(3&"4"JV-J[3@`9W$9.G4$]Q';J&D)Y
M.%5<%F]<`D#`!R22`.!G)`(!Y)XN\"6>JVKDV45O=8=DEBBC4EWPS$21*V)'
M,89Q\S-M#%)`9(KCX[\>?!)!'-]IL(WA0.=_EMY`#'S&P`PN+(3LJEEMIF5;
M.$M-:+&Q6OT>(AO(`2"8W&02,,C`D9'7#*<C(RIY'S(3G!U/P]#=P3+DN&B>
M/!#"3RV0[E#1D>86.0J[5(#G:ZM\Q$VM4[/N@/Y_OC=H@\!Z=<7\$4=O$!<!
M86"+-9R_N1N+LCQ3P0B59H))&;S8CY;EE/VF3Q?]FG]HJVBU.ZA:Y>:$7BHR
M7:L]PJ-)<QPN997#'[1#(QMT?8TP>>W\Z*XCMDMOT'_;!^&4H\+:D8H%4Q3!
MH#OA2XG$6Y8TAD:*0$/*8UF\RXPT$5O%YS3P2!?Y\=.77O`/BL`V+P6-[JPL
MD1GS'/;?:G2V99@9)51H79HQ,/\`28O,('FQB:!MMZ^5GV=K+_*_6^NX']CW
M[/WQ5B\1:18!)PT@2"50L``:!@&@?*_(TC)L>,2QVSE721HXXY&1_MCQ!JDE
MU\*/B9;%_,A;X;^,;J(AODB<:!?I.D0(+&.5Y0P^?8I1G4,9G<_S]_L7_$FY
MG32;6^N`C))'M5MLTDD<TSQS;8EBC58O,CEGN)D7S%1K>V1E\J!9_P!PK^_E
M/PP\;RR`.#X!\50K&"55/M7AO5[4LI.\X7<LA3.&8,`4+EJ0$O\`P3Y_Y,(_
M8A_[-"_9J_\`5,^"Z*/^"?/_`"81^Q#_`-FA?LU?^J9\%T4`?SF_LH?\F^?#
M;_L':M_ZDFM5].6-_P"'?!WA_P`7_&'QW81:AX9^',45KX2T*_AC%EXP^*NH
M6$][X?TVXEG1XI]*TFT'V_48HI+>ZMVDCOEBU!+,:?=?,7[*3*G[/7PX=V"J
MNFZNS,Q"JJKXCUHEF)P```222``,FNN_;@OKKPUX?T[X3VL:65IX%\+VVN:O
M#&(A->>.?&,=KKVN:A?M"##<&&":PL])C,^II96"2)%J,JW<L:_@?C5B,5Q1
MC^"_`_+<9CLNGXJ2S_&\89CEN)G@\QP'A/P93RF?'4,NQE%K$X/&<39AQ%PE
MP!]=PDJ&.RS`<99CG.68W!YKEF`JGJY<HT(8G,IQC-8%4HX>$X\T)X[$.:PW
M/%^[*-&%*OBN65XSGAX4YQE"<D?@U\?_`-H?4?BC\:/%_C'QSK,NIZ[XBU&>
M[FN'FFFM+.TA;RK.PTKS)[A;71M/M%@M=-TZ%GAL86@M1.^TRO\`*GQ!MM!\
M56\QTZ%9F:%T>:,8.\@*`%5D;=$C2,$5@Y5EC23RW,"_)/QV\;W-C\1O$$43
M7#%9@(HC/,%$:DJI9E<+$"NX+'&DNTH06"LK5WGPB\4SZR4CGD<G[.KEI60!
M5=08H4&WY-V8`(T<I&8U5&=I9,?MF4Y3E>0Y7EV29)EV"RC)\HP6&RW*\KRW
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M74;:YX3ULVT$.L:=?,D4J)%=Q3V>I6UE>V_WO^W'\`_AS=>%_"G[=O[.^BV>
M@_!OX_:AJ=K\0OAWI\,EM;_`W]H:"U@USQQ\/(H((#IMGX:\3-<W'BOP!';2
MQHVB0ZBMKI6E:/!HT=YGZA\*],T*6.6;3E";PL-W!()('D"!RGS1JZD@LNR>
M)!*$EV+)&K-7U'^S3:K\3OA[^U[^QI?B/4--^+_[/_C#XG?"W2I[9IY;'X__
M``9TS_A+O!\OATK<1)HUUKV@V&MV'B&[L+:2_P!6T_3+.TG,FFV\]E-_.'C9
M@*7`&8Y3](;)(PP.8<&SRW*/%"-&$:='BSP>Q^94\/GT<XM%1K8SPYGC9^('
M#68UI1K9=3ROB#(Z6)PF6<69RY^OELWBH5,IJ7G#$<]3!7U=#,(PO2=/72.+
M45A*T%I/GI57&4\/3M_)C\9OC->VNH7.E:=/,SF9R8VD.PPE@CO*P52ZRF(E
M5<&02[BV'0X\(\+_`!-\90:YIXCU:51)<QAP"XW`!P!D2!APS#Y64G/)K?\`
MB?X,U:]\4WMW9VS%Y7;SD?>F,22;&;S%&U]I5"J;E.TD[&&9?8/V?/V<[[QG
M?V\NHV3M*)5?<5,J0_O&2)4V.G,D1:5F^8JVU"H8+7]'GD'[,?LV?$J5_`&F
MW5W=N+ZUEWPR)*TQC:10TD+%('"(H+H\,IDW+E)$*2N:X;]I3]K:[\);([?5
M7252JFX>54$7EQV^/*!B6.&*2%8\^6+='18S(2S[D]B\+?!NU\(>`FM88;D/
M''&K-'"TD1EBMQ_HY.TQFZ,064;<O$(D;:RJP/XF_MI/JB^*!%-;R1VOVR5?
M,#L8P$DN!$C1,I\N1B`S,K'#+M8JTC1*`?8'AK]K>V\3S6]G>W'FW)EC6259
M55UB9F.QI8W7&T,0I\L0L[?=<QO*W6^,[U_$J0W=L`\?DR#S(R]P$`,-QNN)
M``59RS,Q94*H1E6*DM^*G@V_N-/\1:9+!(Z*]RD<RJ3B2,Y)#+D!BI^9`QQN
M`#`J64_LA\)IK?6+*RMW:5#):1!E#+Y@%M%/DJQ#KY8?8B%E4LN0J+M.T`\7
MO_#<T4LGV=D`&6^SR-\R9566-)0763=DA3(4VC:'=CN<1Z?X;N;O896,6X*_
MDJN9=F3N$C.52!BNW;N\P@N%=%<;#Z9XP-EID[2RS1PQAB<%2-HD59"GRH!M
MB)+(B!PL3[BPV2X\.G^)`TQI3YT$D@D8*<;4R"I,`=)0-BE2%$R,9"IW.R#<
M`#TK4].BMM'GMFB:(B)I(O+92@2!!.5ZLQ<S;?-9@2^&*R9)<X7PRTQ4U5FE
M5'*7$(PRJ5D@DE"KO4JV6WQJZ*7*HKOG+G`\:UOXK74T4Y6<(K,0Q?:BH#\@
M1YR0)87R8L.S<,AQ*P#5-\.OB>PO&D9RL7F^6Q._S/W1+HR,0)F;+@JK':5E
MB7?!,JA0#^JO]D/7K.TTBSL(9,B2:VRD>UFDMKN"&UA4>;M/[JZM$:4HYF18
MW615R$F_:;P5,D_AK3G5E+`3^8BN&,3O<S3"-\<JWERQN`P4E'1\;6!/\I/[
M+/[0-HFI:/I/]H(V_P`M)%65U^T1,@>1)E9;B24IO5P$\R8!UC1XQ,\:?T>_
M`SQQ9:K;::Z79GBU*UAMM^=B27,B13PRK%!&T,VYW`B=6'EQWSLQB6*6.J6J
M:[V:\VKZ?--V[NRZ@>Z7=S/'XSTJ!)6$,VES))$<,A#&]F8JK`A&>2TMB[IM
M=Q"B,Q0;3)\3;E8_@I\=+5MH-Q\(/B)(C%PI+6_A#6\QJA&79DF>0X.56%CM
M()*\SKEQYWC338]FW[)<Z1;[MV[S-UQ'=[\;1LQ]J\O;EL[-^X;MJZ?Q9_Y)
M'\7?^R2_$_\`]0/Q!535E!]X+\W^C`_I`_9Q_P"3>O@/_P!D9^%__J$:'7LU
M>,_LX_\`)O7P'_[(S\+_`/U"-#KV:LP"BBB@`HHHH`^`?^"HW_)BGQR_[IG_
M`.KA^'U?>6HLR:??NC,CI9W3(ZDJRLL#E65@0592`00000"#FO@W_@J-_P`F
M*?'+_NF?_JX?A]7V[XINUM-'N"6D3SF2$.F1M7)FEWX(;RW@AE1@H8ON"%2K
M,0`?)GQ2O&@LI9MY,<*NCA`C$Q(D<DL8S@;M^\<L&#?+N4#C\O?'\GFQRR>9
MYJMJ[;'W;PT8CNUCVMD@H(PH3!VA`H7Y0*^_OC%XB-KI=\HEC,A29%61?W,D
M[H=R/AD*2L[/M"^6LFV)07)16_-'QCXFTY83')<00V5K(99;R60*LLT<4O[N
MV&?WJK'YI&Q7>=ES"I1`\P!U_AF.XCTF$3\*\DLENI4JR6[ME=P**3YDGFS(
MV7#12H0^TA5YWQ6LT^JV=M&6<O;1+#$6POG37,T>1N(16D*QJS$C(5=QPHQ\
MDZ]^T-I.FW3:?;3VOV='>1H+A[N;]ZKO")G2V9889BBF*2%E:6(HP\Z2-T-1
MZ+\?--U.X",VEF/>L>Q&N;:25Y%?RTBDN&<%O,"#;'!.QW!&$1D1R[=+J_K^
MNWXV`_2_P1?&SU)R`<;8IW9=I;RXG,4L:HPVDRQW+@,67:5X()#+]!JRNJNC
M!E8!E92&5E89#*1D$$$$$$@@Y%?#?@'QG:ZFEM/!>I>302-Y,G*-=6ZH!)$[
M2J7^T")GW%XEE:W>*Z02_/-7V!X8U&*]L0JW*SE"6A&?F%KM15QD!B(Y-\;*
M<O"=L3A!L6D!JP1Z@M[<&>=);(H6@4)&CJ[R`JAVH'/DHK(69R'#QL,L76/H
M?[,N=N[,6=N=FX[LXSMSMV;L\?>VY_BQS5:T1GN(0JEMLB.V.RJP+,3T``_,
MD`9)`/44`?.OB7PY;6-Y]ONQ+/#;P2M'&3'ATMC)*\<\156:6-I.072&7Y-R
M@&6->$BO$U"_L(K73K2T"7<$S&)8Q,PA9I)<RA(5\H1`N8]A8O&"&8D)7TYX
MFTF'4+1U=5)DRN'8[#,(G6,NNUPT;)OCF4JP*-\J;_G'R]J=L=%U&&:T+B,X
MN(=^_:I#LLEN9`P:5`N`XW!_)E5)"Q.]P#Z*\-V%PUE$C,<2$S_-RL$,F"BK
MAF!\P`S*@V'=*P95*N]=A<Z1/+MEB$I+"-2TJN5<;51&#K&268A>N=[-D$<`
M\WX5NY9+&S9HF'F0K$\:@%HA#(T,;2;6D7*!0)2LACW,S*2`HKMS=SP^7MDN
M&&]$4(694'8NI;:(EQAL@@#`((-`%_2-%,'EDHS2'#A%5C*[KE@SJ`2JH!N6
M-2<9^<@AP_336MQ;A6FC**Q(!RK#(&<$HS`$C)`."0#C.#B70;MY&CRH`N$8
M.H/`>+>0XR"<?*X"Y&-_)8J,]+<@M;SJH)8PR@``DDE&```Y))X`')-`'%NN
M]64,R;AC<A`8>NTD,`2.,XR,Y!!P1E/I99F83DEFS\Z9;!;DLP?YF`).=HW-
MUV@Y&J6(=5VD@J[%NRE2@"GC&6#$CD?<.`><:NDJK71)&2D3LO)X8LB$\'GY
M788.1SG&0"`#+@M)(+52$=HDX,I7"EG9B2.VW?E>,A3M5FW$;KBS6XA9#:*9
M6C*>=YK\-U5PC!@&!"EMK`-\R_*C%:6[NY9Y9`)&\G<51%+*A16)1F0XRQP&
M)89SP,`*HEL;.*Z$FZ8I(H.V-5&<$+MD))^9`Q*LB@$';EUW#(!\S_'[PI;Z
MSX3O$^S>8K`AE5Y8D"SHT#>88CO,4;E)9&BQ)$NSCR$<'^;3]H7P?:Z/K%VC
M0MY<=[#-`^Q;??-#<QRAA&,S+$^VTO1ND=)Y)3(9)49D7^ISXD:=%>>'[^V-
MR-B)+\\:@F6,`%RFXX4@*%W;9$5F!&]<;_P'_:W\(PS7[:B84<2MNEGD9@KR
M3,C-&B!I/+DC%QIZE\1AHXI)(&27SE9]']_Z:??KZ`8G[(7BV*P\8Z?90QB9
M[Q#)!O=U4MY5N#(R+$Q`B$"-Y;2PO,EPN-ACS7](*:C]M^$_B\@8#>`-?E^?
M)DVG0[PQL[9*EG,DI<`M@A1D_>?^6;X!K-IGQ$TSRYOL[J+81O;R-$462[B@
M"(RB,KN!,>U<!E;9R&Q7]*?A+6@_P;\7R,&98/AWXG:XD659GE^Q>'=068?,
M%_>M+$2P,@*R*4=OO&CHOFONU_4#W'_@GS_R81^Q#_V:%^S5_P"J9\%T4?\`
M!/G_`),(_8A_[-"_9J_]4SX+HI`?SY?L1Z;%J7PJ^!FDWC310:GJ%O9SO;21
MI<);:AXTOHFD@D>.:..80S[XF>*54?:7B;#(6_M:^&K[5O%GQ4NKU3/%>^)/
M$T5O-;+\S1VFHW,%G8R+'"K>>L5K`B)P9XC,T<SW`E>.?]CR[ET+X/\`P+UJ
M`VKSV<%MK$*7H*V:RV'B_4S&EV5FB+6K/9JUPPE@(B=U#H5\RO?_`(_^'+JS
M\2?$G3+Q;BU:[U36=:C:Z$<[26VH7DNN0F,QNJ&"1)?)A3=YEJF(+A?M%O-&
M/P+%5/8_2DR"GB9I+,O`+B[^QH3C%-RRCQ$X)?$DJ$VE.3BLYX6^LPBW&*^K
M2FHN4&_5BKY)5<5K#-*'M'Y5,)B/8I]%K3KV[ZVO9V_B4_:9^!.J:?XW\2ZS
M+!)/&UP'\R-9`ZK)&Y,@VC@L52\2"3SC!%<`%&)96\#\):V_A)XXQNB=3`F2
MS;GCC"*CNZ_N7!&X,`T0#HCJ\+H7K]^OVI_ASIMKIU_>S[81!!*[&&*0[[>6
M2184N)!)YCR6<D4HCVR2":,2DGS)LP_AEXFTS18=9B\M\+]J'G1.O"'<5E<.
M9$98UD'EM*Y4L<RJ)9(&FF_?3RCZ[^#_`(R?Q!)+;!P8Q%-)L8DL!'(!O0!8
M@J;F*@O$@9C((TRLLLOZF^'--0V"M*.)%WY5FYDE`97&2-K1P^4I4H8RQ)^;
M!+?F_P#`"V\(6UUIC)=I;J)K:6>0^2LJ+$[8EW"*1E0SQ1QR`K$(8,H\,*Q^
M;7ZCVDD$EO$UNP:+8NTC;GH#EMOREFSN)'#;MZDJP)`/&O'^E1C3-0W(\9:W
MN99FCX0S686[@;YD('GM%E^`98PS+M<M)6'^QMK\7AG]N?\`90U*0P(MW\4M
M,T#,T-Q*C2^++2_\*0C;:E9?/:36(DMYG)MX)O)ENPUI%,I][O\`3K?4(_+G
M121]UF4,0""#W!!`9MK*RNA)*L,L&Z']C+X56DG[:OP>U)+43:/X/NO$_P`1
M]<F"W(AT/2_!GA[5+TZB19(UW(@U:33K>TL[>"19KZYM[9D6QNY[>'\9^D;B
M,!A?H^>.E?-%&670\'_$E8RG)Q7MZ%3@[.:<\-!34HSJXGG^KT:?)-U:M2%.
M,)RFHOT<H4I9MEBA\?\`:&#Y7V:Q%-W=ND=V]+)-W1_.I\8_V=6N?VF?C/X=
ML["!XM#^*WQ&T:!;::6>V0:7XKUK34V2W"I=212B!##->!+MT0R73%RRQ_?G
M[-?[.EAX=M;5C8%;8K+]HF=7!9C'L>.&961HO*)C1Y8V8@CR=ER[W;+SOBK4
M],NOBEXP\8/-<W#>(O$FO>)6N;Z22XOY+C6M:NM1?[9*DMV6N9TN))IW+R*S
MRAF>9ECF?ZU^"?B."ZCETU;D,,F:W4M$`8)L,8XD4EY'^T.9)I0"$1H,2/"R
M[/T[AVEC</P_D=#,I<V8T<GRRECY<LH<V-IX*A#%2Y)3JRC>O&H^652I*.SG
M-IR?%5<75JN'P.I-Q_PN3<>BZ6Z+T.X\0?#NTO=`;2[*"WB*;I(Q%#'\CC+$
MQJP2,^:<^8B)%N\V:*,QBXEE7\>?VJ_V0K_Q(]U/_9\WG2B9O*58G$I$IA+V
MP+Q*P.`FT+N$7V;,=NP3?^[%>-_%R#2I=*)OI`DJAGME#']Y=^3(J(4VN'+K
MY4;QD8^SR2S$+L,\7L&9_(=J?[/&I>%O%*PM;W6+<OY4&)FV72,S,CNR;D=(
MUD"QNSC]T68R@$O]M_`K3+^P,,$D4L<B.FYB#'^[#QM*K$D;288YMT1.70-L
M$B,I;]!?%GPU\':UJ[7#BW%W<;YI`/+DDE:3!(4[UDD53&[[LR!2\BY4J^=W
MPW\)_"VC1QRP1)*SB1G>-2NXLZE61R=\;H(HE*D8#(V5#G<`#\XOBCX)UFZB
MN@GFJKL"DZDL7"J^Y(9"8_E*R^7'P1&&@ADP[NL?YV_$CP'XDL)Y7-U=!5D=
MGAW.%\V(&)%58\!2T9#@+CAFV1RF2%%_I(U_X5Z9<:3(8]+GM4F3=#-+!.L5
MP6C+Q)',$4$N@:6(H)&+K'*@(C(;\N/VB_AAJ=E<2)86/F!BQB\JV(9(I`V8
MUE=V9S$,$!7,)B?<LJHIP`?E58V.I03-;73F221XUCB<R>:)),!07G$916!7
M"L"IR'!0;M_K'AGPGJ?G"6*>17=1E8,["A\P!B"!)(0,.I40NJF39YT9<'U;
M2OA5K<[FYN+`AXT4/(Z*BJF1(T/F-AFV$%C]^'!W.@)3?U\6E#P^LC3I(C*@
M#1*F/ORJK,KNW[Y2ZA4E#!2BG&1M"@%7X27NM:#X_P!&\[49;>**5`=QVN#'
MM\O(*ONVL&0*'<N^%*E_E']=G[&OCF6\T_P]+*S2-;"R4P21[#<21;+R%%E3
MS_+5+5KE5D)4ET9IUFD*-+_)U\.(8=5\?Z0K+%YTER%`9MY3>NV-)20[&)@Q
M#(5V%2WEQJ`H7^K+]D/PK-I6D:3/+#<+\JW2?NY`J".&.P1'+J2T+I]KG@=A
M#+(J[FWQQ%I''=>J_,#]+KVX2Y\:I)&&"KK.GVY#@`[[26VM9",,PVM)"Q0Y
MR4*EE5B5'1_%G_DD?Q=_[)+\3_\`U`_$%<Y8VKS>,_*NT:"0:I=W;(C$@/"9
M[Z'8\L2-)!(R1E9#%&9H'#J(RZE>H^*L+2_"#XRNI4"W^$'Q.F<$D$JW@K6K
M<!<`@MOG0D$J-H8YR`ITJV]Q+I!?=T_(#^CO]G'_`)-Z^`__`&1GX7_^H1H=
M>S5XS^SC_P`F]?`?_LC/PO\`_4(T.O9JR`****`"BBB@#X!_X*C?\F*?'+_N
MF?\`ZN'X?5]<_$&\CAM(XFD<*EO<S31J'V@2[(8)6'"N5(G`QN=%WX4;P'^1
MO^"HW_)BGQR_[IG_`.KA^'U?4?Q+_P!7<?\`8*3_`-*;B@#\K?VB/&`MQ<1B
MY$8@AD>:3R[H3KORYW/$<.T5O%-<(4#D3V\;;GDVJ_X=_'3XN75G;:S=Q3"*
M6*SGD@22=1]F#;ULK"-T7*7$C/''YABCVB<2()+B\\]?US_:;TE=7N-1M_WI
MED@$$*1O&F^1TEN(U+2J5&Z>SA3<S*H1Y,D$JZ?@M\?O"\CZ5XBMA*5VP3:L
M#\DC(!(TTZR9\E3B2"=$6-F(1XGWR,K(SZ>NC]-&OQ^^WD!^#GQZ_;.U7PUX
M]UJ*34U%I#)(IDE3SUA9+B02('N)XW@C5I%*VQWBV#%%<QA">J^`O_!1KP_=
MWEK:WU[+#']IBCD421K;-$TDA*7,,LW[E5\UF9T"&23$[BX``;\F_P!L_26L
M?'5U,TV\R:K=*JAI&!1_.96_>.1$W[H@Q1J5Y&'.T"OC*VNKFSF2XM)Y;:>,
MY26&1HW7D'&Y2"0<#*G*L.""*0'^BO\`LN?M3:9XBLM-DM=1:>"X6"78)EFE
MB>58T62&0_)*S%C$CR;5U*,&VNXHKM5:3]N/A+KXU:YMOL\I:UGMYYU59TD2
M(K&3)$&CR)(IF>*YB)95*B.<1*TQ(_SJO^"9W[4^NQ>+M-\':SJ$RF"XC'G^
M9<MFU;R@/+CBECVM(4=E0EO](B22-"T2%/[O/V5O'AGTC2I7D(-O%%YL?FPR
M@6L\<0'F2RJ'BA:.>T@BD4-&L5E,\/ED-;A[_+\MOZ_RV#]2M.L)FM1Y:C*A
M6<,/+9GD^8KS\I:-2%;<P(4+QR%J:6&6$[949">F>0>`3M895L9&<$X)P<'B
MJN@:ZMQ;1.I5UD`DD7"B0`C:67:Q3>N%29,D+*C(/+!#'H]0A:>*.2([_+R0
MJ@L7639ADVYSC`/3!4DY&,%`><ZY?F.*X92@6UCE9=Y(1YPN%5P2F?WF(D`.
MYBQ"L=X`\TTW0SJS(\BQFWBN$Y*K)+YRC</LZ%6"RJ&4"1MNSS,H)"&2O8[C
MPY]L?:;?Y"=XBFM@\2N`V64RE43@D`'IDJIP0HV-%\*K;>5&L>?+`58HQG:N
MX@DL"1'N+*9)6DD9MS%I(V=B0"OH^BF&V2-"L<:A4WD%B0B;%2//SND>T+N=
MP22[`EMRC4ETN51F)UE/=2/+/4`;<LRGJ2<LN`.,DXKT/3K+[)$=Z()6P!LY
MV1A5Q'T"KM8'(3*G"_,P5<4M9V[K?&W?MDW=-VW*;,]]N=^W/&=^.<T`9]C<
M+8L2L0<>6(U&]E*J"N`"0P((49W*6R`0P^8-H)KJ2#*0JX!P2EP&`/!QD1D9
MP0<>XKC+V^5E>"')R=KR`X4J,9"$'+!CE6)^4KD`,&#"+2_^/A_^N+?^AQT`
M=(L3SR-Y$+E2_"KEQ&')V*SD8``XWN0"`22,&M8:=);132BX4DVTJR)Y6593
M&2RABX(P0"K[0<@$J02IFT<C[/(N1N$Q)&1D`I&`2.H!*L`>A(..AJ_=?\>U
MQ_UPF_\`1;4`><7US+!<Q;&^58MVPYV,6+J2P4J6P`"H)PI&1U.9(M5BPQ=7
MB8*V-IWA@5VE`P"D%P64A@$VYW/SBJNJH1+$_&&C*`=\HQ)SQC&)!CGL<@<9
MQ(XF7SM\C.))&*_.XV1L!A%&[Y"I+`%""1M.00`H!S_Q`UZ"WTFZDD8*%7RT
MC/.5D1U93\ZHMQ+&S&)2RJ66-&+$IYGXY?M,7=D(IEEGB8"&]$D27,4<I#6-
MI;A%9A)L=YT>W0M$_P"_5HPC.I2OUR\;:"+O0;R.-B^!YL2NVS;+$C,KR.H^
M:.,!Y2JA6)1%"R@LC?CM^U9I#6ZO<QP3H\GRRQ,LAPL5Q9W4LRJR%P%GEO?M
M#%_+C\L(JQB-Z:Z^CM^OX78'QI\/;Z2W^(.CF!E2:UFBF1OE=E=(YGADV,"N
MW=(X`=65FC[@,M?T._#>[EG^"_CQ&>0[/`WBQ9"TK-Y[OX4GN6E<'JQ:8`EB
MQ)0.6R<#^>SX9Z&UYX]TV2W>-))IH4)D:0+^\E-N`0%DZ7%VDA8`8C:7Y6*1
MHW]!/PR@1/@YX_F!1GG\">)PVURS(D7A"X5(Y%Z(X+22``9,<L;$D%0IT7J_
MT_X('VM_P3Y_Y,(_8A_[-"_9J_\`5,^"Z*/^"?/_`"81^Q#_`-FA?LU?^J9\
M%T4@/Y[?V:(57]F[X,W`+;Y=`UB%@2-H6#Q-J[H0,9#$W#AB6(("X`();ZJ^
M(-__`,)+X)T+QTUO:RS:)I;^!?%6GPV]O;HUWH]K>:AX>U.545Y[F+Q%H#2V
M=U>W$"6-I?:))I=KO00PI\^_LH6']H_LK_"R!1F9-%U*:WYQ^_C\1:WM7ET3
M]ZC/#ND)1/,\P@E!7N_@3Q1:>'=1N[/7+`:QX.\36PT;QEH;2>4NIZ1*MQ$D
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MBYTRZ=_XB_\`@HW\)XO#OC:-8;4*7U%]TAB6&)IHIV1V^=9%%M)'OD1$;SI(
MI"X$L;HQ_1N#>-^&/$3A[`\6<(9I3S7)<Q56,*BI5L+C,%C<-5EA\QRC-\MQ
M=.CF&39YE&-IU\OSG)<SPV%S3*<QP^(P.887#XJA5I1Y,3AJ^$K3H8B#IU(6
M=KJ491DKPJ4YQ;A4I5(M2IU82E"I!J4).+3.Y_9R^-#7%]9&ZN!''(T1(-S$
MUNI"[4=5D^TR`%,0Y7(&48GEF'[I?!/QC!J6G_V=)=+(JPQ369:0$?99`9%"
MM(YG?R6DV;5BB@BMW@?`R2W\L/PKO+O1+VQB1S%'$T48+2M&4C/.^?9Y89@L
M;,<NBQ$(VW.]:_=[]EGQG+<6NERR3EPK&VE;+2B43J8OLQ$R2SV[23I:_-DX
MW--F.-FW_4&!^H,DBQ(\CG"HI8],G'0#)`W,<!1D9)`[U-XC^*<?[,?[+/QY
M_:.UF**W\3_%S2=9_9@^!MLBL]]=P^(K:UU#XH^-K2^@@N6L8_#^BV]MI6GS
MB/3S)J;S11ZBTLB1UZI\'OA!)\0O#VH?$SQYK$7@GX$^";[3YO''C.]FEM[_
M`%J-;BWDN/!'@>*.WNCK'C?4[5VM+:.-'M]+GN;2YO9#<O866I?C[_P5(_:`
MU;]H3Q;HC^%]+_X0[X5?#O0;?P-\)/`$%R\UMX8\)6*[;:YNF=2]]K>N7"'4
M=?OIS=7UP[6&GW%UJ4&D6<Z_S-XA9G'QDXPP?@MPRI8_A3ASB#)\\\=N(J#<
MLIP&#R'$8/B+)?"6CBXQ=''<4<8YG2R;$\5Y50JR>1^'T,RIYW]3Q/%?#=/&
M^SA(?V?AY9C6]RO6I5*6647_`!)2JJ5&ICW'>-##P=14*C7[S%\CI<T:%9P_
M-_6_VB;B[UL(LYAC+R2>:B$E@998XU1F.POY8$41AB8[9#]^)0J??G[*GQ/@
MO4@N)[A79)C%.SRQF6."\(#3H3<1A0DL22F;<(?*$TJP(-AD_#OQ!;WD-S,(
MPJ2E@/FP<&%?+DC5L&,R!T`ZLFQP=P)!'TG^S7XUUKP_J-NDDP6WCN4)CEF,
M<+%VV*[N6>,Q@H!LCV(6RAXW(?Z9/&/Z9SK-N-,;40Z,%3[JDX+G.U0&VD%M
MIVHQ4EP82XD!Q\)_&+XBB\GFE68!&,D5BHC;>J-Y+3OAB,O<$;D1MBB/8\EI
M&)+AA=@^+++X`BM9'B6"5&_>&65[@V\B/NL$CN-JB,'?MF*B*"%?E19(A./S
MV^*GQ1BU._EA@NHY(TNHD?<9&C;:/*15`DC#H)6^4@;&D5A'##)M68`^I?"V
MC/K]W%>M-<2A)8?*\OS))IY"8'B0AU?<SCRXXE*F7!<(5VE)?MOP-\)DLUMK
MW5FWR1;G@B5BT,;B0%'99(XY7FX9]W[M8FE8(L4]LCM\'?`;QUI]_'91/)OF
M@N;:ZF(DB:9S;R1MY:QLT(5VB0M&B!X3N18Y0B$G]A_`DEG=WNF2,C$-;M);
MIMB(6Y2`RAIU);;M023(R'S!<>1)D#<:`/.M2\&Z7?:;-8F%6$B8.\`ECRWW
M^)00^&CW2DQE5*/&Z1RQ_%WQ.^#%J[R-J$$5U`&_=3%3,(E=941;VW9$"!YI
M7ADEC51*\?SK$\\2-^I?C=H196:,%^T-=,T1*$OY*0L)PLFTA5,CVVY-P+D(
MP5O+)7\^OCOXRTW3C*GFPQ+9Q?:)C)*G%ULF\F)75Y=CA9Y9KB.2'Y-T(5MA
M)8`^`?B3X1T;POH\YBM-/E$2(&2&!0$564\1ELJ8RH$)#HAD22.2-D3!_++X
MF^,(YKBZ@1@+>)F17!1590H5R\@>2,HPB.YBVU1&'"QN@$OMGQ]^->I7.N75
MC:ZC)'!*"OE%B^%VLJ';"/**IDO'+'RF1`-H#L?S]\=Z[*R+-(<QW,K;U9LR
MN%EA;"EV8;OG,A4'<5A1/,"*[,`?8_[,FERZU\5?"CI$QB^V0&10=A&9(F)6
M1@JAHVV.GF`)*H)7?]Q_[4?V>O#Z6OA[P;!]G,^R*PBN0\4C><\#QV]S(\#^
M8JH+6V<W,)8QQQX9U^\]?S!?\$\_A6OB*\TG7)+0S1&2%9I9MZI%",/-L="Q
MBE,66AEV1C)AC&]Y5D']9OPN$.D1>&OMC):K#:^5<,Q'EQ3-92VJJS(6C5%?
MRXS("(54>8S*@9Q=-7;?6,7));MK;\0/>WT>!M;@UD(HDCM)H7P2A,Y,<<$^
MU$'F-]F>Z@E::1P$%L(XP8]RU/B9`#\#/CQ<M&V5^$?Q!@CE.X+AO!^N23Q@
M_<9@4MV;@L@*XVASNZ2JGQ5A6+]G+XRNI8FX^%7Q.F<$@@,OA+6K<!<`$+L@
M0D$L=Q8YP0HEMNUW>RLO1=`/Z#?V<?\`DWKX#_\`9&?A?_ZA&AU[-7C/[./_
M`";U\!_^R,_"_P#]0C0Z]FI`%%%%`!1110!\`_\`!4;_`),4^.7_`'3/_P!7
M#\/J^K?B3;%K42JXW7%H]L%(("F*=&#E@22&-U@@+E0F<MNPORE_P5&_Y,4^
M.7_=,_\`U</P^K[#\>1.;&"8+F...]B=LCAY84:-<9W'<L,IR`0-N&(+*"`?
MCM\?M.2VNKF=SOFFCA?#*N(&CNH(P(S\QWXFF5I`P#(^P*!N+_@/^T2)%L==
M?:PCETN:+>5.QS'-=R.BL1@LA:)F"G<H=,X#C/\`07^T9_Q\2_\`7(?^E]K7
MXC?%KP+/XKT/5K="\<C6E_Y,BPO/'FZ3Y6VH`YFC>.+9$K+YA5H6^2X$\=)-
MQ=DW9J_E\6X'\-O[:&I)=^-;V-T`D&K7'V?`9<0H9B)'PSJT@#F-URJ_O`R`
ME#CXCK]2O^"@?[.^L^"?%&H^)-MR\)O;S*-O9&:)P)1DI&&VP+YEOMC9RFTM
M(?/&?RUJ0/L_]A*XNK;X\>'I+=4,8N;7SG8`E<O(B*`6!(D#R(Q"LP&"K1MA
MJ_T%OV4-8NC9:6AVO'<6EK)B4M(\0:Y>R6-)`R$HEO>,J!@0IBAV!45HW_A4
M_P""=?PQU#5_B#IFO&R,WG7"-;*T:`LL?_'NJRN,*9F)9"K!LR0A#'ND<?W=
M?LC^#+J&UM;AA,6:*U&`(UCF9/(%O)#,[!`A:WLA+`!)*@O"TDD.W"-=?1W_
M`$_&P'ZU_#2]NCI:M-&5BM[A5AE`4F>,*89`,80&..-(0A`DX\UW/FH1]`:?
M>IL$4L@QC,4C,-A3`(3=T``Y0DD$':",(#XEX8L1H^@6Z3%5`B:[EV[G5=T:
MM(ZG+.ZR;&G`VJRB3R_+4KMKH+#Q/:%T@6?S"[E(XYEE0Y7<J".5E**L@53&
MC$D@J@1)6*T@/:HO*WKYWF>7SN\K;OZ'&W=\OWL9SVSCG%='93V)`CM@(W8$
ME&4B1@I)^9R6#D`EE'F,54G``!`\8BU*W<?O-T3#L0S@\G[K(I)P`"=RKR<#
M.":ZG1[]YCN65I-H$L+L,D&.0ALEQO8[RN`X884C@8!`/3ZY+7#.9;@)G<(5
M$/!!V;06V%0&9MQDV$9_>87.!@=+%<QRP?:`P"A"T@&6,95=SJ<`,2O^[EAA
ME!##,&+/448X#%"4W8V2I]X*0?O;&R70,"A/WEW*RJ`>'SG41<L(MVT@B/:`
M8MG)&2X*"3CYBV&SPIV%0=NT%QOB*`/.I#$1A@G4`@Y;(CY",S,H())V@X'9
M3Z"Y9G:V63`)+Q2;0_5B0@9'9LD@Y3>QX&X8JLD<<>?+C1,XSL55SC.,[0,X
MR<9Z9-`&SHY/VB1<G:822,G!(>,`D="0&8`]0"<=3715QL$\EM)YD1`;&T@@
M$,N0Q4YY`)49*D-CHPJ_-K4@!*I%"FW!:1MQ5B2`P8[$'48#(PW=<@XH`PM2
MM/,$L2X:2"1Q&QPN[8Q5ASG:'`SC<!N";FP,UD6ECYV]IO,C53M4`!69@2&^
M\"0$(VGY>6)&0485L_;X;F8XE#RR$DXB9`Q`))P$5`2`23P6.2<L>9J`..\2
M6-L-/>W&?WL;I(VX&4+(R1AAD%4(5Y%5@@!P00V#7Y+?M1Z"98)I+NW=A%.\
M3LID`2"[>X:ZAF52CQ9%S9QM(RH4G94AE)+AOV`UFS%Q`SY/W1&P[*-Q*2#E
M22LA&5R=V1G`#9_-G]JC3DMK+69T+(Q2V\V(_,/.NGM_,97S\JAK+.WYP6E8
MJRHJI36Z\]/OT`_)/P1>6VF>-%B@GD(62>.TGB<,X2&Z6:&Z\V,ID>7:,PD@
M!(D,955#`C]V?A!J<5Y\)?B'()(BESX`\3F$@,C-$GAO4X;1RCG>GGQ1L?G5
M=\JLJA2/+'\UFD:I>#XU:;I@D469TZR8Q!%!,GVF*7S"^-Y;("[2WE;0#Y?F
M`/7]&/P#TTCX+^-KA[B:4'X;:V6W\A7M/#.IJH1B3L29F,K1G<?,$S!R9,QG
M3T?Y_P##`?HQ_P`$^?\`DPC]B'_LT+]FK_U3/@NBC_@GS_R81^Q#_P!FA?LU
M?^J9\%T4@/PJ_8W_`.39_A/_`-@74O\`U(]:KT'7+(V.I7$8"K%*QN(`JJBB
M&9F(145F"+$X>$`[<B,.$5645Y]^QO\`\FS_``G_`.P+J7_J1ZU7NOBBR%SI
MQN%#&:R;S%VJSDPR%4G4A6`55`29Y"K;%A(^56=@`<1!XW\8>%]-N+70S9:S
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MA@,)!X/`8K#86=2A4]"CF5>G2CAZT*&-PT+^SP^,@ZD:5VW)4*L)TL3AXR;;
MG'#UZ49R?-).237\O/B7]B7_`()L^`[Z6]UK_@LEX(T/PY)(&@FB_8L_:1U3
MQ=%:0:A-8WDM_P"#[`W%]ITR6[VMS9PSWZ)J37%T(IH]/LUU*Y^M/V;_`-HK
M_@D]^SXVG6'@/7_CK^WOXV40R#7_`!IX>M_V=/@&;Y(K"XMG?P9=7&N_%'4K
MS2[NWNS?Z/X@N+OPQJ=K=+I\J7<;W&HU^?W[=?[&&NZ-?:YKEK;7*V=Q%=3^
M0+69$"M*95D@@A(>%/WWFR6TC;X2T:2.(Y8IY/R0\"PZQ\/M5A\^Z\F1)@%C
MPZ,KOYC/M1VA08CW^8&\UF4.2R+$$KP)^!V?YJGA>,OI!^.?%N2R<HU\CIYA
MX<^'M'&46N54\7GWA%X;^'W&D93AS1K_`-G\4Y=AZO/)QPM)<JCK_:5*'O8?
M*<LP]16:JN&,Q;B^\:6/QF+PS5]N>A-K^9G]K?B?]ISQO^TAI-M/XSUVRT[0
M].O3>^&O`_A33QHG@#PK:W,<OV6V\.>%+*6:&SMX+*9K5+Z^GNM8N'^T+=:C
M=LDKR_FI^TAX:FDT_5X[#]_]G:5HH8+9UBV7"I=I&FW_`%2JLGDPAHT#E%)$
M(8JGC_[.?QL@UW2M/TJ:\?[?%&3%=VS.)D:4[6!>+$I0"40.QPQ4AL;'V#Z\
MO;&[\4)J4EW";Y/LK2:A+MBA1($@,1)*B*,/Y",%CC'F2JDF$<"2OV'ACA;A
MO@O),#PWPGD>6<.Y#ET)0P6591@Z."P='GFZE:I[*C"*J8C$5I3KXO%5>?$X
MO$U*N)Q-6K7JU*DO/K5ZV(J2K5ZLZU6?Q3J2<I.RLE=[**248JRC%)1222/Y
MV?B%JNJ6.N7,#02^6KOSL95"PY16.4>%@(R`)54$H@)=LDGF=`^+$OAZ^2(S
M^3)')$Q!)"*-PF9FD,<<:D(<1^6RGYY%`\R0[OTK_:!^`$:QW6LZ=:*8"LK.
M0N%C48D?$@4;57`D#J`4(W;1B6$?CQ\4O!FHZ9?/<P?*(9V6:)9`,2!DCBE2
M4,L):-2B*BB-D7+*#EF;WS(^_KC]HO4/^$1:-9G57B-N8A*@,>]RZHA7:TBJ
M"F`JHK19$;%@B/\`#?B'X\:M<WTJ0)-+'#=2`222L@*/(#.4CQD$!=D:G:`1
MO8E<1UY`/%^IC2/[,,TC')3S">/()+"/"D+M4G`C\O&`-TC1Y@-KPCX(U7QE
M<;+,E0UPD;.Z2NTN\DRLCA2K,O3DL2[?,``20#]-?V4OB_K>I^(-'W)<M',P
M:7;,PD9)I4:6W7'F#<[QQ^422[*KIE!S7]*OPGU6>X\-:8S9@DB#16QC\R-X
MS9R,L;$;G*7&P!G=60!XP%`^4#\.OV3O@#=Z'#INJZA9L"JQA8_+D\UV8@01
MJK-,9)FW%%C*L3%*\+C/SG]O?!^E2:+I5M%N5)#;P$B%W8!RKR32K(Q#8GEF
MED5,+L1E7:F3%&`=QXI\10Z=87M]>W>^01XDGGD,I#<1(CEF,DKG`C6%"9M@
M(C&\1JWX]_M7?$LV5I<EIG%Q=+/<2!9R=N0L:0.8#%)(\<8MXC,4D<#?)+"I
MD\R3Z\^-_P`4(=)TV_F\YTMM/-PBQ."D=S<Q$,(=@!9F@\IF.YRES=;0J&*"
M"6OP$_:1^-\.O7-X?/CRC.1&C1!''F;<A"IW.IE8&2)2YW\)*J(I`/!?&EXN
ML:^]^TK.Z22RJ$8B/,WF@[UWNKOME(#$;PJ1L)761R_*3^$IO$SVL<5K+.RS
MH@\N%9&D!<$)C&_@AMC`.@!G5HY`SJ/.=/U^]UK7K53YK#S%,:HCF0%ID,P(
MB+!8S&SJ[2%W=5422MD(/UV_8O\`V>;GXE:M9![5Y4DNHTA5HY!YKEB944C>
MZ(40SSA(VF$:2K$'4H0`?KU_P3/^$TFD_#FPN[NR6/*0%PR%Y\8$AM9U,<B(
M)Y/L["TRD4L37"@>9#&Y_="718;#PAHUV8VBNY+IUD&Q$5HYHY=A7]TDK1%+
M**>W+,5)N;B4`B9=GSG^SW\+)O!7@I+&UTT1BPLDEFD7*(D$43-+*XN'W1R-
M)]H:*%6-PT!:-P[PR1P?7FD?9O%.DV=C<QM!%H\]DLR)-&YO$@LI($!VE)[9
M978LY,1!16CM[AI?,>VV@G%*?2ZYNZCTNM_>;7JK/8#OU5G9416=W8*B*"S,
MS$!550"69B0``"22`!FKOQSA^S?`#XQ6^[?]G^#WQ!AW[=N_RO!6KINVY;;N
MVYV[FQG&3UK=\*6`GNI+R6)7AM5`B+AL"Z9E963CRW:&,,6#$M$TD,BKNVNN
M3\??^2$_&K_LDOQ'_P#4.UFL0/WL_9Q_Y-Z^`_\`V1GX7_\`J$:'7LU>,_LX
M_P#)O7P'_P"R,_"__P!0C0Z]FH`****`"BBB@#X!_P""HW_)BGQR_P"Z9_\`
MJX?A]7W!XEL1?Z+>Q?*'CB>>-V+`(8T;S&`7[[&!ID56^4LPR5(#K\/_`/!4
M;_DQ3XY?]TS_`/5P_#ZOOF>%;B":W<L$GBDA<J0&"RH48J2&`8!B02I`.,@C
MB@#\DOVC]!W:=)-';HZH]RRQIN:<&2(R6S*P)DD\RXB@W1*S,2L*LCJ&6/\`
M-K1/A_!>6UWI]Q:M?7=T;R,2HWDO#9K($AE1OM$EO"[B)+A9&PZFY^Q2[U+Q
MR?M_\7?#0U'3+N%H,O)',CQR&YC99"'WQXCRVY)%:2085DWA=NT"OSUG\'W&
MB7+6T=I!"LMRD+S1($`>>9Q%]H"AI%0&3*%?-MXTE2.WD92BTU)I-)VO:_RO
M;\P/PJ_;+_8/T?XA>"M1:;2Q<F43B)GL&MI8B\:[2J/&PCQ-(\:,)9HV:1(#
MY2SP6;?S>:U_P2UDTS7H_LVFW;P)J2LP%G*80AD6:)$\M9+>5G#@F*V:2)5B
M:",-N$@_T3==^'&FZAX8`:S^TNRM/)#)MD\V%HL*97\U?EF1?WNPQI$EP^8X
MX5NDG^-?$/[.7@R74!,FB6PFCG3[5#<'$LP'D(OGS,LWG0A%=RUN;5S;G]T;
MB0Q,#3T_+]7^`'XM?L1_L$Z?X631RFF2VSVA$DTA0)M69`80KH0)I5M_,Q()
MOLX66202,T<MU9_TL?!/X3VNAZ99JJQF"")V1#(PW-+$26:6+9,PS<&8`_*'
MN'984,SQ6>!\+_AKHEC]GBM;*.WM4!5S#;[3<>2H+S2`@QK$SK'!NS(9YDC%
MV]PT)6;Z^T>UBM;15B18T)(15)X1"5`;/5B_F,S9+.6W.Q8G!_7GTO\`+L!Y
MUXINGM-/6""'<'25Q%&`-ZVB(\=NBB-BN]S'M*`%=@4*P8BO$=/U;6&N56(R
MWH>4R20,JL"KE4;]YMS;1*67:0R6\+$%DV%E;Z6UGPV^H,HC9D$1<PLI0JHE
M9"R21R.KN56,*I61>H9BQR@S;#P6MNP,R+,=[.`WEQ6ZLS"0L\43R-([2;RY
M8M')YA\R,G+T@*?AZ>\ELD6XA58XEVQS>:[ESD9B0.BF2.$[HUF_=+M5(EBW
M))L]0\/SQ1HF]L#;)$21@*[2B0;B<84J1\PR`6&2`&(PTT@K&%$D:%5VK&D9
M$:A1A%!!7:H``XC^4<`$`96""[M)E.%,3/&DC!@48.ZJ#M)5]REOE.T$'/5"
M<@'K<5TL5A+"I_>RRL",'B)D0,V2I4YVE,9##=N&,"JD=U):;G241`@!RVW9
MC/&0X*Y!.%.,C)`/S$'$MM10(B3E]XR#(1N!`Y4MCY]W\/"L20&9LDXHZO?1
MKCYMT46W[A4^9(^/N_.%?8OT9?WO44`=@VH7CJ5,[`''*JB-P<\,BJPZ<X(R
M,@\$BDEL;J%=[Q$J`"60APOR[CN"DL`F"&8C8".&(*D\SINI*AC61DDB#`Q.
MQ#QC:W^KD(.&B)&W.?DY4G9RGH46IVL@7>QB<D*5<$@$@<[U!79DD;G*'`)9
M5%`'#2S7J7.U(=\1VA0JDJP)'S&7`V/U!W?(@Y*L`':\!YD8$T:@L`6C)$BC
MG(!)4!B,`GC`8<$@`GKI=.M)-Q\ORV;'S1$IC&/NIS&,@8/R<Y)^\<UDW.ER
MQ`O"3,F?NA3YJ@DX^4`AP!M!9<$DD^6%!(`,VTM(Y)TCB2*)GR"ZHH(4`NWW
M0">%R%R`6`!(ZCIXK"T@3+HDC*AWR2\J1]YFV,3&@&."!E5&"QRQ.;::;<>9
M#-)MB5)$DVL29"%PX^4#"[C\I#,K+R2O`!?K!D#0C=^Z96(3/_+13\S$8Y^5
MU"DDX^?`7)W`'.ZJ]LJ3HK-Y<C$0`##-A@R@!BQV*0`S,0Q3&0KL%K\\/VG(
MK:YBUJ,YD22T8L'2-E!73;YXY8WRP++,&DB)C'E^7#(K,Y(3[:\1ZA]ECNI9
M9.`TR'.,^3'N!CCW%4#L2D:`D%WDX^<EA^>WQX\1+>0ZG(9$FAF@F1%BV-)$
MKPK86J@CR@\`GNYPT[(S2K$7B9PNUG'XH^J_,#\G?"?PYT_4?C/93-:ASYJR
MLT=N()5TY94F+6LL,3OMM"WE'<WV4+;REU4*8A_15\//!R:?\&/&H10);[P!
MXJ99R@MU>:7PW?B)Y(PTTFU]C.S`%765Y50RR>8_Y%?"'PG<W7Q)L;^VB3]P
MR?O'DD",B"Y%M`APT:S%;B<()S$'Q*QD=8U:/]W+'3/[+^%/C*`!E`\`>(D5
M2@C`6+1+A045>$0@[1'R8RI0L2"%&FM&M5?U_K2Z\F!W7_!/G_DPC]B'_LT+
M]FK_`-4SX+HH_P""?/\`R81^Q#_V:%^S5_ZIGP712`_"K]C?_DV?X3_]@74O
M_4CUJOIAU5U9'571U*NC@,K*P(964@AE8$@@@@@D$8KYG_8W_P"39_A/_P!@
M74O_`%(]:KZ:H`\FUG2FTJZ\H,TD$JF2WE92"5W$-&YVA#+$<;]G!5HY"L?F
M"-<2:&.XAEMYEWQ3Q20RIEEW1RJ4==RE67<K$95@PSD$'!KV34=-MM2@,4Z*
M759/(F(;=!(Z%0XVNA90=K-$S>7(47>"54CR2]M9K:6XM)&:&:,R1&2,#<IP
M0LT0GC96!!66$R1,CJ49D93@GX`?`G[3WP(TKQ7X=NM,=6N([FW>2V+6$$K;
MC)*IA&\$7+6L(\R1(FB<QSR1V\,3W$+1?R8_MM?LD^*_`6KW=UX:T"8P)=I,
MXCCDE:$+.)`X`BYM_-3RXW\K+.BQ3PP3)<)'_;OJ$-I+XKCL-;%QJ-M/:PVD
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M2FM_"UR+,J]NPD$9$@,1VX*EAY@4G>JE@\1D$)>4-&P2*/\`#3XB>-]5UBYO
M_)7Y/.E$DL>`H7A9&\HK&V=VY6PCJR)EV6$.DWVYXW^)<GC#PH+3[1++,X8L
MDCRO(6*QNX50X0#(,*D1_,JRQR;7*[_CG_A$M[7TTX,K/)+,K*S*8U=F(\I8
MR^]]S`!IU"L3&HB!WA@#YZ)+$LQ+,Q)9B2223DDD\DD\DGDFOLC]FM+=)8##
M-YCR3.TL9&UHW5<.H!`+*'<D2`;<,J`EE9F^0M1MVM;ZZMW54:*=P43&U,G<
M$&/E^0$*=N5!!"DK@G[&_9ET"ZENK6X+(FV:5PK;U`,I\H(Y*%O,7>Q=%3"X
M!,F2$8`_H4^`"6*Z5X:\QX#O9VN&.UV68V\@M04E*8F1Q$+=,H&G"M"Q9Q(W
MVWK>OZ7I-E-+=7JPEH@L1C$DC&2=2(?+,2L2V#YV$)<0JTP4H,U^:WPQ\6:=
MHNA6<<]W'`RK;R+(LK+,DJ``F,HIVO`5SG<"93M#HT3@\M\=OVE;3PQ:7$L=
M_'<7,EIY37$N%9=\9,20Q0A1&%.6:*)5,@:>1FC+-,H!G_M0^.]"DL=1LS?0
M0WD\D\\D2W&XPPS7!FDRRJ&<!MUL?D5),DABV8J_"[QQ;Z)J-Y<1FZCB#3/M
M61@[*LDJIDJ),.C%0!(C`P&`2-*"LN=/XN_M`:KXOUR_EM7>0M)(OVAG_=`M
M&\15$4G<8OD4'<RN%P2"*E^`OP;\1_&?5XK:U2>662]+AO+80+`RX::Y8C,D
M*NY?,GFJQ"ES*21&`=M^SO\``&_\9_$#0XK2T>;3Y)@MS=-&XAAA5[>:21I7
MEG1,1\?*/,!8*0`VU_[(OV-_V5-$\`Z9X<-K!#:7%W:13SRSV_[[/E&Y>.12
M@)DCCA$T9@FV23-"ZW$21HTORQ^P_P#L4OX0T?3+V]L);K4$2"=A]G22=&1#
M<(J':KR7`)-RD1WQQ`&[FB`,*2_O#H6EV/@GPU`\]E%'-:0JER;-(WFVSW,:
M)!&SNJK'&&@#P12BW5XW>+S#AY*2\F[Z17=W\^G?Y+2]T%^RTC2M%(T>&"]N
M%UJ*Y6:1BK1QVMI"$:.9H?LXMXL71CB>.(N99PC2#]R%V/#VA1Z:BZ;:S/*;
MN^++)/M4*UPT<,2MY:?=CC2(2.%)=Q)(J(K+"ETPQM-'<%<RQ12PH^6^6.=X
M7E7:#M.YK>$Y*EEV84@,P;T7PUHH@CCU&Y53/*JR6@#-F&&2-U+MM<1LT\<H
M(1E;RE"G<)&9(QR;ZO6U_-K;[E9`=#IUA%IMI':Q'?LRTDI54:65SEW8+^"(
M&+LL2(A=]FX^9_'W_DA/QJ_[)+\1_P#U#M9KUJO)?C[_`,D)^-7_`&27XC_^
MH=K-2!^]G[./_)O7P'_[(S\+_P#U"-#KV:O&?V<?^3>O@/\`]D9^%_\`ZA&A
MU[-0`4444`%%%%`'P#_P5&_Y,4^.7_=,_P#U</P^K[^KX!_X*C?\F*?'+_NF
M?_JX?A]7W]0!XU\2M):1GG95DCO$7:6(54:.*.!XV4.6=0ZVLA8QX(D*!6"2
M$_G/\71-ITEKY*F)VO`?.*1DS+&?M"<.7<!+B(3!64)B0!"Z/(M?JGXNTQ;_
M`$UI3YA:T5SL1`X:*9HEE8C!*-"$6=9.518W+*<AX_A+XL^$/[0WI)"K;I-Y
M=O-0$K(K2!YDC$BQ`*LD<<7+`1R284.6`/%_"GB9[^VL[=H3*<K;,R!Q)#*H
M+R`J[2"2!`Z%"KKY-L/FW.C(NCK/A.TU-G<+``0FR!XO+1&!0.8IH-LD`=45
MG5$8R."';8^%S=#M8]+U."SE@2`Q(T4:>:H6&22+>C;E9EE>56,>&8L\DV\D
MRC!]16330JAK>8L%&X[B<G')R)4!Y[A%![*O0`',Z5I4.E1,D3ERZQJV$6.)
M5BWB-8HESL54?:078?*"NT?+78:%YERFU4D02F)D21"K(TB9<2`!B&C4)YJY
M;9@GODP(VF.X4Q2H&PN78A%//)*REANR`2<J,`_*-S'I])CMH)@@4)PWE'<<
M>8W!#9R69E)52S8&-H!)3:`=9IFE)(IV-''Y:A&D"!I79L$Y7<'",06RS;<@
M*@8*=EZ_TN.*%I%;?&NP/',JMG+@`@A0IPQ3"E.,%MV<+46FW"P7&';;'*I1
MB6(56R"C,,$'!!3)P%#LQ8`'/2RJK12*[;4:-U=L@;5*D,V3D#`).2,#J>*`
M/$]1N5LI658RP,LJJN[:%6-L<L0Q)Y4#@YY)((YX?4?%%L`R^:)V48$-KN\I
MF*[U9Y23&RY"JQ5I6C/W8RP>NU\6Z?+<1RB!<M-!,BJ$(4--'Y9)*[BVUU5Y
M-J,V)=Q'&6\DTCPY=S/*+^.5D47&P1[5E):9UCPD8DS';(0JR-M$S+#+B6.1
MP0#/NOB,^FWJ6YADBB)BD8*LK*%8@,3(9(UD^Z26CM9E4?NRLLB.E=9I'BJ/
MQ&K[&&V(;T`8G=AMDF]?(@,;1[H\"0;F64,@V$D\-XL\%7DD0ELXFGFB!=-T
M92X,6]@+=ER/,#%@T<JH5619`R6\;O(:/@*TO["^\JY_=1S/(4B5T8G%M(9&
M<Q%E*,4@VJSMAX2VQ3AG`/:+>X>V?>G*G`=">'']&'.UL9!SP5+*>[T:[DG4
M!MP1HO,59,EDVLJ`*3_RS(.5XP5VLH7+`\WIAC,!V@"0,1*>-S<DH>I.W:<+
MP!N#X&<D]@D=K8E)`[,9RL:LSH0%;#%^-@\O[I9_FQ\N,`G(!Z!9LKVMN5.0
M(D4\$?,BA&'('1E(ST.,@D8-6:P-,O%CS;RLJH=SQN[$!6XW)D_*JMRPY4!M
MP^9G&-*XOX+9Q&^]WQDK&%)0'&-VYE`+#D`$G')`!4D`NU3U"/S+28`+E%\P
M%NWEG<Q4X)#%`RC&,[L$@$FLU-?MGDV!5926P4FC>0@`D'RQ@9(&6`<A1DY;
M'-R[OK?[-($D21IHV5%4DG#@*2V`=A56W;7VEBI48.<`'S5\5;R2RT6[>,?-
M-<2V^X,R/'YLJ[9(W7E7C=4<<'(!4%20Z_CC\>?B9<65^UI&MR+5IK6.1$V(
M6CD1YHU)::0E(K91.(HS$K:@78G:8IH/U@^/&LPVWA^[MUD(DFE=HY$+*\+R
MB8P.=H\P&200)"P554F1VD7RBM?A5\5;E=<OF:T;]W>^(0MN9C@)]I^UA0YC
M,JA0S!F\LN!N8C<QQ33M=]=+?Y^5K;KN!]__`++6ERZG?6%[):I(EU>*7)4.
M\L,<L212S>2IVVT5U971=)=J(9"`CQS%F_:&YL'A^%_CID#.J?#CQK([%D`\
MH>%=5BWA<@\W-P4V_,P7:<;0SG\YOV0/"-N-#T:YDDS^XMY(T=2S0S72J]TA
M$<D<3Q!T7RMRO\AV-RADF_5#Q#IKP?"3XEWLBF//PZ\86L2#@,1X=OI+F0_)
MM<>:BHLD<A!=;@."P!HDVVV]_/?334#SW_@GS_R81^Q#_P!FA?LU?^J9\%T4
M?\$^?^3"/V(?^S0OV:O_`%3/@NBD!^%7[&__`";/\)_^P+J7_J1ZU7TU7S+^
MQO\`\FS_``G_`.P+J7_J1ZU7TU0`5@ZSH<.JCSE=HKN.(QQ.3F%P&+JDR88A
M06<!X]K+YA9EE"+'6]10!X=J%M>P)>6J`6U^D4T<1E`*Q7!C;R9&^616C#E)
M`P21'CPRB16&?,9]/\4Q6EYI^H2K<Z7*T$UUJ4EQ]K>T@@:*XGFMUEGAO)%C
M6/,ENT+%S$PMD5I3))]7ZEIT&I6SP2A5<J1#/Y:/)`VY&RA89"N45955D,D>
M4W*2&'FNK:!=6"NL\:W5G(KJTJQEX3&S>5Y=RC*5C,BNH*.6B??L224AP+C/
MEZ)ZIZJ[5MK>G3IW`^"/C?\`L[>&?&.A+;:DEMJ1U2SE==BQM"TJ)%DQL\4P
MF5(Y8UM[E@WVF,C[3:S)!##)_.E^V#_P3RU?3)KN\^'VBQ&))#<L;>(11M!(
M9)"[%"'4*(@H>598_P!W$<QS-<VZ?U\?V#HOG>?_`&78[_*\K;]GC\G;OWY^
MSX^S^;GCSO*\[;\GF;/EKS[4O!>G>,(KR631_P"QP-T"6U_91&&\$862VF2(
MA)+%U<+]H"07%OOV/$9YEN=SM&6SY;+5M))MZ+1-M>=K][+4#^`N[_9A^-VG
M:B;*31+AAY>44PR/+))(T>TJTA*%64JJQX+^:)1$S*),^N^'/V7_`!XNF7DN
MIZ-,C+!<2,DD1C&.55BER8V4$)MD^6,X:$QR+YC%O[&O$7[*VF:IJ3WDND:7
MJ#S*',L<>G*L3%FW0*;ZU%P5!!E5=S11^:4BV@%%XC7/V1-.-A>$:+IEK:?9
MF$[1V>G37:*21))#-:/"\0"$980D1!7EDE6/<8XY6]K?>O\`,#_/P^+?A&^\
M,^+-0MY;?8@>0-Y<0C(:)FW2/&OS;3'L8S,J@G*G&T%O8?@]X_TGPU$SS7\2
M@"1GB=XXXW,CL50O,!M<(RO(L>)`NU7VG&W^A+]H_P#X)>:=XGU6]U^SCCB,
M]Q(J11+#YDDBR3#>$$:QK(L4B2E"\<MR8IPMK"-\2_!5I_P2HN+NY,'V:]@\
MQV$#/9WRQD`.P$C3VL:PDA55%\V4L[!`Y;!=`?!7BK]I;4H+FXBT[5I6BRZ(
MB/YJ[3$K1+,,$LDN]C*XC8C&WY!MC/DNJ>(?B/\`%&3R;%HIX9B`K>8YEVE%
MF\K:8N$<R;%C$+[D*1@+MDS^V'A+_@C#;ZU<!;R]9$5D#H9$#84%F9Y+9IH[
M9)5218Q,_F,48IDK&MQ]Z_`W_@D[X9\!36TI2*XN$>(PQ.!.DLBR'R?LDL8(
M\\3X;RI+-D4N(4@F"F2)I-[)OTU`_G8^`W["?Q:\?^,-%_M;P].NE33P2RM-
M%+ME9\S.=SE/-,<<<KLI7&0))@B;1)_5E^RC^PEX*^'^GZ,\&C12WT@@?*V0
M7[3(MOND:0-(B[/.(E$LF%BB!FBBA$*ZA-]Q>!?@+I_PZT.!ET*".WCDMSY[
MV=LLRR6[>7;>?`Z--;B,1K&)G7,KLFV<(UNC?2O@W5A(4TY-(BA5(HXWO["W
M$<>((3]G&H84CS)!'<%9S*`\KB-(!N>06H/E<VKI/5772V_5>F_IH!9\%^"=
M+\&6ZVULZ-=26Y0*IVA8$:%IU120]QBX>,RW4B*S%HB8X9)93-V%D;\P#^T5
MM!<AF!-D\S0.F<HP$Z+)&P!*LA:0$KY@<;_+C&L+1[U-1:!6O8X#;QSL6)CB
M+.Q"(6,:,3)(#*J"4H[Q[_+8J>^T?PS/YUO=Z@D0@"F7[))O:9FY$2SQX5$7
M)$K(SN3M$,T0W2*D-W\]%TM:W16TM^>^X%'0=!;46%S<ADL4;@<JUTRG!1",
M%8E((EE!!)!BB._>\/I*JJ*J(JHB*%1%`5550`JJH`"JH````````Q3J*0!7
MDOQ]_P"2$_&K_LDOQ'_]0[6:]:KR7X^_\D)^-7_9)?B/_P"H=K-`'[V?LX_\
MF]?`?_LC/PO_`/4(T.O9J\9_9Q_Y-Z^`_P#V1GX7_P#J$:'7LU`!1110`444
M4`?`/_!4;_DQ3XY?]TS_`/5P_#ZOOZO@'_@J-_R8I\<O^Z9_^KA^'U??U`#7
M575D=5='4JZ.`RLK`AE92"&5@2"""""01BOG7XBZ&J3W>Z)(U+RRQE$5(_)?
M=+$(P8@25BWQY0&-)K9$#8B!/T97&>,=&^WV;7<?WX(C',`LC,T.\/'(H5L#
M[+(S2N"%#1-(TD@6)58`_+7QS=)I-_+=B)U9(T=!"A1C(;B98':15_=*%6,+
M,W"HJ*FYO*C9WA/Q(^JK%%(7</YJYDW/-%<(BS-&\S,!)"$W,C[6<[XU.P`Q
MQ^S^//!"W,UP?(#F0,GF&.-G&W=Y@D;)66-6>03([")T.5$)\EF^?SH[Z`WD
M)`UK^]:5&621PTB%4,B2.[.K+L0["4DC^5F1"PR`>Q6EF;G+LVR-6"DC!9CP
M2JC/R_*?O$$`D85OFQT5>;6?B6U$:.]Q);383S4$<I1G50691&)E:+>6""0[
ML`[EP<G2M?$\=V51+ORY7Z1311QOG>$50VPQ.[D@JB2,Y!^[D,``>RV,9F2T
MB!"^8D*[B1@`HN3R5!('1<@L<*N6(%=L8@T)A9G*F,Q%B07(*["Q8C!<CDDC
M!/..U>/:5JRGY7+D!!OB&/E;@F2)68C9O+*0&4_,&<9V;O1;35BJ!9P94V#9
M+'AG;TWDL%<%2,."#QEMY8L`#)N;?8TEO.JMCY6&<J00&4@\$9!#*>&4X.%8
M<9@TNW'5I3P1@LO<$`\(#D$Y'.,@9!&0=B_N89)9+D%DC*J6\Q0I4JH3`VL^
M[.T8QABS;0I(!..-4MR0"LH!(!)5<#/<X<G`ZG`)]`3Q0!#-I$3J55R00<K,
MJR*Q&"H.`NT`CD[7[$#(YYF^T)X/FC(0$X&27B8X7@-CS$.-QPZMN(.W"@FN
MYBFBF&Z)U<#KC@CD@;E.&7.#C(&0,C(YJAJK`0QIGYFEW`8/(56#'/3@NO!.
M3GC.#@`\]MIVLYF#*2,F.5`?[K8)&#M+(0<9R""P!&[<.A2YCN-NV82%5PJE
MCN5%.`-C?,J@G@8`Y!'!&:D]@D\WFL[*"H#JHY8@$!@S$A>-H("$$+ZDFM9+
M2X.U%MY%&,*"AC4`#@98*J@`8`R.P'.!0!OV<WG6Z-DEE'EODDG<H`R20,EA
MASUQNP22#6;K$P0(#NQ'&\S@=".0N!D`L`C@9QC=P>3C7L+.=+=0L,CL68R&
M-7D7><<$J"H94V`@<9&1G.XYVK>6(XV=RK*7*C`VE<*9"['`4*`I!R>N-I!+
M(`<?::C(;M2[;%9AY*A58))N7RR6V[FS@@DY4LV2JK]WH-1U]+2U:5@$"P.T
MAPV[<J$NT01BRK&,MO(9N0`A;:K\3+Y?F/Y1)CW'9D$?+G@8))P.@+'<0`6`
M)('D?Q.\3W5I`]F&<P?996NVP&D>."%)6C0,VUPT4JA2Y3$OF.P:0Q31`'R=
M^TW\6MNEZ@A3<[QW<44<8=56S^SR2S,28D%S.ZRPW"I.T$$<K0;5?RYD3\R/
M`#7WB?Q1&7\^[,KRI;@LTD5M/=WT,6VV>9Y([59465(V,BCR%;>2B/CU[XT7
MVL^*==OM.B2)@+MK=I93$D4,5M(T\DC&)4F,MU>JTB!()XXHY'B<QK''(?H[
M]DCX#2WEU%>:A9E;BX#-+-]G)B6*0"=9F\Q69V91);PQY@9UE69K>6&_G2JV
M_P"W=_-MZK]/DV!^I'[+OA:*S\)Z;Y-L\$3,@"2))(\1AC2#B1F,P,,L<KM#
M,X91Y[;A&X4_?OQ"@%M\&_'L(C:(K\-_%K21ON#+-)X;U&68,'^96,SN2IQL
M)*@*`%'G?PC\#0V>GP0)!%#;6IB\Y`KQJL0W8AA02[@UQB16D7RVB`E+MYF(
MG]4^+'_)+?B5_P!B!XR_]1W4JD#P'_@GS_R81^Q#_P!FA?LU?^J9\%T4?\$^
M?^3"/V(?^S0OV:O_`%3/@NB@#\*OV-_^39_A/_V!=2_]2/6J^FJ^9?V-_P#D
MV?X3_P#8%U+_`-2/6J^FJ`"BBB@`IKJKJR.JNCJ5='`965@0RLI!#*P)!!!!
M!((Q3J*`.9O?"NGW)>2W:2SD;D","2W#%RS-Y+8894E%2*6*)`$*I@%6XJ]T
M74;%W62WDEC2/S3<6Z22VX3!+,9`@V;,,'$@0J%W8\MD=O6Z*`/F#4-"UV\O
M1+%XBG@MG:;,<2RVQMHMS/;QQQ6TR1W;`OY<DTSP2[%5B9<"-=VQL[J&U-IJ
M%W%J:>4(0\EH8Y)(R'5UNB]Q<)<[D98\E(V958S&9Y&>O:K_`$+3M0P9(O(D
M\QI&FM1'%+(7Y?S28W67<V&+.I<,"5=0SA\&?P<I,C6U\RC;F*.>$,=P7I)/
M&Z`*SY^9;<E%.-KE<M3DVDM--K))_>E<#P[4_AYX7U2,13V<L<>UTD6*=G\Y
M'4J4E-T+DE`&<!$**?,;>'.W;X)>^`?#=I>7=I]@MI/LMS/;^9]EM4W^1*\>
M_9Y+;=VW=MW-MSC<<9/VY_PB&I?\]['_`+^W'_R-6"_@661WDDT#3Y))&9Y)
M'CTQW=W)9G=F<LS,Q)9B222222:<9*[<US^N_P!^[^\#YVT#X?V=]IWVC3([
M*T^SW;VRVKI+%`$6..X:0/%YH):28!H6M]K_`#NTA)VMU,?@"^$D:/>V<=L$
M0,\:3/(C"($I'`4BC9%FS&C&>,M$!*41CY`]ZA\':@L42HUA`BQHJP!Y%$*A
M0%B"Q6[1*(P`F(V:,8PA*X-:D'@Y08VN;YF&W,L<$(4[BIXCGD=P55\?,UN"
MZ@C:A;*OVDDWRI13OHDM/G97_JX'CN@^')M$FD?^U);JWDB=?LGDM#")G>$_
M:-OVF5#*$B\O=Y88JV-X`VGTG3/#M[>3*;F*6TM58^:\J^7,VW:=D44@#[G#
M`"5D\E<.<NZ>4W<:=HEAII9X4:68MD3W&R2:,;2FV)EC01J0S[BBAGW$.S*$
M5=>H;<G=ZOO9+\@,JPT73].PT$.^89_TB8B2?G>/E;:J1?)(8V\E(]Z`"3>1
MFM6BBD`4444`%>2_'W_DA/QJ_P"R2_$?_P!0[6:]:KR7X^_\D)^-7_9)?B/_
M`.H=K-`'[V?LX_\`)O7P'_[(S\+_`/U"-#KV:O&?V<?^3>O@/_V1GX7_`/J$
M:'7LU`!1110`4444`?`/_!4;_DQ3XY?]TS_]7#\/J^_J^`?^"HW_`"8I\<O^
MZ9_^KA^'U??U`!37575D=5='4JZ.`RLK`AE92"&5@2"""""01BG44`>2^,/"
M,'EB>"(O;$$%I#YAMY6=PL;$('6W975(92TDL<F[=)ND59OC_P"(?A=D698H
ML.C-(@4AOGB+A=Q#1QC*AX3NRJ[GD`\J&/'Z+RQ)-%)#*NZ.6-XI%R5W)(I5
MURI##*DC*D$=00>:^?O'G@M9'EC"R.K*7MI)`")DV*&`V[E,L7$4JA59PJR"
M(++Y4P!^4U[JFH1:C=M'=S*(KF>-$W9A5$=XE'D,#"<(!R4)+?O"3)\U:D/B
MI@$%Q9J3N_>20RE1M+=4A=6)94Q\K3@.P^\@.%]2^(GPMN+>YNM1TQ")2-[V
M?(1RF%"VX._:S1%`H\T1;HU5%(N(W'@UQ:W-JVVX@EA)9U4NA"N4(#>6^-DB
M@D?,C,I!4@D$$@'T%X8\037DEMNF$B20^;;NPS,714)@E>)BIVQK,)MY+F0.
MC2DX4^PZ?JC;"T9W`*5:%R2(G.2",8PI8DY7`D&0=KCY/B&UUF31([NY5!+$
M+>226(@$DP1R/&RG*G<A+?)O59%9E+(Q22/YS^$/[>$FB_![XF_$WXTW-O(O
MA'X@:QX?T*/2(+.QN;O3HO"V@^+!8W,EQ);V`M](M=5NTDU6^=)(M.TY+O4I
M[NZ,MP0#]:[[4)C$\DA)10/W4?RJ22H`.221NP<L7V\E1_#7!:AXMATN3_2I
M@0!ND0+"(X0Y`C$KO)$5+%AY:^87(VE^'3?^;FH_\%3/@+/:Z5!<2:[87VJ6
MM\EW;2W?AV.?1M:M8[JZM=!>-M6A%UJ6IZ?9WMU!);?\>UM!<S2L@L;PVOSM
M9?\`!3+X.^,/$NB^'1:Z]/KNNWOB73[6VCDTZZMK?4/!ESIR>/K::XM+B<))
MX7_MG2OM0F7^T;Z6[2V2W\ZUNA;EOZNOZ_KR8'[?:?XIM+ME"N!+PP12T4RG
M:7"I'(<2.A5B[12LJ`;LXVEN@FU>&8JTD[2%<*`(V4`$C)P$5>.K'[Q"X&XA
M5KX$T'QJ[7:0+OL2SAH8GN&FM;F1AM:*5-D*K)(H58R02Y&U)(YEA#^TZ+XV
MOY[B.V=IA+)M/SR?:8)#%'))(")OWMNC!2`(G=VW`-("BO0!]8:4@/G.4!*E
M`CE<X.'WA6(X."NX`]",\$5W]G80)$CR(DLCH&8MM=`&"MM09:,A>@<9+<D,
M%8*/`-!\3-)"6B\Q?+9$D0NA>,%,_=^831#<X@:18R2C@!0`$[^WURX4;TX2
M158>2\L);/*ECN;(`)P"H(SU'((!ZB`%`50`H```````P``.``.`!P!7EGB*
MW>\\V9/E$I.<_,(SYQE0,PP=K%BF[;A2`<$L%K5&M++"(Y;B0!B&>-Q)(0PX
MP7"L60$!E7=MSABJOTY77_$-E9P2/+=1P0Q([-YI"AW16<%_F!V!`)%0['8!
MB$9E4``\?\4K+I$O]KM++'Y(VN"R9ADC0F.*$.P5EN1O"QD&.21F#,PG"U\T
M>/\`Q+]K,Y!5;F]5H50[?-%J[RO//*@5HP9F>2(*OEA?,/DL[6[N<SXW?&=[
M>TO(["9=ZEXH(S)(/-F+J&52BF0M&S+)<2D1[&$:/)#=/;I8_/7PXUCQ5XXO
MKQ;BR$D$L\KPW7ENK":6:+%N7W,TL<*,[/(T<UP\LD<;2/))"DKMI?\`#]>W
MXZO1:@0>'_A3J7B;X@S7,BQR6TEX;RWA18K@W7F3;U1H'!.R+>BSJZIO=MB%
M8`]Y'^RWP+^&4/AVWM?]`9+B>"%Y0!OWOD`0QI@.^)I)(XI(V:<N[3R'S)6#
M>7_!;X2HOV35Y+=(Y66.6T@C1E6WCEC"EYFRC/>20*4E:1_-1>)#M$LE?H]X
M*\,'2XH+N5$3%NAMP&#22M-$";EFC*J$,<CHD;IN)DDD>..10T@W?\_GU?SM
MZ=K`=?H^FKI5C%:@H7R9)FC#!#(P`PBL>$CC6.)<*@81AS&C,PKE/BQ_R2WX
ME?\`8@>,O_4=U*N_K@/BQ_R2WXE?]B!XR_\`4=U*D!X#_P`$^?\`DPC]B'_L
MT+]FK_U3/@NBC_@GS_R81^Q#_P!FA?LU?^J9\%T4`?$/A;_@D3K7@/0[3PGX
M'_;H_:!T#PEI,VH#0-$D^''[-&KMI&GWNI7>HQ:<-3U/X/3ZC?)9M=M!'<WT
M\UU+&B-/*\A9CT/_``ZX^(G_`$?_`/'[_P`-/^RU_P#.8K]>J*`/R%_X=<?$
M3_H__P"/W_AI_P!EK_YS%.7_`()P>+O!1;Q/KG[:OQU\:Z7I<<KW/AB\^'G[
M-VAVVIFZC>RM_-U31O@[#J5J+.YN8=07[-(OGO:K;2DP32@_KQ7%_$/_`)$W
M7/\`KC;?^EUK7X]](;.<UX=\`?'+B#(LPQ64YWD7@]XF9SDV:X&M/#X[+,UR
MS@O.\;E^88/$4VIT,5@\70HXG#UH-3I5J<)Q:<4ST,IITZV:Y92JPC4I5<PP
M5.I":3C.G/$TXSA)/1QE%M-/1IM'Y9?\,RZ=_P!%7^*O_?'PJ_\`G65\>^'O
MBA^SAXM\=7'P_P#"GQ*_;@\3:I:?%/Q/\%[KQ-X>_8K^.VM?">V^(7@KXA:M
M\*?&6G7'QPTW]C&Y^#$.A^$OB!H.N^'?$_C>3QZO@709M%U:]U7Q)::7IUY?
M0_JW7Y9?\$^OA1X\_LWQ[\4?^&FOC?\`\(/_`,-O?\%-/^,<?[`_9N_X4Q_R
M?Q^U?X>_Y#G_``SY_P`-#?\`(7_XKO\`Y+S_`,C7_H?_`"(__%&U_P`J7!_T
MO?I'X[A#C7B3B?Z2WC-1KY%C.'LMR3#8?Q%SG*J6/QV=97QAC_JTIX?A#C&>
M)QDY\-X>G@Z&*_U?RR4:N+>.S[!OV'/^X8C(,GAB,-1H9-ES56-6=23PE.HX
MQI5,-"^N(PZ44JS<FO:ST7+2E>11\/?%;]EOQ-XZN/`6F_'+]JBVN+;XI^)_
M@C)X\\0_LS_$+PE\"6^+'A+XA:M\(M5\"V_[2/BO]D_1?V?+O7+OXMZ+>?"C
MPQ%:_$V:'QK\3YM)^'O@V?7O%^O:%HVH^I_&73?@[\!_^$<M_'GQA_:-U'7/
M%W]L3>&_!7PJ^#US\>_B3JVE>'/[+3Q-XHM_AA\"OV<_B/\`$-?`_A:\\0>%
M])\5>/)O#$7@SPSKWC+P-X>U[7M/USQQX2T_6?SX?XZ?!+QY^P+^WS^Q+X)^
M,7PL\6?M@_%WXI_\%D/@O\/_`-F+P]\0?"6K?';6_B%\9?VPOVQ])\!:=<?"
M^RU>;Q?H.AW-OXMT7Q?XG\;^(])TCP+\//A@=6^+OQ#\2>%OA;X<\1>,-*^W
MOB[\1?#?[-G[6O[0'Q;^+/Q7^%G[-_A#XV_L>_LT_"KX'_'+X^7=A9?!*3XV
M_!CXE_MM^)O$WA/Q3?7WC;X=:7-KFB:7\>/ACXOTOX9ZI\1OASXM^,7A*/X@
MS?"O5[^W^%OQ6UWX>_K&?>.OTF\KX@Q.74?';Z2U*>#S3C/+LOX4QO'V+J<3
M\<8+AO.N#LJR_B'AFOA.#GB:65X_`<2YQQ)4A@>$^+'/*N"<\AA,56A4Q./R
MCAHY7DM2C&;RS)GS0PTYUXX6*HX:5:G7G.C64L19U(RHTZ*<J]#W\33YHWM&
MI[#\./A9\._BWX,T;X@?#_XX?%77/#&N?VC#;W$VE_#_`$/5=-U70]5OO#WB
M?POXH\,>(?@]I7B?P9XX\&>)]*UCPAX\\!^+]'T/QGX"\9Z'KW@[QCH.A^)]
M#U;2;/Y8^&7QW_9,^+G_``KZ[\(_&O\`;$LO#'Q5_P"$3_X5[\2_B#^R#\9_
MA#\&/%/_``L#[!%\.?L'QO\`BU^QSX)^$"?\+,U#6-`T#X9?:_&UM_PL?Q7X
MG\)^$?!/]O>)_%?AS2-3^F?V&?$_Q)\=^%?C1X_^(*?!#Q)I_C7XWOJ_PR^.
MOP&^#^O?!'PK^T_\-K#X,?!GPS8?&^\\)>+/BQ\9_$^M^9XGT#Q9\+?`GQ+O
M_'%_H/Q6^#'PO^%WQ%^&4NJ?"#Q)\/O$FN_$/[!G[/G[2/QD_8'_`."=>B_%
M7X]_!"Z_9YT?X(?L"?&72_`/P^_9E\>>#OC.O_"B=-^"WQX^#7AR_P#C9XC_
M`&KOB'X'O/L?CCX>>!K+XFZQ;_L^:?\`\)UX4@\6:9X5TOX8:OXAT?Q#X2\/
M`?29\<\!'Q%J\8_2K\:LNH<,<4<$9)E,\'XB<0>VHT.*,FXRS?,\+B<'3\/<
MTQ6;\09'+(,%@)9;G-/PSFL?2S+!9Y3X>Q]2M@LFTEDV62>#6'R/+INO0Q-6
MIS82E9NA4PU.$E)XN$:=*HJLI\]-XU<KA*DZT?>J^BS?'']F'^U?%&DZ3\0O
MV_/&/_"'>./'GPXUS7/AQ^P)^TU\3_!G_"9_##QGKWP[\?:-HWC[X=_L-^)_
M`_B?_A&/''ACQ#X8U'4?#'B'6-*_M71[ZWM[Z?R&:CQ=\<?V8?`_Q)N_A%K_
M`,0OV_&^(=O_`,)O-:>'M`_8$_::\7_\)'I7PXU[0/#'C;Q1X)U;PC^PWKFA
M^/O`_A_7/%GA&QN_'G@G4_$'@R7_`(2_PC<VFO7%GXIT"XU'Y+^!'QD^`'A3
M3?C?H'C?_@M7_P`,D^)[#]M[_@HG_:?[/G_"U?\`@F7X;_X5_P#:OV^/VDKV
MR_XDO[0?[-/Q`^+]E_PE>GW-IXV_XJ[Q=J_VG_A)/M>@?8/#$^BZ99?J;X]_
MY21?LH?]F0_\%!?_`%?'_!,NOJ.)_I!>/?"/%U7(LR\<_I-8G+?['\4<?@\7
M3\4\]R:OC*G`/#>/S_!58U^(_!3*\HQ.'QSP$*.*7#F8<482$,7&M3S>-%8*
MMFN%#*LKKX=5899DRG[3`PE%X*G445BJU.E)6HYC4J)QYVX^VA0D^5ITVW-1
MO>+/A9\._`^O?#+PQXH^.'Q5TO7/C'XXO_AQ\.+'^R_A_>_\)'XSTOX;?$'X
MNWVC?:=.^#UW9Z1Y'P\^%?CSQ#_:.O7&EZ5+_87]DPWTFN:IHVF:CV__``S+
MIW_15_BK_P!\?"K_`.=97G7[5_\`R7C_`()E_P#9[WCW_P!=N_\`!06OSJ\'
M^'_B3XKU7X&ZSJ/[3W[4\%Y^TO\`\%3?^"D?[+?CZ'3OC3KUGI6B_LN?"OQG
M_P`%+O'FA_`_X<:"L+Z'\/?.US]FOP18V/Q^\-Z=:?M>?#KP9J6L_#CX+_M$
M_#'X>:1\._"_@3\_R3Z0GTK<]X:R?B'_`(FO\6LEIU^%\1G>9+&<19SF2J8O
M#8_Q@Q-:G@*>"E1G0P]#AKPIQ6(E#$SQ%2OF5=TZ=6-/$4Z-#KJ95D5*M4H_
MV%@:C5>-*'+1IPM%PRZ*<W*Z;=;'15XI)03;3:;E^K7_``S+IW_15_BK_P!\
M?"K_`.=91_PS+IW_`$5?XJ_]\?"K_P"=97Y$_$3XU:Y;_`'X1>&O''BCXI^)
M$TS]HO\`X*,?"3P7+X@_;*_:+_9(\-^-;#]F7]LOQ_\``/X"_"O4_P!H;]F+
MX<?%O]L;]HC]L+4OA?HFE^&_V?OV=M('BOQ)^UA8:%\?OBC\2(?BG\<OAIX!
MU4_.GQ\_:E^)/B/]B6;XP?&/]J'XW_"/XOZY_P`$0_V=?V@_V7-<^#_BG7OA
MKKWQ=_:O^(_PE_:1\0?M>ZGX8^&'PTT>/PQ\9_[`\,:)^S_K7Q8O;CX?^*;+
M]ASX;>*4_:"^'FM?LO:AJ;_&:S^\R3C+Z<N=5L)&G]*7Q6IX;$<:9CP1'$TL
MZSC,:N,S##\6X_@S#8O)LKRW,\7G&88/!9AEN*SCBUXK+\KKY%PM3JYOD]+B
MS$X;&Y9AN6IA^&::;_L3`MK#0Q-G3IP48.A3Q#C4G.$:<92A.-.ARSG&K7?L
MZCH*2G+^@'_AF73O^BK_`!5_[X^%7_SK*/\`AF73O^BK_%7_`+X^%7_SK*_*
M7XK_`!4^.;?\%%O%W@B+XG^!_`WB?1_VI_V5M!^`OAGQ9^V%^T+X.^)/BW]E
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M0IU**ITJ:Y804L-1FU%=$Y2D_5L_(7_AUQ\1/^C_`/X_?^&G_9:_^<Q6)XF_
MX)+^,O%OAOQ!X4UG]OO]H.71_$VB:KX>U6*#X6?LNV\TFFZU87&FWT<,Z?!C
M?#*]K<RK',GS1N0Z\J*_96BO[`/GSFO!?A73O`O@[PGX(T>6\GTGP=X:T+PK
MI<^HR0S:A-IWA[2[72+&6^FM[>UMY;R2VLXGN9(+6VADG+M%;PH5C7I:**`"
MBBB@`HHHH`\*_:8^!&E?M,_`SX@_`W6O%'B'P58>/=.TZT_X2WPI%HEQXA\/
M7NCZ[I7B32M4TNV\2:7K>@W,]KJFC64CVVJZ5?65S`)8)H")-R_/'_#+/[7/
M_23CX_?^&!_8J_\`H>*^_**`/XO[_P#X*6?M]V5]>67_``UO\2Y?LEW<6OF?
M\*U_9&3S/L\SQ;]G_#+[[-^S=MWMMSC<V,FI_P`/-?V^_P#H[3XE_P#AN/V1
MO_H7:^)]=_Y#FL_]A74?_2N:LJO\4\1]([QNIXBO"'B'G2C"M5A%>RRUVC&;
M45=X%MV22NVV];MW=_\`GHQ7TL?I$T\5B:</%3B",*>(K0A'V.4NT85)1BKO
M+6W9)*[;;ZML^[?^'FO[??\`T=I\2_\`PW'[(W_T+M07'_!2S]O.[B,-S^U=
M\2)HSGY9/AM^R*=I*LN]#_PR[NCD"LP61"KKDE6!YKX9HK'_`(F0\</^CB9U
M_P""<L_^8/+\^[,/^)M/I&?]'5X@_P#!&4?_`#M/I_1?^"CW[4OQ"T.T\2>&
M?VN_$_C+PWJ@N!I^O^'/"O[(6N:'?BRN[C3[L6&J:1^S=<V%P+6^M;NQNA;3
ML(KN"ZMIMLT<R#R_5?\`@I3\1U\(6'C_`%K]M:QB\!>(+]M,TKQM?P?L80>$
M=:U.WEOXWT[3?$LW[/Z:-?WL$VC:I$UG:7LL\3Z5?QF)38W"Q?F1_P`$UO\`
MDRGX+?\`=1O_`%;/CNOS&_9)OM(L?&O[%'_">Z"FOZ5=_`?XQP?`*+QEJUSH
MOPSLOVBH/VAOBCJ$-Q)J=S'J&G:?KM]H]EX=T![[2O#GBWQ%8ZYK/PZOK3PW
M>:E:^'+JQ_H++N+/%_&9OXL8*7BSQ;5H>&?%N.R.C0PF#X?^OYY@<!EWB+CI
MS@\3AJ6&PN+E_J3A9UZK=:CA,%B,QQ?U;%2PM+#5OZBRGC?QWQ^>^-^7S\;^
M.*^'\(..,RX<H8?`X#A=9GQ)EV697XK9C4G3EC,)0PF#QLEX>X2IB*S=>A@<
MNQ6:XY83&SP-#"5_Z:9_V^?B)/X$E^(4W[6\9^&D\3Q2>/1IO['D?@MHIM3/
MAY@/%L?[/J:,A;6F.BJZ:BKKJQ&GHPO<15XEXP^-_ASPUH'B/X<^/?V@K/P[
MH=W9W7C[Q/X8\67'[+VC,NE>)(K/X8R^+-1@U;X*VU[9Z+J4LMAX0MM5=X-+
M.LRVME9RIK,L6[\@?C%\1?!/Q%_X)Y?M82^`_A;\./A5I7@[XT:3X"O+#X4Z
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M@N-8U"ZFTFR@G2R%S)<R_9+?]U:U#XB_L[_"_P`9+!K7Q]\#>!?'GAF6_G>P
MU[Q!^RQH/B/2)?%?AKP=IMX]YIFK?"6WO8#K'A?PIX.$7VRVQ)86=I>VH!O[
MFXN_%_V&_P#F\'_L^C]H'_W4JZOPIJGQ?LOBE^TU%\/_``-\-O$VC-\9O#4E
MS?\`C'XJ^)_`VIPZF?V;_@`LUI!I.B_!KXAVMQ81VJ64T6HR:U:W$UQ<75L^
MEP1VD5W>^!F/B[XJX+BCB;)J'B)Q36PG#F1X+,%]=SWA')ZN,Q6+QN14&WF6
M8</T\!A:-.CG24<,Z-;$5JN&<XUU&LZ5+Y?-O'3QIR_C+B_(,/XJ<9XC`\*<
M.9=FB_M#B3@7(:N/QN/S'AK#R;S;->%J668/#TL/Q#:&$EA\1B:];!^TAB5&
MNZ-#[9\6?MTZS\-M7M-*\=_MA6G@379;2#6++2_&%Y^R-X:U.;3WNKFVMM3@
MT_7/@;9W,UC)>6%Y;Q7:0O;27%G=0*[203(DTW_!3[4M(@TB]N?V\/"6G6^L
M:?)J>A7MUJ?[$ELFKZ7#J.I:%-J.EW<_P)3^T;)-7TC5](FO;62>$:GIFI6$
MDOVNSNHH_P`]?`?PZ^)G@3XF2_#KX=?$#P+I_P#PKS]E']E7P5K&L>-?A=K_
M`(M_X23_`(1G7_VA]#T_4],T_0OBWX%_X1OS?[.OKJ\L[J^\3>;]MM((+NV_
ML^:;4?5_C';^)K7X2^$H/&.KZ%KOB./XZ?LS_P!HZKX:\.ZAX3T2ZW?M1_"M
M[3[%X?U3Q1XTO[#R+!K6VN?/\2ZE]JNX9[V+['#<QV%KA5\:O$##YQD>34_%
M;B;-JF:8W(L/4Q&%Q&"R[$/"Y[A</B*&/66XW@6MA<-3A'&8:HJ']O8[$SA*
M-.I3P]2K6^I<];Z0GBAAL^X;X?I>-G&&=U<YS#AK"U<5@L5E^58IX+B7!87%
M8;,XY3F'AOB,%A*5../PE58;_6;,<74IRA3JT<+5JU_[/_032/\`@H9\==0\
M)2_$'0OVN]3O_`D=CJ6JS^-M*T3]D&[\(+IF@R7D>LZC/XCM/V=Y-%%AHTMA
MJ$>J74EY]FT][.]2[>(V\X3O/^&Y?VP/^CE/B+_X0G[+'_T-5?FY^U#_`,FS
M_M$_]D+^+?\`Z@'B"O*/C;X[^*'AWQ-\=M4\+^.O["\.?!/]F[PG\:;#PM'X
M8\/:C_PE'C%=0^/UP^D:]KFJV=[?V_@77K#X>Z9IWBW2-%CTWQ7<_9])N_!O
MCGP)-;>(%\5>)E/C'XX<04*.(RWQ/S/`+$YGF6%ITLU^IU84J-'%<+8++J+Q
M&`R"I.OB\1C.)L/AZM7ZEAL-:G*O)8>FYQ7SN2>/?TC>*<+A\5E/C'G&6+&9
MQF^"I4<Z^H5J='#X?&\&9=E5"6+RSABK4Q&-Q6/XQPN%K5O[/PF$4:,L3-86
MGS0C^O7_``W+^V!_T<I\1?\`PA/V6/\`Z&JLC4/VQ_VJ-5$BZA^T)X^N1*-K
M[_`?[+0)`)(&Y/V;%9<,2XVD$2?O!B3#5^56K^-_'O@F^^*W@SQ%\1;_`%G4
M+#PG\"?$6B^)=,\#^%DUZW\7?''XD_$'X;R^`_AWH,UQIOAC3K"\U/PAH6D_
M">\^*FJ^,$\&^(_%#:W\7?&?Q`\):7<VD7"^"?B_\0O&MK;>`%\5^+/#][+^
MU!KOP*O/&VJ0_!76/BQI&F>'/V=M3^-NK)J,G@6T\8?`D^++/QQI-WX'NUL/
M"]];Z;X+231]6TC3_B5::AXAL^JCXE_2%Q&%QV.H^*W/@\NIT<5B,2UR1>7U
M<GP&>2S*C3J\.0Q%?#4,#F&%^LT:=&684JTU3>"?M:$JW;0\7OI3XK!YCF.'
M\;/:9?E5'#XS%XMKV</[*KY%EG$4LVH4JW"=/$XC"8;+LVP?UO#T:$\TH5ZD
M:3RYJMAIU_U$U/XS?%[694FU/XM^-+J6,.$=O!W[-R%%=MY1?*_9ZC`C#9*1
M@;(\MY:KN;/1^'_VD_V@/"RJF@_&[QQIZ)&L2(G@C]F2=$10X&U+K]G.=%8^
M9)ND`$CEW+,2S$_CWHWQF^+OC70_A=I.B^(O%GCFZ\7W_P"U=KE_XU_9ZTSX
M%:=J>L:/\'_CUI7P]\$W&@0_'#6M6^'MO\-KWPUXKB:1;:_\3>.;VXL_"%W#
MXIU*U'BW4M:^VOA=X@UOQ9\,_AWXI\2IH4?B/Q+X%\(^(/$$?A>_M-5\,QZW
MK.@:?J.JIX=U2PU77;#4M"6_N9UTB_LM<UFTO-/%O<6VJZC#(EW-P<1^+?T@
MN&,.L1CO%*5=_P!IYCE<L-@ZV`GCZ53+<SS;*)XBO@<3E&%Q>'PF)Q628_ZK
M.O2IU94Z<77HT*E14SS.+/''Z47!V%6*S+QGGB7_`&QFV33P>`Q&6SS*C6RC
M.,[R.IB\3EN+R+!XW"X+&8WA[,_J53$T*5>5*E!XC#X:I4C2/OW3_P!O[]M'
M2MGV#]IOXB6XC*E`/AY^R?(!M+$`K-^S)("GS,"C`HRDHRE>*ZA?^"F?[?**
MJ)^UE\241%"HB_#;]D5555`"JJC]ET!54````````8KX4HKX[_B9#QP_Z.)G
M7_@G+/\`Y@\OS[L^"_XFT^D9_P!'5X@_\$91_P#.T^[?^'FO[??_`$=I\2__
M``W'[(W_`-"[7[*?LD^#?VO?VQ?V:[#XC^*?^"AGQR\+)XUE\:>%]5\/:7\%
MOV-;ZV6PL=2U'P],8=1D_9QLKM'O+-2[%45X)')BDX4C^7ZO[`/^"0G_`"8Y
MX`_[&KXC?^ICJE?TM]%3Q?\`$KCGQ.Q&2\6<6YCG>5QX6S7&QP>*IX*--8JA
MC,JIT:Z=#"T:G/"%:K%>_:TY73N?UW]"GQW\7/$?QBQ7#W&_'&:\19-#@S.\
MQC@,;2R^-&.-PV/R6G0Q"EAL'0JJ=.GB*T(^_P`K522:>EONWX+_``OT;X(?
M!WX3_!;PY?ZGJOA[X0_#3P)\+]!U/6WM)-9U+1O`'A;2O">EW^KR6%K8V+ZG
M>6.DP7%^]G96=HUW)*;>UMX2D2%>ET5_HX?ZQA1110`5Q?Q#_P"1-US_`*XV
MW_I=:UVE<7\0_P#D3=<_ZXVW_I=:U^&?2@_Y1I^D/_V8SQ:_]8'B`]/)?^1S
ME/\`V,\!_P"I5(^2Z***_P"'(_I4***XCXF_$?P9\'/AM\0?B[\1]9_X1SX>
M?"OP/XL^(_CSQ#_9VJZO_87@SP/H-_XG\4:S_9.@V.J:YJG]EZ'I=]??V=HV
MF:CJM[Y'V;3K&[O)8;>3HPF$Q>/Q>&P&`PV(QN.QN(HX3!X/"4:F)Q>+Q>)J
M1HX?#8;#T8SK5\17K3A2HT:4)U*M2<80C*4DFI2C&,I2DHQBG*4I-*,8I7<I
M-V222;;;LEJSMZ*_++Q9^T9^VUX<\5_#+0?%_AGX(?`C_A./M^N>&'^)OPV^
M+7Q!\!_$K7O&GQG^(.E?"?\`90^(/Q^^#_Q$UGX8?L2?&_0OAA!^S[X#\6?%
MOQY#^T3\-OCI^TC\?;_PO^R5X%^+/_"J7\'_`!$[C2O^"CGA3Q!X,?QWX=_9
MI_:GUS0_%_\`PH&[_9F^Q^'?@Q;W/[9^@_M(:KXP_P"$$U_]FW^U?CCIUG+_
M`,(Y\//`^O?'GXP^$?C7>?!?XD_`[X!V[?%'XM>"?"&AVFI_V?\`J&(\%^-X
M8:AC,OIY/GN$JXBGAI8[)\ZP-?*J=3$YK+*<#*EG>(J83),TP^,JPJXF6+R3
M,<TPF5X;!YO'/JV4XOA[B+"93Q1S'#.3C)U*4DG+EJ4Y*HU&FJDKTDI58.*:
M7+5A"4Y2I^R4XU:,JGZ*T5^+_B?_`(+N?L/^`?$GB'PG\2KW7/ASK^@ZYJWP
MX.B^)_B9^R;-XDD^/WAZ_N/#GB7X!>(?!/AO]I?Q!X[^$NN>'?'>D>+?`NK?
M'7X[>%_A5^QI'?\`A*X\8V_[3ES\*/&'PN^(?C[U/1O^"M_[._C#X0V/Q4^&
MWA+QQ\5=0C\<?$?P=XU^''PZ^(W[(^OZK\+=*^$/PNT[XR_$_P"*WC_XO/\`
MM/67[*5M\$/A_P"`?%?PMF\<?%OPU^T3XG\&>"_&?QG^%OPD\6:GHGQ?U[4/
M`>C>IB_HY>-^`P^#QF-\.L\PF!Q]2%/"YAB99?1RZ2EA:V+JUZF85,;'!8?!
MX&E0J4\UQV)KTL%D^+='`9K7P>.Q&'PU7..;Y;.4HQQE*4XJ\H1YG/XE%)14
M>9RFY)TXI.52-Y4U**;7ZFT5^67B?_@IWX4\)Z\F_P"#_P`;_$GV_P""'P?^
M*NK?".'PG\&/AI\2?@)_;_PV^+'QM^.-Q^TCX^^-W[3_`,.?AA\-/^&??AA8
M?`'_`(7YX5\8?\(3_P`*$U[]H+]G7^U?'/Q&_P"&JOAKI/A/N!_P4G^&T?\`
MPAMQ??`C]J?2-(\2>./V6/@YXHUC5_A?H-A_PIC]H7]K;_A1VJ>`_@!\;_#D
MWCL>./AUXX\(^!_VA?AQXY^)7C'4?"L_P,T#[?+\*M&^+WB3]H:ZT'X-:WY=
M7P/\4*?U7DX6Q&(^NX?"XK#1H8O+W6JT<7]2IT:L<+4Q5+%O#U,7CZ&78?&K
M#_4,?CU5H9;BL;[-R>BS+!/F_?I<KE&5XRLG'F;7,HN-U&+FXWYHPLYQC<_1
M6OEG]H3]E;2OVB_[3TGQ#\8OC?X.^'GCCP/>_"WXV_"+P3X@\&2_#;X[?"[4
M_P"VK;5O`_B[3/'W@'QWKGPZ_MK0_%?C+PQK_C_]G'Q#\#?B]XAT'Q':6^N?
M$74;SX>_".^^'FW^RM\7?$GQL^#Z^+?&5CH=IXO\-?%/]H3X)^*[GPQ;7^F^
M&_$?B3]FW]H+XH?L[Z[XY\/:#JNIZ]JGA+0_B%JGPNNO'6D^!]2\4>,[_P`"
MV'B*W\'7GCOQU<:')XOUKZ+KY.-?B/PYXLS'#X;$T\!Q#PWFF891B:M*GA<?
M0HYAE>,J8:K4HQQ="OAJM3!X_"PQN68SV/M\#F&%P6:X"IALPP>$Q-'>U'&4
M(2:<J5:$*D4W*#<)Q4DGRM22E&7+.-[2A*5.:E"4HLHHHKY,W/H#X,_\@_7/
M^ORT_P#1$E>T5XO\&?\`D'ZY_P!?EI_Z(DKVBO\`L:_9J_\`*$'@)_V)>*?_
M`%X'%I_/O&/_`"4N:?\`7RA_ZB8<****_N8^9"BBB@`HHHH`****`"BBB@#_
M`#W-=_Y#FL_]A74?_2N:LJM77?\`D.:S_P!A74?_`$KFK*K_`)Y\7_O>*_["
M*W_IR1_RPX[_`'W&?]A6(_\`3TPHHKYN\0?''Q-<_$%/AW\+/`>A>.[^;[?Y
M/B#Q!X[U#P1X4;_A#)=5L/BWLU6S\!>,YK__`(5IXCU+X2>#;_\`L*QUG^TO
M&/Q+U7P\OV"_^$OQ,30NW*<DS+.ZF(IY=0IU7A,-4Q>)J5\7@\#0HX>C%SJ5
M*F)Q^(PV'CR4XSJRA[7G]C2KUN7V5"M.'H9)P]FW$-7%4LJP]&L\%A*N.Q=3
M$X[`9;AL/A:$7.K5JXO,\5@\+'V=*-2O*#K>T6'H8C$<GL,-7J4^Z\-?`;X&
M^"];LO$O@[X,_"CPGXCTW[3_`&=X@\-?#OPAH6MV'VRTGL+O[%JNEZ/:W]K]
MJL+JZLKGR)X_/M+F>VEW0S2(U^[^#?PAO_".F?#^^^%7PWO?`>B7TFIZ-X)N
M_`WABY\(Z1J4LFHRRZCIGAN;2WT:POI9=7U:62[M+**X>34]1=I"U[<F7A-%
M_:-\&S6?AY?%6G>+/#>LZSXLO?A]<FP\#?$3Q9X&LO'.G?%36?@K-I0^)VB^
M"SX/MK#5/B)H=Q8>&[KQ3=^$]8O='U'P]JVM^'?#<FLQ:?#Z3X=^)7@GQ;JU
MQH?AS6O[5U6R_P"$H_M"UM].U9?[+_X0_P`;:O\`#K6/[7GFL(K;2?/\9>'?
M$FC^'?[2FM?^$Q_X1?Q1J'A#^W-*\-:[?:?[V94N/\)6J8S,WQ7&>"Q+I/,:
MU;-*U&EB,LECJ<71S)3J4)_4W6S)4:U#$3A3C7QDZ,^2M5E/Z7-J/B?@:]7,
M,XEQK&IE^+=%YMB*^<UZ%'%9//,:4'A\W52KAJGU!XC-5AZ^&Q4Z=*&)QTZ%
M14Z]>4Z-I\'/A%8>$=3^']C\*_AO9>`M:OH]3UGP3:>!_#%OX1U;4HI=/FBU
M#4_#<.EIHU_?1S:3I4L=W=64LZ2Z9I\BR![*V,?5_P#"+^&?^$F_X37_`(1W
M0O\`A,O["_X1?_A+?[(T_P#X2;_A&?[0_M;_`(1W^WOL_P#:O]A?VK_Q,_[(
M^U_V?_:'^F?9_M/[RO*/#OQLM/%GQ,N/!'A_3]"O](M?^$HLY[[_`(3C1+7Q
MY'=^"]?U?PEXE\3_`/"K+V&VUMOA1IOCC0M5^&?_``G2:HVMWGQ%M?LUAX$N
MOA_/;?$B8\2_M)?!_P`(>*[WP7XAU_7;#7;#7;;PI)L^'OQ'O]$N?&-_X.@\
M?:7X(TKQ5IWA*[\+:WXZUOPM=V5]X?\`!.C:S?\`BOQ!=W]AHFBZ1?Z[?VFF
MS35R;CG$XRK@7A>(,SS"K@,1G.+P>$J8O-L92P6*E0PN.Q69X?!5,57P<I2P
MN$PV8T\PA1Q%.5'"4<;3@XT(DUL@\2,9CZV6_4N*,WS2MEF*S_'8#`5,;GF/
MHY?C)8;!9CC<WPN7U<;B,!.<\'@<)FU/,X8?%4I8?!8?,*5-PPT#U?0_"_AG
MPO\`VQ_PC7AW0O#O_"1:[J'BCQ!_8>D:?I/]N>)M6\G^U?$6L?8+>W_M/7=3
M^SP?VAJ][Y^H7OD0_:;B7RDVWK32],T^XU2[L-.L+*ZUR_CU36KFTM+>VN-8
MU.'3-.T6+4=4FAC234+^+1M'TG28[N[::X33-+TZP606ME;11>47?Q^^&5EH
M.E^()K[Q8\>L>+)/`UIH%I\,?B?J'CZ'Q=%X<U'QBV@ZI\,[#P=<_$30[\^#
M]+N?%T::UX7T])O"TNG>(HG?1M8TF]O:/P\^/_@GXA2_&"[M+C^R_"?PDUVR
ML[CQUJL6K:7X.U[PS=_#[PUX[;QK8>)]<T;1O#DFA1PZSJ+)=Z7K.MZ?<>%+
M+P_\0H]3'A/QUX6O+WDJ<.<7U*&89CB,GSY4*%.DLPQ>+PF-I1E%YC@\LHT:
ME7$P@\14_M*M@\-##0=6M&LHM4DJ$Y4^*KPIQU5PV:9KBLAXE6&PU*BLTQV.
MP68482A+-<OR>AAZM;%P@\556;8C`82&#@ZU>-=0:HJ.&G.EU?C'X-?"#XAZ
MG!K7Q`^%7PV\<ZS:V$6EVVK>,?`WACQ-J=OID%Q=7<.G07^M:7>W4-A#=7M[
M<Q6D<JV\=Q=W4R1B2XE9]W2_`?@;0_#FG>#]%\&>$]'\):/?VFJ:3X6TOP[H
M^G^'-+U/3]>C\56&HZ=HEI9PZ997]EXGAB\1VEW;6L5Q;:]%'K$,B:@BW`\H
ML_VC?!MSJ?B(2Z=XLM?#VBV'@RWL+V3P-\1/^$RUSQSXFN/'ESJWPYM/A.W@
MN/XB#Q9X5\'^$M%^(VHZ3#H=WK!^'?C'2_'ESI&G>"1:>)-4W=3_`&@?A/H]
MOX4N]0\1W\5KXPL/$VJ:?<Q>$?&EY;Z+IG@C4](T7QUJ/CZ:S\.W$?PNL/`>
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M="U/_A*-"A\+^)?[0TC3[W_A(O#-O_;'D>'==^TV\O\`:VA0?\)%X@\G2+_[
M1I\7]N:QLMU_M.]\_D_!WQ;\!>/=3GTGPQJU_=72V$NKZ;+J'AGQ3X?TSQ7H
M,%Q:VT_B;X?ZUXBT72M&^)'A."34=':?Q7X!O_$GAR&W\0>&+N34UM?$_A^;
M4O-_B3^T]X%^'VB?$V<:5XZU+Q3\.?`OCOQQ'X9O_AE\5_#=IXIM/`=WI6D:
MH_A_Q7J/@"70M6T*#7?$7ANUU7Q9X?EU_1-"T36$\8W\O_"+6EWJ<7%@.'.+
M\3F-/)L!D^??VDZF'<<##"8VA6I2Q=>@L/6K0G"FL+3JUZ&&DL37=*BI4*52
M55*C&4//RSA3CK%YK2X?RS(>)?[6E5PKCEM/`YAAJ]">.Q.&CA<17A4A2C@Z
M-?$X?"2CC,2Z-!3PU&K*M%8>,X>Z:AX7\,ZM_;O]J^'="U/_`(2C0H?"_B7^
MT-(T^]_X2+PS;_VQY'AW7?M-O+_:VA0?\)%X@\G2+_[1I\7]N:QLMU_M.]\_
MS;QM\&]!UOP-<^"?"&C?#;PSIEU?Z%=W_AW7_A7X<\9_#;Q+;^'M'TSP[I.E
M^,?`BS^&I-7L-$T;0_#0\-2:-XD\-:GH=]X,\%1)J-UX8T6[\*ZO1^+WQOT_
MX9?#[PYXQL-*_M?5_'.N^%O#G@;POXE/B;P1=ZYJWB2*35WTV]MW\'>(?%FD
M:[8>$].\0ZS;>$#X+OO&WB+6]'@^'OAOPUJ?Q`U_0?#M^6/QX\*:7\/O!7CC
MXD:AH7A/_A,]=U'PU''H%QXQ\6:)I&MZ9%XJU'5++7=4U'P#X.UWPI_PBFA>
M#O$6H?$BY\>^$/!EI\,[OP_XFTWQE/IG_"/W=V_?EN5\<83"Y?GF783,Y8>>
M;O!9?&,(8RI6S7*J'UA>SR6K[?$5XX&E@9>SQ4\!/"4:N7U:-.LL1@*M.CZ6
M4Y-XC8'!Y7Q'E6!SB6&J9\\ORJ$(0Q];$9UDN&6*7LN'JSQ.*Q,,NHY=+V6,
MGEE3`T*V5UL/2Q"Q.65J6'O:1\#O`TO@*S\"_$3P]X3^*-J/%GBSX@ZE'XN\
M(:/JF@OXY\=>*?%'C+Q'JNA^'-<77H]$L(=9\9^(;/PW:W&H:QK&C^'+F'2;
M_P`1:Y="^U74/9J\H_X7/X)N/AU_PLW26UW5M"GUW_A$=,T[_A'=6\.^)M3\
M;2^//^%6V?@W^P/&MMX7O-#UV]^(S1^$,^+1X=TG3-0E^W:]JNDZ%!=ZM;X3
M?$7XF:5+HVB>+OA_X%T+Q9XJUV[T'P='9?%'7]<\'>)=07X??$+QI:Z3!XCB
M^$EEXCTO7;.;P!,?$L>N>`]-\,Z=X4U:VUOPWXM\9>++:?X>'GQ66\69O/'U
MLPC6]KA<SSJ>+PF8XO"9;5P^:0<,9Q"J&4XROA*E.MA4Z>(SB&#PB6!IQA/&
M1H4J<7'EQN4<;YY/,J^:0Q'M<%G'$$\=@<VQV!RBMA<YIRIX_BE8?),?B<#5
MI8C!ITL5GU/`8&*RZC"G4Q\</1I1</=**Y/P'XQTSXA^!O!GC_18+^UT;QSX
M3\.^,=)MM4BMX-3M],\3:/9ZU80:C#:75[:PW\-K>Q1W<5M>W=O'<+(D-U<1
MA97ZROF,3AZ^#Q&(PF)IRHXG"UJN'Q%&=E.E7H5)4JM.:3:4J=2,HRLVKIZG
MQ^+PN(P.*Q.!QE&>'Q>#Q%;"XJA424Z.(P]25&O1FDVE.G5A*$DFUS1=FPK^
MP#_@D)_R8YX`_P"QJ^(W_J8ZI7\?]?V`?\$A/^3'/`'_`&-7Q&_]3'5*_K7Z
M%/\`R>+%?]D9G?\`ZGY,?W%^SS_Y/WC/^S?\1?\`JSX?/TXHHHK_`%E/]O@H
MHHH`*XOXA_\`(FZY_P!<;;_TNM:[2HY8HIXVBFCCFB<8>.5%DC<`@@,C@JP!
M`."#R`>HKX'Q5X,J^(_A?XD>'E#'T\JK\><`\8<&4<TK8>6*I9;5XHX>S'(Z
M>/JX6%6A/$T\'/'+$3P\*U&5:--TXU:;DIKJP.(6#QN#Q;@ZBPN*P^(<$^5S
M5"M"JX*3347)1LG9VO>SV/ANBOM?^Q])_P"@7IW_`(!6W_QJC^Q])_Z!>G?^
M`5M_\:K_``6_XH=<9?\`20O#'_BO\U_^B?U_IZ?J'_$2\/\`]"FM_P"%</\`
MY0?%%>6?'3X1>&_V@?@E\8O@-XROM<TSPA\;?A9\0OA%XKU+PQ<V%EXDT_PW
M\2?"6K^#==OO#UYJNF:UI=IKEII>M74^DW.I:/JUA!?QV\MYIE_;I):R_I5_
M8^D_]`O3O_`*V_\`C5']CZ3_`-`O3O\`P"MO_C5=F7?L2>/\IS#`YKEWTC>'
M,'F.68S"YA@,71X`S15<+C<'7IXG"XBDWQ,TJE"O3A5@VFN:$;IJZ)GXD86<
M90GE%64)QE"47BX6E&2:DG^XV:;3/R"A_9(^%VO>,_"_Q=^)FE?\)+\7[/\`
MX0/Q+X^D\&^)_B]\//@'\2?B]X"TK0;/0_B_XE_9;7XL^)_A!XG\<>&-0\,>
M$[[X9^,OBKIGQ4^*/PVMOAY\(+;2/B9>:A\'OAWK6@G@;]BK]F7X;Z]X5\3^
M#?AI_9>N>!/'%OX[\!WUQXR^(&M?\('<Z7\-OBK\(O"_@?P-;:]XKU.S\'?!
M#X>_#SXY?%_P]\*OV=O#5OI?P#^$O_"Q?%6K?#/X;>%-<U2;4Z_7W^Q])_Z!
M>G?^`5M_\:H_L?2?^@7IW_@%;?\`QJOI*G['OQNJX3$9?+Z6\H9;BLOCE%?*
MZ'#G$^&RJ63PIUJ%/)HY7A^,*6`IY/0H8G$8?#Y53P\,OP^&K5,/0PU.C.5,
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M3I?U]_L?2?\`H%Z=_P"`5M_\:H_L?2?^@7IW_@%;?_&J(?L?/'&#PLH?2]Q4
M)8'$1Q>"E#)>+XO!XN&6SR:&)PK7&B>'Q$,HJU<JC6H\E19;4G@5)86<J0/Q
M`RU\U\@B^9<LKU<.^:/.JG++_9M5[1*I9Z<Z4OB29^07C']BK]F7Q]KWQC\3
M^+?AI_:VN?'[P/\`%[X<?%N^_P"$R^(%A_PEG@SX\?#;X`?"+XK:-]FTSQ79
MV>@_\)5\//V7/@5X>_M'PS;Z-JNA_P#"#?VMX;OM'USQ-XQU/Q!\Z?&/]@;Q
MU\3OVE-;_:.\*?'K0_@QK^@Z'XSUWX(?\*^^&OQ"FO\`PU^T%XD_9H\8?LRZ
M#\=?CIX4\4_M%Z_^S+^T/KG@GPIX_P!=DTC49/V8OAI\8+[PWX2^#OPGU7XY
M7/PH^'^L>$?'']!']CZ3_P!`O3O_``"MO_C5']CZ3_T"]._\`K;_`.-5ZF1?
MLD_'GAR2>6_2RRRI2APWF/!]+!9QP#C>(\LH<+9Q2P.'S7(,-E7$7$&:9;AL
MKS'"Y=@L%C,)A\)2I8C`X>&!JQEA)3HN*O'F65OCR*:;K0Q#E3Q<:,W7IN4J
M=64Z-&$Y3A*4I1DY-J3YE[UF?GC\./AQX,^$G@S1OA_\/]&_L/PQH?\`:,UO
M;S:CJNN:KJ6JZYJM]XA\3^*/%'B?Q#?:KXG\9^./&?B?5=8\7^//'GB_6-<\
M9^/?&>N:]XQ\8Z]KGB?7-6U:\[>OM?\`L?2?^@7IW_@%;?\`QJC^Q])_Z!>G
M?^`5M_\`&J^#Q?[$7CW'XO$X_'_2.R#&X[&XBMB\9C,7P-G.)Q>+Q>)J2K8C
M$XG$5N*9UL1B*]:=2K6K59SJ5:DI3J2E*39U1\2<+",80R>K&,4HQC'%4XQC
M&*LHQ2H)))))))))61\445]K_P!CZ3_T"]._\`K;_P"-4?V/I/\`T"]._P#`
M*V_^-5S_`/%#KC+_`*2%X8_\5_FO_P!$_K_3T?\`Q$O#_P#0IK?^%</_`)0>
M4?!G_D'ZY_U^6G_HB2O:*@@M;:U5DM;>"V5CN98(8X59L8W,(U4$X`&2"<#%
M3U_M9]&#P9Q?T>_`CP]\',=GV'XGQ?!.`S7"5L]PF`J99A\PEF7$6<9ZITL#
M6Q6,J4(T8YI'#-3Q-1U)475]Q35./YSG68QS;-,7F$:3H1Q,J<E2E-3<.2C3
MI6<U&*=^3F^%6O;6UPHHHK][/+"BBB@`HHHH`****`"BBB@#_/<UW_D.:S_V
M%=1_]*YJRJ_N(N/V%/V.KJXGNI_V;_A,\]S-+<3./"E@@>69VDD8)&J1H&=B
M0B*J+G"JJ@`0_P##!G[&O_1MOPG_`/"6LZ_S-K?07XRJUJM5<;\,I5*DZB3P
M>:MI3DY6O[+6UVO.WGI_D!7_`&;O']:O6K+Q%X/BJM6I447@,Z;BJDW.U_8J
M]KM7LKVZ7T_A]KY1T#]G#7]+\0Z[XAM_B_XZ\'7YUWXD?V!/X+@^&>JVDGAG
MXE?%#Q-\9-5\S2?B;\)_'4WA#77\1^,6\*>(_P#A%M=ET_QUHGPX^'GB37/L
M]_:6'ASPK_H8?\,&?L:_]&V_"?\`\):SH_X8,_8U_P"C;?A/_P"$M9UZN5?0
MR\1,FHXRA@N.^$/8X_V+Q-+%9+B<?1G+#QQ%.E)T<;A*]&?+1QF,HNG4ISHR
MCB)3E3=:GAZM#VLE_9_^*V04,?ALN\2N!/89E]7>+H8WA_%YE0J3PL,52HSE
MA\PP&)P]3EH8['4'2K4JE"<,3*<J3KTL-6P_^>?;?L=?"BW^*'AKXH23Z[J=
MSX/UV#Q+X;\,^(++P+XETO3-;M_#U[I`O4\5^(?!.I_%NX^T>(=3U3XJ7]M=
M_$JXM-3^,^JZK\5=1@NO&6IW^IW'I'P=^'VI^$;?Q?XD\5Z5X3TGQY\0O%FL
M>(?$%AX*NKC5/#&A:8-3U!O#OAOP[JVI>'?#.LW5@8[O4?'/B@WNEV=OJGQ?
M\??%7QG8V&G+XPGM(_[Z/^&#/V-?^C;?A/\`^$M9T?\`#!G[&O\`T;;\)_\`
MPEK.N_,?HC>*V<8*6!S7Q*X?Q]-X3`9?&KB,)FSK0P&7XC$8RGA+PA"G5C7Q
MN(6-Q>(Q%.MC<1B<-AZD\4DJL:OIYM]!CQKS[+Y9=G7B[POF5)X'+,KC6Q."
MSQUZ>697BL5CZ6!O"G3I5H8C,,3',,;BL51KYABL9A,+5GC$E7C6_@)\._L_
M>#O#'C:X\7Z9J.NI8-XZ\4?%.Q\$^3X4MO#.F?%#QKI.KZ%XJ\?_`-IZ=X7L
M?B!K^NZOI'B3Q1IOV7QEXX\2^'M,T_7?[/T70]-L/#G@JV\,>;:+^RLFK^'/
M#T7Q.\>^+-6UG3/%E[\9+#P]X?F\(VW@;X:?'[Q!KVL^-]6\=_#2Z;P!I_C/
M6+#PYXS\5>*YO!N@_%C6O'?AJ71]2AMO%OAC7I+2T^R?Z'__``P9^QK_`-&V
M_"?_`,):SH_X8,_8U_Z-M^$__A+6=:4_HF>+5)SJ1\3.&WB91P,(XVIE>+J8
MRC'`0S"%)T,1/"2J4JU59KF#QF+@UC,;+%8AXK$5?K6)576E]!_QQHRJ58>+
MW"+Q<X9=3CF%3)L=5Q]".60S2G0EAL74P,JM#$5EG69RQ^.IN.89A+&XIXS%
M5OKF,5?_`#[->_9KTGQ!X9U;1+CXG_%>RUWQ+KLGB/Q=X]TS4O!-KXF\4:LN
MG^$M+TK4KO1SX$E^'.A:[X6L_A]\/SX*\7^#/`?A?QMX+U#P?9ZWX7\2Z5KN
MN>,M3\37KK]F'X0:_P"'-?\`"OC_`,-6'Q0T;6/%GQ0\5Z4OCW1O#&H:GX'?
MXOZ]=^)_&>D>`]?TG0-%U_P[83Z_?WNIV&IQZG<>+K&XEM@GB9X])T2/3/\`
M0%_X8,_8U_Z-M^$__A+6='_#!G[&O_1MOPG_`/"6LZS7T2/%R-.A2H^*61X6
M.$Q;QN#E@<%C\!6P6)=*.'C/`XC!X:A7P4:&%3P>%HX6I1HX3`N6!PM.CA*D
MZ+R7T&O'.%'#4:'C-PY@HX'&RS'`3R[+\SRVOEV+=".%A4R[%8#!X;$Y?##8
M*/\`9^"H8.K0P^!RYSR[!4L/@:E3#O\`S^K3]GRQMK'5))OB7\2=0\;:A\28
M_BM:?$Z[3X;)XNT/Q<GPVT[X0--I>DV'PXLOAO-83?#>RN?#$EEK7@'6$":Q
MJ.L1-%XABTG5]+'_`&=M!1_`TFG^.OB3I#>#?%B>.;X6.K>')4\9^+I?%VO>
M-M<U[68M2\*ZA'X4O_&&L^,?'5EXT?X1I\-$\4>$?&VM_#_5DN/`=IX<\-Z#
M_H"_\,&?L:_]&V_"?_PEK.C_`(8,_8U_Z-M^$_\`X2UG4OZ(GBLVK^)7#'+'
ME4*:R>LJ-.E3PM7"8?#4Z"P*HT\%@J.(Q#R_`PIQP>75Z];%X&AA\56JUI1+
MZ"OC7)QOXM\'<L.2,*2R'$1P]*C2P=;`X7!TL/'+50I9?E^'Q.*>5Y=3IQP&
M58G$XC&Y;AL+C<16Q$O\_KX-?LS_``P^!6IZUJ?@;2K""34K"WT73#)X.^&6
MF:GX;\.6]P;@^'K3Q=X5\!^&_'GB>PNF@T@ZC>_$GQ5XYU[4[C0=+U/4-9N=
M9;4]2U+S?P[^Q'\./#<7BJ[M?%_CJZ\9>*?^%:O)\2[O2O@^GQ!TZ[^&'Q!M
MOB?I>JKK>G?"?3[;Q-KOB;QEI^E:I\0O$'Q!T[QEK?CJ71=&D\17]Y<Z9:7$
M7^B;_P`,&?L:_P#1MOPG_P#"6LZ/^&#/V-?^C;?A/_X2UG75'Z*?C)'%9CC?
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M70A9+?\`B/XE?"_3;^_LO#MIX?T&QTS7_$FD^']&T6U;0!X?_P!`7_A@S]C7
M_HVWX3_^$M9T?\,&?L:_]&V_"?\`\):SKR,!]#3Q,RN%"GE_B/P[A%AL3+%T
M9T<OQZK0K2P^(PM_;O#.M*G"CC<;&C0G4E0H2QN,JT:=.KB\1.IX.6?0!\7\
MFIX:GE?BQPI@5A,7+&X>=#+,SC7IXB6%Q6#O]9>$>(G2IX?'YA&AAJE66&P\
M\PQ];#T:5?'8NI5_@FA^#WAFW^$GA7X.PWVNIH7@G0O`&D>&-<^TZ>WB;3-0
M^%T^@:AX%\4><VF-H5[KNAZ[X7T+Q!]GU#0+OPSJ>H6/V36/#NH:%<WFCW'"
MWWP'U#3-6@\?^%?&VNZI\8Y-"NO`&I_$KQN?#,^K7'@/Q;XV^'6H^*)K:PT7
MP5:^%K'7?!'A;P9?3?"30-.\*Z?\.K?QMJVKZ_XU\*^(=1\8^,M:U/\`T$_^
M&#/V-?\`HVWX3_\`A+6='_#!G[&O_1MOPG_\):SKHPOT/O$_"5*U2'B+PQ46
M*QN*QV-IXC+,;7IXZKCXPCF5'%J>&<J^"S*-*DLPP,I+"8R6'PM2O1E5PN&J
M4>O!?0.\9,#5KU*?BMP?56,S#&YEF%'%9/F.(I9C6S.-.&;4,<JF#<L1E^;0
MHT%FF6SG]1Q\L+@JN(H3K8+!U,/_``P>%_#6B>"_#/AWP=X:LO[-\.>$]"TC
MPUX?T[[3=WGV#1-"T^WTO2K+[7?SW5_=?9;"U@@^TWMU<W<_E^;<SS3,\C;M
M?W!?\,&?L:_]&V_"?_PEK.C_`(8,_8U_Z-M^$_\`X2UG7A5OH,\<8BM5Q&(X
M]X=KUZ]2=:O7K8;-ZM:M6JR<ZM6K4G"4ZE2I.4ISG.3E.3<I-N39\U7_`&<'
MB-BJ];%8KQ,X4Q.)Q-6I7Q&(KX3/:U>O7K3=2M6K5:E*52K5JU)3G4J3E*<Y
MMRE)RDV?P^U_8!_P2$_Y,<\`?]C5\1O_`%,=4KZ"_P"&#/V-?^C;?A/_`.$M
M9U]`_#[X<>!/A3X9M?!OPX\*Z-X,\*V5Q>75IH&@VBV.F6UQ?SM=7LT-LAV1
MO=7+O/,5P'E=W(W,Q/[-X"?1DXA\(N.*W%>:<2Y-FV&J9%C\I6%P&'QU*NJN
M,Q&`K1JN6(A&G[."PDXR2?,W*-E:]OZ`^C-]#[BKP+\1J_&N<\7</YYA*O#6
M9Y&L%EF%S&CB56Q^+RS$0KN>*IPI>RIQP-2,DGSMS@TK<UNUHHHK^S#^_P`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
4@`HHHH`****`"BBB@`HHHH`__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>pg5c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg5c.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`P`)R`P$1``(1`0,1`?_$`.0```$#!`,!````````
M```````("0H!!@<+`@,$!0$!```'`0$!``````````````$"!08'"`D#!`H0
M```%`P(#`P4'"P\'!P@+`0$"`P0%``8'$0@A$@DQ$PI!<2(4.5%AL3(5MGB!
MDK(CU19V-W=8&9&AP4(SLW2T-76UQA?8.O#14F(DE!IR4S0E9Y<8\:)C5%4V
M*#CATI/3997%)E8G5T@1``(!`P($`P8$!`0%!`(#```!`A$#!"$%,4$2!E$3
M!V%QD2(R"(&AL13!0C,5\-'A(_%28B0T<H(6":+"4V,7_]H`#`,!``(1`Q$`
M/P".1D;KX=72&R#?41';V,GMF4=>%RL6B)4K>$J#1G,.FS=$G-#G]$B2)0_9
MH"S?^(!ZP/Y\.4?_`+&W/N'0%0\0%U@0_P#^X<H\0$-01MS4-0'_`/!`H"R;
M5ZW?5%LAW./K2W;7Y;SRY78R%P.(UK`IJS#\3"8SE\)HLW>*&$PZB&GFH"]?
M^(!ZP`<`WPY1T#@'VFW.S_\`(Z`H;Q`'6!,`A_XXLI!J&FI4;<`0]\!^0^`T
M!YQZ_?6`#0/_`!T99X_ZMN?<*@*FZ_/6"+\;?-EL.&H:EMP`$..@@(P6@@.@
M]GN4!0.OWU@!'0-]&61'_DVW[@B/'Y"TX`%`4'K]=8`2C_\`'/EK02CPY;<X
MAI_,/EH"=GCG>CNCEO"]W9O#?YHNEUN:8X)NJY6.7U@8C<;>=97HG'M'I2@U
M!F)T6`BB'VK30==*`@G!U^^L$.AC;Y\LFX!J!@MP==`TT$0@@[0H"P;HZT?4
MQO>;A[FO#=3>EQW%;YDQA9N580#F1C!3/WJ9FJOR60I#)J<0U`:`OT.OSU@0
M``_\=&6M```#4MM\``-`#A!:```%`<PZ_75_`!UWT9:U'AH!;>`-!`1$=2PI
M..H`'U:`L>VNMGU1[,E9R;M/>#D>!EKH6*YN608)0";F;<D$3$7D3GAE074*
M8PZ"&FFM`7M^GYZP/Y]&6?K;<^X-`?`<=<_JM/+ACKN>;R<CN+KAF3N-B+C5
M0M\TK'1[XQ3/&35<(8I4VSH2^F42CV4!]_\`3\]8'\^C+/UMN?<&@#]/SU@?
MSZ,L_6VY]P:`/T_/6!_/HRS];;GW!H#)>%^O!U<;CS%BBWI?>_E9Y%3N1[)A
MY-FH%O`D[CY&XXYH\:J\D(0_=.&ZIB&T$!T&@'Y_$U=4??\`[0M\&,<?[<MS
M5]XILF6VZV-<KZV[<^1_4%[@E?6`DY-0SV+=+G7=B4NOI:!IV4!'-_3\]8'\
M^C+/UMN?<&@#]/SU@?SZ,L_6VY]P:`/T_/6!_/HRS];;GW!H`_3\]8'\^C+/
MUMN?<&@#]/SU@/+OFRR;W`TMT..O:`A!EX@%`6!*]:'J73MX,,@S.Z:\Y.^8
MHR8QMV/(ZWUIED*`"")T%S1@$(<@&']J/;0%_CU^NL"/$=]&6=1_U;<^X-`'
MZ?GK`_GT99^MMS[@T!0W7ZZP/*/_`,<^6A[.S[W2B'$.("$&4:`V<?05SIES
M<ETM-L^9,YWU+Y(R;>$3<3FXKOG0:A)RBC>Y))LW]8]30;(B+=ND4@"!0$0+
MK0&O9Z@/6\ZJV+-\F[7'%B[SLH6Y9UD[@<HVS:\$Q"`!C$0,-=4DPBX]L12'
M4,";5DF0@:B(CIKK0"0_T_/6!_/HRS];;GW!H`_3\]8'\^C+/UMN?<&@#]/S
MU@?SZ,L_6VY]P:`/T_/6!_/HRS];;GW!H`_3]=8'\^C+/UMN?<(*`L.\NM-U
M-,BK1;F_=U-Z7@YA%>^B'$\Q@'BS!7G[T#MS_)9.02J<0UUXT!>Z/7SZO;9%
M)NWWR971;H)E201(2VRIHHIARII)E""$"IIE#0`]R@.W]/SU@?SZ,L_6VY]P
M:`/T_/6!_/HRS];;GW!H`_3\]8'\^C+/UMN?<&@)"OAE^JAU`MW_`%*6F)]R
M.YZ_<JXZ4PWD.=5M2X0B?DY68BT6`QKX?48UFL"K05#:>EIQ]Z@')/%K[^=X
M&QYGLI6VJYUN["XY`=YF+>86L$:(7`$$C8AH8'HR#%Z(@P&37$O+R\5-1UH"
M&*'7ZZP(AK_XZ,L_6VY]PJ`K^GYZP/Y]&6?K;<^X-`'Z?GK`_GT99^MMS[@T
M`?I^>L#^?1EGZVW/N#0!^GYZP/Y]&6?K;<^X-`'Z?GK`_GT99^MMS[@T`?I^
M>L#^?1EGZVW/N#0!^GYZP/Y]&6?K;<^X-`'Z?GK`_GT99^MMS[@T`?I^>L#^
M?1EGZVW/N#0#B&7^M#U0X'IL[.<P1.\C)S3(=_YNW&V[=UR(IP!'TU"VD6SB
MVW'OSC$&361B/E!<4M"%_=?>H!N_]/SU@?SZ,L_6VY]P:`/T_/6!_/HRS];;
MGW!H`_3\]8'\^C+/UMN?<&@#]/SU@?SZ,L_6VY]P:`/T_/6!_/HRS];;GW!H
M`_3\]8'\^C+/UMN?<&@#]/SU@?SZ,L_6VY]P:`/T_/6!_/HRS];;GW!H`_3\
M]8'\^C+/UMN?<&@*#U^NL#VAOGRR(AV>C;G;[O&![0H!W[PW_40WB[A.KUB:
MT,N9IFKQ@+VM/*;V[V;Z/ATS3[F/M%X_9K/EV[!%<RR3Q`IP,4Q0[>%`*Y\4
MKU,=^&S_`*B-GXTVV[F,A8FL)YMZLJXU[7MARP1C59]_/70W?RBA'+!R<7;A
M!FD43`8`T+II0$;']/!U=/SY<Q_[]$?<B@#]/!U=/SY<Q_[]$?<B@#]/!U=/
MSY<Q_P"_1'W(H`_3P=73\^7,?^_1'W(H`_3P=73\^7,?^_1'W(H`_3P=73\^
M7,?^_1'W(H#L+UY.KF4N@[X,NGXB/,=W$";CY-?DD.`:4!R_3R]7/\][+?\`
MO43]RJ`J'7FZN6H?_&]EOM`/^E1`]H@'_LJ@'(?TOG4__/.RC_\`*/\`?G^Y
MP7_O/_[9_D__`*1[W90$:G+?XU<D?AW=_P#3[Z@,?4!R+RZ^EKIH/9[ODJ#K
MRXDLNJGR<0*`"/D`-?=\E'HB-Q]$5_S'8)4^.FN@:Z#KQ$?)P\E>BM2GK!QI
M[R9QGY,&E_N-Z^[EH=>G^7^;W:EDDG2+JB6:E&5*41P$`'37R=E0(BO<4;NI
MO$]KIVF3$>#KZC`A%X14]_V(SN*062=R*DIZ\+Y4Y%4GC<RHH@<H@()Z![]`
M61FG<&MF5FQ9'Q5B7'24;*.I%N;&UI)VVL9-TV3;C&.E"+JB[9)<HG(4W$AC
MF'7C0">3#S`8W`-=1T#@`:ZCI]2@-DQB?_!S7M]&Z\OG^E0&MG#L#S!\%`5H
M`H`H`H`H"H`(\`[?\N(^\'E]Z@%9XJVER^5[7MVZ&>6L,V:6XIAW$(1%^WNU
M@)5IZIS:R3U`4E?5XQ80`"*FTU,.E`>G)6S.^\7V=*WG,Y&P=-M(E$SE:+M+
M)T+<4VY;`^&/!9C',A[UR!U@U``T'DXCV4`D,P"!A`0Y=!$``>WT1$HZ\>`\
MQ1H#,&WG\?V$/RMX[^=D30$E_P`7][1##_T6\<?9+T!$_H`H`H`H`H`H"]5\
M;Y":().75AWD@W68MY--=2V9A-%2.=F$K5^DH9J!5&;DP?:U/B'\@T!;[^$E
MX@S<)>)E(KU@ASI%D6+A@=<B?:9#UHB8*::\=.R@/DF^*?S!]D6@-PCX:;V,
M^T'^8;H^=DM0&K>ZHOM'=[_TG<Q_/23H!"%`%`%```8>``%"9K7I7U'I!JL*
M0+BDH".H@8X%U+PX#H/DT&IDDY0MU77-.GX>P^A864K,LF4)>1'BSH$-`$=/
M+I\-0^7IC1_,TZ_$^-3C*5(\*%"AJ8H".@"8H"(]@`(@`B/F"H$POF$P%LQF
M4RI/]X2UI.S6:REDUI+'4K+1RMUJ'Y7]NJFCSIKLTT0`1(L('*(!Q'B%`80S
MKC#"N/$H8<2Y\8YK5>/I1I,%8VC,6R2'09$:&9OP&3,;UQO(J+J%)RCP[L1'
MMH!.E`2F?"">UL9?D&RC^\1M`.T>.%_DOI\?PW/7\7QM0&O]#L#S!\%`5H`H
M`H`H`H"H<1T_S?LZ!0"P<)8CVMWO$6^MEO<9(8GEI,EQIRZ?WFO)]I!NF:R)
M;=$_J6JCMK)H&,=02B42"&FM`?$W)8;P9B1U#L\-[CHG<(=VH]+..86SYFUV
MD$FGW2D:JFM*JJ!)^O)'$#@0`%(Q!UH!+%`.K9W]D;L)^D5NO_J'0#5-`%`%
M`%`%`%`%`*FP)A?#>3FS,<E[@8##CI_/O(M/Y6B7DH@QCF<4H]^6I/U0.\1:
MN'@$;I@743',/N4!];<EMKQW@J-MY]9>YW%6?',ZZ$CB-QXE+(N8:.48(O&<
MJ^/))E2!%RJH*(I_NA#E'6@$A_Y<*`D7>%5]M!M__`G+_P`QI*@%3^,H]J38
MGT8K`^<5X4!$JH`H`H`H"I=!,4HZ`4Q@`3\1Y0$=!'0!#@4./U*`7O`[6-NE
MSN'3!AO1QW"NDRPYF3FYK<G&<?(*2%OMI%ZQ(HD4QT7<7,+'9'$VB9S$Y@'0
M:`2EEVQ[=QU?4I:EJY$M_*<*P29G0O*V&[UK#OEG#<JCIL@E($3<">/<"9(Y
MM.4PEU#A0&-*`J':'G#X:`=ZYQ][_P"1_P!__/0#8N6_QJY(_#N[_P"GWU`8
M^H"H!KP]X:@W0@W)44?J;I\2X[8@5[EGX>":%.=S,23*-;)I)&54,L\6(@0>
M0`T,!3J!VB`!K7A>O*S;<Y5HM715^'"I4]BQ;>?N-G`NND[UQ0BW]*;TJ_83
M8\'^$%3REB'%F1IK/]_P<U>UOMIZX;=0M*W!:0B+E--<B;)ZNZ,H[.N@J'=Z
M@(@-:^7/5GU,S(SO[5VK<EBQG)*4[C@Z)T3Z%;DG6E>)D[>.R^RMAWK(VS/W
M/J\OI75;2E'JDD^/4M%7730C==6C8(UZ=6ZR:P##DR`^M9C`QLK;UV9$CV<?
M(761R4`>/6"46F$<#5!T4R8%*(F*(>EY*R]V3O\`O'<NSO.WK!>!G0N.+MOP
M25)\%QJ^7(L_O#8-M[>R;%O;LFWEXU^RIJ4'7I=752\-*>/,:]J[2SPH`H"@
M]@^8?@H#9,8G_P`'->WT;KR^?Z5`:V<.P/,'P4!6@"@X:E=*5).M"RMJ.P?<
MCO0=W`G@NU(Z8:6FT3?W-,3<VU@8>%:+'[E!9T[=`//WZWH$*F!C"<0`0"L>
M=[^J?9?I[Y<>Z,I6;M[Z(I)RE3BTFUHO>9-[2])^\^]L*.?L-B$\>=WHCU2<
M6W1O2D7I1/X,]FZW8#N#V<M+8?9FBK>9M[Q5=I0*D!/)S1E18I@JN+I%-%,[
M4ABCJ0P\#5Y>GOJMV=ZG2OKM2].XL=5FYQ4?A24J_D>G?WI'WAZ;8EG-[GC8
MA8ORI'HFY.OMK"/\1$W,!>`]I>'ZG#A62#&)QYBCVA^L%`5`2B/`-!\P>Y0'
M.@,P[>?Q_80_*WCOYV1-`27_`!?WM$,/_1;QQ]DO0$3^@"@``UJ#=%4<F_!'
M,$S".GH@/OB`?Y#QKTC;N3CU039%+J<:?S?XU.!@$NO,`AIV^][G$.'&H=%;
M?F)IQJ2J2E].H::#S:@(\OHZ<0U'74#?4&I3TG#H=*IZ<A9#'J![Q(X[0S?.
M5S'!C9\+835)TUA7:"5IVZ)?D:&!%S&*I"@P*70AA#GT[1&A(8;RUG_+F=%H
MY;*UY.[N4AUWZ\69VSCFOJ2DH+<SWN@8,V@F34]5(`$,(@&G#3C0&&C?%-Y@
M^R+0&X1\--[&?:#_`##='SLEJ`U;W5%]H[O?^D[F/YZ2=`(0H`H"G,`"`#]7
MWO/1\"*XGJ13YU"%#345"@0=0U$PFX``:ZZB`\*3BX6_,?TTJ>]J$YYL'"+E
M&4TDDM6VZ(?)Q?M6BY?IW3JTOBV%87]>=YIR4!EV>N(Z#PR39`YF5LV]$IIG
M3[MR0-5C'XF$?)I6H'<GJU'%]:K.%@YCGM>)9A"]9CQZI*KJJT>KK6JHCHOV
MSZ"RW#T6NK*LPAW!>LW+D92T@DWU0^:C::CHUT\>8R'*Q:\7)R$0X)R/HU\Y
M8N42:J"5=JJHBJ4!(!N8"G((:]E;@VLJ.9@V<F/E]%R*DJ?51ZZZ4_-G._=,
M&6VY]W`FJ7;$W"7A5/6CYK3G3W'RA`2CH8IBB':!@$HAYP$`$*E/@*4`4`4!
M*9\()[6QE^0;*/[Q&T`[1XX7^2^GQ_#<]?Q?&U`:_P!#L#S!\%`5H`H"NG`1
MU`-/=[1]X/?J,4Y245Q9%*L7*JT^/X%[P^.+SG2MU8R$=+MG1=47@E$C,P_\
MWZR(=T"W^IKS53[VZ8%BZ[%R['SERKJWX(O#:^P^Z-XBKN!C2EC]/5UZ]"2U
MU='^A:C^/=1CIPR>IBBY:JF072'7F35(.ABCJ`>6OLMS5R'F1^DMK-P<G;\R
M6%DJE^+HZ</C_H>*IUJ?(U1T"A`*`*`=6SO[(W83](K=?_4.@&J:`*`H!@$-
M0U[0#301'CY>&O`*`Y``B.GE_4^&HQ3D^E<2#=%5GK08.'/+W0$'FU^,<"Z"
M'[4VOQ3#Y->VO*]=A8=)GW8F!D9DI1M)+I56WHJ?F>91,R9A(;3F`=!`!UTT
M[>/9PJ:,U-57`^>[9E9594H_`X5,>;BTD_$IH'N4(!H`=@!0%:`D7>%5]M!M
M_P#P)R_\QI*@%3^,H]J38GT8K`^<5X4!$JH`H`H`H`H"F@>X'ZE`5H`H"H=H
M></AH!W?^X_0#9&6_P`:N2/P[N_^GWU`8^H#W1T?(2KUO&Q3!W)R+Q0$&D>P
M;K.WCI8_8BW;-R*++*F\A2E$:EDJJA%6W<=(\5K\!]'P^FV:S<V]2['D%F&R
MU[B@,:MY"[7EG2S9PU1>7.P,DC`-)EHL5)<$6[]0%#)"'I<G'A7EF9V/CV5Y
MT4_S+A[>VN[N6YR6/+IN6+;NUX4H;=-N^B(]K!PC1-BW(!`B46$81,C*/,T;
MDU9((D`I446Z:?*4``.6HW&K;_;VI3BY+3Q\2DRP+F;:NW=PA*2DG.3?.CXU
M(8GBK-MU\Y8VWSV1+KA(28F,)7@SNW%MX,D6Z4R&-9U(&-TVT]73(FJX;,Y#
MD4(0XF$IBZAVU2<"[N&-DW,:ZY3M2:^9\:.NGX%];_M/;V?VEM>^]I5\V,+E
MO,@WJI6XQ:DER4NIT\=37(HM'#A)PJ@@X6(U2!9=5%(QTD$?1YE5S::)E`QP
M+Q'MJN&.:,\X]O#@'DH"E`4'L'S#\%`;)C$_^#FO;Z-UY?/]*@-;.'8'F#X*
M`K0!0BEU/I\3L*0X\0*)]!*7E#F$1,<0`H!H&HB(]@>6AZ.PEX5)]G2EP/>>
MT38U9MKW])6<%PY:(RR^ZCHY!`9RW8";53?04/<<@9('2BZB8$6[@1$A#</*
M-<[?NLEL.?WIC_WJ,,C$LXRBH1HY*3=./+ZO@=1?M1[&E<[#L;IEQROFNR<8
MJL4_,BX_*G3@N?*KH8?ZQ&VJ_=X6VB1R!CR1)<-SX8<.;V>V\V1137E;5:-N
M27(R(FF0S@\>D3O.[[`*&M7)]JEWMCM3=LO:\.WT3R8556N+Y'M]WWI]?AV#
MCV,#'N=>%-W6YOJJJU?XO4@\]XFF*H*-N][PYA,<2\HD-SB(EY0#0@@/`0K>
MU<#E?5O5Z2YG#OFW_J@_JC404.HWY1`K?D.'I";FU]$=-``/=T&@.GF`W$`T
M^KK0&8=O/X_L(?E;QW\[(F@)+_B_O:(8?^BWCC[)>@(G]`=K<J!ETRN5#HMS
M&`%%4R`H=,-?C<@CQ"@'`=@6Q]#?KN7L/;18]YST?=5\)2;M&096BM,MXEC$
M-RNW;V001734(U21,`F4UY"#IJ/$*]K%N%R?3<=(T;)+CDK;<:.5.!*1N#PU
MNV'`026/;TRW*YCO5J*0EN^/AQM^-C9)=)-4T=(,DI%USH(J").83`8?*`5J
MEZH^I?>_;O=/]L[==OR*4U::^/(Z!^@GI)Z>]Q]G8F[=U[/?R;\I.K346UXI
M4U7A[/:1C=\VV''^SO,$YBFY[9R$[N%1N6=B72KR*C+96B9$5O4'$0JU3>JO
M612$#4PB`B/`=*SOV-O=_?MD5Z^ZWDDG3CU):U\=36CU^]/=J]/^[EMO;DG^
MPN+J55HHMU27M2=&-OKF(94XI)@DGS"!"`83\I=>`<X@'.(!Y=`J[UPIX&%W
M!6_E3J=51(!0%#?%-Y@^R+0&X1\--[&?:#_,-T?.R6H#5O=47VCN]_Z3N8_G
MI)T`A"@"@.ULN5!RFLHW3=)HF`PH*AJF?7CH<`T$2B/;1`?&Z(>S1+J$;U(3
M%CW#5ESV-;1MF4O?)CU^,PV91D+'"DDW67?HNB"5=X['E23#XP\/)4<QPN85
MU*BE.S)+V.FA5MER;N+N&.[45)K(ARKS)T$3M9PC'(/[`_L^M-K8-DF<#`Q8
M19%V42V8(BW<.46S[O3&7!$H@0R?,;W>-<Y-N])\3+[HW'<-SORL[O+(;=U-
MUG%NL5Q3=%0ZS7>]-RPNW,+'ZW2YBQ3@EI3IHEIH0@.L]A:\]F.>&\9CBZ+'
MNG;YG6'<Y$Q5=T#CZWHF2!FZ>+M;AM:8<JQIWR4M;DJ4R0CS_;""4W;707MJ
MS8Q.V,3"M-W90@EYCXNBX/6O@SEQZ@W,E=UYEJ_9\I2O.?#C6JX\T,+K*JN%
M3K+',JJJ83G.;M,8PZB.@``!V]@!I55+*.``40-S'Y-`U#AKS#_HT!Q*.H`-
M`5H"4SX03VMC+\@V4?WB-H!VCQPO\E]/C^&YZ_B^-J`U_H=@>8/@H"M`%`*K
MV6[1,K[XMQ%A[=,/1`R-T7F^,#IZL<K>+MR"9AWTM<4R^5#U=C'1K<!,9100
M+S"`=HUZV6E)Q>E4(W+5NY%WJ]+DEIKQ)SN+?#*8RL''9,<7YN(O2[6,B,>K
M<Q+-C(=-[!W(0"@=];+A<RG?,_(=3B4Q``0"L1[OV[^X[GAN$;CZK4TZ):-)
M\^3]YO1V+W__`&?T]N=L8]B/[F]9;C=E1:27C32GAQ(QG6/Z/MS=.R<M_(EE
MY,@LWX(O";>VHI=\1,LI*X+*OIF"KDUI7XP:`0T7(N8_E41.)>1300`=>%9-
MQ-,:G,U"[JEGO?;L\Q/5Z/DQBLP:&$-0'0=-0[!T]SWJ^E<"U72NG`I42`4`
M4`ZMG?V1NPGZ16Z_^H=`-4T`:Z<=-=->&HAKP]T.-`7F,Q9?R:BV3M!S\HBW
MY5I!2;5.0S@.U5%L1L0J9?\`5$1\]`*UZ>6QS+_4`W,6=@S$5I*W#WJY)R^'
MSAW\E0MKV0S<)EEIJ=FU>[;QC4A#"FD)C`*JFA0XC2KC\T>)[8[LJ_!Y']'J
M5?<;$EUX=3IF6-C2%MEIMTBI3,4Y9[:W7EU25QW+*6TVN8C`$G<^BV5D^Y;J
MJO3<Q!T,4VH`'"J#N%]JJ5>KD9L[#P]J6=<R=RMQ>S^6W+Y:NE-.GE[Z\B#-
MU@^E%F/IO989O)]E:TQAV_'2S>R[LL.0^582)F6:8*O+-N$`$[B&N-LW,"H(
MK:=XF.H=E57%?5CPD_J<%7WT,8=T1Q/[E?GMT91VYW9>554^2KZ?RH,SU]3*
M!/Z8A4#S"@"@)%WA5?;0;?\`\"<O_,:2H!4_C*/:DV)]&*P/G%>%`1*J`*`Y
MI)+KK$0;I'65/P*FFF=0YAX\"D3`QS#P\@#2C''@?>1M*ZW!#*M[7N)P@0IA
M.LC"2BR10`!U$QB-0`H!I[O"@/@G352.=-9,Z2A#"4Z9R&(<@@.@E,0P<Q3!
M[@\:`YKMUVYB@L3N^8`,4![1`0U#M'4.'&@.F@"@*AVAYP^&@'=_[C]`-D9;
M_&KDC\.[O_I]]0&/J`<FZ26;+&P-OZP+=F0[63N>UK@N,,<O%P!`9*TG60BD
MM6/OJ!*Z*=J:;M5Y(E<H`IZ(Z"`]M2SN7;<7*U]3T_!Z/\CTM24+L9/CU*GO
MY/\`!DJGI=X<@-F?77WCQET74\RU!VI)H-&M_2;-)A)3J]S%1D5I%%@W_P!C
M%S&N7@`H4.0OHB(>Y5I=U=QX/;N7A0OP<K$WJZ<'5+_4S'Z5^G^;ZB=L]P;M
ML\U;WS;HTHW3S$XN32]]/T)KDN@@ZN^(E%B_)D<]"5AK?2`Z[5.:-*-Q=.)5
MR(*<P>@KZ1]`T_:B-7)<C^\4;W&VN'XZGQ;=*S9[:O[9F_[]ZW=C*<GJX4TI
MK[:I:C:G6N>2#/IL9/A;FM=-X]ED@MQLY9-RR@I0)!([3<IN#`NY]64*F4QC
M#RF`2\>%22O3=Z,5JJQ7ZDW;^RX6Z9&]W-JN_P"SC[:KR3T;NN370EXI+\R'
MWE+8MM*Z9O2&/EK<+?,%D/<QO!C7<Y@?&<8S,152`F`:.6:LRHF8SE1I:ZC=
M-998HIH"H;DXB.@?=0Q,[F1;O7<?(5'JJ$094YE%%%#<O,<YSFY`T(`F,(B!
M`'L(`CP]ZH+@>452*2X'"HDQ0>P?,/P4!LF,3_X.:]OHW7E\_P!*@-;.'8'F
M#X*`K0'-,`,H0HCH!C``CVZ`(Z"-0DZ1;]A&*DVE#ZWP]X^;T6NG%A/J'W;G
M>W+TR)*M<HXQL^)NW$>&H*:@[<G<GKIR(*3T@C(SOVMZQMQHW`R[5MJY.134
M`T#6HRNJSB9-^7!69-?!E5V''Q[^ZX]K.DJ/+MIZZ4ZJ,E`7`VDK>>*14N59
M![&1K&`40#18Z"-O,2QZ*1D2:@8A>YX"74!TUKEGZIV'F=T7=PE->7=;5/QX
M?D?I&].-KP,+LO:X8<:*WCVJ/VM+^!>F'Y1!<C^(D7:0P\Q%R<8JEIW:BS.1
M9.6K]DN`_:R).2*:#J%>/IONF'V_W);OS:2XE']9NVL;N#;;VV7K3F[EM52U
MT="#'N1VV/;<WL79@#'\)*W`YN')C.,LVV(!LI)2[]O<LF!VC&/:HE^W.DTU
MC`4`]$`#772NGVT9^/NFSV]RQVG6U%_%)GYZ^]]KAV]WCN.T7[,K?E9-V"JJ
M:1N-+XT%==:;INXTZ;&:L'8JL>]IV8E,@;?;1R5?MJ72LR<7'85Y3(*INX9^
M=D4"H(.U`YTTC@!R$*.NO;7WV;ER[;4KJH^7N+-AU^6NOVT]PS85JS,;D^42
M`'$->ZY?B@.GI:B(=E>I,>$2=V8Q0,!P`1T.7L,'N^[K0&8-O/X_L(?E;QW\
M[(F@)+_B_O:(8?\`HMXX^R7H")_0"H]J>S?/F]&\;GL?`-J-KEF++LN8R#=C
MB2E6<%#6_:<'W0/I.2E9`Z;5$!46*1,FHG4,.@!0$D7PIME2EC;F]UF9/46Q
M+EQ;BA[8#:2U357A/ER4'[YG,<)R&*991&'23*</C`;AH%4G?]QO86T7;MAI
M7>FB_,OSTX[=M=T]XXNUWUU8\IPJO'YHH?:N:_KRO*3O-ZO(NSA)/7+YT#I0
M`D3$=*G%(HZ#S)B4@`&A=:T,WS8<SN/.OSO3K6;K\3O3VYV?L/;N)M>!8A&.
M/9L13TT3Z?\`,C]]?3`EP2&$]OF<3)*O!L9>6QY,RYQ2!=6(DE/E&$465'54
MQ&QM4A%3L'LX<:V2]&99>R8_[2<]9*B_#P.>_P!Y_:NWY]J.^;9;I^VDW*G)
M.O']1E9GTO-W+_9Z[WTM<:2CC;U&0RDS,W8MK&+QK4)D8-)PW9/RIJR;15R)
M3BHB!B"D/,`C6>'UM]4^+U^)SA4Y3K*?&OY"#&/WJF7,+TTJ5`$2\@I"EWA7
M`?&,(`4?M?'A[OETJ!$^2^]0!RH$:=<[,.")G)2%6TXCZ92:E`>/OT!XC?%-
MY@^R+0&X1\--[&?:#_,-T?.R6H#5O=47VCN]_P"D[F/YZ2=`(0H`H!S/:ETR
MLF[J-IFY7=M;=TM(VV=O;Z-@$[-8V]*W1=U_7(_CC3(Q<0RA^=2+;MHX@J&=
M."=T(^B`ZZZ17$@^&O`DL>$.QXY2M[>1D0KT\0Z,-LVX_7,B)5S0\6@_>N(D
MRQ@`6ZCF16(`@.GQ:IV[>0L:]Y^BZ67AV+"$M_Q_*MN4_,C^O^&2;[?%DM/O
MYATV*O(1C@[E5DDN+B,23<G,FJW>.`^U'$H")CEU]$.%:Y8V%MMW=5N-UK]O
M8N-^SCJ=%-VR<[^PV]OM1<7*VNGE*J7(C*>*#VIP<7M^PSEJR7B)XBRLC3C2
M(C6K])USP^1?5GT@DV1^.FDQN`"E3(`"!2J:!VUGK8,[#R8..&T[;CU:?#^)
MI+ZLXV=>E;W7/BU?5SR=>.BD_P#]1E;=!T.\\;4.GCC_`'^9#69V]!W@G8!7
MF-;E701O!!6\_7E$7+95JJ*2;(K4J"I4!+WPE/KY-*N,PL,FL)F+1;."*VLV
M=IKB8><5Q`4RCKH!#"`"40$>V@+.4$AE%#)$[M,QS&(GKS=V41U`G-^VY>S6
M@.%`2F?"">UL9?D&RC^\1M`.T>.%_DOI\?PW/7\7QM0&O]#L#S!\%`5]WW@$
M=.(B.G;II[@4`KS-.R+/6`,/XJS9DVW8Z&M+,$6E-6HBE)(O)<D0]()XJ1DF
MC<Q@:(RA0U2U$1T[0"@'X_#,8[>R61\QWLV5^34Y7[T[0G+A.BJ(PMAQTE]]
MMYJ(KIDYB"_0CDVXE(/,H4P@(<*DNSM0LS=UI::%W=F;?+<]U>)&#FY1X(FU
MS.YYFID^$D2^KVFW9QK^?>PZXE*LYLA`_JL$\<)DU(@,RW3!8A-><":"8`&K
M$GNLOW#M6E_MR=/CH;9[5L.(NS+VW3BY7[59*JU32K_CX$<[KG;;U_[%L^WW
MBMLYG,6[BX:"S#$"T06<QL1>EER#5Q<*3?F-W;)TNP`X:B!#::Z:U<FWI5=.
M!@/U#C8NXEF%^#5RUQTYKG^/'\2$Y@_;9FC<E<JUK88L65O"3034.X]6*5!D
MV,1NHX*V</W'(U3=KD2-W:8FYCB'`*K6O/B8>NRMRN.5K^F^!B2Y+<G+/GYF
MUKFC74-<-O23N(FHEZF*3N.DF*QT';1P3]JHBJ00'R>Y0\SXE`%`.K9W]D;L
M)^D5NO\`ZAT`U30%0#4=/\OUN-`9\QCMLRIEO'V0LE67"I2%KXT&/&YG)W+=
M!1$'R:ZH=P5<Y0.*":`B?WA#36E.9/%T@UXDC+PWUD2=W_VKVO$N',.RR-DS
M'<3?]R,U%6KEMC*P>>\YIDH_0,BJ#%X^2*11(AB\X"&H#V5"O0NI\BJ[+M-S
M<K\;4-)2=$30LJ;JVDAG^R%K7N(6EH17K$!<<`Y409(D55*9K`.E#G`RQ#B(
MD,(B7T0$!$:MC(RJY35=*\#;?MKM[&VKMIXF525V['CQ>O\`#]!C/KLX1?Y5
MP'F>\XF.E21%[,FMPW#;CY,YE+8R]C)/UIK<4>OWRK=>/NBW#Z"N@`$5(`:\
M>%5##R(NYH]*F)_4G9''"MNVODA%)>Y</R->X8P&$H%UYN("7W.(\`U\A0"J
M_>FIJ+7@8)X)1YHR[!X,OVY<47+F.#9MY*TK/D$VERE06#Y2BDECII)R*S02
M@<[`%EBD,<!$"F'C7@0,1&*)=!U`0,`B`AV"`"(:_5TH#C0$B[PJOMH-O_X$
MY?\`F-)4`J?QE'M2;$^C%8'SBO"@(E5`<R%$YN4!$!$!XA[P:U-&/5*A/;MJ
M[/HEP9*"\-[TOYW<EG&$WCY1N>Q\>[;<,7ZRMEN^OLL>Z#*.154TW1;*@8A\
M<@/2-FAP,X5-Z!!.!0YAU"ES+6/HVJ'I9PL_*GY.WQ<Y>PV4]QX\VEGL"YK;
M4M#%]OVE/Q3Z*D7L3:\*S412>I'06.U728`=!RF!^8A@$`*.@\>ROC>XXE?F
MDJE;QNT^Z9Y:QHX,W+C3FS6O==WH>M]FTA=>ZW;!D5'+^WE_<K17)4(J**=X
M8:E[P7,>%6E&Y1)\JVG.+J"DB\1*/=*Z%.!>`AZ0O6<A.Y9HTG1GEN.Q[IMU
M^NY679NQ7!\UX_'3\"+TLH=0X]X<YQ*(@43]H:<!#B(CY*]J%&NR<Y]2X(Z:
M'F%`5#M#SA\-`.[_`-Q^@&R,M_C5R1^'=W_T^^H#'U`9>V^KE:YWPR[.H5$K
M+*-BO3*G^(F#.Y8UT)S>\7N:FC)Q=5ST^(<9R3C;:4VG1OD;9_%&T3;]9UWY
M?SPY*VN'.&Z1-2XK1DI]DJQ86JG"VBQD!1;"8QB.6KQ8P#W_`"ZB8>7LJTNZ
M</'W7#EBYD8/)A_2Y4]_B9T]*MPWK8<CS-AE..Q6LJU',Z565R,VDTWQX-CH
MNW6[)&_L/V_<]]LH,]QPJ#N(7.S*DL5!DPT03.0RP"5/UENEJ.@`(U]/;FY>
M9L<+^5&N1%4FEIHM$_@4?U?[;L=L=]Y7;_;=V[_:\F49UDW12G\U/:DV8,1R
MA"9UFLKXHRU9[.)QX_AUK*C(>20;R+:0;S"@Q7RVFJ9,4VW,W6]$H:"0=*I>
MV=RV<O-RK,?ELPIT)\>JK3UY\M.1>>_>F&3V5V[MF_;#E1RLN_"=W(E#@G&*
M?E2CP:7.M:U(%/BL\.#@B2V!XA8.W,K;N,\+WI;$'*+%41/ZFM>;MVT:':F$
MW=&;M^4I1UT,4H:5>,7)J,G]+7^1@ON#(Q<G?K\L>/39=N+_`/>UKK[^1$(,
M.IC#P#TA[.S77CI]6O>:2DU'Z2AKAKQ.-2D2@]@^8?@H#9,8G_P<U[?1NO+Y
M_I4!K9P[`\P?!0%:`]"*1C:F`Z(:!J`&.)3ZZ=GD#6HQBI247P;"K7Y?J'?^
MADO(0'4QVZ70A(*1X6X[N61[]BJ85")&MR18F(X`@_\`1#F=@!]=0X]E4+N#
M<[.W;+E7+]56VX^''P9D+TD[87=O?6#M\8N5M9$97%75J+K^>A*1NVXG1;DG
M#OWKEU.%D)<II`Y^8XD=O'!BI%3'T-.0^@#V@6N3OJ1FWGW'*.+)JQUN44W6
ME??^)^F/M7MVWB=LX5J,?^QC9M?*OJJDOYN/'B6]8KR5G+GA;0;)NT595^":
MSAN3114@\XB;4H<2!Y1JR=]W%['A+<^NF2HZ?\"M]X6-NVG;<C?;BMOR[6BD
MZK3V/B>"3Z<-PV1OVV6;S+8:*HS&-<V6C+7NP<LS.CW%:B+[N/E%`&^I3*M2
M+B74=1`./DK>C[9?6VSW+LT=BSY*>2K<8I)*/"*7+W''#[EO2'MSU)O9'>O8
MERW8W2U+KR5U=2DY/JN4B](U;=*<.1%MZU=VWGDCJG[SYNZI=_/ORYDG8Z*5
MD7"AC,+?9=VE"Q+0%3#ZNR8-="IIET*'$?+6Y%JY*Y!=2I31?J<X=WP)[9G2
MPINJA1)^.FK^-1KDT6]*`@+9/@(%^.41`==.(Z^0>WC7H4P\!DC(J'2-H)B#
MH;00$-?<U#APTH#,&WG\?V$/RMX[^=D30$E_Q?WM$,/_`$6\<?9+T!$_H!R/
MI4;Y,@["]X6-LG6F,;)6;=\Y!XXS+94\S2D+<OK&%S33%I/PLNQ6U(J+=(_K
M"!M-2+)@.O;0$U6U\*7_`+9=\?4MS-BJRK;L[;3E::L*039,$4(AI$ENBU&4
MHQ-!LD2@F*[M<YE#I):(@&HZ<:QGZK[C+:.UKV3C.C^6M=>-?'VFV'V@=K0[
MB]6+&/DQ<DHIQ7XQ;X>SX%F1V14FKU\\<"FJO)JF.M)G`.Y)W8B!$D"<-5#`
M'9IP$>%:/;!WAYZR+N5.MSKX\/:=UMQ[-NRLPLV4XVXM1Z>=*<W[#`^\6P7.
M['!=P8Q9N%'Z+1D\45B4%0*_(`_;4I1FD8>1=PT,`F`H]H<*R#V+ZHXD=UM/
M)NJ$%)4K\JT9KUZZ^C2[C[2N[-T*-_+BZ7'HJI4H)ZZ_6]',>(-C73FZ?V+;
M@;6=A.^=JUMR^5V;!HR1D;JDK0>IVZTB9%T0HJMXL%8\72[<I2F46-J(CI6\
M6TY.)NV%'+P+L9VE!-T?5RJ]3A)W5VON'96]96R;U%^=CWY03I1.*>C(;+J'
M28H@=*88*G4*(IE1YA.(</1$1#AS>_7UT3BKD?H9;+HWU1^AEOF(8@Z&$HB(
M<P\@Z@&OD$?]+AQJ`.!OBF\P?9%H#<(^&F]C/M!_F&Z/G9+4!JWNJ+[1W>_]
M)W,?STDZ`0A0!0$ACPUF\S(6W+J,8VPPSG'#C#>Z=:0Q9DZPGI2.K>FWLG"R
M1;7FEF:Q%"$?Q,F0@%5)RF,0YB&U*.E$VM5Q1&*ZI*/BTB0CTO-IVY[93`;H
M,PO)JW+0QGD?<EDZ`=6E)**-7DK!H7"Y:(O6+%0@)-$F!UB]VJ;T3Z:%K&WJ
MKN^1MNP2R[,E&[)--M+FN2-H?MO[.M[]WFL3+MN=FW\T4DUP?-KCRTYCF-I9
M81CX"Y6;B.!=!P[53!9)<QCNG*QA%,HJE$!5,8N@Z]FM:M;7O5O.[.SEYR69
M"4VE763KHCH_W'V&[VY8F0KD;;C&*47'1*G&E.8C+J!8=E=T.!(EBBUC)EAC
M^20D)RSW*JKF5<QP/V;Y)5JR3U[U1H=J!A$OI``:^2LB>D7>^W[9MT9]PY,,
M>:CT=$VNJ6JX5U-9O7OTB>]6%:PT_P!QU^9&:JH-J+3]G-Z#'7BB]R.4[[W#
M[<-N3K($Q$8+L7:MAJZ8K'R+M1&V#7;-09"R<\[CD03!])IHH$1**_.9`B>A
M=.-;46YPR8VKV(U/&O14HM:JE*G.?=<"]MFY3VJZFK]EM2;X/CP(JKUFQ:ZH
MLYH')@[1`!*CR\1#33B)N;3R=E3%//A&*!1T`Q3_`.L770?=[??H"E`2F?""
M>UL9?D&RC^\1M`.T>.%_DOI\?PW/7\7QM0&O]#L#S!\%``^Z&O-J`%$/((^[
M[PA0$D#<#GF_-Z/0KVZ&?-F4[>6TS/;[$5X2,;'IFN>2M&8CDG6.4I4[5(IS
MQT<B8441-J`G#CQJ+6L:<R>Q%7)RA+E&J'$.E#A7<]TZ\96;<61(FU4;/W.'
MD&BEO&D4'4VS2=LTCLG2/=`)DI4J*_[D(@)1$0&L==X[S>V].VVNE<-.=-?>
M;C_:IZ=X?<FYW-RS:QE%*C;?S+JX)<%[7S'-7KV<@KF(M=\H)G%\Q;]3E537
MD)2V+?0$6\863-J=)$JA!*/('`A/)5HX6[1_:?O9R55J].2]GN-GH]D7X=R7
M<'&MK^VSOJ,G_P!+='K[BV-QUQYLGMEF3L%P:(R*+Y3UYZOWC<6;FWV:)S]Q
M;;MQS*M%91'B<A`T4$1*-73V[W/;S;ZMPDI1?C1&(?6?T?O6-CRLW#Q9WLB#
M?3TMTZ>6G!D>O:EFQYT_>F%N9S`PM`ILI9:W16W8>%7%PM^Z-`C9K%VYN*;<
MMQ!%RL9B`@F3E$"'-IKVUDV,HTE<E;;MO@T]%IXKB<^9V+V)+]IEVI6LJ+:<
M95JGX$?')V1+FRWD"[LF7HY2?79>TX\N"?>(-R-4%Y)^?O%S)-R")$R:^0*E
M=$E&E)\R6247T_S%B5*2A0#JV=_9&["?I%;K_P"H=`-4T!4!$!`0$0$.P0H!
M:NRK>1D7:7>[X;;B;9O:P<B+0]NY+QE>T6E+VS>,"=Z1)=LJBJ<IX]_ZNL<J
M;I/TB"(:ZA4/YDJT1"6D*ITU_@R<'M[2@]ONYK=A<^!-NK"T-NEW6799XP\<
M4C0,?Y"G;%B5G7R&B``G+IKN5C)G3`H"80X!J-?+NN1:Q<>?2Z3Z=.9D_P!+
M=NO[QW+;P;RK@)JM-&N/\RUXEE%N&[;==,+NO4$7,Q?<JL]ETEE%5)R+8IN@
M(E)3$>("9HD<@@*:>FI2A[P5CNSGJ_YEVY*LXUH;QYG9%S"LXUJPV^NE*MOX
ME[;P\HY/O/;K-X-M9I'3CW*BT58HW(JLBNDM#NTA3:)P+I0AET7;@%RD4#XQ
M0+R]E>^#N_\`O1J^JO@6KZB>G5R/;%_+E!RRH1;35:?!:$$[=9M&R[M(RJYQ
M?E:UWT++N%"N(0QR]X659N7`)H&:F2$Q%%!$X>CP'7AIK61^N%RS;G;BXU6N
MM:F@%R#Q\F5G+B_,J_9S'0M_.7L7;3L$8UV08`MILG>-YX'Q],[H+[G6**-Q
MH73/(MKD&RXMHB7NV:::"R2BZYS"J?F`-`J)X1TE-7.%/E^/YZ#"GZP>0/('
MF#R4(!0$B[PJOMH-O_X$Y?\`F-)4`J?QE'M2;$^C%8'SBO"@(E5`?0BV+Z3D
M&D?&,7DD_>+`W:,(]LL[>NUU`'D0;-FR:JZZIA["E*(B%30E*,JQXD'5)M>#
M-@#T"\4S5R;4]N-G71'R4-#8[F,P9BD;>D(]1D"US.I<8>+=2K)\BBL=5$$4
MS!S!SE`GN#5"WV4X6^N&DV9E]*UCQR;74E*[.=-=:INBT'O;QRNT:G;F2GR*
M124JK`S#<43KLU7[L#%:K>K``E*DDJ(=YR\`#MK'N5E2M7*1?$WFVWL^V\M9
MMR#\]6U37AIPIP,1;G]O%Q;D]K.1K=E+;3)<\UCJZ,9W)#L02?VQ=UK2T>Z=
MVW/)'$`,1Y;,PV0<$45#5$XZ`(!5V[-ESM6.E/1RJ^==#6'UCV.5_/G?A-12
MMM4?'ZG7]35BSE@W'"7[)XV4BGBEV1=SO;3-$E(!W:\JV?FCT6J)"B`'5<K`
M'+Y!UX<*O&$H2M5_G9JO*S=MN2EP3+EN#!N4+4QXPRE<5JO8NR9*\)RPF\L[
M`$Q+=ELG[F<B%&P"*Q5F2_H&$0^,`U`\S$=`5#M#SA\-`.[_`-Q^@&R,M_C5
MR1^'=W_T^^H#'U`>^+>N8V282+,XIO&#QL]:'*(@)7394BR'$!`0^V$#RA4\
M)PA+JFJQ(.'FKRM4Y:+WO@;1?IW[^<?]1+`VVJZ[.9)L;TP3A4N.\H6R=VY(
M]BKO8-T(TQX\YQY7[>59-BK%,;0X'4$.(<:P5ZF[WGX?>&!:Q6UBR7S)\]4C
M<+T)P[.)Z>YV?<Z6LK<;<-55KRU\U?8]::CZVWI.*M6UW$)(.'+8\JF!@CUE
M-2I%5,;CH41T5/KH8.S3RU]'8O<M_<,O+VQJ/2XOI?\`*GPU?^A9GJ]++WON
M);A9M15JU%)N'.G#DO`Q)GFV'L29]<MJJ,2LVR90><JR22G*D[16YT^/,99+
M37A5`P=SL8>Y96/?ETY$+BT7"6KI2M*_`OWTWW7#W'"AL.ZPN.5Z25N*5562
MI+JJU1.GMX$&_P`5%O"PGG_*MG678LPPN:4L*T;7M\'*`B=5G,M#*.[C6[S4
M3)%;*K`W-KH)S`-;#8URU?VFS=MOE_`U9[IVJ[LV[Y.W9%MQS;.1)RX4Z&VX
MI>U+V4(=XCJ(CP#41'0`T`./8`>X%3+@BVJUU*5$%![!\P_!0&R8Q/\`X.:]
MOHW7E\_TJ`ULX=@>8/@H"M`=J:1U/2*4>4#::_YO+4&W%=2XHFA&4YJ$?J;H
MAR;I-93@<1;Y,13-SN"Q\%-O7%K/I!8O!J:7(!&YRB82@4IG*92F'7XIJM3O
MO#AF[!>C*48*$>J5:THEKP3,X_;KN<,#U8VV-N,J9%SRUP^KC5Z\-/>3'[7Q
MRVRMFB1A"NN[B7/RJ[<K`*:0(M4TU!2>%6,/(8Z9N44RZZG#@%<B_5/=L:QN
MU[*QNJ5JW)I)<='Q6O\`$_0?W1W]E>GWIE9W:W:=[<;4K<8QC1\6NJJ?LKPK
MJ.1XXVK0^+[37NMFNVN:[(_E^3Y59)%0B,<JH41$R"0&%-44AT,;34*UR[AW
MW<=YQ92E-_MXZ4_FI[O]32CNOUVW7OK>8;?ERN8NRWU24%HT^?@GK[3)@7_'
M74YQC">JN&4M%9&AF8>J'*DL#%HZ(L^33$QA-ZBX`!UY@`N@CYZS1]IV[;C9
M]4<7#QM<1N*Y^RM3'>1V1F[=B;[DXU]O:KF"[E:NE>E-5]O)TJ:X7K+WS:%_
M=2_=K<EAJ(K02F4IABBZ8JIKM7+R.,1H_4352T(;1RD8HZ:\2C7<>;FY?.X\
M%P]QRLWC(GD9TY3DI-2DJKV28V*4[@X@4IU.\'_TIQXZ:CZ.FE2E+.G0Q1$#
MZ\^NI@'M`1]WM]R@,Q;>?Q_80_*WCOYV1-`27_%_>T0P_P#1;QQ]DO0$3^@/
M;&O58V182*`@"\>]:/DAYA*)3LW*;@@Z@&I0`Y`XAQX4!M,;RS.EG+I7;9,F
MQ#AH]C<IXTMM.:4(@V2>I7':T,G%+D=R:(`O*G%RCJ4ZFHI%#EU"L)^NLWC]
MI3MSK/SI124>5*ZNM.!T8_\`K_LXV5ZFRSXP=<6U#J_]SBJK7Q0TE;EE7M=,
M:9.VXI])"FY,@N4!YB*./2,4Q5#"``4HE'B''LKF+/N';]DNWL/-FXW)3?N_
M$[A[QW/VSL>8WNM^U:HU+7P\/>.0;-MK%PM;A6NJ^V9#IKL4E!CCI"4NJRAN
M7U9R(CHJCKJ8#!H(>[6,.\/42>]Y./MVS25C*<M9132C[W&M/@:2_<=ZW[=E
M8,-C[4G)JS)]-RL:5YUHVQISQ4>U](F(-O6>+=:H),[%DI*Q9OD+RG39S0)O
MF/=I%)W2*2+M$VI2B`&$^NE;]_9[ZA7;FZ9'8^YY-R[D.QUJ4G6+;T;6K=*+
M33C70Y;^KFSW^Z^U<SNB45+<L&Y&5U\W;EHG7GKU5K3A0@]KHG2*'.&G,8>4
M?=_;"(>\(#6_UY*#A:7\L>/)FHTFHN-I.M(UKR:9Y:\P4-\4WF#[(M`;A'PT
MWL9]H/\`,-T?.R6H#5O=47VCN]_Z3N8_GI)T`A"@"@%*;-\JFP=NNV[9=!4R
M)+`R_8MQ.5"*BD)&3.?8@],*@:"F'JJA^/GJ$G2+?L9%2Z'U^&OP-J/OKN,C
MBQ[7CD^ZF+8OZPS9-A'+)NBQB0:W"\CY:.1*5L4"+/6Z+T><XZBH(ZC6`O7*
MY=EVPH).+E!M5]W.G,Z&?91-9_<4LU0ET=2XI:>Q^`UW:P79-II(PB3I91<O
M(DT(0Q@!5+T`=GTU*`D$NNHCK7+O<>^\K:YWX8UUPE&>D6^+7&J]O(Z@;]+M
MK#E&>\.$)QU3?-<DAVK9SMQC[?8$O^^U9"3NY\"Q'C1^!!B5&#@@ET1*8#HJ
MJ`0-!#E'0!&J[VON.5W]O5O=-YG>M6+%AM*+HI335.:7"ISP^X;U8W#<<RYV
M]VUY,=JM4<9Q;4HRC_S-*J5*\&]2&KXL["SZS=VN&<H-FY%+?O\`QRZC8U8@
MZG;#!O!*6+%,I2BDDU06$Y``-``W#A72'[<.^<CN+8LS:LJ4I3PY]%JM*J/#
ME4T?]1,7'R-NP>Y<>#\^Y6W?ERE.FC7OU>NNI$J.FJF)042*GS%YBB`:<P>\
M.H\*V$,0G&@"@)3/A!/:V,OR#91_>(V@':/'"_R7T^/X;GK^+XVH#7^AV!Y@
M^"@*T!('Z!K]/)^4\P;/EEV2DKFVV(*[\7Q4L8JD1)90QK--Y5C&N&*W,D[4
MEH@5DQ#37E)PTJ=)S::_E/HPK,KEV4XM?+'AS?NY?$?<W;3#UCEG+>,._60/
MBK(UNK6D[:G531MZ6"%:N)A&):F4[M)HH\YTQ`````@<*PYZC=$[,KS3I%/W
M\#IM]HT86WB[=.S*W>NR^9S22:?#IHVZ^-4BZ4MP%R'B8>YG#=,2LH%:.D#^
MK(N74J(`0O>OA,D<QU=0Y2E+V@.E:\8G=\)7X8,.J*5Q*2E3I:KJM&]#HQN?
MI/BRVV_NF+/IR+:=WHUK+I75TQIQ;II6FK,P[<8N<S=(OGDXW,A!-SL>X@VC
MQ18Z#8I^;NWB8B4X@MS_`!1((%#A6`O5WUDWKMG<OVG;\^FZWIY;X>_@RP.^
MLG:>VNVNK-MPE*Y9X22JG36OM]@T?XEW"$=A/'VVBTL>1PQ>.!N&]+PE8E`2
M\C6[;B2:D<O'!4@`!!<J?HZZ<HC6UWVC^K>_=]]K96R=PS\[<\>:^=ZI)NM&
M^-:27(X[^NFPV,C'M]VX4(6I7LJ4)QU3<GP:HJ4I3GQJ1"%0T`G'M#7]01#7
M]:MN\A4O-:-I+5</P-=)SA<55_43H_P_XG37D>84`ZMG?V1NPGZ16Z_^H=`-
M4T`4!]^U6Z;NYK=:JK`W3<SL2@HN(B'<IJOD"G6$?("1>(^:I7JT27?Z,DN/
M_$V,N?GDUA7;]B.:B%UE$<MV=9%[0\\BY,+>;&%C(Y$D@LF70B_=N&_='*/'
M0`X5:'<7G7'*W!TJJ&V7VR[5B[IO/FWE_MMT]M5%M":R[B#9`ATY(T(DPNN-
M>LUY24(@B8\HS#5-1J**O,4$>;41$![!X\:PU=WZSME^YAY/5YDGQ5*?FT=0
MNV?3=;[L_P#<'TR4'2"UJO:]*?F61/7M=V4<C6HZAXWU:!L:5*]B(YD<C1(9
MMJF04)(PI<!5(L4#``>6L6[_`.IF+VW=G?\`W$4X2>GN_(RM#T5P,[8_)WM6
MXVY64W)UIJN/"OY&7L];)%MP$7MNOW,5LH7$UM;)@W/>V0GP\TG#P,(<]Q*(
M.#'#[>T54:`D/>>CQ[:O[T3^XK9/4/=[W;%R5R6?%P5N7R]"5)=2?S=5714I
M%G+'[D/1SMG:OW67VM.S*_A0G*[%5ZG5_*XZ:K1UJU0A!;Q<GN\R[H,\9*=N
MRN?OCR-/G8#S<Y$X=B\4C(AL@(!R@@VC&B1":<`*`5M5-.$^GE7B:!6;JG;7
M5%N35:\D)EH>@4!(N\*K[:#;_P#@3E_YC25`*G\91[4FQ/HQ6!\XKPH")50"
MW^G7NSB=DF[K%.XR=QW#90B++D'2,I;,T@V<"5A,MCQCR7B"N4U&I9Z*:.#J
M-#*%Y04#M#M"*XH@VE%M^!LT(+*MB8^O*4Q3BI[\LQF=ML<+N-M.;?1+%.Z[
M1)?!5'86NV!D4B0IRA"E4,"G*'>CS`.E6WW+D1MV*T?,S3Z+8<]Q[JPXQHK-
MJXG)/GK703'=DQ,V59UON9Z/!M<4JZ!V_MEH<CN48L"N`,,D][L#E.[,7B)"
MAH`<-:Q3N-YQ:N<8^SD=*.SL#==TO7;G3_LQJM:Z_P"%^I?-[Y5R(3;WD"PL
M/S4B\NW),.I$V]*-5RIO#&F$A:GB4Q=B!8UR<5!((ZAH`=E5C9]]Q^M8OS>9
M)\=*?J8T]4O2];OA9&ZW+;A=L1E[/Q=..C="!-EG:#ENU.IKBC;_`)SM>Y<4
M7QDC*N/6#YU)#ZFLZ+/3[1D2YHJ5'5!TDH?0P+E$0$WN#65</J\I-_2<QMP?
M1N.1BPJK=NXXT?.CY>P5+U\XG%6WC.#;8_9;AY)3.!B(N;E?0SSN+'4NJZ$R
M3<M..(X1%V^OF9;KIED55="IJ!Z.NHU]A\9'GH"H=H></AH!W?\`N/T`V1EO
M\:N2/P[N_P#I]]0&/J`Y$'0Y-`U](/A\M13I5TJZ'I95;L5_U(G'^%5Q==,5
M8V9KUDV+]K;]U/F*<2XY3@D==%(4C'`@^B8-!U]W7C6LWKIN]G!W'#RXM>=!
MT>JJM>?-<#;KTCRY8GI5>4TXJ6XRIU*G4OEX5XKVHE[JGN.#OV&]1.H>,<'0
M*Z(J.O*F/H*&T'@4H%'72L=^E_J+M>#F/:[RKE79/5\ZODRZX+:\_MK+R+\4
M[Z7RTXZ<-#W9-EV$<[.TD.0\4HT<E6,JL4&A%04*N8.Y[3JJET`!$>SLJ[O4
M+'QL7?,#<\+J2O)*6CIU1==>7"1\_9&V7+JMW<)-9"G'I27S)U=/S-:;UV]O
MZ%D;H+LRI9R0FLJ[Y54%&Z/I!#/W0BX.V<^D8`[U4#&`>P==*V0[4O3R>W[#
ME7@M:&OOK=AYNT>I.9C9+C+KM1;HT]6M>`PZ8-!$-`#RZ!V<0UX?JU7VJ.BX
M&(7)3?4E1,XU`@4'L'S#\%`;)C$_^#FO;Z-UY?/]*@-;.'8'F#X*`K0'-,YB
MB'*8P`(ZB`"/;4)<'0GMS4+D9O@G4O"Q#3*EXVN$"+A2>&X(DD-W!C"N$B+U
M+U?D*&HB'>:"/#R5\.\0P;NU92SOZ;L2K[J,N?LF6ZXG=^UY>T-_NX[A:4%'
M67S3CP2UX<2=UCQ&]F\'9IE':["9^0H$\TZ2.8IU')&;;UM(R@@`FY#\P@'[
M4>RN,?J+>VF>Z9]C%55;R)QC^$J'Z<\'&VN]VMC0W^W"_E+$@IPDDZW/+56T
M^=:B_+>SKD"S9HP1)VSQF+%JT>I22A1:N&H(`*_VDP&**R@:ZFTU$?+6!8;8
ML>W=R'K%\O\`0UMWWTD[,WG;)3NP=F_YC<7;3K%U=/IY>P1KNNRCEI>W[]R#
M8+LT-<41;TT]MIG`.E6SI$X1BX)J"8G'F,<>4HZ"/N5N+]HVT;%B]U6MPNP7
MFNC]J;UH6MZU]OW.V/MTW':]A4Y;HK.MRCZG%)Z5XZJE40`+DE9B3G9A_.++
MKS3Z9DI*86=ZG=*RSM\LN^5<'4#O#*G<F,)M?+762Z[,IN=GZ'0X/NGEQK_4
MUZO?5GS0DGH"'V[4`'XHD3$O#L#3DTT"O,E/(JH990ZI]!.<=3"!0*'U"E`"
MA0&7MO/X_L(?E;QW\[(F@)+_`(O[VB&'_HMXX^R7H")_0%-`&@)??1NREEB\
M]DLO8MS7$['$^.KK?$A8YYSJM$G;]0I""R.IJ+5--/F*8B8@4XCJ(:\:P]ZQ
M68PVFU<NNMJKXM4X:'1S_P"O3*6-W3NRC!RO_MXR5%5_4ASS&N7+BQ^>0;00
MHC$-W_K$8)4!,0RXF,4Q5N8`[Q-4!#3MKE1Z@=K[3NV[7)N:2ZGP:_@SK9W=
MZ>[-WCC6,W/G..1<@E)?,FE[5RH_%#E&&M_=@M;4N..O*V'L5,-&1TX9LV3*
M*SUP!!,JJ0```(4!`1``[/)5C[1VI>VV>=MVU8UN]=R8I6[LJ-IM4T;]_+F:
M2^HOVI]X0WG!N[#?5[:I7*W&YZ1@GS?%LB3=>#JE/\^F+M.LV-F8^UK?EFT[
M=\E-D[AQ*.4T^]8,8Y$PF`S1`#")E-0$P^B%=$/M4^WG-['A_P#-.Y[JGO=R
MU2%)5I#5Q3II55>GB:4_</WMMG;.)E^F';T$MUGTQS)KAT1K\J?/5.O.C(P!
MQ.8!,8XF#T>TVNFHB```"(Z=E;PS<6H=*Y-?`TI<86HQCQE*.C\*<4=-0)2A
MOBF\P?9%H#<(^&F]C/M!_F&Z/G9+4!JWNJ+[1W>_])W,?STDZ`0A0!0``B40
M,4>0Y3`8IP'02F+H)3<P<0Y1#6HI5=/$$_GIV[B<I;G-E>)YK,,XJ]B\46`T
MQU9[UV=4SYX@BKRE9OG`B(/RHIM""D(!WG+H'8%8D]3,+]]<_8[A3R5:>O+A
MX\#??[/N[+6RV,B-NU)W?.2K&+=7HN*6KH*KL+)%QXZ93A(]HW=>NGT2<K)E
M(JFF8XBH"(F`PH`.O#00$0KD'ZF=D;5<[JR7@W9*Z[B^5-]*T^&O,ZF=T]F[
M=WNL+(R)N#C:3:3I5N*I7V^\<WL'?WC-/&1T9U!6*=6?&)"LW32.<3..['TB
M<I=3"<Y1$P\0$.VJEM<NXK.);[7P+35RZU&W.$6WUM457%.BXUKH:!]]_;3W
M-LO<U[<+5Q2VB[<E<N2E+Y5:2;:;?Z+4@Q^(4Z@ME[P\O6-8]BNE9-ABLLJ:
M3?+)@7U22?\`=IC%H:E*)0*`:G#R::5TO^U_TFWSTT[<O9'=-SKW;,^>E:T3
MUHS2CU<[KV3+L6.TNVHK]IC7'YDDE24U5.C^)'!$3&$!,8QA`-`YC".@>X&H
MCH%;*F#RE`%`2F?"">UL9?D&RC^\1M`.T>.%_DOI\?PW/7\7QM0&O]#L#S!\
M%`5H#-&WW+=Z8*S3B_+>.)N3M^][$O"'G(&6B5U&[UH]0=IE`J1TS%,8JZ9S
M$.7L.4P@-3PZDF^1]F-)V<JS>M4=&NI?CP?CH2U9J_)Z^TY7)UU@@XO;)4F2
MZI?U4AR)+OUT$@5=*%5,8X%-SB(AP`#".G"L5]X6X7<._&=.#XF_?H5ON]Y/
M<N!D6O\`;P[#@_!.KHU\#-UF,/E2QGB1ER'%1L<JB1.4Q"J\ACE23,(&Y3")
M0X]H5IX^VYW]SN24U%.3IK3F=I-O[DQ)68^;%2G#'ZVN3:57[Q;VV'/V/[9M
MB-D7#R(C+SBFHQLA%-U$P</(UIKHY?N1(4I#!RZ\W$W:%:E^IOIMW+8[CEDV
M7<N6[LOEHI26K\4FC5GU&[:S>]=PN8MQTPYMW*U^6//I]PQ1UZ]XEG9I@8^R
M6TY%W"O&N2?))FBA'*S=5PH191,%P*0PILR)F`3!P$>`UOY]FWI=N?9G;&9O
MVZ]2RL[6CJFJ5BM'3DD<WONKW+M7:MLPNS=CZ9;E9FY7G%]2ZUX--\J?B14C
MB`@&FO#@'_)\GZ];F).*2E]7$T:AT^5__:Y-O\CJH1"@'5L[^R-V$_2*W7_U
M#H!JF@"@.:9CIJ)JIGY%$CE5(.H@(&3$#%'4!#3TM./:%0YA_2T34[1W[R^Z
M;8CM,M*Z;10M^6PA:+FS&SIFD`,[CC4^9)D]*NY,90'(K(:F*70IAXZ59W<%
MSRW*?-&U_P!M=_\`80O9:T<&G_\`J?'Q3&7$HQFIY\L4S1T_5:L4-2E$B;-(
MRZH`4``!#CVAJ`^6M<>\-MN9-YWX/I=?<=B?0#NBQ?LSP,F-;*C5-K2OOX"E
M=M2T<\EUP>+(I)LYGUAR<?W4A>]T.!1,(!Q*&G#A6G7K%B7XXSLPMIW76OB_
M;3VF<>],YYFP26W.;O.%.E)KEP,^]1[=G&6OM6R%:]JW.V@%'EH2,&JHDJ*2
MZ17K8Z+@Z12B/(LJF&G,``/'6J?]GO9&Z_\`^JK<5U6[$.EOBE+B^>FE/S.>
M_J/V3:[:[%WWN;N6,5=OX\XPZFJMM/\`2J-=RY4%1=PH8YE1.LH85#CJ=4QC
MF$53"(B.I^WSC79>:HNCFI<3B_'S()VHTZ-7^!Y:E(!0$B[PJOMH-O\`^!.7
M_F-)4`J?QE'M2;$^C%8'SBO"@(E5`<TR**G(DD43JJF*DF0OQC'4$"$*7WQ,
M(5&.KH0=*:\#:G8FMC'V)=HN$-REY#(FOU]M;VR8J!PS$3I-RMHL622#954P
MG,JH8YC*AV:E#R5:7=-%CMO@;&>@MCI[EM2TZ7^?N\:B+KDSZW?O9>+;)O9&
M0:.'@,YN0(!E7B:2H"0A]"CW7)\7E#0!'C6H_<??\]FR)8DDY-R:3_$[<]E>
MF5ZUB6\A2C'&G;BW1JBZHI\O?^!:5M94FG-V6VOWCQH6(>C*JHI^B55^Q24<
M--1`H`")EQ#SCP&OM[4W^]DY]N4FZ2:94/43LC;]L[-RY7U"=R[%TDJ/2G"O
MO%7WMMYV]=2C&>U?<CE5*XFVXK;YNJQ_:19R&1`QU&IKP;2L3'3"HG*Y1MD[
M5N80XB!5@X:<*V_V:^KV)%MUFU_`_/MZK[)#9N[LB-F"C8G-M45.?P^!!+ZW
M#R6D.K#OM=S/>>MKY]N@Y`44%0P-DRMD6G*<1$1(""8<OO56#&@UC0%0[0\X
M?#0#N_\`<?H!LC+?XU<D?AW=_P#3[Z@,?4`I#:=@"X]RV=K"Q+;L>X?+7+,L
MT'A6X#S$9&<%`^AN4Q2F6Y1*41T"OBW'=;.R8%W=+[Z;=F#E7VTT_,N'M7M[
M([IW_&V7&:4KDZRK_P#QQUG_`/C4VM73YVSV_M,PS:&,HMDS0;HQS4\@1%%$
MGJ<F*)1<@LLE^[K%-REU'M`*Y?=[=]9?=W=N5FY7_A2FTF^&AM_WC+'MXV+V
M_LD7#;L&VDE_S.BU7P%C9*=)M;9,9BY13=G<@4@Z!WJB?.'!-3M*/NU3^V\F
M/]_P*4KYRI[JE&[+LWLC<G'(B_+Z7[OQ,$Y#@1O6W$K<?._4G$NW+ZNX((BJ
MBJFD4"J+G#0IP'4>T?)6U7JGW/;V':=ORK[?[65Z+E[HI-_D91[.W'_XMOUS
M><>*E8L3BVO%MO2GX$3GJX[2)G^RC+BKDS60;LB+2:$RJ5)99P^;I^LH(I)$
M.8Y`(*7QN`!K6:/3_O;&[DV2QC8D7&TTM3"OKGZ4[GFW\_U3Q[T8[%?Z9^6W
M\W6_TU(/RQ134,0W`P&$H@/$>8H\IN(?ZP5DZ4/+D[=:].AJDW-NMS^IS.%2
MD"@]@^8?@H#9,8G_`,'->WT;KR^?Z5`:V<.P/,'P4!6@*AVA^Q1A*N@\UTGM
MI)\DWXGGB\HTZEH69("WM5%9`W<2MSI\IPDCZ_NK6)U$>'`R@Z>2L/\`K3W'
M<[=[#RIP^J<&OR-R?LQ].X=\>L-G,OJF'M]OSD^74N"][_B2[(CY+)"/$U#I
MN2D;-4&PD2,10CD3$[TX'TT*(_LZ5Q>W7<,K-SIYDOZ=V;E3WG93=OWEW=8R
MN5C:<Y57LHS#V29><;O.ZC4%4"-VZ!2N"F!05P`@"8!T[!+V>6KKV#!Q\J/5
M==&ES,C]D;7M]_&F\B45)O0Q>69EGC91P[6!8IR"@Y[WCH@;T%$SI:^FF)1T
M$/<K>3TC].MBVNU9WFS<75.,)NC7%I-_F8"^X;U!N[%BY?8^U[?.]@7\5J=Q
M)TJUKK1\]2)YU-<$,,*;CI1S;[;U2U,AL0O&(;E#[2T<NE/^MFJ`@&G=@[,)
MBAV@!A"MZ,'RGAVI6FFG!'Y].Y,*&!OF38MVI6;?G2:B_:WP_$;LKZBAA0&8
M=O/X_L(?E;QW\[(F@)+_`(O[VB&'_HMXX^R7H"*"3XP>3@/P#I^O2M-22=>G
M3CI^IZ$4%EUD4D`%0ZRA$4TB`)E#J*&*4I$R!J)CG,(``=HC7O=D\:'FO_'M
M/H:G.XH6%6[<25%XDUO85C0F%]HMFXR>-])28;,;WN5NH(HD>2LKJLT8*D$N
MO(@54.<?=#LK1+[I.\<J<+>U;=-2A1RE1\'1Z:>\[,_89Z6YG9W:UWNO*QY0
MW3.32N/^6-*N/#W4%?Y.2C;?A8%Q&QYFKQV@09!(Y-6P*MP'NO4]!T$.;]MH
M'``K0;MFQ8S[]YYU7+J=3H#V1'<.X,O.QLR7^VG2+KKKHZF%(R[)!^_/*&9`
MJ1)-,IPU`O<B`"!E%.;3E,<.`@&HUFWM/M*>5D67CJO1-/\`,OKNC!VOM38+
M]Z_<48P@Z^W3_/F,1]8C#$>=:RL_P+!1HM)*GMJ\&R1=4><OVZ-D3G+V&,("
M33WPKJ)V.[G_`,;Q[=U4G;73\$O\S\W7W-[;8Q_4&[O&.T\?*GUUY-MO_(8E
M'30VGNAI^O5V\S7)JBN>UK^)PJ)X%#?%-Y@^R+0&X1\--[&?:#_,-T?.R6H#
M5O=47VCN]_Z3N8_GI)T`A"@"@/2R9N9)ZTCF21W#Q^Y09-4$P$RBKATJ1!%,
MI0[3'44``"HKB@3XMI]MQ^"]H&'<2\Y6LLUBFEPW`V(F!5_E1^@18R0KAJ=`
M4?2`PE`#<NH>6M<_N"SKEC9[EFQ7JZ7P.I'V*=K6LC#NW+NEV[\R1GZ1=*JP
M+%T+'G0=I'.HHVYE&YNZ-HKW1QU$P@`ZZ&"N8^%MV;N^Z7,2XFGU?J=*,&-E
M;G<P+MY6[MM+1T7(ZH:7@[??J/9A-HX;O&AVC@AN[6:.V*[<R7<*HEYD/6DP
M$.4>`@(5T%]!_3B&'B6\B]R7-<ZFAWW9^NF#LN'>[$PKCN9LIUEKHH],E^K(
M>W5FV\ML1Y_4ONVTQ^\S*I5Y=F'<`D+*90YDW[17D]%10X:&`WE^I6X<K=NU
M=5FU1TC^B./]R5;ER[SG-OW5=1J2O(B%`%`2F?"">UL9?D&RC^\1M`.T>.%_
MDOI\?PW/7\7QM0&O]#L#S!\%`5H!1.U['2V3,RV=#>JJNHYB_2EY@2IG5(1F
MP.54J9BD`1`%5"@`!VCK[U+U_IQW'P3*AL^WO<<]6G]-42C59;DBCM$6YHQV
MR9),#BY1$JR#,B292I@U-Z:7,F&NH]H5K_WEDW>OILIN;;.N/V^=M[=#8;=R
MZXUM1@^7M_R%'8/$[RW)<Z"R'=1CR).9,#<Z2@.A%!900X=US`?LU[:QEB;!
M>W#,A+-CTKK5*^\V^W;O7;MM[?R+$))]&-<]^D&)VFI5M8UYW.@]0*5!&0D6
MZ:2/(0ZB*BH'*10#"!A*=(_DU$*V+VGL/&M8]K(?T'*[U*^Z+>WN.5LVWQDL
M6,7"M6N*H1WNH#CU"U\J$N^(>N7=MWT19XR;+++J!$/6YA];9-@6$0304.8#
MZ![]9"5J&.E8M_TXJB-&LS,OY^7<S<EMW[LW)^]L0+0^8*`*`=6SO[(W83](
MK=?_`%#H!JF@"@+SQ_9DGD"[H.U(E!1=S*OD4E12*)A;LN<HNW1QTT(F@CJ;
M4?+4DM-2/2Y+3Q).MH1\%:5AV#8,(V3")M1!!NFF`EU76622]8!0!'M]8YA\
MM6%W-G1@I6F_F:H;\_;'VG^QPO[AE+_MI:NJ\4_XBTYITA:F.H(@%!@+6V)"
M8[LH";G>RJG=HE4'M*8R:?#WAK$^39>Z7?VT=6SHQVGF8O:&U7-WMM1MI5UX
M"7;<R7)6X<KAG*J1@N52F=):]\B8HCJ?O$CB(I*:#VEX`-4.[Z:1WS,5K.C_
M`+473AK0^+N#[EL79MF\_#N0DY3K)UYOB-V=32Y[YG;6AKC@[M=O+/D'"4?=
M44F85>Y>G*(-%#+!H!&IS%Y?./O5G?L_TTV/M+'\[;8_/.CGPT:T7ZLY8?<C
M]P7=7J-O3V13KM24JM/35_#@,>B<2ZE#XNG)H/;H(@(_KA60?,E.'0E\J_@:
MESA)I1N/6'#VG77F2A0$B[PJOMH-O_X$Y?\`F-)4`J?QE'M2;$^C%8'SBO"@
M(E5`<TE%$5"*HF$JJ9BJ)F+VE.00,4P>^!@J,7TNI%2Z74V6=I[C,9[E>BKL
M7N.SKV:2ESPMP6K8%\QS`"B_97M9+=P5]!W"B`@];%1;%*=,_*)%`,&@\:MS
MN?#>58^7F;%?;EGRP^XW<NK_`&TU3XNJ_021'Q$O-S\ZZ:"91)@@YD'J28<$
MQ65*DF`AIS`(IAP#776M1N_NT[N5@NZEPD_U9VU]*O4FSNF*MKFUP2I[E3XG
M0,HYM^XV3T@`W4*Z3:+).M2IN$3IF!P"9#`'VTI#@/-[E4KLC:Y8EVW!\FBY
M?5C>L>7;3VZ+3LRU;_+]!TOI53K`F7[_`+,GG+$F(IR&4O\`EQ=N$6:$#/V$
MJ68).^OK&*0Z+4""*FGQ2UM]VY>3=NT^+B_T.,/W'[5CXMW]YC-2E5?FZ4-=
M[U4LU6KN'ZA^[C+]C.&[VS[NS-=B]NR+43"WDXQD],P1D4A,`"9-Z+85"CV"
M40&KR-.I_6_>-_4)2H=H></AH!W?^X_0#9&6_P`:N2/P[N_^GWU`8_`-1_4J
M#))MK@/E=">YH&P=S#N^9H2(I0A(HA7AB$5.U!RJ=-,Z95#`4H%7.&IO)5D^
MHNVY.[]GY6!BOINS4=?^E/5?`S-Z#1P)^H^"MRN>5CS5R#E5K64:*.G_`#/0
MV$>,\Z.X]1A%RRR<FUFEFZ[-VB5,0)ZT`'*<ZA!-Z`D$!X#I7.C>NUL?#P;V
MVT:O1DVG5U;-\N]/3*SGRNYNTMVGCPJUJZTKR>CX:5,[7?=L2]738$%%<@.$
M#)-R*&766<J&+]I*F`F,GVZZ\`JI=B]HY&1G8.X94).VKJ7%K@Z<C$NS[/GX
M6)<W":<+<*]3:IP_0MV^+GA+2N*VV4K(MXY9=@L\%)R<J21$03'G47,?[6@"
M92^\`Z5GGUU[=RMRQ]MV;"C6+C*Y1U?S.D8U?&FCT*YV_M&?N^R9F;APE+'6
M1#JDOT(F&_;+TS=+[/CV7F$SV:U;W0A#F9N3FB'+6/;KD36$^O=*.E"<2B'^
MEV5GWTZ[5M;#V?BN<.G*<%U?Z&L?K?Z@[CO.\9.Q6\B2[>QX1@K<-$YQ5'7C
M74A)NSE5=.%2E$"G<+*)@;XP$45,<FOO\I@K(J=54P%&O2JZNAT5$F*#V#YA
M^"@-DQB?_!S7M]&Z\OG^E0&MG#L#S!\%`5H"I0$1``[1X!^I4'P)[2<KBC'Z
MFR:CT^+5B(K;7A!M:Q4C-5K+0DW:"?H*GDGRG.]<.4]/2$Z@\!'MK4W[L]ZR
M]J[6AML>A*[%_,U7Q]J.IW_UU;9@SVS<]\NR<<VW+IK735I4H.1/)E6VX<4W
M".K15%9!;5,HCJ<-$URF``$HE-Y?)7+C'V*]?N0O1EU]*=5'A6CX+DCH[;VV
M.^YCNX\I.ZI5HG\46K,.F,P#,S%5%9-O&I<I#@)RG$?06,)]0$X^_P"[56VK
M!W6#FKT7&*X437_$K6U6<K:Y2Q[JFHN3]^CT,(78VCHQZW23YFZQA*#E#D'N
MQ15'DYP'73T@-KK6Z/H]MW<.7MT+4I2_:I1XUK2FFI;'J5W?VUM.T7L7=[=N
M[F7K#C%M+JI337Q&-^MO;<>-LX+O!LB5%T5_<$"Y2`=1^UI)N"B&NH@D(Z"`
M:Z!K6^O;<5;VJW:JVX*CJZ\C@'ZY7+5SO-NQ;\O'Z)=->+3N/5OF1[/\N%5X
MPT%`9AV\_C^PA^5O'?SLB:`DO^+^]HAA_P"BWCC[)>@(H1``Q@`>S0?UBB/[
M%0?"GM7ZD'+H75R_ST%=;$\;Q^5MU.)[2DBD/&C.#-.T5``4W"<&@I(D04Y@
M%,"*+(E`=?(-?-O;O7-OO6[?U0MNGY<2[.R+=FYWEM]N23L2R8)U\'Q)H\44
MJ)6[4J*296[@C<G>`!`0-R?:TRF*.AFZ0<`\G8(5RJ]38[AG=PY<,ERFG*;H
MM*.KX/6B/TL=EV<"UV7@V-M_V[%O&AI'1-]"U?BVR^;S[J48-1<]^\]61%)9
MDHF'=)J`F4I#M5=-3\X!V>6L']H[9ND-VN8_DMV')\>/Q\3Z^W'E;5G7;D)*
M-JZZM^S^!@J$*[BE3&;)ID6;G472<NFZ>B95`$H-Q14*<BRI"B.FH=O9I6W?
MHS8A+>%B3:Z>K@^);WW*Y^?'L2_EXKEY3MZT]WY&#-XV%H/*>T?,;1\&JT1;
M#NZX104OMY9&--ZTL4B8<"F-RCR]@!K6_>TV9X=C]NZ=/4WIX-+_`"/S[^J'
M=V-OW_:Y492NX\VHTT>C?'C4A6B`%`Q1^,`@`B'9P'RAIVU7.A>6IF'E=5RT
M]&I51PJ0\RAOBF\P?9%H#<(^&F]C/M!_F&Z/G9+4!JWNJ+[1W>_])W,?STDZ
M`0A0!0"\>F_AQ#,.ZFPVDBR*^@+064O2>34'1$R,,)56+<_`=>_=@7WN%*TU
M\":W'JN1CXR2^+)@S-^=Q(NU6R!&K?E,0"%-WYBI%*)2I%$W!-/3RA6IOK]W
M'@X^,XQUO/BGJO@=I?LO[/RMNVV&\7%)V81HJ<&9\Q]*BRMQRQ=)>LG6;OP:
M`(@=%$%4A-]J*;4"'$3:5IUVWN6'>[FZK,%UW>E4]RHZ&W/>F/&[FO.QDX0T
M;_YFTM4WX>'L,/6W=4<R&4@+D8K/8ASZRH:-:@DBN>2.91%HX,\%(YT$D#CS
M&TX"'#RUT(]/=Q3P88ME4<*-^_@<LOND[5CG9;WEV5'(\VCFEJUTMT_(:EZN
M^&'=V[4TK_:II.GV+;G:NWJJ0B)TV$IJV44*.@\R1"&`/.&M9OL1Z%^X3;N.
M//@<^LJQAXJE)]7G=5..B_(BCT/A"@"@)3/A!/:V,OR#91_>(V@':/'"_P`E
M]/C^&YZ_B^-J`U_H=@>8/@H"M`.Y=/\`MLL!9$U?S4P$EI235:)N=0`S9HPY
M2@4#``&("BA_((#K5-W!W(VFX\&9.],MKQ-PWR%C+D_*G&K2=)57MU'&TKP7
M>B\=.W+E23?I"FHJ[5.H#I8A>4@G6'M*4.P*Q)NEBW#*C?NIN?4_<=$?33+O
M;;M^1AVNM1<%Y=7SC7CX\18.V&8<O8&]XH3`FH0(M95$Q1`#JE5+S+*AS")D
M0+IRE`0T'C1V\3-N6Y78N+C)-=/R\R[-RSL[(V]7K#K"5J<;G5JE.C2\*+V"
M;,TN%E,EW2BZ=F!N,J=,C5<0.8RP%)IRGT`P<./`>S0*R=@[GUXZPY?T8\*<
M?B:1]Z=F84[F1+)<8W;K;JM'5^'@(*WP6/&W5@EY<160)25C/V[]JYYQY^Y7
M4*U?(\=1,02GUJN6Z="<:N-.>K-:-RVRW@9-S&3;=MTJW48YJ<I#T=`H0"@'
M5L[^R-V$_2*W7_U#H!JF@*#P`1]Z@')-BMFHA'W5?2J*8NE'#>(CUS<54$$E
M"J/P2'M*"J9M#Z=H5,HQ<)=5:GU8-MW<J,)?T5J_&O(=)CWIB]T8@).NZ6;)
M%("@I]WS<IB'13`=3'`H=NM8:[OCD1R:V^1T_P#0W<;$NU<7#L6_GO2Z&WKR
MK_`6=FR66"PB."*"4X6_`,$.\`#$(F=,ACIB7AS',!AT'R5;W;UEPSU>G]?Y
M?`V"[_LY>1V%>QK<^A=%/ET?Q&_G4N'(`]VH`_&`.8==>SRZZ]M9GV91G=E*
M48O5O@<R/4;<>X=JV?\`M%FY7%DU5R59U]DJ_P`!/FXHJKS"60BG0.JS"-1<
M&(?TDTED'!3H*@73T3D-QUJY;MZ4EY=$H/P1KWDVKDK,97IR=R:JW773VC)>
MO,',(!J8O'3]7A7E"[*W;=I4Z7X\2ETHU'DCC4AZ!0$B[PJOMH-O_P"!.7_F
M-)4`J?QE'M2;$^C%8'SBO"@(E5`<BCH.OO&^`:4KH2SUB/O=%&[ET[HRC:;N
M>>*-/46\[&VRK(NRL$I`$5D%IQNR[[U5-XF0X%[P"`<0#B(U3-UN2C@RN*G4
MC,/H_?R+?=%O"QJ>7+CI5\B1'BF\ABX;()9'F!XJLV;@Y1+Z9D0534*!N83"
M<->/FK6KNSN7R[,L3Y/+;=737VZU.UOI3Z=1Q,3&W;&\[S[CCU5E6.JY*FG'
MQ,;WS=3B<F'[=]IZHQ.99FJ3E[SF41*03<I0`=!`--*LG9MSE/+3L=/2G3@9
M>]0^Q;-_MFXJW:Z-_-K6G+31>PQ'GA*>D]MF2(NW[EGX)Z6UY35>T)9>-F)&
M%=LP"6CQ<MU43'*X[HO,GJ',`"7CK6T/:L%<=N_.O6H/W:JAQB^XNQ+`R)X+
M<J*2I5U=%(A5/2]V[<)`"@`BNLB4%@`%@!-4Y`!?EX"MP]/_`%M:OTTTE]3]
MYY:$I4.T/.'PT`[O_<?H!LC+?XU<D?AW=_\`3[Z@,?@.E09)*+EP)&O2)Z;V
MZC*NW/+.]7&=D$NK&EK70:SI".C72Y;Q?$AF:<C,R,-$]V4).-C._*"IDC'4
M`VH`'`:EE8ADP=B[]$E0K&SY\]MRK>3:JLBU-3@^2E!UBW[*K4?KP7ND?RD)
M'VI*NG:"L,U;1+<#MEDY*+<,BB"II`ZH$[A-`"B!A,/,3EX@%8$[U]*<#(NO
M)L.*JZZUK^1U`]"_6[![TVG]GW#:C_>;<>F3^7HNI*FBXM^-4AZG918EUYEE
MK2RM).7)K5=W*O;9WHJ]V@^5B-03=(%4`!736*/*80](?<JK=C=EXZNV;S4%
MA6'K&GS-KPTI\6?!]PW?7:/:NU;IV;M-N<=VABQO573TKKJ^GC6JIX4X&!^J
MTXF;!N9"=F1,SA+CD7<)9Q&ZY0(>.A2`,H\7!,1,J05`%/E'4`,`5D'+[>Q]
MQW3]]?47;MM*"?%):Z\C7;;O7[#[4].WVGM[E<W?)M>9.:2Z8RE6D75J75&F
MNE->(SWD7I3[JMYNQO.N?<:K(0L1;]J3\ICRQ9*/=$G,MH0Y#.YIS$&3%)-H
M06R*HME3%^WG+RA[M7)%W%86.TE;2TH:H9>3'/O*_DN3G<N2G<]K>JIXD#EV
MT=,';I@^;JM'S%RNS>-5R&37;.VJID'#=9,_I)K(K$,4Q1X@8!"ISX3ST!0>
MP?,/P4!LF,3_`.#FO;Z-UY?/]*@-;.'8'F#X*`K0')`0!41,.@<-1TUT#3B.
MGET"HJ*D^F6B9Z6I=%V,O!DV/IT;=-SN->G)@G<Y<EJ&/C*[%YZ/@7R!7*LQ
M&6P287(QDYN/,EWS:'?J(G%NL',42EU[!"L)>M?I[;]0-B>!G+Y8IJ$EQ6G/
MP-W_`+-_4W"['S\G9<ZY*-C*GU-)5^5M:ZM<Q8;ZZEL@,&5OL>1NX?'U1(!.
M=0ATR=Z<03[=%BE'0?((A6A';?I%N';.^W\+.MREM]J[.,)*K3@DZ-Z+B=B.
MUM_[:Q,5=Q;?DPD[U'",FD_G=%55=*5\2]6&*YIM91'<1&R+^14,FW1*H43E
M0`3=XNNZTUY$DBZB(@`Z5EG+["P,C;XYV#9EY5:-4HZ^[_4DS_4+'EN4[-Z=
MJ#@Z.KI5Z<'SXB>7T=)W%-F8E16?2AGZ3".013[QQ)/!4!J@R9H$$QUCF6,`
M%``X`/&L^]E;7_;MLMXF#;I<=N'%4Y(TJ]7N[;>1W+/(S;B_91<DG72E70;X
M\03L-W(X'V[[<<W7M'-%[`GKIE(:<0BBJ++V1<#]@@Y@V-QF-S)(KR;<ABIC
MQ+S@)!XUG;9<3(Q,3IR:=<G73W',7UDW^QW!W6KV,DK-JVX)KG\[=?X$3$``
M3:*&$@:^F8--0]W0`X:U5S$QR5*B4X]P<QT_)S!H(#Y>&H]M`9=V\_C^PA^5
MO'?SLB:`DO\`B_O:(8?^BWCC[)>@(H)!`#`(B(!KQTX\/+^J%15$TWP)HJ#D
ME<KT5U%F]/=CDN9WF8`MS#UMKWA?UT7]&VS"VPB8J9IDDX)V3ULJJ8>5!$C(
MYU#G-Z)0)J-3+IEYGF<)Q:/OP,Y[=N5G.L5_VKT9^VB?ZDSFZ+6O#$=\2^/\
MHV\[MB?MM^#6X(=_H*B!"D!056JP"!'+,R>@IJIB8AB^6M,O4OTNR\[.O9%A
M*$)3KU)Z\75<.9VZ^W_U[[=W_MS'P7?N1R;=F->M)+2*K3YGK[#+^,+8=7O)
M3#<B+CY/!!L^CBNC`F"C(_Q';,ZFG?)"`<=.!=.-8T[=])7@S>=?NR45X:O^
M!G[>_438YXJ_M]UN_P`VDJ5_!LQDM;SYE(OM8U9PTCY-\U14!,PD?D;N@$SH
M@Z!WB9>.HAV:5D[L?L!X&]QW#&4EC)_C\/\`4Q-ZQ^LN'+LN[LNXW(?N9PI1
M:OA1<_X&0;UV]7YGG:CF)AA2S)>[+JMZQ;UD+Q=PBP'1;07R6NZ09"DL"1#R
MY>0ZB:*8F54(`\.`5MI@=-RW&=OJ4(Z?,J.O/373P.+/>63M2W:\X1;4OFX*
ME6W[378/6[AHZ>-7**K=PV=+MG#=9,R:Z+A!91)5)=,VADUB*)F`Q1#4!`0J
MK=2Z.GF8YNWNN;C!4MGCJ0\RAOBF\P?9%H#<(^&F]C/M!_F&Z/G9+4!JWNJ+
M[1W>_P#2=S'\]).@$(4`4`[[T8KSA;7W,7#&R/J/K]R6#)MHDC\0[ITHS4(X
M<LBE,(`91P@/`.WAP"H2:46WP2(IM/J7%$F<RJ#9\X%@"OJ;A5)8H%*)10(J
M`]^B9$1$Q$4E=``W8(!6L?J#V)+NS=I7()?M'P4G1_"C_4Z\?;+ZZ879OI]9
MQ]XG&%]I53I7\VA=&T3&C_,KV=8,6XK##(%<&1%,#(BFH10``ZAM"$4,8O``
MUK&FT^@=_;.[;.\/ROV-M:Q4M:TY+II^9ECU#^X[MW(PNO;[O3=^7JJDFZ\*
M4;J);/8;I"^;C@'K=-$$Y679K.C*<"`V>*<J:IA*`$%`Q0+\%;'=I;+EXN3=
MLJ,%9KU1UUI6FNAJ+ZT^H%G>.V(1OT<KEQ.+CK_)+CKIQ$W=2FSY"R]B61W3
MLS=>.O.T72L;W+E)P*@L7H(K$>H)"8Z*R(I\Q2B&HDT$.%9;C\MI0?%(YUW:
M9>1<C.M>IO\`B09P[`\P?!4"0K0!0$IGP@GM;&7Y!LH_O$;0#M'CA?Y+Z?'\
M-SU_%\;4!K_0[`\P?!0%?_I_6`1T#WQTH!YO8^M&#@E$QG;ANHUNU\VD"IZB
M4B*YQ%-X0!``.4WQ1[`"OGRI6[EKRE7KY^!=/9>Y6MKW^&4I23BJ.O"K\-17
MC4H*NUVZ:P"1-4"EY=1,J&G.0Y0`/VVOZM6-N6R7+\HR?3TINFO^ANGV[ZFV
M<';8]5RV[T)IJC_E?U5]M.`OK9?$NGCC(K@PKB"48R0;I]V51-1TDX*J',`G
M`3@4A>.GFJ2QLB4E'3J;21]V7ZK]5O,=J2_L[@Y/_G5%65%6GNU$C9]6%Q?%
MUN0,"BAI84R'[LS<I02#0ZB9%`*(D*(:"(5=&)M/D?73\&:L=_=ZK>LF-S:+
MT_+3UZOE?Y-B6]\,!E&P=I4/=KZT9%>PLFRH6NUO!)NJ:*:.FPE=J-W3LA.1
M%9<NG(!M.?30*K<8QBE&/THQKEWGD5O2JY27$8*#CKIV!PU\@C[PU$H\N)6A
M`*`=6SO[(W83](K=?_4.@&J:`!#4![.P>WAY*`=EV1LQ5P_,=X@ND)+H<BW=
MF2,1-=/N"&/ZJ90">L)\=#"7700T&H-TUY4)HRR()W,>E4N?B+JC?5BMVBB*
MQ4721T^?G#O2F[HQ2B(`'$HB/9VU9^][=^[D[B2HO$W8]#_46>U;'CX>9T*5
MJY636NE&M.%7\!<^78U-UB:'75$"&=1\%WZY#@8Z9-0`IDTC<NG'@/'RU9UC
M;;MK*T2^/^ALKO/J%#*V.6,YNMQ:5X:^.HB5:!:)LW(*K%9*E%0$S''O054(
M(@B"(@`\ICD'4`K(NSQ>.D[G-<C2/U;W2U>LJU;_`*T='X57&C\!-V2IMY;N
M$,P_?*@DLQ=PCJ-:*N3`!EC.U.1GW9/C"H!O_+5>;4G5<#7>5^4K:C<\-!C4
M.`>_IQ_4J!\33ZJE*$P4!(N\*K[:#;_^!.7_`)C25`*G\91[4FQ/HQ6!\XKP
MH")50%0[:5IJQS7O0Z7TF;DB8+<'-LWSTC60G;,>L85$ZQ4?7W::H'4:)"80
M`[@R0ZE+Y0`:I&ZUEARMKZF9<]%,["V_O^Q/<&U9]FOA[423K6<NE$KA8D35
M35[I-^)#!Z1FQ3@74-!'O5A.&G/[G"M,_4"VMM<KF15IS?#7F_<?HX]*K^WW
MNV,.5KYJ]+5/:E2I9U\`\;N!`XEY3)E$J@CH4JH$X%,(`(^D7LTUXU3NS\:Y
M>:N6Z=,I\^6BXGT^IN[2V[;[ERXU^U<:T7&ON_U,#9BO96PL4S]S.%CC&A`R
MR4PTT$"'358K$+W!1](BBNO*/DXUN)VKA7K6+"[+IZ5'QUU1PM^Y_>=OS]YG
M=Q^OZ^:IS][(C<BX2=R,@[0(9)!T^=.44S&YS)I+K'5(03"`"(E*;2KP--9.
MLFUPJ>.A`J':'G#X:`=W_N/T`V1EO\:N2/P[N_\`I]]0&/J`V)?A[MRE\7_T
M6LFX^PG=,?8N=]G&2I*\H5*/;IJ_?/;LPJ25'[ZX;B,O&/4E%4%U#`;0-`#0
M2A2KCJA24FH1XR:7QT,U6XGM1ZB+Y*Z8)_:>TC>Z@L*-_6%)+IPV),MR#13E
MDIRW'YRE80\T[%(3\IP*/,/*<HA7AN6'#*L+7YJ&4O3SO''[([JQ\N\IW,7'
M=9J.M?P6C7M6H]-9EL/,793VN[=K;E-;=AL5SU^NY:'`KV*N&]2(JIR$DD]9
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MH)OJT!BZ@*#V#YA^"@-DQB?_``<U[?1NO+Y_I4!K9P[`\P?!0%!'02A[H_YJ
M`Y@!>\4*)@#4AM.`CJ/*.@</*%`;4OIX;P)0>BAM-R?(0T%DBQ\8M(S$.=+(
M[IH966QTHV4C$W:*'*5*/F(PRJ9RB)=#@4VHZC4V1*S'&;O+J5-2J[#;W2WN
M,;V!<<+R=51NNE/\-%M'V56R\O\`B]P.V2\;?R'MJ>QTU<"*"$HW+=UDSZT:
MN+.QIF*4."YRIO%PY%>77E)H(:<:Q7W#VW:S[=S+PY1X-]-/8]&;R^BGJUN<
M,^SVIW+YD76"A*NC49)]2;Y:,^O@@)J3D;=L]1FN22GRW$1\9<I!08I.$U6_
M**.G.=1`PE`NGE'6L7]KW[D;<=ONQK_NM-?B;D>J=W`AMU_?\2YTXUM6WHZ-
MM)5KR/?AS#-H[&HNX-PNX="*F\QO9&:9[?,0NE4'3LKI1ZH#:]9AJ;F%FF4P
M@9(#AIR\?+6=]LP<7&<9]*.;_J[W_G]VYL<3:Y36U6U2Y+Q:T:3]NK$J>)CS
M$_LWHSXWL2\9EG)9(W%9+M6Z9AL[*@=R";=92<548)F)_LK9GWI4TQ)IP*(5
M=LIQFET<$C6_<\FY?OJ,M86X],?=Q_B:W)"&7<N09IN&@*"(!J98"%#7XH&.
M?T2@'EJ4IIU246O$.19N%6RJH!S"9JN1PEH.F@`<G#7WJ`RCMY_']A#\K>._
MG9$T!)?\7][1##_T6\<?9+T!$_H!VOH7YJ_L`ZJ6T+(JD='R;1+(GWN2+>1(
M0R:3"Z(M]"N7J*ARF]6=,RN^\25#XAP"@-C]U*,5VYNJDLCM\>6^F3<MMTCH
MJXCP*/<F>97PM<3`)'Y1BBI`"T@ZAQX%)Q$.(!P$-/DRMLAN45;R(KRW3_0O
MWL;N[+[8R^E791QYOD^#;_0P%9]O&QAA?;9%7-`II7/>5DW-.*.G<<LB\CX-
M1TL:/CE%U$B]VHFF)2KIG'F(4`T[:Q7W+MV+M65^TA'Y6N)O7Z';[G]Y8&X7
M8WW+]NX]*<M6].7%^PL?).*;FRZGML_L<M>4(\O12XK4-ZBU(C%J231^9P_E
M)-S\9G%MT"F-WJ@:F*&@57>T[=[H3Z%J8H]>,B_@;[GW]ROMJU!=,4_&.GXU
M'9]J#RPL.9%C-H&*S14I]Y=L/KQSS>W=-E$[ANQ^W`!BDC)\Q3ILPU3$5-`(
MD&@<1&L@Q4H_+)49IS=G=O6UD7WU.XNI>YO0U'G4B4@%M_6\%2U8N)A;=/N"
MR6:*BH),J40R:_?&[`J+!,GH$0`PB(`'`!$=*<SXOYA$]1)BAOBF\P?9%H#<
M(^&F]C/M!_F&Z/G9+4!JWNJ+[1W>_P#2=S'\]).@$(4`4!)]\*CLPPQN[WY9
M!=9I!I*0V(,,3-R0MJ.%U6R\M-7"Z+`(2[19(Q.56VDE#KAKJ&I@$0T"G'0B
MG1IKBF2#-WFW.X]I.9IS'R@JREFW`T/,8YNQT5([6<M@YCJ)MU7)-04D(DQC
M(J@4>4-`'CK7Q7L+$=]-11<E[?\`*R[$;4[T[<X/11>@]UTX<$L++QBAE)NX
MASQV7<<(SJ4<[^UR45,11U$9)L0@\%&)RAS"H&@E$:^J[M^)UUHN"_0]H;WG
M9-^Q"[?N.<Y4>KY:(;<W:X58X2OYA&O7+M>2ON%D<@K/&J93LD%Y)^X!K'E4
M/IWI6R1@#0-1$3!4(8MBPW*TDI-?D??W!W5FWH?L;LG*U;ETKCQI05!'=-&P
M-RVQ;*&*\^/&S++69\571(8_%58Z*^,H-JS,>WII)HD=$$Q<OR)F=J'*)E$3
M"`>6O2A9$?ED[O-FIDO*V7%FW==5G.7#=X\M*Y9RV7;MJ(F:.G$#)NHM9TU,
M/$R#A1J)R?ZHA0D+:T$.`]OETH`H"4SX03VMC+\@V4?WB-H!VCQPO\E]/C^&
MYZ_B^-J`U_H=@>8/@H#D&HB`:@&HAZ0]A=>`',/'0I1'C0$XK&G34Q8EL(VU
MQ^*YF-7W,W+C-QD-9%@Y0"#RO'O4U'YHMFBH8BJL_&I`*1N4=1,7@4:]584H
M]6FIZP4%\TJKW#6A&$U;5SHQ#E)9"<92*3268+I*-G46\;NNX>Q;UFX*"I'"
M*@]V;]KQ#0:^/,QOEC375\"IXN;"W&3LW9\-4/@8EL**P\CD6*459J.75HP%
MW)@8P^MPR4U'@=9L"P@!"J)N3Z\HAS]NE?';L=,T]=&79MN^XO["]C9$I.$[
M4HOW-48BS,N`)61S3C;#%O-0N*ZLE$@)IHJQ!9YZRC<B_?'!J41%91%)$WI"
M'`!"JF6G?CM\?_$;8N'?`\MJ#Z7F[#`CNVH>>Q_8K^"M!N\=))?*$)E:+9E?
M.)2/4`#`T7:K)=T(%$##Y:@>4];2KQZ?XLU^.G+P]T"B(:\-1`-1_7J)37Q"
MA`*`=6SO[(W83](K=?\`U#H!JF@.:9#J*$3)\<YRD+_RC"`!IKY>/#WZ`GT1
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M+-@$W9D1_M\E'-DW!@>+RYV&JA2Z`74NFO&JG'@C']V'3;MOQ3(:2B9T5%$5
M2"FJD<Z2B9N!B*)F$AR"'NE,`A43YSA0!0$B[PJOMH-O_P"!.7_F-)4`J?QE
M'M2;$^C%8'SBO"@(E5`'9_EY?)]36H-55"*?2^KP%-8"QUEEO=F/<GV[:]R)
M6LRNYII>;1HN$.W69'!1XV6DB@""!UD0,0I#B`J:Z!QKRSK"\BOBC[,*YE86
M5'<<=],X\T2Q,,7B>>DH1^*"Q8V329QCQRL;0R24F4R)N<H]O=*J`(%'B`UK
MSZA]E?O,!WWQZF_BSLK]IWKO<W'M:QA9\JW(2C'5JM8Z<W[#,^:K(<0!X)R"
M>B+=56-4`VHCHB`G26<!V:G`_,`#Y*M;L[85A6XP>K4_\C-'K#WW>O[7?FI5
MC)::^P0+NOMRX;PP7=EMVI%K3%T2;4&,:S0#E7=F<D%-)NV0*`E,JJ<VFO9[
MM;-;'\F(K?L.+OK+O$\_?/+;JFV_@R+KD[%&1L,W<ZL/*-J2]DW4Q0:N'$1-
MM3-W1&KM,%6KE/B*:[9<@^BH41*/'C5;,+F/J`J':'G#X:`=W_N/T`V1EO\`
M&KDC\.[O_I]]0&/J`=SZ-74=?].G=?;EX3QEY'!^0#IV1G"V155%G+6-.<K"
M365;%`Q!68)KBLFIIS)B34*$T9=+J.S]0_)-B;1-YMS8TFRRC/%^1XZ%S)M_
MR^R04<P%SXRR.@G/VV]:O&ZG.L9HU7!NX.01`JA..@B-0T/17WRI4E)=-G=U
M#[LY].?MI(S>V,%;89RW6:S:0$B;U=G;7<K2)S""ITE'2A!.!T3^@;B:J'@6
M>X5O7[K/7_;THM.7+\C+6Z[KVW'L'#>VMO<87NJ:;3UTKI3V:$7GJF]57%CZ
M]8"(M16:F+@LJR&-B2-FLI=PYCC2D+(2"A9*X7"Q@05,8RPF`O*8Y@'CPTJM
M1@K<YTX.;?Q,;9N;');NK^>-3+W10W;CE["74SNN\84T6KC;:+=LK)_)IE73
M52*462.P7(!@[PB[8R`D$.P0T[*G*00W+MFQN6Z+AN$P'`9N9D)3101,<`>N
M5%PYA'B)M#T!;U`4'L'S#\%`;)C$_P#@YKV^C=>7S_2H#6SAV!Y@^"@*Z\0#
MLYATU'L#ST!ZT6BBIC<IT=$_C"94I0^IKQ'Z@4)H-*:KPJ2]/#Y;K97(&V[>
MCT['!5G=Z3&"KIS#A2-T,L2X)?%ZH7*^MQL*1^9%\X9&4,4--#DU\H:4_4GQ
M<R_M^<LFTJI,^WTW.J)CRZKZ4M&X%YS&V0E8J\H<N.#2:[6,GKI>1$C#,EV;
M@W+'?*#%<XB8JR95""7RZ:U1]QP9Y5BY:MJLY_\`$RSVQW]3>L3*W#^G8N1T
M]^G\20M=EU'VXQ&(,NY+E5;=MIY`23Z4N-=PQ:-V`GA'9&;V17,<$U/5G"A!
M,;4"J"&NHC6(=K[:S<+?WD.+2ZF;S]W>JW:>=Z;;AC0E6[TQT_#4CZDZCL3N
MHWH8GP'9\[=&;;ZR?D2%LQS?C?F)"VU%.I,B8J1I3@*CMNW;!S&,0`('D$0[
M<QK';BFZ5H<_+_=<K]N5NW].M!.WBF]XL3EW>+![4,?RZLS:FTRW(3'TZL0I
MRLW%[QD6U)*%2(8PD.9$3_;!+PY^'D&OLQ[?EQ:\68_N9$\F[.Y/_F9%G,@Z
MU'1NL!M1X@F;377CIP'A7N2G6)%2:`J4Y![0`Y1+P]X!`.&M`9@V\_C^PA^5
MO'?SLB:`DO\`B_O:(8?^BWCC[)>@(G]`9,PUD5[B3*=B9*C@%1U9MQQTT")1
MT,J@V7+ZV0I@'4ISMC&`H^[0&P'W5=3ZUL,7=TY=\5E7D>V6^Y7;K$-H.\'#
M0TC;J,W8Y2VY=EH7FGJ83LGFA$CE-J)!T-J72O*Y6FGBCZYNUY:\U-PT'CK(
MW,&WFV/A=S+N["G)2][5R%)REO6:*38L"WC'9TH)[$/B&5(9%9LGH9,3@<X&
M$=.%6[W-M+WK'5J"JS-GHUWHNU=_C.Q/RU5<?PK\5H(GS9U&G^T'`"KME=UI
MV!$,)"[+*N.0F6P'G[:9M"&!F-L%5$CQ:3E&YQ)SI$$1'L"J1VHLVW%QOQHN
M'P,I?<3@;%:O1OV[JG)I2HGHZJNJY\7^(B#I/]2V!NO;MU0]X$E'2%M6K@G$
M\K'HS4NJHO)SDM=`>IVZ^`PG,9.3?N7@_:P-S%$P5?JIRX&G=V5F4JV%2%/S
M(`5^78]OR]+LO62444?W7<<O<#LRH\RO>RCU9T;O%=1$Y@!0/>UJ)Y%I4!0W
MQ3>8/LBT!N$?#3>QGV@_S#='SLEJ`U;W5%]H[O?^D[F/YZ2=`(0H`H"1EX7;
M+\7B/JD6&I-2!V<5>]LR]C/42'Y0=)SQB-0*HGS%[TB9S@(Z<0`>`#0$VN5F
ML<;EBY8V$YMN]M:&6\79'NA?;ADJ?,JDP5:K2!W:-J2KTPI_N3<Y4N0VG.D8
M!UU+H(#J>.L3R&-8#&]F1<C;,W;]A[?)NV3H,'BD@]+=9DQ37>)F;"`N(>4<
M%,3F-]LYRZ`/#2E2H8V7<L^7;CPZJ_F)PRO@>Q'[/;[F3<7DNWHVW<-6:Z?W
MW`&D4C.[K=-'XOK;B8IJ=8JRXI*\B:Q1YA/R<IM!$1"+J-TR;E[+Z)*D4J_B
M8BQ'NRAL@L]_>Y^YEPCK.L7%3B"MB)^U@K#VRE$R24:4H=YW""KQ14A3E#30
MVON<8%/-1+?\JG,WY>TPG^YRUWW+)I^ESZ$?S+QR74X_'U*H''RT!:PAH0I]
M0],1`"Z^D&@B'$.P`X4!2@)3/A!/:V,OR#91_>(V@':/'"_R7T^/X;GK^+XV
MH#7^AV!Y@^"@*\W+Q[=>&FNA1`>`@;WM!^I0$S_8CE57-72"^6K"G'\;G_I^
MWU#9$A9%%07+]&R)%\FT>*E*F(+NXN.=E*1=$1[L$5-=`U&H'V6_H0JZX'^T
M#J.+X\SU$7=;VU_=7`O;>)N&QY=B+AO9.4VL0HD4M\6(NDJ8"2\@H0#J-Q,4
MOI@(A7O8_F]QZ.-N5N2N.BY&2KCQ_/-]Q&ZVWIU!&78M,=1<BVF8^80581\0
MRCTP=R3$XF3%8YV?I]R(%%/MKX;O]2/O+OM[59EL7GQ?TVVU^"J9JD,G[8=J
M,QCS<?)W8ZOC<-86VQA%X7L0D<FG$JEN9BL6&NF8ES'%)^YC4S'U+P,00T'7
M6O<L\:)W=Y5>L^BC<>19AV@><S_NXR([F#`N11P\?1L<B<Q2&Y@Y2HN)$X<@
M".A=*(^.Y];(:NHCH'D#3]7E*!OJ<P5$D*4`4`ZMG?V1NPGZ16Z_^H=`-4T!
MVMU.Y<-UM.;NET5>7MU[M0I]/)VZ4!L0.B_N(Q=`[*[IOG(3\4\3161\70-]
M/TP(";"V;^C'5M/UG(&YA%%F[2`1X@`<NHU!GT6.#+QC-B.1-K^:-SV0;:@#
M7?B-#'EUW-@.^(=9K(Q-ZPE[E[^-4%<G.45XA!44SE*&B9M`'0>%2S^EGT1B
M[E(Q^IGQK,-<DC>FVZ`?PJ<PVN&T98DR)$S+JL$I6-69I/Y1FF)A3?,'#H"D
M(`:^@-42'_E?B93CC8RV%?N6E\IBO#NRR-V\1^2MVF\P36AC3$LY<Y<66B_`
MS>X\WWZ1RJ:VVD#".>[6-"HK=VHHL"8%`HB/'2JXN!BZXH*Y)6]85=/=R+%M
M7*%ZW3MDWZ;M;YDC1SYSBUS$1*:;A1!C&J76Y%G"PD:)M$C&C6!A)R$$`,("
M(U%<3SE]+('#A057#A41$PJKN%!$>T1.J<PB/;Q$1H4U_6>>HGH%`2+O"J^V
M@V__`($Y?^8TE0"I_&4>U)L3Z,5@?.*\*`B54!4.WL`?<`0$0$?('`0[1HR*
M2;H^!L]]A&S;$64>@U%V7B>T6$D_OG&[K(%SRK]JBC--<E6L!GZS"*.3O'!%
M&`I"':'>$.'91%2QL?&IJ]6QD[;_`(VN*XV4HV@4'24U:#E*4G&0\YT@8M'G
MJZKA1/E,"8HJ(#Q#40,`59N^XCR(-1XZFQ/HONUO;-PC!O3JHAT?-V/'ERV/
M::\:P>/W+][$O7C5)%1$RRQT"I/B*F`IA<'(73B`#R=H:U:6R[:\7+Z'Q<JF
MU_J'OSGL$8V-;LK/^9@C;;B`;\W,6K:[1+FAXHRLTZ>%:$=&A_4S:K)KIJ&*
M.K1N4XB)@#TBZUE2S9<.E\J?P.>>]W+N1GW%EJDFV)S\4M&X)R9MUVWYIM7'
MC>U\AVE-2&/X^ZV"#9,;LL5I(NX\B4HJ@F0[A9-\V%=/GYP3Y]`&OK+'R(1A
M=<8?20=*'@5#M#SA\-`.[_W'Z`;(RW^-7)'X=W?_`$^^H#'U`9_VS[8,V;P,
MRV9@/;Y8LQD#)=\2*3"+AXMNH=!FW$X^NS4V]T!O#P44W^V.'2YBID*4?*(`
M(@U4D4]?'<SB+'VW#9ATH[`N&PLZ9/VB8_M^&W![B8R.CI)ZTNZ*;KD;8FM.
MZ4@%8T';:[U4'14CF(82)E'0P&"A(K48NJJ+8\-9EJX,;=.3JG97EE5AA,.8
MPD$(*1<2B@)-U):`66<QP(*HG!#DU#NE"&Y=1T$/+7VW,ISO?M9O2*5?'5:%
M0L6;SM6TTNBY)T7*BXNGQ(>6<;XL&_KE)<5GV_*1$K*.Y"4NA]*O%'1Y-_(N
M!<'63(<Y^1,G>#I[I?J5\*\VK\VE:Z>U<F?"H.$YQK6'6Z>[0?R\.QOHVCX%
MF]SFT#=]W-B8]WQ8_<8H1SL`=XG8SJ59N8@D1.I"DH1O#R:[TJA')@Y$5TR<
MX@01J),?#ZEOAP,\[*+`OW</@W+F/]TVVVQS)OY^8M=\A&9'LR!>J$,SD+AM
M(ZK@DE')-UTS'>LE3)'*/.4@%&@(VVO`.`=GQ@$1YM=1\P"`<!"@*#V#YA^"
M@-DQB?\`P<U[?1NO+Y_I4!K9P[`\P?!0%!*)C%*4.8QAT`/?X>^`4!Z2LG)1
MU,D&@`(B)C!P``UUXF`--*`E@>'GVEWQM4N:5ZSFZ>0)@W9S@.P+Y^]N2NI'
MU.=SW<%P0B\&SM6QX9T7UF2BGJRPI@ZY.Z56Y2DU#F&A,IM*B(_F8-Q(9>WO
MW5N6M"RX[&:-[YW_`+0K<LFSVZ<>PMV/D+G3=M(M@@CRI)N56X@50``"F4.;
M4-!J>U<N6KBN6J>8N%55:Z<""^OKYUK^*U)C7BOLV2MO[/\`87AR"C)J*6R1
M84/>U\F^2B-TT&+>`C3-8N4D&I0[ETYD'(B=OJ"9@+K[M>'E]>0Z]+OK5T16
MY;MO7[*<9S_["^Z25.+]CY<",=T7=_>)^G#O>LK<3F?#Y,M60U9*V^[.WY#7
M'81919),;XM1HM_L[^6B4B&'N#<O>%U`H@;2O2M=>91E.4$XQYCZ>[_H?8WZ
MI]Z9+W\]*'>=BW-+/-=YR-SW#@_)LPC8V0(&_9E`920M!@Z?'3*,BH)#B@T<
M)%/P$I53%#4!(1&LT8CRUMYRE>^%,Q6U,V)DW&\\]MJ\+5E0$KV*E61RD.D)
MB&41614(('243,8BB9@,`B%`8I4465$!6.HH)>`"<1$0#7L_5H#+FWG\?V$/
MRMX[^=D30$E_Q?WM$,/_`$6\<?9+T!$_H#[ULVY-7C<$%:5N,%I6X+GF8VWX
M*+;%#UB2F9AXA'QK%N8PE)WKMVX*0`$0#CJ-`2XNL_C^'V*]&/IO=.W.S.TK
MBWD1ESW!F)PK$+"[?8DQ],#(K/[>.]`"@LI+R$D@U<%^**K03%X<:A0]%<DO
M#E^1\GPA>8[L6ZA4EA>:F9N6LN8Q1=$_'0[HKV6BX9_;Y"J'41YQ63B4'+=V
M8@_%3,;WZGMR=OZ3RBG&^LB#E&ZO!T_(2MUZ,7YGOW<IN,SJ:X[.#`]BY'+:
MEJV;&7J#J5(BJ^6CPGOO4,<IT'*SXYP/S>F0@!Y`KQC;C;T@DD7/W'OF=O<H
MW,VZYR25/`7)T9AVV;U^D9O)Z4V.+M@<+;[<Q.FUY1C[(LPVC[;S82VYN/EK
M9A8)^LHD#5RU%OZFX;@!U0%0BVAB@.DT4EPYLMA2E+ZJ47"GA[?:1=-TNSG<
MKLLR/(8IW-8BN_$]XL%5$D$+AC%TXJ=13-RED;;G$R'BIR.73#G(JW5.`E'B
M`#PJ8B)EH"AOBF\P?9%H#<(^&F]C/M!_F&Z/G9+4!JWNJ+[1W>_])W,?STDZ
M`0A0!0&9MO6:+GV[9KQIFNT%E4)O'MW0UQ(`BJ=(7:3!XDX<,5#$'BFZ12,7
M3S4!+;ZU&[O+&VO>=B?-RMC.W^V[=W@7#^<(:019+LG(77/6FQ^_-"&N%,I$
MU)F&?`!E6XF`W*H`CP'6@)%?1EWV8NWIR-D$P]+O9!'&>!GUEWMWS]VPFRW"
MNJK*)M[B9.TG*7,F=<QD7`&#0_$NH<*(^ZS*"M1;IUI_Q&)^M!U5+.P8C&[>
M[7;_`'RY]Q@_OZ$5;>N/G</;<=<4PH]B9*;<."(BYE&H',<B9B#J;00T+0CF
MSC=:NNGF<-/`3[@K/^;L3>&QWB9VOEU+2EV[DMPD'ANU;BG`<%<KVM)@JXF9
M%J)M._:M5A4(B)/1+J`:\*'P$._41``[LJ@@'E#4??,/EU$:`X"`".HD`@_Z
M(:AII0%:`E,^$$]K8R_(-E']XC:`=H\<+_)?3X_AN>OXOC:@-?Z'8'F#X*`!
M`![:`>EZ%&YG^Q;?'9N(+S>`?!6[B,E=L^78IZO_`+"E"9.:J1$=<*2*@BD#
MR"G5FZQ#<.&O&E#T5R25%P/EYR?9[Z;>\'(FW_<9;D_)-\:Y#D2VV^>H&9/Y
M>SHV>4/;5PV^\4(1&4@)6*2(<@")B:FTUX5&,W"M.9Z0Z+U8WJM>S3]"5-TC
MKOM7?8ZW9YI0!6:CI["%ZG69RI3`XAIB/8E1;-'S0BB@%!$R(<NG(!B:<=*\
MY0C)J3XHKL=YR;6#+"MN/D.#6JUU7B1?^HKU`Y2[;C;8JL=--"4QI;Y\7S-Y
M))II$]5B'"Q3,8!'D$$P3,<2]X;CP$`J<M[S;GL%T=1G!$W8/A^.E[<L!+'N
MV`F\KY3O6^):W5#2D/%RMZ,FQH]E<CQKWR;*42.UT,1<4Q!0>73LH2-N3J^)
M%BT'W!_RX_!0@4H`H!U;._LC=A/TBMU_]0Z`:IH"H=H:=NO#7LUH"4%T7%,A
MY9Z:76#Q+;:0S[W'6&L>YAM:!$VKI<UL7([>2[5#FU[M$L:V5,`AV#K0GC.4
M/I,I[$.J#.7;B_(UBR^6+G1>-L-N[#L>RIF=56"V1F95-:12@V2IC&=D2,0#
MD.74X!V5!I-4?`^G&R)0R(2=**2'O+JOB3P$EL+S=)OF@Q=QX^F%YY9)J+;U
M]%'OHPTN_>*%!!-PQ.H*OI<>8-?)7SK$LJ?F*O5[V7GW%GQEMD+%IZR6M/\`
M&A&*W[=3>[KTN`]LW7E&Y,TS5N2+]G"H.93UR(MZ)4?+':-$G)2@U!T9$2E4
M[LO/H`!KI7T4+#A.=N"@N"5!5&^#,;;!'1!VTV,<'R&3MZ&0+DR%,LE>=NI%
MV39S)"-CFKA,P\QFR+M<#$`>!C&UJ)%W9M49$Z`>`>;S_K^6E#RHJUYA0B%`
M2+O"J^V@V_\`X$Y?^8TE0"I_&4>U)L3Z,5@?.*\*`B54!V)&`BJ9Q*!P*<AC
M$'B!R@8!,40]P0"A!I-49M).AGN:QY8G39V[WA>$JBTL"3S>[Q1)R!CF-'L'
M=]VVT:,22AA^U)MQD=4S@(>CKKY*$8MP5$]#V7!LNO\`VOS>^.[XBTYUU!RR
M8N,234>V0<Q<I:LZY5E)!-%8HF[YUR*F(F4H>CIK5'SK<U!T1F/TORK<MWA'
M+:Z:JE-/B6S:4Y<MH9`VLQKENK+Q5],DF5P'YBODTH-^4B:[H[8Q153D60*B
M)Q``$#!VU0;$/]_S9?6N'N-F=_WEO!=VXT_+ATQT7#C^+KS,]XIP`39W:F]S
M<+D)1)DU.O<%FXJE%$A2/-!,)K^IR$:FO]M`4$'1BG`.&O'R5>EJ;G;U\$:6
M]V;G?R]V=U=*C5\$D1L.N7/-7_3.VGG7=$71F0N288/ES\[AT]7O-Z0[8/*'
M=%2T#W./NU,6JW5U?$ABT!4.T/.'PT`[O_<?H!LC+?XU<D?AW=_]/OJ`QZ/`
M!'W*`E.;?=V-M=(3I'V)DO;TULE]O7Z@;C(<?<5^R[0KB]<;8@B@7MV.1LYP
MB912*31>&,L<5!*"SDQ3`'`*`BZNY!]+2+^6DW2[^1?N7,A(O72IUW3UZ\6.
MN[>.%5-3*+NG!S',(CJ(FXT!L*^GQ@5OC;PIFZ:XV<9&*S>:<>Y1OB2>LR@F
M_?-6;U%E'(R2YM.]/'M6A@3#W!T\M8EQ^X,V>Z[ID2_\1;C;QX/GU1Z4U3DG
MU<3)CQ<:Q?V[$E]<=NG<EX5?4_Q?RFO%-R^CI_HAK[P\>'ZE9AR)=5SW12,:
MRZ=.GPU]]64`1`P&*82F`0T,&H"7R@8-!`>8I@`0XUX$H_1C+JZ1]E[0'>,K
MK+D"_,RR]J3V/9DTB\`UF2%KO8Q:#@G4B1=13UUW#1`)%*)@`PG+P[`H!A;@
M&NG9P'7CKKY0[1#36@*#V#YA^"@-DQB?_!S7M]&Z\OG^E0&MG#L#S!\%`4-J
M&A@-RB4>&G;J/N?J4!DG$3""G,L8QA;U>JM+0E\@V9&W2YT'1O;SZX8YO,*"
M(F(`%)'J*:CJ``'&@)1/B(^H#@O,]MV;M@VPYD7G,;8X&P(0,:VZS3+C^'AL
M<P\K#1:D8^8G!L60*X5!1VB(&*JKRJE,)M:`B_8<AE;LS-BBWE!!4\[D6R8D
M0'F(`IO[CC6IBCR@!BFY3CV5&*DY)1^JH;Z4Y>"?Z$M_Q9N7LDVCN!Q9A"(E
M&[/&"F"+&@'40#1L[67<0;5N85$W3E-5=B)ATT%(Q#&#MJT=FWY;CW=NF'#K
M4L51@ZTHZKBN/->PR7O.RO`]-MHW272_WMR4E2O4NF4EKHOPXU2(:!5#)F,`
M'Y2F-J;AS"&AM=0U``$0TJ[%P,:R^I^\<IZ=N_Z/V/W)=4S/6#+Y)8S"\3-0
M,2PNIY:Z%OWA#^L)L[G3.R.F99ZBW<&(`#J7EJ)`QWU!]ZTIOHW:9%W.N[59
MV:M>K>`8(0:7(Z43;V_#MHI)W).>8WKLD\%$RBRHB(G,(>Y0"(W+YR]_=3)Z
M!PT(F5,/=$1`H<1H#+&WCAGW!X?]K6.OG9$T!)@\7][1##_T6\<?9+T!$_H#
M*^";E:V9FO$=WO79&#.V,E65..GRI!428MXVX6#M1XHF!BBHFV*B)S!J'`O;
M0#GO7,S==V:=[3X]U7Y9>4"6785IP%MW]C^?"?M>YK6?,@G(AZF8#G^3)=(C
M\R#UL(B9-9(=>-"#=%4="\(U'_>YNGWCYW5*L1'"6SJ^YTKE,P%(DN[,9R`'
M$X@GWAB16A-?VU":*<^`R&7-N1[8)EG+V3;(;9,P[N5R#>GKK:YGJQGSF6^6
MY:32?1#E0ZBL>=(71B@<@`!@((4/)QN/BQ"$/=\S:5V,[PL23E;/F82:+-VQ
M*0T@Y93-ONV[DKA@JPDVJJ+E)=D)"@4P#Z6G$*@B>*HB4[9W5OLSJ2]-[<YM
M7ZH-YV3<F;\:X]>7MM*S!.0Z43?OWY6@Q;'80[BXV[<P/G]QJ&,BJD(E*Y*(
MB;B%1(D3@=#<W,/,;E``$HZEUX#YM`[.'#A0'$WQ3>8/LBT!N$?#3>QGV@_S
M#='SLEJ`U;W5%]H[O?\`I.YC^>DG0"$*`*`7=TU]ESWJ![RL,;5F]UL;&89"
MG%5+ENY]RF"#M.'2"0N!VT2.()JR?J#<Y&Y3<!4.&OHZT`\%XF_=?;%\;D<.
M[$<02SV3P=T_<806)HAZ_7*[>3M[C#QC:;EWCKD*=99M%,&C?4-"ZE-H`4`L
M/P9\_*PNZ7=NY.@DI:D-M]&Y9ITJ]4;&C74;)+>K+))B(ME/6&W>D.<Y1[L`
M`0[*$4VE1#//5!Q]AG)<_F'=EB[*5YY7O6[]PEU,;\478%D+:AF1U7'JZ*$H
MW(5<IXLR)$0,?4BI0U#0*!MOB.I]*+?#M?W\;$UNAOO^N5'$$>]EF;C:7G6*
M1:1[.+O`KM[)0D+=ZI@29'>-)9T(I+N3E*\27%$YBZ%&A`9>ZG_2%W2]*Z_H
M^(S+&L;IQ9>KQXEBW.5E',]LJ^&K;5R1!54PF4AY\K%0BAVBO'0=2&.`"-`-
M0&'E-RB(F$=!U'M]+B`#[X4`4!*9\()[6QE^0;*/[Q&T`[1XX7^2^GQ_#<]?
MQ?&U`:_T.P/,'P4!R`!'33RB!=?(`F[-1\FNE`2%.C#TW+?OZZ+<WY;QIZ0Q
M3LZPC<S>[(8&Z2Z=\9VO&S>:<:VW83$I2NC0$>X:D/(R90[I,H`0IM1U`!!7
M5?WXS_4:WO9AW)R9'#&VY>8"VL:6^JL=5.WL<VRF2+MID43@!N_<MD!<+ZB(
M]\J:A%-K@/T>&.OR1Q[MUZJUZ/'#4MO69MPF))@FY%R5$L^^C'[<I'2Z(@#9
MLJDF`@.NHGTH1ZF1&KMN1_>%Q3%R29RGD)B2>/W!B$*"?^U.%E0`H``"<2`;
M0#&](=.(T)1['I8]4"_MON.\E[.K_;6;E/;=EDH2"V)LK1?WR6T\GN8J3N/A
MBN1/\@O9)L<3IKH=V<JQ0$!U"@,;]6W9MM\V[S^)LN;7Y]Z&,L[P;F8F<6RJ
MJK^2PQ>[<W?2-G)S"@`:4B%43BLT,<`432]$>P*`9S_R_P`WZM`%`.K9W]D;
ML)^D5NO_`*AT`U30!0$KOPK!63')/4,G[M56_LS0V:7#;MY-"G5[AZI=T@I!
MPR"B!5"HK'.Y<&`-0$Q=1$/+0$:BZ6=RX1S/,]U'RUN2%G7U,!&(/6SN/.9C
M'3;@&@)]Z5%19LX;$+Q`3`8HZ\:$LDW%J/$F1]7++2-^]"'IWY,L)Z#1>\#.
ML?R;EB=^H=LX=.TG<DU:R"7=$:B94IBJ@<1,.NA0$-:'M=O7;TH=;^2)$`>V
MACBR\IX\8W5-3JUI#*0CZ_9%LU(K(I,2/6RLBHP;*G-WPBW`_)SZ`;6A+-IS
M;7!LF$=4_8?`=4+9]M!S+TI;XMS-ME;6\53%E7MAV0N-C#Y@05E7#*37F4H%
M^Y1;NWB9FPIB@EZ9PTY>;301*0H[^QS?F*KFD++R59]Q6)=D4IW3ZWKHB7D/
M*-S`82ZF;O$DC&3'3@<NI3>01H"RZ`*`D7>%5]M!M_\`P)R_\QI*@%3^,H]J
M38GT8K`^<5X4!$JH#D3@8!TYN40,)1U](`$!$O#CJ;LH"6GTTYC--P^'HZC"
MMH1<E=9,!;A,2Y'M:)0:O'9VT<T;I*WF5B#0#.0!I'NA<&,GJ9(`$VG"@'.M
M@?5'NO<!M0SHWGLWO)"73L2R[+M*&N1V:1?VVY0?E%VEZB<?6E';5H`$26#4
M#)ZZC4N3&-^'3!:TYEX]L9]O'WJW<C6,4O\`*HZ_><TAB2]MA&3+E;12$//V
MS$)2#E-L)5'*#M9(CY<K-0132*J4XGYQX\VE47^UWU/JK&G^/89FWON?&S-C
MO3LS=8RZ7PX]*?Z-$>SK4=8_)L2XN[;^I>S*\GENWG<C:PXMN1$B4/"*.E$V
M4O=*342"NX;-^5-LF;F$=-:K5M.$.F7$UJGEK)NS;C+JKQTI^HA'K#OLAW#T
ML>CE?DY"3<#!WM864G<LD]:G:IN+@)<0NF3A5$>4.Z>LUE%V^O:D.M3$I&2H
M"H=H></AH!W?^X_0#9&6_P`:N2/P[N_^GWU`8^H#ZCZ<F9-I&1\E+2+]A"-U
M&D,R>/7#AK$M55.^5;QS=50R3-%17TC%(!0$W$>-`?,`PD`^FGI%Y1U]SB-`
M;(?*KYG@?PB<"TC;E,W<7SA&WD&#U`QFQUGEZW.1=S$DY>41,9`%$Q#RUA#`
M@YNVI+_R=_<VO_2X5^%#)^X3E#=LA4HL7:E%/WQJOU:-;T<"@;T>S0![--!$
M`$0]_0:S>WU-LQI=BHW&EPK_``.%#S#R::>77WZ`*`H/8/F'X*`V3&)_\'->
MWT;KR^?Z5`:V<.P/,'P4`"`#IKY.R@.\5U1#3G'00TT#@&GO>Y0'$%3@&@#[
M@@.A0'4!`P&U``$3AIVCQH!4>R1F::WB;7HHR:*@/<]8P3$BA`Y3B:[HL1`X
MEXB`Z=GNU-!TG%_]2_4EFZ0E_P"E_H/]^+*N5Z^ZC[J"530(R@+3MQ-ERG!4
M!*,8W(;T#"(I@`E[/+5@=JXD8=W[[DK^::_0SKWJE;])>U[/-QD_;Q;_`(\2
M+)ZZH7AW26@<-13\@<`U$`UJ_%P,'3^M^]G>G)@0IBG9-%N8-.8Y!U`/<#LJ
M)*=`N$!X^J::\="G-H&OD#AV!0'6<Y#Z"1+N@#@(:B.OO\0"@,O;>?Q_80_*
MWCOYV1-`27_%_>T0P_\`1;QQ]DO0$3^@#R@/N:_K\!`?>$*`J`?K?5T[`TU'
M4=-*,EE5K0EU^'55&PNGUUNLS)E$7$/MM:VLD9(PIN`(\C9M94"*AQ`H>M%'
M3RC3D>UA/J2Y_P"C(L]P9AOFXL869B&6D$7%FV-*2TQ;[0K;D=-G$P83N4W#
MD0YET2&.(IEU$"<PZ4/-Z<=#%=``\1YAUYM>;FU'FU\^NM`&@>EZ7+PU`--=
M1UH"AOBF\P?9%H#<(^&F]C/M!_F&Z/G9+4!JWNJ+[1W>_P#2=S'\]).@$(4`
M4`XSTH\KV-A[?1ABY\CY#_LCLQ^XGK6G,GB151*PR7#"O&K*YW:*)3*+L(V0
M*B*Q2@)CIB(<0H!-^[.^I/)&Y#-%XR]V0-^2$QD">[^][9(Z3@KQ*Q>*L&US
M1B3S[>FTF6K<BY0-H)>\Y=-`"@)0'AM5C8BV)=:'<Z5JD1W:>W0]GQ<FL/=@
MBX=P<XZ,BFL`\Q#'4>)CP[1#3RT!'41GLW[8,:6Y*?*K!_:6XJ!D)UW:$JW*
M^9<I_M2<FLW4YTRO5T7(F(H7B``.O&@$3$7537(Y1.=NNDL"Z"B!C)*-U2J=
MZF=!0@E43,FIQ*(#S%$`\H4`^W;/57ALA=)+/&P3<U,WQD2_@N6TK[V\73=1
MU+I2MN:BI82O(QG+NU%)"`:E@]2_'$IQ$""`@(T`Q!S"(!PTT```!#4=`\HZ
MZ]O;0%*`E,^$$]K8R_(-E']XC:`=H\<+_)?3X_AN>OXOC:@-?Z'8'F#X*`Y:
M&,`E+IQ$OHCPYN.@`'U3=E`2,=WV]BULH[`-G08?S$P@5L+60GAZ?PD9-.&F
MF@'BSQ]UE!!J8@/FLD+GULKH0$S@W`1U*%`,B7YA]G#6L2_K/NB/NFU^:.;R
M``<$92-=R"('(*S<3`)T!5$2@(=G+QH"1]TA':V.^AYUJ<ELW+9%_*VY9UEE
M1=ID+Z\U>B@BNDV7.!!!5,KDPE*4P^D-`12M![=-`$I`\FNI2%`??\M`?0B7
MXQ<K&2@)]\,<_9ONYYC$!8&BY%NY,<FAB@H!1*(AQT&@%,[C-V%\;BVMNQ$\
MQ90UO6M(/Y"(B6*AE"$7>((M.\6.<`.=5)L@!-1$=0&@$KB.HZ_!PH"E`.K9
MW]D;L)^D5NO_`*AT`U30%![!T[?)0$E'P^&<\>X[MKJ!XTNYFZDKAR9@^V92
MVHIH]38*RR5B3[N4E&15CB`J?:G1#=V3TA'0?)0BDWP&7=X<GD*X<SW%<F0+
MOD+U3F'3IW:LT_4*HJ6W0<*%8Q)TB$2]6=PZ0%;*@8-1,37CKK0@2',72J6Z
M#PR66;#2DIQ[>^T'-C"\8^'C6JKQBTM5TY24._?&32,,<8`6/HMS%`>700'@
M(`1\B7OMQ2M)$+DA;LOV_%BM%WL\[,5J!"(H%`(MN10Y$&[=(PB74"G$2A[O
M&@.>)-W5UX*R@I?.)FTE9=N.V!(^6LZ(N258MI)%(FA7RZK=PGH_25T.4Q0`
M>&G90#NCK<\CU"=C>4;,W*.[1>7CBHKVXL,9)>Q\:.2K?0A^=VE;+V=(1*3F
M(J;(4R1DUSJ&#@(::4!'*#40`1#37B'OAKV_JT!6@)%WA5?;0;?_`,"<O_,:
M2H!4_C*/:DV)]&*P/G%>%`1*J`D$=._H17;NIP;%[P-R>:X':YM5EYU2)M>>
M7CCW-D?(IF3E)%\M:%MD51091H*F[E)ZZ,*8KCIRB`4`X[U`.HCM'Z7.T.^.
MESTIH.\82^,J\I-TN;;RDTI>Y#M'<4DS6C6KE`ZT:E<EQ1BHI."MTTTV+53N
MP](1H")Y@[(-Q8[RE8]Q6_*R4<*-VP9WC1C(K,49%`7R**K1X4IP04(LD<Q1
M%0IBAKK4JT=">$YK)7EZ.BU_`V%_B#LUOL&=*_:+=<2RF(R[;RLB$MBU9%I)
ML45+<?RL/'RAG@NTR`\=N6[<`$@)Z$$!`1[1&I^52*SLVTIXDI-VYS<GK^'\
M#7&3UR7!<TX^N2Y)>0N"=D7GKC^7EG"CV0>.>\Y^]<+.#',<QC=H".GDJ70\
MXSCT]%/F9,]#&]P=9GP_>$K8LB[6JFZO8S=N0U;3Q8\E44GN4\?6\B4DC&0[
M80**UQMH$X*,T"B'."?+QY@"H@A82#%U%OGD7(-'#&0CW+AD_9O$5&SMD]:K
M&0<M'+94`4;N&RQ#$4*;B!@\E`>0.T/.'PT`[O\`W'Z`;(RW^-7)'X=W?_3[
MZ@,?4`4!4IB@(@(?&*!3#_HD$Y-1T\HU%<0^!L#.M[*,K$\-OT_['L\RJ=NW
M<TPH1P=-%-,BA4+=7EE0<``\W,=XL8`T[=.-88[.<[^;LV/==9S_`'$G[^N>
MID[=>F-K?,E<5^WC[DTM/R-?NOIWAM.`<``/<T``$/U:S5-Z1CX1I^;,:7/Z
MDGXO^!U5YD@4`4!0>P?,/P4!LF,3_P"#FO;Z-UY?/]*@-;.'8'F#X*`K0!0'
M(I^77[6FIK_S@".GFT]V@%R],Z(+<O4'V:0:3;[<_P!Q6+R?:1$1$4[E9+CR
M$][N]?J5%.E7['^AY7OZ3'0_$]7O'W)U9-P$5ZMZ=K+V]"@=)7]NUA&G>]X&
MG`3<X#I[M4/9<1V\B]>2T9EKO'=;5[LC8]H6MVU8K[4G4CM']5Y1Y$5.;AH)
ME.':':``'DJM\=3%1T\A#=H"3WM>;7_-0'H(FSU+SG5`/VPE[>SR>C[M`"Z;
M3E^T'5,;W%/V!``H#+.WCAGW!X?]K6.OG9$T!)@\7][1##_T6\<?9+T!$_H`
MH```$0`1Y2B(`8P<1`->.@!V\*`EI=&)VE;/0VZZ%T'!99(UI6=`%*`@0AC/
MF*94SZB&H&`3\?=UH%IJN)$N$=0+I_H%`?.`<:#CQ*4!0=-!YA$`]X-?*%`>
M]!@)R"8'228!QY3G*4PAIV@`Z".M`>`W`IP]S_ZQ:`W"/AIO8S[0?YANCYV2
MU`:M[JB^T=WO_2=S'\]).@$(4!P/V?5_8&@.`"&@A[H]M`=@=UZ'%01U'GT`
M.`!V"7C^M0$NSIFO2XZ\-+U?+W3045<WQ?UJV(@?4J94R+,H-N=37@8Q2`YX
MAQ[:`BIWCE6][\@+#M>Z9@TE"XWA#6]:;444TQCHE1<7!FQE"`!W`@H/`QQ$
M0#A0&/2]V)O2U`HF'70-1`HZZ:!KIJ`T!03!J.G$-?='40#XH^Z`T!R`4^[-
MS<W>=A?*73W?>&@.L>T=.S6@)4/@_?:U-?R"Y3_BT=0#M'CAOY-Z?/\`#L]_
MQ?&U`:_6@"@.8FT$!`=1\WU-=!U#6@.TCE<J1VY5UB(J&`RB(*'[I0X?%,9(
M!`AA+KP$0&@)46U)T]LKPP._R858)`CD'<SCRTVL@51(J_=`5JJND8@E$YB&
M[GCH.NE`15:`*`*`*`[$_+]3]F@'6L[^R-V$_2*W7_U#H!JF@"@+NL6^KLQM
M<\;>-DSCRWKBBE!,TD6*ADUBD5**:Z*@!Z*S99,1!1,W`Y>%!5GENB[;AO.8
M=3ERRCB6D'BJRJRS@"@!164,<P(I)@":11$>````%`29O#79*1ORZ]TO3]N2
M9AX.S-W6%[IMYS(3:*2[)&9;1#@\9H18Q"IN#NB<I#@.I1&@(VV6,>2V)<H9
M#QA.)F++8^O2Y+/?B(:`9>!EG4=WH<1]%P5N!R]NH#0&/J`^PQN"<C&CUA'2
MK]BRD2D(_;-'2B"+PI2@4H+I%]%0"EX:#VT!\(V@:AQ[=0U$!]'CIKP[:`X4
M!(T\*C[9_`'X$YA^8DE0"J/&6>U'L3Z,-@?.2\:`B1AQ$`]T:`D23G4DQ]=?
M2CP%M]9W](6-G#!<!/VBQMEFJY5A9R/AKW:W5"2DLU$HHG>7`T5.@`D$.3N]
M1H"/]=MU3-[7+.W;<3M5_-W')NI>5>+',=1P]>*&554$QQ,;0#&T#CV``4!D
MO"F(;QR?<L7][D"[F(N-NBTVDZ+10A'!496::-2)M2B(**.5"'$0`@"(!QH"
M7GXNJ[8JT[1Z:NVR+2FFZECX"97$[3>OUE&J:'R5%P;1NNT4X*R:9T3\ZQO2
M`H`7A0$)Z@'O>E!O4N;"#F,QA;]O.7"S3([7):5U1ZJJ+R,4:MVK(8U8X'Y!
M8R1R@4R?*/./;0%R>()L["L3O1@LBXDMP+&F\Z8EM#*N7+%;(I(1<'D6=0-\
MJ/HMLD5,6",^!`<JH"4O*J83`'I:T`Q.':'G#X:`=W_N/T`V1EO\:N2/P[N_
M^GWU`8^H`H`$H:";74>4/1#M_="<?+VZU%<0^!/<ZUL=(W'X<;IX3KIL\C#V
M>VPT5S'+%Y!,1];;EHFNN73@4W*`D[.VM:_3KN">3WY8V^3MO%PW>C"B^9UE
M)OJ==?P2,N;SA^5M^ZV9?3=\B3?/1+1?XYD"=4=3B(=G#3]3C_YVM;+W4HW9
M*-:5,37&NMI<%H==>9(%`%`4'L'S#\%`;)C$_P#@YKV^C=>7S_2H#6SAV!Y@
M^"@*T`4`4`Z9T2H4EP]638/%'2[X%=PMHN3E\G=L0?/CB/#M)ZL!OJ5-%)ND
MJTH_T/*^I2MN,>+:_55_(NOKJ7,%W=5[>M-+K.5VA\RW`P9+"(&$R$=W#(A2
MB/`"D%$0TKY=KOQG8O*$H7&G_+R]^KX<R[NZL?*LO$4H3MQ5E175P:IQ7`:*
M,*(J%*03%)H(&,?MU`!T\G#C7NN"KQ+6:HZ%3]T7314!\P"/[%1!P\W$/(-`
M%`9AV\_C^PA^5O'?SLB:`DO^+^]HAA_Z+>./LEZ`B?T`4`4!*7Z33M26Z$/7
M1M-NY,@NU@,7708$Q$3BV;O&S=4ARAQ(182@7F\O&@(LX=@>8/@H"M`4$-0T
MH``H<.&N@Z\?+V<!][A0`;XIO,'V1:`W"/AIO8S[0?YANCYV2U`:M[JB^T=W
MO_2=S'\]).@$(4!P/V?5_8&@.L``1XB`>^/^7DH#N33(8XD[PI1$0`IQU`@Z
M\/>$-?UJ`EK;73-X'PI.^%XLJISW+NSMR)2*342"ND6`*0HCIIW9B(F,.G#4
M`H")(8.SL[`[/V=?+0'&@*@&H@'NB`<??X4!]4(LP)JJ>LMOM9>82`H'>'+P
MYBE+V\P4!\D>T?/0$J+P?OM:FOY!<I_Q:.H!VCQPW\F]/G^'9[_B^-J`U^M`
M%`%`5#M#SA0$FVW7L7`>%UOI!"5D4I.\=]<*DYBS&6!@JE&QPF*H0HD%$QM"
MZCH;7WJ`C(T`4`4`4!V)^7ZG[-`.M9W]D;L)^D5NO_J'0#5-`%`%`%`+DZ;V
M;%-ON]#`F3>]52;0>0;?4>@D80]8:>O)`LT5+\4R#E(QBG`P"&@T`OKQ%F%F
MF+>I)?E\PUK-;.M?</:MKYLM^&8`48\J5TQJ!G:S84P`GVYT0QC%#XAA$*`8
MAH`H#J/V_4_9&@.%`2-/"H^V?P!^!.8?F))4`JCQEGM1[$^C#8'SDO&@(D@<
M!UH`UUUU\^N@>_\`"-`4H!1&W;<M?6VFZE+ML=C;LL].>/<`QNJ-^5HI-_%.
MTWL>_*S!9$/6FRZ8"4VO8&E`9XZA?4GW']3/*%J9:W)NK35N6R[*9V'`M;,@
M/O<A6L(S5,X`WR>5TZ`7BZQQ,HIS!S#PT``TH!O^@,T86SE?F![H;7;C]W'M
MY-!PW<'1DH]O(LG0M%"K-TGB*XD!1$BQ`-R:B41#C0'CS-F;(NX+(MRY9RM<
MSRZ[WNAV5S*2KU0PZ$*F5)LP9-_W-HP8(I@1)(@%(0H:`%`8L#M#SA\-`.[_
M`-Q^@&R,M_C5R1^'=W_T^^H#'U`%`<BF,02G*/$IBFT_Y)BG*(#[NI:+1U`]
MGNBZ[6ZS=GLNM[8WDFR<,-<4VM$6)$PTK!6O)-;N0)8#9-K$.@DEY5PV(]63
M2#O3@EH;4=--:QKV_P"E^Q=N[U_>,&=WSG*3=>G^9MO@JOBT7+D=QY&59R;=
MWC?Z:<>"27NY#)AS"8=1T[``-`^'W1U[?=&LGWI1E.L>%"VN;?BSC7D`H`H"
M@]@^8?@H#9,8G_P<U[?1NO+Y_I4!K9P[`\P?!0%:`*`*`4+M1W*W_L^W%8GW
M,XO;0#N_\.7*%U6JVNA@K*0"DHFR?,4AE&"+AJHZ;E3?F-R@H7T@`?)I2KHT
MN+37Q5&23BY)4XJ2?P:9ZMS>YJ]MU6393+.08JV(V[9]U)R,ZO;,<K'-Y64E
MY1W*O9!VDJNN8[DZSL2@/-P3*4/)5#V#M_%[:M7K6#=N75?FY2Z^3?)>PO#N
MWO'.[NCBK+M6[2Q;:BNGG1)5?P$X57%P+3;JZOB%"`4`4!EW;\(AGK"8AVAE
MK'8A]2[8D:`DH^+Q=G4ZD.-&Q_W-GM;Q65+3CP60<+'_`/.UH"*B/#A0!0!0
M"W]M&_K-NU;!6Z_;WCAO:;FQ=X5BQ=@Y.-<44O(2;"+B'IGS=Y;*Z3INFPDC
MB<2"HH14O+V%`=!`!$`<.%`%`%`%`4-\4WF#[(M`;A'PTWL9]H/\PW1\[):@
M-6]U1?:.[W_I.YC^>DG0"$*`X'[/J_L#0'50%0[0XZ>_[E`+_MWJ/9XM?I_7
MGTX(QC908(OG*+/+,U)K0SDU\_?`S[GNVC>:*_*U3BC&;E$4Q;F-P'0P:C0"
M`1$?*'U1[>SLU'R:4!QH`H#ES#[O^?\`5TH"@CK_`)=OOC[]`2H?!^^UJ:_D
M%RG_`!:.H!VCQPW\F]/G^'9[_B^-J`U^M`%`5T'W*`I0"WG>_;,S[8M']/H[
M"ST\*1^6AS(G(I1*Q+S5ND6IF@(+S'KG<'BP3-KW7<Z\W'FH!$6@\?>[?_)V
MT!2@"@"@.Q/R_4_9H!UK._LC=A/TBMU_]0Z`:IH`H`H`H#ZD++O8"7C)N.."
M;^(?-I%DH8.8A'+14BR0G+VG)SD#4*`65O1W]YOWX/,426<$;64E\06*UQW;
MLM`1BT>^?6ZQ,4S1*744=.`=+(`0``P`0/>H!$-`%`=1^WZG[(T!PH"1IX5'
MVS^`/P)S#\Q)*@%4>,L]J/8GT8;`^<EXT!$CH`H`H`H`H`H#N)\4/J_"-`<J
M`J':'G#X:`=W_N/T`V3EK3^U7).NHZ7U=XZ!IQ$)Y\(!]6@'&MNFR7:#*X`L
M3.^\3>>7"YLU7Y+X^Q+C/%%EH9;R#&A!.$&,MD3+40C,1ZMF64W?NB)H)<AW
MCTH&.D&A=!`2=O4VGWALEW,90VTWS-0]S3&/)&/]0NJ`!P2&NNVY^&97#;%Q
M,$'!?66B<Q"RC=845=%$#"<AOBZT!EC<)LJA\);(=D&[=G?[NX)3=RYS0E(V
M2O$E8MK*)BBYV5O(F;27>&/)_*X.A.(\H`3ETH#QW+LSBH+IPXTWVHWXL[EK
M\W)7G@9SCOY.*5M&-K5MEK<"4^$J)P.LN^]8Y12`H\I=!H!-]S[<\^V18D3D
M^],)Y7M+',X9'Y'ORX\?W3#6C*`Z`!:@RGY",0C%A<AQ3'O-%`XE$:`L=W85
M[1Q;5/(V9=;`M]-4WMD^MP<DV"\&BSH6*#JV#+-"_+B*ST!2*9MWI3J>B`ZT
M!?-N;<L_W?<\K95J81RO<MX0,LUM^>MB"L&YY2=@Y]\"AV<1+13.,6>Q\BY3
M1,)$5B)G,(#H'"@/O6QM'W37NRO.2LO;GFZZH_'4B_B+[>6_C&[YAM:<M%"?
MY4C)U>/BETXZ1CN0>^04$%4P#4Q0"@'%.FGT@[EZB&/<_P!\0^8\?60ZPY9]
MR.`M.:EG<9<C"[HY-L\AU;L9/(51!*TW[!%^8WJBRL@*C,Q2H\.($QZUH)O:
M_A$<M6PVG8>YTK<P1D*$^^*W5UW,!-'CLBIMU9"&<.F[1RK'K*D'NQ423/H'
MI%`:`UHP=@>8/@H"M`7%9]IW)?MU6[9-G0CZY+KNR986_;L!&$[V0EIF4<I-
M(]@S3'0#KNUUBE*`B`:CJ(Z4`Z=OWZ4-[=/K;/M<RYE;(5M365<_W)D:(NW%
M]H245<D?B3[QTHA1.WY^YX=X\CW5Z:20C(-$S&*R,`)B(F`U`)ZZ<&U&R=Z.
M[*RL"9)OV;QC8TO:V5+QNJ\K<A4KAGHF&QAC.Z\B/0BX5=1-)\[>(VT*)2F,
M`<QJ`<&L#IN].+>/+R6'M@.^K*T_NC6M^?F\<8GW+82:XU@<Q25O,'4HXL:S
M[SAIJ29L+RD63-0[-%X0J:PD$@#S<``:$QWMBW#Y>N2Y[2Q5@_*^2+@LQX\C
M[KB+$L>?NI[;CZ/75:O&DR$,P=I,5T'2!T^502F,8HZ:T!:#[#^5XMW?+"2Q
MG?K!]C$A%<DL7MJ3C1YC])1QZHFK>39=B1>W43NCE(51V5$AC#H`ZT!;Q;-N
MU6U%[[2M:X360VF"6\O>'R2]&VDI]5`724*I-`A\FEE3M0[P&_>BJ)/2Y=*`
MMF@,N[?OQ\X3_*SCSYV1-`21O%X>THQ]]%S$_P#$G5`1:HZ/<2TDQBV8)B[D
MGS6/:E55(@D9R\<$;H%565,1-%,55``QS"!2AQ'@%`2"[?Z06T6?S%;FQ)EO
MF?2_4,NNUV3Z*AK9QVWN/:Z7),C:0WBTPT.58N:<23V9%CHU5ED6XQZ3T>0=
M0`:`8_LW%3^;SI;&$;B<?(4I*Y6B<63CI#NW8Q$B[NQ&U)%9(2B*3D&+HYS`
M(#RG`O;H.M`/MYYZ<?1PP3N$OC:+>_41W'V1FVQ;K0Q].79<^VY@\P["7:H@
MS$[N9F(RX4YDMK(+O2=XZ31$2):F\E`-,[FMB6>]LFZNY]H4K;+W).38IU'*
MVB;&,9*74URA:UPQZ$U:5YV.UC6CF0DH*Y8-VFZ1,"8B4FH#V4!BB\]KNY''
M-\6[C._L"Y=M#(5WE`]IV9<5@7-$7)<Y1*8PC;T2\C4W<UR@'I>KE4Y1X"&M
M`8SAK#O>X9&<B(&T+CF96UXZ7E[FCHR&D7CVW8J`$?ER2FVR+<RD2QA^42NE
M5P(1`P:'$!H#)DKM=W)0>,&6:I?`>88[$4BFDX99,?8ZNMK8SIFN`"W=I7(M
M%DC!:.0'5-85`34#XHC0&!S?%/Y@^R+0&X1\--[&?:#_`##='SLEJ`U;W5%]
MH[O?^D[F/YZ2=`(0H!:VR_;Y@3-<KEBZ]S.X)+;_`(7PI8:%ZS[N(A6]U9/R
M%*R=PQMMP./\66DX?1R$S<D@Y?G<KJJ*`@S9-U%5.&E`7UORV16?MA@-N^:<
M*Y7=YFVU;L+(GKWP[=MPVRI9-^1IK3G1MN[;3OJU3.'B#.9@I?0H.&JJC5TF
M8#D$.R@,Q].S87MIW';>]X&Z+=;G/)>&<4[3RXI3DPQ784=?]T7`ZRE.OK?C
MTV\9(OH]`A&CQL03B*I0`AA$>R@+XR-TX-IV7=O.:-P?3:W97AGU?;9"L[QS
MC@W,V+O[+<M1>-EW*3%UDNRRLY.4B+NMZ%?KD3?(HB#EN4_.(<O"@&R,:;5]
MS&9[9EKSQ)@',62[1@A7^5[EL;'-UW/!,#MD^\<I+2</%.V8+-TPYE"`<3D#
MB(`%`8R7Q]?;6V'EZN;,NEO9\=<)K2D+H7@91*`8741$S@UMO98[4K%I.E0(
M8XM%#E7Y0$>70*`N>UL$YKOB0LN)LW$F2+JD\CIR"V/V%OV7<4L[O5O$+>KR
MKFUV[&/64G&L8OZ#A5L"B:)N!Q`:`^;D[$>4\*W.M9>7\<WMC"[6Z2;A6V[\
MMB8M69!NKQ2<ECYIFS<J-E?VJA2B0WD&@,=T!*B\'[[6IK^07*?\6CJ`=H\<
M-_)O3Y_AV>_XOC:@-?K0'H9M5WSMJQ:IF5<O'"#5ND0!,=5=PJ5%),I0XF,=
M0X``>41H!]_='TXNG1M%B[AQ[E;?;EQ7=);.,;;N66QO;FW*0E,?L\AW1:;"
MZ&./E\B?*Q&B;AF2132=*<@BD.HZ#H-`,X8*QNEF'-.)\3KR1X9')61;/L56
M8(B#@\82Z)YC"F?$;F'E5,U!YW@%\NFE`/P9KZ<?1OP_N'OO:#<O46W$6-G&
MQ[Z7Q=+77>>VY@YPQ$WHW529J+S$]#W"693M0C]4"G>%0`2)ZG$.4*`:3W$;
M$MQ&W;=;>.SN2LF7R)EJV91%*#:8QB96\$;^MV49HRUN7C9S>*:.'TI;UP0C
ME)VBJ5,0*0X@80Y1&@,3W=MBW'6%?L/BV]L$Y<M3)-QI&<6]8L_CZZ(NZ[@1
M*F=8RT'!NXQ*0ETRIIF$1;IJ```/N4!C6&L6];B=3[&!M*Y)EY:D;)S-T-8R
M$D7KBW(B&-R2\G.I-VZAXEA&']%=5<$R)&X&$!H#)LYM=W)6SC2/S-<.!,P0
M>)95)!>.R3*XZNMC9+QLY`!:ND;D<Q2<49HZU#NE>][M37T3#0&#">7ZG[-`
M.M9W]D;L)^D5NO\`ZAT`U0/-^U#7W:`Y%`PB``41,.@<H=HC[@=O'6@%U[0<
M4;"\C15Y.-XFZG)NWB5C';%.S(^PL+N,I(W$S5(<7[B1=(RL>$6HT.4`*30X
MGUH!1W4^Z?FVW8Y:^VZ5P[N9O#,5VY^L=/*;O'%^8O5QM>>/\;32":MES]UQ
M2K]ZK%/KL`3JMF:NBPM0*J.@#I0'/I\[#-L&X/;+NTW8[LL\9-PQBW:[.XFM
M]ZABFP6&0+HGWF57\G&1YR1LB\CT$6[1TQ+S&%0/1,-`73E'IP[6,F[<,R;E
MNG!NONO<(RVVLXRX<\86S!C(<6Y>MK'LFY+'ER;;;9K(2<1=-JL)-0J+LJ)P
M7;`/.;@.E`-JV+M5W-Y/LR2R-CC;[F2_+!B".59*\K1QO=T];+9)D0RCTPS$
M=%+LE`:$()E>0YN[*&IM*`Q<O8MYM+30OMU:5R(64XGE[62NY:'?I6TI<C1N
M1T\@"S)VX,`FF[<X*&;"IWI4QYA*`4!>UE[=,^Y,GK>MC'F%<I7M<-V6Z>[;
M8AK8L6Y)N1G[43>.8\]SQ+5A'+JO;=!^T51]=(`MN]3,7GY@$*`L6^L?WUB^
MZ).R<DV;=%@WA#*`E+6O>,%)VY/QRA@YB%>1,NV:/D.\+Q*)B`!@XAJ%`2!?
M"H^V?P!^!.8?F))4`JCQE?M1[$^C#8'SDO&@&>\<]&O>SDS$-EY6B8'',+)9
M2MI[>F&L,7=DJV;:SOF.T&"2SA6X\=8SD5TY:9CG*+=0S0#F15>@0>X(<=-0
M&MI*/?1$@^BI1DZCY.,>.8Z2CGR"K5XP?,ESMG;)XV6*15NZ;.$S$.0P`8AR
MB`@`T`]PPZ`V\12V<=7!<66]F./WV5+"M?)-G69D;<W9=F7J^MF](].1MQRO
M`S*3=5DM(MU2\@*&`O,.G-Y:`:XW,[7\Y;/LMW!@[<-84ECS(UNILW:\4^,W
M=LY.)DT0=1%P0$NQ5<1D[;TPS,"K5VV5416(.H#J`@`"?Z`-.&ODUTH#M(/`
M`_RU$1T#SC0'/W?>'0?>'W!]^@*AVAYP^&@'=_[C]`-E99U_M7R1H(A_^^[O
MU$O-J`#//@X<HAQ'LX\/=H!R;:?A?=?M1MS;SU%,;[;\4[IK!R#>-QV#9UOW
M#9SC-T?;60[:D67_`%?>UAPXBZM.Z'1DRJPZ[L@IJ@(G3`1H"[>N[8%MV/O_
M`+DEXJ<FW=X97QCBK,F8K+N6=)<<QA[+^0+6;S%[8G7DDQ'NFUG/E2HMF8CS
M,6PD0,'H4`Y'?&\61VA]&'I'KM=N6V[.Z=[RVZQ8%MQN,#Y!"WSQ60V27<V@
M91_&I1R3X%]5Q`RG.8A.`4`H_&6>,;;O=H'20O3<+AG`&$<,K]7F7M>^+4Q3
M8I,?8FDHY&QHWU&0N&*!Q(-%%GT[ZNB\.<XE.B(@8N@C0&/L8W?OTO#?GU0+
M$WSERTZV?1V%-UQ\XVYDF/DV^#K+LV!B)E3`+VQ$GK8MHV\LWFB0Q+=5AA35
M=)'#EYP$U`8/R?@7.6;K2\.C<.)<:WCD.W$\4VW:I[HM:%=2MNPT_;>X1[(3
MT-/SC5,\9`O(:+(#A<KU5`2(^EV4`L#<AF3,&W]AXEC(>(+RGK`OMMNVP%:X
MWC;CA5A-P[.7N5\UE/D>61*9:,=O4T`2*NB<AQ3'T#!PH"VMK><,F7+M@Z=E
MMYUMC?=@>Y)2X;HF=L^]#8G.L\J67DVX;LOK_KZ1W38C156+<>1HR=4`CX)1
M4SE:(*8.3DYM`(_>^N?W%;4M\&Z[%:6XI2>N2*SW+7/>%ZX=<A9EI7I>K8SY
M="Z$X*W3MHR+DD$9M9-9J0HI-EU%D].%`3;L7+JNO!VW\[<',JZ=[=[[>.UC
M:<R[IWD8'#A<VG[99943&]TPB-`:V(.P/,'P4!6@/9'R$A$2#.4AW[R,DV2Z
M3IE(L'*S-\Q=(F`Z+EF[;'27;N$3AS%.0P&*(:@-`/B;OSNWO1)Z74F\.Y6<
MR.?]X3IW(O#+*+2#U60M11VZ</G!U5GKE901$YQ,/:`=M`8XZ$D5*SO45LF&
M@XU],3$C@K=FRCXJ-;*O)!^[<;9,II(-6C5$IE5UW"A@*0I0$3"(:=M`9PZ0
M^P;==;&_G"^X;*N(LEX$P+MKO8V;LR9IR;;$K8=I619MC(/9EV=Q+W"A&I.)
M"5.D1JW:H"JJX46`H%$!&@%X6$$RYV<SNXN4RYO`8[?]U6_'<)=V&<$].^R8
MJ/RC-77$W.Y!M(9ZS&EW,A!QCI!VB:#B#\Y2<YUN70!$`%4[K,HV]B?K48YP
MMEZ'N"T<3[_>G/B#;)G2.OES#O+O</<JV*XC;.NO(UPM4R1,U?=L7LUCE7TF
M0QA!8B@<VH#0#,'5UM20V+X&VE]*$[N*+>N'DKOW";GA@7*BK>4S/E9^HC:$
M?(K$$$7HVOC1DT*B(B;D%T.E`,&4!EW;]^/G"?Y6<>?.R)H"2-XO#VE&/OHN
M8G_B3J@(M+!B]E)%E&1K59](R+QNPCV3<@J.';YXL5NT;()AQ467<*%*4H=H
MCI0$LJP-FV;.CMBQ&\[(VOYPW&=5;,F+O78&XX/&5TW1A_8S8N0H,Z:LFTFV
M4:Y:WCN&>V^[,F!B*>K08&'M4[0(VNW;Y:_\6^$0N,LA]\?_`(AL>C/%DR+!
M*_+(Y"BAE/E!-4/6`?>NBIWH'#G`^NO'6@'D.K+T^-[NX#J\;NF>)MK6<;N;
MY!SNX3M.=9X]N1"U9)J]C8=)*4&YW;!""0B"`4QSN5%R(IID,83``4`[9>R[
M^\]]NZ64P[N&N"T+7V%],3;UMNW-W_MQL6&S!N'OR5M:.C[4OF$VWN'"JPPD
MK%W(Y*RD+D;J&%JQ;&`1T'4`,#;T,DS>$>E[T_\`=%C>!W>1<QA?J&3]UXJO
MC>G,(3V:9.#B[<B9DZ4;)L"@_M?'5P/XU1+Y,<G`7!^]4(`D,`B!]W>Y9V/]
MH.#=VN^O"3^U>;K13>#[<VN,@%B@SM[&]\$B<H[HXYV(*D"!C@OI(()P*G=E
M%H<Q3<*`5#=)LH;FLN9MQ0\=;P.GENUE-I<S!9(L.XB0V<^EA?>-[7Q&Q>B2
MUWBR2=O8OLVX+;BTE(QZS!3U>56Y2*@J<0H"!LZ1%JLZ;"=-46ZZS?O43<Z"
MHH+<@J(J=ATC::E'R@(4!N"_#3>QGV@_S#='SLEJ`U;W5%]H[O?^D[F/YZ2=
M`(0H!7.U?;7F[-7]J&5,*6!!997VLP%NYAOC&LBR/<,A.V<E=<;".736Q4=9
M&\8.-DGJ'RHV0U.1HH)C:%U&@';>KS(3F;=C73QW69VL=GMYW+7,?).(&FV^
MVX=2PL?EP%82S=>RLL67A]<"+XW:3TJ\5:.-"`G**I@N`FT`:`\'3,Q]?>3N
MC]UG+1QO9MT7[=3]?:(LRMJSX20N&<=H-,DRKATJVBHQ!R]<$:H$$Y^0AN4H
M"/90%V],#;OFS8SB+?\`;U=UV,+JPGALFS;*^WZR6&5(EU9<KF++>94V$#;5
MGV+!3Z;21N)W$"@=Z[431,BV2*!A.`]@#A.WJSLDX>MSI-8[R!EK?UE2\)JR
M<:Y!P;B;8=;UNXMVW6;:5ZWIZ\9/+F6S&3:9&O5,$E#7*X=<_JZ'^SGY0$`$
M"S']KI;E-_G6MZ10LX*`D=T63)G+.V6)E4BQ$+;^YO$L@A<+(L:CH@SCW%[6
MF^D6ZZJ92E5!,!#4!"@,@6[N"N2P=VVY7;?A#!-Z[A=KNQ?8#:>SS)*&!K\C
M+(W+XZA(R1926:,Q[<91$%)22N=[D]=P27%BF==6/2](P%XB`V%UBK#FY+:?
ML<SG"[B<\Y3P?+R&5<?XGQIO*L2.M'=9C$D2^8R<ZTD[C3`TMDS&*CI0A(R5
M<&,0BI3IICIK0$=J@)47@_?:U-?R"Y3_`(M'4`[1XX;^3>GS_#L]_P`7QM0&
MOUH#*&$VDP^S)BAG;CBUFEPN<BV6E!.;W<HL[-0FCW''A%*74[<:(-;>*^[O
MUQ0X@0C?F$>`4!,;QGEOJ.9[WS[K=N/55Q;8*VTQAA+*DEN',WQ7;<%@>P(R
MU,=KNL>Y8Q3EIO!HJ*RSR9;1PQ+YM*+J2?>]V!1X@4"*'LO3:DWL;8TV"AE6
M1=QV*R,U#_'.U+D&&*W4/_K'1`!&@'9NI]T[=\&XGJ\[PHG$^US-=RH9"W+7
M22VKA3Q_<3:TW,=(/6I$Y]6Z73%&";V^B@;OU'9UP1(@43";A0#OF1GSR^-Y
M.^V_\3[CKTM'&6S;8?M@VG;CKRVM61"9<W)9/G;:CHVU+JB]OS]4QC6S$M;D
M2,UE[F;G*"#1`2B?0=:`3_OGRY<>WK8+TH-U=@P.[*(E\-[T,EW-CJZ=Y<VQ
MN#.<S:<4VM^658NY2-`SN!L6XQ0730BG2@FY3G.4.0_$"X-[UBV)LDPUN;W3
MX(<V@NYZT.4L(H[7F"3A@2(B<"W$M$97SE!S?>'(,'$OLB+E@GACB0AFH"!M
M`UH!3^1U,I;GLG[IL<.GN\;I\;K7^U&YF>8L87TC#9OZ8-[V):6-&3Y9O9$X
MX2+`8MM.X(2-24@7S$#=U(+`5,XG,8*`@<*)"BLNB)R*=RJ=+O$C<Z1^[.8G
M,F?]N0VFH#Y0H!U7._LC=A/TBMU_]0Z`:H[PR8@8@Z"(&*.H:\!TUH`+V!Y@
MH!T'HY[<;5W-]0'"EIY%CW$EBC'I[DSMEQJ@W,Z(KCK"T`^OZ=:NTN4R?J4B
M>'2;+";AW:PT`F3>KN8NS>'NFS5N)O%WZS(9'OR7DHALGS),8*SVC@T;9MLQ
M;344F,1;]MM&S9!$FA2$)H`4`[KTZ\<9!RGT7>KS:&,K*NC(%U/,D[0'+:W+
M.A']PS;ALRNJX5W3A*,C$7#Q5%LB/,<2D'E`!H"Y^G'MYS5L=VU]1C>#NMQO
M<V%L5S^T2^MM^-H7*3!W9<YF7+66GD?'0]MV/`316DE.'MQ%L9^[6!N9NW(!
M1$^O"@'=-LUCY"PAN(Z5F',FY2WY9GR:SQS@6?Q[CW:;`VYBK8_8N,[WY9@&
M][W2!D6&2GR$:Z.%UO%RF,Y-S(F$!`I1`19CC'RN\[.76)Z/#$D)"77?FZ6\
MMQ&TR)>G1@(&W,MXTR9(L+TAXAGW2)&25S8SDG`BBD`$4]5`P%T#6@%'GW0D
M->'4#Q986`<P97V%;<\:[9]F$OE79UD1C:NZW"L/A8\DFSNZR$$0/-3F,KUR
M6^E7%P))%(V,J*??'`#<`&;>N/C^\XI[LKRK.;A<CYXLC*6W0`Q,3<-CR-QM
MNFL:Q;3N5[$-+>S9',P];N9<C@Y_DJ:="*KYD`#J)0`:`R;X5'VS^`/P)S#\
MQ)*@%5>,H-R=4JP3\H&Y-L>/C<I@U*;EN6\!Y3!Y0'3C0'VVTCM*WP[X.G/O
M'E=T-V8)RO;C#9_BZZ=ERN+;Z#,_WWXS&!MRVU\&/F[9&VWV,;[(U2?`_.=)
M-LFLXY@.)@H!@3JIFMD>I#O>&T",T[?'<GE/U)..$@LBK!=#[Y1!(4_0T"3[
M[FTX<VM`+:Z^H-PW#[3A)W8KCT[=H0+B7E[P1#'I02%7]L`\NNFODH!R>2Q9
M<V<;4Z!41E3;RPW69?8[2\]79-8NR->86%$/L$6C=C][BB\LXWM('*[C<6V8
MU(J[6%V<O?Q:0I$'E,&H'CW7XRQ+DSIG;H\XWJ[Z=63,^;5LOX"?X\F]A]F*
MP4-8%N7G<CN.F\<Y)FFB#6WK]MF50:@1H311TF9`YA4$!H`D]GNU@=Q(]4QA
MAJRT-A1NG6?>"EBMO&J.\9-MRXP8X@3P4Z:**`BNN.9A/)#'E4[P$$]=.6@/
MO;7+6PQG/`F&L1[9,?;$,L75>>%Y!OFC87N4M5UB+>'?6=YV+GYJX\E8/S3,
ML@+,Q*JJ[-U:C1@J1,C-J"`$-J8P`1%[KAWUNW-<ENRL4ZM^4@9^6AY&WWH\
MSR%?1D@Y9.HMV<1$5',:LD9`QNT1((C0%OAVAYP^&@'=_P"X_0#D67_"H]3Z
M,N"^,AW.^VXVA:#VZ)J55N"Z,PQ\)#LFTQ/*A'E>N7K(I4C.E7B29`'43'.`
M!Q&@%"8#\.KXA3;&SGVNW7,]M8EC+O*12X&5A9^5BXB:."1DVS]9FBU,Q5?(
M('^TNRD!PGKZ)PTH#!%Q>$QZR-WSLM=%V#B.YKFGGR\G-7#/YA^5IJ5D')^\
M</9"2?-EW3MTL?B910QCC[M`7#/>%=ZVUT699F.KCG<:3EAXZ/,J6':$GF@7
MEOV@:XG)'D[][\8LU,VC`EG295%^Z`O>'`!'C0`KX5WK;+6%%XL5G<:GQM!W
M&YO"&L8<UJ?>Q%W6];IM'=Q,(CU?U1M,.6Z12G7*4#B`=M`9UOKP^?B-LLXQ
MB<'Y,W!L[QQ'&)Q[1M8]R[C).3MT&<8F",8WD&BB0JRK.,3``02<F6(B`!R`
M&E`<,?\`AP_$(8IQM,X=QGN*A+#Q9/O`D)6PK4W#S\);2[WG(H9PE'L4TB,E
M5C)E%04!3[W3T^:@+!E_"X=<B?:W^QG,I8^F&>5I6,G,F-9+.,H\0OV9A3&/
M$2EV)KMCEG'\:8VJ*J_.9,>P:`R3AWPZ/B&=OEI3=AX0W&P>+;+N%1=:5M:S
M-P<U"P:KETGW3IXWCVS<&[!^Z3]%1PW!)8X#Z1AH!-4CX0SJY2CM[)2+S!TE
M)R#ER^?OWV5%'+Z0>NU#+.G3UXO'J+N7#E<XG44.)C&,(B(C0$ORQ^EYN=MW
MP]-S=--Z6R#;D)/#]Q62T(C<`*6>,Q*78G,-2+3O=%*DCZB'I'Y-`-Y*`A[D
M\'YU8Q(41#`91$I=2_VEE'E'0-0U^3`UT'R^6@.7_!^=6+_L#_[RB_<V@*#X
M/SJQ=FF!/<U_M*+IQ]_Y-H"]93PH/6@F[+MC',S>.)I6PK+?2LE:5G/\P.G-
MNVY(3IDSS3R&BE&(M(]Q*F2**YTRE,KRAS:Z!H!Z<:>%-ZU.&;UB,CXEOC%>
M-[^M\SH\'>-EYE?6]<<2+YFXCWH,):-:(/&Y73!THBH`&T,D<2CP$:`S1E7P
M[?B*,Y6P>RLQ;H4,EV>JHFJO:]Y[E[JGH!RHB/,D9U$OA58NA3$.'>$-I]2@
M/D8@\-UX@?`%L7/96$]P%LXNM&\Q$]SVW9>?):$AI=<R?<F=KL&C4C=-\9(>
M45TRD6$HZ<VE`9FVT>&3Z@),]VAE?J"%=;C+5Q?!LU[`MZU,^I.+@=W':\HA
M.6E;$].W.@H]96`J^34*Z!LIWZ95!%,`$>(&%MV_AFNL_O*W(Y=W+9)1P"UN
MO+-WOKD<QC?*BSME;T:J(-H&V8Y9VP%=6/M^%:H-2&'4=":CQ$=`$Z?\'YU8
MO^P/_O*+]S:`OK%GA(NJI9N3\<W=*%P2,9:U]VE<,B*.1@55!A#3S&0=F23"
M/**AP;MS<H:AJ-`/!=?'P_N_+J.[R+5SC@$,4C9$1@^P+"<#=-Y?(DH$_;K9
M=*4`&IF:X':"=0.Z.`\0#C0#)\?X0SJX13]G*QCO!3"2CW2#Y@^:Y.[ETR>M
ME"KMG398D<!T7#=8@'(<H@8I@`0'6@%O)=#GQ/"*!&R6]VXDVZ9`3(B3=;>@
M)%(!>3EY`4Y1YB\!U^,';K0"+A\(]U@1N$UVC-85&Z#S`W`:X/[5E`F!G#.Q
M?FEO7PCP<?*!GP]Z*O-S]YZ6NM`+`ENA%XF6<A'=MRV]&<?04@Q/&OHM7=;>
MH-7<>HF9%1DX(FJ056QT3"42".@EX=E`8`P_X77KE[?[W2R3A/*6/,77ZDD\
M;C=EE9MD(.:<-I`-'[5Z[9LTS2#1YKJJDOWB9QXB77C0&0YGPTG7`S'<L6QW
M/9F996Q=+W_`W?DF$=;@G\Q)2";,R4=(REOLYY!:(2N9"WS*I-#"1-,HZ%'A
M0"@^H5X=OJ3[HAP'A[;Y8>-L9;3-IF-EL9X*M/(>9$IO($JG+RJ\]>-^7\[:
M1P1?WS73-KB/<-@!)LV(4A>%`8(?^'B\13+8?)@"2W-L'N%R1R4*7&[K<7<"
MML?(B)@,C!&9'2,)X),W8R,86P:!Z'`*`2F;P?G5B*4>&!1#AZ)<E`(AIH&I
M0",$1$=./NT!L">C5M*ROL=Z=N`=LN;2V^3).-XV<9W`6V),9B'*=_.OY!L#
M:0[E`%Q]7<%$VA=`&@(:V]/PEO4,S[NHW*YYLS)NW(MO95RYD'(EK14E<USL
MY8T;<UP/I:/CGQ?O:4:M9(B*Y2*?;#)`<!T-Y*`0^3P?W5C.740P(4=1`0')
M0AIH.G[>*((@(<=0#2@,FXF\+'UO<"7FPR-A7(V-,87W&IKMV=U63FE_;\RF
MT=`4'3)1VP9)F<,70$+WJ"@'24T#F*.E`<\P>%KZXFX&\7&0LW9)QQE6]G:"
M35:Y+YS9(7#*%9M]?5V2"\@Q6]48H:CR((@1(FO`H4!<6%?#-=>W;BM-N,!Y
MJM'#BURD:)W"ICG/DS:@S2;$RIF993Y(:M@>@T%8XI@IS<O,.G;0!F;PS?7R
MW%'C#YYSE;68`A.<8=+(FX:XKK;11E0Y53Q[281=-F:JA>!C)D*8P=HT!=UJ
M^'6\1#8^*28-L[<G&6QB)-45D,?PFXRX8VW&9CK%<*),6C5NF+!L=<H',B@9
M-$Q@U$HC0"M]BWA^>HIMER]?F\;.5JQN?-ZEM-5I';3<KG/3;[Q6-_R%NO[:
M^_#,;]^P/<DT%K(.R.62"!Q!PHD4JH\H4`@>T_"_=<^P,LO\ZX_R9C>PLMR,
MW-7"ZOJS<UR-O3ZDG<+Q=],F%]',D%E&T@X<G%5$XF24`=#%$*`[<U>&!ZZV
MY.ZVEY9]RSC_`"S<S=LG&-9N_,VR-P+Q4;WG,+2/3>,#HQ[`AS"<4FY$RB(:
MZ"-`?.#P874H$I1'+^V`!Y2F$OWSW@/*82@(E$?O1T'E'@(]@Z4`]#T'_#I[
MR^F-OG;[D\W9!PC<=BI8QO6SE(ZQ)FXY"?/*7&BU38J)HR4#&M2-43("*AA.
M(CJ&@4`K;Q+?2#W9]55MM.0VPDL`P8=<934O`;VN<+=$H7<C9Y8@8_\`V1SZ
MV`F@U@4#T>74HT!%1_X/OJR?Z.!/^\P/N50`'@^^K)J'HX$#CV_VF!P]_P#D
MJ@%079X='Q#E^8ECL#7GN/B;GPW$H-&;'',WN)N!_:Q63`2^H,5HY=N<CQ@P
M`H=P@L*B2.@<A2T`G*(\(GU>("4CIR$?8/B9F(>MY*+DX_*1VC^.D&2I'#1Z
MS=(Q9%F[ENNF!B'*(&*8`$!UH!8LYT'_`!,ERP+ZV)[>9-R=OR;,\=(1+G==
M>XM'C!1/NE&;A,IRBJV42]$Q!'E,7@/"@,%89\+]UU-NUY'R'@S*N/L57NJU
M<,G%R61F^0@Y-\R>&YG3*16:,"%D6BY_2.DN50AC<1#7C0%^O?#-=:_,%U0+
M/=7EYGE;$[S(;"\\A0BNX!_.S;H5`28SDS;+:X6KB*;W2:%*9)N<2D3]$I1]
M$-*`SYU#O#L]3/=?*8-QK@JQ,98PVI;4,6ML0;?+*O[,R,[?JL.9^M,7)>=]
MOVD:,<>Z;LFEQ643;E!%LF0J9.%`8.G/#P^(JN7$*&!)_<S'S&&V\>C$$QU(
M;C+@<VT,.U$/5H9=HJW,9U#-^4.[:*&.W(`:`0*`2N7P?G5C#74N!?J9+*/_
M`.EETH!;N3_#!]2ZZ]B.UO;A&)86-?.(\MYVO2Z3*7\)(XD1D,MJC;XM'@QX
MD<K<T2L"I``!)P&@$2?\'[U8_P#F\!&_Y>2P+IYM(WC0'+_@_.K%_P!@8>\&
M2PT#W@_ZM[`H"];$\*-UI,6RDA-XXO3%5C2\M!2UKR<G:F8GD*^?VY/-C,IJ
M#>.6#-%5>+E6AQ371,(IJD'0P"%`64'@_.K$'9_8&'O?VE!Y?)_)M`9VPQX9
MSKW[<_ES^P3.%IX="Y@:!<08YS[-6F6;]0,H9E\J%AT&H/A:"J;N^\YN3F'3
MMH#KS+X9;KU[B7$6YSSF^U<PJPA%20P9&W`SUV(Q(+@`+&C6\PFZ09'4`/2,
MF4HCY:`O2)\.[XB>!Q=%85A-SK*(Q3!*HJPEBQNX^XV<%$>K+E=-T8Q!!,BC
M%FBY*!RMTCE0*;B!*`5CL<\/SU$=IMV97W5WQ:$)E_?T=A<J.WZ_7>=6:6-[
M?N&^;<D;7G,AY(<.8X]P3=TP+20579)%$Z2ZIBF4U$M`(4Q7X9'KQ8,O^2RK
MAK+UAXSR%.&DC3=TV7F^0@)69"4>*O)%*8%DQ(A)-GKM053)+D.D)AUY0&@+
M8RSX6'K>YYO-]D/-&0\:Y1OB1321>71?&:W]Q3"K=N42MVI'<BQ7.@S;E$03
M13Y$DP^*4*`<IZ''AT>H-T^^HQB;<YG0F(_[-+0MS(49-GMB^/EF:!Q<EKO8
MB-*UCBL&_?`9VN7G-S`!2`-`7CXD/H?]0GJ+[[K6S?M=QQ:5UXZB\&6C93J4
MF[_@+8=)W#$3=QO'S3Y/DUB.3IE0DDC%4`.4VHAKPH!/U@]._P`1M8=@XPB`
MVG[-;JS5@K'J^)\%[K[ME[)EMP>*,>F;N&C"$MRYOEA&'=/;>:.U4HN0>L'+
MU@0^B:FH:T`T3+^%8ZUD]*R<[-XCL.5F9F0>RTM)OLT6DY?2,G(N5'C]\\<*
M.#*N';QTL=10YA$QCF$1XC0#X8[+?$&2EOXSC;]Z;73$RO<N)L<V?B^T<AY,
MM^R;LO).V;$C$HNVDY)\]ND&LDLP;H@(=XCW8F[2Z#I0"7(/I7>)ICMY"^^"
M;LG#=ZY8D+2E,:3%N73?./7.+9+#\W$#;\GAT+"9JLHJ,QTM!&]6(P:]SW10
M`Q3<^IA`NC)W2MZ^]];><N[2;'V0;'\!;;LUO;4E[HQIAZ6M2"19W5:TVC,1
M]WM;AD+AE+D7E2J%%(2N'*Z";<QB))DUX@9=S5T*.KE8?2(Q)TTL6_>)F-W<
MF?+ASKEY^QOV/MZV,?0;5FB6T<7V^^N`(Y_.IN[A7<RK\Y4O5BN!*4FH>E0%
MOXEZ97B,;`L/'#5GMSV-/LQ8;L,<4X@W/7L_LN6W)XVL)L@Y8P\1;MZ$>@P,
M:WV+Y1".>.&JSQHCH!5/1"@&JI?PG/6?GY64G)NS,12DS-2+V6EI-[FFWUWD
MA)R+E1X_?NEC$$RKEVZ6,=0P\3&'6@/FAX2+K%ZA_P#U]AGM_P#]DMW_`.[H
M!?G_``T_51__`(=AK_Y7O[,?QH1__O;_`.K?N?\`T7_TG90$Q3JZ=-6Z.I9B
M"Q<56CF"2PD^@[N-+3-\1TG<1'*<"DT5=I1S2W(IVA"S;ES.M&8&,_(8$$`.
M=(04TH!86UO#C[:;M4L'&4V\?WG<&,[#75N609S-PW6\NBX6#!9[,.8I[=2R
MLTX&7<)#W""Q@[LR@)ET*`4`W3MTZM47E_&N"LTY4;O<#1=YVCN<N^Z\6S./
M)Q_-W%;F!)*3;N;GM*Y"22B+&-81;`JJJ2Z?.X<"<A!#EH"\$.N!M&>MU/DV
MPMS\E+N,<,LU6G;;+!<^:X+_`,)+$[Z3RW:;(SDB;ZR[<1*)WZJRB"Z8:<B2
MFH:@9ZN[J?;;(1M;LA9S#*6:&$MB6$SQ<#S#EAO+O2QQAR>2]9BK[R$`NV*L
M$Q<-TU%00*"KSNT3F[G0NH@9ORYO*P'AS:^YWAW#=3F;P0G;=OW6UN>T(U:X
M'$S"W0Y8,H->'BD`*[D7+YS(HD*CH"@&,("`"`A0"?6'52VSH6?ERYL@Q^5L
M0SF'&5D2<_C3)%B/(7)D[%Y1=$88SD;)MIHN^/<Z=]R9RM69&ZO.1R/(L5,=
M=`/BGZM&VF)M.[Y.^[:S'C'(]EWC8%ANL"Y!L8EOYEEKDRL*A,;(0-OK2JD9
M)1UWF14(W=@]*W342.10Y#%T$"PLN=4UW;$GM$:6'MYS0\-GO<[-;=,E6W>M
MB/;<O/%TA;\*>2E#.8]V_29OU3JG2.BY;+.V2S;G.4^I=*`O?)/4HQ!MYOS/
MK++%ZS-T1%AYBP_A6WK'Q_BR7?7;"W[E6U2SEMVRH\1?*IW<K<1P#NED2))M
MA]`XA\:@/#$=3+%>45L6IVG<5TX7G!W/%V\Y7QAF?%S]G?<5<X6N\N@MKS)2
MROJ=H$DH5$'[>7%5RV,W`0X#PH#(6/NIUMUR#>UGV\WCLF6K9&3YNZ;9P[G"
M\K1/`X=RS<5F)OUYZ(LRYU7RJZJI6L2Z5:G=MFR3U-N<43&T#4#$5V=7;$IL
M?9*N[&^+<Z7&$?BK,60L(75+8RDV>+\]+XAB7CR<;V3<R3M10C))5KW@*/DV
M!7+,JBB`J"72@/@XTZJ=AJV?;.7,YSK[%L5);/L79\N'"KS'4J>]HZ>R#<2-
MO1(6[+-I%V2X#73,.4V<5%$2]96$Y5#&`-:`R*]ZNFV.U\?Y-O/*%N9OQ-<6
M()K&\5?.'[]QL[8998-\P2Q(+&L[&6LP>ODY^W;JDE0117:+K]VKJ14"&*(4
M`HW:MO2QCNNDLHVU:MN9+QWD##,]&P>1<99>M1:S+WM\L_&)S-LRYHH7;YNX
MA;@BE06;+)JFU#@8"F#2@%C4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`:4`
M4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`
M4`4`4`4`4`4`4`4`4`4`4`4`4`4`4`4!Y7B/K#==`%.Z%9!9'G``$Q>]243Y
MBZ^4@FU^I0$=6TNE-ND6QOCG'UXWEAZ.-AK'&]C#]MR\,O<;D+Q@MQLE)R%C
MW-)H';$/%R,0:3,G(M0YR&$.9,WDH!7MM[`,IPV0L7W<XO.REVMD].27V=2"
M"*$J5VM?C]JP0;7&U'N0(%J)BTU$AA]8`-``.'$!!;;HX9LQH-KSEMV[@?.U
MQW1MKQM@[(T7D6^,JV';EE7ACEA)Q#2]+;2L=VS->-FRD5(Z/8F0("IUB:$'
ME,-`*UZB6$I[$_2$?X/L!G:$==MDQ>$[=M]*T[9<LK!9W3'Y%M%<%X^VCK.W
MK6U22G,;NA4,L1#M$3ZT!9N2>G/NBW-3=][B,QWGAJQMQ<;'X)0P#!60G<D_
MC"&4PG>/W_F>Y`<R[-G,R*.0)=0Z"B2"0C&-Q*9,3'`1H#T9&V$;N\^RF;L]
M9DCMJ,KEK)-KXGQ9&[?9N'N:[,*/,28UN.3NN9C)V\521UWL+_NF<EU%8^;8
ME(>'*0A2<#&H#!EP=(+<5=V"\:6-==YVG-Q5F;P&>>(3;[*Y)RBZM;&>(',$
MM;<GBFQ,Q^L%R.=XT*Z4D$C*K]UWH]R4W(.M`*1N+I<9#6S7,WU:=^VC%6*?
M=AMCSA;D)(!/2<U'6)@S'3BRI6W'\DY454D+AEG1B*(.%#G#D_=#<W&@$O[K
M,#A:._'&=B3%WQ5T7=O-WP0N9X*QK:0<_?1:>%;%P',8VO2Y9UR]3%HFC$NY
M(.[,F;D`QB\!&@+NV^='J_,<R6,\5WO8^VB2Q1B-U=Q&^<DG>3K@S'>D%+1D
M[&6H2(LN:FC6-8%[0J4LGZY*HD,4_J_V@@=X:@,_8WV<;^XS"T=LZNG*6!X3
M;ECW"^3L/0UY6U!SDEDG+L5<MJ2=JXY^^AA*(E86*2U$7R:DJHP544D%$_0]
M$1H#!KGI2[G[\M>RIF]LAX<M'*F+MM^WG&ED)6ZSN&X[24RGMGR4SO&S[@FT
MY1%%\I9]VQK$J3Q$@>LME%.8NH$X@9%R%T[MUNYF^+MSYG&Z,+6-EB9N/:Y"
MVY8]B#<<_9ENXUP)E4,FW2Z?S4JV0D9>[[U?F,5D3NRMV"8%*(B(F&@'!L,;
M9+KQQO(W:[CY6XH.2MG<%$8@C[:@VB+PLY`GQW;B\-)!+K*AZHJD^64`R()#
MJ4I=!H!;M`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`
M%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`
-%`%`%`%`%`%`%`?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>pg97a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg97a.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`R@)"`P$1``(1`0,1`?_$`/<```$#!0$!`0``````
M```````&!P@"`P0%"0$*"P$!``$%`0$!`0````````````8"`P0%!P$("0H0
M``$#`P($`P,%!P</$Q`+`0$"`P01!08`!R$Q$@A!(A-1%`EA<8$R%9&A(S,6
M%PJQP4)2-C<X\-%B<B0T5#6U)G:VET@:X?&"0U-C1)355F8G1U=WAQA8F9*B
MLH-D=-0E585&AI:8&3G2I$5E=96EIBB(N$D1``$#`@,%!00(!0(#!P4!``$`
M`@,1!"$2!3%!41,&87$B,A2!D:$'\+'!T>$C%0A"4F(S%O%RDR0)@I)#4X,T
ME+)$)34V&/_:``P#`0`"$0,1`#\`^_C1$:(C1$:(J5FB?D)`)K2E3S^71%P.
MWYQ7>+N>[U^Y.UX-LQ$WBP;:':C"-F[!-R+>J][48[@&[.3LW+(\BR`6BRL^
M]Y2]$LUS@K4I#@6VE'0GS'1$S%K[T^X[M[W`V4V"M6X,7=>R;9[GXIVOYR[>
M,>1[_FN50,>F9!NID<F9<IDC,%1<(B^FU;)3;#<24RU5:E+4=$3/8=WI=V&U
M>%8;,A9!:]^,WSQL9?!W"O:FH-MVKF=T.Z>3L8S:;S*4\Q8!:,)P?'4^E'F+
M2&Y*T!13U4)%(&V]^/>WD^/2\>9R3`\18V]VO[AMW\QW:EXPU?KIE&WFVKEN
MMFW4JW8_;!^3UNR+(\H<>8E);==CN1FRIJJB-$4J>PS<;N`WI[BNY#>#=+/7
M9F/8ALUL#A#&Q=CMS3$#&]Q;IA"-P,TO%M8>(F^]WJ1,0VSZW3U!SI!HG1%R
M_P!VN\SO"RWNFWGS^[87W%;$O;3=LF26['MK,@QAFV;<;4,;J;EV;`,2W@RJ
M^0)DTY1E#MC:N%U;=6W[O`90$]`*5*T1*^[Y/L%MN]O5B,_>O<[*^V67ENQ6
M"X19,?W8N+<GNJ[I&K`_?<\Q['MRKG<$1[=A;KCS"LCD1);,-@+J2.D()%WT
M[.<3R;`.UC:>Q9/<X61WNUXO/GJ58LI.=0&(=RN5WNUFQJS9BZXI>3Q\?M4U
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MR0;@\EF*;8W;$+"72[0:(HM6_OH[Q=W[#8</R[N`QO;'/<5[KNW&^93D6/XC
M;'\#>VGRW,YUGN]CM>?6F9+QZ[XE/E04H;:G(BW1/6/62.&B+W=OXD?=7G>7
M[U[3[?;MVAC&=R]F.ZY[`\SMFWS>.R=J[[L@ZQ$MUXQA'VC=<BN294<O)D+N
MK;'4L>K'0I`KHB<7:WXB7>P_O1MO@$)[`LTPG";UL)M)D+MXEV.U7#>:+F^'
MV>9D.[]D>#CE_E2G7I:E0OL]IVWJ4TI+JTJ)H13A[K#MYFO?GB>U7=?G-SPK
MMQ3VVW7+]K[9,S*Y;>X!F>[*<GN,+.S?\EAS+2S-O^+8<B))M\-R4DCU%.(2
MI7#1%"7N`[^;]V[]OFU5M[-M[LHR_$L7VJW0W,L%QW5P.1D67[BX]@>6?9EK
MBS\KRN7967\%475Q8LB(U)NLUEM#B:H\Q(E58?B2]YAE2-[I4/`LGVIRJ5N[
MAN);+6;$;HC)K9>]O=F[5N7:\K>RAA3LBZMR+N^_'?B!/FBI2$_A`=$2=S_X
MA?=QM]BFVN'8QOYL5W`9AO?DEEFR]R=OL:M]CM7;U9KCAS&5KQC,)]VFJP9<
MZYSW50K:)LAF<A+2_60%T`(I8]I?=9WC=QF^6Q.(YC<]M<#Q:W;"W#=/>*TX
M_;#DLC<.\ISB\X59FL;R0*3;[/;)<6VHER0SZB4K51HJ2=$7;1/(<:\!QX<?
MN`#1%[HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$
M1HB-$1HBY'_$:WWS[&-U>UW83;N^;W63\XMRS;--SY';YBEMR[<<8%AUA<1;
MH[$&>ZTW;[5<,I=::D2$JX`=(YZ(HNV[O\[B.TC;.5`WML]TSV\2L@RO<;%H
M.[DZ#CN\&.=O,*YQ++C3.Y-GQ2UW2#"S7*KTX\FV>\.MH])"4N$JY$6NR#XH
MNY^V5[W3W`WLL=Q=VJ3OKN0-AK+ME.@2,CN&`[.V#'L?N=BS&(N,X_*9RG</
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MTVGR:U66%M[V_P`>+<PG:PVZ[6!MK('[-*A/-1IR9+JG)+O6XDT!((I[_#2W
M"WQW8[1,`W1[BLFM&5[E9]=LSR-Z\8_9_P`G\<<QN5E5U;Q-C'K4LE]BSL6)
MED,J>)><3YEDDC1$M,\[[>V#;7(MQL5S'/KE;+[M2+6O.83."9Y<Q:A>I#,:
MV^A)MF.2XMU]X=?2/YE6\$"I50`Z(GPRG<2)!V>R?=C&8BLBAVS;G(,]L$-R
M/*BNWE%MQR9?($,Q7VFYC"KB&`V4*0EP==*5X:(N3?;O>M]_S?=OW>]N;WV1
MIN/[O6U>8[A;'W?'<6.W=XQ^\62[7RW;<;1"$J-?H.<X;[N&O6#KZY3C#R7D
M`:(FRW1^)[O?=-GKK>7=LF-B/SK[>'=GMES^U9;;-P)MSPG&<QML'*(N=6!,
M2.,=OTK&7E2&4@NLJ4X&NH.C@1+R_?%LS;#\9NF5WOMP%RM6?;=R-R>UE=NS
MZWBX[KV:V95!Q"3"SN"NW_[7MV>DRDS4E?O#*&"6_P`8"-$5N[_%\R;%]^5;
M+Y#VZW"XL;>9#@F![]7?#KM<LDD8IFN<V*%?BO$6V+0+5?,:Q>!=&3-=D2&7
M5CJ+:2!HB3N\?Q&.\R?L?;]W-G.W[;S&<3W(W,P.U['Y?D.[&/3[GD^*3=T&
ML+OC6688N$B?:;I>8#+K[!CEYN.DA+J@O@"+9[L_%>RG&=Z,D[?%X-B=I?R*
MQ;QX9AF<8EFJ<KR'%MSMNMM[KE*;IDMH396,?^QW9T%:$1V)KLN.I`]9`J:$
M3N;M;^[WS^WKX>^$XQN.UMOGW>+<=NL2S;?!-LMTV?B;,O;I.:7^3C5NN2%V
MC\I\MD1#"@%X%#:WNI(*@-$5.2[U[L=C.!;B8]D'<!A?=AD<3<7#K!@4'<R]
MV;!<\VVM>6VAV:;=N9/QJ%>)F6K=>;+UO3%MZ)KL98ZN`)T1,9C7QCMS-R]N
M\/S7:?M:B9/):VEW)W@W8;NVY<.PVW%;#M!G+F%Y9`Q9U^V>]9!<;HB.Y+MR
M'4L#I'2[0\-$3S)^*-E#N/;B=P<;8)E?9IM@O)K)D>YLK<BR1=S7,MQFRP;E
M/BVS;1YE*IUK-SN2(+?IR%OK(+P26QHB9G$_C);D9;@MUG6[M0N4G<*Z9-M%
M:-MK4YDLFT83D]MWCE/-VE%SRB\VF*NVWK&(S:7+BTVT\RYU4:53CHB[.?:V
M\/\`K/Q3]Q?O_P"Z)W]WG_D/^=/Z1_\`=7U_DT1.SHB-$1HB-$7A`(H>6B*&
M%^[+[!=,IRS*[?O7O[B<K,[P]?+U`Q'.(5DMKL]UM#(<]&-8@ZZIJ.@-H4ZM
MQ80`*T`T1-XOX;&T3V3R,X=W"W@=S::E/ON9.9#8%Y5+4EE48./WU6,*N"G3
M%66RKKZB@T)(T164_#.V918+MB:,\W=3BE^:1'O.,_;^/JL-TCMR7);+,^UJ
MQ=462B.\ZI384FC:CU)HH`Z(MG'^'7MQ#@IM<+=??");$V5K&DVYC*K(W"_)
MMA2EL8][LC&4LFS-NGK]WIZ:ECJ()T19ML^']AECNETO5CWN[AK+=[\(0O\`
M<[5GEN@S[]]FQ_=;:;Q+CXZAZ>JWQ@&V2X26VP$C@-$63)["L5G/7.1<-\NX
M:Y/WVVHLV0/7'.K;-<O]F;#J46:\KD8XLW"TH3(="8[G4TGU54`KHB;Z7\+/
MM_N>+V3![ADFY$_#,8<D/8UB4R=BC^-8Z_,3TS9-BLJ\35`M<N<"0\ZTA+CB
M>"B0!HB<*S=AF,XY:;?8,<WX[CL>L-HB-0+18['N##M=GM,%@48@VRW1+`U%
MA0V0:(;;2$I'(:(MF>RAE06#W,=U!ZTE*A^=-%*5)31/V&0`FO(<#3CHBP9_
M8E8+O!?M5\W^[DK]:I(1[S;+UN)%N4"06WD/MEZ+)L*VG/2<0"@$420".(T1
M>7#L0QN[1XT.Z[]=R-SA0I,>;"AW'<6+-C0YL0UB3(K4BPN)8D0_\I4FA:/U
M2-$2?_\`AR;8?EI^<H[H;TJW*^S#93N(O)+`O-U6A3*F'+:YDJ\75='(;C:N
MDH+E.GR_5)&B+0P?A?;$6ZT7K';7E>YUKQ[);LSD&2V.VW3&H-KR"_19`EQ;
MS=XD?%T-3;E$E@.M.K!4VZ.M-%<=$6;;OAD[)V>XW>\6C,]T[5><@5+5?KQ;
M[OC,6ZWO[085%GINT]O%!(G-SX:RT^A9*7FR0L'1%8B_##V/MUVQO(H&8[HP
M\BPNTBPX;?XUUQIJ\8G9$J/HVG';@C%A)M5OB)6I++32DI:"CTTKHBVV:?#I
MVRW*M#>/[F;I;V[D6)F8U<(]HSS*+)E4")/8'2S-A1KQCDIN)*2/K+;"5+_9
M$T&B+`OOPT]F\J_)T97GF[64(Q!KT,38O]XQ>YQL8CJ:##D3'XTG%%LVF$XP
MD(++(2U1(X5T1;J)\/C`+>(8MN\&_-O-OD2IL$P\PM#`AW"<T8TVX14-XXEM
MB9,AGT'5I`]1GR*JGAHB2C7PN=@FL4O6`L9-N0Q@F37,WO)<-9FXHWC>07GJ
M6L7>\6H8I[I.NC:EDMR%H+B">!T1._M9V583M!E^-9?C>XV[$ES%[:FRVZQ7
M+(+0K'C8F4*$6PN0(5@@J;LD1Q9<;C-+;:2X2JE2=$4S1R'S#1%[HB-$1HB-
M$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$5"E$&@IRT
M10CWE[>M\LJWQM>]^SFZNV.W=^MNW;NW2).6;0KSZ^(LDV[IOEPCP;M^5=E]
MRA3+DTVX4!HJ);`*B.&B*(6\?PU=\M_\N9SG=G?79G(LB-@A8I=WX^PUQM,7
M*L9M%Y&16&R99#A;BM-7Z#8;\/>HJ7NH(<)X$$C1%J6OA;[JML99$<W=V&EQ
M<S;RYBZLS>WMZ3[C'SN]-9)DXQU;F>E=@?N&11VYOJ1RA:'D)(-`!HB4^$_#
MP[A]O6\0&/\`<#LW(GX+<\JO>.Y!D.Q,_(,D;O.:VLV/([O/O-TW!DRY\Z?9
ME*B]2U40THA(&B+8[8]@?<?LKD[>9;5[^;&X=?6\"M6V17;^WIY$%[#;+<Y=
MXMD-^&<]+2IT:X3G5>\4ZUA=%$Z(D;:/A>[JV/=7(-Z;=NUL,O.,E?O4^X1[
MAL%<[GAD:[Y/%7!R;(;1A4W<=_'K3D.007%LR9C+"75-+6`1UJJ1;/9WX;.^
M&P%ISBS[5;W;(V&/N1%E6S,9<_86??;K.Q^7'>BIQ&#=+ON%+EVG#H+,EP1K
M;'4B,P5E24@\=$3[81VZ=\.W&(8W@6"]T.R&/XAB%G@X_CEDA]MW7%M5GMK"
M8T""Q_7ZE7IQV$!()J3S.B)1*V@^(,I2E'NUV6JYP<__`(S-GU0*$!PJSLE7
M20"/FT1>G:'X@ZDK;7W;;+.,N)+;K*^V=!:=9*2@LN(_+P)4V4&E.5.&B*'V
M&_"EW'V]W+9W9Q3=?8F'E4&?>[SCMKF[#7:Y8+A5]R424Y%>\&P6?N1(QW&+
MG>4S'`\['8"@%J">D*.B+#Q?X2V<X7(SMZP;I;$TW$CIA7N'>-B;I>X%GM/V
MZG)W;!A4&Y[C2HV&X]*OR1)>B0$,M/*X*!3PT17X7PIMSK==-Q;NSNOL/+D[
MIN0ORG:N>Q5TFVZWP(5\8R1NRX5:WL_7"PJQOWR,B2[%MZ66G71Y@1PT1*6_
M_#;W[RC>*'OS=]^-G/SCQ)5HG/KMVS=\MF*Y'<\?C>YV&\9?B,+<!BQY'=[3
M%HVT_(96LH2E*B0`-$2`_P#A!YN)FX\I6ZNRX&Z*?_'D8[.7Q<7&E_;Z,J6K
M;>&O/S&P`O9$W[VLVU#!+A5X*.B*U&^$%G,+-7=P&=U]E'<E-TOM\B>^;.7V
M39;/>\LLLS'\NO%HQ]W<!=JAW3++7.=3.>2UUNJ655J3HB?/.^Q;N<W+V=M^
MPF:;Z[!WG:ZRVZQV['[%^8*9!EXU^3"&$8U<,<O$#.(]RLUXL(C(]VE,.(=1
M0\34U(F+3\(+/VMOV=MV]X=H!`:SV%NDK,7MH\BD[IR-P;?&5;X>32MQ7]PU
MY(_*8M2UQ$(+WIMQE="0`!HB6>%?"^W7VXQZXXGA&Z?;[9,>NN&95@$^WC8:
MY2S(Q7-[@J[Y7;'9,K/G9+OVU=EJDO.+6IPNK4:\=$6L;^%/N2G<-[<][=#8
M"5D4FR?84BR2]B;G(V_DH5:$8\[>'L#<S_\`)M63/V1M+#D_T/>%D!9/6*Z(
MKF#_``L]X=M[6JSXUOGM',A+RW%\VCIR[:'(<P?M5[PB0\[B+-A?ONX4U=EL
M^/>]K3'C,]+20H`@T&B+K_\`9.XW^O*R?N.]Q_<Q_P"FG^N/^F']*/\`N#ZW
M^>Z(G#T10J[^^]3$^P/M\G=Q&;8;E&>8Y:\RPC$YUAP]R$W>D)S._P`:Q"[(
M$U*FW8=I,H/OH31PM(/3QT1-S>?B/[1VGO5Q;LX7;+GZ]Z[=KSW&7_=UZ=`B
M8!AV/VL1Y<2PWF2_18NUQM,E,T'K"4L$5'&FB+<9K\3/L^PZP[8Y*C=:#E%A
MW6WEL>Q>/S\<BSY2H6=WZ.](M[%_A/0V;E:+9*8CE;4IQE+#R3U(6I-3HB=&
MW]\_:+=)^X-LA;_[=F7M7;)5[S<2+PJ&Q:K3!E&#,N+$J8PQ%O<*/-!96Y`7
M*2'B$5ZB!HB;Y'Q)>T65NAL=M=:MT;7>+GW`6#<K(,'O41F<W86HNU4./.RJ
M/?I<R)'58)D6.ZI?IS$L*"4%1%"DDB5,#X@O9I<\4RS-8?<%@;F/X/<H-HR6
M1[U<&YD2?="4VIF+9WK>W>+NW=J$Q7(<=]N0D5;4H<=$2KO'>=VN8]'V[F7C
M>[!HT7=F)'N.W[Z9[LAF^6Z7)]RCW!3D:.\FUP'9_P#,_KS?=VA(!:*@X"G1
M%O\`&>Z7M^S7=.];)8ENQAU^W4Q]#R[MAMON#CT^.8C;3TQAJ6ED6N;,A,/)
M6\PP^ZZT@U6D#CHB1V=]Y>QNS]YSJ'O1N#A.VUIQ*_V3&X%QNV1(ES[U=[OC
MGY2JMOV%!B/7*+<6+?5Q+(2XMUH=:>`T17MVN[3;C;K8:R]Q&./M;E[?Y/?=
MOK18;GB4UB5$NS&X&4VO%H%SC2B0V(T)^Y!;R2`M'0I*DA0(T1*^\=SO;UCM
MAAY1>]X<'M6.W"+E4N'>9MZ99MS\3!NHY?($E7X-+6/`4DJ40$$:(FPMW?YV
ME90IVU8'O=A&<Y5(Q/,<JL.*6&ZJ^V<@9PJTR+O>+=!$J.RU'O"8K'6B,\I#
MZFU!Q*%-^;1$E-B_B1]I&^&S3N\]KW?P^RVJRXO8LFSRTW2Z]%SP9N_J4U$A
M7!HL-N7-PSTJC(5"0^E<A!;22H4T1.+`[Y.TJZV?;^_0-^<&D6_=3)Y>%;?H
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MD$6-=.ZSMUM&XN*;4S=W\-;W`S.!#N>+X^U<A)5=8MWBF595(N,=MVT1WKW%
M'7":?D-N2TD%I*]$3?;+=\6R&\&UU^W)DY':\&3B-UGV;,L?R>XLQ+IC,G\J
M[OB-B7<T=-6FLHGVE?N9"5%PJ"157#1%L<)[T]ALBR##-O[]N'A>/;G;@-39
M>-86QD(O*[A"9N4^V05MWF+#;M3,RY*MCOHQGG&I#A0H(0JFB*0^X&XF#[4X
MA>\]W%RBSX;AV-Q!-O60WZ4F';K?'*PV@NNJ!4MUYPA#;:`IQQ9"4I)(&B*/
MEX[[>T?']N\<W9O&^>&P\"RVX7&TX_?%*NJG)\^SD"\QC9F[:N^Q5V6H,PO1
MFQ&207"D&NB+=S^\GM:M6<X9MK.WWV]8S;<&SV^_X;8C>TNJO=HNT1R?:)C4
M]A#ELC)NT-E;D5#[S3DE*3Z:54.B+(P7O#[8]RDSEX-O3A&2MV^)D\^0[;IS
M_HF!A;?J99/C//QF6YT''TBDEY@N-MJ!23U`C1$D;]W^]F.-7U.-WSN1VQMM
M\7;D746UZ]J4Z(CUK1>HJ7%LL.,MS;C:EA^+%4H2I;?%EM?'1%(+:[=3;W>G
M";+N/M7EUDSG!LB96]9LEL$KWFWS`RZIB0WYTMOQY,9]"D.M.H0ZTL%*D@BF
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MTZXSD1CWB`]]@NM(+CC5Y].0K[,6VA!)#W00`=$2+E;Y;10<VP;;B1N)BGY;
M;EVN\7W`<>;O$9^=EEFL#9>O-RLGH*<9FQ+:UQ<6E=!HB5[><84]:)N0LY?C
M#M@MS[T:XWMJ_6IRT0),=70_'FW)$I4.*\RLT4EQ:5))`(J=$65)R7'H3MI;
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MKQ=FT,WU[)+`W9'G$,M7E=WMZ+2\\MTL-MM7!4DQ%N./)Z0D+)ZN'/1$C]TM
MX]O=G+7C=YW"OS%@MN69C8,$LLN0DEA_),D6\BTQ7'>#<=MXL*)<60A('$\=
M$2S?R;&X<"%<Y>062-;;D^S&MUQ?ND%B!/D2E%,9B%+<?3'E/2%"B$MJ45'@
M`=$5]V_V)BZ,6-Z]6EJ]R8ZYD:SNW&(BZ2(C9`<E,6]3PENQT$T*TH*0?'1$
MA+AO3M-;<]QC;"9N!BC>X6:1[O)QC$?MF&J^7N/CZ6E7ER##0XI;AMR'TEQ)
MHJAJ`=$3I<*?)][1$4\?'E71$4'L\:_3[?GT1&B*&/?+VPRN[7:C&=K6KG:+
M?;HFZVW^8Y*S>F7WH=WQG&KJJ9>+*E,<*6F3<(YZ6E$=(4*GEHBY'V[X)NZ%
M^PF^67='N!M.0YKDV([\X%?<\MULG1K@_A&2,6JU[%8\$O+2MV%B&/6-F)=#
MU)+Z5*+9KHB6>W'PI=Y,)Q9C)K:UL!BV[\#>?9W.68$-&9Y9B%TQW:RPW/&R
M_=KKDCKER^V)C-T5)CL-L!AA2`V5*0>!$V=L^#?W&7W/,LSK=C<'9?/'I&S&
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M;-SFL2O%G7<)"&[;L\K;5MM`E,NP_M)$PE]"R*!E13ST19-K[#,OM78[B7:F
MQF&/HO>.;K6K/G;VU"DMV5RTP=Z5[FN6>'$2D.15&VN>[-D)#:'!6G3PT10T
MR;X4_<MGEO3M?E&YFS*]G,`9W]@[9E&/7J3EN36[>F[Q+HR<\;>1]EM&QH2[
M'=;8ZTRDK254I31%)B__``U)$R\BYV&\8'CCW_*7SC>D2K9CC4&8BP95LU"V
MQC8ZRY$C)4'X;\+UE(_%%DT`KHBBA9_A7=W36V5HM*]T-@\2SC:79_%MC]M'
MMN\3F6:S[BXC!R9>19-.W&G2[9+?L=_N0*6H;T",^J&^%/H4%K5HB=WLM^%?
MGW;WNEA&YNX68X'DZ\;W?W[W;%IB1+I>9=JG[RV2S6QB%;+[?6TR)-QLIM'X
M2:I#;KU20$U(!$X'>3\/G=C?ONJVTW^VIRC`-NY-GCX3;;]N$EJ[,[C6FV8G
ME#5]DP%V@M7/#=R+/<H:%LL1KBTPY"6X5H=!`J10OV!^&]W'[I[9SK1N;#VM
MVEQ+%,\[MLAVP;BXG/MN[E_O6[V;Y1!B/[HRD,)ANXP;;*,SI8<=7+4IE2_Q
M:=$4HW?A27:XX)'PN9F>+VFXS>XG.MW;_E]BLQBY(<;S';B%@J+;;+H&42OM
M6,(*B2I?08RN@\]$2=[-?AY;R=E%XO&X]LP_:'*LZL>$8;LGASU@O^:NW++\
M)CY1'>ON69?)OKGN&/3HUEJ^BVP&E1C+"B'`%'1$O^^7M_[C-UN]?93)MBL/
MVNNENA]L.]&WN4Y7O+B\R_X78$9QD%FB]-MD04.OQ\L;A^H^PP4^G(;24.'H
M)T11RQ[X*MXP;>C&;C`R#"=R-KY=^V7RW)<BW%N.6HS[$+UL_:8UN;A8G8+5
M)1B]V@W*5%#T)4I31MR5%*4JH*D3U1/A4YBC,>VVZ.;FXZSB.)Y5G%W[E\9C
M6J2M6]MNBY[?-Q]DH_KD=#$O`+[<D!]QX*]X;*DC@1HB;C'?A2;\8=O5L=N#
MC&X^`8X,!N+5\S/.;(W=ORKOUO@YIE64+P*1B%SB3,3O]LN<2]MQV+BXJ--M
MG6YZ*B`G1%TDWZV>W%[L>SO-=K<^P[;FR[A9Q;'T2,0RC[1R+"&Y-OO9F6F/
M+FV^1%N\%V5$BM+1+CK+T-XA:0>FFB+EE=/A7]Y$O8K$=KFMZ\%E1?M7=Y=Z
MPB?/O`@8A9]R+-#M-H8L^YK./_ESET7'7(:G7HLST!.#W0ZZH)!T1.;L!\-;
MN6[<;;:-ML.S;8'(MO\`+,:P9&Z6;9Q@TO(-P\<R'!\<NN/*@;;1I$9VW(L]
MW1-:<BOON(?M1"_2J34D6^R_X;>_6-;9]MF/;"YEM!;<MVL[?=X.W?/#E]DN
MZ,=N5GW=AICS,XL;=H:$I_)+6\E2U)D^227"5$'F19&"?"AN.-V+'H%]ONV^
M17"U]Q>Q>]-QN\C%''7KG:=HL/A8S)M*G92%24RYK\53D8D^DRVJA!T1=$^T
M'M]N/;9MME."7&YVBYJOF\>[6Y$)5DA+M\"!:]PLQGY';K2B,H!"'+;&E!M7
M0$HJ.`T12IT1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(
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M6;7?M<L.2[A;?8AW8;>8-%>RNWX?/Q&R;B6Y#V`WG/K7;<KE6^UR[S)2XB1&
MM,QU#+G3Q0E?`B9ZR_#J[Q96W^_K>1[);@V?$,IR+8',,'VXPW)\%L4M&3X?
M;[W:LUFR]M#F%RP_([03*:,B)-FM.7!LAY1+J.!$L\Z^'SWW99*V+GY_A643
M&X.R.#X!B5AV9S#'[9![?LLQO,Y4^;?+J_D^3EZW3;Y;GH\R5*M+DU3:FUQT
MDI2!HBE]V>=GW<MLM\0O)]P9NW=\1M7>3N8]G.Y>X^66O*;I=9611+<[87]O
MLBMUZ&07.%<KLTXI^WW:WH9MK?XA9ZB`1;S?OX?N[>X&]G<AOUC.-2&-WKAO
MOV^7WM\W$5G<]A_$\$QB)$MV=S;9:47!NVP8C4=U[WB&MFLQ/M--$4'MNNP#
MOAP>R;W/_FUSO+-R?S>9YBF7.9AGV-P]M^X:5DV;2+LBX6M%IR%S(<CGP[2M
M+T1-W5`2E8]W4L-\-$4D^SCL*W[:W2V,N_<)ME=K7M?M/N_W";DXIC%QRBVV
MZTX@C,K78D;>*.%XO>Y]H9,&6W*]*"AZ1'B.+J.-=$3@]\W8IF6\_<?W(9#C
M6PTK*&-_-@^WG"V-T;?E#-F:B?FVWJ8O6=XA=67;K%F1)%SQ%8=CO,-GK2V1
MU!0T118[B_AP=S-FRJ_6/;+!\^N?:99=Z=Q;SA^R6W>66ZZ7IES,\6@L63.+
M5$S+)[=%:L=NNZ74J8<E%R(\LO-MDFNB+H3NUV:;F[I=BO9UVYYC9\AW&N&%
M[K;&WG>"%EV6L_E.G#<3E7&=?F[QDT*6E5RGVZ.^RPX6'E*=`Z0HCCHBYL;Z
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M+MF7F0]`QZ^SK3&=DK3D*4KD.M1DJ40`.HF@IKRNY9/+;N'Q3;?X9]\10D'\
MQ?;(JA_\F9C7V&A.1\"0=*JAT9K@/M6_5^F@]]B4U/;ML2>0-)M\YTY_SJ=#
M@LDVE!L/O5/^&B]])^MVZ[%_Z=OAJ.?C%'CKRJMF%K30@U7O^&B]]/$?\G;8
MRAYCWR]\?G_F;2I7G+9P5)_31>^DF@[==BB>?&;?*\_^]#XZ53E,X%7?\,][
M\"`1V[;$!)`('OM]-!S`X1O#5LS-!HKHM:BH'Q5M?Z:!WW-@=7;IL24C@")E
M]`2#X4,0TKJMDC7[%:DMRUP%-JJ'Z:!WUJ34=N^Q(`%:>^7WP-?Z%]NO2Z@K
MN60+(.B)`.:F&*$_IH'?<H^3MWV)K[3,OU3R\?=?'5LS-"IATV=V!Q68G],T
M[\2`K_D[;#A1'/WV_5I6M*^Z^W6.^YHXBOP6Q;HDKFU#<.]5#],R[\#_`'N^
MPXXUX3;]S\#_`#K\FJ?5_P!7P58Z>GDP`I[4'],T[[AY3V[[$^S^?K[T_/3W
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M_30.^P"@[=]B@/8)E]`I\WNOLU[S@K?Z<X[OBO#^F@]]_P#S>-B*?+-OWT?Z
M%YZ<YO8GZ<[A\4?X:#WW_P#-XV(_T[?O_!=.:WL3].=P^*]_PT#ONI_!WV)_
MT[?:5]O\[5YZ<YJM&SH2*8]Z\_PS[ON\>WC8?E_1E^\"/^YO#5M\M:9315LL
M@X&K<<-Z\5^FA]]K2:'MTV*H!P(G7T#YP/=N6C'$D>+>L22`M.`-%9'Z:1WV
MG@.W78KAX"=?>7^E-950K?*/`I5X!^F3]].6Y_A.*RNW[8YB)DV7XUCTE;4R
M]^LU'O-YA0)#C15&`]5#,@E-32NBMN&4T*_1\Q>Z/WK',?O$E"6I%VL=IN<A
MMHE3*'YUNB2W4-$\?30X^0GV@:+Q;_1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C
M1$:(C1$:(C1$:(C1$:(O"">1H0:_(?D/R'1%\DOQ8/TF:9V"=UF3]K^U&P5L
MW6N^W#$%O<.ZY%D$VP)@7.ZV]JZ6Z-:PQ%D-2FG8KX*E$U%#\FB+F)_AE^_8
M(*^RK`5`T33\X=P/CRX6U)T19@_3*M^ET]/LIP4"@X?G$N">/,FBK<=9,%LZ
M89ALJK;I`TT*V@_3&M]B*J[+\#)`"B$Y_="H$#GQMX'`>.LV73^7`9*&HI]:
MIYS>(5*?TQO?1?XKLMP15:`UW"N+9J*TX*MJB::P.0>U.:WB%</Z8KOQ2I[+
ML")YT.XMP)!X>/V5S%/O:NB!E,=O>G.;V*RY^F.;\H`KV7X$D?R6X=R5R(I]
M6V"E->\F/A\4YS>Q6?\`#(M^1Q_Y%^`&GC^<*Z_=_I=XZ<J/@G.:J/\`#)-]
MBI(7V7[?])K6NX-TIPXCG;A^RXZ<F/A\4YS>Q8Z?TR;?93JT*[,-O5K0$N%`
MW!N8=;2KRI<<0;?U@*/`&G'PTY4?`ISV]BRD_ID&_"^'_(NP`5KSW`NO&O,>
M:V^--.3'P^*<YO8M3(_3%NZ,R'50^S;9Q$;JHP)>;Y,J4&N!`>6RVVV5A53Y
M4@:<F/A\4YS>Q6/\,5[K.!_Y'&RE1R_KVRKA\W#ASTY,?#XKWG-[%Z/TQ;NM
M']YSLH!6I_KVRNE/$\-.3'P^*<YO8J7OTQ[N;84/>.T38YM92:`YSE`=Z:U)
MZ5D*Z*\]><F/@4YS.Q4H_3(>YE;BV4=H>RBW$&BVE9IE2$IHGJ_&&B%^4U%"
M=5QVC9';:-3G-[%D-_IC'=`1Y.SO9=0!``&:94E-:U%*>.LN73HXX\XJ35><
MT=BQ97Z8WW4-JHUV;[*$](!KFN5=7`\N(Y#PUB^E'`^]>\UO8M4?TRWNP2>D
M]F6RH\`/RVRSP^G6`=JNJM/Z9;W6$IZ^S;91-5@$'-\LX@\!X\..O$3N_P"%
MT]SG_-%V@_>P_+S]V>3_`,^_T!_WK_)?6T1?#3W6_P`)WN'/MWJW,_Z[,+LK
M[U-4[UFM3"M@'J^3CJE[\N"OQD`8A7RY44I]_5)EKN629P?X0K9XZ<SL6/)X
MW5V(TYG8K9::8;5ZVCJ<'AP^3VU]NO'2T%:*FC^`]ZVH%`.FO4`!][CPUAD!
MSB:[2M_';-Y379A7*-W8J@RY(!;*#S2>H^%/D\:ZO1O;&"-M54W3G7#_``X@
M=G%;.-:U$E)3SJ.7T#QY5UZ^Y:6D##!2&TZ>>^F8FG=^*S1:%`BB:$>P?XNM
M5+<AAVU6YCZ?,>(!]RV#<%(0`HE*@./EJ!Q/,U]FK1E8YN?-XCN6[BTF-L#2
M[S4X*L0FS7I4'#X)2E1^[PX:M&4UH%;_`$]KCE8*'N6,N$OJ/D4!7V*H![=>
M<^F]>_I3S_HJOLQ2T&A!)Y#I4375<=QB:[%C76ASS-`C-*'<*K&^R)`'3T.4
MY5#2B..KOJ0-ZP!TY=UH7&G=^*V<#&YSM4LLN.T16@0H$"H%>/RG5AUS4X+:
M6O3)&['N6:YBES0>I<9:!PYC5/J3N68>FGE^4"@[EZG')BC0,*!^[^N-4^I/
MT*R6=*2,',?L[ECR;+)C%(6RJJN(%.%/G]O#50N/I56Y="Y>[X+4/0'$DI*"
ME1_D>5.)KQ'@-7VW>&*TM_HP>RC10]RQOL]?[))/T"OZNJ_5`["*K01]-2NJ
M\$FAX?BK8AJZBDMT'$%7B*#GRU=$A+<]5=;I,H/*>*-.TK7OPR@GQI7A3Y?G
MU?B?S&U.VJU\]ERG$#&BQPPH^'#5T@4P)JL(,/,R%M!^%5:6.CFG[^J!4H\-
M9N5O@>-/OZJQ6"8`XEU=N.Q>$`_Q5T"J9"&@CCV*E:>L`$TI]_53793569+-
MLAK6GL_%8ZT`#Z=9(FKN6'+`R+8G*V2;IO1M`NO/<_!.%/\`9/:_'Z-7@ZH!
M6LFA!/,KMW+]V?;_`/<)A/\`8CCG]18&JEAD42PT7B-$1HB-$1HB-$1HB-$1
MHB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB_))_2'03\9;O0'51)NNWU4^T_D/#
MXZ]H3B%X2`N/"(:UJ`Z/4',@&GT_1JN&)\GF&56.?V+;I9:C%-:`]()23QXU
M'/CJ3Z?;LA@J34YCN[EC2UD=F&&'>LM9/0JAI44!\>/"OA[=7KNZ88#!E&[&
MO;W*WRSQ^"US"UH73JKQ/A3Q_6UI_#P7O+/'X+/Z%J\WJ$=7&E.5>-.>K!)J
M:;%YD=Q^""R5)(4NM>7#E]_7E3O0,XN^"URH[B5FBB4A1X4YC[NO=I7O+_J^
M'XJDCTU-K(2"5AE*G4]384[P'4*\/J\#X'5>4KWE_P!7P_%.#,RC$)NVUCP^
M)MQ!MF7V6_SKM+W27<.N[Y%'?!2,<?BAM2%08*4]3:5$4\-,J\Y;MSO@D`5K
M<4DJ(Z@1Q``K]'AH6JES'#&OP6T0#TCCX:MDD&E%4&5&+L>[\553Y?XON:9G
M</BF3^KX?BCBGS"A*>("OJDCB`KAR)YZ5=P^*<O^KX?BMG#N;D"))AMVG&[@
M[<D.!V?.@HEW%EIY/0[%9D.'I89*3P(3U!0''2KN`3(/YOA^*6&1WS/=U;-8
M\)P3:?&9+>$PG9TAZPQV(UY?80VEE*KE,=6V9?32HX<1JGQYLP-!P7A8:X.P
M[DV:8]_M@^SLHM)LM^A+`G6]24E;(-?2*W4$IZE^(H:>W6=#*YSLKS5M-Z\R
M.X_!4*6V2IQU?II*AU*XJ"$T/F5TBO%5`.'&NLFK.Q,CN(]WXK7RHJ?,I"@I
M2%*24]#B5#D4%06E)"5I)H::TLUL&5(=7V?BLT3T`P6E<"NH`BE%MC_KQK#:
M'.KAO5Z-^<$[,5**J?;_`'NE/#ZW[7GKVAX%5J'W=54]S/<.#];\]>Y?S\,P
MNX/R\-4;UFM3%Q4@^IU#]CXZQYR00KS%<="0FE`#4>`!_CZM,))[%4L?5Q>A
MI.Q7$)JH`\C[>6O'$@55^WC_`#1GP9Q.Q;6/#!4"4$?>KQYZQS*VF)"WD=FR
M7^W0]RW;-J+BJ]*BGZQI^Q!Y5\-8+[D`D"FWBI;IW3SY0PN!`(!V)3V^Q_LD
M,NN*40$CTU+3R/$D"E!K"GNGX<NI&*G>G=,P1@U&VB<BS[=W"<CU5>[QT=/J
M!;J^@D<ZA)YGY-8+KUX!J2"IO8Z!:AH#J!*6+MW#2HB0Z\X4#S%I-6U5X<#Q
M',:U5Q?O`*W,72[)C6)A=W*L8I:FJL^Y/K(J?54.73QXBG+];6!#J,QFRFN3
MBJY^D0UM'M+74V$;%H9,/[.#BH\*.5!5!ULI*R/DX5(Y:D\,\;VBKAFIQ6DE
MT"*U)<,1]7T*&K,Y*)D+;8#CR?5]/T^(/3R":<.6L">Y8)G`.&WBJ1TE=7`$
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MJILDN;85>ETKT[:1L+@<30;^"3LF#4%339`->`3Q''ZIIXZVL4A.!P6CGLRX
MEF0@]R3TN$1PZ233B.1J:ZRFS!HH"HG>:8[.[PFG<L&1&4VA)`('2.`\3]&K
MT4X+Q4X*,W5M'"":^(+3/H\JO**@'P%1K.!#O+BM!<O9Q%5BI`Z4\!R'L]FA
MVK$9(QWA:07*KTPKV#[U?O'17LKAC0KQU(2E(X5J:D<S\YIHK9<T8$A8P`(5
M4`^ROM^2NJJD'!8,_BV8IR-D1_MT;/@_[Z6!BGR')[7K,9Y0M7*"&`':OW9,
M"`&#X6!P`Q+'OZD0=75K#M2MT7B-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1
MHB-$1HB-$1HB-$1HB_)9_2#8Z7OC.]YJ'$+H;MMVHD`]/2<-@)K](J-;"TAY
MC*TKXEB7!D#ADK2FY<D4M)9;*N!=`I0<5T/C3GPIK<W%F(AX!56\KN"USJEN
M+*B$D\O/3JX?K<=6HI'QPD$4-2J3@<<%4V'2GS=9/R\N?\;6"^4YZ.V)45HK
M"&G`NI0JE>=/E&F=G$*I;``4'S#]368V(%H.&Q6^8WB%535F:)P(RBJQIY:$
M92O.D?)]P:M\F8#,6NRCL5CFN.`K58\ALJZ.A-2"KD*\P->`%VP50RO;MJ/:
ML`MJ!`Z5>7@!4\*\Z"M!7565PP(-5G0R!T0=55(;65"B2:4/W]>ACW>4$JIQ
M!&"RB70H@*2!7@*^;[E>>K[8P!1U*K$<9<QH#1>_A_:O[FA9&-I"H=)(WS`A
M9"`KI'437C6HX\SJH1-.Q4\YR]"0*@4%>=!2OW-4ED3?,0%[SG*MB1=XDCWB
MT7^[V%Y;)BN/6F8]#5(97YBF0IE:>MM)]NL*5T>>C2*+*BD!95Q%5052'JKF
MRY,^6X0J3,FN*D2I*Q4)6[)425D5^_JG,6>)76N#C1N)5I4CW!3,M'32%,@3
MG6PU[PX]'B24/OLAA0+;A=0GI`YFNO?4'BKF5W!+/<'-+9N/E$O)+7;UVJWF
M#`@-Q50&+:LKBM%*G2Q''22ZI7.GAJS")I7>)CJ5WA,KN!39S(8`"D]0\X-2
M*&@->%:>4'[^LM]L&`%PH*;UDP@AI!XI^O-^V_O<J\_V7[;5C+%Q;MXA7E%3
MNM1T]S_<1QK3>S=!/+_9E=N//6LIBLX<4Q<?FO\`E#^MK'N-RNLV+V0"5@`5
M--6HS0&O%5%4-LJ6JA!'T5U47"F"S;2(RG*.*4T:V)>Z.AH5X?3[23R&L6:3
M)&7%3*VT'G1B@Q*7ELQAZ6XTTA'G(X)2DN+/RA`XG6AN+FA73NG.AW7+0`-J
M=6SX!(CCUE6YZ0RI*4NAUEQL*('$`*!X=>L/U7<IP.F?1X$'PX;$KHD*5;&S
M[O"4V6P4=!820>OP`*:C@.>K\4G,::;EDP6>2H6RMEMR.XK6/<7VT!5$$`@$
M&E"H`#6KNG96N=P!4ALK4<UA=Y<PJG(@X'>78CBI)5&0L("G$D!9)KS%:^.H
MS<W5>Y=1T2VMA1+^P[.LFVJE/O29#@<3U5H/)U54#52J@IUJQ?Y)2-BEEQH%
MM/#SJ>8+$G;6V3U`XY%<Z4ND4IU#Q-2*ZW,&I?4H?>=-6W+?AN'UA.5:<#L:
M83'3:(92A"$AY;2?4]/D5'^2&J)+HN>7<2MVS0K:'3XW4'D&[8DCECN-8RP\
MI+$(NH4$H`Z"03PJ10UUE6,G,>X8[/M4,U>WBRM;'2H<?J4>Y^5/7AWTX\=M
M;76JA:8Z5=*%=)H0/Y'6RW]JAMU;5J3P*=_&<D]ZM;<5Z`E(CMA!7Z06L@$<
M3Y14G5WM6KM[;%*!-^A-I4VAMU`*0**;":'Q/3TG@=%O;>WIWK%`A327@?44
MXXE(;=2G_$-1KT8@_P"TK>06]-J5\+;+[:;Z_L93YZ`0$,=04GY*#@:G7/K_
M`*C&G71%=ZWEOI!N1455L[$6^7,]WD6IV,LE(;*6O3Z5&GC0\SK'_P`V!&U9
MG^(V_!M4V&Y7;9,M+:Y$=3Z5A)6TA:.E)\QH*UY_+X:V%AU:+@TKO6JU+I=D
M8#8P*$;DP;^U>01(Y#UO430K+B1U5^6HU.++4.<W,-B@U[TZ6/+N";>=A4_U
MU^K#?;'&I#2J"A/(^.L_U([%%I]`YCB*&J3LG#Y54I#;HZ:\5MJ^7PK[-78[
MKQTXK07?1!E:YV4^Y(VZX](C$A;*U@A1ZD@I``/&HXZV]M=84*YYK?2KK5Q%
M,.Y)=V"XT*BI'@".('LY\>&L_-7'BH,_3C`\D\2L125I34U3[/E^_P"&J@J'
M.KAP5EQ1/D/$I/UO;]'AJM:V7SJUHK:<S95/3O-M`Y6O^VE@?#YLFM?C]&LR
M/R!:^[VK]V#`C_61A@]F)8]_4B%_&U>*TY%"E;HO$:(C1$:(C1$:(C1$:(C1
M$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1%^3S^D!,`_&3[S7B:TN6W8I3V8=`\?
MIUN=._LG_=]@6NNY<D@']/VE<;W'*NTZ3Q21SY4//EK:7%S1NZJQO4#L6`X.
ME?.O"OWC_&UAM?GB)[54'YQ5915T(*J5H$\-867/*&]_U*MNT*TV\XXOI+)2
M/V_54?/2@U>]/WJY@LQ+963TBH!(*O`??\=;9EL<C<=P5\<B@K2JJ5'<X423
M\W^.=7!;FJUVH7-O;EHPQ!66S:I3XZ@VL"E>KH\M/;7JY:V(MB8"`,SB-BP&
M:E:YQ4C:KS5G=6I:5/,ME'3]97$DU\"13E\NO;>PN/\`RB17@J+G4K:E:A>F
MRK4YT(<2XJE24A736G[8`II\M>&LW]*N'8\GX*B+6;5L8&"K9L<D%1<0AOP'
M6I2@H>U)0E5=7H>G[JY<6B/)05V;5<_6K7L6<WCSSAHEHT"2?6+;B6Z@>U5#
MSU=/1EVXYLIQ6%)K0SG(:-W;%:<L;[:BA:F4GG]91-#R/2D$BORZQY^C;N-H
M=E.U7+?5HY">:00-BP3;G$DI+=%`T\3\Q'SCCK43:/<P.RD8;UDG4;<B@H@6
MB2:\.0KR^4?+K$N=--/:K'JAP6N?9>8)"FR2/E`X?3K6OTPM;G6]L>3+;![Z
M5J5:Y>'W!K!:W-)RMZOS&&-F9E*UXJTZV'0*@U2:I/A7^2]J1J]Z98GJ`J0P
M$<$T/B5*^L#7DFE!35N"XH[VIZD*XML.)`(X@4X_K?=ULY&^HMR_A@LF&Y!:
M>]/G[J/8?X.E.?A_]#Y-:GTPX!7O4!1'[K4@]S7<4JE5?GLW//CS_+2[`\/F
MUH1(^N)6^:T43!,5'7X>4\_U!\NJLS7>?%95O&P@U&];!#'J.HH2"2!4#P-*
MZR)HX6#``8+9#3FRN\-0.P+8QXA]50_:JZ>7/_%.M+<3<O`<%(]+T<%V#=Z7
M]GLTI\!26%+3[14'E1/$4X$GB=:2YO7D%I=@NMZ'HSIG,C#?AV+LMV3=GEGR
M3'[AN5GR%_945`-OCAQ"72\WTU"FU54IMPJY_>UH+FZ=M)Q7T3T;H,;`W,T*
M<6<;`8'>\,NDK&+"F(];([KB'`0D%3+153]B"D]'/6'ZS#<L[6--@#I&L8*Y
MC]?>N93F+Q'9TN$ZRVAV$^IMZG[)0%4*/$5H*ZK;?R,%&&@*@DE@]DPR-\*V
ML:&Q9VG5+0EU)0544A(X)!J`0*T(U2Z[YF#Z$'`J9:;H[)(VYV#$[?H4GFY1
MNCZO24L1DN4](?4)2?H/#6AU!\3?(`%/-,TRWMZ5;7O_`-4[>/RWO='HKI+`
MZT@.<R\B@'50BE0.%![-1B1Y#S(`*%3'+'Z9K6X-I@/L6\?LX]U<F.M(]V;!
M6HJ%.M('UJU^L?DU@QW5TRY`YKLCC3+A0+2R11%SFR,&4CM382,H<'K0XR%M
M,J*V4K`24@&J0LU%>E-=2GER%HRN)JM-<ON,Q@SGD-P`W`>Y,A?L<C7RX.HE
M+??4L]?6VX4I!'*@X@\=9.G-N8I7.?(X-I[\5'-0L6!H<P#,2>/!%GQ2-:7U
M($<])"NCU#521QKQH`>I1K].M_ZK-0;"HO<V8.!&"WJ&_=B6VT!".=$CIX_1
M[-9G-;Q"Q8[".,U#54ZYP]12$J/'F!X#A7AJCGC-EX!98M7$#)X=R46.6=5W
MG1PVV"HJ'10D#J!'210CB*ZBNK:W-:L>QKS&*'Q"E>[$;UT/2]-LS8YYX6O?
M_,:U^!77#9/:Q"K#$=E,`OJ886I2D!1!6$@\2KQ`U\F]6]:7OZD]C9W.`/$?
M<M8;F2VN"R#P,&X?BMIFN`ILDY4XQ&$JCCUJN(!0`FIJ>)'+Y]4:'U!=71K/
M(YS>!_T6TBN[ESL7FAHH];A72RY+'<C27H:G6$`@(#:36E>BJ`G@D\1\NNEZ
M-K5NQAD<UH<';*G'!9I/,QD\6[%1<?LD*69#,9ZJ&>L+-0KJZ33I-3RX:ZCI
M.M&=@DCE+:;&BE#[5J+G2&W,E6B@.ZB;F_8_;&F4J=BM!`64K*!Y^FI!76M:
MC4W@OR^($TKQJHS=:`R#-(200=E$F'MO\?O#;8::<]=T]+)ZAQZAY>`16O3\
M_'57JGAV8.HL:&UB((<T$<%F3NS?)[C9?M"VL+DNR&UO1XKJ%%U:`DFB0CI%
M:D:VEO?2&F*BG4?3]I)%S.2TGV_>H&;D[;WG$+E(M5WM;]IN#"%ER,^PXWUE
M*^DK05<ZD</#6\@O9#0$U"XCJF@P'/2(-.8\>/>F.N$?TD%"FZ*03QX@GE7A
MK;Q3!^!VKGNI:5Z1M6-VU^"U1824K6>?25<1R-/G^36>&-<W-7&BC<48?F,@
MQI@L(\-6ABK<C&,%:53G;*<=Y=G@>7YT<#_MHMFK\3C4"N"UMT69"[**K]UK
M`C_65AG]B6.G_P#2(6LTC"O:HX75D+>Q*_5*J1HB-$1HB-$1HB-$1HB-$1HB
M-$1HB-$1HB-$1HB-$1HB-$1HB\Y`GGJD`C::HOR?OT@59;^,1WFBE3]I[>GJ
MY'CB$`?>&MU9#-#5IRBOV#%:^[8QT@)&Y<8WRI*Z@T/'V>WY]7'&-WF<2M7G
M9_*%92E;J@!52_UN/CKP2,B9E9B*J^P9F9P<HX+-;M\EQ"2MV@42"A*%*4FG
M+J%!0'6UL;#U0$C&^/=]JMF=D9JY]?<E!#LCQ+:7'$+2LT`Z%U%0`D$])%2K
M4JM^G'W+*%A:[B!584^I-;@U]$ZV';);@Y?(1&Q?$[S?%/N(0OW*#(2RR5D>
M94IU"&>D'QK0ZD-IT>9,K'"2FS<M//K!:"6O4X<#^&KN)?1&?R^\V[$8JW$&
M1&JJ7=$MD=71Z22H=9'#AXZEEA\MV7/B#7FA6AOM8:^AF=F(K2IV*7&-_#?V
M:L24F_/Y+E,GU$)*797V=!*:^9(831;BE?M=2RP^6D;9&$PN)!6BDUEH>`UU
M*]J?B#V-]NML8<5^;2$MM``6JX.N/E0Z:I"5%514UKJ9V?R[MB1FC</<M?>:
MS(/+(31;FR=G';Q(4\M.VEC9]!KJ4D%WI4"34"JJ<M2*+Y=Z?RQFC)-%K/UN
MYW.^/X+=#MBV-BD"/M=C/ILGTVRJ.'#P\3P37Z:ZR(_EYI;07.:6X=F*?KER
M/XOC^"W1V3VK;BHAC;_$VF$(Z&T.6F*I('&@24(#AY^-:ZM#H:W.,;06;N-/
M>KK=9G(J7&J2-Y[6MB\D2IF[[<6+\.GH3(@(1`6G^5*0H&GAP&J).@X)&T+&
MGZ=ZNQZY,PFKCBF#S+X:NS5T4M_&I]\QJ4Y^+90XFX0D*2@'K``24(X<=0[4
MOEG&\EPB%/;]ZR8^H)N8T%^&8?6HOY7\-/<FWO+5A]\L^1LJKZ32R83X1TE5
M'"[2JZ@#D!QU#[CY:,DJ(X1CPK]ZD_ZV?YOJ4--U.US=C;-MR9E^&7B#"2:+
MN+3*9$%`'#J]>.IT)1\IH-1S4?E?<LA)95H_E679Z_+S!&)#R^&'W*+D^S+B
M*I4E-."N/3]W7(]2T!FE7#N8VLH-%-8+R&>`':Y:!25)44^HDGV=2:_<I76A
MG)::L;@JLI?BRM%[Z+_B5<>(Y#]4:T$$$D;BYYP6:(H^"MK*D!(*^/6.KB."
M3PX\.%3K=P/(B+6^4E5"-@&`4B*I]H_@Y>T:KRCAO561O#<H<]U/E[G.XG_A
MKW/3]/Y9W57ZFH,=BE\49>!1,*E/6*_+JV3E*S(XW1O$6TNQ^Q;^#%65)5TF
MM>!!%=6[F\92N;%3[1M.DF<*L*<O'\=$]:0M`'5S4H"E.'&OB>.H_>70+J@X
M475]'T.-I#7MHZO#<I`[?80_,=/X,%AEP5(0.AQ(/%/&@4.''4?GN#QJNK:1
MIT%LYA%!(-WL^Q=X^UN%)NF!-62/)2RVRR$N,=12EP`C@4`A!30>.M/.Z9_E
M!*Z?HE]'!1K:9N"EPFS.6K%<E:G(06!!D!*4)\A3[NL`](%#4:P>8\8&M0L^
M6TDGD<]S31Q)]ZXI7>V&1DEV-N<"'5S'E*]0D(*0M0-10`D#AJEUSD\YHK`T
M(22-(;4;UIKI9;DZV6%/)+?0K\*V3Y!3]D1S``U3ZQ@.+L%-=/TJVCAH[*'+
M7X]94,R@$E*H9ZEK6X!P4GZRAU"OF.M1?7.?R&JJN861"C-R5"B;@^VQ;%+<
M2Q4%+'4"`%5)4$\P-0W5-4FM(B""&A8T5Q1V1QP3L-V>[W6VLVYJ-)<0XVEI
MQ2NM(22D<.)XG7.8^K)7W@8#4@UV[MBR[AL;XQR2'/KN2`N6R5^:][ENQ%M1
MDE82JJPE(4DA*W#]57'75-)ZHAGR1%X,@I45QJM)(UAF+"?S`<0F,@6EVU7V
M5&FR6G`VM2$54#TJ2>(YGA0:G;+QKHP[8"K5S8N>P5!I7@LU+$J1<G4A/4PT
MK@H\B"D*\?E.KC9R35I)"T,^G>+%I5N8RV%&J$"BJ$$)J.'W=97J3V*TW2W/
MP:QQ6AD`+=]%("4D`I(Y$TX@>%=4F9V8D\%?9I9!REAS)Z=IK6^_?K,TTT%J
M=D)Z4+3UI6*@%/3Q'5Q\::Y;US<2"RDR'QY@IGR8K72274:ZH7>#:W%1:K%!
M=D(6[6"UU!0'3U`5H02>*/#7QAK)DFU1X)-25SV5IDN3DQ4?]^;V[(0]%;EI
MA>LZI@"M'5(J1TA((JGAKI'3.DRE@(!+:?8MM!%(7#PE0_1M(W):]_<N)>]0
M..NA!Z5(04^7JHKB`>6I.^">$\N.IXK8Y)&R`.%&E-:O$8\"Y26XTQ*6%=8(
M4KS%P$]17QJ05#4ZZ>N'PY6R.H\G8I!;NLV,SO<WF`;/H$R&6_S+.5%DE24J
M=Z6U@T0M))\HIPK777M.NCZ<!YHXG8H]JK!."Z,5%-R7VU&/P+IEV,PG72MN
M5-C("2:IZO4\P`)()Z1K:UF+<P:2U1FWB8QV22F8KJ[D\7\E)%NB6*'[PB/Z
M"'5)9!2E!0CJ">%!0>S61;W30X,)\7!;*[TV&>VQX+F1\0K%+'DSMCN]LAHB
M7MN&AF:6V4-EU*T]74Z4I254\*ZW]O<$D$%<HU70&M>_P89CN7%_)\;:0R\Z
MA'2ZVHI4`BG7QX*2*5X])UNX+D`BI%5ROJ71H6VXJVAQW=R:"2TI(*4I-`%"
MH\:<Z\JZW\4CBWL7$[EC(Y',9M.`6G7P4`>!'AK(8"X8+17+FM.1QH[@G.V3
M_?FV>_X4L"_MHMFK\8(?0[5K+K^T5^ZU@7[BL,_L1QW^I$'6:?+[5'/_`!CW
M)7ZI5Q&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B+SARU27
M-!RDXHORCOT@=AL_%^[RG%!*2;EM]51'$@8C!XU^?6\L`6P4=A5V'=@M?=O:
M)`"<<OWKBL5MJ'40E0K2IX\3\_'6T_3(R<N89EJS!*WS`A;&V15/R0XA!Z&Z
M5Z4DA2E<$IH/K$^S6XLNG#.`S*2\GX+%N+R"VB,<CPV3;0[>Q=)^V[L=S[=U
MF/DV2H_(G"9#B"F7<(ZEWN\M)352H48I2&F#P`40/DXZ[GTGT,,K"Z,YJ'"F
MW!<_O]8>9"&.J?IBNKFW_9?L7MVVR['Q!O*+J@!7O=^<+[16F@2X8Z@I"C45
MZ2*U.NO:?T`]C!(Z!P9QH/O4=GUJ=SZ-)+N"DM"QVW6ZWB+`M]LLT9FA4U`B
M,PT4%*)HRV@J"32E:ZD]IT7#$YKI&96]JT=QK-PXD`FH*VELBLI>ZPWZO2K@
MX@`D5XFI^MQU)+;2K2P;EA:'!QJ>RF"QX9[B\#B:X'ZUO'F;:PZEV85`*4%H
M;;JZMP5KTD4)2H_)K:QRV<0\8:'!8[K:X$E2#E!VJY>+E"%M3'BVN2X])6A*
M%R$K">="JI%36NL6XU2".N0!;*WLA+A(<.U;(6!42U-,%ZVP+C+:"VW7$.N(
M]$U)2Y3RA0KPX:TS^J`QYC%*@K:,T6-P&7$+7NV=,*W.OL7"%/<8/J.=#3@)
M7R*05@@IKR&L:ZZFS14=05V*\.G7.&#4B7+E/*ZNP&'6U*'2A`2E?37B!Q%"
M?#6M'5UO;PM#SB!V+(CZ8G>,`!3C56I98DEIV,';:Y4A3#Q-'"D5XJXI2FOC
M6NLRRZJANB<E105QHL"XT5['9"*$=ZOVR\ED.L25-!0(2TI*PM%.=.H$UJ3K
M;-U:*5N5V_#WK7OL'1FE,4K8,UGT''4MH*P@DG@?+U`<SX@ZV%A;V<AH2U>2
M07D>US?BM)=WH]XA2[3<X,.Y0[@R6E0)D=B3'7QX52ZA2D<N-.>LRXTC3)WN
M$@!JW<K<$\T$^9[PN-7>9V51+;'N&YVU5N+$!E"Y&58;'*W'&I)2%.7&W,!!
MHQS\B2`G7SE\P?E];R/?=VH:VCQMKLQX#:IMIFNQE[8:N+CPHN/=PM34=:W"
MVIM746SUH4FKB20IL)(K5)/'7S[JFB1V<9E>VH;P72K*^A@RQR@DNQJ*+1/.
M.>H`:@=*AQK3D?#4(U&".#P@C'@MDR1LAPP6L="JKZB#UA/3SX`*)H=8%N*-
M)K6I5YS<JD)ZP]A_@XU\-7J_6O*_4H@=U+O7W-]Q%.9WKW.5_P#O.ZBO+V:A
M)&\J96SALWU3*Q6TJ1523S]I'C\^K+A78MS#%GF;AB/O2ULL1R2^PT`3ZKB4
M"@*J`\U4^36CN,6KK_3UMXP,*54B,:LCCTF!!CH2JA!=Z>"B*T)-.(^KK37&
M[N7:-%MX>8WF4S8*7=MB,VNU18C;2$*10JZ4]"^JGBH`UXZTDGF]BFMS#&R.
ML/\`<[%TW[+75O1)$=PN%E;2JD$DCB.'W-4+S2O4^HPKM4[,FOD)C$LOC!2%
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M>&JKGJ.WMB16E`K%QZ4N(WI)9)M?D$6:XXY#=353BEA(44T;-"`>'/56G=46
M]R0"?BJ+:VH4FX.(W&X3&X;,!9],T(%5*ZO'C0:S[S7[6`G$8-!7EU'RIB3P
M"Z`]O>PER#\2[38_NR4/-2`ZZ"CI)3P`)/E`(^G7S_U[UK`8GPL(J7C[5I]3
MO7S6I@9YZ@^Y3HQV[7BSF_6>X7$/,H"T6YP&J1P'2DJKY0FFN%EGJ[@W`QJH
M;!ZGGG;5<Z>XC)+I"N$Q2'7WW$.J+9*BKH4:C@L`A(^C7U)T(+>XMPWE#R#=
MV!=-M?2X<:#O3,XEN'=TV1YN9->7)=2H)2"5H0CIH`5_RVI!J.@QSW(=&S+A
M]JVHBM9!4IM;IDL]B:MUQUVKCJB0%$DU7X#A6NK]OT^(,LM/*JO3VO!:K,5M
MW&U-/)22\I*5!-`7B[4TK2O2FGC[=;&.^Y$HCX*W+;VO+.`3D=M]NES<TQ")
M(25.?:T/I/6>JA?J1RKP'W=2B+4J6YH</IM47=;6OK&[-J^@_(-M(C<-JX/M
MI"DQ:@I()Z@VE55@\SPUJ(]4_P":V[U(GV]KZ8=RXY=X6/6I^6]</>5J6E`;
M])Q0"04!0*/3KR%-26WU+9BH)>6UO+(]E/XB%R7SO%6GH[-TA-(5T>1Q(:Z0
M4JYDI"B#0:WEO?<PCL44U;IVUDLY'Y`Z@X;%$+*+0B*IQUMNK:UN`D(Z**)/
M"G'EJ7V5P71@`XE?,W4&G6\,\C6Q`.QW)K9,>CBC]7@?O<:<]2.VX+CNIVQ]
M1@G$V5%-Y]GA[-T<!_MGM>KX-9J_3<M%>-RL+>U?NL8%^XK#/[$<=_J1!UE'
MR^U1K_QCW)7ZI5Q&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1
M&B*D\]8C_P"\%4-B_*/_`$@Y:A\7KO`0A!6I=VP`$!5*I_)*$.FE-3.PE,=L
MUN3-V^Y:34#28?[?M*X[6RRR9#S+`A/.NO.);:CLM+??<=70-H2RTE2U.+5P
M`%3J4:?I-Q<W+6CBM1<:E@NO_:'V+N*DVK<'=N`/=T-Q[E:L'H43RX5!3$B[
M-.*0EMLCCZ:A6G.E=?0'2O2;.0V2<?F9OA@H!K^I?GTK_`/M7:6'%9ALLL1V
M6&4,M-QXZ&VBAN)&33IBLM)7Z:&D$<M=_P"GM'MHG,!`P!/P7.[O47%Y#"0Y
M8,ZY(MSZ$(/45?7_`):I'#GJ8?J-K&>1A18=C'<W5SOVJX9;#T5;[RUN'FF.
MPCJ<50BB2D*%/N:CEWK(:]S0?"":>];AVG8X[>Y)FXWRQ61E5[R.]IQ*T-$E
M:94A#3[P0"?3;;ZDJ5U\J4YG6DDO);VKF/RY<.^JS;.RY8=WJ+6=]]F*V>:(
M>"X[,O3<)U+3MQF%EN*M*2$^JRMU/6HFE0!K6M]0VY8YTE6ARRI+;P';L2?L
M_?2_EUW:M#>"S7I/J(3UL.]3155(KY0.@`G65<W.T!>VUKC52HE[F98_;XK_
M`%_9:!%36$MII]QLK3U!(>4DJ%*^TZ@FI$>I?-S*5.SV!2:SMO`WN2*D[H9,
MS"D1E70N^NKS!3;0*4$^8IZ$IJ0/EU$]1ZACTR%TDC\PI[MZD5IITMU*R*/B
MDM)S7(UME3(?4WU43(2@BB54_"4"2`1SUQW7/F?:,<T9O$3Q[5-XNDK\%U!X
M-WN2HQK=!:NJ/?8CLQM*0WZR0D+3X%2@`#6FIMIG6\4EA%+;&CW'''=3#XJ/
MW'3$\<SC<"K2,,-ZSA>8[MV]6SJ4]`J"]$4!ZHZ@FI9KR">-?EUT72>HI;IC
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M*Z$$'PYZX!KFDS<P$9LO<5,[:ZS$$$),O-42X5\5)*>@^`230_(=:5MNZW&0
MXDXK=QOSMJ=J?STV_9_>[]/,_B_N\OEU[3ZU=RGX*('=(V1W/=PU*'_;IW/_
M`+=+J:\M0VX/A4VT^W.<'!-'%;44TIRH?N?XVM?S<E1BIK8P?F!/+M_;VW77
MK@\H(:A)2./`*4H'J(\*@#6EN)6@=BZIT]:RYP*[U)3::ULSKG(GGRI0I70%
MBA4.L%/36E02>'MUIIG!^(76+&VD:]KCM`"D-)CI\AZTA72LJXCA0&@/*E-:
M>7S*>L9&^T(:!S\*'>.*Z6]C1#EIO-0$O16TN%9I0)/43U$\NH4^C5M7=)=R
M[FDF.*6>09=-E7S-[$Z\I/J!T%'J<5)*5\0@\3U$`:QIF-`J`*K,FU![IGMC
MW.(^*Y>9A:GE2;JVIEQ/1,D*=ZFU#H0DK-%U'E!UK'\HNI(`33!7K5M_.XN8
MYX:-JC`Q=G[5>'7$@-L=:O.#TI4`H^-:$FF@M6O-6#W*6V5T(&M,QJ1Q4OMA
M\LMUUFK]]2VF,.L=:E)Z?+X@DTXG4;ZBT^ML7!OB[EM3>Q3CP[U/"P"Q28PD
M6Z"T`P>INJDI"CS*T@?R7CK@VJ6CY;ET67'-MXK47=F7R.D:-I24RAW)'7VI
M]JDO(:AI6I<0K<*G%)-`@4^N".0U<_PRU=8F>8-::;:8GL6BN;=[F$28@;*\
M>Q3IV][9,CS;8%_=B)/CKFQ(4A^\V64@MJ#!"E);9Z^*BE*>?A77"];M6P:F
M8+=_@9)0$=E#]ZC4$CK:[)D>>5FP"XX]P%OCS[F_$@8TJ,];E>G,D-TZ">H@
MK!2D=7MU]$]%7\4&F-87#F4WJ>6UW#R0:@EWT^*67;^FXV1IY5JGI0AY"2[%
M=J$%P)Z>D"H"EFE/GUJ>K-7EB+FPAP<0<0K%RV9ASDG+5/5/N\Z[N28KT(=;
M:%H44MU'45`*IP/G.M7TQK[8&AEV_P`=-I3]>,)\6Y&`XI:SDL5QWS)D*4EU
M*$`J;4DT5UBG`ZW.K]0DEW*=F86BAKV*W<:R+N`RM-'5I[ET?N"[9B.*!Z*D
MA#,)M:C0)56AH3P]NN*3V=UK>NADQ(MJ%V.RHV*'13WDE]E8]Q!KA7!1J<W`
M>NCSC;4=4>.'"N45I*'%@D'A4`DE--3"]T6#3K$.C#0ZFY2L6LC81(U@#^.]
M,UN]CT.]VM4J)5+ZFW#)6XD%!`221U?MRCE\NNA=`ZU,=2;#"XB$`5:-GN6Q
MT_Q/`<H@8U9%*D)M\9`$4/$/*(/5]:G&O'I(UW.^UFT9:O=E;S@<#O&"E$?+
M8VF7:K&]V*Q\3L<2\QDD@HZED)-2KRA021X5.M5I>IR7[715)KL5>>*OE"C3
MBF5RYLH^^(6EEPE#/54J4F@("0KAQYZRW:.Z6</&W>O)'Q<HC**J97;M'F,[
MH8\ZRH!+$N/(2APT4BA*U$`\C0T.I)'HA;;5W4^Y0W*X:@UQ-8\QK[EV:MV[
M=UO^5R\?D@F$VPM'%1+9'I=*7$^%#0TUI8](/J?:I8\Q>F`H-BX_][%Z=AYT
M[9_>T!`0V^ING20AQ2BE!XCP.MO':!KLI&S!0/6)X(?[+0UQ.)&U0@D!,^&J
M.'`DK2.GB.(0E1`'MYZD%E`UA)(%2%'+G59&VKF!Y`<,<=M.*A]F<11D3[<I
MI7JM%4A*"BBU=)42I(H":C4DMG%M`%P7J;\Z9Y&-5'R>E25+!24]*U)H12E!
MR^<:DMO+)AB:KA&N1.;<49@EELI7\\^SU>?YT<"_MGM>MG$:NJ5$;T$-(.U?
MNLX%^XK#/[$<=_J1!UG'R^U1G_QCW)7ZI5Q&B(T1&B(T1&B(T1&B(T1&B(T1
M&B(T1&B(T1&B(T1&B(T1&B*THGK'T:MO:.6'T\51BK@`RK\K/X[V/7'+OC0=
MUV.V>*N;=KE>,"C6^,RE;BGI*\0@4#R4)4I#30\W5RYZZKTMIXNXHO"#&0*\
M*J&ZW<OBB>X.(>-G<GF[9>SW%MF8T:[9"&,GW!EMMSWK@^VU)M]A6X4CW2`E
MQ*Q[TA::=7-)&OICI7HZWD&=\32[C1<K_6I9=KW#VJ?]ML[J%"9UI;="BL]9
MHX]P'`U^L.&NM:3H;8'<M[`6@UQ"CNM7>;^/,[+M6_2[#;2KU7>ASPZB$JZC
MRX?M:\_DU**1VT@$8#<#L6CTV`SW`+Q7;M2"O"FFG5++ZW'5+JH!04TTDF@5
M7DD5^_KE_5/4?Z;,7Q$AU=JZ#I=A$SQ-8`_C3%1QW<[CK7LI%>4PTU<;^_5F
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M!VD]@73NF^DY[Z.-[F58X5V;JE+K;O:N\YQ<89DQ9+3+SR/,"NBD+6$K`JGB
MGIU\U]8?-V06\W+><M#0`["NV:-\NHX',N<C06@'8NI4CM4QNS;8MK;B(<E+
MC)47TM@NC\"217V5\=?(9^;6H7_4+;5Y)RR4J=^*Z7-IFFBV:'LHX-X+E]?]
MMY%JO%TCL)>2E$QU(4@+)"$DT'U1SU].Z=UY<,MXV0NH^@JH1JFB6MPVEJVC
MAM]J2$ZWR;/U24ER,['*%CH!4%@$&G*M5D<:^W7T/\O^LG21B2605%#MX+DN
MN:5?LD<R-IY9J#W)RL#W2M64Q)]FD.L1;];&W$QR4])>;:25*2%IK4D<#PUW
MW2>MX+EVW:5SZ]T)]L,0L>W75R0_UN.(Z7EJ6A()(2.H\.0\H/+72]`U>2>[
M$L=<I4)U+3XW/)?YJ)S8"W)49:$>%`>HT"N?%-`>&NI74DM]:B`C"H/N'XJ"
M7L45B3.W;6GO_P!%J)MA;ZG/482YZK10X%-^NRZVNO6R\PKI2XVL<ZG7/.I^
MF9+F.H&"6^H-IVKE3W6]CAO+5SSC:2.6)P#TN_8BA""VZALEQ;MJ624AYT$^
M7R^S7$^H.G9.41OHIQHVHMS!<;+M97;8J;;Y,21!EP'7V9T*4A:7X;[*@E33
MB'`%U5U"A`H?;KAFN:7-93![1AEQ]ZZ-97@DD:>`3L]0_:?WN?H>'/V<^6HU
MS9>!VK>>H''<HC=T'\*#N&!X_P"W5NCS^3,[KJ#W+W`&BGVDO+W@GZ;$V=N8
M#BT@@]"PILTX'KZ>H&O/6EFD<2:[5TS2K1LT[0!X5(:/!9M-@9@L-E+LEM#K
M[G)1)J0.D"M/IUH+ASBNW].:1(?&!AW*0>TL81[-[XM!07%('$4Y$<>7B=8+
M7'+E/%3O)RQXFT(3E3E.O+=90HCB*$<R%&I/MY'6++'09JK+L[YD<X#A7`[^
MQ2R[/-S8V'9K)L5X<*(EX;:@)4ZNC?4HT!XT`))IK'6?&^LO-8I6;SX^YCN=
M0\KA458;TP&G%E16H/%0\B%)\IH#PKX:L3[/8MCIQBDF)<W&N*@AOS=6,73=
M%,,C_P`9J4>NG4I04GRJ3PX#S<=:*Y8YTK2#0!3Z&6VM+4NY=2ZF^GV+GHY;
M[Q?"Z['0YZ:W%52$DJZ5$\E"@%:^S6YM9VQLIES&BB]W,;D.='X*`]J>[:!B
M5;1(M4A\M.`J*5FJ"5`]73Q-:<>.LK4]*-]I_,!RG+LI4_8L>POW6\@B<"X@
MTK53EP_)IUKC"%)?\JDH<4I*JFB0"$C^1*1KE4_3#)@7EP:X;21^*G\4\;[-
MCBW$MK\2I*;?)9OEP:2^M8C]27%N*11*DJ`/3YO974(ZDG;::>^U)K2N(--R
MT]ZZ-S#A0KM/M!<;*G;I[%(TL>XO6EU$MALAM*UN,FBB.(\GC[=?'NKWLL.I
M2.)J.85PKJN\DCO)&QNRAKUQP[A]HXUMNM]5#"G8,MY;A<2$]:5!2N:Z$=).
MIMTQU0Z)P:^N4@85[5M.DM8DOI1`XXQ@';MJ:;%S#N6=3<)R%4&*\MH>MTMF
MM$K+1`%"D&M5"AU]&V>@0ZMI;;UU#F&RE2.VJ[7/%ZNV:!@,,=JZ+;+8M/SG
MW&=)24FXQ8T@^EQ45N)3U$\`"#U>S7`.MHCIE^ZVM)!4;Z?BH'K[XK0Y!BI#
MW#:2+ALD35-N>\*/4%^`ZN(-!7CKF\G4NK.CY#"<"<5H;*<2@Q5RBI3U8AB]
MUSJ.+>['<DQW6T,K0$GR!!!J233A7EK?:3)K]X&"!KC(2#4#=O44ZAZG9HM3
M"?S`?-4>ZG:G"R/MA;L5K_*%^./1A(#LCUDI31"1XT-%-@<OEU+=5N=1MXFV
MMV"'$;?P6/H/S)N->?Z.,\H@#$G,/=0+FMO)EUM@RKG;HBFTM-N*2E(;K4D=
M-`/#77/EOI\=NW]1D(<,,-F[C^"^@-,B-6U.(`]N`46\6MLV;<791_!M+7U-
MA*%`=`5U\2"`22=3[6)HR"&#"3'NW4[5O;IKH0'`[`D1W"WJ8Y9HUF?:6XEQ
MU;383S"2H!*CP/@-;GI,1QO8"*D_<5BP.=,"0:)F<9Q9#,:&XXT/4;4E8J.D
MJ3TIX4YBIU.I7Y'@MP%%=?`]V&93.[<[1TY%-OSK:THM:%K'76I"Z`%!I0]`
M&LE^LQ\@P`>,CBL22P<:N#A7N70G9BWKO$V^97,ZD,1D+896YY4J1U.DNA1H
ME24`5UJXGO,O-#L%>N(S':XXKD5W5W7\K-T[W**JICNAIE25=8+;#KB!Q``(
M`&MQ%(&T<14KG&N6TLC<[7;R:44;GT+980EII16A05PH*@<#3A4<]9?KVM<!
MD-3VKF]]<380Y3OQ4:-QHZF,J9?IT-S(P233D2?,"3S)Y:WUG<"0---J@^K1
M/!\8VJ-N4PU1[B^E*:)5YPW3Q5XUU*+8[CMJN1=16A9*9-HILHMWLO4;T;/^
M4C_;1P+[V3VL??UMH3E/<N;ZD#1S@,,/J_!?NK8%^XO#1_L1QW^I$+6QVLKQ
M42#JSD?TI8:I5Y&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&
MB*T1Y@?93AJB3"(]A^I5!V)9V+X'?B2[00\7^)IWI;XV:TVK*LTFRL`]&'D<
M]JUV^TVV/BL2+-5;Y;Q*43BU53:>:U<!KZ-^7^G.980/`SB1H=LV5PIV[%S/
MJ>];S'PD4*S;7CRC;VI"6?1:?3$D,M$!70E^*E\H!X+2`I?&O/7UCTG87(;5
MPHN/:C('-/I_"?>LMYE]H<``$@``\.''Y>6NA11^F!+FYBM!##+*PLFD&:O#
M=[TG[K'KZ:DJ55=*4/(UKK1:J7/#I!X*>U2338VVP`KG/9]"FBR[WV!#NDIY
MQ0B,Q7WEK)*"GTTDBBC6@'/7$^H8X[J<QO%5T;38VB$2%<9MR<C7F64WJ5<G
MO>&H\Q4>$X5E=&FRM(*.-.JHXZUVEV]2!D(:W#W*Q>2R-C=(#X0ZE$BHMT68
MDBS..ADMM*>A354*E(1^-9^0JJ/'6WN;PVH`;X13'M5^PT]]U#SG/'BW4V?%
M;;$)"69MHEM$)C.76(CU""'.HO(!3YC4@DZC5]U8V&-S'X8'&NQ;6'07OD:,
MPQ(W'[UT[9N[\FVLLQU*_#)#1`!45@!#?#E2M*ZY'UUU]:LTXQ!_CIMJNF].
M=(,DIF('_9/WKHAVY=N;&60H%QN#+CB'/14&5(YD&O&H)`53Y=?G_P#,GYJS
M0OFM(G&C#3-F&.`.RG:OH#1-&M[.PAA:T9VMI79O)74C#.V^U8XS'DLL):Z6
M%+3TM=)0:5`\R0#4\-?,-[\Q;BZSQ%]<_;L[5,;2"=I(#ADH,*+<YK=%6RSN
MV>O6EEGI\Q`2E!24`_RPJ>%-8'3N9^KBZ<6N8#6O'M^A2XD8"Z+*,.Q0KG87
M;9TZ0?29>]X<4Z\OH3Z@2HGJ"2>9.NZCJ"CZ-)#*<,?K6I-J'DY0,Q47-ZMO
MF;+!ES(J4-I?*FC5H!7I]%!Q]H]NNO\`16N2%K2)'[OIM4;U73W,!SM9B#]7
M<N+.[677_9^]2+[;)+SB$2TK#:'.@.-.N!+K3BJ5HH<-?771$QO8Q,W-[<%\
M_P#54PMI_34Q/97XJ=VV69VW.<1Q_)K-&2Z9L6/Z\<.!?N\IU`*FB4]52E5:
MZ^F.C;\V]NT.IS`]V[M[UR[6;3QN<?-E&P]BDQ9;IZ+3+;T4,N>F/#HJ>'74
MUX\>6NYVFJ-=")';>[\5RO5[9\C<@V!W%*@S&WTA*6$*5SXJKQX4'CK;%[;^
MUIAS^.P+2,;'!@_,M"_#BL*6XII+:$++[A;%2@D<D"AJ@<Z4.N7:QI#)('.>
M,178?P6YT[4'LN&L8?`>(7%OO#VF:SC<[=-G&,#8LF0[88U:LEOUXMZT3X^;
MV:_I!:=7%82GW*Y0DC\(/&G'7SUU7IGA<V@IC1=AT:</+0X^(T4%?L:-^U5^
M\7Z/_;/Z'Y?7_D=<U_2F_P`N_BI=E/$>]0;[H_+W0=PX/CO7N=_U^8W98^\-
M<3GQ%5TG2SRI&M=M2.Q@MB="+R>MM+[94CV@EL5^]K1R^:G8NW]*Q-+@]],M
M?N3^B<Q+G]`4E+:4A"4I()2$T``!K4"NM+<-=0X%=]Z>U"SB%'OC:[M<!]94
MK<3M[;6.QTIY*;2I((Z3R!%`*$\2::P6L<:T!I7@MS?2Q3#-$033<056_.]W
M>H?.ZKAU<"?9R'"H&K<L<F0T::]Q4&ENKF*\`RNICN/!7&W'V9,>XQGW8TAE
MU#S;S:@D!QI0<2A8'F!.L(M<-H*FNBO?.WQ@^U=-=C]];'N=BT3;C<9QMF>E
MI?V9<UL%L)=2GT60Z\I*2**`J1XZL3M=3`'8I#I[2R=V84\1VIK.XS96XI92
MV4+>$5M);?*.J._%(J9#3B:A:5BG$\/9K3R1O+P0TD=RE-_*([5O:"H7V#'[
M;8P[']!YQ=25J6/P:34@)37CSY#F=9=M(R.1N8@$'VJ,6\SI,S6XUX+7WG'9
MC<^/<K-ZC8D(]13"$GSKJ.I7%*B.H#PUG7>N"&'(^C8^)V>]5PV]P;FN1],W
M`_<GOVP:O5TNT6!.C>FMQ32$N/A24E/4E)"%+`"ATZYQU9U!!:Z89;1S7O(/
ME(=]2F<<CVV[6-!J!B*;.]=8+;@UNQ_%;?*(81*<90LK0N@+G0`03U4J`:4U
M\KZGU3/J5V;9Q(<3L.W@M'=W;"2PN&>FRHK[MJD?L_D;C<-,)`0%MMH;71Q)
M*T5-34J(H4GGRU!.H=&MW2ND#VYW&M*BHPX+F?5&COEA-W0@OQV%:7=S;K)<
M]C.L6&SJ]R=+@<E,)2\[ZG0?**&A"E>S6MTO1;V)[961R<MI!KE--O&BYYHN
MKQ:%?DOE:"^@(+@-AKO7.&Z]@^3VS)$Y'E%EF2H;JG%LL2`MJA=)]-26B$D'
MJ/M/'7TOI_5,=GH++<2,YV7$!PKLX5JOH[1.I8+VS`C>U[LNX@[1V+I=M#LL
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M0)G;(WO!'UA?.MN9A%PNF0W%24DH4\I74E)4*<36H!%-;WI>\;;:0[Q-`:2-
MHW8+[ATUS&N#216@&WA1::T6J+8HR&)82E]L=/'RJ4DIJ>%1PUO[;4H[V$^-
MID#J`5%?=5;S4,68;:)C=V6(5R4V^ADU:6KI*D$A72KATUX$%(UT+IIKF2QA
MP(..W#<5AV+7!IP.U-Q8[:_>9$6-;F'`X^Z&$!*7"FM!QY'QU(M7N#"*MIE#
M<5G$$;<`NQ6Q&PKC&`6ZV.0B+Y?VJO.I1UN,M+'-8"2M)H3].N;.Z@/KVQYQ
MEK0X]G%4-?$XTJW+WCZUF;_9;BO;S@;V,V^6VN\.P78RFP>IWUW4%*W%("RL
M<5>(UT70IS<-K6H65>-@-OYFGVA<.KR[+R&ZO7204E#ZG%**C2J7%*745H:&
MO#4HR.W`KGUVV"1SF.<W:=X6E5:AUJ!*1Y54J>'L(%>?AJV]A#@2#OW+0S:+
M;3'."TT[:J-.[UG::D0YI7^(4/*.(JD]7/G3A[=22P(`97<N8=4:<&2TC%0.
M"B_F#;<F3'DMH"0Y&"2KC12TGB>)H>'LU+K5[7'`@XKBG4EK6HH<U%?V>C]&
M\6T*N'5^=/`J<N7Y36LF@-=;2,^,C<N7ZE:ED/C!&.]?NB8'3\B<,/C^26.U
M_P#RB%K:CR@+G[V99B>\?%*[1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1
M$:(C1$:(C1$:(K1_6'WN?W-424,3AQ7@PEQWA?&+\17"L:S/O=[FK7E%N1<K
M7)R#!Y#T9;\B,%/0K!#=C+]2.H+*2O@1RX:^ZODCHL.H=+VT\M,P-!7@`%PW
MK>[,.I.8#CE'UE,6FX&.GH<44(#:$!905("6FPRTFB10=+::#7U1'#:6-N0R
M@(7.('NF/CP28N=Q;=<JAT+HD`](*.()X%/,\]1B[U>0.):UQ:.Q9PT[FR!S
M=B23]X4M]2%DJ#5*)(XHKXGI%?NZBFH:T)(71G`D+>66F\N1KW>6JC[W.9@<
M5VNN[[RW&I%U;5`B'I"5U>0:]"2D=1Z3[-<YDD@FNCG<VO>%+WYXK:D8)%-R
MXXP8;<L(4P]YNAU;I=XD/*)*E%)XE1J=9<,T437<L`@<,5A7!+K*G\9(PW^Y
M)&]0Y16AAIRC;,A#JW&TJ24$*`YJ%:*%>'+4%ZBU-X:7$%H:#V*4Z!$XVS&N
M!W)TK;:UNWW#8,<I7$FW&`0EE0+GK*>9XJ0#4$=7'A37S?U;U3):1RO>:,#3
MOVKK_3VC0W-Q"U^PO"[[[0=KUSNK-D?N$?TDR&P^TVMP`J02E040:&I&OEWK
MWY@Q>E<*DGO7:M,T.WMZ`47;7:?#<>VVPL&:H,S&64F.I*4E'E0?+ZI'1U*/
M#@:Z^*>K-0O-<O)7PA_*>_#`\`I9;Q1,H*MP[4MK=N&J^(=CMO/49KT=9'0$
M-DGA4>8*^G43CZ4GBC-P]QSN&S>MBZXBMF!S2"2:88IA-Q'U762_[JXT9$A9
M2I*G*@(KR#8Y*)\*ZFG3D;[6-H?YVC%:B63FR.DXFJU>&;</W=?J24@*;!71
M*20L"O``'@1].LS6.H'63X@#0.<1\%Y'YPHC]W'N5CM;]O;9>1Z05UGT2:*Z
M`"4GP`!K\^NY_+36G3L82:XCZUI=>-&U[#]2^<GNVMDV=8DO-!3COVC%ZFT'
M\;%6\1YN'E6$D$CY-?H5\M=2B](OGWJ:R$S^?@G"[!<]9'VSA0>;DS+?=8ST
M:.5FGIA)*DH02:4\?;KM.E:MEGRQ^6JYGJ$0DC+]VQ=9[ZVS)+<IE2&W$)Z%
MLM^6A/C2I\HIKM&C:H^=@C/"JYAJ=N*GC546E;K72\XA2Q[>::@\N7,#70-.
MN*-ICM47N+<5J%L916%E;8JM1!'(D'G5(/"HKJ_J>GCTCB1M6N+S;S!PVU3-
M+PBR0\@R"ZV^RQXMPRYI%OR::OU'5W6&&WDMQI'JK6"V"H\``!X:X%U'I39&
M/)&(JN@:/J[FSQBNY1M_Y)N$?T)%_<UZOXK_`"K^@OJ_4USW]&'`>937]9D[
M=B^7;NF_A0=PO_#7N3_;9>-?(D_E7>K3_P!PWV)$XZ%F9!"4E04Z@&G/@ILU
M^<:T<M,R[%HW,HS)Y:!."[(9@2UNN]:NATI".JA*DD4X@UH=:^XK3#BIU#<C
MU+>%5,/!<G^TK%#2AM;`::"5>9*QTI2GS&AJ#QUCP>0]ZZ/I]W"U@YA&:GP2
MG4EA2TK=4.NI()^7QY^S5<GD*LW=U#+=AC#XOP6S,,2(R2VOI*7$^4&G4*?6
M^;6EN/L4NT/R+/@39=JE"8BX>ZNQ6PF*&BM)4KJ',IIYB>/SZPIH[DL\/EI\
M%DRZ@&W.2N(=]172383>>T[C6VW[;[CLL+FEHQ(%W>4GU7$.\&T..N'S%%!P
M]FM2^:6W!,E0#C[E-[41ZE`(Y-H%![59W%[1\N^W)*,8MBI#;[C;T.,E%%RF
M5+)0M`">*>GCK1W.O:9`2Z4C,W'W+(CTFWL#7BI*]O78I<<@17,,:F1G61Y0
MMLE)"*E24U3SXZX/UY\Q;J-YBM2?3J,:_JT]B"+>M4H=Y>T2Y[?/HF8?CDYZ
M3';#J`B/Y$$GJ-3T\J<Z:YK#U\+VW]*X^(`CXJ]T_KSWV8FNCXB#7OJ0LC!L
M"W*R;&VV;O9IK@1^#3Z3+M&G4^5P?5K4T%*>S4.<'R:DZYBJ</M4/U/J'39=
M3(8\->#C[TI[#B.X^*WN-9+98KG*?G.MM@-PY#CK0<<2@!2O3Z0!U<>.K6I3
MPR7.>2G,)Q6PNKH:IIY@MSF(;@>*^ASM-[5IYPBV3<G@L/S9J6I3L>0VAQT%
M92OI*5`A*D^S7:NC+"RU33Y(97!N6,$=Y*^0NLK;5+/4BZARAY2Q[I^W6.(+
M<R+9X\=$*&GTVVXC72LI0D^;I1SZQJ$=2Z9'I%P712"E5TSY8]6'+R)#^8,/
M:HU;'[37G)+X+2NT-N172AIQ*HJ5)"6RD4-4\/-QX<=0;2M..MZNYHWGZUU#
MJ?J*"'3G2SS#G4WE36R/LFQ5NPRI\RR,L3UPU*;4/*`L^)3T]7&NII-\M+:V
MM3J,H_/J?AL7RIJ77%[>ZJ[3VNSQX8]ZX7;N8M?-NLPN]B>CS(\-B8X8[P*N
MA:4JY)4*&A]GCKE^IZC+:S>AMMH</@NPZ`QEWIK8)G922#V*..:Y-<;@S(8C
MLOID*`0WZKBJ*`%`KIJ4D$ZPK74M2_5&TJ#5=.T+2[;3QS72C'M6@V_V1OV8
M7%#DN.\^B6L!ML("G7PK]BTGIJ23PUV_1Y-1U.W-IIT3G"E30>]:3J+YHVND
M7`9$\9@:8=BM;X=JMPQ2"]<G[?+@2&FW5E#[)06V^DE/J`H%*#5^VFU#2M0;
M%<,+)!N/?M4OZ3^83]>`;(ZIS`#W57(;<J(\J[_9REH)BK2UTMG@I5*=1``K
MU4^_KZ&Z6FFNV1W9\K,3[B%W&S`#&GB%+OL]V+_*>YM7>Y1P&BYTLLJ0>G\'
MT'U`%)\I\W/5745_DC=&3@157KO^R5U!W5WJV^V#PN5:;`X)F=BWNQD/*Z7_
M`'18;3Z7E`]-(001PXZY7:PFZO@WBY:&(9HGCM"^>3>K.;WN#D<B_7ZY2WY+
M\A;KK+BU>D.H^1*$J-`!QUWGIRW]-:"N&"P]3N_36R95Z6EICI2L5"``!X4H
M*<?#AJ;,-6`]@4%??6SB2[:2M<BY*37J(5P(%?"O/PY$:LS'Q-]JJ9J,437"
M/>$P&\3@5#2I5$EQVB>(\U10$`<0..MC;G#VJ):C_P`P\]JB5DZ5-QXJ5)-6
M@JOS'B"/DU)]*VCO7$.L&^FG*O[0/I.\VT":_P"ZC@1KPI0Y-:^'MU(8F^(K
MC_4-U6#M7[HF!C^LK#33GB6.\?\`S1"UM@?"`N<.=FKWU2NT5"-$1HB-$1HB
M-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$5@\_I7_`-B-6/X!_L*\?YV=
MZ^.COY<+??3W(*!-/MC#>`_L?BZ_0OY$_P#\=9^U?/?7_P#^ZD^F\J-3UODK
MCMJ+2J215H>)X'B3R`&N_:AY5";9-O=X[[*WBV@H+;A0I7/S#GR^?40NYLD;
MAWJ2VGD]I6/:X"4(0X_TJ#[K8<<6.H@%7TFGAKF>J7.+E((6YZ-4$OB27QNV
M*V[Q]@)7%N$:;+6E!4E)<92R&S04J4AS4"?<#U)4N9;?\J*#<N9<.],M-K]$
M>[FE$5`4I/AP]IH::W+;KD0EPV$+'DTZI:>Y:*<9<@/.(B*<2JJUN%WIZDCD
M:5H*'CKE'5VO!UNYAQ"F>EV1C:!Q3Y=GN$W?/MX+1-6\N8QCLE,Q<4$O,QRP
MXV&^ILUJ%!'"O#VZ^7^O;CG:7*\;>62NM].6^6X@=P>%]9N+9!B\6PV.9(Z8
M!AQ"5K]4--M!I".I3RRH!M)(^;7Q5U%9:QJ5\8V@^GJNNVVQ6;[O8<AN$>VV
M.6U=+0T@!T6R2EY%1S4HI613VZJAZ*?';-<6XD*X^=K'%O!6)NYTVUP79=H*
M[?Z39;>5+/IG\&.K@E2JT)'`\M8%QTZ:Y2-A5<<HD-!N6NP_<-O+IS$F!/AW
M";U#WMKWAMWTR%CU?(A9*"GGXZMW^G10V#8S0.:U7%T;VGLK+S25ONH/O7II
M0TTVOJ2Z4\0HT/#C\VN&]4!MOD<TU>7N`'LW*S*&>%SS0`U3&]S6P[-^M]PD
MS(Q$01I#@>](KJ&D?A"%)J%%/AJ7]"=67VE-I.TMC(VFJ3R6][2($5)INWKY
M2.\VS1L6M=^M\12G7GI3J8ZBDA:6&BM`HDBJ:&GLU^CGR4ZD=K6F,$1JYH^`
M7,NN-(BMF$&E**)/8E(59=_L=MR)87(O#KCSZ#Q5T("JIX_64GE3CKZATW4Q
M)<AAP=@/<N'SVX-L2W$5*[_S$I$J<VH%+:"'JJ!3T\Z=5:4X:[MTU+RGME.S
M(1[USR]MOS"*8+W'RF:^IM=?0235:15''V$<-=5T[4&T&.]0_4+8YBG!_)]@
MK;##ZEI6E135)%*))\?"FI/#,+F$TQ469#R75=\4@IL=#%T6AQ1_!O.)J4\/
MJ`_2`?'4#ZBLF"UFST!Y16ZTV02W;2-PHM?T0/:/W*=?(<_;RUP_TS/YOXN*
MF%?_`*5\2_=$">Y_N&'B-ZMR^=/V.87=*JGY"1KXPGIE/<OI&SN!ZAOL2,L"
MUMR(U*5]1I7`\J*22?N(.M).!G[*+M6@7<;&-!Q_T3A7Z&/5;>-*ODN`U-*\
MSS\M=:>YV*1P-FDN6N83DJE]MGEPL$IV)/*G&)(Z6U&A0V3TCE2E`$ZQH?*>
M]3$.<,KJG-E`4B_?6;ETO1R`A(2:!7%0/`'@>6JY/(55`T>I;-CS!7'V'=L3
M@VH-F.%.+HOTZ#CX<36GMKK2W"ZETZ`\#,L&2I*5`J`6A*RJA`J?-S]NL@3/
M,;6UP`&X+!U%K(;M[A_.?K2^P^^L0KQ;)!ZT+9=2XTIK@Z'`0!YN0%?'F/#4
M:ZA!Y+2T5P/V*:]-7\%#G/B!%.S:OI![+=VL1W+L=JQ_)'6F\VM$=MN!+?"%
MKGIZDA+06JE`AD=-`/OZ^8NK7W6>1D9(=0@*3W\S97-H<"NV.V*&;(RXF3:(
M+P],E),=E1(*1152BM2#QUQ;J.XN66QCF=5]-X'!<YZC<[+MH:E+G([%9+\$
M/W&S00P^P&EJ,9L46L=+:"$I%`21KG>GL`E#VU$KCB<:;>&Q:&.XDCTJM:G*
M?K*7^WVU^/XS:>K\F;)(CJ"GVT+@1ZJ2KB.)1U'C\NNZ=*]/0WSAS:&K<<:+
MY2ZQZANK35RZ`N!+L:<%%G?B9=(%P,G&;%;[0Y'?4$KAQ8[9#::'I4I+1-/I
MKJ"]7:/'::E.V)M2R4C`G<NJ_+SKI[X612O_`(!M`X]R</MMWWR>._%M]Z*4
MR$O?5]110H5"0KIZ0FO3K3V?6TVBLY69S1L4CZIT^#68R]H:7NK7W*;V9Y*C
M,6T1+LXEIB0T.E72DIZ0D!2>(!!ZA]W5^YUR'7?'<DN/>1CQPHN566FRZ#<&
M6($-!J?9CO6FVZLULP6X*GQY4=#;RB\TI;*">*TDI!()!I777OEY8],Z</5W
M]'7?',[Z@:?!:'JK49M9>>69.43LJ4\.=;R6J)9GA[FB8\8I"`E/6GJ//G4_
M0=2?KCJG1!I+H;`#G4VU/WT6@Z:T"VEU0->"'@@U)/NQ4"KE<]B]Q;@_!W!L
MT%4EY:DJ+D9*%1UK-.I#B0D.+!/"H.ODNW%Q?ZSFH>82<:;EV:[?!IT`B;3"
MAVG=W)(7OL1[<LJ2V_:;S/@-O++K0;C)6$@BO!8*?+QX`Z[1H'0DFH7#+EK1
M3>5$9_F&ZVD-O(]QC;N'W[5*'M][*]E]LYC%[F7A-X-J(]U1-],MI*1U^?U`
M:``\3X>&OJKHW0-/Z/L7W,P8)LIQ..T=M5S/7+FXU8BY8'.?FV^W@M9WCV/9
MR^X5?6[Q:[*J1,BRD19D,,("4!*D-'K#:2L@#7&NI[^VUS73,`"]OAJ`!_$3
ML%!O7?OE!IVJ27\+C7THIF!&^B^0'=#9;:*RYQ<9<B0N9(7<283,=0<92OU2
M4(=0*`T2==BZ/`BTXPN\K@%]N03,$60>9H6YR;>'&-E[#'QBT)9;RJ\-!;8B
MH;:,"#(3T)42!1+BP@\^.M1U3:$DO#21E^TK(H^>(FN`*AYG%Y;N]NN%ZEW1
MQV5)4\>J:\I;BB4*/EHKB`3PU"M$M9G:I$UC2#F/U%:Q[66M7N/Y-<?IWJ`&
M57%#LM30DI?<*ATI22:<2**J20:Z^A=(LW"U'-!4/ZFO('6WY>Q(:6'E*4"V
M4U)%:DTY\AXZSF"X:^@/Y0.`IN7)X3++,<QJVI]U5H[A.8M3)?E.>4'B`>G@
M`20>(IK-+6/+:XE;AUN8F@L%*[<:J,F99(B_SBD%2FD.JZ`HT`"31-*$#6QA
M8P-P&-%8>Z-K3F\U,$TF;J3Z0XI%&DI'$#E^O36^TKS#A5<$Z[N2Z<YRM'M`
M:;S[14/$;H8'3C7_`-);4?E\=2FW:"<=BX7KTAY9H?#5?NKX$3^16'`^&)8Y
M0?/:(==9]/"%$6\>Y*_7BJ1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB
M-$1HB-$1HBL#CS]OZM`?O:LG8/\`85Z!FRN.VB^.COU;+W?9W*`J`0W?,-*J
MD"J$X]$-*^'#7Z'?(6)TG1MF0>*^<.OIJ:W,'"M"FA4TV8+P10*]W4VR2JH2
M5#]A4D`GY-=QU$S0LK*ZH]BAU@YSG#-B$AQ8$7*W2FWGE1G4+-'U)ZD+>/35
M*S3J'AKG>JWCWS?EX,RC#WJ9V,;#'LWINO3<98D1D^9^*ZX*DD@AL5`Z3PY#
M4&U$`QN<?-522RC9S!@H2?$$Q5G(L,P+-(R`7K.X]#EMDJ\C#[:$JHKJI1+C
M-2>8USZ0#U7M4OD)CMAEP%%R52J%''5)=0TKBID*XU2>":@<30'69JTG+M`(
M30EH^I5V;G3.:),0M9=US'H+_I+=:BJ%/7)0VFE.`0$T6I)U\]]:274310GQ
M!Q]Q4]TIL!;^>*T(IB4[/9WN9?=I]TE72UL-W./<&O<I1>5Z41+)0"7%CIZE
MNI))X\:ZX;>FXU(FSN36)WAV4I7N72-(DAC>PLH#7C]ZG;OWW<S<FMMQQHRY
MV.6=V*B$U>[5)4VV@.`!_P!1ED!;Q23Y1SYZUW^*V$0\0:?>I@V]E9Y7_4G@
M[2[5F-LL<&=8\CN<RTW!+A7>9ZW4)]+H)3TLO%:O4)-=4S],6KK>K:!E,`K8
MUF-LICF9F>#B>/N4U9MU7^#8SF1(N=KE5;:EQGO10%`4"'*I%5GG34&U3IJ"
MWA?+&*OIVX=JVMMJ%O*2(FY'TXG[4^VU7;W@9G6Z[XK<;A9)UR:5,4VU,<<2
M^MZB@5(%>@J/L(`U\W]675W:.>'`9<QW?0+>1L:Z,$DYJ+JEMOL-?40(DJV9
M]=XCJ4)=4'9*PVXI*1^#H.K@`/'7"M9GAN[ZT&8A_..&[$!:[586&$#,X&IV
M=RG!9]N;;D&--8YD8,AU,1Y"9CR2L/N/MD*5UD%*DJ50TISKKZ6_P:SN>F(]
M0S%KPS-X2-PKO!*YMI^MQVNL&VF)H'BG?7!?#/\`&2VYNVT.\-WQF,TT[9+M
M(ERDS(ZNCTFUNJ66B3Y6SPX`#PU]`_MFUB"PFDTYM"*&F;;\*?4MCUHTZG;.
M>"0ZF[\5SW[!,7-Q[A[5DJA[Q!QN#)<=="TK#"S7TF72!0O+3\VOLG2+>>2\
M]5)05>=FRE<%PAS8[2W-K*3S02<>W8NX$G(DW"7>)"VUK;DR/=FFT$(0V&PK
MJ]6H*N!`Y$:[OIVH.CM&L@`,N&WA["H3?QRAY>T"E4YFWUM:18Y5P?;>*%>I
M1D@-MBG3Q;6M)/2?GU/=)NKN1N('Q4)U#G9C0#:E<B41&7(!+;3*"&W4\2LJ
M'11)-0>FO'72-#EG=&<X%%$;MQ<"#P377MU0]>6M1(1%D/*4>8IU<1P`\-1W
MK?.+61\>WTY^LKW1"YMW1N..]-!^4,?_`#=?[@_7^LGZOMY<_EU\X\^Z_I\W
M;]ZG57]GE[5\='=0%([G>X@H/F&]VYXX^S\LKJHGY]?([WYQ0[*+Z$AAN&3M
M=&*IL+5-4VMM=1U-]*@/`E->'/Y=:F[!:<S<5UC19C1HEP<.">4OO7:TQ'P&
M@EHJ:65U!2I/CT@'A\^M!<RM&&*Z]H+8Y8\/$>S%:]N&^P\A1<7T)4"5`J">
MH_L>5*TX\=8L4[`WVK<N:YA\6'>G=PM4R7TK3(DAQ"^D)#RPW2M*J]G#EJI\
M["T@X*J!S>:`"*J2T5Z6RU'1)!)2V.E0'#IXUJKA4U\=:N9S3L(*ZGTWL%5F
MREA307456!PKQ'+F*\CJIDD=``14#BL+J)K\[G1BOB.Q;"V.EE2'DT2ILI()
MY4^4GY=7716TT+F3^8[/M6JT6],,QYC\N(P*D-MAO+?\%R2VWJT71^/)@R6'
M0&E%/E2ZE;C84E502`=<<ZDZ5=+,7P1AX-:4%5U*VO()V!_,;X<<</P^Q?9'
MV7=QV*[P;:V&_29<95T0Q'B3FBZE:^#*4..OIZU*3Q3S.OE7KCI[53<R-9`\
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MN#CMN>?6U524]":`?A`5!1'%0J:5YZT\>E/A%(B/BNGWW3UI-;>+(Z0M.`[1
ML5K+^Y^#:)5JMK%Q;>])L-2")%5!P"A%`JHH?;QKK(M6:A'*(R]V3LJHT[H.
M*.PYPA((&].-L9O='W)RIS'IC`DM+1U-J<60@)3SJ22>D?-J=:/T]?ZS,+>,
M%X/&JXAU5!==/SF]@:0W`84PHG-W:V>C7Z]1/L:`U;W%.)JIH&A(5]9113S#
MPXZF5S\N[_1877C[=P+1YL-^[;7X+76_4,>IVF65_P"<=^[X)?V#%;SB5NBM
M3'%*:C,I"UJ)"3P^LKJ*B":>)UO]$U@Z'I@DG>UKG'VM_P!W!1MFFMU#4>0Q
MCI'G>-B:O=S?2XHC1\,PY\B\)D#[0=BK6LH8-"M2RGDDH%#6FHEJ_P`R-5O?
MR8B]T))%1B/@N_\`2'0EO)`([I@!!&)49=TI]^R?'G+7<YKDH,PU@$O*'2KT
MZJ0!0U\W'5WIZ"[DG;>R`F(NQV[>]?272FF:'HS1'$6\S@-M:;<:+AENOB[&
M!G+=R,HD#[/L;D]-HM+SG29T]7XI0"@@.4/A7V:^D-!FCEB8(C1N]2PMF;(Z
M5H_*.Q<4,MW#R#*,IN.32I#PES9!6UUK+K3$0?B(S222E*4)/,:F=U96EY;!
MCA60C;V*EM_(P<MN_%:&XYW<W6UM2ICRTE'2ED`D`@\2D$CB::U^F=-16]ZR
M<`4!.X[QW*+Z[JTK;=\!KF=3NVA-/*FH7*<D(4M3JCU$*`"J^``J23QUT86[
M8[89=E%`;R]DN8C"TESJ]ZUDZ[S?3(;#@53I2>D\"/EXFNL66:V9$&D@/`[/
MO5O3X7EP;E.8#'#>F.S"Z7"6ZXSZZZ(ZO40:^;EPH.9%#]W6!$^KZ[JX*2OC
M!9EI^":I]IUV0CTT*54@#I2H]*B0!7I!X5UN8!4`;RHAJL4D57-H6[Z)O<X+
M@>4TX#U-M))J".)KRKQKJ0Z;$YAHXA?-_75RT3&I(%59V905;S;/4(X[HX$/
MI.36HZD\&#J+CVI2-GCRMVUVK]UW`_W%X:?;B6._U)A']?6:?+[5'PW*$KM4
MKU&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B*P/9\OZE#JR
M:Y0[=D*5RY6G;1?&QW]S64=]W<S'7U(=7=\2*04\_P"MF,*\ZT-=?>OR6U`6
MG2%E0X4)P[UP'K2VC=JT[I,7$FB9#&KFW.MKS3ZNI]H5:4E2"`0/J_6ZJGV4
MUWYUT=1B+B"&UWJ!6D#H'`R$`!:<S)L.:MYHU%2EUISJ+*^)\_ITZ2M/@=0W
M5+'--6`C*&CWX\%++&>/)E!&WC@M5D%C6Y">N-O2IQ:DJ,M#'GDEQ?#J0R@$
M^GYO'EJ':A87+HW`-)]A^Y2FT?&PAY<WNKBH]WW%%9SB=ZQ2Z(5*C(;F,K2M
MGU5QVG4+)<2A0ZFR%4\U-<^N[&:WGYDE*5[?M"DOJ8[B$1QUK]."X@;DX:[@
MN2W"PS;<U%,&0X(]QN14I+\/J*FEML@=72I)''@:ZTUW.'M((.59=BT1D5(J
M$UEVG1GXY/6NXJB-DM(2I3<)GK(/6`E(44U3X@CAJ!=064-U#5S34`[E)8;@
MBG+J:<$I<*0Y`M46ZR#Z#]SG%27FJI2EDJ\[B3PZ0@&M?#7%=1TR)@D9!&\S
M$&A`V%2FQU%T=,'!W'@LG-[@9BX+%OD%<9,R)%<6M86V^HO=!D<24J#A7SYD
M#5O2M%C<!ZT/`[J?719[]=E9M)7T);5VE^P[9XG;.INC-AAN`1F4MLJ<>CM.
MJ6I0`)('R:W=WTU`YAY`<8MVW8L4=03\TD%N6N\K;MJF25R84Q0FPG*J;#O4
MKT7TFJ.G@4BGSUU`=9T)EO`[`ASZC&JD^A:V^YO6PO<TYN!!]_9]J=Y'<5C6
MS.".9EDSZXC.-!J$\EE03(DO$'TFFD%)4I'4!X:^?.I^AGWS"PQU<3CN^M=3
M&H0@4#DVFVOQNK/:\OB6F0](3;)LPLLQE?AD,,.*Z4^J``>LCC45`UR+7/DO
M(;5MZ6%DD;BYNS$T[#PXJID]M=2-CD=X:\#]R[.Q?BZ;46/`$7R\-1&'8L%(
M@/+E(;0HK94M)4@!9KUGQU18S]0"Q&DELA:WPT[-BCFH](6;-4;?/(;%G!K[
M0ODB^(KW;VOO`W-FW>-*1Z/JR!%@1%?AENK<6ADJ;*4.>DH@$<**\-?2ORAZ
M>&CP#6)2&#-E))`\7`XKSJ'TL=J[D.#C[1]=$[':_LO!VKVZ=R1L)8NF0QFK
MC=)*$I]5+CD<!IH5JILI)XCVZ^TNFYKRXBC=DJPDX@@CX%?.FMQN=.^9]`_A
M4'9LQ&"F'A&+RKHPT^'4B&ISUYDR6%!+KBP>M">7$UYZ[OH.G9\I`)=E^[C@
MN=7U[<DEC1@.Y2`@,R41682E-B%&:#092:,+;2I5'%$<5*57CS'#76='L0QE
M'!0;4[ZX:XU&]>7Z2PW;V(;:0V%*2"4D`)'4*D!/+AKIEGIKV0EL;1FIQ`^U
M:2Z:YHH[:0F9W4O,/&\&N=SE/,1E.M>CZBW4I6&6?/TH%>D=8/$^-=<=^8.K
M,M8)HLS:\DCVU.'TP6TZ;LYI;N@;5Q.&SAWJ!?Y\,:_HQ'[W?O'UV_Q/MY?5
M^]KYK_59.+=O8ND?I-Y_Y>[B/O7S(]TSX1W.]P_4KC^>K<[AQ/$YE=B/#Q3K
MYG=$\C9BNUZ7>EN,^#OIP3+PY*NHJ(H*4!^?6--#3;M4KT[4'/DS;`"GCP6^
M-,.F%+(5#E)(7UT\KU`$J3SZ03J,WEO4DA=EZ2U,9*52_?B)CM.IIZB)*R?6
M)\O2H"A0.8H/U-:9[,AH5TRSY%Z,[SXLU%M\,<?M\L$J4&NL`=2AYN8`IJQ+
M7EE;R'08J"9@Q4NK%*3):CJ<"%H4E-25`]/`<*4J:ZPE+-,A]+1**9%BI0I?
M#H'F``/$5X`4^?5B'^X[O5W58,T1=QQ6D4I:'`I/E:J!3GUUY'PI36U/DIV*
M$06W_,'O2L@=2%-%#:$@%%7*@DGAYJ?/K4RY>8W-Y=_<NBZ?:YK7+Q:NB?9%
MOCD&%9A<,(B7!Z-`R,-M,K4\YT-3A0-!`J`VAQ7LUSCJ+IRWNXIKC=0J86DQ
M%IZ;LHOIV[47\V4EZXW)WUVW0H.J6XI?4DE030JK50/'7QGUMH-C97_J\.8Y
MV*AVMV4#7$2>?>GTNT%&([Q8UF:4&/:;VI,"[K4HML)DO'H074B@K7C4^&N>
MWMO+SL\=2"%$-4M@W3ZP>:N/=13^C9U`Q:RF5`E(<9$/WA!;4VZT$%"ETZC7
MR@_>UN-!N]0@<Z-H.5H7()NFI]8N,KVDMS+Y\>Y+&LRW]W(RJ^.N)-EAR4+#
MGI%9+"2HU03TI`3RUB7M]?NO'B0&@72]#Z9BT"#.T4=(T#W8I\-L#BL/;VS8
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MKG1FNK2-K-Y/VK[&Z?=83Q`0D%Q:#\%'W=K="/8X,A"TLLJCB0M]?2DD-);Z
MBLIX$`<M?2G1=G+<:8R.3:X@CW!372]-<ZXSD;"OEZ[W>YJZ[J9?,QFUR51\
M8Q^:]%6VP`PF:^$$+4OP6:^/'7;=(TTV;6LXJ47;A"T#L7/43P&QT*4OI'30
M<Q0F@)X@D:F36<L-']/VJ,^H'--%C/+31+SX(*B:`\Q4&G$<];:W4,ZCN<'?
M3>D\KT?>*I\P/W1R_5KJ02?^V]BA5G<_\TJ+Q-8A1$];:4+6*MJ-*5H:$\*\
MCJ/7T%0'4VA3FPBR`S#^+'WJ,64W`NW):$K"?.3U#B"">(H!7CK,AM_RV+!O
M-4%N\MPQ6(AYEF,]*\@2VA2@DD!9Z$UH">!-1[-;JUMB7-[U!]4UP!CQ45R'
MZE'O);H9TR4I=>*B$J)!`":\.7LU*;:WH5\U=8W7JIR.U;G94UWFV>_X4\"_
MMFM6MC&W))E7.;@96T7[K6!?N)PS^Q+'OZD0=9IV>U:D[$KM4JE&B(T1&B(T
M1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B+'',_RY_6U3_\`;_\`923S
ML[BOB2^(3?XS_P`0[NFM\::R]-MMWPPS(:'$F3%;&-1G"5-5"BE;8YC7V5\I
MKZ&UZ3M&2>8@GXKB75T7,U*9QXIH;(L0#`G1'0[$?)#E"%)4.'4CJ'!*_94:
M^D]%E]3$1M7.[G8>Y*N:TP9!F-K_`)F>HI2/K+;4>=2#0TX:V#])=,XN&"L6
MUYZ?P'96JQS=(T%Y*X+2BKI57IJX%J4D@`I(H4DGCK'GT1W**WUOJ0H$FIRX
ML'((V10;<N+[ZW[M>8JA6.[U#BXE('2FM:\N6N5]2:(<YP4KTS4J-JH7]X_;
M;:=Q;=%RG&`IR](:+OIL)"6'G$*"TQ5=-"33P^37.;C32`13!3FTGMBUI)&8
M@+D+,QI['TR;+?K;[G<%2O1D15_@WP4+("D]2>#:@*T\=1#7++EV].(*W44\
M3:<OVK0Y(Z'),2S6LJ9BL,'IJDA""H`+!I3I^?7)C;$W&7BY;J&Y\.U2([<M
MA;WN[F5FE2(JV<"L`1-N=R=;6B++FP5EQ$-B0H!#I4I)Z@*TJ-9GZ<5BW-RN
MU5HD,S+9-@05HMH0TS`MK:G`E$532`R@(ZJ%07T@^P$ZW.@V8DN)+>X_M#9[
MECQ,F/YQ'Y)Q",;QV^6!$J3=9320Z'5!(=#O4KB4+H22%*Y\.&H=UCH=R)LU
MNPNC#C[.U;[2]0@MK^$QGQ%U#[OO48N\3"[_`)KL[/E8>5729;'X]QO=K;3_
M`#2Y&8='O$J.@?74TV"JE#Q&N9W=A</C:718GB%/VZSX=OTJN0MOP=K#56;+
MIDPRF+J/>(OJ-!MYE;;I;4P^RX@+:<;<X4-":5UK-7L9&V43)(A1Y(V=BV.F
MZL9+EN.Q*C<?<C)<HL*+7$NDTV]MI34>"A"JO24A26T(],%9`7RX#6JTKI[2
M890^[A`8YP!(&--].VBD^NZH6VP<=PK[A5?8=VH=A_:1W\]DW:ONCN[M5;[/
MNIC6"VK')N:XC'8P[)U7'$G7+>\U>!!9]"Y^NMH+*Y#:GE@A15K\!?GM^[[]
MPO[,?W9=3Z1H-TR^Z(GN!=6MCJ#&SQ&UF+2W('LD,9Q(!\-!O!HM5:V%OU!I
M0FF>6N-<1\%"_N'VEQS;[=:^;2X7?GLBPK!9+4:[27H:H-P<N*$K<<Q^20VT
MF0N"RD=3Z!TN#D=?TZ_M#ZXZE^>'R+Z<^:VM:)'HM_K5KS_2QR"5@:X^"1K@
M^0`3-_,#,W@KE+6TH/G;K(1Z1J4MA`_/&UK37;M%2DA$OSBDHM7N)MUKA^2-
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M0>;VIE8ZO+2G&O#]36)<>8=RWMF)3*TQ^4;?>E+`G%A25(JD@@TH*\/$`@G6
MIN+?-C1=$TC66V1\/A:GAL.4(N,80IKBDALU971(5U42.GD/+PYZT=S:BNS&
MBZ9HG4;9#@ZC<WV)<1PGTDU444XLKK0=?A0UXU--:>2(UR[N"[+I&LV[H@7D
M$)S\0RQ,:1'C7.4W%6BB>E9\KJ?!0-0./+AK77#)&>52JWOK*;8![U(B!<(4
MQKU%2$O-]/4GI*2D(4!TUZ3P%".>C(*`.'F.U9NHF)]J,A&:@^I82DUE`)`+
M*E5%#U<N%30FE/HUE-S!AS*&09(+C\W&IP2LMZ6E]741U>6E5<C7G2M-::Z!
M=X>Q=(TJ>V$8S@9=^)3X;&?S-NCC[PD^B1>H'0L*`KU/('5Q\I`ISU`NL=0F
MTK2GF(D9@:_0J32"Q$/,A:!(!M!)^U?>7VZX7#B[>VBX!QI29=J@R:I"*%18
M22NH_;*/W]?!_7FM37<Q#:YP[`KBW4VJW3-3?"7$C.!\!V)D>XK,A#8E6=Y3
M;32D.*1*J.N.ZP2IIQM*>2P4\]9_36C76H6[7W(+RX#=]RE&F:=#?V`HTYSM
M^Y0"9[_[3(Q>X;=_:S;%XQZ0NTSI)?`==0TI;;7`FJBL$=0'&FNKZ=T+';Q<
MUS0USA7>M[H_3FG0RN$T0(`PQ/WI?;3]RFVTR"Y9+W?K2T[<$%IU;E$N.MJ)
M'IA7F42>KF>.H]JW0LKY3-`*BN-%;U'1O43%D+:1MV;4E=T\0N&.MKR;![@9
MMCD@S$M1WBZWU.T4D(%2:E/"AU%+C0H[,ED\533M6BET*>-U?X0:GN&T*+-O
M?W"W8OJ<9M\"8REQX,/2'0M`:<)Z`.I*C1("JT/#AK)LVQVUIR&LIAVK/BN&
MPQ\N(4C(V8KI;M==K?L-A\+&[O<X<J0R$>^F2\V2#S4AMPKJKS>PUUKQ;W`J
M+<%KJUP6CO=&LM7E<V0`5`PQ4A\&[Y\5QB(JVIG,%3CJ0E1>'0>!H"KJ(H3J
M[#J^OVDG*,C\H!PH/NW+G>I_+!CI\UO0MK6GTQ4F>W:<QW2Y-+RZ\+2JU8I(
MZX$9*BN.\MQ1">H`BJ0`?:-;3IGIZ\ZAU,W=RPOE!VG\,%R_KNWM>EXFNDC_
M`#QA7'[U*+>;;&VLV*5<D)2A(:<2*)*>AM*.(3[`!RU+.H?EQ-I\#9IZ$U]W
MN7OROZ\N+R^;!4EE=_?W+Y/OB9;HVW:K$\A$.:&KG>(LV#;6UDI==4OR$H0/
M.E82JJ32E-=D^7=BQ]BWG-J]C@!MV4"^XM(GB?9A[121V-?8OE_DLW:^^K+F
MO*;2ZI<A2EK"G7/7()6HJ/65D4UVD6;`YI#14*F_M[E[#*7U8T5I@L%MMBVB
MAHZD<2I7$5^[[!K8QVV<9I!5PP'<H-<<V*4G-A[$F;[=6J@(IT\PD$&A4?"G
M'QUFP0T>`1X?P7.]=U42W7I!B]WV),?:D>$%NR'0WY2H!2DII3Q\WMUD3RR!
MN0'PT6NTR$ONO%Q3?9#EQN0]%I2"VV2D#J35=#0*X&HK\FM<+@O?DD%0,%T:
MTN88(7-N*4`PKP31W@]*URI7X,^8MGZM0*=5/#APUO;,"8$`8-I\5RSJ36H(
M9SD(RFOL377[(UK2&6W%!ID\DT'4!SK3B:ZD5M!B#3>N0:QU-YV-=2H/TV)M
MI<GWE16.`))4/G\:^`UN&DLQ;@5RO5+LW!+\U743A[*$?GEV>%1PW2P$\QR_
M*>V<=9<8J`\^8J.2DE@)VK]US`Q_61A9_P!B6/?U(@ZO]BU92MUXO$:(C1$:
M(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(K10#7^62?U_UM6W$B(`
M;#A[%Z<2"=H7YAGQD-W\@V\^,EWG*L=Y<MD^+>=OY,1*U$QGZ8;#/NDEBB@Y
M'>4#4TJ*Z[IT5K[K*RAMYWUC:/".`V_77;50KJ'08[N8SQ-IF&.W$U.*<7MA
M[N<"W9CJQ:_SXF$Y^WT.(Q^ZRO=K7<77*?S39IRZMR&Y)/D2>*::^G^E>LX&
M/#7R#+[%Q_7=&FMY,L(("G@VZ$Q'7#(C);!],.KE,J;)`%>ESK"%`GD1KK#.
MJ+&0@PO:&TX[U#KBRNF2;#FHJ4H+[*78;L8EQ-*-N)=*3]6M$*4L=6LXZU;7
M$7+C>WF'?4;MJKMX[MKQFKEQPHM*Y=9<?KM\MHRH]2A7ICI6E9X$A:Q7@-:?
M4].BU"+\L@S=ZVEAJ,L4V1]<JMMHBR$%AI]Q#?4"MA72X$*2`.1J$K`%"12N
MH1J?23H8N8!XJ54RM]4=7!U$S>XW:[@NYRTS?>8\&ZH=#XDMM(#RB/*H%0/G
M(/MUS'5]",[A'+4"AW*3Z?JI`=G=PX)JK=V`;=6JZ_;65Y'+<@H(=]T:6VTB
M5T$++;KAZG4I<Y'IY5U$/\`!F$T9V&M.*D`UAK(2\'RBJD[:OR.Q.%!QO%K&
MS%@1$!N.Q$2?<&TJ3T.*6``IYYP)!*E5-=;]O0;>1GY7B[S]ZU[NHHGX.V)%
M7"V*N,YSI2^UTR&FH$9I1;>;4IT$NN]/3U\5<*\*:\BZ/L[>(2N:&S4QQ.WW
M\%LX^IVNMVVX=X`,!@MQE9EPIDB.Y-=#EOB1DH:YK==]-*AZ@X@II\G/6-/H
M=K*.4US03@?H5;BO@)VSQ'*]IK7Z8+RSW.WR8P:N,.3'+P0M^4PA3J'%&BGH
M\EA)Z7(SWL(\=174.A+,U.&W@MPS7'&4_F';Q*9O=#MEVTW6C$1?2L<@NEWU
MK:/32'33SB.5);2ZHCD`"-<WZBZ5;;6X$0YCR2`"*Y<-HKL/<I+H^MR-F+XR
M7&@2=P;M&P7;P*DM1F;C)!"E7&\+;?>]1-3U,QGO52A2N54Z@6E]"ZS<78)S
MY2X4K4@5.![AM4CU/JQQBY<X&2E"<,`=JZ"[%]X&]/;W9<9PK#KI:48)CV22
M[Y-L4BWMOO9!#GJ"9MG>D=)<89+55MJ3Q2M(]NN=?,__`*;?R9_<SU'JO4_S
M$TZ<]:7^C?IT5TT'EQ&%HY4PH]M"',K4-J:TJH[)UT-%Y7IY"ZPJ*XX$=H72
MSN(VSP_NCVJMW=)L)':E9#'M@_++&[?##4^](:"7+A'E,H"E_;]F!/&A4ZP*
MU/+7Q-_T^/W&=??L"_<1_P#X)_>`Z9G0UQ<%O3NJ3//IXXW.I`P/?E/*<*`M
M&8,?F%*`$^=>=/6G7_3SNLNCWCU\#*21,P#LFWPMP)IQ&*Y+MQ8#[:U(6AIM
ME:RZ\L^DAIU)(=CO*7TAMUA0(*3123PIK^G6_P!3L[0FU=+%/$T,D9,R@CE9
M,,S2P"@(``H:85PVKXZ?Z^YN3G#P_',#7`BF%$B[[N3M]BS+[U[S/'XK3*"%
M,B>P_(06Z]:E-MOD(2/E%=:S_+;"WP#P/:MI;V=WEKXESN[C_B&XUCMJN6-[
M,SG+E?W4O1WLI4TIJ+:O5HR7+0@.+]:6GJ(ZB1TUKKB77'S"LY-0RLH,-U%,
MM*T25CP^05[\5Q&EY'-N<F=<;FMV?<KC(D3ILQY:I$J1.>=6ZN3)?43ZBEK6
M3P^K6FOGC7^H6:DV1C3AFI3<NGZ5"(B&$!.E]JO>P?O!]7U3]?V<N7R<]07P
M=BD.1O`*$'=.VESN?[AJ`4_/5N6:_P#K==_9QXZA[GN#1B:K<VS6DC`)BTI4
MUP!^7A75IQS'Q+=Q2"$4;@LGU@""D*%->R.#]BS/60#8#\%M85R=94%MGI4.
M!K_&//6#);!_<MOI6H.C=F8?#F^Y+RTY9(9])M]PK90HGS^;IZN!I0U%"=:B
M:S(=FP*Z98=3TC$'B#COPI@EU[S#DI1(CS?44LI<4DG\(V13R-^`'Z^M/<VY
M'<I_H_4T<;?'F/=3[TK\=SB?85];BEJ84>A(=4LDI'`&GU>.JFV_A![%)7]0
MF5HRN/=7%/C8]R8%Q:;]20TVHD`M@I#BE<>(J:>&K,\.7`':L87TL\H?0T!^
MM+UJ_-]+3D=W@0%4*@I2ASH:$BNM8^QD<X$.;AWJ9V>JLBMS4T=E2VQO+)ML
MO%KO,22$.0)L23T=5%J#*ROI`J`:@<M0[J[2F7UD;9P\9"ENE:K'=0B)I-:+
M[C^R;NXL.7[`X:[<)\=-PC6EJ)):2E/6D1VD!)511X<!77R1U;\OW-G.3)7-
MP/9V+0:UHINM0,U#6H[MB:/N/W/LN4QY\JW+]Z4P)((:24*"TA8))!H4@:G7
M0W2[V,C9)D#6TW'[ET'2+?TMDT!I'$[E\CFX&;7B%O#GDF$MR/[UDLM0K(>2
MD(0X4*64<NOCP\.&N]W/2]G-;,R8/IB=Q60-5L^:8`?S6FA/%.+B6=7UV1'<
M>N*ZIHKU?6<_!J''J^LF@\/'4:U70(+6W8VW;60N-3[%MH\I9G9B2NI7;IWF
MLQ;C9\&S.2U<;/-<3%;!)=6E2$]!-%N>6I^Z=0"]Z-==N+R`/8?N6++;225P
M%"IS[H=PNWNTV,OC%8UNBY%>&U/,R2Q1\)6CRKZA104`X.6H/+TC+)?&%F4`
M=^[V+6?I7]!IW+CKO!W993+FK#UQ><4EZIZ9#P"@:D*2%'D0=2G1.CFW%T6.
M:V@&T@TP5DZ1&R7GN!K38E#L[N)DV>NQPS.=)7T$=3BBHE2DE-!4IKJ&]?\`
M3$FG!S[(Q\X.&X[-^Y8<MK()2Z(TPWKZS/AN3I.T6!-.7Z>$N7PL21[RHK2X
ME14?3%:4/G_5U!ND.K=2T.^,;XW.QW`?:OGKYI].3ZVTQ-83(-^*FSW`[Z6=
M6(7!N)-;ZTQY'X+K;X`-DJ_9T``UT9_6DW4,C;&2.0.<[::4^!44^6OR\N['
M41*]F7'>#]R^"7XGV[\7.]X(]F:N'O\`"LSKP?;*R64O*"@`/3*J\O'7T/TI
MI(M+.,M+:.H3[E]BQ0'3+!N<@FE<.[M7-)=W8<2MILE/D\J$IJ`DBH2D"IHD
M<-=.%K5@E%*#<HK=Z]*0YK21'3$)$7:ZL0VB_*=##:"45=(2E1-5<$D]1YZO
M1-;0X':H)?ZM(Z4OS>#93VIF<BW,M#2E1V.AYU54)4T$T2I)IXD'PU=:T$[Q
MWJ$27<4^JLD(.:IX<"FX7=)UW<4MUY26EU511H"FO#I^;Y=8<F6:3E`@&BFF
MG6PA=ZEY&7@D_=KA;;6BJGUNN]-4H:4GJ2NOU3U$"H/.FL^WL(\`X`GCN*T_
M4^NV]K$0QQ#M^Q-5?LHE7!8+SBTH`4E#:2``G@.-3S/R:W]I9!E>6`./:N$:
MYK\;B,V9V:NRF&S:D+(?+H(!/3Q-54ZOE%03K<1M#10[5SS4)1<M<YE1@=JP
M:^5?\K[/E&JMZCPCE_C((3B[)?OT[0?\)V`_VU6W6>SRA8MP*8=B_=FP/]P^
M%_V)8]_4B%JM:@[4K=$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1
MHB-$1HBI\?GI][5A[AA'OJJMR_*"^/I)1`^-%W@RE+"2J[;?M=*OJK_K*@*Z
M1\O#[^IO8S?\FS+4/#0/<L2YE`;RR,2N6]RGS83\:ZQUK0_$#:PIEY;3WIM&
MI;;=:4EQ%*>4@\-2;3-<NX7@YBH?JMK#?OS1LR]]/L4MMD]]KO.M65_^.)5Q
MR5JVQTX=B=XO$Y5KF2$.H,IOJ4^`J26A05551(U.+3JR]8P'.:`K2.T:W::2
MMJ[L3V6#?N^.WV-=,:W$NNUVX#26VI>#9BXM..760WY%,VRXR^MID!?E\Y2"
M2`-2+3>M[EERT/D+6XXDX#!69]'M3$<C*%35P7O<N\`QK5OK@\ZS2BOTXF78
M[%7=+!.60$K>=D1"Y&=%./54#72NG^N(XI.9<7#2SA51*?IQS9C(,N4FN]2]
MQ3=C;#,6RYBV46B>M]I(Z%268TGK=2.*F75A0<)5Q3X'4^_R[3;B+F2S-,9W
M5^@6HDL[FU<YQ(+:G95*>-:S4*1<'D%MQ=>E9<%5*"D^=L*04D<J'6RC@Z?U
M")L[G![CLH=E>*IBU-T6!:X*\[!F*=(E-NW-I/G94\XKH;5X4`'$`>&J'=-6
M[G<RV<W+NK59[==8YAB<'XBFT4^M9T5Z#%ZBJR)2^$BBT\03Q_;$&FL]FC/,
M7*!97V_<J?71<5@/OH*G'D00W*)*@X`*)-.!37S`CAJ*:OHO+#HS#(Z4;7-\
MI[M_P65:ZE;1OK(21WA-S.1=2\OU4"8ZXM1+SH47*=54]9(XA-:#7.OT&[?>
M-$<4H:'8D\%)CK=B8"(JAP&^GWK;0IDIF.([T=*```KT446:\PL\3Q'CJ43]
M.2O&3E5H-JUT>K0><OQ)JM0_;V94PNM-S8ZS2B8[BT(*JGS%(%"HG[NM2[Y>
M/OY`2"T-Q\H-5L[;J<6Q+H"":<4I[5B,N;^$=,Q]2"$I#ZE+0$D\:-I)4%4]
MHU*-/Z+MK,-$L+7,!%<`,-_P6GU;JN]O&E@-&D$;4I'+!8+,R[,N\NWVQ#"'
M%&1=)D>&VV4@D$%]Q-5)`K0"I`U+_5Z+ISPPNI9-']L&G=CV=RA]Y>:I=6[;
M9KBR)N[;7ZE?V4^*?M3V?9XW&MTNXY]BF2W"#;<UQ?&$NS8UK:6[Z3N2VM#8
M6R+C&`_"<`'$>4G7YL_]2C]HGR]_>Y\GSTQ;AEI\V-%+KG1;^-K3,Q]"XVTC
M_"YT<A#1YO`1F#25U+Y1=6WW26K!DQ)TJ?PR-)-#V\*K'^,MVVYC$QS'.\/M
MVW)9L_:=F]MC7G<%C'HDZ6YB=RNS:I2,GB-6X+4+7=EK+3X4D&-*J%D#7Y_?
M].S]^'6&LPW7[3OW+/?:?/?HQDEK:OFD<#>6\!$8C`?3.]K0W*^I)8`0,:#J
M76?0NG\UW4NB-#])N"'$M`\+CNH/;4X8KYWL>W/MUC67\2L1N^(OR&V,SW#W
M$+LAZXV]P@26['&<4VVE<@_BBGJ/$\?9^J4_4=]>9'YRQCSE(J<[7\"WALQK
M[%"K;1(^69'-`A&^F*@WN!D]LO&47LXT5MX^JZSW+0PMI#3@CE[@5%*4%8)/
M"HX:@>L:C->W!G?@1A2M?:MRVUB;0M29M\Z4VVXFH!(/4E0ZJ&E.!/R:CT;'
M/<Y^;:[8K\3!'('C<GP]9?R?P?\`UN7^6>WYODUD<OM6;SSPW**O<[;&$]R'
M<5)D2"V\K>K<XP@6Z)?]/,+NE0'G%.JORTU"W.J**4PVO+`-:^Q1RZNKPI3@
M?G\1]&J"KDV?,,M:45-:<^'S\-*+$]0>/P_!>>LE!IX\ZUX:S88F/A+G4K7[
MEF6MXYAV[UG19BTN)`%>)\I`X\#XG6&;9CY:&E%(+35'->*''@E7!N2XZTN=
M``33@%\*^VG'6%<6#-U%,M-UB4-V_P"B6#.6%YM+,E#?I4H3T(JE('.M*UIK
M7<A@-."DEKJ<D3N:78<*K<0G&9BT*M;U:>8+4KH4V1]9/23XT\=:Z_BREN4<
M5-M&U^.X8\'S-(^-4Y%BS&ZV)8;DMJDM%24]:TI4&T_M@2FBJ#6O&#@I0QC[
MMN5C@`[#;Q3X6/-;).+*EJ"7%(!))"$I404U2KJ'M/S:Q;NP;<;5*=(:_3:9
MG@CO70;M<[P)VU<MO'I]\>:L+LCH1U/DI;:46ZIXU\I^3PU%+SHVVOI"YX%:
M[U+#U!``T.%74VJ>NZ'>[MU"PBX+LN11IUWE07.B.E120X\@]222?`GY]>V_
M24-H`(J#*I1_D$$NGB*.F<KBADVYF-7B\2[W(G`2Y[STA\`@CUWE$GB>-`=2
M9MKEMFL=M`7-Y67$%_)<E^!?6E5N\;W"LI8)1<D!SBE!60E(!/\`(TZN'MUJ
MY[1I/B%1W*8Z'U"XN?')N:*5[TIK9N#$L=WB7=F[-M*BOID-*2H]27>!J/:.
M'$<M6!8PN-,N!P4A&O,&."?7<#N67G#UG<<N:''H<5AA2E.>5Q09".L)'D3P
M2.`U'_\`%X/U1YH*8JX.J(SL:/<F%R'.&9TA2YDN*L^7ZU`:4X<:`ZVEII<-
MF2QK1FJ<:<5[)K3)X^93;V)Z]H.X*SX`II:YL-D(<0IH\P/3-4@T\Q!/,Z@W
M4?2C;Z4SR"K:_6L"*[9=S\G945X;%WV[:_B"V+.<(:@HO41F=CK<9!2'5-(*
M>I(2N@*4\#6OLU`)/EW:12&9K!F/`*[)INGRXSAA=VT5&^'>Q;%X[>VWLM9+
MC\:6TTW&G)<6%*:4D4Z$@BI^74@TCY;0Q3"?+0X'%9SH=)LFYX&L!IV<%\P>
M<9C*R+++_=;A*:F&7.D/1W9"RIST/451?6KBJBO#77--LW6<;8=H!4=UO5&O
MMSE<,!Q"9C)MR8=C0ZJ,6)#R&Z%+2`'"K@FB*B@))^YJ;P-#H,O%<AOM4#(I
M*.&:G$548\AS&]Y2^I^0\N/'"B$10H43TJ-%*/,DUY<M945L,IPWKE^I]0.9
M<9`[:./XI)O3X<=:2>AV0.:*`A)\3U`4-3J[Z3/X<02%B6.IY;MD[S@#7X%9
M"LD<<CJ8!2W7@GI"0:&M?,!PKK6,TMWJ*]JEMQU=R;>C"FYO4]PK4>LDI4:5
MX^)X\C74EMK4-\)&`7&.I-=NKJ1Q#C0N)23?>4YTDDFM?9\GR:VK6!@P4(N+
MB9S6YC4X_8K%5`<C3EQ'Z]-5+%,LF6FZBMDT\*]7E^[KT*PG5VA@N0=Z=GD+
M^NYN5M^XV:<**RBUJX>!YZS(W`L&.*P+D4)[E^ZU@H`PC#:>&*8\!\WV1#U=
M6F.U*O1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(J%?K'
M6*\'G!5;E^3K^D%T_P#C(=X_!)*;KMXI-0"0HX=!14>PE.IEIY;Z9HJ*]ZU]
MT/S!_M7*,/\`VC;VG2LE2FU(=3U=/IN('$$"E>L'63*]T/E!JM=Z=)EF6]8Y
MK+L53K:O72YUMK6E3(2?Q[3@-6W6N8(()U?M-0?RO%4>([54+)K\31/BQO;]
MHPV[+N+CT?/+&V`B+=&6T0,HMS1313K5Q3TIF+3S(4*FGMUD.OFRC(YU`KC-
M.C>[*4[6$YK(MB1^:#=MQR&XE*?R!W("(\<(*0518YEK]VE*IY:!22=5-U(0
M"C9'4[UB7.DPC@G`7N:Q!DH<W"VGOV,2VR#^5>W3PAQG'#YQ+0PPZ[$"?'RU
MJ#J0PZ])Z,>-^/>M'>Z#"Z.H`4C-L>Z*\6PQAM_OO"OK38*$X]N+'5;WD]0_
M%B:[Y7%M$=)IPKKHND=836%K&(WDU%3CP40GZ7$IJ&G"JEICW>7N7%C)&3;6
M1LB;2X%KN>$WF+=6)25FJ5):;47$J4GB``=3ZR^:IAAY3L7$46'-TF>4XM!S
M4*7I[X=NF'&$9-@.>6%Q0\X-HF.)2:#K"E)84*)KX:END?,MDU.:0.\T6G_Q
M2Z_JJMDKO>[;`0J1,R>&HT\KMFE\%<*)45I!''Y-;V3YH::TF![0YPP)P(*P
MSTW=-F+23@>U:B5WN]MH65'\IW%<VRW#="7/8H`H"AU:M#YBZ.&N(8W,1P"V
MD73]QRW`NQHM')[YMD6UJ^R<8S:XR"">AJUR4AQ5/*`L-$%*CXG6J=\P[$$@
MOC!X5"PQTUJ&YDA'&A2>=[WGY;KC>&[#9-,D)IZ4N^.)@Q4K54`NK=]%)1[*
MDTUC7'S/M+-N:-T9+L-H61;].ZDQQ_+E->PI`Y5W>;T7*"\F5?=O-GHJ.L.A
M=TBW.\*`!2H-LPPXZ5`<1YCX:B>H?-ZX(<V-OA((J-U1]FU;JWZ:N'$.DC<"
M*;110WRC?;"KY.>7E6:[B[S7!"NM=ILC,RWV=Z1Q2E'J!Q94@=1!X<CKF>H=
M:2W;:"9M.];DZ`W^0^Y)J?G&X#D-9Q^Q81L3C#S=7[S=7HLO(5QUCRI0J0E4
MI3I',!/#40O=9]0&PR3.;0XO8?%4[*=@V%;[2]&MH8")F$DDT[%U8^$E\4/;
M':O(G^Q#N7S2^[P]OV_5PD8Q`R7-HD-&$;=WC)$/-7&U2G+@D2%8ED\AR@45
M)1$>4%TU^1G_`%#OVD]1]?S1_N1^1V6Q^=G20;<NE@!SW\,57O+LE'.<RC:F
MKO#5I&-1UCH376V$GZ'J]#I$K2T9M@>:9=OM4&OC.=@&YW9!O/"N5NGHOW:1
MNA<94K8JZVIZMIQA'NZ)OY!WM3/5',J(RX3"D%9]Z9*5(Y'78?V2_O&T;]U7
M0D?ZIDLOG;I3/3ZM:N<!(71^#U(CP<&.-:N(P=5M314]4=,.T2^J7ANES8U/
ME%=U5QC4&BM*RE`<2%-I40*IHH=:0JE"4JXG7VI=RQLSL>X9XR`[^DGCPJHD
M&./E%0KCC+K##S@4HJ=4VH*%>`)I2M!2HU8B<&-\>%<17@O*'8G]HW_(_P`'
M>OA];5SFQ_S!5T/P43.[&>]([DM^8B^DH@;U;I%EP?7HO,[K4*(Y`$\*ZA1P
MJ5.6T('8H[]*QQZ2`3S*>!)^6G,ZI[U>9%G%5?6V'JJJ".'E_9?/3E33$;%C
M>E[/BK#D&04^JTPM;8X**`%%)YDJ2"5!-/&E-7&N%/$<5BS,Y;\M-R&TMHHM
M3BTJ3S0L4)^:E:_)KPFN`"NVC@R<..S'ZEM0LK0A3:AT4\30\_9QU0:^U2BW
MN*[-M%?"^`XT50<?"OCK%="23@MAZ^F!W+/@W!R(Z%(>HHJ!%"0#TU^MRJ-8
M\]N:#!;?2M:$#G5.!(^U.1`S%\-)$AMJ0TE/IE*N)`I0](-!K326QY@(VU71
M=/ZB:`VIWA;F-D-K?;9:?*F5$$484$^FKJJ.KCRU>],];[_(X^Q*:/>$(2VV
MW="XM-.EOU"7".JH-32H`UAR6SC(>]5#JEK?`#L[5EBY722X:S/4H?JAQ2JH
M)Y*]1:@-4^E/!;32^KXXY7$G:W[51*BS7@I0#?40312@`33E6A%"=/3.X?%;
M@]06LQYI<*NQ5<<W%ANB3(2Y0>5L=38\115?#5J6V-!59%MK]NQQ+"#4+>M7
M.ZNI"'E/D)33S`@GZ17GK'-O@5F?Y)%QQ6.F1>69"76'9(14`MI6XJ@]H!3P
MY<^>L3TYHLJWZC96M<%??5>Y:U)4)82:'B\ZH^)K4BH^;3TYHML.HV&*E<5J
MENSHB7/5<F.`"C:O465"O@:\N6GZ<+D<IVS:L#_)V029Z\0MG8MSLPQ5;HLM
MSN4%#[7IR`S*E->JGB"DI;6E-"/IU3_CD2P+CK2(X5"5*=W+\DUNETF2%K24
M>F_/DJ!#@(XI4XI/"M>6MX-&@H`:;%9O^O(1'2HV)#Y#N$^[TI1.;;Z`Y0A=
M5@+!'`^/'VZ\_2PQX$>Q0N]ZSBG!H<-B:&=DZFD/K6/?9#JPL.NK*T@#AR^G
M6S@L"T9E`M0UP%QD9B04C'KU.>6IP*+0_:IX`?0=9\5OX?:H4][Y)73/XK7&
M6JJCU>8DDDGQ/$\O;75STYX*X[4VQ,+250J>XFGF!K["?UZ:>G/8L?\`6F;E
MK)4A4A0H":'E3BKG6AY&ORZRFBC0.`4>O+H/>YXV%Q*SXUH>4CWJ4ZB&PFA2
MMVA]11XAM">-5FFJNY:Z*02$G@L6;,8*0U'25`)*2Z4A'6#P*@D$T^]HJWFC
M3W+4>SV52?N&NO5A)W=I)BYN]&S:UUJWN9M\RW6G#IR>UUK3PII&/&[M6#=;
M2OW4,#_<1A?]B>/?U(A:V`V#N6E2LUZB-$1HB-$1HB-$1HB-$1HB-$1HB-$1
MHB-$1HB-$1HB-$1HB-$1HB_)B_2$GRS\9?O*57RBY;=D@4KY<,A*-*_(G63:
M2B.8#BL6?SCN7(^T2/56N.A0"'`5)ZN`J*4J17CQU(?4A657<V%I"FZI)X&H
M)IQ/#PKX:MR/Y@JO-ZT*'7&$T403Q%4_XH'MUK#_`'!WJH>;V?8KQ+*VTE%`
M]7J"^HI<0JG[`BO0JIYC5PK!NMOL2^QS<G/,5Z&[5D$EZ%0>I;[LM5SAN#II
MZ98D]8"*^PC6U9?AK&MJ<``KC:Y1W)<_G8QV^$-9GMY;775BOVGC#J+,XTZ.
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M`'(5-:ZUS^IIW.)&PK+Y%<<4@KGGF*O(6,@WNW!R%*4D>YV&/*2TLGCP6IQD
M'J4:5(Y:-Z@DE-'X45V*`XT257N+MA;%H5;<!N63/N)J)N6W=0+:O%?IQ05'
MK/$I)KX5UZ=:S#+7:%<-N:$K73MZ\R6VJ)87+5B=O)*6XV/6R-&?9:*2GI$Q
M:5O..<?K*).L+U*PTT5PN$^X.K<NEQN%U?*U.!^Y2W9JPI9)KT/*+=>/LH/#
M6++<^/<LV'^VM4L&0VMB0`6G$E)"$@*ZOV/22:)4#R/AX<=6S>NC&#!(TX.8
M=CVG:P]A&U9#)!&ZM*O.#>QQV'V+Z\_A/=Z.UOQ&.W&^?"2[[Y35RRB7B4N'
ML;N#<FX*+A<K!9HR4V:WVZZS5+,?<#"2A+D)Q)2[*C)]/B*C7XB_O.^0O6/[
M5_FC:?O1_;K%(-'=<`Z[IT(HP1EP+SE9CE(+JDM(:X@[J'JO3VJ66N:?_C.N
MNSW1!RN.[AM^]?.CWO\`9CNSV']PF4["[KVR:&(;TFZ;;YF^W6W;AX&N6MFU
M9-"?9K#1/2VGTIK*3ZC3JJ*`U^H7[?OGMT=^Y#Y:6?S1Z+N(W6D[`V_MJCFP
MRY14$8$4-:$MQ`7/-8T:_P!$FY<X.0./NK@?<HF7.2$0^A*@2$I72O`]"TCP
MY5ZM=C$(A:,CBZ)V+:[AN"P#2@(X)].K_P#SO]_VZ\^]*J(O=2XC_E-]Q/$&
MF].YXY_[-+IK0$&BEC;B@3+Q9C/0M#J060.H^*^NE`0?FU200MA:7(RGO5]5
MO0[5Z*[UH10J;4>AZG[*B1X`:\Q6QECA;BU68TB7;WZMJ+9?'2H*HL+9)X)4
M%5X5KKU:N5D<C\RW*[A9Y3:O>X1:FMD-I$4=;#B5D)]X63]0BO(>.E."H9'$
MUP)^M#]D6VB0[:)+5TBQPPI:FS1P./@?@@V>1;)IPTVK,9(V,>%:J4U)B@M2
M651Y``*VG04K"#2BTCD0:Z5W8>Y7?-CCCVK7A140235/+B?'Z?DUX?%@:*Y&
MW&M37O6<U.<;`2E1Y@GAX_/7EJPZ"(G,1BME!J%Q"YH8X4!X56S;G*("JI!]
MH2*U\:\3JWR(^!6R_6;O^8>X*X;DZ`2ETI4.(4GRJ'R!5:@:]%I`<2#57OU)
MQC#G$9SM7K%^F(45>\R%&E/*ZI%#4<>&GHX.'Q5B/7987G&N&X+:HR^XI0$>
M]N`4Z:+45&A\%+J"?GU;-I%7`%;B+J(F,$N(-%LXN?WN."AN8V4TH$T"J<:\
M*U.J#91'S#XT69;=3/A<2TAU0KZ]PKZY]:8!_*T'Z@UX;"WIL/\`WEF#JV8G
M8/<LN/G=W3YS.=4:4H*"GRU\>6L/].AIL^*VEOU(^M0X>X+/&XU[2:B4Z32E
M04_QM6'V,0=0#!9KNK)6^#,*=P6`_FMY=2:R7`21Q(2H4^:M-7K:RBYF(-*%
M8-UU(^:.C'#/7@M/)RBYD=9EKKR^J`.?LY>.M@+*#^KWE1VXUNXWO&/8M!,O
M<U])<=?6M8(I^QY$>PTY:N^D@W`^]:6[UR\<W%PR]RU"KG(6KJ7U*)\2NOWJ
MZK;;Q-V!:ANKW`=MPKP5UN4I?`DU/(5K3QX<=7@<*!9\%VZ2F8U)5XK*A0\_
MFT`IL64^6K<595&>=2?1!6/V2@".DU%0?'GJK-V!:&[RN:2":]ZK%I30*DW!
MA`_:-**W>/[9)X`Z9CV>Y:W*.U4R78S+);CCU5)0$!TIZ5BG#K4/`\->57CF
M-=M6G=E.+"4O.N.)'%"5+/2D^)`Y`\!J]"QKZYEK[DFT(,.!=MKCL_U5A;R%
M`DUJ!P-1X#A7VZO<F-8OK9W8$BG<L?UQ\OW/\73E1IZA_8G2V1<*]Y]G@>7Y
MTL"IPIRR>UZ")@-0K4SBYN8[2OW8L#_</A?]B6/?U(A:O;,%J2E;HB-$1HB-
M$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$7BC0$Z(OR4_TAT.K^,G
MWFE)X)N.WH^G\CH2>/\`D3H/"\/'F"H=&UYJ5QOM\U<9;;O5P"TA7S'G^IK:
M0R->:NV+'E:&"H2\D?S8VA]%>E:$T^<<?IYZSQD:V@K18[275)XI.RH[HX!H
MCY:D\#2O#GJQ*R,-SMKF552,=ZI:AA@AY?73F05$CV\$F@IK&S%6WQMD\RK>
MDIJ/3IQXBHK\O/YM44[2O0T`4"H2\XJM2.'@!P-?:-*=ZJ;X=BS6^:5<`5)`
M-$I'`\_"HTIOQ51=44P5;A;;'G0EP+X44D&E./`TZO'VZJJ51E"UK[;!*"AE
MM`*N'2FA\.9YGB-5B1P%%>;,]C<HI0=BLN,LD"K+1(/,I!5R]NO#(X[5Z;B0
M@MPH>Q"*M_BTA/RI2!]PTX'7E2K&4*^V\XGJJ5GJ%#XU'&O/Y]>5)5326[%3
MU(I0,A/,U2D`U/&M0`3QTKC7>O2YQ%#L7C:U())"CPI]\?QM7>?+_,58Y,7`
M+,1T.)"E`5XCS'CP.K9>YQJ3BJPQK10#!8RE]*^-2FG"G*OMKKPDD4.PJH8&
MHVK8V6_7G'+]8LGQNZS+#DF+W>VY%CE\MK[T>Y6B]VF:U+@36'6BDN):?:`6
MV5`+;40003K#U*PL=9TR?1=6ACN=)NF%DL4@#F2-.!:X>W:"#VJJ-[X9?41$
MMFXC:I_]_OQ-]^?B)0-G86]=HPRS_F:QM5J@.8Q;O1GY-?)3"8]TRFYSI"52
MV57$,`JAMJ$=*SU@5U\S_MW_`&L_+7]L%SKLWRZ]5)^LREP:\N+&5KX6M(`H
M*T!VX;2I#K/5!UN,,N#G>UH`J*8\<*+FDM2^AL.*54F@ZN!Z:BHX\Q4:^F2Z
M=C&ME(YF7&BC,+7!I#^.'<I(^M_G@_@X]?UA]?\`;?/JGF/XJZHA]U@IW.]Q
M%.7YZMSO[<[J1K'RBM-RW@:*IB(ZU(ZBDT]O+C\G'AJS*`2%G6KFL:1VK.;D
M%I8<2XIM20>E20#57L(KR.J!`_L6=+=,>*`K-]Z#M%N)0MQ7/]L?F!\#JVYI
MC.4JW$XEN.)JL<^8$(6@+/)!50\^/('D->,!>[*`>]>3/RQD[U4AZ1&*%DK4
M@.`E#3I`*AQ0HB@XH5Q&KW(=V+#YY6^9R:>IZ2N3Z4YZ1&$=:[@R'W$-@)`#
M:R04*`%`?#5DM(VK<QSMR#;L"%+QV2VPPRS(@/U0)$I;I?:0>2N!(HA5>&O*
M*]'+&:C$+9QL88NLN2U:KQ!5'8;4XM^6L1>M24U]-DN)I4TX4T53GLI5IQ6K
M8QB]RE2C"@/S8\92@N4R$J9/03U%+A4$J'#PUX6FBL^H[UI5LOI6IE3+H<22
M"D(*B"*@CR]0!X:]`H%XZY<X4%0K/0M!H:-GQ]0%%?\`JDCCI2NU8?J)X'&2
M@(.&U4$*-:@])YN)*2FGBH<>-!K(:8@P`[5CON;U[BYHP/:O6SZ1);=4OJ%#
MU#E0UX:M2\MP`;57K2_N[5Q<X`@BFU7?>'/:/N:LA@6=^M7#O#08X+($AQ0Z
MJBGRGEPK7EJY1GT"R(KJY8:EP]ZNI=!`*EHXDBO5P^:O#5A[&YMA6>V^C(_-
M)SK)]4"I2Z$``GU$DT/\B*<23KQK`#A6JN-O(W&D1\5%ANEV0L$>HXB@%0`5
M>/A[!JX&X5WK775XYI.]4L0YD]98B1GI#O[5"*'AQ/UNGC35=**Q)=![<*U7
MB[1+:?,>2A41]*>HH>(3Y:D5X=7&NJJTP6,QLDAS#`!7(8#4A*'**"5J2>-4
MGI2H<^%175"VD$A91I6X-Q9;2VXVS2<TJ@4>+'0#4>7F55UZLITXRUQ6IF7>
M:\MXJ>*$NK"U(;X`T'+_`*H:J:W,:#:M3-<BI+ME5KO>*<>I2E'ZW4/$<!0U
MX\-5\B3L5OU</$JOJ"DUJ*D5Y^)&K)P.4[05YZR'M6$^H)`!\>5/D(K^KK)M
M]_L6!?3,ERY-U?L6&E0H!QKR^Z=9*P!@:JNFE5<SA.IL>:;S[/D^&Z."'[F3
MVLZ\W^U)35@*_=FP,_UD88/9B>/?U(A:J*UA%"E;HO$:(C1$:(C1$:(C1$:(
MC1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1%^2+^D2Y#:K7\97O,:G2/04Y<,`"
M"I)Z26L+MX6*@^!>3]W7A5;6%VS<N*ARO&:4%T;2>8(J34>'$#AKR%TT9JYK
MO<L.:KQ0`IQ<&W,V=A7%QO<].1W[&3;WDM1<5F?9UT:NU"B+)$I04CT&TJ/4
MGQUF^I%,0X=ZQV12-K4':G+N^;=E"\=LCF./[K-7MN]./7V#?I`<6]9@U_.4
M&3'*4-.NG@D^%>.JV3<QV15\M_!-MGN<;%OW.U/[6/9+;K(]8V/MN'ECZ9$^
M/D'JN"4B"H*6V;:6>@HZJFM=7LAXA><M_!(H9IB@`'VDC@*>`_4X?<TR=H3E
MOX*I.9XP:]%R;^6M?HY5TR'B$R/X*K\M,82I/7>FT@]1*0ATE(3Q(Y4K3E[?
M#0MH-H3(_@O?RWQ5SH+=X6@>92PMAT'H2EP$_5(\K@%:TX:MU/`KS(_@4K+_
M`)_LJ<.PJ)CD2\'<7UK@[GV3W*<\JPOQ.M(M-KL=K2!Z<Q`\RWCP4#QU<#21
M6H"]R/X%)!6;8LDE+MT;!2*D)0XHI/L5TI-#0_-JIL1<:`MP[5YD?P5M6<XP
MA2T"XH4&^FI2AQ50>93Y.(2./S:N<AN][0?:J2)`:92O$YWC"C3[1`XK`J@\
M>DT2H\?*E?M/(:I="T;'@^]>4D_E*H_+[%N1N/2>1'I+-#X\14$?+XC5.0?S
M!*2_R%5'/<4'*YU_[2Y_&UYD'\P2DO\`(4#/,34*FZJ2?8&5Z9!_,$I)_(5Z
M,ZPY/$7-9/L6TLC_`!]>Y!_,$I)_(5XK/L3!\MQ%*>#+G/[FF0?S!*2_R%:A
MW-,<D/!7VDXE(KP])9KSIRY<-8,SHYY6OD=*&L80`,H\6-#LV?%4\IK<61N!
M[PKYS#&5A`-P/D4FO6A23Q-#04Y:QH_4<EC'C/(T$$C?B2-O9@KL;)2,0=JD
ME^4V.?T8/X.?1^+5]3_->7U=599OY#\%<Y3^!48^ZUP'N<[AAX_GJW*X<36F
M7W<&E!X:IHMH)FC<4P!6?"H^A7\;7A:"AGX+SK/[8?=&JJ!>\\\5>2^H#FD'
ME4'C3YZZM/8'%9$5P0W:-J]+Y56I34_LOV7T$'7C6934;%4Z;.,IHA+SB2*+
M/!04`345'#Q^35Q6ZA9;<QH^HITGU5`@%)`%1Q'"AYG6,^)U</+571<@#+48
M+9J?A+1&+*60L-I#Y=73J</UBD<.``^C5LM<,,5?BN=N(53E`ZL,.,A"4E:D
MAT+X^)2D\*ZIW5*OMN,Q#>*(MZNL)MR-$N4N*PLDJ99?6AM5:U\M2!7QIJJF
M"N[Z+>6?-KU8FG68BX2VGR5+#\=AYRIYJ"UH*PKZ>>O`*I4#;16U94W+F)E7
M:WQYZ002V0EE-:\2.D\:CAKW([<L>=P+13BMRYE>*NJ46\1BH4OZGX;I"54H
MDUY`5XZ\RN"R8;F%D36NV@)'S9<"5*4MMI$!!YMI6'$#Y`0`*C3*XBN*LW4T
M4C0&4K56'A%"4EAY+JJ#J2#RYU^]JFAW@A8@-#56VY#=4@%L!)ZB%K"0H<BF
MOMXZJRNX%97J>U*6%?[%&(][L<>30"I+PZ3]`U<9%F;4[4]2-Y5<_)[,ZT&X
M5AC,=8J3ZG!//EKUT-!4;52Z^$(S@FNQ8ELRVXVU#B(B+<$.$^5QEI[IJ`.!
M6"0>'S:MEE./N5V.;GBIH<>*P';U<')3DQ,DL/.<S'HRE/\`*)3RU3BKBQ%R
MI#[BW7GW'G%BBG'%E2B#QYZ\*R8*!I[U;+AIS^FO'YZUT5USLK:C:%2XZHHZ
MNH53PX4'#G[>?'50&-%8?<.RFJUSKA(KU<1\H]NLB-M'+2W%P36I6/ZA_;#[
MHUD4"P^>>*N)?4FGF'"G/_'U9=&"2GJ'<5ZITNTJ0>FM*?+3^-KUC`RO:JV2
M&3;N5-:<?9JNH5:R/+T)545//B/EUZB=#9`UWIV?3PI^<_!/[9[7JG?[56\^
M`!?NT8&/ZR,,/MQ/'OZD0M5E:XFI2MT7B-$1HB-$1HB-$1HB-$1HB-$1HB-$
M1HB-$1HB-$1HB-$1HB-$7A('/^+YO:=$7Y-WZ4)VM[[87\5G>K=2];>9`O!M
MZQ9<BVXO5LA/WEF]VJRX[:;/<WU-V]M]V'[O.C.)HX`12NBI+PTTWKYU?S>9
M\GC^0N9G_P!4[W^O#`U=YEU_+]:NB:'?3WA'YO\`.OV6"YF/D_):]`?/01=6
MWF1QJ_`KWG0[J?!'YO\`/"4UP7,DA(I48I>4_=(B5J=>QL<YU&>9#/#3"GP0
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MBEK9N':WO/<,M<:#]XN`9O*+=%DB2LJ9AMF&7'XK<<I!ZO$:H?%.S&I]Q3GP
M;P%NX3>PEOAV1RR]HV]DVZL%I3M^F66_28DILOR%R%?9*;>6'FG&7$-MFH(*
M.)''7@@N'#-XL>]5BYM@*>'WA:Q+>U5OQ^%:H7:?O'-E2I-L?R21<<6O*%W.
M3'N$IZ4;8\W#Z[/'?AN(;#(X$MU\=5!DT.+\V*]]3;?T^\*'V2;6Y[+R"]RK
M#M'N5"LDFZ39%HA/87D)>AVYY];D2*Z4V\A3C#*@DD<R-.:_^KW+SU%ON+?A
M]ZTOYI=T_P#>LW&_]B\B_P!3M.8_^KW*KFP]GP^]4*VEW5K^];N*/GPO(O\`
M4TZ<Q_;[EX9H>Q>JVEW3IPVLW%'SX7D7^IQTYC_ZO<G-A[/I[51^:;=7_>NW
M$_\`8O(O]3-.:\<?<G.B[%ZG:3=3J'^U=N+X\L+R*O+_`/#M6,K^!3GQ=BN?
MFCW5/$;6[B\TCCA>0CQ^6VG7H%P/[>`5#YX@:`!28_-EN5_O9[B_P<O=?W%9
M!^._S+^E_P!;Y.>G_P"1X_4J/6Q]B4W<M_"3[A?WG/WY]Q/Y[_GG]U=X^M_)
M?MOEU2J4RW]Q?1$?W#]$66Q]0_O'?6//YAKQ9,7EW;5?_N':*Z/8C^X?HO5Y
M_<.T7GN1_<.UBW.T;5<C]BI_RT?O(_4_8\N7ZNL?=O5Q9B_Q*/WD>9_EO#GJ
MH+86VWV*A/UD_O'?6'/YQST5V7^X5DO<A^\?S_6UX5BW'E'>L4\_]P[7H5<?
MD&S8@?\`$=H5:N/*-FU5?W$/\C_%R]OR:I6*%BJ_&G]Y#EX\N8Y?K:'9O0^Q
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M1$:(C1$:(O#X<N8Y_K?+HB@WW"_OFX[_``8_W/W+]_K^F_XS_P"P?_NW_-/Y
M/JUF6_DW;5J-0_O#;Y1]93+?]''J[[UZC_HX]>%>JS_T<FJQM0[-Z/\`HX]5
MA4KS_HX]-^]>KW_HY/HUX5Z%DHY#_P"71R\/Y7^+Z-4;_P")-R]3^Q_^7/\`
MY'YA]7^+EJY_Q$0>?_\`SGYCGS^CY?9JAVW^-%5[/_EU?55^KX?R/M^75)V_
MQ(G(M/\`2V%_`6_$_P"@OYT^NK^=_P#._P!?60SRC^_[-GL7A_\`0]NWVK8^
M!_@0?K?3JB3=_>]J\_\`C*@\_P"\>^GGJU_Q%Y_\?V;?8J/_`''=5?\`$57N
M50Y?WC_T<M>?\1>'V+P?_P!'OHT/_J(?8O?_`'']>?\`?7GN0>7]X_\`3RU[
B_P`1>CV*G_W'?']33_B+WW+/_P#<L_I7_%_YKUY_WT7_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>pg97b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg97b.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`O0%_`P$1``(1`0,1`?_$`-T````%!0$!````````
M```````#!08'`@0("0L!"@$!``$%`0$```````````````4!`@,$!@<($```
M!0,#`@,#!P0)"PT+#0`!`@,$!1$&!P`A"#$201,)42(487&!D2,5"J'!,A:Q
MT>%2)#47&!KP0K(TM"5UMBA8.?%B<D-ST\1E)I8G=QF"DE-C@Y/4194V1L(S
MPU24I(569G972"D1``$#`@0$`P<"!@("`04!``$``@,1!"$Q$@5!41,&87$B
M@9&AL<$R%-$'\.%"4B,S\14D%G)B@I*B)4/_V@`,`P$``A$#$0`_`-N7'?DW
ME^U/43R3RLNS(5P37#[E=RGNOA/"VA).16M7%MV8JM)F./KVC'"P@U8L;RN:
M-DHYV8.TIG"J85KMHB5.&W-'D3*EN2W,1VR7+O(_G#R<Y.9@L`F4+BD&&+<%
M\9,67>7'D3<T^=H1Q*!%*R48JUCF#(GF/7)Q'NH&B*?KE]7;,=JXW@;5)QKB
M[OYAI<WXO@U<6(+?NX`L^6NQY;KV[#Y`MFXUBK.D+.2MQ-%ZX*Y(9=H43$/[
MU-$39R%ZH?."PR\LK;<\>,&N)[A#B&SLL9[OD<@3)L=GE;A9N[C5Q'9]&J4D
M_NY2VF]$G"HD13<&`IRCW`&B*;L,>I%R`N7DCB+&>8>/UL8_L[D3Q-NCE+8$
M5&7A\=D3&D39T;'2*L!EI9VFVMUNO=/WD!&BJ/E)ME*E5,(E-0BCC#7JV9'N
M;D[@;%&2[9P$XMKDE(Y+CK;M3#V37=\9/PH&.X*0N<)/+#Y-H%HS;&4BHX2+
M?=2PE:N%"`:O:.B+([TC+RN7)/'#*O(N^KEFI9'-W)//&1+;5GI!PZ:P.-(V
MZW<#9T;%"X'L;1;*&A1.';[H@(CX:(M9'!7U2)S'6%N5F;<H8"YQY;9WWR*Y
M&Y4M[(5I8C=WCB>*QM;$G(VY;!;7N96;9D2MEA&VMW*F*F($,8P[TT19%>EE
MRMR82W.#^"KL:S.0[TY;XHSWS8R9>%SR:ZTGC.R;@OD3XX@"-![Q*+M22(T(
MF<P$0(B($$::(GR?U9<IW>UQ3'X>X^Q5Z7KR`YDYEXU8GAG]VJ0D>..L,QTF
M6Y\SSTD#5R",9&ST8HFJDF01%,M`$#"&B*&$/5ZY=M,8.\P37&?&2=E8JYH-
M^&F47\=>LLX<Y;N9[?<?8RUQ8$:`T%0&$&Y=BHY)(B8ZOE'!.G8:A%*G-7U8
MLH<7K^S(YBK9X]CC/`<I:T?,VE=V55U,XYD).*1J<D..K>MQ!]'VJ[C3R()M
MT)D2J/%2"!0+4*D3DS1ZF/(O]>>6MK<><$6.]M#B)A/%^9+_`,H95NI[$P)I
M:][(3R'(XC08QA%'![U96\<`\P1!!%4Y>_J&B+8S9O)=C='#&#Y=2]OK6C&R
MO'LF<Y"VI%0AW,$@I8Y[P7BG#DIBE$S8*D$X4J&^B+YTN`_++._%;C]FQ'DG
M?US7JGR-XC92]0SCS<%T/3?$VQ).G,\2\,11IW12G,>"-)Q4C'HE,<XM.X0"
MG0BD7"WJ/Y-X[XEPEPWM>YL1RO(#%'&#'V<N2&2>5^2):`C7%SY70=WA#8PM
M@C!!>6G+RFVKT!%03%08(J)5(("%2+9-QS]3-;DWD7AK9UDXN4AV/(WC[D?/
M613S3]1-[C*-Q_<;6RB,4$_*1+()3EVJG*S7,4H+-2`H`4KHB@2XO5NS+/&Q
M5;V!N-L+E._N0?+?D3QVPU#NKS4AHHUD<?D%DIK,]V21FJ_W=;2;\OVYDR"/
ME^Z'O"&B(U]ZB_-F>M'.U]8KP-A:Z[3X6(/X;DO<;Z^)2/C,EY)M&)1N')5H
M\?5"-S?P"S()<@?>4L/E.7E42%J&B)PW%ZGN;\JWI>]H<2<(69,V]8_#>P>6
M-RY4RU=3R'M:UEK[BWMS1V,Y1A%,SO',^[MV-4.51,033H"AZ$T1,>[/5ORM
M,X9X]9-L.SN/^(S95XVH\B;I=\C,H+Q*"0^2\52QY9MJVPB[NI^_E`CU%DI9
MTDFQ3243KW#W4(J<:<N[AYW<LO2XF[70NG&-JSG&W+'+?)-@(RJAD7!7Y&MA
M6+'2RR")4)>$<32CMPU,<">:G0P!L.B+?\4*!X]1V\`IL':`5`"T#8-$56B(
M:(AHBTJ?B#^1-S\:_2JY'W78%Q2EL9)O)G;N+<=RD"<Z<^2Z+ZG&D:@E"'2^
MW"458E7*B"8"H)Q`"@-=$6A'D+ZAV5\[8J]+7TT\;XGYL<=,D9*S9Q^M.^\I
MYDMA]9;Z]K;LMHP>7NM"7&F^=2$R,A(D,HKW$+5N8.X0T1;9KO\`7`F+.PCZ
MHN98?#D7,6AP&S7`<:L0_$W"N#S.F3EU8B(D&3M8GFE8)MI!Y3[$3G/2GZ6B
M([/_`*OO*FT^0\?Q7P!Q7L+(63(+@I$\QLS3%]9%6LRR\1I/(8)IW"3,B+9R
MNNU;E1.D0@E(X5$Q1`.HZ(F7PR]<3D3R8R+Z>*5\\/(C&6'>=['-$#`W87((
M3%V-+IPA!)35UWLRMLS%N1IB9X*A4V;MPH*RU>[H&B)JRGKWY@M;F;B;#%S8
M5X_RF)LU<C1XZ6S`8WSTTR'R*@U%GBK*.R/<]LP3!>V&]MNQ("HH$<F733-O
MN`Z(K'D-Z[G*FTQ]16\,`<0+!OC`_IXY/869>V9;YR<[MIC=Z3=9@RN2VK5A
MD8]5:6O5H_=B5-%)0$TTQ*!Z&$*D6\FY.7L7:/`V5YNW':$I!1D/QU/GF0LI
MZ?\`OJQ2)9Y;G"$<*@`5,!SD3$^U2C71%\BTS;N.KZX>8T]13U3N?W+3%N?^
M:K"Y\B<>#8*?7DGB_C/`I"L^LYLA:5F-%8YU%1,*9FH^4DS%*L(F*41&HZ(L
MQ;CS]ES+N0O0"X]MN5<MFHETL\E\L<NYZLR-D<>,\SXLP7;LJYAWMUVXN87;
M)K,$:`10JP`FNJF8U/>J)$;QK]6B6M;"D%D#CO@*\,J<IO4^YGYTB./>(;ZR
MQ)R5I-X?&DNK`S629F<D4G`V+C5FBT,8&3,@E[@$0'KHBR=_[='*6)\!^HF?
MD_QNMRQ^6?IW-;"5O/']E7PK<^,<D#EARW;X_5LRXU6C>7#XXSDA545$A5$P
MU+MHBCV"]:7U%I#/J_&B0X"XKBLI7EQ(;\K;%8+YR!.'QI:B44M,2:V=9,\:
MH6"!RU3_`((T0HX,JH0AA_2$"*6+<]:S+V0O3<XV\O[3POA2Q\H<A+HN*T%8
MO.&:X_'6)K/):TN\AWU[A+/45+GN>VI!RT[6Z;%N=3N,7N$`T19F>D3ZD<SZ
MDN"\C9!N_'D)85WX>RW<F([G?65<"]T8RO&3MT#&/<V.IUPF@[?03E`?]N*5
M0HB`TT1:D>-F%<@^NKE3F-R6Y%\B\WXQXQ8DSCD+CCQ?P?AB_'6.XV"/C!7[
MOG,H7M)1(HNYNXCRYO,*14Y4!3#?W0T19<RF;.6GI7<)\38VN7.>">9^4IW(
MD_:=@9VS=E*(P_9MO8Q;KB>WS9`E#.)6=OF7A68&:JJQR9A,J4.[1%CU#?B)
M+^D.!D=R-9<986],YO>;49PFM['MC7FYEL?Y=O1RY$5[AQA=2K5.0<0SMF03
M)>:C5(]!/M71%D)C+UILIV!F#G]C+G=Q_M+#;3A)Q^M7DK,2V+KZ'(1?U4O4
M$"6]84\X,U9MBY`>N72:($;@9/O$:A0*Z(GAQO\`4]YVW#*V[EKE;P&2PWPL
MR?AB\,]6OG"R[^)>$IB.R+7MUU=<:VSW#N&T>2$G[N@D4S-$68J_:J`0?&A%
MB3QF_$5W7FSD!QH871A'$T-QEYDY-F,5X6=VAEYO=O(BRW[0SLT-=V;,:H(`
MWM6U+@1:"=,2&%1/O"NP".B*;../J_\`,[EI.9QOO$7#W'L7Q-XT9MR?:64.
M0E[Y/<QK6X,;8G=*+W0]QO")L3JS5TM()FNLL83`S(J!2"(#6A%FF7TKK2=>
MFU=/`&9R5+/).XE;NN9MFYI&(,[F@<IW)>;^^V&0XQH5R;X>5@IQX3RZ*E,=
M(O97WM$3$@?2YR?@N(XHW#Q4Y&15BYJXZ<>GG&RY[IR%CY.\K0RO9,U.%N^9
MFI>W6\K&NHNZ4[S57DT5TUE$S**=BI3%#1$\,(>E1;V*,C\<,G3.6)W(ET8>
MO'.>9LF34_%-"2.9<_YP:,&;W(3]=!44X1G9\<V,SBF*93%0:&*F!Q`!J15Y
M#]+TM_XDYLXX7S,]C97FUGV-RU?=TI6TT.XB;'C'MM_#XO;-5'@_$,`B($S3
MX@YA&C@P]NB)R9U],JWLZY"Y`WG.Y2G(%IE_A[`<1+-8V_'ILI'&$%%33V<E
M+BBY0CDJKY6X'KA)%T@)2D,V3\NM!KHBQUL/TE<MLK[Q1D:^^0^.4)G!?'S+
M.!L86_B'!4'CBTX=;)%MHVJADE^V:R#ET^O%E&)_:B)P3.<QA(`5'1%L7PYQ
M42PAPCMGA_9=W+H'M7"4EB6+OY2+*1VG)24%(QB]X&BTU@(9X$C)'>`GWAWJ
M;";?1%%;/@:G;/IK&]/6R,EOK=`V`GN$S98^ZDUI4CF<8K-;CNW[H*Y31*^F
M%W[M82^91,ZU=Z:(H*G?30RA:F5[+R+QLY&,,3-XOAU;W#.Z&LW8*%URT=:-
MIE.M"WEC%]]YLB6G=:TFH==P*A54E3T&G<`#HB7>,WI:0G&^Z.)%Q(Y<F;P0
MXEX0R[C:":R\(U(XNN_\SW(2X+NRS+N_BS@E.NC&53%(A!`P*FJ;1%3:_I;L
M('%'$W%"V5W4I"<?.53OEK?BKBVF(#E^^UKAN&ZF360;BL)(AFSFI[S>X!.9
M042U#;1%B[=?HGWQ=,/DO%0<CK.C\(9`Y)-.1KUP.%8.6SM<ZY\EH9'E<?WY
MEAZ^"1G;2,X2%HV!,A%DFH$3`>T@!HBRON?TRCSV`N=6'DLPNHV;YQ9/?WC<
MUZDMY$SFU+161MV)BK'C&0NP!PA$VU!"Q26,:H$6';8-$657(7C"&8^'%^<1
MK/N]3&L;>.(D</L[K91R;Y:#MS[M9P+WX>-,HW1.9Y!H*H"'?[GF]!IHBQ&Y
MO^E'9?,#C'QSX\LLC2F*W_'5_CUG`WW;\8BM)2UB6W#1UN7G8SML"K<"Q%_P
M,>5%P0#&(40`>TU*:(FKFOTNK\GLVY=RA@',N.L8Q?(RW;%@LNL[]PE;.4[F
MMN1L*V&]EQMV87FYQ0I+.EU;49(M_)73<-DUB@N4GF%#1$X;P]-S*\1F^$RQ
MQ\Y+DQLDYXGQ?$Z]2W3C]C>%R#;L$==S'WU8LJB]BHZVKS>R#D7#PPME4%E@
M`Q2EIHB5.*'I<P_&"\^*=U#E65OAMQ7X]7]B&':2L,@W=71>^4;I-<=]Y9EI
M#SCG3G)]*C=5,@#[O4PZ(HMNSTK,KN`S[A;'/*D<>\->4.3Y?)^7\;)66D_R
MPP7N\T:M?]FV'DDTH5M!VO?2T>/GBJT5<MTUU2I&]\=$4O,_3/2@,8\[\?VI
MEMY;[GF)#05D6U+M()#NP[CBT["1QW:5J1J?GB>8"*MXJY05.).]181IHB@C
M(WI%WS(O;ZA,-9YLC'E@Y/XOXNXUW%(S^&(>^LI67&8LLB2L=C*8FN^4D"HV
MHVN*/E5%7S,4%$_B*G*'<-0(LJ.(?IYQG%O+,?DX<@*W@-O<3L*<4;.A#P2$
M8A;]N8F%T]E9M!8CA8QGEX3+D7*Q*`!-@#;1%LLT1#1$-$7@[`(_)HBUI^I+
MZ?9?4-M_C?9TMD]YCZS<(\D\?\@+JAF<.E*_RB%QZY,]BK4<'6<(D8-UG9S"
M940/2O2H:(J,]^GTER`]0'AWS3N')#IE;G$2U,DQ]MX<"'(LQFKNO]B:-2O)
M25!P46+B&9"!4R>4:IB!0P:(M2`?AT,C.F<[C"3YUS3OC/,\X6O-)]B#^2V*
M%_=LZ$^E/N[=OBZSRY7LTDD[0(#4XD[$NIBFV#1%G;?OI(R%XY2]3+,;?/;B
M,O?G[A.%P):4@6TFZA<$V!%6^$$ZC8T$W8??A70"8]!%`"`:@=*Z(KFU?1TL
MFWV?%ZV3Y5G`LOB]P8R7PZM./AHU*)EQE\K1;2%NC+L;*(N3_<]P+QZ)BD2(
M&YAJ)AWT182<8?P\-X8*R?PEO>[^6-M7S:_!:[KHG<8V3#<?[1LP]QHS#)XW
MBYF_KIB7A)J[;[8+.0,I)/!4\PI*`4H[Z(INE/0K4E/3_P`U\(G')"3%[R*Y
M<RG*#,&42V@@5]<S29OUC>4A8OW260$A$%6T:W:_$&4,(@D`]E!$-$6[FZL)
MV'?6#YCC]=T428QQ<.-CXMFX=0"D*]M9:`"W5VVQ1*F<S``IM0I@#;1%\Z;;
MT&N84?AMSPLCO56R"SX$%:2%J1>)5<069(9,CL6R3U1T?&Z.27?F.48Y%!3R
M2.DR`MY04`*;:(LP/^QEMZ!S<.5\?YC?VC!V+Z>3_@;@.U30#9ZKBAO*QQXV
M7R>,F5XB63FY-!8QET"D1*<QA][?8BBN3]"IU9N!N`4!QOY,2V(.3/I],KA;
M8[S@O94?/0%[?KNHJO?32\K#<.R-EF%PNG!U!`BM2F-4:Z(FY)>@*I=F$;[M
M/)'*NY\@9VY%\I\6\CN6V;)RU&0?RMQ.*I0\C`XF@;41=`UM&S6"8)IH)IJ*
M]H)@(@(;:(LI+Q])Y_<7(CG_`,CXS.SJ`NSF+Q6M;BE8**%K-CI8-LZW8<T6
M=ZP6,[(K-KO3F`QB"*1>T1+OXD6*%\^@([12X"/L(\E6-A7-PKP/+8"74OK$
M%MY5M"[H>Y14=SUZP-EW,Y/"VO?Z\FX651>%34,D!B[U+42+9-Z6?I],?36X
ML)\<4<B+98<*9'R'DB8OY];[.W'TZ^OV<6F%ROHYDNNV!9H0P)B):$[0H``%
M-$6M6[/0LY!VG?G(R%X=>HUDCBYQ6Y87O,7_`):P;$V-!W/*PT[>`=E^*8TO
M*07!Q:I+H2,8!$A>]/OZC31$Y<T^@C#/[LX7W'Q?SP;$#?B)AFZ,#L8O*=@0
MF>(^?MF[UE'4[>K>/O$ZK%AD]P_<JK$DA`1(H8!*`=H:(K;!7H&1^'[3X&65
M*\B7=Y6UPYY391Y6W(T6L2.B3YEOZ^G"[B#<2H-GIF\*O;9U`H=,A@-3W0*&
MB*<[C]%NQ,G//5,=Y;RS-W.MZE3J#:N'D7#-HF3Q%:5I1S).T(&)<F76^^?N
M.78D<@90I"*@%!+4:Z(O>,?I29GM2.R1$<SN;^1>45KW5QN<<3K4QK"0S?&&
M+[8Q(\A3P!Y1W:<8Y=-)O)*T?Y9`E#]IDQ)L`UIHBA7B#Z(^3.+MQ6RS?\LK
M:NW%F&+'ONR<"6E$<=,:6M=[,;K9R,?;LYE[(S1DI<5]R%DHOOX*<IVYSG3`
MQSU$=$68'&_TOFW';TK\A>G!#Y;?2DMD3$/(JP);-IH!!I*?K5GZ*O&/=WT>
M$*N<BSR"6NDBI$_-#S?A2@)@K71%MHH'L#ZOF_:#1$.TO[T/J#QZ_7HB%`#H
M`;!0-N@>SYM$0H%*4"GL\-^OUZ(O:![/ZOZ@T14&!,`]X"@4/:`4``W]E`I3
M1%\_'JCYKR58W*O$MDYMS[F[AUP#F\9NGRG(7!<"9<K[/QIQP@A:N6[]:QTP
M]QO9S"W")N6JHMP;/')NQ50A=]$3$O/E#S\XQXUXAX:M:]K7YN73R<Y:(6OA
M7D-:LC:K%]=/%&(8M+S>O[Y74%Q;RMZKVV@Z17DFE4`31`]!5$0T19-7)ZSN
M,HB=F[FB<07)<?%BS\LL<(7MR98W]8R$7%7ZM-(6O*+P>.%WI;WNNS+<NE7[
MO=2C8A4O.W(0Q-]$1O(3UCK.PG<?*5O%<;\OY+L'AA=%@P?(7*-NO8*-M>`;
MWRSAWY#6B60'XB^+DB6TTV%>&:B5T<3]H#782+(KC-S^+GSD->W'*YL#W_AB
M[(/$-HY^LMU=DM"RZ5ZXBO:06B8.9>M(8IU[*N(SX@@O$OC&<I`([U`0T10?
MRTRWR#Y!<R;6].[C7E!_Q^C83%),]<G,]V_&1\O?<%9,I)J0%DXWQRWEP/&Q
M-P7D^165<22I#G9M4!%,O<.Y$EL'.9_2W#,V4N2'*FX\\\$8G'+"XH*7S`JS
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MO]'[FB(4"M:!7K6F_P#5OHB':'6@5Z=`T1>T#V?)]'LT1>=H!6@`%>NP;[4W
M]NVB(``!T``^8`#]C1%[HB&B(:(AHB\H'L#ZM$0[2_O2_4'B-1_+HB%`ZT"O
MMT1>=A1K4I=PH.P;@.P@.VX4T1>T#;8-NFP;?-]6B+SM``V``V&E``-$7R,>
MKORNY)VIZC-L<?\`+/-++?ID<*7V'8V<Q'R6QOCY&Y;7R-G)T]42=0&3[U=L
M'<;:T%'![HH'`@']T*AW"8"(_E!ZH?J6\$^%O#G&DU9UG\M^8'*K*O\`)QC#
MD'A)6-N+'%]V6VGV[BWW<;&D6*VD\K7Q9?<=%(@_!-U1,HK40IHBS`SG^()Q
M%@R\;OMAGQMS5ENW..T98A.:&4+/E+/:V_QFN:ZF3,9.V9YC)O&[^]K@M9=T
M=.32ARB")RF*%:4T1/3DEZ[^,L-9;OK#>*>,N<>3\]8/%VT>6L],XL4M]K;,
M3BJZXQ.<3>7!)3+I+]7U64`H#DX*@8R@AY92]U:$2;@/U^,3Y_S9PUQU$<7N
M0UG8]YQQLDGA3-MYL(2)MJ7NVWX]1]<=O-[>!16>?P\4HF*9I@@D9K#02`(;
MZ(I[]9+G?E/A7@K%UK<=(2&G.4?+#,=K<<<!%GB"Z@K:NN\1,5U>TRP`0,_8
MVRU#S01&A5#TJ-*Z(L<L1\._5[XJ9RP7E>6]0<_+_$]SOGI>:6.LU0<#9EK6
M'!&CE9!W=V"58M$[QLC"O"&(5FX.)CHA4:;AHB(MG\0]Q[NC-5DV]&8&S"7B
M[D?.!N.5D<SUWEL%QA<.6S/UXEI$L+33=J7H,%)2B0H(28H@W.;?8-]$6OO.
MW/GF?=UW>K](XHS?<-LP5B<R.'O`WBQ&1R+$[.U[RN_(-M-LG71;QSHB+B4<
M1)W:"XF[TRIF$:`.B+9#=OK=1%G\ALB\7L3\2\^\KG/&>Y[2Q1R+R9C*0LQ&
M1MZ]GK!DG*NH+&<R_:WE?C&/5,95XYCTA2)0_L"I%OMBWJ4I&1TFDW<MDI%@
MT?)MGJ`MGK=-X@FY*@[;FJ9!TD"@`H0=RG`0\-$5]V@(UH%?;0*^SK\VB(4#
MI0*>R@?U>&B(``!L```>P`T1>T#I3;V:(A3^KY^OUZ(AHB&B(:(AHB&B*DQ>
MZFX@)1J%!&@[4H8`$.XHUZ:(M0N6\3>I-8N:L]2&&"\>^4W'+/24;)P^*>2L
M[-VXMA*XT(1&%F(J+.R@;CC;QQY,J(_%F8*I)+$54.4#T&NB+&WCUZ5^=>.-
MU\`BM;FQYD.Q\$%Y.2F8HDLA,VBQL.[N11U7B4E@J`3:2*!+;L1L\5CHZ-74
M0[4A\PIB=W9HBBS`OHW9'QQ<&,L3S^)N*#K$N-,RS.0KFY"/4[CNK+F:+'4O
M%Q>L-:+_`!R_0;6W:EU.)%V0K^6,Y=$'X<#II@<PB)%.\OZ8F=;GXO9`PW<-
MYV(ZO+/?/QER;SC+&7D5HZ0Q3#Y%AKB86<Q$S0ZSN9"U[8CFA@.4$0[1*`T#
M<BSHP1Q5O"P>:?+WE5>TM`/6V9(3$>/,11D6+PSVU<:8[A%OCHZ6!T0C9JO)
M7*Z.N5)&I0*4!'?8"*&.1W%[E+9?,6.YS<+U\67;>-U8I884SOA;,<U+6I;]
MZ6O;\BM+V7=%K7E"QTNXM^XK<>NEDSD.V.BY16H(@(:(L;\W^FOR^Y>X`S4X
MY09?Q]<&;\C9"Q'D"P\&1X3CKB_CJWL,7"2=B,8N4EOAYR>6O53S!FISRDU3
MJB0Q$J)@&B)H-/2XSI=.+^5SE'&?%OC9D3-6)&6#,8VKC%Q<%XFLFU+AF60Y
M<N&?RA,M&<L]7O2!\Y!*/:M4D$@*3O,8VB*45?3SY3V`?E%>6(;OPJZNS),O
MQMLJR;'OV`4FL?7KQDP!C\ED26&;Y0>,7H00WPBX<',Z02<%;',!Q*(C0"*:
M/3(X1Y,XFW!R%N6Y(JT<,8WR[<L',X]XEXQO2X,@8OPXYC(XK:Y;@MN=N%LP
M%BZOF1,+A9@Q;-F3:GND`1'1%MOT1#1$-$0T1#1$-$0T1#1$-$0T1#1$-$0T
M1#1$-$7@C0!'V!7V?E';1%\S7*/@-ZOKJ_.4]AX-R_Q7Y'<3N54U(3C2S^:$
M5<5SW%Q[7GXE2'EF=A-$V$C%2$5'E7%RR(`D%-8I1`2B&B)G/_1;Y78/C/1V
MB./62<7Y9@O3HN.X+CR+`YE>W!#QMU71>+LBCZ[[*.R:2!V1[79N%THMHIV^
M40A-P$1H10WD3T`N02/*SD7,X_B>)61^/W*SD`AG.Z[_`,YIY#D\N8R:SSU.
M2R#8D39D*\:6=>T9(KF5)'K/#@9N0Q1$-J:(LF+S](+DVO;WJ_O[#N[$D%D'
MG1;F,<*<<UC.YYK#8PX^V7;L9;#^VIKR&2RL6JZ9(JJ(M6OG)E`0`3#78BGC
M&?I2Y#LGFWZ=>6G-QV2MQUX"<*I#"-N6@V5?A<$AF:9:MV+Z\V<>9H5@A&>0
M!NU4Q@6,(!4`$=$4_>K;Z?61N=F,<+3>!LD0N+.2W%C-$!GW!-S72P<2%G.[
MNM]%1$UOW6V9@H["'ET3`0YR%,)!\*:(H"X\<+_4_P`SY[5SYZD_).PK?MN`
MQ)>>*+*XQ\5G5RL<82#R^X5U!S>1<AO)L[96XIMLB\,HQ;]HD;J%+00`*:(M
M>G"7T#N0?&_+V'[/O^V.&MW\<^/F3+@R'!95<LL@36<<ID3EGTY8$?-6N]=-
M['LR?@9-PEY\F@58QB$]THB.Y%DCQX]''D;CZV>,\5D^^<93TE%^I/F/G7RE
M>1CJ9<_K>SFV5SFQ!;T"J\CT%))[;,N_9++`OY9""F/8(T"I%CQG/T7O4#Y"
M\G(C(MXS7$JQ;L@\[1V06?/_``HK?N+^3KS$\9(E?M\<7%CR`(VLZXYXT:`,
M%Y1VN<RJ05&M=$7UQ,D3MV;1NHNLY40;((G<N!`5W!TDBD,NL("("JL)>XV_
M4=$5SHB&B(:(AHB&B(:(M3OK2<_,A>FCP5O3E7C&SK6ORZ[7N^Q;=:VW>+B2
M;0;EM=,T$:[764BE4G8K-TC=Q``:5#6&0N#P`:56&0N#A0TJOB__`*:QS;#<
M>)_'40]@3E^!^47U-8P]Q-`['R5K9#45=@CB?C5N;1@K_-+X\#[!^_[X#_AN
MA>\?UCW+)U6\PJOZ:IS9_P`TSCO_`.W[W_\`3M9!**8D53JM5!_QJ_-DM/\`
M)-X[AU_]?7P/_#M4,A=]I`5CI*_:0$6'XU;FV80$.)_'82C3_P!=WV.WCO\`
M&]NK"\UQ=BK2]PS=CY(T?QJ7-<`WXF\=J=/X^O;H/4/[<Z#IU'?W#W*G4=S^
M"\_IJ?-7H'$WCM[/X^O;V`%/[<]@4TZCO[A[DZCO[O@O1_&I<U0#WN)G'00$
M.WWIV^!"@]0H1Y6@_5JAD=_=\%<V4UQ.'DO/Z:IS6'8.)W'2HUV^_+[\>O5Y
M3I[=4$CO[O@K#*ZN!P7O]-1YL"`@;B;QU$!VI]_7M2@>`@+T=7=1W]P]RKU7
M<_@BA_&K<V`4[/YIG'3J`T^^[[J.P!7N!]V]/'IJH><R[!5$AJ"78>2-'\:I
MS8#<.)G'0.FYYZ^AZ=*=CVM0U?UFK)U6\$0?\:OS:`P5XG<<!#H']_+]$=Z5
M`!%[XZL+BXU#J>Q5$C3YHTGXU3FS4?\`),X[E\:_?U[!OL'_`->'P#5-;Q_6
M#[%8Z3#`BJ,'\:GS9`*_S3N.]/;]_P![T_NW3J._N'N5G5=_=\%;#^-;YMD_
M2XF\=/F^^[^_]-UF$C3DLW5:J?Z:[S8_S3N.@?)]]W\/_#M6N<2?2:!6EY)]
M)P\E(6,/QE?,R^LC8]LN1XL\?V#*\+YM*UGCQM.WK\2U:7!/1\4Y<MBJ.S$%
M=!%V)B`8!*)@WVU@DDD`P=\%@EED#<'>X+HK1K@[N/8NS@!3.F;9R8H#4"BN
M@FJ8H#U$"F.(!7>FMMOVCG1;;?M'DKW5RN0T1#1$-$0T1#1%0(B(B%1"@TV\
M=OW=6NJUS3P*NP:/%?%]Z@/XE?DWP^YM9HXXP>#,+RN.L8W>TMEA=UQRUU)3
M;PKB/0>BK(-V*P-4E*J"``4-P+77!;]W5=6MP^WVQA?/$*EM,^&?FO+^X>]K
M^QEEM-KA$M[&*Z:<."A*]/Q5'*R`M:.NN!X]X%N*/D%T40.WN.[1*(+?HG3*
M#D#E$3`(4$`Z#K@.WOW8WF\WB7;]YM!!&P.IA2I'C1>5=O?OEW!NF]3;%NUB
MVUEB!(<:@FGA11$C^,&Y*GE_NMUQTP?'.6:59%F\D[V3<&4/7L%H<KDY#I@`
M5$1`-=A)W9O[(F74<#)+60T!'"F=5W]UWKW9%9,O+>UCDBD)`(X4QQP36N'\
M8'S4;**JVUQ9X]S3!,3%,JK<=YIJD'M[B@8A'1"FI7?8-3UCW0R6/_RP&/*G
MM@[X?=0AF[Q"*YPKP\U9QWXPKFXZ8?%.>)V`&QR'#SA//7PF@5("C[Q#F<'[
MU.X`H%.FM:Z[IZ5QTVN!;PH,ULW'>#1?&&VHZ,BH&:N0_&,<JO),X5XO8&`Q
M*E.)I^\_)]WQ+W*`8.X0"NL__LEW)<"&*(&.@QX^*T']U;_+*V.VAC$1=F1C
MCP36;_C,^93QPH5GQ`P>\23/03-)B^UA$/T>^H*AL4!U*NW1S(P7N8R0BOJR
M\AY\%T+]WNXJ?D20QG3B"*X\E/%C?BHO4,OU(SN%XD<<VC`A"'$9"Y[P9J)E
M$``I3)JNP,`A7J(:\_WO]V]DV%YCNR7/!H=(JO,NX?WT[<[9E,-^_7(TT.D+
MQG^+6Y<-I]S;<UQ3PPI(M#&363B9V[%4_/#<WDK`\,14HTUAO/W`W%NVB_M7
M0#7EJ'`X@E+O]T[]NUMW*VZ`#\M0PH<17V%)5U?B_.3<""C='B[AY)\G4#(R
M4Q=B`%,4PEI[KH-JAX[ZR;1W9W1=ALLWXSX7BM6@X#EDMG8^^^Z+^-L\K;>2
M%V-6C`>&6?%,%C^,,YJRBY6\;Q,P&].KL@1&>OA03FK4:=JH`-*5&@TUUTW<
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M#.4$P4[37)=OF$`P;$4H]H"A:[A[=1#>^MQB=INX6M-?XX*(M_W&WIA#;R*.
MN1_5,*8_&&\U8]8C1#B;@19P81#O_6&\E$C5[>PI?*>=W>._AOKH+3ND3MZK
MBT,\5UUKW@^:(3R]-C!FO([\81S@,_;I3/$;!$?'JB4#N2SE\>:!:_:*]AW0
MT*0N]*:QW_=K!"Y^WOC=.T&C>9X>\K7W'O9IMWOVN2)]TQI.C.I`J`3XY*6[
M'_%E\N[ISOA;&)^-N"5K>RADFQ;+?R4=,WF>1BXZZYYE$.G20*KD0!^V3="=
M,#U((AN%-7=L=S7&].Z=T&1R!;/:'=EQOSA%>].*XIE]%][C5056R"H@8!42
M(<0-3N`3%`1`:;;".NX>W2XMJ#3DO07M+7%II4<D?JU6H:(OFK_%D%KZ-^6A
MK^CE'#H_/_RK+K'(S40[DL<C:T=R7*`(4I!`Q@[REW$O2OAUWIOK1)]5%H.)
M!T#->"KO[H"4/97]S2BM##Q*]!0!$`':O41'\O35NE5T'G\/YJL02.`@)@^K
M50-*8L\5;"D0!H41$?`0'81\!I\^K]95>IX*H$5`ZU'Z/W1U0N!5-?@O3D$A
M0$>HUVITI].@Q5[37%6A5!`:C40ITK^W760MJ,%5S:B@1PC4M0\0J'TZLR-"
M@%,"O434[N\:=*5^FO71W_TA7M;J1Q4P,H*G>``4OL\/GKJ@JZC*8DJKHSI(
M"`JI]_8(=PU\1`-'1/95:O3EI7Z*LY""%`+00WK]'S;:M:3FJ#4TT=FK(YC%
M"N_7VC[!^;69C6N-":+*P-)1K=50E#5J4!'W!+7\M1_8UD,32,"%D(;SQ5P)
M2.:B3W3=:=1I]%/;K5:',P*UAJ:<5;+(%3H)C`(^P2[T\/$-9&O-:`+,QQHI
M0P&J8N>,)4$0_P"E[&M-QV_Y9PORZS"(/:?:%D;&'^GF%W<X#>!A!_XHC?[C
M1UL`4`"W`*"B5]554-$0T1#1$-$0T1%"`CW`&U1]GR!\VVJ`T?CB**I)!!S7
M)X]<]I&2GJ=\WV+Q\9)^3(,<HP:4(*"BOW&V+53OKV`!0V$/$=>0]QR26/<K
M;B`48X^K#A@<UX+W+N-YM_>#;V*$QPN=1U<:@4S-`M->/Y*Z8MY^K0$>.HM]
MYK=`K903LDERB(HK$*;N*"B"@UJ%-]8NX;+;+Q@W!Q:V44)PQ(XC/CE56=UV
MFTWH&[Q]..<4U88N'$<,U9QJ;*2G;E=W8LL65:)*,6+A8IG"JRP^8F50Q4@*
M`%H4.H^.ES+<6EG;1[0T?BR>IPKD*#`'BMIU[>65C:C:-+[)XU/!/V`@4IS/
MN5TUM9R^8EADI-&)$W\-<**JG2554+4$DJC3M\TH`(>VNJR;Q:V9#[F!\KR<
M*9#SP.`6@[>[6UN?R98G3UPH!0"OCC4#V*QNA5W#LHY@U=K'59)@#KSS'HZ4
M4-VU11J?N*4!_2KTUELA:;@XS%FFO"M?C0+;V)EK>7,MZ!TZX@9_I@E:%A86
M7;H-'H`1VM[_`)BIP01+YGO&,(CW=P%'YM:M[=W=K=EUF-5OI``\:8J+W7>;
MJSG?=1ZC`,`T`G+/+]%,D')8_P`?6])MSW''NGP)'**$>B)G*9S`/:9-0Q?>
M*40H/SZX^>#N#>=V:)(G,M#_`%&I%1EAA\UP=W#W1W/NC)&VTK=O<::G./OT
MT'S4$+3\U<:KQU%W'=$`B@H"9UT9!9JV735,/:54I3%[P$*;ATUW<%C%LP9'
M<V]O<5']3,0?'$KTN'9['M]C([VTMKH.XN8*@_%/6T@/!(BY"Y7#E^4YG'Q3
MA4PJ@:G^UG$W=W?.(]VN:W\,OG"(P,$']K?XR7-=Q1P[A((_QXVVW]K?X^B(
MN1M)3,D:18OFLRX6%,[ML_."JQ@,`?:%(*@F[ZC3:NMW;'VMC:B!\;X8AE_%
M`M_;'V&VV`A>Q\$0RIY9Y!+*-_I8_3CR@@S;7`W,(^4U;&7=$.("<H$2[.X1
M*G6H]!UHS]N2]P3UBD<;,YDF@PQQ^"B9NSW]V3FLCG;4[[CJH/"N?&B9MV/C
M7>JM=]UGD5G+JJPPYD13=N4^B:AP*4#IIB(A0`+M\NIG;(CMDHVRR8TGC+J]
M(/'"GU73;+$-BF;M&U1LZ0-#(7`@?#ZI*B[2EYB"?236UW\3&LA2<_>9VIS`
M@T4,4!%,5BE.J8"FW$0Z;ZWKO=(;"^;:.N8YKMQ(#6YN(!)XF@6[?[U8[9O#
M+>2\9/>R:F],4Q<&DY5/).!I;^,VYT%D)Z=N91%H5T[9%\J.1*N!:J$!4PF4
M.)3>S6A+N>_2OZ71;!$30./J-.=!3YJ(EW3N6Y>YLEK%;1U]+SZR1_\`$::>
M]7$3?$(S-(+MHQ)(%2JMF;5\L10_G?[68HG4`3J&$-Q&F^L=YL^XWSV#J!]*
M5(;[SF5CNNV+N]DC<7ZW&A=I%!4Y\3AX*-H^^9U&]6LB]ATA^#>IJF33!`$0
M[50$"F[E#%,4"?)OKI+OMRQEV":UZA;=%E&D9Y8U"[7<.S=O?VI/:,D>V^D9
M1I]F*FO/>;8^9EX9A`M6D<F$<T&44\I$HE="F`G2*9(H%!/N'<0ZZXGL+L)M
M@)I=TEEF;7TBE,:>)*\X_:K]M)]K;=3[W-(]]'=,$<:88$G,I0X@9"?GY6\8
M$G2L5\,;D-B1("A[RRA3WK$%,)*@(E-V^/AKT*R[7LXKK\IA?AP&"]6V_L^T
MM[P7K!(9!CAA]%VS&H4;-P#H"*0!\H`0M!^D-=XP!K`UHHT!>DLKH%10T1^K
MU<AHB^:W\6-_H;<N?]:&'?\`&LFJ.R5KOM7*`IW!2M*AUU&'[U&O_P!GM5/D
M_P"O+J]7U'-$^4<#"-1$`$>E*"'[.FIM*855U"1E@JB@(U``$1#J``(T^K5"
ML4OIIJP5P5`P"4PU"@@(@)1J`!N-0U2H6+4VM*BJNRG0`##7O&FP&"GU;A4=
M64*OH4G+'$YC;4#P#V;!TVUD;@LC2`*'-6%!'P'ZM9ZA9*A7"!A'N#J)=@#Q
MKTI3K76-X`Q5KL,3DGE#VXE*F)\2O\.E2IC]@F$HCT#8=@&FHZ\O3;`&,:B>
M6/O41N6YML0TL]1=7+AYIR*60F5$_P`(<JH`82BI0P")``-P"O348-Y>UP+@
M1BHB+N5O6:QY`!/--5[:YX\PF-58QJT$`$PD\0`:=/IU*0;K^1P4XS=XY#1A
M!\BD-5!1,`J-*#N%`K3Z=;FL.]7-;39.J.IS5'E`IL;8`WW#QZ?)[=4+B/MS
M0ES<6UKX+WX<@!L8OU?NZ=1_BK=4A.(=[E;D$6X]_<8H=-J>/AX[:R8NX8K,
M=3N&*4/AR21#>2:JR9=@'^N_UORCJS46.-?MH@<V/[R&^>"?>"$E$\]83(<!
M*<,O8U`2"42F_P#?2&#H(`.MZ(@LU`C2MN%S#ZA]O/A[UW=+?_B&$#Q"(C0$
M/8/P:/765;*5]$0T1#1$-$0T1#1%0;Q"OA^?5!]X\D!]2Y(OKI,Y)SZMG-1V
MV)Y@)7['%!``,8Y@+!M:F["[T`!J(Z\X[@N;.#<"+D5-33_]?T7D_>]_8C=6
MME`P/LR"U$ED+FL]P1^K5-D],!TA.H4J)"5`%:$$`%-0*#0*A76K'#MV\L,<
M="ZA&!R)YA0S[;;]^BZ4.+LCIQ(.6-%8M)1E<TPFL5=W'1CEV#=VX*00<.43
M'^T4`_;[@%&M/$`'5TL=QM-B^VMV1RSMB`:"?=3'$GPX+//:7/;^VR0Q1LFN
M6Q`,!/$<AQ)X@+,.4F\#VG;/P,:V6N9XNS(T,LY7$7C%V"'>#@5^XP`4JAO=
M`1W``#7CUOMG[@;QNP?<._&M&R`N;H(!8#B,3RJO`=NL_P!S.X-[=)N=;6Q9
M(':6M-"T'$9DXC!8>FNHQY?SE46KTY%E")BZ*4Y4V0U`K<M:`*@E&M?DU[%%
MML<%OIC<`/-?0L&U"UVL/BPD(Q'$)ZVH>R)F:497,K)Q)5$P!JHR(11(J8A4
M`5$5`$@5]M!USVY-O[:#KVU'LKYGW<5QV_MW_;]O9<[0R*4!Q+FG[L^54B2%
MO1[*0?G;N2.V8NG";104S+*K("'N'4"IA$H`&P]*ZW[&]GNK9L;1IG%"13EX
M*;L=^NKR".)[6Q7H8"XX!HYBN5?:G7#XA=W7`)/K?GFSY:.6!8T*97X=^<*@
M)TSM3F(!B;[".HR_[RCVG=/Q]SB>&D4#B,/?3ZJ#W+]Q(-AW5MAO<#Q;/'ID
M<#H/DXBGQ5,M!RL(R<GO"/8Q$:"1P(1%8/C5NP*`!52F&A^[V>&K;:\LMPG:
M_9]4KJU.%0/;DKK._P!LW&X8_8B97$URJ!X)@PS9O-'<C%/CPKE(2)QBZXF,
M42B`")C."FJ<_:->O7PUTUX^ZMVL;=PME@+:G2,1X>!\UTVX336(C?N,3);?
M3BUN)SY#$%2I`7,UL,RK@T(2\+B(S.5S-OVJ;M(AMB%!JDN!_+,0G]=UUQ^Y
M;<-Z;^-;3NM+0NQ:#I.=?-<7NFU'N9G3L+LV&W$^J/4&N=4\`:$X\N"MD\P0
MAY5&X9*QEG$BD)/,(3N!)<2&KV*I&3\LA##T`-J:J>S=PCLCMK+T=!_]8<-0
M]OZJ_P#]$W"*R.U-W!IADR>'@N'M!3NN#/$GET$;32"*L&!D@^!<"R\DK@H(
MI^:`+'#RB(DH4"F$`W#8-]1.W]BV_9#W[R9)[Z[8:C4=6>!IAC@2H;:OVXLO
MV_FDW[5<7^Y0DN:'5=74=)+:#$4)*B64LE2R7BIUI6,N");HA1S"+F>B8E:$
M.J%!42$]?>`0H(Z[&#=1OML&Q,=!*?[FEM/?1=Q%W!'W+&##%);7K/Z9&E@J
M/_D!5,N3:PTR0\@1O\.D@`BHV4+Y#@P%W%P0#=HT$=]M25H;RR_QZP]QX@U]
MBGK!U[;`ZY&NE.=""*\@D=NI:A$#/WICF;-S@"IDU3$4/2H"4A:_:'+3Q'4C
M)'N[6:+8-<^7F/M\Z95JL[F=QR/,=JWU'B14#ECD$RKKD;'<F[[=^]EU50HH
M,C4O8/@!2B8Q?<'I34WM-OO,#3^>(=-#]N?F<3BNNVFT[AC97<'0:!F&YGXG
M%2QPS,4_,#BP!0.-.0F(:@8@TI^O$-T`:AJ>MV,KZB,?)=1!(T8D`47<^;4%
MLW$!J`HI"`AT$!(6E-;)I7#)920349(_5%1#1%\UOXL;_0VY<_ZT,._XUDU1
MV2M=]JY0(:C#]ZC)/O\`:O!,!>M=]55J/23$?M`']$.Z@AU^35E<50W&DZ3P
M1Z;94.Y=0Y"$`M1VI0`W^FNAH:45KC^1@."MUW952T2`0$0$!$:4,([`(>P-
M7!F(JJ,M]+@3P*3^PW^VB!0\*#X_1K-@/M6Y@K@@-0(`&[S&WW`:`.XTZZL)
M-5A<355F2(CVF/N!@VW`:#L/MZZH*E58:E7#-1L*O:`$[A,`A6FXT$:?/I,'
M:<CDL5PV0BM#I3B1ESL3%$`"E?=+38>WZ.@5U%/M3.3B01]5#R;<V\:>J2TC
MZI^Q%U(ND!26+\.>FYDR]P*>%#=>VH?+J'N-LD82\%Q`%<ES%YV]TW=5FIQ;
MB,"DF8?)'$XD`3;CT,4>H4]M0Z:V=M:YA&H$+<V^"5I]32"?`I@/1[Q,)=ZT
MZ;TV^34^*9KK[84@:#G1)1S'+_7B(>WPUD;3@MAF:(%<P#2IA^4*:R!M5F1!
MA.(4$!I\U-7`-&2J*)0B%S)/4!*(T%0"G`/$#=/#H%-8KMFJV-/N6.]BB?8%
MPQGJ:#PHLIL2QMO*Y@PH=%PG\>EEW%PB1*IUOM+V@Q/W=H;B4*A].N?L9[UL
MXC>"(2#6OD5QFV76YLOA%,"+1P=6N0P*[BL!_$4*'LB8X-^O]IH]?EUV#/L'
MD%Z&W[1Y)6U<KD-$0T1#1$-$0T1%C^D/^Q_.&J?U!6C_`&5.5%RB?6\8.VGJ
ML<RY@SALW8N\AQS4BIS@`F$\(T*<HE-N';0>M->.=XNCDW;I5!(!J!B:>68R
M7SQW]*R;>3#$=<@+B0T@T&&8&/!:@+B:M72CIK),V\RDF5))F1)414*<X5!7
ML*(5+\P#J*V][[+U6KM!/$X?-1FTSW-@T.MG&-V-2X4P]N93&=0B":R93-U(
M=J@0`*W:@*KI$QP"ISD*-1$X>'AKHC=/=&)'.:YQ.?##Q73QW\CHW3!XFE.9
M<0`/++-+=TS%N,8&-A;;@W#AR_2`CF7<%,+@KC<IA`O<(@'<-?:`:CMHMMRN
M-PDO+N<,MV&H;6@(&)%?911NQ;=?WVZR7^YW(BM(S72"`"!C0'X9J)TK>N9L
MN4OE1SH5B^:5$5_X04E=U#$ZEI6GTZZZ6ZL'1:G8#R)'O"]$EOMC%KK<7B,C
M`G`>^F*=D6S>(O$55B-VP;$46*H'>`@'Z`^8-!V'4-=7,3K8]%A<X<`#[Z+E
MMPG@=9:K(.>VIPH2?@IT=X\/*Q356'=-V[TJ-%FZ[Q$J_8)1&O:!AJ!J=`W#
M7`P;Q);WSA.QPBX&A&*\[9W$V"<QW<+FQ-KCI(J>`Q2SC6RQB4I1W(39(-X"
M8@4PN1367I6ADS!WB(&\-1?<^].N98VQ1B8#'*M%`]X]P#<9;6*&V_(A%,`"
MZGG3+!,J9/$/USE<D4D5B.3BHJ^6.HFJ!!&A1*40)V&#K34];_DV3`+=G2!`
MR%#BIW;W7-@`+1K8V$84`!Q39>G;L6J@L6!?)[A.B#(I5"MA$/T1,`CVE`?$
M:;:D[-L]Y-6>1^O^W&I]GZ*=M1>7EV'/>XNID[CCP'Z)QV7&V;-,W;B3OEI%
MS@$-Y,0LJH4KE4*"5(RZ9#I@(&'<`&H:U]TDW:WN6PQVI-F30OTG`<^>>&2T
M>X9^X;!^F"P+[&N+])P%<QD4@J0@JO3)2*WELF[A2CH%S@5P<-_*0*4O>H&P
M``TH-=2D-Q)^,,6U`YC!2C-T+;2-\;:S4QYCQ/(^:=4U&6;"XW;2<59$LXNI
M:4%5RZD$3`B<H*C]JW*)NXZ:J8^-*ZB=NN-UO.XS;7-S"=J$5`T$5K3(YXCB
MHFPO=_W7N]]E<WEN-I,&#6N:7`X'2<\1C58OR%W7(I(21$D5(XD@3REF16QD
M4D^T``@`4PCVTIKT^QVO;XV@$M)QQK7->RV.P[/!;M,CVOE;QK7/Q25'/+B;
M&\IW*IH('5&O<B#A<$QKN!/T3%IX:V)S81N+88ZN;A48!2-R=LC8/QXZO`X<
MZ8XKV]HQM##'I)/"2(/VQ7QA32*W\DJP$$?,3K03[_135VUSNG,FII;0CZJW
M8;F2XZW48Y@:0`3QSR3%=)1Z8)F:O%#]U!,"B8#N(`(A4`V"NI>I.%%T/A19
M(\*U44^8G%4QOM2!R&Q$)BEV&GZ[PX?UU`ZCHT&CJ\OT5S1@?+]%W-V@=K5L
M7V()!]1`#6W']@\EM,^P>2N-7J]#1%\UOXL8?_\`&_+=1V'*&'?\:R:PR.((
M`R*Q2DB@'%<G\1`!(!1"@EJ/CK4`!-3FM(M#CXJHI14.4H%$]1I0M1'YJ%WU
MC>:#-4U0Q_[$YF,%(*D$_89(G;W`4Q!`W9X;&"M=:-Q?P1D-:/7Q\U$WVYV&
ML10MI*,":G$^]),JH9,_P@&J4@>_VTH([;#0*U"G36U;OZD8?2BDMN:W09'9
M&E/BD80.(]0IMM[@;>S8*AK8J..:D'=,-)PR594@/L(4^<QM_P`NJ:J+5ZC/
M!%G04`P@4:!M3?Y`KUWZZN$C>.:=2/P5"B2X@%3"--@VKM\P!J^-T9.2-?%7
M@O6[<YU"T$2B!J":@@(#O4=@VUFE^P4RHKIK@-90942R5(Z)1$3%5K^_J-*5
MZ?/K1::DK2CE$I-."LCOE"FHF8R/:._9L4:>W?IK)IJ*'(K/HJ/`JX2=JB'<
M97N[@]X!&M0\/'6NZ!IR"PF"N2J,L4PB``.^U=O$/V]5#=(TJ]K=`THDZ7:7
MWAK78*!X_3\VKVYJJL#)4'80]O\`5[=9=7-7Z^:K*(`-3!4*;]/KWVU19$N-
M8A5<R#B/`%`#<Z90$QR"'4QNW^M&NL4]Q'"S5*5J7=[#;-I(:/\`'DI;PFJ[
MC\^81552.43YAQH4_>40`1+><((;CX;:LB?#<QE[2-0%5K6S(KX%[2":&GN7
M=+@1[H2'-M[T7'&^MFAJ79]@\@NC:*,#>0HE;5RJAHB&B(:(AHB&B*@P[T`=
MQV#Y]AU:*!^/%4J`X:LBN2SZ[SJ1G/5/YJ02#L2FB\D1YDV(%$AW2"\*T.94
M%"^Z!D0\?EUY?OEO!9[T^]F;5TF`/EBO'>X+2PVO?WW_`*`9QIJ1R.H^2UDX
MYMY99\HZ?VY+GC6?:5>3034=MDJ`6AE51$>T1#?Y-<-W)=M;;Z[>5@Y-P!K[
MN:\Y[TW4B'7;3P!X&#<`2>`RXG!-/(K$EN7PU&%>NYJ*?"5RL8R)CJ(IJ>\J
MD5,`$]$AVJ;4YVS.=S[>_P#Z+60R-RQS.14OVK,=W[:ZFXL9!,!AB!4\<:JZ
M@TE&+EXX%1BWB';5=<QYV/5<$34\LY_*3*D4RZ"QP]WN*`@'76>Y$;K=L4<E
M07`>DCG1;%QTI(60-?B7M;Z2,<:8^'-238L!&3,,YGK9AV$E=;ED[*5J^!4S
M1D4Y#ID7:>?V`=7M"I2CU$?;KEMYOKNPO([*\ETV6K&E*T'E5<5ONZ;G:;TS
M9MQDT[.'BA%,:'+#+V*%UI=BZAD;0=0)6EQM9ER1_)()*(R*RPF,5-$0'N(0
MG:-:#X:ZYEI=07#MUMY2=L,3:--.`]66.:]$=936MT=ULIM>T&%FD$\0WU?%
M.!/&THQ>QJ\G/A;T>_3*E'2BKH10\X*`9)P(*"4AR>-?9J*=W%8SVCX[>VZ]
MV'^H`8Z<:G'#EDH9_<]B^T>VWM!=78?BV@P&-78T')*TNP=,B-X]*YH^4)'G
M6^*>PS@57TB4X!Y92E$1`03$/ZT*[ZQ;;=V\DNI]B6@G`.'#WK!MMS!=3$R6
M9@KE@!\BD<7D>DF\-(2RB*:")&XE58`X>K%$:]PB':4IZ[5#Z=;,IN;B8-:W
M&N&.%%LD7UW.&06X!/E3/SJH^6NVW$2GCVL=)+(.%1(JN=V9)50!#M$?)(%2
ME$/94-3S-GO"]MWK#7,;EASKFNJ9VSO#7,OGRQPR-;@#0UQK7PY>Q.V$#'\3
M%.I!&&=)2H%[F*KQT"K=1R8??$B>Z@B4!\0#<-:=U-N\E]&R1^JUQU#V&G#G
M10M[+W1/N4<%Q-&_;<=8&9%#3ASH<TD2MU2BB2"@"U1525157%4"(N#%,-2G
M1*H)1`A"AO0!KK-M^U=9DK1B,5M[;L+9V3#&F*JNC);R4;A%Q\HJ0C1%N5:1
M3354;F7(4AA3*)R=@=IRTK3?PU3:NUK2RG-S(S4YY)I6A-?*A5-D[0M]MEDN
M;F%C^JXD4P<`?$$$53<1<N9B(=.I.3AEE&B!E1HH@@^=%K3Q+4Z@?)OJ2(DA
MN!':,>UGC4T^:EI;06EXQEC%(V,D5!<YP^+BHH=3KD#G%HR!(I*D!=0@+*@0
M!H!R")*=U`ZTUV$-FT,#G4UD"OFNWM]NTTD>?416GZIJ/G!W+@YUG)W0]I`\
MTXTH%!^S*`"!2E)[```UMZ=/V@#R"GX8X@W(#RP_1)PFH82E`*"-/T0Z#MUI
M765HK2N:R.$=#3.BR6X7A3F%Q:"E/\H3$5-J?_',,&LX8VF2LB`=G_&(7=%;
M?VNA_N*?]@75X``H,EM``"@R1VJJJ&B+YJ?Q97^ANRR'MREAW_&L@_FU@E^]
MJPRGU-\UR>@V*'R``?FUK@^JJUVN`=J.2<4.8C0P.E2^9VB!B%+OT"N]1+3K
MK5E:7X!1M[%+/_I(%>?\JIUC=ZQA,`HE*`U"H=0`0'I[W74>[;3(\/<12M5!
M/VD=367#J5Q\2F&[43.Y55'HH;N`.T*@([C7K[=3CN@(61Q`A[:UY>%%T<&O
MHMC;_2B`,C4-A_[T-8J$X#-9"V6G#WG]%?LT@66*0`"IO$U=OFI7?6!Q+,UI
MRES!FEA.WG*NZ=#`(C0U#;[[]"CT'6G)>-:ZF*CI=SAB<6OK4+U6`7;C54W:
M!=QW-X>`5*&XZ-O6\BD>YPS`Z`?@DA1$[56@B!@.8:#0!VJ.X[==2(F>]@Y4
M4NUK9(VD\0$6LL)0*`CL-?#V4^0?;JC12I561MCKIXI*42$XF$NP&J(;^T/K
MUE#J+.UU*!4E(9,*&';PZ?ZNKBZN2S:CP5T3]$!\=_V1UB(J:E8'FKD88YC!
M01KO7H'Y@T`"-`)Q10@`]=55^EJ]\L!`0*%!$*=?#QZCI58]3DZ+5N(+8?).
M54`<H5H9(X`8!`>H#6NVWCJ/W+;7;A#Z<_:/DHC=]K.[1=-F$P&!Q^BGO'EP
MMKNSAA!RR8(L2$S!C(QR)E(`B;]=8,!';<-M:.U6$VWES922T@C,G,+4V2UN
MMHD_'G-2:T]V"[B\!_$<,'LBHT`_^Q(:ZYGV#R7;@U%>)2OJY50T1#1$-$0T
M1#1$5V@(C7]]7J/R:$^L>`1[0^FK@%R6?70<@R]5CF@N[9*"5WDJ*23>-C=C
MCR`@V]4Q,6@T./B.^VO..X==WN3H7D$,;4"@PX9KQSN>SGN]TDA@:'A@)H[&
MG(X\_HL/;'O"U+6LM,\;)R!WK]N8%V[T@"FB[[C_`,'$!J!R&+U&GCKP'N#:
M[W<-YZ9!_'80<#3(^%%\T=T;+O6Y[Y^-)$T6[7#(TI0YU%#@FC&D5?3B]T#'
MH-_BT%&R;4Z*9P.3MH=PW*8H@F4IAJ`%#?4Q/.V*V%@YSBT&N#B/DNBN;EEG
M9-V@R/<YCM1HX\J<T[VEM/#/4(MQ&QJ[N5**\>\>N$T$"$4WHJEV@"1N[H`T
MZ:BY-P;#%5KWAC3E4U]]?YJ%FW4PP>F1X8W@"=7L-?JKJ(MT&\@Z:+.D8QS&
M*>0](R+7L\LWF$5:K(T37$`J(!2M-:-UN/5:R1S7/UN#FN<2:#D:DK1W+<9Y
M[:&20.EU$%I<>!YY^_%8LW,BE"WA(RDY&.'K-1\JJA+IB8':@"(^6X72`2U/
MTZ[Z]=LWR;GM$;+.9K"6T,=!F,#PPKFO;=L?-N6S0VUK.(R6T<P@'SH3S4G6
MM:C/(K9-*8N]@W9%[EVC1<`1K0HB0P-S"40$`KW&]H[ZY&\W:7MJ4BQM'.F<
MX-<[[J5SYX57';IO5SVG==':K)\L[CI<\>H8YYY>Y11<$9$HG>,HYR9):-?G
M;HN6I0*59`H]HJD,&]0$.H5KKM=MO9'V[;NZ;61PKIRS79[7?W\L+;N[B!<]
MM2,J'E@DN?0,ZBB.T%%3K(I^1Y2B9?M2EIW.#FI4PB`[5UFL909JR`9^[P4K
MM]P[K5E-#7,&E/!12Y?_`'<)3I090<IT.54!/Y=:;B??J)OHUV,1;>%H<\"(
M"E,N*[1G_GZ>K,.D!2GM2O;\Q^L+X(Z6$L6JH409+E(!FZ:IZJ"90HA0.@U'
M6ON-A%9PNNV.UQ,%2T&I-33SXK!?6D&W1F\:6R6S!ZF#!QKA@<QB0<\@EB[(
M0QF:(RPDD5X]42HS3+O2:J-_=$I#_H`I0`\:UUH[=?M;5EDPM:<ZX_JM':]V
M:Z5T5BPQQ.S#L3\:IKS+X4[;0201,5D4R9/.:HD`%^RE/-[0[C].HCUU*[?'
M+)?:WDA],`[``G/'Y*5L+>8[F\=4N8:DZOM#N0\.`4=B_;NTC-B)T6.<"I+"
M/DE$:=!.-!$U=3\<<EO+U9&AS*KK66MR)!>2!O29F.?EP3P:03J);(J&7*X6
M<H$,LE0%TDB'*!AH?<.\.FHB;=72SO;&TM:''YJ'N=V-Q)(86N;I><_/Y(^\
M;/2@HF/E'AF93RQ151:H*)&71)0H@HJD4:D*IW>/LTV[=C=W#[?2_4VF-!3Y
MK5V3>)KVZFMG,DU1Z:./VFM<L?#DHF%=(3T(3W>Z@")0`WS]==%TWQ@/<<,Z
M+L7VDS(];G#*M,?T627#/?F%Q7_UO(;$([__`+[A!\*^!=9A*TBHK@$MLC[%
MW06O]K-_]P2_L"ZO:X.;J&2W$?JY$-$7S4_BR?\`0X98_P"M+#O^-1=8)?O:
ML$OW-7)[`HFV#J/3Z-]:M:9K5R&*4P<@FAV!U`-]JU';V_(&L696%6?QIC")
M=MZAK-H("N_&KZJ'%$'#O&HUK\@_M:H#3)9&L+,"J2HG$P"%:5`0^O5X<*@'
M-5)%$LLC&16*IW![OR!^[K4G^*C;C$4&=4](^Y",A[3)]Q:;#3IW;B/UZBI+
M&21W4!-"H"]VEURWJ\2?DK:2GR.Q4,4@E`0KUV]GRAJ^"Q?&[4_$$++8[4;=
ME78C),UR]\Q0W:8`'N';;?Y-@U+,C(:!PHNECC(C:.0"M@5K^E]&VKJ45XC)
MXA%G&M1`=Z;?/351FJ],C&H192&5'WQJ!=^OM]FVKZAN6:NU@!70@D0`$:U\
M-^@_+OTU9F5B/J."I.8Y_=J!MZ^[T\0ZC3VZ99JK2&G%%F(8HT,%-JU\/KZ:
MO8S7D0L[&:_M(5`CVA4IC"/3>@?GU3`X+%IKR5/FB/7N$?H'\^MJWE$1H[[%
MEB=T7:V_>IGX]EIFW#7VBA._+V,P`1#>HWK!TVJ&VM:8&:?T4TFOR6O.'RRB
M5P&`/R7=>M_:"A0]D3&A7V_P)#?6\T4`!S`4JW[1Y)7U550T1#1$-$0T1#1%
M1TK\I@_+32E7`^"NS]RY,7KNPX+^JAS,D@:.C$1R+&*@(K!Y*RGW*T(F0R`"
M-0$X;:\NWZY<S=Y&M+0`,:^)S'->*]R[I^/OKX(WECW5&7MS^2U_,B'+!LSN
MF[+WVI5%VHM@*8PF[@*5,1`#@J`4Z!UUY3/.Z3<9)&G#'_E>)W%])<;K*\2R
M'0XBI_YR\522?*1[%VT\*2-461.M'K*C\.J40'N(0I^@F&G7KJQFV226K[\D
M2-;G3$K$[9NI#+NT9ZK<-5,:!.Y#S`469.//=.'*9`,_,L)U&]!`3*IB.YQ`
MGM]FH%[;>HE<"(ZXBGT7,RFT-)7`M;JI0CYA//&4';#W*-N0DO*/T[<DT7)Y
MEX5R+(.]$E2*%76)V@8Q]AV\>NHGN2[O;?MFXN[*-CKQLH$0`K1I-/5AA09Y
MJ&[MO]TLNS;B\V^-DM]%,T1L9ZB&DTQ%!3#%-'(L5;`93GHN,DFBS`'JB:#A
MZJD\0^!3`"E`QR>Z<Q2AUI4=37:UYO3.V;>]N(B+DL.KG6N.')=#VMN^^O[/
MM;^\A>RZ='4D#UAU?9\UCW?QF#&9:112I&`R0@U<L#F02\H*#V*``IF)YM=N
MO37HFPBZO;5VX/+2":%KACY\5ZCVE'?7^VNOWN!.K$2?=]5&TJ:X"KMT$V*"
M$8Y$B#<J!?MB$[A#S!4,(F,83#N-==7:FQD^QP%S3&N7\>Q=Q;Q[80:2O%T,
M2#@WV8E.DJIDBGCJ`X4*CVG[JB/<<H%``V&HUU!OJVI;@*GYKGW2Z1K%0*E-
MB<C'AG;`[-F<1*<B;E(I![0(&XG'Z-2^WSVALI&3RAMSJJVN5*?.JF-NN[/\
M"47,NFY#CI\J#ZIPMX.'7=H-GC`4G;HHIME$C@F9-7L$""<1$I-_E'<-1'Y]
MU&'%S]4#<^/N4;%?;B*AE98N7/R3U>XSN1W#&=NF$S)QL:F)15:&1,@F"85$
M5&YA$%"$IU`=:]MW/`RX%M$YC)CD'8?JH.W[OLV;C^*Z6**[K]KC1WLP*2+*
MEK`MY.?&_P"Q#7*QD6*3&&E&2ID%HUPDH!W"2J`G(@F)DP$!'M$>[4INUOOF
MYOM_^BNR)V.U2,<*`^DU##4U`S%:8*:W>W[FW9UN_M^\Z4C)"Z1CL-8I_203
M7''&F55B_=4$R2F9=Y`QZR$$H_5,P8NCB91NF;=,@K5]X2E'J&O2=LN[QMBR
M#<J?D!OJ(YKV+9]QOI=LC9?D&9@&NG,)J!)2S(3))J*))B8`.F)A.0@@.X!7
MV:D8;2W>TN=2M%)MV^WNP9F@<^2<A(1S<:B('<"@[5*'9\6L<R)AH'84#F$0
M2#]Z'3?48;J#;G/:0-/@!6O'S4>-RLMNU,:S$',!(\S;+RW5@2DP['7<`E+U
M*H7J!RFZ"`EUL6]ZV_!,9]("V+?<QN0=TCZ0U3OPT.4W,'BP!0I_E"XB'P__
M`#S#:V&`AKO)2%L"*U7<^;!1N@'_`(E/^P#6U%_K"W4=K(B&B+YK/Q9'^ALR
MZ'B.3\/4^7_E63IK#("9&G@/Y*A(&:Y/Z9E/+*`AL!"ATWZ!K3<1J]JBW.:9
M<^*H/4:;"'7K]&BR:AS5&JJJ\T5P^T^Q*29B^24.X`&@[5]M=4X*/<QY?4`T
MJK83B2M/;U\!^;5@;S6Q0\E<)K!Y85'WM_#;J--""E#R11%@*:JG:<M!]P!_
M2'V"/@&E.54H59F.F8YNQ,"F,8PA3>@B(C3VC368`TQR685HKAN@=3N[MZ4I
M0!\:ZQO-,EKSR:*4XJX^$IN.P!N(CT`/$1U:'%86SEQ`YKPY"$`.PQ35ZTIM
MJY9UX*A.P"&0`U*^\%`$:U\1]E=517T:Z12KWLTE2`80HH(AMN/Z50WVU@N&
M.<P!IH:K#<1O>T!AQJBI)Z@[$WDM"MBA0ON&[DJEZTV$>X=7VUM,,2:K-;VL
MV?!)(#3P`?GUE6=5=W^M+]6B*6L$/!'..$`+V@(Y?QJ`@!:!M>D*(=!^366)
MIZ@KP0BH<#P:?DN[-;^\#"C[8B-'_P"Y(:W%O-^T>25]%<AHB&B(:(AHB&B*
MD?\`Y1?S:J/HKA]%RC_6SD(@OJF\UTWOF(N&.0&"A#&`5&JRJ<*U.4A]Z$IW
M`(#XZ\3[PM+FZW<MMS3$U\E\V]_6MS-OW4@X.(\>`6K=K<9KC(FY`IP=1@)F
M1;H([JE`0[CF+6GE=@U^;7&W%A^`X,EPU"A)Y%<'=;6=NO>E*/1,W$\JBO\`
M-$S2RDPW%:5:HF>M%TW#(7':F8S1L/>9(BX>^3S`H&PAK9LIF68%I;8LD-'>
M7#WK:VG_`/G_`/@VA+K244]U51&S#I)$TN@98K,>XZR1SG.9F`&&J"(FJ9=,
M2EW^>FK+RRL)9#;282N;@/$Y?%:^X[78S3BU<`)C@/$G(IX-;XCLE(E8OE4H
M12"0$(P6;=5(\@8GNB918!)V$$HCW`-:CJ'N=FO>W&LU,ZD,XXY`GY^:A']N
M77:$3I(`9WW+AJ#L:?\`'!1K-(6NW6:&!XX5G$G!>QLFF8$7HB(CY*BP#7W@
M&ORZZ7:QNNAPDC`M*8?5=KM[-SEMBXQ`6)8`,,CQ4;W<\5=/6BDV>-8J-U#`
M8R2OF.`1I[B8H@8:&*'372[5;#I.Z.HL=F*4Q_1=KL5@QMFXVVHQD@94Q_1.
MZR9VWG;GX`WDR-4%$V@J*"*Q3`%0'RQ#W1`1'4!OVU[C`WK0$M!.-%R_<VT[
MG;`SP%P:3XT2_-Q#%.VW+R"*NI()KF%RH!`,9&A@``(:@"?K]&M+:+F]EWEM
MI?X1T_C!1&T7=[+O+;/<,(@U,B+FW\*7N?D!=VN@<`*^]P#%$HF(9,XC7NJ-
M*;ZZ*]VR'<WF.S#M+#B1\0NGO-MM]UDZ%F#0/Q(X<PE2SY.0*X<GE;6)<4!-
M&,HFJ7N^+B7Q:E#R0*/?Y?>`"'A36&_M;=ML&6<VF]B%"W(.KS]GQ5W<EC;P
MV+(;"\%O?1`8'B/ZAF/%+89#O>'2D[<CG*Z4*^(NT5;G*/F-T0_3,)A-W$$!
M&@TU&_\`K^SOGCO9G4NVT)]O!0CNR>VK^X@W=_JO64)?SYJ$I-28CVI';,JS
MPK@JQ%V9"FHV4$W85T<HB;N`W=W`;KKMK*&RN9#!4:OF!P7IVV,VJXE,$S@T
M@>@\P!^B<T".,Y2U';6]YARC.^2H+%N*IDW"K[M$$O+)N/84PT^76M=,W_;]
MU8_:[=[]IJ-;P/2.:A;P=V[=OC9NW[1\VSU]3P/2!S*AT8L&S1XV5:&<@F90
M3&`WV@(B(@10W;4P&$-^@ZZW\EC[F-[7`@@5H>*[9MW/<739VG@-0\>(]Z+]
M]JP:`U.51!,IP6!8!1,0!*-.XQMS]INFLQC9<7CN+0%L1.Z]\]D^%10>/DE2
M8G%KE9L^T4GJ;5D1FZ().\""DGVE,0XB':8H:PV5I^+=/D>"UQ!TUPJ>`]JT
MMIV\[/+(VA;+++Z0<":Y44R<++07>\N>+CN),=RD3D+B+S2@)0,@8M[Q!CE.
M0U#`!*==2D>Z,@D$4SFLE.0)H2NC&[QVT@ANG,9.1@":$E=PYL-6R`TI]BGM
M_P!P&I=KM;=?-=$PES`XYD(_5RN0T1?-?^+$`!]&_+8"`#_THX=Z^'_*HNK7
M_:5@FPHN48<"@CL%-@]GR?)J,?\`[/;^JA1_M'M5@<!&E/E_-JY;2+$FPC7Y
M:4_=U<LPR"HT552(&KL8`#V=M?SZKAR1``'Q&OT4_/JAIP1%F.8IA#P"G[`:
MO#00J@(>:'L'Z]-"4*J*L0!`?+H(;]WC7V]/'32ZF:4*N2.@J(>VGA^YJQT;
MG+#-'KIX*Z%RD<Z:9C]M0*F<1#8HB/7V;5U9T2,5KB%S?4!@#5/:!A(MT4IY
M)\50`&I$4_>VZ@(B%*5#;49>W<ML/\8JH;=-TNK9O^%I)3K?MXE%$$6Z#:A2
M"7N,4.Z@AU[O$U!U"-N[J>4RD$5_X4+;7EY<OZT@(<[,>6"C&2(F0XD2*4`^
M00]@[4UT%HY[F^O.B["V=(6^L842,!1*%!^?\NMTG%;52O.XOM_-^SJY47@@
MF;<Q@`?ZO8.JA9&9*3,%B'\O.$J?_P`O8T_)><-K8@^Y;$/^Q=V^W_XAA/\`
M!$;_`'&CK:6VE?1$-$0T1#1$-$0T1$T`IC#01J:OTT``T#&AVH?<0L8/3:]P
MS+OT7*A]:Q&VGWJF\QF\JM'LS(94C'2[D5^UP*18%MWHG2`:*`<-AKL&O#N\
M?^TBWF1]JTECA3XYKYQ_<&;=QW(XV['%DD0;D:#Q\_Y+2P6Y$B7S)C$BJ:,<
MK';HJ$H5)(I.TI"@1*M4NT-Q\=9SML]SL@==.#7Z>.:S7>U7%QVXR*Z($PH<
M<\$\[K9JW>S8Q;<S:*=M0$GQXO52HB*@@(*E*-!,!0+O[*ZAMDEAVB8N?C7F
MH#M]T6SWCWSLZE`*,XG-(#I_:L%;2\!),7,A="#H@,9R/>.4XYZ?M[3@4AJ%
M55$?=`/;K:@M]ROMW-];O8+)V=:$M'$^[&JEK>TW_==Y??64D3-LI5T1%7,:
M,21CP`XC!7%OS+Z)21,^AG,,V.JGYDB[)W&*W5-Y9S%.&R8``]U1VH&M?==L
MBN)28I1/R`/TQ6ANVU17$NJ&5L]<@#C[DR;NFEE+A/&Q4F$TP57`C=9``*)^
MX`$O\(`.P!^G4YM>V00675F88YQ7#Y&GBNJ[>VZUMML<^\88R`?2?/.AYK)V
MU;.Q1(6W'2%S*0*UQHH&25CI%WY8G!,.JHE,!C*"-*&Z:\RW+N+N^TWE]M9Q
M2NL,@YK3AR."\3WCN;O:QW.2':&SMVAS].N-I)%?#'#G@HCN*8*28^[[8M6`
MM)JV5$GWFT-\1\4F`B`*?$B%"E.&U*ZZZRJZW%SN=S-.^F,?(\J4JO0-ILWR
MV+;W=MPENYB*])]!I/EFEZ/GQA%6424$G;=V`+R"PF*!3@L(E$2UKW"0=]16
MX;8+J0W&IP<*:0/K[%#;G8/WF"?=?MN6C`#`X8`*-;S>1KJY@^*`C1B4QD4#
M@;O\PBGN@?M`:E`E:U]NNMVEDL5MH9C3/W+L>V+>Y9LT50=9;4^?FGICY1O%
MN'1V+Q:0:QQ#*J_!JJB3L[#`)CD-4E>T?H'4!W"R>0],MTZB,<N(7-]V6EY>
M'H,921]*&AX$'Z)")<$&YE)I0[N3<1H^:N5N44?B2K*UJ43J=2=_4`UNRV$C
M(X:M`?08_P`?-33=OOV06]&^I@%3X?QQ3/5F`*1\T""<E4JEV2!#"1'R3T\M
M-3LV)6H!\@ZG!;/TQS"<=0"E,*\BI]VWR.E9/%<-,CCBWB"<Q[%$3-[#NIY9
M=W%+.!9K"':F*RGVQ#@4QC&[3!VA^7762P7L&W=)L@!>WYKMY;;<+/;1"R0#
M6/+Q62$[CN(4M1&^27I;J/Q;9(R49'N13D&]4B]R3ILL`?;)`;WO:.O.K'N6
M[CWD;.+64O:XM+BTZ33#56E*'S7E>V]U7[M].QLL)W.;(YNHM<&N(--0-*$.
MSS6-4RDT=1XH1<@>16;]Y5E>WM(3>O:)@J!A&FO38+FZ9<!ETP,CX4S/.J]3
ML!<6UZY^X1=$5&D$^_Z)F1,N\A79'*9"""8`19%0H&243`?M.XO01,&INZM3
M=14::%PH",P3DNJOK6+<XO\`'42`5!&8/`CR6R+A>IC.4Y&\9I)HK)0=SJ\@
M<0G\M)8$T!4&\XCN[$NT`,58=ODUYTR/N^QWMK)61R;8TYD'5_`7E$+.]F=S
M-MGLAFVQIQ=0ZOGF%VDF5?@VM1$P_#H[CU'[,O7Y=>KAXD`>T4!"]PK7&E/#
MDKK540T1?-E^+`[1]''+O=2@9+Q$(5&@=X74GV[[;]=M6N^U8)^"Y1*HE[#`
M40'?:@@.VWYM1<G^SVJ&`_S#EBK0#]H4H(_-JM2ME%&,`]VX;UVKOOX:O&2S
M#((G555>#6@TZT&GSZ#-$/$O^P`1_P!EX_3JN"+P2E$=PJ(Z5(14*)T#8H@-
M>E!K2@^&KFNQQ50O`2`0"M:T"O3]K0O-4JJ@*F00$PF^3I]/AJYLCAD`E489
M5#<P$+WTJ!J;]P!L/7VZN+W.%"!0J[5A2BK2D'1#%`BG:`;4*%-OH'6NZ"/,
MBI6"2")X]8!2J,@X4(!3JFK2@T'?\HCK!^/"'Z@`"M%UM%'*2QHHK-0QC![Q
MC"-:UKOTIK,*4H``%O-E,@$=``.2(,82T`-]O'KU'32%70%9"J80IM]0_MZS
M:`KA&T*D3".JT"N#0%*N!0KG?"0B([9>QK\W_OG"ZRQ_=19H31P"[N]O_P`0
MPG^"(W^XT=9ULI7T1#1$-$0T1#1$-$15#=PUI3O#MH`]-NOTZL+6ND#A6H'L
M0M%*,SK4U^BY/?K5X9O*\_5EYK3\4R;*0:61(X%SJN#("=0D(W$Z0=PB`"H!
M:5^37EG>7>_:^VWXM+P3=<F@TYU'_P!I7@_[@?N#V_MNYMMKULC;QKB*-:2#
MECD<_-:D8..1L_\`6%>YFT0U*9<[-DT;OB`Z[A-V4*<ISG.8I1WV#?4-=M?O
MD,;MI?*;?!QU8<:TR"@=VDFWTV\FPND-O@YVH4P%#3()V6C(6H,A`1\O)-CQ
M<B_/]Z)N@$SR/:IB`E*1P`=WVP#2GR:Y;=;7<3#<W%I&YL\8]%<G'Q'/G2BY
MGN&UWA]M<WEE&YEXQOHPPU?\*3<LP.-$C,G]D1IY5&*3^/>&7="B@BFF:J1T
MBF5"BPB2N]0$/#4%VAN7<<PD@W9K(GOJT:0['5@,R>?!<=V!N7>$[I+7>7".
M64Z`6@@G5A0YX&O"BQ]G;_@)5)9:+:O&Y'"0M7B4@L51KW>6)%$VH&(0!)W!
M4!WIKT#;]BW+;Y&NE#<,<*\>=5Z_MW:VX[9(U]SAI/\`3_.JADRJT=&F:,%`
M3*X<BL4B:?><!`X]ARK4[BB`#T`0`-=@W5<O_P`S<`,3S]B[N+1=:Y)ZEI`%
M#X9JQN1K+))LW3@SI<CA(ICJ(F,(%.&Y:J)]H@8P`-=;NW75N(WP,;&V8',Y
MD<<Z_*JR[)/9QB6"`,;-CF!]OD?FG[`^=)0[5@1R=(!<(B;S3&`1`*>X8QQ,
M82C\^N<O7FVN#*QH&>0X_)<INGXUE=&X=&TN->'Z8*7%;<<(,HU2HF71$0\P
MH5/[VQ"BF8!$Q`'\FN0BW>W,I$E.G4^?Z+A(]P@CO9-9`M'YA1C<MA/EY`%Y
M9<[1R]*;L;''RSU$1\I4A#`8`+3<:>&NELNX+!D>BR:Y[&YG/'E4+L=G[ILX
MH#!9Q]2)AI48T\,$MV[!W5%_`6S%N&C5!9V15>0!3M*]$Y1'RUU.X:I#X![=
M8[W<=IO&NN+AKZ@8CERX*S==ZVN:&2_F9)U&`X`8CEP3M7Q1/2$^I',"L$Y5
M0#JG$BA0;*"0O>`"4O;^ETZ[B.H5O=-@(C)=@B"/*@/#F34>Y<]#WEMT>W&Y
MOW/9"T\J8>T)I7'`W3$NFS"Y&LA#"1(K8Z#=MVM)`2%[?.!8"F`Q=J[C74GM
M][MM_&^YVY\<KGG4*NYGS%%.;7NVR7-N^\V>>.YU4=]U7-KC0T-`1QP3:;XR
MR`]66_4UDF=M3SE4T13*J8HA43'.L:IC=H_-J;=W/L]LT6V]RU>,J$$#RI_-
M3S>^>W8H1;]P2@R<-5</_P`:9)!D;8".(=M?D@#4"K"<[%%3S'WG`($!,OE&
M[*;4&@4`0UO1;J^]G;)LL;GD,`:]S:-(X8T%?-2,.\B^D;+V\QSB(P&.<VC"
M*8$&@J.1J3XI^3AL+R&/'$18D=,1UUL6GQ#A:25`K9TJ4HBL<JANP.X:;%WZ
MZB=KM>\__9#/W(^)VW2._P`89X?=JQ/A2E.*YS:[?]PV]UB?N5T#MIF<.F&8
MD`9ZL3P(I[:K$/N.(^6<XFW[3GH`U#:H@-.E:Z]7#]$KA'_K:TEHY%>XM`MY
M7.8*`-J//@LHN%[]R'+SBJT,L/PQ.0^(1#N[0$:7M$``"80[J!3VZTXX(II7
M32"LAS./ZT6&VMX1<&[#1^1SQ_X^"[DS,*,VH4I1LAM[/LBZDE*DDFIS5SHJ
M(:(OFN_%B_Z&[+G_`%H8=_QK)JUWVK'(TN`/)<H(H[=OR?N:C'-K(HDQD2>U
M%"<`&E-5TE9M!1(C41'VB(ZN"O&`512]U=^FA-%0FBJ\L?:&K=2IK"'EC[0T
MU)K",*"84`P^\`^P?;MX:N!JFL+Q0O<;NJ`=`W_<T)HKFN#C3)%"F8=O;T$!
M_:W#0.&::A7R7@M3#_7=M/WU1^JNKA*WBA>UOW'-4_#T'J`B'LZ#3Y*:KJ+L
MLE4'4*MR5!C@38`"OC[H#H`3Y(,<EY\0?I0/J#5=`S3IM.)I54%.:NYQ+MU&
MH_L5U<0%72T9+TP',-0-W![0V_(-!U3TC!5R16KE5#1%+N!D529SPB<Q!`AL
MO8TH;:@UO.%$/'5\3@7@!7Q$=0+NXV__`!#"?X(C?[C1UL+:2OHB&B(:(AHB
M&B(:(BQK[U*F]X-M@]E`\-6?['TR#?BK@033+FN1MZ\-U76Q]6GFLR@;Q?1(
M(9`C2#$&=?"-%0-!-!$VWV:HB(B&_O!KB=VV?:KR_,EU9LD:"2'X5KAS-5YO
MW'LNR76YB>ZLFS,)-9-))&7+$>[BM/<:P9/'*;V\Y1%L0#F4.JW5,Z7<J&.(
M]I``3$(/?U,(UU&7<LL,?1V:'A0`8`>]0=XZXMK=T7;]NYSZ@`$:0!S]5,AP
M3PO"3QRW7@0LZ07^.<%5;S"DD;N;D<&!,K98@@3W"$'NK7IJ)V>S[@>R4[K$
M!&TU%*'`UK6A*B-AL^Y;@3-WR$-8'U;]N(-:DT*2GKR>;1;E$$$Y!!$5"/'3
M-8QT7)%4Q(G41/V`F0IP-\P:RV\&W.OVO)#2TU&!S!KRXG!;5EMVUNW3U.#'
M1^IHR-6FH\\5&B39!51@T6=/"`;O.<G:(D2]ZG>V"@@<E=JZZJ:[EF!DT`M^
M:ZV:[G<PR%NIJ=!(9T:-=?!.BN'R:E$VX&(#H651[C))5"AS=1\?9J';=:+I
MK7M+8#F>%?B:*(%["ZX:9_1"[`^:>5GL948231?)*&8]OV!ETA,;S``?+[.\
MHF`!WZ:B-]N;2VW",VL@).>:YSN":P@W2,V$P,KACI!R]@2/$`X0=K/')#(?
M"KF(Y3.`"W(D%/*'[+N`IC5'IK?NA'=6376]'24\J^]9]Q<Q\#(F#7,1QP^=
M$[_Y3I@99%8C!,K5L)2M`,102.2$$I*U&H"7NH`]!IJ(@[0L76CGW$C6O().
M(J/#`J+C["VJ;:))+BY#;@9BN(KCP0R3D-2XU6+M_%&":2(FD!&AQ*W9H`;W
M3F%+N.J=2OZ'2G4=6=L]N06AG`GT0.=7U`XFGDL?9W:5MMK)FPW!_%D)=5P.
M)`IA498<$M*W&=[`0@?JZZ,XCS5#[M(J198H)"('=F*!^TH"%?&FHZ+:]-].
MQ]PPQ.R!H.//]:*/9MO_`)MQ$ZYC+'9!U,<<:>05HQNJ\&,S&W/'1DB`%.8J
MJ78Y=)$*D)=Q4[-_=ZA4:ZSS[/LL]E)MTKX1(<O6T$^\K:O]B[6OK"7;;^6&
MKF8`.`).0XCC[%,-RYQEIG[KD)&W6DZ6+42`T:"8E57((`"O>4Y0$G82M:AU
MUQVW]A6MB9(;>]=$Z2M*$^GC0'$4X5!\EYMV]^V5CMT5S:6=Y):&<&CZEP!S
M%#BW$BGD4K9>OMI)QEM2UN-8NR4))JF*K"*=@K*)$3+V*^>BF/V9?,K7NI76
M#M'MZZV^[GAW<.NSJ.A[AZ<_'P6#L;MB[L+NYBWEKMPH]VA\@])QX8@_!893
M*[!26,^=&3E*JB=:1?JG*<A1$14$J`^Z<Q0$1]WJ.O:;*WN&V@MH"8\`!0>G
MV85HOHO;[:[&VMMX3TO0V@:!0"F#1QP4:7K.1CYV5&"060CT@[.X#"D+PM"]
MZA@+[U!,`]M==1MEG+''_P"2X/F&1Q^JZO8]MFMF%]^_J35PKP3"\\X&W^KV
M`'3Y]M2[8P`17$BBZ*73(,%DIPQ5$_,'BQ7_`#A<0@'R=U]0A?SZK'%H2(=,
M'R_1=T1L-6S<?:BE_8%UF6TTZA4(_150T1?-5^+)$0]&[+5/'*.'J_\`.HFJ
M')4=DN3^4QJ5KX>P/VM1Q^ZOBHUP/4]J!0[@$1"HU_,'LU57T*][2^S\H_MZ
M(JB@`=-6."L?CDC"A4Q0'H)@`?I'5M"L:-5(4H`)0IO0=Q']D=42H1(&(%`$
MH";VTW^3>FKQDB/;$346(140`@CN(C3\NCLE9(YS&U;6J=<%&QSAZ"#EV@@F
M(U`R@&$>T?`!`.WIXB(:T;JZFT:(6#E515Y=7Y9IMVDN'DG',6Y%%;B+!TW<
M"F`B<0H01J`4`/>][QU'VDUV)'?E>D84^OT6GMLVX%[_`/L`68C3XYUR]BC1
M9MY9E2B(@*?=MMM2NVIV&1I;GF%TT$C2VE<<4AJ_ICK89]JS#)%ZN5R-*0I@
M_2][Q+3P]NJ>HG`*TFBO&[518#%2H8Y-^SH8U?WM:!M\^L;B!B[!62/;'C(:
M*W6:.$#`4Z2A:]*D$!'Y:>&KF2-?D0KF2,?]I"H%$Q0JH`D^</JU75C0*XU!
MHI8P0NH?.>$$C&J4N7L:T^4/UTA:5^;62)HUU62$#J`KNX6__$,)_@B-_N-'
M6RMI*^B(:(AHB&B(:(AHBH#J;Y3`/[&K!Z2=7$X*C0<3P7(/]>6$&<]83FND
MS33=2),B1"R21UDDB@F2%;>9W>8(%$*%]M=<[NTKK2@E](>2!QJ33#"OQHN/
MWN^%DW4]SFL<2,`<2:<N6"U>_P`ETK<-OOKF-,QC(C-THQ9PB:7Q"KMP@6JP
M%,00\HJ?;41'81\=<PWN>TL+D6TH_P`CB*U'`X+A?_;[';MQCV^6.5\LI;ZM
M1H-1H":GAQ4-GMV0(!#O(YT@110]%13,"2O88*F*<?=$*>%:AKJ(]SCZ3XK)
M["7"A'$CA2J[=^Z11ES8I8I#E04J/@LA7T8G'6@A($O.WD%TVJ(#;*!Q,Z=(
MF)3N<4K10"^`AKS^-TK]S,4EO*7%U-6``/#(^U>=6[S)O3A)92G4Z@?44!)P
M_JRKBHE01<&?MC]R8-C)]Z"YJB5)-:I^RM.@J!0`\-=0)&1QF&0@2C,>*["2
M6..-UNYP$PS%>2<T$X4:SK91PCYC<BE78*@!1$@;`!#")1`HAO7?4->O:;)P
M:?\`,0=)7-;@6?\`7O:/]QKIIS4SW'?<#&-40BET?-$O:>,6(/E@B<@4$AR%
M$QU3'&@``5UQ>V=O;Q?RD78<16H=4?4C!<!L?;&]WMT9[WJ")I+@\.;SRQ(P
MYI-MNRV%[,1DDGJL:<QS.7C&AA45\DU0!5)4R0B0H]`H-=2&Z[E+V\!:R.87
MTH*FOMJT$>\J1WON23MZ\$+&-G+1F<?>14?%2C<5QV<VMF+@@M%@2?:+"@TE
MR,S-4G"!41%0OF*%`IC@;?;<1UR]E9[W=7+KT7!_$S(K7"M5QVSV/<-QO4VY
MRW)=MCAJT!U16N7Q6-Q++?L94\A).I8JDHX%=-D1LN4IDQ,'EID4.44:4Z?)
MKT4[]:W=LR)C&'IMTN<"VM?'&J]:?W'976V-@M1%_A;I=1PJ.=0$Y%IBX(T\
MC#-I5_$&/0R;$Z(I*^2*0]Q#K=AA-YA`&@@(!OK1CM=M=*VZ=&:5S.+?:*U^
M!47':;5*^'<8+=SS7[J@CQ-"['CP4AXOY$1N,K9G;:O6/<2ZZQ/-A5B*).52
M*J"(>6J/E5(`$'VUU$=V_MU?[_=PWFSO$5MAK(H/YKE>^?VGW#NG>;;=.W;E
MUM`*=0"@;A[TU4LL0<XBK)-K<,"X.126:D$@K=BIA]\P=I14-[VXZR,[2O+*
M9EM-,7,#?N)P-!XG!2K^P]SM2RRFOG'TX5-&NTBOD,E8W*A#O623B-CPBY5X
M4Q4P>`H`+U*)C)%.(]J0B'CMK9VMU_'>FTF+76HY$$^U9NWIMPANG07#V/M(
MLZ4J?JL5;B:2+=Z<'93(A4Q2@*ISD*'<(4+WB(!3P^37K5G<V\L;8F-JYK0W
M#.H"]NL)[>6%IB`-6@T&>7O2*@S6=K`W;F^(-VAV@(U[0#J'=^;PUN3`P-#C
M@'*2FE:UH(!'-$.V'P_F`L'8L`&[DPK[I@#YM_;K''-K>`W$5"LCG+W!K<17
M-9`<+0_RP>+/R<A,0B'T7U"C^R&I*H6\,0:<OJ%W2&NS9N'_`(E/^P#1;#/L
M"/T5Z&B+YJOQ9)1'T;<MB'AE'#U?INHNJ%5UAH(/%<H%%(ZE*@)0IT'8?R:C
M7D`^*BYK@!R/*B(U`HB%!W[A'K\E*ZLK56?DTYHLQ>I1W\!T!XJFK5ZN:NR)
M)%(6M=]@IN(C0/V]5UEIKS5>ITP?%716M2"H0H@!-QVWV\0I4-M6&>HIBHV2
M>K])XHM5O7L!(1'N]X0,(![P^/70#!9(GU.(2>("`B`A00&@A_J5UE&2W42<
MP&[:5V.!A^8*ZN"N9FC$'!JF+40`HC4?]:'AMT#5CX@<5:^`.=J'%7Y7RA2B
M`*"`!2E/=V^7]]K7?;MPJ%KRV^+>>*M5'8'4,0P@(G*)A/7VA[*:VHH*,J.`
M6]#`&LKR"3CD`YS`4W3VT#\_761IH,<E<"B#%[3"'6GL^:NKP:XJJ,1_2'YO
MSAK)'Q\E:_(>:5F("*@@F;W_`&4W#I36E<?1:^X4TXY*3&\E$)1ADI4R15RE
M$"J&(!U.[?MJ;K37.S1WSKQIM:]&N*XZ>#=GW8-MJZ-5&#H4%7*JA%RJI"80
M)0*!2M0#Y!#73G!K0?NTA=I`'MB:)/OIBI&P24G\N^$S%,(B&7\:A2@>-Z0O
MR[:RPDZZ+;A/KHN[A;_\0PG^"(W^XT=;2VDKZ(AHB&B(:(AHB&B(LW=7;Y?K
MH%-*M!&K/@J>K6W^RAJN3!ZXT5CB7]57FTVG7CR!O1+)D8:'E43G*U<E-`M0
M!%T1(:]IC`&^O,NZ+ON"QW,/MHQ)MY)UU_I;A1S?'R7CG=VX=T;?OU=MB;-L
M[R0\859E5PPX_1:E(6WYS[Y0@VLD2-:N5P.,FN4Y6#AZ!@`46XG$*"X((=PC
MMXZ@=TFL&6HW%T;IIJ4P&(SQ]BYG>;_;/PG;S/"Z29@+2`,1AF>5%YE&86MY
MRO92;(@OD"$=#]LD\9KJ*%`*L%TP'M*':(F`1#KK+VGM[[PQ[DZ0AKG4(\,Q
M57=D[;'O#(MZBD<+=YH6DXBG/WJ*K91:JQ#\DHV3++JN>YD\5-[Q""-!:@D(
M"02&/M41V#74[H_HWK66H+HP1JI\5V>\7!M+UL5J"Z$4U4\,_@I+\B>CK/1M
M]=O;X$5?`_,]*H@J[(@)1.1N4Y![B)E#P]NN=;-8W&YOTB3C_&:YD7FW7&Z/
M+1(</CQXI%C')G3I3XY!%PT3&E2E[5"!2A2D,7=0I:4"NERR.*/3#J#?%9+T
M,BM0(:@5-/:<596]<<3:E_0US7!$)S,=&O3+J,ETR^0N0G;V%'N$2B)*5`/'
M6:YL+S=-DEL;"0Q7#V_<#0@<<LEDNMKW+=^VIMOVF4P7LC11]<N?O4D9"S[!
M73=C>8L^`_5U,Z)$%FB"!2BZ$J@',9)%&M.X``NN?[;[`GM-O?9=P7!G+B2)
M'$G3[URG:O[8[WM>S2VW<%V+F1Q-)'$X>%34IH7Q<%U7*M'&9-Y9Y',"`]73
M;QRM&3@:"I[P!M4H:G]AVC9=NMGVTTPUO)`K[>:Z+MG:]JVFQDL+CI1RO<0-
M3L3X^WDI+4Y"/'MCM[>EK;*M+0R()1<P`-R*#0?LBN"F#N*9,WMWUR+^P&6^
M\_F6=R6V3S5S03G7/QPP7(,_:**#??\`MK2[='MLQ.M@<=)<36HQXC#)1A'7
M$:1>N)NY7!G4@JJD0Z10`P%2``*)2B``6A"_10-=/=V3HFBWL/5A[UUFZ[5)
M;1C:]H),;175Y8_-/2^L9VO,6FK/PQ^YTL`+IJD6)W%.4O=Y2A.ZA2_+J`V'
MNS>8-X_Z^\8>@'4H?FH/M/O/?;?>1M&YQ$6H=34>2@2Q7:,%*.$Y`@@DZ;'3
M7\U01$BARF\M9,PTH=-0`$0^C7HO<D0W"!DEL,@":?%>E]U6[=UMFOLQ5L9P
M\LC53!+W))SD6QA7+AD5`H]J`E0[':B*)1.FHJOVU$1(&U*ZY.QVRULY3.S"
M8+B[#9;2SF-PS_=Q"8=L)0][W@SM%VN=%L]/\&D_>$[FZ"@`!1.H($[]_#??
MQ'4[NDU[V]MSMYM35U`X@9^K]%TFY7=]VSL,N^08S-QH#C0I?NG"Z%ORSYE$
MR914C5#%^(15(9+L3&HF,2A3%,:F]1';43MG?CMPMFR7D9#I,J\5$[-^Y'_:
M;;%<7L;A)-7`^"C:3LPTH`G+/Q?Q:8B`IK)F04J```CWE[DS5'Q&@:ZVQW:-
MC:Z'>K@NQL-^AA;J=&[2[A^BDWB/!+17,7BPD=^R>"'(7$0"9JJ50I1_7B&V
MJ4`$1V]FNALKV*?[V.#/$+L-JW"*\(HQS?,47<D;?VNA_N*?]@&I+T_T?9P4
MN\4<1XH_16H:(OFP_%AC3T<,M[`/_2AAWJ%?_BHNK7_:5@GX+E'&<`)`$I2@
M<@``4`*#0`#</'45)]_M4)HU2XY*U\\_7W0^8-*++T&>*.(B53M$:]QZ"._B
M/L`-7/`:RHSHJO)C`#<J)VQT:R[D1='\LHC7O,/NATV$!_?;:BKJ6YT_X@"H
M>[N;JG^.E`,<$_FL2S4*(HHIF:TH-=S&&G7N]@CX:Y^3=;J!U'TU5Y+E+K>9
MHI"P@:_))$Q:"*J82#8G<5,1`Z)3B!2;;&[0\*ZW8-ZDD-'$>Y;VW;_*^;I3
MTQ(X449R4>JS<=IB@F0X`8"]*5*`B/TCKH[:7K0-DSK7X%=IUV/QC^TC!)'8
M4?\`5UL+:II9J&=5YY(`!NTP%$U?$`'Z=M7!Q"R!SJ#%%^4H3]+N,!A$`'>@
MB4!$0*/]=M[-5)+D)+LT6<`#N,/:!BA2HB%=PJ4`&OL'507C#'254%X%!6B*
M(3N'<>VO01V[OF]NKB:(<%>D:@)0$0[NN_MW'Y!UA+S7!87.(*,!L!=Z=H>(
M^-/DV#?1LCJX%6ZCQ1Z2K=`:H@H"O[\W0?J'P#1WJ^[%4?\`Y/OH0K9R<[I0
M3F4,-?`35I]'AJK-,8HT`+.T!GVBB(*W$H4`U-Z[;?L!JXOJ<5:]YKBI6P0C
MVYTPF:H#_P!+^,_RWK"?)K)"XEX"R0/)D`7=KM[^(87_``3&_P!PH:VUO)8T
M1#1$-$0T1#1$-$174QMQ*-:=:U#;<`IMJCV%Q:1P5/2QU222>"Y*'KHV_:<C
MZKO-Q])OI!"82R/&D9-FC?S!5-]Q-!(`%+4X^]^SKSO?[_<AN+;<8VE3J+LF
M@\1_`7D7<&\;RS>3;Q,:S;B3J/(8#+^*U6F^9>S"'E@+1TX?QB8G1*]*NB!F
MI?>*H1`:=JQ`$`K36I96MM(\Q.F9%8/!Q;A4\O&I6+;K>PF>8;B2)E@\'$4Q
M<>'(U1[9\K>,<<7Z+:,>I(&(7L14^)54I]FHJY6#N2)W!O36OT8MCG`MGET3
MSE7!M/#+%:0AC[=N!%:/<ZV>ZF>&'@$RET7\:B<JZC8PIF$4GB"A71.X`IY1
MS@(T,4=Z:Z(!LCFRQNTEV=,*U71AL,\C96DT<<>!H<_@J(R07ES?=1'":KE0
MG8@`_8I'4[@-V&5$WN`?5)K>';R;D`>)HLLMCMVW2/O'AYCX)_Q<+,PYBLI0
M46+QV<HI"N>B2274H`<PT$@E\=<]?7D5\_K0"L1PRIB,UR=_?6=TXR6P+HAP
M*OKBC&2<2E'J.6[Z4!<JXG;I%\INF>IBE$U.XYP#J.M:RO)X;DD:A!I(I7#@
ML&W[I=LN"QK"RT`/F3@FVW+'1YR2"S0BH@F8H]M$"-C#VD*NFH!>I3^'4!U+
MEK[N,QEQ##F%-$W%["82YW2)Q;7#W)2ALG7#$-'3-M(.O+,<RB?PBC2BB9RC
M1-[YPB<R8E`:!U]FM2X[8LKB42=)FH#BU:FY]D;3?SMNKIC))&@4+A4@CB$R
M!N@4W[IVZ9G7.Y5$RS;M$B)3'W`2["(E&O4WB.I<;.V2U`8X-#,*#/\`DIG_
M`*@R6K+:V?2-H]QRP]BD!FA#W&Q6317&'6623`Y#'2`Q#FI7L55$O=WB%``?
M;KG9)KO:KD34<]C.5<12GUJN;?<;AL=\T21/FMP2#IS(_P":%.^V<?BA$OF[
MR^XQJT\DRR;!\NJ194H!L4`\WMJ(B&P!]&H6^WZ">\9-!9R=5IQ<&_4!0.Z]
MRQ7%\V6VV^?6#C08?+%1TWB8<TV2+>G8*.#*&3;KB8Z:7:D(@`&54-Y8F4I7
MY==4_<KMEG^6R-QA+02WCCX+KF7UZ+3\VU:X6^FKF\17@1X$J2[C@C-;=*NW
M4:$=1!3.`4.=$P*)IG``2("0]YT^W:FN9VF::ZW%QD8X1..(7+;/>7-QO)_*
M:YML3Y*(HZZ8IS($D$[?9Q<PW4*JB[9'6(T56#M#N72`QA1[Q"HTZ#X:[:ZV
MVXFC_$DD!LY!4@Y^0/(+O=SV:YD8ZVEEU;?**Z3F&G$"M>"G&WHE[<K!V^52
M44>O'!P?.DBK?">6('.!_B%.HD"NVN"W"6VVJ\BL*,+&5Z>5<Q6O]W"G)>5[
MI<6FV7\.W0F,,83TQ05X5KSQRY+'N79A*/UXRWVZQ5TUU$E3J!VE[RG,0:*A
M413$0KOKT2PN7P1QR78CTU!`#1YXKU7:YY+.*.[W'INC;1PH!B,\E-/#2QW@
M<O\`B\83"NJAR$Q*=<$SHI$3`E[1`G-]K0RHEIT#?4XS?8I9>FUL8%.`"ZFV
M[HAO)=,$;6,(PH`*^Y=OMH/<U;&'>J"0U#H/V9=P^0=3C7!S0X9%=.UQ<T..
M!*N-55R&B+YKOQ8O^AORW_UH8=_QK)JQ[@!0YE89N"Y07<!2@4>I@V^K4:YI
M+JC)1G2?JKP5/<8.G]7Y--)6325?LCE36(=0*E$`J'M\=72#4V@SHL,K"[`*
MX$P`<!$W=[XFJ`U$0&FPAMK6T2-!`IB%A9`:%KJ`$?\`*<,3<3QD?R2@*C<=
MA$0IV5IN&^]*ZCY]KBG!<_\`V4/O43=[!;W+NH[[PG*M<R14#)IG4$I@$3@*
M8AN/6F^^H^+99&XOI7S48.W)VRB1H;3S5C:$`7)5\VK9#6<@[8/=EP1D-^L]
MW.BQ=LP)7BWE+RD[(B591K%QR7VJG841$*T`1H&NBLXNC"(CFW]5U-I;OC8&
M&E0.:VP\]O3PXG\4."W%WD)ASDE<7(C(F?\`)^0[37N!C;9[9Q0YA\<H(L[F
M=6.U?H$FY>-:7$J5NE(.!(5R6HE(`:WBPZ=5*-4JYAZ=>%?I1:KN.>`<C\I<
M\XIX[8H8(260\PWM$63;#9P;R62#R4<@1:2DENTX-HJ*:`=RX4$/=13,/AK(
MV$$!U5>R&H#JK?Y8?IE^EOF_*^5^`>$N0?(:ZN;^,K%R3)QN;'<%;A.,V0<F
M8C@WTM>5D04*F*MSM+<\Z-<-&LFJ8/,%/O[>T0#5)`Z,#+2K^F:4J*>2:/HF
M^DAB_FL]?Y+Y!R$I9]HXSR',-72>05&-M8&RO;5LPZZ%T6JTOM.8:7`UO"`G
M%4G*A4$?A"M2>^H41IK&]Q::-_FK3&0*@TI_&:U5^HEQ[QIQ<Y/7;A'&SS(;
MTMF(HI7<OD"VFMLIGN=ZY>/3FL5JV>/3/L>*Q:S<T4\44%1TA]H(;ZIJ);4K
M":Z:E81`^42HF!0$I:>RM.OL^75G3U8U5A97%5?&@I4OEB&PC7NK\G[T/;IH
M+<5:8_%$`:INWIM6NE,*IT_%>F(<`]GR]?SZN&GG@KXR'FF2-2`0+N-1K[*>
MS5KJ5PR5LS=#Z5K@I8P<!29QPA0W<)\O8S&E*4I>D(/M&NLD'^P*ZV_VA=V2
MW_XAA?EB(W^XD`_-K=4@E?1$-$0T1#1$-$0T1%#N81I2@B4!^2G7Y>NJ:7`Z
MJ^FF2M>&AS32KBN0?Z\,P\AO6,YIKME'*JA<C1'DF`Q@124-!M>P3"0!K00]
MFH+N&RLMR@=K&EI%'#B<.:YCNO;+.^A<):!FG$#,B@X_R6`T9<$RN<TN0(Q>
M7>,5XUVM)HE<(@15`I$Q**GNIJ@`>Z(%KMKR&YL[&-S;1HD;;L>'"CN(-:Y?
M!>%7>VVFH0GJLV]D@<"#Q!\DA+VK(MH)*0!1LJNY<G;I%*N1,@B8]%O,3/V'
M$@5V';6PS<;6:]?')JHT`XC//);K-TLI[Y\1+A%&`0",<2<DWPM)Y$R!$#,&
M;@KU$QG*2:@';%*("83U$3E*J7J&_74J=T;*W[^F6TI7CR'!3#MX9.SU2=(M
MR)Q/AR5=NXVB/OQ9X^.J2.2(H\*V;F+YKA5(O>5$IQZ%[@WH%=;4^^ODM>@Y
MA+R"*U_DL6Z=W3_AML8*23.].LBE*X5IC\TRKFG)-Q+]P)@+!0X%0;*B<Z[=
M,GN#0PC4`*(?-J1V>U@;M[87@$@NQ\2:KJ=DV^R9MC!.-5WB2X85J<,$TUKL
MDF[@R%3+N$#"5)<M%%5$P'W2&H7WP`.NI/\`ZB)WJ%**5&QQ2BN`8!7+ZK)S
MBSAK(_+?.F+N.>/HQN-VY;NUC;<<9ZF9)A&IN0$\C/RBA0[T8J&C2+.7!M@*
M1.M=:$ED\G3:O!?Y*,=MCW2B*UD&NO);!>3.$/2%P_;>1L.8GR'RQR=R5Q\5
M_`P6:D(ZUV&`;VR3!O`93<6PMQQ_?]"SRO4EDD78'%53L[J"`ZSC<H(+<ND<
M'$#&C:'YE2DN[;;%:.#FN+PW$_7FL',+XFL:YY2+0R//,[=AGT[&,9ZY!;C)
MEM^!</$DI*6;1:9BK.EV34YCHI*4$QBTJ&O.MU[HO8;]K;-KS;`5)H<^5?)>
M/[UWC=V>Z16VWB06IS=0X&I]^"W&Q?IR^F#RKM/-V.^$F9^31N1V"L.7-G)A
M<&6XB":8GS-!6`U*[NZ.C(^/`\G:+D&P]S55P:@@';N.N[V7>]MW&T,#FZ+T
MMHTNQH0*GEP7J';F\66\V\MH\@WH9Z7$4J>/'##%*?HL^F/AGG/`7'DK,+MY
M:[*V5;]MA)CDY-""PA<BKJSW`VZZMZ\V\FWN!W?UE3`A(OF0IB@+1(#":E=9
M=I;9MNI(7RQ=0<-/'CQ]W@KMJVR&2>2/JL+_`!(K7CQRY+5+SDX[6CQ0Y$7#
M@9BUOJXK>MIC#B>\,@P;"V9Z;E7<:1ZYN&W&,6Z>MG5BRRH]\2X%3O5:G(80
M`1UCNI)H3*Z%[7.:X@-I0.%:9U-/<5HWHGM73-L)F]9AH8R/2_&A]5<.>1JL
M.GL+,*`61BW;Y]$MTU##'+*%5513H-"FW`PE$O3V:P6M[9M>(KAG3N#QX*EI
M=[=-%TKL,CO*YU^J0[6?)23U1I]W*E43.(JIH)&[2E*-3&5$*UI3<=9]VC?`
M&RAX$1;ABMC>V3PPQR/E'1T``U\%E$PNIS'V8K;D*=%()(#@Z%1,?/%%0H@<
MK<!W-W4H-*:\KEVA]SO3=PO'!T;#Z:&OG5>*7';[;WN!FXW;ZQQNJVAYYZA[
M/:L?&S1V1T[%K%R+20*94?.$]$S@41'S11'H8>NO2KFYM9(8V->,`./)>L3/
MM'V\<0E#J4_C/`+('BM!7`GROXM/A:/D5!Y#8@.<P(F$BI!O:($5>X/=$H#U
M]FKMEN[%]Y^.Y["XU`%<1_-;?;VY6,>X?CM?&9:&@)&:[7K.OPC6O7X=&OS^
M66OY=>E:0WTC(+UPU.)S5SHB&B+YK?Q8H&'T;\N4*(TR=AX=O#_E63KK!+][
M>2P2_<T<%R?C"(@4P["4`"GS]:ZU5K+PO>>H@!=OZO;HBK[5"^]7IOUV^K5%
M@.95::Q]_P!$>GA\_L$-6.17:2S@Q3^64P@!3=XA^@`=HU'I4*!\NJ(K,5#[
M>\.XT'Z=`B=UJV!?.1GSJ%L"R;LON918G<FA[-MJ5N:33;F.*0NE6$,S>."M
MP4,`"J8ONF``UDB/J'*O\?\`"R1$ZQRJM^GKB8MR5A3''I@\6%['O1C:6!.&
M=BO9.3=6S--((<K9NDG=XS5NA*'9_=BEQHBNDB=N*GQ`'#M,!:#K;=C'3F?Y
MK=?713F?YJ^]"C`F2L)>I_>ED9:QM<-C9[LOA?R3O/%V,[PCRQEVR^0)C#S]
MW8WW*P56*JK+R,>_^(8$(/G*5`2%KK(PM#!B**]A;I&."M/26QU?W#N&YQ>I
M1R9M&[,:6[B3`&5\58I<Y`C9.U)S(O)G-+9Q:\=;5JLIQ%K(7`\@TG+IW(J)
M%.5`"AW#41UAF(=0-*NJ#E1:2\5<ELXX?:WJTL.^I:*9W[9-X6-<+!9T9ZQ)
M;M_&3-=Z$0Q>*J,XJ1G/+*59T@0KCL`0[O;C?IKY+&][:$5%5"4U-S<^^,_G
MYN7GI/RV[49*:D7<H_.U9H%1:M1>/E7#DS=HV2*FB3N$I"@!2@`;:K4.QPR6
M(->[)OL`4NVU@.X+I@HVX6][8HC49)$%B,)W($1$RC<#*'3`KZ.6JLU.42U[
M1W[:#I5HP!P5I`::'#V+)9#@_82D,61'F1QW;R'W(W=KPRDXZ5=DG52G%:"1
M632\@Z;;L"KFOEF$VJ:M685!ZL*'V*!9+C?<L,S?2IK[PY*-XU)1=1&/R3$K
MO7J3<1-1BS3\M595<OZ*85,/LT(&D_HJ.H`0<\5%!85RX2%0K,QR@.Y2@8##
M\N_B'LU#?FQ,-'/:#YA0<5VQAH7@>U(RK!P!S%1;N2B38Q5$S"`"`[CW=M*:
MW8YXW-!+FX^*WC=0NIJ>VOF%(6#$'!,YX3,H2A2Y?QIX"%*WI"AM4`\=;D#F
M%XTD%;EM)$90&.!*[M-O_P`0PG^"(W^XD=;JD$KZ(AHB&B(:(AHB&B*@?D"N
M_P"U^;1KM51R5:`D$\%R2/7"-:S'U>>9KM8IY&X7.2HNC58I1C6/EPK0?M41
MW4V$/DUYEW+)N;W%D7H@:YQU<3E@%Y-WR[=)W/@@JRV94Z@*%PPJ/9@M3%PA
M)-YDD^5!,[3XY$[ELS.#9J84P+VD%,P]HB)0&@A[=1&T2VT\+X+@:I=#@#F0
M2#CAR.*Y?:9H-PVIVT/!_(##1^9&!Q]B<=Q7T2\",8>$@_NL>Y(J!W%%!.):
M%6(*@``%[C!U'KK0L>WAM!?>W\_5!:*5PI3/WJ$V_MD;%U-QO[DSQEH'#TTX
M_%79H8]NM'"LU(&9E!N=Q((U`YO*,40)Y%=P$0V`0VWUK/N8-TG;'91ESFN'
MVXC/W+%%<C=KIC;""25C9!BT$MP(S(%*>:B>4D/)0;KPTX==)4%5&Y`[@["]
MP]R*HEW[Z#N.NQL[`.>6S,+37BO0;+;;*YNGLW&+I@>%/*E4PG$H]EE.YT=-
M0R`>48"B5&H"`T)WCVU^NNIR.V;"X,CJ6+H8MNAM\;4.$/"J7<;P$8_NQ`CQ
MR=,C5`RYSD2*Y*4Z0D$QDTAJ*I:=0"HZU>Y+BXM-I,D`/5=(UN'C5:G=.XWE
MILI%JUW5=(T5`/$%;W?0RR)8MI>J]QAD+C+&1\3+O<@6C$2$DJ@UBW%SW/9$
MO#VT@^!P*::",E+*)('*<2@)34`:CJ#[8L[MD_7N9VU.8)&'AFN4[/@OXKOK
MW4PZA(.EQRS\?$+9%B*Z,[<DEO4FP!Z@W%?%F+.+V!L(9LN1"^V7'B)Q"I@_
M+=O2KDV+C61?1$6;J6D;P<B0#$*LY,Z(KW``]U==E#`71D.A;7Q'T7H<$;71
MD21,#L<U\P;#`^>VELX0NJ1Q-E=S!<CY`\%@F7)"K!"9:F&TDC$+,K,5$YQF
M'?WDN"9JE+VF^74!?[5.03"R)D7&H^/DN=W+899VN,#(8P/[LP?TX+?S?6)L
MK^E?Q>O?`V.\,95O;GCRKQ_%,.2>0X#'UUW!87%O`LB8)@,1P-Q,(]9E)9"N
MIN`#.N$E3MVB%4JUKK'96$D=L\M8WK`4].)KD<,<5CAV&:QVESFTZTE=6C%S
M:G'*M#EGP6EK%7*W,6!)5%QC:3?1)48:Y[>!1N=:3MMNRO*%-`7(*<`^5".;
M2SN)<&2.Z!/SNI0';7)Q;6;2:2Y$[1<$_82*^[/P7GT>P.M9)+@7Q$Y-=)<`
M[CPSHHXNX$'Y&<HYO.2NR3DF+1MY<R_>2[I@W:H@1I'"YDG#APDV8DH1%,#=
MB92@4H``:TK:^W*YG=^7&^%D9(U$$`CF.!JM2TW?=+J1\5S&611.IJ.&H`T!
M'.J0X:WK.38/T[EN5[;K]1,XD513*X*8XD]U$Z7<02D4Z!K)<W>[.OXQ9PBX
MCPRS]]<UL7FY[K<;A$[:[,W$#::J#B.2C2SV#MI>BK2(?B"+L%TSG.W[`<->
MXP$$X&[NSS2TKOM773[Q+"[9#+=59,P8MXM=Q!\LEV>^3P3=OFXN1TYFC%M?
ML/%OL3QN@LLSD`:F3,Q6*4"HKE,'EI!4!!0IB``=IAZAKG]E;ML]IU7NU:BN
M2[?-A+:E[W!['D5/E5-]2YY5,JC:5*/Q#>H&<[D$Z0%#L$#@/Z)PZB.I`;3#
M+,UULXD$X#/V*7;LML^0#;7ES'FG/,T68'$2\9N7Y'<7&B:2?P_\O^)4T'(B
M42I-0O*(!4._KOT#Y]:%ELEG;[_U9)"+JOV^*B-I[;VJQ[G$UQ.X3@XBO&J[
M-+3^U6W0?X.CN`U`?LR[@/CKW%E=`U9T"^E&Z=(TXMI@KC5RJAHB^;?\5VY,
MU]'++JH$[@')V'2&V[@`#78GN(4'H.L4L9D;AF%JW,1D``7*-5<)N#&'R$-R
MA0"`(&,(4WK38?'47H>V3,TJH=K)&2#$TJK!8#%[:[`-:%`!]T`IU&F^LZV\
M5Z0Y`(;N,%1+L'4:_-N-=,5@<QY=455L94""(@6H&'V#X?1\N@:5FCA<\8C$
M(`Z,&P`)0'8:=P;#\P::"<%D_&=R^*\\TOM'_O3?M:ITG*OX[OX*FO!O);/'
M&2YWM[<?<KWCB*[9*+/"/[BLI^:+EG,2HIYQX]1P"9ZMC*^\/0:ZO:VF!S5X
M;H&D\%)&9>>_,[D1;D39^=.366LJ6O"7&WNR)A+QN1W*QT;<C$:,9QNBIVG^
M-;%_0&M"#6@:R5:,EDU-&2CF7Y.<B)K,K+D7)YGR2\SK%N8UW&98&Y9)*]V"
MD*Q3C8@&<\D<CM%!BP3!%-,!`@)!V4I75`1]M!14!!PX)V\B>;'+;ET,*7DA
MG_)N7FMLF45@8N\9]=U"Q;A4A$E'C*%0%O&)2"Z:0`HX\H53>T=5JUGM6:,4
M!HL;(\A$SB+@#"G7P((%`H4K4=RT^76-Y!-0M"Z)!);]R*<@@HL<40H`5$M!
M+0.N^VJ`D99+);27/GBK8B!3FH<A3GJ%3>X/=[-A((B--9-9`H,EG>^34=1Q
M5T5FG4/-;T+_`+D0*C[*@F&L;Y90*M.*Q/DE#:LKJ2JS1:D43/\`"E,F01$Y
M3$((&$.E*I[4'6I))<$>)4;/)<FHQQ3^:WH9HD*:;1(Q0H;WD]Q$-Z:@CLSR
M:N.*Y6Z[:C?/_O?[_P"2;SV[7[XYSIIHMBB(E,1-(I1-3>NX=1K^34C!M[8&
MZ"23FIB#9HK8!@>Y^%:GQ_X3LPP[.OG3")C`0.[+^,]B4#]&](4:B'RTU-6T
M.EP=R4[8VAA>'G+%=UJ`"D'#![(J-#ZF2&MY2Z5]$0T1#1$-$0T1#1%2'4WS
M_F#5C/N=YJIX>2Y#_KHH&7]8WFN+9JH[.CD"..IV@8"I@$"SJ(F`H]=<7W%+
M''&#*0&EQ'GDO/\`NTMUALCJ,)=ASP;@M2MTH*?_`#YYU!`A2%6"+*HJ93N+
M2O>00IM3QZZA-EFCB=2.`NU8:J88X+FMD=`9-$%N1J--5.!P*NK?N:V(V"5D
M70/!N%N\3%I[W8P,Q'9<YF^XG.`A4*=-8]QVK<+F4V@'_CN&'GR5NX[/N<US
M-8Q-:;)[``>-:E'&=S^49HD1"H$<)_"BNLJB<R:9&N_O.A,82IIT"M!^?2TV
MR'MN(RRX2DT`YE66NTVO:-B);DN;,]U`.;CD/>K)];X14:I44%G$<Z^#*FW4
M*H`B83`?8/8<-Q\=98[^:ZD`-6-\<%8W<)[N[T258UPQKA2B;DA&M%T*BB@@
MX3*/<7N$@F6V]XU*`:GUZEK5UPPT#M3>?T]BFK>:]CN!$QQ?#08_-1RW>*Q;
MLZ[)PNV73,)2.FJYR*@!OTA*(".PTZ=!U-:!<1AEP-49QH1Q"ZYT3)[4,G:'
M8C`^U+,;<EV'D&;N.G)-F_CWK219R;-\NQ>QKUFL"[=\S<MS)K(.D50`Y%"B
M!B&#;50VQM1J=&%JMM=OV_\`S&.A\LUE]F7GOSJY&V'&8KS9R:S1DS&T,*"2
M-IW'<;MW"O19$+\&M<94/)-<*S8Q?LSO16,``%*"&AOV::C.G-93?6E*C3[U
M&I.17)!"-P];Z&;,@&A./,DM.X/ARS;L6&*Y1R[2?NW]H)"()Q+I=\@501*`
M[ZUY+IEPW06U!'-8I+F&=FA@K@LN7?JT^I+<3)PQD.;6?7;:18NHZ315NQ0$
MGK9V@H@]9.S`F558KE%0Y3"8P^Z80#KK2#WVITLP)4$9;JW>Z,BC'89XGWK#
MUG=3E..49J#V&<&5<G45("AUW!C"95<5#%`QU5E#")Q\1URMQM=Q/>?D@'-<
MA<['<W%[^70D)(^+649*NOM!7[@/WJ>Z@`=X"4"TW*81^C?6[';NGD_&/W'#
MW#^2W&6C))Q:!G^0U%?(8_)*RL\RDFJ/Q+!`%D4R%<F5`YR+`0O4IZ"`*%ZA
MOK3;926MUQ%"M)FW3V5W1A(%>&'P3XL=2UFB+Z5?/W!7"A/[W*-DC@4AR[?#
M.`.3N3$P=!&@#3;4#W%_V%U*+9C:CQX^.>*YKN,[S),+.U;5N-=1&->.>*D*
MWOU>>N%74VY;O.AVY'U4Z4[NT#=Q:&$X#M\VN<W.XWAD<=I'&6A@(P`&=.7D
MN*W5^[6,8@LXG!Y^Z@3>NN)AW:RZ[,I%DE!,8Z)4]P2`-T_T:]M`VUM;5=7=
MJUHN"YKLAG@>>*GMDW&^M+2-DU6/<1B>"=?%J1,ARLXNL6$2X*F7D+B&HDJ/
M:7]=X@*&2+N`#[*:]"V:T9^4VXF<"]V-3F?)>D=O[:YU^V\FGC)?E6AQ7:A9
M#5FU&@E^P2V$*"%"%#IM3IKU/3H&D<%[?IT^FH-!FKK1$-$6`'J7\`+#]3'B
MK<W%3(][W/CVV+FN.U+C7N:T6\>[FFKFU9,))L@DWDRF9*(N3AVG[P&@=-]7
M-=0$<T7S8$_!3\-B4IRXY%"`=*V_951^79']C6%T;7&OZ+`Z!KC7Z#]%6/X*
MKAL/7EMR)'Y[?LP?_H=6]%O\`*GX[>?P'Z*G^A3<,ZU_G:\BJ_X!LS]CR=5Z
M?"N'D%E$;0*4^2I-^"EX:&I_E;<B@I_^G[+']E'3I#P]P50T#*BH_H4?#7_.
MWY%?\W[*_P!YU41@&N'N"K1>?T*+AK_G<<B?^;UE?[SJ^@554'X*/AJ'_P#;
M?D3_`,WK*_WG5AC!-?H/T6-T8)K]`A_0I.&O^=OR)_YO65_O.J=(<_@/T5.D
M.?P"K#\%#PS$`'^=QR+W_P"(K&#\@HU#5X8VE*#W*\,;3(>Y#^A0<,O\[?D5
M_P"PK&_WG30SD/<JAK1D`JQ_!3<,A*"8\M^1H@`=H?WALCMW_P#(=M-4T,K6
M@5IC83J(%47_`$*#A@'3EOR)#_\``;%#Y?\`P/LU=I:>`5XPQ"]#\%#PQ`:A
MRXY$@(_\16+41#_R/75-#>05"UKC5P!*J_H4?#0:A_.ZY&#3J'W)8PT\=_LM
MMM-#.0]R!H&0`7O]"DX:T[0Y=\C:>S[DL>GU>5IH;R"H6,)J0"?)>?T*3AH'
M7EUR,`/'^\EC=/\`S6FAG(>Y4,49-2UM?(+S^A1\,QV_G=<BA\?XCL41I_YF
MM-4Z;,Z!.FRM:!."S_P8O#NRKOM*\V'+#D`Z?6A=%OW0S:O(&R/A7+BWY=G+
M)MEQ32!4J*YV@$,)1`P`.V^K\LE>OLB8MR,V;5F0XG*T;(-P,82]YBMTBHE.
M8"[`)@)O3:NB*ZJ%:5"M*TJ%:=*TZTKHB%0#J(?7[.OU:(O=$0T1#1$-$10B
M(";V;]``?`-4+:-);]ROH"/%?,_S`_#.<<N8?(W,G(VY>0F7[)N;,LTWFIN*
MMF,MA9A'+HLP9`BQ6?)&=F2.F2OOCL(;:YN\V.+=)6F\QZ;M3:CB?G[5Q^X]
MK/W6[%Q?2:V,-684H>.5*^16%TA^"_X:20$$W++D8FXH)5'(1UH+"L41J("4
MZ?92@^&I*VV]]KA$YG3Y:6_HIVTV[\6,,:YND<FM'T26/X*?AQV@4>7O(X2T
M[0*:%L<0H/4H`*(TKJ1#&5!H*C);3H6&FD-!'@$X;>_!G<1K:0DDXKE[R+0-
M*MRM7"Z4/91%!;EJ(I@*:7;00J%=A#6G>[;8[BYC[Q@>Z-U6XD4/L./MJ%H7
M^T6FZ&,[@QL@B<'-K7`@U!PSIXX)2@OP;G#J$.=17E)G^5(H8QS$=1EHI`81
M`0J90B1C"(5ZZC-QV%MZ*0OT'P`4=N?;-ON&,;M#N%`/HDJ;_!E<.9HYE0Y5
M\@6!^X>TJ$39ZI4RU]TE3I!W#3Q$*ZV]LVMMC:B&<B24$DNI2M3AAE@MG;=F
M_P"OM1!(X22`DZB.!-1@D$/P5/#,NYN6?(<X4I3[DLDG7H/<5&NI$Q`BD5&N
M\E(.MY"/\=`ZO(?HK]K^"XX8M2CV<JN09A$1J<\59]1`:>[L0`$/9K7DL3)]
MY!]@_189K*XG&F5P(\@G.Z_!O\058]O'-^5.?V229A.N9&'LTQW1A_\`"B9#
MN"E-M]1HV)H=JU_`*+';+`[7U,?(4]V23'GX,KAJY;%02Y3<@FQP_373B[1$
MZ@>P0%,`"OR:R,VDQ.UL<"[R&"V8=B,+NHV3U?\`Q'R5JP_!@\-FB2Z/\ZOD
M(KYXU[C1%H%$H]0$*)@`C36?_KNI*V2>C@WP`^5%G=M)D>'SO#@WA0#Y*P_H
M6?$`RPJ&Y>\C?+`:D2"'LRA`'<2@(D$0"NMX6\`%`P46T+.,"@:RGD/T2PY_
M!F\0UXPL5_.SY#IMRG`PG)#V<*IQ+2G<()5V$`';4?%M<<5[^6`,S\:K2AV6
M&*[_`#,*U)I0<13ZHMA^#)X?,D10-RRY$.$^O:I"6>`5\#>ZD&X?5JVXV>&X
MDZA<0[P:W]%;<[%;7,O5<XAW@UOZ*0H'\()PR@H*1@2<B<ZO?O41,]>NHZU?
MB!#M$""@0B/:B8@C4!#?4'?]F07]]%?&ZG8Z(8-:&4/GA7%<ONG[>0;GN4.X
M_G7,1A%`QC8M+L:^JK:XIB-_P:G$AJX,L3EYR..G_M:*T1:)RDW$:5\L!$`J
M%.E*:Z`;/9'_`&M:XX<`/DNIG[?VR>%L3XVZP,7`"I\^'N3NA/P?W$V'<&<A
MRLY!/A4"AD749:`)[[;`"7<'S#J#W/LRPW+_`/T?%_\`%K:^\BJY_=/V_P!J
MW2$0F22)H_M:WZA/;&_X3+BKC++%B9:B.3&='<Q8]YVU>;:->QEIC'R#NV99
MM+MVKCL1!1)%91L!#"7<"B--]9XNUK>)L;6SR_XZ4P;4TYFBV;;LG;K6".!D
MDA$>1HVI\Z!?5XBF"22:0"(@F0J8"(U$0(`%`3=/>$`J/RZZE=@QH8T,;]H%
M$;HKD-$0T1>4#V!]6B(4#V!]0:(A0/8'U!HB%`]@?4&B(4#V!]0:(A0/8'U!
MHB%`]@?4&B(4#V!]0:(O=$0T14GW(8-@]T=QH`?2(@(?DT1:@.1MG^IU)<_,
M$S^![VL^+X8Q#=NEEQC(122]RHEGE"IOTXN/,\*A.`T3C0$55`*+4K@3)@(Z
M(LUN47(6\^/D':LE9?''*'(E6X95S&/8C&4C:#!];J"#0'))"4/>$Y"-SMEA
M'L*"1U#]W4*;Z(B>+G(V]N03"ZGEY<:\J\=E+;?MF#)GE"0LQ\XN1-=(%3/(
MO]3YV;23;H&]P?.$AA'H%-$6B7G)RZQ[*^I5F'#V=.>^8^'^`^.O'C'4DFCB
M%:1C6-P9.R%*2CZ5E;PGXVV[@19HVS",DB%1<F1`?.KT`1T17'%_U"+GXPV[
MR4R/=^4,W\H>'4_D/$.,>`UT9E:14!E3.^6[TC%ANFWK"GI=E;Q9?%B<B)5$
M)A^D1-%(IQ*8Q:5(LM[O]5=\XX_\\8^Y['88;Y'\9,")Y&90]LY!MS*=K3#'
M(T3(QN.9^U[SM]-!@YD4KM3!FZ:*I$50<IA^F40'1$DR'J(9AXE8.Q]!7MB6
M4S3*8CXUXWRQR'S#?^3+0Q@M<+FY+>:3\Y'8QB)XJLADJ[8IJX4,N@B1LD!R
M`D!Q.(:(DNXO4GR@_P"1^<;\0M><CN!.'?3EL3D7)78V>QL5=XW]FF.DKIM"
MD6Y:*NB7`C;\8=F@V\P4TW!@6H8*!HBFO!WJ$8_Q?QVS<KE`<INYCB%CS%5P
MW0_R9*QDUDK)JN8;(C;SLQL@:/;,V[RY9J4GDH=-$B?]MAVTVJ)$SLB>L2>"
MDKL@[!X^FO&>P1C.U<D\JXB=RS9UC/,/O+IAD[E#%D"C-I@YO_*\-;IC.7D8
MW2031$H)BKWB`"1;-K6Y'V%D+C`RY362[5>8\G<.O,Q03J13!BLI;Z%L.;C`
MKXBANQJLDDW$BH";M*8!WIOHB^73@-FO&G*JT,+7EF?U.N;<-R,SM?DE.EQ=
M9[:\H+'\66>OF8=6?8D>)L?+PY;>;6\1L@9P+L"*ICW=]*")%L8P-S_O*&Y,
M9E9WFZNW)5JYPY^I\+.-=G,G;$S"RHG"./?,RQD`5A0!=RS-)'^(?&`P]ZH;
M4Z:(LG\L^J?9&,;RSOCR-Q+?=_7MB[*V../^.K;M4S)U*YKS?D:W?UI3LRVD
M/=)&M;5@S%=RSQ<PD:-NXXEV`!(HUN[U>66#,<\JI/D_Q\NK%>9.*MOX_O&=
MQ%`7+%7R7(UK93DTH>RI#&MTLFC%K-O'DL8S1PV.W(H@X)0>XN^KP6\:JLI)
M8!%]],:Y)'>^K/D)"XK;Q*'$:0M[D9?<`]RE;6)LA9FL:RVT/@5))`L9D+(M
MV/2*,;2F[CE3JLF,*5-PX.NF/<8A0$=4D$;Z#&BN:[4P-ES'+G\%=2_K*XZ?
MX/XT9%QUC964OWDSE"],+0%F7[?=O8ZL>S,FXX!R6\;>O;*[\CVVXX/.9B2*
M43*I]Y"<GEA41`,88P<Z+6?$=6IAPKQ4I*>HIEV>MW%]JV)PQR,\Y0Y!5R4X
ME\#WG=4#:#.Q+7Q6]9QLS?D_?IT7S!:SKMD'R2%M/$&YRRZA_=`@%,(7+8;I
MKZDR[D]6UHE!X&LZU./=VH<I,X0=X7"OQ[RQ=<#B!;%\#C^64M^Z;BR!>-PE
M4CV%N+SB7P\6Y016&1[BF(4"U$*X'`Y*OH)H:Z59L/60Q[-XEX_WE:6$<AWO
MD_.G(F[.+?\`(K:DG"2EQ6GE2QHV4D+L4<RR2AXF5L^(0CR+'DT1\L6S@AZ5
MJ731$T^G53A_%5;IB:3IU4X?Q5"(]72/:V;E./OKCU><1R4QYR)B^+<!Q]M*
MX(B[7N2\IW+&DG8!*T;L31CV:D,V@5/BI9RJB'W:D0PF*;:HE7`MXJ\NKU87
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MM-V_O.S^N^3M^?1%K?\`49_[/C]5L;_S_?AOU:_6.2_D_P#B_P"4OL^_ON_^
M'=O\F_\`"?[2Z?%?9_O=]$5MZ<O_`&>'W#DC^8'\+]S??K'^4/X?^4[N^^?A
MOX!YO\I'V_\`:WZ/PWV=.N^B+#[@V7"(9B]90W(I6S#7"?E1,#EA*_T(`EN(
M88#'$6%F$8.)=PHZ=VR:&^,%0RR2)0==P$*.PB1:>;Y^XD.$'`!6^@B).RV?
M.W)ZWI_,>3QGD%B^XN.QE)88&.Y+RL&6XIFS;>2M@Q@MIY$,YZ041*@/PI!,
M($(I'F/U%6X:\JW,I_-QC7#SDYQ)4S/"<6_A9S'%O<;R9/MX&;2R+HGOU>R=
M>44XD@,:7<7/#P2B(F4*@BJD4AC$6.G.161+'>K8PE&6$%&JN2)-S%79G>4N
MI'EBPPT)[0%O"\?<?24.XPK+XA)$@H6"E$+F92YFXJF.P*N"91(LV>4!GYN.
M7J/H0:4*E@W[L].-2:E(9=^OD3^0(UEVF#]JI`NF[:VOU+0A`<&CW"4E\2JH
M9P5=%,"D,8B=F?TL9#ZSMC'O![/)\2BV/Q9_E9;,XN%5LE?DE_?,.,09&?.)
M=%5K9_W2*1C"#=9/[R!L4P=HE,!%A_EX^,2<F?4F86,WXDNFK_E?)GR)=/)Y
MY*L>6-IW2,';(9&;8"L%HQD<8Y"M`L64HP*]V7+;"AE#+@=($RIB<B^A+G26
M-#T><]$X^JMS6K_--?%M9Q;#=@1,;$_5YJ%P+P[*'='B@<_JK\88B2"XMO,J
M4JG;[VB+*7B>&*R\4>.P8G-;:L*&`L:A8!E4XE"44:A8<5]S&7(W4<J(O#B`
M"J5,QQ*H)PJ:E1(OF!XTJ9':7KZ6"^"V=B7!F@<O>HXC>\5R%D9NS\7$S,K-
MG_E)D&<_8L7?-UJY*817E?<S-:-(S>-N[SW38=$1F-"91;36&G$>N29]1YMZ
MM_(Q=Y$Y>:-K9P;,W8-A*A+QE]W#9[V[+EMJST\6BU-;SZ)C):3.J4"BT*F8
MYBD2WG?]:5L[Y8<\U!BX_D"[YE<#UN0D-80(3&%8'B\2XGA<*1N$KEN`T'=M
MVVLO>W::Z7T]$PCY)T/:5HH0`.)%(?J(KX[9^I_G-2U(OBO<62'7%'%C>[F?
M.>?O*S+)@EPG+E_4*8X]R5@VW?DK=DV)3*_>D;+-86$!4B/\.$3J>61$9$-)
M1?%;#B]L)<0+ZX1!@*X6W(6,YE+VMBCCNIGHUR*'+,8ZG,'M\SY`1SDFY%5-
M&-BXX[<\<!5/CB.A\L"*UX<FY>M,=\=OYF*!;@Y`N_3SN9"ZOYYCJ?L^1@<3
MJYNN93&4IA$8EG?,M=L\QF3/$H=A='W(R=PY(]5Z\;*'413(FARF/%QO+3"Y
M[O;X7O/D>/IU6BTRTU]3]Y*8SC$U`OY\,/<%MO\`";'+3A;+0W(+H)6'3;$@
M0CP2$LF)QH4BR5X@(X_2Y.^E<0DA:#^'3P[S!%!Q:$-9L1!/.4*DC$FNY.39
MVA.S<)&JM;1%0L.=%=T]<,@(9P5%01(!%C5:0WHA?F'W>-$X*5YT(>L#S#52
M@,IK.[?P9*SQ[%[9=CD.[[;0N6]X"";X[\H]NNXZ#DGRSOO(HW22]_1$O<Z?
MY6487B<_YV?<4CRC#G-DQY8MJ9T\B&X)*6LK8ZI7]N0V0+-"=R,EB5E;WPYH
M>:5MD]TNI4%"N(MNF)C@1;-O1T_D_46Y'NF_\W=IE5W=\8K*P7&WX"1Q?`X_
M^#(6U&%F77)_=>2;MA14`3+.[CAH1T#H1*1MV`!Q(MXVB(:(AHB&B(:(AHB&
..B(:(AHB&B(:(AHB__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>pg97c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg97c.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!;`'!`P$1``(1`0,1`?_$`-P````&`P$!`0``````
M```````%!@<("0,$"@L"`0$!``,!`0$!`0$```````````$"`P0%!@<("1``
M`0,#`P(#!00%!08-#PD)`0(#!!$%!@`A$C$'01,(46$B%`EQ,A46@9%"(Q>A
ML<'14F(S)+4V"O#A<I+24Y,T5"55)G:"HK)#8Y1%97655C<8.!GQPG/3A:66
M)U<:XJ-$U#5&2%@1``(!`@0#!04'!`$%``,````!`A$#(3$2!%$R$T%A<8$%
MD2(S%`;PH;'!0B,'T>%20S3Q8G(5""1$-?_:``P#`0`"$0,1`#\`-,@^IUZ^
MADF4(Q[U29C(M,+(+K'1&;@V9+D%AB=*CH;D1S%4H?"A)J30`Z`U(_U/?J`+
M4"CU09F\`CDI285EH-S5(K%H=AX:`.HGU.O7HNB%>I?-#6M0J#9Z$[]:1:C<
M:`4L/ZE_KM6T`OU*9B5)!.T6V-[=-^,)0-=`',3ZD7KC70GU&9BJM"1\K:JG
MJKJ8N@%1#^HOZWW2"?41F*2*)VBVCH:'PC:`5D#ZA/K16`ISU`Y6H#=PF+;*
MFH'LBBIKH!90O7]ZQ5)"W>_.3*`*0"Y&MNW).P'&+X_R:`5\'UU^K@I4_([Y
MY&MI:O[Z&;:EM'B:K,8#;0&9'U"_4[3R[;WBRF[RROR@41X`B!Q%.7F/KBI;
M5Q)W`.NC;I-NI(=0O65ZR+W,B2I'?"_QD(6KG!AQK>TP0H<4EQPQBIWB1OKH
ME&*BZ)9`>&S>K/U0)2V;AWJR"4X:"B8T-/%)_9_WM37GD#C0?55ZB'PD_P`4
M[ZJH%>;<.I&P/1BF@%G#]3/?KB"[W+O+J-@$K3&ZFI"JI8K70"XM_J)[W2`C
MSL_NPJ?O#Y;>BMM@QM70"UA=^>[[E$OYO=%D#[ZBQ0G:@`2SRWKJ\(.;H@+*
M%WJ[HJ"?,S"XE1\:M>-?^X^S6O0EP8Q%3"[N=QW%-A653P`2HE2&$IV!^]P0
MI1!.U![==+A%YI$FG_&ON+C>;V]Z[99*F8CEWRMNC(D-L^58\@0VL(8<>\M)
M1%N:!1)5MYH`\=1TX88+`$14>I/O]V.]6LSM7W/[F7G(NU_>5M=V[17ZX-1$
M_ER=YBUG&W9"64)*T.!;(YG]H;^.K*$6Z-(SNMJ#:+$(7<;,7U*+M[FA:%!M
M;;C;2'$*2`"5I(`JY]X>[6FB"5**AR5?$6T7-\F6T.=V=75*:I\M'(U`KN!U
M!U'2MUK15&J7%BM@97<UI2%7%ZJ@`Y5'W>O2HW_1J)6K;S2-[#>(HHM\G.%0
M$UUY%:UXI/)=?N$`<@3[-0[5O.F)N'C-SE+;\UQY33304''2I#;2>!HKS''2
M$`@CVZS=NWVI$C7Y?ZC.T^!NJ@W[-HCUX)/&RV0_CEV6#4(3\G#2\6W%*VIT
M!U5V8MTBD!DG\JR+NKD\+*^WO8:X&XL!#<+..X%XNECMZ&D[-OIL,>8W'E@!
M%0'&CX>W4O;6X*MR2(\!W+%VS[OW!YRX9QWBN+0>)6BR8A!BPH491V#:);R/
M-+;8V":;^W7'-)2:CR@D5%;,=IIM;RWU-L--+?=`+SRFDA)=>4F@+B^IH*5U
M4&US3[?Y#_5H#]"@>AT!^Z`^2E)4%E*2I((2H@<DA5.0!Z@*H*^VF@/T^T"I
MZ?:*^%2!MH#\I4UJ12M!M0^_;KH#ZT`-`#0`T`-`#0`T`-`?@2E/W4A-?8`/
MYM`?N@!H`:`^5I"TJ2:@*24U22E0Y`BJ5)(4DT/4$$:`UHT8,A7Q2%<N(XOR
MGI5`GQ!>6LI*CUH=]`;>@!H`:`&@!H`:`&@!H#R\<RM]SM/<3,[EC$I#4G\S
MWQ3T%=4QG.-QE<FT-*HA/-(W!ZZ`.;#DMNR64(;B46#(T4$J%(`:ASG``*QW
M-T-N+Z4'P[:`5[;;T9XI>:+3B%E);41RK\1"TJ'PK:(\1XZ`4T)X`*!V^#^0
MT]W6N@%+`>%4@B@IU_ZDCI]@T`M8#R!XCJ/Y-O9H!51[A'BH49+S$5H[J7)>
M2BJ0!0I`J3R\-`&$/-/F'1'L\)Z33X#+>:6F,/[M*313@IO6@T`O+5:;I>N+
M]QDJD-@I2EM94W&;14;LL)*4GB.E:ZBIO&RG%.K'AL-DAPRPI`2IQ.QHE(`!
MZ<D@`']6M+=QVZT69;H+BQSH"/+6BA`H4$\4)345%10;#;6CW$FJ46)#LI)N
MO8+RWN-K4@<J4*?YS[M8'.+VVN4<HD_"$I-?MX@^SVZ`<&`X"V@`DTXFAVKL
M?=H!PK4]S""I7$C>@WZ*K05T`NX,D$BJN@KMT\.NVPWUI:N.W+4E7`"V@S`>
M))\:4^S]'NUO\V_\5]X%_#DI6.->-0=QU'3W:I\Q+@@&MTM,/([)+L4TDQYC
M)3Y@`\QF2TI+L*2T3LVY&D)"PH;BFM[<W.-7Q)(S=_.VTKU&=C[]AKCP@=Z>
MT$G\?Q&[)0H257ZSH3*BRX900_\`(Y+&C\2$GBERI\=:K,K**E'2Q8^C3OZG
MO=VFM\V]+^3S[#WSB?<6SO.UEPL@MKBHGS!871U+4Y+87R(H"=7J9="/%DX(
M4]`92Z5^4VA'-Q3Q2VAI+8HOFZM24`@CV';70K=MI.KK0=&/%C:Y?ZJ.QO;=
MSY;(>X=FG795`W8,;<.0WI;AJ$LHAVQ+Y*W%'CN4@'3I6_\`)EX04,A-6SU)
M]]NY0\OLIZ>[O;;2I1;;S;NW+;QNV+:5LA]JTJ_PUU*A\20!R(U#M6U%NK+B
MSMWI_P"Z?<)S\1[^=\;Q=&'$H=<P?M>EZPXVVTF@,.1<$*#\H`_?)H3KDD[<
M<*XBI)GM[V4[4=NN*\0P3'X$HD%R[36/Q.\O[;*>GSB\\E0._P`)&^LYRMZ&
MU)ZJ?>*CVI=Y4"E-\4"B4(2$I2/8`CC0#V:X=4O,&TB4/A22D]!4"E?#H-JZ
MC/,&?SD>_P#5H`><CW_JT!LM[CE[?](Z`R:`&@!H`:`&@!H`:`&@!H`:`&@!
MH`:`&@!H`:`&@!H`:`&@!H`:`&@!H`:`&@/,+S99_/68%2COD][Y$D[_`/&4
MKK[=`)R;9(=W:2"/*DM*+C$EH^6XVOP55-"LT\"::`.;5E=VL?R]IS",;I9T
M'RXE^8(1/B-E)"0K[Q<X[`I.U*TT`Z+)CJBIG0)C=S@.@)9E,`_"V1RH^S\2
MXZV^A*MC[=`&@N\.`&S->0P%`\4%0\Y=`=VVZ<B?$5VT`&\LFS%^19V?+:K3
MYM]L%\CV!D?NRHC>N@%59K(_.=1,NTQUU96.'F'S7$;5%&@0RR-]J`G0#[8Y
M$CQ'$)2E')03R6H@N+(!".51MUV`T`\%H%&TI(IQ2G8^"J>SP.H.V'(O`7UL
M`0NA`2I03QVW/3Q&JN48\S+B[B5!`5UHFM?MU"N0>3(DGI?@+*(`/+4D`#X1
M4;;BE?YM:''TYTR%O!D`*"44-`"2-C2H.^U2-">C<IJI@+6VS`A0J0$\:>[P
M]WLT,VJ9B_M4SE0@@BFV]!U]X\/LT`M(,Y51^\9\>B=CN#0&F]0-`+:#*(+1
M)2:%7(IH!0]-J5-*Z`7-MN`#B?BY;'8FOB/;XC6G2N<&!8Q;GN!Q&Z2#2E**
M\":4WIKILQ<84E@Z@169RY.-W*T]S+0VHN693%NRF(Q\3MRQAYQ*OF>'P\YE
MCD*#B:A7P@IZ'6NI1QED21,R3L3WMP?U'WCO+Z8).)6_&>[V/E&?VC)WE&U6
MV^DQ5MY%#MS007I,I"?,HD?`LD#KO>,E+EQ('QM_I:SKN"XS*[]]]LVR]MX*
M6]B^#/?DW%(ZS7BS6-2<^UP44&I(4-5<Y)TQ!+[M;V+[0=KHD9C!^W^.69YM
M*$&XO0&KI=W./*JWKC<DR9*UK4>1-1OO33J3[P2,8E,M?><+RU<?OKYBHIQ&
MX"2$^%!0:K.Y/2\\@'\>X(/$#BA)%"E-`%;5W"0`=_;K"W!7E6;I0!LU</CJ
MA=2#N`M6_N/@=6GMX1@Y*6*0Q#MJXI/`*!305-#38_VJ==<8-[\60-AQH.A-
M2?M)H=]75N;54L`?HN]30<*_I_JU/2N<`?OXFT%?'R"Z@D).WA2FWLU'2N<`
M*JU/F3#0\3U6X.M:T5MO[M4`9:`&@!H`:`&@!H`:`&@!H`:`&@!H`:`&@!H`
M:`&@!H`:`&@!H`:`&@!H`:`&@/+_`,WD(5G.8#I7)KYX_P#C&2?9TWT!HQW5
M!?P$`!'(DDI'B.O3H-`;CMS@(84W-+;B2D\F%)#R^)_L)J.5?T4&^@""Q727
M:I\I^R+E,VY]E:'+>D+=:=))%'PL<2R4^`I0Z`7&*)LN2NNLKG+;O"5"MNFG
MRRZH"H$=YU1V%*FE-M`.O%,2W%,<M?+NM4"TNI`*5)VJI52"#X'Q&@%`C(($
M%"GI$YB.EGB7DN**`GDD*2HK51'$C>M>F@$6SZKNW=MRNS8=!N+=_O\`<;DU
M"^5M3B)WE(Y4==6^T5,ME"*GJ3MH"R+&H]KO-KB7FP2TW&!*34J4NDJ*XV`7
M&939JH.(54=-]0=L.1>`O(\5*"VJO%9`2139/$5KU\:ZY[^2-$*&(LA82K?=
M*2H_KK3[-81YEXDBTBO-\&TUZ&M?MJ!KO*"F@24(7X&J0.M.O0C3L-G\%>?X
MBJ@OI30J<J-QO3J:?W1U)YD\Q8P)-#\+IX*''C[C1.QKXD:%1:PI?%"&^2BA
M)!`30JKL.I/3?0"H9O33-`X\&@!2BU4/CX<J4WU*S`H(^716Q^X*Y+@!*4,!
M2J[CQHD4'CKTB14V^^WB8VDL,_*`BO[Q7)?0"O04%-`+"#R=*?G7U/[IY1^*
M>+E#7@I)*@M%1N"""-97OAL!#C.8W3"LZEX]D[PN4"Y2'[GB=TE-HY2;6ZL"
M=:7`V$LH?LA-6S]Y35-M6V^1!)YBXI0DH0ZTM#G%;;C9^%33B0XVM)KO\-*^
MS6DN9^)(HH5R(%`[RXBO4CH#[">IU`#AB[%=%*<(":$IYG>AW%:[`TT5/U9`
M/8]V0KRRE7`>(YD[TVZD4&I;M_Z\B$&S%V"%?WVO(^TCWTZG56M2T\20W;OE
M2HE8&R1]XGI76?RZ^R(-H7;D`?,ZC^U_IZT4=*T\"3Z3=N)!\SH?[7^GJ0?J
MKOR5R+E.G[7L`'M]VHED_`#R8@]Y]CCN<N57'=ZU\1KS2!3Z`&@!H`:`&@!H
M`:`&@!H`:`&@!H`:`&@!H`:`&@!H`:`&@!H`:`&@!H`:`&@/+.[@7^%!S;,_
M,!>?5EU_"66U@%`3<9"3OX!)T`D6;Q>KN2Q%C&(P%5+KA(Y;`\>=*=/#5)34
M71@55EL0;)7,=<?=60HT-&QXE)!^\D'I341N1DZ(#A0W6&F0PVD)2V1042G<
MC:A-#X'6@$KEM[Q.V,F3>9*+9(BH+K,QAQ#+W/JV7%)4E3@Y&E/'0#)9#ZL%
M"WLV:UHDY'-B.*;;O18^3C%HIHAM]U/[V2EH[]=4E-0=&!@K]F&<9D5_C>02
M3;'UE9M=J=5%AE0J0IU:%AQU0&WM]NLYW4XO2\2]M)S5<AP>PUG@CNI@$5F.
MPSYF0LJ4OX%..48</QN`<B2?:=]<^N?%G9T[?!%V.)WR[X;<WI=KDK\I;A5+
MA.)*XDA(62XDH%$(6L;5IIKN<682A<JU%O22XQK,+/F$9I^WI,:>6O,E6UPC
MS&2@46MHD\B@D';PU#E)YNII:4TWJJ+)D5"./WB*[$<NM*GQ'Z=4DVHMK.AL
M&\5\CC1144[*%:\=_&NM;,YRS;*BC8E`H24JIX$BM=C0^/44UVFBNQ4=,J!L
MF_P8:0F1*:`IRW4E:C3V)K6N^I.;<2MN'NI*5>`:Q,R+E&[;#D2E`@)*FU-H
M-=ZE?0IJ=#D%E;IM]GD&1(8@-@<O+1N:U`H%5Z4.@%M`@H<(7+><F[T^-TI3
ML3^P=MO;XZ`<BWKCM,@(9:0=@>*0"145&PU?J7.+`L+?-"`!R"2!MO3;:@^P
M:=2YQ8%7!NA#B%`_$DFBMZC8U(.H<YM4;;0-'-K*C++)\K&=$*]6]X72Q3TC
MC\M<6"5I;<77DIB8*H<2-B""=%.<>5M`/.UN=NWZU?AT\&/?+,9$>5"4V`XT
MZR4(E1?B->+*OB1_<D'7?%MQ3>="1Z(MW<2@T*@:\30D;CJ/'<5UC?E*-*.A
M`9M799`XJ-3U%3]IKT&N9SF\&W0!U$NRJI'+IX?H^W4PE).B=`&3-X<2ZODX
MKCR/&I-`*^&^O1MXPJ\Z`W_QQ24E7F<4BE3S"?LZ@5TU2XL&XU?U+:)25*2D
M$+<`J$[5Y%7L`.G4BN:E0:SN5Q8P_>3F0KP274J73?H@$DGW:ASA+*B)4M/9
M4+U]P(:&U%*7GJ)7^\>'RK>P.X4JAH/Y=5K#MDJ%E<5::5["6'9R\)OV#6ZY
MMEORWG92`EMT/)JTX$$^8.IVWUR7KEF<OVDDJ=A:\DG1*@Z*31-5'Q_J'].L
M:-9G/;;<:L_>::TKOH7/T$'IH#\Y#V_R'0'UH`:`^2M(-"0/MVT!^\DUI45/
M05%?;TZZ`%0?'H:?I]F@!R&XJ*CK[M``D#K["?T#K^JN@/SDG;?[U*>^N@`5
M)`K78?I\:>'OT!^U&WOZ:`_=`#0`T`-`#0'X2!UT!^Z`&@/PD#J:?Z/]/0'[
MH`:`&@/*ES&%$9SS-WWG!*=3F&1`>:3P_>7.0K<5.Z1T]^N?YA<&#`U=PT4T
M<:;:0FE5<:`[_"`*5J-<UZ3N236&`-*^=UL;Q>V+N%UN,?Y1+RH_[E06ZX^D
M5#+3*3YBE%2:'8#5;=834GBD6C'5)17:,-DGJ2OE[:<:Q&`B!%()8F34J#IX
MI4@#Y<4J`I==]=?S"X,V^7?%#'RY=ROLA=PR"Y3;M(50GYA]8:2%;E+;(/EM
M!).W$#IOI\PN`^7?$,F!%;9X+;2VPGH$CX@*;[]3UUSWI.XTUA1#Y=\0PMSC
M\5X&,:L+)4A"T\ME`D*W/B#K)1DG6JH6C9<9*5<B1'IK95.[[=O&G#0KO+CH
M;XUKY45Q=1N/936AT%VHMU#(4$J%%.'S``#U)Y"OC4ZBA=2CVI^T)'/G;1,;
MN5KD/PI3"N3;C2U`E>U0X`>*FE>(IOH1)IY#Z8?W:AWMY,.[%J#D'%#:TH!0
MQ<T(`"5-@D<9"E#;VG;4Z=7N\<"C=%4=8WZ2751XEJ>^;0$^<U)(0E*E[I4E
M0!#G('H/#71;V[MYNIS]?N#%$>^3T)$J:;>V3L(8HH;_`'356]?';73*D8:J
MX\"\;76744M->RE116RRV^*L>>%3E'XEN2RI9!'0IW%!77$]XT].G[_[$O:U
M_7]W]QP($QMM`0VVTE"00CBD)('(\?;775;GK@I-4J<MR'3FXUK04<*[T<">
M).W7ETZ#^QJY06T*Z*2IL`TYUVKT\2>F@%E"NBU)"N5!7Q]Y'NT`HXMT5447
M7;?I[O=[-`*:%=3R22X*]:?Z[QIH!1Q[QS('.G';?>M2#[-`-OE5R>PS(X.;
M6TN&+.DLPKXR@;LO`)1%F<0.*6G0>*R1O4&NNE;A))4[`/Y$S%BY0XMQAN*4
MQ-0%CH`EP'BXDCXNBAUVJ-9W)RNTTQ=$4E/2TJ9B@C7AXUX.E9]@Y`]>A!3Q
MK3WZ1LRDL<#:,'*+EP/IS-;9;*F;=F&W0=HR%AR23TH&D^_QUI&Q^K4J(HU+
ML1@;[C\WBN-;KHZRDE7S#J&XL=8KL$.J6I1)'N&HEO\`:V8Z926JF7>3&,Y2
M44L6"3W!N#A);=MT):=Z<7)\A*5CJ5.%+2%&FW&N_77/_P"TL_9G3\I>X,)5
MYE,?0MM4NY3U%54E4A<9H*IL`W&2B@J>A)UYU[U=*ZU&#:\?[&\/3I2BI.5&
M^RG]S"W<K[*-(R&HU=R$,J6XKWEYQ2E\_>*:X]QZG<NQ2MIQ:?&IU6-C&U)N
MXU)-<#<_!;E,`7/?6XHBI+[ZU`4Z4HI)V`VUR_.;CMD=/R]JF"Q+)_3;'$/M
M/960OS0)=R/*M>K_`+:GI37L;!2G;ZC>!XF[AT[NANN`[V0RI$/'K[,B+#4J
M)9KM)BN$<@W(CPGG&EE-1R"7$@T]VNW7J6JARQAH]TXULP^J#Z]K'?+Y!8[W
M%+4*]W>+'3^4<=5QBQ;G+CL-J/R7Q+2V$CE[$ZX[F]5O]+?G_8[/E7IU:ON$
M-_\`%H]?55`]\`CCL`<1QL\C2M!_@.U=7M[I7/TT\RG0?$3-Q^K7]0Q7)MCO
MR8BEA24.(P[&5E*Z**"0N!3B2G?H=7^87`?+OB.GA/U1/J!7"Q6R9>>]:79L
MAM7FJ3B&.-I6$K4E#@0B"$IYI'2G74?,=Q/R[XC(]^OK#_4(L-]O]IP7OJW"
M5;L>6ZRD8ACDCC<D,%WS%K>A*4L5&Z134_,+@1\N^(<>CKZJOU(^_P!W4[0X
MQ=N_J7K%>$MW;+`WAV,-EV#;V7%3V'G$0`IAEQU`!4"%"NM;<]:K2AG<AH=*
MU)*XCZT/JB>J/U!=ZK#C_J/L78/M#V2[A1<-1%L&#6:]Y5ED9^.S,:FO3;[$
M=C,E]E2MT)XTZ:N9DUO3?ZWO4I=+7WGQK.>[J\AN_9CN+<[%<LFN6/V>'(?Q
M=-O;ND2XS8\1EIAM2(@41Q'Q>W0#Z9+ZT>\2.SF0=Q<?S]IZ*K%+I?;#<46F
MVJ#OEQG3%<1YC*TT\P`@D$'V:O"&MT!RJ=]?KF?4^Q_O%@N&8GZB46ZV7:\V
MMBYQD83BCZW8SBP9(#SEO4M"5(6/Z]=/RCTUU?<!43?\XB]<O9WU,L6#N5W:
M;RCL_+@6NW7MJ-B-A8N6./SQ3\Q1EL0T%]F.Y4NI4:<1UURW8NVF\Z`NMRCZ
MD/J<_@/>NY.*]XHUS1=7,:3AU^B6.SKARX5S!=<G1@J*I#I<;(!&]#45VUP_
M-_\`;]_]@1$:^K;ZU(!#]_[VR&XJ45;AP<2QMRX3'*_`R@J@@(!Z*72GNU=;
MBJY?O*:WK4*9M8^)@F?5]]8LYI2[-WCNMLG<@@VZ[XMC+R7&?!]A]J`V$JKU
M!3T\=3\QW'9\N^/W!9_\67U[UI_&U)]Z<3QNF_LY02=M/F.[[Q\N^('?JQ>O
M<)%.^*4FO7\HXW[#M_O`:?,+@1\N^)@_^+#Z_CNGOBE0]OY2QL?R?(G4?,=W
MWCY=\0IN'U9_J"/PWVX'?<,3.!4PX,0QI?[Q'Q!*DF!0I52A\=/F%P.<1]C^
ML=]0B0X\U<.^#7G)YM%*</QMM+;K8`H!\A116=ZC6UN>M5I0!^OZNWU!BE24
M]\F4+''D3BF-@(!.Q*OD:';K[-7`G[C]9/U[6Q#SDGU`Q$H8!+CJL4QQMC85
MH'7+>D*/V`Z`87)?KW^O]B6N%C'>M=[EM`U$?#,<3&10T!<?7;B'4CVI&^MU
M935=2,7>:=-+$='^M5]6.\O+F.^HZ)9(SA'&$Q@F(K<:0:D<?,MW)2@.M=.B
MO\D;V$[R>%*#JP?K9?4Z9BQFGN_EEDNMAH*D.]N<3*WTI2E-70(0!<<I51&U
M3KBE>49.-'@S?Y=\2>W_`,5+U_?_`*K8]_\`@3'O_P"GU'77`CHOB<R7<?)8
MT;/,YXN$@9=D?P$BA(NCZ4DGJ*#]>N,YQF+OF$V2E;31#:=P.*DFNYW/6A\-
M"4F\DQE,G/SMRM*GAS"I57PHFB]C0K'0T(K74HUM1DKB;3H$D192I_[RJNJI
M3FJGQ*%!OML.FI.T/6DR"4I*>"3OL#X"H!K7V:`/X\<DI*E#IX]/?MMH!0Q&
MVZIJD'B0`?=3[:4T!)7TJ0VY/J,[9)2@%*;E+*B*D<3!?Y)-#3<@:`O.5`<*
M%A#:AS213@:;^!KOH!&W*UR>2DJ20GKLGQVKX#PT`AIUG4TX9:"I#C?[Q*T%
M2'`4_$/+4*<553M3QU,>9>)$N5^`\6%=U9$!^';,M')@H;#%[25.NL)%$MMR
MAOS338D]!KNUQXHX-$^#]A+"W.1I,5J8AUI^.\GFW);/[A?*I'%7(I!I[]<<
MYS=YQBFX88]AI%W(JE&9';A;H22Y*EQ&$%!KYKS::IZDBJP>@ZZZ.A'3J=*E
MM=S@QM;WZ@NU.)+6BX97"?D-U0J%!4J6^A82*)4B/Y@%3[3X[ZM%P@M-5@92
M4Y/4TZC&7OUS6:,H,XGAUPO$D+4V)<Z0W!ADJ6$!1:%7E(%:^RGCJ>I;_P`E
M[2-,N#)-=@^_YSYF"SG4*#CESO8,C'GH3BOP]TMK4A5LDJ?(*93E*A5:;[:L
MI)Y-#3+@R8+(4&PE*^5"*I20:;^P5U)4/(SOED`K"`>('(@5/L%?'0!U'E<:
M$U%2:$[<NNP\-]`;;V26>V(2N=<8T95=D*?'-1_^B0%*41H`LN&5VK(+;.M#
M5ONMSB7!@QI+K43R0E)KQ>;D2"T4%E1Y)/NT`B,3S:]XPY*Q%:FV7XBFU)5<
MZ*?\E0+<=^/P46G4N-A/(].6NFQ=5N$W2N1I;@I/WG@.7#O4^[+0J[W>ZS%@
MT;A1'Q;V"`:'X6AR>2.E*Z\#>^L].[TI*C;IB>M;LVW;HJ-M8"QA0GET7!M8
MY]"](27GP2.OFN<M]<KW&XOJMJY&,5FJK$WL;*J>J-/$5,:QSW6@+G,3&;5\
M0;4M(0BH_L$BM->;<:<],JN?'L.F&TC;DITR#=N#CT)MOYBY!XM[I2D`)2=J
M_P"J!_DTT/C]YU=3_M?L`K(\?A&D5KYASHHE%=Z==O9X:G+!G/-IR;R/C\X3
MWE%$&W%*!OY@!;(%2D$J4FFPTJBJ3>6(6R[S>I'/SYC4-'`D<E@K%`-B11)_
M1I5$Z99T9:/Z5%EWLUC[BWT22J5<R7$@A)/S%.BM]J:^B].E%[?2FJGS^^E&
M>XK'%=P]F5T&+Y+TVQ^^5_\`-[^NE44&G@ZG-^HX&,P99>O&2..(2M:LAR"J
MU"IVO4O^:NO&W$H\5F>I_K?D,1?(;0YJ0I!6E1*"DBJ1OM1)ZC71ME7+$R$'
M<900P5+`2Z$*-13B>)W423]XZV>9)*C%K5<H6$V>]KB/FV*@AP7%3#BHK;JP
M%-M^8$\`2$U3OO7;0$$,F8N.29K=&(EOESKA,G/"&W%CO.KGQ^"DJ06VDEQ%
M-Z@TJ-2HMY*I#DEFT3B^FU@MQ['8UWY[U=T\<OF*XWV_@7.UXS,N$%Q+TZRS
MW7)DJ;`C+Y/.B,D^6$@<B1TUU68RBGJ36)R7I1E):6GAV$XO03G6*=SLH]3^
M9X;-BW6QW?-,8DP;E'2H)N'*R-N*<=0I".$H4`6*GB:C6K:2J\C$S]FG)S'U
M`/6MV:GQI_Y5[A=M^W6=JD-QGC;A)=@*LUSBN2N'D,R9$5/PBM5`]-1KAQ0)
M+^IE5K[:>E+,[/9V/D+5;,=@XY:F0X%+8CR'6FDM)6=EBBE<B![=;V7654#B
M=S&2YE7JOQVWM.<U1)C:_,Y`E(AU15`']I*1KU/T>8[2-OJ5O#=X[S9HXR]5
MF+.1;$5<"DAN,G@Z@;*`0=P10TKKS-PJMICM+0/IZ>H^]3?3EGW87*,O8N$?
M&L^L=_P2Q7!QQZ]0<>5#=$Z/!6MQ9_"(LE20D"H23X:XNA'N+*+>2;),90MR
M[?+2H+Y;D0TK:2:@I?;<6I9`"16I*NO0_9KGN14941M"R\)/!UR"ZPVB4I2I
M5U<_?%/%#:5=&Z]30BA4-M5.H61>2T`A`(0D)2FM.@`VJ?8=02HR>*3,+LKD
MD)24UJ/O*2-J'ITWWU)$O=QE@N\PKDMH;%''*E1`(WWK0IVVJ-05UPXH+7I3
M<1*EN/(94-@5D<@H[;#J%4KJ#SALKM-M;%V$J*\H(DN(#4,J2"N0#NH*/[*E
M=`?'79M^3S)&5[K]VLGPZX"PVZR$+N;?GP;S.)?AJ:"DI=989044=96JB@HG
MC6NMP-G&L%^R=;%PRR_2I27J.?()6MN.E2ZJ#;:$+X!H@^/CJKE%9M(LHR>2
M;'"M^-VNVM^6W';%/`"I!&U.8).U/`TUB]Q1T61LMOAB\0V+;;?Q(0D$]3Q!
MZ=-S6FJ]=\#6W;T5,2BGS$460%'<I43U3X"I'76#=74U+._+;_VQW]9_KTJ1
MCW%(W<V57N#GJ55H<OR/?;_E>13V>S53S1LW-UD@@@_Z-]2CKV_*_$3-T9*[
MC;55'$^:L^VB6U"GLJ=2=`414!#CB1_MJU?ZY0/\F@%&T.=*;4IU]PKH`T1]
MW[/_`)=`'L3I^K_L=`2V]$T/Y_U-]MH_'F#(N3G'<U\JW2%[CV;:`O\`I%E+
M:5?`":'>BO$5]M*_TZ`;Z\05-E7)O8U%>)VH`=ZZ`;N[,QVVJ/.!M-#11W!`
M"N@WT`W[\ZWKY-\O.6A?%*$CX5(Z%)\1[-0!*YQW0[K8'A[?Y1R'\.LF079N
MSW.!+0F8(K0'G-/PB]\49VJ16AWUI&]H6DAD>;CG&8Y<XM5]R:[S4HYM*_?E
ME#G`@$<&E(XA7MZZI=W'N^8\#2CQFRID`?WLFI45**N2NI6HE1/VZPU:O>(%
M';H+'GI6GXJ+X\1U.]2>I`&VJOL\03#M`8:P?&*K+#GR+LB*XATM2&'/--'6
ME)Z.`IJ->AM^5#L)/]DO4R0IG#LWDJ5=O]ZV"ZK2&D7DB@1%DN.*2A,S>E>A
MUU'GDNVKME,TAQH6BT,J2`5.%-Q?10D\@U7R^1%/'0'TJ*ZXOG=;]<9RC3DS
M'<3`B$5J!P8)6!MH`SB.V:$I+C,&,IQ".*2\5/*0JM2L/.*4I2B=ZD==`&Z,
MA^/9:!4GI\-*BG[-`K;W:`0G<3G+BMY);`XN\V6C@2V169`2DF4TX*_&IEH<
MT>%1J]N5)4XDK,WL`[G+DP8TJ,TU+>!+:$.\/.`50'D#L%-^/MU\UZ[L92NJ
M]V1=?8>QLN>'B2)M>399.:3Q>AV^*M()(4@.=-J5KT&O)L9,^@1N.2^*BJY9
M"5%7Q`ME2EC<GI3B5?R:UDI.+4>8I<>F#?!&H;SC\184HR9ZW-N;RE\!QIOQ
M2?AK7>NL=&ZX'#U_M4RKS"W1D(<;1#BM`CBX\I*4)54D;N$*._MVUM':[J4=
M5,&;1NV'&LVM0E+MW9L<#S7)N10&$I!HTTZVH\NH"$M%16:>&NO;;&]*35S*
MAAN=U9LQ3@\6^P;.=WUM;G,VR'=;TLA0XLQ'BDBFRN2^"0D^[H-=?_KG6E#C
MEZBG%JKQ3+R_05?',C]-V*79Z$N`M^Y9`CY9Q04M"6[DXD5()VIKT]OM/EL\
MSQ"4F7'CBN4D^&.WHT_^SI&M[MK6JK.A98R//GRR[NN9!DG[PJ4C),D1Y:*A
M*C^,R@3N:]$?RZ\:YM-4J4/4_P!?L&YE'Y@UW0I0W"O`U-:TKJT9K;>1B:-F
MQUN_Y5C=HE1);\%^]6\W5N,PMUU%H3);7,>=2V%%AHM)(Y*IL??KH3KCQ+$R
M+FECMA;^Y=N7G,G),5[IWYA^SPI\-I$7`<-L+#:!"L$-24%2E+')YT[JI0&F
MI`>]A'/3I<<8G9#V9?8S:5&G/1KWE4A/"<U=T(*I3#34SRU,-)(I\*:;>S75
MMOS.3<9KP)D9IB>2WCM+C.,6ZW?-0,PO#366R7'X#-OL%@4CSGYMR?EOLQVX
MCS0XJ)K4G;7=?S7@<-C*7B1"[,]R^U'HG=[T?F7(,0EL]TNX1D=H\%[;OQ<B
M\F-C=M;B.+RN[6\N6[&^;K?)Q;KGPE72NVN2[\-U.F$=<E'B0,[C_4.[_P";
M9GG65=HV,<QO(+K#?QW)+3CMV9?L=GPE"E0V[E<;_,2%Y!F$-ODXWY"O):)H
M-<.!T?+^`VN!?4@R?NUB.2>CF]S59S<K&T]DS69JEE^59[;!"UR[;<Y(6$2E
MOK%4I`44G7J;7*/D<TUIDX\&5H]JX9R?U8W:<$N*1CL.?,<>`*6V%%-4APFF
M_P`'\FO7_1YD=I"SN)+-SSO,;@I0'S&0W%P%1KRY/J":$5!V`UYM_F\P/-Z4
M47%C/+Q<+<^J,['L8074`\AYI".!VH>7L.L#KV^99OVZSY^7=I=FF(,F7%;D
M.D<CR\J&V'7'378)2GPUQ7OB/R.JYS^2_`?V#>F9:%.(=:2D4I2@*MJGQIL=
MM9E#97=T^6E`',U(/%)6JA5U-#L-0RKOZ'I""?D$*W!<A^2`6AR##8"W'/[@
M^"2?UZ&%Z[U()=XFSE5VNP)L<$,)<W*G!LO<A067/A20?[.H.4P-8_<9JU/7
M::^"H\RRA9I\/AOM3?4X'9\N^XW7+);417&6(R4J4%?O7"7%H<"?A>;)J4J!
M'\FNNQR>9A=ATY:>X:7N/C*\MP^5'\KS<AQEQ4V"OC5;JF1R5'-*DIE(%5>!
M--;F8T6`7=JXQ6;<X\3+B-TXN_"L('W>=?VT&H/V:\_<'?MLASN:>G(*5TV\
M3XD:I#E7@:RYGXF-:PHK0*_"0.7@:@]/';5BII(22ZE(I7G3J`-C[3MX:@%H
M_!7N_P!<G^O4D511=W*>;>[A9YY3@=;_`#?D=54X[_B[YI]NJGFB!6>!H#3V
M_P"G7IJ4=>WY7XA0ZGSY\))^+BS(*:>!\MSV?9J3H"J/'45J)(J5JK]H.P_D
MU`#V(/B(/M/\B3J0'#3>]/*Y`U.ZBFGV;C0![%:"02XI+9VXH"@2K;;Q-*@Z
M`F)Z!?F#ZM.V*(\94QU?XZEJ,*)\Q0MCQKR-`D)23O6F@.B]Z.W,$AIKFS,;
M6XA4%T`.IX$@E)H$N-HIU%:Z`:++F9,8M,^4*KXAPF@%22%5J/AK0:`8N^0)
M#G/S/BX*5Q&W%-"2F@Z4%/TZ`1<>VAJ;\30HZ2.G[0WKMTT`2=Y[,EOMU9'%
MM)//*00"D5)2VI*3TWXA(UC-+45>9$=F$J--=%*(4M5$^!6H@FGM.VJ.$99Y
M%HXL4D5F-4<E\2=J$D"M=MSXZYISE;FX1Y47TH6%FMZ4OI!2=P5&I5O4;'<^
M.KVIRG*DBDDDL"8-LAL?DS$$N,H64VIQ55(KU<52I/7IKLC=G#E90;?*;8Q<
M&BDT8>94AZ)(;JA<22E1\M]DMT+;B5`;C?6_6N<2O1M\"2G8CU`3W%,X)G#[
M?XK%+3%HNYX<+HRE*`&WUD)/G)2#7Q.NBU)SC5YU.>[&,94CE0E\]?&Y"2IL
MF@H=C7D*TJ/&FK7)JW!S>2,C4-R4O=*RFFQW\=NNQUS+>0)`F[@&GFLDC8A)
M65UZ>/PUKJO7F\4\"IL-WE.X4K=50"H@)W!"@0?A4%)-"#U&NBQ.4FV\T2F,
ME-N)PW+28<E#5JO#GG-\5\Q"F(6%NA24\N,8J._NZ:MN8?,VI0EBW%HWM;B[
M:DG%THQY+7W4:4VX&/Q":MK]VE,9EQQM9XC[BEE*0"3^G7CV_2M"=>TZY^I[
MK]$L/!?T`]W%S"3Q_#[$S$:I5,BZ2D%P_P!G_!6SS2:?LUJ/;KHM^G1C.,FL
M$S.7J.[G%QE/!]R_H%4B\YK.WFY!&AMN5JS`9XN)Z5!4X%D^[IKNZ%K@<_7N
M\?N1HKMT9Y!5<;Q=;BL(55M^XJ;942":%A'%)21U'CKLM]"$%'3D4=R;=6\3
MX3^`05)^6ML0.\05+4/,/ZW"JM#I.5NBT*C*MN69L/7]I#?%`2@@&@2$BGB!
M4"NL]3*T1T2?3LD&5Z6<,?)Y%5TR/XCU/_&;GC[SI*<INLLR27V7!*L8R5)_
M:QV]`BM*_P#%[XZ^'74Q;JEV5*N[&VG7-8GGXYY;(EOR?)O*'Q#(\B='WB"K
M\9EE0W)&_+IKL^3M3BW%4N4SJ<Z]6EJT5]WP&]BVC(;W.;MF/8]<LCOLM++D
M6TVB.9#JF)$IN*9DE84$18L7D5+4?`:^;N^G;EWGUL;7VX'H6=Y;DO>52WR#
MV6P7MQV\LC>,6:+;\PNC$*UY:J:KYRX)NORZGKE):G`'E:'./PI33@4T.KTT
M^ZNP["K7N79LH]1>;Y[:.W2+V8=HM]PP#%;G8;6[,C_C,9D,7B8RT0B&I#KZ
M>%5$TY5%-2#Y[0>AO+?3EVTN%F[V^H:R]C<8NRG;UE8:NL.9W!R.5QJY&BK"
MPS94K2`E*&DK<-2"::UVLI.#EVU,YPC/F&@[_P#KMS/)<78[8=M\X3F7:N&N
M+;+?+D6(*O=V8LB#&B&9<V'XSDU+E/WG-("E'<'5[>XG<<NJZM.B\#..WM1R
M6951F5[[C7]Z)B!2WCEONEV\NSV1CE'CN7*\OI$B4[;8[B5*<D+7R6ZMPI\3
ML-3<FI0:-(PC&2E%8H=7UN_3U]5/I[M_:"T]M\GQ;,L6[OX[C9O>1]N,H:O,
MG%[U>'&F;E8;M'8<,N&[#4LK>**I!-`::YE2N.1MKEW>Q'5MZ!/\W&^GW)[#
M67),PLO=*/W6GXM;UY)W"LW<.YVZ[2+K/@JD7)V.PVT66XS;Y)2VM)!IO77H
M6I.,$UP/.N?$;[RN6Z_0#]6':_OEWOOOI>G6COKV=EVI^-8+YF.16O%\TL<[
MRGW9%GN3,GC&NZV&@`E]OB5TZ5.M_F+U*5P\$4.27N#CF0XKF.88AE-N?M65
M8WD5SM5_M<A)2_#N,.6\B0D!8"G4%22IM7W5I((V.LY2<G5@E)Z,K;&FW+-)
M4FY0;:NEOBMKN(>#)24<B2XPA24&HKO0:Y;UR<.5G7M\_(GK@6+W/&>X=S5=
M80+.06O*HEIN#;K+T&XQUV.6\A^VS&:MN.(>;!4C[R.AIKD4I36J69URQN*O
M<(K`^Y<61`\A;JW9K"U(<2D405A7!:5[?"LKK[O9J487FX<O>.JW<[[=CYD8
M&"E('/DK@".@(4FCAVWIH9PA&Y%3FJR#F';8X)?G.&9(4**3QHQO0\]@"I8Z
M;^!T+=&WP#Y#[+5`V@-@4HE`XH%/8D`#2@Z-O@;R75()5R)V(W)/7[:Z'0KD
MEP]A^%06#[*[]>M-7C<E!4CD5G;A<6N:][(2UR"XD@71H\6@@LST?>HT?A2X
M?[2DJ-?>-M6ZUSB>=-).B(HYE:589F2;G#"3:;VXJ:SY?PI:<*PN9%YC<)(5
MR2*_9K*3<^8F-VY#E8X%LD_,H2^A?)I0*VE;$>6I/PUZ@D)._OT6"HLCN3<D
MF\V@S2$BO'Q))WKN?UZDDU00'22*@+5M2OB?#[=`6?\`FM?V4_ZS4XE=**"<
MTM+\3N1W`4].?FES-,F<"E?N@TDW5\4"0351I^C5:')T+G<(5+5_9G25W-UF
M=:5*K#:CI+<ED;4\Y8'[Y0(\?#4-I9YG1:B[<:2SJ'EI0TY=61'4`4Q'U.-N
M?NUI_=.'H1QZ^_123=#2IH,EMQU:0%NK"EG@TDK5L=QL*5VK]FKZ>]$:NYBG
MAVV:I!<7%0RW4?&^L)\*`\156]?#6>M$U0<)AMJ'QOJ<XU!:0*(%?[M0"@?L
M&FM"ILF.I+T545MEME+:_F$.5=6M9!XE%4@4IUZ::T*DV/ISPOF_6'VZ:6%T
M5`R0J"5E-*6U8HDC=`TUH5.C.[8U+=0415+DA-?EHS[WRTEA:">'R=Q3104J
MG1S8'5DZJI(S]_E2?C;ND5Z4['<#3C:F/)N:$GX4J+/((EM-T/QC[=0W0AN@
MWUPMK-P8>D0EIDM("O,4V>*FJ(H4NMU^!2?8-]M1J3P%1JKY.L./7+&[==;D
MQ!NV69);,6Q>`YS^8O-\NTMN)"C1F^)*VG'G`"Y]T>.^M*=Z(U/@R0?JD]*'
M?[`NW]EBY-VDR]"[?D*'YLBT6N1>8C+!1R#W.W!\E"@L'IMT--8SJI8)LKJ7
M;@599X_#PSYV1D*WK3Y;S49$"7"<CW*5.D+"(\"/$=0V^Y*>6:<$T4/'5K=N
M=QNBI2+>/<3&Y%/Q)8]S_2OW2].?:SMCZ@>Y'92[9IVK[B1[-RCVBYAR[]NG
M[_;O-MV59BAC@6['Y[S=(_Q*1X]->#<WT)[F5I0G5=M%3\3TGL[B@KFJ-'X_
MT&/DRT?F&1!+/EO)4V?A"2V&T-GB&UI-"G@0?=4:]2Q:?/58HX9_X]I+.VGS
M<(Q`I!`-H6*JH!4.J]A.NC0RE!M[XVILKK0T378CH.1)^+C[=:EAI+PI*`B0
MW*#$AAQ$F(\QM)COLJ*DJ0X!5(4=COTUO:NQA&CKF87;4IRJJ9$O.TO>EB_V
M1$"XS4F]6MM+,]E:PAUU%/W3\=2E#SD.*ZTW]VIG<MSCIDG0QE:E".ITH/*,
MEN<P`0;4Z&U#=UYT(!)I2M25=-8:=OP9E4S(FWQUVBI\2`A20A:(C!<?.U#5
MYR@2O;<TU7#LR(`+8RZZ79UTNLT$_P!Z<FEED@]06VDIK7[1K6S<4*UKB:0M
MN>5,#!>;58)MLEVY$)N.N0D%B8E;JY$:0A)*'DNK<)(*B*@[:V=^-,*U+3LS
M4&ZK(),(RZ<N`_;;@1\_89*H,D);0TI;?5AU20KXTEL=>NL]5^[C!I4XG-;4
MU76ZL61R!2G2OS10J)W42?U=-2EN(O5-IQ69H:[M[=)*DN@CQI3;[>G76G7A
MVI@+GKZMRB?,WK151T]M30BE-5_=G[T'2+`6R+TEN@4YX[E(V'O)H-;V;5V3
M:;0"R3E,)A-'9C2>27*56BHX)!W17F*UVVWIKHZ$UC5`Z>/IAW%JY^D+!I+*
MRM'XODS?(I**E%S54@*`-#7;;6`)R92T'\<R!E7W7K%=V24_?^.!(&WZ--6G
M$APA)4DL3A;M?IBS_O+W'O5NQS(FL?QI.6Y(CSYT;R+S\PW?)@F?/Q):N<5I
ML)JE.ZG`H$"FM)>IVU'3;4E/R[,^TY5L[2GK["6.0X[V[^G]BMGR^1!N&8W?
M/LDM>&7J^H40FSP'E$3[S+*$N.0K;&^\$H%%&M=9[O?]6UIM)JYWGJ[?;6:9
M%9/K-^K3V>L'<7"<5[6Y%$5*L^1"XSK_`'X&UV&\V^T,/(EV)II+8=,>XK=W
M>54J*1M0Z\U5IW]IM.4;:J\JT*^.Z/UXLY9O<?MGV%PW$NVN(39C:K]DF,1H
MR[@RNYRO\,?A2@R"EQ3CQ45<NFI,OF(<&,KE]ZB9A=+KW,[T=S\SS"/#EL.I
MQN3-N-V<O;TF.9%O2E7(Q+;&=V*N=%$`BF^K6&K<'%YLVIVC4P>Z%N8B72SX
MS;EXA:GY\BYVMB*6GKI'^?`I`8D%"DQ&65#DI5%522-M8.,ZMIX-B@\/;#NO
MC\"=:<;R&WVVX9#-ART'*I"$NR'@DT5'9\X`LNAE9`<3Q/+>FI2G7'(49T87
MO!85Q]0/H?[>8S8(%JBWSLC8<ARDQ(R1'E+ALO3(\B<WQXR)KJ'/[^H<E'KK
M0DZU.R,"-BO9.>XVA,=N/"D-T3T0B-&\GBGPIR&VNZWR+P."YSOQ$)AUV..^
MG?O/FBRILK@Y;,#H5P*O)MCD=!0K:BN;M4D'8TU<H<('KA]"D#U06U?<3`D0
M[)WMML=YR,_Y:(D3N%!3(,D6*^%M/'YXA1#,JBG`N@)XZ`JC]*.+W&SV;.8-
MZ@*MMVMV;2;%.@.<'/E9-G=<C2XSJP%HD>6XDI-#3<&NN/<'5ML_(GIV!BO7
MN[7[$YKGFQX-^G7W'@\5J%MD?(OQ;C'AUY*8B36'0%H3LI53KDMR2C3O9V/X
MJ\B(?;*V_(YU<H2TH4RO\6+S/$+;+\6:^`1RIL/UZU1AN?ZDK&G"@J6/OK)"
MOA"10$@``$[`:&-JZE%0=:ADP\HH`5TZ[?H^SVZ'5I>G5V&8NMC[RN->E?'W
M"E=20;(E5)2'`5#JFIY)^WX:?JU`/OYA=.I_7_I:%M2TZ>VIK.'S$.(=2AQM
M25!2%#90(.QV]NHDZ*IR/;SG+!H:3)\33>H,_'I2@E12N;8W%U#OGM(+I;V!
MHF@XBE=7A!SR,9VI0P=!GL.N+Z7)5I?"F'(CJD.,+'%2%MDH*&QM5"R.1Z:M
M*W*"JZ'3;N)I1[1R6W$H44$U)I]WH.O6M.NLE)-M+L-W%I5?:9D-$N!530DG
MX*E=#4[#85_3JQ!:#Y2?:_\`ZP?[+0K5]Q1%W'5_^8F>;)_RNR3P_P#'$C0L
M(LN)_:-/=6@^WH=]9SS*LV;9;3,E2IA/FL18RRZRBB5.M)25%M2D_$2"D>S6
M4I:8ZD7M1U7%$.X$"Z2X294*S)M\.H6%);_PA04"$*\U7+J?=N#K+YB1U_+H
M^DM2.?"2A2W#6BG25!-.M.@&MJG"U1FPEMX+":@I/A2@'A0&E*#4D&ZDE!!%
M*IV]HZ4T!/?Z9D9V9ZQ,##*4J>:LN3/-I\"I-N4.AVI0]-`=".8Y9!Q^:_"N
M<>8B2R$O%+:?A<#A)2$).Q!KK99(N(2Y7&W7RV1)BD*<:E%?EEU/&4R\@"H#
MW]\2"*?#6AIJD^PAD#.\G>5&(LWI&-%;.7J<AV7'7U-<2FZW:8(#+LZ(@I1,
M2PXLK*3NI(&^LVZ)L159)<61;[D665;L_P#3QE\NY=R>X%Q[==R,9[AWZ3:B
MW+ARY]CNT>;=(SZ5H0Y:(*FN2&8K845*`%3K#YB1W="/<=D."_6;]$N8JBQ<
MFRK).U,Z?\O\Y:L]L3_D0EEA`,*Y.Q0ZW"G]%!IWXN)!-#MKOL[JWTUJ6)QW
M/3[LYN2>!(6;;?01ZL[?$?D1O3CW97\T+C;I#9QM-YCRB6U-R&RV]%G,R@I*
M350*^1]^NBW>A<>B.#:,WLY[==63JD+?O[Z8<:[]]B<H[!R+M-Q#%,FM%MLP
MGVB*FXJM\6SA!M[4=E9+;T="$)%:]!H_3K'2R_=_N4L^H3E2V<]WJ8^E!C/I
M>P"UYN]WIN.33KIDL;%K2[/LR($%=TGQ'WX4&>.2I"%2"SP#B/A3M7;7##:3
ML7'-OW:4.II.&OMJ0I8@38>!X6)CZ&.$:3`D^4I+C7SD>6\%LM/`T6A320`H
M;$ZV,Q#7JU(7S*RXNJ#LIU130@&E.F@&^GV*/Y8\IE`<*0=Z\3U-2.E::`;Z
M8G\+>6N,IR/*C#DP_&40ZWQ5R50C<I'B#7;4&5[X;'<P[U2V2"\K&,QFIMUR
MM\1I3+TQXTN'(CC58Z.E.X'LU!Q4'LM_=F)?XZ)>*N1+LA+G&077U,(;VW2"
M.E#M70@6",KD*9:=FMQXZR"5LQ9!D(33_NIH23[-2=6W[?(UW<RAG[\V.R$_
M=0MP\E4Z)/B#H;7.1^`A+AF$6)D\:Y1G2J++85;KTI`XH+BMX\KEXE)V)/4:
MZ=OD_$X#5B=T3>GI,?&K5<;V[`DN0;@ZR$1HT64A1*4*=?(2HK;'AMXZZHQU
M-1X@43,CN!.`I`M-M:<^Z9,MQ]\;]%-L?NZI'OUM\MX#$,F<8R:7M<,G#*?%
M%MBI'#;IS6:TH>IUC*.EZ>`-]O!89%9UUO%P]G-X(;"O%02R0=Z4WUOM^9^!
M(D<NQ2):VV9MN0Z4H0''O,6M3G^#N*4LDJ)V*%#74\F#K-^F`PICT>=OJTH]
M/R"0B@`^!Z=R3TI4Z\T@G;?B1:+T?[-GG*%>E1%D5_DU2?*#DG[FYU8NW^;W
MJ\S2EDS\MEW9Z<A982KD^_%"4J;(+I;6V`HGJ#OKS/UKS!7YZQ>_6.]V,5FX
M'+OEQ9MDEWSS(M=P\B3S;)4GA1270"G95#10UHST-O\`F<XWK7[$6/*^VD6?
MV_@O7+*\+E_B#B2/-N-XLDEM?SR"E0)<>84E*P*]`=7C+3+')F>YY/,J_P`/
MPBZJB(NJGHEHB-NI6^9JPTCBPZI"F`V/WSSBRG8)%4G5&ZLXBWIKNSFUPP?`
M.W.<Q,&MF%P\5@R+98,<L:84Z[L.ESY.^97=G29DJZ-4_=@*/05&AZ2R7@,[
M=<0?1/5=,+CW*5:JEM16@D-KJ5+"%*!4XU34DCUX'VYR/*K[@!<Q3D\]?;;:
M&RTKR):VIDMCS)R8J@"M`;W^$]*G0';SA';BV'O]VWOKR4.OX/VJQ;$(:G$A
M*V/+M<</H33IR)T!>HZ&L=[!R"I)2F3!?5Q%?NR`KD#OTITUWPY%X'!<YWXD
M<.^-U1AOT_,ZGH44?C-@D-(-25%5XN#;%0=B*I1^C5BAS3X]&0]<;-%4"$NR
M68R@"*T51GDGF>(7Q7UV%0#H"DBV]H9G:?)NY=FG3&I;%Z[OYM?K(Z)*)CB+
M1-O+RVHTJ4DT7+3U5]FN/<?F=>WP>/`=#T^P)]OS^[7);D%N+$O4*.\IV1'2
MXQ'OUP9@MA32WTK4IQ"_A^&I)VKKBC^9U2IU5Y$.USD89W(R*2^P518N27^V
M+56I2R;K)0X]]B4TUOV&&XR]I):-Y%QCL38;@<CR4)<:6"**!KO[A70Y+?,;
MJ&RT`E76GZ/#3M/3?P_/\@O<FK3?L=LL)#,B[WZX(B0V7U4889']^F2!XH;/
MAJ3,F#FO:J3+7VYQNU,6U-QO<):Y4^-#1&>9+;96X\\A!/FH"1X^[0$6I+:X
MDR;#4M+IA39,-3@%`I<9U32B`.E2FN@,/(FH-*$$?R:I/E\U^)>',$-\;2[Y
M3_G!J6P0Y&.W.K8')"=Z@+0*'VZZ-N<NYS\AA^XEG$"1&S:!1#<Y;#4]IH!"
M8\M(`')`_P!MKO[SK6]EY&5FNM>(9VV6)L>-(32BTBNVX70%:%'Q**]??K@A
MS/R/0GRKS#]HDEK<CDM221[$A5*?JUJ9EHG#^[7^L?U:DS*!>Y,P_P`1,\!!
M'_._)*':FUW?K0@D4U56->%N23-K\]C%?LIN0C&G527FX[*'9,EU7%F/&97)
MD.'V(:82XM6_NU6[;L[6T[N[W,(7%DJK%?\`4Y;=W<7X.U9@]-<Z,?K"<5OU
MC;<-^QVXVB9=/*E6UB\P7XJIMM4TI)F-LO)0M;'/QIL::\2[N(;BU*5O<1FE
MV*F./<>WL++V\=%Q>^QU&K3';9"9LEM1`)$1J@2CQ!'$'I[->=5]YZ5$%UQQ
MZ+-04-04-I(_=R%@)=_NC55$4(_DUIM]SNJTU/,XI[:4ZKB(.Y8@[";*VIC+
MP36B!]Y)K]T_HUZ]O<W7'WWJ?>>=>VRL2HVZM">\IQ(H1N!0]>HV.M%<=UZ'
M@F<\XI1;+"?I8-D^LG$Y#J4%N!B>6R%!1.X$$@4H:\N735UMX\6=>VQ]I>_W
M@QB3<)$6^3);;7S3"@8_()<C-(W0DA=2:#KKIC[L5'@C66VC*3DVZMC51)UE
MD1+1:O.3%=B%U3Y4`"^20D.*4=OBXT)U-5I<IX12,IV]M9QN2EU*/2E3%K.I
M7GZW.WKA,:_XB\';BQ,MMYAV^.6^=QD6A_YEQ,5:*J^:2R%!-:!1-!OKR?4/
M5]EZ3Z._6/4I:+6O2N#]I[?I'T[ZI]5>HV/3?2(J5V<'.5:^[2O#LPQ"/M=D
M^42K?:\G\I4F-<F438MSB.LJ<B.H=X.-R&DBA>BR*A:5IYH4D5U^0>N__0G\
M?_3MR-GU&5_J3Y7%5C[:'[]Z;_\`)W\H>K;*._V5NT]N\VY*B[Z5J(JU=M>[
M3EKSBVW^XVO*!?NZ5\S&SW28D.3W8EUAQ&><Q:D\O-CEC@A/W.(Z:XU_]!?0
M,I2EN)7E@FM*KFL.QGIQ_P#D3^4;FYM;;87-E<A<A)XZU*+B\:UHJ&#)>WG=
MK%9]LNV&7>#@"J^4I5P<>EL7!UL))ELHMKD:3%E(4"0.0`2>E=]???1_\@^A
M?5FJ?H=R?546Z--/35*N*2S:/R'^2/XG^L/XUWEK9?4UNWT;B?[EN2E'7V0S
M;JU5^1*WL5]1+U6]H;JQC0[S9VJ):(X97*>;?OF/RI:"7$M-PKL7U,05A?$$
M*)'4[:^X^;N9RQ?%U/RR=M0FXJI+JZ?6Z:[R62U]K^]N&)C3;1>94G\WP[!^
M.N1;HBWOP(4J7;8R$P?)>#A4E2$<VCO7;4?-3?8OO,9VE-4;&>P'$EP^U^)0
M9<N+=6W6,@NB%,O_`#,69'GWB7,AO!U9+K3OE.BJ004G8]-=EN74S-(1Z>"Q
M":YXVX6ER+4\94.,@JND+CSG68`;O.-BKDF)_=MU!]FKE!F;K)9:*'&%.R(J
MU56M#:E-K2%%)HI(^(;>X^%-`(B_VHJ0F9;HCJXDIM8\SRZ@$`DA0`J@5VWU
M:$5*2B\@QB'\-8?S^RNSHL:1YXF5#[2%DJ3'26PHD5HCPU6[[F1%235HM"8&
M/3T6]`CSE9#9$^="+:2EAZ(\V\E:4J3\((]AWU58JIB[$6ZML5?R[@+9EO29
M"D)(`4HC]I23R":=>.I(^7CQ88LN0F:*1%92Z*&JPIQ7,=%?O.5%5THB?EX<
M69)+R;A'=B.(:*)"2TI*6TIJ""H$E("@$J3[=0XINI'R\>+$1BKK^%9A&N"U
MK39KP46F\>6H^4W(2KA$N:^O(/5#:E*V]FNBU<::CA1DJQ&+33>!,>-`4ZRT
MXE7,I*02G="@L!06@TKQ(.NHT%%&M3Q-"T"D[%5#R*2`21[Z:`4D2R)^`>6H
M@FAY)'OK3IN=`?.28N'H*P(R7&_EY-24[A3C'$%(!`K\.V@>1T7?2T4I7HR[
M<)4%#R9V21P%;*3Y%V=:H12@^Y^O4G`3?[@+<:P7-G&7%M.HQ')%M.(-%-N(
MLTPH6GV*2H`C482DH<616C[CS'<L]1E]KGB<JOMXR!4R9EV/62=+D'C;;O:<
MCN#R[88CH(4EQM`4TZG=0\=<N]VKVM^,8U<&F\2R=MK/$II=]9N=MYK>+-F=
MU8E6V3+=:LMQ1#=A-V](<4#$?0ZX'E*9'WUDU).VPUM8VL+J]]M2*R_[<26^
M`93.RF*Q,MCGXY,E@):3%6)K+;CE`$O\%'R0H*Z+VH=8W-A&2HW)1KW'9"]T
M;>F%&WQ#^_\`I0M-Z7#O][Q2VR+D+C%GKM4.ZO0HY<0I3BG+A&84EA]'-7+B
M0=TC;7-)=#EQ[<2\8*^ZRPQ[!;3^PT2YWI-YR5V,OY6)&BPK>VMSRV8T4?N&
M&U)6`$,C:A\*ZLL<32E,!5LVF':4?*1([;#*$AM+::\0E-4BE37I[=2"0?I7
MM]LO'?CM["N]R@6VWP;@Y/?F75^/#MD9N&A"_+D2Y;[#3:U]3OL-0#KR[?Q8
MMV[AR;K;UQ9]M?=BQXEPA/-RX#[$=$=EIR+)9*VGF2$U"DJ(.I!:9WME_@G9
MVS0&U@?-1XT95#2GF-))XTVI55*'PUW6^1>!P7.=^)$;ZBER3C'H<Q_'6G/E
MG+[.Q*"A"#Q*DM$3GD@#P4.H]^KE#GTPME*\BM[AH$PDRIZ2H`H2(4"0\EU0
M4:?"EJI^S0-M*JS.3/OWWHQ''\BS)F_R^X5UNMYR;*Y]HLT+(56?\!6_D$MR
M7=S,<2^T^BX,*"V4_=&WLIKBELK<KFO4TR9;R]*UTM"T^8HH^;X#F'I\[<8+
M@3>4=K.X?=;*+MD5@OUUO+][R#.9V!M/S,<@7Z>%H^1AWB^PBW$<;0A"2*FN
MMG8BW6K,H)JWWXFCVV[@O]S\<1D-R2XK(&9$FWY,POXGF[LTM4=]3A`"5&0X
MQ4JI\777/=@K>137=_Q-;//5[']/KGY<3;6<IN\J&)#,)R5Y#%F;4$EE3U`5
M.A:U'X!OK.%9*J1K%MJKS''[->K;-LT8C77/,(M]FL=RE18-C1&2N+>+I+EO
MMLM%B*XM0$%)<%5E(!VIJ22U*!@MC.:8-<4VYH7Q#[,5MW=2X_S#2''D(HKA
MR3RI6F]-0"=L^T.?QMP2`EO@;3@]REO%(H4I$!386?`$)6=`53WM:V,GR-*O
M,^4D7:=,CJZ-U=D++J#X41QV^W4DJ_=M^["*:"5ZZ(XJ+-%CI4$UJ330B6YO
MSBTXJC&PR?`!FM_LM^F7&[0#8WD/,QH,Y<2/)<0H*'S031;J*"A!V(\-#'7=
M_P`4+:ZV9,J/+A3P%P;DQY:":%MJ04#XQL$U2K>M-*G;'<244J+(92P(D6"Z
M3,?N`4E33W)MPUXNH6.+3C6VZ5I1OI4UM77<N*#2HQR4-*6ED$#XW*=1U/(C
M^?0Z&J-HLZ\E/^BO]>K&14I9K7Z5CW#S4YI<,DRB^*S3)0[99,UFR6QOE=WZ
M-K*%A;_(#]G7YIZYN?J)VW\O%0PS5?S9[_ID?35/]Q)^)89VY3VULEKCS\&Q
MKM?VZMRTD(FMQH%YOBD)HGF),DR7TNJ0!6E#77Y3ZCO/J"%MV]]KG>;PK7!<
M,.\^YVD/29S]R,5&G9Q(R>I+*8=V[J6]2K[,OT6/B4<OS9"5L(8`<HEB"GBA
M+3*C0T2-]?J'T1Z??N^CSW>X24XI=KKBZ=K/D?7I6K7JD%8?N5?X/@,.<OL\
M5M`A1E.$KH7'*.**4G=52>HU]5T.]G)\R^[[PBN&7R91#3;9#>_$[!*:&HVK
ML3[M=%FRHO'!'"_4;R=-(FWI3[ZBI;JC4G8*4$C]%::ZY6ZTZ>*,+FXE?:E-
M4:--8V)IOUKX]=]3"$H24I*D48SDG%EA7TKHWS?J_LK0%2,*RU9Z=!%:"02:
M=5'77#WN4ZMMA[2]ONO(,VX2&GG$A$*,&FTH"7EDD<5A255"2GCOJ[33H\SM
M*O>^7>-?:N\VY3J&I$6XJ1&`4IQIT)!*B2*`)V)IX:SN.+73N.EN2=6%"#GU
M)QU*,7Y51%/NMZD;2G&9F:Q4R8[D!^!#\ESE)CLLKE(*W$,J*JJ6DG>E377Y
MK_)WI5_ZD^C+OH>P;^9I)PI@ZT=&GV'Z;_"7K=CZ<_D':>J;ZG_K*Z+B=6FI
M.CCYK#AWD3;/ZFY;%ZO,WMA?T6F'+=^;O^,7"&';`]<I/%#DZWU2E5O??K5Q
M#>RCN=]]?S7Z9_#?J/K7IUOTWZAVKG>A2EUZ7EYU^X_L/US^?O2_2/5I0^G_
M`%"YMXI^[8DY=-]U%J7W#JV_Z@&.62S9QA]ZRL-9Z]\M&Q*XVBPO3(EGGT:<
MD(DR5O-Q2$U-*A>VON=K_$WH_P!.[1[?Y1;OU)+-I.+KBE[U,E19'R_JG_T'
M_(WKF_LRAN-EZ?Z:HM7+D%1R7=IA6K\L1?\`IY[Q1<YMF4*R/)\QSF'<LC;N
M4N^WPM-QH,]+*HKR<9:IQ8BMFO)J@"@0?#7V_P#'GH_U!Z9OYSW^TVNT]-=F
M2BH**FY:HTJXQRI6N.=#\B_F?ZN^GO7_`$/:VMCO-UNO5(7T[G4E)PY95:U2
M>-<L.)*]7;YJ9&1<K<MJ\V=Q)6U*CBC[#=31N=%J%-KJ#T!!I77Z\?S-/W[C
M<,4$;6(6AJ_P@J!"4@1I2G$%"2V5?+N%/.B"@K!Z5WU%:4KQ*SM3MQU35(DT
M<#BE';C"&VAY26K(Z@-H4HI2GYAT[;_=57H->M93BE*6"J%&4L4L#)-3-Q^:
MU=&XJ/.H'/F$*6E]M*AU02*.`C8H7R0H'<:N8'P<(QWN*@'!7(EBS>47''\6
MG+3%QW(UBJWA:Y3A2BT7IRM4H4/)=70<@335HPE)5BL":.E>PC)F=XM';*X_
ME_+KE"LERG+D(.)WZ4B'>N<0*<>X0%+0XM"/+)J*)4!\).M(1E"6J2I$SU1;
MTI^\.1V/BXWD<&'WHM?:)ON7C-TD-XU;8.1LN6Q.*NOS&XUSS2ZV\26+@(=N
M8;*HZ%;2$GH1K&][W+B6+\_4!Z->TG=WTC*SCLECEKQ[,+3!@96'[/$5$$Y=
M@C%F]VE;#94X&D_W]I)/W%T%0-5CRJN="3GQ;1(=<<B)0V;A%XIFL`N?`X@#
MSEMD@+4A3A-1^R1JP/E=OE+<4`Q&'(FBRHBE?VB?"F@,"+++4MPJFELA)"&V
M0GXBH<2$JK6@KXG0`@8-&AQ93#LB=<8T]PJG*G.NR%--*67&_D:D^0B*XKDD
M?LD;;ZM!TDF\@2Q[/LO7>U+L<WB_=<:X1I*]N4RW``V^X@*^):%L$))ZE8.V
MNKJ6^)6C']BX];V$K>DS849`!*O/E1VDMT&X4%.@I2*;F@H-3KB^TJY).C#$
M3L"A^4B;DUB\U))#49Y4QXUK7BA@*J3^FNI4D\F-40T5/Q6YPGV++;,IR"4Z
M`EE%NQJ<XT-N%2I;2$D<_'5N\.2IF7S?3PL$_&?2_B%HN-NF6M]J[Y,\W$GL
M*C2DL2;HM]"W&5`%/+F>ND91DJQ=4<)*[N&1^1,VJ0$_D_)JDF@H;+-K6NP&
MHBG\Q"O*GB4N248M5]X\E/N+F^&JRO->W5YN$F'%N>89>MF\L-+=?L-T9R">
MJV3XGEMK=>;;DI2ASB""V2#MKZ7U"UM;JA<MM2HCP'<W4;ZE)-6L>'EVU(0]
MXO3Y,S"))1)3!M7>RRLN3W;4T^D6CN'8'$_X+>\?;44A,E]D!:B-BY5)`(U\
MCO=YM]I*DY47F?4>FPZ\$WS$Z/2SV8B]I^UT1N([<D93EMJ8N.2R9<@E=JGN
M-J9;CP6G"M#+T-*CR``!(!KMKU-=F_LH;JPU*U)X-=M,\\<#EC*4[S@NQO[F
M31M=8-N@0W)+\UV)%99=FRG`X_*<0@<WW5$"BUUW&^O#W'Y'JV/<7O88B>N]
MP:Y%-.=0KX`/$5WZ>!U*R)>8V5R=?4IQ;E6TA1XT/$A-?'B=2")/J,1WG9LM
MDRCM3B&098QA%V_,62R+'"F7E-K:"D-1'LAM4!M3CUF<6`A06E2%;<M%WD2:
MBJO(ZN/\W,NWJ:S[L;EF5>H6!<X%DR;N]"=[50[Q!E65W\+\AE=X1;;=*0B0
MQ94N@)0W_>^2@4@:8%.K;XG5%ZFY`$3`\99;`,JZ6Z.J.D[_`+UUEE(^*@52
MNWOUW0Y%X''-IS;652%'U<[NF%VX[.8*V$CYF[O3U!(W#=KMJ&$J--N(*3_1
MJY4HYQ@6Z*_>W[N7FK1`Q++)-SD16E/RVK>JV.L+6S&*T>;Y*'MD`A2JT'71
MNBJ\B4JM+O./+UU^BWOEVN[B]M,AG0KE/[<>I:Y\.UF6O/1Y41427<W$KM!+
M!4W`>AQ'O,5&6>;?&G4:R5ZV\FOO.KY=>9IV7&I>6]Z+EEN,QGKGC/8VS6_L
M5V1@VUM4D9EW7-M<L%G5;66PD*M\.]2W[E<9('%EIL%9J=3U8<<S-V9:Z)/2
M2#[>]I'NS<"1AUX<9>RA-P2[ET]IQ2D/WI27')*65+*:,MN+%-@:G7-?DI<I
MIT(E5/?9$JT^H.\S,L9DJ@HR"#.CAU"E)?LB"TIM4=*ZI<:"4[`;'IJ+49JS
M1+%U_$PG:DIT2P)CX#W)[?=W?4+VFM-EO5]?;G9)CL:+9(-N5;[8VJWJ:(5*
M22%$D((-*-^T=-4<)156L"CC)8LZ3\/LSEW[HXS$C,/.-1C)E*<9:4IIDM.A
MILJ=0GRTG<`5/+?52I-UFT?,>H#,5GD4XQVBG$K))X.&(E(2=SQ<Y&E.OMU7
M7'B24UY5:UN74+6MX,J>DJ<;;<*15;KE:@*H2HC^35DT\4;V[2G&KSJ%;<**
MV1Q8`IX*"".GB*$$ZFAI\O$V>#9V*$$>SBG^K0=")BDQ!-C.0TT3YB%);-*!
M"Z5!3M1))%*CVZ&,K-Q-T6`TF;VA#T%-V;86U=K`A+$^@'*1$2I)"T\:DJ0$
M=?`'0O9MSC=4I*B-JROHGLP7D;_$RNAWZA/WO$G0ZY8MM95+3?*/]A'^M.K>
M96A23W6[<6.Z9]G#\F"R'DY?D?!U%:I4;J^I!'$I4%4\:Z\J_N5>CI<4='RL
MX8PS&H18\MQ!:9&,Y)/BK;<\]J),=,R(2`!4-*)XI(32E?#7G7-GZ;N+;CNH
MQ5VN&'9_U-[=_>;>#T)XO[=HO8N4YKF\:;=,Q?8EW2#;4VMIV&SY32X,=:`S
M^['1TGQZT&N[8;/;[2R[=F?NO]./]#@NW[]RXIW5[R9KL(4EM"2E2?W:2`?A
M`!&_4@"IUV=*(ZL^\R`$F@&_LUQO,DR);7_9.NFQROQ*L^@A8-2@GW:O=^&R
MLLBQGZ6,=?\`[5+4A`+:F,`RATN#J@4CBHZ=:TU;;G=MOS+H>Z$:4_>92VVI
M(00DK6Q1/-1-3XGER]NM9\[\1/<:9./!D.,A[/XUF.:,1<[MK,Y$ZWN+M)GO
M)#$5RHX%:2>*7J"@%?'5)6^HO`K\Y22A_D%I]*G;]A3L25B<.1!>43\M*2)$
M9[@?@)955"E!0V/LUY5[;14ZSY.WP[3U=O>GM:.TZ7'2CX/L?M&?]7MA]-WI
MV[(1<JSOM6MRSY%-?QZ3><#MUK@99;W&(_GL-Q9+S)90W-XEI3E`XBM0=>WZ
M9:],U+!9GF>J+=SF[UVZ^NNWO*T<$]0OT\S%[8JOOIN[C1)60W*ZRL<R1W)H
M-Q5`BN2%VV+C&7VM]-;A)=ET=\]`JD+I6@U[.Y]-]%N0Z[4>J^[A@C@V_J7K
M*2M3O2TKO9+/`NV46T7_`+F0++!APK6QD\&YPK4TV`W;F[Q;D2DQVDIXH0T6
MN&P%.0.OEK\+,)M6COE*Y.WJN3<G7*I*#%XUQM#33D=;T12$$)6TK@$CD=N!
MJVM'M!!J-8$6N8,9C2\GR*#%C1XS5V=BR&RY'^!,A0865.K:2`VE7V#5;GZ?
M_)'I3M=:UIX8DM.U%ANKUCPC&C9;J_+1C[\DRF(#TB`[%9DNB4\N0R%!GY4"
MJ@KQZ:]I_"7B>+N;OR[I5C]Y%VV@2L60L/!5X9\WBTI#BFGHY!X*+E`$+`'0
MBNA!4)ZZ/4,/1OVO_/,>TM7_`"Z^W,6##;0MTMPU7/B9#D^X@<71$MZ$<_A(
M)4!KJL<C\33_`%>;*8+LW?\`NMZF?3/W,]27J(QGNF.^</\`'KO!PR7+FSNV
M=N\YN-;,6R-EKRG&"R7@?+02M21\1IJ][X;.&/Q5YG3/Z:T=BNRN;WGLIC&?
M6"YR\PAVNWY$N1E+\]IR2TV7K:MN9+=,*%*(4E`A(4'$D<377$=1>-]/;O*<
M?RW)O3WEK[KS<AF1-QYF804R2RTII<,I>KM)@K6VI-36B?9H"L;UZ^FJ=V)[
M_P!YD8M!6UC66*D93CODI5Y"H,Y:WI-L\P%24NL2E*2I/@*;:`B7!@NW-891
M%8^>XJ=E1%/-)#35*E:1]Y83X@"N@#IG$[DZL>6F"A*:"A034G<C>G30"F@8
M5<G`L/26D)\6FV:\TCJE)*A2HT`\/;3MOC$C*+9$RV!<7H[C2F8[L&XR8#TF
M$XI:_DY;L<I+Y:=75-34`TT!81B?8CL#$2A0P.T.24(H7+W<G)=3UW0^^I16
M?&IUR7(WW-N%=)U0E84$I<Q("Q8=VIM:64VS'<%MRVPD48M<)UT\3L"X$+<5
MO[^NIMQW%7F6U;;N':M4BQ1]F!`:04%*3!M[2!N#LD)0E=:^T]=;*.XS[")2
MV^ETI6C)Z]E^'Y!MA05E)>E;N(*%?WP?L%2N/Z]=UCD/"[!0=PV6Y&`YQ'77
MB_A^3,K(-"$KLDX<@?`@:Z'[KUDNVI.M#R3;K<NX':+N3F[;F+-9)%DY)G=F
MAYA$M4.7=XF/7+(;D+A"")*%A#CR%\?.H5H'2AUI8]2A&YHN<M&9W=IJA1KM
M0CKMAT'*LBQZY1,FL5JPVV6]J-C+TE]T9_VTN;9+D]F.T^4_C%KNW$^:VXH\
M%[I&O,W\=MN7CC4VV]SY7!8$J)EU:M=DAL8S*5D463$C"3>(Z?WC:V4D*D2(
MV[\=;U:E-*5KOKOLWK,/3K6QM\T6W[:_U+VK6FYU*9U^\,K1D[\MAN,^I=*"
MJQR*E;)34T'PG;I6NO,W'Y'4'KZD%-`2LJ%`\KX6T5_MJ5N/U:+(L-GDM_8A
M\DH9<?W4@K!"4\TFAX$UY)KXZD%Y'T/L;C7J#Z@\Y;MS3K+HL&(J$R.W+C.%
M:A/E,%I\*0[52-ZA0%>FA#CJ6GB='/96T&1GW;6W0XS$>%^,3[D\U%CLQF6F
M8O!*`TQ&0TPTA2D4^%(&VH,_ET2G[X.*O'>_MM80?-2FY6R0AO<D?+OE]2B/
MVC5GV^.O0AR+P.-YE=OU;[\)7=+MIC;;FULQ.?,=1]X-N3Y:VVU<=@"&TG[:
MZL04]Y.XFW]M.[]Q2YY<AO!Y<*.I(H4N3Y;#(XGP*T5V'LU6?(_!EH<Z\4,+
MV@RRS7'MY%[4]T+)!S3ME,F19=JMMYB,SIN*Y2XA<=N]8=,F%QRP39/.CQ8*
M014TKKRCU1E^Q&&X/:+_`)/!QW`<4QMO#,YO]GQF-;[>PX+)#=<5\W/B/&M+
MQ<^9,B3NXKD0"!K19&<LRMWO$AY7<[/6TMKJC))R!YB0005`J7P-"I2O[5=M
M6(&WA^EJS>JC);#@EUM,<W*2F2J/D[JC&=L%OAM^9,F2Y+0*UV^&R*\%$`J\
M=3UM"IP*NA,WTM?3@],/9G);+WFPNW=PO4#)Q&5+?_.")";1A5F?A.+AW"59
MVG5E=Y-M4'`4$<S0T]NIE>UK25=N,\"ZV8SB6%=M9USL,N`Y(OL)Z\8S,;A%
MJ8MMQUN<F.'"BO%A*"DA13XZI@1\NBM/TG_4=P+.^\GJ4QSOO<;!VSRUW$+E
MCF`7-;A8L68NQY2H#<(+4G_`KPIUH5#GWN6M?E_$XAJLO84Q-C\@4EY'F@'I
M0@N!25;I6A?.H4#0C590T.AUV.3S$HAH.)4LDC?I3VG53<V6FD@&OQ;^/V:`
MRAKD0$M;U^$U\1N#H`DO<()=:F/,<FGJ1KBA*`I+L922E2U#]GB3H!G;>MC#
MKS,MEZD-QX7S0DVZ2^:)<A/K+C0;;KR66@M*:;;ZNK<WC3`BJ+4_S;BO_+2O
M^\5?UZMTI\/P(U%1_<%Q(SO.*J)IE^1'P_8N<A'M\0:Z^;/:$@NTR+DV%,QG
MWAP6NK+#CQ2VV.2UJX"@2CJ?9KFO<Z*3Y3?PB"IN'=5D)*`E8J4`@A2R`=]_
M'QUZ6WSB>3=Y_,/'[-">+=6`H);;)``'QTJ%$Z[RH2KQ9"EE492DI'(DN4Z[
M[`]![-5T0X(FH52+3+:64I;!`KN$FGZQJ4E'+`@T'FR@%M0*'*#J.)'OJ1JE
MWD9.99)]+.,/_:/GO)7\2>VV3@;[J)^6-.A]FIV^7D7C*47[K:+P<JM8?:0^
M'W'9LR<['1#;0.3:DK"6%..$U`)IMTUU22U,JTFZO,@MWCMMP:R)3+ZW6YC+
MK*E);6I*6W65I/[KB?AH.M-2L(NA*A!XM*JR)2364KQ;&YK=$NB-$#BDBBU5
M8;*EJ5O4UWKKS=Q1X/(Z5.<I1<FVTU0KP^K-'BW#T.WN6ZAA#EIR>T.-.O!*
M4LK?0^AQ2EJ(""Z>/CN::MM;=N#]U)%MTE-N4\95.52\SFK?C'8*8B6VU\O"
M5</F'9"$-?!D[KA*7"L"G[NM2?#7H7.7#@<%J,7)U2:J=!^$9E<E7O+)@!4Q
M<X^#R`ME1*2#8C\514*20H;Z\ZW%.YBJX'?.W;C;K%).I*C\PJ8L(D*C\U%D
M**B*+">/)5%*-14>.L[B2FTCIL2M1MJJ6KP$EA=RN[N;?F.'-MJ[?$MMP\MI
MMY*9$=:H+O`K0#1]25TKJ;48RFE+%'2KZ2:C1.A-KMQZI>XO:7MGV_R>P/65
M=WLUI*Y$6Z1A(;O(F3W4J9<0NO\`@ZVOA4#L1UU[5F*DJ-51Y6[E9D_>46^\
MM]].6?>DCU/]JK=W3[B9S;>T67W>YRK-?\9E2K9:K7#OT9`!1:G)"VDS&)HH
MMI*:FJN(&NC1#@CR.I/BRNSZJGTI>TGJD[?P\([=]Y8T')+)<OS3BU\F069+
M$"X/(4H6>]PV%_,?(SXZOO)HI`H?9JDI1MO2L#ILRE*&+>9S3X%]$CU`]H.Z
MV/77NU?\'@]N3=9L9J_81<9,R7.=8CN)8\B*]';>MZWE*112EBG4=-9W+BE%
MHNHJM:8B?M>!9G>_3KW,[-+7*LV7^F_OA=W7[F6Y4'(KQ#_&$Y!:LF<O3B42
M)DAM@#@ZI:JUH#37.7.BSMEWVQ_-,5[4^ICLSE[65.8(_9;)E=[B-KXG(+!$
MA-9#$ENAQ(>=2_4N%/(*54BHU!PRG-2:J\R[GUH7_L_WN]*UA[FR\VPW%<M8
ML?YMP^+D=[M=HF720N.A%\L49,MYM]Q`EK#B6T5H"331&UB4I)ZFV416C&)E
MYQ"QWR-\I"R:%,?B746]Y#L)B4^XEV*IJ2V3\W&<BJY)5N%@[:DZ!Z,1QU_(
M_.C!Z'`N-O"$R8_DI>^;20!\]'"J*+*E[&G16@'BL_:]"EMB7.=>55%4MM,1
MVA[A3XRD'].K059I/*I2=5!M9T'8M':^W-KCNAY/G1W$O1U.R*AM\4XJ!I45
MI3;79HAP1Q]2?%CUXWB&/O(C2'9B6W)3DEKY:0Z%//2(XY25-))#BVO80*[Z
MMICV)%=4GBV2#Q3#L64B/5(5T*>,>0X?#VBH^W6^WLJXVEA1"KXDD<7PRPI#
M:D0G'QQ_X/0]?[*P5)UTO9T3=>PC4^)+G#8D:%8(D>*VIII)=(0I/$U*AR-/
M>=>>DHJBP0/S.4I.%Y>*`_\`-?(`>G0V>:-_MU$GAW$IL\O'N+"7:\AS1A3C
MB6W<GRWY=0J"I?Y@GK*5'VD;_HUY+45.O:7BYRPJZ$/)<&4_<'_-:;4HO.+\
MU;:5+)434J44]2!UU-(O,EVF\PZAN3;5(0[!D.Q7.`0HLJ6D*`(V6E-`I-1X
M]-7C<A&6J-%*G`ZU2E.X<:Q99=6W`J1):*2:J6AE@+4J@J5%8Y<O;X:.]"6=
M&2*"?=94R%+?2ZN1^Y5S:\TM^6D#<A`H.5#M[].M#N`R5_N4ETM>>Z7/)04I
M9%0VE`1S305HKKN?;JRFIXHDZOOH<X4JS>BB_9HXVIN5FW<N^36E^7P"X5H8
M;B)HN@YD.&H\!759U46T4N2<8.4<&=`/ILQ]O^(]E2:."TXXIY2B`KBN6IYX
MD^"5+)I7QUO82>>.)R]:]_E*GB+I2SDOJSM#9_>-V%FX22/OI:;8C_![D)YK
MH/>K7:99E2_U+[R+YZHK]#VICV-X[;6U!5:*<BJDNA/]D\W/B'MU#R?@2LRL
M[N;&+'9W.7W'/*3/N=BM"E$A(<;67'W$D_M)2I`)'MUYUZY--I-TP[3T+-N#
MA5I5HR.-CC-1+986.(2EIQF6"@`%P\@$NFG4\:D'6)%7Q&N[-RK_`&_,^YDJ
MVV\7^WN]R'/.8,I$0VRU*`5=;JIQ0*I#<4))+:=SX;ZUCD6S(R9IVCS'N1WF
MS!>&V9-RM$J9'E-7"3(#,9E<ELF0B02E3@4TL>-#OJP)#XUV6RCTQ=O<TSR;
M#1EF;9I#&$X]9,<#KDBW6R4HNY#/4LI6L)CQ^->(`4-M5<8MU:50'?T\^[DS
MM39NZV`=TX[F.]O(]RNN>89)N<&2DK5</BO%EMD&0$OW(2U`J0VR"VVHJ)&B
MC%9)$IM8K,7V:^M3M;!Q:X]NF;?-AQ\C?R.Y6C(,A>AB/CUH6RM3$%CR559<
M4M0_<J*5I00"-6)USXLY-<JX7/,LYFASSW)-VN$F-("N:F5NW5Q4>8TO=0!(
M2H$=1XZ]$\LN2]/O=21W6[78^;R0K)</;_+=]>"U+5(^62#"ECD2M/F1P*UZ
M@:Y+_/Y'78Y/,?%I`4V0E-*^Q-.AK[-8FYL(0AI)\PH%2:<BDGX157Z@-`:Z
M9\=:PJ,5R0@D%#"*!5!0T<`V%?'0&RMJ[W)*T)8CQHZFU,J"VB\XM#E#\1(J
M./']-=0#'"PZU7N;"B7ZVQ[A(MBVFFGI325.&.HA7)@JJ"E-!]E*:[X\J\"I
M:A_#W"_^"-?[FQ_L=6*U.?'N+++6>9OR13EE^2)WZ45=GP2>NVOD#W!(R,VR
M"P,)5CDAMM\-NL.(6.3;\:2VXS(96*T*5I4-NAIJT8QEC))G)N)24DDW2@K>
MVUPD)PN;)N324/-M.M**4E1>H^.*RH[I"4]/8-M=%G":2R.2:357F*9BY)4V
MVKR"GDTV05I^\..Q34&HUW&1HR[B_P#ND,M?"ZHA?%5"T!^UTW%=`:A4Z2ZC
MSUCXNJ30;@;T-=]`)EZWR%3/F')CBVDK`4RI((4.5*%7+V^[6=WX;)69:!],
M&,RWZAL@4D!/#MED*4GIQ6M<8`U\:C[-3MR>TN7[EK;MUX<BH\YSE:XSZDL$
MCRI"VP2Y5(5Q6L_I!UURS9(QMY[0Y#ETB#,:6P&)+(4'WG@Z_P`0*.!T%2%<
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M=E=5/5V4R.F5S5'30D?W9QJ7;,34J,H(0E(31H%-4$4H5`^PTUP7&W-MX,SU
M26%<".':5^0B[2E.-%QM$.5P;5SH%.)6V"=Z$I`.KV%6?D6C*6./865=N.VW
M:_.<$Q2-W*SBZ8);6\;9^6<LUB_'+G=9(GN\FHT9(*DEI)J*@C7IV[W3[#S=
MPY5'/LOI)[4YVK'IEASN1B';SMTFZW7&9V9.1V9$C)FWD^9DMY@H4XT)+<@A
M33:4+6D@5%-=?6M<3@ZS_P`6?G=#M#WC]1N/"WXSDEP[9MX)=EPHG<:T7Y][
M*\]7;%%,J[WN,M3,>5)NCS85%04<4,\4T--<E^ER>J#PH=^U>NW6E,17V?MS
MW%9[83L,S?(9F9W)-NB/VB_72&(>1LWF-O*CWI4=?R)4M*04>4$E5=]9*+3K
M7`Z:"(OW9"R=X\1M\"5>8^#761C=SMN4W5ZRQH+M]@I^9MB1=93Y0B1*CJ!*
M%@\U-`'IK0D:3T8^DGLWZ,(C^"]M^]%Q[IR>[%\DXZ]C^;W2T.=G\=SB&AVZ
M-Q8L>W.>;`N]\;6$-I6JJP*U/353SI\[\6/#ZB[?8?5YZ?\`/NTT7').,>IK
MTT2GL@G]M9/EMWVR"!%D*<N%IC^6#>,`RJW,K^2EL)6CD0E9"M:VX:ZU=#2U
M<T5PK4BIZ!NY[.865O`LED)CS$0EX_*;GK"9$:2T\58L^JJBOS67`Y'>52H4
M@).KRM)1;U+`UZ[_`,1W>XW>GN3V][U,X-C78#.<G8L>.2;Q=.XMNG0H./E3
M*PTNU16W5(7.>4W4K2%$H*:T.L*FUM]2+E2E&63]L[K-GXRSDN;6FTVQB1;+
M3>H=P@R'7?FK?D!4F%#ELN+46;@PM/!PCX>=>FKV^=>)C=NT3C0?^RW>R)X!
MB&TZV`BBDK0%I7L4FIK2GL\==YRA9W/F2D6R%F6/L)AWO$I[-VM_)R/PN(CI
M#$F"ZA"*B+/C.K;5RZ$\O"F@)0X!W0Q')L=LF30+A!3`N\-N6PAR1&:7%<<`
M$J$MHKY(>B26U)4D^[71MHN4G26FB(EJI[JJ/Q9^[V)6UI"'+W;$%(()^89)
MH230T63T.NIVI*+;NJE.']RM9_X_>2W[<9'`RG%8-XMDEF5#>7(;0ZR>25*;
M<`-%"@V^S7DJ]9G\.2DC0,<W_P`C,Q_Z+W[_`!1+U,^7$+,\S[.;?&?R#,&'
MV@X1EF4+3RIR0%WF?4\C7[NO,IJG3Q.ZU95M]1NJIEXD3KUC@M\YUQMDJ9<<
M)!V(JHT)!]E!TUE<GT^\WUPX/VA'.M=$@H(2=MRCP)Z=1K/I2>.HR;-",VMD
M']JA5[NM-.E+_(BHL([IAVE[YEGS#,"DM)'QK#8'(K\O[RJ#H-.C+_(5$ODN
M*6]>,G*(ET;=:+3B3;U@IEAS@L*2$J51`212A]NNBS%QBTW7$E':M],_#7,*
M^GQZ=[06'$.7G&9F0.-.-A#WFWRZON.%P#=1"6TA)/4:V4.H]&52EWX;+>?3
M$RO\S9I=E-\&849J*A2D5\E+$?9NOO54ZZK=GI]M3A-/L@MR]^H?N#?""ZB!
M:'&0O<\#*FI1SJ?NT0ST_JUN"DKU?7DY+ZC^[-PY^<!DCT%AVO+BS`;0PV!4
M#;:E-97;FA99BM"!WJ&N1M?:+$K-Q<5+S#N<TPVE"D)4Y&@1PEXT6H<FVPYN
M:@#7!-:W4ZK>X44HT^_B1BQ9R=-SBZ1KVB2Q:&HC$"W.1%5M,9N(D'SY4H#R
MD./4-=Z)Z;ZC0:UCQ0@)_?7MCVRS>;:8F38?;I5^NBA<)4N2W-AV:.D!V5<;
M@TW\,AGD/BJ1RI32NG`E-=F05VGU0^G'!W;S^0E]QN\>:Y*[/O&0S>WN..VJ
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MFW;O`3'4%)>2FH'LUT?,=QA\OWFGZ*EI&(90F'Y*9MQO++P1(6E"7XS<;@I;
M*B%)4HI7R%*UI365R>N5<L#6"5M:6R;,>T7R>VMW_"`E`4?A2"W0$[*4UYB@
MD@T)H::H6U1XB[LW:3*KE":NMNQN9=H,E,[_`(QCEMR,P+<UYTQY_FZAQ+3;
M5?V*FAVT&J/%&&T6R&^RAR"F,ZRXI:&WHQ2ZRZEFJ'5H4*'BA8I0@'VZ%A7M
M6A:0E*6DFHW(0-J>[E[]`;<S&E)5!N<84EPR"ZTV*%Z/MS9`2/BY`UI[=6US
MXL%@7.#_`,"N7^YK_KU.N?%E#FY[D%2^X&;I*C3\W9+UJ>EV?]].NO`T'H_,
M]WWC;2SM3V4_G.E=+T\3&Y/J.M*8#OX14XLZ`W\!<6E2200JJZ$G;WUUVVK5
M&IUR,I<H<\5*\MM7PA">*=OV1T%*^&N@Q,R8_$GBK<U!^[O^@Z`_!&0FO)-2
M234_R]#H`GGA+:T=$H+J$J)-$U*TD`D^)U2XFX-+,E%F'TQF0[Z@+^EH(-<%
MNJ%'E7BU\Q%\RE#_`&*C4V*I8\">TM^O-Q5,NV5NI;<?=_&XT1D*;*UB&A*@
M/AXD@)I7;72VJLD6;#J(\:$TA*64I9(*0"GB.(ZU%14ZRG**S:(86K5#F.".
MH`C<+XBJ>1)ITJ*ZRE*+BTFJT(69"KUIVB'8;'V&SR]PUS.W>"]]\1OW<4):
M\]BVVI:E185UFL!+A7"M4Z0EQ2B*((W(U6PFEC@;55!\>\V'/]PS&N%FN,2[
M1WNXMOE0[U&<9=A3FI5@AKA3(\MLN-AMYE8(^+8=>FNEO]RO9A^!/@0<],W9
MI,'UJ][\0A66T0NW.9V54^UWVP(1\O?NXN)*\C*I$5U!,>4W$:4$NNM`A;A-
M34:G>[A6=NI1QEJ6"QXDI.3HLR<O=[TULW.$]`0]*CPUI*F7&E!9K4<>:0#0
M>[Q&O(5WJ^^\&^PAIK!D3&/3[:L#M\R<R\Y,FI1(YN+21\*23P0WM\*03OX:
MZ+*<95E@J$K!.O`P95EU_P`+Q/`8%N@1[B;Q9WG+4H-I4[#D)>7';;9>H>`4
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MD!#B5K:DD'8&FH<W'!5-]M",M6JF!=GVT^F#Z7L!]/\`9>X'82P7^=W78L+-
MZF9=G=ZE7JXY#<6D)>RR#?8#2VXD=Q,\J?0MI(6CER3MIU99.M/`Z>C#N]I4
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M.N'>V[NXA&.WFHR3QQ65#HVURW;DW-530Y*_61;(K9\MN"A8!`+B&UKVI0$D
MFH_HUYWR&_>#O1H^]'6]S9<6J=AT=_3BSU/<WTK89EZ2R?G;KD;)4PGBTHQ;
MDMJH`J*@"GZ-=VU]->T?-5U/-3PH3#S;_)#+!_:Q>_5'M_XLDC^8Z]"?*%F>
M:WGUO7^9,O<X*'_.C)0E5%`$&]3]@>F^O-3_`'?)GJ_ZWY#$7J,T^@1_+#:T
M(Y4-0K91Y+HK>@*A^O7/?C)O!-F0WMPA*;(;54J430TH:()"AO["1J\6J4KB
M0:$*S*F2DM(!#6[CZP*EI"-U':H'*O\`)JQ!OP8:)=V>E$*7;K/Q557+@"D_
MNT5K0572H/70#CQ/3GW0[OBZ+[16J#>(EKCHFY-9I,^'$D%E5//EV.`ZL2[E
M(0R"M26P4``5IK2!9%_G=CZGN+>F/T?VW'NUN+NVONUVI[<X98K=@?<&`J-/
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M-TN=[Q]<JSX%;,JS.9$M++:;BM%K8D2&_D`V@_X0I]"5B@)52N^AP]65>5C,
M_2J^HM#]7ML]1OI$ROMF\Y;;Q@5TR"XY,W'EH-F@P[DK&58OD:9#8;F/SK=(
M#[95MYJ0`-B-6::SR/73J4S>HW'^XGH3N60]LL&QUG)9C6876[XI=R^S(EP\
M-=0J;;TIM?-+UQN41MSBXW0CBFNHS.+<N?46F+:IV(87M=WP[_=_NZ'9^SR^
MZ-\[41KO?;=C5TD-1V1%R*\2YB4,K3;$L.-VV.X%AM[S:!JM::42\3F<KL<7
M&5#K$])WICN'IV]1UKD]Z<LA]U+5W6CJA6FWO-2(]EPQ]IA,6Y6]B&`W&GJN
M*)(=+G$GJ1MJ"O4E_BQ9Y5Z<,6M=F[FX1$L:+3E7:O*KX;,_"2VPU,L4N2JX
MQ_FT(2DOM&(Y1)IO2M=#U(3CH56JT1$ZWXVN152&$DE05P2E1"`I*0&TT-2`
M03J3123R:8N8F'!0;6\&8X3P*O-6AJG&E:>;Q--O?H23U_!K9_MT'_7M?UZF
MA&)R1]QU_P#/W."%?%^<,E]E>/XL]X>RNO'TRX,TJANI52/;T)_6:G64XR4U
M@R:H>O"2!B@"".2EN&B:$D!S8TZTUZ%J2TTKB1+(-TA2D(6L'E\0J13QZ>&M
M3$VU>4EL+*DBH)J?:.H^TZ`PE32T<PZF@2I7B>GO'V:`(YK/S*1Q(IY[3N]=
MTI(V%`=SH"S+Z9#B87>W*YB4'S$X%<FV4T))6^^P#5/CQ2DDZ`NNL6(9?E'<
M-A.)Q+5(GY"XS'BPWYK"%NNMLA+R2RH%*'>1IOOH!<9AV;[KXJIPWW!;]&6@
MN>?(C0G)D44V)#T<+;2@=1MT.JRM]3`E#'V\OHD.)=#L=Y+J^3$AEV,Z%(60
M>*7PWSW'AJJV]'7`G$6%PMEKR"T2\8R&S0<@L.0Q'+7>;%<T)D0;I!G#RI##
MS/Q"I2HE"JA2%@$;C6A4KCN'H3DVB5D.+8WW\[L8AVF9[G(LT;M/:KS(,9-M
M>BQ94AB+>7)!GLE:91;3O\#8H-2C6'*6`MV;MAVX[]>D3&\*MS&.XI8^VO=J
MP-VY#!^80ZS&;=D2)[Y4IZ9-DR:N.O+*EN*5OX:YMU\+S1T[?XGD2LR!J%*B
MI>86'V76@6JMBA2II(Y4550!Z^[7!#XGF1>^*_(A#W4M#;>/WDM-)2L,SN*T
MI)/][<^Z*54?&FO0N?#7B83(^65]3_;#$[3&_+WG-6*2Y)>G+:?OTI,B4XEN
M+`C*2IU#:'14\?C(Z:Z=OEYF9!OU/^E;.I+<#.LTQW(+O;3A\NTHNTK'+I`4
MP7WE/P)S<^3';;<5!:(`)5N!0:[MMMO8<FXS\B&F#8GZAKU(Q)K`,(RG([3A
M&22)%WF,X[,89R&/)A*C!B>#&0@K8JAY*@KHD;U.O3GMO<R..S72_$S9WWB]
M04FV7#%+6W(M]LP>ZW*1G4IIIZ"[YBXY6_&O'F-)E.Q414%/$$@'<;Z\>]9T
M2U<#8=OM#ZP>Z>)=G,YF8CEDF;CN'08=\=M5VR-Q%RNMD<2.<&(Z^IV3-9;D
MJ6&(S1JE(^(#6)!!#/>Z??#U+7ZUY5VES[(,)QR1"NWYCQV1F+UDMMRN+RDO
M.7%4)2P`\VS\(0"*]*:E'IW/A+_Q7X%C'TM('=O`9F589W8SFT2NU^?OHDXE
MC5XN#S]_B9FLA^/>L>3,Y*7!FD46IM8',#;?0\_JNVW1TJ=?_P!/WOBJYM7_
M`+191*AIR/&`W<+=%N4AEA>0QXZ/+G1X:9:V53I$ZW)`<:0"KFFI&I2JZ<2T
M;\I24:K%E57JN^GBBV>H7O!+S5YSN'B64W)[O)V<C+>\G),0LD]I4:6QC<MM
M:5ERP7PUD1S\#K>FC1AQ.U$*>R_>G#/3KVP[JX;WZNCUN85W&GXU%@0(YND]
M[\X6MVVPVYUN9J_:T3WRBI="4A==]97OA2\#2VXJ:<N6N)`WN>UW!NEX83V2
MA/XM%;GI9<B95%=DI>BMDM-QXJV$N_N7.7(*KXT/36.WX]PW-S:DZ4^DWN%`
M]/N0=X;C>+<U<<:FV6$_:6G*MWM5VC,><S$"AY[,M$E9(13B0/;KLE34SC5E
M36J--+(GN6/.Y#@<,".PE(4VMU4T)6@H.[2T@\SQ4:'V'PU7`I=M=-)\686\
M9S>8RLNEN(I'.J5R`X*`GBI*DD_>2*[G:NBS1@=I'T8+;-M7H'[;0Y[R'Y*+
M_F:U.-JYI(<O"E#?Q(WUZ1)9;FG^2F5?]%[_`/XN?U6?(R8\R/.;S.!YU_R@
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MW;+Y$_MC$SR+*CR56"Y-3##R.&%)\M5LA3>+C8CST*(6`2>E-:0R++(K>S[.
M+]F\/U8]X)ZYT>%W2[KV.%;[-<Y[\V7CJ8414AZRH>D*)9C04@)\I(2@J/(#
M6UKXB*7?AL0W;>,(?;6"TRI*H<N\,/S5%:5J#$5XOK\U()5P)%/<==QPE@OT
M6(\2_>IKU?Y0XJ$),3&\8LD*&T\S\T[$>GRGG'8K',..M)#*5.*2"!3?7!<Y
MWXL@Z,51BE/+?<JX+^()40DI`4E02:IY:S!`KUDYQEN*=P+3EGX<TWV_Q7TY
M]QE0Y2'U?.)RN"0F0[\JW7C'<3<4!+A\:C0M#G7BCF.[L9E=>\N-MP_D4RKQ
M8EF\6B>]!,K\.?4E8=\[S$J4W"?)W52@-*ZL>B,A@V+=R(Y@0&[?<+Q=''O,
MDF/'\Z/%Y.;*\QML-AD!6Q/PTZ;:QFZ.O`A*LDN\F%"]'_<'.\BQW%\XO%EP
M*9?_`,.E6R!<);*;N_'F)#L.0Q'3R<2B0L4J"*]-5^8.CY?[4%1&]+7<F+D^
M6]N<UM=]QJ)8H\^VP\Y=80(+)(3^'SK(IPA%PES6J4;1R*3][?6&K5><O`K<
MCHAI[BVGT$=EXO:7TX-V-^>]?)T_(\BNLJ\SG`]*N">?%IQ]:?@;6D"G`?=K
M37H5K'AB>5+,NS].4*#9>P/=:]3FTHB6[MS<4\DL\@!-6L_'4'S`X#0@@_#M
MJA47WI%[9]L,<]&4S/<'[=89B^4=R<YN0OV5V#'8$"^9#&C3'0S'O%S80'GX
MS#R2L)V%5=-6/2.=3URVS%KAZQI7;WNCVUN<B+?$VC).V&>Q09<!%RB1A!DQ
M'GHKJ7;4?F6Z#S#^\K]VF@-.W=FL7P2XVO(,?Q2SP[M#DQK^3)8:4\W=V'4K
M><05I(:+A3R!%-_?J#*]\-EVF;Y%+R3M)@'=6#Q1+Q.3CF4<FC5Q+'F,1[VW
MYH^\I*0-AMQU!PDD\[$:?WBQ;-V4-&R=[NU=O,FA`B/7ZSH5;+@E8-0EY3*0
MHGQKH"!4_MU=K1D5[M3DUJ+'@W66VTF(SR>6QYBBTH.K'P`((`_3J4=6WR8N
M;1@<`*86N,J8Z%(/FW!:I))-.1^(E"0JO2FVI.K3+@R;OY::_P""P/\`O2/_
M`/5Z8%:/@<4G<E7#/\V)W_YVY'_C:1K`J("0^D(4>)W04^&N6_SKP+(>7"EB
M+BR'G=DAEUWWE'F]0/'5;7.@\@X7+0ZPPICS'$*HNJ6UT*2:U/2@3KL*A9)<
MN<L>3&B2%,';S_A;"#4TJ%CD>1V]V@-J)&N$1E32X3CQ)'):G$%OIT52BA^C
M0'PVQ<OF6EJ\AJ*E9+C1J7"@`\0V1_953J>@T!87]/N9*8[I9:[%6@/IP"^%
MGE\#:UI;^ZM]!!:"4FM=<E^[."]UXU)["_KTDNO/=U>U*GU\G5OLK=XNK>!=
M<;<+A#JSS<J4#<[FFILW)S2U/'`%_JI3J"L*45I<6OFE02M*^*U`!:5@I4D#
MP(IKT4E%8=I-!!Y!V[[>94%G(L%QBZ%94I;[UJB(E;@A2DR&6DO(53H0=35Y
M$D>LL])O:FX2X:[!$N&-O+4J5_@4E;L=M;044CR90/PG^RFE=4TQ(HB%9]&^
M=YO<NY"\-S&Q*G8OW<<=$6^L/1#/#%CM[QX/L\T-J*BD;4&VJ2P>`JU@LB%/
M=ZSHP;UA=A.V^;WJTLYE9\7[FF]PH-P;=\N7<HH,1N*/[X?/2LT"J<B-M]<F
MZ^'YHZ=K)NYCP)1^:[;K:B++D/%;38:;#[:$.<?V.2:"IX4_1K@6#JLSLE:A
M)U:Q&`[JQ_,QZ2TQ\+CT>0KD/B5S6E:>=34C97AJ\KUQI)O"IC>M04*I8D>N
MV?<;%>V_Y`BW;`K9E<^QW>TWHK^5$BYR($:8X9MO\U04JKJMT#[H\=>[L8QE
M%.1Y-Z<HND66Y>HSZJ?86WXTCMUFO863E5JO6,Q7I%KE7"UI@0F)T(\(Z#\L
M'(\J&E7QTH`1KNC?T/W6<SK+/$I*RWZ@7J@L5GN>2]B.PS#O9?Y*;$LR[;;F
M[Y.@QK<XEGSK@B(VV2AKCQ"R"H@&NM7ZCI6FXZFUFU;TY=I4)W.]6]V[XWV4
MGN5:(.'R9DV2]<HUCM*,?G7=996`W<VPU'<F)\Q("TN5)14#7)N=Y9N6GI7O
M_P!S>.WA<>F*Q&RL7H_SGN>S:;[V^A7B#C(F2\RMWR,1UVVB7^]^?AQDT+8C
M#F:M&J.1V`UYO61K_P"O8T6:=H+WVINMLP!$2=!RVUQI>3&(83<4NHO8<_#5
M7-E\T;ANJ<!2JGQ;;:\+U/Z@M^F[^W8FJPFE@=UKT^YO+;Z;IIP]@S_>[//4
M1V=PFU1\DN-[Q;N3@F28ID>/&;)=9E0+8Y(1*AQV`@K+=DDI;2E*17D%;[`:
M^BMWK=]*Y;34&CYZ_:2NNW/&46=(G9W-<)]9/;GTD^JM^\Y':<B[:Y59<LNL
M;#\EDV<G.\6>:;O5CR=N&ZVN=99[D<J+#E`XA5"*'5TVG59E(PA%ZDO>1T[^
MHMB%G7;3M]ZD<:;-RC]O7FKG/8C(\U^;VQSUM$7)[46TG[MDO#G,5^X$U%-)
MNY/&K-U=N=C.8[ZHWI3N%KO-ZOG:;MQ(S/,?4.YB;K=VQMI]R1=KWAMSB76V
M7&^/2UHA0X"K"\5><CB24[U.LW&3PE5Q+1N3E+2W@RM2U]U^Y/IV[G]ENQW<
M?&9V0Y?W)[DW:PW%<ZXEJV8LZ[+1-@VV',;947G;?#2LJ0M:@J@IXZM&$8\J
M-);6Q/F7WO\`J=36#XW`R_#.S/;&4@+CYOW/;NTM)6IE3[%F>2I+ZJ+/!EMI
ML_W-=]7>+J=%O]J"MPP@LO\`KF5N>K<8C<_4AW9<P6SPK/B-ORV99;3`ML8,
MP3^%4AR9=$GBN1,>;*EFFY^W4"?[BI/%#`?A2"VI*6'2E8-2BG`[>_XJ>W4I
M8HR=FW3+$ZX?I)11"]$O;U@(X<;WEFU"G_PLO>AUZ)Q%@N9"N*95_P!&KVG]
M"K;(J-4N<I:/,>>I-QN3<\GR-"4N.J<RO(T):0GXBI5[FA!V37B%$5UY<G2>
M'>>H\+?L+^?3MZ->Q'?[T;XKVJ]2G:7&>Z6("_3KXW:,DA+=?A7%1H9=KGL)
M^<M[G%("E,J3R`H:C;5E*29Y5Z_=CRO\"7/;GTK>G7LQ@4#M9VJ[)]N\.[;6
MAYV5!Q2WXY`<9,B2*29<J0\RN1(E/?M+6I2U:NVY9EE>N4S""]^ESLG)>7-@
M81^69;Q\PRL3O5QQP[G[JFXDD,TKU'&GNU72AU;G$KX]4?I;OJX]QB]I\PM#
M-Q81YWX7W8Q>QY[9;R5`4M\R[36#=8\=P;50:I-"=JZS.Q9'.1ZH6LA[71V\
M;[D>FS#\#R*'=_Q2-W,[=0YL3%+H^`2PS!45?*QF0M-5)*0D'KJ4VLB2)*O2
M/G'JA[&=PIEO[OX#V>7C+V9]Z<5Q/-GG;;>.]<RW6DRLJ9Q^[Q1Y$UFSQ&/W
M)5L73P`.M;4VKBKD0UJ6EY%"D+,>X=@0F/#NE]C-J*G$QT./RF@EP<>"FSR1
MN0=C6M>@UW*:93I0X$IO1_GBK%W8%]N^?WWM5ET&V*7B63V*X2,=N,^]N/$M
M0[DE2VH=S@*0NJF7O@6#0ZRN1C34@K5NN1U#]D/J)Y+CUOMUE]5=A:N%H#;3
M$/OQ@$54R&MB@89?SK'HJ'7HBD+H%2HY+)W5Q'77`I/53L(=J"54L1[_`%=]
MU;$U@>.]P\)RK`K[V\NN%Y3&R7(Y_P`CD=GN>-3$QU*M,01UJ=@R9C[:>A2X
ME8^+Q&K59Y\Y2C..GB<GC?>N0UE.>2["W&C0[S<)"68C-66D6@2:L1*4X^0M
M(J$CPZZZK<8RL:WS'I692F_>Q+B/3#VPR[O*S=I^-7JRXU"LW;=>49--DH;9
M:7#8MK[RX<=#:./F/+;2BM/A)VUQPE!:Y7L8:7W8T.FVEUFNQ1JO&E0[S?&(
M]Z]2O:#*9%_AVZ-8;'BBW2Y++J7_`,"A!R<VP$)JM:55HDU43MKQ[TYR6JSA
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MSK9ZPNP<6!>[8<`[\]U;M@.-Q)C]VQ3"KHNVY*T"UYJ+9-7&>8DS4)=YJ0M0
M4`DT!(UMT;?`B5R<E1O`G1Z/_5[9/4KVNRO'<?[59OVSQ7'G[CATBS]QHKL2
M[AR?;GID&>VW(9:5P+K:04@D!6WNUQWTH.D2A/\`[=Y&<W]*F)WXN./Y#V-[
M@-Q[DD+)6BR7!\6F<A2Z\E->:A"Z&HJK;6<<4F0+KN5B[+UQLV1PN(AY/:FY
M"G4HW9EQ_P!V]S_9Y*ZD'H!J2\9RARN@36JST"*)4JBD[I02"0I.Y53B*ZD[
M([GW57,EM^&_]R7^K_2U:A'7\3A/[E+4>X>=))^%.6Y'04&W_&S_`(TKKG+"
M!D4\M5>HZ^[5)0C)UDL2:CPX>IMZSVQE0*A\J\VI!42GB7RJA3T/316X)U2Q
M%1PUI2([24(2@(*``VD)V'@>(%1JY!KN2$GS$I/QH(K6A'4=-]]`:CDI2$\3
MU5O4`4\/?H!/7.8^AI26UE`<"DE0^\#2NU*>(T!.[Z:85([H96B7(!:&%W=$
MAYSK&B/-+0^^VC_MBFQ0TVZ:X-U^9/87S^B-O+6O4;B4:XY5^8<2;#8QGCCW
MX4&O*2\'7%3%J\R<IU-*GB*>&K;?)>1/8=%3NZU'VK<'ZEJUZGZ428CT/V'^
M;0!--6$38Q-?O`;?ZD_9[-0!HNQ[J!?.]I4#Q/=J37;P-EM_V^&JJ+N7-"SH
M59S!>L^%DLOZT!EQ;#D$JU6IV,EVYL6NX2+>PEQE*@CYM+!C\$I-5GE\--]<
M^YM2IH[5B=&U^+Y?T+1<@N,66XV74L*/#@2:\@I"0A5012J2*?HUY9Z0@KQ8
M+)=H+R'TGSW&'6$NI<4`E+C:DU"*4!WVT47)X&=V+E&B(=RYV`]LLH:-R<E2
MKU$@JBQ'0@EN.PI]3H>6V&U(4^4GV_;KW]E-0@D\SQMQ:DFW5"=MN!8#WYRR
M==KS-F7*-:W$D0F5%M$A#P(\F2L$_N4KI5(-2-85D8=&7%%X_I%[?XA9.R\B
MS6S'+/$M"+Y,CHMXA-*:2PZP%.L\B`IQIUW<A5?'5HPC/&>9O:@X1H^)&+UN
M>B/T87W%,I[N]S>V6%VJ2S\I^.93,=;Q^VVYI'./'<3(BI8:@.R'=BZ03R(Z
MG5+]F+M-0PGWFJE*+U1YB#W8#`NU6-VZV8C@]TGOX=`^<1"8MF31KM&^4E*#
MD9AJ9$4M:VVU*J5%(Y#KKR(J4[G3352W7W&545/>O#L';\T]4V3]RV),JYP[
M+_#_`!"YO0KPE@MV]&T(?AK2PJ:I"R$50"`0:TU.[]'VV^W5N_?R@DN_`VAO
M;]F+C8=&\R'7U?'<7@]B^W<6)B2[?DEJR"U-9#G%P3(=OV51`PEJW0+D\Z%4
M9MS;?[E"0$I%=]>W"%J*TVL(+B>;*U.Y-S;6IYB,^E[WIF]@O3OW>SO),UP:
M[=L\@R:VMVKMC<<D_",ZM>0,3/D[I=+5%?6IA<>XQ7BHIVY+0D';5]/>BOR\
M^*)5VKZZWJ;PC,[)VY.5X]A_9;`<KM\^'AC<%R0>\/;C()K+=^L%^?=\Z5,6
MJ(LAIMA/!+J`H&F^M+<HQKJJ3T)\43<]0?UF;-']35H]/JL,[>V3L;!F8Y!Q
MO+[M<)$;-XMGS6UM3[-/CI?;#7R]CEO&$M(V"$@$ZO*Y;<6DG4E6I6WK;5$$
MWJAS.T8[WUQ>5-B8C,LT@X]DDFZR6!*NEIBS+*IDY%;28KR&),@GD'FU)44$
MGV#7.=$)*>0:>GWZA;7:CO+W3[IYG=<B[AX!VC<Q#MOV@[?0$")(<RO.H;T5
M>1VIR<VVJ3$8=>\U8IT23UVT+M:706<TRI\^=<I;8D3KO-G7:6Z25+6]/E.R
M7"\I2B5N@NA))":\>FI(/UJ`XM!HSP("B104%">F^BS1#R?@=7/TL$E/HVP$
M*%"+OE%:_P#E1>O1/.)WY@DJQ7*$_P!O'+V!_P";7QO^O59JL28X,XGNW.'6
M]V\9!=Y+*''3D64!KD/NK3=WSR5MM0@4IKQ[LE!U>1ZC^&_(Z+/3[:19>S>%
MQ@`GG:%2U)'@J42L[$#J=_TZTM^_D>-N,J]XXCC92`*@U`_DUIE@662">5%7
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MLXW%BL'WD<XMDG-W,L_*N(4Y(2RMMQ);<+H<2'&_+7127`=J$"O7IKHA=C&U
MTW6ITVHN#Q+Z?0OW*NF#X)WGR%J"BYQ\&PUN5>+4M=%.VBTPEOS&I"""$Q5%
M`"@=C05UXGJ4KBVLX6T]6B6/9DSKLI2O5JEK2BN[LJ^X:OMIF5W[B7?MU?KT
MN/;'KIFT86.>ID/O)_$9BW6'&6E+;0]'A>>E/%5$J`H=;>D6)7?3*W*:J&\]
ML[<^GJBWW5)>?4!MN1]ONR[4;![_`"$9998T^0Y=[>VN(F==I,B./F7H33J$
ME"RZI"$5(0*4UT;.RK=I*6.+_$RW=N6WM^_P++;<['PGTZXE=<KN3<!FS=N,
M9EY'=IRE-QHX<M465.D2Y2OW3:VWUJ/Q$5K0;FFO7M3@_=BG4\=IN.OL)#]N
M/JH^@I_TT9=VMA=Y%,Y9E-SM-M@W.XV6Y1L7G%AE#90U=UL(:"5O`H2M1"5'
MQIK8J7E]F+-CO=3TW=CF,&RBRWNQM8^S(=O]BFL72`AY+ZPZRVY'+C?S#:Q1
M254IKEGMI1QU1?M*Q;EA1H8G%_HI_3EC]Y,Q]169]C+?W=[Q9MD"<CNN1]R)
M2K];XMR:2V$JM-C4EN'#2T6D<2>?W1MMK6RM,*=Y=JA9E:.UW;O%H$:T8U@&
M"6&U1DI4W;K7B./QHZ70`GSE`6]2RLH%#R*JC6I`3Y#VJ[:W^+)CW7MYADIJ
M4MM<Q#.-6>$9*VZE"UKA1(SA6`JE:UUS7;,IO!H$&;SZ*>W';BQ=[[IV[3>[
M?9\_L&17&\8.>,^WQIK<%4QE.,1R`Y&<,N*%I02HE9HG5%MYI4J@4P>G[UY>
MF;U,8L_V;P#.E([U]NITY<O#,KLL^U7-UN%,=L][BI<DH2E<IN3&)4T2%>-.
MFJ3MN%*]I!*FW8U*>*%R+E+*$K3SCQPB*U^S^[2I"0KB@]*U.VLP2O\`P.%_
M:G_^<%?UZF@.";N00GN+GBCT&6Y%7]-V?IK$]`;>8XE*GU;D.I/&@W'A\5:?
MTZ`?'"HX_"H3PH`FWI5N34\W:`#WI(WT`XS?W$_9H`D>8##JG-Z*/Q"O7<@4
M\1H#3>4E9!3M0>VOCH!/71:2`@`U!4>M=Z;[:`G7]/.L?/LV6W5*S@=\^+]H
M?N5=#U&N#==C[R>PZ+/1ZM:N\7:P$D@(;7U/WE,+YFG0%5=]6V^2\B67TNO+
MYK&U`X[X?]T5_5KU/TDF(O+\:4\=O#0!-<)"#.A@]"OVCP0K4`:#L8ZV[>N]
M25"H7W>F(-"02G\#@T`Z4-?'5MO\=^!5D(.[,*?>OJ)X_(,B2C'\:]+_`'0N
M!M;3W"#<+P_=VH?ST^/QXO3HK"BEM:JJ1X$:QW.-QTX%HSZ;U#"W1;9*'%"J
M]EFI.Q60H^X[G7B+(].Q+7:4N(7RWFQ#J!3@H*V-/N@FAIO36EO,T>153ZCI
M4I_NE/3";DJ9#3=7$$E#9+;Q6>M%`J2-O=KU]NU3S/+W/;X#W>D#RF7,C7,F
M,1TR%P/*3,D,0?.4I?Q&.))JL`=1JIB="OI@MZU]J9!9;6ZE613MV2EQ)2(R
M5(*2#N"?UZTAD635"*OU><:A97].GU,XY<6E.0[CBUO,A*2I+E69O(%*TE*D
M<>-=B-9[B6BS*2X"O`X0?0.K(.W7JS[16G&LMRF#8)UZN#4VV)OEP-LF16+-
M.6^U)BO/N-JHX@%.PI37S%O<2^98+(<LNDNY9]A$Q+Q<FW"ZS?FY3RB7G_EK
MTLQUE7*CORZ:E!4"0#[]?31=8I]Q47$^^67.>\&8V?U,]KH.4^GS%+`S?K#D
M#LMNXO7*>PVD7(7&W.,K?2F`@E;?ED423[!JD[CA2G:2@[[?>G?TK=U>ZEM[
M@]F'.V6<]D9JEXQ&[)R,+AVJWV7(V&V"O(9^0?+IN;TM#KZE5=)"2*TVU6%Y
MRFEC2I(W>0>B?++'ZL<1]0#_`*=/Q+M5B.2)AXQ(LJX5[Q^;A^-R749+;Y"=
MU,(=4'%L/!(HTC;7;7L)%+]23L?Z6>RGJ?Q;OCA^)VCO3@/>'L>F;8+9,RNV
MW&U]D46ED2H\2[/E3\F%,:N$@AEETI?=2CA4:%+GPWX#UP[A;^\S_9;(K3-Q
MN]XNWVTBXUD#%C5"E0(^73),5N/9K@M+DA]J5:[)12&BNK8\!J.PIM_R')SC
MM=V)[RX>[W:3;%2,W[?9_`Q'%[E#EOVVU(NF%J#"Q/L;*F&;E)9:/P./-JI7
MKIV'1<:UNAE;C+65K<IYA(\PI`3R<55:S2M-U*U)4-H[`0T#\7*BZ[[=3X#;
MIJ8YKQ(>1U/?3``'H^P.G_*V4?XU<UZ!YQ.7+?\`)C(_^CU[_P`7O:K/E9,<
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M=[<BUHRBVM6V\K<MDHMH<A_.`+>0TZE0):5Q*5:]_;M=P[1R_5UZ'>U'9_ME
M=K#V>Q*WPLQR[&)\%)A18\>1,G3(JVW#Q06UK(;<^Z5#D==5_)^!S1^*_$IE
M>[10NP_9:[8NU9),"\1;>+?(1,8<@I5>+PZS`<FM!8HL)7(V"%JZ:\BY-VY.
MG:>Q9IH=0PSGZ"F<X[C&,YE.[LX[=H>36RUWQ,:/%=1,BOW2.S,,?RPX!YL5
M3VZ_$C?40OR<TFL&SCO\WL(5^I/T0]F>S4?%;=FG<?%XO<R6^VJVV^[2HT"Z
MW=#,EMF.[Y*/A0U4A(<<%%$@:]$R(RX3W;8[,VOOK:,!GV1G.<OO%Q[:W+&[
MNPB[IGV6[PTQ+I=1&HMB'!CQUU0M0`*B"-?*?6WU%:]#]'4J?N4=?#%GL^C^
ME3]0O43HGEXGQZ=;C:X?=/M_`RMMNX72S7AWR;14JAK">(BF"VA(2#&51?$#
MPUS_`$5]4Q]:].48X51U;_TBYZ=N:S=:%J%^[%O^H2=>+?=,YL>)_@DU5T>&
M8R8T6UOPXQ$EQ3JWY#+OE`!(2AM"JTZ@Z^UM1T6U%]_XGE>ISZEI2*Z_4[ZU
M.ZF<=H?65VPE9/C-P[18NW@>+6:58,=793(GINC%LDQDR9;\B:N(8[7)._%V
MO(=-==CG\CQE\'S*M[-GO;>Y=NL3Q*WY+;9%]%^CMO6@A:)C3+9\OS6B`GF4
M%-4UZ'<:ZS-8O`]"[Z%_?7&;YZ=<5].V.*L$JY]L\?@S7I-D?/GJ1?I,A^X/
MY#'=/-N6R\`@&NO$V>[E?>F69[6^V4=O'4L$7Q2KI&LS3;<7_#IRRI#,9KX@
MM7(A;JE>#*#X]3KW914*)<*GB*6JK[PJBWZ:[+D*<6RMY`3S2TKFP*GB$MJ)
MW*:[^S520Y,Q:^+K@*4C8IK2M?';IMH!,7.\?O)!8^,1N*AQHE25)36A-#R/
M,4T!P5_41[?8SZ,/K:X5F6$0H^)X?WZAV[,Y4:$V(L)&09"ZZQ>I#:17RU.W
M`)4X!0%2NF^N7<?I\P=%=AELO0XDGS8:D2HT>2ET2&PVX'4-J)02JJE<E=-R
M-<Q!*+SV/[<3_OA']>M*H'GZ=RE%?<//4GH<OR,[;':[R`-]<QZ`V\P!*:"M
M"FNYKXD:`?W"G%?E^WIVH(Z4=-^*7`14^VJCH!Q4@!"J?L4I^JN^@":7U_7_
M`-EH`H3]QW[=`$LA8\SCO6JA^D5/\V@)W>@%0'</.03N>WUV_G3K@W/YD]AT
M4>CKX>]':\GP9=.WN@,ZMM\EY$]A?"Z[^\64_P"V.UJ/^Z*.O5[/,DQN.!2!
M7JFI5M[!J`)2YNI2[%1OR:#Y/L_O:SMXG;4(#+^G>:B7+[T*65>6.\,]ODD5
MXK:L,!1`2#R)H=M6L?\`(?@0Q@LVML>/ZW;5%"U+EW3TH]Z'>+H*5N>1>FI3
M:D@U)"F@2/?J)_'?_B_R"(07JZ(:9CH>64+*4`U!.Z``>FW4:\.YSL]/;_!7
MV[0MDRE?A;[OF\D^6L)!V^(IV/4TUF^SQ-2J#O3*FO9O.=+KK1;BLA"$.<4_
M`Y+4:BFRB->CMN5'E[G,+\>PF-W+QE%HD9/=\=N34^.NRS;<)*O.DR&RTMN8
M(BT/!*5#X5BH]NNRW!WWICB<>XW%3#>)'JJ]+EMEWO&?4GES%HM5PM\:79(-
M[O#;\94UY#3;DBUS_/0OFW\(/0@^[6D]N]L^F^W$XH3UIOO+\OJ-9/<)WTH^
MYV2R9+DR]3NT.&S[A)=XI7+GW)F"N1)63Q'->]?>=<]_X4O`Z+/Q$<'OHXMT
MY/K.[32GKN%B;>[S<$15+'*'Y5@GEU*1N*.?;6FOG+7_`"G]N!VHL\L]JO.4
M9G@CD**7A&R*7#0&IC0<F"5=7@"EFO/@V*_8-?1E25W>?MI,QS!.Z5Z7\$:%
MV^RF2ZV*\FG%PD$)7T"C0TZ]=8;CX+)(W_3>1<X/:"]1<9;^6R>^9>BWV^:M
MMEV,RY?7XD:6[Y)2'')345XK0H;HXD^&N;9?J#+>?6SG>?>GSTT=QL^[=9+,
MD0NWO:1.)67M@S"96Q*S*?.+=VS3\4#;UQG+;M;[RODTIJ2`0=M=_P"KR!RA
MV'L[C]P])_=3U%^H2/FD#'8%X@8S@^/RLDO-AO-^O%WB.WF9FMSL*W''I=DC
MNN#R4KXHKX#IKT[.16YR/P$;Z(/7.SZ6<&EV:RV.\]UL1R+-(UVGK%ODQF;'
M?7VUP&H<9;D=3;LQ45P.%U2OA":G6&X_,X3H2[2>H/M7W_[?QKOVC@3;?9+5
M?IC.7IN-O5;U3LYI'1<+@A\.!NX.*0HH+B=B4ZYX<J-+?,._&2D$J37=/C]N
MKH].7P_/\@T8_:_U*_\`L=#%Y,ZBOIA?^Z#@G_E;*?\`&RM=>WY#SED3<S10
M9P_*WJ5*<:OJOMX6N4LC_6H.M;F19<QQ0=GO5)V:O^5)Q6[7E6)WIG.KM;Y"
M;^6V($E;F2O,E3,T`LM(2I%25$"FO)GSKS/3?P_8=2EG<A2L9MS]GG0;O:FX
M,-F%/M4MBY1)*&XC52R]#6\A2>1.YIL#H9=H3J50J4D@[FA\""=:GGO-^(4W
M(J4T5JZ)23M[$$*/\AT(*W?63+0WV([X.U7P';K*FW"C97ERHRT$`[_LG?5;
M^3\3IL<WF>;7ZB>XLB=FS6/VV2A5DQ)IR&TV5EQ#T]P5=`-/@6DFG+PUX=^T
MYSJCMN91\/S&QQ',H-\NC=IGI<@K'%#[[AYM>2K]T$N_W)*O9[]<U[:S5IMY
M/^J,SL[_`,VZP0Q^W_=&_LS)%QMV0=U+%;+<R[+>?B0F8#3,E2H++A4B-YJJ
M)=":5Z^&N_TW;*E`7<_4H[_]K^PTK'LU[K9`<8P^V7JWV>5>G&7Y3,6X3N,>
M*'H["5.I9"_O*IQ"177NW;VB&AY)'E?_`+$_$9"98.RWJFP%*%S;%W#PB]_A
M=Y@WW&[HPZZ%0Y#,N"^+C%6MR.I#[*?W2N*O[0UP0NJY)T[#TH\J)F9M/5)P
M_'&4((:L]N@06D/T=3Y,-EMA(504W;;%32IK7QU>7*_`DYVOJ3_2%D>K_OSV
M^]0>/=Y9F"R85BLECS'&W8#D]F;;[-+9EL.V%Y+B&X\R20H.A:0#L:ZWL_\`
M&QX$YO@49=[O4)VU[:^HON9A&<>E'"K\,>O*L3>[BX-=+OAF=S(EG;:C*NLT
MMKFV^9/6&PIQ12D.*WJ*Z^*^H/05Z_MYV)Y03:\4J_D>QL=ZMG%2EW_B//Z/
M>Z'HWM/J/[?]X<@O_>;!HF'SKE>G+!W/MN.S<8N0<BN(9BMWYMQZ;S/_`&NL
M<J7TJ-='TM],0]-VZ;PH5WWJ<-S6C)6^K^;V/]762V/NEZ</5#VVP'(46Y=G
MN_:?N/#N^,VR_L(DJ6IVS9*T&H/F2&Z;.@`G;IKZ_3&.$.4\F+JJE4?K4[)=
MT<(]/I4N%!QZPR+TF;D:XC\.3%[@75A])LK]JN+:O^.X<%8YMJ!)2*C5H-*5
M7D5N4T.N9'GTW_3C[XYYEG;+)<D59<-9RIR'EF)6FZ(D/7K*;!&EH9?N,5J&
MAQB'&:=(JIY0'76=WU:WM\'S'7Z1Z5OMS>U;>+<4SJ:^CA>,K[">OKN3V?9L
MD6TXQDF&2HERO06T&+G?[2XEYJ0N0Z?W+"G^7%""$@;D:X/2]]'<321V?4=C
M?*=+Z:1USP;S*ERBB.^+W?I1#;C-L(_#;0VL#@7Y;=`M2D$'8G<TU]/=332?
M`^8C%05$+UD*MZXMK>=CB4VQYDDMM\R3R*U!9-*<?UZR+!Q"N:Y25^8ZA;K[
MJDLD(X`H:3Q!Z[C;KH!L,[OTNQ)N*TI0R78Z7$N+H:!`25J6"0GI70'(/]<#
MTG^J3U8^I'TZ=XNQ>-XW?,<PZRIPA%]F9%;[,XSW`B7MF\1H,^/(4'&87RK)
M/F*^$\AK&_\`"8%G9^[G=[L[W#C=F^Z-EF6N]1U8RHP;FM*I-M>N-L8+RHCR
M26)ULD2N98<03S:*3KA62(+9?SY._L2?^]FM7P!Q)=S#3N%GA/\`Z7Y'_C>1
MK`]`;60H(0I)ZJ-1]AJ/Z-`2)P[;&X*#]XQV3[J*6Z0:G;IH!?I6CR0FN_$#
MQZ_S:`*)/'E\9HFBM_?O3V_M:`)7#P;/'JH[U_D]FA(G9#R0YR)H05GH:5XD
M>SVZ$$Z/0*XISN+F_`U([>7)2@-OOE)KN1[-<&Y_,GL.C3T<[]Y.VO'?RHA5
MO[%6]H*)KUHH>&K;?)>1+R+U5O+\QS9-"LJ3L>BMZ]?[5=>K^DDQ&035'$;_
M``UK[1[/TZJ!.W17^&,@$5)=%3T2%-%-2#UK6FHU(BJ(H^GBX2/)]1XM\E4:
M=&[K9`($PU4(\DV6`@/!!^$T&V_341<H3ZD*8X$2:5J=YM*U"FIU6%<N\@)Z
MAO71V3[9?4B["X?DEQS^9E6/>GCN%V[SF+"P";<X-WO>>1RNQ3X^20Y*;?#:
MBOU\P.HJH=*:\N]ZYZ9;W4]M<W%E;R+TN&I5J\E2IVKTSU.6W6\C8NO:N&O7
MHEIT*E76G>1ON693A?&+=*6M;;Z'Y3)6`C@V)*D);4T>90M2=Z5V.VN=RU2E
M7F4FGXIT?WG39T]*.CE:JO,6L^\H;QMU:4JY%;:$U4:$K4`*[4ZG4/L(N.2<
M5'ME1^!5GZA;FF'W)N4=MWB@L1`:*XU#C$E2B$T^'XM>AM^5'E[OJ_.*PE[C
M6/$6/IWN#=PO]@;+JD-QY*)/^#(+JW)+"0_&CD)2OB7E@"M/AKOKU?37"UNJ
M3=+/8SS-[9E"-8IY#H^O2ZR+UVKR3([M;7;?=I]XQ.+*-$+CN-19G[IG@"HI
M>;+GQ4!'CXZ[O4)V;LNI7WTJ*G:CBV'5=5)>Y7^A=#Z@NS#OJ;^GTOT]1L\M
M/;>Z]SNT^"0+=E-R=AOBU")!BR%2C:G9+#\II2&Z$)I2M.NO"E-3MR@^=Y+\
M3VU9TS4H5T<3G`P+Z,V<>F_NOCO=6]]_L#[AP^WL*_74HM-I7:YDT-6*<P6_
MCF.H#B^2:&O4]->?'9:9]1)ZO%&N!'/M>Y?)7??L7(MWFKMSV5--W=49U@-,
M-F].K"9K)4E[S%U.Z17PU[5J-AP_<;4Z?>8-WJX+`N+]3N'77*.V^?X/BK<$
MY1GEM?PS'X]PDB!$=FW5U/EN/OK)*&VT#XC3W;:\^_)Z91EEV?F7MN;YT1+]
M"_I\[B]A>Z!P/NG;K0U(QB*<G@.6:Z-W*V2+I<7(S$-*W$!(+T*,RM8'7X]P
M-<NTNPA)QD_>;HO$OV$Y_J`Y3^7>PTZ=:)BK;>EW^*8S[4:/("YKD28B.E\2
MVG&$(<#M5$I-1T&N^6M26G(M'13WLSEG[^6_UD/S+1'[O8J\GMUW\F6'&[`N
MY16+AC<RRM^4AN3;7HJEHC(;2@NJ04H4:$="!KLMWFE1TK0R]Z4U&7PV\?`:
MK)T]V/3'?9WIZ7:K?8.R-VN1N]W[H6;%K=/7;;.VVTW<[[:VWDE:)$=M]*0A
M=5D`4&VDY.?,9SL)+W*LOM["V3#+/VQQ)';NYL9%B4BWL3+?E$9B/$.1N2&4
MJ=N<UB#PCBXNI%744Y(/W@-4225$6MVDDI.NH?J*X*<0:J`%10^W4G0Y-QH&
M*5K;2>E>*JUZ;C[?9J5BZ,Y+DMRE[L53\O:=2/TP?_<_P,_^-LH_ENJ_ZM=\
M(*"HLCG)MYTD'"LM!K3\L9#_`"V>:/Z=1<QC]N!*>)YAV9,H.498$MI4DY9D
MS?Q`*XG\>G.J("OA"@H;&E1X:\QJMRC[SU,[?L))>F7U+^HCL]FV'V;M7W4R
MFR6Z[9-9;>_CDF>_=<>E,SKC'C2D.VRX/.LMA;+W$>6!0>&K:$9T1VX-/+,>
M,'P/F#!@.R%)H$F2['0N3Q2``E!=)(`&PVU)PSMRC5M85"VZ/\8[M$E24,/+
M41M0%-/'_4Z&94A]13*7L2]'_J-OK2%KE,X)<(T=MDI#BE3WOEF>*C5*3Q4"
M:^%>FN3U*].QMW?A33Q9T6.;S/.KS+"C,9F2U%J3/D\Y<AUL!+B)+Q*W%J*C
M3DDT%`3KYF'J5^3U/3I;X?W.^YDO!_B(K&>WLJVV\W%1$E^<^1S6TD.MIKQ*
M2HK',`$J'V:]"WO+5Z2A-TBUE]D9'>9_FX6$+Q[TDX7<%MN-KR7N/EN0K<6.
M)5'B+3%;)!JI:4<:C:HU[&QUJY2"K;PQ`W_^<8W5Z_=K86)MNJ4]?<M;<0"5
M**T6Z,M]H>55)<\MV@`.U-J:CU6XK5QT>;=3RO\`]B?BR"G^;CFXLL>J>S.3
MYSUNM0Q!R+;7Y+ZH$24MY*GWHT-YPQXSCR#5?EA/+QUQ[.<$G)O%GI0JXKP.
MDW(LO99QM]I]UYQ44K960/@!05"GBH\1MT.NQW;;5&\"^F01Y+=8TBQ6^B2L
M+ALJJ.0)-`4IW2%'V[:M&_"-OIIK2*2X'+1W*]*[F>=[^_'<2T6H99-;N^6.
MRK(D19#R>;R&UR(4>@6ZN"A/,ME7)?W1OJ;:CI]UX,Y=Q.<OVGA%#4=G_IPY
MYW;'</N58?R/G+^!M(9OF'9M>DX_<K'&NS*H]O58,;N19^?N[2E?`RE*U"@.
MNE-JWTUA$C;VHO-O(1T+Z,7K1QS,K;>SVAOCEBA-/YFPS=WQ!C3K!:T&;=4M
MID+:8?>BQJJ\I)YJ2!Q336<$HK0G5HZ;W[2I`JG[G=P<ZE>H9.$9;DF0Y5@?
M:S/#?+#A%UN,F7;;?;&74./VZ!;7W%)#(YJ_=@<0.@UK*,XQK3,\Z6YN.XHR
M58)]F'WG4!Z`;=Z@LZ['XIGO;O(>T5\PW.+SF,&/;>X\1YN\]N\43(X(M-AF
MMM)=C05O-E9;)0`XG8Z^9WVPW5Z7[<6UW-'ZS]'_`%-LO3X:%&#N4QU)O\BR
MGT\^DK)^T/?C`.Z&29UCF:MW%^\1\CLEE@NLQ)C=R8<0TTW+='S'%LD4)\03
MXZGTG;3V5U=5-2KVNOX'+]4^LV_4H-OIUQY8M?B=$6)9+CEDQ^-;X49-H*44
MBMI897&>%$I2I<MGD[5HII19KK[FY<=S3)TY4?F*[3.74/,&5Y@D7"XR5LMK
M;5510H$;4K^[4DG>NLR39*E1)4/A1/RRFV5$?=3R%72`#U!.@$7W:2E]+,<!
M#J)L)QE1>`-4N)*0`I?%*>376O34P3N5T8T!0#V\SQ[N8[ZRL.8N<>X/8KD=
MOSG`7`4.IBNX+<!!O,5FM7%2!"*@OI4&I!VUSWY1TN%?>`AOJ-X<J[R/2QZH
M+(\#-R#&K3VXRV.LJ^7<O%E2U)LTY;B03YJX_P"Z`VV3KB65.X@=S\RY7_M$
M+_=W]:@Y&>Y;J5=P<]IU&79(?U7B1XTUS'H#92%^82FE*4%>O0D_TZ`D5B;@
M&/P0I-4B)%KN16A61T]YT`N8Q0IA"D"G(;C?;]>@"^8ZDDI!W\/?\5?9[M`%
M3WW/TC0"5E"KA'^K_G.@)Q>@5:D]R\X0-O\`\NIXK_I>[7!N<O,GL.CWT:.$
M=YNW2*5_XN._C_O-']6K;?)>1)>@IX5JK;:@IOTK_7KU?T^9)\U!4%#I4'^;
M57D!'W^5Y;B5GX:L/+*AOQX$#;;QUB4(D>F%\R8GJ(D\:%[N[?D!%2?_``3"
MH1T))IK"VXW-W\O%N-QXU>6"(WNS;]*G?G&+M7+D5@_>P=,5_<J<[YYA9KEW
MT[ENRH$IR;!OT6PR\@_#XST&.M+#:84"1.\M4N(X#RXI2JIWWVU_FQ]6[NZO
MY:W.ZE<W;T>MV;55*6BDI/"FJGZ>!_H7Z'L[,?XHCM+%S;SE_P"GG)VY16I)
M)8UH\JI>8PUZN#Z,JM8*E)4S;U@M!7+@?F2$\S5=.77KT.O]$X))8<6_:S^$
M[BC&XXQR3'1O%[?5B,M2EA*F^#I0/'RU<D[[=%`'4LQES1_\D5&][[^Y<<]E
M2GY"ENOM-+<4">K2):0/U:]';\J\#SMW_P#TXB:ML'N9E-EM$/M-+N<:^L75
MQQ2+/+^2GOQG(@(6'2H52TI)WUG8AN=2SS-_4);;2)+NCA/J:QO$)-U[HW?(
MI.(M38"IR;M>_G5?-NN$QB&`M0#W*AJ?9KU*35M*YGB>#:<'C;Y:FO']2LP7
M$R\D:S[)6(\6WQK6U<,TGL_@S,.*B.XS$")`;CPY)0%!`3\/0:\]?&7G^9ZR
M^$_!?B1EO/<K,+CDDV1$RK,842=.D*:A.Y-=7D1XSZBX(W^^O+>9X;$$;C72
M8BSQ'+;ICN:8EF%ID!N[VN7;9K-2XIMN9#DJ+*U-!S@0X>M0:DZ`E/F_?;/\
MWR;\3R>[7!B*TTK(GX\2XOM+MLB&A+<5,1Q/EE*ITGHG:I/NU#M]15)1*_Z?
METOEVR6_R,BNERGW6??+I<I!N,Y^4[%$DQ$1(;;LEUP%$>*3\(-03TUYOR^B
M_%]BDAV$N/J%LM1^RL2#**S;;IW"L[;[JEI+T9(@R5I22L\G`I0VITUZ9!S>
MPLNS.Z]Y;"U<<BOM\L]DNS4:U8O+O$E5IC%H^7&5;X4IY4*`MU!^(A.^I6:)
M18IWV],..]]L=Q_'\_FY)8+:J.F?%E8PXY$7>6I02Y)M[LM32DO18[@X/)%"
MKC[#K8L8O3AZ5F^RL^WW!S.[W<+=CJ;C$Q+#[9-GL8<Q;+BD(5,N5OD*6A^]
MGC7FDTY=!H";\=U16:?#05V\=^A]V@#AMX+20HT4$J)_0-O#QT6:\2'D_`ZE
M_I=N%ST>8&HBG_&^4"E:_P#A5>O1/.)Q9Q_D7EO_`$8R#_%$S59Y?;@R5F>8
MYEP2O(LM5Q"2G,LI.V_2\W`Z\O\`V+S/5_UOR'%]-UG=OG?OLS:6DA9F]Q,<
M)!ZA$>:W)<`&X(*6M:F9W$?B(,J4`JH:+;24T\$(`!_0!34,QO\`P_,+[U=5
MHMDU*:#_``9TU(W'PGW>[4'$48_5ZR1^S^@KOK(:D.,.W%FQ6QMX'B2)EUCM
MN-#VCBJ@^W7!ZQ__`"7XLZ=OS>9PQW6<EM,=M+?G4:;2ZE`HI2N"2H*H%<B2
MK7Q=KX:\#MN=GA^8=OO,.6=L%KR@B,5H"?A4VHL';8#<>.NJQ\:/B9GH&?1?
MPY&)>DWL,CY<QQ'[=RL@EA1W\Z[*5)\SB0/O@@U\=?:^G9>P@J#^O#EXN/<3
MM39UR2I*)>07=UH'J@(^794I.^P4=CK@];^(_$\M_P#(GXC;_0)L0M$SU@26
M_-\N1=\)4QR/WFG&`XOC0[#:GZ=<>WY3U+7*O`N[RRZ1OP6ZAMU)I+D.J17X
M@?,6HHWZZZ#84EYNT7\K07%!7)%OBK0&PA2ZI0@D)^+;X:_HU(*2<TRF3VE[
M[9#-A)CMPLFN\VYE<(*;HRZM'S3$JBPI:W'`2:#7=8Y%XGG[CXK\BV_T1=U_
M2+?\H:N?=?MY:!F;K"$6;+WV&Y4*Z7=MYO\`#T3[3#0EU5TC@<&G'`H4ZG73
MV&NV_(N'[ZY!CN>81?\`%)<]V+YUJFSL;GI_</VJ1+MSL8-QDA*5MI>0I*%M
MDT(%-9Q^(_$ONL_8>=)WD^C#ZO\`OGW\SKN!@>+7^TP9]XFB(ZFQ2VI1<1(?
MC?.)D*>89#,U-%HH3LKW:[KCI:7B>4OB27<7C>G_`+3SO2#Z9NRW8;N5S;N%
MM1<?XAR92`T^F[-7:1);COO-N4;CN<QY@"RI?LURL][T3XS)/X3WAR['.Z';
M6X65VVW[&&,E0BZ1%2VT1[!8):TLP.49XEUU4U9"4HW5KS9_\A+O/2]0WFVH
MR\;&;S:[^Y,3!@1K5$>4M\L1G%/17B34/MH<-65J)W144IKZ1<D?_%'R\KD+
MDG*WD+*UY%*BW%EPV\O,,LF&P&DE#=2I20ZJ@4.0)KH0.;;4Q9$`N%[E-><<
M+C823Y2RK8%1(*B$TT`D\[@!RTQ(ZN3SS[@84%#DH<_@3P5U0.1\/#;6FSSG
MXL(Y(?3QGMI[%?4Y[T=H\KN%KLF'Y7W'R:RH?NTMF':&?S;%5%F0'I<IQ$="
M7GI*%I!-2I/37G7_`(K!,;U<'++U]/WO_9<"CV^Y9EV+ODK,L?7(0F8Q"C8M
M,N$.;+88)5\PDP0'$E)H4BNL2"CO_P!M3U%?\NV;_P##BO\`9:FH*^^Y"RCN
M)GJJ%5,NR,4^V[R!K.\J5IAB>BQOWG4J05BB2#0TH#[3TUA:;:=>(9(?$WFS
MCL`*":&.$E1']DIXU)]E=M:D"Q94M++802!0FB>G7;IH`MD$^>[UV`(]WMI[
M/?H`OD2`A!%:_P`M*?9OH!+2I!#SAI0>74;;`D=?<370$UO0%,/\3>X!4?N]
MMIZAO7B>0%4[G<ZX-S^9/8=(_HS4O^-';YS=2?D"M/Q`CA^'-[TJ:)YG]>K;
M?)>1+R+RU/\`(K^&H\PE.W[/$=!T`KKU?THD_!)"2`3Q`(KX4'V5U"Q=`-SF
M4Y$=E"E+)2IB0#0G[OQ&I]U0-87\.4@BSZ3VD7RR=\(*9,B"W=>ZM[AN3XSA
M$F*[(ML)I+[8%#S3M\74<M<]E._N+5N]A;2E27?C_P!#.=JRK%V[<27O1=>W
M"A0_WG[SX+VZ]8'>GL)?H,QW,%=RK:(=\C_,242H2X2/*,@J)8"EJ^^:<JZ_
MCGUO^*?K6_\`6+N[.#?I;]7M[B3=:-0<\7Q:U/$_L+TO^3/HN'T6]M=<'Z@_
M2KEG4DM59*/;G^D5^76BU6-<1ULN)EO2"'9:_B<>9=7YO#>I"$%5`/"FOZVZ
M=RTE;NT=U+&G$_E:WT]-;3E*#;:<L\6_PR\`RN4Z*]B<QE)2I^2VIJBC5:$A
M)3Y@!-14T-=0^SQ+LI[[[)%J[B7""E[S`S\J`NI/POMR-MNE5&GVZ]#;<J/+
MW7/U'STS[1]_2]&+>>8NVAQD-,%V?,#SRV4J@16RM](4V0I2U-FB1X[Z]_T/
M9=7=RA=>J*[&<'J>ZA_Z]345KXTQ'F]=[N.SNT&<WO'8J(ENEWK$P8-%L-QE
M-.']X@NGXOF$BH`ZTUKO+"MQFG1M2=.Y88'G[*XIV%.*2*5I&88I*6J)%OEF
M7,4I<<,KN$='&0@?O&G.2P`4>(/V:\6S"+C*32;3S/2M3FYJ+;T\!GV<SQ]>
M0OQTWVWK4Q(6Q\<MI(+Z44*6UJ4E*PD["G0:UHCJHAV;1E6-0[OCRI.0VJ--
M<4REV$]<HR9,F.E0)4A@N<W'4*^X:=.FE$!UF\\P++,GDVIS)8Z;0F2R_>%,
MRF6WGX]L41"@(`6"R#+;\Y9\=5DW'+`JR?'HQ[B8-!R6YVS)LIBV*P"^/WBU
M7)N3!8G766AZ,F-;R^I:7V&EI0>0_P"V#KK)I-U>9!D^JCZPXN;]ND]G.U^/
M7K(LD<R*UWA-XL5XM8<AMPE+:!;C-E;S:5-'[WB":ZT@D\RR.?OMKB\*]=R+
M!9)^5YNWF=YO*D3$OS//AVZ[(>2M2UOH4`HQT_V2-QMJ]$2=#V+(S8MV./E&
M;W?(8EAC,1X-M6ZXW;?F4,HCJE'S%*D**D-CD>AU('OMLL);\M5$A0I0%7`>
M*>/(DT2H[:`.VG%)JH+(K05KL?TZ`W$R2$$"JE<554#OXTK]FBS1#R\CJM^E
MB2KT;8$22:WC*=R:_P#A5>O1/.)U9Q_D7EO_`$8R#_%$S599?;@R5F>8YEQ"
M<ERX=!^<,J]PK^-7$:\M_$7F>K^CV$C/0U:_Q+U6]E4J3R3%R%RX`$5`^3B/
M+\RG0<"KKX:U,SKYMUT4^MQQ9*5+)*B2:K]BCO4T&H//E*3;3;I4RW24E5NN
M16Y0?*\45)ZDJY4W.YU!0Y_/KC9$;?Z%LL@^9Y:;UG6'0$HY<0I#,YI][B.A
MJ&ZG7G^K_P#%</T<#IL5U*G$XQ;9/C2)*BRT'5-A7-2TA1*D`)Y@D="$_P`F
MOC[2Q:[*G;<RCX?F;DI2I8C0VZMKG38\5/&H*E2Y3;02`*U*^=!]NO7M6X:5
M*BU>!F>E-Z$;"G">P6(VU""PQCW:G&+40I);XJ5:6'GVU]`"GS14:^E].R]A
M!RO_`%I\P1>/5'CUC6XDIL6&+D.(Y<@%SIJJ%0W`*J:\;UF_3<SCPD5Z=NM:
M*K[B4'T*;>%XIZF;J/\`MV18E&0`/OH:M[*_+3[4T)--;[%PG9;254D3DTEE
MB3@SK)Y#<3)VVY/#R[G<6R@)KP#;JT+03_<G;6=]N,G3`]&U"+CBJAC-RB?'
MQBTCYE3ZI-M90`H$$<@CX00?$;4UKM_>YL2FXC&*]U4*F_5,RNZ]S\1)ER8+
MLBZOQ4.15E%%KW;41]U5-MCL=>FHI1P1P*,9+5))LD#V:[9]R$=O)7?7&\CA
M6X8+D$.WN262U'O$>8933*)34!?^#2!Y9W52HK75:LE)1Y<"1/?WU@=P<*]3
MMAC.=[XDCMSCW;'$[KF?;^VV6+?7[W=;I$*YRIUP:<6NTRDN5>4I'&@H#TUI
M:G!2Q562TI<V)&'OI]?7">W$1<'TU8]`[R9KC]LN-TS6+?;I*LV/8U;;:LUM
MK?DNF1=+L]44\L_!U\->HW;G;221SWH02U)).I05ZE_K)>K/OWDXMUUQ;%.W
MF,_C-ORZXXXU'?N4]AM]34IITWP*\Q4>7&50$G[VQUGTX<$96[ERTZVI.+[G
M0O?[?(R7.NU_;?N9B#B.VL/*;.,CO$N\.MS9]QN5ELPNT68V_(4EF';#)C*X
M`;E2NM=?0;#;^F+;MW[-J5[BXJIXGJ2W-W<IVYS5NN*3=#IC]#[&>=U^PO;#
M/<KMGR%RR7'&I;SB8P9CRZ+6TB8TV$H"$20CE[SOXZ\:\DKC4<(]G@>M",8P
M2@DL,:<>/B3BMV#(B.R&YL]UJ.A-6F2V!Q7O4FG4<M9E@XC6:WMA"(;[BG4@
MGD$E`KRZG85W\>N@,60V)R1#8?CLJG2HA+P90M+#BE-#ELH[&A%:^.IBW#EP
MJ#@/^N;Z/,^L'J)RY_(I4ZQ0.[]T_B+@F1V664K<D,EGS[:^XT6Z3X3[?@KF
MFH.N7<824NT%V?8>QP;38K?V;NTIY_%^['ISP>US)]Q=<?D3TY'@5OM-[E2G
MUE7S,YN<I:BH$FH).^N-SB@.K_\`"*]/_P#Z0O?Z]7^RU.J/"7L(.+WN2]7N
M)GHX_P#^79$>O_C>0?9JNX_,])]@W,A?!"DTKR-:UI2M1[#[-<]GE?B0R16&
M*0Y8("33X6*D>TGCL/936Q`K/.*`$E0`\!N*#;V'0!6^ZOS5*K]X&G7:GZ=^
MF@".4ZX`OXO'_3T`FY;JOC454"FRC[*)K7KO6FJREIBY<"2;OT\)OR?=C/IP
MAM7-4/MI<WQ`D.>2S-"`5*B..J"FF$O@T+AIQ\-<-W]SNQ)H="'H"QZZV3OW
M8KO<K=;;1$O\%+T.%;;S<KQY"U1TNJCD3SY;`:YT/E[&FVNBS:TQ3KV$,Z!7
M%B@XE?C7X"/_`)VN^,E)4>!-37XOK6."75I)'+B@JXBH!)`)-`-3@L:Y$C9]
MQVW&+<'75(C)$:15<A^/'0`:E)*GWFZ5/ZAKGN?N=Q6I!KTC]XNU^#6SO*YG
M?<W!,5CL]Y;HKSK_`)-;((<91$@*+S"//<6ZTD(54CI35(P:T:G509#49QE;
MNJMN79P.5_UH^H#M1?OJE]UNXF.9O9<DP;\]VQYC*+$ZN=:YK,2(R)#D&0VC
MB^&G#Q-*;C4>H7MU?:T34-O_`(I8UXUK]U"WI]BUMX].WA/B_P#'MC3\Z^1(
M/N1ZQ^UU^EQT8]-N-R:94E7FICEE"DI0DU2'-Z$CW:X[.S735)<3V-4>Y".3
MZMX-PX6^/:768JTE"I3ZFU+43_>T_"":*<H?9MK1[/\`[ON,KMU6XZL\2'?>
MG,%WO-'+Q);#;T]N(IQM!XI06?,5MM\7,+UO;M]-)5J>;=GU.XQV[OC?NV,:
MR99CZ(3LUN0[%";FA;L<*=:JD\$%"B1T`K3VZ[_3[MW8WG>;U5[,OZE=W;M;
MG:K;Z=-.W,(.YWJ\[L=U,:F8]E;MKD6=U:9BH4.T,L1P[$0H15.*'(J2U7Q-
M=M;W=T[L91DL92;_`+');V:M05N+P1";M<[C5_%RD9[A>-9.T[<)Z&I+4-=G
MN<=:7AY;_P`Q%D-M.I;(!(*15-=]<D%HBX\6;PLZ):JCNVVT]A;-)1,F*QZV
M3TN.!F(WC\>YOQ`H?[Y2Z7GE*>;1L"H&IU)L-O'[2]F(^:7'NS:IF=Y(^TJ3
M+:7>)4>S6E9:3Y:DP8S+;BT,O)2`E`"2.6@'%Q;MEB5_FPKM^4V<25<&W+C=
M+;;9+TE3BWG"XV94^65.*6MDA0XT`Y$4U64:D-5'LQO$L7BO3S`MR`N)+:8:
M=<<^9?2FG-025U`)`IM[:ZKH%!H'L:OMK[GY+ES=M>;@49CVU:'6T!Y;@X(0
M[P3YP:!-32H]NK)4"P&<[1V6ZH]0-DE7%$<R8F7S)#_RR2&$AZBN+:CNI(KM
M4`G5B2_JRJ#@;"`I:MRH)`^$!74DD?S:`6\=T"H`V&W(&O0`UI3PIH`ZC3:@
MI(*J#[/'WU]N@#!N4E*5**3NDBE?M]VBS(>3\#J^^E6OS/1E@"J4K>,IVZ]+
MJO7HGG$[\Y_R+RW_`*,9!_BB9JL\OMP9*S/,?S!!1DN7*4@J'YLRA5!O]^]W
M"GZM>7_L7F>K_K?D2]^G+;W9WJBPV50J1;;/?9044G]TYY*$(5UVJ#36AP7-
MTK=?=K3O.I7'92BVKS`5D]#7I\0'C74&%:X\0]NZJVJ?MN&D?IYD_P`U-"#F
MO^O_`#%M^E'#+*EXH%X[NVWS>)X%<>'"7(4*>/%9`_1KSO5&YV7%+,Z+'-YG
M(U;X:[0EY+J@5+=4XEQ.X#+GQI0:&M4@^W7S.UVSGJDW2DOR.ZYDO#\Q5XDN
MVKSC"!>90BV5K*K'+NLM7+RXELC3V)<N4XE`6HML,M$JH.@U[.UV_4N1L5I7
M"M#"4M,:G>EV(^JEZ!'>T656:!ZB,>C7FW6V+;HMKO%ON5F7<6H-O8AHD6Z5
M,83'=ANNM\`Y6AI77TNVVG0_57R,>OW?><M/U%>ZV.=V_5AEV68M>(&08ZJT
M6.';)UMF(G0EMK;+JFV9C2?*=*'#3X=M?$^M:I>I3M)YMO\`L;J6J-<BX3Z#
M;"9';?U$KXA"#FEA9!^\%%JSI)4*4^Z$]/?KN]$<I[:4WX>PA\R'&S^_K+V:
M-MK"RG(KT@(Y4)"ISBJ@`'[H136VXYGQ/4L\OD&,S)5G&;/5WXVF(HJ2#1*2
ME7#PIK7;YLSW.1`SU*RD+SCMS<B5-M)OX===0`0`EOD3RK0&HI7VZ]/52/D>
M<I*,77LJ2]].\^==O2UW?M<AUBTVTY$9OXY?)"K;9_EVT\Y#K<QQ3/SBXP%>
M#/)2B*`:[;.Q=ZUU-5/+^Y\SZE]6>G>F[B&VG[UR3XTI^)7+E?8QKTJYME'=
MOU!]P\>[D]I.X=BLF3J5BEY6UFE\Q:6XIY=OM=NF<)A8CQ$AOS$I("36FN*Y
MMW"ZZ2R[O[GJP]4C=:Z,'*VU@ZT^ZG85V?42P#T>76S=J<Z^GQVVSN'DF:R%
MW/(;+;!=KG:[DQ=$+\VVL61*7'VGV"FKSBE46LGB`#KJM7'%TED=5RYK@L*8
MD3NSWT^_4!D5WQC+.]5MN_8;MCDN7V7%KADV:F3%E/,3EO/L1H]M?4Z^IE2&
M^/-P)2W44&M'?2=*5,3O"],?I"[7=W\!PJUWRUF]=I_3U:K!&L#$"Y.QK?FL
MJ,VTQ&MMYF07`FY0"KDZ\R20HGBJHUM+?MO!47C_`&"I3%59TA8+:H5BQFSV
MZ##BV>WPK9$@VBU6Z.B-#M\=AA"&8L:,D48CMI^Z!X:MUNO[]*=G$A'[D(;^
M82'@5/NI`*4&G"G4J(K6NA)\Q&?,9+"6@A+02H+^$*4Y3X05$#;W=-`$[]P"
MQ,#K7[R`4!:&W-UJI5(`">AIOH"./J=])W8SUC]MX?;GO78E27(RQ><3RNVO
M-1,GPR[</AFVV8I-'(Y7]]A54J'AK*Y;ZE,:4!43WZ[)9AZ4,'[-Y)FURB3<
M=[72YN"3^X$>IM1Q-V:X<9NU_<`"+4XB$E*7N0"$N)-*`C6'RWB,!T__`&I^
MSO\`^MG;S_\`$UL_V6IZ'B*'##W*4/XAY[0BOYMR+Q!_\+OU_5KEOIO+B>B-
MW)6"DU4-J>(]IUSVDTFGAB0Q^,/?4FUV]"*I"F.HZ'IN:@]=:D"Y<\M26RXH
MUXFE`3_-H`MD2&R0$4K2E0:]/UTJ-`$$M:@RX2:&IH3UZI_H.H<HK-I`2LV4
ME2.%1R*:'<==@??TU2;3@TG5DH57;O*<UQ$9'<<(R%_&KK,B1[=*G-,MR!*M
MKSA\ZWO,OM.MJ8D4XJ-*@'8ZY=$N#+%DG:3ZMO=CLOD>+9"QVJP[(+CCS`M\
M=J3.G1H\E+41$3YA]M*.+9#B.=$G;79#D7@5'1SC_.$_7->9#\?%<:[3X7'<
M4"TIFRRKG,CHH:!#LI?E.G[1X:K<<E334(A5GGU<_J4YW\U^(^I*_P!@:EO.
M(1'Q&T6JPF&RO9/RCD2,74*/0*Y5'6HU13G7%.A)#K,_49ZKNYTI2,U]07>#
M+"^4M*1/S2\%!Y&A_<L/-H'7>AUKKAQ1`6RX%SN-MMT2Y3[E/6$W-,E<B?+E
MKD/J@OAQ4GD\0XXLD`J54ZE-/%9$#)V^SN07&4M,M,H0!1I`\L=02>(5N33<
M]3K.\FX47$M&;@ZK,>VPW)Y/%+SBTE*4IH5FGP[`"O78:M:JK:3+=>?8W[!U
M+5=^(;*E^4E"T*<45!-$<T@TZ;[ZNVEG0AW935'D$?>^]W2+:F[U8W6DS(KL
M!AI+M7FWH[J'@IU:1R)4%`4]IIHL<BA%JT]U.Z681+G:;TJT,PK/)4Y'<AP^
M,FJZ,M\O,"4I):'(^/+IK<N&%WPZ7-F-RY>3Y"]$X-D6QE\P8;;BT)4M3JF%
M<U-FO3W:BJ`:0[9%CH1;XRU1([SB6UMA1(<+JDI6I3E=N=*G??2J`T>8VN^]
MO.X4S%VA;[NA<MIYZ[0YK;K4>SS(K<N&2\A:DJD-<N+B00010ZD$E,#N@18+
M:9JH[D=/S:G4/\?*6"M105I<-`%JH=]`'E@>S)\7)YFY(8A//.K8;AOLN$,J
M51#;:EJHCBCP&@'8P6<J#'NRGYG(MSFFZO/M\QQ8(6XLA?$@*.YZ#0!9EU_F
M./BV6B4$3O/%P`:=9<97%%`$\UJ->*JG8]=`-9V^=FL]S8TD'S;@YD4-:G4D
M*_?+\L/*)1R3Q`._AH"YNVQ);UPMTY4ER,F&A;+\4!?EO.2$I(><2FE>`34$
M[;Z`9C*.[7=#&\LN%LMC+#]I;=;3$?DVE;[124$J"7D#914?T:`4S7?#-V\&
M=R5ZVP571J]L6X0S&D,LNQB@EQU+80IPFOZ/?H#]Q7U!99=KW:[//LEM:;N,
MUB*X[Y4M+B&E!7-356P/-!(J/#19HAY'</\`2B)/HN[?U-:7C*1X=1=5@]/&
MNO1/.)[YQ_D7EO\`T8R#_%$S59Y?;@R5F>9AF"VSDV6`+0:Y?DP("DGX/QNX
M4VKTUY?^Q>9ZJY.XGU],FUF7WVNT]H@)M.).K'$5"52'5((J*@%7'6B/(W%N
M<DZ1;\CI$QL(#)Y4"J@;['I6E/MU%2(^][JQE04=T`%GF%0`*E,IJ=J@DA(%
M>M3TTJB^B7!E8GK9](G:WU?X-"[?]UI&2V^WV2[NW^Q7;%I;,6;;;LA`:*G$
MOU:D,.#8-'?J=<LX=7"61O934L5@<[W=SZ'W<&S.3E=D^\F/Y;%"W'HUDSF$
M_9+EY:$DH85<XZY$-QY0VZ`$ZXKVVZ<ETTVFCLN-.E.!4WZBO2-ZE?3C8+_?
MNZ7;&[V''X-MD0UY9`>3<L:`D\F&W$W.*:1O/YD("^(W`]VM=C":W4&TZ5X=
MS.>[\-D#\<[L9#FETMD.\"`Y%M.-0L<@(CQFV>$"WK4II#R2BKD@J5R6K]H[
MZ^E.,F3ARK6W;+=%MLIV4IN(P_</-:4A,2XOOD""Q7=QI#8(*A4!0IKX_P!2
MM*7J;DE5:?O.R%R"BE55IQ.J[Z#2`GLUWXEA''S.X]O;4`""0FP%1KX[G6_I
MEKI;-Q::EJ>&1>CDUIQ$7F5W!R'+B#\)RJ^!?Q;;3'MCX=1JNXA.KE1TH>K9
MC+1DPQO%V*++!0GD$?+-J4A*J**J`IXJ/W%=3OX:;:<.*,-SRD0^\MGS"\7F
M3>H5SB/VR&S$CQ\>EQFWK>OS312UOM@RF%/?M.)Y`5KTVUZ=5)4BZMY'B2A.
M[N%MZ.DY*-?'#\RJSU4?4&[E8VYD79*TQYJ;?@<:):L:MIDF5B&%7>X15+NS
MZ%1$L1;O<7/-Y,.3*J;)IQVU[^S3CM],DU+@\#YG=_27IUKU=W=_.+OQQ4&U
MJ?@LV6!]D_47Z?\`OQZ0.V?\5)D##/49CW:6Y=L#WA[D629DUG:PM+LIQT8U
MC_\`@]L7?W`X`)3Q'$;)VIKS;L9NXW1T\#ZO;V;%W;Z[,5!QJM/:J.F6='FO
M&HE?3S=O1UAU[BX3VL[B]WN[^88[;I5\N<RR*M&"6=^UL$LO*DR7429,&W0W
MDJ4DMJ3L0>FL^G<>46_(Y93C&KDTHC]6WU)Q>\S5X6]C+$KM=#D/0#A&4R9%
M^=F2K*I<=<E$ZX($E,J225H?91^\&Z3357&2S31$;EN>$))^#.MKT2]C\;[.
M>D#M3A^*VNYV"%F[\3-G+5<)\J>_"5?7T7'Y!Q^5S><8C,N`(!5L-3HGP9<M
MCMT=H?O1P!BQ6D!((^(MBE4I)IN!KJL)J%&J.I(T%CR-Z_7S*($QI;2+3-*8
M4\-J5\TDUJS2E$!!Z>TZV`J%6N;=&_*6U)CI%3Y_F*:0XD'8GH`?#0")O<"9
M!<;9L[WRDM]?R[\J8%.I=H*%$>OWU@'KOMH#\67XD9+TYU+\V&MF/RHG]\:$
M@\-J<1[-`);,QC63V6YXOF]@M.4XADT!VV7O&<BBM7&TW>WR4K1)B/Q'T.-K
M;='*AIR3U&@&@_\`9`]"W_\`RYVG_P#,1_\`J]`>:SW(5Q[B9X3_`.EV2#]=
MWD:\X](;E]7-#A`I\1_FUE/,JQZ,2FA-N@H!)*6*;'VD)\?9JI`NWI*SP`-*
M)W]]::`U%T2"KD/;3[3]IT`1SY`6@I2KA04\#O7KJLK6O$E"-=6A2B0H%2>6
MW]HBI/6G6FH5G2]7`G$<#MPPNY/W>,A'*D..Z4U&]7:"G3[NKE12NX2R7V#*
M7P4MU]0Y>'Q5VJ>F@-&;@\!$DK40I/%'$@?K]OMT`17'&X#8-&MC]TT'*E*5
MK[1X:4K@#'CENA,RDI5'"@'4\2H#D#RK0D^[67RY;$W;P2VP?+90A*;I.2A2
M"DFBHPY`@;TUI&.A:2!E9T8)?20=QON*['].I(-IF46U!0-!MM4;4-?Y=`*)
MN^+2T`*[@CJ/8:>&VXUC>Y5XDH5M^";MC+*9!2L^7:%+JJE`'=U$GPKKHV_Y
MDC#B"W:K=D3D,,K2_.:8<6T"XODA:BXD4`W`'7?6A)]R,OF7MEN%8[&^^8W!
MJ3,4W\2."$A14LD)2V#T)UG/,JS3D/7!J(IEQJ)\VM"5EMHJ6MI)<`/)0/&I
M!WII'F"S&UEQ'I%XJM+BW74J0M2UJ6>0%0"I1*BD#8`^&M2PX;<*9(MMOMR%
MK:80UYBDI4I)6HT)2H@_=J-`;K-HF,A09E2F*H_O:)"P@E/BD<]NN^@-06BZ
MO-N%$V<`E);6V9+H2L^*O@6#R/OT!HN"^1O.AMSY;;+S*F5.AU1D--<@KR@Z
MM1H%GV:`/<;E7:VLS';/->MMW8+!@SH]'7V'VU;.`NA?)V@`Z$5T`[$#O;ZI
M+:A)&;7EQ;9'-$FW19*7$@?"3Y;392%)IUKH!2,^J;U*1:)7-M\GA]],W&V7
M4J_M!9H"0H==P=`'T7UD=^HJ"9EBPN0H)(0MW&U-)J>I+27_`"U$#H:5KH`]
MMGK;[F1UIDW'`,&FO,U<;6B`_%6EY"2GS`I)46RJE20:Z+-$/)^!Z"'T(^YE
MU[N_3A[3YQ>K1$LEPN-_S=AZWP7W9$=`B7I3:%I<>_>$K&^^O1/.+7LY_P`B
M\N_Z,9!_BB;JL\OMP9*S/,?RP!.69:">F4Y,JOV7J>?Z=>9_L7F>JL+;7@3]
M^FKW&[?=M\F[IY;W$RRS8M;8F/PH\:7>)*(J7EID*<=1&"SS>6E)W2D$[ZT,
MR:O=/ZRW8#`8<RW=JK;.[GY`VZMI)3YL*P-+`40ZM\T+K14`#3<ZQ9Q6;.BZ
MY4SJ0"G?6B]34W)E7F)9,(BX[S4!A[T)V5%2WO1(DK5S0L#HM.^H.H>;&?K"
MV+)FT1^Y':=^S..;2+GBMQ;N$92QOYJXK_!S90Z5J-`/Y8O5WZ=^X`:7:\\B
M6Z9)XTMV1I<M*T<Z$I*U@(/$FFQ.^@&F]=>)-]\_0_ZB,)Q:X1<CDS,"E7VU
MQK;-;N#4EZPI_$^$1##ZG"0W'V245K0ZUL?%CXE+G(SSVK/=I%BG-2`'6W&"
M6UQR.)6M!2VMM=?B"PM)KL*>.O3.,L]])&-S_4IW4[1]K(&0_ER^Y1>;9BUD
M=B6GYJ.M$F6M4I5V;;J[(3#CN<BJA.VN'>;:UIZD>=_B86_BR\3N+^GGZ/,S
M]%?;[NK@>7Y%9,M=O^:OWJSWC'F)+;:K7#MST4*GLNHYQI`<004J`H->+;M;
MMRE_C@>K&YTU%\2J^[R;]E><9#C.)V6]9/?[KFE\CV^T62VS)\E]U5P>;"2&
M&2A`*U4J2![];.SN6G%K!GIV=S^V_`LEQ;Z6/K8S^PVV9)Q+'L)C2XT)09R>
M](8N$9!0A:B]#9YNMK2D[I/MU;:^G.IY^XW(V'JE^G1ZX^RB\4R/#NW%O[L8
MPQ\B_P!P)V%R!<%6+';6@.W:9)@N(3**X[*%*!0E1(Z:]2UM7:NQCVJ2_$X7
M-R4)Q='J6/?7,H4LWIJ]6O<WM!ZVL)[4>B*_=X;?W([W6K/++W+&)3766X=I
M4Q)%AQZ>['1(=?0Y&4T^E!`-2->Z^)\1ZWM/5U]9;?>MREME%5=*I4J-IZQO
M1AZ^;QV`MG'TD]QNW&.6.-;LKRG#['A]]ERG[I*93!>0'&XSKWR<)MD*^4;2
M$I3OU&N*]SL^X]-W'S5V_N*4KA3P5/OH5`]L^Y_=SM`O/<,BXY=<6=SJTQL>
MRN'<+1,LM\AV2(\ZX_&A?/-1YD7S^`\TIWH"3MJ]A^^_`XKMK5;:P>-3HC^E
MSCN<^K&S]I+:_;'+S>[UW0M&,27+';'5?+X/B#[$==SOBF&U1H?*&P4.J<(6
M[7EO77#N<_,R],VW[K;/0O39S:/PFQP[:N-:<;L\&)#"(Y#*U18[$6.A@`<4
M\`V22-M;G<;N7]PE6)YG';5$?N%R<0VJX+903Y*EI!#*5[!*@D#[*Z`T.WJK
MQ)OQ9DH7&8>;4Z(J6PGB\I*^*E.J%5'E2OOT`\;]XDPVWQ)D)1%;2Z/,X(22
M&@>:4DUJH*!H-`-#B4^YY;EESR:0DLX]:4KM-@B)`XR):BLR9[W*J2\L)]FV
M@$/EM\;;R:^VV.PM]$5MAU;X6HMHE$*+B5%.P(Y#QT`Q^:Y>($FYM"476;%%
M1)N'(\FV)$MI(AL15=$NI2I15U(%=M`:O\0XO_*7_6J_KT!YO/<MU7\0L]^(
M5_-V14V'_*\BOAKSCTAN775#X0H<3N>G4D@[^&HE%.->TACE8U<$MQXB&QR<
M;94I6^RD\J"E2:4.N2,I.ZHOE82%DK(N1H6^*D@`U\=OLUU:8BB-9JZ2GR\E
M12!M0@)J*FII0"M1JEY**]TBAJ2G%\2:FE*DT%*U^RFLK-R='CV]P>`FGW."
MR0NAHL[D'P5[:^&M7.35'D!V>R#BUWJ[E1J!:HYK0`<2]N=@!352!T,K+9?M
MS:'5-K;#KJQ6@.]0DUK][]>@"EU:N5%*/W$TY'>E54Z[TVT`G;FN@H"-C2FQ
M\#]NI6:)"F,H,^<XD`J0R\XVC_;'D,N*9;KU'-P`;:WU,L1,[&]T<WSYW)QD
MUNDPX%IN\J+'N#D9#<=VX_,O-28R7>*`IR/%2FJ>-0?UZK<BM.KMH5'-GU+U
M1TXC<=/UZXX3DYT>5!V&@4@[D?SZV(/EQQ26R$JZ!1\#N$J-=Z^.L;V2\24+
MV4IV5CD&*XE]3,RU-^:ZP0ATNM'DRVT0`D%1&]==&W_,D9V%A%X3*@71B;<5
M0+J752[:^\M3$:0VX0E?$JY$J1T)UJ2.5:L;:MR5+4NBE-E+B:4"QR)X+&P7
M3WUU5Q3Q(H%LJV!F6GX$54A8!2@)_=[J2"$I`.H:255F,A"IB!60MM)2/WJU
MD>\A%*#5=3(JQ=F'Y'!!25#Y8<>-3Q!34FJ:>(ZZT618V8MO2M,=T_$7$C]I
M50"E1-0#U*J?9J08;;'4MJ22>1^96FH--@NA'ZM`:4JU/3$)HJG!U510`J0E
M)52H`5X?;H`BQ13KUZ<90?A1<XR%IX`U"7TA=:@GIU]F@)R6^WM+=4A;;?!0
M)-0$UI4)^(4)%!MOH!*3X5P:N,@,1$.1T<5M@MI(510Y)*N-34>_0&XJVO.V
ML2W[9&4X)(!:6PBOED;\1QK^G0&.WV:),E-,/62&VTXXL*46@.2"DT!V%*$T
MKXZ+-$/)GH"_0FMT:U?3D[50HC*&&&LBSCBTVGBA-;THF@\-]>B><6N9S_D7
MEW_1C(/\43=5EE]N!*/,9S-U`RC+U*21QRS)`%5H/_[S/J*].FO*ESU1T6[U
MR3TMX>1J8[VKNW<G'9UXCLJ<C6R>F`I09:<:+[C9?`=:"T*HEL`U*:;ZG5(W
MJQ#WKL/>HD=L)AMNCER*&4M,*WJ3\.R5`5]AU4@02^VUUMZJOQ[BRVDD!;@Y
M-C>G%(2*A(T`6BTW"WJ=D!/)I'Q.ES]W\(-"0"$\:#>N@-AN:AZCB@4)5^T$
M"E:TJEVA-?`$&N@%CCV;Y#C"_,L.37BU>876Y2(UPD)9?84@I=8DLJ<4VZR\
MVGBI*@4D'<4KJLG<4:VG2[V&MFS\Q<5G_+^E2&6:>A!'=E[)V^P';?)<T[I9
ME,CN-6VTA^9:[$J7,\Z=<%>2A$:(E\*4#YBPE-=A77I;&SO;_P`1OV+^A\QO
MOJ7T7T978;[3*Y&M,7A[&=3W^;C?1>F>FZXY=ZF/59A;*N\N/W1JP]HK#<Y;
M,VS62!*B%5ZO3D`.NB1>&RHMMK5LUU`KKU)[.U"-9+]RF.>97TOU?9>M[=;S
MT^BA*-72KS\3L#D0K("&5V2Q.PWVUMR4_A[`+@6FBPY1L*<._B2377)11=(I
M'KN3E%5[!O[7:NVG;:[*=;[0XCB#$AQ<A.8X_CUK84%NTJ9;S,8RT*?43R(4
M`=]&ZJC+*[<BJ)X#LNF(_P#+7,.(>A2T(4F<AQ$E+C7`EIU"DJ6&R$FA!W]N
MHA[G+@9R][FQ"=N\>1?&FUO."Q/@,B>#^X<E`;0I?"G[AW<*Y?"2:'V:LY2<
MM3S*N*<.G^D4-I;MMFAB/88D*SVEEU]UF#968=LM@<=6IQ]UN/%0RQYJE$J4
MHCD3JW6N<?P.A;BZJ8K!454GAYH(+[W'QR(I41=ZA3WTU"XJ$":[R6FJ@\VO
MSFW%;T)H=4;;=7F96Y.S*4K6$I9D"O4]Z%/19ZY;7^&=]^P6.W"ZB/*CV_N+
MBME@XIF=K:E-*0^E&0PHD5Y:7DJ(*7.:1U`&IC*476.96B7F*_T6^@+TU?3W
M[1([0^EZVO0<5>OLJ^W*9DTEF]9C=[G/5SD25Y&IOYCY9BOE^5R2$@;#6<HQ
MGS8EK;=IZK>$B9<^X2$15.!CS%,)YN(%`8Y&X"RO;?V#;5B#6:?L-SAM71JV
MVV0^T4HGN)0A;RG4D%(=-2M*D5'LT!OPXR?GBTVTEMSY,F(XD!"@IRI^*@%$
MH!ZG;0"/RMW\-QJ4]<EH1)=4[%:2I2>2'5N%(=0T3\14G>M-`$6,W*PX/V^N
M&0W^Y-VRQVE$J3*N,A7EMA]Q)6EM!5LMQ]:N("05<C0:`CPO+4V;LQGG="\L
M"'`NYEWF!*FHI(2PM=(C4:M"X'F@D@$5^+0$4LG7,>P_"+9)4Z[DG<N]Q\JO
M7$*Y1[0\TE,&*$@!828RD52:==`2+_AW!_VM_P#W'_\`=T!YJ/<]Q([C9V:]
M,OR3P/\`RM(UYQZ0W+I'E*/7XJ_Z*Z?IH!:XVZXAR"A:%#S(#JA0`[!V@KN-
MR-_LUS*S)7%/"B(%J("WTESF$@'H%I2=_:%E.NDDUG9L6VMK6_*810BE'$*5
MUX]$DFI)U2Y%S5$103<W-[>W4(4X]0&M$A39WW!H?Z-8V[4H)UIBPT(R?E\B
M7S#+`2"%\:`)(%#0I^+;8:T<6E4B@]7I\OJG[]D#4AWCY=DC%5>@!?J4@UW)
MI]FJD$C[C+MLTI6ZGS%I51OB$\@@=`232N@$I<)"5KY-A0"1ORI7CX#8G0"3
MFNJ\U'Q#]Z4D;FH%:4/7KH`JO,%VXVFYP&9:H$B9`E,19R%<5Q)2VE".^@^"
MDN4W\*ZTUHM4C=B6-]S+)E#D[);38\:QEZQL6]NT6BY)GHR*]Q'5)?R=U(`,
M:5.0*N5HHGPTE-.-,:D5'$>^-!I^S\1K[!^O??7-&#4]3X"IHJ''C7]JE*>\
M`[_KUJ0:SB2$*Z;I6/\`K%'^C5+D7-47$E#H-I_XCQ9)Z+2USZ;BG3<>PZTM
M/1F*F\6P5-\`4(:/PHZ)IM7VBNM2Q]%D+2L&A*ED^-*&E/TZAR2(J)JXM*$I
MH@@@MNI`_P!2A7NU5O5@A6N`V[#*_P`T013JJ6L4]B$5/Z3730R*#A/MEL#E
M3X(:D&GM4B@_5JY8_8">"8R#N4MDDCI\041_-J0:%G5QCR"0JAGRA4`G]H^`
MW/Z-`;S4*Y71KY&SI6N<Z\GCP;Y>6W]UQQ:B"$)"?TZJY)9D5H.OA/;&R662
MT])A?,71R8V^_,+JU)4ZI7)Q/E$!''GXZC6A5$H8MJ:40I,1@`!!H4U/&@`&
MU16HTUH5#`VBWK/[R.D*41R`2*`G;;?V:LL<23,;3`*.!83Q&Z?:#T_534@Q
ML6"#Y@7\NGX`HU`]NX\/"NI6:\2'D_`[DOHBMI;^GQVR2G[OYCS>G_GI6O0/
M.+0\YVPK+C[,7R#_`!/-U6>7VX,'F`YR^XJ_Y@G[H.892%$GJ/QN?ML3KRY*
MLS6SST[B-&;7/)8UP4+!DV16'RF$K(LMRF0VG7:G@X]'9=0R\XVD$`E)-%4K
MJ=#.N@AH'?7O7C3_`):,QDW=E!^)B_QT3N2`=J.\4+20!3QU#BTL10=2S>L'
M*6>'YDPVSW**V`EPP28SSB@!4\5!5"?U:J0*V1ZF.V>36ZXPKMC-UL%Q>A/(
MB.R(2)T1N2X@B.MUQEP$-H>(*MON^&@"7L-'Q9&(KA]R.YN/W+(IEYFR(*&&
MG(C<6`ZY6)%<^89:3R2G[13:NHDU&#F^PB3HN^I(!G"Y=PNF-X3VRQBP=R\B
M[D7VWV"&^]<6/(PYIE],F;D\L1GT/OP(<3DMT`*V`%#TUOZ8Y[K=PA"W-IO@
MN#[SYSZM^H]K]*>EW=_N9Z;D8526=6TEG3B=)_;N1V@].>`VW%,73C\-Z'!M
ML7)KM96;?%N&47]IM#DV5(<4CYE<<RN80DJHE`]IU^E>G;+0OW+<EXG\6_4?
MUA=]5WMR]KE*U)NB7>.)Z>/J`6G&LP[L6.+B;F;8_8)EB?MSL2[Q;>U`N4UI
M7G6[S>*R7E_M"E#KPO4I:-S=BHO"31^_?P+<W&X].O0W%>FU[E>Q%@V'>KGN
M!W4BE.-=LD=NK>P\!/R')9[%V"HRT)4V+1%;:2)3KJDJ2%DT!UXT$[LVEA3B
M?LLZ[=N$\95>1):P]PI5T8@.W&/\\V7'(=R;N$(?+260BB7J+`0D^/2@\-:]
M"7%%5>3=*,PY#AE_CLF\]G[M&@R_.2[<<*OQ<E8K>D+/F/(865J<MTFFZ5I(
M3X4TZ$N*-@MQWNBZQ*D8IDG;^]8;=;@I45BZ35IN.&R;BY\+,=%R"U-QTRG3
M1OD$@'8FNLI1<9:6#ZN[>;1G?PZ_XC'G0@DEMY5[<A6MQDGFDB)$!7(044I\
M217QU4"WQ-S&FD<C8K!`<2@5=CM$)9]J4R9'F+53QKO70&[G&=6C%;<RTFD^
M3<?+3;K7#<:6])"J@O*:2D+;9;\2JE:[5T`F++D:F5!B\MMB#*^-*8K?E*C+
M7\2@5$[FIW56I.@%X6(5QC^6IU2FGDE+00ZKD2K[H</[=?TZ`;:5$N>*S%_A
M;#K396AV7&<"G69S04:A(`*BM033;?0"I?[EX_:8CE_GLO0PQ'4R_%0A3D@J
M*"-F5J#@2"KQIH"%?<WO-?2&\CBVN/>+SDLTVW%[/(6ZDQ8R70A#RXJ"4JJ-
MU)I[ZTT`QG<[),USW)\3[?Y5DEMMV*X\8LB\VBU*2W"E7ELB;*4([+CBW$0V
MG*+6Y\/+8;Z`PY[FD_O9F./=F\9EK7AT5Z$9S,=!9AMVNV+072^E(-2?**CR
M%*:`=[%+(<GSV\92Y%#MHL'RN/XPPI-4!JUM)AAUML`!+;JV:I/NT!,3RI/_
M`":G_<SH#RA^\>:8?:NXO<`SL@A-^7FF3("&%KD2%`7B:`%LI%4$<!KSCTB.
MUY[\XU"8=3:84ZZK23NL"(DJV`2//(4010U&WAH!=63,[A=K+:;XTIV"N2VL
M%D*J6$&I`"AL0.E?'0!^+W<I":JG25U%#R=5M4`T30[#0&J79;ZJ+2XX23\2
MG%*Z5/MT!M--2"A23^[J=P*;[#?<:`_3&)Y`.$FBM@*'H:BO^GJLN4,>3LFV
MER_WYA`4E9L<<**205?OQU->@IOK(H2KAVQ*&P%@E24CD>1-:;D[FN@$U<E%
MMU2$[)Z>W;?VZ`0]T>4B;'`(XI05=!U'Q#?[1H#91*#B4J50D;C;H>G2AT`G
M<D<4O\/%>24A[BD@;54I1\`>N@$CU!'@10_9H#&MI!`J/NBJ=SX"GZ=`:*D%
MSBD>)57[."P?Y]`.>4%NSXJD]0['2/<A0.WZM`'I0@U%/T5/]>MBYA=2$I^`
M4.WM/\]=4GF58G[DA(D1R!\7!PCJ>J5`[&NHCF%F-W%25Y/#5S""GY\4*:[>
M4G<ZT+"VE)JM:3O^XW(VK1/74@QQ0`(RNG[O<^&R54]PT!M8;:9M^>5;K:A"
MI`E2'5%Q1#3:"K^_+6!LD==`2=P["[9CL(18ZE293ZRY(FN5"G'%`!24$G9M
M))`&VLYD,7K.,MM\5MJ`55*P*G8[&@/A35"HJ6H$IH#]YL4)`Z'VFFYK45T!
MO,1)2E#F@J34;]*C;V:UCD708_).'HP?]<K5@?8COMI4$L$42JM23M3<[Z+-
M>)#R?@=N7T4&TM_3][8I2"!^/YFJAKU5>%$]=>B><6:Y\2,'S$CJ,5R,_JLL
MX_T:K+('ER9I*"LERQ-5$',<LJ"33X;_`#T?HV&O+_6:V.?R&3N92]*D.\>2
MBH(-:G9.W0ZU.T;?(K4IY*93;*3S5Q```.U17;?:FJ3R(>0W[EL^(A;:FU?W
M"E`TZC<*VWUF5,C%A=F.-L-*+32G4N.#8<N.Y"B/BXFGMZZ`<^)887E,-K9;
M=\I2456DJXFE?A*R2*>[6%YM-?XD6X__`),;CY$A\?35W[M/8GN1W0N=LM\(
MYC8<)B,8XB:M0+5MO!/XS/@*7S0S<%*)2`!4H\=???3>[VVV@KL8IWDL/P/Y
MD_GVWO/4_4;&QM2DMI<:4J5IACCYI##=Q_6!W?[AXUW"[DXW?;@R,(G263`7
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M`?7'?J:^D]ZW.3&+EGT&*6TI=ANXXX\2L43Y:O+7QV'L\=/F?$RH;LKZF/I'
MN3#EKG?G&=!E,AMZ.]B;BO-;X`(2%+55"D]4JV*5;U!UK&6N.HB@1,_4T]-F
M-);A,?Q`ON.J/[J//L(>N%J;Y;,-/O*4ZXPCP!.PVU8"AB>LKM+W.+K_`&9N
M#5ZOZTE"L0RCAC[O-8^%YMF6EIJ:M)-`AM1J=NNV@$E9,U:BWFXS\AMF;QLM
M1R=E6JZ6[RW'"%)6&+,X5%OY)"02V$4)2-]`.!$]4O;%LF'>&;_;WD%2"N78
M)1;;<3LKSEH51._B.N@%?:_4YVGM)BN7#+V(-O\`.:#<JZL/V]E"W'4H;2DO
M`K6E15U.@)2W^X1[]:V)]EO,"6$L,W"(NW*;DB0TMM+@\E^E`%H(H#N#H"MK
MU,=S\8QR6U;G\O,>^SXYE3X4</RI3*`L!(=810#I2B>N@(83_47E$1Q5TB".
MY(1"5`L=PNC2([=M2H%DS;?`\M3XG.,G;EOI5`3%AS[#;!9YCK+>39'W`O\`
MSC"Y70*;7\Q-4!Y45#SBCY!?57X:5&^@)-=M\5>[/]NKC>KK+<5W$[D.&'$<
M=/(VF-.VDAEPUX%B-R.VP.@)U]KH]KMS-AB2'Q'>:A1`PPX4AVXR`A*TNJ34
M*4%%14"=C70$J_F'/^#,_P#6_P!>@/%2[H6EU[NEW*KYBP<_S"J2-S2^S:$[
M$Z\X](2S&-R%I*@A217]K>NP]B=`22QJ,M&+6N(J@\I"CU\>8!KL=`+B&RWY
M5-ZCC7?W:`,V'$E"D[UJ!T]G^D-`9M`?20>0-#2HWU6?*R'D/7V*'+*KR!X6
M=P_]<-9%26JOB2:>*/\`YM-`-A=UA,MP&NW7^30")NB2M]E8I0U4*]:#;]>V
MJRY7X`QMOANM*U50>SQ]QU3;YENTT;JX%NQ*J%4QYSAW_92V!M[]=%SF\B&(
MA)!"5`@@[BG6FVJ$&R[(*DA*.@'CM]N@/F/_`'T?8K^;0#I2T%4+%SM3YU@?
MR5]F@#1;*4NN.)Z$[>WK3IK<N?F@$M(0?Q&&K:C;3Y5]B%\33;?=0U661#R&
M^C*:5DSA42/)1.4?>%I!%-]S0ZR*BSE;J44F@4UQ23M^SX]>HULLB_88<=LE
MZS66U;;0RY'M[3B69LTMU2"@D+05"HW%?MU()=89@EMQ*`Y`@H_>NK\Z7(XU
M7)4152>0_O3:3]U.^@%L+<4!-&U4*DJ.QZ#](WWT`H8A')*%)4`JB14>WP.^
MV@%*U$2XA-*;%)-2?]%:#0!VF.DI21[!2I/4?HT!F;;*"22-QX5_J&@,@;55
MQ>U%(('M^[3V>W19D/)G:G]%Y)3Z!NV8/47W,@?_`#N?ZM>B><64Y_\`Y#9E
M[L4R11^P66:/Z=5GD#RP,HE)<R[,4%2?BR_,`-_'\PSJ>[7E_K7F.P;Q*TN*
M=4FM/,4-_<::T/1VV7F%4Y(6.)KO7H*^/LU6>1,LWXB=%F;6E3CM*\E;`GIM
M3;].LRAMQK8F*V4-T42:^:K9:JFM"*;!(Z:`-6TTH@D`D=2=NE.I]^H7-Y&2
M;6ZBWR4Q]I!COMW+O':3OOCN3(MSC]DFXX+;=TIBU1.CK44K+2W$*;<=9310
MK_9U[&UEHE&7VR/GOJCZ6V_K5F4HM=9I4\L1P.U(L^9RKS?\/MUV9P;)'UPL
M@L][CJ3;KNR\%*DN*0I(Y$+KQ*=M]:[G<H^:^G=CZYZ/O5MX5Z"?>2(QGME@
M&)379^*XQ:+5(#8:CEB"PLH)(Y2$2GD+D(6L^`-!KQ9.LFS],DY-MSY^T3S6
M5]X,7[EVF_\`9W.QB=TBW4LW*U71MR7B^10"&R_$NMK0K@2Y39:?B234:A7.
MGCQ"+A,&[]V+(8L9K(DP;#?E-,_/EI:OPMR<H`R1##JBM,=;I)2%;T.I5^KI
MCB22*Q'([7:;BQ>O.1=H)6$383)2Y&E0WQ1P(0%?"ZT#R2?!0UJ22/5B,>_I
MBS<24;K&GI!B1(;05/CH<34,25#<.,G8J/7799Y$4GROP#^#VDR][_!56B2Q
MQH"9C"T]14%MTI/,U._2FM3@-]?8S*U26GG9L:W362%1Y:7W(+C200I)3,86
MVX5BFQ&Z3H"2^%=U^ZO;V,Q:<LRB^9[:T!,:V^;;3?+K8R!Q9`NKR2\BW`UK
MR4201OK.Y/1&O>`RR;N;DU[6W;7+`EZ>\X"J3;6V`Q(+OQ(\U*]V%!/WD[T.
MLEN$!"W7LYF.3LN7'+)\5NV2&E)MML<E*<9C.?LI<;+@`6@[TUT@V,0SSO+Z
M>D-_(YG^*XPFK4>Q7:2[.*G`=D,%#RE(:2``G;8:`Q2?4/D-WG2\ANV,8?/R
M.Z\O-G2[894F,VDE2&D-O%2$MM^TUJ1J)7.DM?VQ`R60Y'E6<7)UMAN&].#P
M6$1XK4*''YJ`\Y*64\DAL&G$==<-Q?,8H$@>T&*8K@TR/F>=W=FY7&V%+WDJ
M`=;9=;'F-".R\E0KRZ$@Z[81TP4>"0'VQ"^O][LZCWE<:7`M$+YEJT15K\U2
MF:K_`,+0T@^31Q9!(/0:L"?EAPF#:K:F\SKC(%U8"%IGN+)+26`GRVFFC1"!
M04-*:`=G\SI_Y6D?J;T!X_W<J(P.YO<9P)HHYWE3GAU<O<XJZCIMKSCTA)$5
MIN10>&WB3^O?0#J6-`%BBJWJDE(Z4HH\C7;K4Z`/V_,XCATVKU]@]A&@#&-U
M->M=_P!1T`8H0%`UKUU23:R(88%E'#IX#^C57)M4(J.SV'-<LN_OM3J3]@-?
MUUU4@EH-T`_W']&@&IR!11)?4.H(Z_HT`BYCX)2"?B0"A--NM3O4[TKJ&JJ@
M"Y3@(',G8U''VZB,5#E)J%=R<*GHY!-/D;A3V[(`_HU=MR=6!)15$LM+)->!
M%/#<^S]&H(-H+)(&W7_1XZ`VF"0^T/[2BD_84J.WZM`.\ZA*H.-UK\,UDC[:
M$:`.WHXHKA6O+Q/A7[-6ULFH7O)+2"?'P\1J\75$H3<@`W%A/@6'2?\`JU<U
M?RI&DL@\AIF%*5DDO>G[J0C;V%7']=!K(J.M9+4;[=+9:WI"H3$X(_PI*>:_
M+0G]ZEM))JLA)%?"NMED7["7V,6:S62,BWVR$$1&4\*I3Y;CSK8^-Y]02"IQ
MTFI.W34@7<:&'XRBRRM%34GIQ%3]TTV`IXZ`S)A/(%5N<4CP4:DT'@:=-M`;
M,5`6_P`!102FJ5>)/@2?'0"G8:+:!7Q`_D_^70!C'/(4/0;"GV5T!M<![_Y/
MZM`?I%$D>X_TZ+,AY':=]&'_`-PCMK_Y?S'_`!N=>B>:LBR3N$:8'FO_`$0R
M;_$LP_T:I/(D\I/)75#,LO*E*H,QS%1H:`!-_N!)--Z``Z\S]?M`S+7>#MNT
MM<5S,[$W+2\\RY$>D+8?CR$.*2H/(>2E7EBGWA\-:ZT-87YP7NT#B-FN+W!0
M^7R2P.JI4!$]LA0--T\R`14]:ZK&,YRT]G@>@M$E5YOO#4W2WK3\,ZWO)(V#
M,Z,:@T^*O/:HUA>UPY<A2WW^TP"YI)"4*9<!K1;:^5*=!0;'66N[W"EO[,_5
MS2L4X*4-]T#<?I]NM[-95<\RDXPDJ+(P2X]KN<:,S=+1#NC;;A+:;E%9F%/5
M0"5/I64I)\!0:[(W9Q5%0PCMK:PK.C[_`.P:Q7F&&TLQH[4)AD<6HT9MJ/';
M2?V4,M)2V`*>S6<VY\QT0MV88Q3KQK_8-8LE*:J^^/O**:?`*5JKPV(UQ2E<
MC+2J41$J-MC.07A(S5GF5)0JXJ6DMGBHGINK<4V&VLYZYYT()$3I*2V@><E%
M5I-.BP0NGPJ&_AJ(0:FGWDCQ8_GU\QMJ._#NSW#R4CR'%E3?+X4IJ"?A2:TU
MZ0).]I/J@=P>R603L/E8Y9;OCT5Z%YLF0PW(DCYL)=>5YK;0>2EOF=N1Z?HU
MI"Y*-(_IJ5FO=?@301]5DY#':^5FX?"B%M:EM.Q5P94=?527''@E*DBM`=M=
M74B<.EFP?6K=+V69D1ZPR&G$H62J2U+CE+@%"@H="*%)Z`5'VZ:XC2QX;'ZG
M;Q=;:IA2K)!?F,E@J@2W6TOL!)(<<"E<6J*0/>-8;AJ<**N9#36(DGN\-YC)
M"H9::E%WS$.MW/S>;H)"G>8(-%#]GPUR:%Q9`<([]Y;/*XC]R0XTU1#:>2]B
M?O+)6`DK5XG7I:XBA^M9!<+\2]/6M\)<0$\7"M5%&I'!)!(%?`C6-R]*,J1I
M2@#"Y350(W^",%#GG>7(2H%2T-&GQ*)-:D'7/>NRG!QEDVOQ`90;Y'QZ,J:M
MR.PZ[&<7*EO$A,>*D%P<4A0\U]Q0H!6IUMM6XY`8IWO[)R3*A;WK?.59(1"'
M(+BU1W[G%+G%4@N<D^6D-]!U`VJ==;=74%UOI"OW;J1C4E=KMTRQ3+>\(DEJ
MYR&?\&2MD.M/QY#IJXRM*CM]F@+`T2L6NK4:([<I*F5!M*F6VDGSPI(Y<5CJ
M%]:Z`<3\!Q'_`(//_4?Z]`>/KW401W*[B*"0$_GC)QM0;F]3_#KKSCTAO]`.
MK8EI%CC;_MTZ'K0"G3VZC("I0DA*010T'L\>G\FHU1(J@P9_O2O^I_HU8D,4
MH4M(I38#Q]VLYYD,VE?<_0/Z-4*CH]AE`9C=0>IM3Q'V)4*_SZ`EJI0\DJ\.
M!/\`)H!H[W42WP?9_.3H!%RW$I!J=T^X]1N1TT;HJ@(ERC^^\!Q&]/'D#X=.
MFHC)2Y2:!?='UAV,*4_XOG>/_<T[U&K--.C($M">4&&?,V244!K7<D>`]VH`
M9I-2"/:/Y]`&4%)5+82.I7M^HZ`>:0VKR<:&W^_&5=?!M/Q?JT`?JXJY`G8[
MC;WU'AJVF1-&$DN,D+"B3Q(H/'<5\/L.KQ32Q)0E'W6T71BJ@H)C2^=/B\OS
M%`(YTK0@"ONTDJK`,V,6[$YQE]UE7V$E$.U!!<9=GE4?Y]2E52S&2II2UMK\
M54&J:&11DH^W791=BE,7G)Q'-PB\F(UKCGS6(B*[R%O(/%:B/#8[ZT618?)%
MIC,\PAE*D%Q2D!M!'%)H!4FA-=2`XC,(C(!;CETJ37C2GE^\GV`Z`*Y41105
MK;X<E*J*I.ZCM2GLT!@8B%MQE1!V*2#04_7H!0M,N<@2DIJ:`*V/@:T.]*:`
M-!'!H2.OO`&@-L--<`*[@]*5_EIH#`Y%"N2AN*&AK3H/9HL'4AY,[1/HPU'H
M([;5Z_C^9?XW5KOC*,\8Y'G+(LC[A_Y`YQ_T.R?_`!-,TGD2>3YE$V(SD>>/
M2)"6FV<FSEU:U5I1N^7->YITVUY?Z\.\CL*?97='#U7VZ1LXQFWWN.].EANX
M16$K+D1<A9;#JV0F2VM)0*CE2AUU0VUV?+3VD$F^R';'TO=\<ELEF<[H3.VD
M^X2V1.6]/87;V82`2IGY>>['<0&6ZHJ%5H?'79:A"$O?KD74F2Y[(_31F=W<
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MMM_,?@T5I"'6&U?$DW*6M(8A*!(J.04D>\:UC9U8Q&`A;!ZO[O<I42-<^UUV
M@V1YQEIVZ0)BKHHQRZA*)3/DAUF0V@*^.A^'59Q<.85'@R.YMO9E>9#8<;9F
MHM<B,'DK0XXRMELA?%8"B*G?:E>FJ5JJQ)5.W(-&7D*8<0M"5!Q!956@V<J#
M]NVJ5N\/O-/V^/W#CX\68=NC,,N2$(:;(3P<*4"BRJNQK32MWA]XI;X_<32]
M$=S<NWJ;P.R7GYF\XLJRY#/R&US'G'H2HS$933/F,+H%)4YXDT`U>W&[-TIV
M<3FW*CH6GB=#5\]._ITNUPES+3A;5N;FQO/:_#;D^VTE2T)4OBWR*4'F3L-A
MK;H7."]IPD`;SC5E@Y1DEKCKEV]%DD.)B,M.)XHBI7P!WKYBZCIUUS>_P^\D
M3$C*YV/NI>M"FG4Q@OS7W$E:EN*2-Z#8FE/L.K*M,<P$Q[@9-=4+0)+4<ND.
M.NQD$)6YRK\8-:!('Z=1/E`7IE7-R0B7<[A)FP)8I<8KGQL6N65U2^EI%7/(
M>`!K3B-=.W_,"I9[1Y'F4B-=<.1&EW.(0^VU&6A:7XB?B4PKBL*_?;=*Z[`2
MZ[3=VIG;N["P=U;->+`MV&VV+8F(J.Z3'"O)=9><1Y,EKCO4JJ>F@+>.V7=G
M#<RQQJ;C5_BNRH2&FWX#QXS61Y02@/-TJR:=:;>&@)*?F&3_`,)C?[J/]AH#
MR2>YJ0KN3W$!Z?GC)_\`'4_7G'I#>O-I"A2OW1[/:?=H!Q["FMFBI\//4/U$
MZK+E88L0=R/[(2!^K_2UD4#%L)`&P`IN*;=/9J:OB35FRE9I\*B![B1J"#*/
M,ZJY<>IJ33I[-`.GV,<\O,;F*`J-J?Z]0.0KX=#H"6!62D$[)6!1._&A'2G2
MF@&DRAPMSG0%E'P@$`D;T!\/'?0""DK)`)434@[D[U)K_)H`FDJ*`H@5YF@Z
M4/C]O34))98`TITCS)$8<4J_P">.GL:3MT\#J<\P):$Z2RRAP4(3X[T5X#[2
M-`'<9+BE\:*)-`D?>W/3;?Q.@%?;;1(06GW_`(%!P`#HKE^CH*`Z`=YY#:FK
M""H)6F4L!/B`(X((^U6@#I44)V-`?=6OAT_7J:LD1MYG*8*HD1"I<MQ(XJW+
M4.I(#C@K0DD?=/76D<42A[.SGI^FW1;&29FE8MSBVYD2&Z%)D77XJ\GDJ!^6
MAI)^Z:!=*4WU8DFW%Q]B,@1F68K,>.WY<=E#:0VRWU2VB@```^P:`TG("&ED
M*95SXTH0.*DCI0?V/8-`?(M:%?O`0".K=.(-:_LC8Z`R(A*!%$\0:5`%-O$$
M=-`%\R,-P4!8ZT4D$"@KXUVKH`IX.@!10DI20`..^W0=-`&K"RX4<Q\0Z5W)
MZ5K7I30!@M20HCI2FP'N'LT!]-E)KT\.OZ?;H#[5]Q5/[*J4^P_TZ+,AY/P.
MSGZ,E/\`V".VE.OX[F-?M_&%UK[]>@DEE@><60]P]L!SC_H=D_\`B69J)\I*
MQ9Y#?=6]NP5]UY+O$)9R/N`4G;9(O5S2D?ZFIZ:\O_8O,]+IV^G72JX=A3Y8
M;H+@Z1+M5F*W''"DJ@A2BBM?B**`DDGWG73KG!TC*1Y%]M)TP)6=LL<Q29(3
M(FXE89$AGRU-E4(H`X\5??;D!8!(Z=#75-<^+.BPE*24L<"64-C'7D%/Y/Q>
M&A;(:<B1XTE#3[?W>#Z$2TH<4KJ:^W57CGB=FB'!"FM\/#X?%EG"\20BA(2J
MVNJ(XBHXA4GB4II^C4D:(<$;<+O!VAP2^07LUL&!N6=*)34BV)LAEO.^8PXT
MRZAMB6'$N-.T()/$'WZ%E%1R5!C9?J`['MKE^2F=%\UYU31CLR64)272IL*X
MK*O@;V&Y(T3:Q69)\6?U3=M+%)6NUY)=8<AQ:4MI7^(.!1W345\P`)KTVK75
MM4\ZL"W;]8=F\T-C,906E*5&@FA26U&J5D*9*`"?;4:JW7%Y@QS?5#C%\0AZ
M9D4J8VTY4MM721"<)`X\B6V4[$:AI/,#.R8WI%R27<+KDT'.Y$^YO%V>Y&SF
M6`\2JI`:=;4"VFFR34:O&Y**HB&DQY^W.4^E+MU%?CX?>^[-D$IM2&XC]^LM
M\A1VU"JA'CW*(4Q^3@Y'CN3UU$I.7,*)8#@N=VO33>98NN0Y3W/NMX#34*3=
MIDBPMN"+'2$,I;:;;0R2RE(":4V&YU6B61)L.9;VNOH'\/+KDUSCLJI-<O\`
M$BQDI-*H$9Z(LH>42/BZ>W4@);UWAM&&PG'KDS*#,,H!;CH2XX^7SQ0$I43L
M:Z`L8^EOD;?<WNAW@SV+%DQ8V`8!!L=O$E37)V?=WA<G"6VD_P!]<ADI)\0`
M-;6.=^!AN.1>)T6V?)9`PVU7>(TI+4ZW*")+I'%+@40I(4=TJ!'3V:ZSD*_^
MYMXDPLZ7+C$%,]:A-2Z5$255!*5`UYCEN:ZITX<$`I5';N$(K;AH;<^)Q;=?
M+:57>BFT@`[>[7+?24Z)45`(!YN5;I9+3(3&6I(=92D?NP5;E(%!0D[^[7//
ME\P.QCELBNN_.NH0["EQA$N*0D$N1WP4`4/WE-J-4UZ$;:Z=N!\L-P',NW\1
MV?8Y[URQM\!=HO$52D7.VI50JME[:552PV2`TZGX2D;[Z[`2%S2XW//<%M;&
M0VVT3+E$CH;;NG!)G!II*4<GEK!4LK50"A`KH!,]M;I<^WDJ)D#:W&4ST)M\
M]-4LH<2VORFUK-.#M$"FU#30%C7\6FO[<;_=3_L]`>8_W,*/XE=Q.G^6^3>'
M_CF=[M><>D(-P(/Q$)H-JD#^JN@%W82!:XJ3U\]9`]QY$?9JL^5D,5R.@!^]
M0<J]?=4^.LBIN(=Y$)XTVZU]@]E/=H#<1T_3_0-`&!%44]H`_730#C=F.+.:
MW$J5]ZSO&G3HI/OWT!+(?O&VPGP2FGL/P@#[-`-=DMMG2YCSS<=13RJ>'QD"
MB0/!/6F@&UN,22R5!?)%"0$*0I)Y`4XTWW)T`GEK70A:5`I(V4"/=U).@-%2
M_,?952G"'<12M:_`GW#0!5:V),EQM#312'-BM8/$)V!\.N@'1MEH:A)031QW
M]M2D[$E513<TVVT`K6$-/)2$TJEQ/(4K0UZ=1[=`*^1Q";,ZM*4--RW$J<*J
M4X1R*D4'6M>N@-&1>95P=;MUB9<>6\ZVTF2A"GO-63Q#,%*45?D+)HG<#0$P
M.S_IX<MJ6<@S2`B9=U!,V)9'SYB8:TA+B9=T15(=?X_=;(XI(]YUI#(LB6)B
M(:;;:0WR4OR_,);"`:$<4)2D4;;3X`#5R3[=MZ_-H&^/*A-.7N'L%=`%#D!?
MS+O-%0D4!(.P!`IT.@/@P0?NCC[=CO\`JIH#\^0-=S1/&I5Q5U]E*_TZ`*Y-
ML"E%8<!*21Y?#[^PWKRVZ4Z:`U?PMQ3?PM!!4>:2024U'LVK30&TW;(P:5YB
M#YH`Y'[M?9MU&]=`:@M+;I4H%0&Y\3T%?;[M`8UVH(`*`M1)H:<A0?HT!J.0
MW4\@"4T2?A(43TK2M1UT6:(>3\#LZ^C(E2?03VVY`I)O^9&A\*WA7V:]$\XL
M=[D.):[>YXXO9#6%Y2M9]B4V*<M1_0$Z.-8EHK&O>>-YWV[E8/+A=WX%KR>!
M,O#V39U&C0&55>>==R&>."!6I/Z->=*WIN9GJ?Z_85S8K:9:78[RHY2%@)*5
M_"I"@D%51ON#H\S@N;7J+FIY?W)?X*XW:X0>?*6Z4/(KIS`H30'H4@ZA&ENS
MTY5K7`6-P[GVR$E*(K<B8^M7"C8X)"J;@KHJE/;3QU)N-ID&?YA=UJ89G/6J
M"I)2(D'X#QK\7)Y25.$JIO2F@&GN%K>6I;R@MU;@/-Q\?,.5)))"W`JAJ:["
MF@$S,L:RT"4'<TJ4&M1XD;#>F@$'<[?\HZAWR4*\MR@*DD$$D;CJ`-*NE.P&
M[$\ER=(<*@E0AL?#L4E=*E'$FA&^@#T/M!M0#;32`E(/P-@%1J*[-^)T!EM]
MJGW)YQJ!#>FR%[I:BQP\#44`*TM'@3[QH!^L>[#9=<FX[]V=AV",M"2H.4?F
M*:*0H@-(;06U$>TZ`<F#VGP[%,C^2=0N^N-,Q7$NSTDLEQX`JI'55)"55I6H
M^W0#_P!HBQ$)$>+&9B,A54MQVFVD)HCA]QM*0330$<^]SI9GRH2G%)92W;G@
MHI)2?C!*:<O;H"[;Z)3++6&]]+@XA7_'N?6^S"0$U(3&QKB$A6X!0NE$^(.M
MK'/Y&%_D7B7B=L<C7-PR1`?=\Y%GO,J"Y%6LGR0RM2E*+?4%VE==9R$9.[,=
MZ-D*+BJGRBI_[I=:CBH@';8"N@-S\88MZX[3T-UW=D+\L?"6W4I*5GX3OOTU
MC<M=26JO8!8R>WBKK(3);8667&6WVEM;*5R();('0@'?64MK54U`45NQHV&0
MV5L2'[>H(2\G@I?ED'=:J`T2A0UK;M=/MJ"8/9RYP'FY<14UMZ`Z:J9"2^U(
M1PHJ*L<5%DJ&PJ*I5]FM@+Q[)<,[37-AKN'AET';K,7D,X]F3T5WA;Y2U*6Y
M;I*UMI9:<*_[V5J!6!L-"DY:(N7`;3NOA5Q:<@7'"V8N3X+<TKE66[0YX<2A
M+W[TL2V6EJ7$?9YA)2L#<;;:4*QO0:3[AQ/PN]_\"1_NS_\`L-30GJPXGGO]
MV+6ZQW*[BI6A2?\`GQDW!93LH?C,ZOC7IKS3UAL'&B&U))H>5.GN&_70"KLO
M[N'&*E?"AX]=N@/C7;?59<K#%T@A20L'[X!I[-O;XZR*&ZAM"2%!Q)/]D*!.
MX_HT!M((`W(Z_P!6@-E"E53R)X[5KTI]IT`X_:(US690U'X-(Z=/OMZ`E8S(
MXM-II4A"1XU.V@-%U:2XHD<:'J=J_P!!IH`IE-1WJ^>VTXW^SR"`#_J5D=2?
M'0"'N5DL]Q?$&-'D_/O.)2PW$Y/NN.J6`E#3+"5*<*B`#MTU-&2/GC7HI[AW
M:*S>Y$FUVU3\=?RMCN*U"0ZV^GD')*T$(B*6`/A50^W?2C%&(^_>FSNSB7)2
M\.E3(K!"W)%I7%N"5)`5\2&D%3R*4Z:48&PEPI]L5Y-QB3;>^"H>5.8=C.@@
MG8I=2G<:48HS-:5?+NI2I8>2\%.U*N0J$U&XV!TH^T@74*V3\I-IL=MBO3KC
M,D<HT1@J+KW+X5J!0%%M(3L5':FH!83V;['VK`F(MRN33$S*G&DJ(4EM<&P$
M]6HR5U"Y@'5T>.IHR:$E&HD:B@%I*Q_?5*-%+56I45;$IY'[-7CD2C*J)$*A
MR4GE6HK3J-ZC](U<D_4Q6%.`I*5`#<DCV^/N&@"J7%:^8=X\**&W$@A1J-@1
MU/V:`+G8Z&TU*1O7<^X'W#0&B6U+2@(;*@:+4`FH(V^(T\-`:[]L<X![BMM*
ME`<B"D`GP)(\=`:_R[K#I!0M:>9^/B2$@UH:@``#0'P\QRIQ016O*@._LKL?
M;H#`&%-C:H`'3?I_K?9H#\XU!VJ!N=J@?;[-`:K\;[[A/$<:FHH!\(IO2F^B
MS(>1V-_1Q%/0CVX%*?\`'V8[?;>%D?R'7HGG%@W=D5[7=RZ?_I]F0_3^7KAM
M]NIJDL2T<UXGAV9):%/]Q,]D-1R5CN)G-'D-5H$9/<$@A0%-AMK@NM.YY'IK
MX3\OS%5`M+#-"I"OO%?`))JHI%5';J3JA04:4R%@L?O0RBA;3\80%;5IMUW.
M@/IF(ZE)"V7"2HD$H5TH*>&@-DPY#E`([U?V2&EU'CL:>P:FCX`!M$QP;LR*
M?_1J_J.E'P8,$G'YBTI3\DM2?]50?;3P)U%'F!)W3MU<)[*PW%*5J)4@*7M7
MVG[*:BJ`AHO:G*HDN=*DJCMQ([1DK=<?2$A*05(8+9(^-0%`?'[=35-8`=/M
M_A%BF7E)O#0GQFTL?X.M:T-&0ML/.(4I%1^Z"AL=14$F&FX-LC*C6F'"@--J
MXH^7:0TXXV#NCS`E+JZU(W.E4!4*NO*"CS#\90D'DH\]J"E>5>FVE4*B7NDP
MJO[;U$`J:MPYJ/Q$``K^([[#]6F8'#M,FCB":?$*CV'KTZUU($#FMHL>3729
M#N$=MQUEF/YBDNN-N)0KB6RO:G``DCVZ`N0^CF&+=V*[HW6W.>=#E]_D,PTK
MISK"LS<5YQ`I4H)-`1L=:V6HRQ=,#"_R>99QB]U.,9;EEO=6$IO4Y<MM'+BT
MVMY1')P&@34;:ZM<.*.0TNY5N;NEMG*+J>;3:I"?+4%)"FJ+Y)(K150--<.*
M*ZX<49L?L(RG"X&0LM\IWEH9>;:25@/0T@);64U(#B*:E-/+$E-/(ESVBQU6
M5V"-);\QN3:FPS,C;IJ0KWIJ*BH^S4DDK\:[-,R6D`0VVW"XU(4TML.*4ASB
MI50H'X"":Z`=9KTRX_<)*;A:7W<;EM@.NR;<A#+4IQ(YE"XR>*%!:^JC]N@'
M/O?;K&<WP2\X!?&W;E;+Y;VX=VC3E^>U;[A%4E$:_P`3S$J^5DL.T4E3=!0&
MIT,KR;MM+,IMMEJS#M+?,BL$-ZX-3++?)]NEQ'E2'6)UOC/J$2>&W5*8\F7'
M*5`H`J3J3CCA%)YT)N?GV^_\FL?][C^O0O\`;,X:N[/;^TW3N+GB7V:%67Y*
MXGB.*RK\5DD*!^U1K[=>:?0$=[]V5N[B'%V9UMSC4EAU!;414D);6=E&GLT`
MVTJUW+'F41+U#?MP0X05NLN)2[OQ!2ZI(`!--_'599$/(-(4M26P2M*FU(Y-
M%)K4`@5)W&Y.L]+X$48>,NIH%D]/#J344/ZJZ@@,000"#6O\F@,BE$%""NO*
MFWNH#_-H!S.SZ@G,9)/15JD-_K4E5?T4T!*%+Z?A36E`!RJ/#:M.N@$_<[FW
M&Y%;@H`HDU`"0D"IW!&U1MH`QP[#\L[DRT1K!#=:MJ'/+EWJ4@MVV(*<E)\U
M81YSI0?A2FO([5U*S)1.SMCV;QCMS':F)B_BF0*2"Y=)Z`IU+BE`GY1H\D1V
M_P"RH;^&MBQ(9IU\T6XM0*DI''X:@#I6E$DD=3XZ`W$37T;)42/>3R_70@@^
M((IH#1ND2RWUM3%^L5GN[2MO\,M41UT)I0I#WEA0)3M7J-`,=D?IC[7Y8M]=
MNLLG$Y3J5*;F6B:XIAE8!HHPWZMFI.]-4GD0\AR>T?9#'NU=M6($@WB_W%0\
M[(I<1EM]J$FH,.(S1264K_:6-SK,J.J[;)#=%)0"!\3BTI(!H=CUZ#6Y<P2G
M%^6FJ.*DBJ%-B@(IMS'CH#22E\H"VSR0NI4I0(4"*FB:[[G;0`9?>0I85MMQ
MY'H#M0TT!A>=""VHC8+*:C^Y`%?L.@,2Y+:B/NE(K4'QK2F@/J(4*E]/@*1L
M/[-*4T!MR4!RK0V:!J4^U0Z':G0Z`*#L\MN@)%3OT/NI^G0'Z0L%(2VW\2@G
M>@W/3H=`?4NW>4GFZI`+H%.*3U4*#H33?0!2Y'#8!K5)-%#??V;^XG0!<ZT7
M6'4\J<@JFU:!-0!X>S19AY/P.Q+Z/".'H5[<@FO_`!YEQ_\`O4C^C7HGFEA/
M<X)/;;N"%"J581E@4!XI_`+A4?I&J3R)CF>+QD]LALYIGR&F&D?\_P#.EC]W
M0T7E-QVUYG^Q>9ZJ^'[`N:A-@\O)0KJ-DT\!K4S%1&CH+*2`D#:@\M%13WTT
M`9):21LV#3:H0CP_1[-`;P0W0#IL.B&P1_)KF>XQI@1B?):;/4<O>0D?S#4?
M,>`Q`8R"-FT[TZT_T=-2KVK#`,W6(S9206T"E`-@?;JQ4:ON2F=:(4B:N!);
MM,YR+&$\IX1%N`T<:2L]7$@]-:QR++(2.*SF+5<8;+[[279"5R^"7!R*E@!M
ML#Q4&P!743#'37?X3LEJ&F9&$Q0\U,-;R$R5(21N&OO&HJ?T:S*A[,N*41>7
M,**$!114))%1M0^-1[-M`%]R<<7/B/5%'6(B@.M.3+?CX[:UCREED.#;)B@X
MTDU_<_"3R'Q5344VVVU8DVH7:V[=S<CN[F*/`9/'QB>W#M\F0&(-V?<+3+;4
MAT$^6(;14X#2I.@+K?IQ6:+VY]/=]QE"6DR,9[Q1+=<GT*#@1*5%C(=<0YMY
MZG7W%541TIJ"DX:U0EQW)E3+7F5ZCNL.QWU^7+:44EIN7&\P/(7YI!310_L]
M-,#/Y;P%39%)O%J?:2I16Z%(F15'S:$IXI6E?@D\M,3C^6_[6.5Z<FW;9>\A
MP*X-DH>6+K:2\DEEQ""EMYM*S\*#Q(H/=KLL<GF3T^G[M*$JNT5[9[<]T[GB
MU\:4;-E*VD-2>(*(DATJ0EQ!V2&02`?9K8%LN,V(M(C/)"`4MAIQ300I#C2-
MHZP2"%>8S0[5T`[,>S-B.EV*D+)24E/$I(44'96]#0G0#6*+EBNSK5V83&8D
M<V7B2*J#JAPX`#XQOO[-`,)WL[3655WQ_-@$OQITIFUWXK0BJ8;Y*H4D@)^+
MY90HHJJ:'6ZLMJN)P2?O/Q'#_(.&?\*A?ZQO_P"KU'1?>6J^!P#]P((3W!S9
M2Z%W\W9-Q`%30W5^IY;Z\@]\(8L52J@(3N?VDU/0>P=-`9I%DBSHY:F1([[/
MQ)=1(BL/H<36A!"D\MZ[>(T`V.0]A,5N8\^U,S<>DN)<6#`?4N(XI8`Y.17:
MI"17H-`-+>^R^<V0K7;1#R2%0J;$0_+S4I2?NN1W5`+<"1X$;[ZKIB11#9N3
M9-N>,2?%F6Z2'"VN/<(_RQ0X#3@'%T0NO@0=4DDG@0S,9;U0ORT\A0A5=A["
M/#6<JZ<,P.-VPGO,9,MY:?+5\@_7;=0JGVBE!K']WB3@228N:Y26FHC+DF:^
M0(\:.D.2'EJ-$H::!JHDFG36\:Z57,J2&P+TXW*[F)?>X)<A1G*.LXZAWC(>
M0O=OYIQ":LMN@"H!KX;:O%)YDHFO8K)`M<-F!`@QX,)A"6T1&&4MH0E*>-%4
M)4I7`?>))/75]*)HA4,LL)J%-DHXA-:J6I":U'&I)`KJQ)OAMQ1:*!1LU'&E
M=ALFIW(*J>W0!LS&CN#BX2AP"H2BJJ^VH'0;]=`;26$MD("!0':J:]37J:GQ
MT!]*:JM>ZF_@V('PDDI'&E*"M=0TGF!;H9*$0$*0`0PB@3O1%!0_934:8D40
MII,=E,.B6P"L$*&]2#UZ[C]&K$B(<C!9+24A-.E16@WVJK0!:[%*DJ3R"5,A
M7Q[`*J"*4V2370!$M)*>/*E=E[)',]0=]_U4T!KO--EO@L5XC:I-:["O70!-
MY8\RA2>-#[:=3XZ`VFY"&74\*#B0FM*[;`[DD4T`;^8'&BX`*`?&O:H-">G0
MZ`))`YO*3'/FK<;^+P(KU*0.M=`:S;3K;B>9*16JD\MS0[5%:BA.@#]Y;;C`
M45GE5("3OQ\*4(V'OT`F'7'EE2:!02O8&B:"GM%"=`?(1\`!2`2ASDD;C?F1
M^O19D/)^!V$_1^!3Z&>W0H0!>LLV/_E95>NO2>9YQ8-W,W[=9\GVX3E=1_\`
M8,\?TZSGE]N!:.9XT^;0%(R[/%@@DYUFFX`ZG)+@K<C^ZUYG^Q>9ZG^M^0FF
M&5!L`*%3NH4J>70_9TUJ9ATTV$I"4C8#IOUVK[3JLG18$,,6`H((`/WCX>X:
MIJD15F2@K2F_L\?U:RZ<.`JS[0@%7Q#;WU'B-1TH<!5ABE#82GH!04W/2GVZ
ME6X)U2Q%3X=>:99<65)2`A2BL&I3Q'7<T\=7('4R[T\8QFMJLG<&YY5=F+)8
M\,D2#BB7UIL\ZZMQ"MJ=LI(2\'J<PH?$=@=;1?NT+(K5N$2\*O[,BWI8+94E
M"9('[M*6RI"%@'HI/C3;1I/,D3]FQ_+&NY42XSUO/M,242'[J"6HH82VLAA)
M6$@B@I0==6I#1IIB5ICW$B94]4@GF^H`)-""FE/=QZI&J:431"K?D'_`E!SF
MEJ%&<J>-1Q9217:NQU*5,B16VRX^:XP:GXQR6:;*5Q`\-2!9V#,;M@]^9R+'
MW&VY[;3C2@Z%!MQ+J>*@Y2JEGC2E.FV@+>?0E>)MR]/O=FYS0I3S_<./?W97
MP@.+66O.2VI*04I;6H?934$IM.J)U9?-?O\`8K#/?=4^ZNVOLID.A*U%HM<F
MV_-WY#D-B:GV:4+:Y!)VLS5F,F1%FE8=<*8GF%(*T450K*2*U/M(^S4E"?'9
MVQP9>6M7)"O-2B*IH.$54OS4(*3M0#XO93778Y/,Y+_.O`>?O5A;J[3:\IA-
MI$FWNK9N7$E"U0G>/"2`DC@XP*T(`H=;&`_7II[TWF5`8Q"_7E*)MOCLNV>1
M<5MJ_$+?SXI82M8!6\A&PW)]N@+)K?<_F8#4N*26'2A0.P6E8"0XV=J[J.@#
MF?:8-]84F3%8><2D*0ZZD521O1*P!N2G73MXVI)]1)@;2]6*'?+!<K1)2GR^
M,EE\N;\4']TV4`_=+-*I/7?7H)P2HE@8.Q5YA'_"6S_\I._Z/^JU'N]Y/2[S
MSXL^C^3W!S)!^,JRW)O-(^(()ND@H(4.M?MZ:^6/8"2.RIE8Y?&'#\%!]P[=
M2-_UZ`.(W,?"17XB-TC>A'@1H`Y834I'!)!22HJ)'Q?T;:`VTVR.-TH1S(VY
MIY)!4*5XU&X)VT`6W+#;+=6%1;O:H-TCO)/FI>B-+4I52-G."7&S0=0:ZI*-
M2&JC+7_TNXS=E..XM.F8Q+7\7RSE9MG35055++[B5MJIL3O[M%"CQR%,1+XG
MZ=NYEOR=N&M5MEVJ4TXP<BCR^,>&`M)\V1#X^<5<.@34;:O2!)9#VL[687@C
M#,F.47C(E,AM^_SHS:W$+4-TP6%%;;48*^ZF@4!XZS<,<,B*#[I0M?%2G.13
M0\%_>`/0B@V2:;#PU,4T$@VB'B7%'<$>'79)U<D-4$-4*B"5#[H^\![2#30!
M@TI1:0M*TA)41Q/WA11^T5T`:QU,MK4M?PK`X!9^ZL*H3QIN02-`&+)#CBN6
MZ*?"/$$`5/LZZ@E*I]*I5L*/PEQ((W)(WV`IUT#5!?,-!2XA6**X(2GW,TJ1
MX[FFI(%-(,=,=*-W'$BG-`!33IL54-=`(F4U^\*DT":"I/MW]@]F@"25P*U\
MR$A`H:?<56M"1U_T]`)>4II;@2T:E*PI7OV'3WT^S0&-]'+C10!.]#6OW>FP
M.@"PD+"4UXA:_+"E?="J&@-*G?0`3$IQ2454"!4%-":]?;30&RL*:0&DD)YC
MXDD;KIM5-*^W?0&HT/)=4YY2@YNGF.-`!4;^.V@-MIA#ZTNI4E7([FA'3J-Q
M78Z`SNQ%?$.24@@A-:[_``^X>W0"?=;+3B@L@#P5O0[JZ;5T`$-GBMP$%)2?
M;7X:UZCW:+,AY'81](;_`-QSMR?[5ZRT_P#WLH?T:]$\XG_W*_\`5YGW_0G*
M?\1S]4N<I*S/'0S5AO\`-6=4%/\`G[F->G_I'<=>9_L7F>K^CV"`0@)=/'H!
MR/Z"1MK4S-Y+S;*N2EI/P$T2=STVH:;ZJU54(9]JGH"4J0O8C[E1R!]_@-M5
MT,BA^HG(<>24(<6:$42!7I0GJ!0'5"`]CM27E!+*$4*>1*Z['V?"%=1K.=Q0
M='4FAKN*6PZ]%D+2I]*0KB@DA"54*0:T_9U$;JDZ48H:RVPZVM"BGC2I221R
M2:AP&G]P=O?K4@R7[N;EL?MZO!$2V?PX%<8S?)K.-OY<A$#G*E*;<NNM8Y(N
MLB.###9EH0D40$KHGH`JE33KM7?[=6!KR9<ALK0M==U)KX4IM4$=`-`9!)4I
MM-%`T00>A]G](T`OOF%)1&4H<@JVQS0`;@!((/VTT`L[-,:6(P`XT)--N73Q
MW&V@#J8^GS4*`-$5ZTH:A)\#TT!<Y]/OS9/IS[@("D%$C(K@DM_$IM24Q_-J
M$T)ZI'AJ"DYJ"JR;.(2%7+#+0R\M3B4.!I*E`T:<2HCRE`[I`IMI4S^8CP8V
M;I?QK*E/J2D0WG@9`"@0V1]U21TX@]=2;51:3Z1[BS>92TEWS5*8;))(4$IY
M_"I`!-#3VZZ[')YG)??O^19G;,6MEY:N=ON$9,N%,M;C;B'$U"7%<DA:1N*G
M;WZV,2NW.L-OO;7(9$)*I"K6Q.+]KD^:XQ(8\USDV6G@`2VP#3C6F@)7^GGU
M-.XW=&,)[E7A1AW)2?PB[S#5I!<-62XZ"0D*2`*G;?0%JMIF1Y<5N2S*:>86
MA+C#C2@ME]"D\PM"D[+30BA%0=2FUD!&7U8A2G'N2`F4E:O))2$`*-2KD?O[
MG[OM.M%=D@*;YP_[0Q^I.G6GQ(IWGG+YXPXK/,YHG[N7W[<]%?\`&$G[OMI7
M7DGIA2U'=*-D%1]@Z]!H`V;;0G@5-KY``$4%>1%#_*=`&K3":*"D]"/9XC[-
M`&J8RJN`&O$(X4!]U?MT!OQ&G5+'F$>4.J2BA]Y!I7QT`H8\,%;G$4!0FE.H
M'PTW\=M`'MMAA"E4`'P\.A'PJJ2`/:2.N@%[;'DL\``*I*0:@'I]N@%K$N!2
M`.=>1W*@">@\3N:5T`IX<QI20D@\U;5WI4I(!]G70!L0/@=%25`))J2FE?`5
MH-`&;:$J;0D[;FE#3]HG0!NVIAU8`<!+*:4I4*57;[:C0!HVHT\PA*'2#1L4
MHL`4"ATXT&H+K(^4.U4/,`4*B@I^U44/ZM$1+(<2&M*O)57[K:2.1W&Q%.NX
MU)4/W7D+90TD)*%"I7L%;4H/`[UT`D[F>"0V@T2I1Y>)\1UZCIH!,22I2E)`
M22L$$'H>/\VPT`E7%%,@K0WP4C8_M)4=C7V&E-`?B5*<="E=:JK38`D*\.@T
M!J-\4H#A7Q4AZJ*IY#?E4E)V-*?HT!O-L<BI7F*4G<I/)0KXBF@/AU!-.*O;
MNKXE>'0]1H#12@!WXU*("SR^(T(!-=`',<,K;3Q4&7>1XCB`E032H(.PV_2=
M`9WC\P@)2.);2?UI%>M:$:`+7HI<0`YQ/$DC8=:'K30&)N`I3-=@*+!'3:J@
M=J:+-$/)G7K](Q(1Z(.W:$BB4WO+0D&O3\77[=>B><3Z[FGCVX[@+_LX1E9K
M[A8;@K^C5)\I,<SQH,WSFW?F[.6T-N<CGF:T"U(2.2,HN*/;4$#7FT?46'$]
M2JT9KL&Z<RUSS"IEE!"DTW4FO4FE*G6E&9U0&KG,EK*BI+:$%)2?AH*GII1B
MJ%'!C^?5YQY*:FBEN.)0R.(KN:@@Z48J@X<R;%[0VAM5TM29*=G4F8E]Q5=C
MY;;27#4>X:QH^#*F6-W$L;:EN1XU[F%**%QJVOLP@M1HD+DNAL<!UJ`=M2K3
MGC1DJAIVVZ?.R9,A[B5R'U.*/($II4(2E5=DI3M[-2[&E:L<!AQ#IYYLI)00
M"$J'W@:UH.E=4HR*H1=\"5Q7`H_#S5XT]GC^G6R3THM54&W9*$STA*D_=<_:
M!_9^W4T8J@DN:DA0HM-5N%)^(>)X[;Z49-5Q0&$!MO=8-4D;J%=*,50XBU)#
M4.JD[6UCJ1UJ-COI1BJ#>S.H3,0WR%5-@H^+H:[FE>A&E&15"P6XA=2".()H
M":[C8^^A(THQ5%P7H`GN?P-S&.R_Y;K>3K"$MN!`6EQE*7$$`T-0?Y-*,QOT
M<%XD\>S\EB5;UPW%^9PNBUJ2I85Q>;<("0":["FWCJ*,XPZ[DXI!?9D2XP5&
M6&E><AX)"UFE4J214`5'AJ:&77[F.]Z$<X%B[FM8U>70S%OJ#&BRWU(2PU*3
MQ2PPA9(^-Y6U.FNNQA#S-(RUJI?SB#4QIZ>S-B.PB$I0RZX$J2\@$DT)]H%=
MM;%A+]Y>U:>X..2'(BV#<[>A3K:5-)/GH2FOEI*=PNNPT!6E?<8ELQIUCN(^
M2NMC?26/.`2]\L/^U-J(%:>WJ-`3%].GJ3O%CAV[!,MF_,!EGRK-/?<\U,9E
M)XICON*JH(I3C[!H"9=YS=-\8C(EQVFH'F!P7&&XB0D&E$K5Q4%H:*3T-3H!
MR/G;#_RXC_7+T!YZ.;-N?GK-@M1*49A?J4J#_O\`DC<^.O./2"R&:+"BZ4J%
M0`1RKM[-`'#7,U6Z>20:G8)KOMTZ;D:`/VF$K2%K'W@.-*C:G^GH`R8;2'$\
M0H&AZ].F@#1AA:CR'&@(!W/N/LT`=Q$E'Q$$A/LWKM3;]>@#Z$DJ=2=@`.?Q
M&A(2-Z>T[Z`4D<B0GD@\=@:*V7^A.]5:`4,)HH3R=070.-"O[R.M2V`3R-#O
MH!21WBW2E%-T%`K:HIT5[!O3[-`'+4KFCBETI(']['][I7I78TIH`V$HJ\AV
M@XI^$MH-?[DTZ==`'$5PA1<#:$#@17EOU!"=O;30&V)E5M*WHCE44K6I.P-:
MZ`,F9:S118;HH<05+.Q-#7QW%-`+&/(2M#3:CQ61_?$[G:OP]>@T!ONRBVGE
M4*^(;)%3U]AH#H!.SY:BI:ON\MP#U(IX^'4:`)WI0JCFH!"@=R3X`GW[:`+5
M/M%1XDD>T`TZ>%0-`?"7*>8@H7N"KE0<:+(()-?9H#!Y20."R"4U-4JV^+W_
M`*-`;#+JF=N#:TTHE95NV/:-J%0T!A=7Q4?*0E:5;DJ44D*/785ZG0&F%!QQ
M2.2$+W4020D'Q`)&^^@-M#I#WP-AS9(*U*H$;D@@"H7R/V=-`&W%U0YJ6JI%
M24IXIV]B0O;;0'X`KH"MPD]*=.O]T=`93&V)4**H:BONV_DT69#R.N'Z2@IZ
M)>WH_P#'>7?XX<UZ)YJR+%KQ:8E]METLUQ:\ZVWBWS+7.:2XI"GHEPC.0Y20
MH"K9,=Y0!'CH2403O\V<^D/<;A<[G+[`Y`Y,N]QFW::Y_$C*J+G7"4],ENH2
M91#?FOOJ)`\-`8&_\V4^D&V:I[`Y#[?_`%D95_,)(T!O?_LTGTC/++8[!Y$D
M$4JCN7ES:P/<M$U*@1H!/G_-@?H_.R4R)78O,YR$JY&'+[M9L["7_<K8$]')
M/NKH!50_\VM^D/;F_*M_IQEPD^)CYQDB7%>RKBI*W-A["-`97O\`-N/I-/MJ
M:=[%9&MI1_O:NY.6E`'L2DS2$I]PT!JQO\VK^DA$"@SV#OZ0HD_^L?*S2IKM
M_A8T!M?_`+-Q])KP[$Y"G[.XV4G_`+*4=`:[_P#FUWTDY+9:>[#9"M!5R(_B
M/E>ZC6I(^;H.OAH`J3_FRGT@DN^</3_D'F4IR_B1E73I_P`+T!J._P";$?1]
M>4%+]/V1_"L+3Q[G9<D!0/*O$2^(WT!D'^;&?1^'_P#K_D1W!W[E96>AJ.LO
M0!BY_FT'TB70@+[`W\\$\`1W(RNO$#BFO^%^`T!E;_S:;Z1K+J'VNP>0)<0G
M@DCN/E?W1T!_PLG0&[_^S;_28\.P^0#J=NX^5[$FIH?G/:=`//VW^AK].?M/
M:I-DPKM%>;?;I;_S+[3V;Y!)*WB""ODX_6M#H!QK%](KT-8Y(7)M7;.Z-.N/
M_,JYY9>EH+P_:XEX`5T`J;G]+OT;7=HL3NV\QQI25)4$Y)=TD@^_S>NYT`DX
M7TA_0W;I29D/MK>(\AOB6GF\QOR7&G$.)>;=:4F0"VXVXFH(T!,:-Z>NV,:T
MP+*+3,D0[=&8B1U2KI*>DJ:CIXMJ>D$\W7```2>N@,L?T_=KXW/RK&\D+3Q4
MG\0EE)'MIS&^@&ORKT.^G/,YYN=^PV1(FT*?/9O$Z*HIW^%7D*1R&_C4Z`3\
M+Z?'IAM[S3\7#;BT\RX'$+_,5S4:@UXGDL_"?$>.@'*MWI3[+6I!;AXY,;05
ME7E_BL]QO<U(XK<*:&M*=*:`6'\#>V?_`*/?_P`=W_9:`\PK.FU?G?-?&F8W
MY)I[3<)'\F^O./2"=EEPN)(34)`!.U*]?Y-`&[">:2@ME>YJBE:E*DFGZ*5T
M`?-)2TKE4T4`2DC[E*;>WIH`W;>0ZGFV!1.QK6H/3^?0!O%`I3P)!/\`)_7H
M`X#J6N#)`Y+`X_H`5_*!H`]A!+CB0:A822BAH#MO7V[TT`I8S254*^+:@!5:
M1Q`-?O$#KH`ZC+4@FBO,"0**)JDU&^U>HIH`Q;DI0E/+<)W5L>E:D5^S0&^A
MX*0'&PD)5TVJ=`&D*64IH:5`5X$=3X'W5T`9M3$AM)6XJG(?M'?J?U4T`9?,
M<AR;(X4^$TKTV_G&@-N+(2I!)>\PH25A(/B"`"?:-]`*"-<EU;W3\*:TX^WK
M70&TJ>X4D*6@#VH<!-?#;V:`*7Y3A02^\`NIX@BGP?LUZ>-=`%<AYP\`AX$I
M%1QV4!7<[UV`T!A,Q:P`BKH0*%PT`4?=0=!H#9#R_OJ4?B0`H$T%`/9X4T!\
MI6"`E*B>)))*B2>7M.WLT!\J4NA82=R#)#G7<#9L[Z`_&7_,*DCKQ)3O7<?>
MJ?970&N7O,*PXT4NH26_,2.()`ZBOB3H#Z:HMD5D!!*JJ0/A6VI%*(6=ZJ]N
M@#Z.Z5A*ER`H``E(-*@4J/TC0&ZGS0M*FU!"%;<U`$)ZD<O&AUI:A&;>HAAH
MA!<6A+HW4A7*FU>(-%#V`@:VZ,%Q*MNAUK?2<0$>BKM\E-:?C66=??=UZW//
M619+H2#0`T`-`#0`T`-`#0`T`-`#0`T`-`#0`T`-`#0`T`-`#0`T`-`#0`T`
M-`#0'E8Y^HLYUG/``_\`/"_CXA7K/E"OAN*:QZ$.\];]O[/^P714^9P)4I)0
MS4<32OQ$DJV->NL+L%"5%E0I+37W<@U;%$$I)2K:BA][KUK[3K,@-$IY(223
M6FY\3]N@#:*TE*2AFJJ[GK78<B=]`;;*AS*1N0:$4.VQZ_KT`?-O)4WYJ:_`
M>/Q"AJ#Q-`=`'<-YQ:DT3R'&I!(2`=@%$TVIX#0"@9<0$U=54*W4I(K44W('
MOT`9QW`XE?$_NVPFA.QH1[.M=M`&3"TN-I*>E#UVZ5_JT`9QWTH"4BI4M`(V
MV`Y`;D[`U.@,[-4N%3E!6E#X+%!3CX&GC[-`;K;[;;B5!/$5H5;%)ZBE>E3H
M#=Y/*4"EVB7"HH%010$UW&@#&,^4CBXZ%[?=2/&HITWT`;,2G6C\#@2CP'C7
MV[Z`^W)ZT.`N%(37J!4^'@!OTWT`6O26W7%+4GE4[544GC[.(\-`?J5%P-%T
MAE*.7)(^(*!!`!5[#MH#Z,EMHI0R\&PH5\L5(3O38CKH#Z^>57R@I!0Y4O$J
M'WTBB2![Z>&@/H+0>A/F"I2FAK2NY4/9MMH`"15274+\M=./*M0ISW]*)J-`
M??/E52B`H"JE@T"J#J-AOH#7:>0IT*'(T6/V34U/LZZ`-&Y#!4M!4`I*J*"A
M3XA_\N@-YFA>1S(X!"BV4[UZTZ4VKJZM3:JLB*ADRX$KH4\T%*BK>E`D5)&V
M^MK4)0;J0P^MS3DM*24,I:"':%0*G.!)"36O6E/LUN0\F=;/TIF"QZ,<`;I\
M*;OE`;-:DI_%%[GV5U)P%CV@!H`:`&@!H`:`&@!H`:`&@!H`:`&@!H`:`&@!
MH`:`&@!H`:`&@!H`:`&@!H#RM,V*1G6;<ASKEU^6$D_LJGR4@[^_593C'&61
M?6POB@A"JJY55M_<B@^'7)=N1N2K'L.FRVXOQ#EN2R&PL+2:'RRDU%5\3L13
M;IUUF;&TP4!`^,%1!4JIV%/8>G3PT`:,U+1X]:H(W(]A\*'IH`R2XMI38*4$
ME->GA6@Z$5IH`Q%5&J0`5`#B-DUV).^]3]N@#J*\J.`5`;BG&E4J%.I]XKH`
M[8>0XV/B;^)(2&FZ\T`BG)52H<0-`&#*E)(0#L2*^_;0!Q%D!/[L4\!^DU'@
M=`;;4D`K\R@#BZ)(_9(3T&_2F@-Z,^ORAYB5.\5.<5$5"4\S]T@`=.OOT!F4
M^AP!"4J2`0KBK[FVU:4K7?VZ`W6I("&R=BT"`C?X^1ZIW.PKOH#?94A8"DFB
MNNU`"/U>WWZ`W?F2E3:2H\:GS=P.(\.-?$^_0&5YYM7[Q*E%'2IW&_3V:`UA
M(:2OS."G#QX_W%*G8[UKOH#/YZWDFOE`+^ZU\0=!ZIY?%2A4/9H#1JVI?-P4
M0BB"036HH5=:TWT!F4^WY7-L`DJ*4DUZ;T/4&NW70'[&EJ"G5*6@.!I2@M7W
ME`$#C[./Q:`RAQL)KR)3R\SBG[E:5H-J\=`8G72^WY33O%=04IKMQ32H`K6F
M^@/ME]+:DI"P%!0JH]`I/4_9MH#;`;?<4NBN?+S%+!'%:E#P('0<=`&#<A+?
ME@KH6QQW.P!)J30CI779;Y$5>8=P)453@\Q;G%2%)4M)''XA3X:@[C6A`L;7
M+9886"2GRTJ2%+^ZI%:@[4^+A3].H#R9UM?2GDMRO1AV_=:-4?B^4!)^RZ+Z
M^_5C@+'-`#0`T`-`#0`T`-`#0`T`-`#0`T`-`#0`T`-`#0`T`-`#0`T`-`#0
M`T`-`#0'EV9?_"'\]9CYO\5^?YGO?F<?R7Y7+\1D_P![Y?'QK[=Z:YMQD`N5
M_"?;ROXM\:;^5^2:5J>O+>M-<D*8^)UV.5TXAA'_`(7<7?\`UK\>3?\`Z"4Y
M<13C7QIUKXZO@;8AHG^%_DII_%2O)-*?D3EQWK6NU-,!B;T3^&55<?XG5HNE
M?RE_9/7PK[-!B&C?\,O*9\[^)G+F*<ORERX^-?'C73VDX]QML_PS\U[R_P")
MG*@X_P"25.HZ?HTP&/<&43^''FCS_P")?E<37G^4^/A3IIAWCP#>/_#&J_EO
MXC<Z'A3\J=/"OCQK[?#3`&]'_A_P;^8_B+Q\Q=>'Y3Y<=NO'>FF`Q#I/\-^!
M\O\`/_E\T4_R3\[C45Z_'6NF!&)NO?PU\U''^(U?-'#_`"5IR\HU_1J<.\8F
M['_(/D*K_$>O-7'_`"5Z<MJ4VU&`Q-G_`/+[]K^(M/?^5NNF`Q-EK^'U6J?Q
M#IR^&OY4Z<OBI7XJ>W3`8FY_S!YJ_P#6+3S/@X_E:E?"G'PTP&)N+_(GD_'_
M`!#K4U_R4K2IXUTP&)]G^'W"/P_B)QJ/_1;C3PY>'73`EU[#"O\`A]S57^(G
M7;C^5Z4H.E-,",3"C\A\_C_B+Y]1QI^5N=*[5X^''08]QM.?D6@X_P`0Z4/*
MGY3I6O[5?'3`8FL[_#^J>/\`$/G3Q_*O"OO\.-=,!CW&<_P\\L>?^?.-=O*_
M*E>5-N?#?V>[3`8F)?Y#Y*I_$3COU_*OETIX_L\=,!B!W^'_`.\Y?G_GY'P?
M+_E6M*IK]SQ_HTP&)^C^'7/?^(=*[U_*WZ>FF`Q[C:1^2N8\O^(OE4/'_);C
MT'6ONTP&/<;,/\A?_P`Y_$/CO7G^5>E=^GN]NNVWR(KB*2'_``[XBGY^^7H/
M+K^5_O5^&E-]7&(:C\E>6CS/XA4XN_>_+'ETH?+\RFU*?IT(=:/P.M+Z3GR/
M_L5=O/P[YWY3\7ROA\_\O\SR_%E<N?RO[FE>E/#4G"62Z`&@!H`:`&@!H`:`
D&@!H`:`&@!H`:`&@!H`:`&@!H`:`&@!H`:`&@!H`:`&@/__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
